Авторы трудов (статей) использованные при подготовке материалов по отравлениям в медицине (токсикологии)
В ходе подготовки статей по отравлениям в медицине (токсикологии) для пользователей сайта МедУнивер использованы труды следующих авторов:
Tintinalli JE, Ruiz Е, Krome RL, eds. Emergency medicine. A comprehensive study guide. 4th ed. New York: McGraw-Hill, 1996.
Strange GR, Ahrens W, Lelyveld S, Schafermeyer R, eds. Pediatric emergency medicine. A comprehensive study guide. New York: McGraw-Hill, 1996.
Koppel С. Clinical symptomatology and management of mushroom poisoning. Toxicon 1993;31:1513-1540.
Trestrail JH. Mushroom poisoning in the United States. An analysis of 1989. United States Poison Center data. Clin Toxicol 1991;29:459-465.
Margot P, Farquhar G, Watling R. Identification of toxic mushrooms and toadstools (Agarics). An on-line identification program. In: Alikin R, Bisby FA, eds. Databases in systematics. London: Academic Press, 1984.
Hogue K. Another look at mushrooms. Rocky Mountain Poison Center Bulletin. 1988;7(2):6—7.
Pickering CAC. Mushrooms and the lungs. J R Soc Med 1987;80:667.
Tarvainmen K, Salonen J-P, Kanerva L, Estlander T, Keskinen H, Rantanen P. Allergic and toxicoderma from shitake mushrooms. J Am Acad Dermatol 1991 ;24:64.
Satre J, Ibanez MD, Lopez M, Lehrer SB. Respiratory and immunological reactions among shitake (Lentinus edodes) mushroom workers. Clin Exp Allergy 1990;20:13-19.
Phillips MS, Robinson AA, Higenbottom TW, Calder IM. Mushroom compost workers’ lung. J R Soc Med 1987;80:674-677.
Nakazawa T, Tochigi T. Hypersensitivity pneumonitis due to mushroom (Pholiata mameko) spores. Chest 1989;95:149-151.
Lampe KF, McCann MA. Differential diagnosis of poisoning by North American mushrooms with particular emphasis on Amanita phalloides-like intoxication. Ann Emerg Med 1987;16:956-962.
Hall AH, Spoerke DG, Rumack BH. Mushroom poisoning. Identification, diagnosis and treatment. Pediatr 1987;8:291-298.
Lincoff G. Presentation. Mushroom workshop. International Congress of Clinical Toxicology. September 9. 1993.
Koppel C. Clinical symptomatology and management of mushroom poisoning. Toxicon 1993;31:1513-1540.
Jaeger A, Jehl F, Flesch F, Sander P, Kopferschmitt J. Kinetics of amatoxins in human poisoning: therapeutic complications. Clin Toxicol 1993;31:63-80.
Floerscheim GL. Influence of ethanol on toxicity of paraquat and Amanita phalloides. Lancet 1992;339:437.
Belliardo F, Massano G, Accomo S. Amatoxins do not cross the placental barrier. Lancet 1982; 1:11 387.
Paydras S, Kocak R, Erturk F, Erken E, Zaksu KS, Gur-cay A. Poisoning due to amatoxin-containing Lepiota species. Br J Clin Pract 1990;4:450-453.
Jehl F, Gallion C, Birchel P, Jaeger A, Flesch F, Minck R. Determination of alpha-amantin and beta-amantin in human biological fluids by high performance liquid chromatographic determination with amperometric detection of alpha-amantin in human plasma based on its volta-metric study. J Chromatogr Biomed Appl 1991;563:299-311.
Jehl F, Gallion C, Birckel P, Jaeger A, Flesch F, Minck R. Determination of alpha-amanitin and beta-amanitin in human biological fluids by high performance liquid chromatography. Anal Biochem 1985;149:35-42.
Becker CE, Tong TG, Boerner V et al. Diagnosis and treatment of Amanita phalloides-type mushroom poisoning. West J Med 1976;125:100-109.
Feinfeld DA, Mofenson HC, Caraccio T, Кее M. Poisoning by amatoxin-containing mushrooms in suburban New York — report of four cases. Clin Toxicol 1994;31(6):715-721.
Ponikvar R, Drinovec J, Kandus A, Vari J, Gucek A, Malovich M. Plasma exchange in management of severe acute poisoning with Amanita phalloides. Prog Clin Biol Res 1990;337:327-329.
Mecuriali F, Sirchia G. Plasma exchange for mushroom poisoning. Transfusion 1977;17:644-646.
Floerscheim GL. Treatment of human amatoxin mushroom poisoning: myths and advances in therapy. Med Toxicol 1987;2:1-9.
Neftel K, Keusch G, Cottagnoud P, Widner U, Hany M et al. Sind cephalosporine bei der intoxikation mit knol-lenblatterplilz besser winksam als penicillin-G? Schweiz Med Wochenschr 1988;118:49-51.
Caraceni P, Van Thiel DH. Acute liver failure. Lancet 1995;345:163-169.
Klein AS, Hart J, Brens JJ, Goldstein L, Lewin K, Bu-suttil RW. Amanita poisoning: treatment and the role of liver transplantation. Am J Med 1989;66:187-193.
Pinson CW, Daya MR, Benner KG, Norton RL, De-veney KE, Aschen ML, Roberts PL et al. Liver transplantation for severe Amanita phalloides mushroom poisoning. Am J Surg 1990;159:493-499.
Jaeger A, Jehl F, Flesch F, Sander P, Kopferschmitt J, Minck R, Mantz JM. Amatoxin kinetics in Amanitaphalloides poisoning. Vet Hum Toxicol 1989;31:360.
Jaeger A, Kopferschmitt J, Flesch F, Berton C, Leveres H, Sander P. Liver transplantation for Amanita poisoning. Proc Eur Assoc Pois Cont Cent Toxicol XV Congress, Istanbul, May 24—27, 1992; p. 103.
Kern C, Zilker T, Clarmann M. Successful liver transplantation in a child after Amanita poisoning. Proc Eur Assoc Pois Cont Centers Toxicol XV congress, Istanbul, Turkey, May 24—27, 1992; p. 126.
Zilker T, v Clarmann M, Felgenhaser N, Hibler A. Arar-ity in Western Europe: a mushroom poisoning with Gy-romitra esculenta. Proc XIV Internal Congress Eur Assoc Pois Control Centers. Milan, Italy, Sept. 25—29, 1990; p. 98.
LincoffG, Mitchel DH. Toxic and hallucinogenic mushroom poisoning. A handbook for physicians and mushroom hunters. New York: Van Nostrand Reinhold, 1977; pp. 156—157.
Lewis WH, Elvin-Lewis MPF. Medical botany. Plants affecting man’s health. New York: John Wiley, 1977; p. 398.
Vachuska C, Vachuska P. "Puff ball madness" or "How low can you go to get high." The spore print. J Los Angeles Mycolog Soc. -»01, December 1994 (Biology Department, California State University, 5151 State University Drive, Los Angeles, CA).
CDC. MMWR. Respiratory illness associated with inhalation of mushroom spores — Wisconsin, 1994. JAMA 1994;272:508.
Strand RD, Neuhausen EBD, Sornberger CF. Lycoperdonosis. N Engl J Med 1967;277:89-91.
Lincoff G, Mitchell DH. Toxic and hallucinogenic mushroom poisoning. A handbook for physicians and mushroom hunters. New York: Van Nostrand Reinhold, 1977; pp. 19; 190-191; 49-61.
Vanden Hoek LL, Erickson T, Hryhorczuk D, Narasim-han K. Jack O’Lantern mushroom poisoning. Ann Emerg Med 1991;20:559-561.
Cochran KW. Mushroom poisoning case registry. JAMA 1984;252:1685.
Chilton WS, Ott J. Toxic metabolites of Amanita panth-erina, A. cothurnata, A. muscarina and other Amanita species. Lloydia 1976;39:150-157.
Clitton WS, Hsu CP, Zdybak WT. Stizolobic and Sti-zolobinic acid: L-dopa oxidation products of A. panthe-rina. Phytochemistry 1974;13:1179-1181.
Benjamin DR. Mushroom poisoning in infants and children. The Amanita pantherina/muscarina group. Clin Toxicol 1992;30:13-22.
Schwartz PH, Smith DE. Hallucinogenic mushrooms. Clin Pediatr 1888;27:70-73.
Spoerke DG, Hall AH. Plants and mushrooms of abuse. Emerg Clin North Am 1990;8:579-593.
Stenklyft PH, Augenstein WL. Chlorophyllum molybdites-severe mushroom poisoning in a child. Clin Toxicol 1990;28:159-168.
Levitan D, Macy JI, Weissman J. Mechanism of gastrointestinal hemorrhage in a case of mushroom poisoning by Chlorophyllum molybdites. Toxicon 1981; 19:179— 180.
Michelot D, Tebbett I. Poisoning by member of the genus Cortinarius — a review. Mycol Res 1990;94:289.
Bouget J, Bousser J, Pats B, Ramee M-P, Chevet D, Rifle G et al. Acute renal failure following collective intoxication by Cortinarius orellanus. Intensive Care Med 1990;16:506-510.
Moore B, Burton ВТ, Lindgren J, Rieders F, Kuehnel E, Fisher P. Cortinarius mushroom poisoning resulting in anuric renal failure. Vet Hum Toxicol 1991 ;33:360.
Andar C, Rapior S, Delpech N, Huchard G. Laboratory confirmation of Cortinarius poisoning. Lancet 1989;1:213.
Lampe KF, Ammirati JF. Human poisoning by mushrooms in the genus Cortinarius. Mellrainea 1990;9:225.
Pohland АЕ. Mycotoxin in review. Food Addit Contam 1993;10:17-28.
De Vries HR, Maxwell SM, Hendrickse RG. Foetal and neonatal exposure to aflatoxins. Acta Paediatr Scand 1989;78:373-378.
Sabino M, Prado G, Inomata El, Pedroso MO, Gardia RV. Natural occurrence of aflatoxins and zearalenone in maize in Brad. 11. Food Addit Contam 1989;6:327-331.
Wild CP, Rasheed FM, Jawla MFB, Hall AJ, Jansen LAM, Montesano R. In-utero exposure to aflatoxin in West Africa. Lancet 1991 ;337:1602.
Wild CP, Pionneau FA, Montesano R, Mutino CF, Chetscaga CJ. Aflatoxin detected in human breast milk by immunoassay. Trap Dis Bull 1988;85:908.
Lamplugh SM, Hendrickse RG, Apeagyei F, Muanmut DD. Aflatoxins in breast milk, neonatal cord blood and serum of pregnant women. Br Med J 1988;296:968.
Hendrickse RG, Maxwell SM. Heroin addicts, AIDS and aflatoxins. Br Med J 1988;296:1257.
Hendrickse RG, Maxwell SM, Young R. Aflatoxins and heroin. Br Med J 1989;299:492-493.
Hendrickse RG. Clinical implication of food contaminated by aflatoxins. Ann Acad Med Surg 1991 ;20:84—90.
Denning DW. Aflatoxin and human disease. Adverse Drug React Acute Pois Rev 1987;4:175-209.
Patel P, Stephenson J, Scheuer RJ, Francis GJ. p 53 codon 249 set mutations in hepatocellular carcinoma patients with low aflatoxin exposure. Lancet 1992;339:881.
Autrup JL, Schmidt J, Seremet T, Autrup H. Determination of exposure to aflatoxins among Danish workers in animal feed production through the analysis of aflatoxin B, adducts to serum albumin. Scand J Work Environ Health 1991;17:436-440.
Campbell TC, Junshi C, Brun TA, Liu C, Geissler CA. Aflatoxin and liver cancer. Lancet 1990;335:1165.
Denning DW, Sykes J A, Wilkinson AP, Morgan MRA. High serum concentrations of aflatoxin in Nepal as measured by enzyme-labeled immunosorbent serum assay. Hum Exp Toxicol 1990;9:143-146.
Scott PM. Methods for determination of aflatoxin N| in milk and milk products — a review of performance characteristics. Food Addit Contam 1989;6:283-305.
Aflatoxin in corn. FDA Consumer 1989;23 (4):2—3.
Degan P, Montagnoli G, Wild CR. Time-resolved fluoroimmunoassay of aflatoxins. Clin Chem 1989;32:2308— 2310.
Wilkinson AP, Denning DW, Morgan MRA. Analysis of UK sera for aflatoxin by enzyme-linked immunosorbent assay. Hum Toxicol 1988;7:353-356.
Hsieh L-L, Hsieh T-T. Detection of aflatoxin B,-DNA adducts on human placenta and cord blood. Cancer Res 1993;53:1278-1280.
Chao T-C, Maxwell SM, Wong S-T. An outbreak of aflatoxicosis and boric acid poisoning in Malaysia: a clin-icopathological study. J Pathol 1991;164:225-233.
Okoye ZSC, Neal GE, Judah DJ. The detection of exposure to aflatoxins using EUSA. Hum Toxicol 1985;5:400-401.
Cheschan J, Neal GE, Woods H. A rapid enzyme immunoassay for extracted aflatoxin. Hum Toxicol 1986;5:405.
Selected mycotoxins: ochratoxins, trichothecenes, ergot. Environmental Health Criteria 105. Geneva: World Health Organization, 1990.
Bhat RV, Beedu SR, Ramakrishna Y, Munshi KL. Outbreak of trichothecene mycotoxicosis associated with consumption of mould. Danish wheat products in Kashmir Valley, India. Lancet 1982;1:35-37.
Friche RF, Jorge J. Assessment of efficacy of activated charcoal for treatment of acute T-2 toxin poisoning. Clin Toxicol 1990;28:421-431.
He F, Zhand S, Li C, Qia F, Liu X, L X. Mycotoxin induced encephalopathy and dystonia in children. Fifth World Congress in Intensive and Critical Care Medicine, Kyoto, Japan, September 3—8, 1989.
He F, Quan F, Zhang S, Liu X, Zhang C, Lo X. Mycotoxin induced encephalopathy and dystonia in children. In: Volans GN, Sims J, Sullivan FM, Turne P, eds. Basic science in toxicology. London: Taylor and Francis, 1990; pp. 596-604.
Kulig K, Moore LL, Kirk M, Smith D, Stallworth J, Rumack B. Bromocriptine-associated headache. Possible life-threatening sympathomimetic interaction. Obstet Gynecol 1991;78:941-943.
Vermund SH, Goldstein RG, Romano AA, Atwood SJ. Accidental bromocriptine ingestion in childhood. J Pedi-atr 1984;105:839-840.
Warren DE, Nakfoor E. Acute overdose of bromocriptine. Drug Intell Clin Pharm 1983; 17:374.
Mack RB. Mairzy doats and dozy doats and a kiddle eat almost anything. Bromocriptine (Parlodel) overdose. NC Med J 1988;49:17-18.
Canterbury RJ, Haskins B, Kahu N, Saathoff G, Yazel JJ. Postpartum psychosis induced by bromocriptine. South Med J 1987;81:1463-1464.
Perovich RM, Lieberman JA, Fleischhacker WW, Alvir J. The behavioral toxicity of bromocriptine in patients with psychiatric illness. J Clin Psychopharmacol 1989;9:417-477.
Iffy L, Tentlone W, Frisole G. Acute myocardial infarction on the puerperium in patients receiving bromocriptine. Am J Obstet Gynecol 1986;155:371-372.
Bakht FR, Kirshon B, Baker T, Cotton DB. Postpartum cardiovascular complications after bromocriptine and cocaine use. Am J Obstet Gynecol 1990;162:1065-1066.
Maurel C, Abhay K, Schaeffer A, Lange F, Castot A, Melon E. Acute thrombotic accidents in the postpartum period in a patient receiving bromocriptine. Crit Care Med 1990;118:1180-1181.
Ruch A, Duhring JL. Obstet Gynecol 1989;74:448-451.
McElvaney NG, Wilcox PG, Chung A, Fleetham JA. Phenopulmonary disease during bromocriptine treatment of Parkinson’s disease. Arch Intern Med 1988;148:2231-2236.
Kains J-PD, Hardy J-C, Chevalier C, Collier A. Retroperitoneal fibrosis in two patients with Parkinson’s disease treated with bromocriptine. Acta Clin Belg 1990;45:306-310.
Auster SM, El-Hayek A, Comianos M, Tamulonis DJ. Mitral valve disease associated with long-term ergotamine use. South Med J 1993;86:1179-1181.
Redfield MM, Nicholson WJ, Edward WD, Tajik AJ. Valve disease associated with ergot alkaloid use. Echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50-52.
Gill R, Key JA. High-performance liquid chromatography system for the separation of ergot alkaloids with applicability to the analysis of illicit lysergide (LSD). J Chromatogr 1985;346:423-427.
Feng N, Minder El, Grampp T, Vonderschmitt DJ. Identification and quantification of ergotamine in human plasma by gas chromatography-mass spectrometry. J Chromatog 1992;575:289-294.
Edwards RJ, Fulde GWO, McGrath MA. Successful limb salvage with prostaglandin infusion: a review of ergotamine toxicity. Med J Aust 1991; 155: 825— 827.
Chin D, Wei-liang С. Auricular tachycardia with auric-ulo-ventricular block in oleander leaf poisoning. Chin Med J 1957;75:74-77.
Spevak L. Dva slucaja trovanja cajem od oleanderovog lisca. Arh Hig Rada 1975;26:147-150.
Osterloh J, Harold S, Pond S. Oleander interference in the digoxin radioimmunoassay in a fatal ingestion. JAMA 1982;247:1596-1597.
Haynes BE, Bessen HA, Wrightman WD. Oleander tea: herbal draught of death. Ann Emerg Med 1985; 14:350— 353.
Cheung K, Hinds JA, Duffy P. Detection of poisoning by plant origin cardiac glycoside with the Abbott TDx analyzer. Clin Chem 1989;35:295-296.
Shumaik GM, Wu AW, Pine AC. Oleander poisoning: treatment with digoxin-specific FAB antibody fragments. Ann Emerg Med 1988;17:732-735.
Safadi R, Ley I, Amitai Y, Caraco Y. Beneficial effect of digoxin-specific Fab antibody fragments in oleander intoxication. Arch Intern Med 1995;155:2121-2125.
Furbee RB, Curry SC, Kunkle DB: Ingestion of Argyreia nervosa (Hawaiian Baby Woodrose) seeds. Vet Hum Toxicol 1991 ;33.
Hong CY, Huang JJ, Wu О. The inhibitory effect of gos-sypol on human sperm motility: relationship with time, temperature and concentration. Hum Toxicol 1989;8:49-51.
Reidenberg MM, Flack MR, Pyle RG, Mullens NM, Lorenzo B, Wu YW et al. Gossypol treatment of metastatic adrenal cancer. Clin Pharmacol Ther 1992;51:145.
Bernardi LC, Goldblatt LA, Liener IE, ed. In: Toxic constituents of plant foodstuffs. 2nd ed. New York: Academic Press, 1980; pp. 184—230.
Wu D-F, Yu Y-W, Tang Z-M, Wang M-Z. Pharmacokinetics of (4—)-, (+)-, and (-)- gossypol in humans and dogs. Clin Pharmacol Ther 1986;30:613-618.
Wu D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs 1989;38:333-341.
Wang MZ, Wu DF, Yu YW. High-performance liquid chromatography with electrochemical detection of gossypol in human plasma. J Chromatogr (Biomed Appl) 1985;343:387-391.
Diammo X, Xiao-Lu W, Jun-bao Z, Hua-Cu C. Effects of gossypol on phorbol ester-calcimycin-induced prostaglandin synthesis by macrophages. Chinese Med J 1991;104:321-325.
Larrey D, Vial Т, Pauwels A, Castot A, Biour М, David М et al. Hepatitis after germander (Teucrium chamae-drys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992;117:129-132.
De Smet PAGM. Health Risks of herbal remedies. Drug Safety 1995;13:81-93.
Huxtable RJ: The myth of beneficent nature. The risks of herbal preparations. Ann Intern Med 1992;117:165— 166.
MacGregor FB, Abernethy VE, Dahabras S, Cobden I, Hayes PC. Hepatotoxicity of herbal remedies. Br Med J 1989;299:1150-1157.
Chaparral. Lawrence Review of Natural Products. St. Louis: Facts and Comparisons, August 1993, pp. 1—2.
Nightingale SL Public warning about herbal product "chaparral." JAMA 1993;269:328.
CDC. Chapparal-induced toxic hepatitis in California and Texas 1992. MMWR 1992;41:812-814.
Katz M, Saibil F. Herbal hepatitis: subacute hepatic necrosis secondary to chapparal leaf. J Clin Gastroenterol 1990;12:203-206.
Ridker PM, McDermott WW. Comfrey herb tea and hepatic occlusive disease. Lancet 1989;1:657-658.
Abbott PJ. Comfrey: assessing the low-dose health risk. Med J Aust 1988;149:678-682.
Winship KA. Toxicity of comfrey. Adverse Drug React Toxicol Rev 1991;10:47-59.
Huxtable RJ. Activation and pulmonary toxicity of pyr-rolizidine alkaloids. Pharmacol Ther 1990;47:371-389.
Roulet M, Laurini R, Rivier L, Calane A. Hepatic venoocclusive disease in newborn infant of a woman drinking herbal tea. J Pediatr 1988;112:433-436.
Bach N, Thung SN, Schaffner F. Comfrey herb tea-induced hepatic veno-occlusive disease. Am J Med 1989;87:97-99.
Cui J, Garle M, Eneroth P, Bjorkhem 1. What do commercial ginseng preparations contain? The Lancet 1994;344:134.
Koren G, Randor S, Martin S, Danneman D. Maternal ginseng use associated with neonatal androgenization. JAMA 1990;264:2866.
Basett IB, Pannowitz DL, Barnetson RS-C. A comparative study of tea-tree oil versus benzoyl peroxide in the treatment of acne. Med J Aust 1990;153:455-458.
Koren G. Maternal use of ginseng and neonatal androgenization. JAMA 1991 ;265:1828.
Frank BS, Michelson WB, Panter KE, Gardner DR. Ingestion of poison hemlock (Conium maculatum). West J Med 1995;163:573-574.
Holstege DM, Seiber JN, Galey FD. Rapid multiresidue screen for alkaloids in plant material and biological samples. J Agricult Food Chem 1995;43:691-699.
Siegel RK. Ginseng abuse syndrome: problems with the panacea. JAMA 1070;241:1614-1615.
Hornfeldt CS. Malaleuca oil poisoning. A case report. Vet Hum Toxicol 1993;35:329.
Segelman AB, Segelman FP, Karliner J et al. Sassafras and herb tea. Potential health hazards. JAMA 1976;236:477.
Grande GA, Dannewitz SR. Symptomatic sassafras oil ingestion. Vet Hum Toxicol 1987;29:463.
Haines JD Jr. Sassafras tea and diaphoresis. Postgrad Med 1991;9:75-76.
Pilapil VR. Toxic manifestations of cinnamon oil ingestion in a child. Clin Pediatr 1989;28:276.
Perry PA, Dean BS, Krenzelok EP. Cinnamon oil abuse by adolescents. Vet Hum Toxicol 1990;32:162-163.
Mant AK. Association proceedings. VI. A case of poisoning by oil of citronella. Med Sci Law 1961 ;112:170— 171.
Temple WA, Smith NA, Beasley M. Management of oil of citronella poisoning. Clin Toxicol 1991;29:257-262.
Hartnoll G, Moore D, Douek D. Near fatal ingestion of oil ofcloves. Arch Dis Child 1993;69:392-393.
Lane BW, Ellenhorn MJ, Vulbert TV, McCarron M. Clove oil ingestion in an infant. Hum Exp Toxicol 1991;10:291-294.
Olin BD, ed. Feverfew. The Lawrence review of natural products. St. Louis: Facts and Comparisons, June 1990.
Baldwin CA, Anderson LP, Phillipson JD. What pharmacists should know about feverfew. Pharm J 1987;239:237-238.
Heptinstall S. Feverfew — an ancient remedy for modem times. J R Soc Med 1988;81:373-374.
Murphy JJ, Heptinstall S, Mitchell JRA. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;2:189-192.
Johnson ES, Kadam MP, Anderson D, Jenkinson PC, Dewdrey RB, Blowers SD. Investigation of possible genotoxic effects of feverfew in migrans patients. Hum Toxicol 1987;6:5333-5334.
Kudzu: Lawrence review of natural products. St. Louis: Facts and Comparisons, June 1994.
Anonymous. Kudzu extract shows potential for moderating alcohol abuse. Am J Hosp Pharm 1994;51:750.
Spoerke DG, Murphy MA, Wruk KM, Rumack BH. Five cases of Thermopsis poisoning. Clin Toxicol 1988;26:397-406.
Lowen RJ, Alam FKA, Edgar J A. Lupin bean toxicity. Med J Aust 1995;162:256-257.
Guar gum. The Lawrence review of natural products. St. Louis: Facts and Comparisons, November 1990.
Lewis JH. Esophageal and small bowel obstruction from guar gum-containing "diet pills." Analysis of 26 cases reported to the Food and Drug Administration. Am J Gastroenterol 1992;87:1424-1428.
Phillips RW, Moses FR. Sunflower seed syndrome: a prickly proctological problem. Ann Emerg Med 1991;20:1049-1050.
Melchreit R, McGowan G, Hyams IS. "Colonic crunch" sign in sunflower-seed bezoar. N Engl J Med 1984;310:1748-1749.
Cloonan CC, Kleinschmidt K, Gatrell C. Rectal bezoar from sunflower seeds. Ann Emerg Med 1988; 17:161 — 162.
Folpini A, Furfori Р. Colchicine toxicity — clinical features and treatment. Massive overdose case report. Clin Toxicol 1995;33:71-77.
Terrier N, Urtizberrea M, Scherrmann JM. Influence of goat colchicine-specific antibodies on murine colchicine disposition. Toxicology 1989;59:11-22.
Terrier N, Urtizberrea M, Scherrmann JM. Reversal of advanced colchicine toxicity in mice with goat colchicine-specific antibodies. Toxicol Appl Pharmacol 1990;104:504-510.
Baud FJ, Sabouraud A, Vicaut E, Taboulet P, Lang J, Bismuth C, Rouzioux JM, Scherrmann J-M. Brief report. N Engl J Med 1995;332:642-645.
Sabouraud A, Urtizberrea M, Scherrmann JM, Caraux J, Baud FJ, Bismuth C. First pharmacokinetic investigation of colchicine-specific FAB fragments in one case of human colchicine poisoning. Eur Assoc Pois Cent Clin Toxicol XIV Congress, Istanbul, May 24—27, 1992 (abstract Pl 1).
Scherrmann JM, Subouraud A, Urtizberea M, Rouzioux J, Lang J, Baud F, Bismuth C. Clinical use of colchicinespecific Fab fragments in colchicine poisoning. Vet Hum Toxicol 1992;34:334.
Katz R, Chuang LC, Sutton JD. Use of granulocyte colony-stimulating factor in the treatment of pancytopenia secondary to colchicine overdose. Ann Pharmacother 1992;26:1087-1088.
Frohme D, Pfander HJ. A colour atlas of poisonous plants. Stuttgart Wolfe Publishing, 1984; p 64.
Georgiou M, Siandidou L, Hatzis T, Papadatos J, Kout-selinis A. Hepatotoxicity due to Atractylis gummifera L. Clin Toxicol 1988;26:487-493.
Nogue S, Sanz P, Botey A, Esforzado N, Blanche C, Alvarez L. Insufficance renale aigue due a une intoxication par le chardona glu (Atractlyis gummifera). Presse Medicale 1992;21:130.
Spiller НА, Willias DB, Gorman SE, Sanftleban J. Retrospective study of mistletoe ingestion. Clin Toxicol 1995;33:475-486 (abstract 156).
Krenzelok EP, Jacobsen TD, Aronic JM. Mistletoe exposures — the kiss of death? Clin Toxicol 1995;33:475— 486 (abstract 150).
Rosling Н. Cassava toxicity and food security. 2nd ed. UNICEF, 1988, pp. 1-40.
Osuntokun RO, Durooju JE, McFarlane WJ. Plasma aminoacids in the Nigeria nutritional ataxic neuropathy. Br Med J 1968;3:647-649.
Rauws AG, Oiling M, Timmerman A. The pharmacokinetics of amygdalin. Arch Toxicol 1982;49:311-319.
Moertel CG, Ames MM, Kovach JS et al. A pharmacologic and toxicological study of amygdalin. JAMA 1981;245:591-594.
Sadoff L, Fuchs K, Hollander J. Rapid death associated with laetrile ingestion. JAMA 1978;239:1582.
Humbert JR, Tress JH, Braico KT. Fatal cyanide poisoning. Accidental ingestion of amygdalin. JAMA 1977;238:482.
Townsend WA, Boni B. Cyanide poisoning from ingestion of apricot kernels. Morbid Mortal Week Rep 1975;24:427.
Rubino MJ, Davidoff F. Cyanide poisoning from apricot seeds. JAMA 1979;241:359.
Shragg TA, Albertson ТЕ, Fisher CJ. Cyanide poisoning after bitter almond ingestion. West J Med 1982;136:65— 69.
Sayre JW, Kaymakcalan S. Cyanide poisoning of apricot seeds among children in central Turkey. N Engl J Med 1964;270:1113-1115.
Smith FP, Butler TP, Cohan S et al. Laetrile toxicity: a report of two cases. JAMA 1977;238:1361.
Hall AH, Linden CH, Kulig KW et al. Cyanide poisoning from laetrile ingestion: role of nitrite therapy. Pediatrics 1986;78:269-272.
Cordell GA, Araujo DE. Capsaicin: identification, nomenclature and pharmacotherapy. Ann Pharmacother 1993;27:330-331.
Don PC. Topical capsaicin for treatment of neuralgia associated with herpes zoster infection. J Am Acad Dermatol 1988;18:1135-1136.
Kurkcuoglu N, Alaybeyi F. Topical capsaicin for psoriasis. Br J Dermatol 1990;123:549-550.
Tandan R, Lewis G, Fried T, Kallal J. Safety of topical capsaicin in diabetic neuropathy. Neurology 1990;40(Suppl l):160.
Ross DR, Varepapa RJ. Treatment of painful diabetic neuropathy with topical capsaicin. N Engl J Med 1989;321:474-475.
Levy DM, Abraham RR, Tomkinson DR. Topical capsaicin in the treatment of painful diabetic neuropathy. N Engl J Med 1991 ;324:776.
Breneman DL, Cardose JS, Kaufmann PS, Lather RM. Topical capsaicin for treatment of pruritus related to hemodialysis. Clin Pharmacol Ther 1989;45:188.
Weintraub M, Golik A, Rubio A. Capsicum for treatment of post-traumatic amputation stump pain. Lancet 1990;336:1003-1004.
Kakas JF Jr. Topical capsaicin induces cough in patients receiving ACE inhibitors. Ann Allergy 1990;65:322.
Blanc P, Liu D, Juarez C, Boushey HA. Cough in hot pepper workers. Chest 1991;99:27-32.
Tominack RL, Spyker DA. Capsicum and capsaicin — review: case report of the use of hot peppers in child abuse. Clin Toxicol 1987;25:591-601.
Jones LA, Tandberg D, Troutman WG. Household treatment for "chili burns" of the hand. Clin Toxicol 1987;25:483-491.
Williams SR, Clark RF, Dunford JW. Contact dermatitis associated with capsaicin. Hunan hand syndrome. Ann Emerg Med 1995;25:713-715.
Cohle SD, Trestrail JD III, Graham MA, et al. Fatal pepper aspiration. Amer J Dis Child 1988; 1242:633.
Sheahan K, Page DV, Kemper T, Suarez R. Childhood sudden death secondary to accidental aspiration of black pepper. Am J Forensic Med Pathol 1988;9:51-57.
El-Mofty MM, Soliman AA, Abdel-Gawad AF, Sakr SA, Schwairib MA. Carcinogenicity testing of black pepper (Piper nigrum) using the Egyptian toad (Bufo regularis) as a quick biological test animal. Oncology 1988;45:247-252.
Myers BM, Smith JL, Graham DY. Effect of red pepper and black pepper on the stomach. Am J Gastroenterol 1987;82:211-214.
Sir John Harrington: The Englishman’s Doctor. 1609.
Olin BR, ed. The Lawrence review of natural products. St. Louis; Facts and Comparisons. Garlic. January 1988, pp. 1—2.
Parish RA, McIntire S, Heimbach DM. Garlic burns: a naturopathic remedy gone awry. Pediatr Emerg Care 1987;3:258-260.
Kleijnen J, Knipschild P, Ter Piet G. Garlic, onions and cardiovascular risk factors. A review of the evidence for human experiments with emphasis on commercially available preparations. Br J Clin Pharmacol 1989;28:535-544.
Caporaso N, Smith SM, Eng RHK. Antifungal activity in human urine and serum after ingestion of garlic (Allium sativum). Antimicrobial Agents Chemother 1983;23:700-702.
Bordia A. Effect of garlic on blood lipids in patients with coronary heart disease. Am J Clin Nutr 1991;34:2100.
Ariga T, Oshiba S, Tamad T. Platelet aggregation inhibition in garlic. Lancet 1981;1:150-151.
Aier W, Eiher A, Hertkorn E, Hoehfeld E, Koehnle U, Lorenz A, Mader FV. Garlic therapy: hypertension and hyperlipidemia: garlic helps in mild cases. Br J Clin Pract 1988;44(Suppl 69).
LybargerJA, Gallagher JS, Pulver DW, Litwin A, Brooks S, Bernstein IL. Occupational asthma induced by inhalation and ingestion of garlic. J Allergy Clin Immunol 1982;69:948-957.
Editor. Well loved he garleek, oynons. Lancet 1989;2:1409-1410.
Persaud TVN. Foetal abnormalities caused by the active principle of the fruit of Blighia sapida (Ackee). West Indian Med J 1967;16:193-197.
Golding J, Foster-Williams K, Coard K, Ashley D. A cluster of central nervous system defects in Jamaica. Hum Exp Toxicol 1990;9:13-16.
Duffield AM, Lidgard RO. Analysis of Kava resin by gas chromatography and electron impact and negative ion chemical ionization mass spectrometry. New trace constituents of Kava resin. Biomed Environ Mass Spectrom 1986;13:621-626.
Droege H, Walter K, Huber HD, Knoch A, Gay S, Stanislaus F. Preliminary results of Kavain on pharmacokinetics and bioavailability from Neuronika in man. Eur J Drug Metab Pharmacokin 1990; 15:26.
Droege H, Walter K, Huber HJ, Jank P, Schmoll H, Stanislaus F. Metabolic profile of Kavain in human plasma. Eur J Drug Metab Pharmacokin 1990; 15: 28.
Koppel C, Tenczer J. Mass spectral characterization of urinary metabolites of D,L-Kawain. J Chromatography (Biomed Appl) 1991;562:207-210.
Editor. Kava. Lancet 1988;1:258-259.
Mathews JD, Riley MD, Fejo L, Munoz E, Milns MR, Gardner ID et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med J Aust 1988;148:548-555.
Ruze P. Kava-induced dermopathy: a niacin deficiency? Lancet 1990;335:1442-1445.
Schelovsky L, Raffauf C, Jendroska K, Poewe W. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry 1995;58:639-640.
Olin BR, ed. The Lawrence review of natural products. St. Louis: Facts and Comparisons. Ginkgo. February 1988.
Gingko biloba extract: over 5 million prescriptions a year. (West Germany). Lancet 1989;2:1513-1514.
Hofferberth B. Effect of Ginkgo biloba extract on neurophysiological and psychomatic measurement results in patients with cerebro-organic syndrome. A double-blind study versus placebo. Arzneimittel-forsch/Drug Res 1989;39:918-919.
Mate. Lawrence review of natural products. St. Louis: Facts and Comparisons, April 1988.
De Stefani E, Munoz N, Esteve J, Vasallo A, Victora CG, Teuchmann S. Mate drinking, alcohol, tobacco, diet and esophageal cancer in Uruguay. Cancer Res 1990;5:426— 431.
Arnold WN. Vincent van Gogh and the thujone connection. JAMA 1988;260:3042-3044.
Arnold WN. Absinthe. Sci Am 1989;260(6): 112— 117.
Wormwood. Lawrence review of natural products. St. Louis: Facts and Comparisons, April 1991.
Ashby J, Styles JA, Boyland E. Betel nuts, arecaidine, and oral cancer. Lancet 1979; 1:112.
Wilcox G, Wahlqvist ML, Burger HG, Medley G. Oestrogen effects of plant foods in postmenopausal women. Br Med J 1990;301:905-906.
Farnsworth NR, Bingel AS, Cordell GA, Crane FA, Fong HHS. Potential value of plants as sources of new antifertility agents. II. J Pharm Sci 1975;64:714.
Lewis WH, Elvin-Lewis MPF. Medical botany. Plants affecting man’s health. New York: John Wiley, 1977.
Frohne D, Pfander HJ. A colour atlas of poisonous plants. London: Wolfe, 1983; pp. 129—130.
Hasler J, Lee S. Acute hemolytic anemia after ingestion of fava beans. Am J Emerg Med 1992;! 1:560—561.
Cooper RA, Bunn HF. Hemolytic anemias. In: Wilson JD, Braunwald E, Isselbacher KJ, Petersdorp RG, Martin JB, Fauci AS, Root RK, eds. Harrison’s principles of internal medicine. 12th ed. New York: McGraw-Hill, 1991; p.1542.
Spoerke D, Evans В, Linaburg В. The hidden hazards in house and garden plants. Missoula, MT: Pictorial Histories, 1991; p. 75.
Spencer PS. Guam ALS/parkinsonism—dementia. A long-lasting neurotoxic disorder caused by "slow tox-in(s)" in food? Can J Neurol Sci 1987;14:347-357.
Editorial. A poison tree. Lancet 1987;2:947-948.
Duncan MW, Kopin IJ, Garruto MM, Lavine L, Markey SP. 2-amino-3-(methylamino) propionic acid in cycad-derived form is an unlikely cause of amyotrophic lateral sclerosis/parkinsonism. Lancet 1988;2:631 — 632.
Duncan MW, Steele JC, Kapin IJ, Markey SR. 2-ami-no-3-(methylamino) propionic acid (BMAA) in cycad flour: an unlikely cause of amyotrophic lateral sclerosis and parkinsonism—dementia (ALS-PD) of Guam. Neurology 1990;40:767-772.
Duncan MW, Kopin IJ, Crowley JS, Jones SM, Markey SP. Quantification of the putative neurotoxin 2-amino-3-(methylamino) propionic acid (BMAA) in Cycadales: analysis of the seeds of some members of the family Cycadaceae. J Anal Toxicol 1989;13:169— 175.
Hall WTK. Cycad (Zamia) poisoning in Australia. Aust Vet J 1987;64:149-150.
Meier КН, Hemmich RS. Bradycardia and complete heart block after ingestion of rhododendron tea. Vet Hum Toxicol 1992;34:351.
Yavuz H, Ozel A, Akkus I, Erkul I.Honey poisoning in Turkey. Lancet 1991;337:789-790.
Biberoglu K, Komsuoglu B, Biberoglu S. Transient Wolff—Parkinson—White syndrome during honey intoxication. Isr J Med Sci 1988;24:253-254.
Willis GA. Common poisoning by plants. Medicine. North America. December 14, 1990; pp. 1753—1759.
Spoerke DG, Hall AH. Plants and mushrooms of abuse. Emerg Med Clin North Am 1990;8:579-593.
Henry JA. Eur Assoc Pois Cont Centers Newsletter. May 1985.
Abuelo JG. Renal failure. Arch Intern Med 1990;150:505-510.
CDC. MMWR 1995;44:42-44.
Toxic plant substances. The chemistry of poisonous and medicinal plants. In: Blackwell WH, ed. Poisonous and medicinal plants. Englewood Cliffs, NJ: Prentice-Hall, 1990; pp. 34-52.
Fassett DW, Chap IC. Oxalates in toxicants occurring naturally in foods. 2nd ed. Washington, DC: National Academy of Sciences, 1973.
Gopalakrishnakone P. A computer based colour-photo database system for dangerous animals and plants. Academic and public information networks. Toxicon 1990;28:1285-1292.
Metsger DA. Microcomputer-assisted telephone identification of plants in response to Poison Control calls. Clin Toxicol 1990;28:135-157.
Spoerke DG, Spoerke SE, Rumack BH. Berry identification using a modified botanic key. Vet Hum Toxicol 1988;30:260-264.
Wagstaff DJ, Raisbeck M, Wagstaff AT. Poisonous plant information system (PPIS). Vet Hum Toxicol 1989;31:237-238.
Wisepelaere C. Identification of berries with a microcomputer. Vet Hum Toxicol 1987;29(Suppl 2): 149.
Wagstaff DJ, Wagstaff AT, Goshorn JC. A poisonous plant file in Toxline. Toxicon 1989;27:259-263.
Murray V, Knott C (National Poisons Unit, Guy’s Hospital, London) and Leon C (Royal Botanic Gardens, Kew). An image-based computerized identification system for poisonous plants and fungi. (A pilot study in the United Kingdom).
Larkin T. Unsafe herbs. FDA Consumer 1993;14:5-10.
Ridker PM. Potential toxicity of herbal teas. Arch Environ Health 1987;42:133-136.
Kassler WJ, Blanc P, Greenblatt P. Use of medicinal herbs by human immunodeficiency virus infected patients. Arch Intern Med 1991;151:2281-2289.
D’Arcy PF. Adverse reactions and interactions with herbal medicines. I. Adverse reactions. Adverse Drug React Toxicol Rev 1992;10:189-208.
Huxtable RJ. The harmful potential of herbal and other plant products. Drug Safety 1990;5(Suppl 1):126—136.
But P P-H. Need for correct identification of herbs in herbal poisoning. Lancet 1993;341:637.
Chapparal-induced toxic hepatitis in California and Texas 1992. MMWR 1992;41:812-814.
Katz M, Saibil F. Herbal hepatitis: subacute hepatic necrosis secondary to chapparal leaf. J Clin Gastroenterol 1990;12:203-206.
Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M et al. Hepatitis after Germander (Teucrium chamae-drys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992;117:129-132.
Ogzewalla CD, Bonfiglio JF, Sigell LT. Common plants and their toxicity. Pediatr Clin North Am 1987;34:1557-1598.
Bisset NG. Arrow and dart poisons. J Ethnopharmacol 1989;25:1-41.
Bisset NG. Arrow poisons in China. II. Aconitum—botany, chemistry and pharmacology. J Ethnopharmacol 1981;4:247-336.
D’Arcy PF. Adverse reactions and interactions with herbal medicines. 1. Adverse reactions. Adverse Drug React Toxicol Rev 1991;10:189-208.
D’Arcy PF. Adverse reactions and interactions with herbal medicine. 11. Drug interactions. Adverse Drug React Toxicol Rev 1993;12:147-162.
Murray V, Perharic-Walton L. Toxicological problems resulting from exposure to traditional medicines and food supplements. National Poisons Unit, Guy’s Hospital, St. Thomas Street, London, SEI, 9RT (Tel. 071-639-9653) and Simpson G, Edwards N. National Poisons Information Service, Avonley Road, London SEI, 45ER (Tel 071-635-9191).
Kirkland J, Matthews HF, Sullivan CW III, Baldwin K, eds. Herbal and magical medicine. Traditional healing today. Durham, NC: Duke University Press, 1992; pp. 235.
Perharic L, Shaw D, Murray V. Toxic effects of herbal medicines and food supplements. Lancet 1993;342:180—181.
Joubert PH, Mathibe L. Acute poisoning in developing countries. Adverse Drug React Acute Poisoning Rev 1989;8(3): 165—178.
Goldman L, ed. Cross cultural medicine in MKSAP 10: General Internal Medicine. American College of Physicians, 1994; p. 142.
De Smet PAGM. Health risks of herbal remedies. Drug Safety 1995;13:81-93.
Mofenson HC, Caraccio TR, Brody G, Greensher J, Leggiadro R, Mancini R, Sherman J. Herbal products. Poison Perspective for Health Professionals 1994; 13:54— 62.
Espinoza ЕО, Mann M-J, Bleasdell В. Arsenic and mercury in traditional Chinese herbal balls. N Engl J Med 1995;333:804-805.
Nelson L, Shih R, Hoffman R. Aplastic anemia induced by an adulterated herbal preparation. Clin Toxicol 1995;33:467-470.
Martindale: The extra pharmacopoeia. 30th ed. London: The Pharmaceutical Press, 1993, p. 1410.
Peacock S, Murray V, Turton C. Respiratory distress and royal jelly. Br Med J 1995;310:1472.
Bullock RJ, Rohan A, Straatmans JA: Fatal royal jelly-induced asthma. Med J Aust 1994; 160:44.
Abt AB, Oh JY, Huntington RA. Chinese herbal medicine-induced acute renal failure. Arch Intern Med 1995;155:211.
Parry C, Easton J. Kohl: a lead-hazardous eye make-up from the Third World to the First World. Environ Health Perspect 1991;94:121-123.
Ali A, Smales O, Aslam M. Surma and lead poisoning. Br Med J 1978;2:915-916.
Snodgrass G, Ziderman D, Gulati V, Richards J. Cosmetic plumbism. Br Med J 1973;27:230.
Pontifex AH, Gary AK. Lead poisoning from an Asian Indian folk remedy. Can Med Assoc J 1985; 133:1227— 1228.
Zaloga CP, Deal J, Spurting T, Richter J, Chernow B. Unusual manifestations of arsenic intoxication. Am J Med Sci 1985;289:210-214.
Aslam M, Healy MA, Daris SS, Ali AR. Surma and blood lead in children. Lancet 1980;1:568-569.
Dolan G, Jones AP, Blumsohn A, Reilly JT, Brown MJ. Lead poisoning due to Asian ethnic treatment for impotence. J R Soc Med 1991;84:630-631.
Lead poisoning with the use of Asian medicine. Pharmacy J 1991;5:248.
CDC. Cadmium and lead exposure associated with pharmaceuticals imported from Asia—Texas. MMWR 1989;38:612-614.
Fernando A, Healy M, Aslam M, Davis S, Hussein A. Lead poisoning and traditional practices: the consequences for world health. A study in Kuwait. Public Health 1981;95:250-260.
Abdullah MA. Lead poisoning among children in Saudi Arabia. J Trop Med Hyg 1984;87:67-70.
Van der Gusti S. Tetracycline against children’s diarrhea. A note from South Asia, Africa, Middle East. Cameroon, Amsterdam (CASA) 1985.
But PP-H. Need for correct identifying of herbs in herbal poisoning. Lancet 1993;341:637.
Tomlinson B, Leung SKF, Chan TYK, Critchley JAJH. Adverse effects and usage of Chinese traditional medicine in Hong Kong. Br J Clin Pharmacol 1991;31:6115.
Goldman JA. Chinese herbal medicine: Camouflaged prescription antiinflammatory drugs, corticosteroids and lead. Arthritis Rheum 1991 ;31:1207.
Segasothy M, Samad S. Illicit herbal preparation containing phenylbutazone causing analgesic nephropathy. Nephron 1991;59:166-167.
Gertner E, Marshall PS, Filandrinos D, Potek AS, Smith TM. Complications resulting from the use of Chinese herbal medications containing undeclared prescription drugs. Arthritis Rheum 1995;38:614-617.
Mitchell-Higgs CAV, Conway M, Cassar J. Herbal medicine as a cause of combined lead and arsenic poisoning. Hum Exp Toxicol 1990;9:1994-195.
Balint GA, Balint EE. On the medico-social aspects of khat Catha edulus: chewing habit. Hum Psychopharma-col 1994;9:125-128.
Otieno LS, McLigeyo SO, Luta M. Acute renal failure following the use of herbal remedies. East Afr Med J 1991;61:993-998.
Hutchings A, Terblanche SE. Observations on the use of some known and suspected toxic Liliiflore in Zulu and Xhosa medicine. S Afr Med J 1989;75:62-69.
Yesilada E, Honda G, Sezik E, Tabata M, Goto K, Ikeshino Y. Traditional medicine in Turkey. IV. Folk medicine in the Mediterranean subdivision. J Ethnop-harmacol 1993;39:31-38.
Akintonwa A, Mabadeje AFB, Odutola TA. Fatal poisonings by copper sulfate ingested from "spiritual water." Vet Hum Toxicol 1989;31:453-454.
El-Ansary EH, Ahmed MEK, Clague HW. Systemic toxicity of para-phenylenediamine. Lancet 1983;1:1341.
Ashraf W, Dawling S, Farrow J. Systemic para-phenylenediamine (PPD) poisoning: a case report and review. Hum Exp Toxicol 1994;13:167-170.
Yagi H, El Hind AM, Khalil SI. Acute poisoning from hair dye. East Afr Med J 1991;68:404-411.
Lifshits M, Yagupsky P, Sofen S. Fatal paraphenylenediamine (hair dye) intoxication in a child resembling Ludwig’s angina. Clin Toxicol 1993;31:653-656.
Suliman SM, Homeida M, Aboud OI. Paraphenylenediamine induced acute tubular necrosis following hair dye ingestion. Hum Toxicol 1983;2:633-635.
Schneider JA, Sigg EB. Neuropharmacological studies on ibogaine, an indole alkaloid with central stimulant properties. Ann NY Acad Sci 1956;66:766-776.
EndabuseR (Ibogaine hydrochloride). NDA International Inc, 46 Oxford Place, Staten Island, NY 10 301.
Isbell H. USPHS Hospital, Addiction Research Center, Lexington, KY. Preliminary trials with ibogaine, November 1956. Personal communication to Ciba.
Dhahir HI. A comparative study on the toxicity and serotonin. Doctoral Dissertation. University Microfilm International 71-25-34. Ann Arbor, MI. Indiana University, PhD. 1971. Pharmacology, p. 151.
Maissoneuve IM, Keller RW, Glick SD. Interactions between ibogaine, a potential anti-addictive agent and morphine: an in vivo microdialysis study. Eur J Pharmacol 1991;199:35-42.
Schneider JA, Rinhart RR. Analysis of the cardiovascular action of ibogaine hydrochloride. Arch Int Pharmacodyn 1957;110:92-102.
.O’Hearn EO, Molliver ME. Degeneration of Purkinje cells in parasagittal zones of cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 1993;55:363-370.
CDC. Lead poisoning associated with use of traditional ethnic remedies — California, 1991 — 1992. MMWR 1993;24:521-524.
Steyn JM, Hundt HKL. GC/MS identification and quantitation of cantharidin in post-mortem serum. Uges DRQ, deZeeuw RA, eds. Proc. 25th International Meeting, Int Assoc Forensic Toxicol. Groningen, June 27, 1988.
Hundt HLK, Steyn JM, Wagner L. Post-mortem serum concentration of cantharidin in a fatal case of cantharides poisoning. Hum Exp Toxicol 1990;9:35-40.
Lecritier MA. A case of cantharidin poisoning. Br Med J 1954;2:1399-1400.
Craven JD, Polak A. Cantharidin poisoning. Br Med J 1954;2:1386-1388.
Nickoils LC, Teare D. Poisoning by cantharidin. Br Med J 1954;2:1384-1386.
Kok-Choi C, Hee-Ming L, Bobby SSF, David YCP. A fatality due to the use of cantharides from Mylabris Phalerata as an abortifacient. Med Sci Lau 1990;30:336-340.
Cantharidin. The Merck Index. 9th ed. Rahway, NJ: Merck and Co., p. 222.
Till JS, Majmuder BN. Cantharidin poisoning. South Med J 1981;74:444-447.
Harrisberg J, Deseta JCH, Cohen L, Temlett J, Milne FJ. Cantharidin poisoning with neurological complications. So Afr Med J 1984;65:614-615.
Edwards WC, Edwards RM, Ogden L, Whaley M. Cantharidin-Content of two species of Oklahoma blister beetles associated with toxicosis in horses. Vet Hum Toxicol 1989;31:442-444.
Andrews CH. A case of poisoning by cantharidin. Lancet 1921;2:654-655.
Rosin RD. Cantharides intoxication. Br Med J 1967;4:33.
Graziano MJ, Waterhouse AL, Casida JE. Cantharidin poisoning associated with specific binding site in liver. Biochem Biophys Res Commun 1987;149:79-85.
Weakley DR, Eikenbinder JM. The mechanics of cantharidin acantholysis. J Invest Dermatol 1962;39—45.
Oaks WB, DiTunno JF, Magnani T, Levy HA, Mills LC. Cantharidin poisoning. Arch Intern Med 1960; 105:574— 582.
Avery JS. A case of acute cantharides poisoning. Lancet 1908;2:800.
Tenschert W, Behrenbeck T, Rolf N, Ahlmann J, Win-terberg B, Heepe J et al. Kantharidin—Intoxikation. Fortschr Med 1987;105:686-688.
Fisch HP, Reutter FW, Gloor F. Schadigung der nieren und der ableitenden harnwege durch kantharidin. Schweiz Med Wochenschr 1978;108:1664-1667.
Ewart WB, Rabkin SW, Mitenko PA. Poisoning by cantharides. Can Med Assoc J 1978;118:1199.
Presto AJ, Muecke EC. A dose of Spanish fly. JAMA 1970;214:591-592.
Perhark L, Shaw D, Murray V. Toxic effects of herbal medicines and food supplements. Lancet 1993:342:180— 181.
China: attack on bogus drugs. Lancet 1992;340:1243 (editorial).
Winship KA. Toxicity of lead: a review. Adverse Drug React Acute Pois Rev 1989;8:117-152.
Lightfoote J, Blair HJ, Cohen JP. Lead intoxication in an adult caused by Chinese herbal medication. JAMA 1977;238:1539.
Levitt C, Paulson D, Duvall К et al. Folk remedy-associated lead poisoning in Hmong children. JAMA 1983;250:3149-3150.
Chan H, Yeh Y-Y, Billmeier GJ, Evans WE, Chan H. Lead poisoning from ingestion of Chinese herbal medicine. Clin Toxicol 1977;10:273-281.
Kang-Yum E, Oransky SH. Chinese patent medicine as a potential source of mercury poisoning. Vet Hum Toxicol 1992;34:235-238.
Gorey JD, Wahlqvist ML, Boyce NW. Adverse reaction to a Chinese herbal remedy. Med J Aust 1992; 157:484— 486.
Tai Y-T, But PP, Young K, Lau CP. Adverse effects from traditional Chinese medicine. Lancet 1993;341:892.
Kang-Yum E. Personal communication. Nyack, NY: Hudson Valley Regional Poison Center, Tel. 915-348-2615.
Huang КС. The pharmacology of Chinese herbs. Boca Raton, FL: CRC Press, 1993, pp. 388.
Guang-Sheng D. Important Chinese herbal remedies. Clin Ther 1987;9:345-357.
Zhen-Gang W, Gan-Zhong L. Advances in natural products in China. Trends Pharmacol Sci 1985;6:423— 426.
Martz W. Plants with a reputation against snakebite. Toxicon 1992;30:1131-1142.
Schaumburg NH, Berger A. Alopecia and sensory polyneuropathy from thallium in a Chinese herbal medication. JAMA 1992;268:3430-3431.
Fitzpatrick AJ, Crawford M, Allan RM, Wolfenden H. Aconite poisoning managed with a ventricular assist device. Anaesth Intensive Care 1994;22:714-717.
But PP-H, Tai Y-T, Young K. Three fatal cases of herbal aconite poisoning. Vet Hum Toxicol 1994;36(3):212— 215.
Shannon M. Herbal medicine — the aconites. Clin Toxicol Rev 1995; 17(4): 1—2.
Chan TYK, Tomlinson B, Critchley JAJH, Cockram CS. Herb-induced aconitine poisoning presenting as tetraplegia. Vet Hum Toxicol 1994;36:133-134.
Chan TYK, Critchley JAJH. The spectrum of poisonings in Hong Kong: An overview. Vet Hum Toxicol 1994;36(2):135—137.
Taylor ТЕ, Wilk BA, Kazembe P, Chisak M, Wirima JJ, Ratsma EYEG, Molyneux ME. Rapid coma resolution with artemether in Malawian children with cerebral malaria. Lancet 1993;341:661-662.
Van Thiel PPAM, van Gool T, Burna APCCH, Ten-deloo CH, Leentraar-Kuijpers A, Kager PA. Artemisinin compounds in treatment of malaria. Lancet 1993;34:1034-1035.
Izumotani T, Ishimura E, Tsumura K, Goto K, Nishizawa Y, Morii H. An adult case of Fanconi syndrome due to a mixture of Chinese crude drugs. Nephron 1993;65:137-140.
Dicke W. Ancient Chinese herbal remedy found to curb desire for alcohol. New York Times, November 2, 1993.
Catlin DH, Sekera M, Adelman DC. Erythroderma associated with ingestion of an herbal product. West J Med 1993;159:491-492.
Bullock C. Herbal diet causes one death and other attacks. Emerg Med News, August, 1994; p. 8.
Atherton DJ, Rustin MN, Brostoff J. Need for correct identification of herbs in herbal poisoning. Lancet 1993;341:637-638.
Van der Weghem J-L, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M et al. Rapidly progressing interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387-391.
Cosyns J-P, Jadol M, Squifflet J-P, de Plaen J-F, Fer-luga N, de Strihou CW. Chinese herbs nephropathy: A clue to Balkan endemic nephropathy. Kidney Int 1994;45:1680-1685.
Van Ypersele de Strihou C, Vanherweghen JL. The tragic paradigm of Chinese herbs nephropathy. Nephrol Dial Transplant 1995;10:157-160.
Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992;340:1136-1139.
Hill GJ. Lead poisoning due to Hai Ge Fen. JAMA 1995;273:24-25.
Markowitz SB, Nunez CM, Klitzman S, Munshi AA, Kim WS, Eisinger J, Landrigan PJ. Lead poisoning due to Hai Ge Fen. The porphyric content of individual erythrocytes. JAMA 1994;271:932-934.
Harper J. Traditional Chinese medicine for eczema. Br Med J 1994;308:489-490.
CDC. Jin Buttauan toxicity in adults — Los Angeles, 1993. MMWR 1993;42:920-922.
Woolf GM, Petrovic LM, Rojter SE, Wainwright S, Villamil FG, Katkov WN et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Intern Med 1994;121:229-235.
CDC. Jin Bu Huan toxicity in children — Colorado 1993. MMWR 1993;42:633-636.
Feldhaus КМ, Horowitz RS, Dart RC, Brent J, Gomez H, Moore L et al. Life-threatening toxicity from tetrahy-dropalmitine (THP) in an herbal medicine product. Vet Hum Toxicol 1993;35:329.
Jin Bu Huan toxicity in children — Colorado 1993. JAMA 1993;270:1298-1302.
Liu G-Q, Algeri S, Garattini S. D-L-Tetrahydropalmi-tine as monoamine depletor. Arch Int Pharmacodyn 1982;258:39-50.
Chan JCN, Chan TYK, Chum KL, Leung NWY, Tomlinson B, Critehley JAJH. Anticholinergic poisoning from Chinese herbal medicines. Aust N Zeal Med J 1994;24:317-318.
Kwan T, Paiusco AD, Kohl L. Digitalis toxicity caused by toad venom. Chest 1992;102:949-950.
Karuranithy R, Smita KP. Undeclared drugs in traditional Chinese antirheumatoid medicine. Intern J Pharm Pract 1991;1:117-119.
Hughes JR. Higgins EM, Pembroke AC. Oral dexamethasone masquerading as a Chinese herbal remedy. Br J Dermatol 1994; 130:261.
Chan TYH. Anticholinergic poisoning due to Chinese herbal medicine. Vet Hum Toxicol 1995;32:156-157.
Hien TT, White NJ. Quinghaosu. Lancet 1993;341:603— 608.
Fernando A. Medicinal plants. Ceylon Med J 1992;37:90-95.
McElvaine MD, Harder EM, Johnson L, Baer RD, Satzger ND. Lead poisoning from the use of Indian folk medicine. JAMA 1990;264:2212-2213.
CDC. Acute hepatitis and renal failure following ingestion of raw carp gallbladders — Maryland and Pennsylvania, 1991 and 1994. MMWR 1995;44:565-566.
Chan TYP, Chan JCN, Tomlinson B, Critchey JAJH. Chinese herbal medicines revisited: a Hong Kong perspective. Lancet 1993;342:1532-1534.
CDC. Folk remedy associated lead poisoning in Hmong children - Minnesota. MMWR 1983;32:555-556.
CDC. Folk remedy associated lead poisoning in Hmong children. JAMA 1983;250:3149-3150.
Hall SW, Night FE, Holtan NR, Eberhardt MS. Arsenic poisoning in Hmong adults. Vet Hum Toxicol 1989;31:351.
CDC. Non-fatal arsenic poisoning in three Hmong patients — Minnesota. MMWR. 1984;33:347-349.
Rubio EL, Ekins BR, Singh PD, Docus J. Hmong opiate folk remedy toxicity in three infants. Vet Hum Tox 1987;29:323-325.
Tay C-H. Arsenic poisoning from anti-asthmatic herbal preparations. Med J Aust 1975;2:424-428.
Tay CH. Cutaneous manifestations of arsenic poisoning due to certain Chinese herbal medicines. Aust J Dermatol 1974;15:121-131.
CDC. Lead poisoning associated death from Asian Indian folk remedies — Florida. MMWR 1984;33:638-645.
Smitherman J, Harber P. A case of mistaken identity: herbal medicine as a cause of lead toxicity. Am J Ind Med 1991;20:795-798.
Saryan LA. Surreptitious lead exposure from an Asian Indian medication. J Anal Toxicol 1991;15:336-338.
Kew J, Morris C, Aihie A, Fysh R, Jones S, Brooks D. Arsenic and mercury intoxication due to Indian ethnic remedies. Br Med J 1993;305:506-507.
Keen RW, Deacon AC, Deities HT, Moreton JA, Frost PG. Indian herbal remedies for diabetes as a cause of lead poisoning. Postgrad Med J 1994;70:113-114.
Jani JP, Raiyani CV, Mistry JS, Kashyap SK. Polycyclic aromatic hydrocarbons or traditional medicinal preparations. Hum Exp Toxicol 1991;10:347-350.
Gymnema. Lawrence Review of Natural Products. St. Louis: Facts and Comparisons, August 1993.
Kuman S, Roy AK. Occurrence of aflatoxin in some liver curative herbal medicine. Lett Appl Microbial 1993;17:112-114.
Pickwell SM, Schimelpfening S, Palinkas LA. "Betelmania." Betel quid chewing by Cambodian women in the United States and its potential health effects. West J Med 1994;160:326-330.
Chu N-S. Effects of betel chewing on electroencephalographic activity: spectral analysis and topographic mapping. J Formosa Med Assoc 1994;93:167-169.
Homma M, Oka K, Niitsuna T, Itah H: Pharmacokinetic evaluation of traditional Chinese herbal remedies. Lancet 1993;341:1595.
Sarai K. Oriental medicine as therapy for resistant depression: use of some herbal drugs in the Far East (Japan). Prog Neuropsychopharmacol Biol Psychiatry 1992;16:171-180.
Fushimi R, Kohn T, lyama S, Yasuhara M, Tachi J, Ko-hda К et al. Digoxin-like immunoreactivity in Chinese Medicine. Ther Drug Monit 1990;12:242-245.
Yamashiki M, Kosaka Y, Nishimura A, Okuta Y, Hamaguchi К et al. The herbal medicine sho-saiko-to improves cytokine production of peripheral blood mononuclear cells in patients with liver cirrhosis. Curr Ther Res 1993;54:86-97.
Rosti L, Nardini A, Bettinalli ME, Rosti D. Toxic effects of a herbal tea mixture in two newborns. Acta Paediatr 1995;83:683.
Mitchell-Heggs CAW, Conway M, Cassar J. Herbal medicine as a cause of combined lead and arsenic poisoning. Hum Exp Toxicol 1990;9:195-196.
Chung JG, Yoon YB. Kirn CY. A case of lead poisoning by herbal medicine. J Korean Med Assoc 1980;23:517— 522.
Ibrahim N. Trace element analysis of the tradition medicine, Jamu. Bull Environ Contain Toxicol 1993;51:199-202.
Malik AS, Zabidi MH, Noor AP. Acute salicylism due to accidental ingestion of a traditional medicine. Singapore Med J 1994;35:215-216.
Anderson PA. Hazardous Mexican drug alert: metami-zol. Vet Hum Toxicol 1992;34:555.
Foulke JE. Toddler’s blood test leads to FDA recall. FDA Consumer 1992;41.
Sankury T, Cooper D, Bradley R et al. Lead poisoning from Mexican folk remedies — California. JAMA 1983;250:3149.
Trotter RT III. The cultural parameters of lead poisoning: a medical anthropologist’s view of intervention in environmental lead exposure. Environ Health Perspect 1990;89:79-84.
Bose A, Vashishta K, O’Loughlin BJ. Azarcon por em-pacho — another cause of lead toxicity. Pediatrics 1983;72:106-110.
Levitt C, Godes J, Eberhardt M, Ing R, Simpson JM. Sources of lead poisoning. JAMA 1984:252:3127—3128.
CDC. Use of lead tetroxides as a folk remedy for gastrointestinal illness. MMWR 30;546—547.
Corchado A. Folk healers stay popular with poor in rural southwest. Wall Street Journal, January 4, 1989.
Huxtable RJ. The harmful potential of herbal and other plant products. Drug Safety 1990;5(Suppl 1): 126—136.
Bah M, Bye R, Pereda-Miranda P. Hepatotoxic pyr-rolizidine alkaloids in the Mexican medicinal plant Pack-era candidissima (Asteraceae Senecioneae). J Ethnophar-macol 1994;43:19-30.
Cone LA, Boughton WH, Cone LA, Lehr LH. Rattlesnake capsule-induced Salmonella arizonae bacteremia. West J Med 1990;153:315-316.
Waterman SH, Juarez G, Carr SJ, Kilman L. Salmonella arizonae infections in Latinos associated with rattlesnake folk medicine. Am J Public Health 190;80:286—289.
Babu К, Sonnenberg М, Kathpalia S, Ortega Р, Suriatlo AL, Коска FE. Isolation of Salmonella from dried rattlesnake preparations. J Clin Microbiol 1990;28:361 — 362.
Riley KB, Antoniskis D, Maris R, Leedon JM. Rattlesnake capsule-associated Salmonella arizonae infections. Arch Intern Med 1988;148:1207-1210.
Bhatt BD, Zuckerman MJ, Foland JA, Guerra LG, Polly SM. Rattlesnake meat ingestion — a common Hispanic folk remedy. West J Med 1988; 149:605.
Noskin GA, Clarke JT. Salmonella arizonae bacteremia as the presenting manifestation of human immunodeficiency virus infection following rattlesnake meat ingestion. Rev Infect Dis 1990;12:514-517.
Casner PR, Guerra GG. Prescription medications on the U. S.-Mexican border. J Clin Pharmacol 1990;30:831 — 862.
Casner PR, Guerra LG. Purchasing prescription medication in Mexico without a prescription. The experience at the border. West J Med 1992;156:512-516.
Tabet SR, Wiese WH. Medications obtained in Mexico by patients in southern New Mexico. South Med J 1990;83:271-273.
Rubin FK, Le Gatt DF, Audette RJ. The Mexican asthma cure. Systemic steroids for gullible gringos. Chest 1990;97:959-961.
Chavaje N. The Mexican asthma "cure." Chest 1991 ;99:1052.
Blackburn JL, Hindmarsh KW. Corticosteroids contained in Mexican cures for arthritis and asthma. Can Med Assoc J 1976; 1114:299-300.
Ruiz-Arguelles GJ, Alarcon-Segovia. Letter to the Editor: Mexican aspirin — a derogatory term. Am J Hematol 1990;34:159.
Sandler B, Bouchet H. Intoxication grave par 1’acide thi-azolidine carboxylique. Pediatrie 1972;27:76.
Baer RD, Ackerman A. Toxic Mexican folk remedies for the treatment of empacho. The case of azarcon, greta and albayalde. J Ethnopharmacol 1988;24:31-39.
Vlachos P, Kanitsakis NN. Fatal cardiac and renal failure due to Ecbalium Elaterium (squirting cucumber). Clin Toxicol 1994;32:737-738.
Tuncok Y, Kozan O, Cavdar C, Guven H, Fowler J. Vrginea maritime! (Squill) toxicity. Clin Toxicol 1995;33:83-86.
Healy MA, Aslam M, Bamgboye DA. Traditional medicine and lead containing preparations in Nigeria. Public Health (London) 1984;98:26-32.
Michie CA, Hayhurst M, Knobel GJ, Stokol JM, Hensley B. Poisoning with a traditional remedy containing potassium dichromate. Hum Exp Toxicol 1991; 10:129— 131.
Wood R, Mills PB, Knobel GJ, Hurlow WE, Stokol JM. Acute dichromate poisoning after use of traditional purgatives. A report of 7 cases. So Afr Med J 1990;77:640— 642.
Epstein P, Yudkin JS. Agranulocytosis in Mozambique due to amidopyrine, a drug withdrawn in the West. Lancet 1980;2:254-255.
Yudkin JS. Ciba-Geigy, amidopyrine and the Third World. Lancet 1981;2:114.
Foukaridis GN, Joubert PH, Forte M. A computerized library search routine using an HPLC diode array detector for the identification of poisoning by traditional medicines. Clin Toxicol 1992;30:149-151.
Nyazema NZ. Poisoning due to traditional remedies. Cent Afr J Med 1984;30:80-83.
McVann A, Havlik 1, Joubert PH, Monteagudo FST. Cardiac glycoside poisoning involved in deaths from traditional medicines. So Afr Med J 1992;81:139-141.
Bye SN, Dutton MF. Poisonings from the incorrect use of traditional medicaments — an introduction. Proc Int Assoc Forensic Toxicol. Edinburgh: Scottish Academic Press, 1992; pp. 120—122.
Bye SM, Dutton MF. Development of an Elisa and immunochemistry for atractyloside, a toxin from Cal-lilepsis laureola. In: Oliver JS, ed. Forensic Toxciolo-gy. Edinburgh: Scottish Academic Press, 1992; pp. 123-127.
Savage A, Hutchings A. Poisoned by herbs. Br Med J 1987;295:1650-1651.
Nyazema NZ. Poisoning due to traditional remedies. Cent Afr J Med 1984;30:80-83.
Kasilo OMJ, Nhachi CFB. The pattern of poisoning from traditional medicine in urban Zimbabwe. S Afr Med J 1992;82:187-188.
Kasilo OMJ, Nhachi CFB. A pattern of acute poisoning in children in urban Zimbabwe: ten years experience. Hum Exp Toxicol 1992;11:335-340.
Joubert PH. Poisoning admission of black South Africans. Clin Toxicol 1990;28:85-94.
Venter CP, Joubert PH. Aspects of poisoning with traditional medicines in southern Africa. Biomed Environ Sci 1988;1:388-391.
McVann A, Havlik I, Joubert PH, Monteagudo FSE. Cardiac glycoside poisoning involved in deaths from traditional medicines. S Afr Med J 1992;81:139-141.
Baer RD, Ackerman A. Arsenic as a home remedy. Treatment of Susto in Western South America. Social Pharmacol 1988;2:37-49.
Santa-Maria SF. Health mission at 5000 m. J Wilderness Med 1992;3:460-461.
Erspamer V, Erspamer GF, Severini C, Potenza RL, Barra D, Mignogna G, Bianchi A. Pharmacological studies of"Sapo" from the frog Phyllomedus bicolor skin: a drug used by the Peruvian Matses Indians in Shamanic limiting practices. Toxicon 1993;31:1099-1111.
Diamond JR, Pallone PL. Acute interstitial nephritis following use of Tung Shueh pills. Am J Kidney Dis 1994;24:219-221.
Bayly GR, Braithwaite R, Sheehan TMT, Ferner RE. Lead poisoning from traditional Asian remedies in the West Midlands. Hum Exp Toxicol 1994; 13:626.
Editor: Native Hawaiian medical lore. Hawaii Med J 1993;52:l 56.
Blum JE, Coe FL. Metabolic acidosis after sulfur ingestion. N Engl J Med 1977;297:869-870.
Lin AN, Reimer RJ, Carter DM. Sulfur revisited. J Am Acad Dermatol 1988;18:553-558.
Croom EM Jr. Herbal medicine among the Lumbee Indians. In: Kirkland J, Mathews HF, Sullivan CW Ill, Baldwin K, eds. Herbal magical medicine. Traditional healing today. Durham, NC: Duke University Press, 1992; pp. 137-169.
Meier B. New York Times, April 8, 1990; p. 50.
Fung MC, Weintraub M, Bowen DL. Colloidal silver proteins marketed as health supplements. JAMA 1995;274:1196-1197.
CDC. Deaths associated with a purported aphrodisiac — New York City, February 1993—May 1995. MMWR 1995;44:853-855; also JAMA 1995;274:1828-1829.
CDC. Unexplained severe illness possibly associated with consumption of Kombucha tea — Iowa 1995. MMWR 1995;44:892-900.
Perron AD, Patterson JA, Yanofsky NN. Kombucha "mushroom" hepatotoxicity. Ann Emerg Med 1995;26:660-661.
Auerbach PS. Marine envenomations. N Engl J Med 1991;325:486-493.
McGoldrick J, Marx JA. Marine envenomations. II. Invertebrates. J Emerg Med 1992;10:71-77.
McGoldrick J, Marx JA. Marine envenomations. I. Vertebrates. J Emerg Med 1991;9:497-502.
Russell MT, Tomchik RS. Sea bather’s eruption or "sea lice": New findings and clinical implications. J Emerg Nurse 1993;19:197-201.
Freundentel AR, Joseph PR. Sea bather’s eruption. N Engl J Med 1993;329:542-544.
Tomchik RS, Russell MT, Szmant AM, Black NA. Clinical perspectives on seabathers’ eruption also known as "sea lice." JAMA 1993;269:1169-1172.
Burnett JW, Fenner PJ, Kokelj F, Williamson JA. Serious Physalia (Portuguese man o’war) stings: implications for scuba divers. J Wilderness Med 1994;5:71-76.
Stein MR, Marraccini JV, Rothschild NE, Burnett JW. Fatal Portuguese Man-O-War (Physalia physalis) envenomation. Ann Emerg Med 1989;18:312-315.
Williamson JA, Callanan VI, Hartwick RF. Serious envenomation by the northern Australian box jellyfish: the continuing search for lethal mechanisms. Med J Aust 1980;1:13-15.
Williamson J. Current challenges in marine envenomation: an overview. J Wilderness Med 1992;3:422-431.
Burnett JW. Human injuries following jellyfish stings. Maryland Med J 1992;41:506-513.
Fenner PJ. Irukandji — a "new" danger. In: Pearn J, Covacevich J, eds. Vernons and victims. South Brisbane: The Queensland Museum and Amphion Press, 1988.
Fenner PJ, Williamson JA, Blenkin JA. Successful use of Chironex antivenom by members of the Queensland Ambulance Transport Brigade. Med J Aust 1989;151:708-710.
Burnett JW, Calton GJ. Response of the box jellyfish (Chironex fleckeri) cardiotoxin to intravenous administration of verapamil. Med J Aust 1983;2:192-194.
Burnett JW, Othman IB, Endean R, Fenner PJ, Callanan VI, Williams J A. Verapamil potentiation of Chironex (box jellyfish) antivenom. Toxicon 1990;28:242— 244.
Beadnell CE, Rider TA, Williamson JA, Fenner PJ. Management of a major box jellyfish (Chironex fleckeri) sting. Lessons from the first minutes and hours. Med J Aust 1992;156:655-658.
Bengston K, Nichols MM, Schnadig V, Ellis MD. Sudden death in a child following jellyfish envenomation by Chiropsalmus quadrumanus. Case report and autopsy findings. JAMA 1991;266:1404-1406.
Wachsman M, Aurelian L, Burnett JW. Human immunosuppression induced by sea nettle (Chrysavra Quinquecirrha) venom. Toxicon 1991;29:386-390.
Hartwick R, Callanan V, Williamson J. Disarming the box jellyfish. Nematocyst inhibition in Chironex fleckeri. Med J Aust 1980;1:15-20.
Wingert W. Poisoning by marine animals. Personal communication.
Laird P. Sea-urchin injuries. Lancet 1995;346:1240.
Garcia PJ, Shein MH, Burnett JW. Fulminant hepatic failure from a sea anemone sting. Ann Intern Med 1994;120:665-666.
Burnett JW. Human injuries following jellyfish stings. Maryland Med J 1992;41:506-513.
Fenner PJ, Williamson J, Callanan VI, Audly 1. Further understanding of and a new treatment for "Irukandju" (Carukia barnesi) stings. Med J Aust 1986;145:569-574.
Martin JC, Audley I. Cardiac failure following irukandji envenomation. Med J Aust 1990;153:166-168.
Fenner PJ, Williamson JA, Burnett JW, Colquhoun DM, Godfrey S, Gunawardane K, Murtha W. The "Irukandji Syndrome" and acute pulmonary edema. Med J Aust 1988;149:150-156.
Das SK, Johnson MB, Cohly HHP. Catfish stings in Mississippi. South Med J 1995;88:809-812.
Shepherd S, Thomas SH, Stone CK. Catfish envenomation. J Wilderness Med 1994;5:67-70.
Blum MS. Antivenoms: chemical and pharmacological properties. J Toxicol Toxin Rev 1992;11:115-164.
Sutherland SK. Antivenom use in Australia. Premedication, adverse reactions and the use of venom detection kits. Med J Aust 1992;157:734-739.
Warrell DA, Fenner PJ. Venomous bites and stings. Br Med Bull 1993;49:423-439.
Schmidt JA. Toxinology of venoms from the honey bee genus apis. Toxicon 1995;33:917-927.
Schumacher MJ, Egen NB. Significance of Africanized bees for public health. A review. Arch Intern Med 1995;155:2038-2043.
Sherman RA. What physicians should know about Africanized honey bees. West J Med 1995; 163:541— 546.
McKenna WR. The Africanized honey bee. Allergy Proc 1992;13:7-10.
Watenberg N, Weizman Z, Shahak E, Aviram M, Maor E. Fatal multiple organ failure following massive hornet stings. Clin Toxicol 1995;33:471-474.
Franca FOC, Benvenuti LA, Fan HV, Dos Santos DR, Hain SH, Picchi-Martins FR et al. Severe and fatal mass attacks by "killer" bees (Africanized honey bees — Apis mellifera scutellata) in Brazil: clinicopathologic studies on measurement of serum venom concentrations. Q J Med 1994;8:269-282.
Tunget CL, Clark RF. Invasion of the "killer" bees. Separating fact from fiction. Postgrad Med 1993;94:92-102.
Sutherland SK. Venomous arthropods of medical importance, other than spiders and ichs in Australian Animal Toxins. The Creatures, Their Toxins and Care of Poisoned Patient. Melbourne: Oxford University Press, 1983, pp. 316-326.
Matuszek MA, Hodgson WC, Sutherland SK, King RG. Pharmacological studies of jumper ant (Myrmecia pilo-sula) venom: evidence for the presence of histamine and haemolytic anc cicoanoid-releasing factors. Toxicon 1992;30:1081-1091.
Golden DBK, Schwartz HJ. Guidelines for venom immunotherapy. J Allergy Clin Immunol 1986;77:727.
Reisman RE. Insect stings. N Engl J Med 1994;331:523-527.
De Shazo RD, Butcher ВТ, Banks WA. Reactions to the stings of the imported fire ant. N Engl J Med 1990;323:462-466.
Hayes J. Fire ants — forensic implication and potential impact upon determination of post mortem interval. Abs G88. Proc American Academy Forensic Sci, February 14-19, 1994.
Ponder RD, Stafford CF, Kiefer CR, Ford JL, Thompson WO, Hoffman DR. Development of an enzyme-like immunosorbent assay for measurement of fire and venom-specific IgE. Ann Allergy 72:329—332.
Freeman TM, Hylander R, Ortiz A, Martin ME. Imported fire ant immunotherapy: effectiveness of whole body extracts. J Allergy Clin Immunol 1992;90:210-215.
De Shazo RD, Williams DF. Multiple fire ant stings indoors. South Med J 1995;88:712-715.
Valentine MD, Schuberth КС, Kagey-Sobotka A, Graft DF, Kurterovich KA, Szklo M, Lichtenstein LM. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 1990;323:1601— 1603.
Lockey RF. Immunotherapy for allergy to insect stings. N Engl J Med 1990;323:1627-1628.
Herrera AM. Review of Schwartz HJ, Golden DB, Lockey RF: J Allergy Clin Immunol 1990;85:709-712. Pediatrics 1991 ;87(Suppl):990.
Frazier CA. Emergency first aid for allergic reactions to insect bites or stings. Cutis 1977;19:770-772.
Pinson RT, Morgan JA. Envenomation by the pass caterpillar (Megalopyge Opercularis). Ann Emerg Med 1991;20:562-564.
Edwards EK Jr, Edwards EK, Kowalczyk AP. Contact urticaria and allergic contact dermatitis to the saddleback caterpillar with histologic correlation. I nt J Dermatol 1986;25:467.
Finkelstein Y, Raikhlin-Eisenkraft B, Taitelman U. Systemic manifestation of erucism: A case report. Vet Hum Toxicol 1988;30:573-574.
Everson GW, Chapin JB, Normann SA. Caterpillar envenomations: a prospective study of 112 cases. Vet Hum Toxicol 1988;30:368 (abstract).
Everson GW, Chapin JB, Normann SA. Caterpillar envenomations: a prospective study of 112 cases. Vet Hum Toxicol 1990;32:114-119.
Barnett PU. Centipede ingestion by a six-month-old infant: Toxic side effects. Pediatr Emerg Care 1991 ;7:229.
Anderson PC. Necrotizing spider bites. Am J Fam Pract 1982;26:198-203.
Wasserman GS, Anderson PC. Loxoscelism and necrotic arachnidism. J Toxicol Clin Toxicol 1983— 1984;21:451-472.
Russell FE. Bite of the spider Phidippus formosus: case history. Toxicon 1970;8:193-194.
Gorham JR, Rheney ТВ. Envenomation by the spiders Chiracanthium inclusum and Argiope aurantia. JAMA 1968;206:1958-1962.
Furman DP, Reeves WC. Toxic bite of a spider: Chiracanthium inclusum Hentz. Calif Med 1947;87:114.
Russell FE, Madon NB. New names for the brown recluse and the black widow. Postgrad Med 1981 ;70(6):31.
Wasserman GS, Siegel C. Loxascelism (brown recluse spider bite): a review of the literature. Clin Toxicol 1979;14:353-358.
Chu JY, Rush CT, O’Connor DM. Hemolytic anemia following brown spider (Loxosceles reclusa) bite. Clin Toxicol 1978;12:531-534.
Vorse IT, Seccareccio P, Woodruff К et al. Disseminated intravascular coagulopathy following fatal brown spider bite (necrotic arachnidism). J Pediatr 1972;80:1035— 1037.
Madrigal GC, Ercolani RL, Wenzl JE. Toxicity from a bite of the brown spider (Loxosceles reclusus): skin necrosis, hemolytic anemia and hemoglobinuria in a nine year old child. Clin Pediatr 1972;11:641-644.
Walker JS, Hogan DE. Bite to the left leg. Acad Emerg Med 1995;2:223-237.
Murray LM, Seger DL. Hemolytic anemia following a presumptive brown recluse spider bite. Clin Toxicol 1994;32:451-456.
Barrett SM, Romine-Jenkins M, Blick KE. Passive he-moglutination inhibition test for diagnosis of brown recluse spider bite envenomation. Clin Chem 1993;3:2104— 2107.
Rauber A. Black widow spider bites. J Toxicol Clin Toxicol 1983—1984;21:473-485.
Rauber AP. The case of the red widow: a review of la-trodectism. Vet Hum Toxicol 1980;22(Suppl 2):39—41.
Clark RF, Wethern-Kestner S, Vance MV, Gerkin R. Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases. Ann Emerg Med 1992;21:782-787.
Schtorntham S, Roberts JR, Nilsen GJ. Dramatic clinical response to the delayed administration of black widow spider antivenom. Ann Emerg Med 1994;24:1198— 1199.
Russell FE. Black widow spider envenomation during pregnancy: report of a case. Toxicon 1979;17:188-189.
Allen RC, Norris RL. Delayed use of antivenom in black widow spider (Latrodectus mactans) envenomation. J Wilderness Med 1991;2:181-192.
Arnold RE. Brown recluse spider bites: five cases with a review of the literature. JACEP 1976;5:262-264.
Auer Al, Hershey B. Surgery for necrotic bites of the brown spider. Arch Surg 1974;108:612-618.
Anderson PC. What’s new in locoscelism — 1978. Mo Med 1977;74(7):549—552, 556.
Rees R, Shack B, Withers E et al. Managment of the brown recluse spider bite. Plast Reconstruct Surg 1981;68:768-773.
King LE Jr. Brown recluse spider bites: Stay cool. JAMA 1985;254:2895-2896.
King LE, Rees RS. Dapsone treatment of a brown recluse spider. JAMA 1983;250:648.
Rees RS, Altenbern DP. Lynch JB et al. Brown recluse spider bites: a comparison of early surgical excision versus dapsone and delayed surgical excision. Ann Surg 1985;202:659-663.
Iserson KV. Methemoglobinemia from dapsone therapy for a suspected brown spider bite. J Emerg Med 1985;3:285-288.
Berger RS. Management of brown recluse spider bite. JAMA 1984;251:889.
Murray LM, Seger DC. Hemolytic anemia following a presumptive brown recluse spider bite. Clin Toxicol 1994;32:451-456.
Sutherland SK. Treatment of arachnid poisoning in Australia. Aust Fam Physician 1990;19:1-10.
Brown AFT. Delayed diagnosis of red-back spider envenomation; a timely reminder. Med J Aust 1989;151:705-706.
Jelinek GA, Banham NDG, Dunjey SJ. Red-back spider bites at Freemantle Hospital, 1982—1987. Med J Aust 1989;150:693-695.
Sutherland SK. Australia animal toxins. Melbourne: Oxford University Press, 1983, p. 276.
Duncan AW, Tibbales J, Sutherland SK. Effects of Sydney funnel-web spider envenomation in monkeys and their clinical implications. Med J Aust 1980;2:429-435.
Newland G, Atkinson P. Review of Southern African spiders of medical importance with notes on the signs and symptoms of envenomation. S Afr Med J 1988;73:235-239.
Newland G, Atkinson P. Behavioural and epidemiological considerations pertaining to necrotic arachnidism in Southern Africa. S Afr Med J 1990;77:92-95.
Ribeiro LA, Jorge MT, Presco PV, Nishioka SdA. Wolf spider bites in Sao Paulo, Brazil: a clinical and epidemiological study of 515 cases. Toxicon 1990;28:715-717.
Campbell DS, Rees RS, King LE. Wolf spider bites. Cutis 1987;39:113-114.
Barbara КС, Cardoso JLC, Eikstedt VRD, Mota I. IgG antibodies to Loxosceles sp. spider venom in human envenomation. Toxicon 1992;30:1117-1121.
Theakston RDG, Warrell DA. Antivenoms: a list of hyperimmune sera currently available for the treatment of envenoming by bites and stings. Toxicon 1991;29(12):1419—1470.
Bawaskar HS, Bawaskar PH. Scorpion sting: a review of 121 cases. J Wilderness Med 1991;2:164-174.
Krishna Murthy KR, Zolfagharian H, Medh JD, Kad-alkar J A, Yeolekar M E, Sandit SP et al. Disseminated intravascular coagulation and disturbances in carbohydrate and at metabolism in acute myocarditis produced by scorpion (Buthotus tamulus) venom. Indian J Med Res 1988;87:318-325.
Sofer S, Shahak E, Slonim A, Gueron M. Myocardial injury without heart failure following envenomation by the scorpion Leiurus quinquestriatus in children. Toxicon 1991;29:382-385.
Sofer S, Gueron M. Respiratory failure in children following envenomation by the scorpion Leiurus quinquestriatus: Hemodynamic and neurological aspects. Toxicon 1988;26:931-939.
Sofer S, Shaler H, Weizman Z, Shahak E, Gueron M. Acute pancreatitis in children following envenomation by the yellow scorpion Leiurus quinquestriatus. Toxicon 1991;29:125-128.
Bogomolksi-Yahalom V, Amitai Y, Stalnikowicz R. Paresthesia in envenomation by the scorpion Leiurus quinquestriatus. Clin Toxicol 1995;33:79-82.
Gueron M, Sofer S. The role of the intensivist in the treatment of the cardiovascular manifestations of scorpion envenomation. Toxicon 1994;32:1027—1029.
Gueron M, Margulic G, Ilia R, Sofen S. The management of scorpion envenomation. Toxicon 1993;31:1071-1083.
Ismail M. Serotherapy of the scorpion envenoming syndrome is irrationally convicted without trial. Toxicon 1993;31:1077-1083.
Gueron M, Sofer S. Scorpion envenomation and the heart. J Wilderness Med 1991;2:175-177.
Rachesky IJ, Banner W, Dansky J et al. Treatments for Centruroides exilicauda envenomation. Am J Dis Child 1984;138:1136-1139.
Sofer S. Gueron M. Vasodilators and hypertensive encephalopathy following scorpion envenomation in children. Chest 1991;97:118-120.
Bond GR. Antivenin administration for Centruroides scorpion sting: risks and benefits. Ann Emerg Med 1992;21:788-791.
Binder LS. Acute arthropod envenomation. Incidence, clinical features and management. Med Toxicol Adverse Drug Exp 1989;4:163-173.
Bond GR. Antivenin administration for Centruroides scorpion sting — risks, benefits. Vet Hum Toxicol 1990;32:367.
Baker MS, Strunk HK. Medical aspects of Persian Gulf operations. Environmental hazards. Mil Med 1991;156:381-385.
Harvey AL, ed. International encyclopedia of pharmacology and therapeutics. Set 134, Snake toxins. Elmsford, NY: Pergamon Press, 1991.
Tu AT, ed. Reptile venoms and toxins. In: Handbook of natural toxins, vol. 5. New York: Marcel Dekker, 1991.
Covacevich J, Davie P, Peam J, eds. Toxic plants and animals. A guide for Australia. Queensland Museum, 1987.
Sutherland SK. Australian animal toxins. The creatures, their toxins and care of poisoned patient. Melbourne: Oxford University Press, 1983.
Edmunds C. A diving medical centre monograph. Biomedical Marine Services Pty Ltd., 25 Battle Blvd. Seaforth 2092, Australia, 1984.
Sutherland SK. Venomous creatures of Australia. A field guide with notes on first aid. Melbourne: Oxford University Press, 1988.
Pearn J, Covacevich J. Venoms and victims. South Brisbane: The Queensland Museum and Amphion Press, 1988.
Sutherland SK. First aid for snake bites and stings in Australia, with notes on first aid for bites and stings by other animals including spiders. CSL, April 1991.
Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia-Pacific region). Singapore: Venom and Toxin Research Group, National University of Singapore, 1990.
White J, Snake bite: an Australian perspective. J Wilderness Med 1991;2:219-244.
lyaniwura TT. Snake venom constituents: biochemistry and toxicology. 1 and II. Vet Hum Toxicol 1991 ;33:468.
Phelps T. Poisonous Snakes. Revised editions. London: Blandford Press, 1990.
Russell FE. Snake venom immunology. Historical and practical considerations. J Toxicol Toxin Reviews 1988;7:1-82.
Tneakston RDG, Warrell DA. Antivenoms: a list of hyperimmune sera currently available for the treatment of envenoming by bites and stings. Toxicon I991;29(12): 1419-1470.
Kochva E. The origin of snakes and evaluation of the venom apparatus. Toxicon 1987;25:65-106.
Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia-Pacific region). Singapore: Venom and Toxin Research Group, National University of Sig-napore, 1990, p. 670.
The International Society of Toxinology newsletter: 1ST Bite, Sting, and Poison Newsletter. Editors: Prof. Dr. G. Habermehl, Dept of Chemistry, Veterinary University, D-3000 Hanover, Germany. Prof. Dr. D Mebs. Zentrum der Rechtsmedizine, University of Frankfurt, D-6000 Frankfurt, Germany.
Sutherland SK. Treatment of snake bite. Aust Fam Physician 1990;19:21-41.
White J. Snake bite: an Australian perspective. J Wilderness Med 1991;2:219-244.
Sutherland SK. Deaths from snake bites in Australia, 1981-1991. Med J Aust 1992;157:740-746.
Gilon D, Shalev O, Benbassat J. Treatment of envenomation by Echis coloratus (Mid-East Saw Sealed Viper): a decision tree. Toxicon 1989;27:1105-1112.
Russell FE. Venomous snakes of the Middle East. Vet Hum Toxicol 1991;33:68.
Kirchberg JS, Davidson TM. Envenomation by the col-ubrid snake Atarctaspis bibronii: a case report. Toxicon 1991;29:379-381.
Mirtschin PJ, Crowe GR, Davis R. Dangerous snakes of Australia. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific Region). Singapore: Venom and Toxin Research Group. National University of Singapore, 1990, pp. 1 — 174.
White J. Venomous snakes of medical importance in Australia. Clinical toxinology. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore: Venom and Toxin Research Group. National University of Singapore, 1990.
White J. Snakebite: an Australian perspective. J Wilderness Med 1991;2:219-244.
Sutherland SK. Treatment of snakebite. Aust Fam Physician 1990;19:1-13.
Covacevich J. Australia’s dangerous snakes. In: Pearn J, Covacevich J, eds. Venoms and victims. South Brisbane: The Queensland Museum and Amphion Press, 1988, pp. 73-86.
Pearn J. Snakebite victims. In: Pearn J, Covacevich J, eds. Venoms and victims. South Brisbane: The Queensland Museum and Amphion Press, 1988, pp. 87—96.
Pearn J. Human snakebite — effects and first aid. In: Pearn J, Covacevich J, eds. Venoms and victims. South Brisbane: The Queensland Museum and Amphion Press, 1988, pp. 97-110.
Sutherland SK. First aid for snakebite in Australia. CSL Commonwealth Serum Laboratories, April 1991.
White J. Management of snakebite in South Australia. A management plan. South Australian Health Commission. Country Health Services Division, August 1991, PP 1-36.
Sutherland SK, King K. Management of snakebite injuries. Monograph Series Number One. Royal Flying Doctor Service of Australia, 43 Bridge Street, Hurstville NSW 2220, 1991.
Jamieson R, Peam J. An epidemiological and clinical study of snakebites in childhood. Med J Aust 1989;150:698-702.
Sutherland SK, Coulter AR, Harris RD. Rationalization of first-aid measures for elapid snakebite. Lancet 1979;1:183-186.
Warrell DA, Fenner PJ, Venomous bites and stings. Br Med Bull 1993;49:423-439.
Phelps T. Poisonous snakes. Revised edition. London: Blandford Press, 1989.
Progress in the characterization of venoms and standardization of antivenoms. WHO Offset Publication No. 58. Geneva: World Health Organization, 1981.
Harborne DJ. Emergency treatment of adder bites: case reports and literature review. Arch Emerg Med 1993;10:223-243.
Audebert F, Grosselet O, Sabouraud A, Bone C. Quantitation of venom antigens from European vipers in human serum or urine by ELISA. J Anal Toxicol 1993;17:236-240.
Warrell DA. The global problems of snake bites: its prevention and treatment. In: Proc 10th World Congress on Animal Plant and Microbial Toxins, National University of Singapore, November 3—8, 1991. Abstract A004, p. 56.
White J, Duncan B, Wilson C, Williams V, Lloyd J. Coagulopathy following Australian elapid snakebite: a review of 20 cases. In: Proc 10th World Congress on Animal Plant and Microbial Toxins, National University of Singapore, November 3—8, 1991. Abstract A022, p. 84.
Sutherland SK. Treatment of snake bite. Aust Fam Physician 1990; 19:26.
Sutherland SK. Treatment of snake bite. Aust Fam Physician 1990;19:1-13.
Ryan КС, Caravati EM. Life-threatening anaphylaxis following envenomation by two different species of Cro-talidae. J Wilderness Med 1994;5:263-268.
Davidson TM, Schafer SF, Jones J. North American pit vipers. J Wilderness Med 1992;3:397-421.
Meier J. Effects of snake venoms on hemostasis. CRC Cnst Rev Toxicol 1991;21:171-182.
Hutton RA, Warrell DA. Action of snake venom components in the haemostatic system. Blood Rev 1993;7:176-189.
Theakston RDG, Warrell DA. Antivenoms: a list of hyperimmune sera currently available for the treatment of envenomation by bites and stings. Toxicon 1991 ;29( 12): 1419—1470.
Warrell DA. Treatment of snake bite in the Asia-Pacific Region: a personal view. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore: Venom and Toxin Research Group. National University of Singapore, 1990, pp. 641—670.
Burgess JL, Dart RC. Snake venom coagulopathy use and abuse of blood products in the treatment of pit viper envenomation. Ann Emerg Med 1991;20:795-801.
Jamieson R, Pearn J. An epidemiological and clinical study of snake bites in childhood. Med J Aust 1989;150:608-702.
White J. A review of snake bites and suspected snake bites treated in South Australia with particular reference to reptile handlers. In: Proc 10th World Congress on Animal Plant and Microbial Toxins, National University of Singapore, November 3—8, 1991. Abstract 181. p. 33.
O’Shea MT. The highly and potentially dangerous elap-ids of Papua, New Guinea. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore: Venom and Toxin Research Group. National University of Singapore, 1990, pp. 585-640.
Hudson BJ. Positive response to edrophonium in death adder (Acanthophis antarcticus) envenomation. Aust NZ J Med 1988;18:792-794.
Currie BJ, Richens J, Korinihona A, Worthington J. Anticholinesterase therapy for death adder envenomation. Aust NZ J Med 1990;20:190.
Mirtschin PJ, Crowe GR, Davis R. Dangerous snakes of Australia. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp. 1—173.
Sutherland SK. Australian animal toxins. The creatures, their toxins and care of the poisoned patient. Melbourne: Oxford University Press, 1983.
White J. Venomous snakes of medical importance in Australia: clinical toxinology. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp. 175-210.
Sutherland SK, King K. Management of snakebite injuries. Monograph Series Number One. Royal Flying Doctor Service of Australia, 43 Bridge Street, Hurstville, NSW 2220, 1991.
White J. Snakebite: an Australian perspective. J Wilderness Med 1991;2:219-244.
Aye MM. Venomous snakes of medical importance in Burma. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp.211—241.
Soe-Soe, Than-than, Khin-Ei-Han. The nephrotoxic action of Russell’s viper (Vipera russelli) venom. Toxicon 1990;28:461-467.
Tun-Ре, Warrell DA, Tra-Nu-Swe, Phillips RE, Moore RA, Myint-Lwm. Acute and chronic pituitary failure resembling Sheehan’s syndrome following bites by Russell’s viper in Burma. Lancet 1987;2:763-767.
Proby C, Tha-Aung, Thet-Win, Hla-Mon, Burrin JM, Joplin GF. Immediate and long-term effects in hormone levels following bites by the Burmese Russell’s viper. Q J Med 1989;276:399-411.
Zhao E. Venomous snakes of China. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp. 243-268.
Chen Yuan-Cong. Venomous snake bites and snake venom research in China. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp. 269—279.
Yu P-N, Lian Z-J, Lu Z-Y. Emergency treatment of respiratory arrest due to Chinese banded krait bite (33 case reports). Int Symp Natural Toxins (ISNt-89), Builin, China. J Toxicol Tox Rev 1990;9( 1): 134.
Cockram CS, Chan JCN, Chow KY. Bites by the white lipped pit viper (Trlmeresurus albolabris) and other species in Hong Kong. A survey of 4 years’ experience at the Prince of Wales Hospital. J Trop Med Hyg 1990;93:69-86.
Shastry JCM, Date A, Carman RH, Johny KV. Renal failure following snake bite. A clinicopathological study of nineteen patients. Am J Trop Med Hyg 1977;26:1032-1038.
Murthy TSN. Venomous snakes of medical importance in India (part A). In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp. 281—297.
Khaire A, Khaire N, Joshi DN. Venomous snakes of medical importance in India (Part B) — clinical aspects. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp. 299—309.
Toriba M, Sawai Y. Venomous snakes of medical importance in Japan. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp. 323—347.
Murata R, Fukishima H. Immune response of man to habu venom toxoid. Jpn J Med Sci Biol 1981 ;34:197— 212.
Liat LB. Venomous land snakes of Malaysia. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp. 387—417.
Reid HA, Thean PC, Chan KE et al. Clinical effects of bites by Malayan viper (Ancistrodom rhodostoma). Lancet 1963;1:617-621.
Tau KK, Choo KE, Ariffm WA. Snake bite in Kelanta-nese children: a five-year experience. Toxicon 1990;28:225-230.
Tau NH, Saifuddin MN. Isolation and characterization of a hemorrhagin from the venom of Ophiophagus Hannah (king cobra). Toxicon 1990;28:285-292.
Benbassat J, Shalev O. Envenomation by Echis coloratus (Mideast saw-scaled viper): a review of the literature and indications for treatment. Isr J Med Sci 1993;29:239— 250.
Porath A, Gilon D, Schulchynska-Castel H, Shalev O, Keynan A, Benbasset J. Risk indications after envenomation in humans by Echis coloratus (Mideast saw-scaled viper). Toxin 1992;30:35-42.
Schulchynska-Castel H, Dvilansky A, Keynan A. Echis colorata bites: clinical evaluation of 42 patients. A retrospective study. Isr J Med Sci 1986;22:880-883.
Kochva E. Venomous snakes of Israel. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp. 311—326.
Strunk HK. Guidebook of infections and communicable diseases and other health hazards of the Arabian Peninsula. Pearl Harbor, HI: US Naval Forces Central Command, 1984.
Baker MS, Strunk HK. Medical aspects of Person Gulf operations: environmental hazards. Mil Med 1991;156:381-385.
Vick JA. Medical studies of the poisonous land and sea snakes found in and around Saudi Arabia. Mil Med 1992;157:159-162.
Coppola M, Hogan DE. Venomous snakes of Southwest Asia. Am J Emerg Med 1992;10:230-236.
Toriba M. Venomous snakes of medical importance in the Philippines. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp. 463—469.
Watt G, Padre L, Tuazon L, Theakston RDG, Laughlin L. Bite by the Philippine cobra (Naja naja philippinensis): prominent neurotoxicity with minimal local signs. Am J Trop Med Hyg 1988;39:306-311.
Watt G, Theakston RDG, Hayes CG, Yamboa ML, Sangalang R, Ranoa CP, Alquizalas E, Warrell DA. Positive response to edrophonium in patients with neurotoxic envenomation by cobras (Naja naja philippinensis). A placebo-controlled study. N Engl J Med 1986;315:1444-1448.
Drachman DB. Myasthenia gravis. N Engl J Med 1978;298:136-142, 186-193.
Watt G, Hayes CG. Edrophonium for cobra bite. N Engl J Med 1987;316:1609.
Riding JE, Robinson JS. The safety of neostigmine. Anaesthesia 1961;16:346-354.
Arsura EL. Edrophonium for cobra bite. N Engl J Med 1987;316:1608-1609.
de Silva A. Venomous snakes, their bites and treatment in Sri Lanka. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp. 479—556.
Phillips RE, Theakston RDG, Warrell DA, Galigedara Y, Abeysekera DTDJ, Dissanayaka P et al. Paralysis, rhabdomyolysis and haemolysis caused by bites of Russell’s viper (Vipera russelli pulchella) in Sri Lanka. Failure of Indian (Haffkine) antivenom. Q J Med 1988;68:691-716.
Jintakune P, Limthongkul S, Mahasandana S, Meemano K, Pochanugool C, Sitprija V. Venomous snakes and snake bite in Thailand. In: Gopalakrishnakone P, Chou LM, eds. Snakes of medical importance (Asia Pacific region). Singapore. Venom and Toxin Research Group. National University of Singapore, 1990, pp. 557—579.
Sanguanvungsirikul S, Chomdej B, Suivanprasert K, Wattanavah P. Acute effect of Russell’s viper (Vipera russelli siamensis) on renal hemodynamics and antiregulation of blood flow in dogs. Toxicon 1989;27:1199—1207.
Sitprija V, Suvanpha R, Pochanugool C, Chusil S, Tung-sanga K. Acute interstitial nephritis in snake bite. Am J Trop Med Hyg 1982;31:408-410.
Mitrakul C, Juzi V. Pongrujikorn W. Antivenom therapy in Russell’s viper bite. Am J Clin Pathol 1991 ;95:412.
Malasit P, Warrell DA, Chanthavanich P, Viravan C, Mongkolsapaya J, Singhthong B, Supich C. Prediction, prevention, and mechanism of each (anaphylactic) antivenom reactions in victims of snake bites. Br Med J 1986;292:17-20.
Pochamgool C, Limthogkul S, Meemano K. Clinical features of non-antivenom treated neurotoxic snake bite patients. In: Gopalakrishnakone P, Tan CK. Progress in Venom and Toxin Research. Proc First Asia-Pacific Congress on Animal, Plant and Microbial Toxins. Singapore: June 24—27, 1987, pp. 46—51.
Chinonavanig L, Karnchaachetanee C, Pongsettakul P, Ratanabanangkoon K. Diagnosis of snake venoms by a reverse latex agglutination test. Clin Toxicol 1991;29:493-503.
Persson H. Features of viper bites in Europe. Management and indications for antivenom immune therapy. Proc Eur Assoc Pois Cont Cent Toxicol Technical Meeting. Lyon, France: May 22—24, 1991.
Persson H, Irestedt B. A study of 136 cases of adder bite treated in Swedish Hospitals during one year. Acta Med Scand 1981;210:433-439.
Reid HA. Adder bites in Britain. Br Med J 1976;2:153.
Audebert F, Sorkine M, Bon C. Clinical gradation and ELISA quantification of envenomations following viper bites in France. In: Proc. 10th World Congress on Animal Plant and Microbial Toxins, National University of Singapore, November 3—8, 1991. Abstract 127, p. 179. (Also see Toxicon 1992;30:599-609.)
Alldridge G, Campbell A, Routledge PA, Volans GN. Survey of enquiries concerning Vipera berus bites received by United Kingdom Poison Center 1983—1991. In: 10th World Congress on Animal Plant and Microbial Toxins, National University of Singapore, November 3— 8, 1991. Abstract 128, p. 180.
Audebert F, Grosselet O, Sabourand A, Bon C. Quantification of venom antigens from European vipers in human serum or urine by ELISA. Personal communication, June 18, 1993.
Stahel E, Wellauer R, Freyvogel TA. Vergiftungen durch einheimische Vipera (Vipera berus and Vipera aspis). Schweiz Med Wochenschr 1985;115:890-896.
Pozio E. Venomous snake bites in Italy: epidemiological and clinical aspects. Trop Med Parasitol 1988;39:62-66.
Theakston RDG, Reid HA. Effectiveness of Zagreb antivenom against envenomation by the adder, Vipera berus. Lancet 1976;2:121-123.
Antonini G, Rasura M, Conti G, Mattia C. Neuromuscular paralysis in Vipera aspis envenomation: pathogenetic mechanisms. J Neurol Neurosurg Psych 1991.
Hawley A. Adder bites in the British Army 1979—1988: a decade of experience. J R Army Med Corps 1990;136:114-118.
Smith DC, Reddi KR, Laing G, Theakston RGD, Landon J. An affinity purified ovine antivenom for the treatment of Eipera Berns envenomation. Toxicon 1992;30:865-871.
Persson H. Initial experience with Vipera berus specific Fab antivenom. Proc Eur Assoc Pois Centers Clin Toxicol, Istanbul, May 1991, p. 3.
Rodrigues D, Machado MA. Poisonous animals: a study of human accidents in the State of Bahia, Brazil. II. Ophidian accidents. Vet Hum Toxicol 1987;29(Suppl 2):76—78.
Burdmann E, Barcellos MA, Cardoso JL, Malheiros R, Abdulkader R, Dakes E et al. Acute interstitial nephritis after snake bite. Ren Fail 1989;11:51-52.
Selistre HS, Queiroz LS, Cunha OAB, De Souza GEP, Giglio JR. Isolation and characterization of hemorrhagic, myonecrotic and edema inducing toxins from Both-rops insularis (Jararaca Ilhoa) snake venom. Toxicon 1990;28:261-273.
Barral-Netto M, Schreifer A, Vinhas V, Almeida AR. Enzyme linked immunosorbent assay for the detection of Bothrops jararaca venom. Toxicon 1990;28:1053-1061.
Fortes-Dias CL, Fonseca BCB, Kochva E, Diniz CR. Purification and properties of an antivenom factor from the plasma of the South American rattlesnake (Crotalus durissus terrificus). Toxicon 1991;29:997-1008.
Jaeger A, Sander PH, Kopferschmitt J, Flesch F. Afibrinogenemia and rhabdomyolysis following rattlesnake bite (Crotalus durissus terrificus). XIII I nt Cong Eur Assoc Pois Control Centers, Edinburgh. September 12—14, 1988.
Davidson TM, Schafer SF, Moseman J. Central and South American vipers. J Wilderness Med 1993;4:416— 440.
Cardosa JLC, Fan HW, Franco FOS, Jorge MT, Leite RP, Nichioka SA et al. Randomized comparative trial of three antivenoms in the treatment of envenoming by lanceheaded vipers (Bothrops jaruaca) in Sao Paulo, Brazil. Q J Med 1993;86:312-325.
Bratt DE, Boos HEA. Bothrops atrox snakebite in a six-year-old child. West Ind Med J 1993;41:130.
Sano-Martins IS, Fan HW, Castro SCP, Tomy SC, Franca FOS, Jorge MT et al. Reliability of the simple 20 minute whole blood clotting test (WBCT20) as an indicator of low plasma fibrinogen concentration in patients envenomated by Bothrops snakes. Toxicon 1994;32:1045-1050.
Cogo JC, Prado-Franceschi J, Rodrigues, Simioni L. Effect of Bothrops insularis on the neuromuscular junction. In: Proc 10th World Congress on Animal Plant and Microbial Toxins, National University of Singapore, November 3—8, 1991. Abstract 135, p. 187.
Kamiguti AS. Coagulopathy induced by Bothrops jararaca envenomations. In: Proc 10th World Congress on Animal Plant and Microbial Toxins, National University of Singapore, November 3—8, 1991. Abstract 152, p. 204.
Moreno RA, Gutierrez JM, Prado-Franceschi J. The neutralization by commercial antiserum (AS) of the systemic and local effects induced by Bothrops neuwiedipau-loensis venom. In: Proc 10th World Congress on Animal Plant and Microbial Toxins, National University of Singapore, November 3—8, 1991. Abstract 159, p. 211.
Nunes ТВ, Rodrigues DS. Poisonous animals. A study of human accidents in the State of Bahia, Brazil, Vet Hum Toxicol 1987;29(Suppl 2):73—75.
Kamiguti AS, Cardoso JLC, Theakston RDG, Sano-Martins IS, Hutton RA, Rugman RF et al. Coagulopathy and haemorrhage in human victim of Bothrops jararaca envenoming in Brazil. Toxicon 1991;29:961-972.
Chaves F, Gutierrez JM, Brenes F. Pathological and biochemical changes induced in mice after intramuscular injection of venom from newborn specimens of the snake Bothrops asper (Terciopelo). Toxicon 1992;2:1099— 1109.
Desmond HP, Crampton JM, Theakston RDG. Rapid isolation and partial characterization of two phospholipases from Kenyan Echis carinatus leakeyi (Leakey’s saw-scaled viper) venom. Toxicon 1991;29:536-539.
Pugh RNH, Theakston RDG. The incidence and mortality of snake bite in savanna Nigeria. Lancet 1980;2:1181-1183.
Warrell DA, Davidson N McD, Greenwood BM, Ormerod LD, Pope HM, Watkins J, Prentice CRM. Poisoning by bites of the saw-scaled or carpet viper (Echis carinatus) in Nigeria. Q J Med 1977;46:33-62.
Brown R, Brasch L, Leichter D, Canfield D. Gabon viper envenomation: An unexpected big city emergency. Pediatr Emerg Care 1989;5:248-249.
Russell FE, Carlson RW, Wainschel J et al. Snake venom poisoning in the United States: experience with 550 cases. JAMA 1975;233:341-344.
Watt CH. Poisonous snake bite treatment in the United States. JAMA 1978;240:654-656.
Curry SC, Kunkel DB. Death from a rattlesnake bite. Am J Emerg Med 1985;3:227—235.
Wingert WA. Poisoning by animal venoms. Top Emerg Med 1980;2(3):89— 118.
Gerkin R, Curry S, Vance M et al. Life-threatening airway obstruction from rattlesnake bite to the tongue. Vet Hum Toxicol 1986;28:487 (abstract).
Clement JE, Pietrusko RG. Pit viper snakebite envenomation in the United States. Clin Toxicol 1979; 14:515— 538.
Russell FE. Snake venom poisoning. Great Neck, NY: Scholium International, 1983.
Bush SP, Jansen PW. Severe rattlesnake envenomation with anaphylaxis and rhabdomyolysis. Ann Emerg Med 1995;25:845-848.
Ouyang C, Teng C-M, Huang T-F. Characterization of snake venom components acting on blood coagulation and platelet function. Toxicon 1992;30(9):945—966.
Swindle GM, Seaman KG, Arthen DC, Almquist TD. The six-hour observation rule for grade I crotalid envenomation: is it sufficient? Case report of delayed envenomation. J Wilderness Med 1992;3:168-172.
Blackman JR, Dollon S. Venomous snakebite: past, present and future treatment options. J Am Board Fam Pract 1992;53:399-405.
Wingert WA, Chan L. Rattlesnake bites in Southern California and rationale for recommended treatment. West J Med 1988;148:37-44.
Walter FG, Olson KR. First aid for snakebite. AACT Clinical Toxicology Update 1995;8:1.
Sutherland SK. First aid for snakebite in Australia with notes on first aid for bites and stings by other animals including spiders. Fourth Revision. April 1991. Commonwealth Serum Laboratories, pp. 4—5.
Sutherland SK, Coulter R, Harris RD. Rationalisation of first aid measures for Elapid snake bite. Lancet 1979;1:183-186.
Gellert GA. Snake venom and insect venom extractors: an unproved therapy. N Engl J Med 1992;327:1322.
Sutherland SK Premedication before antivenom therapy. Med J Aust 1991; 155:722.
Fatovich DM, Turner VF, Hirsch RL. Premedication before antivenom therapy. Med J Aust 1992; 156:510.
Kirkland G. Snake venom allergy. Med J Aust 1990;153:570-571.
Caravati EM, Wallace DE. Anaphylactic reaction to snake venom. Vet Hum Toxicol 1990;21:66.
Bucknail NC. Electrical treatment of venomous bites and stings. Toxicon 1991;29:397-400.
Dart RC, Gustafson RA. Failure of electric shock treatment for rattlesnake envenomation. Ann Emerg Med 1991;20:659-661.
Sullivan JB Jr. Past, present, and future immunotherapy of snake venom poisoning. Ann Emerg Med 1987;16:938-944.
Kelly JJ, Sadeghani K, Gottlieb SF, Ownly CL, Van Meter KW, Torbati D. Reduction of rattlesnake venom-induced myonecrosis in mice by hyperbaric oxygen therapy. J Emerg Med 1991;9:1-7.
Stolpe MR, Norrus RL, Chisholm CD, Hartshorne MF, Okerberg C, Ehler WJ, Posch J. Preliminary observation on the effects of hyperbaric oxygen therapy on western diamondback rattlesnake (Crotalus atrox) venom poisoning in the rabbit model. Ann Emerg Med 1989; 18:871 — 874.
Audebert F, Gorsselet O, Sabourand A, Bond C. Quantitation of venom antigens from European vipers in human serum or urine by ELISA. J Anal Toxicol 1993;17:236-240.
Watt G. Ancillary treatments of neurotoxic envenomation. Toxicon 1993;31:932-933.
Sutherland SK. Commonwealth Serum Laboratories, Melbourne, Australia: Personal communication. May 4, 1992.
Mars M, Hadley GP, Aitchison JM. Direct intracompartmental pressure measurement in the management of snakebites in children. S Afr Med J 1991;80:227-228.
Blackman JR, Dillon S. Venomous snakebite: past, present and future treatment options. J Am Board Fam Pract 1992;5:399-405.
Dart RC, Horowitz R, Gomez H. Management of poisonous snakebite in the United States. Rocky Mountain Poison and Drug Center and University of Colorado, Denver, CO. Revised September 18, 1994.
Sing K, Erickson T, Aks S, Rothenberg H, Lipscomb J. Eastern massasauga rattlesnake envenomations in an urban wilderness. J Wilderness Med 1994;5:77-87.
Parrish HM, Carr C. Bites by copperheads (Agkistrodon contortrix) in the United States. JAMA 1967;201:107— 112.
Rodgers GC, Roe D, Matyunas NJ. Copperhead (Agkistrodon contortrix) envenomations in children. Report of thirty-two cases. In: Proc 10th World Congress in Animal Plant and Microbial Toxins, National University of Singapore, November 3—8, 1991. Abstract 166. p. 218.
White BD, Rodgers GC, Matyunas NJ, Allen F. Copperhead snake bites reported to the Kentucky Regional Poison Center 1986: epidemiology and treatment suggestions. J Kentucky Med Assoc 1988;86:61-66.
Watt CH. Poisonous snake bite treatment in the United States. JAMA 1978;240:654-656.
Treatment of snakebites in the USA. Med Lett 1982;24:87-89.
Russell FE. Bites by the Sonoran coral snake, Micru-roides euryxanthus. Toxicon 1967;5:39-42.
Mandell F, Bates J, Mittleman MS et al. Major coagulopathy and "non-poisonous" snake bites. Pediatrics 1980;65:314-317.
MckKinstry DM. Evidence of toxic saliva in some col-ubrid snakes of the United States. Toxicon 1978; 16:523— 534.
Cable D, McGehee W, Wingert WA et al. Prolonged defibrination after a bite from a "nonvenomous" snake. JAMA 1984;251:925-926.
Minton SA. Beware: nonpoisonous snakes. Clin Toxicol 1978;15:259-265.
Vest DK. Envenomation following the bite of a wandering garter snake (Thamnophis elegans vagrans). Clin Toxicol 1981;18:573-579.
Weed HG. Nonvenomous snakebite in Massachusetts: prophylactic antibiotics are unnecessary. Can Emerg Med 1993;22:220-224.
Golay P, Stocklin R. Azemiops: a worldwide database on venomous snakes. In: Proc 10th World Congress on Animal Plant and Microbial Toxins, National University of Singapore, November 3—8, 1991. Abstract 102, p. 154.
Mochca-Morales J, Martin BM, Possani LD. Isolation and characterization of helothermine, a novel toxin from Heloderma horridum horridum (Mexican beaded lizard) venom. Toxicon 1990;28:299-309.
Bou-Abboud CF, Karassakis DG. Acute myocardial infarction following a Gila monster (Heloderma suspectum cinctum) bite. West J Med 1988;148:577-579.
Preston CA. Hypotension, myocardial infarction and coagulopathy following Gila monster bite. J Emerg Med 1989;7:37-40.
Hooker KR, Caravati EM. Gila monster envenomation. Ann Emerg Med 1994;24:731.
Fletcher JE, Jodokowsky M, Tripolitis L. Calcium release induced by Naja naja kaouthia cardiotoxin in skeletal muscle sarcoplasmic reticulum exhibits a species-dependent association with the threshold of cardiotoxin-induced calcium release. In: Proc 10th World Congress on Animal Plant and Microbial Toxins, National University of Singapore, November 3—8, 1991. Abstract 021, p. 73.
Habermehl G. Chemistry and pharmacology of amphibian venoms. In: Proc 10th World Congress on Animal Plant and Microbial Toxins, National University of Singapore, November 3—8, 1991. Abstract 113, p. 165.
Palumbo NE, Perri S, Read G. Experimental induction and treatment of toad poisoning in the dog. J Am Vet Med Assoc 1975;167:1000-1005.
Hitt M, Ettinger DD. Toad toxicity. N Engl J Med 1986;314:1517.
Daly JW. Biologically active alkaloids from poison frogs (Dendrobatidae). J Toxicol Toxin Rev 1982;1:33-86.
Mensah-Dwumah M, Daly JW. Pharmaclotical activity of alkaloids from poison-dart frogs (Dendrobatidae). Toxicon 1968;16:189-194.
Myers CW, Daly JW, Malkin B. A dangerously toxic new frog (Phyllobates) used by Enbera Indians of western Colombia with discussion of blowgun fabrication and dart poisoning. Bull Am Mus Nat Hist 1978;101:31 1-365.
Daly J, Witkop B. Batrachotoxin, an extremely active cardioand neurotoxin from the Colombian arrow poison frog (Phyllobates aurotaenia). Clin Toxicol 1971;4:331 — 342.
Daly JW, Myers CW, Warnick JE et al. Levels of batrachotoxin and lack of sensitivity to its action in poisondart frogs (Phyllobates). Science 1980;208:1383-1385.
Brown GB. 3H-Batrachotoxin — a benzoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin. J Neurosci 1986;6:2064-2070.
Wayne Moore GR, Boegman RJ, Robertson DM et al. Acute stages of batrachotoxin-induced neuropathy: a morphologic study of a sodium channel toxin. J Neuro-cytol 1986;15:573-583.
Bradley SG, Klika LJ. A fatal poisoning from the Oregon roughskinned newt (Taricha granulosa). JAMA 1981;246:247.
Brodie ED Jr. Investigations of the skin toxins of the adult rough-skinned newt, Taricha granulosa. Copeia 1974;68(l):306—313.
Brodie ED Jr, Hansel JL, Johnson JA. Toxicity of the urodele amphibians Taricha notophthalmus cynops and Paramesotriton salamandridae. Copeia 1974(2):506—511.
Poklis A, Hameli AZ. Two unusual barbiturate deaths. Arch Toxicol 1975;34:77-80.
Clark MA, Jones JW. Suicide by intravenous injection of a veterinary euthanasia agent: report of a case and toxicologic studies. J Forensic Sci 1979;24:762-767.
Smith RA, Lewis D. Suicide by ingestion of T-61. Vet Hum Toxicol 1989;31:319-320.
Nicolas F, Rodineau P, Rovzioux J-M, Tack I, Chabac S, Meram D. Fulminant hepatic failure in poisoning due to ingestion of T-61, a veterinary euthanasia drug. Crit Care Med 1990;18:573-575.
Cordell WH, Curry SC, Furbee RB, Mitehell-Flynn DL. Veterinary euthanasia drugs as suicidal agents. Ann Emerg Med 1986;15:939-943.
Kingston RL, Saxena K. Intentional poisoning by injection of veterinary euthanasia drug. Clin Toxicol 1979; 15:492 (abstract).
Brown M. An overdose of dog’s heart tablets. Hum Exp Toxicol 1990;9:201.
Cavaliere U, Andreano C, Raducci G, Andreioni C, lacovella A. Intossicazione da T-61 (TanaxR). MinAnest 1982;48:861-864.
Cohen ML, Ming RH, Gogel HK, Davis M, Pitcher JL. Horse pill ("bute") hemorrhage. J Clin Gastroenterol 1988;10:210-212.
Newton TA, Rose SR. Poisoning with equine phenylbutazone in a racetrack worker. Ann Emerg Med 1991;20:204-207.
Thompson JD. Human intoxication with banamine. Vet Hum Toxicol 1990;32:352.
Markus CK, Chow LH, Wycoff DM, McManus BM. Pet food derived penicillin residue as a potential cause of hypersensitivity myocarditis and sudden death. Am J Cardiol 1989;63:1 155-1156.
Boutelba K, Belmati E, Merad R, Drif M. Talking of a strange intoxication by an anti-coccidian of veterinary use. Proc Intern Cong Clin Toxicol Pois Cont Anal Toxicol. LuxTox ’90, Luxembourg, May 2—5, 1990, p. 499.
Martinez-Navarro JF. Food poisoning related to consumption of illicit beta-agonist in liver. Lancet 1990;336:1311.
Woodward KN, Gray AK. Adverse reactions in humans following occupational exposure to veterinary drugs. Hum Exp Toxicol 1990;9:326.
Sidhu KS, Collisi MB. A case of an accidental exposure to a veterinary insecticide product formulation. Vet Hum Toxicol 1989;31:63-64.
Woodward KN, Gray AK. Adverse reactions in humans arising from the use of veterinary drugs. Abstract 338. Brighton, England: Fifth International Congress of Toxicology, July 16—21, 1989.
Woodward KN. Veterinary Medicines Directorate, UK. Personal communication. August 6, 1990.
Schenker MB, Samuels SJ, Green RS, Wiggins P. Adverse reproductive outcomes among female veterinarians. Am J Epidemiol 1990; 132: 96—106.
Reid FM, Tracey JA. Parenteral exposure to detomidine and butorphanol. Clin Toxicol 1994;32:465-469.
McGuigan MA. Human exposures to tilmocosin (Mico-tilR). Vet Hum Toxicol 1994;36:306-398.
Vazquez C, Labayru T, Rodriguez-Soriano J. Poor bronchodilator effect of oral etamphylline in asthmatic children. Lancet 1984; 1:914.
Addis GJ. Absence of bronchodilator effect from etamphylline. Lancet 1984; 1:1083.
Gray AK. Suspected adverse reaction surveillance scheme 1991: summary of results. Vet Rec 1993; 132:4— 6.
Murray VSG, Wiseman HM, Dawling S, Morgan I, Ho-sue IM. Health effects of organophosphate sheep dips. Br Med J 1992;305:1090.
Strong JE, Wilson J, Douglas JF et al. Phenylbutazone selfpoisoning treated by charcoal haemoperfusion. Anaesthesia 1979;34:1038-1040.
Berlinger WC, Spector R, Flanigan MJ et al. Hemoperfusion for phenylbutazone poisoning. Ann Intern Med 1982;96:334-335.
Clutton RE. Attempted suicide with acepromazine maleate: a case report. Vet Hum Toxicol 1985;27:391.
Berns SD, Wright JL. Pediatric acepromazine poisoning. The importance of child-resistant packaging for veterinary drugs. Am J Emerg Med 1993; 11:247—248.
Van Boren M, Daenens P. Analysis and identification of azaperone and its metabolites in humans. J Anal Toxicol 1992;16:33-35.
Woodward KN. Hypersensitivity in humans and exposure to veterinary drugs. Vet Hum Toxicol 1991 ;33:168— 171.
Hoen E, Hodgkin C, Mikevicious D. Harmful human use of donated veterinary drugs. Lancet l993;342:308— 309.
Amery WF, Veys P, Gheuens J. Beerse, Belgium, Janssen Research Foundation. Personal communications, March 2, 1993.
Martinez-Frias ML, Cereijo A, Rodriguez-Pinilla E, Uriose M. Methimazole in animal feed and congenital aplasia. Lancet 1992;339:742-743.
Bedello PG, Goitre M, Cane D, Roncarolo G. Allergic contact dermatitis to Bayo-N-Ox-1. Contact Dermatitis 1985;12:284.
Francalanci S, Gola M, Giorgini S, Muccinelli A, Sertoli A. Occupational photocontact dermatitis from olaquin-dox. Contact Dermatitis 1986;15:112-114.
Luehr JG, Meyerle KA, Larson EW. Mail-order (veterinary) drug dependence. JAMA 1990;263:657.
Paggiaro PL, Loi AM, Toma G. Bronchial asthma and dermatitis due to spiramycin in a chick breeder. Clinical Allergy 1979;9:571-574.
Davies RJ, Pepys J. Asthma due to inhaled chemical agents — the macrolide antibiotic spiramycin. Clinical Allergy 1975;1:99-107.
Braselton WE Jr, Ray JS, Slanker MR, Rumler PC. Determination of embutramide in mammalian tissues. Vet Hum Toxicol 1988;30:536-539.
Miller CD, Songer JR, Sullivan JF. A twenty-five year review of laboratory-acquired human infections at the National Animal Disease Center. Am Ind Hyg Assoc J 1987;48:271-275.
Geller RJ. Human effects of veterinary biological products. Vet Hum Toxicol 1990;32:479-480.
Gulasekharan J. Illness following accidental self-inoculation of Brucella abortus strain 19 vaccine. Med J Aust 1970;2:642-643.
Committee on Safety of Medicines. Accidental self-injection of oil-based veterinary vaccines. London Committee on Safety of Medicines 1981;20:3-4.
Woodward KN. Veterinary Medicines Directorate. Wey-bridge, Surrey, UK: Personal communication. August 6, 1990.
Warning about veterinary vaccines. Br Med J 1987;7:294-352.
Joffe B, Diamond MT. Brucellosis due to self-inoculation. Ann Intern Med 1966;65:564-565.
Constable PJ, Harrington JM. Risks of zoonosis in a veterinary service. Br Med J 1982;284:146-148.
Crosby AD, Geller RJ. Human effects of veterinary biological products. Vet Hum Toxicol 1986;28:569-571.
McCaullugh NB. Medical care following accidental injection of Brucella abortus, strain 19 in man. J Am Vet Med Assoc 1963; 143:617.
Trammel HL. National Animal Poison Control Center. Urbana, IL: Personal communication, December 3, 1990.
Bonsall JL, Turnbull GJ. Extrapolation from safety data to management of poisoning with reference to amitraz (a formamide pesticide) and xylene. Hum Toxicol 1983;2:587-592.
Hollingworth RM. Chemistry, biological activity, and uses of formamidine pesticides. Environ Health Perspect 1976;14:57-62.
Besbelli N, Oto N, Yalcinlar O, Ikinciogullari A. Poisoning cases with amitraz, 1990. Proc XIV Int Congress Eur Assoc Poison Control Centres. Milan, Italy: September 25—29, 1990.
Jones RD. Xylene/amitraz: a pharmacologic review. Vet Hum Toxicol 1990;32:446-448.
Kucera J. Exposure to fat solvents, a possible cause of sacralagenesis in man. J Pediatr 1968;72:857-859.
Azia SA, Knowles CO. Inhibition of monoamine oxidase by the pesticide chlordimeform and related compounds. Nature 1973;242:417-418.
Hsu WH, Schaffer DD. Effects of topical application of amitraz on plasma glucose and insulin concentrations in dogs. Am J Vet Res 1988;49:130-131.
Yamaguchi Y, Shirakawa Y, Ogura S, Ameno K, Fuke C, Ogli K. A case of Amitraz poisoning. Jpn J Toxicol 1989;2:289-292.
Ameno K, Fuke C, Ameno S, Kiriu T, Shinohara T, Ijiri I. A rapid and sensitive quantitation of Amitraz in plasma by gas chromatography with nitrogen-phosphorus detection and its application for pharmacokinetics. J Anal Toxicol 1991;15:116-118.
Hovda LR, McManus AC. Yohimbine for treatment of Amitraz poisoning in dogs. Vet Hum Toxicol 1993;35:329.
Reynolds JEF. Martindale: The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989, p. 663.
Abaru DE, Lewo DA, Isakina D, Okori EE. Retrospective long-term study of effects of berenil by follow-up of patients treated since 1965. Trop Med Parasito! 1984;35:148-150.
Poklis A, Machell MA, Case MES. Xylazine in human tissues and fluids in a case of fatal drug abuse. J Anal Toxicol 1985;9:234-236.
Gallanosa G, Spyker DA, Shipe JR, Morris LD. Human xylazine overdose: a comparative review with clonidine, phenothiazines and tricyclic antidepressants. Clin Toxicol 1981;18:663-678.
Spoerke DG, Hall AH, Grimes MJ, Honea BN, Rumack BH. Human overdose with the veterinary tranquilizer xylazine. Vet Hum Toxicol 1985;28:190.
Mackintosh C. Potential antidote for Rompun (xylazine) in humans. New Zeal Med J 1985;9:714-715.
Carruthers SG, Nelson M, Wexler HR, Stiller CR. Xylazine hydrochloride (Rompun) overdose in man. Clin Toxicol 1979;15:281-285.
Thompson C. Laser tackles bone. Lancet 1995;345:1001.
Healing with light. Harvard Medical School Letter 1988;13:3-5.
Sliney DH, Bosnjakovic B, Court LA, McKinlay AF, Szabo LD, Coppee GH. The Use of Lasers in the Workplace. Occupational Safety and Health Series No. 68. International Nonionizing Radiation Committee of the International Radiation Protection Association and the International Labour Organization, 1993, Geneva.
Gelb AF. Lasers in pulmonary treatment. West J Med 1990;153:70-71.
Nightingale SL. Warning about gas/air embolism during intrauterine laser surgery. JAMA 1990;264:168.
Edmunds D. Laser protective eyewear: determining the correct lens. Occup Health Safety, July/August 1994;31—34.
Patlak M. Light for sight. Lasers beginning to solve vision problems. FDA Consumer 1990;24:15-17.
Lewis R. Erasing skin marks with lasers. FDA Consumer 1992;26:23-26.
Tanner M. Increasing use, power of lasers make eye protection essential. Occup Health Safety, July 1990;44—45.
American National Standards Institute. May 23, 1989. 3rd printing. September 1989. AN SI Z136.1-1986. The Laser Institute of America, 12 424 Research Parkway, Orlando, FL 32 826.
Wald N. Ionizing radiation. ATSDR October 1993.
Guidelines for protecting the safety and health of health care workers. US Dept of Health and Human Services. September 1988; DHHS (NIOSH) Publication No. 88— 119. pp. 5-71.
Leonard RB, Ricks RC. Emergency department radiation accident protocol. Ann Emerg Med 1980;9:462— 470.
Whalen JP, Balter S. Radiation risks associated with diagnostic radiology. Disease-А-Works, Yearbook, 1982; pp. 1-92.
Pearson R. Radiography in women of childbearing ability. Br Med J 1989;299:1175-1176.
Swartz HM, Reichling BA. Hazards of radiation exposure for pregnant women. JAMA 1978;239:1907-1908.
Upfal M, Sanat JM. Radon toxicity. ATSDR Case Studies in Environmental Medicine 14. September 1992.
Woolf AD. Radon. Clin Toxicol Rev 1991;43:1-2.
Brill AB, Becker DV, Donahoe K, Goldsmith SJ, Greenspan B, Kase К et al. Radon update: facts concerning environmental radon: levels, mitigation strategies, dosimetry, effects and guidelines. J Nucl Med 1994;35:368-385.
Leary WE. Studies raise doubts about need to lower home radon levels. New York Times, September 6, 1994;27, B7.
A Citizen’s Guide to Radon. 2nd ed. The Guide to Protecting Yourself and Your Family From Radon. United States Environmental Protection Agency. Air and Radiation (ANR-464), May, 1994. NCRP Report No 103. Control of Radon in Houses. Bethesda, MD: National Council on Radiation Protection and Measurements.
McLaughlin JR, King WD, Anderson TW, Clarke EA, Ashmore JP. Paternal radiation exposure and leukaemia in offspring. The Ontario case-control study. Br Med J 1993;307:959-966.
Godlee F. Sellafield cancer link "fragile" says HSE. Br Med J 1993;307:1096.
Lushbaugh CC. Keynote address: radiation accidents worldwide. An additional decade of experience. In: Ricks RC, Fry SA, eds. The medical basis for radiation accident preparedness II. New York: Elsevier, pp. xxxv-xxx-ix.
Becker DV. Reactor accidents. Public health strategies and their medical implications. JAMA 1987;258;649— 654.
Hatch MC, Beyena J, Nieves JW, Susser M. Cancer near the Three Mile Island nuclear plant: radiation emissions. Am J Epidemiol 1990;132:397-412.
Jablon S, Hrubec Z, Boice JD Jr, Stone BJ. Cancer in populations living near nuclear facilities. Volume for Report and Survey. National Cancer Institutes NIH Publication No. 90—874, July 1990; pp. 1—96.
Liebow AA, Warren S, DeCoursey E. Pathology of atomic bomb casualties. Am J Pathol 1947;25:853— 1028.
Liebow AA. Encounter with disaster — a medical diary of Hiroshima, 1945. Yale J Biol Med 1965;38:61-239.
Keller PD. A clinical syndrome following exposure to atomic bomb explosions. JAMA 1946;131:504-506.
Randall T. A lean mean cyclotron revs up neutron therapy. JAMA 1992;267:614-616.
NRCP Report No. 38. Protection Against Neutron Radiation. Washington, DC: January 4, 1971.
Henshaw DL, Eatough JP, Richardson RB. Radon as a causative factor in induction of myeloid leukemias and other cancers. Lancet 199O;335:1008—1012.
Llewellyn C. Medical aspects of thermonuclear disasters. In: Reis MD, Dolve E, eds. Manual of disaster medicine. Civilian and military. Berlin: Springer-Verlag, 1989; pp. 124-148.
Gofman JW. Radiation-induced cancer from low-dose exposure: an independent analysis. San Francisco Committee for Nuclear Responsibility, 1990.
Marwick C. More studies pending of low-dose radiation. JAMA 1990;264:944.
Marwick C. Low-dose radiation: latent data renew questions of "safe" level. JAMA 1990;264:553-554.
Yalow RS. Concerns with low-level ionizing radiation. Mayo Clin Proc 1994;69:436-440.
Mountford PJ, Coakley AJ. Radioactive patients. Patients given radioactive substances represent a small risk to others. Br Med J 1989;298:1538-1539.
Mountford PJ, Coakley AJ. Guidelines for breast feeding following maternal pharmaceutical administration. Nuclear Med Comm 1986;7:399-401.
Berger ME, Thompson DW, Ricks RC, Kaufmann D. The medical technologist and the radiation-accident victim. Am J Med Technol 1981;47:831-834.
Bloomer WD, Hellman S. Normal tissue responses to radiation therapy. N Engl J Med 1975;293;80—83.
Brahan D. Radiotherapy overdose. Lancet 1988;2:975.
Polish RA. Prediction of radiation-related small bowel damage. Radiology 1980;135:219-221.
Jiang GL, Tucker SL, Guttenberger R, Peters LJ, Morrison WH, Garden AS et al. Radiation-induced injury to the visual pathway. Radiotherap Oncol 1994;30:17-25.
Bevers RFM, Bakker DJ, Kurth KM. Hyperbaric oxygen treatment for hemorrhagic radiation cystitis. Lancet 1995;346:803-805.
Pottern LM, Kaplan MM, Larsen PR, Silva JE, Koenig RJ, Lubin JH et al. Thyroid nodularity after childhood irradiatin for lymphoid hyperplasia: a comparison of questionnaire and clinical findings. J Clin Epidemiol 1990;43:449-460.
Leith JT, Hercbergs AA. Radiation-induced breast cancer: long-term follow-up of radiation therapy for benign breast disease. J Natl Cancer Inst 1994;86:393-394.
Morris JGL, Grattan-Smith P, Panegyres PK, O’Neill P, Soo YG, Langlands AO. Delayed cerebral radiation necrosis. Q J Med 1994;87:119-129.
Malapert D, Brugieres P, Degos J D. Motor neurone syndrome in the arms after radiation treatment. Thorax 1991 ;54.
Gibson PG, Bryant DH, Morgan GW, Yeates M, Fernandez V, Penny R et al. Radiation-induced lung injury: A hypersensitivity pneumonitis? Ann Intern Med 1988;109:288-291.
Phillips TL. Radiation injury. In: Wyngaarden JB, Smith LH Jr, eds. Cecil textbook of medicine. 18th ed. Philadelphia: WB Saunders, 1988; pp. 2375-2378.
De Neve W, Fortan L, Storme G. Increased mucosal and cutaneous epus radiation toxicity in two patients taking amiodarone. Int J Radiat Oncol Biol Phys 1992;22:224.
Vanek N, Horotobagyi GN, Buzden AV. Radiotherapy enhances the toxicity of aminoglutethimide. Med Pediatr Oncol 1990;18:162-164.
Ramakrishnas S, Macleod P, Tyrrell CJ. Acute radiation skin reaction and persistent photosensitivity after benox-apropon. Lancet 1988;2:913.
Shelley WB, Shelley ED, Campbell EAC, Weigensberg IJ. drug eruptions presenting at sites of prior radiation damage (sunlight and electronic beam). J Am Acad Dermatol 1984;11:53-57.
Boivin J-T. Second cancers and other late side effects of cancer treatment. A review. Cancer 1990;65:770-775.
Curtis RE, Boise JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326:1745-1751.
Weber E, Laarbai F, Michel L, Donckier J. Abdominal pain: do not forget Thorotrast! Postgrad Med J 1995;7:367-369.
Geiger HJ. The accident at Chernobyl and the medical response. JAMA 1986;256:609-612.
US and IAEA Chernobyl delegations assess radiation effects. J Nuclear Med 1991 ;32:1 IN—13N.
Linnemann RE. Soviet medical response to the Chernobyl nuclear accident. JAMA 1987;258:637-643.
Rich V. New hazard at Chernobyl. Lancet 1994;343:108.
Boice J, Linet M. Chernobyl, childhood cancer, chromosome 21. Probably nothing to worry about. Br Med J 1994;309:139-140.
Kingman S. Thyroid cancer increases around Chernobyl. Br Med J 1993;307:1230.
Furmanchuk AW, Averkin JI, Egloff B, Ruchti C, Abelin T, Schappi W. Korotkevich EA. Pathomorphological findings in thyroid cancers of children from the Republic of Belarus: a study of 86 cases occurring between 1986 ("post-Chernobyl") and 1991. Histopathology 1992;21:401-408.
EMF in your environment. Magnetic field measurements of everyday electrical devices. US Environmental Protection Agency. 402-R-92 008, December 1992.
Hughes RS. Laser safety. Principles of laser action. University of Southern California Institute of Safety and Systems Management Professional Program, 1990.
Extremely low frequency (ELF) fields. Environmental Health Criteria 35. Geneva: World Health Organization, 1984.
Magnetic Fields. Environmental Health Criteria 69. Geneva: World Health Organization, 1987.
Harvard Medical School Health Letter 1990; 15(8): 1—4.
Saritz DA, Pearce NE, Pook C. Methodological issues in the epidemiology of electromagnetic fields and cancer. Epidemiol Rev 1989;11:59-78.
Savitz DA, Calle EZ. Leukemia and occupational exposure to electromagnetic fields: review of epidemiologic surveys. J Occup Med 1987;20:47-51.
Herring A. Hazards of magnetic resonance imaging. Lancet 1991 ;337:1477.
The Use of Lasers in the Workplace. A Practical Guide. Occupational Safety and Health Series No. 68. Geneva: International Labour Office, 1993; pp. 49—56.
Magnetic Resonance Diagnostic Panel. Panel recommendations and report on petitions for MR reclassification. Fed Reg 1988;53:7575-7579.
Jauchem JR. Potential confounders in epidemiologic studies of electric and magnetic fields and childhood leukemia. Environ Carino Ectox Revs 1993;11:163-183.
Connor S. No risk of cancer from electromagnetic fields. Br Med J 1992;304:938-939.
Draper G. Electromagnetic fields and childhood cancer. No causal relation has been established. Br Med J 1993;307:884-885.
Feychting M, Ahlbom A. Magnetic fields and cancer in children residing near Swedish high-voltage power lines. Am J Epidemiol 1993;138:467-481.
Hoffman DA. Biologic effects of infrared radiation. JAMA 1988:260:703.
Performance Standards for Light-emitting Products. Code of Federal Regulations. HL Part 1040.10 (Laser Products), April 1, 1995; pp. 344—360.
Council on Scientific Affairs. Lasers in medicine and surgery. JAMA 1986;256:900-907.
Healing with light. Harvard Medical School Health Letter, February 1988; 13(4):3—5.
Nightingale SL. Warning about gas/air embolism during intrauterine laser surgery. JAMA 1990;264:168.
Pathak MA, Fitzpatrick ТВ, Greiter FJ, Kraus EW. Principles of photoprotection in sunburn and suntanning and topical and systemic photoprotection in health and diseases. J Dermatol Surg Oncol 1985;1:575-579.
Gillow JT. Another weapon too far: the anti-personnel laser. J R Soc Med 1995;88:347P—349P.
Chalmers JWT, Maclean 1H, Breen DA. Hazards of magnetic resonance imaging. Lancet 1991 ;237:1477.
Johnson GC. Need for caution during MRI imaging of patients with aneurysm clips. Radiology 1993;188:287-288.
Moseley I. Safety and magnetic resonance imaging. Avoid imaging patients with metal objects in their body. Br Med J 1994;308:1 181-1 182.
Shellock FG, Morisoli S, Kanal E. MR procedures and biomedical implants, materials and devices: 1993 update. Radiology 1993;189:587-599.
Brent RL: X-ray, microwave and ultrasound: the real and the unreal hazards. Pediatr Ann 1989;9:43-47.
Forman SA. Sublethal exposure to microwave radar. JAMA 1988;259:3129.
Council on Scientific Affairs. Harmful effects of ultraviolet radiation. JAMA 1989;262:380-384.
Harvard Medical School Health Letter 1990; 15(9):3.
Diffey BL. Tanning with ultraviolet A sunbeds. Should be discouraged. Br Med J 1990;301:773-774.
Choo V. Ultraviolet radiation and carcinogenesis. Lancet 1994;344:1499.
The melanoma epidemic. Harvard Medical School Health Letter 1990;15:1-3.
Walter SD, Manrett LD, Shannon HS. From Hertzman C: The association of cutaneous malignant melanoma and fluorescent light fixtures. Am J Epidemiol 1992;135:749-762.
Griffiths AP, Faimey A. Fluorescent lights, ultraviolet lamps and cutaneous melanoma. Br Med J 1988;297:1041.
Cheng H: Causes of cataract. Age, sugars and probably ultraviolet В radiation. Br Med J 1989;298:1470-1471.
Taylor HR, West SK, Rosenthal FS, Munoz B, Newland HS, Abbey H, Emmett EA. Effect of ultraviolet radiation on cataract formation. N Engl J Med 1988;319:1429— 1433.
Hendricks WM. Sun protection. NCMJ 1989;50:435— 440.
Hendricks WM. How much sun is enough? NCMJ 1989;50:272-273.
Jones PR. Ozone depletion and cancer risk. Lancet 1987;2:443-446.
Pitts DG. Threat of ultraviolet radiation to the eye — how to protect against it. J Am Optom Assoc 1981;52:949-957.
McDonagh AF, Nguyen ML. Spectacles, ultraviolet radiation and formation of cataracts. N Engl J Med 1989;321:1478-1479.
Secretariat for Governmental Relations and Public Information Committee. American Academy of Ophthalmology. Video display terminals (VDTs) and the eye, July 1984.
DahlquistNR, Mellinger JF, Klass DW. Hazard of video games in patients with light-sensitive epilepsy. JAMA 1983;249:776-777.
Hart EJ. Nintendo epilepsy. N Engl J Med 1990;322: 1473.
Knave B, Repacholi M, Stolwijk J, Stuchly M, Bergqvist U. Visual Display Units: Radiation Protection Guidance. Occupational Safety and Health Series 70. Geneva: International Labour Office, 1994.
Ziegler JF, Zabel TH, Curtis HW. Video display terminals and radon. Health Phys 1993;65:252-264.
SchnorrTM, Grajewski BA, Murray WE, Hornung RW. Magnetic fields of video display terminals and spontaneous abortion. Am J Epidemiol 1993;138:902-903.
Bentur Y. Ionizing and nonionization radiation in pregnancy. In: Koren G, ed. Maternal-fetal toxicology. New York: Marcel Dekker, 1990; pp. 205—251.
Perry G, Weissenberger DI, Milroy WC, Clever LH, Ducatman AM, Anstadt GW et al. VDT exposure and pregnant workers. J Occup Med 1991;33:675-676.
Schnorr TM, Grajewski BA, Hornung RW, Thun MJ, Egeland GM, Murray WE et al.Video display terminals and the risk of spontaneous abortion. N Engl J Med 1991;324:727-733.
Schnorr TM. The NIOSH study of reproductive outcomes among video display terminal operators. Reprod Toxicol 1990;4:61-65.
Bergqvist UO, Knave BG. Eye discomfort and work with visual display terminals. Scand J Work Environ Health 1994;20:27-33.
Council on Scientific Affairs. Health effects of video display terminals. JAMA 1987;257:1508-1510.
Guidelines for Protecting the Safety and Health of Health Care Workers. US Department of Health and Human Services. DHHS (NIOSH) Publication No. 88— 119, pp. 5-72, 5-73.
Enterline РЕ, Henderson V, Marsh G. Mortality of workers potentially exposed to epichlorhydrin. Br J Ind Med 1990;47:269-276.
Tsai SP, Cowles SR, Tackett DL, Barclay MT, Ross CE. Morbidity prevalence study of workers with potential exposure to epichlorhydrin. BrJ Ind Med 1990;47:392-399.
Tassignon JP, Bas GD, Craigen AA, Jacquet B, Kueng HL, Lanouziere-Simon C, Pierre C. Mortality in an European cohort occupationally exposed to epichlorhydrin (ECH). Int Arch Occup Environ Health 1983;51:325— 333.
CDC. NIOSH alerts on work place hazards: falls through skylights and roof openings, death of farm workers in manure pits and exposure to dimethylformamide. MMWR 1991;40:142-143.
Fleming LE, Shalat SL, Redlich CA. Liver injury in workers exposed to dimethylformamide. Scand J Work Environ Health 1990;16:289-292.
Potter HP. Dimethylformamide-induced abdominal pain and liver injury. Arch Environ Health 1973;27:340— 341.
Redlich CA, Beckett WS, Sparer J, Barwich KW, Riely CA, Miller H et al. Liver disease associated with occupational exposure to the solvent dimethylformamide. Ann Intern Med 1988;108:680-686.
Tolot F, Arcadio F, Lenglet JP, Roche L. Intoxication par la dimethylformamide. Arch Mai Prof 1968;29:714— 717.
Tolot F, Droin M, Generois M. Intoxication par la dimethylformamide. Arch Mai Prof 1958;19:602-606.
Reinl W, Urban HJ. Erkrankungen durch dimethylformamide. Int Arch V Gewerbepathol Gewerbehyg 1965;21:333-346.
Lyle WH, Spence TW, McKinneley WM, Duckers K. Dimethylformamide and alcohol intolerance. Br J Ind Med 1979;36:63-66.
Chivers CP. Disulfiram effect from inhalation of dimethylformamide. Lancet 1978;1:331 (letter).
Wang J-D, Lai M-Y, Chen J-S, Lin J-M, Chiang J-R, Shiau S-J, Chang W-S. Dimethylformamide-induced liver damage among synthetic leather workers. Arch Environ Health 1991;46:161-166.
Nicolas F, Rodineau P, Rouzioux J-M, Tack I, Chabac S, Merain D. Fulminant hepatic failure in poisoning due to ingestion of T61, a veterinary euthanasia drug. Crit Care Med 1990;18:573-574.
Levin SM, Baker DB, Landrigan PJ etal. Testicular cancer in leather tanners exposed to dimethylformamide. Lancet 1987;2:1153 (letter).
CDC. Testicular cancer in leather workers — Fulton County, New York. MMWR 1989;38:105-114.
Ducatman AM. Dimethylformamide, metal dyes, and testicular cancer. Lancet 1989;1:911.
Gollins WJF. Dimethylformamide and testicular cancer. Lancet 1991;337:306-307.
Chen JL, Kennedy GL Jr. Dimethylformamide and testicular cancer. Lancet 1988; 1:55.
Chen J L, Fayerweather WE, Pell S. Cancer incidence of workers exposed to dimethylformamide and/or acrylonitrile. J Occup Med 1988;30:813-818.
Office of the Federal Register. Code of Federal Regulations: occupational Safety and Health Standards. Subpart Z: Air contaminants — permissible exposure limits. Table Z-l-A. Washington, DC: Office of the Federal Register. National Archives and Records Administration, 1989 (29CFR1910.1000).
NIOSH pocket guide to chemical hazards. DHHS (NIOSH) Publication No. 90-117. NIOSH. US Government Printing Office, Washington, DC: June 1990.
Kimmerle G, Eben A. Metabolism of A,A-dimethylfor-mamide. I. Studies in rats and dogs. Int Arch Arbeitsmed 1975;34:109-126.
Kimmerle G, Eben A. Metabolism studies of N,N-dimethylformamide. Int Arch Arbeitsmed 1975;34:127— 136.
Baselt RC, Cravey RH. Disposition of toxic drugs and chemicals in man. 3rd ed. Chicago: Year Book, 1989; pp. 280-282.
Yonemoto J, Suzuki S. Relation of exposure to dimethylformamide vapor and the metabolite, methylformamide, in urine of workers. Int Arch Occup Environ Health 1980;46:159-165.
Lauwerys RR, Kivits A, Lhoir M, Rigolet P, Houbeau D, Beucket JP, Roels HA. Biological surveillance of workers exposed to dimethylformamide and the influence of skin protection on its percutaneous absorption. Int Arch Occup Environ Health 1980;45:189-203.
NIOSH alert on dimethylfonnamide. [DHHS (NIOSH) 90-105].
Barnes JR, Henry NW III. The determination of A-methylformamide and A-methylacetamide in urine. Am Ind Hyg Assoc J 1974;35:84-87.
Seij K, Inoue O, Cai S-K, Kowai T, Watane T, Ikeda M. Increase in sister chromatid exchange rates in association with occupational exposure to A-A-dimethylfor-mamide. Int Arch Occup Environ Health 1992;64:65— 67.
Rubin RJ, Ness PM. What price progress? An update on vinyl plastic blood bags. Transfusion 1989;29:358-361.
Toxicological profile for di (2-ethyl hexyl) phthalate. Agency for Toxic Substances and Disease Registry, US Public Health Service. ATSDR/TP-88/15, 1989.
Kluwe WM. Overview of phthalate ester pharmacokinetics in mammalian species. Environ Health Perspect 1988;45:3-10.
Pearson SD. Leaching of diethylhexylphthalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm 1993;50:1405-1409.
Alexander M, Matsumura F, Lech J (Peer review panel). ATSDR. Toxicological profile for diethyl phthalate draft. May 1993.
Dickson SJ, Missen AW, Down GJ. The investigation of plasticizer contaminants in post-mortem blood samples. J Forensic Sci 1974;4:155-159.
Albro PW, Lavenhar SR. Metabolism of di (2-ethyl hexyl) phthalate. Drug Metab Rev 1989;21:13-34.
White RD, Carter DE, Earnest O, Mueller J. Absorption and metabolism of three phthalate diesters by the rat small intestine. Food Cosmet Toxicol 1980;18:383-386.
Albro PW, Thomas R, Fishbein L. Metabolites of dietary diethylhexyl phthalate by rats. Isolation and characterization of the urinary metabolites. J Chromatogr 1983;76:321-330.
Jaeger RJ, Rubin RJ. Migration of phthalate ester plasticizer from polyvinyl chloride blood bags into stored human blood and its localization in human tissues. N Engl J Med 1972;287:1114-1118.
Sjoberg POJ, Bondesson VG, Sedin EG, Gustaffson JP. Exposure of newborn infants to plasticizers. Plasma levels of DEHP and MEHP during exchange transfusion. Transfusion 1985;25:424-428.
Pollack GM, Buchanan JF, Slaughter RL, Kohli RK, Shen DD. Circulating concentrations of DEHP and its de-esterified phthalic acid products following plasticizer exposure in patients receiving hemodialysis. Toxicol Ap-pl Pharmacol 1985;79:257-267.
Shaffer CB, Carpenter CB, Smyth HF. Acute and subacute toxicity of DEHP with note upon its metabolism. J Ind Hyg Toxicol 1945;27:130-135.
Schmid P, Schlatter C. Excretion and metabolism of DEHP in man. Xenobiotica 1985;15:251-256.
Albro PW, Corbett JT, Schroeder JL, Jordan S, Matthews HB. Pharmacokinetics, interactions with macromolecules and species differences in metabolism of DEHP. Environ Health Perspect 1982;14:19-25.
Woodward KN. Phthalate esters, cystic kidney disease in animals and possible effects on human health: a review. Hum Exp Toxicol 1990;9:297-301.
Dunnill MS, Millare PR, Oliver D. Acquired cystic disease of the kidney. A hazard of long-term intermittent hemodialysis. J Clin Pathol 1977;30:868-877.
Roth B, Herkenrath P, Lehmann HJ et al. Di-(2-ethyl hexyl) phthalate as plasticizer in PVC respiratory tubing systems: indications of hazardous effects on pulmonary function in mechanically ventilated pre-term infants. Eur J Pediatr 1988;147:41-46.
Bommer J, Ritz E, Andrassy K. Necrotizing dermatitis resulting from hemodialysis with polyvinylchloride tubing. Ann Intern Med 1979;91:869-870.
Gilioli R, Bulgheroni C, Terrana T, Filippini G, Mas-selto N, Bocri R. A neurological, electromyographic and electroneurographic study in subjects working at the production of phthalate plasticizers: preliminary results. Med Lavoro 1978;69:620-622.
Nielsen J, Akesson B, Skerfring S. Phthalate ester exposure — air levels and health of workers processing polyvinyl chloride. Am Ind Hyg Assoc J 1985;46:643-647.
Bommer J, Ritz E, Andrassy K. Necrotizing dermatitis resulting from hemodialysis with polyvinyl chloride tubing. Ann Intern Med 1979;91:869-870.
Neergaard J, Nielsen B, Faubry V, Christensen DH, Nielson OF. Plasticizers in P. V. C. and the occurrence of hepatitis in a haemodialysis unit. Scand J Urol Nephrol 1971;5:141-145.
Plasticizers in food. Lancet 1990;336:1309 (editorial).
Loftus N-J, Laird WJD, Leeser JE, Steel GT, Woolen BH. The metabolism and pharmacokinetics of Deuterium labelled di-(2-ethyl hexyl) adepate (DEHA) in human volunteers following oral administration. Hum Ex-per Toxicol 1990;9:326.
Di-n-butyl phthalate. Toxicological profile. Agency for Toxic Substances and Disease Registry. TP-90-10. 1990.
Milkov LE, Aldryeva MV, Poporia ТВ et al. Health status of workers exposed to phthalate plasticizers in the manufacture of artificial leather and films based on PVC resins. Environ Health Perspect 1973;3:175-178.
Keys N, Erickson T, Lipscomb J. Glow compound exposure. Clin Toxicol 1995;33:475-486 (abstract 5).
Deisher JB. Poisoning with a liquid plastic catalyst. Northwest Medicine 1958;57:46.
Snell RB, Capillary GC. Analysis of compounds leach into parenteral solutions packaged in plastic bags. J Chromatogr Sci 1989;27:524-528.
Strong MJ, Wolff AV, Yanagahira R, Garruto RM, Chou SM. V-butyl benzene sulfonamide: a plasticizing agent inducing a chronic neurofilamentous degenerative neurology. 1990;40(Suppl l):430.
Sheldon LS, Hites RA. Sources and movement of organic chemicals in the Delaware River. Environ Sci Technol 1979;13:574-579.
Deaper DM, Henderson BE. A case-control study of amyotrophic lateral sclerosis. Am J Epidemiol 1986;123:790-797.
Rubin RJ, Ness PM. What price progress? An update on vinyl blood bags. Transfusion 1989;29:358-361.
Snell RB. Capillary GC analysis of compounds leach into parenteral solutions packaged in plastic bags. J Chromatogr Sci 1989;27:524-528.
Cohen H, Charrier C, Sarfaty J. Extraction and identification of a plasticizer, di(2-ethylhexyl) phthalate from a plastic bag containing contaminated cor n. Arch Environ Contain Toxicol 1991;210:437-444.
Dirven HAAM, Van den Broek PHH, Arends AM, Nor-dkamp HH, de Lepper AJGM, Henderson PT et al. Metabolites of the plasticizer di (2-ethyl hexyl) phthalate in urine samples of workers in polyvinylchloride processing industries. Int Arch Occup Environ Health 1993;64:549-554.
Peterson MC, Vine J, Ashley JJ, National RL. Leaching of 2-(2-hydroxyethylmercapto) benzothiazole into contents of disposable syringes. J Pharmaceut Sci 1981;70:1139-1143.
Meek JH, Pettit BR. Avoidable accumulation of potentially toxic levels of benzothiazoles in babies receiving intravenous therapy. Lancet 1985;2:1090-1092.
Bonnevie P, Marcussen PV. Rubber products as a widespread cause of eczema. Report of 80 cases. Acta Der-matovener 1945;25:163-178.
Cronin E. Shoe dermatitis. BrJ Dermatol 1966;78:617— 625.
Wilson HTH: Rubber dermatitis. An investigation of 106 cases of contact dermatitis caused by rubber. Br Med J 1969;81:175-180.
Salmone G, Assaf A, Bayte-Sorbier A, Airauda ChB. Mass spectral identification of benzothiazole derivatives leached into injections by disposable syringes. Biomed Mass Spectrom 1984;9:450-454.
Kine ВВ, Novak RW. Acrylic ester polymers. In: Kirk-Othmer encyclopedia of chemical Technology. 3rd ed. Vol 1, New York: John Wiley, 1978; pp. 386—408.
Autian J. Structure-toxicity relationship of acrylic monomers. Environ Health Perspect 1975;11:141-152.
Hyderally H, Miller R. Hypotension and cardiac arrest during prosthetic hip surgery with acrylic bone cement. Orthop Rev 1976;5:55-61.
Scolnick B, Collins J. Systemic reaction to methylmethacrylate in an operating room nurse. J Occup Health 1986;28:196-198.
Crout DHG, Corkill JA, Jones ML, Ling RSM. Methylmethacrylate metabolism in men. The hydrolysis of methylmethacrylate to methacrylic acid during total hip replacement. Clin Orthop 1978;141:90-95.
Donaghy M, Rushworth G, Jacobs JM. Generalized peripheral neuropathy in a dental technician exposed to methyl methacrylate monomer. Neurology 1991;41:1112-1116.
Kine BB, Novak RW. Methacrylic polymers. In: Kirk-Othmer encyclopedia of chemical technology, 3rd ed. Vol 1, New York: John Wiley, 1978; pp. 377—398.
Kechijian P. Dangers of acrylic fingernails. JAMA 1990;236:458.
Fisher AA. Permanent loss of fingernails due to allergic reaction to an acrylic nail preparation. A sixteen-year follow-up study. Cutis 1989;43:404-405.
Hecht A. Artificial fingernails: apply with caution. FDA Consumer 1988;22.( 1): 18—21.
Brune E, Beltesbrekke H. Levels of methylmethacrylate, formaldehyde and asbestos in dental workroom air. Scand J Dent Res 1981;89:113-116.
Guidelines for Protecting the Safety and Health of Health Care Workers. 5.1.9. Methyl Methacrylate. Centers for Disease Control. US Department of Health and Human Services. September 1988, pp. 5-30—5-31. DHHS (NIOSH) Publication No. 88-119.
McLaughlin RE, Barkalow JA, Allen MS. Pulmonary toxicity of methyl methacrylate vapors: an environmental study. Arch Environ Health 1979;34:336-338.
Reference Deleted
Orzel PA. Toxicological aspects of firesmoke: polymer pyrolysis and combustion. In: Shusterman DJ, Peterson JE, eds. De nova toxicants: combustion toxicology mixing incompatibilities and environmental activation of toxic agents. State of the Art Reviews 1993;8:415-429, Philadelphia: Hanley & Belfus, 1993.
Kim КС, Ritter MA. Hypotension associated with methylmethacrylate in total hip arthroplasty. Clin Orthop 1972;88:154-160.
Rijke AM, Johnson RA. On the fate of methyl methacrylate in blood. J Biomed Mater Res 1977;11:211—221.
Rajaniemi R, Pfaffli P, Savolainen H. Percutaneous absorption of methyl methacrylate by dental technicians. Br J Ind Med 1989;46:356-357.
McDonald AD, Lavoie J, Cote R, McDonald JC. Spontaneous abortion in women employed in plastics manufacture. Am J Ind Med 1988;14:9-14.
Kassis W, Videl P, Darre E. Contact dermatitis to methyl methacrylate. Contact Dermatitis 1984;11:26-28.
Fisher AA. Reactions to acrylic bone cement in orthopedic surgeons and patients. Cutis 1986;32(6):425—426.
Rajaniemi R, Tola S. Subjective symptoms among dental technicians exposed to the monomer methyl methacrylate. Scand J Work Environ Health 1985; 11:281 — 286.
Durbin FC, Jeffery CC, Jones CB, Ling RSM, Scott PJ, Woodyard JE et al. Cardiac arrest and bone cement. Br Med J 1970;2:176-177.
Schuh FT, Schuh SM, Viguera MG, Terry RN. Circulatory changes following implantation of methylmethacrylate bone cement. Anesthesiology 1973;39:455-459.
Gresham GA, Kuczynski A. Cardiac arrest and bone cement. Br Med J 1970;2:465.
Learned DW, Hantier CB. Lethal progression of heart block after prosthesis cementing with methylmethacrylate. Anesthesiology 1992;77:1044-1046.
Rajanieni R. Clinical evaluation of occupational toxicity of methylmethacrylate monomer in dental technicians. J Soc Occup Med 1986;36:56-59.
Seppalainen AM, Rajanieni R. Local neurotoxicity of methyl methacrylate among dental technicians. Am J Ind Med 1984;5:471-477.
Innes DL, Tansy MF. Central nervous system effects of methyl methacrylate vapor. Neurotoxicology 1981;2:515-522.
Cant AJ, Lenney W, Kirkham N. Plastic material from a syringe causing fatal bowel necrosis in a neonate. Br Med J 1988;296:968-969.
Kepes ER, Underwood PS, Becsey L. Intraoperative death associated with acrylic bone cement. Report of two cases. JAMA 1972;22:576-577.
Walker AM, Cohen AJ, Loughlin JE, Rothman KJ, de Fonso LR. Mortality from cancer of the colon or rectum among workers exposed to ethyl acrylate and methyl methacrylate. Scand J Work Environ Health 1991;17:7.
Collins JJ, Page LC, Caporossi JC, Utidjian HM, Saipher JM. Mortality patterns among men exposed to methyl methacrylate. J Occup Med 1989;31:41-46.
Shelley ED, Shelley WB. Chronic dermatitis-simulating smallplaque parapsoriasis due to cyanoacrylate adhesive used on fingernails. JAMA 1984;252:2455-2456.
Reynolds JEF. Martindale: The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, pp. 1561.
Blais P, Campbell RW. Cyanoacrylates in medicine. Can Med Assoc J 1982;126:227-228.
Diamond JP. Temporary tarsorrhaphy with cyanoacrylate adhesive for seventh-nerve palsy. Lancet 1990;335:1039.
Watson DP. Use of cyanoacrylate tissue adhesive for closing facial lacerations in children. Br Med J 1989;299:1014.
Refojo MF, Dohlman CH, Koliopoulos J. Adhesives in ophthalmology: a review. Surv Ophthalmol 1971;15:217-236.
Nakazawa T. Occupational asthma due to alkyl cyanoacrylate. J Occup Med 1990;32:709-710.
Coover HW Jr, McIntire JM. Two cyanoacrylic ester polymers. In: Kirk-Othemer encyclopedia of chemical technology. 3rd ed. Vol 1. New York: John Wiley, 1978, pp. 408—413.
Lozewicz S, Davison AG, Hopkirk A, Burge PS, Boldy D, Riordan IF et al. Occupational asthma due to methylmethacrylate and cyanoacrylates. Thorax 1985;40:836-839.
De Fonsek ACP. Danger of instant adhesives. Br Med J 1976;2:234.
Dean BS, Krenzelok EP. Cyanoacrylates and corneal abrasions. Clin Toxicol 1989;27:169-172.
Andrews LS, Clary JJ. Review of the toxicity of multifunctional acrylates. J Toxicol Environ Health 1986;19:149-164.
Hiatt P. Toxic Information Center Case Rounds. Tox Info Center, San Francisco General Hospital Medical Center, January 16, 1990.
Dewan PA. Is injected polytetrafluoroethylene (Polytef) carcinogenic? Br J Urol 1992;69:29-33.
International Agency for Research on Cancer. Tetrofluoroethylene and polytetrafluoroethylene. IARC Monogr Eval Carcinog Risks Hum 1979;19:285-301.
Roe FJC. Br Med J 1988;297:783 (letter).
Shusterman DJ. Polymer fume fever and other fluorocarbon pyrolysis-related syndromes. In: Shusterman DJ, Peterson JE, eds. De nova toxicants: combustion toxicology mixing incompatibilities and environmental activation of toxic agents. State of the Art Reviews 1993;8:415-429, Philadelphia: Hanley & Belfus, 1993.
Sokol WN, Aelony Y, Beall GH. Meat-wrappers’ asthma: a new syndrome? JAMA 1973;226:639-641.
Skevfving S, Akesson B, Simonsson BG. "Meat wrappers" asthma caused by thermal degradation products of polyethylene. Lancet 1980; 1:211.
Acquavella JF, Douglass TS, Phillips SC. Evaluation of excess colorectal cancer incidence among workers involved in the manufacture of polypropylene. J Occup Med 1988;30:438-440.
Acquavella JF, Douglass TS, Vernon S, Hughes JI, Thar WE. Assessment of colorectal cancer screening outcomes among workers involved in polypropylene manufacture. J Occup Med 1989;31:785-791.
Dougherty J. Polypropylene and colorectal adenomas: searching for prevalence. J Occup Med 1990;32:l 141 — 1142.
Gibbs GW. Colorectal cancer and polypropylene exposure: how good is the evidence? J Occup Med 1990:32:1143.
Garland ТО, Patterson MWH. Six cases of acrylamide poisoning. Br Med J 1967;4:134-138.
Spencer PS, Sabri MI, Schaumberg HH et al. Does a defeet of energy metabolism in the nerve fiber underly axonal degeneration in polyneuropathies? Ann Neurol 1979;5:501-507.
Brimijoin SW, Hammond PI. Acrylamide neuropathy in the rat: Effects on energy metabolism in sciatic nerve. Mayo Clin Proc 1985;60:3-8.
Kaplan ML, Murphy SD, Gilles FH. Modification of acrylamide neuropathy produced by selected factors. Toxicol Appl Pharmacol 1973;24:564-579.
Auld RB, Bedwell SF. Peripheral neuropathy with sympathetic overactivity from industrial contact with acrylamide. Can Med Assoc J 1967;96:652-654.
Le Quesne PM. Clinical and morphological findings in acrylamide toxicity. Neurotoxicology 1985;6:17-24.
Mapp C, Mazzotta M, Bartolucci GB et al. Five cases of acrylamide intoxication. Med Lav 1977;68:1-12.
Donovan JW, Pearson T. Ingestion of acrylamide with severe encephalopathy, neurotoxicity and hepatotoxicity. Vet Hum Toxicol 1987;29:462.
Kennedy GL Jr. Biological effects of acetamide, formamide and their monomethyl and dimethyl derivatives. CRC Crit Rev Toxicol 1986;17:129-182.
NIOSH Pocket Guide to Chemical Hazard. DHHS (NIOSH) Publication No 90—117. Washington, DC: US Government Printing Office, p. 94.
Proctor NH, Hughes JP, Fischman ML, Hathaway GW. The chemical hazards. In: Proctor NH, Hughes J P, Fischman ML, eds. Chemical hazards of the work place, 2nd ed. New York: Van Nostrand Reinhold, 1989; pp. 206-207.
Borm PJA, de Jong L, Vliegen A. Environmental and biological monitoring of workers occupationally exposed to dimethylacetamide. J Occup Med 1987;29:898-903.
Leonardous G, Kendall D, Barnard N. Odor threshold determinations of 53 odorant chemicals. J Air Pollut Control Assoc 1965;19:91-95.
Maxfield ME, Barnes JR, Azar A, Trochimowicz HT. Urinary excretion of metabolite following experimental human exposures to DMF or to DMAC. J Occup Med 1975;17:506-511.
Kennedy GL Jr, Pruett JW. Biologic monitoring for dimethylacetamide: measurement for 4 consecutive weeks in a work place. J Occup Med 1989;31:47-50.
Stula EF, Karuss WC. Embryotoxicity in rats and rabbits from cutaneous application of amide-type solvents and substituted ureas. Toxicol Appl Pharmacol 1977;41:35— 55.
Threshold limit values for chemical substances and physical agents in the work environment. Cincinnati: American Conference of Governmental Industrial Hygienists, 1982, p. 17.
Corsi GC. Dimethylacetamide-induced occupational disease; with particular attention to hepatic functions. Med Lav 1971;62:28-42.
Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold DP, Schabel FM. Toxicity and anticancer activity of a new triazine antifolate (NSC 127 755). Cancer Res 1982;42:1707.
Weiss AJ, Mancall EL, Koltes JA, White JC, Jackson LG. Dimethylacetamide: a hitherto unrecognized hallucinogenic agent. Science 1962;136:151-152.
Weiss AJ, Jackson LG, Carabasi RA, Mancall EL, White JC. A phase 1 study of dimethylacetamide. Cancer Chemother Rep No. 16; February 1972, p. 477.
Fisher LB, Maibach HI. Effect of some irritants on human epidermal mitosis. Contact Dermatitis 1975;] :273— 276.
National Institute for Occupational Safety and Health. Manual of Sampling Data Sheets. Washington, DC: US Department of Health, Education and Welfare, 1977, Publication No. 254-1-3.
Barnes JR, Henry NW III. The determination of A-methylformamide and A-methylacetamide in urine. Ind Hyg Assoc J 1974;35:84-87.
Reigner BG, Bois FY, Tozer TN. Assessment of pentachlorophenol exposure in humans using the clearance concept. Hum Exp Toxicol 1992; 11:17—21.
Jorens PG, Janssens JJ, Van Tichelen WI, Van Paess-chen W, De Deyn PB, Schepens PJC. Pentachlorophenol concentrations in human cerebrospinal fluid. Neurotoxicology 1991;12:1-8.
Gerhard I, Derner M, Runnebaum B. Prolonged exposure to wood preservatives induces endocrine and immunological disorders in women. Am J Obstet Gynecol 1991;165:487-488.
O’Malley MA, Carpenter AV, Sweeney MH, Fingerhut MA, Marlow DA, Halperin WE et al. Chloracne associated with employment in the production of pentachlorophenol. Am J Indust Med 1990;17:411-421.
Cordier S, Poisson M, Gerin M, Vaum J, Conso F, He-mon D. Gliomas and exposure to wood preservatives. Br J Ind Med 1988;45:705-709.
Sanger B, Wegman RCC, Hofstee AWM. Nonoccupa-tional exposure to pentachlorophenol: clinical findings and plasma PCP concentrations in three families. Hum Toxicol 1982;1:123-133.
Gray RE, Gilliland RD, Smith EE et al. Pentachlorophenol intoxication: Report of a fatal case with comments on the clinical course and pathologic anatomy. Arch Environ Health 1985;40:161-164.
Benvenue A, Emerson M L, Casarette U et al. A sensitive gas chromatographic method for the determination of pentachlorophenol in human blood. J Chromatogr 1968;38:467-472.
Colosio C, Maroni M, Garratini S, Knoffel H. Abstract 223. V Internal Congress of Toxicology, July 16—21, 1989, Brighton, England. London: Taylor & Frances, p. 75.
Jackson RJ, Faw AM. Pesticides in food. West J Med 1990;152:286-287.
Shabecoff P. 100 chemicals for apples add up to enigma on safety. New York Times, February 5, 1989.
Ames BN, Gold LS. Pesticides, risk and applesauce. Science 1989;224:755-756.
Alar withdrawn in US. Lancet 1989;1:145 (editorial).
Consumers Union. Alar free juice. Wall Street Journal, March 20, 1989.
Alar vanishing. FDA Consumer 1990;24(7):4—5.
Spencer JR, Bissell SR, Sanborn JR, Schneider FA, Maytich SS, Kriger MI. Chlorthalonil exposure of workers on mechanical tomato harvesters. Toxicol Lett 1991;55:99-107.
Chlorthonil. In: Morgan D, ed. Recognition and management of pesticide poisonings. 4th ed. Washington, DC. US Environmental Protection Agency (ЕРА-540/ 9-88-001), 1989; p. 95.
Jongen MJ, Engel R, Leenheers LH. Determination of the pesticide Chlorthalonil by HPLC and UV detection for occupational exposure assessment in Greenhouse Carnation Culture. J Anal Toxicol 1991;15:30-34.
Litovitz TL, Bailey KM, Schmitz BF, Holm КС, Klein-Schwartz W. 1990 Annual Report of the American Association of Poison Control National Data Collection System. Am J Emerg Med 1991;9:461-499.
Lewis DR, Madel GA, Drury J. Fatal poisoning by "Meta" fuel tablets. Br Med J 1939;1:1283-1284.
Longstreet WT, Pierson DJ. Metaldehyde poisoning from slug bait ingestion. West J Med 1982;137:134-137.
Moody JP, Inglis FG. Persistence of metaldehyde during acute molluscicide poisoning. Hum Exp Toxicol 1992;11:361-362.
Booze TF, Oehme FW. Gas chromatographic analysis of metaldehyde in urine and plasma. J Anal Toxicol 1985;9:172-177.
Keller KH, Shimizu G, Walter FG, Olson KR. Acetaldehyde analysis in severe metaldehyde poisoning. Vet Hum Toxicol 1991;33:374.
Anderson A. V,jV-diethyl-w-toluamide (DEET). Clin Toxicol Rev 1989; 11(7): 1-4.
Laurie AA, Gleiberman SE, Tsizin YS. Pharmacokinetics of insect repellent Z/V-diethyltoluamine. Med Parazitol 1979;47:72-76.
Knaak JB. A Toxicological Review of the Insect Repellent DEET. Hazard Evaluation Section, Office of Environmental Health Hazard Assessment. California Department of Health Services, Berkeley, CA, March 1987;! —12.
Mofenson HC, Caraccio TR et al. Update on DEET. Poison Perspectives for Health Professional. LI Regional Poison Center at Winthrop University Hospital. 1993; 12(6):23—26.
Schreek CE, Snoddy EL, Spielman A. Pressurized sprays of permethrin or DEET on military clothing for personal protection against Ixodes dammini (Acari: Ixodidae). J Med Entomol 1986;23:396-399.
Tenenbein M. Toxicity of diethyltoluamide-containing insect repellents. JAMA 19 088;259:2339—2340.
Lipscomb JW, Kramer JE, Leikin JB. Seizure following brief exposure to the insect repellent N, /V-diethyl-Af-tol-uamide. Ann Emerg Med 1992;21:315-317.
CDC. Seizures temporally associated with use of DEET insect repellent — New York and Connecticut. MMWR 1989;38:678-680.
Maibach HI, Johnson HL. Contact urticaria syndrome. Arch Dermatol 1975;111:726-730.
Von Mayenburg J, Rakoski J. Contact urticaria to die-thyl-toluamide. Contact Dermatitis 1983;9:171.
Miller JD. Anaphylaxis associated with insect repellent. N Engl J Med 1982;307:1341-1342.
Smallwood AW, De Bord KE, Lowry LK. ACAOdiethyl-w-toluamide (/и-DEET): analysis of an insect repellent in human urine and serum by high performance liquid chromatography. J Anal Toxicol 1992;16:10-13.
Leikin JB, Kramer J, Lipscomb JW, Stewart MD. Seizure following brief exposure to the insect repellent N,N-diethyl-/n-toluamide. Vet Hum Toxicol 1990;32:363.
Insect Repellents. Med Lett Drugs Ther 1989;31(792):45—48.
Edwards DL, Johnson CE. Insect repellent induced toxic encephalopathy in a child. Clin Pharm 1987;6:496-498.
Singer PP, Jones GR. Distribution of diethyltoluene (DEET) after fatal overdosage. Bull Int Assoc Forensic Toxicol 1993;23(2):23—25.
Wu A, Pearson NH, Shekoski LL, Sato RJ, Steward DR. High resolution gas chromatography/mass spectrometric characterization of urinary metabolites of TV,7V-diethyl-л-toluamide (DEET) in man. J High Resolution Chro-matogr Commission 1979;2:558-562.
Davies MH, Soto RJ, Stewart RD. Toxicity of diethly-toluamide-containing insect repellents. JAMA 1988;259:2329.
Tenenbein M. Severe toxic reactions and death following the ingestion of diethyltoluamide-containing insect repellents. JAMA 1987;258:1509-1511.
Crowley RJ, Geyer R, Muir SG. Analysis of A'.A-die-thyl-m-toluamide (DEET) in human post mortem specimens. J Forensic Sci 1986;31:280-282.
Heick HMC, Peterson RG, Dalpe-Scott M, Quresli IA. Insect repellent, V,A-diethyl-/n-toluamide, effect on ammonia metabolism. Pediatrics 1988;82:373-376.
Morgan DR. Recognition and management of pesticide poisonings. 4th ed. US Environmental Protection Agency. EPA-540/9-88-001. March 1989, p. 132.
Chopra JS, Kabra OP, Malik WS, Sharma R, Chandra A. Aluminum phosphide poisoning: a prospective study of 16 cases in one year. Postgrad Med J 1986;62:113— 115.
Banjaj R, Wasir HS. Epidemic aluminum phosphide poisoning in Northern India. Lancet 1988;1:820-821.
Kabra SG, Narayanan R. Aluminum phosphide: worse than Bhopal. Lancet 1988; 1:1333.
Misera VK, Bhargava SK, Nag D, Kidwai MM, Lol MM. Occupational phosphine exposure in Indian workers. Toxicol Letters 1988;41:257-263.
Chugh SN, Dyhyant SR, Arora B, Malhotra КС. Incidence and outcome of aluminum phosphide poisoning in a hospital setting. Indian J Med Res 1991;[B]94:232— 235.
Feldstein A, Heitmann M, Barnett M. Fumigant intoxication during transport of grain by railroad. J Occup Med 1991;33:64-65.
Misera VK, Tripathi AK, Pandey R, Bhargwa B. Acute phosphine poisoning following ingestion of aluminum phosphide. Hum Toxicol 1988;7:343-345.
Augenstein WL, Sokol R, Kulig K, Rumach BH. Phosphine poisoning: a report of six cases. Vet Hum Toxicol 1988;30:344.
Khosla SM, Nand M, Kumar P. Cardiovascular complications of aluminum phosphide poisoning. Angiology April 1988, pp. 355—357.
Mital HS, MehrotraTN, Dwivedi KK, Gera M. A study of sluminum phosphide poisoning with special reference to its spot diagnosis by silver nitrate test. J Assoc Physicians India 1992;40:473-474.
Singh RB, Singh RG, Singh U. Hypermagnesemia following aluminum phosphide poisoning. Int J Clin Pharmacol Ther Toxicol 1991;29:82-85.
Rosenberg HD, Chang CC, Watson WA. Zinc phosphide ingestion. A case report and review. Vet Hum Toxicol 1989;33:359-360.
Casteel SW, Bailey EM Jr. A review of zinc phosphide poisoning. Vet Hum Toxicol 1986;28:151-154.
Mack RD. A hard day’s knight. Zinc phosphide poisoning. NC Med J 1989;50:17-18.
Stephenson J BP. Zinc phosphide poisoning. Arch Environ Health 1967;15:83-88.
Buckley LA, Jiang XZ, James RA, Morgan KT, Burrow CS. Respiratory tract lesions induced by sensory irritants at the RD50 concentration. Toxicol Appl Pharmacol 1974;30:408.
Proctor NH, Hughes JP, Fischman ML, eds. Chemical hazards of the workplace. 2nd ed. New York. Van Nostrand Reinhold, 1989, p. 149.
Gonmonri K, Muto H, Yamamoto T, Takahashi K. A case of homicidal intoxication by chloropicrin. Am J Forensic Med Pathol 1987;8:135-138.
Chloropicrin. Documentation of TLVs and BEs. 5th ed. Cincinnati: American Conference of Governmental Industrial Hygienists (ACGIH), 1986 p. 134.
Stokuyer HE. Aliphatic nitro compounds, nitrates, nitrites. In: Clayton GD, Clayton FE, eds. Patty’s industrial hygiene and toxicology. 3rd ed. Vol 2C. Toxicology. New York: Wiley-Interscience, 1982; pp. 464—466.
Flury F, Zernik F. Schadliche gas. Berlin. Springer, 1931, p. 418.
Heyndrickx A, Van Peteghem C, Van den Heede M et al. A double fatality with children due to fumigated wheat. Eur J Toxicol 1976;9:113-118.
Wilson R, Lovejoy FH, Jaeger RJ et al. Acute phosphine poisoning aboard a grain freighter. JAMA 1980;244:148-150.
Singh S, Dilawandi JB, Vashist R et al. Aluminum phosphide ingestion. Br Med J 1985;290:l 110— 1111.
Phosphine: Hazardous Materials Medical Management Protocols. Calif Emerg Med Services Authority and Toxins Epidemiology Program, Los Angeles County Department of Health Services, March 26, 1989.
Brouwer DH, Brouwer EJ, de Vreede JAF, von Welia PTH, Vermeulen NPE, van Hemnen JJ. Inhalation exposure to 1,3-dichloropropene with Dutch flower-bulb culture. I. Environmental monitoring. Arch Environ Contam Toxicol 1991;20:1-5.
Van Wehe RTH, van Duyn P, Brouwer DH, van Hemnen JJ, Brouwer EJ, Vermeulen NPE. Inhalation exposure to 1,3-dichloropropene in the Dutch flower bulb culture. II. Biological monitoring by measurement of urinary excretion of two mercapturic acid metabolites. Arch Environ Contam Toxicol 1991;20:6-12.
Flessel P, Goldsmith JR, Kahn E, Weslolowski JJ. Acute and possible long-term effects of 1,3-dichloropropene. MMWR 1978;27:50.
Dammann KZ, Nuchols J, Wiley SH, Spyler DA. Delayed deaths following Vikane exposure. Vet Hum Toxicol 1987;29:464.
Scheuerman EH. Suicide by exposure to sulfuryl fluoride. J Forensic Sci 1986;31:1154—1158.
Morgan DP. Recognition and management of pesticide poisonings. 4th ed. Washington, DC. US Environmental Protection Agency, 1989, pp. 135, 138.
Sunshine I, Finkle BS. Fluoride type В procedure. In: Methodology for analytical toxicology, Cleveland: CRC Press, 1975.
Toxic Information Center Case Recors. San Francisco Poison Information Center, September 18, 1989.
Yamarick W, Walson P, DiTraglia J. Strychnine poisoning in an adolescent. Clin Toxicol 1992;30( 1): 141 —148.
Heiser JM, Daya MR, Magnussen AR, Norton RL, Spyker DA, Allen DW, Krasselt W. Massive strychnine intoxication: serial blood levels in a fatal case. Clin Toxicol 1992;30(2):269—283.
Litovitz TL, Schmitz BF, Bailey KM. Annual Report of the American Association of Poison Control Centers. National Data Collection System. J Emerg Med 1990;8:394-442.
Bum DJ, Tomson CRV, Seviour J, Dale G. Strychnine poisoning as an unusual cause of convulsions. Postgrad Med J 1989;65:563-564.
Smith BA. Strychnine poisoning. J Emerg Med 1990;8:321-325.
Van Heerden PV, Edibaum C, Augustson B, Thompson WR, Power BM. Strychnine poisoning — alive and well in Australia. Anaesth Intensive Care 1993;21:876-878.
Carpenter К, Cottrell HJ, De Silva WH, Hewyood BJ, Leeds WG, Rivett KF et al. Clinical and biological properties of two new herbicides — ioxynil and bromoxynil. Weed Res 1964;4:175-195.
Flanagan RJ, Ruprah M. HPLC measurement of chlorphenoxyherbicides, bromoxynil and ioxynil in biological specimens to aid diagnosis of acute poisoning. Clin Chem 1989;35:1342-1347.
Abi Khalil F, Alvoet C, Ectors M, Molle L. Acute fatal ioxynil intoxication. The International Association of Forensic Toxicologists: Proceedings of the 24th International Meeting, Banff. 1988; pp. 512—515.
Dickey W, McAleer JJA, Callender ME. Delayed sudden death after ingestion of MCPP and ioxynil. An unusual presentation of hormonal weedkiller intoxication. Postgrad Med J 1988;64:681-682.
Vogelaers D, Ectors M, de Wilde V, Klostin M, Khalil A, de Wispelaere I, Heyndrickx A. lonxynil intoxication. Proc Eur Assoc Pois Control Cent. Edinburgh, September 1988. Newsletter Europ Assoc Pois Control Cent, March, 1989.
Smysl B, Smyslova O, Kosatik A. Akute todliche ioxynil vergiftung. Arch Toxicol 1977;37:241-245.
Conso F, Neel P, Pouzoulet C, Efthymiou ML, Gervais P, Gaultier M. Toxiclte aigue chez 1’homme des derives halogenes de 1’hydroxybenzonitrile (ioxynil, bromoxynil). Arch Mai Prof 1977;38:674-677.
Bismuth С, Baud FJ, Djeghout Н, Astier A, Rubriot D. Cyanide poisoning from propionitrile exposure. J Emerg Med 1989;5:191-195.
Bismuth C, Baud FJ, Djeghout H, Astier A. Blood cyanide and thiocyanate kinetics after propionitrile exposure: effects of hydroxocobalamin and thiosulfate. Vet Hum Toxicol 1987;29(Suppl 2):41.
Jackson JR. Toxicity of herbicide containing glyphosate. Lancet 1988;1:414.
Glyphosate. WHO Monograph. Food and Agriculture Organization, United Nations Pesticide Residue in Food Evaluation. Part 2. Toxicology. Rome, 1986. Paper 78/2.
Tominack RL, Yang G-Y, Tsai W-J, Chung H-M, Deng J-F. Taiwan National Poison Center Survey of glyphosate-surfactant herbicide ingestions. Clin Toxicol 1991;29:91-109.
Glyphosate. In: [Humburg, NE, Chairman] Chicago, IL: Herbicide Handbook of the Weed Science Society of America. 6th ed. Weed Science Society of America, 1989.
Kawamura K, Nobuhara H, Tsuda K, Tanaka A, Mat-subara Y, Yamauchi N. Two cases of glyphosate (Roundup) poisoning. Pharmaceuticals Monthly 1987;29:163 (Japanese, translated).
Tominack RL. Acute human exposure to glyphosate surfactant herbicide. Proc Internal Cong Ciin Toxicol, Poison Control, Anal Toxicol. LuxTox’90, May 2—5, 1990, Luxembourg.
Talbot AR, Sahw MH, Huang J-S, Yang S-F, Goo T-S, Wang S-H, Chen C-L, Sanford TR. Acute poisoning with a glyphosate-surfactant herbicide ("Roundup"): a review of 93 cases. Hum Exp Toxicol 1991;10:1-8.
Tominack R, Conner P, Yamashita M. Clinical management of Roundup herbicide exposure. Jpn J Toxicol 1989;2:187-192.
Kubota T, Hamada K, Nika H, Konoe A, Ikeda K, Hisaaki I et al. A case of glyphosate poisoning. Gekkan Yakuji 1986;28(8):7 (abstract) (Japanese, translated by Dr. Alan Talbot).
Sawada Y, Nagai Y: Roundup poisoning — its clinical observation. Possible involvement of surfactant. J Clin Exp Med (Igaku No Ayumi) 1987; 143( 1 ):25—27 (Japanese, translated).
Sawada Y, Nagai Y, Veyama M, Yamamoto I. Probable toxicity of surface-active agent in commercial herbicide containing glyphosate. Lancet 1988;1:299.
Deng J-F, Chung H-M, Yang Y-G, Tsai W-J, Ger J. The treatment of Nien Nien Chun ingestion poisoning. Clinical Medicine (Taiwan) 1988;22:469-473 (Translation).
Talbot AR, Chen ZL, Goo TS, Huang JS, Wang SH, Sa-hw MH, Yang SF. Plasma levels and hemodynamics in acute glyphosate poisonings. Vet Hum Toxicol 1990:32:370.
Jauhiainen A, Rasanen K, Sarantila R, Nuutinen J, Kangas J. Occupational exposure of forest workers to glyphosate during brush saw spraying work. Am Ind Hyg Assoc J 1991;52:61-64.
Duke SO. Overview of herbicide mechanism of action. Environ Health Perspect 1990;87:263-271.
Orlorunsogo OO, Bababunmi EA, Bassir O. Effect of glyphosate on rat liver mitochondria in vivo. Bull Environ Cont Toxicol 1979;22:357-364.
Yamashita M, Mizutani T, Nakamura K, Koike J, Tsuchiya Y, Yamamoto S. Four cases of Roundup poisoning. 1CU to CCD 1987; 11 (Autumn Suppl): 156—157 (abstract) (Japanese, translated by Dr. Alan Talbot).
Nonaka J, Niki H, Aizawa K, Ikeda K, Makino Y, Itoo M, Isshiki J. A case of glyphosate poisoning. Tokyo Idai Shi 1986;44(3):575 (abstract) (Japanese, translated by Dr. Alan Talbot).
Nishimoto K. Pesticide poisoning in our hospital — especially in regard to poisoning with glyphosate (Roundup). Masui to Sosei 1987;23(2): 149 (abstract) (Japanese, translated by Dr. Alan Talbot).
Martinez TT, Long WC, Hiller R. Comparison of the toxicology of the herbicide Roundup by oral and pulmonary routes of exposure. Proc West Pharmacol Soc 1990;33:193-197.
Martinez TT, Brown K. Oral and pulmonary toxicology of the surfactant used in Roundup herbicide. Proc West Pharmacol Soc 1991;34:43-46.
Maibach H. Irritation, sensitization, photoirritation and photosensitization assays with a glyphosate herbicide. Contact Dermatitis 1986;15:152-156.
Hoogheem TJ. The safety of Roundup pesticide. JAMA 1989:262:2679.
Deyrup CL, Chang SM, Weintraub RA, Moye HA. Simultaneous esterification and acetylation of pesticides for analysis by gas chromatography. 1. Derivatization of glyphosate and (aminomethyl) phosphoric acid with fluorinated alcholosperfluorinated anhydrides. J Ag Food Chem 1985;33:944-947.
Moye HA, Miles CJ, Scherer SJ. A simplified high-performance liquid chromatographic residue procedure for the determination of glyphosate herbicide and (aminomethyl) phosphoric acid in fruits and vegetables employing postcolumnar fluorogenic labelling. J Ag Food Chem 1983;31:69-76.
Cowell JE, Kumstman J, Nord PJ, Steinmetz JR, Wilson GR. Validation of an analytical method for analysis of glyphosate and metabolite: an interlaboratory study. J Ag Food Chem 1986;34:955-960.
Kageura M, Hara K, Heida Y, Kashimura S. A derivatization of glyphosate and aminomethylphosphoric acid for GC/MS analysis. Bull Int Assoc Forensic Toxicol 1988;20(l):43.
Dickson SJ, Meinhold RH, Beer ID, Koelmeyer TD: Rapid determination of glyphosate in post-mortem specimens using 31P NMR. J Anal Toxicol 1988;12:284-286.
Tomita M, Okuyama T, Watanabe S, Uno B, Kawai S. High performance liquid chromatographic determination of glyphosate and (amino methyl) phosphoric acid in human serum after conversion into p-toluenesulphonyl derivatives. J Chromatogr Biomed Appl 1991;566:239-243.
Hara Y, Hiraoka H, Morimoto T, Sasaki H, Ishikawa K, Kirimoto К et al. Three cases of pesticide poisoning focusing on fatalities due to glyphosate. Iryo 1985;39(Suppl 2):310 (abstract) (Japanese, translated by Dr. Alan Talbot).
Ong HC, Tsai WJ, Deng JF. An analysis of the clinical findings observed in the case of glyphosate ingestion. Poisonings XIVth International Congress of European Association of Poison Control Centres. Milan, Italy, September 25—29, 1990, p. 168.
Harry P, Tirot P, Maigret P, Bouachour G. Haemodialysis in glyphosate poisoning. Toxicol Lett 1992;5 (Sup-pl):319.
Moses M. Glyphosate herbicide toxicity. JAMA 1989;261:2549.
Moses M. The safety of Roundup pesticide. JAMA 1989;262:2679.
Medical Toxicology Branch. Summary of Toxicology Data: Glyphosate, Isopropylamine Salt. Sacramento. State of California Dept of Food and Agriculture, 1988, Publication SB950-241.
Wada S, Ushlimaru H, Nozawa К et al. A case of acute intoxication of bialophos. Jpn J Acute Med 1988;12:245-247.
Matsukawa Y, Hachisuka H, Sawada S, Horie T, Kita-mini Y, Nishijima S. Bialophos poisoning with apena and metabolic acidosis. Clin Toxicol 1991;29:141-146.
Koyama K, Matsuo H, Saraki H, Andou Y. The acute oral toxic dose of herbicide containing glufosinate. Clin Toxicol 1995;33:475-486 (abstract 85).
Winchester JF. History of paraquat intoxication. In: Bismuth C, Hall AH, eds. Paraquat poisoning: mechanisms—prevention—treatment. New York: Marcel Dekker, 1995.
Dawling S, Braithwaite RA. Fatal poisoning by paraquat injection. Bull I nt Assoc Forensic Toxic 1991;21:33-35.
Ong ML, Glew S. Paraquat poisoning per vagina. Postgrad Med J 65:835—836.
Kline JN Darden IL, Lohne E, Larson RK. Pulmonary function of San Joaquin Valley agricultural laborers with occupational paraquat exposure. Chest 1990;98(Sup-pl):65S.
Paraquat. In: Hazardous Substances Data Bank. National Library of Medicine, Bethesda, MD (CD-ROM version). Denver, CO. Micromedex, 1994.
Hayes WJ Jr, ed. Paraquat. In: Pesticides studied in man. Baltimore: Williams & Wilkins, 1982; pp. 543—558.
Hall AH. Paraquat usage. Environmental fate and effects. In: Bismuth C, Hall AH, eds. Paraquat poisoning: mechanisms—prevention—treatment. New York: Marcel Dekker, 1995.
Hayes WJ Jr, Laws ER Jr. Quaternary nitrogen compounds. In: Handbook of pesticide toxicology. Vol 3. Classes of pesticides. San Diego, CA: Academic Press, 1991; pp 1356-1408.
Baselt RC. Paraquat. In: Biological monitoring methods for industrial chemicals. 2nd ed. Littleton, MA: PSG Publishing Company, 1988; pp. 240-243.
Pond SM. Manifestations and management of paraquat poisoning. Med J Aust 1990;152:356-359.
Hall AH, Becker CE. Occupational health and safety considerations in paraquat handling. In: Bismuth C, Hall AH, eds. Paraquat poisoning: mechanisms—prevention—treatment. New York: Marcel Dekker, 1995.
Morgan DP. Paraquat. In: Recognition and management of pesticide poisonings. 4th ed. Washington, DC: U. S. Environmental Protection Agency, EPA-540/9-88-0015, Government Printing Office, 1989; pp. 76—82.
Onyon LJ, Volans GN. The epidemiology and prevention of paraquat poisoning. Hum Toxicol 1987;6:19.
Vale JA, Meredith TJ, Buckley BM. Paraquat poisoning: clinical features and immediate general management. Hum Toxicol 1987;6:41-47.
Selden BS, Clark RF, Curry SC. Marijuana. Emerg Med Clin North Am 1990;8:527.
Cant JS, Lewis DRH. Ocular damage due to paraquat and diquat. Br Med J 1978;2:224.
Joyce M. Ocular damage caused by paraquat. Br J Ophthalmol 1968;53:688.
Vlahos K, Goggin M, Coster D. Paraquat causes chronic ocular surface toxicity. Aust NZ J Ophthalmol 1993;32(3): 187.
Watanabe 1, Sakai H, Toyama K, Veno M, Watanabe M. Ocular impairment due to paraquat dichloride. Jpn Rev Clin Ophthalmol 1979;73:660.
Guardascione V, Mazella di Bosco M. Contribution to the knowledge of occupational intoxication with paraquat, dipyridilium herbicide. Folia Med (Naples) 1969;52:728.
Oishi S. A cause of ocular injury by paraquat dichloride. Jpn J Ind Health 1975; 17:522.
Howard JK, Sabapathy NN, Whitehead PA. A study of the health of Malaysian plantation workers with particular reference to paraquat spraymen. Br J Ind Med 1981;38:110.
Hoffer E, Taitelman U. Exposure to paraquat through skin absorption. Clinical and laboratory observations of accidental splashing in healthy skin of agricultural workers. Hum Toxicol 1989;8:483-484.
Daniel JW, Gage JC. Absorption and excretion of diquat and paraquat. Br J Ind Med 1966;23:133.
Proudfoot AT, Stewart MS, Levitt T, Widdop B. Paraquat poisoning. Significance of plasma paraquat concentrations. Lancet 1979; 1:330.
Clark DG, McElligott TF, Westonhurst E. The toxicity of paraquat. Br J Ind Med 1966;23:126.
Sharp CWM, Ottolenghi A, Posner HS. Correlation of paraquat toxicity with tissue concentrations and weight loss of the rat. Toxicol Appl Pharmacol 1972;22:241.
Baud FJ, Houze P, Bismuth C, Scherrmann J-M, Jaeger A, Keyers C. Toxicokinetics of paraquat through the heartlung block. Six cases of acute human poisoning. Clin Toxicol 1988;26:35-50.
Houze P, Baud FJ, Mouy R, Bismuth C, Bourdon R, Scherrmann JM. Toxicokinetics of paraquat in humans. Human Exp Toxicol 1990;9:5-12.
Hawksworth GM, Bennett PN, Davies DS. Kinetics of paraquat elimination in the dog. Toxicol Appl Pharmacol 1981;57:139.
Ragoucy-Sengler C, Pileire B, Daijordin JB. Survival from severe paraquat intoxication in heavy drinkers. Lancet 1991 ;380:1461.
Talbot AR, Fuh CC, Hsieh MF, Shaw HJ. Paraquat intoxication during pregnancy. A report of 9 cases. Vet Hum Toxicol 1988;30:12-17.
Fennelly JJ, Gallagher JT, Carroll RJ. Paraquat poisoning in a pregnant woman. Br Med J 1968;3:722.
Musson FA, Porter CA. Effect of ingestion of paraquat on a 20 week gestation fetus. Postgrad Med J 1982;58:732.
Bismuth C, Wong A, Hall AH. Paraquat ingestion exposure. In: Bismuth C, Hall AH, eds. Paraquat poisoning: mechanisms—prevention—treatment. New York: Marcel Dekker, 1995.
Pasi A. The Toxicology of paraquat, diquat and morfam-quat. Bern, Switzerland: Hans Humber, 1978.
Ackrill P, Haselton PS, Ralston AJ. Oesophageal perforation due to paraquat. Br Med J 1978; 1:6122, 1252.
Frelon JH, Merigot P, Garnier R, Bismuth C, Efthymi-ou ML. Facteurs prognostiques de 1’intoxication aigue par le paraquat. Etude retrospective des cas enrigistres au Centre Anti-Poisons de Paris en 1981. Toxicol Eur Res 1983;5:163.
Malone JDG, Carmody M, Keogh B, O’Dwyer WF. Paraquat poisoning. A review of nineteen cases. J Irish Med Assoc 1971;64:59.
Kodagoda N, Jayewardene RP, Attygalle D. Poisoning with paraquat. Forensic Sci 1973;2:107.
Vaziri ND, Ness RL, Fairshter RD, Smigh WR, Rosen SM. Nephrotoxicity of paraquat in man. Arch Intern Med 1979; 139:172.
Baguley E, Iles PB, Wright N. Serial lung function tests in paraquat poisoning. Hum Toxicol 1983;2:418.
Lewis CPL, Nemery B. Pathophysiology and biochemical mechanisms of the pulmonary toxicity of paraquat. In: Bismuth C, Hall AH, eds. Paraquat poisoning: mechanisms—prevention—treatment. New York: Marcel Dekker, 1995.
Bismuth C, Garnier R, Dally S, Fournier PE, Scherrmann JM. Prognosis and treatment of paraquat poisoning: a review of 28 cases. J Toxicol Clin Toxicol 1082;19:461.
Reif RM, Lewinsohn G. Paraquat myocarditis and adrenal cortical necrosis. J Forensic Sci 1983;28:505.
Pronczuk de Garbino J. Epidemiology of paraquat poisoning in Bismuth C, Hall AH, eds. Paraquat poisoning: mechanisms—prevention—treatment. New York: Marcel Dekker, 1995.
Proudfoot AT, Prescott LF, Jarvie DR. Hemodialysis for paraquat poisoning. Hum Toxicol 1987;6:63.
Ohkubo T, Takeda К, Okano T, Shigeizumi Y, Oikawa M, Toyohara T, Hayashi S et al. A case of death due to paraquat intoxication. J Jpn Soc Rural Med 1979;28:472.
Takagoshi K, Nakanuma Y, Ohta M, Thoyanna T, Oku-da K, Kono N. Light and electron microscopic study of the liver in paraquat poisoning. Liver 1988;8:330-336.
Dabney BJ. Genetic, carcinogenic and reproductive effects of paraquat. In: Bismuth C, Hall AH, eds. Paraquat poisoning: mechanisms—prevention—treatment. New York: Marcel Dekker, 1995.
IRIS, Integrated Risk Information System, U. S. Environmental Protection Agency (CD-ROM version). Denver, CO. Micromedex, edition expires 7/31/94.
Talbot AR, Fu CC, Hsieh MF. Paraquat intoxication during pregnancy: a report of 9 cases. Vet Hum Toxicol 1988;30:12.
Scherrmann JM, Houze P, Bismuth C, Bourdon R. Prognostic value of plasma and urine paraquat concentrations. Hum Toxicol 1987;6:91-93.
Fuke C, Amero K, Arneno S, Kirin T, Shinohara T, So-go K, Ijiri 1. A rapid simultaneous determination of paraquat and diquat in serum and urine using second-derivative spectroscopy. J Anal Toxicol 1992; 16:214— 216.
Scherrmann JM. Analytical procedures and predictive value of late plasma and urine paraquat concentrations. Personal communication. Jan 7, 1993. To be published.
Kuo H-W, Wang J-D, Lin J-M. Determination of 4,-4’-bipyridine vapor. Am Ind Hyg Assoc J 1992;53:514— 518.
Nagao M, Takatori T, Terazawa K, Wu R, Wakasugi C, Masui PM, Ikeda N. Development and application of immunoassay for paraquat radioimmunoassay. J Forensic Sci 1989;34:547-552.
Bismuth C, Hall AH. Pulmonary dysfunction in paraquat poisoning survivors. In: Bismuth C, Hall AH, eds. Paraquat poisoning: mechanisms—prevention—treatment. New York: Marcel Dekker, 1995, pp. 349—355.
Hart ТВ, Nevitt A, Whitehead A. A new statistical approach to the prognostic significance of plasma paraquat concentrations. Lancet 1984;2:1222.
Scherrmann JM, Galliot M, Garnier R, Bismuth C. Acute paraquat poisoning: prognostic significance and therapeutical interest of blood assay. Toxicol Eur Res 1983;3:141.
Hampson ECGM, Pond SM. Failure of haemoperfusion and haemodialysis to prevent death in paraquat poisoning. Med Toxicol 1988;6:91.
Proudfoot AT. Predictive value of early plasma paraquat concentrations. In: Bismuth C, Hall AH, eds. Paraquat poisoning: mechanisms—prevention—treatment. New York: Marcel Dekker, 1995.
Yamaguchi H, Sato S, Watanabe S, Naito H. Pre-em-barkment prognostication for acute paraquat poisoning. Hum Exper Toxicol 1990;9:1384.
Im JG, Lee KS, Han MC, Kim SJ, Kim IO. Paraquat poisoning: findings on chest radiography and CT in 42 patients. Am J Roentgenol 1991 ;4:697.
Sawada Y, Yamamoto I, Hirokane T, Nagai Y, Satoh Y, Ueyama M. Severity index of paraquat poisoning. Lancet 1988;1:1333.
Duke SO. Overview of herbicide mechanism of action. Environ Health Perspect 1990;87:263-271.
Meredith T, Vale JA. Treatment of paraquat poisoning. Gastrointestinal decontamination. In: Bismuth C, Hall AH, eds. Paraquat poisoning: mechanisms—prevention—treatment. New York: Marcel Dekker, 1995.
Widdop B, Medd RK, Braithwaite RA. Charcoal haemoperfusion in the treatment of paraquat poisoning. Eur Soc Toxicol 1977; 18:156.
Smith LL. Mechanism of paraquat toxicity in lung and its relevance to treatment. Hum Toxicol 1987;6:31.
Bismuth C. Treatment of paraquat poisoning. Modification of toxicokinetics in Bismuth C, Hall AH, eds. Paraquat poisoning: mechanisms—prevention—treatment. New York: Marcel Dekker, 1995.
Hampson ECGM, Pond SM. Failure of haemoperfusion and haemodialysis to prevent death in paraquat poisoning: a retrospective review of 42 patients. Med Toxicol 1988;3:64.
Pond SM, Johnston SC, Schoof DD, Hampson ED, Boules M, Wright DM, Petrie JJ. Repeated hemoperfusion and continuous arteriovenous hemofiltration in a paraquat poisoned patient. Clin Toxicol 1987;25:305— 316.
Proudfoot AT, Prescott LF, Jarvie DR. Haemodialysis in paraquat poisoning. Hum Toxicol 1987;6:69-74.
Pond SM, Chen N, Bowles MR. Prevention of paraquat toxicity in alveolar type II cells by paraquat-specific antibodies. Vet Hum Toxicol 1993;35:337.
Paraquat poisoning. Lancet 1986; 1:333.
Bateman DN. Pharmacological treatments of paraquat poisoning. Hum Toxicol 1987;6:57.
Pond SM. Treatment of paraquat poisoning. In: Bismuth C, Hall AH, eds. Paraquat poisoning: mechanisms—prevention—treatment. New York: Marcel Dekker, 1995.
Talbot AR, Barnes AAR. Radiotherapy for the treatment of pulmonary complications of paraquat poisoning. Hum Toxicol 1988;7:325-332.
Yamashita M, Maito H, Takagi S. The effectiveness of a cation resin (Kayexalate) as an adsorbent of paraquat. Experimental and clinical studies. Hum Toxicol 1987;6:89-90.
Blain PG. Aspects of pesticide toxicology. Adverse Drug React Acute Pois Rev 1990;9:37-68.
Perriens JH, Benimadho S, Kiauw IL, Wisse J, Chee H. High-dose cyclophosphamide and dexamethasone in paraquat poisoning: a prospective study. Hum Exper Toxicol 1992;11:129-134.
Mahieu P, Bonduelle Y, Bernard A et al. Acute diquat intoxication: Interest of its repeated determination in urine and the evaluation of renal proximal tubule integrity. Clin Toxicol 1984;22:363-369.
Wood ТЕ, Edgar H, Salcedo J. Recovery from inhalation of diquat aerosol. Chest 1976;70:774-775.
Clark DG, Hurst EW. The toxicity of diquat. Br J Ind Med 1970;27:51-55.
Daniel JW, Gage JC. Absorption and excretion of diquat and paraquat in rats. Br J Ind Med 1966;23:133-136.
Vanholder R, Colardyn F, De Reuck J, Praet M, La-meire N, Ringoir S. Diquat intoxication. Report of two cases and review of the literature. Am J Med 1981;70:1267-1271.
Sechi GP, Agnetti V, Piredda M, Canu M, Deserra F, Omar HA et al. Acute and persistent parkinsonism after use of diquat. Neurology 1992;42:261-263.
McCarthy LG, Speth CR. Diquat intoxication. Ann Emerg Med 1983;12:394-396.
Casey PB, Buckley BM, Vale JA. Methemoglobinemia following ingestion of a monolinuron/paraquat herbicide (Gramonol®). Clin Toxicol 1994;32:185-189.
Demers R, Perrin E. Dioxin toxicity. Case studies in environmental medicine. 7. Agency for Toxic Substances and Disease Registry, June 1990.
Skene SA, Dewhurst IC, Greenberg M. Polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans: the risks to human health. A review. Hum Toxicol 1989;8:172-204.
Schecter A, Dai LC, Bich LT, Quynh HT, Minyh DQ, Cau HD, Phiet PH et al. Agent Orange and the Vietnamese: the persistence of elevated dioxin levels in human tissues. Am J Public Health 1995;85:516-522.
Svensson B-G, Nilsson A, Hansson M, Rappe C, Ake-sson B, Skerfung S. Exposure to dioxins and dibenzofurans through the consumption of fish. N Engl J Med 1991;324:8-12.
A daily dose of dioxin. Lancet 1989;2:59 (editorial).
Dickson LC, Buzik SC. Health risks of "dioxins": a review of environmental and toxicological considerations. Vet Hum Toxicol 1993;35:68-77.
Dickey W, McAleerJJA, Callender ME. Delayed sudden death after ingestion of MCPP and ioxynil. An unusual presentation of hormonal weedkiller intoxication. Postgrad Med J 1988;64:681-682.
Osterloh J, Lotti M, Pond SM. Toxicologic studies in a fatal overdose of 2,4D, MCPP and chlorpyrifos. J Anal Toxicol 1983;7:125-129.
Kintz P, Tracqui A, Mangin P. Accidental death caused by the absorption of 2,4-dichlorphenol through the skin. 1992;66:298-299.
Meulenbelt J, Zwaveling JH, van Zooner P, Notermans NC. Acute MCPP intoxication. Report of two cases. Hum Toxicol 1988;7:289-292.
Centers for Disease Control Vietnam Experience Study. Health status of Vietnam veterans. I. Psychosocial characteristics. JAMA 1998;259:2701-2707.
Wolfe WH, Michalek JE, Miner JC, Rake A, Silva J, Thomas WF et al. Health status of air force veterans occupationally exposed to herbicides in Vietnam. I. Physical health. JAMA 1990;264:1824-1831.
Michalek JE, Wolfe WH, Miner JC. Health status of air force veterans occupational exposed to herbicides in Vietnam. II. Mortality. JAMA 1990;264:1832-1836.
McCarthy M. Agent Orange. Lancet 1993;342:367.
Veterans and Agent Orange: health effects of herbicides used in Vietnam. Washington, DC: National Academy Press, 1993.
Baiker JCH. How dangerous is dioxin? N Engl J Med 1991;324:260-262.
Fingerhut MA, Halperin WE, Marlow DA, Piactelli LA, Hanchar PA. Cancer mortality in workers exposed to 2,3,7,8-tetrachIoro dibenzo-p-dioxin. N Engl J Med 1991;324:212-218.
Fingerhut MA, Steanland K, Sweeney MH, Halperin WE, Piactelli LA, Marlow DA. Old and new reflections on dioxin. Epidemiology 1992;3:69-72.
Eriksson M, Hardell L, Adani HO. Exposure to dioxins as a risk factor for soft tissue sarcoma. A population based case-control study. J Natl Cancer Inst 1990;82:486-496.
Donovan JW, MacLennan R, Adena M. Vietnam service and the risk of congenital abnormalities: a case control study. Med J Aust 1984;140:394-397.
Erickson JD, Mulinare J, McClain PW et al. Vietnam veterans’ risks for fathering babies with birth defects. JAMA 1984;252:903-912.
Reggiani G. Anatomy of a TCDD spill: the Seveso accident. Hazard Assess Chem Curr Dev 1983;2:269-342.
Mastroiacovo P, Spagnola A, Marni E, Meazzo L, Ber-tollini R, Segni G. Birth defects in the Seveso area after TCDD contamination. JAMA 1988;259:1668-1672.
Flanagan RJ, Ruprah M. HPLC measurement of chlo-rphenoxyherbicides, bromoxynil and ioxynil in biological specimens to aid diagnosis of acute poisoning. Clin Chem 1989;35:1342-1347.
Kahn PC, Gochfeld M, Nygren M, Hansson M, Rappe C, Velez H et al. Dioxins and dibenzofurans in blood and adipose tissue of Agent Orange-exposed Vietnam veterans and matched controls. JAMA 1988;259:1661-1667.
CDC Serum dioxin in Vietnam-era veterans. Preliminary report. MMWR 1987;36:470-475.
Kang HK, Watanabe KK, Breen J, Renuvers J, Cono-mos MG, Stanley J et al. Dioxins and dibenzofurans in adipose tissue of US Vietnam veterans and controls. Am J Public Health 1991;81:344-349.
Patterson DG, Hampton L, Lapeza CR Jr, Belser WT, Green V, Alexander L et al. High resolution gas chro-matographic/high resolution mass spectrometric analysis of human serum on a whole-weight and lipid basis for2.3.7.8-tetrachlorodibenzo-p-dioxin. Anal Chem 1987;59:2000-2005.
Patterson DG, Fingerhut MA, Roberts DW, Needham LL, Sweeney MH, Marlow DA et al. Levels of polychlorinated dibenzo-p-dioxin and dibenzofurans in workers exposed to 2,3,7,8-tetrachlorbenzo-p-dioxin. Am J Ind Med 1989;16:135-146.
Mocarelli P, Needham LL, Marocchi A, Patterson DG Jr, Branbille P, Gerthoux PM et al. Serum concentration of 2,3,7,8-tetrachloro dibenzo-p-dioxin and test results for selected residents of Seveso, Italy. J Toxicol Environ Health 1991;32:357-366.
Neuberger M, Landvoight W, Derntl F. Blood levels of 2.3.7.8-tetrachlordibenzo-p-dioxin chemical workers after chloracne and in comparison groups. Inst Arch Occup Environ Health 1991;63:325-327.
Sauerhoff MW. Braun WH, Blau GE, Gehring PJ. The fate of 2,4-dichlorophenoxy acetic acid (2,4-D) following oral administration to man. Toxicology 1977;8:3111.
Schecter A, Ryan JJ. Persistent brominated and chlorinated dioxin blood levels in a chemist 35 years after dioxin exposure. J Occup Med 1992;32:702-707.
Durakovic Z, Durakovic A, Durakovic S, Ivanovic D. Poisoning with 2,4-dichlorophenoxy acetic acid treated by hemodialysis. Arch Toxicol 1992;66:518-521.
Flanagan RJ, Meredith TJ, Ruprah M, Onyon U, Liddle A. Alkaline diuresis for acute poisoning with chlorophenoxy herbicides and ioxynil. Lancet 1990;335: 454-458.
Donner A, Lenz K, Wagner L, Walgran M, Hruby K. Survival after massive self-poisoning with sodium chlorate. Proc Eur Assoc Pois Cont Cent Clin Toxicol, 1988; p. 80.
Lee DBN, Brown DL, Baker LRI et al. Haematological complications of chlorate poisoning. Br Med J 1970;2:31-32.
Sanger B, Wegman RCC, Hofstee AWM. Nonoccupa-tional exposure to pentachlorophenol: clinical findings and plasma PCP concentrations in three families. Hum Toxicol 1982;1:123-133.
Steffen C, Wetzel E. Pathologic aspects of chlorate poisoning. Hum Toxicol 1985;4:541-542 (abstract).
Helliwell M, Nunn J. Mortality in sodium chlorate poisoning. Br Med J 1979;1:1119.
Kobel W, Sumner DD, Campbell JB et al. Protective effect of activated charcoal in cattle poisoned with atrazine. Vet Hum Toxicol 1985;27:185-188.
Castano P, Ferrario VF, Vizzotto L. Sciatic nerve fibres in albino rats after atrazine treatment: a morpho-quantitative study. Int J Tissue React 1982; 4: 269— 275.
Pommery J, Mathieu M, Mathieu D, Lhermitte M. Atrazine in plasma and tissue following atrazine-aminotri-azole-ethylene glycol-formaldehyde poisoning. Clin Toxicol 1993;31:323-331.
Scott AR. Questions. Br Med J 1989;299:615.
Pommery J, Mathieu M, Mathieu D, Lhermitte M. High performance liquid chromatographic determination of atrazine in human plasma. J Chromatogr 1990;526:569— 574.
Lucas AD, Jones AD, Goodrow MH, Saiz SG, Blewett G, Seiber JN et al. Determination of atrazine metabolites in human urine: development of a biomarker of exposure. Chem Res Toxicol 1993;6:107-116.
Balkisson R, Murray D, Hoffstein V. Alveolar damage due to inhalation of amitrole-containing herbicide. Chest 1992;101:1174-1175.
Morgan DP. Recognition and management of pesticide poisonings. 4th ed. Washington, DC. US Env Prot Agency. EPA-540/9-88-001. 1989, pp. 154-155.
Day LC. Delayed death by endothall, a herbicide. Vet Hum Toxicol 1988;3O:366.
Casey Р, Vale JA. Deaths from pesticide poisoning in England and Wales: 1945—1989. Hum ExperToxicol 1994;13:95-101.
Thompson JP, Casey PB, Vale JA. Suspected paediatric pesticide poisoning in the UK. II. Home accident surveillance system, 1989—1991. Hum Exp Toxicol 1994;13:534-536.
Casey PB, Thompson JP, Vale JA. Suspected paediatric poisoning in the UK. 1. Home accident surveillance system, 1982—1988. Hum Exper Toxicol 1994;13:529— 533.
Morgan DR. Recognition and management of pesticide poisonings. 4th ed. Washington, DC: US Environmental Protection Agency EPA-540/9-88-001, 1989.
Hayes WJ Jr. Toxicology of pesticides. Baltimore, MD. Williams & Wilkins, 1975, p. 317.
Brewster MA, Hulka BS, Lavy TL. Biomarkers of pesticide exposure. Rev Environ Contain Toxicol 1992;128:17-42.
Karalliedde L, Senanayake N. Ariaratnam A. Acute organophosphorus insecticide poisoning during pregnancy. Hum Toxicol 1988;7:363-364.
Weeks DB, Ford D. Prolonged suxamethonium-induced neuromuscular block associated with organophosphate poisoning. Br J Anaesth 1989;62:237.
Karalliedde L, Henry JA. Effects of organophosphates on skeletal muscle. Hum Exp Toxicol 1993;12:289-296.
de Bleecker JL, Van den Neucker K, Colardyn F. Intermediate syndrome in organophosphorus poisoning: a prospective study. Crit Care Med 1993;21:1706-1711.
de Bleecker J, Van den Neucker K, Willems J. The intermediate syndrome in organophosphate poisoning. Presentation of a case and review of the literature. Clin Toxicol 1992;30:321-329.
de Bleecker J, Willems J, Van der Neucker K, De Reuck J, Vogelaers D. Prolonged toxicity with intermediate syndrome after combined parathion and methyl parathion poisoning. Clin Toxicol 1992;30:333-345.
Lankisch PG, Muller C-H, Niederstadt H, Brand A. Painless acute pancreatitis subsequent to anticholinesterase insecticide (Parathion) intoxication. Am J Gastroenterol 1990;85:872-875.
Weizman Z, Sofen S. Acute pancreatitis in children with anticholinesterase insecticide intoxication. Pediatrics 1992;90:204-206.
Stephens R, Spurgeon A, Calvert IA, Beach J, Levy LS, Berry H et al. Neuropsychological effects of long-term exposure to organophosphates in sheep dip. Lancet 1995;345:1135-1149.
Gerkin R, Cury S. Persistently elevated plasma insecticide levels in severe methylparathion poisoning. Vet Hum Toxicol 1987;29:483-484.
He F. Organophosphates and delayed neuropathy — is NTE alive and well? Toxicol Appl Pharmacol 1990;102:395-399.
Lotti M. Scientific basis of risk assessment and biological monitoring for organophosphorus induced polyneuropathy. In: Volans GN, Smith J, Sullivan FM, Turner P, eds. Basic science in toxicology. London: Taylor & Frances, 1990; 133-142.
Mandel JS, Berlinger NT, Kay N, Conwett J, Reape M IIL Organophosphate exposure inhibits nonspecific esterase staining in human blood monocytes. Am J Indust Med 1989;15:207-212.
Zovot U, Castorena JJ, Garriott JC. A case of fatal ingestion of malathion. Am J Forensic Med Pathol 1993;14:51-53.
Golsousidis H, Kokkas V. Use of 19,590 mg of atropine during 24 days of treatment after a case of unusually severe parathion poisoning. Hum Toxicol 1985;4:339.
Le Blanc FN, Benson BE, Gilg AD. A severe organophosphate poisoning requiring the use of an atropine drip. Clin Toxicol 1986;24:69-76.
Burgess ED, Audette RJ. Limited effectiveness of charcoal hemoperfusion in malathion poisoning. Pharmacotherapy 1990;10:410-412.
Haley KJ, Mortensen ME. Intraosseous infusion of antidote in an organophosphate poisoned child. Vet Hum Toxicol 1990;32:370.
Shockley LW. The use of inhaled nebulized atropine for the treatment of malathion poisoning. Clin Toxicol 1989;27:183-192.
Farrar НС, Wells TG, Kearns GL. Use of continuous infusion of pralidoxime for treatment of organophosphate poisoning in children. J Pediatr 1990;116:648-661.
Johnson MK, Vale JA, Marrs TC, Meredith TJ. Pralidoxime for organophosphorus poisoning. Lancet 1992;340:6.
Vale JA, Meredith TJ, Heath A. High dose atropine in organophosphorus poisoning. Postgrad Med J 1990;66:878-881.
Bentur Y, Nutenko I, Tsipinicek A, Raichlin-Eisenkraft B, Teitelman U. Pharmacokinetics of obidoxime in organophosphate poisoning associated with renal failure. Clin Toxicol 1993;31:315-322.
Selden BS, Curry SC. Prolonged succinylcholine-induced paralysis in organophosphate insecticide poisoning. Ann Emerg Med 1987;16:215-217.
Goldstein DA, McGuigan MA, Ripley BD. Acute tricresylphosphate intoxication in childhood. Hum Toxicol 1988;7:179-182.
Winek CL, Whaba WW, Edelstein J. Sudden death following accidental ingestion of chlormequat. J Anal Toxicol 1990;14:257-258.
Koppel C, Forycki Z, Ibe K. Hemoperfusion in severe dimethoate poisoning. Intensive Care Med 1986;12:110-112.
Lie B, Breder O, Rygnestad T, Stromme JH, Wickstrom E, Jacobson D. Dimethoate self-poisoning in three cases. Proc Eur Assoc Pois Cont Centers Clin Toxicol, 1988; p. 16.
Javanovic D, Randjelovic S, Joksovic D. A case of unusual suicide poisoning by organophosphorus insecticide methoate. Hum Exp Toxicol 1990;9:99-151.
Okonek S, Henningsen B, Bork R, Kusche P, Maintz J, Schuster CJ. Hemoperfusion zar behandling von in-toxikatimen dutch die insektizide demeton-S-methylsul-foxide und dimethoate. In: Mengler S, Kleber B, Seiffert B, eds. Moglichkeiten und Granzen der Hemoperfusion. Fresenices, Wetzlar, 1978; pp. 66.
Jackson RJ. Pesticides as a public health concern in California. West J Med 1983;139:363-364.
Desi 1, Nagymajtenyi L. Acute and subacute neurotoxicity and cardiotoxicity of anticholinesterases. In: Bal-lantyne B, Marrs TL, eds. Clinical and experimental toxicology of organophosphates and carbamates. Oxford: Butterworth-Heinemann, 1992, pp. 84—89.
Okonek S, Boelcke G, Hohmann N. Therapeutic properties of hemodialysis and blood exchange transfusion in organophosphate poisoning. Eur J Intensive Care Med 1976;2:13.
Heath A, May DG, Naukam RJ, Kamban JR, Branch RA. Insecticide overdose. A case study on carbaryl kinetics. Proc Euro Assoc Pois Cont Center Toxicol, 1988; p. 65.
Burgess JL, Bernstein JN, Hurlbut K. Aldicarb poisoning. A case report with prolonged cholinesterase inhibition and improvement after pralidoxime therapy. Arch Intern Med 1994;154:221-224.
Lifshitz M, Rotenberg M, Sofer S, Tamiri T, Shahak E, Almog S. Carbamate poisoning and oxime treatment in children: a clinical and laboratory study. Pediatrics 1984;93:652-655.
Sterr SH, Rognerud B, Fiskum SE, Lyngaas S. Effect of toxogonin and P25 on the toxicity of carbamates and organophosphates. Acta Pharmacol Toxicol 1979;45:9-15.
NatoffIL, Reiff B. Effects of oximes on the acute toxicity of anticholinesterase carbamates. Toxicol Appl Pharmacol 1973;25:569-573.
Casey P. Should we recommend the use of pralidoxime in carbamate insecticide poisoning. Personal communication. Birmingham, UK: First European Training Course for Poisons Information Specialists and Clinical Toxicologists, November 1992.
Garber M. Carbamate poisoning. The "other" insecticide. Pediatrics 1987;79:734-738.
Kurtz PH. Pralidoxime in the treatment of carbamate intoxication. Am J Emerg Med 1990;8:68-70.
Saiyed HN, Sadhu HG, Bhatnagar VK, Dewan A, Venkaiah K, Kahyap SK. Cardiac toxicity following short-term exposure to methomyl in spraymen and rabbits. Hum Exper Toxicol 1992;11:93-97.
Liddle JA, Kimbrough RD, Needham LL, Cline RE, Smrek AL, Yert LV et al. A fatal episode of accidental methomyl poisoning. Clin Toxicol 1979;15:159-167.
Michalodimitrakis EN, Tsatsakis AM. Fatal methomyl poisoning in Crete. Abstract K20. Proc Am Acad Forensic Sci, New Orleans, February 17—22, 1992.
Miyazaki T, Yashiki M, Kojuma T, Chikasue F, Ochiai A, Hidam Y. Fatal and non-fatal methomyl intoxication in an attempted double suicide. Forensic Sci Int 1989;42:263-270.
Natoff I, Reiff B. Effects of oximes on the acute toxicity of anticholinesterase carbamates. Toxicol Appl Pharmacol 1973;25:469-473.
Martinez-Chuecos J, Molinero-Somolino F, Sole-Vio-lan J, Rubio-Sanz R. Management of methomyl poisoning. Hum Exp Toxicol 1990;9:251-254.
Kojima T, Noda J, Yashiki M, Chikasue F, Miyazaki T. Methomyl poisoning: an intoxication case and an animal experiment. Proc 24th Meeting Int Assoc Forensic Toxicol. Banff, Canada, July 28—31, 1987; pp. 505—511.
Tsatsakis AM, Michalodimitrakis EN, Tsakalof AK. Three lethal cases of poisoning involving lannate (methomyl). Bull Int Assoc Forensic Toxicol 1992;22:23-26.
Morse DL, Baker EL Jr, Kimbrough Rd, Wisseman CL. Propanil-chloracne and methomyl toxicity in workers of a pesticide manufacturing plant. Clin Toxicol 1979;15:13-21.
Chapman RA, Harris CR. Determination of residues of methomyl and oxamyl and their oximes in crops by gasliquid chromatography of oxime trimethylsilyl ethers. J Chromatogr 1979;171:249-262.
Driskell WJ, Groce DF, Hill RH Jr. Methomyl in the blood of a pilot who crashed during aerial spraying. J Anal Toxicol 1991;15:339-340.
Tsakalof AK, Tsatsakis AM, Mixadodimetratis. Two fatal poisonings due to methomyl. Bull Int Assoc Forensic Toxicol 1993;23:24-27.
Ekins BR, Geller RJ, Khasigian PA, Carlson TS. Severe carbamate poisoning caused by methomyl with clinical improvement produced by pralidoxime. Vet Hum Toxicol 1993;35:358.
Koyama K, Andon Y, Saruki K, Matsuo H. Delayed and severe toxicities of a herbicide containing glufosinate and a surfactant. Vet Hum Toxicol 1994;36:17-18.
Stehr-Green PA, Wohlleb JC, Royce W, Head SL An evaluation of serum pesticide residue levels and liver function in persons exposed to dairy products contaminated with heptachlor. JAMA 1988;259:374-377.
Steentoft A. A case of fatal dieldrin poisoning. Med Sci Law 1979;19:268-269.
Reddy DB, Edward VD, Abrahams GJS et al. Fatal endrin poisoning: a detailed autopsy, histopathological and experimental study. J Ind Med Assoc 1966;46:121-124.
Davies JE, Dedhia HV, Morgade C et al. Lindane poisonings. Arch Dermatol 1983;119:142-144.
Tenenbein M. Seizures after lindane therapy in adults. Vet Hum Toxicol 1990;32:363.
Burton ВТ, Will UK, Brunett PH, Chandler DB, Wagner S, Giffin S. Seizure following lindane ingestion in a patient pretreated with phenytoin. Vet Hum Toxicol 1991;33:391.
Rao CVSR, Shreenivas R, Singh V, Perez-Atayde A, Woolf A. Disseminated intravascular coagulation in a case of fatal lindane poisoning. Vet Hum Toxicol 1988;30:132-134.
Verderber L, Lavin P, Wesley R. Pseudotumor cerebri and chronic benzene hexachloride (lindane) exposure. Thorax 1991 ;454:1123.
Farley D. From tainted feed to mother’s milk. A pesticide’s devastating journey through the food chain. FDA Consumer 1987;21:38-40.
Curley A, Copeland MF, Kimbrough RD. Chlorinated hydrocarbon insecticides in organs of stillborn and blood of newborn babies. Arch Environ Health 1969; 19:628.
Konje JC, Otolorin EO, Sotunmbi PT, Ladipo OA. Insecticide poisoning in pregnancy. A case report. J Reprod Med 1992;37:992-994.
Hadrzynski CL, Morgan DR, Winsett O, Roy D, Snodgrass WR. Mobilization of a halogenated hydrocarbon pesticide from body fat in man: lindane. Vet Hum Toxicol 1986;28:471.
Bernardelli BC, Gennari MC. Death caused by ingestion of endosulfan. J Forensic Sci 1987;32:1109—1112.
Shemesh Y, Bourvine A, Gold D, Bracha P. Survival after acute endosulfan intoxication. Clin Toxicol 1988;26:265-268.
Tsai WJ, Yang GY, Ger J, Chung HM, Deng JF. Acute massive endosulfan poisoning. A study of 14 cases. Vet Hum Toxicol 1988;30:370.
Coronado JLB, Gomez RJG, Rubi JCM, Rull JRV, Martinez AMS, Martinez MP. Acute intoxication by endosulfan. Proc 5th World Congress on Intensive and Critical Care Medicine. Kyoto, Japan, September 3—8, 1989, p. 225.
Blanco-Coronagc JL, Repetto M, Ginestal RJ, Vincente JR, Yelamis F, Lardelli A. Acute intoxication by endosulfan. Clin Toxicol 1992;30:575-583.
Menendez M, Martinez D, Gimenez P, Jurado C, Repetto M. Five cases (one of them fatal) of endosulfan poisoning. Bull Int Assoc Forensic Toxicol 1988,20(1 ):28—29.
Wax PM, Hoffman RS, Goldfrank LR. Fatality associated with inhalation of a pyrethrum insecticide. Vet Hum Toxicol 1991;33:363.
Tucker SB, Flannigan SA. Cutaneous effects from occupational exposure to fenvalerate. Arch Toxicol 1983;54:195-202.
He F, Wang S, Liu L, Chen S, Zhang Z, Sun J. Clinical manifestations and diagnosis of acute pyrethroid poisoning. Arch Toxicol 1989;63:54-58.
Chen S, Zhang Z, He F, Yao P, Wu Y, Sun J et al. An epidemiological study on occupational acute pyrethroid poisoning in cotton farmers. Br J Ind Med 1991 ;48:77— 81.
Taplin D, Meinking FL. Pyrethrins and pyrethroids in dermatology. Arch Dermatol 1990;126:213-221.
Paton DL, Walker JS. Pyrethrin poisoning from commercial shampoo. Flee and tick spray. Am J Emerg Med 1988;6:232-235.
Culver CA, Malina JJ, Talbert RL. Probable anaphylactoid reaction to a pyrethrin pediculicide shampoo. Clin Pharm 1988;7:846-849.
Fumigants. In: Morgan DR, ed. Recognition and management of pesticide poisonings. Washington, DC. US Environmental Protection Agency. EPA-540/9-88-001. 1989, pp. 131-145.
Reynolds JEF. Martindale: The extra pharmacopoeia. London: The Pharmaceutical Press, 1989, p. 918.
Physicians desk reference. 45th ed. Oradell, NJ: Medical Economics, 1991, p. 2294.
Arditti J, Jouglard J. Surdosage percutane de crotaminon et suspission de methemoglobinemic. Bull Med Leg Toxicol 1978;21:661-662.
Green RC. Westwood Squibb. Buffalo, NY: Personal Communication, March 20, 1991.
De Wilde A-R, Heyndrickx A, Carton D. A case of fatal rotenone poisoning in a child. J Forensic Sci 1986;31:1492-1498.
Trabes J, Rason N, Abrahami E. Computed tomography demonstration of brain damage due to acute sodium monofluoroacetate poisoning. Clin Toxicol 1982;20:85— 92.
Omara F, Sisodia CS. Evaluation of potential antidotes for sodium fluoroacetate in mice. Vet Hum Toxicol 1990;32:407-431.
Thomas HM, Sumpan D, Prescott LF. The toxic effects of alpha-chloralose. Hum Toxicol 1988;7:285-287.
Katz МА. The expanding role of oxygen free radicals in clinical medicine. West J Med 1986;144:441-446.
Hadjimarkos DM. Selenium in relation to dental caries. Food Cosmet Toxicol 1973;11:1083—1095.
Committee on Dietary Allowances Food and Nutrition Board Recommended Dietary Allowances, 9th rev ed. Washington, DC: National Academy of Sciences, 1980, p. 162.
Welsh SO, Holden JM, Wolf WR et al. Selenium in selfrestricted diets of Maryland residents. J Am Diet Assoc 1981;79:277-285.
Selenium intoxication — New York. MMWRT 1984;33:157-158.
Civil IDS, McDonald MJA. Acute selenium poisoning. Case report. NZ Med J 1978;87:354-356.
Natal AJ, Brown M, Dery P et al. Acute poisoning by selenious acid. Vet Hum Toxicol 1985;27:531-533.
Koppel C, Baudisch H, Beyer KH et al. Fatal poisoning with selenium dioxide. Clin Toxicol 1986;24:21-35.
Medinsky MA, Cuddihy RG, McClellan RO. Systemic absorption of selenious acid and elemental selenium aerosols in rats. J Toxicol Environ Health 1981;8:917-928.
Weissman SH, Cuddihy RG, Medinsky MA. Absorption, distribution and retention of inhaled selenious acid and selenium metal aerosols in beagle dogs. Toxicol Appl Pharmacol 1983;67:331-337.
Yang G, Wang S, Zhou R et al. Endemic selenium intoxication of humans in China. Am J Clin Nutr 1983;37:972-981.
Quercia RA, Korn S, O’Neill D et al. Selenium deficiency and fatal cardiomyopathy in a patient receiving longterm home parenteral nutrition. Clin Pharm 1984;3:531-535.
Carter RF. Acute selenium poisoning. Med J Aust 1966;1:525-528.
Normann SA, Nisbet K, Manoguerra AS. Acute selenious acid poisoning — case report. Vet Hum Toxicol 1984;26 (Suppl 2):48 (abstract A-40).
Sioris LJ, Guthrie K, Pentel PR. Acute selenium poisoning. Vet Hum Toxicol 1980;22:364.
Sheehan TMT, Gao M. Simplified fluorometric assay of total selenium plasma and urine. Clin Chem 1990;36:2124-2126.
Aggarwal SK, Kinter M, Herold DA. Determination of selenium in urine by isotope dilution gas chromatography mass spectrometry using 4-nitro-o-phenylenediamine, 3,5-dibromo-o-phenylenediamine, and 4-trifluorome-thyl-o-phenylenediamine as derivatizing reagents. Anal Biochem 1992;202:367-374.
Schecter A, Shanske W, Stenzler A et al. Acute hydrogen selenide inhalation. Chest 1980;77:554-555.
Shall L, Stevens A, Millard LG. An unusual case of acquired localized argyria. Br J Dermatol 1990; 123:403-407.
Raiber A, Bruner B. Ingestion of concentrated silver nitrate. A report of two cases. Vet Hum Toxicol 1987;29:321-322.
Fung MC, Weintraub M, Bowen DL. Colloidal silver proteins marketed as health supplements. JAMA 1995;274:1196-1197.
Finkel AJ, Hamilton A, Hardy HL. Tellurium. In: Finkel AJ, ed. Hamilton and Hardy’s industrial toxicology. 4th ed. Bristol, UK: John Wright, 1983; pp. 128—130.
Schroeder HA, Buckman J, Belasse JJ. Abnormal trace elements in man. J Citron Dis 1967;20:147-161.
De Meio RH. Tellurium: effect of ascorbic acid on the tellurium breath. J Ind Hyg Toxicol 1947;29:393-395.
Shie MD, Deeds FE. The importance of tellurium as a health hazard in industry. Public Health Perspect 1970;35:939-954.
Duckett S. Teratogenesis caused by tellurium. Ann NY Acad Sci 1972;192:220-221.
Blackadder ES, Manderson WG. Occupational absorption of tellurium. A report of two cases. Br J Ind Med 1975;32:59-61.
Tabandeh Н, Crowston JG, Thompson FM. Ophthalmological features of thallium poisoning. Am J Ophthalmol 1994;112:243-248.
Wax PM. Tortilla the votoxicosis. Clin Toxicol 1995;33:265.
Moeschlin S. Thallium poisoning. Clin Toxicol 1980;17:133-146.
Schwartz JG, StucheyJH, Kunkel SP, Dowd DC, Ka-gen-Hallet. Poisoning from thallium. Texas Med J 1988;84:46-48.
Villanueva E, Hernandez-Cueto C, Lachica E, Rodrigo MD, Ramos V. Poisoning by thallium. A study of five cases. Drug Safety 1990;5:384-389.
Tabandeh H, Thompson GM. Visual function in thallium toxicity. Br Med J 1993;307:324.
Herrero F, Fernandez E, Gomez J, Pretel L, Canizares F, Frias J et al. Thallium poisoning presenting with abdominal colic paresthesia and irritability. Clin Toxicol 1995;33:261-264.
Moore D, House I, Dixon A. Thallium poisoning. Grand Rounds, Guy’s Hospital., BrMedJ 1993;306:1527-1529.
Shelton D, Urch В, Tarlo SM. Occupational asthma induced by a carpet fungicide-tributyl tin oxide. J Allergy Clin Immunol 1992;90:274-275.
MMWR. Acute effect of indoor exposure to paint containing bis(tributyrin) oxide. 1991;40:280-281.
Office of the Federal Register 1989;29:CFR:1910.1000.
Barnes JM, Stoner HB. The toxicology of tin compounds. Pharmacol Rev 1959;11:211-231.
Toxicological Profile for Tin and Compounds. Life System Inc. Agency for Toxic Substances and Disease Registry. ATSDR/TP 91/26. September 1992.
Kreyberg S, Torvik A, Bjorneboe A, Wiik-Larsen W, Jacobsen D. Trimethyl tin poisoning: report of a case with postmortem examination. Clin Neuropathol 1992;11:256-259.
Alajouanine T, Derobest L, Theffry S. Etude clinique d’encemble de 210 cas d’intoxication par les seis orga-nique d’etain. Rev Neurol (Paris) 1958;98:85-96.
Wax PM, Dockstader L. Tributyl tin use in interior paints: a continuing health hazard. Clin Toxicol 1995;33:239-241.
Chen JL, Fayerweather WE. Epidemiologic study of workers exposed to titanium dioxide. J Occup Med 1988;30:937-942.
Redline S, Barna BP, Tornashefski JF Jr, Abraham JC. Granulomatous disease associated with pulmonary deposition of titanium. Br J Ind Med 1986;43:652-656.
Archer VE. Health concerns in uranium mining and milling. J Occup Med 1981;23:502-505.
Chavil A. The epidemiology of primary lung cancer in uranium miners in Ontario. J Occup Med 1981;23:417-421.
Key ММ, Henschel AF, Butler J, eds. Occupational diseases: a guide to their recognition. Rev ed. Washington, DC: US Department of Health, Education and Welfare, 1977, pp. 406-408.
Perry GF. Occupational medicine forum. J Occ Med 1994;36(10): 1061 —1063.
Blount BW. Two types of metal fume fever: mild vs serious. Mil Med 1990;115:372-377.
Evans EH. Casualties following exposure to zinc chloride smoke. Lancet 1945;2:368-370.
Hjortso E, Zvist J, Bud MI, Thomsen JL, Andersen JB, Wiberg-Jorgenson F et al. ARDS after accidental inhalation of zinc chloride smoke. Intensive Care Med 1988;14:17-24.
Prasad AS, Brewer GJ, Schoomaker ER, Rabbani P. Hy-pocupremia induced by zinc therapy in adults. JAMA 1978;240:2166-2168.
Brown ER, Greist A, Tricet G, Hoffman R. Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. JAMA 1990; 164:1441 — 1443.
McKinney PE, Brent J, Kulig K. Zinc chloride ingestion in a child: Exocrine pancreatic insufficiency. Ann Emerg Med 1995;25:562.
McKinney P, Brent J, Kulig K, Rumack B. Zinc chloride soldering flux ingestion in a child. Vet Hum Toxicol 1991 ;33:366.
Burkhart KK, Kulig KW, Rumack B. Whole bowel irrigation as treatment for zinc sulfate overdoses. Ann Emerg Med 1990;119:1167-1170.
Hedtker J, Daja MR, Neac G, Burton ВТ. Local and systemic toxicity following zinc chloride (ZnCl2) ingestion. Vet Hum Toxicol 1989;31:342.
Potter JL. Acute zinc chloride ingestion in a young child. Ann Emerg Med 1981;10:267-269.
Chobasanian SJ. Accidental ingestion of liquid zinc chloride: local and systemic effects. Ann Emerg Med 1981;10:91-93.
Banner W, Koch M, Hopf S et al. A-acetylcysteine in the chelation of zinc sulfate. Vet Hum Toxicol 1985;28:293 (abstract).
Hadjimichael ОС, Brubaker RE. Evaluation of an occupational respiratory exposure to zirconium-containing dust. J Occup Med 1981;23:543-547.
Liippo KK, Anttila SL, Taikina-Aho O, Ruokonen E-L, Toivonen ST, Tuomi T. Hypersensitivity pneumonitis and exposure to zirconium silicate in a young ceramic tile worker. Am Rev Respir Dis 1993;148:1089-1092.
Lesser SH, Weiss SJ. Art hazards. Am J Emerg Med 1995;13:451-458.
Cormish Н, Kniep TJ, Sunderman FW Jr. Toxicological profile for nickel. Agency for Toxic Substances and Disease Registry and EPA ATSDR/TP-88/19, December 1988.
Sunderman FW Jr, Dingle B, Hopfer SM, Surft T. Acute nickel toxicity in electroplating workers who accidentally ingested a solution of nickel sulfate and nickel chloride. Am J Ind Med 1988;14:257-266.
Sunderman FW Jr. A pilgrimage into the archives of nickel toxicology. Ann Clin Lab Sci 1989;19:1-16.
Kurta DL, Dean BS, Krenzelok EP. Acute occupational nickel carbonyl poisoning. Vet Hum Toxicol 1991 ;33:372.
Spyker DA. Nickel toxicokinetics. A white paper. Pharmaceutical Research Association, Inc., Charlottesville, VA 22 901.
National Research Council, Canada. Effects of nickel in the Canadian environment, 1981; citation 18 568.
Sunderman FW Jr. Mechanisms of nickel carcinogenesis. Scand J Work Environ Health 1989;15:1-2.
US ЕРА, CEC, Energy, mines and Resources, Canada, National Health and Welfare, Canada, Ontario Ministry of Labour, Nickel Producers Environmental Research Association. Report of the International Committee on Nickel Carcinogenesis in Man. Scand J Work Environ Health 1990;16:1-82.
OSHA (Occupational Safety and Health Administration). Occupational Standards Permissible Exposure Limits. 29 Code of Federal Regulations 1910.10 000.
Angerer J, Lehnert G. Occupational chronic exposure to metals. 11. Nickel exposure of stainless steel welders — biological monitoring. Int Arch Occup Environ Health 1990;62:7-10.
Webster JD, Parker TF, Alfrey AC, Smythe WR, Kubo H, Neal G et al. Acute nickel intoxication by dialysis. Ann Intern Med 1980;92:631-633.
Zhicheng S. Acute nickel carbonyl poisoning: a report of 179 cases. Br J Ind Med 1986;43:422-424.
Fisher AA. Medico-legal aspects of the use of stainless steel sutures in nickel-sensitive persons. Cutis 1988;45:25-26.
US EPA. Project Survey, Health Assessment Document for Nickel. EPA/600/58-3/012, July 1990.
Fisher AA. The dimethylglyoxamine test in the prevention and management of nickel dermatitis. Cutis 1990;46:467-468.
Ong CN, Chua LH, Lee BL, Ong HY, Chia KS. Electrothermal atomic absorption spectrometric determination of cadmium and nickel in urine. J Anal Toxicol 1990;14:29-33.
Rasanen L, Tuomi M-L. Diagnostic value to the lymphocyte proliferation test on nickel contact allergy and provocation in occupational coin dermatitis. Contact Dermatitis 1992;27:250-254.
Mastromatteo Е. Palladium alloys and compounds. In: Parmeggiani L, ed. Encyclopaedia of occupational health and safety. 3rd ed. Geneva: International Labour Office 1991; pp. 1587-1588.
Aberer W, Holub H, Strobal R, Slavick R. Palladium in dental alloys — the dermatologist’s responsibility to warn? Contact Dermatitis 1993;28:163-165.
Olivarius F de F, Menne T. Contact dermatitis from metallic palladium in patients reacting to palladium chloride. Contact Dermatitis 1992;27:71-77.
Stockwell HG, Lyman GH, Waltz J, Peters JT. Risks associated with residence in the central Florida phosphate mining region. Am J Epidemiol 1988;128:78-84.
Van den Anker JN, Fetter WPF, Sauer PJJ. Acute phosphorous intoxication in very low birthweight infant. Eur J Pediatr 1992;151:619-620.
Wilson R, Lovejoy FH, Jaeger RJ et al. Acute phosphine poisoning aboard a grain freighter. JAMA 1980;244:148-150.
Singh S, Dilawandi JB, Vashist R et al. Aluminum phosphide ingestion. Br Med J 1985;290:l 110—1111.
Vaisrub S. Humble therapeutic beginnings for a noble metal. JAMA 1979;241:2738.
Krakoff 1H. Nephrotoxicity of cis-dichlorodiamine platinum (II). Cancer Treat Rep 1979;63:1523-1525.
Woolf AD, Ebert TH. Toxicity after self-poisoning by ingestion of potassium chloropalatinite. Clin Toxicol 1991;29:467-472.
Illingworth RN, Proudfoot AT. Rapid poisoning with slow-release potassium. Br Med J 1980;28:485-486.
Saxena K. Clinical features and management of poisoning due to potassium chloride. Med Toxicol Adverse Drug Exp 1989;4:429-443.
Survival after massive overdose of slow release potassium. Scott Med J 1988;33:279.
Steedman DJ. Poisoning with sustained release potassium. Arch Emerg Med 1988;5:206-211.
Restuccio A. Fatal hyperkalemia from a salt substitute. Am J Emerg Med 1992;10:171-173.
Sporer KA, Mayer AP. Saltpeter ingestion. Am J Emerg Med 1991;9:165.
Picaud JC, Cochat Р, Parchoux JC, Berthier JC, Gilly J, Careyre S et al. Acute renal failure in a child after chewing of match heads. Nephron 1995;57:225-226.
Middleton SJ, Jacyna М, McClaren D, Robinson R, Thomas HC. Hemorrhagic pancreatitis — a cause of death in severe potassium permanganate poisoning. Postgrad Med J 1990;66:657-658.
Rabinerson D, Gruber A, Kaplan В, Royburt М, Ovada J. Accidental cardiopulmonary arrest following magnesium sulphate overdose. Eur J Obstet Gynecol Reprod Biol 1994;55:149-150.
Rizzo AM, Fisher M, LockJP. Hypermagnesemia pseudocoma. Arch Intern Med 1993;153:1130-1136.
Ashton R, Sutton D, Nielson M. Severe magnesium toxicity after magnesium sulfate enema in a chronically constipated child. Br Med J 1990;300:541.
Brown AT, Campbell WAB. Hazards of hypertonic magnesium enema therapy. Arch Dis Child 1978;53:920.
Outerbridge EW, Papageorgiou A, Stern L. Magnesium sulfate enema in a newborn. Fatal systemic magnesium absorption. JAMA 1973;224:1392-1393.
Green J, Woolf A. Hypermagnesemia associated with catharsis in a salicylate-intoxicated patient with anorexia nervosa. Ann Emerg Med 1989;18:200-203.
Woodard JA, Slauson M, Lacouture PG, Woolf A. Serum magnesium concentrations after repetitive magnesium cathartic administration. Am J Emerg Med 1990;8:297-300.
Jones J, Heiselman D, Dougherty J, Eddy A. Cathartic-induced magnesium toxicity during overdose management. J Ann Emerg Med 1986;15:1214-1218.
Weber CA, Santiago RM. Hypermagnesemia. A potential complication during treatment of theophylline intoxication with oral activated charcoal and magnesium-con-taining cathartics. Chest 1989;95:56-59.
Brand JM, Greer FR. Hypermagnesemia and intestinal perforation following antadel administration in a premature infant. Pediatrics 1990;85:121-123.
Alison LH, Bulugahapitiya D. Laxative induced magnesium poisoning in a 6 week old infant. Br Med J 1990;300:125.
Mofenson HC, Caraccio TR. Magnesium intoxication in a neonate from oral magnesium hydroxide laxative. Clin Toxicol 1991;29:215-222.
Hoffman RS, Smilkstein MJ, Rubenstein F. An "amp" by any other name: the hazards of intravenous design. JAMA 1989;261:557.
Graber TW, Yee AS, Baker FJ. Magnesium: Physiology, clinical disorders and therapy. Ann Emerg Med 1981;10:49-57.
Roels НА, Ghyselen Р, Buchet JP, Ceulemans Е, Lau-werys RR. Assessment of the permissible exposure level to manganese in workers exposed to manganese dioxide dust. Br J Ind Med 1992;49:25-34.
Lesser SH, Weiss SJ. Art hazards. Am J Emerg Med 1995;13:451-458.
Wennberg A, Iregren A, Struwe G, Cizinsky G, Hagman M, Johanssen L. Manganese exposure in steel smelters a health hazard to the nervous system. Scand J Work Environ Health 1991;17:255-262.
Ejima A, ImamuraT, NakamuraS, Saito H, Matsumoto K, Momono S. Manganese intoxication during total parenteral nutrition. Lancet 1992;229:426.
Newland MC, Ceckler TL, Kordower JH, Weiss P. Visualizing manganese in the primate basal ganglia with magnetic resonance imaging. Exp Neurol 1989; 106: 251-258.
Angle C, Nelson K. Manganese encephalopathy. Utility of early magnetic resonance imaging. Vet Hum Toxicol 1992;34:350.
Shuqin K, Haishang D, Peiyi X, Wanda H. A report of two cases of chronic serious manganese poisoning treated with sodium para-aminosalicylic acid. Br J Ind Med 1992;49:66-69.
Taueg С, Sanfilippo DJ, Rowens В, Szejde J, Hesse JL. Acute and chronic poisoning from residential exposure to elemental mercury — Michigan 1989—1990. Clin Toxicol 1992;30:63-67.
Campbell JS. Acute mercurial poisoning by inhalation of metallic vapour in an infant. Can Med Assoc J 1948;58:72-75.
Bluhm RE, Bobbitt RG, Welch LW, Wood AJJ, Bon-figlio JF, Sarzen C, Heath AJ, Branch RA. Elemental mercury vapour toxicity, treatment and prognosis after acute intensive exposure in chloralkali plant workers. 1. History, neuropsychological findings and chelator effects. Hum Exp Toxicol 1992;11:201-210.
Jaffe KM, Shurtleff DB, Robertson WO. Survival after acute mercury vapor poisoning. Role of intensive supportive care. Am J Dis Child 1983;137:749-751.
Berlin M, Fazackerley J, Nordberg G. The uptake of mercury in the brains of mammals exposed to mercury vapor and to mercuric salts. Arch Environ Health 1969;18:719-729.
Bidstrup PL, Bonnell JA, Harvey DG, Locket S. Chronic mercury poisoning in men repairing direct-current meters. Lancet 1951;2:856-861.
Vroom FQ, Greer M. Mercury vapour intoxication. Brain 1972;95:305-318.
Levin M, Jacobs J, Polos PG. Acute mercury poisoning and mercurial pneumonitis from gold ore purification. Chest 1988;94:554-556.
Erickson T, Aks S, Branches FJ, Naleway C, Chou H-N, Hryhorszuk DO. Fractional mercury levels in Brazilian gold refiners and miners. Vet Hum Toxicol 1992;34:354.
Branches F, Erickson T, Aks S, Hryhorczuk DO. The price of gold: mercury poisoning in the Amazonian rain forest. Vet Hum Toxicol 1992;34:354.
Kanluen S, Gottlieb CA. A clinical pathologic study of four adult cases of acute mercury inhalation toxicity. Arch Pathol Lab Med 1991;115:56-60.
Tennant R, Johnston HJ, Wells J B. Acute bilateral pneumonitis associated with the inhalation of mercury vapor. Report of five cases. Connecticut Med 1961 ;25:106— 109.
Weiss SW, Wands JR, Yardley JH. Demonstration by electron diffraction of black mercuric sulfide: (beta-HgS) in a case of "melanosis coli and black kidneys" caused by chronic inorganic mercury poisoning. Lab Invest 1973;28:401-402.
Snodgrass W, Sullivan JB, Rumack BH, Hashimoto C. Mercury poisoning from home gold ore processing. Use of penicillamine and dimercaproL JAMA 1981;246:1929-1931.
Wands JR, Weiss SW, Yardley JH, Maddrey WC. Chronic inorganic mercury poisoning due to laxative abuse. Am J Med 1974;57:92-101.
Williamson AM, Тео RKC, Sanderson J. Occupational mercury exposure and its consequence for behaviour. Int Arch Occup Environ Health 1982;50:273-286.
Troen P, Kaufman SA, Katz KH. Mercuric bichloride poisoning. N Engl J Med 1951;244:59-71.
Barregard L, Sallsten G, Jarvholm B. Mortality and cancer incidence in chloralkali workers exposed to inorganic mercury. Br J Ind Med 1990;47:99-104.
Lindstedt G, Gottberg I, Holmgren B, Jonsson T, Karlsson G. Individual mercury exposure of chloralkali workers and its relation to blood and urinary mercury levels. Scand J Work Environ Health 1979;5:59-69.
Bell ZG, Lovejoy HB, Vizena TR. Mercury exposure evaluations and their correlation with urine mercury excretions. III. Time-weighted average (TWA) mercury exposures and urine mercury levels. J Occup Med 1973;15:501-508.
Yoshida M. Relation of mercury exposure to elemental mercury levels in the urine and blood. Scand J Work Environ Health 1985;11:33-37.
Jaeger A, Livardjani F, Dahlet M, Flexch F. Plasma and blood mercury concentrations in a non-occupationally exposed population. 1990;LuxTox’90, Luxembourg.
Arnold W. Elimination of mercury in urine after aspiration into the lungs. TIAFT, Proceedings of the 25th International Meeting, The International Association of Forensic Toxicologists. Groningen, June 27—30, 1988.
Manoukian SV, Wenger NK. Mercury in the heart. Am J Cardiol 1991;67:317-318.
Will VK, Burton ВТ, Magnusson AR, Solter J. Mercuric chloride: intravenous (IV) injection resulting in transient anuric renal failure. Vet Hum Toxicol 1991 ;33:388.
Stahl MG, Bonekat HW, Shigeoka JW. Concomitant pulmonary thromboembolism and metallic mercury embolism. A diagnostic dilemma. Chest 1985;88:787-789.
Clague JR, Gray HH, Kay PH. Self injection with mercury. BMJ 1989;299:1567.
Murray KM, Hedgpeth JC. Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy. Drug Intell Clin Pharm 1988;22:972-975.
Zillmer EA, Lucci К-A, Barth JT, Peake TH, Spyker DA. Neurobehavioral sequelae of subcutaneous injection with metallic mercury. Clin Toxicol 1986;24(2):91 — 110.
Friberg L, Hammarstrom S, Nystrom A. Kidney injury after chronic exposure to inorganic mercury. Arch Ind Hyg Occup Med 1953;8:149-153.
Langolf GD, Chaffin DB, Henderson R, Whittle HP. Evaluation of workers exposed to elemental mercury using quantitative tests of tremor and neuromuscular functions. Am Ind Hyg Assoc J 1978;39:976-984.
Sexton DJ, Powell KE, Liddle J, Smrek A, Smith JC, Clarkson TW. A nonoccupational outbreak of inorganic mercury vapor poisoning. Arch Environ Health 1978;33:186-191.
Blair E, Cross RE, Stave GM et al. Elemental mercury vapor poisoning. MMWR 1989;38:770-772.
Toxic Information Center Case Rounds. What is the proper technique for cleaning a mercury spill in a home? San Francisco Regional Poison Center, February 11, 1991.
Muhlendahl KEV. Intoxication from mercury spilled on carpets. Lancet 1990;336:1578.
Warkany J, Hubbard DM. Mercury in the urine of children with acrodynia. Lancet 1948;May 29:829—830.
Mellick C. Mercury poisoning from paint exposure. Rocky Mountain Poison Center Bulletin 1991; 10( 1): 1— 4.
Warkany J. Acrodynia. Postmortem of a disease. Am J Dis Child 1966;112:147-156.
Dathan JG. Acrodynia associated with excessive intake of mercury. Br Med J 1954;1:247-249.
Tunnessen WW, McMahon KJ, Baser M. Acrodynia from exposure to mercury in fluorescent light bulbs. Pediatrics 1987;79:786-789.
Rapaport DS. Exposure to mercury vapor endangers workers’ mental, physical health. Occup Health Saf 1989;58(10):47—50.
Schuckmann F. Study of preclinical changes in workers exposed to inorganic mercury in chloralkali plants. Int Arch Occup Environ Health 1979;44:193-200.
Smith RG, Vorwald AJ, Patil LS, Mooney TF Jr. Effects of exposure to mercury in the manufacture of chlorine. Am Ind Hyg Assoc J 1970;3:687-700.
Ladd AC, Zuskin E, Valic F, Almonte JB, Gonzales TV. Absorption and excretion of mercury in miners. J Occup Med 1966;8:122-137.
Danziger SJ, Possick PA. Metallic mercury exposure in scientific glassware manufacturing plants. J Occup Med 1973;15:15-20.
Stonard MD, Chater BV, Duffield DP, Nevitt AL, O’Sullivan JJ, Steel GT. An evaluation of renal function in workers occupationally exposed to mercury vapor. Int Arch Occup Environ Health 1983;52:177-189.
Naleway C, Sakaguchi R, Mitchell E, Muller T, Ayer WA, Hefferren JJ. Urinary mercury levels in US dentists, 1975—1983: review of Health Assessment Program. JADA 1985;222:37-42.
Hancocks S. Is dental amalgam bad for you? Br Med J 1991;302:488.
Litovitz TL, Schmitz BF, Bailey KM. 1989 Annual Report of the American Association of Poison Control Centers National Data Collection System: 433. Case 124.
Fung YK, Molvar MR Toxicity of mercury from dental environment and from amalgam restorations. Clin Toxicol 1992;30(l):59—61.
Bergman M. Side-effects of amalgam and its alternatives: local, systemic and environmental. Int Dental J 1990;40:4-10.
Ericson A, Kallen B. Pregnancy outcome in women working as dentists, dental assistants or dental technicians. Int Arch Occup Environ Health 1989;61:329— 333.
Tuffs A. Germany: amalgam fillings. Lancet 1992;339:419.
Olstad ML, Holland RI, Pettersen AH. Effect of placement of amalgam restorations on urinary mercury concentration. J Dent Res 1990;69(9): 1607—1609.
Molin M, Bergman B, Marklund SL, Schutz A, Skerfv-ing S. Mercury, selenium and glutathione peroxidase before and after amalgam removal in man. Acta Odontol Scand 1990;48:189-202.
Snapp KR, Boyer DB, Peterson LC, Svare CW. The contribution of dental amalgam to mercury in blood. J Dent Res 1989;68(5):780—785.
Eti S, Weisman RS, Hoffman RS. Lack of renal toxic effect of mercury amalgam fillings. Vet Hum Toxicol 1992;34:354.
Panel advises further research on dental amalgam. FDA Consumer 1991 ;25(5):4—5.
Friedman PK. Safety of dental amalgam. JAMA 1988;260:2295.
Nightingale SL. Safety of dental amalgam. JAMA 1991;215:2934.
Baratz R. Dental amalgam. Heavy metal. Harvard Health Letter. 1991;16(11):4— 5.
Melkonian R, Baker D. Risks of industrial mercury exposure in pregnancy. Obstet Gynecol Survey. 1988;43(l 12):637—641.
Lauwerys R, Roels H, Genet P, Toussaint G, Bouckaert A, De Cooman S. Fertility of male workers exposed to mercury vapor or to manganese dust: a questionnaire study. Am J Ind Med 1985;7:171-176.
Cordier S, Deplan F, Mandereau L, Hemon D. Paternal exposure to mercury and spontaneous abortions. Br J Ind Med 1991;48:375-381.
Kuhnert PM, Kuhnert BR, Erhard P. Comparison of mercury levels in maternal blood, fetal cord blood and placental tissues. Am J Obstet Gynecol 1981; 139:209— 213.
Urbach J, Boadi W, Brandes JM, Kerner H, Yannai S. Effect of inorganic mercury on in vitro placental nutrient transfer and oxygen consumption. Reprod Toxicol 1992;6:69-75.
Takahata N, Hayashi H, Watanabe S, Anso T. Accumulation of mercury in the brains of two autopsy cases with chronic inorganic mercury poisoning. Folia Psychiatrica et Neurologica Japonica 1970;24:59-69.
Erfurth EM, Schutz A, Nilsson A, Barregard L, Skerfv-ing S. Normal pituitary hormone response to thyrotropin and gonadotrophin releasing hormones in subjects exposed to elemental mercury vapour. Br J Ind Med 1990;47:639-644.
McGregor AJ, Mason HJ. Occupational mercury vapour exposure and testicular, pituitary and thyroid endocrine function. Hum Exp Toxicol 1991;10:199-203.
Pesce AJ, Hanenson I, Sethi K. Beta2 microglobulinuria in a patient with nephrotoxicity secondary to mercuric chloride ingestion. Clin Toxicol 1977;11:390-395.
Hunter D, Lister A. Mercurialentis. Br J Ophthalmol 1953;37:234-235.
Tubbs RR, Gephardt GN, McMahon JT, Polh MC, Vidt DG, Barenberg SA, Valenzuela R. Membranous glomerulonephritis associated with industrial mercury exposure. Study of pathogenetic mechanisms. Am J Clin Pathol 1982;77:409-413.
Buchet JP, Roels H, Bernard A, Lauwerys R. Assessment of renal function of workers exposed to inorganic lead, cadmium or mercury vapor. J Occup Med 1980;22:741 — 750.
Clarkson TW. The pharmacology of mercury compounds. Annu Rev Pharmacol Toxicol 1972; 12:375— 406.
Rosenman KD, Valciukas JA, Glickman L, Meyers BR, Cinotti A. Sensitive indicators of inorganic mercury toxicity. Arch Environ Health 1989;41:208-215.
Ehrenberg RL, Vogt RL, Smith AB et al. Effects of elemental mercury exposure at a thermometer plant. Am J Ind Med 1991;19:495-507.
Leaback DE, Walker DG. The fluorometric assay of A-acetyl-beta-glucosaminadase. Biochem J 1981;78:151.
Elemental mercury vapor poisoning — North Carolina 1988. MMWR 38:770—777.
Fahn S. Differential diagnosis of tremors. Med Clin North Am 1972;56:1363-1375.
Langworth S, Almkvist O, Soderman E, Wikstrom B-A. Effects of occupational exposure to mercury vapor on the central nervous system. Br J Ind Med 1992;49:545-555.
Battigelli MC. Mercury toxicity from industrial exposure. A critical review of the literature. II. J Occup Med 1960;Aug:394—399.
Verberk MM, Salle HJA, Kemper CH. Tremor in workers with low exposure to metallic mercury. Am Ind Hyg Assoc J 1987;47(8):559—562.
Cavanaugh JB. Long-term persistence of mercury in the brain. Br J Ind Med 1988;45:649-651.
Miller JM, Chaffin DB, Smith RG. Subclinical psychomotor and neuromuscular changes in workers exposed to inorganic mercury. Am Ind Hyg Assoc J 1975;Oct:725.
Chapman LJ, Sauter SL, Henning RA, Dodson VN, Reddan WG, Matthews CG. Differences in frequency of finger tremor in otherwise asymptomatic mercury workers. Br J Ind Med 1990;47:838-843.
Albers JW, Kallenbach LR, Fine U et al. Mercury Workers Study Group. Neurological abnormalities associated with remote occupational elemental mercury exposure. Ann Neurol 1988;24:651-659.
Nylander M, Friberg L, Weiner J. Muscle biopsy as an indicator for predicting mercury concentrations in the brain. Br J Ind Med 1990;47:575-576.
Magos L. Mercury-blood interaction and mercury uptake by the brain after vapor exposure. Environ Res 1967;323—337.
King GW. Acute pneumonitis due to accidental exposure to mercury vapor. Ariz Med 1954; 11:335.
Bluhm RE, Breyer J, Bobbitt RG, Welch LW, Wood AJJ, Bonfiglio JF, Branch RA. Hyperchloremia as a manifestation of elemental mercury vapor toxicity in chloralkali workers. Vet Hum Toxicol 1991 ;33:373.
Freeman JR. Mercurial disease among hatters. Trans Med Soc NJ, 1960; pp. 61-64.
Wedeen RP. Were the hatters of New Jersey "mad"? Am J Ind Med 1989;16:225-233.
De Bout B, Lauwerys R, Govaerts H, Moulin D. Yellow mercuric oxide ointment and mercury intoxication. Eur J Pediatr 1986;145:217-218.
Bourgeois M, Dooms-Goossens A, Knockaert D, Sprengers D, Van Boven M, Van Tittelboom T. Mercury intoxication after topical application of a metallic mercury ointment. Dermatologica 1986;172:48-51.
Hursh JB, Clarkson TW, Miles EF, Goldsmith LA. Percutaneous absorption of mercury vapor by man. Arch Environ Health 1989;44:120-127.
Godlee F. Skin lighteners cause permanent damage. BMJ 1992:305:333.
Barr RD, Woodger BA, Rees PH. Levels of mercury in urine correlated with the use of skin lightening creams. Am J Clin Pathol 1973;59:36-40.
Dyall-Smith DJ, Scurry JP. Mercury pigmentation and high mercury levels from the use of a cosmetic cream. Med J Aust 1990;153:409-415.
Moria A. Health hazards from mercury soap. Lancet 1989;1:448.
Becker CG, Becker EL, Maher JF. Nephrotic syndrome after contact with mercury. Arch Intern Med 1962;110:178-186.
Silverberg DS, McCall JT, Heut JC. Nephrotic syndrome with use of ammoniated mercury. Arch Intern Med 1967;170:581-586.
Schrallhammer-Benkler K, Ring J, Przybilla B, Meurer M, Landthaler M. Acute mercury intoxication with lichenoid drug eruption followed by mercury contact allergy and development of antinuclear antibodies. Acta Derm Venereol (Stockh) 1992;72:294-296.
Gaffin SL, Hornung H. Rapid determination of mercury in urine by flameless atomic absorption spectrometry. Clin Toxicol 1977;10:345-351.
Krull IS, Bushee DS, Schleicher RG, Smith SB Jr. Determination of inorganic and organomercury compounds by high-performance liquid chromatography-inductively coupled plasma emission spectrometry with cold vapour generation. Analyst 1986;111:345-349.
Magos L, Clarkson TW. Atomic absorption determination of total, inorganic and organic mercury in blood. J Assoc Off Anal Chem 1972;55:966-971.
Landrigan PJ. Occupational and community exposure to toxic metals: lead, cadmium, mercury and arsenic. West J Med 1982;137:531-539.
PineauA, Piron M, Boiteau H-L, Etourneau M-J, Guillard O. Determination of total mercury in human hair samples by cold vapor atomic absorption spectrometry. J Analyt Toxicol 1990;14:235-238.
Giovanoli-Jakubczak, Greenwood MR, Smith JC, Clarkson TW. Determination of total and inorganic mercury in hair by flameless atomic absorption and of methylmercury by gas chromatography. Clin Chem 1974;20:222-229.
Kazantzis G, Schiller KFR, Asscher AW, Drew RG. Albuminuria and the nephrotic syndrome following exposure to mercury and its compounds. Q J Med 1962;31:403-419.
Zalups RK, Cherian MG. Renal metallothionein metabolism after a reduction of renal mass. 1. Effect of unilateral nephrectomy and compensatory renal growth on basal and metal-induced renal metallothionein metabolism. Toxicology 1992;71:83-102.
Mant TGK. Clinical studies with dimercaptopropane sulphonate in mercury poisoning. Hum Toxicol 1985;4:346.
Campbell JR, Clarkson TW, Omar MI. Therapeutic use of 2,3-dimercaptopropane-l-sulfonate in two cases of inorganic mercury poisoning. JAMA 1986;256:3127— 3130.
Lamm O, Pratt H. Subclinical effects of exposure to inorganic mercury revealed by somatosensory-evoked potentials. Eur Neurol 1985;24:237-243.
Ellingsen D, Morland T, Anderson A, Kjuus H. Nervous system effects associated with previous exposure to inorganic mercury. Neurotoxicology 1991; 12(4):808.
Nielsen JB. Andersen O. Effect of four thiol-containing chelators on disposition of orally administered mercuric chloride. Hum Exp Toxicol 1991;10:423-430.
Toet AC, van Dijk A, Savelkoul TJF, Meulenbelt J.A case of severe mercury chloride poisoning treatment with dimercapto-1-propane sulfonate (DMPS). Proc Eur Assoc Pois Cont Centers Clin Toxicol, Istanbul, May 24— 27, 1992.
Hla KK, Ashton CE, Henry JA, VolansGN, Mant TGK. Adverse effects of 2,3 dimercapto-1-propane sulfonate (DMPS). Proc Eur Assoc Pois Cont Centers Clin Toxicol, Istanbul, May 24—27, 1992; p. 13.
Aposhlan HV, Maiorino RM, Hurlbut KM, Dart RC, Bruce DS, Aposhlan MM. Pharmacokinetics of DMPS and DMSA in humans. Proc Eur Assoc Pois Cont Centers Clin Toxicol, Istanbul, May 24—27, 1992; p. 12.
Maiorino MM, Bruce DC, Aposhian HV. Determination of dithiol chelating agents. VL Isolation and identification of the mixed sulfides of meso-2,3 dimercaptosuccinic acid with L-cysteine in human urine. Toxicol Appl Pharmacol 1989;97:338-349.
Roels HA, Boeckx M, Ceulemans E, Lauwerys RR. Urinary excretion of mercury after occupational exposure to mercury vapour and influence of the chelating agent meso-2,3-dimercaptosuccinic acid (DMSA). Br J Ind Med 1991;48:247-253.
Girardi G, Elias MM. Effectiveness of N-acetylcysteine in protecting against mercuric chloride-induced nephrotoxicity. Toxicol 1991;67:155-164.
Feychting K, Kulling P, Skold H, Sjerstrom H, Furuland H, Bennis J. DMPS and DMSA in mercury poisoning. Presentation at Eur Assoc Pois Cent Clin Toxicol 1994, Krakow.
Lyle WH. Evaluation of the chelating action of methicillin in prolonged experimental metallic mercury poisoning. Br J Ind Med 1987;44:71.
Keller F, KoefferC, Von Keyserling HJ, Schutze G. Hemoperfusion for organic mercury detoxication. Klin Wo-chenschr 1981;59:865-866.
Clarkson TW. Recent advances in the toxicology of mercury with emphasis on the alklymercurials. Crit Rev Toxicol 1972;1:203-234.
Leumann EP, Brandenberger H. Hemodialysis in a patient with acute mercuric cyanide intoxication. Concentrations of mercury in blood, dialysate, urine, vomitus and feces. Clin Toxicol 1977;! 1:301—308.
Worth DP, Lewins AM, Davison AM, Ledgerwood MJ, Taylor A. Haemodialysis and charcoal haemoperfusion in acute inorganic mercury poisoning. Postgrad Med J 1984;60:636-638.
Lowenthal DT, Chardo F, Reidenberg MM. Removal of mercury by peritoneal dialysis. Arch Intern Med 1974;134:139-141.
Cunningham LE, Kostyniak PJ, Goldstein J, Greizerstein HB, Lachaal M, Reddy P et al: Extracorporeal regional complexing hemodialysis. Treatment of acute inorganic mercury intoxication. Kidney Int 1990;37:292.
Al-Abbasi AH, Kostyniak PJ, Clarkson TW. An extracorporeal complexing hemodialysis system for the treatment of methylmercury poisoning, ill. Clinical applications. J Pharmacol Exp Ther 1978;207:249-254.
Ferguson CL, Cantilena LR Jr. Enhanced mercury clearance during hemodialysis with chelating agents. Clin Pharmacol Ther 1991 ;49:131.
Ferguson CL, Cantilena LR. Mercury clearance from human plasma during in vitro dialysis: screening systems for chelating agents. Clin Toxicol 1992;30:423-441.
Ferguson CL, Cantilena LR Jr. In vitro equilibrium dialysis as a screening procedure for chelating agents effective in enhancing mercury clearance from human plasma. Am Soc Clin Pharmacol Ther 1992;Feb: 186.
Barregard L, Sallstein G, Schutz A, Attewell R, Skerfv-ing S, Jarvholm B. Kinetics of mercury in blood and urine after brief occupational exposure. Arch Environ Health 1992;46:176-184.
Wulf HC, Kromann N, Kousgaard N, Jansen J, Niebuhr E, Alboge K. Sister chromatid exchange (SCE) in Greenlandic Eskimos. Dose-response relationship between SCE and seal diet, smoking and blood cadmium and mercury concentrations. Sci Total Environ 1986;48:81-94.
Davis LE, Kornfeld M, Mooney HS et al. Methylmercury poisoning: long-term clinical, radiological, toxicological and pathological studies of an affected family. Ann Neurol 1994;35:680-688.
Friedman РВ, Bekes СЕ, Scott WE, Bartter Т. ARDS following acute lithium carbonate intoxication. Intensive Care Med 1992;18:123-124.
Lewis DA. Unrecognized chronic lithium neurotoxic reactions. JAMA 1983;250:2029-2030.
Soul RF, Hamburger HA, Seihorst JB. Pseudotumor cerebri secondary to lithium carbonate. JAMA 1985;253:2869-2870.
Wagner KD, Teicher MH. Lithium and hair loss in childhood. Psychosomatics 1991;32:355-356.
Labelle A, La Pierre YD. Keratoderma: side effects of lithium. J Clin Psychopharmacol 1991;1:149-150.
Rudolph RI. Lithium induced psoriasis of the fingernails. J Am Acad Dermatol 1992;26:135-136.
Terao T, Terao M, Yoshimina R, Ave K. Restless legs syndrome induced by lithium. Biol Psychiatry 1991;30:1167-1170.
Bateman AMS, Larner AJ, McCartney SA, Rifkin IR. Rhabdomyolysis associated with lithium-induced hyperosmolar state. Nephrol Dial Transplant 1991;6:203-205.
Simard M, Gumbiner B, Lee A, Lewis H, Norman D. Lithium carbonate intoxication. A case report and review of the literature. Arch Intern Med 1989;149:36-46.
Amdisen A. Clinical features and management of lithium poisoning. Med Toxicol 1988;3:18-32.
Groleau G, Barch R, Tso E, Shye D, Brown B. Lithium intoxication: manifestations and management. Am J Emerg Med 1987;5:527-532.
Marcus S. Lithium. Clin Toxicol Rev 1980;2(5): 1—2.
Friedberg RC, Spyker DA, Herold DA. Massive overdoses with sustained release lithium carbonate preparations: pharmacokinetic model based on two case studies. Clin Chem 1991;37:1205-1209.
Anton RF, Paladino JA, Morton A et al. Effect of acute alcohol consumption on lithium kinetics. Clin Pharmacol Ther 1985;38:52-55.
Jaeger A, Sander P, Kopferschmitt J et al. Toxicokinetics of lithium intoxication treated by hemodialysis. Clin Toxicol 1985;23:501-517.
Jaeger A, Sauder P, Kopferschmitt J, Tritsch L, Flesch 1. When should dialysis be performed in lithium poisoning: A kinetic study in 14 cases of lithium poisoning. Clin Toxicol 1993;31:429-447.
Hunter R. Steady state pharmacokinetics of lithium carbonate in healthy subjects. Br J Clin Pharmacol 1988;25:375-380.
Jermain DM, Crismon ML, Martin ES HI. Population pharmacokinetics of lithium. Clin Pharm 1991;10:376— 381.
Chapron DJ. Comment on pharmacokinetics of lithium in the elderly. J Clin Psychopharmacol 1988;8:78.
Bijnen JH, Vlasveld LT, Wander J, Huinik WWB, Ro-denhuis S. Effect of cisplatin-containing chemotherapy on lithium serum concentrations. Ann Pharmacother 1992;26:488-490.
Griffin JH, Halu SM. Lisinopril induced lithium toxicity. DICP Ann Pharmacother 1991;25:101.
Binder EF, Cayabyab L, Ritchie DJ, Birge SJ. Diltiazed-induced psychosis in a possible diltiazem-lithium interaction. Arch Intern Med 1991;151:373-374.
Sacristan JA, Iglesias C, Arellano I, Leguesica J. Absence seizures induced by lithium: possible interaction with fluoxetine. Am J Psychiatry 1991;148:146-147.
Dinan TG, O’Keene V. Acute extrapyramidal reactions following lithium and sulpiride co-administration: two case reports. Hum Psychopharmacol Clin Exp 1991;6:67-69.
Helhmuth D, Ljaljevic Z, Ramirez L, Meltzer HY. Choreoathetosis induced by verapamil and lithium treatment. J Clin Psychopharmacol 1989;9:450-455.
Austin LS, Aran GW, Melvin JA. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. J Clin Psychiatry 1990;51:344-345.
Herbert V, Hirschman S, Jacobson J. Lithium for zidovudine-induced neutropenia in AIDS. JAMA 1988;260:3588.
Abou-Saleh MF. Reply. Br Med J 1987;294:1405.
Simon G. Combination angiotensive converting enzyme inhibitor/lithium therapy contraindicated in renal disease. Am J Med 1988;56:893-894.
D’Arcy PF. Nephrotoxic interaction: lithium and metronidazole. Int Pharm J 1988;2:44-45.
Jacobson SI, Jones KL, Johnson K, Ceolin L, Kaur P, Saber D et al. A prospective multicenter study of pregnancy outcome following lithium exposure during the first trimester of pregnancy. Pediatr Res 1992;31 (4):691.
Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Salm D et al. Prospective multicentre study of pregnancy outcome after lithium exposure during the first trimester. Lancet 1992;39:530-533.
Cunniff CM, Salm DJ, Johnson KA, Jones KJ. Pregnancy outcome in women treated with lithium. Clin Res 1988;36:217A.
Schou M. Lithium treatment during pregnancy, delivery, and lactation: an update. J Clin Psychiatry 1990;51:410— 413.
Schou M, Goldfield MD. Weinstein MP, Elleneuve A. Lithium and pregnancy-1 report from the Register of lithium babies. Br Med J 1973;2:135-136.
Schou M, Amdisen A, Steenstrup OR. Lithium and pregnancy. 11. Hazards to women given lithium during pregnancy and delivery. Br Med J 1973;2:137-138.
Linden S, Rich CL. The use of lithium during pregnancy and lactation. J Clin Psychiatry 1983;44:358-361.
Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of the in utero exposure to lithium. JAMA 1993;271:146-150.
Connoley G, Menahem S. A possible association between neonatal jaundice and long-term maternal lithium ingestion. Med J Aust 1990;157:272-273.
Ananth J. Lithium during pregnancy and lactation. Lithium 1993;4:231-237.
Hansen HE, Amdisen A. Lithium intoxication. Q J Med 1978;186:123-144.
Gitlin MJ. Lithium-induced renal insufficiency. J Clin Psychopharmacol 1993; 13:276—279.
Bendz H, Aurell M, Balldin J et al. Kidney damage in longterm lithium patients: a cross-section study of patients with 15 years or more on lithium. Nephrol Dial Transplant 1994;9:1250-1254.
Walker RG. Lithium nephrotoxicity. Kidney Int 1993;44(Suppl 42):S93—S98.
Bismuth C, Baud FJ, Musczynski J, Galliot M. Renal function in lithium treatment. About 50 cases. Proc Eur Assoc Pois Cont Centers Toxicol 1988;83.
Tilkan AG, Schroeder JS, Kao JJ et al. The cardiovascular effects of lithium in man. A review of the literature. Am J Med 1976;61:665-670.
Kachel F, Boning JAL. Recurrent asystole due to arrhythmic changes during treatment with lithium. Pharmacopsychiatry 1991 ;24:104.
Ong ACM, Handler CE. Sinus arrest and asystole due to severe lithium intoxication. Int J Cardiol 1991;30:364-366.
Kast R. Reversal of lithium-related cardiac repolarization delay by potassium. J Clin Psychopharmacol 1990;10:304-305.
Chow CC, Cockram CS. Thyroid disorders induced by lithium and amiodarone: an overview. Adverse Drug React Acute Pois Rev 1990;9:207-222.
Stancer НС, Forbath N. Hyperparathyroidism, hypothyroidism and impaired renal function after 10 to 20 years of lithium treatment. Arch Intern Med 1989; 149:1042— 1045.
Santiago R, Rashkin MC. Lithium toxicity and myxedema coma in an elderly woman. J Emerg Med 1990;8:63—• 66.
Jaeger A, Sauder P, Kopferschmitt J, Tritsch L, Flesch F. When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. Clin Toxicol 1993;31:429-447.
Moskowitz AS, Altschuler L. Increased sensitivity to lithium-induced neurotoxicity after stroke: a case report. J Clin Psychopharmacol 1991;1:272-273.
Smith SJM, Kocen RS. A Creutzfeldt-Jacob like syndrome due to lithium toxicity. J Neurol Neurosurg Psychiatry 1988;51:120-123.
Stevenson RM, Blanshard C, Patterson DLH. Ventricular fibrillation due to lithium withdrawal — an interaction with chlorpromazine? Postgrad Med J 1989;65:936— 938.
Risby E, Potter WZ, Moses F. Effects of lithium withdrawal on human platelets and lymphocyte adenylate cyclase activity. Clin Pharmacol Ther 1989;45:172.
Mander AJ. Loudon JB. Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet 1988;2:15-17.
Martin TG, Mallinger AG, Michelson EA, Schneider SM. RBC lithium kinetics during an acute intoxication treated with hemodialysis. Vet Hum Toxicol 1991;33:363.
Thornley-Brown D, Galla JH, Williams PD, Kart S, Rashkin M. When toxicity is associated with a trichobezoar. Ann Intern Med 1992;116:739-740.
Massey EW, Folger WN. Seizures activated by therapeutic levels of lithium carbonate. South Med J 1984;77:1173-1174.
Kulig K. All lithium overdoses deserve respect. J Emerg Med 1992;10:757-758.
Larkens RG. Lithium and hypercalcemia. Aust NZ J Med 1991;21:675-677.
Cohen LS, Cohen DE. Lithium-induced hyperbilirubinemia in an adolescent. J Clin Psychopharmacol 1991;1:274-275.
Arden A. Clinical features and management of lithium poisoning. Med Toxicol 1988;3:18-32.
Shannon MW, Eisen T, LinakusJ, Woolf A. Clinical features of acute versus chronic lithium intoxication. Ann Emerg Med 1990; 19:630.
Dyson EH, Simpson D, Prescott LF, Proudfoot AT. Self-poisoning and therapeutic intoxication with lithium. Hum Toxicol 1987;6:325-329.
Schonwald S. Lithium. Clin Toxicol Rev 1990; 12(7): 1— 2.
Smith SW, Ling U, Halstenson CE. Whole bowel irrigation as a treatment for acute lithium overdose. Ann Emerg Med 1991;20:536-539.
Tomaszevski C, Musso C, Pearson JR, Kulig K, Marx JA. Lithium absorption prevented by sodium polystyrene sulfonate in volunteers. Ann Emerg Med 1992;21:130— 131.
Belanger DR, Tierney MG, Dickinson G. Effect of sodium polystyrene sulfonate on lithium bioavailability. Ann Emerg Med 1992;21:1312-1315.
Linakis JG, Lacouture RG, Eisenberg MS et al. Administration of activated charcoal or sodium polystyrene sulfonate (Kayexalate) as gastric decontamination for lithium intoxication: an animal model. Pharmacol Toxicol 1989;65:387-389.
Roberge RJ, Martin TG, Schneider SM. Use of sodium polystyrene sulfonate in lithium overdose. Ann Emerg Med 1993;22:191 1-1915.
Clendeninn NJ, Pond SM, Kaysen G et al. Potential pitfalls in the evaluation of the usefulness of hemodialysis for the removal of lithium. J Toxicol Clin Toxicol 1982;19:341-352.
Bellomo R, Kearly Y, Parkin G, Lowe J, Boyce N. Treatment of life-threatening lithium toxicity with continuous arteriovenous hemodiafiltration. Crit Care Med 1991;19:836-837.
Karkal SS, Mateer JR, Groleau G. Reducing the lethal potential of lithium intoxication. Emerg Med Rep 1989;10(18):141—148.
Graef J. Lead poisoning. I, IT, and III. Clin Toxicol Rev 1992;14:8,9,12.
Commonwealth of Massachusetts: MGL Chapter III, SS190—199a. Childhood lead poisoning prevention act. Regulation for lead poisoning prevention and control. 105CMP560.000, 7/29/91.
Agency for Toxic Substances and Disease Registry. The nature and safety of lead poisoning in children in the United States: a report to Congress. Washington, DC: Superintendent of Documents, US Dept Health Human Services, July, 1988.
A new look at lead toxicity. Conference on Childhood Lead Toxicity. Comtact Corp CHE019, 1991.
Royce SE, Needleman HL. Case Studies in Environmental Medicine. Lead Toxicity. Atlanta: Agency for Toxic Substances and Disease Registry, June 1990.
The Lead Paint Primer. Questions and Answers on Lead Paint Poisoning. Melrose, MA: Star Industries.
Centers for Disease Control: Preventing Lead Poisoning in Young Children. Atlanta: US Dept Health Human Services. Public Health Service, October 1991.
Toxicological Profile for Lead. Agency for Toxic Substances and Disease Registry. ATSDR/TP-88/17, June 1990.
Committee on Environmental Health. Lead poisoning: from screening to primary prevention. Pediatrics 1993;92:176-183.
Piomelli S, Wolff JA. Childhood lead poisoning in the ’90s. Pediatrics 1994;93:508-510.
Harvey B. Should blood lead screening recommendations be revised? Pediatrics 1944;93:201-204.
Royce SE, Needleman HL. Case studies in environmental medicine. 1. Lead toxicity. ATSDR, June 1990. Public Health Service.
Gloag D. Sources of lead pollution. Br Med J 1981;282:41-44.
Public Health Service. Healthy People 2000: National Health Promotion and Disease Prevention Objectives. Washington, DC: US Department of Health and Human Services, Public Health Service 1990; DHHS Publication No (NHS) 90-50 212.
New Jersey Department of Health. Accident Prevention and Poison Control Program. Manual for Safe Removal of Lead Paint, March 1992.
Consumer Product Safety Alert. CSSC warns about hazards of "do-it-yourself removal of lead-based paint. Washington, DC: US Consumer Product Safety Commission, February 1989.
Smitherman J. Household lead exposure. Newscare Poison Prevention and Hazardous Materials Information, San Francisco Bay Area Regional Poison Center. 1989;5(1):1—2.
Amitai Y, Graef JW, Brown MJ, Gertler RS, Kahn N, Cochran PE. Hazards of "deleading" homes of children with lead poisoning. Am J Dis Child 1987;141:758-760.
Amitai Y, Brown MJ, Graef JW, Cograve E. Residential deleading: effects on the blood lead levels of lead-poi-soned children. Pediatrics 1991;88:893-897.
CDC. Preventing lead poisoning in young children. US-DHHS, October 1991; p. 71.
Newton D, Pickford CJ, Chamberlain AC, Sherlock JC, Hislop JS. Elevation of lead in urine blood from its controlled ingestion in beer. Hum Exp Toxicol 1992; 11:3—9.
Goldberg RC, Hicks AM, O’Leary LM, London S. Lead exposure at uncovered outdoor firing ranges. J Occup Med 1991;33:718-719.
Tripathi RK, Sherertz PC, Llewellyn GC, Armstrong CW. Lead exposure in outdoor firearm instructors. Am J Public Health 1991;81:752-755.
ATSDR (Agency for Toxic Substances and Disease Registry). The nature and extent of lead poisoning in children in the United States: a report to Congress. Atlanta: ATSDR, 1988.
Parras F, Patier JL, Ezpeleta C. Lead-contaminated heroin as a source of inorganic lead intoxication. N Engl J Med 1987;316:755.
Montefort S. Lead poisoning in heroin addicts. Br Med J 1987;299.
CDC. Lead poisoning associated with intravenous amphetamine use — Oregon 1988. MMWR 1989;38:830— 831
Norton RL, Kauffman KW, Chandler DB, Burton ВТ, Gordon J, Fostern LR. Intravenous lead poisoning associated with methamphetamine use. Vet Hum Toxicol 1989;31:379.
Allcott JV III, Barnhart RA, Mooney LA. Acute lead poisoning in two users of illicit methamphetamine. JAMA 1987;258:510-51 1.
Shannon MW, Graef JW. Lead intoxication in infancy. Pediatrics 1992;89:87-90.
Selbst SM, Henretig F, Fee MA, Levy SE, Kitts AW. Lead poisoning in a child with a gunshot wound. Pediatrics 1986;77:413-416.
Kikano GE, Stange КС. Lead poisoning in a child after a gunshot injury. J Fam Pract 1992;34:498-504.
Nordberg GF, Mahaffey KR, Fowler BA. Introduction and summary. International Workshop on lead in bone: implications for dosimetry and toxicology. Environ Health Perspect 1991;91:3-7.
Hu H, Milder FL, Burger DE. The use of x-ray fluorescence for measuring lead burden in epidemiological studies: high and low lead burdens and measurement uncertainty. Environ Health Perspect 1991;94:107-110.
Rosen JF, Markowitz ME, Baer PE, Jenks ST, Wielo-polski L, Kalef-Ezra JF et al. Sequential measurements of bone lead content by x-ray fluorescence in CaNa2EDTA-treated lead-toxic children. Environ Health Perspect 1991;91:57-62.
Wedeen RD. In vivo tibial XFR measurement of bone lead. Arch Environ Health 1990;45:69-70.
Shannon M, Lindy H, Anast C, Graef J. Recurrent lead poisoning in a child with immobilization osteoporosis. Vet Hum Toxicol 1988;30:586-588.
Sublet VH. Lead. A Reproductive Toxin in Humans. Fact or Fiction. Atlanta, GA: Agency for Toxic Substances and Disease Registry, US Department of Health and Human Services.
Needleman HL, Rabinowitz M, Leviton A et al. The relationship between prenatal exposure to lead and congenital anomalies. JAMA 1984;251:2956-2959.
Shukla R, Bornschein RL, Dietrich KV, Buncher CR, Berger OG, Hammond PB et al. Fetal and infant lead exposure: effect on growth in stature. Pediatrics 1989;84:604-612.
Winder C. Reproductive and chromosomal effects of occupational exposure to lead in the male. Reprod Toxicol 1989;3:221-233.
Lancranjian I, Popescu HI, Gavanescu O, Klepsch I, Serbanescu M. Reproductive ability of workmen occupationally exposed to lead. Arch Environ Health 1975;30:396-401.
McGregor AJ, Mason HJ. Chronic occupational lead exposure and testicular endocrine function. Hum Exp Toxicol 1990;9:371-376.
Mg TP, Goh HH, Ng LY, Ong HY, Ong C, Chia SE et al. Male endocrine function in workers with moderate exposure to lead. Br J Ind Med 1991;48:485-491.
Ernhart CB, Greene T. Postpartum changes in maternal blood lead concentrations. BrJ Ind Med 1992;49:11-13.
Lead in table wines could pose hazards for pregnant and nursing women. FDA Med Bull 1991 ;21 (3):6—7.
Mahaffey KR. Biokinetics of lead during pregnancy. Fundam Appl Toxicol 1991;16:15-16.
Goyer RA. Transplacental transport of lead. Environ Health Perspect 1990;89:101-105.
McMichael AJ, Vimpani GV, Robertson EF et al. The Port Pirie Cohort Study: maternal blood lead and pregnancy outcome. J Epidemiol Cancer Health 1986;40:18.
Bellinger DC, Leviton A, Needleman HL etal. Low level lead exposure and infant development in the first year. Neurobehav Toxicol Teratol 1986;8:151.
Levine F, Muenke M. Vacterl association with high prenatal lead exposure. Similarities to animal models of lead teratogenicity. Pediatrics 1991;87:390-392.
Farni A, Sciame A, Bertazzi PA, Alesio L. Chromosomal and biochemical studies in women occupationally exposed to lead. Arch Environ Health 1980;35:139-146.
Wong GP, Ng TL, Martin TR, Farquharson DF. Effects of low level lead exposure in utero. Obstet Gynecol Survey 1992;45:285-289.
Bernard BP, Becker CE. Environmental lead poisoning and the kidney. Clin Toxicol 1988;26:1-34.
Staessen J, Yeoman WB, Fletcher AE, Markowe HLJ, Marmot MG, Rose G et al. Blood lead concentration, renal function and blood pressure in London civil servants. BrJ Indust Med 1990;47:442-447.
Staessen JA, Lauwerys RR, Buchet J-P, Bulpitt CJ, Rondia D, Vanrenterghem Y et al. Impairment of renal function with increasing blood lead concentrations in the general population. N Engl J Med 1992;237:151-156.
Endo G, Horiguchi S, Kiyota I. Urinary V-acetyl-beta-D-glucosaminidase activity in lead-exposed workers. J Appl Toxicol 1990;10:235-238.
Pirkle JL, Schwartz J, Landis JR, Harlan WR. The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Am J Epidemiol 1985;121:246-258.
Osterloh JD, Selvy JV, Bernard BP, Becker CE, Menke DJ, Tepper E et al. Body burdens of lead in hypertensive nephropathy. Arch Environ Health 1989;44:304-310.
Kosnett MJ, Becker CE, Osterloh JD, Kelly TJ, Pasta DJ. ( actors influencing bone lead concentration in a suburban community assessed by noninvasive x-ray fluorescence. JAMA 1994;271:197-202.
Royce SE, Needleman HL. Case studies on environmental medicine. Lead toxicity. US Department of Health and Human Services, Agency for Toxic Substance and Disease Registry.
Schwartz J, Landrigan PJ, Feldman RG, Silbergeld EK, Baker EL, von Lindern IH. Threshold effect on lead-induced peripheral neuropathy. J Pediatr 1988;112:12-17.
Roelofs-Iverson PA, Mulder DW, Elvebach LR, Kurland LT, Molgoard CA. ALS and heavy metals: a pilot case-control study. Neurology 1984;34:393-395.
BoothbyJA, de Jesus PV, Rowland LP. Reversible factor of motor neuron disease. Arch Neurol 1974;21:18-23.
Marecek J, Shapiro IM, Burke A et al. Low level exposure in childhood influences neuropsychological performance. Arch Environ Health 1983;38:355-359.
Baghurst PA, McMichael AJ, Wigg NP, Vimpani GV, Robertson EF, Roberts RJ et al. Environmental exposure to lead and children’s intelligence at the age of seven years. The Post Pirie Cohort Study. N Engl J Med 1992;327:1275-1284.
Pocock SJ, Smith M, Baghurst P. Environmental lead and children’s intelligence: a systematic review of the epidemiological evidence. Br Med J 1994;309:l 189— 1197.
Rosen JF. Health effects of lead at low exposure levels. Expert consensus and rationale for lowering the definition of childhood lead poisoning. Am J Dis Child 1992;146:1278-1281.
Thecker SB, Hoffman DA, Smith J, Steinberg K, Zall M. Effect of low-lead body burdens of lead on the mental development of children: limitations of meta-analysis in a review of longitudinal data. Arch Environ Health 1992;47:336-346.
Chisolm JJ Jr. The continuing hazard of lead exposure and its effects in children. Neurotoxicology 1984;5:23— 42.
Needleman HL, Gatsonis CA. Low-level lead exposure and the IQ of children. A meta-analysis of modern studies. JAMA 1990;263:673-678.
Needleman HL, Schell A, Bellinger D, Leviton A, Allred EN. The long-term effects of exposure to low doses of lead in childhood. An 11-year follow-up report. N Engl J Med 1990;322:83-88.
Fergusson DM, Fergusson JE, Horwood U, Kinzett NG. A longitudinal study of dentine lead levels, intelligence study of school performance and behavior. I. Dentine lead levels and exposure to environmental risk factors. J Child Psychol Psychiatry 1988;29:781-792. II. Dentine lead and cognitive ability. J Child Psychol Psychiatry 1988;29:783-809.
Sargent JD, Meyers A, Weitzman M. Environmental exposure to lead and cognitive deficit in children. N Engl J Med 1989;320:595.
Smith M. The neuropsychological effects of lead in children. A review of the research 1984—1988. Report from the Medical Research Council (UK) Advisory Group on Lead and Neuropsychological Effects in Children. June 1988.
Emhart CB. A critical review of low-level prenatal lead exposure in the human. II. Effects on the developing child. Reprod Toxicol 1992;6:21-40.
Cooney GH, Bell A, McBride W, Carter C. Low level exposure to lead: the Sydney lead study. Develop Med Child Neurol 1989;31:640—649.
Bellinger D, Leviton A, Sloman J. Antecedents and correlates of improved cognitive performance in children exposed in utero to low levels of lead. Environ Health Perspect 1990;89:5-11.
Schwartz OD. Lead and minor hearing impairment. Arch Environ Health 1991;46:300-305.
Clark M, Royal J, Seeler R. Interaction of iron deficiency and lead and the hematologic findings in children with severe lead poisoning. Pediatrics 1988;81:247-254.
Graef J. Lead poisoning. 1. Clin Toxicol Rev 1992;14(8):1—2.
Durbach LF, Wedin GP, Seidler DE. Management of lead foreign body ingestion. Clin Toxicol 1989;27:173— 182.
Wiley JF II, Henretig FM, Selbst SM. Blood lead levels in children with foreign bodies. Pediatrics 1992;89:593.
Hugelmeyer CD, Morrhead JC, Horenblas L, Bayer MJ. Fatal lead encephalopathy following foreign body ingestion: case report. J Emerg Med 1988;6:397-400.
CDC. Preventing lead poisoning in young children. US-DHHS, October 1991; p. 53.
CDC. Preventing lead poisoning in young children. US-DHHS, October 1991; p. 46.
Hazardous Substances Public Health Agency for Toxic Substances and Disease Registry, 1992;2( 1).
Piomelli S, Rosen JF, Chisolm JJ Jr, Graef JW. Management of childhood lead poisoning. J Pediatr 1984;105:523-532.
Markowitz ME, Rosen JF. Need for the lead mobilization test in children with lead poisoning. J Pediatr 1991;119:305-310.
CDC. Preventing lead poisoning in young children. US-DHHS, October 1991; pp. 53-54.
Markowitz ME, Rosen JF, Bijur PE. Effects of iron deficiency on lead excretion in children with moderate lead intoxication. J Pediatr 1990;116:360-364.
Markowitz ME, Rosen JF. Assessment of lead stones in children: validation of an 8-hour CaNa2EDTA provocative test. J Pediatr 1984;104:337-342.
Weinberger HL, Post ER, Schneider T, Helu B, Friedman J. An analysis of 248 initial mobilization tests performed on an ambulatory basis. Am J Dis Child 1987;14:1266-1270.
Shannon MW, Kassner J, Garef J. Use of urinary creatinine in the interpretation of the lead mobilization test. Vet Hum Toxicol 1990;32:365.
Batuman V, Wedeen RR. Impairment of renal function with increasing blood lead concentrations. N Engl J Med 1992;327:1394-1395.
CDC. Preventing Lead Poisoning in Young Children. US Department of Health and Human Services, October 1991, pp. 57.
Chisolm JJ Jr, Thomas DJ. Use of 2,3-dimercaptoprane-l-sulfonate in treatment of lead poisoning in children. J Pharmacol Exp Ther 1985;235:665-669.
CDC. Preventing Lead Poisoning in Young Children. US Department of Health and Human Services, October 1991, pp. 57-59.
Shannon M, Graef J, Lovejoy FH. Efficacy and toxicity of D-penicillamine in low-level lead poisoning. J Pediatr 1988;12:799-804.
Adelman HM, Winters PR, Mahan CS, Wallach PM. D-penicillamine-induced myasthenia gravis: diagnosis observed by coexisting chronic obstructive pulmonary disease. Am J Med Sci 1995;309:191-193.
Graef J. Lead poisoning management. II. Clin Toxicol Rev 1992;14(9):1—2.
Shannon М, Grace A, Graef JW. Use of penicillamine in children with small lead burdens. N Engl J Med 1989;321:979-980.
Graziano JH. Use of penicillamine in children with small lead burdens. N Engl J Med 1990;322:1888.
Liebelt EL, Shannon MW. Oral chelators for childhood lead poisoning. Pediatr Annals 1994;23:616-626.
Donner A, Hruby K, Pirich K, Kahls P, Schwarzacher K, MeisingerV. Dimercaptopropansulfonate (DMPS) in the treatment of acute lead poisoning. Vet Hum Toxicol 1987;29(Suppl 2):37.
Chisolm JJ Jr. BAL, EDTA, DMSA and DMPS in the treatment of lead poisoning in children. Clin Toxicol 1992;30:493-504.
Liebelt EL, Shannon M, Graef JW. Efficacy of oral meso-2,3-dimercaptosuccinic acid therapy for low-level childhood plumbism. J Pediatr 1994;124:313-317.
Graziano JH, Lolacono NJ, Moulton T, Mitchell ME, Slavkovich V, Zarate C. Controlled study of meso 2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. J Pediatr 1992;120:133-139.
Ching GWK, Rogers SM, Braithwaite RA, Vale JA. An oral treatment for lead toxicity. Postgrad Med J 1991;67:953-956.
Rosen JF, Markowitz ME. Trends in the management of childhood lead poisonings. Neurotoxicology 1993;14:211-218.
Aposhian HV, Aposhian MM. Meso-2,3,dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Ann Rev Pharmacol Toxicol 1990;30:279-306.
Hurlbut KM, Dart RC, Gercina RA, Brad GR, Philips S. Changes in white blood cell counts (WBC) associated with dimercaptosuccinic acid (DMSA) therapy. Vet Hum Toxicol 1993;35:353.
Chisolm JJ Jr. Evaluation of the potential role of chelation therapy in treatment of low to moderate lead exposure. Environ Health Perspect 1990;89:67-74.
Lovejoy FH. Shannon M, Woolf AD. Recent advances in clinical toxicology. Curr Probl Pediatr 1992 (March), pp. 119-129.
Liebelt E, Shannon M, Graef J. The efficacy of oral DMSA for lead childhood plumbism. Vet Hum Toxicol 1992;24:360.
Graziano JH. Role of 2,3-dimercaptosuccinic acid in the treatment of heavy metal poisoning. Med Toxicol 1986;1:155-162.
Ruff HA, Bijur PE, Markowitz M, MA Y-C. Rosen JF. Declining blood lead levels and cognitive changes in moderately lead-poisoned children. JAMA 1993;269:1641-1646.
Pedersen RS. Lead poisoning treated with haemodialysis. Scand J Urol Nephrol 1978;12:189-190.
Roberge RJ, Martin T, Michelson EA. Whole bowel irrigation in acute lead ingestion. Vet Hum Toxicol 1991;33:353.
Murphy DG, Gerace RV, Peterson RG. The use of whole bowel irrigation in acute lead ingestion. Vet Hum Toxicol 1991;33:353.
Kim JS, Crichlow EC, Blakley BR. The effects of thiamine on the neurophysiological alterations induced by lead. Vet Hum Toxicol 1990;32:101-105.
Flora SJS, Singh S, Tandon SK. Thiamine and zinc in prevention therapy of lead intoxication. J Int Med Res 1989;17:68-75.
Roberge RJ, Martin TG. Whole bowel irrigation in an acute oral lead intoxication. Am J Emerg Med 1992;10:577-583.
Graef J. Lead poisoning. I, 11, and III. Clin Toxicol Rev 1992;14:8,9,12.
Graef JW. Lead poisoning. III. Therapeutic protocols. Clin Toxicol Rev 1992; 14(12): 1—2.
Committee on Drugs American Academy of Pediatrics. Treatment guidelines for lead exposure in children. Pediatrics 1995;96:155-160.
Waldron HA. Chasing the lead. Br Med J 1985;291:366.
Sawyer M, Kerny T, Spector S et al. Lead intoxication in children — Interdepartmental Conference, University of California, San Diego. (Specialty Conference) West J Med 1985;143:357-364.
Greeley A. Getting the lead out. FDA Consumer 1991 ;25(6):26—31.
Centers for Disease Control. Preventing lead poisoning in young children. A statement by the Centers for Disease Control. Atlanta, GA: US Dept of Health and Human Services, 1991.
Mills КС, Curry SC. Acute iron poisoning. Emerg Med Clin North Am 1994; 12:397.
CDC. Toddler death resulting from ingestion of iron supplements — Los Angeles 1992—1993. MMWR 1993;42:111-113.
Ling LJ, Hornfeldt CS, Winter JP. Absorption of iron after experimental overdose of chewable vitamins. Am J Emerg Med 1991;9:24-26.
Linakis JG, Lacouture PG, Woolf AD. Iron absorption from chewable multivitamins with iron vs ferrous fumarate tablets. Vet Hum Toxicol 1989;21:342.
Everson GW, Oudjhane K, Young LW, Krenzelok EP. Effectiveness of abdominal radiographs in visualizing chewable iron supplements following overdose. Am J Emerg Med 1989;7:459-463.
Vernon DD, Banner W, Dean JM. Hemodynamic effects of experimental iron poisoning. Ann Emerg Med 1989;18:863-866.
Tenenbein M. Israels SJ. Early coagulopathy in iron poisoning. J Pediatr 1988;113:695-697.
Rosenmund A, Haeberli A, Straub PW. Blood coagulation and acute iron toxicity. Reversible iron-induced inactivation of serine proteases in vitro. J Lab Clin Med 1984;103:524-533.
Bentur Y, St Louis P, Klein J, Koren G. Misinterpretation of iron-binding capacity in the presence of deferoxamine. J Pediatr 1991;118:139-142.
Tennenbein M, Yatskoff BW. The total iron-binding capacity in iron poisoning: Is it useful? Am J Dis Child 1991;145:437-439.
Burkhart KK, Kulig KW, Hammond KB, Pearson JR, Ambrusco D, Rumack B. The rise in the total iron-binding capacity after iron overdose. Ann Emerg Med 1991;20:532-535.
Benson BL, Cheney K. Survival after a severe iron poisoning treated with high dose deferoxamine (DFL) therapy. Vet Hum Toxicol 1992;34:(abstract 53).
Ling LJ, Hornfeldt CS, Winter J P. Absorption of iron after experimental overdoses of chewable vitamins. Am J Emerg Med 1991;9:24-26.
Chyka PA, Butler AY. Assessment of acute iron poisoning by laboratory and clinical observations. Am J Emerg Med 1993;11:99-103.
Everson GW, Bertaccini EJ, O’Leary J. Use of whole bowel irrigation in an infant following iron overdose. Am J Emerg Med 1991;9:366-369.
Durbin DR, Wood BP. Acute iron poisoning and gastrointestinal decontamination procedures. Am J Dis Child 1992;146:765-766.
McCarthy T, Olson KR, Spangler S. Documentation with serial radiographs of successful whole bowel irrigation with Golytely solution in a massive iron ingestion. Vet Hum Toxicol 1989;31 :333.
Banner W, Vernon DD, Ward R, Sweeley J, Dean JM. Continuous arterio-venous hemofiltration (CAVH) in experimental iron intoxication. Vet Hum Toxicol 1988;30:755.
Robotham JL, Leitman PS. Acute iron poisoning. A review. Am J Dis Child 1980;134:875-879.
Cheney K, Gumbiner C, Benson B, Tenenbein M. Survival after a severe iron poisoning treated with intermittent infusions of deferoxamine. Clin Toxicol 1995;33:61-66.
Jackson TW, Ling LJ, Washington V. The effect of oral deferoxamine on iron absorption in humans. Clin Toxicol 1995;33:325-329.
Bosse GM. Conservative management of patients with moderately elevated serum iron levels. Clin Toxicol 1995;33:235-240.
Bentur Y, Klein J, Koren G. Misinterpretation of iron-binding capacity in the presence of deferoxamine. J Pediatr 1991;118:139-142.
Weinberg K. Novel uses of deferoxamine. Am J Pediatr Hematol Oncol 1990;12:9-13.
Allain P, Mauras Y, Chaleil D, Simon P, Aug KS, Can G et al. Pharmacokinetics and renal elimination of des-ferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. Br J Clin Pharm 1987;24:207-212.
Walker JA, Sherman RA, Ensinger RP: Thrombocytopenia associated with intravenous deferoxamine. Am J Kidney Dis 1985;6:254-256.
Milteer RM, Sarpony S, Poydras U. Yersinia enteroco-litica septicemia after accidental oral iron overdose. Pediatr Infect Dis J 1989;8:537-538.
Mofenson HC, Caraccio TR, Sharieff N. Iron sepsis: Yersinia enterocolitica septicemia possibly caused by an overdose of iron. N Engl J Med 1987;316:1029-1093.
Bentur Y, McGuigan M, Koren G. Deferoxamine (des-ferrioxamine). New toxicities for an old drug. Drug Safety 1991;6:37-46.
Ammon A, Rumpf KW, Homverich CP, Behrene-Bau-man W, Ruche] R. Rhinocerebral incormyosis during deferoxamine treatment. Dtsch Med Wochenschr 1992;117:1434-1435.
Cohen A, Martin M, Mizanin J, Konkle DF, Schwartz E. Vision and hearing during deferoxamine therapy. J Pediatr 1990;117:326-330.
Li Volti S, di Gregorio F, Schiliro G. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1990;144:1069-1070.
Koren G, Bentur Y, Strong D et al. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1989;143:1077-1080.
Tenenbein M, Kowalski S, Roberts D. Pulmonary toxicity in iron poisoning: deferoxamine induced? Vet Hum Toxicol 1990;32:343.
Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IYR. Pulmonary toxic effects of continuous des-ferrioxamine administration in acute iron poisoning. Lancet 1992;339:669-701.
Roberts JC, McElhatton PR, Sullivan FM. Consequences of iron overdose and desferrioxamine treatment in pregnancy. Proc Lux-Tox ’90 meeting, Luxembourg, 1990;OR518.
McElhatton PR, Roberts JC, Sullivan FM. The consequences of iron overdose and its treatment with desferrioxamine in pregnancy. Hum Exp Toxicol 1991;10:251-259.
Blanc P, Hryhorczuk D, Danol I. Deferoxamine treatment of acute iron intoxication in pregnancy. Obstet Gynecol 1984;64:125-145.
Van Ameyde KJ, Tenenbein M. Whole bowel irrigation during pregnancy. Am J Obstet Gynecol 1989;160:646— 647.
Turk J, Aks S, Ampuero F, Hryhorezuk DO. Successful therapy of iron intoxication in pregnancy with intravenous deferoxamine and whole bowel irrigation. Vet Hum Toxicol 1993;35:441-443.
Schauben JL, Augenstein WL, Cox J, Sato R. Iron poisoning. Report of three cases and review of therapeutic intervention. J Emerg Med 1990;8:309-319.
Henretig FM, Temple AR. Acute iron poisoning in children. Emerg Med Clin North Am 1987;21:153-159.
Engle JP, Polink S, Stile IL. Acute iron intoxication: treatment controversies. Drug Intell Clin Pharm 1987;21:153-159.
Yatscoff RW, Wayne EA, Tenenbein M. An objective criterion for the cessation of deferoxamine therapy in the acutely iron poisoned patient. Clin Toxicol 1991 ;29:1 — 10.
Comes J, Walter FG, Kozaki К, Ekins BR, Lindsey J, Сох К et al. Liver transplantation for fulminant hepatic failure due to acute iron poisoning. Vet Hum Toxicol 1993;35:337
Lerner S, Hong CD, Bozian RC et al. Cadmium nephropathy — a clinical evaluation. J Occup Med 1979;21:409-412.
Cadmium and the lung. Lancet 1973;2:1134-1135 (editorial).
Kressel J. Cadmium. Clin Toxicol Rev 1983;5:1-2.
Gloag D. Contamination of food: mycotoxin and metals. Br Med J 1981;282:879-882.
Perry HM, Thind CS, Perry AB. The biology of cadmium. Med Clin North Am 1976;60:759-768.
Goyer RA. Transplacental transfer of cadmium and fetal effects. Fundam Appl Toxicol 1991;16:22-23.
Buel G. Some biochemical aspects of cadmium toxicology. J Occup Med 1975;17:189-195.
Kalian E, Derazne E, Rosenboim J, Ashkenazi R, Ribak J. Adverse health effects in workers exposed to cadmium. Am J Ind Med 1992;21:527-537.
Nakada T, Furuta H, Koike H, Katayama T, Teranishi H. Impaired urine concentrating ability in Itai-Itai (ouch-ouch) disease. Int Urol Nephrol 1989;21:201-209.
Angle CR, Thomas DJ, Swanson SA. Cadmium and bone toxicity. Protective effect of 1,25 (OH)2 vitamin D3. Vet Hum Toxicol 1989;31:351.
Karakaya A, Yucesoy B, Sardas OS. An immunological study on workers occupationally exposed to cadmium. Hum Exp Toxicol 1994;13:73-75.
Ong CN, Chua LH, Lee BL, Ong HY, Chia KS. Electrothermal atomic absorption spectrometric determination of cadmium and nickel in urine. J Anal Toxicol 1990;14:29-31.
Agency for Toxic Substances and Disease Registry: Toxicological Profile for Cadmium. March, 1989;TSDR/ TP-88/08.
Baker EL Jr, Coleman C, Peterson WA, Holtz JL, Lan-drigan PJ. Subacute cadmium intoxication in jewelry workers. An evaluation of diagnostic procedure. Arch Environ Health 1979;39:173-177.
Buchet JP, Lauwerys R, Roels H, Bernard A, Bruaux P, Claeys F et al. Renal effects of cadmium body burden of the general population. Lancet 1990;336:699-702.
Basinger MA, Jones MM, Holscher MA, Vaughan WK. Antagonists for acute oral cadmium chloride intoxication. J Toxicol Environ Health 1988;23:77-89.
Andersen O, Nielsen J. Chelation in acute oral cadmium intoxication. Fifth Int Congress of Toxicology July 16— 21, 1989, Brighton, England. London: Taylor & Francis, 1990; p. 177.
van Heerden PV, Jenkins IR, Woods WPD, Rossi E, Cameron PD. Death by tanning — a case of fatal basic chromium sulphate poisoning. Intensive Care Med 1994;20:145-147.
Kapil V, Krogh J. Chronic toxicity. Case studies in environmental medicine. Agency for Toxic Substances and Disease Registry, June, 1990.
Sarayan LA, Reedy M. Chronic determinations in a case of chromic acid ingestion. J Anal Toxicol 1988;12:162.
Schonwald S. Chromium. Clin Toxicol Rev 1989;11(5):1—2.
Stoner RS, Tong TG, Dart R, Sullivan JB, Saito G, Armstrong B. Acute chromium intoxication with renal failure after 1 % body surface area burns from chromic acid. Vet Hum Toxicol 1988;30:361.
Fristedt B, Lindqvist B, Schutz A, Orrum P. Survival in a case of acute oral chromic acid poisoning with acute renal failure treated by hemodialysis. Acta Med Scand 1965;177:153-159.
Pedersen RS, Morch PT. Chromic acid poisoning treated with acute hemodialysis. Nephron 1978;22:592-595.
Wang X-W, Davies JWL, Sirvent Z, Robinsons WA. Chromic acid burns and acute chromic poisoning. Burns 1985;11:181-184.
Proctor J, Doering D, Barnhill D, Park R. Bowel perforation associated with intraperitoneal chromic phosphate instillation. Gynecol Oncol 1990;39:125-127.
Langard S, Vigander T. Occurrence of lung cancer in workers producing chromium pigments. Br J Ind Med 1983;40:71-74.
Donner A, Meisinger V, Scholtz 1, Prick K, Hruby K. Dimercapto-propane-sulphuric acid (DMPS) in the treatment of an acid copper and an acid chromium poisoning. Toxicol Lett 1986;31 (Suppl): 154.
Randall JA, Gibson RS. Hair chromium as indices of chromium exposure of tannery workers. Br J Ind Med 1989;46:171-175.
Michie СА, Hayhurst М, Knobel GJ, Stokol JM, Hensley В. Poisoning with a traditional remedy containing potassium dichromate. Hum Exp Toxicol 1991; 10:129—-131.
Cooper P. Poisoning by drugs and chemicals. 3rd ed. London: Alchemist, 1974, pp. 180—181.
Castera J, Bourdais A, Bonsom R et al. Intoxication aigue par ingestion massive de bichromate de potassium. Guerison Bull Med Leg Toxic Med 1969;12:134-143.
Banner W, Frank J, Iserson К et al. Coagulopathy following ingestion of potassium dichromate. Vet Hum Toxicol 1982:24:288 (abstract).
Sharma BK, Singhal PC, Chugh KS. Intravascular hemolysis and acute renal failure following potassium dichromate poisoning. Postgrad Med J 1978;54:414-415.
Ellis EN, Brouhard BN, Lynch RE et al. Effects of hemodialysis and dimercaprol in acute dichromate poisoning. J Toxicol Clin Toxicol 1982;19:249-258.
Grusz-Harday E. Acute lethal potassium dichromate poisoning. Bull Int Assoc Forensic Toxicol 1974;10( 1 ):7.
Meert KL, Ellis J, Aronow R, Perrin E. Acute ammonium dichromate poisoning. Ann Emerg Med 1994;24:748-750.
Vassallo S, Howland MA. Severe dichromate poisoning: survival after therapy with IV N-acetylcysteine and hemodialysis. Vet Hum Toxicol 1988;30:347.
Sjogren I, Hillerdal G. Andersson A, Zetterstron O. Hard metal king disease importance of cobalt in coolants. Thorax 1980;35:653-659.
Coates EO, Watson J HL. Diffuse interstitial lung disease in tungsten carbide workers. Ann Intern Med 1971;75:706-711.
Harding H. Notes on the toxicology of cobalt metal. Br J Ind Med 1950;276:78.
Kusaka Y, Yokoyama K, Sera Y, Yamamoto S, Sone S, Kyono H et al. Respiratory disease in hard metal workers; an occupational hygiene study in a factor. Br J Ind Med 1986;43:474-485.
Shirakawa T, Kugaka Y, Fujimura N, Goto S, Kato M, Heki S et al. Occupational asthma from cobalt sensitivity to workers exposed to hard metal dust. Chest 1989;95:29-37.
Cugell DW, Morgan WKC, Perkins DG, Rubin A. The respiratory effects of cobalt. Arch Intern Med 1990;150:177-183.
Shirakawa T, Kusaka Y, Fujimura N, Kato M, Heki S, Morimoto K. Hard metal asthma: cross immunological and respiratory reactivity between cobalt and nickel? Arch Intern Med 1990;150:177-183.
Ratto D, Balmes J, Boylen T, Sharma OP. Pregnancy in a woman with severe pulmonary fibrosis secondary to hard metal disease. Chest 1988;93:663-664.
Demedts M, Gheysens B, Nagels J, Verbeken E, Law-eryns J, Van den Eeckhout A et al. Am Rev Respir Dis 1984;130:1330-1335.
Nemery B, Nagels J, Verbeken E, Dinsdale D, De Medis M. Rapidly fatal progression of cobalt lung in a diamond polisher. Am Rev Respir Dis 1990;141:1373-1378.
Barborik M, Duslek J. Cardiomyopathy accompanying industrial cobalt exposure. Br Heart J 1972;34:113-116.
Jarius JQ, Mammond E, Meier R, Robinson C. Cobalt cardiomyopathy. A report of two cases from mineral assay laboratories and a review of the literature. J Occup Med 1992;34:620-626.
Jensen AA, Tuchsen F. Cobalt exposure and cancer risk. Crit Rev Toxicol 1990;20(6):427—438.
Austenfeld JL, Colby TV. Recognizing lung diseases induced by hard metal exposure. J Respir Dis 1989; 10:65.
Henretig F, Joffe M, BaffaG, Burns R, Bingham P, Burg F et al. Elemental cobalt toxicity and effects of chelation therapy. Vet Hum Toxicol 1988;30:372.
Beyersmann D, Hartwig A. The genetic toxicology of cobalt. Toxicol Appl Pharmacol 1992;115:132-145.
Lamont DL, Duflou JALC. Copper sulfate; not a harmless chemical. Am J Forensic Med Pathol 1988;9:226.
Muhlendahl K, Lange H. Copper and childhood cirrhosis. Lancet 1994;344:1515-1516.
Scheinberg IM, Sternlieb N. Is non-Indian childhood cirrhosis caused by excess dietary copper? Lancet 1994;344:1002-1004,
Committee on Dietary Allowances, Food and Nutrition Board, National Research Council. Recommended dietary allowances. 9th Ed. Washington, DC: National Academic Press, 1980.
Turnlund JR. Copper nutriture, bioavailability and the influence of dietary factors. J Am Diet Assoc 1988;88:303-310.
Turnlund JR, Keen CL, Smith RG. Copper status and urinary and salivary copper in young men at three levels of dietary copper. Am J Clin Nutr 1990;51:658-664.
Cousins RJ. Absorption, transport and hepatic metabolism of copper and zinc: Special reference to metal-lothionein and ceruloplasmin. Physiol Rev 1985;65:238-300.
Cartwright GE, Wintrobe MM. Copper metabolism in normal subjects. Am J Clin Nutr 1964;14:222-232.
Bentur Y, McGuigan M, Spielberg AP. An unusual skin exposure to copper: clinical and pharmacokinetic evaluation. Clin Toxicol 1988;26:371-380.
Yelin G, Taff ML, Sadowski GE. Copper toxicity following massive ingestion of coins. Am J Forensic Med Pathol 1987;8:78-85.
Chuttani HK, Gupta PS, Gulati S et al. Acute copper sulfate poisoning. Am J Med 1965;39:849-854.
Cianciulli P, Sorrentino F, Forte L, Palombi M, Paili G, Meloni C et al. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis. Haematologia 1992;77:515.
Yelin G. Taff ML, Sadowski GE. Copper toxicity following massive ingestion of coins. Am J Forensic Med Pathol 1987;8:78-85.
Mittal SR. Oxyhaemoglobinemia following copper sulphate poisoning. A case report and a review of the literature. Forensic Sci 1972;1:245-248.
Klein WJ Jr, Metz EN, Price AR. Acute copper intoxication. A hazard of hemodialysis. Arch Intern Med 1972;129:580-582.
Bluhm RE, Welch L, Branch RA. Increased blood and urine copper after residential exposure to copper naphthenate. Clin Toxicol 1992;30:99-108.
Holgzman NA, Elliott DA, Heller PH. Copper intoxication: report of a case with observations on ceruloplasmin. N Engl J Med 1966;275:347-352.
Burnett JW. Copper. Cutis 189;43:322.
Akintonwa A, Mabadeje AFB, Odutola TA. Fatal poisonings by copper sulfate ingested from "spiritual water." Vet Hum Toxicol 1989;31:453-454.
Farmer JG. A fatality following copper sulphate ingestion. Bull I nt Assoc Forensic Toxicol 198l;16(2):22— 23.
Hla KK, House IM, Henry JA. Toxicity from ingestion of cupramonium carbonate. Proc Eur Assoc Pois Cont Centers Toxicol 1988; p. 94.
Gulliver GJM. A fatal copper sulphate poisoning. Bull Int Assoc Forensic Toxicol 1991 ;21 (1): 19—20.
Chugn KS, Sharma BK, Singhal PC, Das КС, Dotta BN. Acute renal failure following copper sulphate intoxication. Postgrad Med J 1977;53:18-23.
Harpe PL, WalsheJM. Reversible pancytopenia secondary to treatment with tetrathiomolybdate. Br J Haematol 1986;6:851-853.
Dash SC. Copper sulphate poisoning and acute renal failure. Int J Artif Organs 1989; 12:610.
Krapf R, Schaffner Т, Hen РХ. Abuse of germanium associated with lactic acidosis. Nephron 1992;62:351-356.
Sanai T, Okuda S, Onoyama K, Oochi N, Oh Y, Kobayashi К et al. Germanium dioxide-induced nephropathy: a new type of renal disease. Nephron l990;54:56— 60.
St. Georgieu V. New synthetic immunodilating agents. Trends Pharmaceut Sci 1988;9:446-451.
Okada K, Okagawa K, Kawakani K, Kuroda Y, Mori-zumi K, Sato H et al. Renal failure caused by long-term use of a germanium preparation as an elixir. Clin Nephrol 1989;31:219-224.
Germanium danger. Lancet 1989;2:755 (editorial).
Stopping toxic tablets. FDA Consumer 1989;23( 10):34— 35.
Van der Spoel JI, Stricker BHC, Esseveld MR, Schipper MEI. Dangers of dietary germanium supplements. Lancet 1990;336:117.
Taleuchi A, Yoshizawa N, Oshina S, Kubata T, Os-hikawa Y, Akashi Y et al. Nephrotoxicity of germanium compounds. Report of a case and review of the literature. Nephron 1992;60:436-442.
Gleichman Е, Kubicka-Murangi М, Kind Р, Golder-mann Р, Goertz G et al. Insights into the mechanism of gold action provided by immunotoxicology: biooxidation of gold (I) to gold (III) detected from sensitized T-cells. Rheumatol I nt 1991;11:219-220.
Barelli A, Calimici A, Paia F. Gold salts acute poisoning: a case report. Vet Hum Toxicol 1987;29(Suppl 2): 108.
Gortenuti G, Parrinello A, Vicentini D. Diffuse pulmonary changes caused by gold salt therapy. Report of a case. Diagn Imag Clin Med 1985;54:298-303.
Richard AM. Gold lung. New Zeal Med J 1982;2:897—-898.
McFadden RG, Traher U, Thompson JM. Goldnaproxen pneumonitis. A toxic drug interaction? Chest 1989;96:216-218.
Cohen MAH. Adverse reactions to gold compounds. Adverse Drug React Acute Poison Rev 1988;4:163-178.
Healey LA, Baches MB. Nitritoid reactions and angiotensin-converting-enzyme inhibitor. N Engl J Med 1989;326:763.
Jackson CW, Habouli NY, Whorwell PJ, Schofield PF. Gold-induced enterocolitis. Gut 1986;27:452-456.
Martin DM, Goldman JA, Gillian J, Nasrallah SM. Gold-induced eosinophilic enterocolitis: response to oral cromolyn sodium. Gastroenterology 1981 ;80:1567— 1570.
FarreJM, PereeT, Hautefemille P, Tonnel F, Columbee JF et al. Cholestasis and pneumonitis induced by gold therapy. Clin Rheumatol 1989;8:538-540.
Brown SL, Hill ER. G-CSF in gold-induced aplastic anemia. Ann Rheum Dis 1994;53:213.
Rollins SO, Craig JP. Gold-associated lymphadenopathy in a patient with rheumatoid arthritis. Arch Pathol Lab Med 1991;115:175-177.
Spark RP. Cold-associated lymphadenopathy in a patient with rheumatoid arthritis. Arch Pathol Lab Med 1991;115:861-862.
Hall CL. The natural coma of gold nephropathy. Br Med J I988;296:293.
Hall CL, Fothergill NJ, Blackwell MM, Harrison PR, Mackenzie JC, Maciver AG. The natural course of gold nephropathy: long term study of 21 patients. Br Med J 1987;295:745-748.
Madhok P, Capell HA, Waring R. Does sulphoxidation state predict gold toxicity in rheumatoid arthritis? Br Med J 1987;294:483.
Winship КА. Toxicity of bismuth salts. Adverse Drug React Acute Pois Rev 1982;2:103—121.
Serfontein WJ, Mekel R. Bismuth toxicity in man. II. Review of bismuth blood and urine levels in patients after administration of therapeutic bismuth formulations in relation to the problem of bismuth toxicity in man. Res Commun Chem Pathol Pharmacol I979;26:39l—411.
Hoffman RS, Mendelowitz PC, Weber S. Bismuth absorption and myoclonic encephalopathy after bismuth subsalicylate therapy. Vet Hum Toxicol 1989;31:380.
Mendelowitz PC, Hoffman RS, Weber S. Bismuth absorption and myoclonic encephalopathy during bismuth subsalicylate therapy. Ann Intern Med l990;l 12:140.
Hudson M, Ashley N, Mowat G. Reversible toxicity in poisoning with colloidal bismuth substrate. Br Med J I989;299:l59.
Nwokolo CV, Gavy CJ, Smith JTL, Pounder RE. The absorption of bismuth from oral dose of tripotassium dicitrate bismuthate. Aliment Pharmacol Ther 1989;3:29-39.
Lauritsen K, Laursen LS, Rask-Madsen J. Clinical pharmacokinetics of drug used in the treatment of gastrointestinal diseases. I. Clin Pharmacokinet 1990;19:11-31.
Supino-Veterbo V, Sicard C, Risvegliato M, Rancurel G, Buge A. Toxic encephalopathy due to ingestion of bismuth salts: clinical and EEG studies of 45 patients. J Neurol Neurosurg Psychiatry 1977;40:748-752.
Buge A, Supino-Viterbo V, Rancirel G, Pontes C. Toxic epileptic phenomena in bismuth toxic encephalopathy. J Neurol Neurosurg Psychiatry 1982;44:62-67.
Gordon MF, Abrams RI, Rubin DB, Barr WB, Correa DD. Bismuth subsalicylate toxicity as a cause of prolonged encephalopathy with myoclonus. Movement Disorders 1995;10:220-222.
Emil J, De Bray JM, Bernat M et al. Osteoarticular complications in bismuth encephalopathy. Clin Toxicol 1981;18:1285-1290.
Szymanska J A, Zelazowski AJ, Kawiorski S. Some aspects of bismuth metabolism. Clin Toxicol 1981;18:1291-1298.
Basinger MA, Jones MM, McCroskey SA. Antidotes for acute bismuth intoxication. J Toxicol Clin Toxicol 1983;20:159-165.
Hasking G, Duggan J. Encephalopathy from bismuth subsalicylate. Med J Aust 1982;2:167.
Huwez F, Pall A, Lyons D, Stewart MJ. Acute renal failure after one dose of colloidal bismuth subcitrate. Lancet 1992;340:1298.
Slikkerveer A, Helminth RB, Jong HB, de Wolff TA. Development of a therapeutic procedure for bismuth intoxication using chelating agents. Hum Exp Toxicol 1993;12:77-78.
Behrendt WA, Groger C, Kuhn D, Schulz H-V, Topf-meier P. A study relating to bioavailability and renal elimination of bismuth after oral administration of basic bismuth nitrate. Internal J Clin Pharmacol Ther Toxicol 1991;29:357-360.
Slikkerveer A. Bismuth: biokinetics, toxicity and experimental therapy of overdosage. PhD thesis. S. Graven-lage, Pasmans Opfset Drukerij 1992; pp. 1 — 185.
Slikkerveer A, de Wolff FA. Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adverse Drug Dep 1989;4:303-323.
Irth H, Brouwer E, de Jong GJ, Brinkman UA Th, Free RW. Trace enrichment and separation of AsIH, Sblll as diethyldithiophosphate complexes by reversed phase high performance liquid chromatography. J Chromatog 1988;439:63-70.
Buge A, Supino-Viterbo V, Rancirel G, Pontes C. Toxic epileptic phenomena in bismuth toxic encephalopathy. J Neurol Neurosurg Psychiatry 1981;44:62-67.
Hasking GJ, Duggen JM. Encephalopathy for bismuth subsalicylate. Med J Aust 1982;2:167.
Woo OF, Jackson GM. Radiopacity of chewable Pepto-Bismol® tablets: report of two patients. Vet Hum Toxicol 1993;35:317.
Nwokolo CU, Pounder PE. D-penicillamine does not increase urinary bismuth excretion in patients treated with tripotassium dicitrato bismitate. Br J Clin Pharmacol 1990;30:648-650.
Molina JA, Calandre L, Bermajo F. Myoclonic encephalopathy due to bismuth salts: treatment with dimerc-aprol and analysis of CSF transmitters. Acta Neurol Scand 1989;79:200-203.
Playford RJ, Matthews CH, Campbell MJ, Delves VT, Hla KK, Hodgson HJF et al. Bismuth induced encephalopathy caused by tripotassium dicitrato bismethate in a patient with chronic renal failure. GUT 1990;36:359— 360.
Johnson CH, Van Tassell VJ. Acute barium poisoning with respiratory failure and rhabdomyolysis. Ann Emerg Med 1991;20:1138-1142.
Stedwell RE, Allen KM, Binder LS. Hypokalemic paralyses: a review of the etiologies, pathophysiology, presentation and therapy. Am J Emerg Med 1992;10:143-148.
Environmental Health Criteria 107. Barium. Geneva. World Health Organization, 1990; p. 89.
Wetherill SF, Guarino MJ, Cox RW. Acute renal failure associated with barium chloride poisoning. Ann Intern Med 1981;95:187-188.
Phelan DM, Hagley SR, Guerin MD. Is hypokalemia the cause of paralysis in barium poisoning? Br Med J 1984;289:882.
Deng JF, Jan IS, Cheng HS. The essential role of a poison center in handling an outbreak of barium carbonate poisoning. Vet Hum Toxicol 1991;33:173-175.
Layzer RB. Neuromuscular manifestations of systemic disease. Philadelphia: FA Davis, 1985; pp. 54—57.
Boehmert M, Shore N, Timperi R et al. Measurement of serum levels in acute barium chloride overdose. Vet Hum Toxicol 1985;28:291 (abstract).
Johnson CH, Van Tassell VJ. Acute barium poisoning with respiratory failure and rhabdomyolysis. Ann Emerg Med 1991;20:1138-1142.
Buylaert W, Vanhoe H, Van den Bogaerde J, Vogelaers D, Derom E, Versieck J, Verstraete A. Acute poisoning with barium carbonate. A case report. Proc Eur Assoc Pois Contr Cent Clin Toxicol 1988; p. 42.
Mills K, Kunkel D. Prevention of severe barium carbamate toxicity with oral magnesium sulfate. Vet Hum Toxicol 1993;35:347.
Boehmert M. Soluble barium salts. Clin Toxicol Rev 1988;10(5):l—2.
Scharn ThF, Olbricht CH, Schuler A, Franz A, Wittek K, Balks H-J et al. Barium carbonate intoxication. Intensive Care Med 1991;17:60-62.
Kriebel D, Brain JD, Sprince NL, et al. The pulmonary toxicity of beryllium. Am Rev Respir Dis 1988; 137:464— 473.
Cotes JE, Gilson JC, McKerrow CB et al. A long term follow up of workers exposed to beryllium. Br J Ind Med 1983;40:13-21.
Hasan F, Kazemi H. Chronic beryllium disease: a continuing epidemiologic hazard. Chest 1974;65:289-293.
Sprince NL, Kanarek DJ, Weber AL et al. Reversible respiratory disease in beryllium workers. Am Rev Respir Dis 1978;117:1011-1017.
Williams WJ. Beryllium disease. Postgrad Med J 1988;64:511-516.
Hooper WF. Acute beryllium lung disease. NC Med J 1981;42:551-553.
Rom WN, Lockey JE, Bank KM et al. Reversible beryllium sensitization in a prospective study of beryllium workers. Arch Environ Health 1983;38:302-307.
King ME, Shefner AM, Ehrlich R. Effectiveness of aurin tricarboxylic acid as an antidote for beryllium poisoning. Ind Med Surg 1964;33:566-569.
Aronchik JM. Chronic beryllium disease. Radiol Clin N Amer 1992;30:1209-1217.
Saracci R. Beryllium and lung cancer: adding another piece to the puzzle of epidemiologic evidence. J Natl Cancer Inst 1991;83:1362-1363.
Vainio H, Kleihues P. IARC Working Group on Carcinogenicity of Beryllium. J Occup Med 1994;36:1068— 1069.
Newman LS, Kreiss К. Non-occupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis 1992;145:1212-1214.
Sprince NL, Kazemi H. Beryllium disease. In: Rom W, ed. Environmental and occupational medicine. 1st ed. Boston: Little, Brown, 1983; pp. 481—490.
Steinland K, Ward E. Lung cancer incidence among patients with beryllium disease: a cohort mortality study. J Natl Cancer Inst 1991;83:1380-1385.
Kreiss K, Newman LS, Mroz MM, Campbell PA. Screening blood test identifies subclinical beryllium disease. J Occup Med 1989;31:603-608.
Newman LS, Kreiss K, King ТЕ Jr, Seay S, Campbell PA. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis 1989;139:1479-1489.
Epstein PE, Dauber JH, Rossman MD, Daniele PP. Bronchoalveolar lavage in a patient with chronic berylliosis: evidence for hypersensitivity pneumonitis. Ann Intern Med 1982;97:211-213.
Rossman MD, Kern JA, Elias JA, Cullen MP, Epstein PE, Preuss OP et al. Proliferative response of bronchoalveolar lymphocytes to Beryllium. A test for chronic beryllium disease. Ann Intern Med 1988;108:687-693.
Saltini C, Winstock K, Kirby M, Pinkston P, Crystal RG. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T-cells. N Engl J Med 1989;320:1103-1109.
Williams WJ, Wallach ER. Laser microprobe mass spectrometry (LAMMS) analysis of beryllium, sarcoidosis and other granulomatous disease. Sarcoidosis 1989;6:111-117.
Winship КА. Toxicity of aluminum: a historical review. I. Adverse Drug React Toxicol Rev 1992;11:123-141.
Wilhelm M, Jager DE, Ohnesorge FK. Aluminum toxicokinetics. Pharmacol Toxicol 1990;66:4-9.
Nemery B. Metal toxicity and respiratory tract. Eur Respir J 1990;3:202-209.
4
Sedman A. Aluminum toxicity in childhood. Pediatr Nephrol 1992;6:383-393.
Committee on Nutrition. Finberg L, Dwech HS, Holmes F, Kretchmer N, Mauea AM, Reynolds JW et al. Aluminum toxicity in infants and children. Pediatrics 1986;78:1150-1153.
Henry PA, Goodman WO, Nudelman RK et al. Parenteral aluminum administration in the dog. I. Plasma kinetics, tissue levels, calcium metabolism and parathyroid hormones. Kidney Int 1984;25:362-369.
Williams JW, Santiago RV, Peters TG et al. Biliary excretion of aluminum in aluminum osteodystrophy with liver disease. Ann Intern Med 1986;104:782-785.
Lione A. Aluminum toxicology and the aluminum-con-taining medications. Pharmacol Ther 1986;29:255— 285.
Liukkonen-Lija, Piepponen S. Leaching of aluminum from aluminum dishes and packages. Food Addit Contain 1992;9:213-223.
Fleming LW, Prescott A, Steward WK, Cargill RW. Bioavailability of aluminum. Lancet 1981;9:433.
Monteagudo FSE, Cassidy MJD, Fold PL Recent developments in aluminum toxicology. Med Toxicol 1989;4:1-16.
Van de Vyver FL, Silva FJE, D’Haese PC, Verbucken AH, de Broe Ml. Aluminum toxicity in dialysis patients. Contrib Nephrol 1987;55:198-220.
Federal Register 1990;55:No. 98:5/21; p. 20:799.
ASCN/Aspen Working Group on Standards for Aluminum Content of Parenteral Nutrition Solutions.Parenteral drug products containing aluminum as an ingredient or a contaminant: response to FDA. Notice of Intent. Am J Clin Nutr 1991;53:399-402.
Bolla KI, Briefel G, Spector D, Schwartz BS, Wider L, Herron J et al. Neurocognitive effects of aluminum. Arch Neurol 1992;49:1021-1026.
Bartter T, Irwin RS, Abraham JL, Dascal A, Nash G, Himmelstein JS et al. Zirconium compound-induced pulmonary fibrosis. Arch Intern Med 1991;I51:1197— 1201.
Bia MJ, Cooper K, Schnell S, Daffy T, Kenderl E, Mal-luche H, Solomon L. Aluminum induced anemia: pathogenesis and treatment in patients in chronic hemodialysis. Kidney Int 1989;36:852-853.
Rosenlof K, Fahrquist F, Tenhunen R. Erythropoietin, aluminum and anaemia in patients on haemodialysis. Lancet 1990;335:247-249.
Alfrey AC, Mishell MM, Burks J, Contiguglia SR, Rudolph H, Lewin E et al. Syndrome of dyscrasia and multifocal seizures associated with chronic hemodialysis. Trans Am Soc Artif Intern Organs 1972;18:257-261.
Alfrey AC. Dialysis encephalopathy. Kidney Int 1986;29(Suppl 18):S53-S57.
Garrett RJ, Mulcahy D, Carmody M, O’Dwyer WS. Aluminum encephalopathy: clinical and immunological features. Q J Med 1988;69:775-783.
McLaughlin AIG, Kazantzis G, King E et al. Pulmonary fibrosis and encephalopathy associated with the inhalation of aluminum dust. BrJ Ind Med 1962;16:123-125.
Longstretch WT, Rosenstock L, Heyer NJ. Potroom palsy? Neurologic disorder in three aluminum smelter workers. Arch Intern Med 1985;145:1972-1975.
White DM, Longstretch WT Jr, Rosenstock L, Clay-poole KHJ, Brodkin CA, Townes BD. Neurologic syndrome in 25 workers from an aluminum smelting plant. Arch Intern Med 1992;152:1443-1448.
Theriault G, Cordier S, Harvey R. Skin telangiectases in workers at an aluminum plant. N Engl J Med 1980;303:1278-1281.
Gibbs GW, Horowitz I. Lung cancer mortality in aluminum plant workers. J Occup Med 1979;21:347-353.
Theriault G, Tremblay C, Cordier S et al. Bladder cancer in the aluminum industry. Lancet 1984;1:947-950.
Kongerud J, Boe J, Soyseh V, et al. Aluminum potassium asthma: the Norwegian experience. Eur Respir J 1994;7:165-172.
Desjardins A, Bergeron J-P, Ghezzo H, Cartier A, Malo J-C. Aluminum potassium asthma confirmed by monitoring of forced expiratory volume in one second. Am J Respir Crit Care Med 1994;150:1714-1717.
Musk AW, Greville HW, Tribe AE. Pulmonary disease from occupational exposure to an artificial aluminum silicate used for cat litter. Br J Ind Med 1980;37:367-372.
Seear MD, Dinmick JE, Rogers PC. Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis. Urology 1990;36:353-356.
Kavoussi LR, Gelstein GD, Andriole GL. Encephalopathy and an elevated serum aluminum level in a patient receiving intravesical alum irrigation for severe urinary hemorrhage. J Urol 1986;136:665-667.
Shoskes DA, Radzinski CA, Struthers NW, Honey RJ. Aluminum toxicity and death following intravesical alum irrigation in a patient with renal impairment. J Urol 1992;147:697-699.
Murphy CP, Cox RL, Harden EA, Stevens M, Heye M, Herzig RH. Encephalopathy and seizure induced by intravesical alum irrigations. Bone Marrow Transplant 1992;10:383-385.
Tsou WM, Young RM, Hart MH, Vanderhoof JA. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. Pediatrics 1991;87:148— 151.
Bishop N, McGraw М, Ward В. Aluminum in infant formulas. Lancet 1989; 1:565.
Yasvi M, Yase Y, Oka K, Mukoyama M, Adachi K. High aluminum deposition in the central nervous system of patients with amyotrophic lateral sclerosis from Kae Kii peninsula, Japan. Two case reports. Neurotoxicology 1991;12:277-284.
Yaqoob M, Ahmad R, Roberts N, Helliwell T. Low-dose desferrioxamine test for the diagnosis of aluminum related bone disease in patients on regular hemodialysis. Nephrol Dial Transplant 1991;6:484-486.
Felsenthal AJ, Harrelson JM, Gutman RA, Wells SA, Drezner MK. Osteomalacia after parathyroidectomy in patients with uremia. Ann Intern Med 1982;97:34-39.
Pizzarelli F, Giordano R, Ballanti P, Costantin S, Mocetti P, Maggiore Q. Bone aluminum intoxication. An unpreventable sequel of parathyroidectomy? Nephron 1988;48:250-251.
Alfrey AC. Aluminum metabolism. Kidney Int 1986;29:(Suppl 18):S8—SI 1.
Ellis GL. Are aluminum foreign bodies detectable radiographically? Am J Emerg Med 1993;11:12-13.
Chazan JA, Lew NL, Lowrie EG. Increased serum aluminum. An independent risk factor for mortality in patients undergoing long-term hemodialysis. Arch Intern Med 1991;151:319-320.
Czapla K, Rodger RSC, Halls DJ, Muralikrishna GS, MacDougall Al, Fell GS. Ranitidine reduced aluminum toxicity in patients with renal failure. Nephrol Dial Transplant 1992;7:1246-1248.
Arze RS, Parkinson IS, Cartlidge NEF et al. Reversal of aluminum dialysis encephalopathy after desferrioxamine treatment. Lancet 1981;2:1116.
Brown DJ, Dawborn JK, Ham KN et al. Treatment of dialysis osteomalacia with desferrioxamine. Lancet 1982;2:343-345.
Freundlich M, Zilleruelo G, Faugere M-C et al. Treatment of aluminum toxicity in infantile uremia with deferoxamine. J Pediatr 1986;109:140-143.
Savory J, Berlin A, Courtoux C et al. Summary report of an international workshop on the role of biological monitoring of aluminum toxicity in man: Aluminum analysis in biological fluids. Ann Clin Lab Sci 1983;13:444-451.
Pogglitsch H, Knoff C, Wawschinek D et al. Aluminum intoxication in dialysis patients. Int J Artif Organs 1982;5:293-296.
Milliner DS, Nebeker HG, Ott SM et al. Use of deferoxamine infusion test in the diagnosis of aluminum related osteodystrophy. Ann Intern Med 1984; 101:775.
Adhemar JP, Laederich J, Jaudon MC et al. Removal of aluminum from patients with dialysis encephalopathy. Lancet 1980;2:131 I.
Dialysis patients face dangers from aluminum and other trace elements. FDA Med Bull 1992;22(2):8.
Kruch TPA, Fisher EA, McLachlan DRC. Suppression of deferoxamine mesylate treatment-induced side effect by coadministration of isoniazid in a patient with Alzheimer’s disease subject to aluminum removal of ion-specific chelation. Clin Pharmacol Ther 1990;48:439-441.
Altman P, Plowman DH, Marsha F, Cunningham J. Aluminum chelation therapy in dialysis patients: evidence for inhibition of hemoglobin synthesis by low levels of aluminum. Lancet 1988;1:1012-1015.
Coburn JW, Norris КС, Sherrard DJ, Bia M, Llach F, Alfrey AC, Slatopolsky E. Toxic effects of aluminum in end stage renal disease. Discussion of a case. Am J Kidney Dis 1988;12:171-184.
Coburn JW, Norris КС, Sherrard DJ, Bia M, Llach F, Alfrey AC, Slatopolsky E. Toxic effects of aluminum in end stage renal disease. Discussion of a case. Am J Kidney Dis 1988;12:171-184.
Toxicological Profile for Antimony. Agency for Toxic Substances and Disease Registry. TP-91/02, September, 1992.
Lauwers LF, Roelants A, Rosseel PM, Heyndrickx B, Baute L. Oral antimony intoxications in man. Crit Care Med 1990;18:324-325.
de Wolff FA. Antimony and health incriminating stibine in the sudden infant death syndrome is difficult in current evidence. Br Med J 1995;310:1216-1217.
Berman JD. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy and future strategies. Rev Infect Dis 1988;10:560-586.
Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pento-stam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306.
Winship KA. Toxicity of antimony and its compounds. Adverse Drug React Acute Pois Rev 1987;2:67-90.
Robbins A. Stibine, NIOSH Current Intelligence Bulletin 32. Vet Hum Toxicol 1980;22:108-109.
Jones PD. Survey of antimony workers: mortality 1961 — 1992. Occup Environ Med 1994;51:772-776.
Aaseth J. Recent advances in therapy of metal poisoning with chelating agents. Hum Toxicol 1983;2:257-272.
1
Teisinger J. BAL. In: Occupational Health and Safety. Vol. 1. Geneva: International Labour Office/New York: McGraw-Hill, 1976, p. 154.
Foa V, Colombi A, Maroni М, Buratti М. Arsenic. Biological Indicators for Assessment of Human Exposure to Industrial Chemicals. Commission of the European Committee. EUR11 135. 1987; pp. 25—46.
Smith PH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Piccioto 1, Duggan JM, Wood R et al. Cancer risks for arsenic in drinking water. Environ Health Perspect 1992;97:256-267.
Done AK, Peart AJ. Acute toxicities of arsenical herbicides. Clin Toxicol 1971;4:343-355.
Boyd SD, Wasserman GS, Green VA et al. Lead arsenate ingestion in eight children. Clin Toxicol 1981 ;18:489— 491.
Watson WA, Veltri JC, Metcalf TJ. Acute arsenic exposure treated with oral D-penicillamine. Vet Hum Toxicol 1981;23:164-166.
Kingstrom RL, Hall S, Sioris L. Clinical observations and medical outcome in 149 cases of arsenate ant killer ingestion. Clin Toxicol 1993;31:581-591.
Scaizo AJ, Thompson MW, Peters DW. Asymptomatic presentation of pediatric arsenic ingestion from sodium arsenate ant killer. Vet Hum Toxicol 1989;31:340.
Parish GG, Glass R, Kimbrough R. Acute arsine poisoning in two workers cleaning a clogged drain. Arch Environ Health 1979;34:224-227.
Daya MR, Irwin R, Parshley MC, Handuy J, Burton ВТ. Arsenic ingestion in pregnancy. Vet Hum Toxicol 1989;3I:347.
Marcus SM. Survival after massive arsenic trioxide ingestion. Vet Hum Toxicol 1987;29:481.
Di Napoli J, Hall AH, Drake R, Rumack BH. Cyanide and arsenic poisoning by intravenous (IV) injection. Vet Hum Toxicol 1988;30:360.
Sanz P, Corbella J, Nogue S, Munne P, Rodriguez-Pa-zos M. Rhabdomyolysis in fatal arsenic trioxide poisoning. JAMA 1989;212:3271.
Gorby MS. Arsenic poisoning. West J Med 1988;149:308-315.
Pinto SS. Arsine poisoning: evaluation of the acute phase. J Occup Med 1976;18:633-635.
Kleinfeld MJ. Arsine poisoning. J Occup Med 1980;22:820-821.
Chen C-J. Blackfoot disease. Lancet 1990;2:442.
Lu FJ. Blackfoot disease: arsenic or humic acid? Lancet 1990;336:115-116.
Lu FJ, Shih SR, Liu TM, Shown SH. The effect of fluorescent humic substances existing in the well water of Blackfoot Disease in endemic areas in Taiwan on prothrombin time and activated partial thromboplastin time in vitro. Thromb Res 1990;57:747-752.
Shen M-C, Tsong W-P, Chen C-S. Increased circulating platelet aggregation and coagulation factors in patients with Blackfoot Disease. J Formosa Med Assoc 1983;82:816-821.
Tallis GA. Acute lead arsenate poisoning. Aust NZ J Med 1989;19:730-732.
Moyer TP. Testing from arsenic. Mayo Clin Proc 1993;68:1210-1211.
Mathieu D, Mathieu-Nolf M, Germain-Alonso M, Neviere R, Furon D, Wattel F. Massive arsenic poisoning — effect of hemodialysis and dimercaprol or arsenic kinetics. Intensive Care Med 1992;18:47-50.
Kosnett MJ, Becker CE. Dimercaptosuccinic acid: utility in acute and chronic arsenic poisoning. Vet Hum Toxicol 1988;30:369.
Shum S, Whitshead J, Vaughan L, Shum S, Hale T. Chelation of organoarsenate with dimercapton succinic acid. Vet Hum Toxicol 1995;37:239-242.
Moore DF, O’Callaghan CA, Berlyne G et al. Acute arsenic poisoning: absence of polyneuropathy and after treatment with 2,3-dimercaptopropanesulfonate (DMPS). J Neurol Neurosurg Psychiatry 1994;57:1133.
Hazardous Materials Medical Management Protocols. (California Emergency Medical Services Authority and Toxics Epidemiology Program, Los Angeles County Department of Health Services. March 26, 1989; p. 22.
NIOSH Alert: Request for assistance in preventing death from excessive exposure to chlorofluorocarbon 113 (CFC-113). Washington, DC: US Government Printing Office. DHHS (NIOSH). Publication No. 89-109.
CDC-polymer-fume fever associated with cigarette smoking and the use of tetrafluoroethylene — Mississippi. MMWR 1987;36:515-522.
Albrecht WN, Bryant CJ. Polymer-fume fever associated with smoking and use of a mold-release spray containing polytetrafluoroethylene. J Occup Med 1987;29:817— 819.
CDC. Criteria for a recommended standard: occupational exposure to decomposition products of fluorocarbon polymers. Cincinnati, OH: US Department of Health, Education and Welfare, Public Health Service, 1977; DHEW Publication No. (NIOSH) 77-193.
Begley S. Holes in the ozone treatment. Newsweek, September 25, 1995, p. 70.
Ruth JH. Odor thresholds and irritation levels of several chemical substances: a review. Am Ind Hyg Assoc J 1986;47:A142—A151.
Woollen BH, Guest EA, Howe W, Marsh JR, Wilson HF, Auton TR et al. Human inhalation pharmacokinetics of 1,1,1,2-trichloro-1,2,2 trifluoromethane (FC-113). Int Arch Occup Environ Health 1990;62:73-78.
McGee MB, Meyer RF, Jejurikai SG. A death resulting from trichlorotrifluoromethane poisoning. J Forensic Sci 1990;35:1453-1460.
Tsatsakis AM, Smialek J. A fatal case due to Freon-22 inhalation. Bull Int Assoc Forensic Toxicol 1991;21:33— 36.
Thompson JD, Snodgrass WR. Inflatable toys — an unusual source of Freon toxicity. Vet Hum Toxicol 1991;33:363.
Holness DL, House RA. Health effects of Halon-1301 exposure. J Occup Med 1992;34:722-725.
Denborough MA, Hopkinsin КС, Banney DG. Firefighters and malignant hyperthermia. Br Med J 1988;296:1442-1443.
Lerman Y, Winkler E, Tirosh MS, Danon Y, Almog S. Fatal accidental inhalation of bromochlorodifluor-omethane (Halon-1211). Hum Exper Toxicol 1991;10:125-128.
Pierce RJ, Seale JP, Ruffin RE Inhaled respiratory medications and the use of chlorofluorocarbons (CFCs). Med J Aust 1991;154:701-704.
Rusznak С, Devalia JL, Davies RJ. A hole in our knowledge of ozone toxicity? Allergy 1994;49:21-27.
Paulo M, Gong H Jr. Respiratory effect of ozone: whom to protect, when and how? J Respir Dis 1991; 12:482— 499.
Lippman M. Health effects of ozone. A critical review. J Am Poll Control Assoc 1989;32:672-695.
Kinney PL, Ware J H, Spengler JD, Dockery DW, Speiz-er FE, Ferris BG Jr. Short-term pulmonary function change in association with ozone levels. Am Rev Respir Dis 1989;139:56-61.
Aris R, Christian D, Sheppard D, Balmes JR. The effects of sequential exposure to acidic fog and ozone on pulmonary function in exercising subjects. Am Rev Respir Dis 1991;143:85-91.
Beritic Т. The challenge of fire effluents. Poisonous gases are potential killers. Br Med J 1990;300:696-698.
Norris JC, Moore SJ, Haine AS. Synergistic lethality induced by the combination of carbon monoxide and cyanide. Toxicology 1994;40:121-129.
Birky MM, Paabo M, Brown JF. Correlation of autopsy data and materials involved in the Tennessee jail fire. Fire Safety J I979;8O;2:17—22.
Birky MM, Clarke FB. Inhalation of toxic products from fire. Bull NY Acad Med 1981;57:997-1013.
Hoffman RS, Sauter P. Methemoglobinemia resulting from smoke inhalation. Vet Hum Toxicol 1989;31:168— 170.
Witten ML, Quan SF, Sobonya RE, Lemen RJ. New developments in the pathogenesis of smoke inhalation-induced pulmonary edema. West J Med 1988;148:33— 36.
Jones JG, Lawler P, Crawley JCW et al. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1980;1:66-68.
Minty BD, Rayston D, Jones JG et al. Changes in permeability of the alveolar-capillary barrier in fire fighters. Br J Ind Med 1985;42:631-634.
Sammut P, Cunnigham J, Witten M et al. Pulmonary epithelial permeability to 99m Tc DTPA in cystic fibrosis patients compared with normal subjects. Am Rev Respir Dis 1987;235: A464.
Baud FJ, Barriot P, Toffis V, Riou B, Vicaut E, Lecar-pentier Y et al. Elevated blood cyanide concentrations in victims of smoke inhalation. N Engl J Med 1991;325:1761-1766.
Hart GB, Strauss MB, Lennon PA, Whitcraft DD III. Treatment of smoke inhalation by hyperbaric oxygen. J Emerg Med 1985;3:211-215.
Kulig K. Cyanide antidotes in fire toxicology. N Engl J Med 1991;325:1801-1802.
Hall AH, Rumack BH. Hydroxocobalamin/sodium thiosulfate as a cyanide antidote. J Emerg Med 1987;5:115-121.
Weiss SM, Lakshminarayan S. Acute inhalation injury. Clin Chest Med 1994;15:103-116.
Wald PH, Balmes JR. Respiratory effects of short-term high intensity toxic inhalation: smoke, gases and fumes. J Intensive Care Med 1987;2:260-278.
Wald PH, Balmes JR. Respiratory effects of short-term, high-intensity toxic inhalations: smoke, gases, and fumes. J Intensive Care Med 1987;2:260-278.
Lee HS, Chan CC, Tan KT, Cheong TH, Chee CBE, Wang YT. Burnisher’s asthma — a case due to ammonia from silverware polishing. Singapore Med J 1993;34:565-566.
Wason S, Stephan M, Breide C. Ingestion of aromatic ammonia "smelling salts" capsules. AJDC 1990;144:139-140.
Lopez GP, Dean BS, Krenzelok EP. Oral exposure to ammonia inhalants. A report of 8 cases. Vet Hum Toxicol 1988;30:350.
Wallace DE. Consequence of exposure to aromatic ammonia solution in 15 patients. Vet Hum Toxicol 1989;31:399.
Beare JDL, Wilson RD, Marsh RJ. Ammonia burns of the eye: an old weapon in new hands. Br Med J 1990;296:590.
Rabinovitch S, Greyson ND, Weiser W, Hoffstein V. Clinical and laboratory features of acute sulfur dioxide inhalation poisoning: two-year follow-up. Am Rev Respir Dis 1989;239:556-558.
Avol EL, Linn WS, Shamoo DA, Anderson KR, Peng R-C, Hochney JD. Respiratory responses of young asthmatic volunteers in controlled exposures to sulfuric acid aerosol. Am Rev Respir Dis 1990;142:343-348.
Koenig JQ, Covert DS, Pierson WE. Effects of inhalation of acidic compounds on pulmonary function in allergic adolescent subjects. Environ Health Perspect 1989;79:173-178.
Utell MJ. Effects of inhaled acid aerosols on lung mechanics. An analysis of human exposure studies. Environ Health Perspect 1985;63:39-44.
Folinsbee LJ. Human health effects of exposure to airborne acid. Environ Health Perspect 1989;79:195-199.
Kitagawa T. Cause analysis of the Yokkaichi asthma episode in Japan. J Air Pollution Control Assoc 1984;34:743-746.
Lippman M. Airborne acidity: estimates of exposure and human health effects. Environ Health Perspect 1985;63:63-70.
Samet JM, Marbury MC, Spengler JD. Health effects and sources of indoor air pollution. I. Am Rev Respir Dis 1987;136:1486-1508.
Spengler JD, Duffy CP, Letz R, Tibbitts TW, Ferris BG Jr. Nitrogen dioxide inside and outside 137 homes and implications for ambient air quality standards and health effects research. Environ Sci Technol 1983;17:164-168.
Spengler JD, Sexton K. Indoor air pollution: A public health perspective. Science 1983;221:9-17.
SoparkarG, Mayers I, Edouard L, Hoeppner VH. Toxic effects from nitrogen dioxide in ice skating arenas. Can Med Assoc J 1993;148:1181-1182.
Elsayed NM. Toxicity of nitrogen dioxide: an introduction. Toxicology 1994;89:161-174.
Hajela R, Janigan DT, Landrigan PL, Boudreau SF, Sebastian S. Fatal pulmonary edema due to nitric acid fume inhalation in three pulp-mill workers. Chest 1990;97:487-489.
Ice hockey lung: NO2 poisoning. Lancet 1990;335:l 191 (editorial).
Hedberg K, Hedberg CW, Iber C, White KE, Osterholic MT, Jones DBW et al. An outbreak of nitrogen dioxideinduced respiratory illness among ice hockey players. JAMA 1989;262:3014-3017.
Ford DP, Rothman N. Nitrogen dioxide-induced respiratory illness in ice hockey players. JAMA 1990;263:3024.
Hedberg K, MacDonald KL, Osterholm M, Hedberg C, White K. Nitrogen dioxide-induced respiratory illness in ice hockey players. JAMA 1990;263:3024-3025.
Dawkins SA, Gerhard H, Nevin M. Pulmonary alveolar proteinosis: a possible sequel of NO2 experience. J Occup Med 1991;33:638-641.
Martinez-Lopez MA, Gomez-Cerazo G, Villasante C, Molina F, Diaz S, Cobo J, Medrano C. Pulmonary alveolar proteinosis: prolonged spontaneous remission in two patients. Eur Respir J 1991;4:377-379.
Blanc PD. Chlorine gas inhalation. AACT Update 1994;7(4):1—2.
Martinez TT, Long C. Explosion risk from swimming pool chlorinators and review of chlorine toxicity. Clin Toxicol 1995;33:349-359.
Krenzelok E, Mrvos R. Chlorine/chloramine. Clin Toxicol 1995;355—357.
Baxter PJ, Davies PC, Murray V. Medical planning for toxic releases into the community: the example of chlorine gas. Br J Ind Med 1989;46:277-285.
Heidemann SM, Goetting MG. Treatment of acute hypoxemic respiratory failure caused by chlorine exposure. Pediatr Emerg Care 1991;7:87-88.
Vinsel PJ. Treatment of acute chlorine gas inhalation with nebulized sodium bicarbonate. J Emerg Med 1990;8:327-329.
Zucker AR. Therapeutic strategies for acute hypoxemic respiratory failure. Crit Care Clin 1988;4:813-830.
Bosse M. Nebulized sodium bicarbonate in the treatment of chlorine gas inhalation. Vet Hum Toxicol 1993;35:357.
Vinsel PJ. Treatment of acute chlorine gas inhalation with nebulized sodium bicarbonate. J Emerg Med 1990;8:327-329.
Chisholm CD, Singletary EM, Okerberg CV, Langlinais PL. Inhaled sodium bicarbonate therapy for chlorine inhalation injuries. Ann Emerg Med 1989; 18:466.
Stueven HA, Coogan P, Vallery V. A hazardous material episode: sulfur trioxide. Vet Hum Toxicol 1993;35:37.
Lorin HG, Kulling PEJ. The Bhopal tragedy — what has Swedish disaster medicine planning learned from it? J Emerg Med 1986;4:311-316.
Mehta PS, Mehta AS, Mehta SJ, Makhijani AB. Bhopal tragedy’s health effects. A review of methyl isocyanate toxicity. JAMA 1990;264:2781-2787.
Salmon AG. Bright red blood of Bhopal victims: cyanide or MIC? Br J Ind Med 1986;43:502-504.
Nemery B, Sparrow S, Dinsdale D. Methyl isocyanate. Thiosulphate does not protect. Lancet 1985;2:1245— 1246.
Anderson N. Long-term effects of methyl isocyanate. Lancet 1989; 1:1259.
Anderson N, Ajwani MK, Mahashabde S, Tiwari MK, Muir MK, Mehra V et al. Delayed eye and other consequences from exposure to methyl isocyanate. 93 % follow-up of exposed and unexposed cohorts in Bhopal. Br J Ind Med 1990;47:553-558.
Persson P, Dalene M, Skarping G, Adensson M, Hag-man L. Biological monitoring of occupational exposure to toluene diisocyanate: measurement of toluenediamine in hydrolysed urine and plasma by gas chromatographymass spectrometry. Br J Ind Med 1993;50:1111-1118.
Frazier CA. Contact allergy to mace. JAMA 1976;236:2526.
Danto BL Medical problems and criteria regarding the use of tear gas by police. Am J Forensic Med Path 1987;8:317-322.
Toxic gas in Tbilisi. Lancet 1989;1:1462-1663.
ACLU report calls pepper spray potentially deadly. New York Times, June 19, 1995.
Hu H, Fine J, Epstein P, Kelsey K, Reynolds P, Walker B. Tear gas-harrassing agent on toxic chemical weapon? JAMA 1989;262:660-663.
Beswick FW. Chemical agents used in riot control and warfare. Hum Toxicol 1983;2:247-256.
Chapman AJ, White C. Death resulting from lacrimatory agents. J Forensic Sci 1978;23:527-530.
Cucinell AA, Swentzel КС, Biskup R et al. Biochemical interactions and metabolic fate of riot control agents. Fed Proc 1971;30:86-91.
Leopold IH, Lieberman TW. Chemical injuries of the cornea. Fed Proc 1971;30:92-95.
Thorburn KM. Injuries after use of the lacrimatory agent chloroacetophenone in a confined space. Arch Environ Health 1982;37:182-186.
Park S, Giammonia ST. Toxic effects of tear gas on an infant following prolonged exposure. Am J Dis Child 1972;123:245-246.
Beswick FW, Holland P, Kemp KH. Acute effects of exposure to o-chlorobenzylidenemalononitrile (CS) and the development of tolerance. Br J Ind Med 1972;29:298-306.
Hu H, Christian D. Reactive airways dysfunction after exposure to teargas. Lancet 1992;339:1535.
Wheeler H, Murray V. Poisons centre will monitor cases. Br Med J 1995;331:871.
Sidell FR. Civil emergencies involving chemical warfare agents: medical considerations. In: Somani SM, ed. Chemical warfare agents. San Diego: Academic Press, 1992; pp. 341-356.
Holland P. The cutaneous reactions produced by diben-zoxazepine (CR). Br J Dermatol 1974;90:657-659.
Penneys NS. Contact dermatitis to chloroacetophenone. Fed Proc 1971;30:96-99.
Wils ERJ, Hulst AG. Gas chromatographic-mass spec-trometric identification of tear-gases in dilute solutions using large injection volumes. J Chromatogr 1985;330:379-382.
Ferslew KE, Orcutt RH, Hagardon AN. Spectral differentiation and gas chromatographic/mass spectrometric analysis of the lacrimators 2-chloroacetophenone and o-chlorobenzylidene malononitrile. J Forensic Sci 1986;31:658-665.
Wils ERJ, Hulst AG. Gas chromatographic-mass spectrometric identification of tear gases in dilute solubions using large injection volumes. J Chromatogr 1985;330:379-382.
Ferslew KE, Orcutt RH, Hagardorn AN. Spectral differentiation and gas chromatographic/mass spectrometric analysis of the lacrimators 2-chloroacetophenone and o-chlorbenzylidene malononitrile. J Forensic Sci 1986;31:658-665.
Gray PJ. Treating CS injuries to the eye. Br Med J 1995;311:871.
Scott RAH. Illegal "Mace" contains more toxic CN particles. Br Med J 1995;311:871.
Morse DL, Woodbury МА, Rentmeester К et al. Death caused by fermenting manure. JAMA 1981;245:63-64.
Peters JW. Hydrogen sulfide poisoning in a hospital setting. JAMA 1981;246:1588-1589.
Thoman M. Sewer gas: hydrogen sulfide intoxication. Clin Toxicol 1969;2:383-386.
Vannatta JB. Hydrogen sulfide poisoning: report of four cases and brief review of the literature. J Okla Med Assoc 1982;75:29-32.
Adelson L, Sunshine I. Fatal hydrogen sulfide intoxication: Report of three cases occurring in a sewer. Arch Pathol 1966;81:375-380.
Dalgaard JB, Dencker F, Fallentin В et al. Fatal poisoning and other health hazards connected with industrial fishing. Br J Ind Med 1972;29:307-316.
Beauchamp RO Jr, Bus JS, Popp JA et al. A critical review of the literature on hydrogen sulfide toxicity. CRC Crit Rev Toxicol 1984;13:25-97.
Hurwitz LJ, Taylor GI. Poisoning by sewer gas with unusual sequelae. Lancet 1954; 1:1110—1111.
Milby TH. Hydrogen sulfide intoxication: review of the literature and report of unusual accident resulting in two cases of nonfatal poisoning. J Occup Med 1962;4:431 — 437.
Smith RP, Gosselin RE. Hydrogen sulfide poisoning. J Occup Med 1979;21:93-97.
Nicholls P. The effect of sulphide on cytochrome a3, isosteric and allosteric shifts of the reduced alpha peak. Bi-ochim Biophys Acta 1975;396:24-35.
Winek CL, Collom WD, Wecht CH. Death from hydrogen sulphide fumes. Lancet 1968; 1:1096.
Evans L. The toxicity of hydrogen sulphide and other sulphides. Q J Exp Physiol 1967;52:231-248.
Simson RE, Simpson GR. Fatal hydrogen sulphide poisoning associated with industrial waste exposure. Med J Aust 1971;1:331-334.
Stine RJ, Slosberg B, Beacham BE. Hydrogen sulfide intoxication. A case report and discussion of treatment. Ann Intern Med 1976;85:756-758.
Burnett WW, King EG, Grace M et al. Hydrogen sulfide poisoning: review of 5 years experience. CMA J 1977;117:1277-1280.
Arnold IMF, Dufresne RM, Alleyne BC et al. Health implication of occupational exposures to hydrogen sulfide. J Occup Med 1985;27:373-376.
Gaitonde VB, Sellar RJ, O’Hare AE. Long term exposure to hydrogen sulphide producing subacute encephalopathy in a child. Br Med J 1987;294:614.
Matsuo F, Cummins JW, Anderson RE. Neurological sequelae of massive hydrogen sulfide inhalation. Arch Neurol 1979;36:451-452.
McAnalley BH, Lowry WT, Oliver RD et al. Determination of inorganic sulfide and cyanide in blood using specific ion electrodes. Application to the investigation of hydrogen sulfide and cyanide poisoning. J Anal Toxicol 1979;3:111-114.
Millar JD. NIOSH alert. Request for assistance in preventing deaths of farm workers in manure pits. DHHS (NIOSH) Publication No. 90-103, May, 1990.
Ravizza AG, Carugo D, Cerchiari EL et al. The treatment of hydrogen sulfide intoxication: oxygen versus nitrites. Vet Hum Toxicol 1982;24:241-242.
Kemper FD. A near fatal case of hydrogen sulfide poisoning. CMA J 1966;94:1130-1131.
Whitcraft DD III, Bailey TD, Hart GB. Hydrogen sulfide poisoning treated with hyperbaric oxygen. J Emerg Med 1985;3:23-25.
Smilkstein MJ, Bronstein AC, Pickett HM et al. Hyperbaric oxygen therapy for severe hydrogen sulfide poisoning. J Emerg Med 1985;3:27-30.
Beck JF, Bradbury CM, Connors AJ et al. Nitrite as an antidote for acute hydrogen sulfide intoxication? Am Ind Hyg Assoc J 1981;42:805-809.
Hoidal CR, Hall AH, Robinson MD et al. Hydrogen sulfide poisoning from toxic inhalations of roofing asphalt fumes. Ann Emerg Med 1986;15:826-830.
Marcus SM. Hydrogen sulfide. Clin Toxicol Rev 1983;5(4):1— 2.
Wright SP, Pottier ACW, Taylor JC, Normal LL, Anderson HR, Ramsey J D. Trends in deaths associated with volatile substances 1971 — 1989. London: St. George’s Hosp Med Sch 1991 ;337:548.
Breath of death. Lancet 1991 ;337:548 (editorial).
Flanagan RJ et al. Clinical toxicology of volatile substances. Drug Safety 1990;5:359-383.
Miller NS, Gold MS. Organic solvents and aerosols. An overview of abuse and dependence. Ann Clin Psych 1990;2:85-92.
Frenia ML, Schauben JL. Methanol inhalation toxicity. Ann Emerg Med 1993;22:1919-1923.
Troutman WG. Additional deaths associated with the intentional inhalation of typewriter correction fluid. Vet Hum Toxicol 1987;29:479.
Wodka RM, Jeong EWS. Cardiac effects of inhaled typewriter correction fluid. Ann Intern Med 1989;110:91 — 92.
Poklis A, Burkett CD. Gasoline sniffing: A review. Clin Toxicol 1977;11:35-41.
Edminister SC, Bayer MJ. Recreational gasoline sniffing: acute gasoline intoxication and latent organolead poisoning. Case reports and literature review. J Emerg Med 1985;3:365-370.
Sweeney B, Bingham RM, Amos RJ et al. Toxicity of bone marrow in dentists exposed to nitrous oxide. Br Med J 1985;291:567-569.
Gillman MA. Analgesic nitrous oxide for addictive withdrawal states. S Afr Med J !989;75:100—101.
Gillman MA. Haematological changes caused by nitrous oxide: cause for concern. Br J Anaesth 1987;59:143-146 (editorial).
Tenenbein M, Pillay N. Evoked potentials in clinically normal inhalant abusing adolescents. Vet Hum Toxicol 1990;32:343.
Askew GL, Finell L, Genese CA, Sorhage FE, Sosin DH, Spitalney КС. Boilerbaisser. An outbreak of methemoglobinemia in New Jersey in 1992. Pediatrics 1994;94:381-384.
Lu G, Yan-Sheng G. Acute nitrate poisoning. A report of 80 cases. Am J Emerg Med 1991;9:200-201.
Marshall JB, Eckland RE. Methemoglobinemia from overdose of nitroglycerin. JAMA 1980;244:330.
Gibson GR, Hunter JB, Raabe DS et al. Methemoglobinemia produced by high dose intravenous nitroglycerin. Ann Intern Med 1982;96:615-616.
SobrinoJM, Fernandez N, Martinez A, Pedrote A. Massive ingestion of isosorbid-5-mononitrate and nitroglycerin: suicide attempt by an adolescent girl without previous heart disease. Eur Heart J 1992;13:145.
Marietta MA: Nitric oxide, nitrovasodilators, and L-Ar-ginine — An unusual relationship. West J Med 1991;154:107-109.
Vallance P, Moncada S. Hypodynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991;337:776-778.
Griffith T, Randall M. Nitric oxide comes of age. Lancet 1989;2:875-876.
Svendsen JH, Klarlund K, Aldershrile J, Waldorff S. N-Acetylcysteine modifies the acute effects of isosorbid-5-mononitrate in angina pectoris patients evaluated by exercise testing. J Cardiovasc Pharmacol 1989;13:320-323.
Hogan JC, Lewis MJ, Henderson AH. N-acetylcysteine fails to attenuate haemodynamic tolerance to glyceryl trinitrate in healthy volunteers. Br J Clin Pharmac 1989;28:421-426.
Ehrenpreis ED, Young MA, Leikin JB. Symptomatic nitroglycerin toxicity from erroneous use of topical nitroglycerine. Vet Hum Toxicol 1990;32:138-139.
Abrams J. Pharmacology of nitroglycerin and long-acting nitrates. Am J Cardiol 1985;56:12A—18A.
Yano SS, Danish EH, Hsia YE. Transient methemoglobinemia with acidosis in infants. J Pediatr 1982; 100:415.
Chailoner KR, McCarron MM. Ammonium nitrate cold pack ingestion. J Emerg Med 1988;6:200-201.
Senecal PD, Dyer JE, Osterloh JD. Nitrate as a cause of decreased anion gap. Vet Hum Toxicol 1991 ;33:375.
Rodriguez FS, Santiyan MPM, Zamorano JDP. Evaluation of reagent strips for the rapid diagnosis of nitrite poisoning. J Anal Toxicol 1992; 16:63—64.
Baskurt OK. Acute hematologic and hemorheologic effects of sulfur dioxide inhalation. Arch Environ Health 1988;43:345-348.
Park CM, Nagel RL. Sulfhemoglobinemia. Clinical and molecular aspects. N Engl J Med 1984;310:1579-1584.
Sills MR, Zinkhaim WA. Methylene blue-induced Heinz body hemolytic anemia. Arch Pediatr Adolesc Med 1994;148:306-310.
Rom WN, ed. Environmental and occupational medicine. Boston: Little, Brown, 1983.
Last JM. Maxey-Roseman: public health and preventive medicine. 11th ed. New York: Appleton-Century-Crofts, 1980.
Klaassen CD, Amdun MO, Doull J, eds. Casarett and Doull’s toxicology: basic science of poisons. 3rd ed. New York: Macmillan, 1986.
Finkel AJ, ed. Hamilton and Hardy’s industrial toxicology, 4th ed. Boston: John Wright, 1983.
Key MM, Henschel AF, Butler J et al, eds. Occupational diseases. A guide to their recognition. Washington, DC: US Department of Health, Education and Welfare, US Government Printing Office, 1977.
Empey DW, Laitinen LA, Jacobs L et al. Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infections. Am Rev Respir Dis 1976;113:131-139.
Gannon PFG, Burge PS, Benfield GFA. Occupational asthma due to polyethylene shrink wrapping (paper wrapper’s asthma). Thorax 1992;47:759.
Richerson HB, Bernstein L, Fink JN, Hunninghake GW, Novey HS, Reed CE, Salvaggio JE, Schuyler MR, Schwartz HJ, Stechschulte DJ. Guidelines for the clinical evaluation of hypersensitivity pneumonitis. J Allergy Clin Immunol 1989;84:839-844.
Rose C, King ТЕ Jr. Controversies in hypersensitivity pneumonitis. Am Rev Respir Dis 1992;145:1-2.
Brinton WT, Vastbinder EE, Greene JW, Marx JJ Jr, Hutcheson RH, Schaffner W. An outbreak of organic dust toxic syndrome in a college fraternity. JAMA 1987;258:1210-1212.
Emanual DA, Wenzel FJ, Lawton BP. Pulmonary my-cotoxicosis. Chest 1975;67:293-297.
Van Essen S, Robins RA, Thompson AB, Rennard SI. Organic dust toxic syndrome: an acute febrile reaction to organic dust exposure distinct from hypersensitivity pneumonitis. Clin Toxicol 1990;128:389-426.
Yoshida K, Ando M, Araki S. Acute pulmonary edema in a storehouse of moldy oranges. A severe case of Organic Dust Toxic Syndrome. Arch Environ Health 1989;44:382-384.
Melinn M, McLaughlin H. Farmer’s lung: a three year survey and comparison of ELISA and CI EP techniques in antibody detection. Irish J Med Sci 1989; 158:173— 174.
Muller-Wening D, Repp H. Investigation on the protective value of breathing masks in Farmer’s Lung using an inhalation provocation test. Chest 1989;95:100— 105.
Malmberg P, Rask-Anderson A. Organic dust toxic syndrome. Semin Respir Med 1993;14:38-48.
Silicosis and Silicate Disease Committee. Diseases associated with exposure to silica and nonfibrous silicate minerals. Arch Pathol Lab Med 1988;112:673-720.
Kales SN. Case 35-1995. Weekly clinicopathological exercises. Case records of the Massachusetts General Hospital. N Engl J Med 1993;333:1340-1346.
Classification of Radiographs of the Pneumoconioses. Med Radiogr Photogr 1981 ;57:3,4,7,17.
Shepherd JD. Case 35-1995. Weekly clinicopathological exercises. Case records of the Massachusetts General Hospital. N Engl J Med 1993;333:1340-1346.
Lippmann M. Review. Asbestos exposure indices. Environ Res 1988;46:86-106.
Morgan RW, Foliart DE, Wong O. Asbestos and gastrointestinal cancer. A review of the literature. West J Med 1985;143:60-65.
Smith AH, Shearn VI, Wood R. Asbestos and kidney cancer. The evidence supports a causal association. Am J Ind Med 1989;16:159-166.
Ehrlich A, Gordon RE, Dikman SH. Carcinoma of the colon in asbestos-exposed workers: Analysis of asbestos content in colon tissue. Am J Ind Med 1991; 19:629— 636.
Anttila S, Kajalainen A, Taikino-aho O, Kyrronen P, Vainio H. Lung cancer in the lower lobe is associated with pulmonary asbestos fiber count and fiber size. Environ Health Perspect 1993;101:166-170.
Castellan RM, Olenchock SA, Kinsley KB, Hankinson JL. Inhaled endotoxin and decreased spirometric values. An exposure-response relation for cotton dust. N Engl J Med 1987;317:605-610.
Schachter EN, Kapp MC, Beck GJ, Maunder LR, Witek TJ. Smoking and cotton dust effects in cotton textile workers. Chest 1989;95:997-1003.
Milton DK, Godleski JJ, Feldman HA, Greaves IA. Toxicity of intratracheally instilled cotton dust, cellulose and endotoxin. Am Rev Respir Dis 1990;142:184-192.
Lippmann M. Man-made mineral fibers (MMME): human exposures and health risk assessment. Toxicol Ind Health 1990;6:225-246.
Marsh GM, Enterline PE, Stone RA, Henderson VL. Mortality among a cohort of US man made mineral fiber workers: 1985 follow-up. J Occup Med 1990;32:594— 604.
Miettinen OS, Rossiter CE. Man-made mineral fibers and lung cancer. Epidemiologic evidence regarding the causal hypothesis. Scand J Work Environ Health 1990;16:221-231.
Man-made mineral fibers. Environ Health Criteria No. 77; International Programme on Chemical Safety (IPCS), 1988.
Doll R. Symposium on MMMF Copenhagen, October 1986: Overview and conclusions. Am Occup Hyg 1987;31:805-819.
Seaton A. Management of the patient with occupational lung disease. Thorax 1994;49:627-628.
Michaelis НС, Clemens С, Kijewski Н, Newath Н, Eggert A. Acetonitrile serum concentrations and cyanide blood levels in a case of suicidal oral acetonitrile ingestion. Clin Toxicol 1991;29:447-458.
Pozzani UC, Carpenter CP, Palin PE, Weil CS, Nair JH HI, Spracuse MS. Mammalian toxicity of acetonitrile. J Occup Med 1959;1:634-642.
Turchen SG, Manoguerra AS, Whitney C. Severe cyanide poisoning from the ingestion of an acetonitrile-con-taining cosmetic. Am J Emerg Med 1991;9:264-267.
Rainey PM, Roberts WL. Diagnosis and misdiagnosis of poisoning with the cyanide precursor acentonitrile: nail polish remover or nail glue remover? Am J Emerg Med 1993;! 1:104—108.
Feierman DE, Cederbaum Al. Role of cytochrome P-450 11E1 and catalase in the oxidation of acetonitrile to cyanide. Chem Res Toxicol 1989;2:359-366.
Kurt TL, Day LC, Reed WG, Gandy W. Cyanide poisoning from glue-on-nail remover. Am J Emerg Med 1991;9:271-272.
Geller RJ, Ekins BR, Iknoian RC. Cyanide toxicity from acetonitrile-containing false nail remover. Am J Emerg Med 1991;9:268-270.
Caravati EM, LitovitzTL. Pediatric cyanide intoxication and death from an acetonitrile-containing cosmetic. JAMA 1988;260:3470-3473.
Jaeger A, Temper J D, Porte AD, Stoeckel L, Mantz JM. Acute voluntary intoxication by acetonitrile. Acta Pharmacol Toxicol (Suppl): 1977;41:340.
Swanson JR, Krasselt W. An acetonitrile related death. Proc Am Acad Forensic Sci, 44th Annual Meeting, New Orleans, February 17—22, 1992, p. 196.
Becker СЕ. The role of cyanide in fires. Vet Hum Toxicol 1985;27:487-490.
Clark CJ, Campbell D, Reid WH. Blood carboxyhaemoglobin and cyanide levels in fire survivors. Lancet 1981;1(8234):1332—1335.
Hall AH, Rumack BH. Hydroxocobalamin/sodium thiosulfate as a cyanide antidote. J Emerg Med 1987;5:115-121.
Hall AH, Kulig KW, Rumack BH. Suspected cyanide poisoning in smoke inhalation: complications of sodium nitrite therapy. J Toxicol Clin Exp 1989;9:3-9.
Hart GB, Strauss MB, Lennon PA, Whitcraft DD III. Treatment of smoke inhalation by hyperbaric oxygen. J Emerg Med 1985;3:211-215.
Kizer KW. Hyperbaric oxygen and cyanide poisoning. Am J Emerg Med 1984;2:113 (letter).
Symington IS, Anderson RA, Thomson I, Oliver JS, Harland WA, Kerr J W. Cyanide exposure in fires. Lancet 1978;2(8080):91 —92.
Agency for Toxic Substances and Disease Registry: Toxicological profile for cyanide. Oak Ridge, TN: Oak Ridge National Laboratory, 1989.
Environmental Protection Agency. Drinking water criteria document for cyanide. Cincinnati: Office of Health and Environmental Assessment, 1988.
Environmental Protection Agency. An exposure and risk assessment for cyanide. Washington, DC: Office of Water Regulations and Standards, 1981.
Amdur ML. Accidental group exposure to acetonitrile. J Occup Med 1959;1:627-633.
Garbois B. Fatal exposure to methyl cyanide. NY State Dept of Labor, Division of Industrial Hygiene Mon Rev 1955;34(2):7—8.
Willhite CC. Inhalation toxicology of acute exposures to aliphatic nitriles. Clin Toxicol 1981;18:991-1003.
Langvardt PW, Potzig CL, Braun WH. Identification of the major urinary metabolites of acrylonitrile in the rat. J Toxicol Environ Health 1980;6:273-282.
Sakurai H, Onodera M, Utsunomiya T et al. Health effects of acrylonitrile in acrylic fibre factories. Br J Ind Med 1978;35:219-222.
Butts WC, Kuehneman M, Widdowson GM. Automated method for determination of serum thiocyanate to distinguish smokers and non-smokers. Clin Chem 1974;20:1344-1348.
Tarkowski S. Studies in acrylonitrile effect on some properties of cytochrome oxidase. Med Pract 1968;19:525-530.
Magos L. A study of acrylonitrile poisoning in relation to methemoglobin — CN complex formation. Br J Ind Med 1962;19:283-286.
Wilson RH, McCormick WF. Plastics and rubbers. Elastomers and monomers. Ind Med Surg 1954;23:479— 486.
O’Berg MT. Epidemiologic study of workers exposed to acrylonitrile. J Occup Med 1980;22:245-252.
Delzell E, Monson RR. Mortality among rubber workers. VI. Man with potential exposure to acrylonitrile. J Occup Med 1982;24:767-769.
Fourth Annual Report on Carcinogens. Research Triangle Park, NC: National Toxicology Program, 1985, Publication 82-330.
Council on Scientific Affairs. Effects of toxic chemicals on the reproductive system. JAMA 1985;253:3431 — 3437.
Page NP, Cook B. Assessment of risk from exposure to acrylonitrile: the general approach used by a consultant. Sci Total Environ 1990;99:307-317.
Keough JP, Pestronek A, Wertheimer DS, Moreland R. An epidemic of urinary retention caused by dimethylaminopropionitrile. JAMA 1980;243:741-745.
Kreiss K, Wegman DH, Niles CA. Neurological dysfunction of the bladder in workers exposed to dimethylaminopropionitrile. JAMA 1980;243:741-745.
Hall AH, Rumack BH. Management of cyanide poisoning. Ann Emerg Med 1988;17:108-109.
Kirk MA, Gerace R, Kulig KW. Cyanide and methemoglobin kinetics in smoke inhalation victime treated with the cyanide antidote kit. Ann Emerg Med 1993;22:1413-1418.
Van Heijst ANP, Meredith TJ. Antidotes for cyanide poisoning. In: Volans GN, Sims J, Sullivan FM, Turner P, eds. Basic science in toxicology. London: Taylor & Francis, 1990; pp. 558—566.
Israeli A. Management of cyanide poisoning. Ann Emerg Med 1988;17:108.
Weger N. Aminophenole als Blausaure-antidote. Arch Toxikol 1968;14:49-50.
Kiese M, Weger N. Formation of ferrihaemoglobin with aminophenols in the human for treatment of cyanide poisoning. Eur J Pharmacol 1979;7:97-105.
Weger NP. Treatment of cyanide poisoning with 4-dimethylaminophenol (DMAP) — experimental and clinical overview. Fundam Appl Toxicol 1983;3:387-396.
Klimmek R, Krettek C, Szincicz L, Eyer P, Weger N. Effects and biotransformation of 4-dimethylaminophe-nol in man and dog. Arch Toxicol 1983;53:275-288.
Marrs TC. Antidotal treatment of acute cyanide poisoning. Adverse Drug React Acute Poisoning Rev 1988;4:179-206.
Van Dijk A, Glerum JH, Van Heijst ANP, Douze JMC. Clinical evaluation of the cyanide antagonist 4-DMAP in a lethal cyanide poisoning case. Vet Hum Toxicol 1987;39(Suppl 2):38—39.
Van Heijst ANP, Douze JMC, Van Kesteren RG, Van Bergen JEAM, Van Dijk A. Therapeutic problems in cyanide poisoning. Clin Toxicol 1987;25:383-398.
Persson H. Swedish Poison Information Center. Personal communication. July 19, 1990.
Meredith TJ, Jacobsen D, Haines JA, Berger J-C, Van Heijst ANP, eds. Antidotes for poisoning by cyanide: International Program on Chemical Safety/Commission of the European Communities. Cambridge University Press, 1993.
Langford RM, Armstrong RF. Algorithm for managing injury from smoke inhalation. Br Med J 1989;299:902— 905.
Clark CJ, Campbell D, Reid WH. Blood carboxyhemoglobin and cyanide levels in fire survivors. Lancet 1981;1:1332-1335.
Moertel CG, Fleming TR, Rubin J et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 1982;306:201-206.
Berumen U. Dog poisons man. JAMA 1983;249:353.
Graham DL, Laman D, Theodore J et al. Acute cyanide poisoning complicated by lactic acidosis and pulmonary edema. Arch Intern Med 1977;137:1051-1055.
Beamer WC, Shealy RM, Prough DS. Acute cyanide poisoning from Laetrile ingestion. Ann Emerg Med 1983;12:449-451.
Vesey CJ, Cole PV, Simpson PV. Cyanide and thiocyanate concentrations following sodium nitroprusside infusions in man. Br J Anaesth 1976;48:651-660.
Way JL. Cyanide intoxication and its mechanism of antagonism. Annu Rev Pharmacol Toxicol 1984;24:451 — 481.
Osintokun BD, Adenja AOG, Aladehoyinbo A. Free cyanide levels in tropical ataxic neuropathy. Lancet 1970;2:372-373.
Zerbe NF, Wagner BKJ. Use of vitamin B12 in the treatment and prevention of nitroprusside-induced cyanide toxicity. Crit Care Med 1993;21:465-467.
Rieves RD. Importance of symptoms in recognizing nitroprusside toxicity. South Med J 1984;77:1035-1037.
Blanc P, Hogan M, Mallin К et al. Cyanide intoxication among silver reclaiming workers. JAMA 1985;253:367— 371.
Ghawabi SH, Gadfar MA, El-Saharti AA et al. Chronic cyanide exposure: a clinical radioisotope and laboratory study. Br J Ind Med 1975;32:215-219.
TylleskarT, Legue FD, Peterson S, Kpizingui E, Stecker P. Konzo in the Central African Republic. Neurology 1994;44:959-961.
Drew RH. The use of hydroxocobalamin in the prophylaxis and treatment of nitroprusside-induced cyanide toxicity. Vet Hum Toxicol 1983;25:342-345.
Holzbecher M, Ellenberger HA. An evaluation and modification of a microdiffusion method for the emergency determination of blood cyanide. J Anal Toxicol 1985;9:251-253.
Fligner CL, Luthi R, Linkaityte E, Raisys VA. Paper strip method for detection of cyanide in blood using CY-ANTESNO test paper. Am J Forensic Med Pathol 1992;13:81-84.
LaForge M, Buneaur F, Hoveto P, Bourgeois F, Bourdon R, Levillein P. A rapid spectrophotometric blood cyanide determination applicable to emergency toxicology. J Anal Toxicol 1994;18:173-175.
Shusterman D, Hargis C. Surrogate laboratory measures of cyanide intoxication. Ann Emerg Med 1994;74:527— 538.
Rosenberg NL, Myers JA, Martin WRW. Cyanide-induced parkinsonism: clinical, MRI and 6-fluorodopa (FD) position emission tomography (PET) studies. Neurology 1988;38(Suppl l):203.
Kadushin FS, Bronstein AC, Riddle MW, Gilmore DA. Cyanide induced parkinsonism: Neuropsychology and radiological findings. Vet Hum Toxicol 1988;30:359.
Grandas F, Artieda J, Obeso J A. Clinical and CT scan findings in a case of cyanide intoxication. Movement Disorders 1989;4:188-193.
Rosenberg NL, Myers A, Martin WRW. Cyanide-induced parkinsonism: clinical, MRI and 6-fluorodopa PET studies. Neurology 1989;39:142-144.
Isom GE, Way JL. Effect of oxygen on cyanide intoxication. VI. Reactivation of cyanide-inhibited glucose metabolism. J Pharmacol Exp Ther 1974;189:235-243.
Litowitz TL, Larkin RF, Myers RAM. Cyanide poisoning treated with hyperbaric oxygen. Am J Emerg Med 1983;1:94-101.
Kizer KW. Hyperbaric oxygen and cyanide poisoning. Am J Emerg Med 1984;2:113.
Way JL. Cyanide antagonism. Fundam Appl Toxicol 1985;3:383-386.
Holmes RK, Way JL. Mechanism of cyanide antagonism by sodium nitrite. Pharmacologist 1982;24:182 (abstract 478).
Burrows GE, Way LJ. Antagonism of cyanide toxicity by phenoxybenzamine. Fed Proc 1976;35:533 (abstract 1805).
Vogel SN, Sultan TR. Cyanide poisoning. Clin Toxicol 1981;18:367-383.
Cotrell JE, Casthely P, Brodie JD et al. Prevention of nitroprusside induced cyanide toxicity with hydroxocobalamin. N Engl J Med 1978;298:809-811.
Dodds C, McKnight C. Cyanide toxicity after immersion and the hazards of dicobalt edetate. Br Med J 1985;291:785-786.
Nagler J, Provoost RA, Parizel G. Hydrogen cyanide poisoning. Treatment with cobalt EDTA. J Occup Med 1978;20:414-416.
Kunkel DB. Cyanide: looking for the source. Emerg Med 1987;19(9):115-125.
Willhite CC. Inhalation toxicology of acute exposure to aliphatic nitriles. Clin Toxicol 1981;18:991-1003.
Caravati EM, LitovitzTL. Pediatric cyanide intoxication and death from an acetonitrile-containing cosmetic. JAMA 1988;260:3470-3473.
Turchen SG, Managuera AS. Severe cyanide poisoning following suicidal ingestion of acetonitrile. Vet Hum Toxicol 1989:31:351.
Boggild MD, Peck RW, Tomson CRF. Acetonitrile ingestion delayed onset of cyanide poisoning due to concurrent ingestion of acetone. Postgrad Med J 1990;66:40-41.
Kirk MK, Voorhees SL, Kulig R, Rumack BH. Cyanide leverls after acetonitrile exposure. An in-vitro study. Ann Emerg Med 1990; 19:628.
Geller RJ, Ekins BR, Iknoian RC. Cyanide toxicity from acetonitrile-containing false nail remover. Am J Emerg Med 1991;9:268-270.
Kurt T, Day LC, Reed WG, Gandy W. Cyanide poisoning from glue on nail remover. Am J Emerg Med 1991;9:271-272.
Bismuth C, Baud FJ, Djeghout H, Astier A, Aubriot D. Cyanide poisoning from propionitrile exposure. J Emerg Med 1987;5:191-195.
Vogel RA, Kirkendall KM. Acrylonitrile (vinyl cyanide) poisoning: a case report. Texas Med 1984;80:48-51.
Scolnick B, Hamel D, Woolf AD. Successful treatment of lifethreatening propionitrile exposure with sodium ni-trite/sodium thiosulfate followed by hyperbaric oxygen. J Occup Med 1993;35:577-580.
Hryhorczuk DO, Aks SE, Turk JW. Unusual occupational toxics. Occup Med State of the Art Reviews 1992;7:567-586.
Michaelis HC, Clemens C, Kijewski H, Newath H, Eggert A. Acetonitrile serum concentrations and cyanide blood levels in a case of suicidal oral acetonitrile ingestion. Clin Toxicol 1991;29:447-458.
Geller RJ, Ekins BR, Iknoian RC. Cyanide toxicity from acetonitrile-containing false nail remover. Am J Emerg Med 1991;9:268-270.
Winter ML, Nelson DA, Snodgrass WR. Industrial exposure to acetone cyanohydrine. Delayed onset cyanide toxicity. Vet Hum Toxicol 1989;31:354.
Westlake EK, Simpson Т, Kaye М. Carbon dioxide narcosis in emphysema. Quart J Med 1955;24:155-172.
National Institute for Occupational Safety and Health. Criteria for a recommended standard. Occupational exposure to carbon dioxide. DHEW (NIOSH) Publication No. 76-194; pp. 67-72, 114-116. Washington, DC: US Government Printing Office, 1976.
Razis PA. Carbon dioxide — a survey of its use in anaesthesia in the UK. Anaesthesia 1989;44:348-351.
McGrath BJ, Zimmerman JE, Williams JF, Parmet J. Carbon dioxide embolism treated with hyperbaric oxygen. Can J Anaesth 1989;36:586-589.
Baxter PJ, Kapila M, Mfonfu D. Lake Nyos disaster, Cameroon, 1986: the medical effects of large scale emission of carbon dioxide. Br Med J 1989;298:1437-1441.
Key MM, Henschel AF, Butler J, Ligo RN, Tabershaw 1R, eds. Occupational diseases. A guide to their Recognition. Rev. edition. June 1977. DHEW (NIOSH) Publication No. 77-181. Washington, DC: Superintendent of Documents USGPO, pp. 415—417.
Slonim NB, Hamilton LH. Respiratory physiology. 2nd ed. St. Louis: CV Mosby, 1971; pp. 16—25, 76—89, 207-210.
Proctor NH, Hughes JP, Fischman ML. Chemical hazards of the workplace. 2nd ed. New York: Van Nostrand Reinhold, 1989; pp. 119-120.
Johnston RF. The syndrome of carbon dioxide intoxication. Its etiology, diagnosis and treatment. Univ Mich Med Bull 1959;25:280-292.
Davidon М, Feinleib М. Carbon disulfide poisoning: а review. Am Heart J 1972;83:100— 114.
Goroy ST, Trumper M. Carbon disulfide poisoning. JAMA 1938;110:1543-1549.
Feldman RG, Ricks NL, Baker EL. Neuropsychological effects of industrial toxins: a review. Am J Ind Med 1980;1:211-227.
Foreman W. Notes of a fetal case of poisoning by bisulphide of carbon with post-mortem appearances and remarks. Lancet 1886;2:118—119.
Teisinger J, Soucek B. Absorption and elimination of carbon disulfide in man. J Ind Hyg Toxicol 1949;31:67-73.
Cohen AE, Scheel LD, Kopp JF et al. Biochemical mechanisms in chronic carbon disulfide poisoning. Am Ind Hyg Assoc J 1959;20:303-323.
Kleinfeld M, Tabershaw IR. Carbon disulfide poisoning. Report of two cases. JAMA 1955;159:677-679.
Corsi A, Maestrelli P, Picotti G etal. Chronic peripheral neuropathy in workers with previous exposure to carbon disulfide. Br J Ind Med 1983;40:209-211.
Partanen T. Coronary heart disease among workers exposed to carbon disulfide. Br J Ind Med 1970;27:313— 325.
Ratney RS, Wegman DH, Elkins HB. In vivo conversion of methylene chloride to carbon monoxide. Arch Environ Health 1974;28:223-236.
Lawwerys RR. Industrial chemical exposure: guidelines for biological monitoring. Davis, CA: Biomedical Publications, 1983, p. 83.
Fagin J, Bradley J, Williams D. Carbon monoxide poisoning secondary to inhaling methylene chloride. Br Med J 1980;281:1461.
Di Vincenzo GD, Kaplan CJ. Effect of exercise or smoking on the uptake, metabolism and excretion of methylene chloride vapor. Toxicol Appl Pharmacol 1981;59:141-148.
Stewart RD, Dodd HC. Absorption of carbon tetrachloride, trichloroethylene, tetrachloroethylene, methylene chloride and 1,1,1-trichloroethane through the human skin. Am Ind Hyg Assoc J 1964;25:439-446.
Di Vincenzo GD, Kaplan CJ. Uptake, metabolism and elimination of methylene chloride vapors by humans. Toxicol Appl Pharmacol 1981;59:130-140.
Steward RD, Fisher TN, Hosko MJ et al. Carboxyhemoglobin elevation after exposure to dichloromethane. Science 1972;176:295-296.
Friedlander BR, Hearne T, Hall S. Epidemiologic investigation of employees exposed to methylene chloride. Mortality analysis. J Occup Med 1973;20:657-666.
Langehennig PL, Seeler RA, Berman E. Paint removers and carboxyhemoglobin. N Engl J Med 1976;295:1137.
Stewart RD, Hake CC. Paint remover hazard. JAMA 1976;235:398-401.
Hall AH, Mountain R, Kulig KW et al. Methylene chloride poisoning without significantly elevated carboxyhemoglobin level. Vet Hum Toxicol 1986;28:482-483 (abstract).
Mavalankar DV. Indoor air pollution in developing countries. Lancet 1991;1:358-359.
Behera D, Dash S, Malik SK. Blood carboxyhaemoglobin levels following acute exposure to smoke of biomass fuel. Indian J Med Res 1988;88:522-524.
Peterson JE, Steward RD. Absorption and elimination of carbon monoxide by inactive young men. Arch Environ Health 1970;21:165-171.
Longo LD. Carbon monoxide effects on oxygenation of the fetus in utero. Science 1976;194:523-525.
Longo LD. The biological effects of carbon monoxide on the pregnant woman, fetus, and newborn infant. Am J Obstet Gynecol 1977;129:69-103.
Singh J, Scott U. Threshold for carbon monoxide induced fetotoxicity. Teratology 1984;30:253-257.
Venning H, Robertson D, Milner AD. Carbon monoxide poisoning in an infant. Br Med J 1982;284:651.
Muller GL, Graham S. Intrauterine death of the fetus due to accidental carbon monoxide poisoning. N Engl J Med 1995;252:1075-1078.
Goldstein DP. Carbon monoxide poisoning in pregnancy. Am J Obstet Gyencol 1965;9:526-528.
Cramer CR. Fetal death due to accidental maternal carbon monoxide poisoning. J Toxicol Clin Toxicol 1982;19:297-301.
Margulies JL. Acute carbon monoxide poisoning during pregnancy. Am J Emerg Med 1986;4:516-519.
De Haas JH. Parental smoking. Its effect on fetus and • child health. Eur J Obstet Gynecol Reprod Biol 1975;5:283-296.
Harrison KL, Robinson AG. The effect of maternal smoking on carboxyhemoglobin levels and acid-base balance of fetus. Clin Toxicol 1981;18:165-168.
Coburn RF. Mechanisms of carbon monoxide toxicity. Prev Med 1979;8:310-322.
Meyers RAM, Lindberg SE, Crowley RA et al. Carbon monoxide poisoning. The injury and its treatment. JACEP 1979;8:479-484.
Opeskin K, Drummer OA. Delayed death following carbon monoxide poisoning. A case report. Am J Forens Med Pathol 1994;15:36-39.
Thorpe T. Chronic carbon monoxide poisoning. Can J Psychiatry 1994;39:59-61.
Lowe-Pohsford FL, Henry JA. Clinical aspects of carbon monoxide. Adverse Drug React Acute Pois Rev 1989;8:212-220.
Atkins EH, Baker EL. Exacerbation of coronary artery disease by occupational carbon monoxide exposure: a report of two fatalities and a review of the literature. Am J Ind Med 1985;7:73-79.
Fawcett TA, Moon RE, Fracica PJ, Mebane GY, Theil DR, Piantadosi LA. Warehouse worker’s headache. Carbon monoxide poisoning from propane-fueled forklifts. J Occup Med 1992;34:12-15.
Balzan M, Cacciottolo JM, Casha S. Intestinal infarction following carbon monoxide poisoning. Postgrad Med J 1993;69:302-303.
Sanchez R, Fosarelli P, Felt B, Greene M, Lacovara J, Hachett F. Carbon monoxide poisoning due to automobile exposure: disparity between carboxyhemoglobin levels and symptoms of victims. Pediatrics 1988;82:663— 666.
Hyperbaric Center Advisory Committee Emergency Medical Service, City of New York. A registry for carbon monoxide poisoning in New York City. Clin Toxicol 1988;26:417-441.
Anderson R, Allensworth DC, De Groot WJ. Myocardial toxicity from carbon monoxide poisoning. Ann Intern Med 1967;67:1172-1182.
Sone S, Higoshihari T, Kotake T et al. Pulmonary manifestations in acute carbon monoxide poisoning. Am J Roentgenol 1974;120:865-871.
Sawada Y, Takahashi M, Ohashi N et al. Computerized tomography as an indication of long term outcome after acute carbon monoxide poisoning. Lancet 1980;l:783— 784.
KanagaN, Imaizumi H, Nakayana M, Nagai H, Yamaya K, Namiki A. The utility of MRI in acute stage of carbon monoxide poisoning. Intensive Care Med 1992;18:371 — 372.
Chiulli DA, Rivers EP, Kristal S, Smithline HA, Blake H, Reiser E et al. Metabolic abnormalities in patients with severe carbon monoxide poisoning: insights into pathophysiology. Ann Emerg Med 1992;22:180.
Watcha MF, Conner MT, Hing AV. Pulse oximetry in methemoglobinemia. AJDC 1989;143:845-847.
Yelderman M, New W. Evaluation of pulse oximetry. Anesthesiology 1983;59:349-352.
Ralston AC, Webb RK, Runciman WB. Potential errors in pulse oximetry. I. Pulse oximeter evaluation. Anaesthesia 1991;46:202-206.
Webb RK, Ralston AC, Runciman WB. Potential errors in pulse oximetry. II. Effects of changes in saturation and signal quality. Anaesthesia 1991;46:207-212.
Ralston AC, Webb RK, Runciman WB. Potential errors in pulse oximetry. Ill. Effects of interference dyes, dys-haemoglobins and other pigments. Anaesthesia 1991;46:291-295.
Gordon Kill. Pulse oximetry in emergency medicine. West J Med 1989; 151:67.
Battito MF. The effect of fingerprinting ink on pulse oximetry. Anesth Analg 1989;69:260-269.
Schiller MS, Unger RJ, Kelner MJ. Effects of intravenously administered dyes on pulse oximetry readings. Anesthesiology 1986; 65:5 50—552.
Jennis MS, Peabody JL. Pulse oximetry: an alternative method for the assessment of oxygenation in newborn infants. Pediatrics 1987;79:524-528.
Barker SJ, Tremper KK. The effects of carbon monoxide inhalation on pulse oximetry and transcutaneous PO2. Anesthesiology 1987;66:677-679.
Alexander CM, Teller LE, Gross JB. Principles of pulse oximetry: theoretical and practical considerations. Anesth Analg 1989;68:368-376.
Kessler MR, Side T, Humayun B, Poppers PJ. Spurious pulse oximeter desaturation with methylene blue injection. Anesthesiology 1986;65:435-436.
Miyasaka K, Ohata J. Burn erosion, and "sun" tan with the use of pulse oximetry in infants. Anesthesiology 1987;67:1008-1009.
Sloan ТВ. Finger injury by an oxygen saturation monitor probe. Anesthesiology 1988;68:936-938.
Murphy KG, Secunda JA, Rockoff MA. Severe burns from a pulse oximeter. Anesthesiology 1990;73:350-352.
Myers RAM, Snyder SK, Linberg S et al. Value of hyperbaric oxygen in suspected carbon monoxide poisoning. JAMA 1981;246:2478-2480.
Neubauer RA. Carbon monoxide and hyperbaric oxygen. Arch Intern Med 1979; 139:829.
Olson KR. Carbon monoxide poisoning: mechanism, presentation and controversies in management. J Emerg Med 1984;1:233-243.
Kumar S. Hyperbaric oxygen in treatment of carbon monoxide poisoning. Br Med J 1984;289:1315.
Myers RAM, Messier LD, Jones DW et al. New directions in the research and treatment of carbon monoxide exposure. Am J Emerg Med 1983;2:226-230.
Myers RAM, Snyder SK, EmhoffTA. Subacute sequelae of carbon monoxide poisoning. Ann Emerg Med 1985;14:1163-1167.
Matthieu D, Wolf M, Durocher A et al. Acute carbon monoxide poisoning. Risk of late sequelae and treatment by hyperbaric oxygen. Clin Toxicol 1985;23:315-324.
Min SK. A brain syndrome associated with delayed neuropsychiatric sequelae following acute carbon monoxide intoxication. Acta Psychiatr Scand 1986;73:80-86.
Ginsburg R, Pomano J. Carbon monoxide encephalopathy: need for appropriate treatment. Am J Psychiatry 1976;133:317-320.
Kanaya N, Imaizuni H, Nakayana M, Nagai H, Yamaya K, Niniki A. The utility of MRI in acute stage of carbon monoxide poisoning. Intensive Care Med 1992; 18:371 — 372.
Raphael J-C, Elkharrat D, Jars-Guincertie M-C, Chas-tung C, Charles V, Verchen J-B, Gajdos P. Trial of nor-mobaric and hyperbaric oxygen for acute carbon monoxide intoxication. Lancet 1989;2:414-419.
Van Hoesen KB, Camporesi EM, Moon RE, Hage ML, Piantadosi CA. Should hyperbaric oxygen be used to treat the pregnant patient for acute carbon monoxide poisoning? A case report and literature review. JAMA 1989;261:1039-1043.
Raphael J-C, Elharrat D, Jars-Guincestre M-C, Chastang C, Chasles V, Vercken J-P et al. Trial of nor-mobaric and hyperbaric oxygen for acute carbon monoxide intoxication. Lancet 1989;2:414-419.
Goulon M, Barois A, Rapin M, Nouailhat F, Grosbuis S, Labrousse J. Carbon monoxide poisoning and acute anoxia. J Hyperbar Med 1986;1:23-41.
Thom SR, Tabe Rl, Mendiguren 11, Clark JM, Hardy KR, Fisher AR. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. Ann Emerg Med 1995;25:474— 480.
Broome JR, Sykes JJW, Francis TJR, Tighe SQM, Ert-monstone WM, Clark RJ. Hyperbaric oxygen for carbon monoxide poisoning. Lancet 1990;335:549-550.
Grim PS, Gottlieb LJ, Boddie A, Batson E. Hyperbaric oxygen therapy. JAMA 1990;263:2216-2220.
Ingle R. Hyperbaric oxygen therapy. JAMA 1990;764:1811.
Kindwall ER, McQuilen MP, Khatri BO, Gruchow HW, Kindwall ML. Treatment of multiple sclerosis with hyperbaric oxygen. Results of a National Registry. Arch Neurol 1991;48:195-199.
Sloan EP, Murphy DG, Hast R, Crope MA, Turnbull T, Barrea RS, Ellerson B. Complications and protocol considerations in carbon monoxide poisoned patients who require hyperbaric oxygen therapy: report for a ten-year experience. Ann Emerg Med 1989;18:629-634.
Krenzelok EP, Full R, Roth R. Carbon monoxide. The silent killer with an audible slution. Clin Toxicol 1995;33:475-486 (abstract 132).
Smith AG. Toxicology of the lung. Hum Exper Toxicol 1993;12:415-416.
Wheeldon EB. Mechanism of lung toxicity. Proc Br Toxicol Soc, September 1992. Hum Exper Toxicol 1993;12:419.
Witschi H, Oreffo V, Pinherton KE. Cell types and their importance in pulmonary toxicology. In: Volans GN, Sims J, Sullivan FM, Turner P, eds. Basic science In toxicology. London: Taylor & Francis, 1990.
Dobbs LG, Williams MC, Gonzalez C. Biochimica Bi-ophysica Acta 1988;970:146-156.
Hansen K, Mossman B. Generation of superoxide from alveolar macrophages exposed to asbestiform and non fibrous particles. Cancer Research 1987; 47: 1681 — 1686.
Schoenberger Cl, Hunninghake GW, Kawanami O, Fer-rans VJ, Crystal RG. Role of alveolar macrophages in asbestosis: modulation of neutrophil migration to the lung after acute asbestos exposure. Thorax 1983;37:803-809.
Moldeus P, Cotgreave 1. Mechanisms of endothelial lung damage. In: Volans GN, Sims J, Sullivan FM, Turner P, eds. Basis science in toxicology. London: Taylor & Francis, 1990, pp. 242—249.
James DG. Respiratory disease. Postgrad Med J 1992;68:160-173.
Sangster B, Meulenbelt J. Acute pulmonary intoxications. Overview and practical guidelines. Netherlands J Med 1988;33:91-100.
Cooper JAD Jr, Matthay RA. Drug-induced pulmonary disease. Dis Mon 1987;33:61-122 (Chicago: Year Book).
Smith LL, Cohen GM, Aldridge WN. Morphological and biochemical correlation of chemical-induced injury to the lung. Arch Toxicol 1986;58:214-218.
Technical Progress on Protecting the Ozone Layer Electronics, Degreasing and Dry Cleaning Solvents Technical Options Report. United Nations Environment Programme. June 30, 1989.
US EPA Future Concentrations of Stratospheric Chlorine and Bromine, July 1988.
Scientific Assessment of Stratospheric Ozone, 1989. Volume II. Appendix: Alternative Fluorocarbon or Environmental Acceptability Study (AFEAS). World Meteorological Organization. Global Ozone Research and Monitoring Project. Report No 20. National Aeronautics and Space Administration, United Kingdom and United Nations.
Browne MW. Ozone hole reopens over Antarctica. New York Times, October 12, 1990.
Profitt MH, Martitan JJ, Kelly KK, Loewenstein M, Podolske JR, Chan KR. Ozone loss in the Arctic polar vertex inferred from high-altitude aircraft measurements. Nature 1990;347:31-36.
Broad WJ. Some say the rocket’s red glare is eating away at the ozone layer. New York Times, May 14, 1991.
Logan M, Farmer JG. Anaesthesia and the ozone layer. Br J Anaesth 1989;63:645-647.
Lyles WB, Greve KW, Bauer RM, Ware MC, Scharans-mke CJ, Crouch J et al. Sick building syndrome. South Med J 1991;84:65-71.
Norback D, Michel I, Widstron J. Indoor air quality and personal factors related to the sick building syndrome. Scand J Work Environ Health 1990;16:121-128.
Boxer PA. Indoor air quality. A psychosocial perspective. J Occup Med 1990;32:425-428.
Hicks JB. Tight building syndrome: when work makes you sick. Occup Health Saf 1984;53:51-56.
Brooks BO, Utter GM, De Broy JA, Schinke RD. Indoor air pollution: an edifice complete. Clin Toxicol 1991;29:315-374.
Quinlan P, Macher JM, Alevantis LE, Cone JE. Protocol for the comprehensive evaluation of a building-associated illness. In: Occupational medicine: state of the art reviews. Philadelphia: Hanley & Belfus, 1989;4:771-797.
Woods JE. Cost avoidance and productivity in owning and operating buildings. In Cone JE, Hodgson MJ, eds. Problem buildings: building-associated illness and the sick building syndrome. Occup Med Soc Art Rev 1989;4:753-770.
Angle C. Indoor air pollutants. Adv Pediatr 1988;35:239-280.
Arundel A, Sterling E, Biggen J, Sterling T. Indirect health effects of relative humidity in indoor environments. Environ Health Perspect 1986;351—361.
Koenig JD, Pierson WE. Air pollutants and the respiratory system. Toxicity and pharmacologic interventions. Clin Toxicol 1991;29:40-41.
Boulet L. Increases in airway responsiveness following acute exposure to respiratory irritants. Reactive airway dysfunction syndrome or occupational asthma? Chest 1988;94:476-481.
Mahoney M, Lakhani A, Stephens A, Wallace JG, Youngs ER, Harper D. Legionnaire’s disease and the sick building syndrome. Epidemiol Infect 1989; 103:285.
Norback D, Ediing C. Environmental, occupational and personal factors related to the prevalence of sick building syndrome in the general population. Br J Ind Med 1991;48:451-462.
Samet JM, Marbury MC, Spengler JD. Health effects and sources of indoor air pollution. Part I. Am Rev Respir Dis 1987;136:1486-1508.
Building Air Quality. A Guide for Building Owners and Facility Managers. US Environmental Protection Agency, Indoor Air Division and National Institute for Occupational Safety and Health. Washington, DC: US Government Printing Office, December 1991.
Cone JE. Building associated illness and the tight building syndrome. San Francisco General Hospital, August 1982.
Samet JM, Marbury MC, Spengler JD. Health effects and sources of indoor air pollution. Part II. Am Rev Respir Dis 1988;137:221-242.
American Society of Heating, Refrigeration and Air Conditioning Engineers. Ventilation for Acceptable Indoor Air Quality. ASHRAE Standard 62, 1989; Atlanta, GA. ASHRAE, 1989.
Sim MR, Abramson MJ. Indoor air quality and sick buildings. Med J Aust 1991,155:651—652.
Samet JM, Spengler JD, eds. Indoor Air Pollution: a Health Perspective. Baltimore: Johns Hopkins University Press, 1991; p. 407.
Wyon D. The effects of moderate heat stress on typewriting performance. Ergonomics 1974;17:309-318.
Koren HS, Graham DE, Devlin RB. Exposure of humans to a volatile organic mixture. HI. Inflammatory response. Arch Environ Health 1992;74:39—44.
Kreiss K. The epidemiology of building-related complaints and illness. Occup Med 1989;4:575-592.
Brandt-Rauf PW, Andrews LR, Schwarz-Miles J. Sick hospital syndrome. J Occup Med 1991;33:737-739.
Goldstein E, Hackney JD, Rokaw SN. Photochemical air pollution. Part 1. West J Med 1985;142:369-376.
De Nevers N. Community air pollution. In: Rom WN, ed. Environmental and occupational medicine. Boston: Little, Brown, 1983, pp. 797—810.
Logan WPD. Mortality in the London fog incident 1952. Lancet 1953;1:336-338.
Summer Olympics to be under ozone cloud. JAMA 1981 ;246:202 (editorial).
Hackney J D, Linn WS, Buckley Rd et al. Vitamin E supplementation and repiratory effects of ozone in humans. J Toxicol Environ Health 1981;7:383-390.
French JG, Lowrimore G, Nelson WC et al. The effect of sulfur dioxide and suspended sulfates on acute respiratory disease. Arch Environ Health 1973;27:129-133.
Schlessinger RB. Comparative irritant potency of inhaled sulfate aerosols. Effects on bronchial mucociliary clearance. Environ Res 1984;34:268-279.
Buechley RW, Riggan WB, Hasselblad V. Sulfur dioxide levels and perturbations in mortality: a study of New York-New Jersey metropolis. Arch Environ Health 1973;27:134-137.
Chapman RS, Calafiore DC, Hasselblad V. Prevalence of persistent cough and phlegm in young adults in relation to long-term ambient sulfur dioxide exposure. Am Rev Respir Dis 1985;132:261-267.
McDonnel WF, Horstman DH, Hazucha MJ et al. Pulmonary effects of ozone exposure during exercise: doseresponse characteristics. J Appl Physiol 1983;54:1345— 1352.
Dungworth D, Goldstein E, Ricci PF. Photochemical air polution. Part II. West J Med 1985;142:523-531.
Acid-rain and human health. Lancet 1985;1:616-618 (editorial).
Abelson PH. Air pollution and acid rain. Science 1985;230:617.
Hallowell М. Acute haemolytic anemia following ingestion of paradichlorobenzene. Arch Dis Child 1959;34:74-75.
Agency for Toxic Substance Disease Registry. US Public Health Service. Toxicological profile for 1,4-dichlo-robenzene. January 1989. ATSDR/TP-88/14.
Part 1910. Occupational Safety and Health Standards. Subpart Z — Toxic and Hazardous Substances 695 to 702-0-30.
Ducatman AM, Prader-Willi. Syndrome and paternal hydrocarbon exposure. Lancet 1988;!:646.
Cherry NM, Labreche FP, McDonald JC. Organic brain damage and occupational solvent exposure. Br J Ind Med 1992;49:776-781.
Seaton A, Jellinek EH, Kennedy P. Major neurological disease and occupational exposure to organic solvents. Q J Med 1992;84:707-712.
Seedorff L, Olsen E. Exposure to organic solvents. I. A survey on the use of solvents. An Occup Hyg 1990;34:371-378.
Stewart RD, Hake CL, Peterson JE. "Degreaser's flush" dermal response to trichloroethylene and ethanol. Arch Environ Health 1974;29:1-5.
Grasso P, Sharra M, Davies DM, Irwin D. Neurophysiological and psychological disorders and occupational exposure to organic solvents. Ed Chem Toxicol 1984;22:819-852.
Errebo-Knudsen EO, Olsen F. Organic solvents and presenile dementia (The Painter’s Syndrome). A critical review of the Danish literature. Sci Total Environ 1986;48:45-67.
Bolla KI, Schwartz BX, Agnew J, Ford PD, Blecker ML. Subclinical neuropsychiatric effects of chronic low-level solvent exposure in US pain manufacturers. J Occup Med 1990;32:676-677.
Daniell WE, Couser WG, Rosenstock L. Occupational solvent exposure and glomerulonephritis. A case report and review of the literature. JAMA 1988;259:2280— 2283.
Narvarte J, Saba SR, Ramirez G. Occupational exposure to organic solvents causing chronic tubulointerstitial nephritis. Arch Intern Med 1989;149:155-158.
Nelson NA, Robins TG, Port FK. Solvent nephrotoxicity in humans and experimental animals. Am J Nephrol 1990;10:10-20.
Harrington JM, Whitby W, Gray CN, Reid FJ, Aw TC, Waterhouse JA. Renal disease and occupation exposure to organic solvents: a case report approach. Br J Ind Med 1989;46:643-650.
Laass W. Therapy of acute oral poisonings by organic solvents. Treatment by activated charcoal in combination with laxatives. Arch Toxicol Suppl 1980;4:406-409.
Moosa MR, Jansen J, Edelstein CL. Treatment of methyl bromide proisoning with hemodialysis. Postgrad Med J 1994;20:733-735.
Wabeke R, Weinstein R, Letz G. Polychlorinated biphenyl toxicity. Case studies in Environmental Medicine. 12. Agency for Toxic Substances and Disease Registry, June 1990.
Agency for Toxic Substances and Disease Registry. Toxicological Profile for Chlorinated Dibenzofurans Draft. US Department of Health and Human Services. October 1992.
Pott Р. Chirurgical observations relative to the cataract, the polypus of the nose, the cancer of the scrotum, the different kinds of ruptures, and the mortification of the toes and feet. London: Hawkes, Clark and Collins, 1775.
Sherson D, Sabro P, Sigsgaard T, Johansen F, Acetrup H. Biological monitoring of foundry workers exposed to polycyclic aromatic hydrocarbons. Br J Ind Med 1990;47:448-453.
Buckley TJ, Lioy PJ. An examination of the time course from human dietary exposure to polycyclic aromatic hydrocarbons to urinary elimination of 1-hydroxy pyrene. Br J Ind Med 1992;49:113-124.
Zedeck MS. Polycyclic aromatic hydrocarbons: a review. J Environ Pathol Toxicol 1980;3:537-567.
Brudzewski J, Shusterman D. Polynuclear aromatic hydrocarbons (PAH) toxicity. Agency for Toxic Substances and Disease Registry. Atlanta. US Department of Health and Human Services, June 1990.
Landrigan PJ. Health risks of creosotes. JAMA 1993;209:1309.
Karlehagen S, Andersen A, Ohlson C-G. Cancer incidence among creosote exposed workers. Scand J Work Environ Health 1992;18:26-29.
Agency for Toxic Substances and Disease Registry. Toxicological Profile for Creosote. Atlanta, GA. Dept of Health and Human Services, Public Health Service, 1990; Publication TP 90-09.
Henson EV. Cresols, creosote and derivatives. In Parmeggiani L, ed. Encyclopaedia of occupational health and safety. 3rd (revised) ed. Geneva: International Labour Office, 1991; pp. 569—570.
Juntumen J, Kaste М, Markovan Н. Cerebral convulsions after enflurane anaesthesia and occupational exposure to tetrahydrofuran. J Neurol Neurosurg Psychiatry 1984;47:1258-1259.
Occupational Exposure Limits for Airborne Toxic Substances. 3rd ed. Geneva: International Labour Office, 1991; pp. 382-383.
Garnier R, Rosenberg N, Puissant JM, Chauvet JP, Efthymious ML. Tetrahydrofuran poisoning after occupational exposure. Br J Ind Med 1989;46:677-678.
Viader F, Lechevalier B, Morin P. Polynevrite toxique chez un travailleur du plastique. Role possible du methyl-ethyl-cetone. Presse Med 1975;4:1813-1815.
Stoughton RW, Robbins BH. The anesthetic properties of tetrahydrofuran. J Pharmacol Exp Ther 1936;58:171 — 173.
Klunk WE, McKeon AC, Covey DF, Farrendelli JA. Alpha substituted gamma-butyrolactones: new class of anticonvulsant drugs. Science 1982;217:1040-1042.
Moody DE. The effect of tetrahydrofuran on biological system: does a hepatotoxic potential exist? Drug Chem Toxicol 1991;14:319-342.
Elovaara E, Pfaffli P, Savolainen H. Burden and biochemical effects of extended tetrahydrofuran vapour inhalation of three concentration levels. Acta Pharmacol Toxicol 1984;54:221-226.
Nagata T, Hara M, Kageura M, Hara K, Kimura K. A fatal case of tetrahydrofuran poisoning. In Maes RAA, ed. Topics in forensic and analytic toxicology. Amsterdam: Elsevier, 1984; pp. 33—37.
Ong CN, Chia SE, Phoon WH, Tan KT. Biological monitoring of occupational exposure to tetrahydrofuran. Br J Ind Med 1991;48:616-621.
Cyclohexanone. Occupational Safety and Health Guidelines for Chemical Hazards. Cincinnati, OH: US Dept Health and Human Services. DHHS (NIOSH) Publication No. 89-104, Supplement II-OHG.
Sakata M, Kikuchi J, Haga M. Disposition of acetone, methyl ethyl ketone and cyclohexanone in acute poisoning. Clin Toxicol 1989;27:67-77.
Mills GA, Walker V. Urinary excretion of cyclohexanediol, a metabolite of solvent cyclohexanone, by infants in a special care unit. Clin Chem 1990;36:870-874.
DeetzJS, LuehrCA, Vallee BL. Human liver alcohol dehydrogenase isozymes: reduction of aldehydes and ketones. Biochemistry 1984;23:6822-6828.
Stave U. Liver enzymes. In: Stave U, Weech AA, eds Perinatal physiology. New York: Plenum Medical, 1978; pp. 499—521.
Flek J, Sedivec V. Identification and determination of metabolites of cyclohexanone in human urine. Prac Lek 1989;41:259-263.
Flek J, Sedivec V. Identification and determination of metabolites of cyclohexanone in human urine. Prac Lek 1989;41:259-263.
Proctor NH, Hughes JP, Fischman ML. Chemical hazards of the workplace. 2nd ed. New York: Van Nostrand Reinhold, 1989, pp. 171-172.
Burger LM, Chandor SB. Fatal ingestion of plastic resin catalyst. Arch Environ Health 1971;23:402-404.
Ong CN, Sia GL, Chia SE, Phoon WH, Tan KT. Determination of cyclohexanol in urine and its use in environmental monitoring of cyclohexanone exposure. J Anal Toxicol 1991;15:13-16.
Devillers J, Boule Р, Vasseur Р, Prevot Р, Steinman R, Sei-gle-Murandi F et al. Environmental and health risks of hydroquinone. Ecotoxicol Environ Safety 1990;19:327-354.
Key MM, Henschel AF, Butler J, Ligo RN, Tabershaw IR, eds. Occupational diseases. A guide to their recognition. Revised edition. DHEW (NIOSH). Publication No. 77-181. Washington, DC: US Government Printing Office, 1977; pp. 249-250.
Carlson AJ, Brewer NR. Toxicity studies on hydroquinone. Proc Soc Exp Biol 1953;84:684-688.
Deichmann WB, Keplinger ML. Phenols and phenolic compounds. In: Patty FA, ed. Industrial hygiene and toxicology. 2nd revised ed. Vol II. New York: Interscience, pp. 1380—1383.
Zeidman I, Deutl R. Poisoning by hydroquinone and monomethyl-paraminophenol sulfate. Report of 2 cases with autopsy findings. Am J Med Sci 1945;210:328-333.
Harbison KG, Belly RT. The biodegradation of hydroquinone. Environ Toxicol Chem 1982;1:9-15.
Grant WM. Hydroquinone in toxicology of the eye. 2nd ed. Springfield, IL: Charles C Thomas, 1974; pp. 564—567.
Subrahmanyam UV, Kolachana P, Smith MT. Metabolism of hydroquinone by human myeloperoxidase: mechanisms of stimulation by other phenolic compounds. Arch Biochem Biophys 1991;286:76-84.
CDC. Hydroquinone poisoning aboard a navy ship. MMWR July 14, 1978; pp. 237-243.
Occupational Safety and Health Standards. Support Z-Toxic and Hazardous Substances. Code of Federal Regulations. Title 29, Section 1910.1000 air contaminants.
Anderson B. Corneal and conjunctival pigmentation among workers engaged in manufacture of hydroquinone. Arch Ophthalmol 1947;38:812-826.
Anderson B, Oglesby F. Corneal changes from quinone-hy-droquinone exposure. Arch Ophthalmol 1958;59:495-501.
Scarpa A, Guerci A. Depigmenting procedures and drugs employed by melanoderm populations. J Ethnopharma-col 1987;19:17-66.
Schulz EJ, Summers B, Summers RS. Inappropriate treatment of cosmetic ochronosis with hydroquinone. S Afr Med J 1988;73:59-60.
Williams H. Skin lightening creams containing hydroquinone. The case for a temporary ban. Br Med J 1992;305:963.
Anonymous. Hydroquinone. Dangerous Properties of Industrial Materials. Report No. 3 518 820 000 8. 1988; pp. 51—60.
Logan D, Dart R. Gasoline Toxicity. Case studies in environmental medicine. 31. Agency for Toxic Substances and Disease Registry, September 1993.
Edminster SC, Bayer MJ. Recreational gasoline sniffing. Acute gasoline intoxication and latent organolead poisoning. J Emerg Med 1985;3:365—370.
Weaver NH. The petroleum industry. State Art Rev Occup Med 1988;3(5).
Dabney BJ, Brent J. Jet fuel toxicity. Case studies in environmental medicine. 32. Agency for Toxic Substances and Disease Registry, September 1993.
Davies NE. Jet fuel intoxication. Aerospase Med 1964;35:481-482.
Cocchiarella L, Hryhorczuk D, Garrettson LK. Stoddard solvent toxicity. Case studies in environmental medicine. 33. Agency for Toxic Substances and Disease Registry, September 1993.
McDermott HJ. Hygienic guide series: Stoddard solvent (mineral spirits, white spirits). Am Ind Hyg Assoc J 1975;36:553-558.
Zreve L, Nagasawa НТ. Methanethiol and derivatives in hepatic failure. J Lab Clin Med 1988;! 11:595—597.
Blom HJ, van den Elzen JPAM, Yap SH, Tangerman A. Methanethiol and methylsulfide formation for 3-meth-ylthiopropionate in human and rat hepatocytes. Bioch Biophys Acta 1988;972:131-136.
Chen S, Zieve L, Mahadevan V. Mercaptans and dimethyl sulfide in the breath of patients with cirrhosis of the liver. J Lab Clin Med 1970;75:628-635.
Garrettson LK, Warren DA. Chronic methanethiol poisoning. Vet Hum Toxicol 1990;32:365.
Reynolds JEF, ed. Martindale: The extra pharmacopoeia. 30th ed. London: The Pharmaceutical Press, 1993, p. 1390.
Monooctanoin for gallstones. Med Lett Drugs Ther 1987; p. 52.
Hejka AG, Poquett M, Wiebe DA, Huntington RW III. Fatal intravenous injection of monooctanoin. Am J Forensic Med Pathol 1990;11:165-170.
Minuk GY, Hoofnagle JH, Jones EA. Systemic site effects from the intrabiliary infusion of monooctanoin for the dissolution of gallstones. J Clin Gastroenterol 1982;4:133-135.
Shustak A, Noseworthy TW, Johnston RG et al. Non-cardiogenic pulmonary edema during intrabiliary infusion of monooctanoin. Crit Care Med 1986;14:659-660.
Physicians desk reference. 41st ed. Oradell, NJ. Medical Economics, 1987;924—925.
Litovitz TL, Schmitz BF, Holm КС. 1988 Annual Report of the American Association of Poison Control Centers National Data Collection System. Case 436. Am J Emerg Med 1989;7:495-545.
Zeiss CR, Wolkonsky Р, Pruzansky JJ, Patterson R. Clinical and immunologic evaluation of trimellitic anhydride workers in multiple industrial settings. J Allergy Clin Immunol 1982;70:15-18.
Patterson R, Zeiss CR, Pruzansky JJ. Immunology and immunopathology of trimellitic anhydride pulmonary reactions. J Allergy Clin Immunol 1982;70:19-23.
Leach CL, Hatoum NS, Ratajczak HV, Zeiss CR, Garvin PJ. Evidence of immunologic control of lung injury induced by trimellitic anhydride. Am Rev Respir Dis 1988;137:186-191.
Zeiss CR, Leach CL, Smith LJ, Levitz D, Hatoum NS, Garvin PJ, Patterson R. A serial immunologic and histopathologic study of lung injury and histopathologic study of lung injury induced by trimellitic anhydride. Am Rev Respir Dis 1988;137:191-196.
Hathaway GJ, Proctor NH, Hughes JP, Fischman ML, eds. Proctor and Hughes’ Chemical Hazards of the Workplace. 3rd ed. New York: Van Nostrand Reinhold, 1991; pp 568-569.
Wilcken B. Acid soaps in the fish odor syndrome. Br Med J 1993;307:1497.
Ayesh R, Mitchell SC, Zhang A, Smith RL. The fish odour syndrome: biochemical, familial and clinical aspects. Br Med J 1993;307:655-657.
McGuigan МА. The management of petroleum distillate hydrocarbon ingestions. Clin Toxicol Rev 1978;1(3):1— 2.
Geehr E. Management of hydrocarbon ingestions. Top Emerg Med 1979; 1(3):97— 110.
Goldfrank L, Kirstein R, Bresnitz E. Gasoline and other hydrocarbons. Hosp Physician 1979; 14(9):32—39.
Flanagan RJ, Ruprah M, Meredith TJ, Ramsey JD. An introduction to the clinical toxicology of volatile substances. Drug Safety 1990;5:359-389.
Gerarde HW, Toxicological studies in hydrocarbons vs kerosene. Toxicol Appl Pharmacol 1959;1:462-474.
Chellino MA. Petroleum distillate hydrocarbons. San Francisco Poison Control Center Newslett 1980;2(2):2.
Beerman B, Christensson T, Moller P et al. Lipoid pneumonia. An occupation hazard of fire-eaters. Br J Med 1984;289:1728-1729.
Burns CR, Currie B. The efficacy of chelation therapy and factors influencing mortality in lead intoxicated petrol sniffers. Aust NZ J Med 1995;25:197-203.
AnasN, Namasonthia V, Ginsburg CM. Criteria for hospitalizing children who have ingested products containing hydrocarbons. JAMA 1981;246:840-843.
Eade NR, Taussig LM, Marks MI. Hydrocarbon pneumonitis. Pediatrics 1974;54:351-357.
Banner W, Walson PD. Systemic toxicity following gasoline aspiration. Am J Emerg Med 1983;3:292-294.
James FW, Kaplan S, Benzing G. Cardiac complications following hydrocarbon ingestion. Am J Dis Child 1971;121:431-433.
Decker WJ. Adsorption of solvents by activated charcoal, polymers and mineral sorbents. Vet Hum Toxicol 1981;23(Suppl 1):44—46.
Ng RC, Darwish H, Stewart PA. Emergency treatment of petroleum distillate and turpentine ingestion. CMA J 1974;111:537-538.
Marks MI, Chicoine L, Legere G et al. Adrenocorticosteroid treatment of hydrocarbon pneumonia in children — a cooperative study. J Pediatr 1972;81:366-369.
Gurwitz D, Kattan M, Levison H et al. Pulmonary function abnormalities in asymptomatic children after hydrocarbon pneumonitis. Pediatrics 1978;62:789-794.
Milby TH, Wharton D. Epidemiological assessment of occupationally related, chemically induced sperm count suppression. J Occup Med 1980;22:77-82.
Wharton D, Milby TH, Krauss RM, Stubbs NA. Testicular function in DBCP exposed pesticide workers. J Occup Med 1979;21:161-166.
Goldsmith JR, Potashnik G, Israeli R. Reproductive outcome in families of DBCP-exposed men. Arch Environ Health 1984;39:85-89.
Eaton M, Schenker M, Wharton MD, Samuels S, Perkins C, Overstreet J. Seven-year follow-up of workers exposed to 1,2-dibromo-3-chloropropane. J Occup Med 1986;28:1145-1150.
Olson GW, Lanham JM, Bodner KM, Hylton DB, Bond GG. Determinants of spermatogenesis recovery among workers exposed to l,2-dibromo-3-chloropropane. J Occup Med 1990;32:979-984.
Zhang AQ, Mitchell SC, Barrett T, Ayesh R, Smith RL.Fat of dimethylamine in man. Xenobiotica 1994;24:379-387.
Ying W, Jing X, Qin-Wai W. Clinical report on 62 cases of acute dimethyl sulfate intoxication. Am J Ind Med 1988;13:455-462.
Dimethyl sulfate. Environmental Health Criteria 48. Geneva: World Health Organization, 1985, pp. 1—55.
von Nida S. Fatal edema of the glottis following inflammation of the upper digestive tract due to dimethyl sulfate. Klin Wochenschr 1947;24/25:633—634.
Ip M, Wong K-L, Wong K-F, So S-Y. Lung injury in dimethyl sulfate poisoning. J Occup Med 1989;31:141 — 143.
Moeschlin S. Poisoning. Diagnosis and treatment. New York: Grime & Stratton 1965, pp. 1—707.
Kleinfeld M. Acute pulmonary edema of chemical origin. Arch Environ Health 1965;10:942-946.
Dimethyl sulfate. In: Encyclopedia of occupational health and Safety. Vol 1. International Labour Office. New York: McGraw-Hill, 1971, pp. 388-389.
Littler TR, McConnell RB Dimethyl sulfate poisoning. Br J Ind Med 1955;12:54-56.
IARC (International Agency for Research or Cancer). Monograph on the evaluation of the carcinogenic risk of chemicals to humans. Supplement 4, 1987.
Ellgehausen D. Determination of volatile toxic substances in the air by means of a coupled gas chromatographmass spectrometer system. Anal Lett 1975;8:11—23.
Ellgehausen D. A gas chromatographic monitor for dimethyl sulfate in air. In: The monitoring of hazardous gases in the working environment. London, December 12—14, 1977. London: The Chemical Society, pp. 27— 28.
Roux H, Gallet M, Vincent V, Frantz P. Poisoning by dimethyl sulfate (clinical aid bibliographic study). Acta Pharmacol Toxicol 1977;41 (Suppl 2):428—433.
Reynolds JEF. Martindale: The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989; pp. 1426-1427.
Physicians Desk Reference. 46th ed. Montvale, New Jersey: Medical Economics Company, 1992, pp. 1836— 1837.
McGann LE, Walterson ML. Cryoprotection by dimethyl sulfoxide and dimethyl sulfone. Cryobiology 1987;24:11-16.
Arndt K, Haschok WM, Jeffrey EH. Mechanism of dimethyl sulfoxide protection against acetaminophen hepatotoxicity. Drug Metab Rev 1989;20:261-269.
Park Y, Smith RD, Combs AB, Kehrer JP. Prevention of acetaminophen-induced hepatotoxicity by dimethyl sulfoxide. Toxicology 1988;52:165-175.
Waller FT, Tanabe CT, Paxton HD. Treatment of elevated intracranial pressure with dimethyl sulfoxide. Ann NY Acad Sci 1983;411:286-292.
Karaca M, Bilgin UY, Akar M, de la Torre JC. Dimethyl sulfoxide lowers ICP after closed head trauma. Eur J Clin Pharmacol 1991;40:113-114.
Hull FW, Wood DC, Brobyn RD. Eye effects of DMSO. Report of negative results. Northwest Med 1969:68:39— 41.
Gordon DM. Dimethyl sulfoxide in ophthalmology with special reference to possible toxic effects. Ann NY Acad Sci 1967;141:392-401.
Bennett WM, Munther RS. Lack of nephrotoxicity in intravenous dimethyl sulfoxide. Clin Toxicol 1981;18:615-618.
Munther RS, Bennett WM. Effects of dimethyl sulfoxide on renal function in man. JAMA 1980;244:2081-2083.
Hucker HB, Miller JK, Hochberg A, Brobyn RD, Riordan FH, Calesnick B. Studies on the absorption, excretion and metabolism of dimethyl sulfoxide (DMSO) in man. J Pharm Exp Ther 1967;155:309-317.
Kolb KH, Janicke G, Kramer M, Schulze PE. Absorption, distribution and elimination of labeled dimethyl sulfoxide in man and animals. Ann NY Acad Sci 1967;141:85-95.
Jacob SW, Bischell M, Herschler RJ: Dimethyl sulfoxide (DMSO). A new concept in pharmacotherapy. Curr Ther Res 1964;6:134-135.
Rubin LF. Toxicity of dimethyl sulfoxide, alone and in combination. Ann NY Acad Sci 1975;243:98-103.
Szmant HH. Physical properties of dimethyl sulfoxide and its function in biological systems. Ann NY Acad Sci 1975;243:20-23.
Wood DC, Wood J. Pharmacological and biochemical considerations of dimethyl sulfoxide. Ann NY Acad Sci 1975;234:7-19.
Kligman AM. Topical pharmacology and toxicology of dimethyl sulfoxide — part IL JAMA 1965; 193:923— 928.
Reinstein L, Mahon R Jr, Russo GL. Peripheral neuropathy after concomitant dimethyl sulfoxide and sulindac therapy. Arch Phys Med Rehabil 1982;63:581-584.
Boby RB. The human toxicology of dimethyl sulfoxide. Ann NY Acad Sci 1975;243:497-506.
Garretson SE, Aitchison P. Comparison of dimethyl sulfoxide levels in whole blood and serum using an auto sampler-equipped gas chromatography. Ann NY Acad Sci 1983;411:328-331.
Clark N, Cutter Т, McGrane J-A. Ventilation, a practical guide. New York: Center for Occupational Hazards, 1984.
McCann M. Artist beware: the hazards and precautions in working with art and craft materials. New York: Watson-Guptill, 1979.
McCann M. Health hazards manual for artists. 3rd ed. New York: Nick Lyons Books, 1985.
Rossol M. Ceramics and health. Compilation of articles from Ceramic Scope (1980—82).
Rossol M. Stage fright: health and safety in the theater. New York: Center for Occupational Hazards, 1985.
Seeger N. Alternatives for the artist. Revised editions. Chicago; School of the Art Institute of Chicago, 1984. An Introductory Guide to the Safe Use of Materials.A Printmaker’s Guide to the Safe Use of Materials.A Photographer’s Guide to the Safe Use of Materials. A Painter’s Guide to the Safe Use of Materials.A Ceramist’s Guide to the Safe Use of Materials.A Sculptor’s Guide to the Safe Use of Materials — Welding and Founding
Lucas AD, Salisbury SA. Industrial hygiene survey in a university art department. J Environ Pathol Toxicol Oncol 1992;11:21-27.
Meister J F, Ogle JL. A waste disposal program for a university art department. J Environ Pathol Toxicol Oncol 1992;11:33-37.
Babin A. Center for Safety in the Arts Art Hazards Information Center. Health and Safety Resources for the Arts. Hazards News 1992;15:4-7 Art.
Center for Safety in the Arts. Arts Hazards News 1993;16:1.
Fuortes L, Leo A, Ellerbeck PG, Friell LA. Acute respiratory fatality associated with exposure to sheet metal and cadmium fumes. Clin Toxicol 1991;29:279— 283.
Miller BA, Blair A, McCann M. Mortality patterns among professional artists. A preliminary report. J Environ Pathol Toxicol Oncol 1985;6:303-313.
Miller BA, Silverman DT, Hoover RN, Blain A. Cancer risk among artistic painters. Am J Ind Med 1986;9:281 — 287.
McCann M. Ceramics. In: McCann M: Artists beware.New York. Lyons & Burford, 1992. See also Art Hazards News 1993; 16(1): 1 —18.
Ministry of Education. Administrative Memorandum No. 517: Restrictions on the use of certain types of glazes in the teaching of pottery. London. 1973.
Muller C, Bertram HP, Ran W, Morandini T. Diagnosis and DM PS-treatment of accidental cobalt chloride ingestion — case report. Antidotes. Seminar on the Use of Chelating Agents in Poisoning, Munster, Germany. Eur Assoc Pois Control Center; May 31, 1989.
Everson GW, Normann SA, Casey JP. Chemistry set chemicals: an evaluation of their toxic potential. Vet Hum Toxicol 1988;30:589-592.
McCann M. Children and arts materials. In: Health hazards manual for artists. 3rd ed. New York: Lyons & Burford, 1985.
Lesser SH, Weiss SJ. Art hazards. Am J Emerg Med 1995;13:451-458.
Babin A, Peltz PA, Rossol M. Children’s art supplies can be toxic. New York: Center for Safety in the Arts, 1989.
Rossol M. Fiber art hazards and precautions. New York: Center for Safety in the Arts, 1985.
Rossol M. Dye hazards and precautions. New York: Center for Safety in the Arts, 1984.
Conklin BR. Environmental hazards to elderly artists. JAMA 1984;252:3130.
Glasbrenner K. Maladies may be linked to artists’ materials. JAMA 1984;251:1391-1395.
Letts N. Dutch mordant and etching hazards. Art Hazards News 1990.
Anderson LA Jr, Huntebrinker T. Exposure to methylene chloride in small furniture stripping shops. In: McCann M. Health hazards manual for artists. 3rd ed. New York: Nick Lyons Books, 1985, pp. 65—74.
Young RJ, Infante PF. Consumer’s benzene exposure during a furniture stripping operation. In McCann M. Health hazards manual for artists. 3rd ed. New York: Nick Lyons Books, 1985, pp.75—79.
Health hazards manual for artists. 3rd ed. New York: Nick Lyons Books, 1985, pp. 75—79.
White NW, Chetty R, Bateman ED. Silicosis among gemstone workers in South Africa: tigers’-eye pneumoconiosis. Am J Ind Med 1991;19:205-213.
Braun SR, Tsiatis A. Pulmonary abnormalities in art glass-blowers. J Occup Med 1979;21:487-489.
Royce SE, Needleman HL. Lead toxicity. Case studies in environmental medicine. Agency for Toxic Substances and Disease Registry. Public Health Series. June 1990.
Katagiri Y, Toriumi H, Kawai M. Lead exposure among 3-year-old children and their mothers living in a potteryproducing area. Int Arch Occup Environ Health 1983;52:223-229.
De Rosa E, Toffalo D, Sigon M, Brighenti F, Gori GP, Bartolucci GB. Evaluation of the current risk of lead poisoning in the ceramics industry. Scand J Work Environ Health 1983;9:463-469.
CDC. Lead ingestion associated with ceramic glaze — Alaska, 1992. MMWR 1992;41:781-783.
Avila MH, Romieu I, Rios C, Rivero A, Palazuelos E. Lead-glazed ceramics are major determinants of blood lead levels in Mexican women. Environ Health Perspect 1991;91:117-120.
Ooi DS, Perkins SL. A ceramic glazer presenting with extremely high lead levels. Hum Toxicol 1988;7:171 — 174.
Rossol M. Lead poisoning. New York: Center for Safety in the Arts, November 1981.
Reducing exposure to lead from ceramic ware. FDA Backgrounder, November 1991. Arts Hazards News 1991;14(6): 1—3.
Bradley J, Vance M, Curry S. Environmental lead contamination in nursing homes. Vet Hum Toxicol 1988;30:361.
Lecos CW. Pretty poison: lead and ceramic ware. FDA Consumer 1987;21 (6):6—9.
Fischbein A, Wallace J, Sassa S, Kappas A, Butts G, Rohl A, Kaul B. Lead poisoning from art restoration and pottery work. Unusual exposure source and household risk. J Environ Pathol Toxicol Oncol 1992;11:7-11.
Vance MV, Curry SC, Bradley JM, Kunkel DB, Geskin RD, Bond GR. Acute lead poisoning in nursing home and psychiatric patients from the ingestion of lead-based ceramic glazes. Arch Intern Med 1990;150:2085-2095.
Pederson LM, Permin H. Rheumatic disease, heavy metal pigments and the great masters. Lancet 1988;1:1267-1269.
Babin A. Art painting and drawing. Art Hazards News 1991;14(6):3—6.
Fuchs R, Babin A, Rossol M. Paint Removers. New York: Center for Safety in the Arts, 1988.
Davidson R. Health hazards in the performing arts. In: McCann M. Health hazards manual for artists. 3rd ed. New York: Nick Lyons Books, 1985, pp. 23—27.
McCann M. Photographic processing hazard in schools. Art Hazards News 1990; 13(9): 1—3.
Fuchs R, McCann M. Silk screen printing. New York: Center for Safety in the Arts, 1988.
Lucas AD. Health hazards associated with the cyanotype printing process. J Environ Pathol Toxicol Oncol 1992;11:18-20.
McCann M, Barazeni G, ed. Proc 50EH Conference on Health Hazards in the Arts and Crafts. Society for Occup Environ Health, Washington, DC.
Hart C. Art hazards. An overview for sanitarians and hygienists. J Environ Health 1987;49:282-287.
Sidelecki JT. Potential health hazards of materials used by artists and sculptors. JAMA 1968;204:86-90.
Eckardt RE, Hindin R. The health hazards of plastics. J Occup Med 1973;15:808-819.
Woodcock R. Toxic woods. Art Hazards News 1990;13(5).
Wills JH. Nasal carcinoma in woodworkers: a review. J Occup Med 1982;24:526-530.
Babin A. Adhesives. Art Hazards News 1989; 12(6):3.
Lesser SH, Weiss SJ. Art hazards. Am J Emerg Med 1995;13:451-458.
McCann M. Health hazards manual for artists. 3rd ed. New York: Lyons & Burford, 1985; pp. 100.
McCann M, Barazani G, eds. Health hazards in the arts and crafts. Washington, DC. Society for Occupational and Environmental Health, 1980, pp. 232.
Babin A. Center for Safety in the Arts. 5 Beekman Street, New York, NY 10 038, 212-227-6220. Health and Safety Resources for the Arts. Art Hazards News 1992;15:4-7.
Thomas TL, Stewart PA. Mortality from lung cancer and respiratory disease among pottery workers exposed to silica and talc. Am J Epidemiol 1987;125:35-43.
Forastiere F, Lagorio S, Michelozzi P, Cavariani F, Area M, Borgia P, Perucci C, Axelson O. Silica, silicosis and lung cancer among ceramic workers: a case-referent study. Am J Ind Med 1986;10:363-370.
De Rosa E, Toffolo D, Sigon M, Brighenti F, Gori GP, Bartolucci GB. Evaluation of the current risk of lead poisoning in the ceramics industry. Scand J Work Environ Health 1983;9:463-469.
Annest JL, Pirkle JL, Makuc D, Neese JW, Bayse DD, Kovar MG. Chronological trend in blood lead levels between 1976 and 1980. N Engl J Med 1983;308:1373-1377.
Lead Toxicity. Case Studies in Environmental Medicine ATSDR, US Department of Health and Human Services, June 1990.
Stopford W. Safety of lead-containing hobby glazes. N C Med J 1988;49:31-34.
Ministry of Education. Administrative Memorandum No. 517: Restrictions on the use of certain types of glazes in the teaching of pottery. London. 1973.
Lecas CW. Lead and ceramic ware. FDA Consumer 1987;21(6):6—9.
Bradley J, Vance M, Curry S. Environmental lead contamination in nursing homes. Vet Hum Toxicol I988;3O:361.
Fuortes U. Health hazards of working with ceramics. Recommendations for reducing risks. Postgrad Med 1989;85:133-136.
Rossol M. Environmental industrial mini course: art hazards: toxic risks to artists and craftsmen. New York: Art Hazards Information Center of the Center for Occupational Hazards, December 3, 1984.
Pike S. Hazards from hobbies, arts and crafts. Proc Fourth Annual Southwestern Poison Symposium. Scottsdale, AZ. Arizona Poison and Drug Information Center, November 2—3, 1984, pp. 34—49.
Reproductive hazards in the arts and crafts. New York: Center for Occupational Hazards, 1986.
Miller BA, Silverman DT, Hoover RN, Blair A. Cancer risk among artistic painters. Am J Ind Med 1986;9:281 — 287.
Miller BA, Blair A, McCann M. J Environ Path Toxicol Oncol 1985;6:303-313.
Franklin BA. Paint use is linked to artists’ cancer. New York Times, May 17, 1981.
Glasbrenner K. Maladies may be linked to artists’ material. JAMA 1984;251:1391-1395.
Conklin BR. Environmental hazards to elderly artists. JAMA 1984;252:3130.
Consumer product safety alert. CPSC promotes safety labeling for art and craft materials. Washington, DC. US Consumer Product Safety Commission, July 1990.
McGill DC. Art supply makers to label hazardous items. New York Times, February 3, 1985.
Stover B. Toxicity of school supplies. Rocky Mountain Poison Center Bulletin 1987;6(3):5—6.
Pedersen LM, Permin H. Rheumatic disease, heavy metal pigments and the great masters. Lancet 1988;1:1267-1269.
Teitelbaum SB, Teitelbaum DT. Hobbies and hazards. Personal communication, March 1982.
Katagiri Y, Toriumi H, Kawai M. Lead exposure among 3-year-old children and their mothers living in a potteryproducing area. Int Arch Occup Environ Health 1983;52:223-229.
Jacobziner H, Raybin HW. Briefs in accidental chemical poisonings in New York City. Poisonings associated with bizarre behavior. NY State J Med 1960;60:1634-1637.
Lutz WK, Poetzsch J, Schlatter J, Schlatter C. The real role of risk assessment in cancer risk management. Trends Pharmacol Sci 1991;12:214-217.
Muller C, Bertram HP, Rau W, Morandini T. Diagnosis and DM PS — treatment of accidental cobalt chloride ingestion — Case report. Antidotes. Proc of Seminar on the use of chelating agents in poisoning. Munster, Germany. Eur Assoc Poison Control Centres, CED, I PCS, May 31, 1989.
Everson GW, Normann SA, Casey JP. Chemistry Set chemicals. An evaluation of their toxic potential. Vet Hum Toxicol 1988;30:589-592.
Everson GW, Normann SA, Casey JP. Chemistry set chemicals. An evaluation of their toxic potential. Vet Hum Toxicol 1987;29:485-486.
McConnell WJ, Flinn RH. Summary of twenty-two trinitrotoluene fatalities in World War 11. Ind Hyg Toxicol 1946;28:76-86.
Crawford MAD. Aplastic anemia due to trinitrotoluene intoxication. Br Med J 1954;2:430-437.
Paterson JD. 2,4,6-trinitrotoluene in Encyclopaedia of Occupational Health and Safety. Vol 2. Geneva, International Labour Office. New York: McGraw-Hill, 1976; p. 1436.
Yinon J. Toxicity and metabolism of explosives. Boca Raton, FL: CRC Press, 1991; pp. 3—67.
Sax N1. Dangerous properties of industrial materials. 5th ed. New York: Van Nostrand Reinhold, 1979; pp. 1065-1066.
Occupational exposure limits for airborne toxic substances. Occupational Safety and Health Series 37. Geneva: International Labour Office. 2,4,6-trinitrotoluene. 1991; pp. 408-409.
Hathaway JA. Trinitrotoluene: a review of reported dose-related effects providing documentation for a workplace standard. J Occup Med 1977;19:341-345.
Ryon MG, Ross RH. Water quality criteria for 2,4,6-trinitrotoluene. Regul Toxicol Pharmacol 1990;! 1:104-113.
Ross RH, Hartley WR. Comparison of water quality criteria and health advisories for 2,4,6-trinitrotoluene. Regul Toxicol Pharmacol 1990; 11:114—117.
Hilton J, Swanston CN. Clinical manifestations of tetryl and trinitrotoluene. Br Med J 1941;2:509-510.
Almog J, Kraus S, Basch A. Determination of TNT metabolites in urine. Arch Toxicol 1983;(Suppl 6):351—353.
Yinon J, Hwang D-G. Metabolic studies of explosives. V. Detection and analysis of 2,4,6-trinitrotoluene and its metabolites in urine of munition workers by micro liquid chromatography/mass spectrometry. Biomed Chroma-togr 1986;1:123-125.
Woollen BH, Hall MG, Craig R, Stal GT. Trinitrotoluene assessment of occupational absorption during manufacture of explosives. Br J Ind Med 1986;43:465-473.
Channon HJ, Mills GT, Williams RT. The metabolism of 2:4:6-trinitrotoluene (alpha-TNT). Biochem J 1944;38:70-85.
Ahlborg G Jr, Einisto P, Sorsa M. Mutagenic activity and metabolites in the urine of workers exposed to trinitrotoluene (TNT). Br J Ind Med 1988;45:353-358.
Goh CL, Rajans VS. Contact sensitivity to trinitrotoluene. Contact Dermatitis 1983;9:433-434.
Voegtlin C, Hooper CW, Johnson JM. Trinitrotoluene poisoning — its nature, diagnosis and prevention. J Indust Hyg 1921 —22;3:239—254.
Voegtlin C, Hooper CW, Johnson JM. Trinitrotoluene poisoning — its nature, diagnosis and prevention (continued). J Indust Hyg 1921 —22;3:280—292.
Djerassi LS, Vitany L. Haemolytic episode in G6PD deficient workers exposed to TNT. Br J Ind Med 1975;32:54-58.
Yinon J, Hwang D-G. Metabolic studies of explosives 1-EI and CI mass spectrometry of metabolites of 2,4,6-trinitrotoluene. Biomed Mass Spectrom 1984;11:594-600.
Yinon J, Hwang D-G. Identification of urinary metabolites of 2,4,6-trinitrotoluene in rats by liquid chromatography—massspectrometry. Toxicol Lett 1985;26:205-209.
FetterolfDD, Mudd JL, Teten K. An enzyme-linked immunosorbent assay (ELISA) for trinitrotoluene (TNT) residue on hands. J Forensic Sci 1991;36:343-349.
Hamilton AM. Monocytosis as an index of TNT absorption. Br J Ind Med 1946;3:24-26.
Webster TA. On the metabolism and excretion of 2,4,6-trinitrotoluene. Br Med Res Council. Special Rep Ser 1921; No. 58:49-52.
Cone ТЕ Jr. Trinitrotoluene poisoning. US Naval Med Bull 1944;42:731-734.
Eddy JH Jr. Some toxic reactions of common explosives. Ind Med 1943;12:483-486.
Lawrence RD. Discussion on trinitrotoluene poisoning. Proc R Soc Med 1942;35:553-560.
Jie L, Quan-Guan J, Wei-Dong Z. Persistent ethanol drinking increases liver injury induced by trinitrotoluene exposure: an in-plant case-control study. Hum Exp Toxicol 1991;10:405-409.
Holland LM, McKone T, Spanggord R (Peer Review Panel). ATSDR. Toxicological Profile for 2,4,6-Trinitro-toluene. Draft. May 1993.
Evans ЕН. Casualties following exposure to zinc chloride smoke. Lancet 1945;2:368-370.
Blom L, Hven PE. Forgiftning med hexit-vogammuni-tion (Poisoning with hexite smoke ammunition). Ug-eskr-Laeger 1986;148:454-455.
Hjortso E, Bud J Ml, Thomson JL, Jensen NK, Qvist J. Zinkklorid forgiftning (Zinc chloride poisoning). Ugeskr Laeger 1987;149:2381-2384.
Karlsson N. Poisoning from smoke grenades is not due to phosgene. Eur Respir J 1988; 1:575.
Karlsson N, Cassel G, Fangmark I, Bergman F. A comparative study of the acute inhalation toxicity of smoke from TiO2-hexachloroethane and Zn-hexachloroethane pyrotechnic mixtures. Arch Toxicol 1986;59:160-166.
Clode SA, Riley RA, Blower SD, Marrs TC, Anderson D. Studies on the mutagenicity of a zinc oxide-hexachlo-roethane smoke. Hum Exp Toxicol 1991;10:49-57.
SaxNI. Dangerous properties of industrial materials. 5th ed. New York: Van Nostrand Reinhold, 1979; p. 889.
Yinon J. Toxicity and metabolism of explosives. Boca Raton, FL: CRC Press, 1991 pp. 123-132.
McEvoy GK, ed. AHFS Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, 1992; p.1022.
Basch A, Margalit Y, Abramovich-Bar S, Bamberger Y, Daphna D, Tamiri T, Zitrin S. Decomposition products of PETN in post-explosion analysis. In: Heyndrickx B, ed. Proc Int Assoc Forensic Toxicol. 23rd European International Meeting, Ghent: August 24—27, 2986; pp. 322-331.
Sutton WL. Aliphatic nitrocompounds, nitrates, nitrites. In: Patty FA, ed. Industrial hygiene and toxicology. Vol 2. Second Revised Edition. New York: Interscience, 1963; p. 2097.
von Oettingen WF. Acute toxic manifestations of PETN. US Public Health Bulletin, 1944;282:23-30.
Donahue DD, Monaco AR. Chronic toxic manifestations of PETN. US Public Health Bulletin 1944;282:30— 38.
Gilbert JD, Aylott RI, Darffan GH, Sogtrop HH. A study of the plasma levels of pentaerythritol mononitrate following administration of pentaerythritol tetranitrate in combination with meprobamate and diphenhydramine. Arzneim-Forsch/Drug Res 1982;32:571-574.
Posadas del Rio FA, Juarez FJ, Garcia RC. Biotransformation of organic nitrate esters in vitro by human liver, kidney, intestine, and blood serum. Drug Metab Dispos 1988;16:477-481.
DiCarlo FJ, Hartigan MJ Jr, Phillips GE. Enzymatic degradation of pentaerythritol tetranitrate by human blood. Proc Soc Exp Biol Med 1975;118:514-516.
DiCarlo FJ, Crew MC, Sklow NJ, Coutinho CB, Nonkin P, Simon F, Bernstein A. Metabolism of pentaerythritol tetranitrate by patients with coronary artery disease. J Pharm Exp Ther 1966;153:254-258.
Reynolds JEF, ed. Pentaerythritol tetranitrate in Martindale: The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989; p. 1515.
Olsen CS, Scroggins HC. High performance liquid chromatographic determination of the nitrate esters isosorbide dinitrate, pentaerythritol tetranitrate and erythrityl tetranitrate in various tablet forms. J Pharm Sci 1984;73:1303-1304.
Berberich DW, Yost RA, Fetterolf DD. Analysis of explosives by liquid chromatography, thermospray/mass spectrometry. J Forensic Sci 1988;33:946-959.
Voyksner RD, Yinon J. Trace analysis of explosives by thermosp ay high-performance liquid chromatographymass spectrometry. J Chromatogr 1986;354:393-405.
Yu WC, Goff EU. Determination of vasodilators and their metabolites in plasma by liquid chromatography with a nitrosyl-specific-detector. Anal Chem 1983;55: 29-32.
Forman SA. A review of propylene glycol dinitrate toxicology and epidemiology. Toxicol Lett 1988;43:51-65.
Forman SA, Helmkamp JC, Bone CM. Cardiac morbidity and mortality associated with occupational exposure to 1,2 propylene glycol dinitrate. J Occup Med 1987;29:445-450.
Godin S, Gregory A, Holland LM (Review Panel) for ATSDR. Toxicological Profile for OTTO Fuel and its Components. Draft profile. May 1993.
KleinhofsA, OwaisWM, Nilan RA. Azide. Mutation research 1978;55:165-195.
Graham JDP, Rogan JM, Robertson DG. Observations on hydrazoic acid. J Ind Hyg Toxicol 1948;30:98-102.
Winning CH. Explosives industry. In: Encyclopaedia of occupational health and safety. Vol 1. International Labour Office. New York: McGraw-Hill, 1976; pp. 493— 496.
Fairhall LT, Henrette WV, Pritchard EA. The toxicity of lead azide. Public Health Rep (USA) 1943;58:607-617.
Finklea JF. Explosive azide hazard. Current Intelligence Bulletin 12. NIOSH. August 16, 1976.
Shaney Felt W. Complexities of lead azide. Govt Reports Announcements & Index (GR & I). Issue 23, 1985.
Klein-Schwartz W, Gorman RL, Oderda GM, Massaro BP, Kurt TL, Garriott JC. Three fatal sodium azide poisonings. Med Toxicol Adverse Drug Exp 1989;4:219-227.
Binder L, Frederickson L. Poisonings in laboratory personnel and health care professionals. Am J Emerg Med 1991;9:11-15.
Gordon SM, Crachman J, Bland LA, Reid MH, Favero M, Jarvis WR. Epidemic hypotension in a dialysis center caused by sodium azide. Kidney Int 1990;37:110-115.
Judge KW, Ward NE. Fatal azide-induced cardiomyopathy presenting as acute myocardial infarction. Am J Cardiol 1989;64:830-831.
Howard JD, Skogerbae KJ, Case GA, Raisys VA, Lac-sina EQ. Death following sodium azide ingestion. J Forensic Sci 1990;35:193-196.
Abrams J, El-Mallakh RS, Meyer R. Suicidal sodium azide ingestion. Ann Emerg Med 1987;16:1378-1380.
Finklea JF. Explosive azide hazard. Current Intelligence Bulletin 13. N1OSH. August 16, 1976.
Precautions for hemodialysis filters. FDA Drug Bulletin 1989; 19(2): 18-19.
Graham J DP. Actions of sodium azide. Br J Pharmacol 1949;4:1-6.
Occupational Exposure Limits for Airborne Toxic Substances. Occupational Safety and Health Series 37. Geneva: International Labor Office, 1991.
Black MM, Zweifach BW, Speer FD. Comparison of hypotensive actions of sodium azide in normotensive and hypertensive patients. Proc Soc Exp Biol Med 1954;85:11-16.
Maher FT, Bollinan JG. Hypotensive effects of sodium nitroprusside and sodium azide in dogs. Fed Proc 1955; 14:412 (abstract).
Edmonds OP, Bourne MS. Sodium azide poisoning in five laboratory technicians. Br J Ind Med 1982;39:308— 309.
Haas JM, Marsh WW Jr. Sodium azide: a potential hazard when used to eliminate interferences in the iodometric determination of sulfur. Am Ind Hyg Assoc J 1970;31:318-321.
Richardson SGN, Giles C, Swan CHJ. Two cases of sodium azide poisoning by accidental ingestion of isoton. J Clin Pathol 1975;28:350-351.
Kleinhofs A, Owais WM, Nilan RA. Azide. Mutat Res 1978;55:165-195.
Roberts RJ, Simmons A, Barrett DA II. Accidental exposures to sodium azide. Am J Clin Pathol 1974;61:879— 880.
Emmett EA, Ricking JA. Fatal self-administration of sodium azide. Ann Intern Med 1975;83:224-226.
Albertson ТЕ, Reed S, Siefkin A. A case of fatal sodium azide ingestion. Clin Toxicol 1986;24:339-351.
Robertson HE, Boyer PD. The effect of azide on phosphorylation accompanying electron transport and glycolysis. J Biol Chem 1955;214:295-305.
Foulkes EC, Leinberg R. The azide inhibition of catalase. Enzymologia 1949;13:302-312.
Gobbi A. Tre casi di intossicazione da sodio-azide. Med Laboro 1967;58:297-300.
Kozlicka-Gajdzinska H, Brzyski J. A case of fatal intoxication with sodium azide. Archiv f Toxikolog 1966;22:160-163.
Lanbert W, Meyer E, De Leenheer A: Cyanide and sodium azide intoxication. Ann Emerg Med 1995;36:392.
Burger E, Bauer HM: Akuter vergiftungs fall durch ver-schentliches trinken von natriumazid losung. Archiv f Toxikolog 1965;20:279-283.
Swarin SJ, Waldo RA. Liquid chromatographic determination of azide as the 3,5-dinitrobenzoyl derivative. J Liq Chromatog 1982;5:597-604.
Lawson KS. Sodium azide. Clin Toxicol Rev 1993;15(4):1—2.
Upton D, Donelson V: Proper disposal of liquid laboratory waste containing sodium azide. Am Ind Hyg Assoc J 1981 ;42:A-16—A-18.
Yinon J. Toxicity and metabolism of explosives. Boca Raton, FL: CRC Press, 1990;69—80.
Sax N1. Dangerous properties of industrial materials. New York: Van Nostrand Reinhold, 1979;1022—1023.
Parmeggiam L. Tetryl. Encyclopaedia of occupational health and safety. Vol 2. Geneva: International Labour Office. New York: McGraw-Hill, 1976; 1397—1398.
Bergman BB. Tetryl toxicity: a summary of ten years’ experience. Arch Ind Hyg Occup Med 1952;5:10-20.
NIOSH Pocket Guide to Chemical Hazards. DHHS (NIOSH) Publication No 90-117, Washington, DC: US Government Printing Office, 1990; pp. 212—213.
Occupational Exposure Limits for Airborne Toxic Substances. n-Methyl-«,2,4,6-tetranitroaniline. Occupational Safety and Health Series 37. Geneva: International Labour Office, 1991; pp. 276—277 Hem 1374.
Hilton J, Swanston CN. Clinical manifestations of tetryl and trinitrotoluene. Br Med J 1941;2:509-510.
Witkowski LJ, Fischer CN, Murdock HD. Industrial illness due to tetryl. JAMA 1942; 119:1406—1409.
Brabham VW. Tetryl illness in munitions plants. J SC Med Assoc 1943• 39 93—95
Troup HB. Clinical effects of tetryl (CE powder). Br J Ind Med 1946;3:20-23.
Hardy HL, Maloof CC. Evidence of systemic effect of tetryl and summary of available literature. Arch Ind Hyg Occup Med 1950;1:545-550.
Lyter AH III. A high-performance liquid chromatographic (HPLC) study of seven common explosive materials. J Forensic Sci 1983;28:446-450.
Farey MG, Wilson SE. Quantitative determination of tetryl and its degradation products by high-pressure liquid chromatography. J Chromatogr 1975;114:261 — 265.
Borges T, Edwards G, Spanggord R (Peer Review Panel). ATSDR. Toxicological profile for tetryl. Draft, May 1993.
Nitroglycerin. N1OSH Pocket guide to chemical hazards. DHHS (N1OSH) Publication No. 90-117. Washington, DC: US Government Printing Office, pp. 166— 167.
Glycerol trinitrate. Occupational exposure limits in airborne toxic substances. 3rd ed. Occupational Safety and Health Series. Geneva: International Labour Office, 1991; pp. 210-211.
Glycerol trinitrate. Occupational exposure limits in airborne toxic substances. 3rd ed. Occupational Safety and Health Series. Geneva: International Labour Office, 1991; pp. 210-211.
Yamaguchi S. Nitroglycerin. In: Encyclopaedia of occupational health and safety. Vol 2. International Labour Office. New York: McGraw-Hill, 1976; pp. 942—944.
Panacek EA, Munger MA, Rutherford WF, Gardner SF. Report of nitropatch explosions complication defibrillation. Am J Emerg Med 1992;10:128-129.
Wrenn K. Hazards of defibrillation through nitroglycerin patches. Ann Emerg Med 1990;19:1327-1328.
Daum S. Nitroglycerin and alkyl nitrates. In: Rom WN, ed. Environmental and occupational medicine. Boston: Little, Brown, 1983; pp. 639—648.
Darlington T. The effect of the products of high explosives, dynamite and nitroglycerin on the human system. Med Rec 1890;38:661-662.
Anon. The effects of nitroglycerin upon those who manufacture it. JAMA 1898;31:793-794.
Laws CE. Nitroglycerin head. JAMA 1910:54:793.
Ebright GE. The effects of nitroglycerin on those engaged in its manufacture. JAMA 1914;62:201-202.
Rabinowitch IM. Acute nitroglycerin poisoning. Can Med Assoc J 1944;50:199-202.
Schwartz AM. The cause, relief and prevention of headaches arising from contact with dynamite. N Engl J Med 1946;235:541-544.
Bresler RR. Nitroglycerin reactions among pharmaceutical workers. Ind Med 1949;18:519-523.
Symanski H. Schwere gesundheits schadingungen durch berufliche nitroglykoleinwirkung. Arch Hyg (Berlin) 1952;136:139-158.
Barsotti M. Attacchi stenocardici mei lavoratori adettie alia produzione della dinamit con nitroglicole (Attacks of stenocardia in workers engaged in the production of dynamite with nitroglycol). Med Lavoro 1954;45:544— 548.
Carmichael P, Liebgen J. Sudden death in explosives workers. Arch Environ Health 1963;7:424-439.
Lund RP, Haggendal J, Johnsson G. Withdrawal symptoms in workers exposed to nitroglycerin. Br J Ind Med 1968;25:136-138.
Lange RL, Reid MS, Tresch DD, Keelan MH, Bernhard VM, Coolidge G. Nonatheromatous ischemic heart disease following withdrawal from chronic industrial nitroglycerin exposure. Circulation 1972;46:666-678.
Hogstedt C, Axelson O. Nitroglycerin-nitroglycol exposure and the mortality in cardio-cerebrovascular diseases among dynamite workers. J Occup Med 1977;19:675— 678.
Ben-David A. Cardiac arrest in an explosives factory worker due to withdrawal from nitroglycerin exposure. Am J Ind Med 1989;15:719-722.
Wei JY, Reid PR. Quantitative determination of trinitroglycerin in human plasma. Circulation 1979;59:588— 592.
Armstrong PW, Armstrong JA, Marks GS: Blood levels after sublingual nitroglycerin. Circulation 1979;59:585— 588.
Frank SE, Snyder JT. Survival following severe overdose with mexiteline, nifedipine and nitroglycerin. Am J Emerg Med 1991;9:43-46.
Mittal CK, Murad F. Guanylate cyclase: regulation of cyclic GMP metabolism. In: Nathanson JA, Kebabian JW, eds. Cyclic nucleotides. Handbook of experimental pharmacology. Vol 8. Berlin: Springer-Verlag, 1982; pp. 225-260.
Murad F. Cyclic guanosine monophosphate as an mediator of vasodilation. J Clin Invest 1986;78:1-5.
Winniford MD, Kennedy PL, Wells PJ, Hillis LD. Potentiation of nitroglycerin-induced coronary dilatation by A-acetylcysteine. Circulation 1986;73:138-142.
Ranft K. Nitrate collapse. Munch Med Wochenschr 1991;133:589-593.
Einert C, Adams W, Crothers R, Moore H, Ottoboni F. Exposure to mixtures of nitroglycerin and ethylene glycol dinitrate. Ind Hyg J 1963; 435—447.
Eherenpreis Ed, Young MA, Leikin JB. Symptomatic nitroglycerin toxicity from erroneous use of topical nitroglycerin. Vet Hum Toxicol 1990;32:138-139.
Woodward AJ, Lewis PA, Aylward M, Rudman R, Maddock J. Determination of nitroglycerin and its dinitrate metabolites in human plasma by high performance liquid chromatography with thermal energy analyzer detection. J Pharm Sci 1984;73:1838-1840.
Lloyd JBF. Glyceryl dinitrates in the detection of skin contact with explosives and related materials of forensic science interest. J Forensic Sci Soc 1986; 26: 341-348.
Lee FW, Watari N, Rigod J, Benet LZ. Simultaneous determination of nitroglycerin and its dinitrate metabolites by capillary gas chromatography with electron-capture detection. J Chromatogr Biomed Appl 1988;426:259-266.
Yinon J. Toxicity and metabolism of explosives. Boca Raton, FL: CRC Press, 1990; pp. 81 — 117.
National Institute for Occupational Safety and Health. Criteria for a Recommended Standard. Nitroglycerin and Ethylene Glycol Dinitrate. DHEW Publication No. (NIOSH) 78-167. Washington, DC: US Government Printing Office, 1978.
Morikawa Y, Muraki K, Ikoma Y, Honda T, Takamatsu H. Organic nitrate poisoning at an explosives factory. Plethysmographic study. Arch Environ Health 1967;14:614-621.
Lloyd JBF. Transfer of nitroglycerin from cardiovascular tablets to hands. J Forensic Sci Soc 1983;23:307-311.
Turibell JD, Home JM, Smalldon KW, Higgs DG. Transfer of nitroglycerin to hands during contact with commercial explosives. J Forensic Sci 1982;27:783-791.
Von Burg R, Stout T. Toxicology update. Hydrazine. J Appl Toxicol 1991;11:447-450.
Hydrazine in Proctor NH, Hughes JP, Fischman ML. Chemical hazards of the workplace. 2nd ed. New York: Van Nostrand Reinhold, 1989; pp. 272—273.
NIOSH Pocket Guide to Chemical Hazards. DHHS (N1OSH) Publication No. 90-117. Washington, DC: US Government Printing Office, 1990; 124—125 (Hydrazine); 152—153 (Methylhydrazine); 96—97 (1,1 dimethylhydrazine); 180—181 (phenylhydrazine).
Thomas AA. Hydrazine and derivatives. In: Encyclopaedia of Occupational Health and Safety. International Labour Office. Vol 1. New York: McGraw-Hill, 1976.
Occupational exposure limits for airborne toxic substances. 3rd ed. Occupational Safety and Health Series No. 37. Geneva, International Labour Office, 1991.
HSDB Hazardous Substance Data Bank. Washington, DC: National Library of Medicine. Toxicology Information Program, 1991.
Harati Y, Niakan E. Hydrazine toxicity, pyridoxine therapy, and peripheral neuropathy. Ann Intern Med 1986;104:728-729.
Reidenberg MM. Aromatic amines and the pathogenesis of lupus erythematosus. Am J Med 1983;75:1037-1042.
Bhide SV, Bhalerao E, Saride A, Marude GB. Mutagenicity and carcinogenicity of mono- and diacetyl hydrazine. Cancer Lett 1984;23:235-240.
Keller WC. Toxicity assessment of hydrazide fuels. Aviat Space Environ Med 1988;59(Suppl 11):А100—A106.
Sotaniemi E, Hirvonen J, Isomaki H, Takkunen J, Kaila J. Hydrazine toxicity in the human. Report of a fatal case. Ann Clin Res 1971;3:30-33.
Comstock CC, Lawson LH. Greene EA, Oberst FW. Inhalation toxicity of hydrazine vapor. Arch Ind Hyg Oc-cup Med 1954;10:476-490.
Wrangsjo K, Martensson A. Hydrazine contact dermatitis from gold plating. Contact Dermatitis 1986; 15:244.
Reidenberg MM, Durant PJ, Harris RA, De-Baccardo G, Lahita R, Stenzel KH. Lupus erythematosus-like disease due to hydrazine. Am J Med 1983;75:365-370.
[ARC. Monographs on the evaluation of the carcinogenic risk of chemicals to man: overall evaluations of carcinogenicity. (Geneva) World Health Organ Tech Rep Ser 1987;S7:223—224.
Wald N, Boreham J, Doll R, Bonsall J. Occupational exposure to hydrazine and subsequent risk of cancer. Br J Ind Med 1984;41:31-34.
EPA — Methodology for Evaluating Potential Carcinogenicity in Support of Reportable Quantity Adjustments Pursuant to CEPCLA Section 102, EPA 600/8-89/053. Washington, DC: Office of Health and Environmental Assessment, 1988.
Back КС, Carter VL Jr, Thomas AA. Occupational hazards of missile operations with special regard to the hydrazine propellants. Aviat Space Environ Med 1978;49:591-598.
Key MM, Henschel AF, Butler J, Ligo RN, Tabershaw 1R. Occupational diseases. A guide to their recognition. DHEW(NIOSH) Publication No. 77-181, Washington, DC: US Government Printing Office, 1977;296—298.
1ARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. Some Aromatic Amines, Hydrazine and Related Substances, N-Nitroso Compounds and Miscellaneous Alkylating Agents. (Geneva) World Health Organ, Tech Rep Ser 1974;4:127-130.
Hydrazine. Environmental Health Criteria 68. (Geneva) World Health Organ Tech Rep Ser 1987; 1—89.
von Oettingen WF, Donahue DD, Yagoda H, Monaco AR, Harris MR. Toxicity and potential dangers of cy-clotrimethylene-trinitramine (RDX). J Indust Hyg 1949;31:21-31.
Ketel WB, Hughes JR. Toxic encephalopathy with seizures secondary to ingestion of composition C-4. A clinical and electroencephalographic study. Neurology 1972;22:871-876.
Yinon J. Toxicity and metabolism of explosives. Boca Raton, FL: CRC Press, 1991; pp. 145—164.
Occupational exposure limits for airborne toxic substances. Occupational Safety and Health Series 37. Geneva: International Labour Office, 1991; pp. 120—121 (Item 599).
Encyclopaedia of Occupational Health and Safety. International Labour Office (Geneva). Vol 1. New York: McGraw-Hill, 1976; p. 494.
Stone WJ, Paletta TL, Heiman EM, Bruce JI, Knep-shield JH. Toxic effects following ingestion of C-4 plastic explosive. Arch Intern Med 1969;124:726-730.
Etnier EL. Water quality criteria for hexahydro-1,3,5-trinitro-l,3,5-triazine (RDX). Regul Toxicol Pharmacol 1989;9:147-157.
Woody RC, Kearns GL, Brewster MA, Turley CP, Sharp GB, Lake RS. The neurotoxicity of cyclotrimethylenetrinitramine (RDX) in a child: a clinical and pharmacokinetic evaluation. Clin Toxicol 1986;24:305-319.
Vogel W. Hexogen poisoning in human beings. Zbl Ar-beitsmed 1951;1:51-54. Indust Hyg Dig 1952; 16:Hem 310 (abstract).
Schneider NR, Bradley SL, Andersen ME. Toxicology of cyclotrimethylenetrinitramine. Distribution and metabolism in the rat and the miniature swine. Toxicol Appl Pharmacol 1977;39:531-541.
Kaplan AS, Berghout CF, Peczenik A. Human intoxication from RDX. Arch Environ Health 1965;10:877-883.
Barsott M, Crotti G. Attacchi epilettici come mani-festazione di intossicazione professionale da trimetilen-trinitroamino (T4). Med Lavoro 1949;40:107-112.
Hollander Al, Colback EM. Composition C4 induced seizures. A report of five cases. Milit Med 1969;134:1529-1530.
Merrill SL. Ingestion of an explosive material, Composition C-4. A report of two cases. US Army Vietnam (USARV) Med Bull 1968;3:5-11.
Litovitz TL, Schmitz BF, Bailey KM. 1989 Annual Report of the American Association of Poison Control Centers. National Data Collection System. Am J Emerg Med 1990;8:431.
Goldberg DJ, Green ST, Nathwani D, McMenamin J, Hamlet N, Kennedy DH. RDX intoxication causing seizures and a widespread petechial rash mimicking menin-gococcemia. J R Soc Med 1992;85:181.
Turley CP, Brewster MA. Liquid chromatographic analysis of cyclotrimethylenetrinitramine in biological fluids using solid phase extraction. J Chromatogr 1987;421:430-433.
Berberich DW, Yost RA, Fetterolf DD. Analysis of explosives by liquid chromatography (thermospray) mass spectrometry. J Forensic Sci 1988;33:946-959.
Lyter AH 111. A high-performance liquid chromatographic (HPLC) study of seven common explosive materials. J Forensic Sci 1983;28:446-450.
Safire W. Object survival. New York Times, November 5, 1990, p. A19.
Yinon J. Toxicity and metabolism of explosives. Boca Raton, FL: CRC Press, 1991; pp. 165—170.
Toxicological Profile for HMX. Draft. Agency for Toxic Substances and Disease Registry, June 1994.
Hathaway JA, Buck CR. Absence of health hazards associated with RDX manufacture and use. J Occup Med 1977;19:269-272.
Litovitz TL, Schmitz BF, Bailey KM. 1989 Annual report of the American Association of Poison Control Centers. National Data Collection System. Am J Emerg Med 1990;8:431.
Garry V, Holland LM, Spanggord R. (Peer Review Panel). ATSDR. Toxicological profile for 1,3-dinitrobenzene and 1,3,5-trinitrobenzene. Draft. May 1993.
Von Burg R. Dinitrobenzene. J Applied Toxicol 1989;9:199-203.
Hogstedt С, Andersson К. A cohort study on mortality among dynamite workers. J Occup Med 1979;21:553— 556.
Parmeggiani L. Ethylene glycol dinitrate. In Encyclopaedia of occupational health and safety. Vol 1. International Labour Office. New York: McGraw-Hill, 1976; pp. 483-484.
Proctor NH, Hughes JP, Fischman ML. Chemical hazards of the workplace. 2nd ed. New York: Van Nostrand Reinhold, 1989;247.
Ethyleneglycol dinitrate. NIOSH Pocket guide to chemical hazards. DHHS (NIOSH) Publication No 90-117. Washington, DC: US Government Printing Office, June 1990, pp. 110-111.
Key MM, Henschel AF, Butler J, Ligo RN, Tabershaw 1R. Occupational diseases. A guide to their recognition. DHEW (NIOSH) Publication No. 77-181. Washington, DC: US Government Printing Office, 1977, pp. 282— 284.
Craig R, Gillis CR, Hole DJ, Paddle GM. Sixteen year follow up of workers in an explosives factory. J Soc Occup Med 1985;35:107-110.
Carmichael P, Lieben J. Sudden death in explosives workers. Arch Environ Health 1963;7:424-439.
Lund RP, Haggendal J, Johnsson G. Withdrawal symptoms in workers exposed to nitroglycerin. Br J Ind Med 1968;25:136-138.
Gross E, Kiese M, Resag K. Resorption von athylene glykol dinitrat durch die haut. (Absorption of ethylene glycol dinitrate through the skin). Arch Toxicol 1960;18:194-199.
Fukuchi Y. Nitroglycol concentrations in blood and urine of workers engaged in dynamite production. Int Arch Occup Environ Health 1981;48:339-346.
Btirtalini E, Cavagna G, Foa V. Epidemiological and clinical features of occupational nitroglycol poisoning in Italy. Med Lavoro 1967;58:618-623.
Clark DG, Litchfield MH. Metabolism of ethyleneglycol dinitrate (ethylene dinitrate) in the rat following repeated administration. Br J Ind Med 1969;26:150-155.
Forssman S, Masreliez N, Johansson G, Sundell G, Wi- Ir lander O, Bostrom G. Untersuchungen des gesundheit-szustandes von nitroarbeitern bei drei schwedischen spreng stoffabriken. Arch Gewerbepath Gewerbehyg 1958;16:157-177.
McGuiness BW, Harris EL. "Monday Head." An interesting occupational disorder. Br Med J 1961;2:745-747.
Havi Hau A, Hardy HL. Industrial toxicology. 3rd ed. Acton, MA: Publishing Sciences Group, 1974; pp. 317— | 319.
Hogstedt C, Axelson O. Nitroglycerin-nitroglycol exposure and the mortality in cardio-cerebrovascular disease among dynamite workers. J Occup Med 1977; 19:675— 678.
Hogstedt C, Axelson O. Mortality from cardiocerebrov-ascular diseases among dynamite workers — an extended case referent study. Am Acad Med (Singapore) 1984;23(Suppl 2):399-403.
Symansky H. Schere gesundheits schadigungen durch berufliche nitroglykoleinwirkung. (Serious injuries to health by occupational exposure to nitroglycol). Arch Hyg Bacteriol 1952;136:139-158.
Yinon J. Toxicity and metabolism of explosives. Boca Raton, FL: CRC Press, 1990; pp. 133—143.
Litchfield MH. The determination of di- and mononitrates of ethylene glycol and 1,2-propylene glycol in blood by colorimetric and gas chromatographic methods. Analyst 1968;93:653.
Lawrence AH, Neudorfl P. Detection of ethylene glycol dinitrate vapors by ion mobility spectrometry using chloride reagent ions. Anal Chem 1988;60:104-109.
Trainor DC, Jones RC. Headaches in explosive magazine workers. Arch Environ Health 1966;12:231-234.
Linch AL. Aromatic nitrocompounds. In: Encyclopedia of occupational health and safety. Vol 2. International Labour Office. New York: McGraw-Hill, 1972;942— 944.
Spanggord RJ, Myers CJ, Le Valley SE, Green CE, Tyson CA. Structure-activity relationship for the intrinsic hepatotoxicity of dinitrotoluenes. Chem Res Toxicol 1990;3:551-558.
Key MM, Henschel AF, Butler J, Ligo RN, Taberslaw IR. eds. Occupational diseases. A guide to their recognition. Revised edition. (DHEW [NIOSH] Publication No. 77-18). Washington, DC: US Government Printing Office, pp. 278-279.
Occupational exposure limits for airborne toxic substances. Occupational Safety and Health Series No 37. 3rd ed. International Labour Office, Geneva: 1991; pp. 877— 880.
NIOSH Pocket Guide to Chemical Hazards. CDC, DHHS (NIOSH) Publication No. 90-117. Washington, DC: US Government Printing Office, June 1990; pp. 100-101.
Proctor NH, Hughes JP, Fischman ML. Chemical hazards of the workplace. 2nd ed. New York: Van Nostrand Reinhold, 1989; pp. 218—219.
Levine RJ, Andjelkovoch DA, Kersteter SL, Arp EW Jr, Balogh SA, Blunden PB, Stanley JM. Heart disease in workers exposed to dinitrotoluene. J Occup Med 1986;28:811-816.
Data Sheet 658: Dinitrotoluene. Chicago: National Safety Council (Chemical Section), 1976.
McGee LC, McCausland A, Plume CA et al. Metabolic disturbances in workers exposed to dinitrotoluene. Am J Dig Dis 1942;9:329-332.
Richert DE, Butterworth BE, Popp JA. Dinitrotoluene: acute toxicity, oncogenicity, genotoxicity, and metabolism. CRC Crit Rev Toxicol 1984;13:217-234.
Hogstedt C, Andersson K. A cohort study of mortality among dynamite workers. J Occup Med 1979;21:553.
Hogstedt C, Axelson O. Nitroglycerin — nitroglycol exposure and the mortality in cardiocerebral vascular disease among dynamite workers. J Occup Med 1977;19:675-678.
Rieder RF. Methemoglobinemia and sulfhemoglobine-mia. In: Wyngaarden JB, Smith LH, eds. Cecil. Textbook of medicine, 16th ed. Philadelphia: WB Saunders, 1989 p. 896.
Chemical Safety Data Sheet. SD-93. Dinitrotoluene. Washington, DC: MCA, Inc., 1960 pp. 5—6, 14—15.
Physicians Desk Reference. 49th ed. Oradell, NJ: Medical Economics, 1995, p. 264.
Brewer C. How effective is the standard dose of disulfiram? A review of the alcohol-disulfiram reaction in practice. Br J Psychiatry 1984;144:202-207.
Manoguerra AS, Kerney ТЕ. Acute disulfiram toxicity. Vet Hum Toxicol 1982;24(4):282.
Klein LP, Fowler JF. Nickel dermatitis recall during disulfiram therapy for alcohol abuse. J Am Acad Dermatol 1992;26:645-646.
Gamboa P, Jauregui I, Urrutia I, Antepara I, Peralta C. Disulfiram-induced recall of nickel dermatitis in chronic alcoholism. Contact Dermatitis 1993;28:255.
Wright С IV, Vafier JA, Lake CR. Disulfiram-induced fulminating hepatitis: guidelines for liver panel monitoring. J Clin Psychiatry 1988;49:430-434.
Mason NA. Disulfiram induced hepatitis: case report and review of the literature. DICP Ann Pharmacother 1989;23:872-875.
Phillips M. Disulfiram-induced fulminating hepatitis and monitoring guidelines. J Clin Psychiatry 1990;51:168.
Wright C, Moore R, Grodin DM, Spyker DA. Disulfiram hepatotoxicity: incidence of enzyme elevation and predictors of fatal outcome. Vet Hum Toxicol 1991;33:38.
Spyker D. Disulfiram package insert warning? FDA/ AACT Memo, September 29, 1991.
Fisher CM. "Catatonia" due to disulfiram toxicity. Arch Neurol 1989;46:798-804.
Raing JM. Disulfiram toxicity and carbon disulfide poisoning. Am J Psychiatry 1977;134:371-378.
Peters HA, Levine RL, Matthews CG, Chapman W. Ex-trapyramidal and other neurologic manifestations associated with carbon disulfide fumigant exposure. Arch Neurol 1988;45:537-540.
Laplane D, Attal N, Sauron B, de Billy A, Dubois B. Lesions of basal ganglia due to disulfiram neurotoxicity. J Neurol Neurosurg Psychiatry 1992;55:925-929.
Mari M, de Blasi R, Lamberti P, Carella A, Ferrari E. Unilateral pallidal lesions after acute disulfiram intoxication. A clinical and magnetic resonance study. Movement Disorders 1993;8:247-249.
Riley D. Pallidal and putaminal lesions resulting from disulfiram intoxication. Movement Disorders 1992;7:189.
Krauss JK, Mohadger M, Wakahloo AK, Mindinger S. Dystonia and akinesia due to pallido putaminal lesions after disulfiram intoxication. Movement Disorders 1991;6:166-170.
Krauss J K, Wakahloo AK. Pallidal and putaminal lesions resulting from disulfiram intoxication. Movement Disorders 1992;7:188-189.
Blanc D, Deperz P. Unusual adverse reaction to an acaricide. Lancet 1990;335:1291-1292.
Burgess I. Adverse reactions to monosulfiram. Lancet 1990;336:873.
Lipsky JJ, Mays DC, Naylor S. Monosulfiram, disulfiram, and light. Lancet 1994;343:304.
Knowles RS, Virden JA. Handling of injectable antine-oplastic agents. Br Med J 1981;281:589-591.
Petras WP, Evans WE. Pharmacokinetics and pharmacodynamics of anticancer agents: contributions to the therapy of childhood cancer. Pharmacotherapy 1990;10:313-325.
Drugs of choice for cancer chemotherapy. Med Lett Drugs Ther 1995;37:25-32.
Potter JF, Schoeneman М. Metastasis of maternal cancer to the placenta and fetus. Cancer 1970;25:380-388.
Nieminen V, Remes N. Malignancy during pregnancy. Acta Obstet Gynecol Scand 1970;49:315-318.
Barber HRK. Fetal and neonatal effects of cytotoxic agents. Obstet Gynecol 1981 ;58:41 S—47S.
Frei E. Curative cancer chemotherapy. Cancer Res 1985;45:6523-6537.
Pons G. Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol 1985;14:177-183.
Beely L. Adverse effects of drugs in the first trimester of pregnancy. Clin Obstet Gynecol 1986;13:177-195.
Doll DC, Ringenberg Q, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol 1989;16:337-346.
Garber JE. Long-term follow-up of children exposed in utero to antineoplastic agents. Semin Oncol 1989;16:437-444.
Kalter H, Warkany J. Congenital malformations. N Engl J Med 1983;308:424-431, 491-497.
Malfetano JH, Goldkrand JW. Cis-platinum combination chemotherapy during pregnancy for advanced epithelial ovarian carcinoma. Obstet Gynecol 1990;75:545-547.
Schafer Al. Teratogenic effects of antileukemic chemotherapy. Arch Intern Med 1981;141:514-515.
Neubert D, Tapken S, Merker HJ. Induction of skeletal malformations in organ cultures of mammalian embryonic tissue. Naunyn Schmiedebergs Arch Pharmacol 1974;286b:271—282.
Lilleyman JS, Hill AS, Anderton KJ. Consequences of acute myelogenous leukemia in early pregnancy. Cancer 1977;40:1300-1303.
Manson JM, Dourson ML, Smith CC. Effects of cystine arabinoside on in vivo and in vitro mouse limb development. In Vitro 1977;13:434-442.
Barber HRK. Fetal and neonatal effects of cytotoxic agents. Obstet Gynecol 1981 ;51:41S—47S.
Averette HE, Boike GM, Jarrell MA. Effects of cancer chemotherapy on gonadal function and reproductive capacity. CA Cancer J Clin 1990;40:199-209.
Blatt J, Mulvill J, Ziegler J, Young RC, Poplach DC. Pregnancy outcome following cancer chemotherapy. Am J Med 1980;69:828-831.
Ruskin GJS, Booth M, Dent J, Salt S, Rustin F, Bag-shawe KD. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J 1984;288: 103-105.
Moloney WC. Management of leukemia in pregnancy. Ann NY Academy Sci 1964;114:857-867.
Meador J, Armentrout S, Slater L. Third trimester chemotherapy and neonatal haemotopoiesis. Cancer Chem-other Pharmacol 1987;19:177-179.
Zemlickis D, Loshner M, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med 1992;152:573-576.
Raffles A, Williams J, Costeloe K, Clark P. Transplacental effects of material cancer chemotherapy. Case report. Br J Obstet Gynaecol 1989;96:1099—1100.
Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low dose methotrexate in eight patients with rheumatic disease. Am J Med 1990;88:589— 592.
Powell H, Ekert H. Methotrexate-induced congenital malformations. Med J Aust 1971;2:1076-1077.
Emerson DJ. Congenital malformations due to attempted abortion with aminopterin. Am J Obstet Gynec 1962;84:356-357.
Beeley L. Drugs and breast feeding. Clin Obstet Gynecol 1986;13:247-251.
Smith IJ, Wilson JT. Infant effect of drugs excreted into breast milk. Pediatr Rev Commun 1989;3:93-113.
Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1988; 14:217—240.
Amato D, Niblett JS. Neutropenia from cyclophosphamide in breastmilk. Med J Aust 1977;1:383-384 (letter).
Duradola JI. Administration of cyclophosphamide during late pregnancy and early lactation. A case report. J Nat Med Assoc 1979;71:165-166.
Rieder MJ: Drugs and breastfeeding. In: Koren G, ed. Maternal-fetal toxicology. New York: Marcel Dekker, 1990, p. 72.
Giacoia GP, Catz CS. Drugs and pollutants in breast milk. Clin Perinatol 1979;6:181-196.
Chaplin S, Sanders GL, Smith JM. Drug excretion in human breast milk. Adverse Drug React Acute Pois Rev 1982;1:255-287.
Berlin CM Jr. Drugs and chemicals: exposure of the nursing mother. Pediatr Clin North Am 1989;36:1089— 1091.
Committee on Drugs. American Academy of Pediatrics. The transfer of drugs and other chemicals into human breast milk. Pediatrics 1983;72:375-383.
La Leche League International. Breast feeding and drugs in human milk. Vet Hum Toxicol 1978;2:346-375.
Redman JR, Bajorunas DR, Goldstein MC et al. Semen preservation and artificial insemination for Hodgkin’s disease. J Clin Oncol 1987;5:233-238.
Recommendations for the safe handling of parenteral an-tineoplastic drugs. Dept of Health and Human Service Publication. (NIH) 83-2621, Bethesda, MD: National Institutes of Health, 1982.
Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA 1985;253:1590-1592.
ASHP Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. Am J Hosp Pharm 1990;47:1033-1049.
McDiarmid MA. Medical surveillance for antineoplastic drug handlers. Am J Hosp Pharm 1990;47:10-25.
Christensen CJ, Lemasters GK, Wakeman MJA. Work practices and policies of hospital pharmacists preparing antineoplastic agents. J Occup Med 1990;32:508-512.
Valanis B, Vollmer WM, Labuhn K, Glass A, Corelli C. Antineoplastic drug handling protection after OSHA guidelines comparison by profession, handling activity and work site. J Occup Med 1992;34:149-155.
Falck K, Rohn P, Sorsa M et al. Mutagenicity in urine of nurses handing cytostatic drugs. Lancet 1979;!: 1250— 1251.
Norppa H, Sorsa M, Vaino H, Grohn P, Heinonen E, Holski L et al. Increased sister chronatid exchange frequencies in lymphocytes of nurses handling cytostatic drugs. Scand J Work Environ Health 1980;6:299-301.
Wakvik H, Kleppo, Brogger A. Chromosome analyses of nurses handling cytostatic agents. Cancer Treat Rep 1981;65:607-610.
Sotaniem EA, Sutinen S, Arranto AJ, Sutinen S, Sot-aniem KA, Lehtola J et al. Liver damage in nurses handling cytostatic agents. Acta Med Scand 1983;214:181— 189.
Selevan SG, Lindbohm M-L, Hornung RW, Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med 1985;313:1 172-1 178.
Stacker I, Caillard J-F, Collin R, Gout M, Poyen D, Hemon D. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health 1990;16:102-107.
Thiringer G, Graining G, Holmen A, Hogstadt B, Jar-rholm B, Jonsson D, Persson L et al. Comparison of methods for the biomonitoring of nurses handling antitumor drugs. Scand J Work Environ Health 1991;17:133-138.
Staiano N, Galleli JF, Adamson RH, Thorgiersson SS. Lack of mutagenic activity in urine from hospital pharmacists admixing antitumour drugs. Lancet 1981; 1:615— 616.
Ames BN, McCann J, Yamasahi E. Methods for detecting carcinogens and mutagens with the Salmonella/ mammalianmicrosome mutagenicity test. Mutat Res 1975;35:347.
Skov T, Lynge E, Maarup B, Olsen L, Rorth M, Win-thereik H. Risks for physicians handling antineoplastic drugs. Lancet 1990;2:1446.
Lunn G, Sansone EB, Andrews AW, Hellwig LC. Degradation and disposal of some antineoplastic drugs. J Pharm Sci 1989;78:652-659.
Carpenter L, Beral V, Roman E, Swerdlow AJ, Davies G. Cancer in laboratory workers. Lancet 1991;338:1080-1081.
Savitz DA, Chen J. Parental occupation and childhood cancer: review of epidemiologic studies. Environ Health Perspect 1990;8:325-327.
Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol 1982;9:23— 33.
Makinen L, Makipernaa A, Rautonen J, Heino M, Pyrhonen S, Laitinen LA et al. Long-term cardiac sequelae after treatment of malignant tumors with radiotherapy or cytostatics in children. Cancer 1990;65:1913-1917.
Mills BA, Robert RW. Cyclophosphamide-induced cardiomyopathy. A report of two cases and review of the English literature. Cancer 1979;43:2223-2226.
Dresdale A, Bonow RO, Wesley R et al. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from post-surgical adjuvant treatment of patients with soft tissue sarcoma. Cancer 1983;52:51-60.
Porembka DT, Lowder JN, Orlowski JP, Bastilli J, Lockren J. Etiology and management of doxorubicin cardiotoxicity. Crit Care Med 1989;17:569-572.
Sriskandan S, O’Brien MER, Smith IE, Collins P, Gore ME. Aggressive management of doxorubicin-induced cardiomyopathy associated with "low" doses of doxorubicin. Postgrad Med J 1994;70:759-761.
Hale JP, Lewis IJ. Anthracyclines: cardiotoxicity and its prevention. Arch Dis Child 1994;74:457-462.
Steinherz U, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992;89:942-949.
Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-815.
Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med 1991;324:843-845.
Yeung ST, Yoong C, Spink J, Galbraith A, Smith PJ. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 1991 ;337:816.
Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
Stover DE. Pulmonary toxicity. Section 5 in De VitaVT Jr, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. 3rd ed. Philadelphia: J В Lippincott, 1989; pp. 2162-2169.
Weiss RB, Portero DS, Penta JS. The nitrosoureas and pulmonary toxicity. Cancer Treat Rev 1981;8:111-125.
Maher J, Daly PA. Severe bleomycin lung toxicity: reversal with high dose corticosteroids. Thorax 1993;48:92-94.
Fields SM, Lindley CM. Thrombotic microangiopathy associated with chemotherapy: case report and review of the literature. DICP 1989;3:582-588.
Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984;101:41-44.
Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 1989;34:201-230.
Gomez J-L, DuPont A, Cusan L, Tranblay M, Tremblay M,Labre F. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen Nilutamide (anan-dron). A case report. Am J Med 1992;92:563-566.
Gomez J-L, DuPont A, Cusan L, Tremblay M, Subaru R, LaMay M, Labrie F. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 1992;92:465-470.
Blaker IC, Sawyer AM, Dooley JS, Sheuer PJ, McIntyre N.Severe hepatitis caused by cyproterone acetate. Gut 1990;31:556-557.
Parys ВТ, Hamid S, Thomson RGN. Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J Urol 1991;67:312-313.
Levesque H, Trivalle C, Manchon ND et al. Fulminant hepatitis due to cypnoterone acetate. Lancet 1989;1:215-216.
Cox K, Stuart-Harris R, Abdini G, Grygiel J, Raghaven D. The management of cytotoxic-drug extravasation: guidelines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 1988;148:185-189.
Ignoffo RJ, Friedman МА. Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 1980;7:17-27.
Rudolph R, Larson DL. Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 1987;5:1116-1126.
Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer 1982;49:1796-1799.
Scarim SK. Treatment of doxorubicin extravasations. DICP 1989;23:386-387.
Loth TS. Minimal surgical debridement for the treatment of chemotherapeutic agent-induced skin extravasations. Cancer Treat Rep 1986;70:401-404.
Duvall E, Baumann B. An unusual accident during the administration of chemotherapy. Cancer Nursing 1980;3(4):305—306.
Harwood KY, Aisner J. Treatment of chemotherapy extravasation: current status. Cancer Treat Rep 1984;68:939-945.
Olver IN, Schwarz MA. Use of dimethylsulfoxide in limiting tissue damage caused by extravasation of doxorubicin. Cancer Treat Rep 1983;67:407-408.
Olver IN, Aisner J, Hament A, Buchanan L, Bishop JF, Kaplan RS. A prospective study of topical dimethylsulfoxide for treating anthracycline extravasation. J Clin Oncol 1988;6:1732-1735.
Burlock AL, Howser DM, Hubbard SM. Nursing management of adriamycin extravasation. Am J Nursing 1979;79:94-96.
Cox RF. Managing skin damage induced by doxorubicin hydrochloride and daunorubicin hydrochloride. Am J Hosp Pharm 1984;41:2410-2414.
Dorr RT, Albert DS. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. JNCI 1985;74:113-120.
Argenta IC, Manders EK. Mitomycin C extravasation injuries. Cancer 1983;51:1080-1082.
Umstead GS, Fryer NL, Decker DA. Local tissue reaction to intravenous fluorouracil and leucovorin. DICP 1991;25:249-250.
Tsavaris NB, Komitsopoulou P, Karagiouris P, Louka-tou P, Zannou 1 et al. Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 1992;30:330-333.
Peters FTM, Beijnen JH, ben Bokkel HuininkWW. Mi-toxantrone extravasation injury. Cancer Treat Rep 1987;71:992-993.
Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Intern Med 1981;94:66— 72.
Rogers BB. Toxol: a promising new drugs of the ’90s. Oncol Nurs Forum 1993;20:1483-1489.
Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 1989;7:1142-1149.
Craig JB, Powell BL. Review: the management of nausea and vomiting in clinical oncology. Am J Med Sci 1987;293:34-44.
Grunberg SM. Making chemotherapy easier. N Engl J Med 1990;322:846-848.
Siegel LJ, Longo DL. The control of chemotherapy-induced emesis. Ann Intern Med 1981;95:352-359.
Morrow GR. Chemotherapy-related nausea and vomiting: etiology and management. CA Cancer J Clin 1989;39:89-104.
Graves T. Ondansetron: a new entity in emesis control. DICP 1990;24(Suppl):S51—S54.
Nicolson M, Leonard RCF. Adverse effects of cancer chemotherapy. An overview of techniques for avoidance of minimisation. Drug Safety 1992;7:316-322.
New anti-nausea medication approved. FDA Medical Bulletin 1991;21(1):6.
Ondansetron hydrochloride injection (Zofran). Manufacturers’ Insert. Glaxo Pharmaceuticals, January 1991.
Marty M, Poisillart P, Scholl S, Droz JP, Azab M, Brion N et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38 032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816-821.
De Mulder PHM, Seynaeve C, Vermorken JB, Liessum PA, Mols-Jevdevic S, Allman EL et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter randomized double-blind crossover study. Ann Intern Med 1990;113:834-840.
Pinkerton CR, Williams D, Wootton C, Meller ST, McElwain TJ. 5HT3 antagonist ondansetron — an effective outpatient antiemetic in cancer treatment. Arch Dis Child 1990;65:822-825.
Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR38 032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990;322:810-816.
Vermeulen LC Jr, Matuszewski KA, Ratko TA, Butler CD, Burnett DA, Vlasses PH. Evaluation of ondansetron prescribed in US Academic Medical Centers. Arch Intern Med 1994;154:1733-1740.
Foot ABM, Hayes C. Audit of guidelines for effective control of chemotherapy and radiotherapy induced emesis. Arch Dis Child 1994;71:475-480.
Bone ME, Wilkinson DJ, Young JR, McNeil J, Charton S. Ginger root — a new antiemetic. The effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery. Anaesthesia 1990;45:669-677.
Liu WHD. Ginger root, a new antiemetic. Anaesthesia 1990;45:1085.
Dundee JW, Ghaley RG, Fitzpatrick KTJ, Abram WP, Lynch GA. Acupuncture prophylaxis of cancer chemotherapy-induced sickness. J Roy Soc Med 1989;82:268— 269.
Dundee JW, Yang J, Ghaly RG. Vomiting and chemotherapy. Lancet 1990;535—541.
Jay GR, Wallace M, de Fusco P. Focus on granisetron. The second 5T3-receptor antagonist approved for chemotherapy-induced emesis. Hosp Formul 1994;29:191 — 201.
Solberg LA, Wizk MR, Bruckman JE. Doxorubicin-en-hanced skin reactions after whole-body radiation for leukemia cutis. Mayo Clin Proc 1980;55:711-715.
Shelly WB, Shelley ED, Campbell AC, Weigerberg H. Drug eruptions presenting at sites of prior radiation damage (sunlight and electron beam). Am Acad Dermatol 1984;11:53-57.
Vanek N, Hortobagyi GN, Buzdar AV. Radiotherapy enhances the toxicity of aminoglutethimide. Med Pediatr Oncol 1990;18:162-164.
Williams DS, Leslie MD. Skin reaction following aminoglutethimide and radiotherapy. Br J Radiol 1987;60:1226-1227.
Kellie SJ, Plowman PN, Malpas JS. Radiation recall and radiosensitization with alkylating agents. Lancet 1987;6:1149-1150.
D’Angio GJ, Farber S, Maddock CL. Potentiation of x-ray effects by actinomycin D. Radiology 1959;73:175— 177.
Donaldson SS, Glick JM, Wilbur JR. Adriamycin activating a recall phenomena after radiation therapy. Ann Intern Med 1974;8:407-408.
Philips TL. Radiation-drug interactions in the treatment of cancer. New York: Wiley, 1980.
Vassal G, Hartmann O, Habrand JL, Pico JL, Lemerle J. Radiosensitization after busulphan. Lancet 1987;1:57L
Nemecheck PM, Corder MC. Radiation recall associated with vinblastine in a patient treated for Kaposi Sarcoma related to Acquired Immune Deficiency Syndrome. Cancer 1992;70:1605-1606.
Parry BR. Radiation recal induced by tamoxifen. Lancet 1992;340:49.
Kaldor JM, Day NE, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV et al. Leukemia following Hodgkin’s disease. N Engl J Med 1990;322:7-13.
Devereau S, Selassie TG, Hudson GV, Hudson BV, Linch DC. Leukemia complicating treatment for Hodgkin’s disease: the experience of the British National Lymphoma Investigation. Br Med J 1990;301:1077— 1080.
Valagassa P, Santoro A, Fossati-Bellani F, Banfi A, Bo-nadonna G. Second acute leukemia and other malignancies following treatment for Hodgkin’s disease. J Clin Oncol 1986;4:830-837.
Ingram L, Mott MG, Mann JR, Raafat F, Darbyshire PJ, Jones PHM. Second malignancies in children treated for non-Hodgkin’s lymphoma and T-cell leukemia with the UKCCSG regimens. Br J Cancer 1987;55: 463-466.
Glayney DW, Longo DL. Leukemia after treatment of ovarian cancer or Hodgkin’s disease. N Engl J Med 1990;322:1818-1821.
Kaldor JM, Day NE, Petersson F, Clarke EA, Pedersen D, Mehnert W et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990;322:1-6.
Chambers SK, Chopyk RL, Chambers JT, Schwartz PE, Duffy TP. Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer. Cancer 1989;64:2459-2461.
Reed E, Evans M K. Acute leukemia following cisplatinbased chemotherapy in a patient with ovarian cancer. J Natl Cane Inst 1990;82:431-432.
Brenez D, Devriendt J, Lenclud C, Schmerber J. Acute non-lymphocytic leukemia following chemotherapy with cisplatin and etoposide for non-small-cell carcinoma of the lung. Cancer Chemother Pharmacol 1990;26:235— 236.
Van den Anker-Lugtenburg PJ, Sizoo W. Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythermia with hydroxyurea. Am J Hematol 1990;33:152.
Pui C-H, Hancock ML, Raimondi SC, Head DR, Thompson E et al. Myeloid neoplasia in children treated for solid tumors. Lancet 1990;336:417-421.
Hawkins MM, Kingston JE, Wilson LMK. Late deaths after treatment for childhood cancer. Arch Dis Child 1990;65:1356-1363.
Neugat Al, Robinson E, Nieves J, Murray T, Tsai W-Y. Poor survival of treatment-related acute nonlymphocytic I leukemia. JAMA 1990;264:1006-1008.
Hirota Y, Matsumoto I, Aso T, Kondou S, Ikematsu W et al. Hepatocellular carcinoma and bladder cancer as complications following five years of chemotherapy for acute myeloblastic leukemia. Jpn J Med 1990;29:203— 207.
Sartori S, Nielsen 1, Trevisani L, Pazzi P, Malacarne P. Barrett’s esophagus after anti neoplastic chemotherapy. Endoscopy 1990;22:152.
McKay PJ, Docherty JG, laFerla G, Lucine NP. Carcinoma of the small intestine following treated acute my- ; eloid leukemia. Eur J Cancer 1990;26:543-544.
Weiss RB. Leukemia following cisplatin therapy. J Natl Cancer Inst 1990;82:795.
Goodman A, Zukerberg LR, Nikrui N, Scully RE. Vaginal adenosis and clear cell carcinoma after 5-fluorour-acil treatment for condylomas. Cancer 1991;68:1628— I 1637.
Casciato DA, Scott JL. Acute leukemia following prolonged cytotoxic agent therapy. Medicine 1979;58:32— 47.
Boivin J-F: Second cancers and other late side effects of cancer treatment. A review. Cancer 1990;65:770-775.
Chasen MR, Falkson GL. Leukemia after chemotherapy for cancer. Cancer Biotherapy 1993;8:115-122.
Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987;70:1412-1417.
Burde B, Haim N, Gez E, Polliack A. Acute myeloblastic leukemia following treatment with mitomycin C; a case report. Cancer Chemother Pharmacol 1989;24:71.
Flaherty LE, Schwert R, Redman BG. Case report: Development of Hodgkin’s disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic melanoma. J Natl Cane Inst 1990;82:360.
Toh ВТ, Gregory SA, Knospe WH. Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard. Am J Hematol 1988;28:58-60.
Andersson M, Philip P, Pedersen-Bjergaard J. High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer. Cancer 1990;65:2460-2464.
Kreissman SG, Gelber RD, Cohen HJ, Clavell LA, Leavitt P, Sallan SE. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer 1992;70:2208-2213.
Curtis RE, Boice JD Jr, Moloney WC, Ries LG, Flannery JT. Leukemia following chemotherapy for breast cancer. Cancer Res 1990;50:2741-2746.
Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philips D, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin and bleomycin forgerm-cell tumors. Lancet 1991;338:359-363.
Potts M. Non-surgical abortion: Who’s for methotrexate. Lancet 1995;346:655-656.
Coltman CA Jr, Dahlberg S. Treatment-related leukemia. N Engl J Med 1990;322:52-53.
DeVore R, Whitlock J, Hainsworth JD, Johnson DH. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome llq. Ann Intern Med 1989;110:740-742.
Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
Cohen LF, BalowJE, Magrath IT, Poplack DG, Ziegler JL et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt’s lymphoma. Am J Med 1980;68:486-491.
Simmons ED, Somberg KA. Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer 1991;67:2062-2065.
List AF, Kummet TD, Adams JD, Chun HG. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fluderabine phosphate. Am J Med 1990;89:388-390.
Loosveld OJL, Schouten HC, Gaillard CA, Blijham GH. Acute tumour lysis syndrome in a patient with acute lymphoblastic leukemia after a single dose of prednisone. Br J Haematol 1991;77:122-123.
Fields AL, Josse RG, Bergsagel DE. Oncologic emergencies, metabolic emergencies. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: JB Lippincott, 1985; pp. 1866-1881.
Flotre M, Borenstein M, Blair TMH, eds. Evaluation and management of oncologic emergencies. Emerg Med Rep 1991;12(2):11 —16.
Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The retinoic acid syndrome in acute promyelo-monocytic leukemia. Ann Intern Med 1992; 117:272— 296.
Chanarin N, Smith GB, Green A, Andrews MU. Retinoic acid syndrome. Lancet 1993;341:1289-1290.
Malinakis T, Papadimitriou CA, Koufos C, Fertakis A. A recently recognized entity associated with the treatment of acute promyelocytic leukemia: the retinoic acid syndrome. Haematologica 1993;18:192-194.
Frankel SR, Eardley A, HellerG, Berman E, Miller WH Jr et al. M\-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 1994;120:278-286.
Thomas LLM, Mertens MJF, von dem Borne AEFK, van Boxtel CJ, Veenhof CHN, Veies EP. Clinical management of cytotoxic drug overdose. Med Toxicol 1988;3:253-263.
Von Hoff DD, Maxwell WL et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979;91:710-717.
Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm 1974;8:650-655.
Cox J, Penn N, Masood M, Hancock AK, Parker D. Drug overdose — a hidden hazard of obesity. J R Soc Med 1987;80:708-709.
Back H, Gustavsson A, Ellsborg S et al. Accidental doxorubicin overdosage. Acta Oncol 1995;34:533-536.
Curran CF. Adria Laboratories. Personal communication. February 3, 1989.
Wolfson S, Olney MB. Accidental ingestion of a toxic dose of chlorambucil. JAMA 1957;165:239-240.
Galton DAG, Israels LG, Nabario JDN, Till M. Clinical trials of p-(DI-2-chloroethylamino)-phenylbutyric acid (CB 1348) in malignant lymphoma. Br Med J 1955;2:1172-1176.
Green AA, Naiman JL. Chlorambucil poisoning. Am J Dis Child 1968;116:190-191.
Amment A, Reitter B, Muller-Wiefel DE. Chlorambucil neurotoxicity. Report of two cases. Helv Paediatr Acta 1980;35:281-287.
Enck RE, Bennett JM. Inadvertent chlorambucil overdose in adult. NY State J Med 1977;77:1480-1481.
Byrne TN Jr, Moseley TAE HI, Finer MA. Myoclonic seizures following chlorambucil overdose. Ann Neurol 1981;9:191-194.
Vandenberg SA, Kulig KW, Spoerke DG, Hall AH, Bailie VJ, Rumack BH. Chlorambucil: accidental overdose of an antineoplastic. Vet Hum Toxicol 1987;29:479.
Vandenberg SA, Kulig K, Spoerke DG, Hall AH, Bailie VJ, Rumack BH. Chlorambucil: accidental ingestion of an antineoplastic drug. J Emerg Med 1988;6:495-498.
Bambarola FA. Overdosage associated with Ifex (sterile ifosfamide). Personal communication. Bristol-Myers Oncology Division, March 12, 1991, and March 21, 1991.
Brade WP, Herdrich K, Klein HO. Ifosfamide-dose and scheduling. Contrib Oncol 1987;26:22-52.
EliasAD, EderJP, SheaT, BeggCB, Frei E Ill, Antman KH. High-dose ifosfamide with mesna uroprotection. A phase I study. J Clin Oncol 1990;8:170-178.
Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard and high-dose schedules. Semin Oncol 1990;17:68-73.
Altman LK. Overdoses of cancer drug revealed by patient’s death. New York Times, March 24, 1995.
Coates TD. Survival from melphalan overdose. Lancet 1984;2:1048.
Jost LM. Uberdosierung von melphalan (Alkeran): symptome unde behandlung. Eine Ubersicht. Onkologie 1990;13:96-101.
Volkin RL, Shadduck KK, Winkelstein et al. Potentiation of carmustine-cranial irradiation-induced myelo-suppression by cimetidine. Arch Intern Med 1982; 142:248.
Foon KA, Haskell CM. Inadvertent overdose with lomustine (CCNU) followed by hematologic recovery. CancerTreat Rep 1982;66:1241-1242.
Hornsten P, Sundman-Engberg B, Gahrton G, Johansson B. CCNU toxicity after an overdose in a patient with Hodgkin’s Disease. Scand J Haematol 1983;31:9-14.
Bambarola F, Bristol-Myers Oncology Division. Mesna (Mesnex). Personal communication, April 2, 1991.
Schoenik SE. Ifosfamide and mesna. Clin Pharm 1990;179—191.
Lampkin BC, Higgins GR, Hammond D. Absence of neurotoxicity following massive intrathecal administration of methotrexate. Case report. Cancer 1967;20:1780-1781.
Pruitt AW, Kinkade J M Jr, Patterson JH. Accidental ingestion of methotrexate. J Pediatr 1974;85:686-688.
Winchester JF, Rahman A, Tilston WJ, Bregman H, Mortensen LM, Gelfand MC et al. Will hemoperfusion be useful for cancer chemotherapeutic drug removal? Clin Toxicol 1980;17:557-569.
Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977;297:630.
Hande KR, Balow JE, Drake JC, Rosenberg SA, Chabner BA. Methotrexate and hemodialysis. Ann Intern Med 1977;87:496.
Addiego JE Jr, Ridgway D, Bleyer WA. The acute management of intrathecal methotrexate overdose: pharmacologic rationale and guidelines. J Pediatr 1981 ;98:825— 828.
Ettinger U. Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 1982;50:444-450.
Howell SB, Enxminger WD, Krishan A, Free E III. Thymidine rescue of high-dose methotrexate in humans. Cancer Res 1978;38:325-330.
Spiegel RJ, Cooper PR, Blum RH, Speyer JL, McBride D, Mangiardi J. Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Engl J Med 1984;31 1:386-388.
Poplach DG. Massive intrathecal overdose: "Check the label twice." N Engl J Med 1984;311:400—402.
Williams WM, Chen TS, Huang КС. Effect of penicillin on the renal tubular secretion of methotrexate in the monkey. Cancer Res 1984;44:1913-1917.
Haim N, Kedar A, Robinson E. Methotrexate-related deaths in patients previously treated with cis-diam-minedichloride platinum. Cancer Chemother Pharmacol 1984;13:223-225.
Ellison NM, Servi RJ. Acute renal failure and death following sequential intermediate dose methotrexate and 4-FU: a possible adverse effect due to concomitant indomethacin administration. Cancer Treat Rep 1985;69:342-343.
Thyss A, Milano G, Kubar J, Narner M, Schneider M. Clinical and pharmacokinetic evidence of a life threatening interaction between methotrexate and ketoprofen. Lancet 1986;1:256-258.
Yap AKL, Janmashanker JJ, Luscombe DK. Methotrexate toxicity coincident with packed red cell transfusion. Lancet 1986;2:641.
Bouffet E, Frappaz D, Laville M, Finaz J, Pinkerton CR, Philip T et al. Charcoal haemoperfusion and methotrexate toxicity. Lancet 1986;1:1497.
Frappaz D, Bouffet E, Cochat P, Laville M, de Vilaire JF, Philip T et al. Hemoperfusion sur charbon active et hemodialyse dans 1’intoxication aigue au methotrexate. Presse Med 1988;17:1209-1213.
Brown MA, Corrigan AB. Pancytopenia after accidental overdose of methotrexate. A complication of low dose therapy for rheumatoid arthritis. Med J Aust 1991;155:493-494.
Mclvon A. Charcoal hemoperfusion and methotrexate toxicity. Nephron 1991 ;58:378.
Ettinger U, Freeman Al, Creaven PJ. Intrathecal methotrexate overdose without neurotoxicity. Case report and literature review. Cancer 1978;41:1270-1273.
Jakobson AM, Krereger A, Mortimer O, Henningsson S, Seidel H, Moe PJ. Cerebrospinal fluid exchange after intrathecal methotrexate overdose. A report of two cases. Acta Paediatr 1992;81:359-361.
Hendrik D, Mirkin BL. Metabolic disposition and toxicity of 6-mercaptopurine after massive overdose. Lancet 1984;1:277.
Brooks RJ, Dorr RT, Durie BGM. Interaction of allopurinol with 6-mercaptopurine and azathioprine. Biomedicine 1982;36:217-222.
Laidlaw ST, Reilly JT, Suvarna SK. Fatal hepatotoxicity associated with 6-mercaptopurine therapy. Posgrad Med J 1995;71:639.
Harvey VJ, Slevin MJ, Dicloway MR, dark Pl, Johnston A. The influence of cimetidine on the pharmacokinetics of5-FU. Br J Clin Pharmacol 1984;18:421-430.
Product Literature. Fluorouracil injection. Roche Laboratories; July 1988.
McLachlan S-A, Millward MJ, Toner GC, Guiney MJ, Bishop J F. The spectrum of 5-fluorouracil cardiotoxicity. Med J Aust 1994;161:207.
Pawlicki M, Zuchowska-Vogelgesang B, Sliz E. The case of vespesid overdosage in a patient with Hodgkin’s Disease. Cancer Chemother Pharmacol 1990;25:387.
Berenson MR Recovery after inadvertent massive overdosage of vincristine (NSC-67 574). Cancer Chemother Rep 1971;55:525-526.
FDA Reports of Suspected Adverse Reactions to Drugs. 69(3):9 (no year given).
Suskind RM, Brusilow SW, Zehr J. Syndrome of inappropriate secretion of antidiuretic hormone produced by vincristine toxicity (with bioassay of ADH level). J Pediatr 1972;81:90-92.
Kaufman IA, Kung FH, Koenig HM, Giammona ST. Overdosage with vincristine. J Pediatr 1976;89:671-674.
Grush ОС, Morgan SK. Folinic acid rescue for vincristine toxicity. Clin Toxicol 1979;14:71-78.
Barna P. Vincristine overdose. Clin Pediatr 1980; 19:440.
Wakem CJ, Bennett JM. Inappropriate ADH secretion associated with massive vincristine overdosage. Aust NZ J Med 1975;5:266.
Thomas LLM, Braat PC, Somers R, Goudsmit R. Massive vincristine overdose: failure of leucovorin to reduce toxicity. Cancer Treat Rep 1982;66:1967-1969.
Gaidys WG, Dickerman JD, Walters CL, Young PC. Intrathecal vincristine, report of a fatal case despite CNS washout. Cancer 1983;52:799-801.
Beer M, Cavalli F, Martz G. Vincristine overdose: Treatment with and without leucovorin rescue. Cancer Treat Rep 1983;67:746-747.
Maeda K, Ueda M, Ohtaka H, Koyama Y, Ohgani M, Miyazaki A. A massive dose of vincristine. Jpn J Clin Oncol 1987;17:247-253.
Dyke RW. Treatment of inadvertent intrathecal injection of vincristine. N Engl J Med 1989;321:1270-1271.
Jackson DV, Wells H B, Atkins JN et al. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 84:1016-1022.
Fiorentin MW, Scalvagno L, Sileni VC, Paccagnella A, Ferrazzi E, Zagorel V, Fosser V. Vindesine overdose. Cancer Treat Rep 1982;66:1247-1248.
Pierga J-Y, Beuzebox P, Dorral T. Palangic T, Pouillart P. Favourable outcome after plasmapheresis for vincristine overdose. Lancet 1992;340:185.
Ohnuma T, Holland JF, Freeman A, Sinks LF. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 1970;30:2297-3305.
Pfeifle CE, Howell CB, Felthouse RD, Woliver TBS, Andrews PA et al. High dose cisplatin with sodium thiosulphate protection. J Clin Oncol 1985;3:237-244.
Schiller JH, Rozental J, Tutsch KD, Trump DL. Inadvertent administration of 480 mg/m2 of cisplatin. Am J Med 1989;86:624-625.
Fassoulaki A, Pavlov H. Overdose intoxication with cisplatin — a cause of acute respiratory failure. J R Soc Med 1989;82:689.
Borch RF, Katz JC, Lieder PH, Pleasants ME, Effects of diethyldithiocarbamate rescue on tumor response to cisplatinum in a rat model. Proc Natl Acad Sci USA 1980;77:5441-5444.
Mollman JE, Glover DJ, Hogan WM et al. Cisplatin neuropathy: risk factors and a possible protective agent. Neurology 1985;35(Suppl l):80.
Schweitzer VG, Dolan DF, Abrams GE et al. Amelioration of cisplatin-induced ototoxicity by fosfomycin. Laryngoscope 1986;96:948.
Chu G, Mantin R, Shen Y-M, Baskett G, Sussman H. Massive cisplatin overdose by accidental substitution for carboplatin. Toxicity and management. Cancer 1993;72:3707-3714.
Koppensteiner R, Minar E, Marosi L, Ehringer H. Survival following an extremely high dose of mitoxantrone in a 73-year-old female with small cell bronchial carcinoma. J Cancer Res Clin Oncol 1988; 114:324.
Reid FJ. Hydrazine Poisoning. Br Med J 1965;2:1246.
Scaes MDC, Tinbrell JA. Studies on hydrazine hepatotoxicity. I. Pathological findings. J Toxicol Environ Health 1982;10:941-953.
Harati Y, Niakan E. Hydrazine toxicity, pyridoxine therapy and peripheral neuropathy. Ann Intern Med 1986;104:728-729.
Steffen RO, Lederle Laboratories. Novantrone mitox-antrone HC1. Personal communication. March 21, 1991.
Hall C, Dougherty WJ, Lebish I J, Brock PG, Man A. Warning against use of intrathecal mitoxantrone. Lancet 1989; 1:734.
Siegert W, Hiddemann W, Koppensteiner R, Buchner T, Essink M, Huhn D et al. Accidental overdose of mitoxantrone in three patients. Med Oncol Tumor Pharmaco-ther 1989;6:275-278.
Procarbazine. Product Information. Roche Laboratories, January 1987.
Chabner BA, Myers CE. Clinical pharmacology of cancer chemotherapy. In : De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 3rd ed. Philadelphia: J В Lippincott, 1989, pp. 349— 395.
Buice RG, Sidhu P. Reversed-phase high-pressure liquid chromatographic determination of serum methotrexate and 7-hydroxymethotrexate. J Pharm Sci 1982;71:74— 77.
Kato Y, Matsushita T, Yokoyama T, Mohri K. Determination of 6-mercaptopurine in acute lymphoblastic leukemia patients. Plasma by high-performance liquid chromatography. Ther Drug Monit 1991;13:220-225.
Kato Y, Kaneko H, Matsushita T, Inamori K, Egi S, Togawa A et al. Dire'ct injection analysis of melphalan in plasma using column-switching high-performance liquid chromatography. Ther Drug Monit 1992;14:66-71.
Zulian GD, Tullen E, Maton B. Methylene blue for ifos-famide-associated encephalopathy. N Engl J Med 1995;332:1239-1240.
Dextrazoxane for cardiac protection against doxorubicin. Med Lett Drugs Ther 1995;37:110—111.
Gibson TP, Reich SD, Krumlovsky FA, Ivanorich P, Conczy C. Hemoperfusion for methotrexate removal. Clin Pharmacol Ther 1978;23:351-355.
Wadleigh RG, Redman RS, Graham ML. Krasnow SH, Anderson A, Cohen MH. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med 1992;92:481-484.
Mostyn G, Souza LM, Keech J, Sheridan W, Campbell L, Alton NK et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988;1:667-672.
Jenney MEM, Jones PHM. Long-term survival after heart transplantation for doxorubicin-induced cardiomyopathy. Arch Dis Child 1992;67:153.
Howell SB, Enxminger WD, Krishan A, Free E Ill. Thymidine rescue of high-dose methotrexate in humans. Cancer Res 1978;38:325-330.
Lafolie P, Liliemark J, Bjork O, Aman J, Wranne L, Peterson C. Exchange of cerebrospinal fluid in accidental intrathecal overdose of cytarabine. Med Toxicol 1988;3:248-252.
Wood JH. Physiology, pharmacology and dynamics of CSF. Neurobiology of cerebrospinal fluid. New York: Plenum, 1980, pp. 1 — 16.
Committee on Drugs and Contrast Media, American College of Radiology. Manual on Iodinated Contrast Media. 1991.
Reynolds JEF, ed. Martindale: The extra pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993; pp. 702—711.
McEvoy GK, ed. AHFS Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, 1992; pp. 1420—1474.
Westhoff-Bieck M, Bieck JS, Josk S. The adverse effects of angiographic radiocontrast media. Drug Safety 1991;6:28-36.
Almen T. Relations between chemical structure, animal toxicity and clinical adverse effects of contrast media. In: Enge I, Edgren J, eds. Patient safety and adverse events in contrast media examinations. Amsterdam: Elsevier, 1989. Nycomed Scientific Symposium 1988. Oslo, Norway: October 18, 1988, p. 25—45.
Siegle RL. Treatment of contrast reactions. Hosp Formul 1991;26:662-665.
Spinier SA, Goldfarb S. Nephrotoxicity of contrast media following coronary angiography: pathogenesis, clinical course and preventive measures including the role of low osmolality contrast media. Ann Pharmacother 1992;26:56-64.
Leeds NE. The clinical application of radiopharmaceuticals. Drugs 1990;40:713-721.
Parfery PS, Cramer BC, McManamon PJ. Should nonionic radiographic contrast media be given to all patients? Can Med Assoc J 1988;138:497-500.
Katayama N, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsurra K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990;175:621-628.
Wolf GL, Arenson RL, Cross AP. A prospective trial of ionic vs nonionic contrast agents in routine clinical practice. Comparison of adverse effects. Am J Radiol 1989;152:939-944.
Goldstein HA, Kashanian FK, Blumetti RF, Holyoak WL, Hugo FP, Blumenfield DM. Safety assessment of gadopenetate dimeglumine in US clinical trials. Radiology 1990; 174:1723.
Harbury OL. Generalized seizures after IV administration of gadopenetate dimeglumine. Am J Neurol 1991 ;12:666.
Peck WW, Slutsky RA, Mancini GBJ, Higgins CB. Combined actions of verapamil and contrast media on atrioventricular conduction. Invest Radiol 1984;19:202.
Maley P, Olivecrona H, Almen T, Golman K. Interaction between chlorpromazine and intrathecally injected nonionic contrast media in non-anesthetized rabbits. Neuroradiology 1984;26:235.
Dehmer GJ, Gresalfi N, Daly D, Oberhardt B, Tate DA. Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents. J Am Coll Cardiol 1995;25:1069-1075.
Oldham RK, Grobley J, Braud E. Contrast medium "recalls”. Interleukin-2 toxicity. J Clin Oncol 1990;8:942— 943.
Abi-Aad AS, Figlun RA, Belldegrum A, de Kernion JB. Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection. J Immunother 1991;10:292-295.
Zukowski AA, David CL, Coan J, Wallace S, Gutterman JV, Margalit GM. Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration. Cancer 1990;65:1521 — 1524.
Heinzer H, Huland E, Huland H. Adverse reaction to contrast material in a patient treated with local interleukin-2. Am J Roentgenol 1992; 158:1407.
Goodkin DA. Radiographic contrast medium-induced glossitis. Arch Intern Med 1985;145:171-172.
Rao AK, Thompson R, Durlacher L, Jones F. Angiographic contrast agents-induced acute hemolysis in a patient with hemoglobin SC disease. Arch Intern Med 1985;145:759-760.
Doyama K, Kosuga K, Morikawa M, Watanabe Y. Coronary artery spasm induced by anaphylactoid reaction to a new low osmolar contrast media. Am Heart J 1990;120:1453-1455.
Shehadi WH, Toniolo G. Adverse reactions to contrast media: a report from the Committee on Safety of Contrast Media of the International Society of Radiology. Radiology 1980;137:299-302.
Gluck BS, Mitty HA. Reactions to iodinated radiographic contrast agents. How to identify and manage patients at risk. Postgrad Med 1990;80:187-194.
Stejskall V, Nilsson R, Grepe A. Immunologic reactions to radiographic contrast media. Acta Radiol 1990;31:605-612.
Lang DM, Alperin MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid reactions from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med 1991;115:270-276.
Benotti JR. The comparative effects of ionic versus nonionic agents in cardiac catheterization. Invest Radiol 1988;23(Suppl 2):S366—S373.
Steinberg EP, Moore RD, Powe NR, Gopalan R, Dav-idoffAJ, Litt M etal: Safety and cost effectiveness of high osmolality as compared with low osmolality contrast material in patients undergoing cardiac angiography. N Engl J Med 1992;326:425-437.
Cooper MW, Reed PJ. QT prolongation with intracoronary contrast agents: significant difference between ionic and nonionic agents. Clin Res 1990;38:25A.
Glober JR, Thomas BM. Severe adverse reaction to oral iohexol. Clin Radiol 1991;44:137-138.
Martin ES. Danger of epidural use of ionic contrast media. Clin Pharm 1992;11:105.
Minuk J, Melancon D, Tampieri D, Ethier R. Transient global amnesia associated with cerebral angiography performed with use of iopanidol. Radiology 1990; 174: 285.
Lantos G. Cortical blindness due to osmotic disruption of the blood-brain barrier by angiographic contrast material: CT and MRI studies. Neurology 1989;39:567— 571.
Mallat Z, Vassal T, Naouri JF, Prier A, Laredo J D et al. Aseptic meningoencephalitis after iopamidol myelography. Lancet 199;338:252.
Bell JA, Dowd TC, Melwaine GG, Brittain GPH. Post myelographic abducent nerve palsy in association with the contrast agent iopentol. J Clin Neuro Ophthalmol 1990;10:115-117.
Noda K, Miyamoto K, Beppu H, Hirose K, Tanabe H. Prolonged paraplegia after iohexol myelography. Lancet 1991;337:681.
Junck L, Marshall WH. Neurotoxicity of radiological contrast agents. Ann Neurol 1983;13:469-489.
Nelson M, Bartlett RJV, Lancet JT. Seizures after intravenous contrast media for cranial computed tomography. J Neurol Neurosurg Psychiatry 1989;52:1170-1175.
May P, Bach-Gan smo T, Elmquist D. Risk of seizures after myelography: comparison of iohexol and metriza-mide. Am J Neuroradiol 1988;9:879-883.
Eliashiv S, Wirguon I, Brenner T, Argov Z. Aggravation of human and experimental myasthenia gravis by contrast media. Neurology 1990;40:1623-1625.
Michelis AA. Effect of intravascular contrast media on blood-brain barrier. Comparison between iothalmate, iohexol, iopentol and iodixanol. Acta Radiol 1987;28:329-333.
Van de Kelft E, Bosmans J, Parizel PM, Van Vyve M, Selosse P. Intracerebral hemorrhage after lumbar myelography with iohexol: report of a case and review of the literature. Neurosurgery 1991;28:570-574.
Bouachour G, Varache N, Szapiro N, L’Hoste P, Harry P, Alquier P. Noncardiogenic pulmonary edema resulting from intravascular administration of contrast material. Am J Radiol 1991;157:255-256.
Kozlowski C, Killef MM. Noncardiogenic pulmonary edema associated with intravenous radiocontrast administration. Chest 1992;102:620-621.
Van den Plas O, Hantson P, Dive A, Mahieu P. Fulminant pulmonary edema following intravenous administration of radiocontrast media. Acta Clin Belg 1990;45:334-339.
Borish L, Matloff SM, Findlay SR. Radiographic contrast media-induced noncardiogenic pulmonary edema: case report and review of the literature. J Allergy Clin Immunol 1984;74:104-107.
Jennings CA, Deveikis J, Azyni N, Yerager H Jr. Eosinophilic pneumonia associated with reaction to radiographic contrast media. South Med J 1991;84:92-95.
Berns AS. Nephrotoxicity of contrast media. Kidney Int 1989;36:730-740.
Cronin RE. Southwestern Internal Medicine Conference: renal failure following radiologic procedure. Am J Med Sci 1989;298:342-356.
Barrett BJ, Parfrey PS, Vavasour HM, McDonald J, Kent G, Hefferton D et al. Contrast nephropathy in patients with impaired renal function. High versus low osmolar media. Kidney Int 1992;41:1279.
Dawson P, Trewhella M. Intravascular contrast agents and renal failure. Clin Radiol 1990;41:373-375.
Harding MB, Davidson CJ, Pieper KS, Slatky M, Schwab SJ, Morris KG et al. Comparison of cardiovascular and renal toxicity after cardiac catheterization using a nonionic versus ionic radiographic contrast agent. Am J Cardiol 1991;68:117-119.
Brezis M, Epstein FH. A closer look at radiocontrast-induced nephropathy. N Engl J Med 1989; 320: 179— 181.
Moore RD, Steinberg EP, Powe NP, Brinker JA, Fishman EK, Graziano S et al. Nephrotoxicity of high-osmolality versus low-osmolality contrast media. Randomized clinical trial. Radiology 1992;182:649-655.
Cedgard S, Herlitz H, Deterud K, Attman P-О, Aureli M. Acute renal insufficiency after administration of low-osmolar contrast media. Lancet I986;2:1281.
Heller CA, Knapp J, Halliday J, O’Connell D, Heller RF. Failure to demonstrate contrast nephrotoxicity. Med J Aust 1991;155:329-332.
Katzberg RW. What do we really know about contrast medium-induced acute renal failure? Invest Radiol 1989;24:219-220.
Rucnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF et al for the Iohexol Cooperative Study. Nephrotoxicity of ionic and nonionic contrast media in 1,196 patients: a randomized trial. Kidney Int 1995;47:254-261.
Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320:143-149.
Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989:86:649— 652.
Warning added to labeling of iodinated contrast agents. FDA Drug Bulletin 1989; 19(2): 19.
Robertson HJ. Thrombogenic potential of nonionic contrast media. Mayo Clin Proc 1990;65:603-604.
Grollman JH Jr, Liu CK, Astone RA, Lurie MD. Thromboembolic complications in coronary angiography associated with the use of nonionic contrast media. Cathet Cardiovasc Diagn 1988;14:159-164.
Stormarken IJ. Present state of contrast media as related to thromboembolic complications. Sem Hematol 1991 ;28(Suppl 7):69—72.
Brinker JA. Contrast and clotting. The cardiologist’s perspective. Semin Hematol 1991 ;28(Suppl 7):3—10.
Dawson P. Nonionic contrast agents and coagulation. J Invest Radiol 1988;23(Suppl 2):S310—S317.
Arora R, Khandelwal M, Gopal A. In vivo effects of nonionic and ionic contrast media on beta thromboglobulin and fibrinopeptide levels. J Am Coil Cardiol 1991;17:1533-1536.
de Bruin TWA. Iodide-induced hyperthyroidism with computed tomography contrast fluids. Lancet 1994;343:1160-1161.
Karpman BA. Rapaport B, Filetti S, Fisher DA. Treatment of neonatal hyperthyroidism due to Graves’ disease and sodium ipodate. J Clin Endocrinol Metab 1987;64:119-123.
Reiner RG, Lawson MJ, Marshall J, Read TR, Beng CG, Davies GT et al. Thyroid, renal and hepatic function tests following cholecystography with high-dose contrast agents. Dig Dis Sci 1980;25:379-383.
Kim S-J, Salem MR, Joseph NJ, Madayag MA, Caval-lino RP, Crystal GJ. Contrast media adversely affect oxyhemoglobin dissociation. Anesth Analg 1990;71:73-76.
Wylie EJ, Mitchell DB. Case report: iodide mumps following intravenous urography with iopanidol. Clin Radiol 1991;43:135-136.
Rosati G, di Priolo SL, Tirone P. Serious or fatal complications after inadvertent administration of ionic watersoluble contrast media in myelography. Eur J Radiol 1992;15:95-100.
May EF, Ling GSF, Geyer CA, Jabbari B. Contrast agent overdose causing brain retention of contrast, seizures and parkinsonism. Neurology 1993;43:836-838.
Tartiere J, Gerard J-L, Репу J, Hurpe J-M, Quesnol J. Acute treatment of accidental intrathecal injection of hypertonic contrast media. Anesthesiology 1989;71:169.
Nakazawa K, Yoshinari M, Kinefuchi S, Amaha K. Inadvertent intrathecal administration of amidetrizoate. Intensive Care Med 1988;15:55-57.
Vossler DG, Wright Jr SJ. Convulsive status epilepticus following intrathecal iopamidol administration. J Epilepsy 1994;7:18-20.
Olsen J. Seizures after myelography with iopamidol. Am J Emerg Med 1994;12:329-330.
Harash LT. Mallinckrodt Medical. St Louis, MO. Con-ray (iothalamate meglumine injection USP 60 %) product literature. MKP0 953 790. Revised 7/90. Personal communication. September 2, 1992.
Gray C, Sivaloganathan S, Simpkins КС. Aspiration of high density barium contrast medium causing acute pulmonary aspiration. Report of two fatal cases in elderly women with disordered swallowing. Clin Radiol 1989;40:397-400.
Parcy JPM, Montgomery BPO, Reading N. Acute pneumonitis caused by low-density barium sulphate aspiration. J Laryngol Otol 1993;107:347-348.
Page B, Dallara JJ. Does Reglan (metoclopramide) prevent vomiting of oral CT contrast in stable multiple trauma patients? Acad Emerg Med 1994; 1 :A65.
Gelfand DW, Ott DJ, Klein A. Massive iopanoic acid (Telepaque) overdose without ill effects. Am J Roentgenol 1978;130:1174-1175.
McLennan BL, Kassner EG, Becker J A. Overdose at excretory urography. Toxic cause of death. Radiology 1972;105:383-386.
Ansell G. Fatal overdose of contrast medium in infants. BrJ Radiol 1970;395—396.
Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-1420.
Barrett BJ, Parfrey PS: Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 1994;331:1449-1450.
Medical Manual of Defense Against Chemical Agents. JSP 312. Ministry of Defense. London: Her Majesty’s Stationery Office, 1987; pp. 8-1 to 8-5.
Harris R, Paxman J. A higher form of killing. The secret story of chemical and biological warfare. New York: Hill & Wang, 1982.
Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries. Field Manual Army FM-8-285; Navy Navmed P-5041; Air Force AFM 160-11. Departments of the Army, the Navy and the Air Force. February 1990; pp. 6-1 to 6-2.
Compton JAF. Military chemical and biological agents. Chemical and toxicological properties. Caldwell, NJ: Telford Press, 1987; pp. 87—110.
Vick JA, Froehlich H. Treatment of cyanide poisoning. Milit Med 1991;156:330-339.
Medical Manual of Defence Against Chemical Agents. Ministry of Defense JSP 312. London: Her Majesty’s Stationery Office, 1987; pp. 7-1 to 7-4.
Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries. Army FM 8-285; Navy Navmed P-5041, Air Force AFM 160-11. Departments of the Army, the Navy, and the Air Force, February 1990; pp. 3-1 to 3-4.
Corupton JAF. Military chemical and biological agents. Clinical and toxicology properties. Caldwell, NJ: Telford Press; pp. 253—335.
Harris R, Paxman J. A higher form of killing. The secret study of chemical and biological warfare. New York: Hill & Wang, 1982; pp. 187-188, 206-210.
Douglass JD Jr, Livingston NC. America the vulnerable. The threat of chemical/biological warfare. Lexington, MA: Lexington Books, 1987. pp. 4—5.
Potential Military Chemical/Biological Agents and Compounds. Army Field Manual No. 3-9. Washington DC: December 12, 1990; pp. 14-17, 46-47, 71.
Medical Manual of Defense Against Chemical Agents. JSP 312. Ministry of Defense. London: Her Majesty’s Stationery Office, 1987; pp. 5-1 to 5-4.
Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries. Field Manual. Army FM 8-285, Navy Navmed P-5041, Air Force AFM 160-11. Departments of the Army, the Navy, and the Air Force, February 1990; pp. 5-1 to 5-3.
Harris C, Paxman J. A higher form of killing. The secret story of chemical and biological warfare. New York: Hill & Want, 1982; pp. 1-3, 17-20.
Compton JAF. Military chemical and biological agents. Chemical and toxicological properties. Caldwell, NJ: Telford Press, 1987; pp. 111 — 134.
Wang Y-T, Lee LKH, Poh S-C. Phosgene poisoning from a smoke grenade. Eur J Respir Dis 1987;70:126— 128.
Diller WF. Early diagnosis of phosgene overexposure. Toxicol Indust Health 1985;1:73-80.
Diller WF: Therapeutic strategy in phosgene poisoning. Toxicol Ind Health 1985;1:93-99.
Diller WF, Zantz R. A literature review: therapy for phosgene poisoning. Toxicol Ind Health 1985;1:117— 128.
Sjogren B, Plato N, Alexandersson R, Eklund A, Falken-berg C. Pulmonary reactions caused by welding-induced decomposed trichlorethylene. Chest 1991;99:237-238.
Proctor NH, Hughes JP, Fischman ML. Chemical hazards of the workplace. 2nd ed. New York: Van Nostrand Rheinhold, 1989; p. 149.
NIOSH. Pocket Guide to Chemical Hazards. U. S. Department of Health and Human Services. June 1990.
Krolikowski FJ. Oleo capsicum (О. C.): the need for careful evaluation. Am J Forensic Med Pathol 1994;15:267.
Wiley J, Billmire D, Farina P, Freedman S, Henretig F, Panitch H et al. Severe pulmonary injury in an infant after pepper gas self defense spray exposure. Clin Toxicol 1995;33:475-486 (abstract 86).
Chapman AJ, White C. Death resulting from lacrimatory agents. J Forensic Sci 1978;23:527-530.
Thorburn KM. Injuries after use of the lacrimatory agent chloroacetophenone in a confined space. Arch Environ Health 1982;37:182-186.
Park S, Giammonia ST. Toxic effects of tear gas on an infant following prolonged exposure. Am J Dis Child 1972;123:245-246.
Medical Management of Chemical Casualties Course. Office of the Surgeon General and US Army Medical Research Institute of Chemical Defense, January 1992.
Field Manual. Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries. Army FM 8-285, Navy Navmed P-4051, Air Force AFM 160-11. Departments of the Army, the Navy and the Air Force, February 1990.
Potential Military Chemical/Biological Agents and Compounds. FM 3-9, NAVFAC P-467, AFR 355-7, Headquarters, Departments of the Army, Navy and Air Force, December 12, 1990.
Douglass JD Jr, Livingstone NC. America the vulnerable. The threat of chemical/biological warfare. Lexington, MA: Lexington Books, 1987; pp. 204.
Harris R, Paxman J. A higher form of killing. The secret story of chemical and biological warfare. New York: Hill & Wand, 1982; pp. 274.
Compton JAF. Military chemical and biological agents. Chemical and toxicological properties. Caldwell, NJ: Telford Press, September 1987, pp. 458.
Proc 4th Internal Symp on Protection against Chemical Warfare Agents. Stockholm, Sweden: 8—12 June, 1992. National Defence Research Establishment. Department of NBC Defence S-901. 82 Uniea, Sweden.
Somani SM, ed. Chemical warfare agents. San Diego: Academic Press, 1992; pp. 443.
Medical Manual of Defence Against Chemical Agents. JSP 312 Ministry of Defence (UK). D/Med (Fond S) (2)/l0/11. Sixth Edition, 1987. Second Impression 1990. London: Her Majesty’s Stationery Office.
Medical Manual of Defence Against Chemical Agents. Ministry of Defence. JSP 312 A/24/Gen/4392. First published 1939, Fifth Edition, 1972. London: Her Majesty’s Stationery Office, 1972.
Maynard RL, Beswich FW. Organophosphorus compounds as chemical warfare agents. In: Ballantyne B, Marris TC, eds. Clinical and experimental toxicology of organophosphates and carbamates. Oxford: Butterworth-Heinemann, 1992; pp. 373—385.
Sidell FR. What to do in case of an unthinkable chemical warfare attack or incident. Postgrad Med 1990;88:70— 84.
NATO Handbook on the Concept of Medical Support in NBC Environments. A MED P-7(A). Unclassified. August 1982.
Arad М, Epstein Y, Krasner Е, Danon YL, Atsomon J. Principles of respiratory protection. Isr J Med Sci 1991;27:634-642.
Huminer D, Pitlik SD, Katz A, Metzker A, David M. Untoward effects of gas masks during Persian Gulf War. N Engl J Med 1991;325:582-583.
Borkan J, Reis S. Untoward effects of gas masks during Persian Gulf War. N Engl J Med 1991 ;325:583.
Amitai Y, Almog S, Singer R, Hammer R, Bentur Y, Danon YL. Lessons from the Gulf War: atropine poisoning in children during the gulf crises: a national survey in Israel. JAMA 1992;268:630-632.
Amitai Y, Singer R, Almog S, Bentur Y. Atropine poisoning in children from automatic injector during the Gulf crisis. Vet Hum Toxicol 1991 ;33:36.
Sharabi Y, Danon YL, Berkenstadt H, Almog S, Mi-mouni-Block A, Zisman A, Dani S, Atsmon J. Survey of symptoms following intake of pyridostigmine during the Person Gulf War. Isr J Med Sci 1991;27:656-658.
Keeler JR, Hurst CG, Dunor MA. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. JAMA 1991;266:693-695.
Meisel SR, Kutz I, Dayan KI, Pauzner H, Chetboun I, Arbel YT, David D. Effect of Iraqi missile war on the incidence of acute myocardial infarction and sudden death in Israeli civilians. Lancet 1991;338:660-661.
Roberts J. Chemical weapons did not cause the Gulf war syndrome. Br Med J 1995;310:692.
Kobrick JL, Johnson RF, McMenemy DJ. Effects of at-ropine/2-РАМ chloride, heat, and chemical protective clothing on visual performance. Aviat Space Environ Med 1990;61:722-830.
Kolka MA, Cadarette BJ. Heat exchange after cholino-lytic and oxime therapy in protective clothing. Milit Med 1990;155:390-394.
Kobrick JL, Johnson RF, McMenemy DJ. Effects of nerve agent antidote and heat exposure in soldier performance in the BDU and MOPP-IV ensembles. Milit Med 1990;155:159-162.
Wyant KW, Walker JM. Urine specific gravity and other correlates of chemical warfare protective clothing. Milit Med 1987;152:649-652.
Fischetti М. Gas vaccine. Bioengineering immunication could shield against nerve gas. Sci Am April 1991;l53:l54.
Orma PS, Middleton RK. Aerosolized atropine as an antidote to nerve gas. Ann Pharmacother 1992;26:937— 938.
Doctor BP, Blick DW, Recht KM, Castro CA, Hively HE, Murphy MP et al. Protection of rhesus monkey against soma toxicity by pretreatment with cholinesterase. Proc 4th Int Symp Protection against Chemical Warfare Agents, Stockholm, Sweden, 8—12 June, 1992; 335-340.
Treatment of chemical agent casualties and conventional military chemical injuries. Field Manual. Army FM 8-285, Navy Navmed P-5041, Air Force AFM 160-11. Departments of the Army, the Navy and the Air Force. February 1990.
Medical Manual of Defence Against Chemical Agents. JSP 312, Ministry of Defence. D/Med (F +S) (2)/10/ 11. London: Her Majesty’s Stationery Office, 1987.
Murray VSG, Volans GN. Management of injuries due to chemical weapons. Most patients exposed to mustard gas recover completely. Br Med J 1991;302:129-130.
Munro NB, Watson AP, Ambrose KR, Griffin DG. Treating exposure to chemical warfare agents: implications for health care providers and community emergency planning. Environ Health Perspect 1990;89:205-215.
Sidell FR. What to do in case of an unthinkable chemical warfare attack or accident. Postgrad Med 1990;88:70— 84.
Shalit I. Chemical warfare and disasters: medical organization and treatment. In: Reis ND, Dolve E, eds. Manual of disaster medicine, civilian and military. Berlin: Springer Verlag, 1989; pp. 113—123.
Newman-Taylor AJ, MarrisAJR. Experience with mustard gas casualties. Lancet 1991 ;337:242.
Wormser U. Toxicology of mustard gas. Trends Pharma-ceut Sci 1991;12:164-167.
Aasted A, Darre E, Wolf HC. Mustard gas: clinical, toxicological and mutagenic aspects based on modern experience. Ann Plastic Surg 1987;19:330-333.
Balali-Mood M. Sulfur mustard poisoning in the Iran-Iraq War. Clin Pharmacol Ther 1990;47:183-184.
Willems JL. Clinical management of mustard gas casualties. Ann Med Mitt Beig 1989;3(Suppl 1):1—61.
Papirmeister B, Feister AJ, Robinson SI, Ford RD. Medical defense against mustard gas: toxic mechanisms and pharmacological implications. Boca Raton, FL: CRC Press, 1991; pp. 1-42.
Watson AP, Jones TD, Griffin GD. Sulfur mustard as a carcinogen: application of relative potency analyses to the chemical warfare agents H, HD and HT. Regul Toxicol Pharmacol 1989;10:1-25.
Yanagida J, Hozawa S, Ishioka S, Maeda H, Takahashi К, Oyana T et al. Somatic mutation in peripheral lymphocytes of former workers at the Okunojima poison gas factory. Jpn J Cancer Res 1988;79:1276-1286.
Requena L, Requena C, Sanchez M, Jaqueti G, Aguilar A, Sanchez-Yus E, Hernandez-Moro B. Chemical warfare. Cutaneous lesions from mustard gas. J Am Acad Dermatol 1988;19:529-536.
Easton DF, Peto J, Doll R. Cancers of the respiratory tract in mustard gas workers. Br J Indust Med 1988;45:652-659.
Somani SM, Babu SR. Toxicodynamics of sulfur mustard. Int J Clin Pharmacol Ther Toxicol 1989;27:419— 435.
Sohrabpour H. Observation and clinical manifestations of patients injured with mustard gas. Med J Islamic Rep of Iran 1987;1:32-37.
Goldman M, Jacre JC. Lewisite. Its chemistry, toxicology and biological effects. Rev Environ Contain Toxicol 1989;110:76-114.
Papirmeister B, Gross CL, Meier HL, Petrall JP, Johnson JB. Molecular basis for mustard induced vesication. Fund Appl Toxicol 1985;5:S134—S149.
Wulf HC, Aasted А, Darre E, Niebuhr E. Sister chromatid exchanges in fishermen exposed to leaking mustard gas shells. Lancet 1985;1:690-691.
Heyndrickx B, ed. Proceedings of the Second World Congress. New Compounds in Biological and Chemical Warfare: Toxicological Evaluation. Industrial Chemical Disasters. Civil Protection and Treatment. Ghent, The Internal Assoc For Toxicol. 23rd Eur Internal Mtg Terrorism: Analysis and Detection of Explosives, August 24—27, 1986. (See references 23 through 34.)
Balali-Mood M, Navaeian. Clinical paraclinical findings in 233 patients with sulfur mustard poisoning, pp. 464— 473.
Crombez R. Medical use of mustard gas derivatives. A review, p. 474.
Balali-Mood M, Farhoodi M, Panjvani FK. Report of three fatal cases of war gas poisoning, pp. 475—482.
Dhont S, Cordonnier J, Vanheule A, Heyndrickx A. Evolution of serum and erythrocyte magnesium leads in patients attacked by the chemical warfare agent mustard gas (Yperite), pp. 483—488.
Balali-Mood M. First report of delayed toxic effects of Yperite poisoning in Iranian fighters, pp. 489—495.
Colardyn F, de Keyser K, Vogelaers D, Vandenbogaende J. The clinics and therapy of victims of war gases, pp. 506-510.
Vossaert K, Geerts ML, de Bersaques J, Kint A. Dermatological aspects of intoxication by mustard gas. pp. 511-513.
Neyrick B, Wauters A, Heyndrickx A. Treatment of intoxicated soldiers by war gases, pp. 539—541.
Coppens M, Roels H, Van den Heede M, Heyndrickx A. Clinical history and autopsy observations associated with the toxicological findings in an Iranian soldier exposed to Yperite (mustard gas), pp. 542—552.
Heyndrickx B. Report and conclusion of the biological samples of men intoxicated by war gases sent to the Department of Toxicology of the State University of Ghent for toxicological investigation, pp. 553—582.
Heyndrickx A, Van den Heede M. The toxicological analysis of chemical warfare agents in samples originating from Iranian soldiers, pp. 598—618.
Drasch G, Kretschmer E, Kauert G, Meyer L. Yperite concentrations in the tissues of a victim of a vesicant exposure. pp. 592—597.
Vycudilik W. Detection of bis(2-chlorethyl) sulfide lyperite in urine by high resolution gas chromatogra-phy/mass spectrometry. Forensic Sci Int 1987;35:67— 71.
Wils ERJ, Hulst AG, Van Laar J. Analysis of thiodiglycol in urine of victims of an alleged attack with mustard gas. IL J Anal Toxicol 1988;12:15-19.
Harris R, Paxman J. A higher form of killing. The secret story of chemical and biological warfare. New York: Hill & Want, 1982; p. 274.
Douglass JD Jr, Livingstone NC. America the vulnerable. The threat of chemical/biological warfare. The new shape of terrorism and conflict. Lexington, MA: Lexington Books, 1987; p. 204.
Compton JAF. Military Chemical and Biological Agents. Chemical and Toxicological Properties. Caldwell, NJ: The Telford Press, 1987; p. 458.
Blodi FC. Mustard gas keratopathy. Internal Ophthal Clin 1971;11:1-13.
Pechura CM, Rail DP, ed. Veterans at risk. The health effects of mustard gas and lewisite. Committee to survey the health effects of mustard gas and lewisite. Institute of Medicine. Washington, DC: National Academy Press, 1993.
Norman JE Jr. Lung cancer mortality in World War I veterans with mustard-gas injury: 1919—1965. JNCI 1975;54:311-317.
Hay A, Roberts G. The use of poison gas against the Iraqi Kurds: analysis of bomb fragments, soil and wool samples. JAMA 1990;263:1065-1066.
Maynard RL, Meredith TJ, Marren TC, Vale JA. Management of chemical warfare injuries. Lancet 1991;337:122.
Lieske CN, Klopcic RS, Gross CL, Clark JH, Dolzine TW, Logan TP et al. Development of an antibody that binds sulfur mustard. Immunol Lett 1992;31:117-122.
Minton N, Murray SG. A review of organophosphate poisoning. Med Toxicology 1988;3:350-375.
World Health Organization report on the hazards to civilian health from chemical weapons. Executive Board Paper, World Health Organization, 1988.
Hohnstedt B. The third symposium on prophylaxis and treatment of chemical poisons. April 22—24, 1985. Stockholm. Sweden. Fund Appl Toxicol 1985;5: S1 —S9.
Clement JG. Hormonal consequences of organophosphate poisoning. Fund Appl Toxicol 1985;5:S61— S77.
Treatment of chemical agent casualties and conventional military chemical injuries field manual. Army FM 8-285, Navy Navmed P-5041, Air Force AFM 160-11, Departments of the Army, the Navy and the Air Force. February 1990.
Grob D. Anticholinesterase intoxication in man and its treatment in Oehler O, Farah A, Koelle GB, eds. Hand-buch de Experimentalla Pharmacologic XV. Cholinesterase and anticholinesterase agents. Berlin: Springer-Verlag, 1963:990-1022.
Wills JH. Pharmacological antagonists of the anticholinesterase agents in Handbook de Experimentalla Pharmacologic XV. Cholinesterase and anticholinesterase agents. Berlin: Springer-Verlag, 1963:883—920.
Sidell FR. Clinical considerations in nerve agent intoxication. In: Somani SM, ed. Clinical warfare agents. San Diego: Academic Press, 1992; pp. 155—194.
Leadbeater L, Inns RH, Rylands JM. Treatment of poisoning by soman. Fund Appl Toxicol 1985;5:S225— S231.
Inns RH, Leadbeater L. The efficacy of bispyridium derivatives in the treatment of organophosphate poisoning in the guinea pig. J Pharm Pharmacol 1983;35:427-433.
Grubic Z, Tomazic A. Mechanism of action of HI-6 on soman inhibition of acetylcholinesterase in preparations of rat and human skeletal muscle; comparison to SAD-128 and PAM-2. Arch Toxicol 1989;63:68-71.
Churchill L, Pazdernik TL, Cross RS, Nelson SR, Samson FE. Soman- or kainic acid-induced convulsions decrease muscarinic receptors but not benzodiazepine receptors. Neurotoxicology 1990;11:57-72.
Lee MJ, Clement JG. Effects of soman poisoning in hematology and coagulation parameters and serum biochemistry in rabbits. Milit Med 1990;155:244-249.
Inns RH, Tuckwell NJ, Bright JE, Marrs TC. Histochemical demonstration of calcium accumulation in muscle fibres after experimental organophosphate poisoning. Hum Exp Toxicol 1990;9:245-250.
Bright JE, Inns RH, Marrs TC, Tuckwell NJ. Histochemical demonstration of sarin-induced calcium influx in mouse diaphragm. Hum Exp Toxicol 1990;9:120 (abstract).
Shih T-M, Whalley CE, Valdes JJ. A comparison of cholinergic effects of HI-6 and pralidoxime-2-chloride (2-PAM) in soman poisoning. Toxicol Lett 1991;55:131-147.
Munro NB, Watson АР, Ambrose KR, Griffin GD. Treating exposure to chemical warfare agents: implications for healthy care providers and community emergency planning. Environ Health Perspect 1990;89:205— 215.
Karalliedde L, Ganci CA, Carter M. Chemical weapons. Br Med J 1991:302:474.
Dunn MA, Sidell FR. Progress in medical defense against nerve agents. JAMA 1989;262:649-652.
Prevention and treatment of nerve gas poisoning. Med Lett Drugs Ther 1990;32(831): 103—105.
Treatment of chemical agent casualties and conventional military chemical injuries field manual. Army FM 8-285, Navy Navmed P-5041, Air Force AFM 160-11, Departments of the Army, the Navy and the Air Force. February 1990; pp. 2—15 to 2—19.
Sundwall A. Minimum concentrations of A-methylpy-ridinium-2-aldoxime methane sulphonate (P2S) which reverse neuromuscular block. Biochem Pharmacol 1961;8:413-417.
Vale JA, Meredith TJ, Heath A. High dose atropine in organophosphorus poisoning. Postgrad Med J 1990;66:878-881.
Wilson IB, Ginsburg S. A powerful reactivator of alkyl-phosphate-inhibited acetylcholinesterase. Biochem Bio-phys Acta 1955;18:168-170.
Christenson I. Stability of the nerve gas antidote bis (4-hydroxyiminoethyl-l-pyridinomethyl ether dichloride (toxogonin). Drug Intelligence 1968;2:234-243.
Vojvodic VB. Blood levels, urinary excretion and potential toxicity of N Nl-trimethylenebis (pyridinium-4-al-doxime) dichloride (TMB-4) in healthy man following intramuscular injection of the oxime. Pharmacol Clin 1970;2:216-220.
Sidell FR, Groff WA, Kaminskis A. Toxogonin and pra-lidoxime: Kinetic comparison after intravenous administration to man. J Pharm Sci 1972;61:1765-1769.
Erdmann WD. Vergleichende untersuchungen uber das penetrations vermogen einiger esterasereaktivierender oxime in das zentrale nervensystem. Arzneimittel-forsch 1965;15:135.
Shapira Y, Bar Y, Berkenstadt H, Atsmon J, Damon YL. Outline of hospital organization for a chemical warfare attack. Isr J Med Sci 1991;27:616-622.
Sidell FR, Groff WA, Kaminskis A. Pralidoxime-meth-ane sulfonate. Plasma levels and pharmacokinetics after oral administration to man. J Pharm Sci 1972;61:1736— 1740.
Calesnick B, Christensen JA, Richter M. Human toxicity of oximes. 2-pyridine aldoxime methyl chloride, its methane sulfonate salt and l,l’-trimethlyenebis-(4-formylpyridinum chloride). Arch Environ Health, 1967;15:599-608.
Sidell FR, Groff WA, Ellin RI. Blood levels of oxime and symptoms in human after single and multiple oral doses of 2-pyridine aldoxime methochloride. J Pharm Sci 1969;58:1093-1098.
Simon GA, Tirosh MS, Edery H. Administration of obi-doxime tablets to man. Plasma levels and side reactions. Arch Toxicol 1976;36:83-88.
Sidell FR, Groff WA. Toxogonin: Blood levels and side effects afer intramuscular administration in man. J Pharmaceut Sci 1970;59:793-797.
Sidell FR, Groff WA. Intramuscular and intravenous administration of small doses of 2-pyridinium aldoxime methochloride to man. J Pharm Sci 1971;60:1224-1228.
Sundwall A. Plasma concentration curves of A-methyl-pyridinum-2-aldoxime methane sulphonate (1-2S) after intravenous intramuscular and oral administration in man. Biochem Pharmacol 1960;5:225-230.
Gallagher K, Kerney T, Mangione A. A case report of organophosphate poisoning supporting the use of pral-idoxime (2PAM) by continuous infusion (Personal communication).
Farrar HC, Wells TG, Kearns GL. Use of continuous infusion of pralidoxime for treatment of organophosphate poisoning in children. J Pediatr 1990; 116:658—661.
Jeevarathinan K, Ghosh AK, Srinivasan A, Das Gupta B. Pharmacokinetics of pralidoxime chloride and its correlation to therapeutic efficacy against diisopropyl fluor-ophosphate intoxication in rats. Pharmazie 1988;43:114-115.
Jovanovic D. Pharmacokinetics of pralidoxime chloride. A comparative study in human volunteers and in organophosphate poisoning. Arch Toxicol 1989;63:416-418.
Scott RJ. Repeated asystole following PAM in organophosphate self poisoning. Anaesthesia Intensive Care 1986;14:458-468.
Keppens C, Maes V, Vinchen W. Severe organophosphate poisoning successfully treated by prolonged obi-doxime and atropine infusion. Proc Eur Assoc Pois Cont Centers, 1988.
de Kort WLAM, Kienstra SH, Sangster B. The use of atropine and oximes in organophosphate intoxications: a modified approach. Clin Toxicol 1988;26:199-208.
Sidell FR, Groff WA. The reactivability of cholinesterase inhibited by VX and sarin in man. Toxicol Appl Pharmacol 1974;27:241-252.
Grob D, Harvey JC. Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphono fluoridate). J Clin Invest 1958;37:350-360.
Grob D. The manifestations and treatment of poisoning due to nerve gas and other organic phosphate anticholinesterase compounds. Arch Intern Med 1956;98:221-238.
Kristof ND. Poison gas kills 6 in Tokyo subway; sabotage is seen. New York Times, March 20, 1995; pp. Al—A2.
Poison fumes in Tokyo subway kill 6, hurt 900. Los Angeles Times, March 20, 1995; pp. Al & A7.
Yokoyama K, Ogura Y, Kishimoton M, Hinoshita F, Hara S, Yamada A et al. Blood purification for severe sarin poisoning after the Tokyo subway attack. JAMA 1995;274:379.
Morita H, Yanagisawa N, NakajimaT, Shimizu M, Hir-abayashi H, Okudera H et al. Sarin poisoning in Matsumoto, Japan. Lancet 1995;346:290-293.
Sidell FR. Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol 1974;711—717.
Oberst FW, Koon WS, Christensen MK, Crook JW, Cresthull P, Freeman G. Retention of inhaled sarin vapor and its effect on red blood cell cholinesterase in man. Clin Pharmacol Ther 1968;9:421-422.
Rubin LS, Goldberg MN. Effect of sarin on dark adaptation in man. Threshold change. J Appl Physiol 1957;11:439-444.
Duffy FH, Burchfield JL, Bartels PH, Gaon M, Sim VM. Long-term effects on organophosphate from the human electroencephalogram. Toxicol Appl Pharmacol 1979;47:161-176.
Burchfield JL, Duffy FH. Organophosphate neurotoxicity: chronic effects of sarin on the electroencephalogram of monkey and man. Neurobehav Toxicol Teratol 1982;4:767-778.
Burchfield JL, Duffy FH, Sim VM. Persistent effects of sarin and dieldrin upon the primate electroencephalogram. Toxicol Appl Pharmacol 1976;35:365-379.
Vale JA. Oximes-pharmacokinetic aspects. Drugs in dose and overdose. Recent advances in clinical pharmacology and toxicology abstracts. Birmingham, UK: Dudley Road Hospital, October 28—30, 1987.
Willems JL. Anticholinesterase poisoning. An overview of pharmacotherapy and clinical management. In: Bal-lantyne B, Marrs T, eds. Clinical and experimental toxicology of anticholinesterases. Guildford, UK: Butterworth, in press.
Ligtenstein DA. Evaluation of the pyridinium-aldoximes available for therapy of organophosphate intoxications with some remarks on the required further research for therapy of soman intoxication in humans. Proc Int Symp Protection against Chemical Warfare Agents. Stockholm, Sweden: June 6—9, 1983, pp. 129—140.
Marrs TC. Toxicology of oximes used in treatment of organophosphate poisoning. Adverse Drug React Toxicol Rev 1991;10:61-72.
Briggs CJ, Simons KJ. Treatment of organophosphorous poisoning. Pharmaceutical aspects of antidotes. Proc In-ternatl Assoc Forensic Toxicol, Ghent. August 24—27, 1986; pp. 514-523.
Jovanovic D, Maksimovic M, Koksovic D, Kovasevic V. Oral forms of the oxime Hl-6: a study of pharmacokinetics and tolerance after administration to healthy volunteers. Vet Hum Toxicol 1990;32:419-421.
Worek FS, Scinicz L. Effect of soman, atropine and HLo7—dimethane sulfonate on respiration and circulation of anesthetized guinea pigs. Akademic Symposium 1991. Role of oximes in the treatment of anticholinesterase agent poisoning. October 7, 1991. Munich. Akade-mie des Sanitats und Gesundheits wesens der Bundeswe-hr, Nacherbergstr 11, 8000 Munchen 45, pp. 25.
Bismuth C, Baud FJ, Kiffer D. Potential antidotes to anticholinesterase chemical weapons. Proc Eur Assoc Pois Cont Centers, 1988, p. 7.
Gunderson CH, Lehmann Cr, Sidell FR, Jabbai B. Nerve agents. A review. Neurology 1992;42:946-950.
Sidell FR. What to do in case of an unthinkable chemical warfare attack or accident. Postgrad Med 1990;88(7):70—84.
Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries. Field Manual. Army FM8-285, Navy Navmed P-5041, Air Force AFM 160-11. Departments of the Army, Navy and the Air Force, February 1990.
JSP 312: Medical Manual of Defence Against Chemical Agents. Ministry of Defense. London: Her Majesty’s Stationery Office 1987; pp. 4—2 to 4—3.
Mofenson HC, Caraccio TR. "War gases". Part II. РР/ T News, Nassau County Medical Center Regional Poison Control Center 1991; 10(2):240—245.
Yang Y-C, Baker J A, Ward JR. Decontamination of chemical warfare agents. Chem Rev 1992;92:1729— 1734.
Ray R, Clark DE HI, Ford KW, Knight KR, Harris LW, Broomfield CA. A novel tertiary pyridostigmine derivative [3-(V,V-Z)-methylcarbamyloxy)-l-methyl-3-tet-rahydropyridinej: anticholinesterase properties and efficacy against soman. Fund Appl Toxicol 1991;16:267— 274.
Aquilonius S-M, Eckernas S-A, Hartvig P, Lindstrom B, Osterman PO: Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur J Clin Pharmacol 1980;18:423-428.
Brayer-Pfaff V, Schwezer A, Maier V, Brinkman A, Schumer F. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis. J Neurol Neurosurg Psychiatry 1990;53:502-506.
Keeler JR. Interaction between nerve agent pretreatment and drugs commonly used in combat anesthesia. Milit Med 1990;155:527-533.
Miller RD. Booij LHDJ, Agostom S, Crul JF. 4-Aminopyridine potentiates neostigmine and pyridostigmine in man. Anesthesiology 1979;50:416-420.
Gall D. The use of therapeutic mixtures in the treatment of cholinesterase inhibition. Fund Appl Toxicol 1981;1:214-216.
Gordon JJ, Leadbeater L, Maidment MP. The protection of animals against organophosphorus poisoning by pretreatment with a carbamate. Toxicol Appl Pharmacol 1978;43:207-216.
Harris LW, Anderson DR, Pastelak AM, Vanderpool B. Acetylcholinesterase inhibition by (+) physostigmine and efficacy against lethality induced by soman. Drug Chem Toxicol 1990;13:241-248.
Almog S, Winkler E, Amitai Y, Dani S, Shell M, Tirosh M, Sherner J. Acute pyridostigmine overdose: a report of nine cases. Isr J Med Sci 1991;27:659-663.
Ellin RT, Zvirblis P, Wilson MR. Method for isolation and determination of pyridostigmine and metabolites in urine and blood. J Chromatogr 1982;228:235-244.
Prevention and treatment of nerve gas poisoning. Med Lett Drugs Ther 1990;32(831): 103—105.
Green DM, Muir AW, Stratton JA, Inch TD. Dual mechanism of the antidotal action of atropine-like drugs in poisoning by organophosphorus anticholinesterases. J Pharm Pharmacol 1977;29:62-64.
Schenk J, Loftier W, Weger N. Therapeutic Effects of HS-3, HS-6, benactyzine and atropine in soman poisoning of dogs. Arch Toxicol 1976;36:71-81.
Weger N, Szinicz L. Therapeutic effects of new oximes, benactyzine and atropine in soman poisoning. I. Effects of various oximes in soman, sarin and VX poisoning in dogs. Fund Appl Toxicol 1981;1:161-163.
Brown B, Haegerstrom-Portnoy G, Adams AJ, Jones RT, Jampolsky A. Effects of an anticholinergic drug, benactyzine hydrochloride, on vision and vision performance. Aviat Space Environ Med 1982;53:759-765.
Zvirblis P, Ellin Rl. Kinetics and stability of multi-component organophosphate antidote formulation in glass and plastic. J Pharm Sci 1982;71:321-325.
Sidell FR, Borak J. Chemical warfare agents. II. Nerve agents. Ann Emerg Med 1992;21:865-871.
Recommendation for protecting human health against potential adverse effects of long-term exposure to low doses of chemical warfare agents. MMWR 1988;37:72.
Carnes SA, Watson AP. Disposing of the US chemical weapons stockpile. An approaching reality. JAMA 1989;262:653-659.
Lenz DE, Brimfield AA, Hunter KW Jr, Benschop HP, De Jong LPA, van Dijk C, Clow TR. Studies using a monoclonal antibody against soman. Fund Appl Toxicol 1984;4:S 156—S164.
Maxwell DM, Brecht KM, O’Neill BL. The effect of carboxyl esterase inhibition on interspecies differences in soman toxicity. Toxicol Lett 1987;39:35-42.
Little JS, Broomfield CA, Fox-Talbot MK, Boucher U, Maclver B, Lenz DE. Partial characterization of an enzyme that hydrolyzes sarin, soman, tabun and diisopropyl phosphofluoridate (DFP). Biochem Pharmacol 1989;38:23-29.
Ray RR, Boucher W, Broomfield CA, Lenz DE. Specific soman-hydrolyzing activity in a clonal neuronal cell culture. Biochem Biophys Acta 1988;967:373-381.
D’Agostino РА, Hansen AS, Lockwood PA, Provost LR. Capillary column gas chromatography-mass spectrometry of tabun. J Chromatogr 198;33l:251 — 266.
D’Agostino PA, Provost LR. Gas chromatographic retention indices of chemical warfare agents and stimulants. J Chromatogr 1985;331:47-54.
Barr SJ. Chemical warfare agents. Top Emerg Med 1985;7( 1 ):62—70.
Phelps RG, Fleischmajor R. Clinical, pathologic and im-munopathologic manifestations of the toxic oil syndrome. J Am Acad Dermatol 1988;18:313-324.
Gilsanz V, Alvarez JL, Serrano S, Simon J. Evaluation of the alimentary toxic oil syndrome due to ingestion of denatured rapeseed oil. Arch Intern Med 1984; 144:254— 256.
Kilbourne EM, Ragau-Perez JG, Heath CW Jr, Zack MM, Falk H, Martin-Marcos M, de Carols A. Clinical epidemiology of toxic oil syndrome. Manifestations of a new illness. N Engl J Med 1983;309:1408-1414.
James TN, Posada-de la Paz M, Abaitua-Borda I, Gomez-Sanchez MA, Martinez-Tello FJ, Soldevilla LB. Histologic abnormalities of large and small coronary arteries, neural structures, and the conduction system of the heart found in postmortem studies of individuals dying from the toxic oil syndrome. Am Heart J 1991;121:803-813.
Tabuenca JM. Toxic allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 1981;2:567-568.
Roncero AV, del Valle CJ, Duran PM, Constante EN. New aniline derivative in cooking oils associated with the toxic oil syndrome. Lancet 1983;2:1024-1025.
Kammuller ME, Penninks AH, Seiner W. Spanish toxic oil syndrome and chemically induced graft-versus-host-like reactions. Lancet 1984;2:805-806.
Kammuller ME, Bloksma N, Seinen W. Chemical-induced autoimmune reactions and Spanish toxic oil syndrome. Focus on hydantoins and related compounds. Clin Toxicol 1988;26:157-174.
Kammuller ME, Penninks AH, Seinen W. Spanish toxic oil syndrome is a chemically induced GVHD-like epidemic. Lancet 1984;1:1174-1175.
McMichael J. Erucic acid and the Spanish oil epidemic. Lancet 1981 ;2:1172.
CDC. Follow-up on toxic pneumonia — Spain. MMWR 1981;30:436-438.
Schoental R. The toxic oil syndrome in Spain. Was it due to a combined action of trichothecene mycotoxins and of inhibition of carboxyesterase? Hum Toxicol 1988;7:365-369.
Alonso-Ruiz A, Calabozo M, Perez-Ruiz F, Mancebo L. Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients. Medicine 1993;72:285-295.
Gomez-Sanchez MA, Mestre de Juan MJ, Gomez-Pa-juelo C, Lopez JI, de Ataun MJD, Martinez-Tello FJ. Pulmonary hypertension due to toxic oil syndrome. A clinical pathologic study. Chest 1989;95:325-331.
Escribano PR, Diaz de Atauri MJ, Gamez Sanchez MA. Persistence of respiratory abnormalities. Four years after the onset of toxic oil syndrome. Chest 1991; 100:336— 339.
Alonso-Ruiz A, Zea-Mendoza AC, Gonzalez-Lanza M, Gomez-Catalan E. Digital tuft alterations in toxic oil syndrome. Lancet 1984;2:520-521.
Garcia MC, Posada M, de Rojas FD, Borda IA, Oliver J MT. Hypercoagulable states and the toxic oil syndrome. Ann Intern Med 1986; 104:730.
Bronchide MH. Toxic oil syndrome. N Engl J Med 1984;310:1260-1261.
Garzon FJO, Santana CL, Ruiz AA, Meana SR. The toxic oil syndrome: a new cause of carpel-tunnel syndrome. N Engl J Med 1983;309:1455.
Oliver JMT, Garcia MC, Galiana JR, Alvarez-Arenas RP, de la Paz MP, Borda IA et al. Spanish toxic oil and congenital malformations. Lancet 1983; 1:181.
Martines-Frias M-L, Salvador J, Prieto L. Spanish toxic oil and congenital malformations. Lancet 1982;2:1349.
Gilsanz V. Late features of toxic syndrome due to denatured rapeseed oil. Lancet 1982;1:335-336.
Miller DD, Chartman BR. Toxic oil syndrome. N Engl J Med 1984;310:1260-1261.
Gutierrez C, Gaspar L, Muro R, Kreisler M, Ferriz P. Autoimmunity in patients with Spanish toxic oil syndrome. Lancet 1983; 1:644.
Brostoff J, Blanca M, Boulton P, Serrano S. Absence of specific IgE antibodies in toxic oil syndrome. Lancet 1982;1:277.
Gutierrez-Millet V, Navas-Palacios J, Gomez-Reino J, Fernandez-Epifanio JL. Renal involvement in the toxic oil syndrome. Lancet 1982;l:1120.
Vicarico JL, Serrano-Rios M, San Andres F, Amaiz-Vii-lena A. HLA-DR3, DR4 increase in chronic stage of Spanish oil disease. Lancet 1982; 1:276.
Pereira RS, Black CM, Arnaz-Villena A, Vicario JL, Gomez-Reino JJ. Collagen autoantibodies.in toxic oil disease. Lancet 1985; 1:273.
Melius J, Binder S. Industrial disasters. In: Gregg MB, French J, Binder S, Sanderson LM, eds. CDC Monograph. The Public Health Consequences of Disasters 1989. Atlanta, GA: US Department of Health and Human Services, Center for Disease Control, September 1989; pp. 97-102.
US Congress, Office of Technology Assessment. Transportation of Hazardous Materials. Washington, DC: US Government Printing Office, 1986.
Bourdeau P, Green G, eds. Methods for assessing and reducing injury from chemical accidents. SCOPE 40 (Scientific Committee on Problems of the Environment) 1PCS Joint Symposia 11. Scientific Group on Methodologies for the Safety Evaluation of Chemicals (SGOM-SEC). Chichester: John Wiley, 1989.
Ferner RE. Chemical disasters. Pharmacol Ther 1993;58:157-171.
Dolezal V, Pokorny J. Evaluation of exposure and hazard in chemical catastrophes. In: Bourdeau P, Green G, eds. Methods for assessing and reducing injury from chemical accidents. Chichester: John Wiley, 1989; pp. 89—104.
Govaerts-Lepicard M. Definition of a major incident involvingchemicals. In: Murray V, ed. Major chemical disasters — medical aspects of management. London: Royal Society of Medicine Service, 1990; pp. 125—129.
Seliger JS, Simoneau JK. Emergency preparedness: disaster planning for health facilities. Rockville, MD: Aspen, 1988.
Waeckerle JF. Disaster planning and response. N Engl J Med 1991;324:815-821.
Dwyer BJ, Cheu D. Emergency medical response to civilian disasters. Emerg Med Rep 1990; 11(8): 169—176.
Plante DM. EMS response at a hazardous material incident: some basic guidelines. J Emerg Med 1989;7:55— 64.
Haines JA. Technological disasters global trends. Regional Symposium on Chemical Disaster, Addis Ababa. From IPCS/WHO Geneva, Switzerland: May 30, 1991.
Krishna Murti CR. Biological effects of chemical disasters’ human victims. In: Bourdeau P, Green G, eds. Methods for assessing and reducing injury from chemical accidents. Chichester: John Wiley, 1989.
Aydellote C. Bhopal tragedy focuses on change in chemical industry. Occup Health Saf 1985;54:33-59.
Isman SE. Emergency responders at a hazardous materials incident. JEMS 1982; :26—32.
Canadine IC. The possibility of major incidents in chemical distribution. In: Murray V, ed. Major chemical disasters — medical aspects of management. London: Royal Society of Medicine Service, 1990; pp. 11—43.
US Environmental Protection Agency, Office of Toxic Substances, Acute Hazardous Events Database, Report No. EPA 560-5-85-029, 1985.
McQuaid J, Vilain J, Peterson P, Sriram M, Gupta VP, Sarda PK et al. The assessment and control of chemical accidents. In: Bourdeau P, Green G, eds. Methods for assessing and reducing injury from chemical accidents. Chichester: John Wiley, 1989.
Green MA, Heumann MA, Wehr HM, Foster LP, Williams LP, Polder A et al. An outbreak of watermelon-borne pesticide toxicity. Am J Public Health 1987;11:1431-1434.
Vilain J. The nature of chemical hazards, their accident potential and consequences. In: Bourdeau P, Green G, eds. Methods for assessing and reducing injury from chemical accidents. Chichester: John Wiley, 1989; pp. 252-290.
Ferrer A, Cabral JRP. Epidemics due to pesticide contamination in food. In: World Conference on Chemical Accidents. Edinburgh: CEP Consultants, 1985; pp. 385— 387.
Volans GN. Medical management of chemical disasters involving food or water. In: Murray V, ed. Major chemical disasters — medical aspects of management. London: Royal Society of Medicine Service, 1990; pp. 173— 179.
James F, Farwell K. Lessons learnt from the River Dee pollution incident, January 1989 — Public Health. In: World Conference on Chemical Accidents. Edinburgh: CEP Consultants, 1987;223—226.
Roth PB: Status of a national disaster medical response. JAMA 1991;266:1266.
Wood DR, Cowan ML. Crisis intervention following disasters: are we doing enough? (A second look.) Am J Emerg Med 1991;9:598-602.
Facts on the National Disaster Medical System. National Disaster Medical System Implementation Task Force. Room 16A-54, Parklawn Building, 5600 Fisher’s Lane, Rockville, MD 20 857. Revised July, 1986. Tel: (301) 443-4893.
Chemical emergencies: guidance for the management of chemically contaminated patients in the prehospital setting. Washington, DC: Agency for Toxic Substances and Disease Registry.
Baxter PJ. Major chemical disasters. Britain’s health services are poorly prepared. Br Med J 1991;302:61-62.
Harrison M, AW TC, Krishman C, Jones AF, Vale JA. Major chemical disasters. Br Med J 1991; 302:657.
Koplan JP, Falk H, Green G. Public health lessons from the Bhopal chemical disaster. JAMA 1990;264:2795— 2796.
Papanek PJ Jr, Karbus J, and Subcommittee members. Guidelines for hospital and emergency rooms in managing victims of hazardous materials release. Los Angeles County Department of Health Services, January 15, 1988.
Green G, Falk H, Kielling P, Levine A, McQuaid J. Disaster emergency planning. In: Bourdeau P, Green G, eds. Methods for assessing and reducing injury from chemical accidents. Chichester: John Wiley, 1989; pp. 75-81.
Leonard RB. Community planning for hazardous materials. Top Emerg Med 1986;7:55-64.
Savelkoul TJF. Triage of victims in chemical disasters. Prehospital Disast Med 1995; 10(Suppl):S81.
Chemical emergencies: hospital emergency department guidelines. US Department of Health and Human Services, Agency for Toxic Substances and Disease Registry.
Hazardous Materials Medical Management Protocols. 2nd ed. California Emergency Medical Services Authority. Hazardous Materials Advisory Committee. Koehler G, Project Manager, February 1991; pp. 21—24.
Guidelines for ambulance response to hazardous material spills. Health Department, County of Santa Clara, CA:1985.
Willis ML Immediate response: ambulance service — the response to chemical incidents. In: Murray V, ed. Major chemical disasters — medical aspects of management. London: Royal Society of Medicine Services, 1990; pp. 69-72.
Volans GN. Medical management of chemical disasters involving food or water. In: Murray V, ed. Major chemical disasters — medical aspects of management. London: Royal Society of Medicine Services, 1990; pp. 173-181.
Kulling P. Immediate response. Poison centres: their role in the management of major incidents involving chemicals. In: Murray V, ed. Major chemical disasters — medical aspects of management. London: Royal Society of Medicine Services, 1990; pp. 79—86.
Kulling P. Biological effects on humans, initial management and role and responsibility of poison centres in chemical accidents. In: Bourdeau P, Green G, eds. Methods for assessing and reducing injury from chemical accidents. Chichester: John Wiley, 1989; pp. 127—140.
Australian Counter Disaster College Report, Toxic Chemical Incidents. Mount Macedon: Australian Counter Disaster College, October 5—9, 1981.
Jamsek M, Mozina M, Рапсе I, Krejei F. Preventive role of poison control centers in major chemical disasters. Proc Internal Congress Clin Toxicol Poison Control and Analytical Toxicology, Lux Tox ’90, Luxembourg 2—5, May 1990.
Tong TG. Risk assessment of major chemical disasters and the role of the poison centre. In: Murray V, ed. Major chemical disasters — medical aspects of management. London: Royal Society of Medicine Services, 1990; pp. 144-148.
Thanabalasingham T, Beckett MW, Murray V. Hospital response to a chemical incident report on casualties of an ethyldichlorosilane spill. Br Med J 1991 ;302:101 — 102.
McQuaid J. Dispersal of chemicals. In: Bourdeau P, Green G, eds. Methods for assessing and reducing injury from chemical accidents. Chichester: John Wiley, 1989; pp. 157—158.
Musk AW, deKlerk NH, Eccles JL, Hobbs MST, Armstrong BK, Layman L, McNulty JC. Wittenoom, Western Australia: a modern industrial disaster. Am J Emerg Med 1992;21:735-747.
A guide to the safe handling of hazardous materials accidents. 2nd ed. ASTM Manual; IP. ASTM, 1916 Rose Street, Philadelphia, PA 19 103-1187.
Altenkirch H, Stoltenburg-Didinger G, Koeppel C. The neurotoxicological aspects of the toxic oil syndrome (TDS) in Spain. Toxicology 1988;25—34.
Auf der Heide E. Disaster response. Principles of preparation and coordination. St. Louis: CV Mosby, 1989; pp. 363.
Baxter PJ, Kapila M, Mfonfu D. Lake Nyas disaster, Cameroon, 1986. The medical effects of large scale emission of carbon dioxide? Br Med J 1989;298:1437-1441.
Borak J, Olson KR, Sublet V, Koehler G. ATSDR. US Department of Health and Human Services Medical Management Guidelines for Acute Chemical Exposures. December 1992.
Cheng СТ. Supplementary report on perak mass poisoning. Malaysia: November 14, 1988.
Cheng CT, Nan Chee DW, Lyen K, Kuan CH. Report of the special team to investigate perak mass poisoning. Malaysia: October 1988.
Eastwood JB, Levin GE, Pazianas M, Taylor AP, Denton J, Freemont AJ. Aluminum deposition in bone after contamination of drinking water supply. Lancet 1990;336:462-464.
Glavin GB, Bose R, Pinsky C. Infestions and toxic syndromes from fish and shellfish consumption. Arch Intern Med 1990; 150:2425.
Bolletta G, Bacchiocchi I, Durnati G, Maffei C. Arch Intern Med 1990;150:24-25.
Cassidy K. National and international legislation on major chemical hazards. In: Murray V, ed. Major chemical disasters — medical aspects of management. London: Royal Society of Medicine Service, 1990.
Chemical Hazard Response Information System (CHRIS), Hazardous Chemical Data, Washington, DC: Department of Transportation, US Coast Guard. Commandant Instruction M16 465.12A.
Erlander S. An explosion, a flash fire and a Thai slum's slow poison. New York Times, March 21, 1991.
Leonard R. Mass evacuation in disasters. J Emerg Med 1985;2:279-286.
Leonard RB. Community planning for hazardous materials. Top Emerg Med 1986;7:55-64.
Leonard RB. Emergency evacuations in disasters. Pre-hosp Disast Med 1991;6:463-466.
Mahoney LE, Reuterschan TP. Catastrophic disasters and the design of disaster medical care systems. Ann Emerg Med 1987;16:1085—1091.
Managing Hazardous Materials Incidents. Vol I: Emergency Medical Services. A Planning Guide for the Management of Contaminated Patients; Vol II: Hospital Emergency Departaments. A Planning Guide for the Management of Contaminated Patients. Atlanta, GA: Agency for Toxic Substances and Disease Registry.
Murray V, ed: Major chemical disasters — medical aspects of management. London: Royal Society of Medicine Service, 1990; pp. 1—204.
Occupational Safety and Health Guideline for Chemical Hazards. Cincinnati: National Institute for Occupational Safety and Health. DHHS (NIOSH) Publication No. 88-118, Supplement 1-ONG, 1988.
Organization for Economic Cooperation and Development Environment Monograph No. 81. UNER IE/PAC Technical Report No. 19, Health Aspects of Chemical Accidents. Guidance on Chemical Accident Awareness, Preparedness and Response for Health Professionals and Emergency Responders. Paris: 1994.
Simeons C. Dangerous substances — sources of information. Toxic Subst J 1988;8( 1): 1 — 5.
Sorensen JH. Evacuation due to off-site releases from chemical accidents. Experiences from 1980 to 1984. J Haz Mat 1987;14:247-257.
Van der Torn P. Health risk assessment of major accidents with toxic chemicals for disaster preparedness and response. Doctor of Environmental Science and Engineering Dissertation. Los Angeles: University of California, 1991.
Criteria for recommended standard occupational exposure to waste anesthetic gases and vapors. US Department of Health Education and Welfare. NIOSH DHEW (N1OSH). Publication No. 77-140.
Following up day care anaesthesia in general practice.Drug Ther Bull 1990;28(21 ):81 —82.
Reynolds JEF. Martindale: The extra pharmacopoeia. 13th ed. London: The Pharmaceutical Press, 1993; pp. 781-805.
Reynolds JEF. Martindale: The extra pharmacopoeia. 13th ed. London: The Pharmaceutical Press, 1993; pp. 785-786.
Handbook of Pharmaceutical Excipients. Washington, DC: American Pharmaceutical Association; London. The Pharmaceutical Society of Great Britain, 1986; pp. 27-28.
Beasley CRW, Rafferty P, Holgate ST. Bronchoconstriction properties of preservatives in ipratroopium bromide (Atrovent) nebuliser solutions. Br Med J 1987;294:1197-1198.
Zhang YG, Wright WJ, Tam WK, Nguyen-Dang TH, Salome CM, Woolcoch AJ. Effect of inhaled preservatives on asthmatic subjects. 11. Benzalkonium chloride. Am Rev Respir Dis 1990;141:1406-1408.
Beasley R, Rafferty P, Holgate ST. Adverse reactions to the non-drug constituents of nebuliser solutions. Br J Clin Pharmacol 1988;25:283-287.
Akutsu I, Motojima S, Ogata H, Fukuda T, Ikemori R, Makino S. A case of acute benzalkonium chloride intoxication. Jpn J Med 1990;29:239-240.
Van Berkel M, de Wolff FA. Survival after acute benzalkonium chloride poisoning. Hum Toxicol 1988;7:191 — 193.
Stoye H, Bittersohl G. Todliche vergiftung dutch das desinfecktionsmittel C4 bei einem kleinkind. Zeitsch f Arztliche Fortbild 1968;62:436-438.
Olin BR, ed. Drug facts and comparisons. St. Louis: Facts and Comparisons 1992, pp. 2307—2308.
Wilson JT, Burr IM. Benzalkonium chloride poisoning in infant twins. Am J Dis Child 1975;120:1208-1209.
Tiess D, Nagel KH. Beitrag zur morphologie und ana-lytik der invertseifenintoxikation. Zwei todliche vergif-tungen dutch perorale sufnahine de desinfections mittels. Arch Toxicol 1967;22:333-348.
Wolff F. Todliche vergiftung dutch trinken des desin-fecktionsmittels C4. Arch Toxikolog 1961;19:8-14.
Miezkiel KA, Beasley R, Rafferty P, Holgate ST. The contribution of histamine release for bronchoconstriction provoked by inhaled benzalkonium chloride in asthma. Br J Clin Pharmacol 1988;25:157-163.
Gaylord MS, Pittman PA, Bartness J, Tuinman AA, Lorch V. Release of benzalkonium chloride from a heparin-bonded umbilical catheter with resultant factitious hypernatremia and hyperkalemia. Pediatrics 1991;87:631-635.
Gershanik JJ, Boeder B, Ensley H et al. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med 1982;307:1384-1388.
Anderson CW, Ng KJ, Andresen В et al. Benzyl alcohol poisoning in a premature newborn infant. Am J Obstet Gynecol 1984;148:344-346.
Mucklow ES. Accidental feeding of a dilute antiseptic solution (chlorhexidine 0.05 % with cetrimide 1 %) to five babies. Hum Toxicol 1988;7:567-569.
Isomaa R, Reuter J, Djupsund BM. The subacute and chronic toxicity of cetyltrimethyl ammonium bromide (СТАВ), a cationic surfactant. Arch Toxicol 1976;35:91-96.
Arena J M. Poisoning and other health hazards associated with use of detergents. JAMA 1964; 190:56.
Davies DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1985, p. 653.
De Christoforo R, Corden BJ, Hood JC et al. High-dose morphine infusion complicated by chlorbutanol induced somnolence. Ann Intern Med 1983;98:335-336.
Bowler GMR, Galloway DW, Meiklejohn BH et al. Sharp fall in blood pressure after injection of heparin containing chlorbutol. Lancet 1986;1:848-849.
Salva KM, Kuhn JG. Overdose of morphine sulfate injection during refilling of an implanted infusion pump. Clin Pharm 1987;6:577-580.
Windom H, Burgess C, Crane J, Beasley R. Airway effects of inhaled chlorbutol in asthmatic subjects. Thorax 1990;45:343.
Valentour J, Sunshine I. Chlorbutanol poisoning. Report of a fatal case. Z Rechtsmedizn 1975;77:61-63.
Borody T, Chinwak PM, Graham GG, Wade DN, Williams KM. Chlorbutol toxicity and dependence. Med J Aust 1979; 1:288.
Reynolds JEF, ed. Martindale: The extra pharmacopoeia. 13th ed. London: The Pharmaceutical Press, 1993, pp. 788-791.
Van der Vorst MMJ, Tamminga P, Wijburg FA, Schut-gens RBH. Severe methaemoglobinemia due to parachloroaniline intoxication in premature neonates. Eur J Pediatr 1990;150:72-73.
Roche S, Chinn R, Webb S. Chlorhexidine-induced gastritis. Postgrad Med J 1991;67:210-212.
Tabor E, Bostwich DC, Evans CC. Corneal damage due to eye contact with chlorhexidine gluconate. JAMA 1989;261:557-558.
Quinn MW, Bini RM. Bradycardia associated with chlorhexidine spray. Arch Dis Child 1989;64:892-893.
Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial for povidone-iodine, alcohol and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991;338:339-343.
Emerson D, Pierce C. A case of a single ingestion of 4 % Hibiclens. Vet Hum Toxicol 1988;30:583.
Massano G, Ciocatto E, Rosabianca C, Vercelli D, Actis GC, Verme G. Striking aminotransferase rise after chlorhexidine self-poisoning. Lancet 1982;1:289.
Rushton A. Safety of Hibitane. II. Human experience. J Clin Periodontal 1977;4:73-79.
Cowen J, Ellis SH, McAinsh J. Absorption of chlorhexidine gluconate from the intact skin of newborn infants. Arch Dis Child 1979;54:379-383.
Waclawski ER, McAlpine LG, Thompson NC. Occupational asthma in nurses caused by chlorhexidine and alcohol aerosols. Br Med J 1989;298:929-930.
Okano M, Nomura M, Hata S, Okada N, Sato K, Kitano Y et al. Anaphylactic symptoms due to chlorhexidine gluconate. Arch Dermatol 1989;125:50-52.
Wong WK, Goh CL, Chan KW. Contact urticaria from chlorhexidine. Contact Dermatitis 1990;22:52.
Moghadam BKH, Drisko CL, Gier RE. Chlorhexidine mouthwash-induced fixed drug eruption. Oral Surg Oral Med Oral Pathol 1991;71:431-434.
Seal D, Ficker L, Wright P, Andrews V. The case against thiomersal. Lancet 1991;338:315-316.
Varley GA, Meisler DM, Benes SC, McMahon JT, Zakov ZN, Fryczkowski A. Hibiclens keratopathy. A clinicopathological case report. Cornea 1990;9:341 — 346.
Huston CE, Wainwright P, Cooke M, Simpson R. High performance liquid chromatographic method for the determination of chlorhexidine. J Chromatog 1982;237:457-464.
Joubert P, Hundt H, Du Toit P. Severe Dettol (chloroxylenol and terpineol) poisoning. Br Med J 1978; 1:890.
Chan TYK, Sung JJY, Critchley AJH. Chemical gastro-esophagitis, upper gastrointestinal hemorrhage and gastroscopic findings following Dettol poisoning. Hum Exp Toxicol 1995;14:18-19.
Chan TYK, Lau MSW, Critcheley JAJH. Serious complications associated with Dettol poisoning. Q. J Med 1993;86:735-738.
Agency for Toxic Substances and Disease Registry. Toxicological Profile for Cresols, July, 1992.
Hathaway GJ, Proctor NH, Hughes JP, Fischman ML, eds. Proctor and Hughes’ chemical hazards of the workplace. 3rd ed. New York: Van Nostrand Reinhold, 1991; pp. 189-190.
National Institute for Occupational Safety and Health. Criteria for a Recommended Standard. Occupational Exposure to Cresol. DHEW (NIOSH). Pub N 78-133, p. 117. Washington, DC: US Government Printing Office, 1978.
Key MM, Hinschel AF, Butler J, Ligo RN, Tabershaw 1R, eds. Occupational Diseases. A Guide to Their Recognition. Revised Edition. Washington, DC: National Institute for Occupational Safety and Health. DHEW (NIOSH). Publication No 77-181. June 1977; pp. 246— 249.
Pegg SP, Campbell DC. Children’s burning due to cresol. Burns 1985;11:294-296.
Bruce AM, Smith H, Watson AA. Cresol poisoning. Med Sci Law 1976;16:171-176.
Thomas BB. Peritonea] dialysis and lysol poisoning. Br Med J 1969;3:720.
Arthus GJ, Wise CC, Coles GA. Poisoning by cresol. Anaesthesia 1977;32:642-643.
Green MA. A household remedy: misused fatal cresol poisoning following cutaneous absorption (a case report). Med Sci Law 1975;15:65-66.
Herwich RR, Treweek DN. Burns form anesthesia mask sterilized in compound solution of cresol. JAMA 1933;100:407-408.
Isaacs R. Phenol and cresol poisoning. Ohio St Med J 1922;18:558-561.
Dellal V. Acute pancreatitis following lysol poisoning. Lancet 1931; 1:407.
Cason JS. Report on three extensive industrial chemical burns. Br Med J 1959;1:827-829.
Finzer KH. Lower nephron nephrosis due to concentrated lysol vaginal douche. A report of two cases. Can Med Assoc J 1961; 84:549.
Vance BM. Intrauterine injection of lysol as an abortifa-cient. Report of a fatal case complicated by oil embolism and lysol poisoning. Arch Pathol 1945;40:395-398.
Chan TK, Mak LW, Ng RP. Methemoglobinemia, heme bodies, and acute massive intravascular hemolysis in lysol poisoning. Blood 1971;38:739-744.
Cote M-A, Lyonnais J, Leblond PF. Acute Heinz-body anemia due to severe cresol poisoning. Successful treatment with erythrocytoapheresis. Can Med Assoc J 1984;130:1319-1322.
Pike S, Shanly EH. An outbreak of disease due to a spill of cresylic acid, methylene chloride, and phenol among scores of postal workers at a mail processing facility at Springfield, OR. Vet Hum Toxicol 1987;29:476.
Bieniek G, Wilczok T. Separation and determination of phenol, alpha-naphthol, m- and p-, o-cresols and 2,5-xylenol, and catechol in the urine after mixed exposure to phenol, naphthalene, cresol, and xylenols. Br J Ind Med 1986;43:570-571.
Nieminen E, Heikkila P. Simultaneous determination of phenol, cresol and xylenols in workplace air using a polystyrenedivinyl benzene column and electrochemical detection. J Chromatogr 1986;36:271-278.
Green MA. A household remedy misused — fatal cresol poisoning following cutaneous absorption (a case report). Med Sci Law 1975;15:65-66.
Arthurs GJ, Wise CC, Coles GA. Poisoning by cresol. Anaesthesia 1977;32:642-643.
Pols M, Green L, eds. Clinical toxicology. 3rd ed. London: Pitman Books, 1983, p. 295—296.
Acetol lysol to list of abused drugs. The Forensic Drug Abuse Advisor 1991 ;3(3): 19—20.
Guidelines for Protecting the Safety and Health of Health Care Workers. U. S. Department of Health and Human Services, NIOSH, Sept. 1988.
Ethylene oxide sterilizers in health care facilities. Engineering controls and work practices. Current Intelligence Bulletin 52. NIOSH, USA HHS, July 13, 1989.
Estrin WJ, Bowler RM, Lash A, Becker CE. Neurotox-icological evaluation of hospital sterilizer workers exposed to ethylene oxide. Clin Toxicol 1990;28:1-20.
Vermylen J, Janssens S, Ceuppens J, Vermylen C. Transfusion reactions in haemophiliac caused by sensitization to ethylene oxide. Lancet 1988; 1:594.
Hertz-Piccioto I, Neutra RR. Ethylene oxide and leukemia. JAMA 1987;257:2290.
Becker CE. Ethylene oxide carcinogenicity. West J Med 1990;152:175.
Landrigan PJ, Meinhardt TJ, Gordon J, Lipscomb JA, Burg JR, Mazzukelli LF et al. Ethylene oxide: an overview of toxicologic and epidemiologic research. Am J Ind Med 1984;6:103-115.
Steenland K, Stayner L, Greife A, Halperin W, Hayes R, Hornung R, Nowlin S. Mortality among workers exposed to ethylene oxide. N Engl J Med 1991 ;324:1402— 1407.
Crystal HA, Schaumburg HH, Grober E, Fuld PA, Lipton RB. Cognitive impairment and sensory loss associated with chronic low-level ethylene oxide exposure. Neurology 1988;38:567-569.
Schroder JM, Hoheneck M, Weis J, Deist H. Ethylene oxide polyneuropathy: clinical follow-up study with morphometric and electron microscopic findings in a sural nerve biopsy. J Neurol 1985;232:83-90.
Klees JE, Lash A, Bowler RM, Shore M, Becker CE. Neuropsychologic "impairment" in a cohort of hospital workers chronically exposed to ethylene oxide. Clin Toxicol 1990;28:21-28.
Katzenstein AW. Ethylene oxide and CNS dysfunction. Clin Toxicol 1991;29:285-288.
Sarto F, Tornqvist MA, Tomanin R, Bartolucci GB, Os-terman-Golkai SM, Ehrenberg L. Studies of biological and chemical monitoring of low level exposure to ethylene oxide. Scand J Work Environ Health 1991; 17:60.
Fost U, Hallier E, Otterwalder H, Bolt HM, Peter H. Distribution of ethylene oxide in human blood and its implications for biomonitoring. Hum Exp Toxicol 1991;10:25-31.
Ethylene oxide sterilizers in health care facilities. Engineering controls and work practices. NIOSH. Current Intelligence Bulletin 52. July 13, 1989.
Harris JC, Rumack BH, Aldrich FD. Toxicology of urea formaldehyde and polyurethane foam insulation. JAMA 1981;245:243-246.
Report of the National Testing Survey on Urea Formaldehyde Foam Insulation. Ottawa, Canada: Department of Consumer and Corporate Affairs, 1981.
Norman GR, Newhouse MT. Health effects of urea formaldehyde foam insulation: evidence of causation. CMA J 1986;134:733-738.
Godish T. Formaldehyde exposure from tobacco smoke: a review. Am J Pub Health 1989;79:1044-1045.
Schutz P, Jones JL, Patten BM. Encephalopathy and rhabdomyolysis from ingesting formaldehyde-dipped cigarettes. Neurology 1988;38(Suppl):207.
Eells JT, McMartin KE, Black К et al. Formaldehyde poisoning: rapid metabolism to formic acid. JAMA 1981;246:1237-1238.
Koppel C, Baudisch H, Schneider V, Ibe K. Suicidal ingestion of formalin with fatal complications. Intensive Care Med 1990;16:212-214.
Burkhart K, Kulig K, Rumack BH. McMartin K. Formate and methanol levels following formalin ingestion. Vet Hum Toxicol 1989;31:375.
29 CFR 1910.1048.
Guidelines for protecting the safety and health of health care workers. U. S. Department of Health and Human Services, NIOSH. September 1988, pp. 5.23—5.25.
Frigas E, Filley WV, Feed CE. Bronchial challenge with formaldehyde gas: lack of bronchoconstriction in 13 patients suspected of having formaldehyde induced asthma. Mayo Clin Proc 1984;59:295-299.
Imbus HR. Clinical evaluation of patients’ complaints related to formaldehyde exposure. J Allergy Clin Immunol 1985;76:837-840.
L’abbe KA, Hoey JR. Review of the health effects of ureaformaldehyde foam insulation. Environ Res 1984;35:246-263.
Albert RF, Sellakumar AR, Laskin S et al. Gaseous formaldehyde and hydrogen chloride induction of nasal cancer in rats. J Natl Cancer Inst 1982;68:597-603.
Grafstrom RC, Fornace AJ, Autrup H et al. Formaldehyde damage to DNA and inhibition of DNA repair in human bronchial cells. Science 1983;220:216-218.
Halperin WE, Goodman M, Stayner L et al. Nasal cancer in a worker exposed to formaldehyde. JAMA 1983;249:510-512.
Wald N, Richie C. Formaldehyde process workers and lung cancer. Lancet 1984;1:1066-1067.
Acheson ED, Barnes HR, Gardner MJ et al. Formaldehyde in the British chemical industry. Lancet 1984;1:611-616.
Stayner L, Smith AB, Reeve G et al. Proportionate mortality study of workers in the garment industry exposed to formaldehyde. Am J Ind Med 1985;7:229-240.
Olsen JH, Asnaes S. Formaldehyde and the risk of squamous cell carcinoma of the sinonasal cavities. Br J Ind Med 1986;43:769-774.
Infante PF, Ulsamer AG, Groth D et al. Health hazards of formaldehyde. Lancet 1981;2:980-981.
Report of the Federal Panel on Formaldehyde. Environ Health Perspect 1982;43:139-168.
Ashford NA, Ryan CW, Caldart CC. Law and science policy in federal regulation of formaldehyde. Science 1983;222:894-900.
Wartew GA. The health hazards of formaldehyde. J Appl Toxicol 1983;3:121-126.
Kallos GJ, Solomon RA. Formation of bis (chloromethyl) ether in simulated hydrogen chloride formaldehyde atmospheric environments. Am Ind Hyg Assoc J 1973;34:469-473.
Hayes RB, Blair A, Stewart PA, Herrick RF, Mahar H. Mortality of US embalmers and funeral directors. Am J Ind Med 1990;18:641-652.
Alexandersson R, Kolmodin-Hedmun B, Hedenstierna G. Exposure to formaldehyde: effects on pulmonary function. Arch Environ Health 1982;37:279.
Kilburn KH, Warshaw R, Boylen CT et al. Pulmonary and neurobehavioral effects of formaldehyde exposure. Arch Environ Health 1985;40:254-260.
Levine RJ, Corso RDD, Blunden PB et al. The effects of occupational exposure on the respiratory health of West Virginia morticians. J Occup Med 1984;26:91-98.
Orringer EP, Mattera WD. Formaldehyde-induced hemolysis during chronic hemodialysis. N Engl J Med 1976;294:1416-1420.
Meglio C, Garnier R, Castot A, El Yafi S, Efthymiou M-L. Intoxication accidentelle par le formaldehyde au cours d’une seance d’hemodialysis. Therapie 1988;43:321-323.
Maurice F, Rivory J-P, Larsson PH, Johansson SGO, Bousquet J. Anaphylactic shock caused by formaldehyde in a patient undergoing long-term hemodialysis. J Allergy Clin Immunol 1986;77:594-597.
Klein E. Effects of disinfectants in renal dialysis patients. Environ Health Perspect 1986;69:45-48.
Samet JM, Marbury MC, Spengler JD. Health effects and sources of indoor air pollution. 11. Am Rev Respir Dis 1988;137:221-242.
Binding N, Witting U. Exposure to formaldehyde and glutaraldehyde in operating theatre. Int Arch Occup Environ Health 1990;62:233-238.
Bartone NF, Grieca RV, Henn BS. Corrosive gastritis due to ingestion of formaldehyde. JAMA 1968;203:50-51.
Docampo R, Moreno SNJ. The metabolism and mode of action of gentian violet. Drug Metab Rev 1990;22:161-178.
Drinkwater P. Gentian violet — is it safe? Aust NZ J Ob-stet Gynaecol 1990;30:65-66.
DHSS puts restrictions on use of crystal violet. Pharm J 1987;239:655.
Beeley L. Any questions. Br Med J 1988;297:607.
Reynolds JEF. Martindale: The extra pharmacopoeia. 13th ed. London: The Pharmaceutical Press, 1993; p. 793.
Churchman JW, Russell DG. The effect of gentian violet on protozoa and on growing adult tissue. Proc Soc Exp Biol Med 1913-1914;! 1:120-124.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994, pp. 2281-2282.
Jones BM, Gault DT. Blue dyes in reconstructive surgery. Lancet 1988;1:949-950.
Young HH, Hill JH. The treatment of septicemia and local infections by intravenous injections of Mercuro-chrome 220 and gentian violet. JAMA 1924;82:669-675.
Quinby GE. Gentian violet as a cause of epidemic occupational nosebleeds. Arch Environ Health 1968;16:485-489.
Walsh C, Walsh A. Haemorrhagic cystitis due to gentian violet. Br Med J 1986;293:732.
Hanson PJV, Gor D, Jeffries DJ, Collins JV. Chemical inactivation of HIV on surfaces. Br Med J 1989;298:862-864.
Fowler JF Jr. Allergic contact dermatitis from glutaraldehyde exposure. J Occup Med 1989;31:852-853.
Piccolo R, Berkowitz 1, Sacho H, Elias D, Schmeizer B, Strimling M. Glutaraldehyde disinfection. In use testing following repeated gastroscopies. S Afr Med J 1990;78:362.
Stonehill AA, Krop S, Borck PM. Buffered glutaraldehyde — a new chemical sterilizing solution. Am J Hosp Pharm 1963;20:458-465.
Proctor NH, Hughes JP, Fischman ML. Chemical hazards of the workplace. 2nd ed. New York: Van Nostrand Reinhold, 1989; pp. 264—265.
Glutaraldehyde. Guidelines for protecting the safety and health of health care workers. U. S. Department of Health and Human Services. NIOSH. September 1988, pp. 5-12-5-13. DHHS (NIOSH) Publication No. 88-119.
Symptoms of irritation associated with exposure to glutaraldehyde — Colorado. MMWR 1987;36:190-191.
Bardazzi F, Melino M, Alagna G, Veronesi S. Glutaraldehyde dermatitis in nurses. Contact Dermatitis 1986;6:319-320.
Nethercott JR, Holness DL, Page E. Occupational contact dermatitis due to glutaraldehyde in health care workers. Contact Dermatitis 1988;18:193-196.
Hansen KS. Glutaraldehyde occupational dermatitis. Contact Dermatitis 1983;9:81-82.
Connaughton P. Occupational exposure to glutaraldehyde associated with tachycardia and palpitations. Med J Aust 1993; 159:567.
Marks TA, Worthy WC, Staples RE. Influence of formaldehyde and Sonacide (potentiated acid glutaraldehyde) on embryo and fetal development in mice. Teratology 1980;22:51-58.
Gorman SD, Scott EM, Russell AD. Antimicrobial activity, uses and mechanism of action of glutaraldehyde. J Appl Bacteriology 1980;48:161-190.
Norbach D. Skin and respiratory symptoms for exposure to alkaline glutaraldehyde in medical services. Scand Work Environ Health 1988;14:366-371.
Holness DL, Nethercott JR. Health status of funeral service workers exposed to formaldehyde. Arch Environ Health 1989;44:222-229.
Wiggin P, McCurdy SA, Zeidenberg W. Epistaxis due to glutaraldehyde exposure. J Occup Med 1989;31:854-856.
Babb RR, Paaso ВТ. Glutaraldehyde proctitis. West J Med 1995;163:477-478.
Binding N, Witting U. Exposure to formaldehyde and glutaraldehyde in operating theatres. Int Arch Occup Environ Health 1990;62:233-238.
Reynolds JEF, ed. Martindale: The extra pharmacopoeia. 13th ed. London: The Pharmaceutical Press, 1993, p. 796.
Kaelin RM, Kapanci Y, Tschopp MJ. Diffuse interstitial lung disease associated with hydrogen peroxide inhalation in a dairy worker. Am Rev Respir Dis 1988;137:1233-1235.
Rosengarten MD, Portnoy D, Chiu R-C, Paterson AK. Reuse of permanent cardiac pacemakers. Can Med Assoc J 1985;133:279-283.
Patterson WB, Craven DE, Schwartz DA, Nardell EA, Kasmer J, Noble A. Occupational hazards to hospital personnel. Ann Intern Med 1985;102:658-680.
Advisory Committee on Dangerous Pathogens. LAV/ HTLV III — the causative agent of AIDS and related conditions. Revised Guidelines. London: Department of Health and Social Security, 1986.
Tyrala EE, Hillman LS, Hillman REet al. Clinical pharmacology of hexachlorophene in newborn infants. J Pediatr 1977;91:481-486.
Conte JE Jr. Infection with human immunodeficiency virus in the hospital. Epidemiology, infection control and biosafety considerations. Ann Intern Med 1986; 105: 730-736.
Memorandum on the control of viral haemorrhagic fevers. Department of Health and Social Security. London: HM Stationery Office, 1986.
Shuman RM, Leech RW, Alvord ED. Neurotoxicity of hexachlorophene in the human. I. A clinicopathologic study of 248 children. Pediatrics 1974;54:689-695.
Martin-Bouyer G, Toga M, Lebreton R et al. Outbreak of accidental hexachlorophene poisoning in France. Lancet 1982;1:91-95.
Plueckhahn VD. Hexachlorophene preparations and the newborn infant. Aust Paediatr J 1980;16:40-43.
Liu J, Wang C-N, Yu J-H et al. Hexachlorophene in the treatment of Clonorchiasis sinesis. China Med J 1963;82:702-711.
Herskowitz J, Rosman NP. Acute hexachlorophene poisoning by mouth in a neonate. J Pediatr 1979;94:495— 496.
Lustig FW. A fatal case of hexachlorophene ("pHiso-Hex") poisoning. Med J Aust 1963; 1:737.
Henry LD, DiMaio VJM. A fatal case of hexachlorophene poisoning. Military Med 1974;139:41-43.
Mullick FG. Hexachlorophene toxicity — human experience at the Armed Forces Institute of Pathology. Pediatrics 1973;51:395-399.
Kimbrough RD. Review of recent evidence of toxic effects of hexachlorophene. Pediatrics 1973;51:391-394.
Ulsamer AG, Yoder PD, Marzulli FN. Determinations of hexachlorophene in human and experimental animal tissues. Toxicol Appl Pharmacol 1972;22:276-277 (abstract).
Gowdy JM, Ulsamer AG. Hexachlorophene lesions in newborn infants. Am J Dis Child 1976;130:247-250.
Brandt 1, Denker L, Larsson Y. Transplacental passage and embryonic fetal accumulation of hexachlorophene in mice. Toxicol Appl Pharmacol 1979;49:393-401.
Hailing H. Suspected link between exposure to hexachlorophene and malformed infants. Ann NY Acad Sci 1979;320:426-435.
Anderson JM, Cockburn F, Forfar J et al. Neonatal spongioform myelinopathy after restricted application of hexachlorophene skin disinfectant. J Clin Pathol 1981;34:25-29.
Boehm RM, Czajka PA. Hexachlorophene poisoning and the ineffectiveness of peritoneal dialysis. Clin Toxicol 1979;14:257-262.
Litovitz TL, Bailey KM, Schmitz BF, Holm КС, Klein-Schwartz W. 1990 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1991;9:461-509.
Humberston CL, Dean BS, Krenzelok EP. Ingestion of 35 % hydrogen peroxide. Clin Toxicol 1990;28:95-100.
NIOSH Pocket Guide to Chemical Hazards NIOSH. US Dept Health and Human Services, June 1990, p. 126. DHHS (NIOSH) Publication No. 90—117.
Giberson TP, Kern JD, Pettigrew DW HI, Eaves CC Jr, Haynes JF Jr. Near-fatal hydrogen peroxide ingestion. Ann Emerg Med 1989;18:778-779.
Olim CB, Ciuti A. Meconium ileus: a new method of relieving obstruction. Ann Surg 1954;140:736-739.
Pogrebniak AE, Sugar A. Corneal toxicity from hydrogen peroxide-soaked tonometer tips. Arch Ophthalmol 1988;106:1505.
Brenman AK, Milner RM, Weller CR. Use of hydrogen peroxide to clear blocked ventilation tubes. Am J Otol 1986;7:47-50.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994; pp. 1840-1841.
Proctor NH, Hughes JP, Fischman ML. Chemical hazards of the workplace. 2nd ed. New York: Van Nostrand Reinhold, 1989, pp. 281-282.
Hyperoxygenation therapy. US Food and Drug Administration, April 14, 1989.
Thompson JD. New health food hazard — 35% hydrogen peroxide. Vet Hum Toxicol 1989;31:339.
Reynolds JEF, ed. Martindale: The extra pharmacopoeia. 13th ed. 1993. London: The Pharmaceutical Press, p. 798.
Oberst FW, Comstock CC, Hackley EB. Inhalation toxicity of nine per cent hydrogen peroxide vapor. Acute, subacute and chronic exposures of laboratory animals. Ind Hyg Occup Med 1954;10:319-327.
Blakely WF, Fuciarelli AF, Wegher BJ, Dizdaroglu M. Hydrogen peroxide-induced base damage in deoxyribonucleic acid. Radiat Res 1990;121:338-343.
Oberg M, Lindsey D. Do not put hydrogen peroxide or povidone iodine into wounds. Am J Dis Child 1987;141:27-28.
Shaw A, Cooperman A, Fusco J. Gas embolism produced by hydrogen peroxide. N Engl J Med 1967;277:238-241.
Gerrish SP. Gas embolism due to hydrogen peroxide. Anaesthesia 1985; 10:1244.
Bassan MM, Dudai M, Shalev O. Near-fatal systemic oxygen embolism due to wound irrigation with hydrogen peroxide. Postgrad Med J 1982;58:448-450.
Sleigh JW, Linter SPK. Hazards of hydrogen peroxide. Br Med J 1985;291:1706.
Schneider DL, Hebert LJ. Subcutaneous gas from hydrogen peroxide administration under pressure. Am J Dis Child 1987;141:10-11.
Cina SJ, Downs CU, Conradi SE. Hydrogen peroxide: a source of lethal oxygen embolism. Am J Forensic Med Pathol 1994;15(1):44—50.
Swayne LC, Ginsberg HN, Ginsburg A. Pneumoretroperitoneum secondary to hydrogen peroxide wound irrigations. Am J Radiol 1987;148:149-150.
Danis RK, Brodeur AE. The danger of hydrogen peroxide as a colonic irrigating solution. J Pediatr Surg 1967;2:131-133.
Meyer CT, Brand M, DeLuca VA, Spiro HM. Hydrogen peroxide colitis: a report of three patients. J Clin Gastroenterol 1981;3:31-35.
Sheehan JF, Brynjolfsson G. Ulcerative colitis following hydrogen peroxide enema: case report and experimental production with transient emphysema of colonic wall and gas embolism. Lab Invest 1960;9:150-157.
Jonas G, Mahoney A, Murray J, Gertler S. Chemical colitis due to endoscope cleaning solutions. A mimic of pseudomembranous colitis. Gastroenterology 1988;95:1403-1408.
Pumphrey RE. Hydrogen peroxide proctitis. Am J Surg 1951;81:60-62.
Rees TD, Orth CF. Oral ulcerations with use of hydrogen peroxide. J Periodontol 1986;57:689-692.
Tripathi BJ, Tripathi RC. Hydrogen peroxide damage to human corneal epithelial cells in vitro. Implications for contact lens disinfection systems. Arch Ophthalmol 1989;107:1516-1519.
McNally JJ. Clinical aspects of topical application of dilute hydrogen peroxide solutions. CLAO J 1990; 16(Sup-pl):S46—S52.
Chandler JW. Biocompatibility of hydrogen peroxide in soft contact lens disinfection: antimicrobial activity vs biocompatibility — the balance. CLAO J 1990;16(Sup-pl):S43—S45.
Timperley AJ, Bracey DJ. Cardiac arrest following the use of hydrogen peroxide during arthroplasty. J Arthroplasty 1989;4:369-370.
Zecevic D, Gasparec Z. Death caused by hydrogen peroxide. Z Rechtsmed 1979;84:57-59.
Giusti GV. Fatal poisoning with hydrogen peroxide. Forensic Sci 1973;2:99-100.
Seymour WB Jr. Poisoning from cutaneous application of iodine. A rare aspect of its toxicologic properties. Arch Intern Med 1937;59:952-966.
Pennington JAT. A review of iodine toxicity reports. J Am Diet Assoc 1990;90:1571-1581.
Dyck RF, Bear RA, Goldstein MB, Halperin ML. lo-dine/iodide toxic reaction: case report with emphasis on the nature of metabolic acidosis. Can Med Assoc J 1979;120:704-706.
Moore M. The ingestion of iodine as a method of attempted suicide. N Engl J Med 1938;219:383-388.
Finkelstein R, Jacobi M. Fatal iodine poisoning: a clin-icopathologic and experimental study. Ann Intern Med 1937;10:1283-1296.
d’Auria J, Lipson S, Garfield JM. Fatal iodine toxicity following surgical debridement of a hip wound: case report. J Trauma 1990;30:353-355.
Goldenheim PD. Inactivation of HIV by povidone-io-dine. JAMA 1987;257:2434.
dela Cruz F, Brown DH, Leikin JB, Franklin C, Hry-horczuk DO. Iodine absorption after topical administration. West J Med 1987;146:43-45.
Means LJ, Rescorla FJ, Grosfeld JL. Iodine toxicity. An unusual cause of cardiovascular collapse during anesthesia in an infant with Hirschsprung’s disease. J Pediatr Surg 1990;25:1278-1279.
Roslyn JJ. Peritoneal irrigation with povidone-iodine. JAMA 1988;260.
McEvoy GK. AHFS Drug Information 94. Bethesda, MD. American Society of Hospital Pharmacists, 1994; p. 2305.
Reynolds JEF. Martindale: The extra pharmacopoeia. 13th ed. London. The Pharmaceutical Press, 1993; pp. 970-972.
Litovitz TL, Martin TG, Schmitz B. 1986 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1987;5:405-445.
Shetty KR, Duthie EH Jr. Thyrotoxicosis induced by topical iodine application. Arch Intern Med 1990;150:2400-2401.
Smerdely P, Lim A, Boyages SC, Waite K, Wu D, Roberts V et al. Topical iodine-containing antiseptics and neonatal hypothyroidism in very low birthweight infants. Lancet 1989;2:661-664.
1’Allemand D, Gruters A, Heidemann P, Schurnbrand P. Iodine-induced alterations of thyroid function in newborn infants after prenatal and perinatal exposure to povidone-iodine. J Pediatr 1983;102:935-938.
Kurt TL, Morgan ML, Hailica V, Bost R, Petty CS. Fatal iatrogenic iodine toxicity in a 9-week-old infant. Vet Hum Toxicol 1992;34:333.
Cohn BNE. Absorption of compound solution of iodine from the gastrointestinal tract. Arch Intern Med 1932;49:950-956.
Sandell E, Koithoff IM. Microdetermination of iodine by a catalytic method. Mikrochim Acta 1937; 1:9.
Hunt JL, Sato R, Heck EL et al. A critical evaluation of povidone-iodine absorption in thermally injured patients. J Trauma 1980;20:127-129.
Pietsch J, Machins JL. Complications of povidone-iodine absorption in topically treated burn patients. Lancet 1976;1:280-282.
Baker MD, Baldassano RN. Povidone iodine as a cause of factitious hematuria and abnormal urine coloration in the pediatric emergency department. Pediatr Emerg Care 1989;5:240-241.
White A, Joseet M. Burns from iodine. Anaesthesia 1990;45:75.
Vulisma T, Menzel D, Abbad FCB, Gons MH, De Vi-jlder JJM. Iodine induced hypothyroidism in infants treated with continuous cyclic peritoneal dialysis. Lancet 1990;336:812.
Reynolds JEF, ed. Martindale: The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989, pp. 964-965.
Scarlett Ml, Furman U. Disease transmission in the dental office: guidelines for disinfection. JAMA 1988;259:1081.
Guidelines for Health Care Workers. NIOSH U. S. Department of Health and Human Services, 1988, pp. 5—7.
Barnett JM, Ptotnick M, Fine КС. Intoxication after an isopropyl alcohol enema. Ann Intern Med 1990;113:638-639.
Corbett J, Meier G. Suicide attempted by rectal administration of drug. JAMA 1968;206:2320-2321.
Schich JB, Milstein JM. Burn hazard of isopropyl alcohol in the neonate. Pediatrics 1981;68:588-589.
Arditi M, Killner MS. Coma following use of rubbing alcohol for fever control. Am J Dis Child 1987; 141:237— 238.
Vicas I, Beck R. Fatal inhalational isopropyl alcohol poisoning in a neonate. Vet Hum Toxicol 1989;341:346.
Russo S, Taff ML, Mirchandani HG, Monforte JR, Spitz WV. Scald burns complicated by isopropyl alcohol intoxication. A use of fatal child abuse. Am J Forensic Med Pathol 1986;7:81-83.
VivierPM, LewanderWJ, Martin HF. Isopropyl alcohol intoxication in a neonate through chronic dermal exposure. Vet Hum Toxicol 1991 ;33:391.
Hunziker N. Theilsothiazolinone story. Dermatology 1992;184:85-86.
De Groot AC, Herxheimer A. Isothiazolinone preservative: cause of a continuing epidemic of cosmetic dermatitis. Lancet 1989;1:314-316.
Fransway AF. Sensitivity to Kathon CG: findings in 365 consecutive patients. Contact Dermatitis 1988; 19:342— 347.
Barid EA. Greig D. Kathon CG — can New Zealand avoid the epidemic? NZ Med J 1991; 104:290.
Magarey J A. Absorption of mercurochrome. Lancet 1993;342:1404.
Whittet HB, Shinkwin C, Freeland AP. Anosmia due to nasal administration of corticosteroids. Br Med J 1991;303:651.
FDA Consumer 1991 ;25(8):2— 3.
Gross BG. Cardiac arrhythmias during phenol face peeling. Plast Reconstr Surg 1984;73:590-594.
Warner MA, Harper JV. Cardiac arrhythmias associated with chemical peeling with phenol. Anesthesiology 1984;62:366.
Easton JKM, Ozel T, Halpern D. Intramuscular neurolysis for spasticity in children. Arch Phys Med Rehabil 1979;60:155-158.
Haddad LM, Dimond KA, Schweistris JE. Phenol poisoning. JACEP 1979;8:267-269.
Cronk JD. Phenol with glucagon in cardiotherapy. N Engl J Med 1971;784:219-220.
Liao JF, Oehme FW. Literature review of phenol compounds. 1. Phenol. Vet Hum Toxicol 1980;22:160.
Anderson W. Fatal misadventure with carbolic acid. Lancet 1869;!: 179.
Leider M, Moser HS. Toxicology of topical dermatology preparations. Arch Dermatol 1961;83:928-929.
Conning DM, Hayes MJ. The dermal toxicity of phenol: an investigation of the most effective first aid measures. Br J Ind Med 1970;27:155-159.
Piotnowski JK. Evaluation of exposure to phenol: absorption of phenol vapour in the lungs and through the skin and excretion of phenol in the urine. Br J Ind Med 1971;28:172-178.
Lucus RC, Lane WA. Two cases of carbolic acid coma induced by application of carbolic acid compresses to the skin. Lancet 1895;1:1362-1364.
Jarvis SN, Straube RC, Williams AU et al. Illness associated with contamination of drinking water supplies with phenol. Br Med J 1985;290:1800-1802.
Baker EL, Landrigan PJ, Bertozzi PE. Phenol poisoning due to contaminated drinking water. Arch Environ Health 1978;33:89-94.
Stajduhar-Caric Z. Acute phenol poisoning. Singular findings in a lethal case. J Forensic Med 1968;15:41-42.
McGuiness JP, Cantees KK. Epidural injection of phe-nol-containing ranitidine preparation. Anesthesiology 1990;73:553-555.
Foxall PJD, Bending M, Gartland KPR, Nicholson JK. Acute renal failure following accidental cutaneous exposure to phenol application of PM R (proton nuclear magnetic resonance spectroscopic) urinalysis to monitor the disease process. Hum Exp Toxicol 1990;9:351.
Foxall PJD, Nicholson JK, Bending MR, Eisinger AJ. Monitoring phenol-induced nephrotoxicity by high-resolution proton NMR spectroscopy. Renal Failure 1989;1 1:57-58.
Foxall PJD, Bending MR, Gartland KPR, Nicholson JK. Acute renal failure following accidental cutaneous absorption of phenol. Application of NMR urinalysis to monitor the disease process. Hum Toxicol 1989;9:491-496.
Cohen N, Modai D, Khahil A, Golik A. Acute resin phenolformaldehyde intoxication. A life-threatening occupational hazard. Hum Toxicol 1989;8:247-250.
Ho S-L, Hollinrake K. Acute epiglottis and Chloraseptic. Br Med J 1989;298:1584.
Spiller HA, Quadroni-Kushner DA, Cleveland P. A five-year evaluation of acute exposure to phenol disinfectant (26 %). Clin Toxicol 1993;31:307-313.
Harrison LM, Morrison JE, Fennessey PV. Microtechnique for quantifying phenol in plasma by gas chroma-tography-mass spectrometry. Clin Chem 1991:37:1739— 1742.
Soares ER, Tift JP. Phenol poisoning: three fatal cases. J Forensic Sci 1982;27:729-731.
Nomoto Y, Fujita T, Kitani Y. Serum and urine levels of phenol following phenol blocks. Can J Anaesth 1987;34:307-310.
Brancato DJ. Recognizing potential toxicity of phenol. Vet Hum Toxicol 1982;24:29-30.
Mofenson HC, Caraccio TR, Laudano J. Glucagon for propranolol overdose. JAMA 1986;255:2025.
Litton C. Chemical face lifting. Plast Reconstr Surg 1962;29:371-380.
Lo Dico C, Caplan YH, Levine B, Smyth DF, Smialek JE. Phenol: tissue distribution in a fatality. J Forensic Sci 1989;34:1013-1015.
Chamberlain JM, Gorman PL, Young GM. Silver nitrate burns following treatment for umbilical granuloma. Pediatr Emerg Care 1992;8:29-30.
Marroni M, Menichetti F. Accidental intravenous infusion of sodium hypochlorite. DICP 1991;25:1008-1009.
Leafer DJ. Eusol. Still awaiting proper clinical trials. Br Med J 1992;304:930-931.
Burton JL. Eusol. The continuing controversy. Br Med J 1992;304:1636.
Watson ID, McBride D, Paterson KR. Fatal xylenol selfpoisoning. Postgrad Med J 1986;62:411-412.
McGarvie MJ, Volans GN. Ingestion of sterilising tablets for baby feeding bottles. Vet Hum Toxicol 1987;29(Suppl 2): 126.
Reynolds JEF, ed. Martindale: The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989, p. 969.
Williams DC. Acute respiratory obstruction caused by ingestion of a caustic substance. Br Med J 1985;291:313-314.
Siodlak MZ, Gleeson MJ, Wengraf CL. Accidental ingestion of sterilizing tablets by children. Br Med J 1985;290:1707-1708.
Bonadio WA. ТАС: a review. Pediatr Emerg Care 1989;5:128-130.
Mofenson НС, Caraccio TR. Tack up a warning on TAC. Am J Dis Child 1989;143:519-520.
Wehner D, Hamilton G D. Seizures following topical application of local anesthetics to burn patients. Ann Emerg Med 1984;13:456-458.
Dailey RH. Fatality secondary to misuse of TAC solution. Ann Emerg Med 1988;17:159-160.
United States Code 1982. Title 21, Subchapter V, Section 360 (g), p. 783.
Doya MR, Burton ВТ, Schleiss MR, DiLiberti JH. Recurrent seizures following mucosal applications of TAC. Ann Emerg Med 1988;17:646-648.
DiFazio C. Local anesthetics. Action, metabolism and toxicity. Otolaryngol Clin North Am 1981;14:515-518.
Meyers EF. Cocaine toxicity during dacryocystorhinostomy. Arch Ophthalmol 1980;98:842-843.
Patel D, Chopra S, Berman MD. Serious systemic toxicity resulting from use of tetracaine for pharyngeal anesthesia in upper endoscopic procedures. Digest Dis Sci 1989;34:882-884.
Duffin RM, Olson RJ. Tetracaine toxicity. Ann Ophthalmol 1984;16:836-837.
Amitai Y, Zylber-Katz E, Avital A, Zangen D, Noviski N. Serum lidocaine concentrations in children during bronchoscopy with topical anesthesia. Chest 1990;98:1370-1373.
Lie RL, Vermeer BJ, Edelbroek PM. Severe lidocaine intoxication by cutaneous absorption. J Am Acad Dermatol 1990;23:1026-1028.
Wason S, del Rey JG, Druckenbrod R. Avoiding lidocaine toxicity in the treatment of acute herpetic gingivostomatitis. Vet Hum Toxicol 1989;31:361.
Benowitz N, Forsyth RP, Melmon KL et al. Lidocaine disposition kinetics in monkey and man. 1. Predication by a perfusion model. Clin Pharmacol Ther 1974;16:87-98.
Boyes RN, Scott DB, Jebson PJ et al. Phannacokinetics of lidocaine in man. Clin Pharmacol Ther 1971;12:105-116.
Baselt RC, Cravey RH, eds. Lidocaine. In: Disposition of toxic drugs and chemicals in man. Chicago: Year Book, 1989, pp. 455-460.
Strong JM, Mayfield DE, Atkinson AJ et al. Pharmacological activity, metabolism and pharmacokinetics ofgly-cinexylidide. Clin Pharmacol Ther 1975;17:184-194.
Pottage A, Scott DB. Safety of "topical" lignocaine. Lancet 1988;l:1003.
Adriani J, Zepernick R. Clinical effectiveness of drugs used for topical anesthesia. JAMA 1964;188:711-716.
Mofenson HC, Caraccio TR, Miller H, Greensher J. Lidocaine toxicity from topical mucosal application with a review of the clinical pharmacology of lidocaine. Clin Pediatr 1983;22:190-192.
Adriani J, Campbell D. Fatalities following topical application of local anesthetics to mucous membranes. JAMA 1956;162:1527-1530.
Vuignier BI, Henretig F, Kearney T, Clark M, Hicks M, Vaicious T. Death in a child ingesting dibucaine hydrochloride. Vet Hum Toxicol 1988;30:345-346.
Goldberg G, Goodman DH. Case report of a hexylcaine reaction. Anesthesiology 1957;18:652-653.
Spellberg МА. Hexylcaine (Cyclaine) as topical anesthetic in gastroscopy and esophagoscopy. Gastroenterology 1959;36:120-121.
Collins JF. Methemoglobinemia as a complication of 20 % benzocaine spray for endoscopy. Gastroenterology 1990;98:211-213.
Gentile DA. Severe methemoglobinemia induced by a topical teething preparation. Pediatr Emerg Care 1987;3:176-178.
Anderson ST, Hajduczek J, Barker SJ. Benzocaine-induced methemoglobinemia in an adult. Accuracy of pulse oximetry with methemoglobinemia. Anesth Analg 1988;7:1099-1101.
Curry S. Methemoglobinemia. Ann Emerg Med 1982;11:214-221.
Hansen-Flaschen J. Methemoglobinemia after lidocaine administration. Chest 1990;98:519-520.
Ruffles SP, Ayres JG. Fatal bronchospasm after topical lidocaine before bronchoscopy. Br Med J 1987;294:1658-1659.
Garrettson KF, McGee EB. Rapid onset of seizures following aspiration of viscous lidocaine. Clin Toxicol 1992;30:413-422.
Mather LE, Cousins MJ. Local anesthetics and their current clinical use. Drugs 1979;18:185-205.
Bulmer NJ, Duchett AC. Absorption of lignocaine through split skin donor sites. Anaesthesia 1985;40:808-809.
Gorman RL, Kin JC, Oderda GM. Ingestion of topical lidocaine. It’s time to stop the pain. Vet Hum Toxicol 1984;26:413.
Mittlemen RE, Wetli CV. Death caused by recreational cocaine use. JAMA 1984;252:1889-1893.
Hess GP, Walson PD. Seizures secondary to oral viscous lidocaine. Ann Emerg Med 1988;725—727.
Severinghaus JW, Xu F-D, Spellman MJ Jr. Benzocaine and methemoglobin. Recommended actions. Anesthesiology 1991;74:385-386.
Duncan J, Carter J A. Overdose of atracurium. Anaesthesia 1986;41:767.
Charlton AJ, Harper NJN, Edwards D, Wilson AC. Atracurium overdose in a small infant. Anaesthesia 1989;44:485-486.
Product literature. Atracurium besylate (Tracrium Injection). Burroughs Wellcome, December 1989.
Goonewardene TW, Sentheshanmuganathan S, Kamalanathan S, Kanagasunderain R. Accidental subarachnoid injection of gallamine. A case report. Br J Anaesth 1975;47:889-893.
Poklis A, Melanson EG. A suicide by pancuronium bromide injection. Evaluation of the fluorometric determination of pancuronium in post-mortem blood, serum and urine. J Anal Toxicol 1980;4:275-280.
Vandenbrom RHG, Wierda JMKH. Pancuronium bromide in the intensive care unit. A case of overdose. Anesthesiology 1988;69:996-997.
Devlin E, Bali I. Accidental intraarterial injection of tubocurarine. Anaesthesia 1991;416:75-76.
Siegel H, Rieders F, Holmstedt B. The medical and scientific evidence in alleged tubocurarine poisonings. A review of the so-called Dr К case. Forensic Sci Int 1985;29:29-76.
Constantini D. In tema di iperdosaggio da tubocurarina: considerazioni su due casi. Acta Anaesthesiol 1966;17:253-258.
Forrest ETS, Vanner RG. "Overdose" of vecuronium. Anaesthesia 1990;45:997.
Foldes FF. Distribution and biotransformation of succinylcholine. Int Anesth Clin 1975;13:101-115.
Cook DR, Wingard LB Jr, Taylor FH. Pharmacokinetics of succinylcholine in infants, children and adults. Clin Pharmacol Ther 1976;20:493-498.
Chestnut RJ, Healy TEJ, Harper NJN, Faragher ER. Suxamethonium — the relation between dose and response. Anaesthesia 1989;44:14-18.
Viby-Mogensen J, Hanel HK. Prolonged apnoea after suxamethonium. An analysis of the first 225 cases reported to the Danish Cholinesterase Research Unit. Acta Anaesth Scand 1978;22:371-380.
Kent RS. Revised label regarding use of succinylcholine in children and adolescents. II. Reply. Anesthesiology 1994;80:244-245.
Ostergaard D, Engbaek J, Viby-Mogensen J. Adverse reactions and interactions of the neuromuscular blocking drugs. Med Toxicol Adverse Drug Exp 1989;4:351-368.
Miller RD. Neuromuscular blocking agents. In: Smith et al, eds. Drug interactions in anesthesia. Philadelphia: Lea & Febiger, 1981; pp. 249—269.
Driessen JJ, Crul JF, Vree ТВ et al. Benzodiazepines and neuromuscular blocking drugs in patients. Acta Anaesth Scand 1986;30:642-646.
Roizen MF, Feeley TW. Pancuronium bromide. Ann Intern Med 1978;88:64-68.
Azar 1, Cottrell J, Gupta B, Turndorf F. Furosemide facilitates recovery of evoked twitch response after pancuronium. Anesth Analg 1980;59:55-57.
Wood M. Neuromuscular blocking agents. In: Wood M, Wood AJJ, eds. Drugs and anesthesia. Pharmacology for anesthesiologists. 2nd ed. Baltimore: Williams & Wilkins, 1990; pp. 271-318.
Argov Z, Mastaglia FF. Disorders of neuromuscular transmission caused by drugs. N Engl J Med 1979;301:409-413.
Miller RD, Way WL, Katzung BG. The potentiation of neuromuscular blocking agents by quinidine. Anesthesiology 1967;28:1036-1041.
Baraha A, Yazigi A. Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. Anesthesiology 1987;67:806.
Doll DC, Rosenberg H. Antagonism of neuromuscular blockade by theophylline. Anesth Analg 1979;58:139.
Ornstein E, Matteo RS, Schwarts AE et al. The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium. Anesthesiology 1987;67:191-196.
Voetmann C, Jest P. A myasthenic reaction provoked by treatment with lithium carbonate. Ugestk Laeger 1978;140:2375-2376.
Gramstod L. Atracurium, vecuronium and pancuronium in end-stage renal failure. Br J Anaesth 1987;59:995— 1003.
Gramstod K, Gjerlov JA, Hysing ES et al. Interaction of cyclosporin and its solvent, cremophor with atracurium and vecuronium. Br J Anaesth 1986;58:1149—1155.
Laflin MJ. Interaction of pancuronium and corticosteroids. Anesthesiology 1986;65:93-94.
Thomas J, Climie CR, Mather LE. The placental transfer of plucuronium. A preliminary report. Br J Anaesth 1969;41:297-302.
Shearer ES, Fahy LT, O’Sullivan EP, Hunter JM. Transplacental distribution of atracurium, laudanosine and monoquaternary alcohol during elective caesarean section. Br J Anaesth 1991;66:551-556.
Kivalo I, Saarikoski S. Placental transfer of 14C-Dimethyltubocurarine during caesarean section. Br J Anaesth 1976;48:239-242.
Duvaldestin P, Demetriou M, Henzel D, Desmonts JM. The placental transfer of pancuronium and its pharmacokinetics during caesarian section. Acta Anaesth Scand 1978;22:327-333.
Ramzan MI, Somogyi AA, Walker JS, Shanks CA, Triggs EJ. Clinical pharmacokinetics of the non-depolarizing muscle relaxants. Clin Pharmacokinet 1981;6:25-60.
Mirakhur RK. Side effects of atracurium. Br J Anaesth 1990;64:124-126.
Agoston S, Vermeer GA, Kersten UW, Meijer DKF. The fate of pancuronium bromide in man. Acta Anaesth Scand 1973;17:267-275.
Youngman PR, Taylor KM, Wilson JD. Anaphylactoid reactions to neuromuscular blocking agents: a commonly undiagnosed condition? Lancet 1983;2:597-599.
Lumb AB, Calder I. "Cured" myasthenia gravis and neuromuscular blockade. Anaesthesia 1989;44:828-830.
Yentis SM. Suxamethonium and hyperkalaemia. Anaesth Intensive Care 1990;18:92-101.
Ramzan IM, Shanks CA, Triggs EJ. Relationship between gallamine plasma concentration and neuromuscular paralysis in surgical patients. J Clin Pharmacol 1983;23:243-251.
Stevens HM, Moffat AC. A rapid screening procedure for quaternary ammonium compounds in fluids and tissues with special reference to suxamethonium (succinylcholine). J Forensic Sci Soc 1974;14:141-148.
Horowitz PE, Spector S. Determination of serum d-tubocurarine concentration by radioimmunoassay. J Pharm Exp Ther 1973;185:94-100.
Meulemans A, Mohler J, Henzel D, Duvaldestin P. Quantitation of r/-tubocurarine in plasma using high performance liquid chromatography. J Chromatogr 1981;226:255-258.
Bitetti J. Neuromuscular blockade. In: Firestone LL, Lebowitz PW, Cook CE, eds. Clinical anesthesia procedures of the Massachusetts General Hospital. Boston: Little, Brown, 1988, pp. 167—184.
Gooch JL. Neuromuscular junction blocking agents in the 1CU. Complications of long term use. Salt Lake City, UT: North American Congress of Clinical Toxicology-94. September 23—26, 1994.
Segneno V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992;327:524-528.
Gooch JL, Moore MH, Ryser DK. Prolonged paralysis after neuromuscular junction blockade: case reports and electrodiagnostic findings. Arch Phys Med Rehabil 1993;74:1007-1011.
Barolin RJ, Jackson CE, Rogers SJ, Ridings LW, McVey AL. Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids. Muscle Nerve 1994;12:647-654.
Partridge BL, Abrams JH, Bazemore C, Rubin R. Prolonged meuromuscular blockade after long-term infusion of vecuronium bromide in the intensive care unit. Crit Care Med 1990;18:1177-1179.
Kupfer Y, Namba T, Kaldawi E, Tessier S. Prolonged weakness after long-term infusion of vecuronium bromide. Ann Intern Med 1992;117:484-486.
Vanderheuden BA, Reynolds HM, Gerold KB, Emanuele T. Prolonged paralysis after long-term vecuronium infusion. Crit Care Med 1992;20:304-307.
Hirano M, Ott BR, Raps EC, Minetti C, Lennihan L, Libbey NP et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992;42:2082— 2087.
Ramsay DA, Zochodne DW, Robertson DM, Nag S, Ludwin SK. A syndrome of acute severe muscle necrosis in intensive care unit patients. J Neuropath Exp Neurol 1993;52:387-398.
Al Ahdal O, Bevan DR. Clindamycin-induced neuromuscular blockade. Can J Anaesth 1995;42:617.
Gooch JL. Prolonged paralysis after neuromuscular blockade. Clin Toxicol 1995;33:419-426.
Gooch JL, Suchyta DO, Balbierz JM, Petajan JH, Clammer TP. Prolonged paralysis after treatment with neuromuscular junctive blocking agents. Crit Care Med 1991;19:1125-1131.
Kupfer Y, Okrent DG, Twersky RA, Tessier S. Disuse atrophy in a ventilated patients with status asthmaticus receiving neuromuscular blockade. Crit Care Med 1987;15:795-796.
Zochodnu DW, Ramsay DA, Saly V, Sheppy S, Moffatt S. Acute necrotizing myopathy of intensive care: electrophysiological studies. Muscle Nerve 1994;17:285-292.
Parnass SM, Schmidt KJ. Adverse effects of spinal and epidural anaesthesia. Drug Safety 1990;5:179-194.
Williamson JA. Inadvertent spinal subdural injection during attempted spinal epidural steroid therapy. Anaesth Intens Car 1990;18:406-408.
Reynolds F, Speedy HM. The subdural space: the third place to go astray. Anaesthesia 1990;45:120-123.
Nakazawa К, Yoshinari М, Kinefuchi S, Amaha К. Inadvertent intrathecal administration of amidetrizoate. Intensive Care Med 1988;15:55-57.
Reisner LS, Hochman BN, Plumer MH. Persistent neurologic deficit and adhesive arachnoiditis following intrathecal 2-chlorprocaine injection. Anesth Analg 1980;59:452-454.
Goonewardene TW, Sentheshanmuganathan S, Kamalanathan S, Kanagasunderam R. Accidental subarachnoid injection of gallamine. Br J Anaesth 1975;47:889-893.
Mesry S, Baradaran J. Accidental intrathecal injection of gallamine triethiodide. Anaesthesia 1974;29:301-304.
Peduto VA, Gungui P, diMartino MR, Napoleone M. Accidental subarachnoid injection of pancuronium. Anesth Analg 1989;69:516-517.
Katz Y, Markovits R, Rosenberg B. Pneumoencephalos after inadvertent air injection during epidural block. Anesthesiology 1990;73:1277-1279.
Tomarken JL, Britt BA. Malignant hypothermia. Ann Emerg Med 1987;16:1253-1265.
Petersdorf RG. Hypothermia and hyperthermia. In: Wilson JD, Braunwald E, Isselbacher KJ, Petersdorf RG, Martin JB, Fauci AS, Root RK, eds. Harrison’s principles of internal medicine. 12th ed. New York: McGraw-Hill, p. 2197-2198.
Strazis KP, Fox AW. Malignant hyperthermia. A review of published cases. Anesth Analg 1993;77:297-304.
Lucke JN, Denny HR. The role of the sympathetic nervous system in the pathogenesis of halothane-induced malignant hyperthermia in the Pietran pig. Br J Anaesth 1978;50:75-76.
Wingard DW. Malignant hyperthermia. A human stress syndrome? Lancet 1974;2:1450-1451.
Drug reactions during anaesthesia. Lancet 1985; 1:1195— 1197 (editorial).
Scholz J, Troll U, Schulte AM, Esch J, Hartung E, Patten M, Sandig P et al. Inosital-1,4,5-triphosphate and malignant hyperthermia. Lancet 1991 ;337:1361.
MacLennan DH, DuffC, Zorato F et al. Ryanodine receptorgene is a candidate for predisposition to malignant hypothermia. Nature 1990;343:559-561.
McCarthy TV, Healy J MS, Hefferon WA et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19 q 12-13.2. Nature 1990;343:562-564.
Firestone LL, Lebowitz PW, Cook CE, ed. Clinical anesthesia procedures of the Massachusetts General Hospital. 3rd ed. Boston: Little, Brown, 1990; pp. 476—479.
Barash PG, Cullen BF, Stoelting RK. Handbook of clinical anesthesia. Appendix D. Malignant hyperthermia protocol. Philadelphia: JB Lippincott, 1991.
The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984;56:1267-1269.
Fletcher JE, Rosenberg H. Laboratory methods for malignant hyperpyrexia diagnosis. In: Williams CH, ed. Experimental malignant hyperthermia. Berlin: Springer-Verlag, 1988; pp. 121-140.
Melton AT, Marticci RW, Kien ND, Gronert GA. Malignant hyperthermia in humans — standardization of contracture testing protocol. Anesth Analg 1989;69:437-443.
Larach MG for the North American Malignant Hyperthermia Group. Standardization of the caffeine halothane muscle contracture test. Anesth Analg 1989;69:511 — 515.
Rosenberg H. Standards for halothane/caffeine contracture test. Anesth Analg 1989;69:429-430.
Fletcher JE, Huggins FJ, Rosenberg H. The importance of calcium ions for in vitro malignant hyperthermia testing. Can J Anaesth 1990;37:695-698.
Urwyler A. Ellis FR. Halsall PJ, Hopkins PM. Muscle relaxation rates in individuals susceptible to malignant hyperthermia. Br J Anaesth 1990;65:421-423.
Fletcher JE, Rosenberg H. In vitro muscle contractures induced by halothane and suxamethonium. Br J Anaesth 1986;58:1433-1439.
Larach MG, Landis JR, Bunn JS, Diaz M, The North American Malignant Hyperthermia Registry. Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. Anesthesiology 1992;76:16— 27.
Emergency Therapy for Malignant Hyperthermia. Revised 1993. Malignant Hyperthermia Association of the United States.
Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome. Review and analysis of 115 cases. Biol Psychiatry 1987;22:1004-1020.
CaroffSN, Mann SC, Rosenberg H, Fletcher JE, Heiman-Patterson ID. The relationship between malignant hyperthermia and neuroleptic malignant syndrome. Anesthesiology 1989;70:172-173.
Hermesh H, Aizenberg D, Lapidot M, Munitz H. The relationship between malignant hyperthermia and neuroleptic malignant syndrome. Anesthesiology 1989;70:171-172.
Hermesh H, Aizenberg D, Lapidot M, Munitz H. Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families. Am J Psychiatry 1988;145:1431-1434.
Flewellen EH, Nelson ТЕ, Jones WP, Arens JF, Wagner DL. Dantrolene dose response in awake man. Implications for management of malignant hyperthermia. Anesthesiology 1983;59:275-280.
Allen GC, Cattran CB, Peterson RG, Lalande M. Plasma levels of dantrolene following oral administration in malignant hyperthermia in susceptible patients. Anesthesiology 1988;69:900-904.
Communale ME, DiNardo JA, Schwartz MJ. Pharmacokinetics of dantrolene in an adult patient undergoing cardiopulmonary bypass. J Cardiother Vase Anesth 1991;5:153-155.
Harrison GG. Propofal in malignant hyperthermia. Lancet 1991 ;337:503.
Douglas MJ, McMorland GH. The anaesthetic management of the malignant hyperthermia susceptible parturient. Can Anaesth Soc J 1986;33:371-378.
Bristow G, Patel L. Hyperthermia. In: Hall J, Schmidt GA, Wood LDH, eds. Principles of critical care. New York: McGraw-Hill, 1992; pp. 858—868.
Pamukeoglu T. Sudden death due to malignant hyperthermia. Am J Forensic Med Pathol 1988;9:161-162.
Cain AG, Bell AD. How much dantrolene? A case of fulminant malignant hyperthermia. Anaesth Intensive Care 1989;117:500-509.
Hill LW. MH Association of the United States. Professional letter, November, 1944.
Zuckerberg AL. A hot mnemonic for the treatment of malignant hyperthermia. Anesth Analg 1993;77:1077— 1086.
Gallen JS. Propofol does not trigger malignant hyperthermia. Anesth Analg 1991;72:413-414.
Harrison GG. Propofol in malignant hyperthermia. Lancet 1991;337:503.
MacKenzie SJ, Kapadia F, Grant IS. Propofol infusion for control of status epilepticus. Anaesthesia 1990;45:1043-1045.
Boulard G, Miet G, Guerin J, Sabathie M. Surdosage accidentel en alfatesine chez un enfant polymalforme. Can Anaesth Soc J 1980;27:576-577.
Wood M. Intravenous anesthetic agents. In Wood M. Wood AJJ, eds. Drugs and anesthesia. Pharmacology for anesthesiologists. 2nd ed. Baltimore: Williams & Wilkins, 1990; pp. 216-217.
Reynolds JEF. Martindale: The extra pharmacopoeia. 29th ed. London: Pharmaceutical Press, 1989; p. 1114
Voulgaropoulos DS, Johnson MD, Covina BG. Local anesthetic toxicity. Sent Anesth 1990;9:8-15.
Dershowitz M. Local anesthetics. In: Firestone LL, Leb-owitz PW, Cook CE, eds. Clinical anesthesia procedures of the Massachusetts General Hospital. 3rd ed. Boston: Little, Brown, 1988; pp. 185-198.
Finucane ВТ. Regional anaesthesia: complications and techniques. Can J Anaesth 1991;38:R3—R10.
Covino BG, Vassallo J. Local anesthetics. Mechanisms of action and clinical use. New York: Grune & Stratton, 1976; pp. 67-78.
Ravindran RS, Bond VK, Tasch MD, Gupta CD, Lu-erssen TG. Prolonged neural blockade following regional analgesia with 2-chloroprocaine. Anesth Analg 1980;59:447-451.
Atlee JL III, Bosnjak ZJ. Mechanisms for dysrhythmias during anesthesia. Anesthesiology 1990;72:347-374.
Albright GA. Cardiac arrest following regional anesthesia with Etidocaine or bupivacaine. Anesthesiology 1979;51:285-287.
Davis NL, de Jong RH. Successful resuscitation following massive bupivacaine overdose. Anesth Analg 1982;61:62-64.
Edde RR, Deutsch S. Cardiac arrest after interscalene brachial plexus block. Anesth Analg 1977; 56: 446— 447.
Prentiss JE. Cardiac arrest following caudal anesthesia. Anesthesiology 1979;50:51-53.
Gould DB, Aldrete JA. Bupivacaine cardiotoxicity in a patient with renal failure. Acta Anaesthesiol Scand 1983;27:18-21.
Conklin KA, Ziadlou-Rad F. Bupivacaine cardiotoxicity in a pregnant patient with mitral valve prolapse. Anesthesiology 1983;58:596.
Bota A. Bupivacaine induced cardiac arrest. Anesth Analg 1990;70:464-465.
Long WB, Rosenblum S, Grady IP. Successful resuscitation of bupivacaine induced cardiac arrest using cardiopulmonary bypass. Anesth Analg 1989;69:403-406.
Cardiotoxicity of local anaesthetic drugs. Lancet 1986;2:1192-1194 (editorial).
Finkelstein F, Kraft J. Massive lidocaine poisoning. N Engl J Med 1979;301:50.
Arens JF, Carrera AE. Methemoglobin levels following peridural anesthesia with prilocaine for vaginal deliveries. Anesth Analg 1970;49:219-222.
Weiss LD, Generalovich T, Heller MB, Paris PM, Stewart RD, Kaplan RM, Thompson DR. Methemoglobin levels following intravenous lidocaine administration. Ann Emerg Med 1987;16:323-325.
Hollmen H, Korhonen M, Ojala A. Bupivacaine in paracervical block plasma levels and changes in maternal and foetal acid base balance. Br J Anaesth 1969;41:603.
Moore DC, Balfour RI, Fitzgibbons D. Convulsive arterial plasma levels of bupivacaine and the response to diazepam therapy. Anesthesiology 1979;50:454-456.
Hasselstrom U, Mogensen T. Toxic reaction of bupivacaine at low plasma concentrations. Anesthesiology 1984;61:99-100.
Gross TL, Kuhnert PM, Kuhnert BR. Plasma levels of 2-chloroprocaine and lack of sequelae following an apparent inadvertent intravenous injection. Anesthesiology 1981;54:173-174.
Bromage PR, Robson JG. Concentrations of lignocaine in the blood after intravenous, intramuscular, epidermal and endotracheal administration. Anaesthesia 1961;16:461-478.
Gorman RL, King JD, Oderda GM. Ingestion of topical lidocaine. It’s time to stop the pain. Vet Hum Toxicol 1984;26:413.
Fruncillo RJ, Gibbons W, Bourman SM. CNS toxicity after ingestion of topical lidocaine. N Engl J Med 1982;306:426-427.
Edgren B, Tilelli J, Gehrz R. Intravenous lidocaine overdosage in a child. Clin Toxicol 1986;24:51-58.
Jonville AP, Barbier P, Blond MH, Boscq M, Autret E, Breteau M. Accidental lidocaine overdosage in an infant. Clin Toxicol 1990;28:101-106.
Morishima HO, Daniel SS, Finster M, Poppers PJ, James LS. Transmission of mepivacaine hydrochloride (Carbocaine) across the human placenta. Anesthesiology 1966;27:147-154.
Finster M, Popper PJ, Sinclair JC, Morishima HO, Daniel SS. Accidental intoxication of the fetus with local anesthetic drug during caudal anesthesia. Am J Obstet Gynecol 1965;92:922-924.
Kaliciak HA, Chan SC. Distribution of prilocaine in body fluids and tissues in lethal overdose. J Anal Toxicol 1986;10:75-76.
Usubiaga JE, Wikinski J, Ferrero R, Usubiaga LE, Wikinski R. Local anesthetic induced convulsions in man. An electroencephalographic study. Anesth Analg 1966;45:611-620.
Wikinski JA, Usubiaga J E, Wikinski RW, Cardiovascular a neurological effect of 400 mg of procaine. JAMA 1970;213:621-623.
Green RL, Lewis JE, Kraus SJ, Frederickson EL. Elevated plasma procaine concentrations after administration of procaine penicillin G. N Engl J Med 1979;91:223-226.
Kasten GW, Martin ST. Bupivacaine cardiovascular toxicity. Comparison of treatment with bretylium and lidocaine. Anesth Analg 1985;64:911-916.
Freedman MD, Gal J, Freed CR. Extracorporeal pump assistance — novel treatment for lidocaine poisoning. Eur J Clin Pharmacol 1982;22:129-135.
Noble J, Kennedy DJ, Latimer RD, Hardy 1, Bethune DW, Collis JM et al. Massive lignocaine overdose during cardiopulmonary bypass. Successful treatment with cardiac pacing. Br J Anaesth 1984;56:1439-1441.
Siegel RK. Phencyclidine and ketamine intoxication. A study of four populations of recreational users. National Institute of Drug Abuse Research Monograph series. 1978;21:119-147.
Wood M: Intravenous anesthetic agents. In: Wood M, Wood AJJ, eds. Drugs and anesthesia. Pharmacology for anesthesiologists. Baltimore: Williams &Wilkins, 1990; pp. 193—196.
Licata M, Pierini G, Popo I. A fatal ketamine poisoning. J Forensic Sci 1994;39:1314-1320.
Committee on Drugs. American Academy of Pediatrics. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Pediatrics 1992;89:1110— 1115.
Haas DA, Harper DG: Ketamine. A review of its pharmacologic properties and use in ambulatory anesthesia. Anesth Prog 1992;39:61-68.
Reich DL, Silvay G. Ketamine. An update on the first twentyfive years of clinical experience. Can J Anaesth 1989;36:186-197.
Kharasch EDR. Metabolism of ketamine sterioisomers by human liver microsomes. Anesthesiology 1992;77:1201-1207.
Peyton SH, Couch AT, Bost RO. Tissue distribution of ketamine: two case reports. J Anal Toxicol 1988; 12:268— 269.
Domino EF, Domino SE, Smith RE, Domino LE, Goulet JR, Domino KE, Zsigmond EK. Ketamine kinetics in unmedicated and diazepam-premediated subjects. Clin Pharmacol Ther 1984;36:645-653.
Hirshman CA, Krieger W, Littlejohn G, Lee R, Julien R. Ketamine-aminophylline induced decrease in seizures threshold. Anesthesiology 1982;56:464-467.
Richard BM, Donaldson MDJ. Ketamine and muscle spasm. Br J Anaesth 1994;73:432.
Burmeister-Rother R, Streatfield KA, Yoo MC. Convulsions following ketamine and atropine. Anesthesia 1993;48:82.
Murphy JL Jr. Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse. Can J Anaesth 1993;40:160-164.
Schultz CH. Intramuscular ketamine and apnea. Ann Emerg Med 1994;23:139.
Smith JA, Sauter J. Intramuscular ketamine and apnea. Ann Emerg Med 1994;23:140-141.
Jansen KLR: Ketamine — can chronic use impair memory? Int J Addict 1990;25:133-139.
Tarnow J, Hess W. Pulmonary hypertension and pulmonary edema caused by intravenous ketamine. Anesthetist 1978;22:486-487.
Wood М. Intravenous anesthetic agents. In: Wood M, Wood AJJ, eds. Drugs and anesthesia. Pharmacology for anesthesiologists. 2nd ed. Baltimore: Williams & Wilkins, 1990.
Barash PG, Cullen BF, Stoelting RK. Handbook of clinical anesthesia. Philadelphia: J В Lippincott, 1991.
Simon B, Young GP. Emergency airway management. Acad Emerg Med 1994;1:154—157.
Cote D. Dosage of transdermal fentanyl. Clin Pharm 1993;12:718.
Sear JW. Toxicity of IV anaesthetics. Br J Anaesth 1987;59:24-45.
Rose PG, Macfee MS, Boswell MV. Fentanyl transdermal system overdose secondary to cutaneous hyperthermia. Anesth Analg 1993;77:390-391.
Miser AV, Narang PK, Dothage JA et al. Transdermal fentanyl for pain control in patients with cancer. Pain 1989;37:15-21.
Zech DFJ, Grand SUA, Lynch J et al. Transdermal fentanyl and initial dose finding with patient controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 1992;50:293-301.
Physicians desk reference. 49th ed. Montvale, NJ: Medical Economics, 1995; pp. 1175—1178.
Hudson RJ, Thomson IR, Cannon JE, Friesen RM, Meatherall RC. Pharmacokinetics of fentanyl in patients undergoing abdominal aortic surgery. Anesthesiology 1986;64:334-338.
Singleton MA, Rosen JI, Fisher DM. Pharmacokinetics of fentanyl in the elderly. Br J Anaesth 1988;60:619— 622.
Gauntlett IS, Fisher DM, Hertzka RE, Kuhls E, Spellman MJ, Rudolph C. Pharmacokinetics of fentanyl in neonatal humans and lambs: effects of age. Anesthesiology 1988;69:683-687.
Duthie DJR, McLaren AD, Nimmo WS. Pharmacokinetics of fentanyl during constant rate IV infusion for the relief of pain after surgery. Br J Anaesth 1986;58:950— 951.
Duthie DJR, Rowbotham DJ, Wyld R, Henderson PD, Nimmo WS. Plasma fentanyl concentrations during transdermal delivery of fentanyl to surgical patients. Br J Anaesth 1988;60:614-618.
Rowbotham DJ, Wyld R, Peacock JE, Duthie DJR, Mimmo WS. Transdermal fentanyl for the relief of pain after upper abdominal surgery. Br J Anaesth 1989;65:56-59.
Stoeckel H, Hengstmann JH, Schuttler J. Pharmacokinetics of fentanyl as a possible explanation for recurrence of respiratory depression. Br J Anaesth 1979;51:741 — 745.
Craft JB Jr, Coaldrake LA, Bolan JC, Mondino M, Maze! P, Gilman RM et al. Placental passage and uterine effects of fentanyl. Anesth Analg 1983;62:894-898.
Gourlay GK, Kowalski SR, Plumer JL et al. The transdermal administration of fentahyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. Pain 1989;37:192-202.
Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR. Absorption characteristic of transdermally administered fentanyl. Anesthesiology 1989;70:928-934.
Marquardt KA, Tharratt S. Inhalation abuse of fentanyl patch. Clin Toxicol 1994;32:75-78.
Baselt RC, Cravey RH. Disposition of toxic drugs and chemicals in man. 3rd ed. Chicago: Year Book, pp. 350— 352.
De Sio JM, Bacon DR. Peer G, Lerna MJ. Intravenous abuse of transdermal fentanyl therapy in a chronic pain patient. Anesthesiology 1993;79:1139-1141.
McCarthy M. Fentanyl patch misuse. Lancet 1994;343:351.
Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Mlyao J et al. Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography-mass spectrometry. Anesthesiology 1984;61:73-77.
Payne R, Moran K, Southan M. The role of transdermal fentanyl in the management of cancer pain. In: Esta-fanous FG, ed. Opioids in anesthesia II. Boston: Butterworth-Heinemann, 1991; pp. 215—222.
Taylor G. Acid pulmonary aspiration syndrome after antacids. A case report. Br J Anaesth 1975;47:615-617.
Mendelson CL. The aspiration of stomach contents into the lungs during obstetric anesthesia. Am J Obste Gynecol 1946;52:191-205.
Sweeney B, Wright I. The use of antacids as a prophylaxis against Mendelson’s syndrome in the United Kingdom. A survey. Anaesthesia 1986;41:419-422.
Taylor G, Pryse-Davies J. The prophylactic use of antacids in the prevention of the acid-pulmonary-aspiration syndrome (Mendelson’s Syndrome). Lancet 1916;1:288-291.
Tordoff SG, Sweeney BP. Acid aspiration prophylaxis in 288 obstetric anaesthetic departments in the United Kingdom. Anaesthesia 1990;45:776-780.
Barash PG, Cullen BF, Stoelting RK. Handbook of clinical anesthesia. Philadelphia: JB Lippincott, 1991, pp. 148-158.
Dale O, Brown BR Jr. Clinical pharmacokinetics of the inhalational anaesthetics. Clin Pharmacokinet 1987;12:145-167.
Wrigley SR, Jones RM. Inhalational agents — an update. Eur J Anaesthesiol 1992;9:185-201.
Sutton J, Harrison GA, Hickie JB. Accidental intravenous injection of halothane. Case report. Br J Anaesth 1971;43:513-520.
Wig J, Chakravarty S, Krishnamurthy K, Mehta D. Coma following ingestion of halothane. Its successful management. Anaesthesia 1983;38:552-555.
Curelaru I, Stanciu S, Nicolau V, Fuhrer H, Iliescu M. A case of recovery from coma produced by the ingestion of 250 mL of halothane. Br J Anaesth 1968;40:283-288.
Martin ST. Hazards of agent-specific vaporizers: a case report of successful resuscitation after massive isoflurane overdose. Anesthesiology 1985;62:830-831.
Dooper PMM, Beerens J, Brenninkmeijer VJ, Gerlag PGF. Fatal intoxication after ingestion of isoflurane. Netherlands J Med 1988;33:74-77.
Lingenfelter RW. Fatal misuse of enflurane. Anesthesiology 1981;55:603.
Spencer JAE, Green NM. Suicide by ingestion of halothane. JAMA 1968;205:112-113.
Lampe GH, Wauk LZ, Donegan JH, Pitts LH, Jackler RK, Litt LL et al. Effect on outcome of prolonged exposure of patients to nitrous oxide. Anesth Analg 1990;71:586-590.
Jarnberg PO, Estrand J, Irestedt L. Renal fluoride excretion and plasma fluoride levels during and after enflurane anesthesia are dependent on urinary pH. Anesthesiology 1981;54:48-52.
Karl HW, Swerdlow DB, Lee KW, Downes JJ. Epinephrine-halothane interactions in children. Anesthesiology 1983;58:142-145.
Smith NT, Eger El II, Stoelting RK, WhayneTF, Cullen D, Kadis LB. The cardiovascular and sympathomimetic responses to the addition of nitrous oxide to halothane in man. Anesthesiology 1970;32:410-420.
Frank EJ Jr, Ghantous H, Malan TP, Morgan S, Fernando J, Gandolfi AJ et al. Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. Anesth Analg 1992;74:231-235.
Halsey MJ. Drug interactions in anaesthesia. Br J Anaesth 1987;59:112-123.
Oikkonen MR Isoflurane inhibits enflurane metabolism in man. Anaesthesia 1989;44:763-764.
Ueland PM, Refsun H, Wesenberg F, Kvinnsland S. Methotrexate therapy and nitrous oxide anesthesia. N Engl J Med 1986;314:1514.
Lampe GH, Donegan JH, Rupp SM, Wauk LZ, Whitendale P, Fonts KE et al. Nitrous oxide and epinephrine-induces arrhythmias. Anesth Analg 1990;71:602-605.
Krause JG, McCarthy WB. Sudden death by inhalation of cyclopropane. J Forensic Sci 1989;34:1011-1012.
Young WL. Effects of desflurane on the central nervous system. Anesth Analg 1992;75:S32—S37.
Muzzi DA, Losasso TJ, Dietz NM, Faust RJ, Cucchiara RF, Milde LN. The effect of desflurane and isoflurane on cerebrospinal fluid pressure in humans with supratentorial mass lesions. Anesthesiology 1992;76:720-724.
Schmeling WT, Warltier DC, McDonald DJ, Madsen KE, Atlee JL, Kampine JP. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991;72:137-144.
Denlinger JK, LeckyJH, Nahrwold ML. Hepatocellular dysfunction without jaundice after enflurane anesthesia. Anesthesiology 1974;41:86-87.
Ona FV, Patanella H, Ayub A. Hepatitis associated with enflurane anesthesia. Anesth Analg 1980;59:146-149.
Lewis JH, Zimmerman HJ, Ishak KG, Mullick FG. Enflurane hepatotoxicity. A clinicopathologic study of 24 cases. Ann Intern Med 1983;98:984-992.
Brune EM, White H, Marsh JW, Holtmann B, Peters MG. Fulminant hepatic failure after repeated exposure to isoflurane anesthesia: a case report. Hepatology 1991;13:1017-1021.
Elliott RH, Strum L. Hepatotoxicity of volatile anaesthetics. Br J Anaesthesia 1993;70:339-348.
Tanigaki T, Kondo T, Ohta Y, Yamabayashi H. Transient neuromuscular impairment resulting from prolonged inhalation of halothane and enflurane. Chest 1990;98:1012-1013.
Parke TJ, Jags RH. Focal seizure following enflurane. Anaesthesia 1992;67:79-80.
Weiskopf RB, Cahalan MK, Eger El II, Yasuda N, Rampil J, lonescu P et al. Cardiovascular actions of desflurane in normocarbic volunteers. Anesth Analg 1991;73:143-151.
Thomas DW, Dev VJ, Whitehead MJ. Malignant hyperpyrexia and isoflurane. A case report. Br J Anaesth 1987;54:1196-1198.
Koblin DD, Tomerson BW, Waldman FM, Lampe GH, Wauke LZ, Eger El II. Effect of nitrous oxide on folate and vitamin B,2 metabolism in patients. Anesth Analg 1990;71:610-617.
Kones R. Folic acid 1991: an update with new recommended daily allowances. South Med J 1990;83:1454— 1458.
No laughing matter. Harvard Med Sch Health Letter 1991;16(7).
Lassen HCA, Henriksen E, Neukirch F, Kristensen HS. Treatment of tetanus. Severe bone-marrow depression after prolonged nitrous oxide anaesthesia. Lancet 1956;1:527-530.
Layzer RB. Myeloneuropathy after prolonged exposure to nitrous oxide. Lancet 1978;2:1227-1230.
Amos RJ, Amess JAL, Hinds CJ, Mollin DL. Incidence and pathogenesis of acute megaloblastic bone marrow change in patients receiving intensive care. Lancet 1982;2:835-839.
Russell GB, Snider MT, Richard RB, Loomis JL. Hyperbaric nitrous oxide as a sole anesthetic agent in humans. Anesth Analg 1990;70:289-295.
Davidson JR, Chinyanga HM. Cardiovascular collapse associated with nitrous oxide anaesthetic. A case report. Can Anaesth Soc J 1982;29:484-488.
Van Achterbergh SM, Vorster BJ, Heyns ADP. The effect of sepsis and short-term exposure to nitrous oxide on the bone marrow and the metabolism of vitamin B,2 and folate. So Afr Med J 1990;78:260-263.
Randall B, Corbett B. Fatal halothane poisoning during anesthesia with other agents. J Forensic Sci 1982;27:225-230.
Rowland AS, Baird DD, Weinberg CR, Shore DL, Shy CM, Wilcox AJ. Reduced fertility among women employed as dental assistants exposed to high levels of nitrous oxide. N Engl J Med 1992;327:993-997.
Guidelines for protecting the safety and health of health care workers. US Department of Health and Human Services. September 1988. Comments abstracted and modified from DHHS (N1OSH) Publication No. 88-119.
Guirghuis Ss, Pelmear PL, Roy ML, Wong L. Health effects associated with exposure to anaesthetic gases in Ontario hospital personnel. Br J Ind Med 1990;47:490-497.
Rajhans GS, Brown Da, Whaley DA, Wong L, Guirghuis SS. Evaluation of occupational exposure to waste anesthetic gases in Ontario hospitals. Ann Occup Hyg 1989;33:27-45.
Tannenbaum TN, Goldberg RJ. Exposure to anesthetic gases and reproductive outcome. A review of the epidemiological literature. J Occup Med 1985;27:659-668.
Peric M, Vranes Z, Marusic M. Immunological disturbances in anaesthetic personnel chronically exposed to high occupational concentrations of nitrous oxide and halothane. Anaesthesia 1991;46:531-537.
Harrison CA, Rogers DW, Rosen M. Blood contamination of anaesthetic and related staff. Anaesthesia 1990;45:831-833.
Maz S, Lyons G. Needlestick injuries in anaesthetists. Anaesthesia 1990;45:677-678.
Sendak MJ. Getting the patient to surgery — and back. Anesthesia in pregnancy. Emerg Med 1986; 18( 13): 111 — 132.
Friedman JM. Teratogen update: anesthetic agents. Teratology 1988;37:69-77.
Sylvester GC, Khoury MJ, Lu X, Erickson JD. First-trimester anesthesia exposure and the risk of central nervous system defects. A population-based case-control study. Am J Public Health 1994;84:1757-1760.
Crawford JS, Lewis M. Nitrous oxide in early human pregnancy. Anaesthesia 1986;41:900-905.
Rowland AS, Baird DD, Weinberg CR, Shore DL, Sky CM, Wilcox AJ. Reduced fertility among women employed as dental assistants exposed to high levels of nitrous oxide. N Engl J Med 1992;327:993-997.
Berman Р, Tattersail М. Self-poisoning with intravenous halothane. Lancet 1982; 1:340.
Stiruda AJ, McGlothlin. Fatal abuse of nitrous oxide in the workplace. J Occup Med 1990;32:682-684.
Rosenwasser GOD, Holland S, Pfugfelder SC, Lugo M, Heidemann DG, Culbertson WW et al. Topical anesthetic abuse. Ophthalmology 1990;97:967-972.
Kintner JC, Grossniklaus HE, Lass JH, Jacobs G. Infectious crystalline keratopathy association with topical anesthetic abuse. Cornea 1990;9:77-80.
Reiser HJ, Laibson PR. Anesthetic abuse of the cornea. Ophthalmic Surg 1989;20:72-73.
Modica РА, Tempelhoff R, White PF Pro and anticonvulsant effects of anesthetics. 1. Anesth Analg 1990;70:303-315; II. ibid 70:443-444.
Gumpert J, Paul R. Activation of the electroencephalogram with intravenous Brietai (methohexitone): the findings in 100 cases. J Neurol Neurosurg Psychiatry 1971;34:646-648.
Paul R, Harris R. A comparison of methohexitone and thiopentone in electrocorticography. J Neurol Neurosurg Psychiatry 1970;33:100-104.
Ferrer-Allado T, Brechner VL, Dymond A, Cozen H, Crandall P. Ketamine-induced electroconvulsive phenomena in the human limbic and thalamic regions. Anesthesiology 1973;318:333-344.
Yamashita М, Matsuhi A, Oyama Т. Illicit use of modern volatile anesthetics. Can Anaesth Soc J 1984;31: 76-79.
Gravenstein JS, Kory WP, Marks RG. Drug abuse by anesthesia personnel. Anesth Analg 1983;62:467-472.
AMA Council on Mental Health. The sick physician — impairment by psychiatric disorders, including alcoholism and drug dependence. JAMA 1973;223:684-687.
Hughes PH, Conard SE, Baldwin DC Jr, Storr CL, Sheehan DV. Resident physician substance use in the United States. JAMA 1991;265:2069-2073.
Kamerow DB, Pincus HA, Macdonald DI. Alcohol abuse, other drug abuse, and mental disorders in medical practice. Prevalence, costs, recognition and treatment. JAMA 1986;255:2054-2057.
Wood PR, Soni H. Anaesthesia and substance abuse. Anaesthesia 1989;44:672-680.
Wood M, Wood AJJ. Drugsand anesthesia. Pharmacology for anesthesiologists. 2nd ed. Baltimore: Williams & Wilkins, 1990.
Chopra V, Borill JG, Spierdijk J. Accidents, near accidents and complications during anaesthesia. Anaesthesia 1990;45:3-6.
Cohen MM, Duncan PG, Pope WDB, Wolkenstein C. A survey of 112,000 anaesthetics at one teaching hospital (1975-1983). Can Anaesth Soc J 1986;33:22-31.
Kubota Y, Toyoda Y, Kubota H, Yeda Y, Asada A, Okamoto T et al. Frequency of anesthesia cardiac arrest and death in the operating room at a single general hospital over a 30-year period. J Clin Anesth 1994;6:227— 238.
Beecher HK, Todd DP. A study of the deaths associated with anaesthesia and surgery based on a study of 599,548 anaesthesias in 10 institutions 1948—1952 inclusive. Ann Surg 1954;140:2-35.
Lunn HN, Mushin WW. Mortality associated with anaesthesia. London: The Nuffield Provincial Hospital Trust, 1962.
Craig J, Wilson ME. A survey of anaesthetic misadventures. Anaesthesia 1981;36:933-936.
Cooper JB, Newbower RS, Kitz RJ. An analysis of major errors and equipment failure in anaesthesia management: consideration for prevention and detection. Anaesthesiology 1984;60:34-42.
Lewis B. Deaths and dental anaesthetics. Br Med J 1983;286:3-4.
Dinnick OP Deaths associated with anaesthesia. Anaesthesia 1964;19:536-556.
Forrest JB. Rehden K, Cahalan MK, Goldsmith CH. Multicenter study of general anesthesia. 111. Predictors of severe perioperative adverse outcomes. Anesthesiology 1992;76:3-16.
Catanzaro JМ, Smith JG Jr. Propylene glycol dermatitis. J Am Acad Dermatol 1991;24:90-95.
Demey HE, Daelemans RA, Verpooten GA, de Broe ME, Van Campenhout CM, Lakiene FV et al. Propylene glycol-induced side effects during intravenous nitroglycerin therapy. Intensive Care Med 1988;14:221-226.
Smolinske SC. Handbook of food, drug and cosmetic excipients. Boca Raton, FL: CRC Press, 1992.
Speth PAJ, Vree ТВ, Neilen NFM, de Mulder PHM, Newell DR, Gore ME et al. Propylene glycol pharmacokinetics and effects after intravenous infusion in humans. Ther Drug Monitor 1987;9:255-258.
Kelner MJ, Bailey DN. Propylene glycol as a cause of lactic acidosis. J Anal Toxicol 1985;9:40-42.
MacDonald MG, Getson PR, Glasgow AM, Miller MK, Boeckx RL, Johnson EL. Propylene glycol: increased incidence of seizures in low birth weight infants. Pediatrics 1987;79:622-625.
Lehman AJ, Newman HW. Propylene glycol: rate of metabolism, absorption and excretion with a method for estimation in body fluids. J Pharmacol Exp Ther 1937;60:312-322.
Martin G, Finberg L. Propylene glycol: a potentially toxic vehicle in liquid dosage. J Pediatr 1970;77:877-878.
Arulanantham K, Genel M. Central nervous system toxicity associated with ingestion of propylene glycol. J Pediatr 1978;93:515-516.
Cate JC, Hendricks R. Propylene glycol intoxication and lactic acidosis. N Engl J Med 1980;303:1237.
Huggon 1, James 1, Macrae D. Hyperosmolarity related to propylene glycol in an infant treated with enoximone infusion. Br Med J 1990;301:19-20.
Lolin Y, Francis DA, Flanagan RJ, Little P, Lascelles PT. Cerebral depression due to propylene glycol in a patient with chronic epilepsy — the value of the plasma osmolal gap in diagnosis. Postgrad Med J 1988;64:610-613.
Maurer H, Kessler C. Identification and quantification of ethylene glycol and diethylene glycol in plasma using gas chromatography-mass spectrometry. Arch Toxicol 1988;62:66-69.
Glasgow AM, Boeckx RL, Miller MK, MacDonald MG, August GP, Goodman SI. Propylene glycol plasma level. Pediatrics 1985;76:654.
Smolinske SC, Vandenberg SA, Spoerke DG, Rumack BH. Propylene glycol content of parenteral medications. Vet Hum Toxicol 1987;29:491.
Wax PM. Elixirs, diluents and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann Intern Med 1995;122:456-461.
Bowie MD, McKenzie D. Diethylene glycol poisoning in children. S Afr Med J 1972;46:931.
Van der Linden-Cremers PM A, Sangster B. Diethylene glycol in wine: experiences in the Netherlands. Summer 1985. Vet Hum Toxicol 1987;29(Suppl 2): 12—13.
U. S. finds traces of poison chemical in 10 more wines. Los Angeles Herald-Examiner, April 16, 1986.
Woolf A, Pearson K. Presence of diethylene glycol in commercial polyethylene glycol (PEG) solutions. Clin Toxicol 1995;33:475-486 (abstract 10).
Cantarell MC, Fort J, Camps J, Sans M, Piera L, Ro-damilans M. Acute intoxication due to topical application of diethylene glycol. Ann Intern Med 1987;106:478-479.
McAlinney PG. Silver sulfadiazine and oliguric renal failure. Ann Intern Med 1987; 107:264.
Pandya SK. An unmitigated tragedy. Br Med J 1988;297:117-119.
Hanif M, Mobarak MR, Ronan A, Rahman D, Donovan JJ Jr, Bennish ML. Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. Br Med J 1995;33:88-91.
White FH Jr. Reduction and reoxidation of sulfide bonds. Methods Enzymol 1972;25(Part B):387—392.
Erikson A, Mohlin L, Nilsson L, Sorbo B. Mercaptoethanol poisoning. Report of a fatal case and analytical determinations. J Anal Toxicol 1989;13:60-62.
Wess JA. Reproductive toxicity of ethylene glycol monomethylether, ethylene glycol monoethyl ether and their acetates. Scand J Work Environ Health 1992; 18(Suppl 2):43—45.
Johanson G. Urine butoxyacetic acid as a therapeutic guide. Clin Toxicol 1993;31:501-552.
Rambourg-Schepens MO, Buffet M, Bertlaut R, Jaus-saud M, Journe B, Fay R et al. Severe ethylene glycol butyl ether poisoning. Kinetics and metabolic pattern. Hum Toxicol 1988;7:187-189.
Felgenahuer N, Zilker T, Clarmann M. A case of severe ethylene glycol monobutyl ether poisoning. Proc Eur Assoc Pois Cont Clin Toxicol, Birmingham, UK: May, 1993.
Dean BS, Krenzelok E. 10 mL of 10 % solution is not "significant." Clin Toxicol 1993;31:503-504.
Cullen MR, Rado T, Waldron JAet al. Bone marrow injury in lithographers exposed to glycol ethers and organic solvents used in multicolor offset and ultraviolet curing printing processes. Arch Environ Health 1983;38:347— 354.
Hardin BD, Lyon JR Summary and overview: N1OSH symposium on toxic effects of glycol ethers. Environ Health Perspect 1984;57:273-275.
Larese F, Fiorito A, de Zotti R. The possible haematological effects of glycol monomethyl ether in a frame factory. BrJ Ind Med 1992;49:131-133.
Johanson G, Kronborg H, Naslund PH, Nordqvist MB. Toxicokinetics of inhaled 2-butoxyethanol (ethylene glycol monobutyl ether) in man. Scand J Work Environ Health 1986;12:594-602.
Nitter-Hauge S. Poisoning with ethylene glycol monomethyl ether. Acta Med Scand 1970;188:277-280.
Ohi G, Wegman DH. Transcutaneous ethylene glycol monomethyl ether poisoning in the work setting. J Occup Med 1978;20:675-676.
Groeseneken D, Veulemans H, Maaschelein R, Van Vlem E. Ethoxyacetic acid: a metabolite as ethylene glycol monoethyl ether acetate in man. Br J Ind Med 1987;44:488-493.
Welch LS, Plotkin E, Schrader S. Indirect fertility analysis in painters exposed to ethylene glycol ethers. Sensitivity and specificity. Am J Ind Med 1991;20:229-290.
Cook RR, Bodner KM, Kolesar RC, Utilmanu CS, Van Peenen PFD, Dickson GS etal. A cross-sectional study of ethylene glycol monomethyl ether process employees. Arch Environ Health 1982;37:346-351.
Dean BS, Krenzelok EP. Clinical evaluation of pediatric ethylene glycol monobutyl ether poisonings. Clin Toxicol 1992;30:557-563.
Bauer P, Weber M, Mur JM, Protois JC, Bollaert PE, Condi A et al. Transient non-cardiogenic pulmonary edema following massive ingestion of ethylene glycol butyl ether. Intensive Care Med 1992;18:250-251.
Dean BS, Krenzelok EP. Clinical evaluation of pediatric ethylene glycol monobutyl ether poisonings. Vet Hum Toxicol 1991;33:362.
Gijsenbergh FP, Jenco M, Veulemans H, Groeseneken D, Verberckmoes R, Delooz HH. Acute butylglycol intoxication. A case report. Hum Toxicol 1989;8:243-245.
Morton WE. Occupational phenoxyethanol neurotoxicity: a report of three cases. J Occup Med 1990;32:42-45.
Buckley N, Whyte IM, Dawson AH. Letters to the Editor: EGBE. Clin Toxicol 1993;31:499-500.
Browning RG, Curry SC. Effect of glycol ethers on plasma osmolality. Hum Exp Toxicol 1992;11:488-490.
NEG and NIOSH basis for an occupational health standard: propylene glycol ethers and their acetates. Center for Disease Control USDHHS. DHHS (NIOSH) Publication No. 91-103.
Schiller LR, Emmett M, Santa Ana CA, Fordtran JS. Osmotic effects of polyethylene glycol. Gastroenterology 1988;94:933-941.
Greene MH, Young TI, Eisenbarth GS. Polyethylene glycol in suppositories: cardinogenic? Ann Intern Med 1980;93:781.
Rodriguez ZM, Gutierrez JCL, Jimenez JMT, Mor ZR. Metabolic acidosis, intoxication caused by polyethylene glycol. Proc Eur Assoc Pois Cent Clin Toxicol, Birmingham, UK: May 26-28, 1993.
Farrell M, Herrod J, Smith B, Strang J. Detection of intravenous drug use. Br Med J 1990;300:612-613.
Weissman DB, Jackson SH, Heicher DA, Rockoff MA. Benzyl alcohol administration in neonates. Anesth Analg 1990;70:673.
Lopez-Herce J, Bonet C, Meana A, Albajara L. Benzyl alcohol poisoning following diazepam intravenous infusion. Ann Pharmacother 1995;29:632.
Gershanik J, Boeder B, Ensley H et al. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med 1982;307:1384-1388.
Hiller JL, Benda Gl, Rahatzad M et al. Benzyl alcohol toxicity: impact on mortality and intraventricular hemorrhage among very low birth weight infants. Pediatrics 1986;77:500-506.
Nieper HA. A comparative study of the clinical effect of CA-l-dl-aspartate (Calciretard) of Ca-2-aminoethanol phosphate (Ca—EAP) and of the cortisones. Aggressol-ogie 1968;9:471-475.
Nieper HA. A clinical study of the calcium transport substances Ca 1-dl-aspartate and СА-2-amino ethanol phosphate as potent agents against autoimmunity and other anticytological aggressions. 2nd communication. Aggressologie 1967;8:395-406.
Sauter D, Goldfrank L, Charash BD. Cardiopulmonary arrest following an infusion of calcium-2-amino-ethanol phosphate. J Emerg Med 1990;8:711-720.
Scully R, Galdabini J, McNealy В. Case records of the Massachusetts General Hospital. Discussion of Levinsky NG. Case 38:1979. N Engl J Med 1979;301:650-657.
Stokes JB, Averon F. Prevention of organ damage in massive ethylene glycol ingestion. JAMA 1980;243:2065-2066.
Von Oettinggen VF. Ethylene glycol. US Public Health Bull 1943;281:166-174.
Beasley VR, Buck WB. Acute ethylene glycol toxicoses: a review. Vet Hum Toxicol 1980;22:255-263.
Peterson DC, Collins AJ, Himes JM et al. Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis. N Engl J Med 1981 ;304:21 — 23.
Gabow PA, Clay K, Sullivan JB et al. Organic acids in ethylene glycol intoxication. Ann Intern Med 1986;105:16-20.
McChesney EW, Goldberg L, Parekh CK et al. Re-appraisal of the toxicology of ethylene glycol. IE Metabolism studies in laboratory animals. Food Cosmet Toxicol 1971;9:21-38.
Clay KL, Murphy RC. On the metabolic acidosis of ethylene glycol intoxication. Toxicol Appl Pharmacol 1977;39:39-49.
Brown CG, Trumbull D, Klein-Schwartz W et al. Ethylene glycol poisoning. Ann Emerg Med 1983; 12:501 — 506.
Bobbit WH, Williams RM, Freed CR. Severe ethylene glycol intoxication with multisystemic failure. West J Med 1986;144:225-228.
Spillane L, Roberts JR, Meyer AE. Multiple cranial nerve deficits after ethylene glycol poisoning. Ann Emerg Med 1991;20:208-210.
Factor SA, Lava NS. Ethylene glycol intoxication: a new stage in the clinical syndrome. NY State J Med 1987;87:179-180.
Thomas D, Claussen G, Suggs S, Oh SJ, Joy JL. Ethylene glycol-induced peripheral neuropathy. Neurology 1990;40(Suppl 1):344.
Turk J, Morrell L, Avioli LV. Ethylene glycol intoxication. Arch Intern Med 1986;146:1601-1603.
Terlinsky AS, Grochowski J, Geoly KL et al. Identification of atypical calcium oxalate crystalluria following ethylene glycol ingestion. Am J Clin Pathol 1981;76:223-226.
Burns JR, Finalyson B. Changes in calcium oxalate crystal morphology as a function of concentration. Invest Urol 1980;18:174-177.
Jones AW, Nilsson L, Gladh SA, Karlsson K, Beck-Friis J. 2,3-Butanediol in plasma from an alcoholic mistakenly identified as ethylene glycol by gas-chromatographic analysis. Clin Chem 1991;37:1453-1455.
LeGatt DF, Tisdell RH. Ethyleneglycol quantifications. Avoid propylene glycol as an internal standard. Clin Chem 1990;36:1860-1861.
Winter ML, Ellis MD, Snodgrass WR. Urine fluorescence using a Wood’s lamp to detect the antifreeze additive sodium fluorescein: a qualitative adjunctive test in suspected ethylene glycol ingestion. Ann Emerg Med 1990;19:663-667.
Goodkin DA. Ethylene glycol poisoning. Am J Med 1990;88:20I.
Hewlett TP, McMartin KE. Ethylene glycol poisoning: the value of glycolic acid determinations for diagnosis and treatment. Clin Toxicol 1986;24:389-402.
Parry MF, Wallach R. Ethylene glyco! poisoning. Am J Med 1974;57:143-150.
Godolphin W, Meagher EP, Sanders HD et al. Unusual calcium oxalate crystals in ethylene glycol poisoning. Clin Toxicol 1980;16:479-486.
Groszek B. Ethylene glycol poisoning: why so high mortality? Proc Eur Assoc Pois Cont Clin Toxicol, Binning- j ham, UK: May 26—28, 1993.
Malmkind Н-О, Berg A, Korlman G, Magnusson А, Lillman В. Considerations for the treatment of ethylene glycol poisoning based on analysis of two cases. Clin Toxicol 1991;29:231-240.
Jacobsen D, Orrebo S, Ostborg J, Sejerst OM. Glycolate causes the acidosis in ethylene glycol poisoning and is effectively removed by hemodialysis. Acta Med Scand 1994;21'6:409-416.
Baud FJ, Galliott M, Astier A, VuBien D, Garnier R, Likforman J, Bismuth C. Treatment of ethylene glycol poisoning with intravenous 4-methylpyrazole. N Engl J Med 1988;319:97-100.
Baud F, Bismuth C, Garnier R, Galliott M, Astier A, Maistre G et al. 4-Methylpyrazole may be an alternative to ethanol therapy for ethylene glycol intoxication in man. J Toxicol Clin Toxicol 1986—87;24:463—483.
Saladino R, Shannon M. Accidental and intentional poisoning with ethylene glycol in infancy: diagnostic clues and management. Pediatr Emerg Care 1991;7:93-96.
Christiansson KK, Kapersson KB, Kulling PEJ, Orrebo S. Treatment of severe ethylene glycol intoxication with continuous arterio-venous hemofiltration dialysis. J Toxicol Clin Toxicol 1995;33:267-270.
McCormick MJ, Mogabgab Е, Adams SL. Methanol poisoning as a result of inhalational solvent abuse. Ann Emerg Med 1990;19:639-642.
Pamies RJ, Sugar D, Rives L, Herold AH. Methanol intoxication. Case report. J Fla Med Assoc 1993;80:465— 467.
Bennett JL, Gary FH, Mitchell GL et al. Acute methyl alcohol poisoning: a review based on experiences in an outbreak of 323 cases. Medicine 1953;32:431-463.
Swartz RD, Millman RP, Billi JE et al. Epidemic methanol poisoning: clinical and biochemical analysis of a recent episode. Medicine 1981;60:373-382.
Fraser AD, MacNeil W. Gas chromatographic analysis of methyl formate and application in methanol poisoning cases. J Anal Toxicol 1989;13:73-76.
D’Alessandro A, Osterloh J, Chumers P, Quinlan P, Kell T, Becker C. Formate in serum acid urine following controlled methanol exposure at the threshold limit value. Vet Hum Toxicol 1993;35:358.
Keller K, Pearigen PD, Olsen KR. Severe methanol poisoning and chemical burn after submersion in a furniture stripping solution. Vet Hum Toxicol 1991;33:366.
Brent J, Lucas M, Kulig K, Rumack BH. Methanol poisoning in a 6-week-old infant. J Pediatr 1991; 118:644— 646.
Kawai T, Yasugi T, Mizunama K, Horiguchi S, Hirase Y, Uchida Y, Ikeda M. Methanol in urine as a biological indicator of occupational exposure to methanol vapor. Int Arch Occup Environ Health 1991;63:311-318.
Mahieu P, Hassoun A, Lauwerys R. Predictors of methanol intoxication with unfavourable outcome. Hum Toxicol 1989;8:135-137.
Harchelroad F. Hypomagnesemia during methanol intoxication. Vet Hum Toxicol 1993;35:364.
Hassoun A, Mahieu P, Lauwerys P. Hypokalemia in acute methanol poisoning. Proc Eur Assoc Pois Cont Clin Toxicol, Birmingham, UK: May 1993.
McGuigan MA. Analysis of the temporal development of acidosis in uncomplicated methanol poisoning. Ann | Emerg Med 1995;26:725.
Bernstein JM, McNally J, Boyer L. Magnetic resonance | imaging of methanol-induced optic nerve toxicity. Vet Hum Toxicol 1993;35:365.
Carroll RB. Analysis of alcoholic beverages by gas-liquid chromatography. QJ Stud Alcohol 1970;5 (Suppl)6—19.
Tintinalli JE. Serum methanol in the absence of metha-nol ingestion. Ann Emerg Med 1995;26:393.
Lee CY. Acree ТЕ, Butts RM. Determination of methyl alcohol in wine by gas chromatography. Anal Chem 1975;47:747-748.
Martensson E, Olofsson U, Heath A. Clinical and met-1 abolic features of ethanol-methanol poisoning in chronic alcoholics. Lancet 1988;1:327-328.
Phang PT, Passerini L, Mialke B, Berendt R, King EG. I Brain hemorrhage associated with methanol poisoning. | Crit Care Med 1988;16:137-140.
McCoy HG, Cipolle RJ, Ehlers SM et al. Severe meth-, 1 anol poisoning: application of a pharmacokinetic model I for ethanol therapy and hemodialysis. Am J Med 1979;67:804-807.
Whalen JE, Richards CJ, Ambre J. Inadequate removal | of methanol and formate using the sorgent based regen- 1 eration hemodialysis delivery system. Clin Nephrol | 1979;11:318-321.
Settler JG, Singh R, Brackett NC et al. Studies on the ] dialysis of methanol. Trans Am Soc Artif Intern Organis 1 1967;13:179-182.
Gonda A, Gault H, Churchill D et al. Hemodialysis formethanol intoxication. Am J Med 1978;64:749-1 758.
Jacobsen D, McMartin KE. Methanol and ethylene gly- I col poisoning: 4-methylpyrazole or ethanol. Proc Intern I Cong Eur Assoc Poison Control Centres, Milan, Italy: I September 25—29, 1990; p. 142.
Palatnick W, Redman LW, Sitar DS, Tenenbein M. I Methanol half-life during ethanol administration: implications for management of ethanol poisoning. Ann I Emerg Med 1995;26:202-207.
McCarron MM. Methyl alcohol. September, 1993 (Per- I sonal communication).
King ML. Acute methanol poisoning: a case study. Heart I Lung 1992;21:260-264.
Lacoutre PG, Heldreth DD, Shannon M, Lovejoy FH Jr. The generation of acetonemia/acetonuria following ingestion of a subtoxic dose of isopropyl alcohol. Am J Emerg Med 1989;7:38-40.
Bailey DN. Detection of isopropanol in acetonemic patients not exposed to isopropanol. Clin Toxicol 1990;28:459-466.
Levey S, Balchun OJ, Medrano V, Jung R. Studies of metabolic products in expired air. II. Acetone. J Lab Clin Med 1964;63:574-584.
Jones AW. Driving under the influence of isopropanol. Clin Toxicol 1992;30:153-155.
Stead AN, Moffat AC. A collection of therapeutic, toxic and fatal blood drug concentrations in man. Hum Toxicol 1983;3:437-464.
Kelner M, Beuley DN. Isopropanol ingestion: interpretation of blood concentrations and clinical findings. J Toxicol Clin Toxicol 1983;20:497-507.
Vicas IMO, Beck R. Fatal inhalational isopropyl alcohol poisoning in a neonate. Clin Toxicol 1993;31:473-481.
Braden GL, Strayhorn CH, Germain MJ, Mulhern JG, Skutcher CL. Increased osmolal gap in alcoholic acidosis. Arch Intern Med 1993;153:2377-2380.
Burkhart KK, Martinez MA. The absorption of isopropanol and acetone by activated charcoal. Clin Toxicol 1992;30:371-375.
Ellenhorn MJ. The alcohols. In: Hall JB, Schmidt GA, Wood LDH eds. Principles of critical care. New York: McGraw-Hill, 1992, 2080-2093.
MMWR. Update. Alcohol-related traffic fatalities — United States 1982-1993. JAMA 1994;272:1892.
Guppy A. At whole blood concentration should drunkdriving be illegal? Something lower than 17.4 mmol/L (0.8 g/L). Br Med J 1994;308:1055-1056.
Bradley KA, Donovan DM, Larson EB. How much is too much? Advising parents about safe levels of alcohol consumption. Arch Intern Med 1993;153:2734-2740.
Canfield DV, Kupiec T, Huffine E. Postmortem alcohol production in fatal aircraft accidents. J Forensic Sci 1993;38:914-917.
CDC. Alcohol use and aquatic activities — United States, 1991. MMWR 1993;42:675-682.
CDC. Alcohol involvement in pedestrian fatalities — United States, 1982-1992. MMWR 1993;42:716-719.
CDC. Quarterly table reporting alcohol involvement in fatal motor vehicle crashes. MMWR 1993;42:729.
Jurkovich GJ, Rivara FP, Gurney JG, Fligner C, Ries R, Mueller BA, Copass M. The effect of acute alcohol intoxication and chronic alcohol abuse on outcome for trauma. JAMA 1993;270:51-66.
Foulke FL. Alcohol beverages under investigation. FDA Consumer 1993;27( 1 ):23.
Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. Higher blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and firstpass metabolism. N Engl J Med 1990;322:95— 99.
Schenker S, Speeg KV. The risk of alcohol intake in men and women. All may not be equal. N Engl J Med 1990;322:127-129.
Seitz HK, Egerer G, Simanowski UA. High blood alcohol levels in women. N Engl J Med 1990;323:58.
Lieber CS. Biochemical and molecular basis of alcohol-induced injury to liver and other tissues. N Engl J Med 1988;319:1639-1650.
Holt S. Alcohol and H2 receptor antagonist: over the counter, under the table? Am J Gastroenterol 190; 185:516-517.
Roine R, Gentry T, Hernandez-Munoz R, Baraona E, Lieber CS. Aspirin increases blood alcohol concentrations in humans after ingestion of ethanol. JAMA 1990;264:2406-2408.
Bailey DN. Cocapropylene (propylcocaine) formation by human liver in vitro. J Anal Toxicol 1995;19:1-4. I
Novy FG. Some higher analogues of cocaine. Am Chem J 1988;10:145-148.
Harada S, Misawa S, Agarwal DP, Goedde HW. Liver alcohol and aldehyde dehydrogenase in the Japanese: isozyme variation and its possible role in alcohol intoxications. Am J Hum Genet 1980;32:8-15.
Jones AW, Neiman J, Hillbom M. Concentration-time profiles of ethanol and acetaldehyde in human volunteers treated with the alcohol-sensitizing drug calcium carbamide. Br J Clin Pharmacol 1988;25:213-221.
Brien JF, Loomis CW. Pharmacology of acetaldehyde Can J Physiol Pharmacol 1983;61:1-22.
Schootstra R, Bloemhof H, Bouma P, Uges DRA. An unusual case of acetaldehyde intoxication. In: Uges DRA, de Zeeuw RA, eds. Proc Int Assoc Forensic Toxicol. 25th Meeting, Groningen, Netherlands: June 1988, pp. 85-91.
Mills JL, Graubard BL Is moderate drinking during pregnancy associated with an increased risk for malformations? Pediatrics 1987;80:309-314.
Karl PI, Gordon BHJ, Lieber CS, Fisher SE. Acetalde- ; hyde production and transfer by the perfused human placental cotyledon. Science 1988;242:273-275.
Rosett H L. A clinical perspective of the fetal alcohol syndrome. Alcohol Clin Exp Res 1980;4:119-122.
Autti-Ramo I, Korkman M, Hilakivi-Clarke L, Lehto-! nen M, Halmesmaki E, Granstrom M-L. Mental devel- : opment of 2-year-old children exposed to alcohol in ute-ro. J Pediatr 1992;120:740-746.
CDC. Fetal alcohol syndrome — United States 1979- I 1992. MMWR 1993;42:339-341.
Mennella JA, Beauchamp GK. The transfer of alcohol to human milk. Effects on flavor and the infant’s behavior. N Engl J Med 1991;325:981-985.
Amadeno S, Abbou M, Fourcade ML, Waksman G, Ler- I oux MG, Madec A et al. DZ dopamine receptor genes and alcoholism. J Psychiatr Res 1993;27:173-179.
Noble EP, Blum K. Alcoholism and the D2 dopamine I receptor gene. JAMA 1993;270:1547.
Gelernter J, Risch N, Goldman D. Alcoholism and the D2 dopamine receptor gene. JAMA 1993;270:1547-1548.
Allen JP, Maisto Connors GJ. Self-report screening tests for alcohol problems in primary care. Arch Intern Med 1995;155:1726-1730.
Kitchens J M. Does this patient have an alcohol problem? JAMA 1994;272:1782-1787.
Engel PA, Grunnet M, Jacobs B. Wernicke—Korsakoff syndrome complicating T-cell lymphoma: unusual or unrecognized. South Med J 1991;84:253-256.
Fried RT, Levy M, Leibowitz AB, Bronster DJ, Iberti I TJ. Wernicke’s encephalopathy in the intensive care patient. Crit Care Med 1990;18:779-780.
Da Dalt L, Dall’Amico R, Lawerda AM, ChemolloC, Chiandelti L. Percutaneous ethyl alcohol intoxication in a one-month-old infant. Pediatr Emerg Care 1991 ;7: 343-344.
Watkins AMC, Keogh EJ. Alcohol burns in the neonate. J Paediatr Child Health 1992;28:306-308.
Hornfeldt CS. A report of acute ethanol poisoning in a child: mouthwash versus cologne, perfume and aftershave. Clin Toxicol 1992;30:115-121.
Lammingoa A, Vilska J. Acute alcohol intoxications in children treated in hospital. Acta Paediatr Scand 1990;79:847-854.
Kingston R, Saxona K, Sioris LJ, Lelwica T. Alcohol abuse in a 47-month-old child. Vet Hum Toxicol 1991;33:385.
Minocha A, Roberson DG, Herold DA et al. Impairment of cognitive and neuromuscular function by ethanol in social drinkers. Vet Hum Toxicol 1985;28:319.
Elphinstone PE, Black AK, Greaves MW. Alcohol-induced urticaria. J Roy Soc Med 1985;78:340-341.
Thorton JR. Atrial fibrillation in healthy non-alcoholic people after an alcoholic binge. Lancet 1984;2:1013— 1014.
Lang RM, Borow KM, Neumann A et al. Adverse cardiac effects of acute alcohol ingestion in young adults. Ann Intern Med 1985;102:742-743.
Criteria Committee, National Council on Alcoholism. Criteria for the diagnosis of alcoholism. Am J Psychiatry 1972; 129:129.
Morse RM, Flavin DK. Joint Committee of the National Council on Alcoholism. JAMA 1992;268:1012—1014.
Neiman J, Lang AE, Fornazzari L, Carlen PL. Movement disorders in alcoholism: a review. Neurology 1990;40:741-746.
Gill JS, Shipley MJ, Tsementzis SA, Hornby RS, Gill SK, Hitchcock ER et al. Alcohol consumption — a risk factor for hemorrhagic and non-hemorrhagic stroke. Am J Med 1991;90:489-497.
Steel JK, Cockcroft JR, Ritter JM. Blind drunk: alcoholic pancreatitis and loss of vision. Postgrad Med J 1993;69:151-152.
Chedid A, Mendenhall CL, Gartside P, French SW, Chen T, Rubin L, VA Cooperative Study Group. Am J Gastroenterol 1991;86:210-216.
Sherlock S. Alcoholic liver disease. Lancet 1995;345:227-229.
Diamond 1. Alcoholic myopathy and cardiomyopathy. N Engl J Med 1989;320:458-460.
Urbano-Marquez A, Estruch R, Navarro-Lopez F, Grau JM, Mont L, Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989;220:409— 415.
Aiderman LE, Coltart DJ. Alcohol and the heart. Br Med Bull 1982;38:77-80.
Moushmoush B, Abi-Mansour P. Alcohol and the heart. The long-term effects of alcohol on the cardiovascular system. Arch Intern Med 1991;151:36-42.
Knieriem HJ, Herbertz G. Electron-microscopic findings and photometric activation analytical results in experimental cardiac insufficiency caused by cobaltous chloride. Virchows Arch В Cell Pathol 1969;2:32-46.
Munzinge W. Cardiomyopathy and arsenic intoxication. Arch Klin Med 1987; 19:444.
Urbano-Marquez A, Estruch R, Fernandez-Sola J, Nicolas JM, Parc JC, Rubin E. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 1995;274:149-153.
Day CP, James OFW, Butler TJ, Campbell RWF. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet 1993;341:1423-1428.
Abe H, Kawano Y, Jojima S et al. Biphasic effects of repeated alcohol intake on 24-hour blood pressure in hypertensive patients. Circulation 1994;89:2626-2633.
Kei N, Swales JD, Grobbee DE. Alcohol intake and its relation to hypertension. Cardiovasc Risk Factors 1993;33:189-200.
Kaplan NM. Alcohol and hypertension. Lancet 1995;345:1588-1589.
Felson DT, Kiel DP, Anderson JJ, Kannel WB. Alcohol consumption and hip fractures. The Framingham Study. Am J Epidemiol 1988;128:102-110.
Bikie DD, Stesin A, Halloran B. Steinbach L, Recher D. Alcohol-induced bone disease: relationship to age and parathyroid hormone levels. Alcohol Clin Exp Res 1993;17:690-695.
Rico H. Alcohol and bone mineral density. Br Med J 1993;307:939.
MacGregor RR. Alcohol and immune defense. JAMA 1986;256:1474-1479.
Laitinen K, Lamberg-Allardt C, Tunninen R, Karonen S-L, Tahtela R, Ylikahri R et al. Transient hypoparathyroidism during acute alcohol intoxication. N Engl J Med 1991;324:721-727.
Freedland ES, McMichen DB. Alcohol-related seizures. II. Clinical presentation and management. J Emerg Med 1993;11:605-618.
De Marchi S, Cecchin E, Basile A, Bertotti A, Nardini R, Bartoli E. Renal tubular dysfunction in chronic alcohol abuse — effects of abstinence. N Engl J Med 1993;329:1927-1934.
Adams SL, Mathews JJ, Flaherty J J. Alcoholic ketoacidosis. Ann Emerg Med 1987;16:90-97.
Thompson CJ, Johnston DG, Baylis PH, Anderson J. Alcoholic ketoacidosis: an underdiagnosed condition? Br Med J 1986;292:463-465.
Duffens K, Marx JA. Alcoholic ketoacidosis — a review. J Emerg Med 1987;5:399-406.
Wrenn KD, Slovis CM, Minion GE, Rutkowski R. The syndrome of alcoholic ketoacidosis. Am J Med 1991;91:119-128.
Schelling JR, Howard RL, Winter SD, Unas SI. Increased osmolal gap in alcoholic ketoacidosis and lactic acidosis. Ann Intern Med 1990;113:580-582.
Milas AA, Tavassoli M. Laboratory markers of ethanol intake and abuse: a critical appraisal. Am J Med Sci 1992;303:425-428.
Wax PM, Hoffman RS, Goldfrank LR. Rapid quantitative determination of blood alcohol concentration in the emergency department using an electrochemical method. Ann Emerg Med 1992;21:254-259.
Christopher TA, Zeccardi J A. Evaluation of the QED saliva alcohol test: a new rapid accurate device for measuring ethanol in saliva. Ann Emerg Med 1992;21:1 135— 1136.
Lopez GP, Yealy DM, Krenzelok EP. Survival of a child despite unusually high blood ethanol levels. Am J Emerg Med 1989;7:283-285.
Beckett GJ, Hayes JD. Plasma glutathion-S-transferase measurements and liver disease in man. J Clin Biochem Nutr 1987;2:1-24.
Blake J, Orrego H. Monitoring treatment of alcoholic liver disease: evaluation of various severity indices. Clin Chem 1991;37:5-13.
Chedid A, Mendenhall CL, Gartside P, French SW, Chen T, Rabin L et al. Prognostic factors in alcoholic liver disease. Am J Gastroenterol 1991;86:210-216.
Geller RJ, Spyler PA, Herold DA, Bruns DE. Serum osmolal gap and ethanol concentration: a simple and accurate formula. Clin Toxicol 1986;24:77-84.
Angeli P, Gatta A, Caregaro L, Luisetto G, Menon F, Merkel С et al. Hypophosphatemia and renal tubular dysfunction in alcoholics. Are they related to liver function impairment? Gastroenterology 1991;100:502-512.
Naughton M, Grand J. Hypophosphatemia in a comatose alcoholic. Med J Aust 1991;155:723-724.
MacDonald L, Kruse JA, Levy D, Marulendra S, Sweeny PJ. Lactic acidosis and acute alcohol intoxication. Am J Emerg Med 1994;12:32-35.
Jones AW. Update on the concentration of acetone in blood from drinking drivers, Type-1 diabetes, out-patients and healthy blood donors. Proc Am Acad Forensic Sci, 44th Annual Meeting, New Orleans: February 17— 22, 1992; p. 193.
Stibler W. Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. Clin Chem 1991;37:2029-2093.
Koppel C, Muller C, Wrobel N. Diagnostic value of carbohydrate-deficient transferring for identifying patients with drug overdose at risk of developing an alcohol withdrawal syndrome (Personal communication).
Koppel C, Rosick U, Bratter P. Influence of chronic alcohol abuse on selenium status in ICU patients. Ann Emerg Med 1995:26:723.
Donnelly A, Paloucek F, Leikin J. Possible reversal of ethanol-induced respiratory depression of flumazenil. Vet Hum Toxicol 1991;33:389.
Koch HP. The story of the anti-alcohol drug RO 15-4513. Int Pharmacol J 1988;2:85-86.
Littleton J. Alcohol intoxication and physical dependence. A molecular mystery tour. Br J Addict 1989;84:267-276.
Naranjo CA, Sellers EM, Wu PH, Lawrin MO. Moderation of ethanol drinking: role of enhanced serotonergic neurotransmission. In: Naranjo CA, Sellers EM, eds. Research advances in new psychopharmacological treatments for alcoholism. Amsterdam: Elsevier, 1985.
Cook C, Lipsedge M. Chlormethiazole and alcohol: a lethal cocktail. Br Med J 1987;294:1099.
Agricola R, Mazarino M, Urani R. Treatment of acute alcohol withdrawal syndrome with carbamazepine: a double-blind comparison with tiapride. J Int Med Res 1982;10:100-105.
Ballenger JC, Post RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenia psychoses. Psy-chopharmacol Bull 1984;20:572-584.
Yam PCI, Forbes A, Kox WJ. Clonidine in the treatment of alcohol withdrawal in the intensive care unit. Br J Anaesth 1992;68:106-108.
Gallimberti L, Canton G, Gentile N, Ferri M, Cibin M, Ferrara SD et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 1989;2:787-789.
Flemenbaum A. Affective disorders and "chemical dependence": lithium for alcohol and drug addiction? Dis Nerv Syst 1974;35:281-289.
Flemenbaum A. Lithium carbonate prophylaxis of alcoholism: its time has come. Arch Gen Psychiatry 1989;46:290.
Fawcett J, Aagesen CA, Tilkin JM, McGuire M, Clark DC, Pisani VD et al. Lithium carbonate prophylaxis of alcoholism. Its time has come. Arch Gen Psychiatry 1989;46:290-291.
Baud FJ, Galliott M, Astier A, VuBien D, Garnier R, Likforman J, Bismuth C. Treatment of ethylene glycol poisoning with intravenous 4-methylpyrazole. N Engl J Med 1988;319:97-100.
Naltrexone for alcohol dependence. Med Lett Drug Ther 1995;37(Issue 953):64—66.
Monti J, Alterwain P. Ritanserin decreases alcohol intake in chronic alcoholics. Lancet 1991 ;337:60.
Peters DH, Vaulds D. Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 1994;47:1010-| 1032.
Lewis DC, Femind J. Management of alcohol withdraw-j al. Pharmacol Physicians 1982; 16:1.
Baumgartner GR, Rowen RC. Clonidine vs chlo-rdiazepoxide in the management of acute alcohol with- ‘ drawal syndrome. Arch Intern Med 1987; 147:1223-1226.
Pol S, Nalpas B, Berthelot P. Dexamethasone for alcohoi withdrawal. Ann Intern Med 1991; 114:705 — 706. j
Ives TJ, Mooney AJ III, Gwyther RE. Pharmacokinetic dosing of phenobarbital in the treatment of alcohol withdrawal syndrome. South Med J 1991;84:18-21.
Rosenbloom A. Emerging treatment options with alcohol withdrawal syndrome. J Clin Psychiatry 1988;49(Suppl 12):28—31.
Gillman MA, Lichtigfeld FJ. Analgesic nitrous oxide for alcohol withdrawal: a critical appraisal after 10 years’ use. | Postgrad Med J 1990;66:543-546.
Haddox VG, Bidder TG, Waldron LE, Derby P, Aches SMW. Clorazepate use may prevent alcohol withdrawal convulsions. West J Med 1987;146:695-696.
Fish SS, Heeren T. Does phenytoin prevent alcohol i withdrawal seizures: a meta analysis. Vet Hum Toxicol 1993;35:366.
Korsakoffs syndrome. Lancet 1990;336:912-913.
Neuberger JM. Transplantation for alcoholic liver dis-: ease contraindicated by alcohol dependence or extrahe- i patic disease. Br Med J 1989;299:693.
Moss AH, Siegler M. Should alcoholics compete equally for liver transplantation? JAMA 1991;265:1295-1298. |
Cohen C, Benjamin M, and the Ethics and Social Irn-j pact Committee of the Transplant and Health Policy Center. Ann Arbor, MI: JAMA 1991;205:1299-1301. I
Bird GLA, O’Grady JG, Harvey FAH, Caine RY, Williams R. Liver transplantation in patients with alcoholic cirrhosis: selection criteria and rates of survival and relapse. Br Med J 1990;301:15-17.
Vogel C, Caraccio T, Mofenson H, Hail S. Alcohol in-1 toxication in young children. Clin Toxicol 1995;33:25-| 33.
Leung AK. Ethyl alcohol ingestion in children. A 15-year review. Clin Pediatr 1986;25:617-619.
Redetzki HM. Ethanol (Management Treatment Protocol): Poisindex Information System. Rumack BH, ed. Colorado: Micromedex, Inc. Edition expires 8/30/92. I
Ashraf W, Dawling S, Farrow LJ. Systemic paraphenylenediamine poisoning: a case report and review. Hum Exp Toxicol 1994;13:167-170.
Averbuch A, Modai D, Leonov Y. Rhabdomyolysis and acute renal failure induced by paraphenylenediamine. Hum Toxicol 1989;8:345-348.
Editorial. Clay eating. Lancet 1978;2:614-615.
Crosby WH. Pica. JAMA 1976;235:2765.
Crosby WH. Pica: a compulsion caused by iron deficiency. BrJ Hematol 1976;34:341-342.
Callinan V, O’Hare JA. Cardboard chewing: cause and effect of iron deficiency anemia. Am J Med 1988;85:449.
Olynyk F, Sharpe DH. Mercury poisoning in paper pica. N Engl J Med 1982;306:1056-1057.
Sheahan K, Page DV, Kemper T, Suarez R. Childhood sudden death secondary to accidental aspiration of black pepper. Am J Forensic Med Pathol 1988;9:51-53.
Vermeer DE, Frate DA. Geophagia in rural Mississippi: environmental and cultural contexts and nutritional implications. Am J Clin Nutr 1979;32:2129-2135.
Korman SH. Pica as a presenting symptom in celiac disease. Am J Clin Nutr 1990;51:139-141.
Keeling PJ, Ransay J, Shand WS. Pica, paper and pseudoporphyria. Lancet 1987;2:1095.
Uretsky BF. Paper bezoar causing intestinal obstruction. Arch Surg 1974;109:123.
Johns T, Duquette M. Detoxification mineral supplementation as function of geophagy. Am J Clin Nutr 1991;53:448-456.
Hladik CM, Gueguen L. Geophagy and mineral nutrition in wild primates. C R Acad Sci 1974;279:1393-1396 (in French).
Halstead JA. Geophagia in man: its nature and nutritional effects. Am J Clin Nutr 1968;21:1384-1393.
Roselle HA. Association of laundry starch and clay ingestion with anemia in New York City. Arch Intern Med 1979;125:57-61.
Warshauer SE. Starch eater’s anemia. South Med J 1966;59:538-540.
Leming PD, Reed DC, Martello DJ. Magnesium carbonate pica: an unusual case of iron deficiency. Ann Intern Med 1981;94:660.
Gonzalez JJ, Owens W, Ungaro PC, Werk EE Jr, Wentz PW. Clay ingestion. A rare cause of hypokalemia. Ann Intern Med 1982;97:65-66.
Severance HW Jr, Holt T, Patrone NA, Chapman L Profound muscle weakness and hypokalemia due to clay ingestion. South Med J 1988;81:272-274.
Gelfand MC, Zarate A, Knepshield JH. Geophagia: a cause of life-threatening hyperkalemia in patients with chronic renal failure. JAMA 1975;234:738.
Minnich V, Okcuoglu A, Tarcon Y, Arcasoy A, Cin S, Yorukoglu О et al. Pica in Turkey. II. Effect of clay upon iron absorption. Am J Clin Nutr 1968;21:78-86.
Coltman CAJ. Pagophagia and iron lack. JAMA 1969;207:513-516.
Woolf AD, Saperstein A, Zauvin J, Cappock R, Sue Y-J. Radiopacity of household deodorants, air fresheners and moth repellents. Clin Toxicol 1993;31:418-428.
Diagnosis and Statistical Manual of Mental Disorders. 4th ed. DSM-IV. Washington, DC. American Psychiatric Association, 1994.
Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995;333:1196-1203.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991;86:1119-1127.
Benowitz NL. Cigarette smoking and nicotine addiction. Med Clin North Am 1992;76:415-537.
Byrd JC. Environmental tobacco smoke: medical and legal issues. Med Clin North Am 1992;76:377-386.
Fisher EB, Jr, Haire-Joshu D, Morgan GD, Rehberg H, Post K. Smoking and smoking cessation. Am Rev Respir Dis 1990;142:702-720.
Tonnesen P, Norregaard J, Simonsen K, Sama V. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 1991 ;325: 311-315.
Daughton DM, Heatley SA, Brendergast JJ, Causey D, Knowles M, Rolf CN et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study. Arch Intern Med 1991; 151:749— 752.
Hjalmarson A, Franzon M, Westin A, Wiklind O. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Arch Intern Med 1994;154:2567-2572.
Aspseloff G, Ashton HM, Friedman H, Gerber N. The importance of measuring cotinine levels to identify smokers in clinical trials. Clin Pharmacol Ther 1994;56:460-462.
Gourlay SG, Benowitz ML. Is clonidine an effective smoking cessation therapy? Drugs 1995;50:197-207.
Berlin I, Said S, Spreux-Varoquaux O, Launay J-M, Olivares R, Millet V et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995;58:444—452.
Sachs DPL. Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers. Arch Intern Med 1995;155:1973-1980.
Blanchard J. Nicotine. I. Clin Toxicol Rev 1993; 15(1): 1-2.
Malizia E, Andreucci G, Alfani F et al. Acute intoxication with nicotine alkaloids and cannabinoids in children from ingestion of cigarettes. Hum Toxicol 1983;2:315— 316.
McGee D, Brabson T, McCarthy J, Picciotti M. Four-year review of cigarette ingestions in children. Pediatr Emerg Care 1995;11:13-16.
Gehlbach SH, Williams WA, Freeman JI. Protective clothing as a means of reducing nicotine absorption in tobacco harvests. Arch Environ Health 1979;34:111 — 114.
West R. Corticotrophin injections to treat cigarette withdrawal symptoms. J R Soc Med 1985;78:1065-1066.
Pechacek RF, Folsom AR, de Gaudermaris R et al. Smoke exposure in pipe and cigar smokers. Serum thiocyanate measures. JAMA 1985;254:3330-3332.
Mensch AR, Holden M. Nicotine overdose after a single piece of nicotine gum. Chest 1984;86:801-802.
Smolinske SC, Spoerke DG, Spiller SK, Wruk KM, Kulig K, Rumach BH. Cigarette and nicotine chewing gum toxicity in children. Hum Toxicol 1988;7:21-31.
Saxena K, Scheman A. Suicide plan by nicotine poisoning. Vet Hum Toxicol 1985;28:299 (abstract).
No smoking deterrents. FDA Consumer 1985;19(8):2—3.
Steinfeld JL. Smoking and health. West J Med 1984;141:878-883.
Council on Scientific Affairs. Health effects of smokeless tobacco. JAMA 1986;255:1038-1044.
Lyon J D. Cancer in situ of the uterus and cigarette smoking. West J Med 1985; 143:659.
Brinton LA, Schairer C, Haenszel W et al. Cigarette smoking and invasive cervical cancer. JAMA 1986;255: 3265-3269.
Office on Smoking and Health. The health consequences of smoking: cardiovascular disease. A report of the Surgeon General. Rockville, MD: US Public Health Service, US Department of Health and Human Services, 1983.
Ramsdale DR, Faragher EB, Bray CL et al. Smoking and coronary artery disease assessed by routine coronary arteriography. Br Med J 1985;290:197-200.
Rogers RL, Meyer JS, Judd BW et al. Abstention from cigarette smoking improves cerebral perfusion among elderly chronic smokers. JAMA 1985;253:2970-2974.
Doll DC, Greenberg BR. Cerebral thrombosis in smoker’s polycythemia. Ann Intern Med 1985; 102: 786— 787.
Hallstrom AP, Cobb LA, Ray R. Smoking as a risk factor for recurrence of sudden cardiac arrest. N Engl J Med 1986;314:271-275.
Burrows B, Knudson RJ, Cline MG et al. Qualitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 1977;115:195-205.
Nieburg P, Marks JS, McLaren NM et al. The fetal tobacco syndrome. JAMA 1985;253:2998-2999.
Rosenberg L, Kaufman DW, Helmirch SP et al. Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA 1985;253:2965— 2969.
Baird DD, Wilcox AJ. Cigarette smoking associated with delayed conception. JAMA 1985;253:2979-2983.
MacMahon B, Trichopoulos D, Cole P et al. Cigarette smoking and urinary estrogens. N Engl J Med 1982;307:1062-1065.
Pemberton J. Oesophageal obstruction and ulceration caused by oral potassium therapy. Br Heart J 1970;32:267-268.
Nandi P, Ong GR. Foreign body in the oesophagus. Review of 2394 cases. Br J Surg 1978;65:5-9.
McCord GS, Clouse RE. Pill-induced esophageal strictures: clinical features and risk factors for development. Am J Med 1990;88:512-518.
Minocha A, Greenbaum DS. Pill-esophagitis caused by nonsteroidal antiinflammatory drugs. Am J Gastroenterol 1991;86:1086-1089.
Ovartlarnporn B, Kulwichit W, Hiranniramol S. Medication-induced esophageal injury. Report of 17 cases with endoscopic documentation. Am J Gastroenterol 1991;86:748-750.
Bott S, Prokash C, McCallum RW. Medication-induced esophageal injury. Survey of the literature. Am J Gastroenterol 1987;82:758-763.
Kikendall JW, Friedman AC, Oyewole MA, Fleischer D, Johnson LF. Pill-induced esophageal injury. Case reports and review of the medical literature. Dig Dis Sci 1983;28:174-182.
Shirazi SS, Zike WL, Brubacker M et al. Effect of aspirin, alcohol and pepsin on mucosal permeability of esophageal mucosa. Gastroenterology 1974;66:A-123/777.
Hey H, Jorgensen F, Sorensen K, Hasselbalch H, Wamberg T. Oesophageal transit of six commonly used tablets and capsules. Br Med J 1982;285:1717-1719.
Perry PA, Dean BS, Krenzelok EP. Drug-induced esophageal injury. Vet Hum Toxicol 1988;30:349.
Mrvos R, Dean В, Krenzelok Е. Hair relaxers: lack of morbidity despite high pH. Clin Toxicol 1995;33:475— 481 (abstract).
Fassett DW. Gamma-butyrolactone. In Fassett DW, Irish DD, eds. Toxicology. In Patty FA. Industrial hygiene and toxicology. New York. Interscience Division of John Wiley and Sons, 1962; pp 1824—1825.
Windholz M, ed. Merck Index. 9th ed. Rahway Merchant, 1976; p. 1590.
Fogh A, Ihnestedt B, Wickstrom E. Gamma-butyrolactone poisonings in children. Experiences in Scandinavia. Proc Eur Assoc Pois Cont Centers Toxicol 1988;55.
Roth RH, Giarman NJ. Preliminary report on the metabolism of gamma-butyrolactone and gamma-hydroxybutyric acid. Biochem Pharmacol 1965;14:177-178.
Borbely AA, Huston JP. Gamma-butyrolactone. An anaesthetic with hypothermic action in the rat. Experientia 1972;28:1455-1456.
Tatsuta M, lishi H, Baba M, Nakaizui A, Euhara H, Tanegushi H. Effect of gamma-butyrolactone on baclofen inhibition of gastric carcinogenesis induced by Y methyl-jV -nitro-TV-nitrosoguanidine in wistar rats. Oncology 1992;49:123-126.
Jenney EH, Murphree HB, Goldstein L, Pfeiffer CC. Behavioral and EEG effects of gamma-butyrolactone and gamma hydroxbutyric acid in man. Pharmacologist 1962;4:166.
Inderson M, Wetterstrom B. Loss of consciousness after ingestion of nail varnish remover. Ugeskr Laeger 1992; 154:3064.
Temple DM, McNeese МС. Hazards of battery ingestions. Pediatrics 1983;71:100-103.
Rumack BH, Rumack CM. Disc battery ingestions. JAMA 1983;249:2509-2510.
Rumack CM, Rumack BH. Battery ingestion. Pediatrics 1992;89:771-772.
Litovitz TL. Button battery ingestions: a review of 56 cases. JAMA 1983;249:2495-2500.
Blatnick BS, Toohill RJ, Lehman RH. Fatal complications from an alkaline battery foreign body in the esophagus. Ann Otol Rhinol Laryngol 1977;86:611-615.
Votteler TP, Nash JC, Rutledge JC. The hazards of ingested alkaline disc batteries in children. JAMA 1983;249:2504-2506.
Willis GA, HoWC. Perforation of Meckel’s diverticulum by an alkaline hearing aid battery. Can Med Assoc J 1982;126:497-498.
Maves MD, Carithers JS, Birck HG. Esophageal burns secondary to disc battery ingestions. Ann Otol Rhinol Laryngol 1984;93:364-369.
Langkau JF, Noesges RA. Esophageal burns from battery ingestion. Am J Emerg Med 1985;3:265.
Kulig K, Rumack CM, Rumack BH et al. Disc battery ingestion: elevated urine mercury levels and enema removal of battery fragments. JAMA 1983;249:2502-2504.
Reilly DT. Mercury battery ingestion. Br Med J 1979; 1:859.
Lewis RJ, Tatken RL. Registry of Toxic Effects of Chemical Substances. Cincinnati, Ohio. US Department of Health and Human Services, 1980, vol 2.
Barber ТЕ, Manke RD. The relationship of ingested iron to the absorption of mercuric oxide. Am J Emerg Med 1984;2:500-503.
Kaplan DS. Battery ingestion and EKG interference. Gastrointest Endosc 1990;36:162-163.
Proctor MH. Assault by battery. N Engl J Med 1987;316:554.
Litovitz T, Schmitz BF. Ingestion of cylindrical and button batteries: an analysis of 2382 cases. Pediatrics 1992;89:747-757. Commentary by K. Kulig in AACT Update 1992;5(4):1—2.
Blume CM, Thompson MW, Scalzo AJ. Use of IV glucagon to facilitate the passage of a penny from the distal esophagus into the stomach. Vet Hum Toxicol 1993;35:335.
Kavanaugh KT, Litovitz T. Miniature battery foreign bodies in auditory and nasal cavities. JAMA 1986;255:1470-1472.
Sheikh A. Button battery ingestions in children. Pediatr Emerg Care 1993;9:224-229.
Wong IC, Heimbach MD, Truscott DR et al. Boric acid poisoning: report of 11 cases. Can Med Assoc J 1964;90:1018-1023.
Linden CH, Hall AH, Kulig KW et al. Acute ingestions of boric acid. Clin Toxicol 1986;24:269-279.
Martin GI. Asymptomatic boric acid intoxication. NY Stat J Med 1971;71:1842-1844.
Schillinger BM, Berstein M, Goldberg LA et al. Boric acid poisoning. J Am Acad Dermatol 1982; 7: 667— 673.
Baker MD, Bogema SC. Ingestion of boric acid by infants. Am J Emerg Med 1986;4:358-361.
Ross CA, Conway JF. The dangers of boric acid: its use as an irrigant and report of a case. Am J Surg 1943;60:386-395.
Valdes-Dapena MA, Arey JB. Boric acid poisoning: three fatal cases with pancreatic inclusions and a review of the literature. J Pediatr 1962;61:534-546.
Balaih T, MacLeish H, Drummond KN. Acute boric acid poisoning: report of an infant successfully treated by peritoneal dialysis. Can Med Assoc J 1969; 101:166— 168.
Stein KM, Odom RB, Justice GR et al. Toxic alopecia from ingestion of boric acid. Arch Dermatol 1973;108:95-97.
Gordon AS, Prichard JS, Freeman MH. Seizure disorders and anemia associated with chronic borax intoxication. Can Med Assoc J 1973;108:719-722.
Litovitz TL, Klein-Schwartz W, Oderda GM, Schmitz BP. Clinical manifestations of toxicity in a series of 784 boric acid ingestions. Am J Emerg Med 1988;6:209— 213.
ZoletDl, Miller T, Yarborough Bet al. Pentaborane poisoning causing extreme acidosis and death. Vet Hum Toxicol 1982;24:277-278 (abstract).
Silverman JJ, Hart RP, Garrettson LK et al. Posttrau-matic stress disorder from pentaborane intoxication. Neuropsychiatric evaluation and short-term follow-up. JAMA 1985;254:2603-2608.
Restuccio A, Mortensen ME, Kelley MT. Fatal ingestion of boric acid in an adult. Am J Emerg Med 1992;10:545-547.
Oderda GM, Klein-Schwartz W, Insley BM. In vitro study of boric acid and activated charcoal. Vet Hum Toxicol 1985;28(4):314 (abstract).
Goldbloom RB, Goldbloom A. Boric acid poisoning: report of four cases and a review of 109 cases from the world literature. J Pediatr 1953;43:631-643.
Litovitz TL et al. Clinical manifestations of toxicity in a series of 784 boric acid ingestions. Vet Hum Toxicol 1986;28:505 (abstract).
Yelin G, Taff ML, Sadowski GE. Copper toxicity fol-1 lowing massive ingestion of coins. Am J Forensic Med Pathol 1987;8:78-85.
DeBakey M, Ochsner A. Bezoars and concretions. A comprehensive review of the literature with an analysis of 303 collected cases and a presentation of 8 additional cases. Surgery 1938;4:934-963; 1939;5:132-160.
Eshel G, Broide E, Azizi E. Phytobezoar following raisin ingestion in children. Pediatr Emerg Care 1988;4:192-1 193.
Deal DR, Vitale Q, Raffin SB. Dissolution of a postgastrectomy bezoar by cellulose. Gastroenterology 1973;64:467-470.
Carrougher JG, Barrilleaux CN. Esophageal bezoars: the i sucralith. Crit Care Med 1991;19:837-839.
Singer JI. Lactobezoar causing an abdominal triad of col- i icky pain, emesis and mass. Pediatr Emerg Care 1988;4:194-196.
Schreiner RL, Brady MS, Franken EA. Increased inci- ? dence of lactobezoars in low birth weight infants. Am J Dis Child 1979;133:936-940.
Reddy ER, Joseph S. Lactobezoars in the low birth weight neonate. CMAJ 1985;133:297.
Delpre G, Glanz I, Neeman A, Aridor 1, Kadish V. New therapeutic approach in postoperative phytobezoars. J Clin Gastroenterol 1984;16:231-237.
Schneider RP. Perdiem causes esophageal impaction and bezoars. South Med J 1989;82:1449-1450.
DePiro JT, Bowden TA Jr. Treatment of gastric bezoars. Clin Pharm 1989;8:181-182.
Zarling EJ, Moeller DD. Bezoar therapy. Complication using Adolph’s Meat Tenderizer and alternatives from literature review. Arch Intern Med 1981;141:1669-1670.
Andrus CH, Ponsky JL. Bezoars: classification, pathophysiology and treatment. Am J Gastroenterol 1988;83:476-478.
Schlang HA. Acetylcysteine in removal of bezoar. JAMA 1970;214:1329.
Cooper SG, Tracey EJ. Small-bowel obstruction caused by oat bran bezoar. N Engl J Med 1989;320:1148— 1149.
Ernst RW, Leventhal М, Luva R et al. Total esophagogastric replacement after ingestion of household ammonia. N Engl J Med 1963;208:815-816.
Vancura EM, Clinton JE, Ruiz E et al. Toxicity of alkaline solutions. Ann Emerg Med 1980;9:118-122.
Muhlendal KE, Oberoisse V, Krienke EG. Local injuries by accidental ingestion of corrosive substances by children. Arch Toxicol 1978;39:299-314.
Warren JB, Griffin DJ, Olson RC. Urine sugar reagent tablet ingestion causing gastric and duodenal ulceration. Arch Intern Med 1984;144:161-162.
Grenga ТЕ. A new risk of lye ingestion by children. N Engl J Med 1983;308:156-157.
Early SH, Simpson RL. Caustic burns from contact with wet cement. JAMA 1985;254:528-529.
Hadley CM, Laubacher MA, Watson PD. Dermal and inhalation burns caused by the automotive air bag inflation system. Vet Hum Toxicol 1993;35:358.
Homan CS, Maitra SR, Lane BP, Thode HC, Finkelshteyn J, Davidson L. Effective treatment for acute alkali injury to the esophagus using weak-acid neutralization therapy: an ex-vivo study. Acad Emerg Med 1995;2:952-958.
Smilkstein MJ. Should we add an acid to an alkali injury? For now, let’s remain neutral! Acad Emerg Med 1995;2:945-946.
Meredith JW, Kon ND, Thompson JN. Management of injuries from liquid lye ingestion. J Trauma 1988;28:1173-1180.
Gaudreault P, Parent M, McGuigan M et al. Predictability of esophageal injury from signs and symptoms: a study of caustic ingestions in 378 children. Pediatrics 1983;71:767-770.
Crain EF, Gershel JC, Mezey AP. Caustic ingestions: symptoms as predictors of esophageal injury. Am J Dis Child 1984;138:863-865.
Knopp R. Caustic ingestions. JACEP 1979;8:3 29- 336.
Krenzelok EP, Clinton JE. Caustic esophageal and gastric erosion without evidence of oral burns following detergent ingestion. JACEP 1979;8:194-196.
Mallory A, Schaefer JW. Clinitest ingestion. Br Med J 1977;2:105-107.
Meredith JW. Personal communication, May 11, 1993.
Thompson JN. Corrosive esophageal injuries. I. A study of nine cases of concurrent accidental caustic ingestion. Laryngoscope 1987;97:1060-1068.
Friedman EM, Lovejoy FH. The emergency management of caustic ingestions. Emerg Med Clin North Am 1984;2:77-86.
Okonek S, Bierbach H, Atzpodien W. Unexpected metabolic acidosis in severe lye ingestion. Clin Toxicol 1981;18:225-230.
Hoffman RS, Howland MA, Kamerow HN, Goldfrank LR. Comparison of titratable acid/alkaline reserve and pH in potentially caustic household products. Clin Toxicol 1989;27:241-261.
Wasserman RC, Ginsburg CM. Caustic substance injuries. J Pediatr 1984;107:169-174.
Rumack BH, Burrington JD. Caustic ingestion: a rational look at diluents. Clin Toxicol 1977;11:27-34.
Estrera A, Taylor W, Mills U et al. Corrosive burns of the esophagus and stomach. A recommendation for an aggressive surgical approach. Ann Thorac Surg 1986;41:276—283.
Webb WR, Koutras P, Ecker RR et al. An evaluation of steroids and antibiotics in caustic burns of the esophagus. Ann Thorac Surg 1970;9:95-102.
Anderson KD, Rouse TM, Randolph JG. A controlled trial of corticosteroids in children with corrosive injury of the esophagus. N Engl J Med 1990;323:637-640.
Lovejoy FH Jr. Corrosive injury of the esophagus in children. Failure of corticosteroid treatment reemphasizes prevention. N Engl J Med 1990;323:668-670.
Wijburg FA, Heymans HSA, Urbanus NAM. Caustic esophageal lesions in childhood: prevention of stricture formation. J Pediatr Surg 1989;24:171-173.
Howell JM, Dalsey WC, Hartsell FW, Batzin CA. Steroids for the treatment of corrosive esophageal injury. A statistical analysis of past studies. Am J Emerg Med 1992;10:421-425.
Di Costanzo J, Nouclere M, Jougland J et al. New therapeutic approach to corrosive burns of the upper gastrointestinal tract. Gut 1980;2:370-375.
Moore WR. Caustic ingestions: pathophysiology, diagnosis, and treatment. Clin Pediatr 1986;25:192-196.
Eugen Т. The potential usefulness of sensations of odor and taste in keeping children away from harmful substances. Ann NY Acad Sci 1974;237:224-228.
Berning CK, Griffith JF, Wild JE. Research on the effectiveness of denatonium benzoate as a deterrent to liquid detergent ingestion in children. Fundam Appl Toxicol 1982;2:44-48.
Lawless HT, Hammer LD, Corina M D. Aversions to bitterness and accidental poisonings among preschool children. J Toxicol Clin Toxicol 1982—83; 19:951—964.
Robertson WO. American Association of Poison Control Centers Resolution. Vet Hum Toxicol 1989;31:479.
Hinds M de C. Mother fights to ruin the taste of poison. New York Times, May 20, 1989.
Klein-Schwartz W. Denatonium benzoate. Review of efficacy and safety. Vet Hum Toxicol 1991;33:545-547.
Rich V. Poland: curbing ethylene glycol abuse. Lancet 1993;341:169.
Sibert JR, Frude N. Bittering agents in the prevention of accidental poisoning: children’s reaction to denatonium benzoate (Bitrex). Arch Emerg Med 1991;8:1-7.
Hansen SR, Janssen C, Beasley VR. Denatonium benzoate as a deterrent to ingestion of toxic substance: toxicity and efficacy. Vet Hum Toxicol 1993;234—236.
Mofenson НС, Greensher J. The non-toxic ingestion. Pediatr Clin North Am 1970;17:583-590.
Friedman EM, Lovejoy FH. The emergency management of caustic ingestions. Emerg Med Clin North Am 1984;2:77-80.
Maull KI. Liquid caustic ingestions: an in vitro study of the effects of buffer, neutralization, and dilution. Ann Emerg Med 1985;14:1160-1162.
Nicosia JR, Thornton JR, Folk FA. Surgical management of corrosive gastric injuries. Ann Surg 1974;180:139-143.
Kirsh MM, Ritter F. Caustic ingestion and subsequent damage to the oropharyngeal and digestive passages. Ann Thorac Surg 1976;21:74-82.
Kunkel DB. Burning issues: acids and alkalis. II. Skin and eye exposures. Emerg Med 1984;16(11):165—171.
Occupational Disease. A Guide to their Recognition. Revised edition. Publication No. DHEW (NIOSH) 77-181. National Institute for Occupational Safety and Health. Washington, DC. US Government Printing Office, June 1977, pp. 178—180.
NIOSH Pocket Guide to Chemical Hazards. NIOSH t Publication No. 90-117. US Department of Health and I Human Services. Washington, DC. US Government I Printing Office, June 1990, pp. 30—31.
Kern DG. Outbreak of the reactive airways dysfunction I syndrome after a spill of glacial acetic acid. Am Rev I Respir Dis 1991;144:1058-1064.
Hall S, Saliares R, Arrigoni J, Flynn T. Systemic acido- I sis, hemolysis and hemoglobinuria renal failure from ace- I tic acid ingestion. Vet Hum Toxicol 1985;28:291.
Naik RB, Stephens WP, Wilson DJ, Walker A, Lee HA. I Ingestion of formic acid-containing agents — report of | three fatal cases. Postgrad Med J 1980;56:451-456.
Rosewarne FA. Self-poisoning with formic acid. Anaes- I thesia 1983;38:1104-1105.|
Rajan N, Rabim R, Kumar SK. Formic acid poisoning | with suicidal intent: a report of 53 cases. Postgrad Med I J 1985;61:35-36.?
Wiemikowski A, Guzik E. Ostre zatrucie Kwasem I mrowkowyn. (Acute poisoning from formic acid). Prze- I glad Lekarski 1973;30:395-396.
Malizia E, Reale C, Pietropaoli P, De Ritis GC. Formic I z acid intoxications. Acta Pharmacol Toxicol I 1977;41(Suppl):342—347.
Jeffrys DB, Wiseman HM. Formic acid poisoning. Post- I grad Med J 1980;56:761-762.| q
Verstraetz AG, Vogelaers DP, Van den Bogaerde JF, Colardyn FA, Ackerman CM, Buylaert WA. Formic acid poisoning. Case report and in vitro study of the hemolytic activity. Ann J Emerg Med 1989;7:286-290.
Chan TC, Williams SR, Clark RF. Formic acid skin burns resulting in systemic toxicity. Ann Emerg Med 1995;26:383-386.
NIOSH. Pocket Guide to Chemical Hazards. DHHS (NIOSH). Publication No. 90-117. Washington, DC. US Government Printing Office, June 1990, pp. 118-119.
Key MM, Henschel AF, Butler J, Ligo RN, Tabershaw IR. Occupational Diseases. A Guide to their Recognition. Revised Edition. DHEW (NIOSH). Publication No. 77-181. Washington, DC. US Government Printing Office, Revised June 1977, pp. 180—181.
Occupational Exposure Limits for Airborne Toxic Substances. Occupational Safety and Health Series 37. Geneva. International Labour Office, 1991, pp. 206— 207.
Penner GE. Acid ingestion: toxicology and treatment.Ann Emerg Med 1980;9:374-379.
Tintinalli JE. Of anions, osmols and methanol poisoning. JACEP 1977;6:417.
Moore DF, Bentley AM, Dawling S, Hoare AM, Henry JA. Folinic acid and enhanced renal elimination in formic acid intoxication. Clin Toxicol 1994;32:199-204.
Meuchel SM, Dunn WA. Hydrofluoric acid poisoning. Am J Forensic Med Pathol 1984;5:245-248.
Curry AS. Twenty-one uncommon causes of poisoning.Br Med J 1962;1:687-689.
Degawa K. A fatal case of hydrogen fluoride poisoning. Bull Int Assoc Forensic Toxicol 1984; 17(3):35.
Rieders MF, Morrow PL, Rieders F, Crookham S, Zelo-nis S. A case of suicidal ingestion of a hydrofluoric acid/ ammonium bifluoride rust remover solution with fatal outcome during antidepressant treatment with fluoxetine. Abst K36. Proc Am Acad Sci, February 18-23, 1991.
Manoguerra AS, Neuman TS. Fatal poisoning from acute hydrofluoric acid ingestion. Am J Emerg Med 1986;4:362-363.
Upfal M, Doyle C. Medical management of hydrofluoric acid exposure. J Occup Med 1990;32:726-731.
Caravati EM. Acute hydrofluoric acid exposure. Ami Emerg Med 1988;6:143-150.
Stremski ES, Grande GA, Ling LJ. Survival following hydrofluoric acid ingestion. Vet Hum Toxicol 1991;33:363.
El Saadi MS, Hall AH, Hall PK, Riggs BS, Augenstein WL, Rumack BH. Hydrofluoric acid dermal exposure. Vet Hum Toxicol 1989;31:243-247.
Sadove R, Hainsworth D, Van Meter W. Total body conversion hydrofluoric acid. South Med J 1990;83:698— 700.
Siegel DC, Heard J M. Intra-arterial calcium infusion for hydrofluoric acid burns. Aviat Space Environ Med 1992;63:206-211.
Henry JA. Intravenous regional calcium gluconate perfusion for hydrofluoric acid bums. Clin Toxicol 1992;30:203-207.
Bentur Y, Tannenbaum S, Yaffe Y, Halpert M. The role of calcium gluconate is the treatment of hydrofluoric and eye burns. Ann Emerg Med 1993;22:1488-1490.
Kulling P, Andersson H, Bostrom K, Johansson LA, Lindstrom B. Nystrom B. Fatal systemic poisoning after skin exposure to monochloracetic acid. Clin Toxicol 1992;30:643-652.
Feldhaus K, Hudson D, Rogers D, Horowitz RS, Brent J, Dart RC, Gomez H. Pediatric fatality associated with accidental oral administration of monochloroacetic acid (MCA). Vet Hum Toxicol 1993;35:344.
Key MM, Henschel AF, Butler J, Ligo RN, Tabershaw IR, eds. Occupational diseases. A guide to their recognition. National Institute for Occupational Safety and Health, Washington, DC. US Government Printing Office. DHEW (NIOSH). Publication No 77-181, Revised Edition June 1977, p. 156.
Fassett DW. Organic acid, anhydrides, lactones, acid halides and amides, thioacids. In Patty FA, ed. Industrial hygiene and toxicology. Second Revised Edition. Vol 2 (Fassett DW, Irish DD, eds), New York. Interscience, 1963, pp. 1795-1796.
Hunter D. The Diseases of Occupations. London. Hodder and Stoughton. 1975 p. 1121.
Tallqvist H, Vaananen. Death of a child from oxalic acid poisoning due to eating rhubarb leaves. Ann Paediatr Fenn 1960;60:144-147.
Fane M, Xirgu J, Salgado A, Penacaula R, Reig M, Sanz P. Fatal oxalic acid poisoning from sorrel soup. Lancet 1989;2:1524.
Occupational Disease. A Guide to their Recognition. Revised edition. Publication No. DHEW (NIOSH) 77-181. National Institute for Occupational Safety and Health. Washington, DC. US Government Printing Office, June 1977, pp. 182—184.
NIOSH Pocket Guide to Chemical Hazards. NIOSH Publication No. 90-117. US Department of Health and Human Services. Washington, DC. US Government Printing Office, June 1990, pp. 1701 — 1771.
Woolf A. Oxalates. Clin Toxicol Rev 1993;16:1-2.
CDC. Outbreak of gastrointestinal illness associated with consumption of seaweed — Hawaii, 1994. MMWR 1995;44:724-727.
CDC. MMWR 1994;43:677, 683-684: Ostrich fern poisoning — New York and Western Canada, 1994, JAMA 1995;273:912-913.
Haber LM, Hawkins ЕР, Seilheimer DK, Saleem A. Fat overload syndrome. An autopsy study with evaluation of the coagulopathy. Am J Clin Pathol 1988;89:223— 227.
Halberg D. Elimination of exogenous lipids from the blood stream. Acta Physiol Scand 1965;65(Suppl 254):1—23.
Johnson WA, Freeman S, Meyer KA. Some effects of intravenous fat emulsions on human subjects. J Lab Clin Med 1952;39:176-183.
Watkin DM. Clinical, chemical, hematologic and anatomic changes accompanying the repeated intravenous administration of fat emulsion in man. Metabolism 1957;6:785-806.
Kollef MH, McCormack MT, Caras VVE, Reddy VVB, Bacon D. The fat overload syndrome: successful treatment with plasma exchange. Ann Intern Med 1990;112:545-546.
Stolee B, Purssell R, Ashbourne JF, Vicas IMO. Intralipid overdose in a neonate. Vet Hum Toxicol 1994;34:375.
Campbell AN, Freedman MH, Pencharz PB, Zlotkin SH. Bleeding disorders from the fat overload syndrome. J Parenter Enteral Nutr 1984;8:447-449.
Meng HC, Kaley JS. Effects of multiple infusions of a fat emulsion on blood coagulation, liver function and urinary excretion of steroids in schizophrenic patients. Am J Clin Nutr 1965;16:156-164.
Belin RP, Bivins BA, Jona JZ, Young VL. Fat overload with a 10 % soybean oil emulsion. Arch Surg 1976;111:1391-1393.
Heyman MB, Storch S, Ament ME. The fat overload syndrome. Report of a case and literature review. Am J DisChild 1981;135:628-630.
Levene MI, Wigglesworth JS, Desai R. Pulmonary fat accumulation after interlipid infusion in the preterm infant. Lancet 1990;2:815-819.
Taylor RF, Buckner CD. Fat overload from 10 percent soybean oil emulsion in a marrow transplant recipient. West J Med 1982;136:345-349.
Venus B. Fat emulsion and ARDS. Chest 199O;98:510.
Hesson I, Melsen F, Haug A. Postmortem findings in three patients treated with intravenous fat emulsions. Arch Surg 1979;114:66-68.
Levene MI, Batisti O, Wigglesworth JS, Desai R, Meek JH, Bulusu S, Hughes E. A prospective study of intrapul-monary fat accumulation in the newborn baby following intralipid infusion. Acta Paediatr Scand 1984;73:454.
Reynolds JEF. Martindale: The extra pharmacopoeia. 13th ed. London: Pharmaceutical Press, 1993.
"French bronze" fades away. FDA Consumer 1990;24(l):34—35.
Herbert V. Canthaxanthin toxicity. Am J Clin Nutr 1991;53:573.
Oosterhuis J A, Nijman NM, de Wolff FA, Remky H. Canthaxanthin retinopathy with and without intake of canthaxanthin as a drug. Hum Toxicol 1988;7:45-47.
Mathews, Roth MM. Reply to V Herbert. Am J Clin Nutr 1991;53:573-574.
Kubler W. Biokinetic evaluation of canthaxanthin plasma levels after multiple doses of 1 mg and 8 mg canthaxanthin. Unpublished report submitted to WHO by F. Hoffmann-La Roche and Co., Basle, Switzerland. In: Toxicological evaluation of certain food additives and contaminants. Geneva: WHO Food Additive Series 76, 1990; pp. 45-73.
Schalch W. Biokinetic evaluation of canthaxanthin in humans. Unpublished Research Report. No. B-107, 134 submitted to WHO by Hoffmann-La Roche & Co, Basle, Switzerland. In: Toxicological evaluation of certain food additives and contaminants. Geneva: WHO Food Additives Series 26, 1990; pp. 45—73.
Hoffmann-La Roche. Canthaxanthin. Unpublished Research Report. No. B-107, 134 submitted to WHO by F. Hoffmann-La Roche & Co, Basle. Switzerland. In: Toxicological evaluation of certain food additives and contaminants. Geneva: WHO Food Additives Series 26, 1990; pp. 45-73.
Harnois C, Samson J, Malenfant M, Rousseau A. Canthaxanthin retinopathy. Anatomic and functional reversibility. Arch Ophthalmol 1989;107:538-540.
Canthaxanthin. Toxicological evaluation of certain food additives and contaminants. Geneva: WHO Food Additives Series 26, 1990; pp. 45—73.
McGuiness R, Beaumont P. Gold dust retinopathy after the ingestion of canthaxanthin to produce skin-bronzing. Med J Aust 1985;143:622-623.
Weber U, Goerz G. Ophthalmological disorders through carotenoid ingestion. Dtsch Artzeblatt 1985;41:181-182.
Arden GB, Oluwole JOA, Polkinhorne P, Bird AC, Barker FM, Norris PG et al. Monitoring of patients taking canthaxanthin and carotene: an electroretinographic and Ophthalmological survey. Hum Toxicol 1989;8:439-450.
Bluhm R, Branch R, Johnston P, Stein R. Aplastic anemia associated with canthaxanthin ingested for "tanning" purposes. JAMA 1990;264:1141 — 1142.
Boudreault G, Cortin P, Corriveau LA, Rousseau AP, Tardif Y, Malenfant M. Canthaxanthin retinopathy. I. Clinical study in 51 consumers. Can J Ophthalmol 1983;18:325-328.
Hart L, Mowers RM. DIAS rounds — drug information analysis service. Drug Intell Clin Pharmacol 1987;21:173-174.
Evaluation of certain food additives and contaminants. Thirty-third Report of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organization Technical Report Series 776. Geneva: WHO, 1989.
Frazier L, Darcely DJ, Langley RL. Food safety. Lead pesticides, antibiotics, hormones and irradiation. NC Med J 1992;53:372.
Lecos С. Food preservatives: a fresh report. FDA Consumer 1984; 18(3):23—25.
Levine AS, Labuza TP, Morley JE. Food technology. A primer for physicians. N Engl J Med 1985;312:628-634.
Verhagen H, Maas LM, Beckers RHG, Thijssen HHW, Ten Hoor F, Handerson P Th, Kleinjans JCS. Effect of subacute oral intake of the food antioxidant butylated hydroxyanisole on clinical parameters and phase-I and -II biotransformation capacity in man. Hum Toxicol 1989;8:451-459.
Simon RA, Green L, Stevenson DD. The incidence of ingested metabisulfite sensitivity in an asthmatic population. J Allergy Clin Immunol 1982;69:118.
Sulfiting agents: revocation of GRAS status for use on fruits and vegetables intended to be served or sold raw to consumers. Fed Reg 1986;51 (131 ):25 021—25 026.
Sogn D. The ubiquitous sulfites. JAMA 1984;251:2986— 2987.
Davies RC, Spencer Н, Wakelin РО. A case of human protothecosis. Trans R Soc Trop Med Hyg 1964;58:448-451.
Heney C, Greeff'M, Davis V. Hickman catheter-related protothecal algaemia in an uncompromised child. J Infect Dis 1991;163:930-931.
Evaluation of certain food additives and contaminants. Thirty-third Report of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organization Technical Report Series 776. Geneva: WHO, 1989.
Pollock I, Warner JO. Effect of artificial food colours on childhood behavior. Arch Dis Child 1990;65:74-77.
Blumenthal D. Red No. 3 and other colorful controversies. FDA Consumer May 1990, pp. 18—21.
Gross PA, Lance K, Whitlock RJ, Blume RE. Additive allergy: allergic gastroenteritis due to yellow dye . Ann Intern Med 1989;111:87-88.
Zautcke JL, Schwartz JA, Mueller EJ. Chinese restaurant syndrome: a review. Ann Emerg Med 1986;15:1210-1213.
Olney JW. Excitatory neurotoxins as food additives: an evaluation of risk. Neurotoxicology 1980;2:163-192.
Olney JW. Excitatoxicity and neuropsychiatric disorders. In: Ascher P, Choi DW, Cristen Y, eds. Glutamate, cell death and memory. Berlin: Springer Verlag, 1991.
MSG judged safe for most people. FDA Consumer 1995;29:2.
Pulce C, Vial T, Verdier F, Testud F, Nicolas B, Descotes J. The Chinese restaurant syndrome: a reappraisal of monosodium glutamate’s causative role. Adverse Drug React Toxicol Rev 1992;11:19-39.
Squire EN Jr. Angioedema and monosodium glutamate. Lancet 1987; 1:988.
Allen DH, DelohenyJ, Baker G. Monosodium L-glutamate-induced asthma. J Allergy Clin Immunol 1987;80:530-537.
Goldberg LH. Supraventricular tachyrhythmia in association with the Chinese restaurant syndrome. Ann Emerg Med 1982;1 1:333.
Gann D. Ventricular tachycardia in a patient with the "Chinese restaurant syndrome." South Med J 1977;70:874-881.
Ratner D, Ethel E, Shoshani E. Adverse effects of monosodium glutamate: a diagnostic problem. Isr J Med Sci 1984;20:252-253.
Swan GF. Management of monosodium glutamate toxicity. J Asthma 1982;19:105-110.
FDA Background. Monosodium glutamate (MSG). HF1-40, October 1991.
Swan GF. Management of monosodium glutamate toxicity. J Asthma 1982;19:105-110.
Lee W. Seafood leader 1992;12(3):I, Lambert A et al: FEBS Lett 1987;219:355-359.
Dickey RW, Fryxell GA, Granada HP, Roelka D. Detection of marine toxins okadaic acid and domoic acid in shellfish and phytoplankton in the Gulf of Mexico. Toxicon 1992;30:355-359.
Stone R. Hot field: neurotoxicology. Science 1993;259:1397.
Perl TM, Bedard L, Kosatsky T, Hockin JC, Todd ECD, Remis RS. An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med 1990;322:1775-1780.
Teitelbaum JS, Zatorre RJ, Carpenter S, Gendron D, Evans AC, Gjedde A, Cashman NR. Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med 1990;322:1781 — 1787.
Neurological complications of domoic acid intoxication. Lancet 1990;336:601 (editorial).
Glavin GB, Bose R, Pinsky C. Infections and toxic syndromes from fish and shellfish consumption. Arch Intern Med 1990; 150:2425.
FDA warns against eating organs of Dungeness crab. Los Angeles Times, December 28, 1991, p. Al 9.
Glavin GB, Pinsky C, Bose R. Mussel poisoning and excitatory amino acid receptors. Trends Pharm Sci 1989;10:15-16.
Morris PD, Campbell DS, Taylor TJ, Freeman JI. Clinical and epidemiological features of neurotoxic shellfish poisoning in North Carolina. Am J Public Health 1991;81:471-474.
Holliman CJ. Something fishy. Prehospital management of toxic seafood ingestions. Emerg Med Services January 1994, pp. 32-37.
Sorokin M. Human poisoning by ingestion of a sea hare. (Dolabella auricularia). Toxicon 1988;26:1095-1097.
Price RJ. Safe handling and storing of seafoods. Leaflet 21 119. California Sea Grant Marine Advisory Publication, Division of Agricultural Science, University of California, 1979.
Pelander A, Ojanpera I, Vouri Е. Cyanobacterial toxins. Bull Int Assoc Forensic Toxicol 1995;25:6-10.
Stevens DH, Krieger RI. Analysis of anatoxin-a by GC/ ECD. J Anal Toxicol 1988;17:126-131.
Baxter IJ. Toxic marine and freshwater algae: an occupational hazard? Br J Indust Med 1991;49:505-506.
Proci VP. Blue-green algae: fact or fantasy? Med J Aust 1992;156:366-377.
Haffejee IE. The pathophysiology, clinical features and management of rotavirus diarrhea. Q J Med 1991;79:289-299.
Herrmann JE, Taylor DN, Echeverria P, Blacklow NR. Astroviruses as a cause of gastroenteritis in children. N Engl J Med 1991;324:1757-1760.
CDC. Viral gastroenteritis. 1990;39:6.
Molbak К, Hojlyng N, Gottschau A, Correia SJC, Ing-holt L, da Silva APJ, Aaby P. Cryptosporidiosis in infancy and childhood mortality in Guinea Bissau, West Africa. Br Med J 1993;307:417-420.
Hojlyng N, Jensen BN. Respiratory cryptosporidiosis in HIV-positive patients. Lancet 1988;1:590-591.
Connolly GM, Gazzard BG. Toxic megacolon in cryptosporidiosis. Postgrad Med J 1987;63:1103— 1104.
Current VL, Carcia LS. Cryptosporidiosis. Clin Microbiol Rev 1991;4:325-358.
Wofsy C. Cryptosporidiosis and isosporiasis. AIDS Clin Care 1991;3(4):25—27.
Peterson C. Cryptosporidium and the food supply. Lancet 1995;345:1128-1129.
CDC. Assessing the public health threat associated with waterborne cryptosporidiosis: report of a workshop. MMWR 1995;44(RR-6):I—19.
Weiss LM . .. And now microsporidiosis. Ann Intern Med 1995;123:954-956.
Halstead BW. Current status of marine biotoxicology — an overview. Clin Toxicol 1981;18:1-24.
Mills AR, Passamo R. Pelagic paralysis. Lancet 1988;1:161-163.
Mills AR, Passmore R. Pelagic paralysis. Lancet 1988;1:161-162.
Lombet A, Didard JN, Ladzunski M. Ciguatoxin and brevetoxins share a common receptor site on the neuronal voltage-dependent NA+ channel. FEBS Lett 1987;219:355-359.
Listemick R. Fish-roe poisoning childhood. J Pediatr 1987;111:729-731.
Gellert GA, Ralls J, Brown C, Huston J, Merryman R. Scombroid fish poisoning underreporting and prevention among non-commercial recreational fishers. West J Med 1992;157:645-647.
Но АМН, Fraser IM, Todd EDC. Ciguatera poisoning: a report of three cases. Ann Emerg Med 1986; 15:1225— 1228.
Bagnis R, Chanteau S, Chungue E et al. Origins of ciguatera fish poisoning: a new dinoflagellate, Gambierdiscus toxicus Adachi and Fukuyo, definitely involved as the causal agent. Toxicon 1980; 18:199—208.
Lewis RJ, Sellin M, Poli MA, Norton RS, Macleod JK, Sheil MM. Purification and characterization of ciguatoxins from Moray eel (Lycodontus Javanicus, Muraenidae). Toxicon 1991;29:1115-1127.
Juranovic LR, Park IL. Foodborne toxins of marine origin. Ciguatera. Rev Environ Contain Toxicol 1991;117:51-52.
Chanfour B, Longjon B, Lionet Ph, Jaeger A. Cardiovascular disturbances in 27 cases of ciguatera fish poisoning. Proc Eur Assoc Pois Cont Center, 1988, p. 29.
Setliff J, Rayner MD, Hong SK. Effect of ciguatoxin on sodium transport across the frog skin. Toxicol Appl Pharmacol 1971;18:676-684.
Swift AEB, Swift TR. Ciguatera. Clin Toxicol 1993;31:1-29.
Cameron J, Caupra MF. The basis of the paradoxical disturbance of temperature perception in ciguatera poisoning. Clin Toxicol 1993;31:571-579.
Adams MJ. An outbreak of ciguatera poisoning in a group of scuba divers. J Wilderness Med 1993;4:304— 311.
Swift AEB, Swift TR. Ciguatera. Clin Toxicol 1993;31 (1): 1 —29.
Di Nuble MJ, Kohami Y. Ciguatera poisoning syndrome from farm-raised salmon. Ann Intern Med 1995;122:113-114.
Palafox NA, Jain LG, Pinano AZ, Gulick TM, Williams RK, Schatz IJ. Successful treatment of ciguatera fish poisoning with intravenous mannitol. JAMA 1988;259: 2740-2742.
Pearn JH, Lewis RJ, Ruff T, Tait M, Quinn J, Murtha W et al. Ciguatera and mannitol: experience with a new treatment regimen. Med J Aust 1989;151:77-80.
Williamson J. Ciguatera and mannitol: a successful treatment. Med J Aust 1990;153:306-307.
Williams RK, Palafox NA. Treatment of pediatric ciguatera fish poisoning. Am J Dis Child 1990;144:747-848.
Eastaugh J, Shepherd S. Infectious and toxic syndromes from fish and shellfish consumption. A Review. Arch Intern Med 1989;149:1735-1740.
Lange WR, Kreider SD, Hattwick M, Hobbs J. Potential benefit of tocainide in the treatment of ciguatoxin: report of three cases. Am J Med 1988;84:1087-1988.
Lange WR, Snyder RF, Fudala PJ. Travel and ciguatera fish poisoning. Arch Intern Med 1992;152:2049-2053.
Lange WR, Kneider SD, Hattwich M, Hobbs J. Potential benefit of tocainide in the treatment of ciguatera: report of three cases. Am J Med 1988;84:1087-1088.
Etkind P, Wilson ME, Gallagher K, Cournoyer J. The working group on foodborne illness control. JAMA 1987;258:3409-3410.
Withers NW. Personal communication. Marine Medicine Symposium, University of California at San Diego, July 10-14, 1989.
CDC. Scombroid: fish poisoning — Illinois, South Carolina. MMWR 1989;39:140-147.
Kow-Tong C, Malison MD. Outbreak of scombroid fish poisoning, Taiwan. Am J Public Health 1987;77:1335— 1336.
U. S. Food and Drug Administration. Defect action levels for histamine in tuna: availability of guide. Fed Reg 1982;47:40 487
Morrow JD, MargoliesGR, Rowland J, Roberts U. Evidence that histamine is the causative toxin of scombroid fish poisoning. N Engl J Med 1991;324:716-720.
Auerbach PS. Persistent headache associated with scombroid poisoning: resolution with oral cimetidine. J. Wilderness Med 1990;1:279-283.
Smart DR. Scombroid poisoning. A report of seven cases involving the Western Australian salmon, Arripis trutta-ceus. Med J Aust 1992;157:748-751.
Wingert W. Poisoning by marine animals. Personal communication.
Eastaugh J, Shepherd S. Infectious and toxic syndromes from fish and shellfish consumption. A review. Arch Intern Med 1989;149:1735-1740.
Taylor SL. Histamine food poisoning: toxicology and clinical aspects. CRC Crit Rev Toxicol 1987; 17(2):91 —128.
Llewellyn LE, Endean R. Paralytic shellfish toxins in the xanthid crab (Atergatis floridus) collected from Australian coral reefs. J Wilderness Med 1991;2:118-126.
Paralytic shellfish poisoning. LA County Public Health Lett 1983;5:26.
Ogata T, Sato S, Kodama M. Paralytic shellfish toxins in bivalves which are not associated with dinoflagellates. Toxicon 1989;27:1241-1244.
Wingert W. Paralytic shellfish poisoning. Personal communication on poisoning of marine animals.
Watters D, Lavin M. Toxins ’89 Symposium. Toxicon 1990;28:245-260.
Stabell OR, Hormazabal V, Steffenak I, Pedersen K. Di-arrhetic shellfish toxins: improvement of sample cleanup for HPLC determinations. Toxicon 1991;29:21-29.
Fenicol W. Personal communication. Proc Marin Medi-cone Symposium. University of California San Diego, July 10-14, 1989, pp. 331-333.
Dickey RW, Rynell GA, Granade HR, Roelke D. Detection of the marine toxins okadaic acid and domoic acid in shellfish and phytoplankton in the Gulf of Mexico. Toxicon 1992;30:355-359.
Thibault P, Pleasance S, Laycock MV. Analysis of paralytic shellfish poisons by capillary electrophoresis. J Chromatogr 1991;542:483-501.
Cheng H-S, Chua SO, Hung J-S, Yip K-K. Creatine kinase MB elevation in paralytic shellfish poisoning. Chest 1991;99:1032-1033.
Price DW, Kizer KW. California’s paralytic shellfish poisoning prevention program 1927—1989. California Department of Health Services, 1990, pp. 1—36.
Oda K, Araki K, Totoki T, Shibasaki H. Nerve conduction study of human tetrodotoxication. Neurology 1989;39:743-745.
Deng J-F, Tominack RL, Chung H-M, Tsai W-J. Hypertension as an unusual feature in an outbreak of tetro-dotoxin poisoning. Clin Toxicol 1991;29:71-79.
Habermetil GG, Krebs HC, Rasormaivo P, Ramishali-hariso A. Severe ciguatera poisoning in Madagascar. A case report. Toxicon 1994; 1539—1541.
Bower DJ, Hart RJ, Matthew PA et al. Nonprotein neurotoxins. Clin Toxicol 1981;18:813-863.
Rivier L, Benedek C. Evidence for the presence of tet-rodotoxin in a powder used in Haiti for zombification. Toxicon 1989;27:473-480.
Kao CY, Yasumoto T. Tetrodotoxin in "Zombie Powder". Toxicon 1990;28:129-132.
Kao CY. Pharmacology of tetrodotoxin and saxitoxin. Fed Proc 1972;31:1117-1123.
Chew SK, Chew LS, Wang KW et al. Anticholinesterase drugs in the treatment of tetrodotoxin poisoning. Lancet 1984;2:108.
Giron JA, Jones T, Millan-Velasco F, Catro-Munoz E, Zarate L, Fry J et al. Diffuse adhereing Escherichia coli (DAEC) as a putative cause of diarrhea in Mayan children in Mexico. J infect Dis 1991;163:507-513.
Borcyzk AA, Karmali MA, Lior H, et al. Bovine reservoir for verotoxin-producing Escherichia coli 0157:H7. Lancet 1987;1:98.
McCarty M. US seeks to rid beef of E. Coli. Lancet 1993;341:687.
Swerdlow DL, Woodruff BA, Brady RC, Griffen PM, Tiffen S, Donnell HD et al: A waterborne outbreak in Missouri of Escherichia coli 0157-H7 associated with bloody diarrhea and death. Ann Intern Med 1992;117:812-819.
CDC. Community outbreak of hemolytic uremia syndrome attributable to Escherichia coli:0\ 11 :NM — South Australia, 1995. MMWR 1995;44:550-558.
Woodruff BA, Griffin PM, McCroskey, Smart JF, Wainwright RB, Bryant RG et al: Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975—1988. J Infect Dis 1992;166:1281-1286.
Davis LE, Johnson JK, Bichnell JM, Levy H, McEvoy KM. Human type A botulism and treatment with 3,4-diamino pyridine. Neurology 1991 ;41(Suppl 1):142.
Frankovich TL, Amon SS. Clinical trial of botulism immune globulin for infant botulism. West J Med 1991;154:103.
Schwartz PJ, Amon SS. Botulism immune globulin for infant botulism arrives — one year and a Gulf War later. West J Med 1991;156:197-198.
Mechen CC, Walter FG. Wound botulism. Vet Hum Toxicol 1994;36:233-237.
Weber JT, Goodpasture HC, Alexander H, Werner SB, Hatheway CL, Tauxe RV. Wound botulism in a patient with a tooth abscess: case report and review. Clin Infect Dis 1993;16:635-639.
Burmingham MD, Water FG, Mecham C. Wound botulism. Ann Emerg Med 1994;24:1184.
Glanzman RL, Gelb DJ, Drury I, Bromberg MB, Truong DD. Bracheal plexopathy after botulinum toxin injections. Neurology 1990;41:1143.
Botulinum toxin for ocular muscle disorders. Med Lett Drugs Ther 1990;32(830): 100-101.
Janovic J, Brin MF. N Engl J Med 1991;324:1186— 1194.
Andrew PI, KainerG, Yong LCJ, Tobias VH, Rosenberg AR. Glomerulonephritis, pulmonary hemorrhage and anemia associated with Campylobacter jejuni infection. Austral NZ J Med 1989;19:721-723.
de Bois MHW, Schoemaker MC, van der Werf SDJ, Puylaert JBCM. Pancreatitis associated with Campylobacter jejuni infection: diagnosis by ultrasonography. Br Med J 1989;298:1004.
Berche P, Reich KA, Bonnichon M, Beretti J-L, Geoffrey C, Raveneau J et al. Detection of anti-listeriolysin 0 for serodiagnosis of human listeriosis. Lancet 1990;335:624-627.
Pigrau C, Almiran B, Pahissa A, Gasser I, Vazquez JMM. Clinical presentation and outcome in cases of listeriosis. Clin Infect Dis 1993;17:143-146.
Blatt SP, Zajac RA. Treatment of listeria bacteremia with vancomycin. Rev Infect Dis 1991;13:181-182.
Guerrant RL, Bobak DA. Bacterial and protozoal gastroenteritis. N Engl J Med 1991;325:327-340.
Smith PD, Lane HC, Gill VJ, Manischewitz JF, Quin-nan GV, Fauci AS, Masur H. Intestinal infections in patients with acquired immunodeficiency syndrome (AIDS). Etiology and response to therapy. Ann Intern Med 1988;108:328-333.
Laughon BE, Druckman DA, Vernon A, Quinn TC, Polk BF, Modlin JF et al: Prevalence of enteric pathogens in homosexual men with and without acquired immunodeficiency syndrome. Gastroenterology 1988;94: 984-993.
Perlman DM, Ampell NM, Schifman RB, Cohn DL, Patton CM, Aquirre ML et al. Persistent Campylobacter jejuni infections in patients infected with human immunodeficiency virus (HIV). Ann Intern Med 1988;109: 540-546.
Farley D. Food safety crucial for people with lowered immunity. FDA Consumer 1990;24:7-9.
Johanson JF, Sonnenberg A. Efficient management of diarrhea in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112:942-948.
Greenson JK, Belitsos PC, Yardley JH, Bartlett JG: AIDS enteropathy: occult enteric infections and duodenal mucosal alterations in chronic diarrhea. Ann Intern Med 1991;114:366-372.
Archer DL. Food counseling should be given to all persons infected with the human deficiency virus. J Infect Dis 1990;161:358-359.
Borowitz SM, Saulsbury FT. Treatment of chronic cryptosporidial infection with orally administered human serum immune globulin. J Pediatr 1991 ;119:593—595.
Cook DJ, Kelton JG, Stanisz A, Collins SM. Somatostatin treatment for cryptosporidial diarrhea in a patient with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988;108:708-709.
Fafard J, Lalonde R. Long-standing cryptosporidiosis in a normal man: clinical response to spiramycin. J Clin Gastroenterol 1990;12:190-191.
Ungar BLP, Ward DJ, Fayer R, Quinn CA. Cessation of cryptosporidium-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum. Gastroenterology 1990;98:486-488.
Hale D, Aldeen W, Carroll K. Diarrhea associated with cyanobacteria-like bodies in an immunocompetent host. An unusual epidemiological source. JAMA 1994;271:144-145.
Shera AG. Specific granular lesions associated with intestinal Spirochaetosis. Br J Surg 1962;50:68-77.
Harland WA, Lee FD. Intestinal Spirochaetosis. Br Med J 1967;3:718-719.
Kaplan LR, Takeuchi A. Purulent rectal discharge associated with a non-turponemal discharge. JAMA 1979;241:52-53.
Malnick H, Thomas M, Lotay H, Robbins M. Anaerobiospirillum species isolated from humans with diarrhea. J Clin Pathol 1983;36:1097-1101.
Malnick H, Jones A, Vickers JC. Anaerobiospirillum: cause of a "new" Zoonosis? Lancet 1989;1:1145-1146.
Shlaes DM, Dul MJ, Lerner PL Anaerobiospirillum bacteremia. Am Intern Med 1982;97:63-64.
Abuelo JF. Renal failure caused by chemicals, foods, plants, animal venoms, and misuse of drugs. An overview. Arch Intern Med 1990;150:505-510.
CDC. Bacterial enteritis. MMWR 1990;39:3.
Eherer AJ, Fordtran JS. Fecal osmotic gap and pH In experimental diarrhea of various causes. Gastroenterology 1992;103:545-551.
CDC. The management of acute diarrhea in children: oral rehydration, maintenance and nutritional therapy. MMWR 1992;41:1-20.
DuPont HL. Bismuth subsalicylate in the treatment and prevention of diarrheal disease. Drug Intell Clin Pharm 1987;221:687-693.
Horwitz ES, Barrett MJ, Bregman D et al: Public Health Service Study of Reye’s syndrome and medications: report of the main study. JAMA 1987;257:1905-1911.
Barrett MJ. Association of Reye’s syndrome with use of Pepto-Bismol (bismuth subsalicylate). Pediatr Infect Dis 1986;5:611.
Abramson JS, Givner LB, Woods CR Jr. Bismuth in infants with watery diarrhea. N Engl J Med 193;329:1762.
Pickering LK, Feldman S, Ericsson CD et al: Absorption of salicylate and bismuth from a bismuth subsalicylatecontaining compound (Pepto-Bismol). J Pediatr 1981;99:654-656.
Levine RA. Risk of hypercalcemia from prophylaxis of traveler’s diarrhea. JAMA 1983;249:1151 — 1152.
Mendelowitz PC, Hoffman RS, Wacher S. Bismuth absorption and myoclonic encephalopathy during bismuth subsalicylate therapy. Ann Intern Med 1990;l 12:140— 141.
Du Pont HL, Ericsson CD, Johnson PC, Javier de la Ca-boda F. Use of bismuth subsalicylate for the prevention of traveler’s diarrhea. Rev Infect Dis 1990; 12(Suppl 1):564—567.
Hasking GJ, Duggan JM. Encephalopathy from bismuth salicylate. Med J Aust 1982;2:167.
Farley D. Food safety crucial for people with lowered immunity. FDA Consumer July—August 1990;24:7-9.
DuPont HL. Traveller’s diarrhoea. Which antimicrobial? Drugs 1993;4:917.
DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993;328:1821-1827.
Farthing MJG. Traveller’s diarrhoea. Mostly due to bacteria and difficult to prevent. Br Med J 1993;303:1425— 1426.
Bacillus cereus food poisoning associated with fried rice at two child day care centers — Virginia 1993. MMWR 1994;43:177-178.
Ericsson CD, DuPont HL. Traveler's diarrhea: approaches to prevention and treatment. Clin Infect Dis 1993;16:616-626.
Fey H. Staphylococcal enterotoxins. In Kohler RB, ed. Antigen to diagnose bacterial infection, Vol 2, Boca Raton, FL: CRC Press, 1986.
Ehringhaus C Dominick H-C, Schuller M. Protein-losing enteropathy associated with Clostridium perfringens infection. Lancet 1989;2:268-269.
Abdominal pain, total intravascular hemolysis and death in a 53-year-old woman. Clinicopathologic conference. Am J Med 1990;88:667-674.
Lindsay VA, Mach AS, Wiulkinson MA, Martin LM, Wallace FM, Keller A. Clostridum perfringens type A cy-totoxin-enterotoxin(s) as triggers for death in the sudden infant death syndrome. Development of a toxico-infec-tion hypothesis. Curr Microbiol 1993;27:51-59.
Bennish ML, Harris JR, Wojtyniak BJ, Struelens M. Death in Shigellosis: incidence and risk factors in hospitalized patients. J Infect Dis 1990;161:500-506.
Babu K, Sonnenberg M, Kathpalia S, Ortego P, Swiatlo AL, Коска FE. Isolation of Salmonellae from dried rattlesnake preparations. J Clin Microbiol 1990;28;361 —-362.
Cone LA, Boughton WH, Leliu LH. Rattlesnake capsule-induced Salmonella arizonae bacteremia. West J Med 1990;153:315-316.
Noskin GA, Clarke JT. Salmonella arizonae bacteremia as the presenting manifestation of human immunodeficiency virus infection following rattlesnake meat ingestion. Rev Infect Dis 1990;12:514-517.
CDC. Outbreak of Salmonella enteritidis infection associated with consumption of raw shell eggs. MMWR 1992;41:369-372.
Blumenthal D. From the chicken to the egg. FDA Consumer 1990;24(3):7—8.
Advisory Committee on the Microbiological Safety of Food. Report on Salmonella in Eggs. London: HM Stationery Office, 1993.
Rampling A. Salmonella enteritis five years on. Lancet 1993;324:317-318.
Desenclos J-C, Bouvet P, Benz-Lemoine E, Grimont F et al. Large outbreak of Salmonella enterica serotype paratyphin В infection caused by a goat’s milk cheese, France, 1993: a case finding and epidemiologic study Br Med J 1996;12:91-94.
CDC. Outbreak of Salmonella enteritidis associated with nationally distributed ice cream products — Minnesota, South Dakota and Wisconsin, 1994. MMWR 1994;43:740-741.
Lee LA, Taylor J, Carter GP, Quinn B, Farmer JJ HI, Tauxe RV, and the Yersinia enterocolitica Colloborative Study Group. Yersinia enterocolitica 0:3: an emerging cause of pediatric gastroenteritis in the United States, J Infect Dis 1991;163:660-663.
Tacket CO, Narain JP, Sattin R, et al. A multistate outbreak of infection caused by Yersinia enterocolitica transmitted by pasteurized milk. JAMA 1984;251:483— 486.
Cover TL, Aber RC. Yersinia enterocolitica. N Engl J Med 1989;321:16-24.
CDC. Yersinia enterocolitica bacteremia and endotoxic shock associated with red blood cell transfusions — United States, 1991. MMWR 1991 ;40; 176—178.
Munro R, Lye A. Yersinia enterocolitica bacteraemia after blood transfusion. Med J Aust 1990; 152:280.
Case 41-1989. Case records of Massachusetts General Hospital. 1989;321:1029-1038.
Ali MB, Raff MJ. Primary Vibrio vulnificus sepsis in Kentucky. South Med J 1990;83:356-357.
Bullen JJ, Spalding PB, Ward CG, Gutteridge JMC. Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch Intern Med 1991;151:1606-1609.
CDC. Multistate outbreak of viral gastroenteritis related to consumption of oysters — Louisiana, Maryland, Mississippi and North Carolina, 1993. MMWR 1993;42:945-948.
Concern continues about Vibrio vulnificus. FDA Drug Bulletin 1988; 18( 1 ):3.
Johnston JM, Becker SF, McFarland FM. Vibrio vulnificus: man and the sea. JAMA 1985;253:2850-2853.
Tacket CO, Brenner F Blake PA. Clinical features and an epidemiologic study of Vibrio vulnificus infection. J Infect Dis 1984;149:558-561.
Morris JG. Antibiotic therapy for Vibrio vulnificus infection. JAMA 1985;253:1121-1122.
CDC. Update: cholera — Western Hemisphere, 1992. MMWR 1993;42:89-91.
Swerdlow DL, Ries AA. Cholera in the Americas. Guidelines for the clinical. JAMA 1992;267:1495—1499.
CDC. Update. Vibrio cholerae 01 — Western hemisphere, 1991 — 1994, and V. cholerae 0139 — Asia, 1994. JAMA 1995;273:1169.
CDC. Imported cholera associated with a newly described toxigenic Vibrio cholerae 0139 strain — California, 1993. MMWR 1993;42:501-503.
Cholera Working Group, International Centre for Diarrhoeal Diseases Research, Bangladesh. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae 0139 synonym Bengal. Lancet 1993;342:387— 390.
Mathewson JJ, Johnson PC, Du Pont HL, Morgan DR, Thornton SA, Wood LV, Ericsson CD. A newly recognized cause of traveler’s diarrhea: enteroadherent Escherichia coli. J Infect Dis 1985;151:471-475.
Eisbruch A, Lewinski U, Djaldett M. Severe opisthotonus and trismus associated with water intoxication. J Roy Soc Med 1984;77:158.
Gold I, Koenigsberg M. Infantile seizures caused by voluntary water intoxication. Am J Emerg Med 1986;4:21 — 23.
Medani CR. Seizures and hypothermia due to dietary water intoxication in infants. South Med J 1987;8:421 — 425.
Vercammen M, Ramet Sacre L. Water intoxication in infants: report of twin brother case and review of the literature. Vet Human Toxicol 1987;29(Suppl 2):28—30.
Finberg L. Water intoxication. A prevalent problem in the inner city. Am J Dis Child 1991;145:981-982.
Cosgray R, Davidhizar R, Giger JM, Kreisl R. A program for water-intoxication patients at a state hospital. Clin Nurse Spec 1993;7:55-61.
Harris CP, Towsend JJ, Baringer JR. Symptomatic hyponatraemia: can myelinolysis be prevented by treatment? J Neur Neurosurg Psych 1993;56:626-632.
Thompson PD, Gldehill RF, Quinn NP et al. Neurological complication associated with parenteral treatment: central pontine myelinolysis and Wernicke’s encephalopathy. Br Med J 1986;292:684-685.
Gill G. Treatment of hyponatraemic seizures with intravenous 29.2 % saline. Br Med J 1986;292:625.
Naims RG. Therapy of hyponatremia. Does haste make waste? N Engl J Med 1986;314:1573-1575.
Ohya Y, Ochi N, Mizutani N, Hayakawa C, Watanabe K. Non-ketotic hyperglycinemia: treatment with NMDA antagonist and consideration of neuropathogenesis. Pediatr Neurol 1991;7:65-68.
Laurence RL, Karp Bl. Pontine and expontine myelinolysis following rapid correction of hyponatremia. Lancet 1988;1:1439-1441.
Soupart A. Optimal management of severe hyponatremia: a therapeutic dilemma. Acta Clin Beig 1991 ;46:277— 282.
Sarnaik AP, Meert K, Hachbarth R, Fleishman L. Management of hyponatremia seizures in children with hypertonic saline. A safe and effective strategy. Crit Care Med 1991;19:758-762.
Brunner JE, Redmonds JM, Haggar AM, Kruger DF, Elias SB. Central pontine myelinolysis and pontine lesions after rapid correction of hyponatremia. A prospective magnetic resonance imaging study. Ann Neurol 1990;27:61-66.
Arieff Al, Tien R, Kucharczyk J. Central pontine myelinolysis is not a complication of hyponatremia or its therapy. Kidney Int 1990;37:212.
Haibach H, Ansbacher LE, Dix JD. Central pontine myelinolysis a complication of hyponatremia or therapeutic intervention? J Forensic Sci 1987;32:444-451.
Arieff AL, Ayus JC, Fraser CL. Hyponatraemia and death or permanent brain damage in healthy children. Br Med J 1992;304:1218-1222.
Keating JP, Schears GJ, Dodge PR. Oral water intoxication in infants. American epidemic. Am J Dis Child 1991;145:985-990.
Swales JD. Management of hyponatremia. Br J Anaesth 1991;67:146-153.
Alkan ML, Gegztes T, Koter S, Ben-Ari J. Near drowning in the Dead Sea. Isr J Med Sci 1977;13:290-294.
Porath A, Mosseri M, Harman I, Orsyshcher 1, Keynan A. Dead Sea water poisoning. Ann Emerg Med 1989;18:187-191.
Cohen DS, Matthay A, Cogan NG, Murray JF. Pulmonary edema associated with salt water near-drowning: new insights. Am Rev Respir Dis 1992; 146:794— 796.
Yagi Y, Stalnikowciz R, Michaeli J, Mogle P. Near drowning in the Dead Sea. Electrolyte imbalances and therapeutic implications. Arch Intern Med 1985;145:50-53.
Neale TJ, Dewar JM, Parr R, Kimber J, Hatfield PJ, Dixon P. Acute renal failure following near drowning in salt water. N Z Med J 1984;97:319-322.
Russell HH, Jackson RJ, Spath DP, Book SA. Chemical contamination of California drinking water. West J Med 1987;147:615-622.
California Safe Drinking Water Act of 1986. Cal Health and Safety Code, Div 5, Chap 7, p. 4010.
Allen HE, Halley-Henderson MA, Hass CN. Chemical composition of bottled mineral water. Arch Environ Health 1989;44:102-116.
Medical Staff Conference. The clinical significance of water pollution. West J Med 1988;148:192-196.
Farrar HC, Chande VT, Fitzpatrick DF, Sheina SJ. Hyponatremia as the cause of seizures in infants: a retrospective analysis of incidence, severity and clinical predictors. Ann Emerg Med 1995;26:42-48.
Barabal HS. Water intoxication in a mental case. Psy-chiatr Q 1938;12:767-771.
Raskind M. Psychosis, polydipsia and water intoxication. Report of a fatal case. Arch Gen Psychiatry 1974;30:112-114.
Ferrier IM. Water intoxication in patients with psychiatric illness. Br Med J 1985;291:1594-1595.
Emsley RA, Taljaard JJF. Self-induced water intoxication. A case report. S Afr Med J 1988;74:80-81.
Vieweg WVK, David JJ, Rowe WT, Wampler GJ, Burns WJ, Spradlin WW. Death from self-induced water intoxication among patients with schizophrenic disorders. J Nerv Ment Dis 1985;173:161-165.
Cooney JA. Compulsive water drinking, water intoxication and alcohol abuse. Irish J Psycholog Med 1991;8:22-25.
Singh S, Padi MH, Bullard H, Freeman N. Water intoxication in psychiatric patients. Br J Psychiatry 1985;146:127-131.
Barrter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormones. Am J Med 1967;42:790-800.
Bremner AJ, Regan A. Intoxicated by water. Polydypsia and water intoxication in a mental handicap hospital. Br J Psychiatry 1991;158:244-250.
Nishikawa T, Tsuda A, Tanaka M, Nishikawa M, Koga 1, Uchida Y. Naloxone attenuates drinking behavior in psychiatric patients displaying self-induced water intoxication. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:149-153.
Arieff A. Managing hyponatremia. Br Med J 1993;307:305-308.
Arieff Al, Ayus JC. Treatment of symptomatic hyponatremia: neither haste nor water. Crit Care Med 1991;19:748-751.
Harris CP, Townsend JJ, Baringer JR. Symptomatic hyponatraemia: can myelinolysis be prevented by treatment? J Neur Neurosurg Psych 1993;56:626-632.
Ко MLB, Liberman ММ, Salzmann М. Chronic vitamin D overdosage: a reminder. Arch Dis Child 1991 ;66:1002.
Jean PC, Stems G. The effect of vitamin D on linear growth in infancy. II. The effect of intakes above 1,800 USP units daily. J Pediatr 1938;13:730-740.
Haynes RC Jr. Agents affecting calcification, calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman’s The pharmacological basis of therapeutics. 8th Ed. New York. Pergamon, 1990.
Jacobs CH, Holick MF, Shao Q, Chen TC, Holm I A, Kolodney JM et al. Hypervitaminosis D associated with drinking milk. N Engl J Med 1992;326:1173-1177.
Kurtzweil Р, Young ТА. FDA Consumer 1991 ;25(4):36.
Coronary Drug Project Research Group. Clofibrate and niacin. Coronary heart disease. JAMA 1975;231:360— 381.
Centers for Disease Control. Niacin intoxication from pumpernickel bagels — New York. MMWR 1983;32:305.
Toxic effects of vitamin overdosage. Med Lett Drug Ther 1984;26(667):73—74.
Earthman TP, Odom L, Mullins CA. Lactic acidosis associated with high-dose niacin therapy.
Millay RH, Klein ML, Illingworth DR. Niacin macu-lopathy. Ophthalmology 1988;95:930-936.
Litin SC, Anderson CF. Nicotinic acid-associated myopathy. A report of three cases. Am J Med 1989;86:481 — 483.
Fischer DJ, Knight LL, Vestal RE. Fulminant hepatic failure following low-dose sustained-release niacin therapy in hospital. West J Med 1991;155:410-412.
Rader JI, Colvert RJ, Hathcock JM. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992;92:77-81.
Kim S, Sporer К. Acute niacin ingestion associated with third-degree atrioventricular block. Vet Hum Toxicol 1993;35:347.
Schwartz ML. Severe reversible hyperglycemia as a consequence of niacin therapy. Arch Intern Med 1993;153:2050-2052.
Roenigk НН Jr. Retinoids. Cutis 1987;39:301-308.
Millan SB, Flowers FP, Sherertz EF. Isotretinoin. South Med J 1987;80:494-499.
Goldfarb MT, Ellis SM, Voorhees JJ. Retinoids in dermatology. Mayo Clin Proc 1987;62:1161-1164.
Reynolds JEF, ed. Martindale: The extra pharmacopoeia. 29th ed. London: Pharmaceutical Press, 1989.
Physicians Desk Reference 1992. Accutane. Mountvale, NJ: Medical Economics, 1992.
McEvoy GK, ed. AHFS Drug Information 92. Bethesda, MD: Soc Hosp Pharm 1992;2175-2180.
Strauss JS, Ropini RP, Shalita AR et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984;10:490-496.
David M, Hodak E, Lowe NJ. Adverse effects of retinoids. Med Toxicol 1988;3:273-288.
Teelmann K. Retinoids: toxicology and teratogenicity to date. Pharm Ther 1989;40:29-43.
Bigby M, Stern RS. Adverse reactions to isotretinoin. A report from the Adverse Drug Reaction Reporting System. J Ann Acad Dermatol 1988;18:543-552.
Lebowitz MA, Berson DS. Ocular effects of oral retinoids. J Am Acad Dermatol 1988;19:209-211.
Brown RD, Grattan CEH. Visual toxicity of synthetic retinoids. Br J Ophthalmol 1989;73:286-288.
Fraunfelder FT. Ocular side effects of isotretinoin therapy. JAMA 1983;250:2545.
Roenigk HH Jr. Liver Toxicity of retinoid therapy. Pharm Ther 1989;40:145-155.
Dai WS, La Braico JM, Stem RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992;26:599-606.
Mitchell AA. Oral retinoids. What should the prescriber know about their teratogenic hazards among women of child-bearing potential. Drug Safety 1992; 7: 79— 85.
Rizzo R, Lammer EJ, Parano E, Pavone L, Argyle JC. Limb reduction deficits in humans associated with prenatal isotretinoin exposure. Teratology I991;44:599— 604.
McBride WG. Limb reduction deformities in child exposed to isotretinoin in utero on gestation days 26—40 only. Lancet 1985; 1:1276.
Rosa E. Isotretinoin dose and teratogenicity. Lancet 1987;2:1154.
Ayne S, Julian S, Gambarelli D, Mariotti B, Movrin N. Isotretinoin dose and teratogenicity. Lancet 1988; 1:655.
Kligman AM. Is topical tretinoin teratogenic JAMA 1988;259:291-318.
Camera G, Pergliasco P. Malformation in baby born to mother using tretinoin cream. Lancet 1992;339:687.
Saich G, Rosa F. When a uniquely effective drug is teratogenic: the case of isotretinoin. N Engl J Med 1989;321:756-757.
Rappaport EB, Knapp M. Isotretinoin embryopathy — a continuing problem. J Clin Pharmacol 1989;29:463.
Accutane risks evaluated. Strong precautions needed. FDA Drug Bull 1990;20(2):5—6.
The Teratology Society Public Affairs Committee. Recommendations for isotretinoin use in women of childbearing potential. Teratology 1991;4:1.
CDC: Birth defects caused by isotretinoin — New Jersey. JAMA 1988;239:2362-2365.
Cordero J, Kochbar D, Fantel A. Teratology Society. Recommendations of isotretinoin use in women of childbearing potential. Teratology 1991;44:1-6.
FDA panels urge Accutane labeling changes. FDA Med Bull; 1991 ;21 (2):4.
Continued reports of birth defects with isotretinoin engender labeling packaging changes. FDA Drug Bull 1988;18(3):27—28.
Accutane. Med Economics. Dec 19, 1988. Roche Dermatologies. Pl 1088.
Howard WB, Willhite CC. Toxicity of retinoids in humans and animals. J Toxicol (Toxic Reviews) 1986;5:55-94.
Dear Doctor Letter. Roche Dermatologies, September, 1988.
Willis J: New warning about Accutane and birth defects. FDA Consumer 1988;22(8):25—29.
Stern RS. When a uniquely effective drug is teratogenic. The case of isotretinoin. N Engl J Med 1989;320:1007— 1009.
Blake KD, Wyse RKH. Embryopathy of infant conceived one year after termination of maternal etretinate. A reappraisal. Lancet 1988;2:1254.
Lammer EJ. Embryopathy in infant conceived one year after termination of maternal etretinate. Lancet 1988;2:1080-1081.
Hopf G, Mathias P. Teratogenicity of isotretinoin and etretinate. Lancet 1988;2:1143.
Vahlquist A, Rollman O. Etretinate and the risk for teratogenicity: drug monitoring in a pregnant woman for 9 months after stopping treatment. Br J Dermatol 1990;123:131.
Kistler A, Hummler H. Teratogenesis and reproductive safety evaluation of the retinoid etretin (RO 10-1670). Arch Toxicol 1985;58:50-56.
Pittsley RA, Yoder FW. Retinoid hyperostosis: skeletal toxicity associated with long-term administration of 13-cis-retinoic acid for refractory ichthyosis. N Engl J Med 1983;308:1012-1014.
Ellis CN, Madison КС, Pennes DR et al. Isotretinoin therapy is associated with early skeletal radiographic changes. J Am Acad Dermatol 1984; 10:1024—1029.
White SI, McKie RM. Bone changes associated with oral retinoid therapy. Pharm Ther 1989;40:137-144.
Lindemayr H. Isotretinoin intoxication in attempted suicide. Acta Derm Venereol 1986;66:452-453.
Sutton JD: Overdose of isotretinoin. J Am Acad Dermatol 1983;9:600.
Munter DW, Wilkinson JA. Isotretinoin ingestion in a pediatric patient. J Emerg Med 1988;6:273-275.
Dwyer МА. Rose dermatologies. Personal Correspondence, May 3, 1989.
Hepburn NC. Deliberate self-poisoning with isotretinoin. Br J Dermatol 1990;122:840-841.
Physicians Desk Reference 1992. Tegison. Mountvale, NJ. Medical Economics, 1992.
Tricot G. Effect of isotretinoin on survival of patients with myelodysplastic syndrome. Lancet 1987;1:I271.
Lippman SM, Meyskens Jr. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 1987;107:499-501.
Kraemer KH, Di Giovanna JJ, Moshell AM, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318:1633-1637.
Hang WV, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990;323:795-901.
Warren EW, Khanderia U. Use of retinoids in the treatment of psoriasis. Clin Pharm 1989;8:344-351.
Tretinoin for photodamaged skin. Med Lett Drugs Ther 1992;34(Issue 866):28-29.
Rafal ES, Griffiths SEM, Ditre CM, Finkel U, Hamilton TA, Ellis CM, Voorhees J J. Topical tretinoin (retinoic acid) treatment for liver spots associated with photodamage. N Engl J Med 1992;326:368-374.
Vane FM, Rugge CJL. Identification of 4-oxo-12-cis-retinoic acid as a major metabolite of 13-cis-retinoic acid in human blood. Drug Metab Dispos 1981 ;9:515— 550.
Vane FM, Stoltenborg JK, Bugge CJL. Determination of 13-cis-retinoic acid, its major metabolite 4-oxo-13-cis-retinoic acid in human blood by reversed-phase high-performance liquid chromatography. J Chromat 1982;227:471-487.
Allen JG, Bloxham DP. The pharmacology and pharmacokinetics of the retinoids. Pharm Ther 1989;40:1-27.
Kawashima H, Ohno I, Veno Y, Nakaya S, Kato E, Tan-iguchi N. Syndrome of microtia and aortic arch anomalies resembling isotretinoin embryopathy. J Pediatr 1987;111:738-740.
Grote W, Harms D, Janig V, Kietzmann H, Ravens V, Schwarz 1. Malformations of fetus conceived 4 months after termination of etretinate treatment. Lancet 1985;2:1276.
Henderson CA, Highet AS. Depression induced by etretinate. Br Med J 1989;298:964.
Dwyer JM, Kenicer K, Thompson ВТ, Chen D, LaBra-ico J et al. Vasculitis and retinoids. Lancet 1989; 1:494— 496.
Herse E, Schnuch A. Taste and olfactory disturbance after treatment for acne with isotretinoin, a 13-cis-isomer of retinoic acid. Eur Arch Otolaryngol 1990;247:382— 383.
Van Ditzhuijsen TJM, Van Haelst JJGM, Van Dooren-Greebe RJ, Van de Kerkhof DCM, Yag SH. Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin). J Hepatol 1990;11:185-188.
Naldi L, Rozzoni M, Finazzi G, Pini P, Marchesi L et al. Etretinate therapy and thrombocytopenia. Br J Dermatol 1991; 124:295.
Flynn WJ, Freeman PG, Wickboldt LG. Pancreatitis associated with isotretinoin-induced hypertriglyceridemia. Ann Intern Med 1987;63:65.
Weber V, Melnik B, Goerz G, Michaelis L. Abnormal retinal function associated with long-term etretinate. Lancet 1988;1:235-236.
Rudman D, William PJ. Megadose vitamins. Use and misuse. N Engl J Med 1983;309:488-489.
Toxic effects of vitamin overdosages. Med Lett Drugs Ther 1984;26(issue 667):73—74.
Wason S. Vitamin A. Clin Toxicol Rev 1982; 5 (3): 1 — 2.
Wason S, Lovejoy FH. Vitamin A toxicity. Am J Dis Child 1982; 136:174.
Fairman II. Acute hypervitaminosis A in an adult. Am J Clin Nutr 1973;26:575-577.
La Mantia RS, Andrews CE. Acute vitamin A intoxication. South Med J 1981;74:1012-1114.
Hathcock JN, Hattan DG, Jenkins MY, McDonald JT, Sundaresen PR, Wilkening VL. Evaluation of vitamin A toxicity. Am J Clin Nutr 1990;52:183-202.
Hathcock JN, Hattan DG, Jenkins MY, McDonald JT, Sundaresea PR, Wilkening VL. Evaluation of vitamin A toxicity. Am J Clin Nutr 1990;52:183-202.
Kizer KW, Fan AM, Bankowska J, Jackson RJ, Lyman DO. Vitamin A — a pregnancy hazard alert. West J Med 1990;152:78-81.
Teratology Society position paper. Recommendations for Vitamin A use during pregnancy. Teratology 1987;35:269-277.
Martinez-Frias, ML, Salvador J. Megadose vitamin A and teratogenicity. Lancet 1988;1:236.
Fossler MJ. The acute toxicity of vitamin A. Toxalert. Maryland Poison Center 1991 ;8:(3): 1.
Barone JA, Peppers MR Use of dantrolene in the management of amphetamine-induced hyperthermia. Clin Pharm 1989;8:324-325.
Broide DH. Eosinophilia-myalgia syndrome. West J Med 1991;154:459.
Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians 1975;88:70-86.
Varga J, Uitto J, Jimenez SA. The cause and pathogenesis of the eosinophilia-myalgia syndrome. Ann Intern Med 1992;116:140-147.
Jaffe I, Kopelman R, Baird R, Grossman M, Hays A. Eosinophilic fasciitis associated with the eosinophiliamyalgia syndrome. Am J Med 1990;88:542-546.
Kaufman LD, Gruber BL, Gregersen PK. Clinical fol-iow-up and immunogenetic studies of 32 patients with eosinophilia-myalgia syndrome. Lancet 1991 ;337:1071— 1074.
Hertzman PA, Clauw DJ, Kaufman LD, Varga J, Silver RM, Thacker HL et al. The eosinophilia-myalgia syndrome: status of 205 patients and results of treatment 2 years after onset. Ann Intern Med 1995;122:851-855.
Naeyaert JM, Cuelenaere C, De Bersaques J, Platevoet D, Kint A. A Belgian case of the eosinophilia-myalgia syndrome. Br J Dermatol 1991;124:303-305.
Martin R et al. Eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clin Res 1990;38:318.
Silver RM, Heyes MP, Maize JC, Quearry B, Vionnet-Fuasset M, Sternberg EM. Scleroderma, fasciitis and eosinophilia associated with the ingestion of tryptophan. N Engl J Med 1990;322:874-881.
Troy JL. Eosinophilia-myalgia syndrome. Mayo Clin Proc 1991;66:535-538.
Saag KG, Goldschmidt R, Vernof H, Golbus J. An eosinophilia-myalgia syndrome associated with an L-tryp-tophan-containing product. J Rheumatol 1990; 17: 1551-1553.
Kilbourne EM, Swygert LA, Philen RM, Sun RK, Auerbach SB et al. Interim guidance on the eosinophiliamyalgia syndrome. Ann Intern Med 1990;1 12:85-87.
Montanaro A, Wakefield D. Eosinophilia-myalgia syndrome associated with L-tryptophan use. Med J Austral 1990;153:491-493.
Gibbons RB, Metzger JR. Eosinophilia-myalgia syndrome. Arch Intern Med 1990;150:2175-2177.
Hertzman P, Falk H, Kilbourne EM, Page S, Shulman LE. The eosinophilia myalgia syndrome: the Los Alamos Conference. J Rheumatol 1991;18:867-873.
Update. Analysis of L-tryptophan for the etiology of eosinophilia-myalgia syndrome. MMWR 1990;39(43): 789-790.
Lewkonia RM. Myalgia and eosinophilia associated with ingestion of tryptophan. An intriguing new syndrome. Arch Intern Med 1990;150:2005-2007.
Hedberg K, Urbach D, Slutsker L, Matson P, Fleming D. Eosinophilia-myalgia syndrome. Natural history in a population-based cohort. Arch Intern Med 1992;152: 1889-1892.
Banner AS, Borochovitz D. Acute respiratory failure caused by pulmonary vasculitis after L-tryptophan ingestion. Am Rev Respir Dis 1991;143:661-664.
Strumpf IJ, Drucker RD, Anders KH, Cohen S, Fajolu O. Acute eosinophilic pulmonary disease associated with ingestion of L-tryptophan-containing products. Chest 1991;99:8-13.
Campagna AC, Blanc PD, Criswell LA, Clarke D, Sach A-E, Gold WM, Golden JA. Pulmonary manifestations of the eosinophilia-myalgia syndrome associated with tryptophan ingestion. Chest 1992;101:1274-1278.
Hertzman PA, MaddouxGL, Sternberg EM, Heyes MP, Mefford IN, Kephart GM, Gleich GJ. Repeated coronary artery spasm in a young woman with the eosinophilia-myalgia syndrome. JAMA 1992;267:2932— 2934.
Ivey M, Eichenhorn MS, Glasberg MR, Hyzy RC. Hypercapnic respiratory failure due to L-tryptophan-in-duced eosinophilic polymyositis. Chest 1991;99:756— 757.
Tazelaar HD, Myers JL, Drage CW, King ТЕ Jr, Aguayo S, Colby TV. Pulmonary disease associated with L-tryp-tophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features. Chest 1990;97:1032—1036.
Read CA, Clauw D, Weir C, Da Silva AT, Katz P. Dyspnea and pulmonary function in the L-tryptophan-asso-ciated eosinophilia-myalgia syndrome. Chest 1992; 101: 1282-1286.
Tolander LM, Bamford CR, Yoshino MT, Downing S, Bryan G. Neurologic complications of the tryptophan-associated eosinophilia-myalgia syndrome. Arch Neurol 1991;48:436-438.
Tolander LM, Bamford CR. Central and peripheral nervous system involvement in the L-tryptophan-associ-ated eosinophilia-myalgia syndrome. Intern J Neurosci 1991;61:69-75.
Smith BE, Dyke PJ. Peripheral neuropathy in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Neurology 1990;40:1035-1040.
Dicker RM, James N, Cunha BA. The eosinophilia-myalgia syndrome with neuritis associated with L-tryp-tophan use. Ann Intern Med 1990;112:957-958.
Selwa JF, Feldman EL, Blaivas M. Mononeuropathy multiplex in tryptophan-associated eosinophilia-myalgia syndrome. Neurology 1990;40:1632-1633.
Heiman-Patterson TD, Bird SJ, Parry GJ, Varga J, Shy ME, Culligan NW, Edelsohn Let al. Peripheral neuropathy associated with eosinophilia-myalgia syndrome. Ann Neurol 1990;28:269-270.
Chiba S, Miyagawa K. Tanaka T, Moriya K, Takahashi K, Hirai H, Takaku F. Tryptophan-associated eosinophilia-myalgia syndrome and pancreatitis. Lancet 1990;336:121.
Yakovlevitch M, Siegel M, Hoch DH, Rutlen DL. Pulmonary hypertension in a patient with tryptophan-induced eosinophilia-myalgia syndrome. Am J Med 1991;90:272-273.
Andre M, Canon JL, Levecque P, Dermine P, Mortiar C, Leveau F. Eosinophilia-myalgia syndrome associated with L-tryptophan. A. case report with pulmonary manifestations and review of the literature. Acta Clin Belg 1991;46:278-282.
WHO. Toxic oil syndrome and eosinophilia-myalgia syndrome. Pursuing parallels in pathogenesis. Report on WHO meeting. Washington, DC, May 8—10, 1991.
Varga J, Peltonen J, Uitto J, Jimenez S. Development of diffuse fasciitis with eosinophilia during L-tryptophan treatment: demonstration of elevated type I collagen gene expression in affected tissues. A clinicopathologic study of four patients. Ann Intern Med 1990; 112:344— 351.
Hatch DL, Garona JE, Goldman LR, Waller KO. Persistent eosinophilia in an infant with probable intrauterine exposure to L-tryptophan-containing supplements. Pediatrics 1991;88:810-813.
Winkelman RK, Connolly SM, Quimby SR, Grilling WL, Lie JT. Histopathologic features of the L-tryp-tophan-related eosinophilia-myalgia (fasciitis) syndrome. Mayo Clin Proc 1991;66:457-463.
Belongia EA, Hedberg CW, Gleich GJ, White KE, May-eno AN, Loegering DA, Dunnette SL et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990;323:357-365.
Werner-Felmayer G, Werner ER, Weiss G, Wachter H. Peak E contaminated L-tryptophan and immune activation. Lancet 1991;338:511.
Slutsker L, Hoesly FC, Miller L, Williams LP, Watson C, Fleming DW. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. JAMA 1990;264:213-217.
Yamaoka KA, Miyasaka N, Kashiwazaki S. L-tryptophan contaminant "peak E" and interleukin-5 production from T cells. Lancet 1991;338:168.
Mayeno AN, Lin F, Foote CS et al. Characterization of "Peak E" a novel amino acid associated with eosinophilia-myalgia syndrome. Science 1990; 150:1707— 1708.
Duffy J. Eosinophilia-myalgia syndrome. Mayo Clin Proc 1992;67:1201-1202.
Mayeno AN. Belongia EA, Lin F, Lundy SK, Gleich GJ. 3-(phenylamino) alanine, a novel amiline-derived amino acid associated with the eosinophilia-myalgia syndrome. A link to the toxic oil syndrome? Mayo Clin Proc 1992;67:1134-1139.
Milburn DS, Myers CW. Tryptophan toxicity: a phar-macoepidemiologic review of eosinophilia-myalgia syndrome. DICP Ann Pharmacother 1991;25:1259-1262.
Culpepper RC, Williams RG, Mease PJ, Koepsell TD, Kobayashi JM. Natural history of eosinophilia-myalgia syndrome. Ann Intern Med 1991;115:437-442.
Martinez-Osuna P, Espinoza LR. On the treatment of the eosinophilia-myalgia syndrome. Arch Intern Med 1991;151:1239.
Dietz РЕ. Dangerous information. Product tampering and poisoning advice on revenge and murder manuals. J Forensic Sci 1988;33:1201-1217.
Cheung JF, Chong S, Kitrenos GG, Fung HL. Use of refractometers to detect control substances tampering. Am J Hosp Pharm 1991;48:1488-1492.
Logan B. Product tampering crime: A review. J Forens Sci 1993;38:918-927.
Wolnik KA, Riche FL, Bonnin E, Gastron CM, Satzger RD. The tylenol tampering incident — tracing the source. Anal Chem 1984;56:466A—474A.
Gates TN. McNeil Consumer Products Company Dear Doctor Letter. October 8, 1982.
Tracy PR. Burroughs Wellcome Company Dear Doctor Letter. March, 1990.
Modeland V. Ninety year prison term in tampering deaths. FDA Consumer 1988;22(8):34— 35.
Brahams D. "Sudafed" capsules poisoned with cyanide. Lancet 1991 ;337:968.
CDC. Cyanide poisoning associated with over-the-counter medication — Washington State, 1991. MMWR 1991;40:161-168.
Lifshultz BD, Donoghue ER. The tylenol cyanide poisoning. Am Acad Sci, Las Vegas, NV. February 15, 1989.
Cyanide yogurt case still puzzles officials. New York Times, January 5, 1989.
Tamperer sentenced. FDA Consumer 1991 ;25(7):4.
Tainted milk prompts a recall. New York Times, March 15, 1991.
Grigg B, Modeland V. The cyanide scare. A tale of two grapes. FDA Consumer 1989;23(6):7—11.
Drug tampering suspected in illness of Hawaiian. New York Times, March 11, 1991.
Scientist accused of spiking spray in attempt to kill Texas colleague. New York Times, May 4, 1991.
Cramer T. Look twice. How to protect yourself against drug tampering. FDA Consumer 1991 ;25(8):20—23.
Tips against tampering. Office of Public Affairs. The Proprietary Association, Washington, DC 20 056.
Snyder NA, Feigal NW, Arreff Al. Hypernatremia in elderly patients. A heterogenous morbid and iatrogenic entity. Ann Intern Med 1987;107:309-319.
Elisaf M, Litou H, Siamopoulos KS. Survival after severe iatrogenic hypernatremia. Am J Kidney Dis 1989;14:230-231.
Cassorla FG, Gill JR Jr, Gold PW, Rosen SW. Nosocomial hypernatremia. N Engl J Med 1985;313:229.
Star MA. Southwestern Internal Medicine Conference. Hyperosmolar states. Am J Med Sci 1990;300:402-420.
Mirchandani HG, Mirchandani 1Н, Parith SR. Hypernatremia due to amniotic fluid embolism during a saline-induced abortion. Am J Forensic Med Pathol 1988;9:48-50.
De Villota EJ, Cavamilles JM, Stein L, Shubin H, Weil MH. Hyperosmolar crisis following infusion of hypertonic sodium chloride. Am J Med 1973;55:116-122.
Winter M, Taylor DJ. Danger of saline emetics in first aid for poisoning. Br Med J 1974;3:802.
Mattar JA, Weil MH, Shubin H, Stein L. Cardiac arrest in the critically ill. II. Hyperosmolar states following cardiac arrest. Am J Med 1974;56:162-168.
Johnston GG, Robertson WW. Fatal ingestion of table salt by an adult. West J Med 1977;126:141-143.
Addleman M, Pollard A, Grossman RF. Survival after severe hypernatremia due to salt ingestion by an adult. Am J Med 1985;78:176-178.
Raya A, Giner P, Aranequi P, Guerrero F, Vazquez G. Fatal acute hypernatremia caused by massive intake of salt. Arch Intern Med 1992;152:640-646.
Smith EJ, Palevsky S. Salt poisoning in a 2-year-old child. Am J Emerg Med 1990;8:571-582.
Moder KG. Fatal hypernatremia from exogenous salt intake: report on a case and review of the literature. Mayo Clin Proc 1990;65:1581-1594.
Aerif AP, Carroll HJ. Cerebral edema and depression of sensorium in nonketotic hyperosmolar coma. Diabetes 1974;23:525-531.
Rude RK, Singer FR. Magnesium deficiency and excess. Ann Rev Med 1981;32:245-259.
Humphrey M, Kennon S, Pramanik AK. Hypermagnesemia from antacid administration in a newborn infant. J Pediatr 1981;98:313-314.
Mofenson HC, Caraccio TR. Magnesium intoxication in a neonate from oral magnesium hydroxide laxative. Clin Toxicol 1991;29:215-222.
Jones J, Heiselman D, Dougherty J, Eddy A. Cathartic-induced magnesium toxicity during overdose management. Ann Emerg Med 1986;15:1214-1218.
Smilkstein MJ, Smolinske SC, Kulig KW, Rumack BH. Severe hypermagnesemia due to multiple dose cathartic therapy. West J Med 1988;148:208-211.
Woodard J A, Shannon M, LaCouture PG, Woolf A. Serum magnesium concentrations after repetitive magnesium cathartic administration. Am J Emerg Med 1990;297—300.
Fine KD, Santa Ana CA, Fordtran JS. Diagnosis of magnesium induced diarrhea. N Engl J Med 1991;324:1012-1017.
Hoffman RS, Smilkstein MJ, Rubenstein F. An "amp" by any other name. The hazards of intravenous magnesium dosing. JAMA 1989;261:557.
Ortiz-Interian CJ, Schlessinger FB, Oster JR. Severe hypermagnesemia without reduction in the anion gap. Magnesium Trace Elem 1991;9:110-114.
Gerard SK, Hernandez C, Khayam-Bashi H. Extreme hypermagnesemia caused by an overdose of magnesium-containing cathartics. Ann Emerg Med 1988;17:728-731.
McCubbin JH, Sibai BM, Abdella TN, Anderson GD. Cardiopulmonary arrest due to acute maternal hypermagnesemia. Lancet 1981; 1:1058.
Vigorito C, Giordano A, Ferraro P, Acanfora D, Ce Caprio L, Naddes C et al. Hemodynamic effects of magnesium sulfate on the normal human heart. Am J Cardiol 1991;67:1435-1437.
Kulick DL, Hong R, Ryzen E, Rude RK, Rubin JN, Elkayan U et al. Electrophysiologic effects of intravenous magnesium in patients with normal conduction system and no clinical evidence of significant cardiac disease. Am Heart J 1988;115:367-373.
Tsivoni D, Banai S, Schuger C et al. Treatment of torsades de pointes with magnesium sulfate. Circulation 1988;77:392-397.
Tsivoni D, Keren A, Cohen AM et al. Magnesium therapy for torsade de pointes. Am J Cardiol 1984;53:528— 530.
L’Hommedieu CS, Nicholas N, Armes DA. Potentiation of magnesium sulfate-induced neuromuscular weakness by gentamicin, tobramycin and amikacin. J Pediatr 1983;102:629-631.
Lantner RR, Espiritu BP, Zumerchik P, Tobin MS. Anaphylaxis following ingestion of a psyllium-containing cereal. JAMA 1990;264:2534-2536.
Malo J-L, Carter A, L’Archeveque J, Ghezzo H, Lagier F, Trudeau C, Dolovich J. Prevalence of occupational asthma and immunologic sensitization to psyllium among health personnel in chronic care hospitals. Am Rev Respir Dis 1990;142:1359-1366.
Nelson WL. Allergic events among health care workers exposed to psyllium laxatives in the workplace. J Occup Med 1987;29:497-499.
Fleisher D, Ament ME. Diarrhea, red diapers and child abuse. Clinical alertness needed for recognition: clinical skill needed for success in management. Clin Pediatr 1977;16:820-821.
Mrvos R, Swanson-Bierman B, Dean BS, Krenzelok AP. Acute phenolphthalein ingestion in children. A retrospective review. J Pediatr Health Care 1981;5:147-151.
Sarcinelli L, Signore L, Malizia. Lethal phenolphthalein poisoning in a child. Proc Eur Soc Study Drug Tox 1970, XI, Venice March—April 1979; Amsterdam Exerpta Med 1970.
Kendall AC. Fatal case of encephalitis after phenolphthalein ingestion. Br Med J 1954;2:1461-1462.
Sidhu PS, Wilkenson ML, Sladen GE, Filipe Ml, Tose-land PA. Fatal phenolphthalein poisoning with fulminant hepatic failure and disseminated intravascular coagulation. Hum Toxicol 1989;8:381-384.
Cleeves M. Poisoning by "Ex-Lax" tablets. JAMA 1932;99:657.
Brunton LL. Agents affecting gastrointestinal water flux and mobility digestants and bile acids. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1991.
McEvoy GK, ed. AHFS Drug Information 92. Bethesda. Am Soc Hosp Pharm 1992;1728—1731.
Kar PK, Dutta RK, Shah BH. Toxic epidermal necrolysis in a patient induced by phenolphthalein. J Ind Med Assoc 1986;84:189-190.
Baer RL, Harris H. Types of cutaneous reactions to drugs. JAMA 1967;202—210.
Buchanan N, Cane RD, Glantz R, Hunt JA. Phenolphthalein poisoning. S Afr Med J 1976;50:1060-1061.
Lambrianidis AL, Rosin RD. Postgrad Med J 1984;60:491-492.
Blatt ML, Steigmann F, Dyniewica JM. J Pediatr 1943;22:719-725.
Lillemore KD, Romolo JL, Hamilton SR, Pennington LR, Burdick JF, Williams GM. Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbital enemas — clinical and experimental support for the hypothesis. Surgery 1987;101:267-372.
Wootton FT, Rhodes DF, Lee WM, Fitts CT. Colonic necrosis with Kayexalate-sorbital enemas after renal transplantation. Ann Intern Med 1989;111:947-954.
Shepard KV. Cleansing enemas after sodium polystyrene sulfonate enemas. Ann Intern Med 1990;! 12:711.
Janco N. Seasonal topics. Halloween hazards. Rocky Mountain Poison Center Bulletin 1988;7(3):6—7.
Rocky Mountain Poison Center Bulletin 1990;9(2) and 1988;(7):4.
Long Island Regional Poison Control Center. Holiday Hazard Prevention for Parents, November/December, 1991.
Edmondson S, Almquist TD. Iatrogenic hypocalcemic tetany. Ann Emerg Med 1990;19:938-940.
Hunter MF, Ashton MR, Griffiths DM, Ilangovan P, Roberts JP, Walker V. Hyperphosphatemia after enemas in childhood: prevention and treatment. Arch Dis Childh 1993;68:233-234.
Edmonson S, Almquist TD. Iatrogenic hypocalcemic tetany. Ann Emerg Med 1990;19:938-940.
Martin RR, Lisehora GR, Braxton M Jr, Barcfia RJ. Fatal poisoning from sodium phosphate enema. Case report and experimental study. JAMA 1987;257:2190-2192.
Wason S, Tiller T, Curra G. Severe hyperphosphatemia, hypocalcemia, acidosis and shock in a 5-month-old child following the administration of adult Fleet enema. Ann Emerg Med 1989;8:696-700.
Grosskopf 1, Graff E, Charach G, Binyamin G, Spinrad S, Blum I. Hyperphosphatemia and hypocalcemia induced by hypertonic phosphate enema. An experimental study and review of the literature. Hum Exper Toxicol 1991;10:351-355.
Augenstein WL, Spoerke DG, Hall, AH, Hall PK, El Saadi MS, et al. Fluoride ingestion in children — a review of 87 cases. Vet Hum Toxicol 1987;29:471-472
Abukurah AR, Moser AM Jr, Baerd SL, Randall RE Jr, Selter JG, Blanke RV. Acute sodium fluoride poisoning. JAMA 1972;222:816-817.
Swanson L, Filandrinos DT, Shevlin JM, Willett JR. Death from accidental ingestion of an ammonium and sodium bifluoride glass etching compound. Vet Hum Toxicol 1993;35:351.
Pilling KJ, Jones HW. Inhalation of degraded sulphur hexafluoride resulting in pulmonary edema. J Soc Occup Med 1988;38:82-84.
Kraut A, Lilis R. Pulmonary effects of acute exposure to degradation products of sulphur hexafluoride during electrical cable repair work. BrJ Indust Med 1990;47:829-832.
Danielson C, Lyon JL, Egger M, Goodenough GK. Hip fractures and fluoridation in Utah’s elderly population. JAMA 1992;268:746-748.
Skolnick A. New doubts about benefits of sodium fluoride. JAMA 1990;263:1752-1753.
Riggs BL, Hodgson SF, O’Fallon WM, Chao EYS, WahnerHW, MuhsJM etal. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;232:802-809.
Mamelle N, Dusan R, Martin JL, Prost A, Meuxier DJ, Guillaume M et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988;2:361-365.
Hedlund LR, Gallagher JC. Increased incidence of hip fracture in osteoporotic woman treated with sodium fluoride. J Bone Miner Res 1989;4:223-225.
Cooper C, Wickham C, Lacey RF, Barker DJP. Water fluoride concentration and fracture of the proximal femur. J Epidemiol Commun Health 1990;44:17-19.
Environmental Protection Agency. National primary and secondary drinking water regulation: fluoride. Fed Reg 1986;51:11 396-11 412.
McGuire S. Fluoride content of bottled water. N Engl J Med 1989;321:836-837.
Ohlson G, Sheridan F. Blood fluoride by ion-specific potentiometer. Bull Int Assoc Forensic Toxicol 1991;21(4):36—78.
Saadi JJ, Rose SS. A case of nonfatal sodium fluoride ingestion. J Anal Toxicol 1988;2:270-271.
Harchelroad F, Goetz C. Systemic fluoride intoxication with leucocytosis and pyrexia. Vet Hum Toxicol 1993;35:35l.
Augenstein WL, Spoerke DG, Kulig KW, Hall AH, Hall PK, Rigs BS et al. Fluoride ingestion in children: a review of 87 cases. Pediatrics 1991;88:907-912.
Higgins GL HI, Campbell В, Wallace К, Talbot S. Pediatric poisoning from over-the-counter imidazoline-con-taining products. Ann Emerg Med 1991;20:655-658.
Adler AG, McElwain GE, Merli GJ, Martin JH. Systemic effects of eye drops. Arch Intern Med 1982;142:2293-2294.
Fraunfelder FT, Meyer SM. Systemic reactions to ophthalmic drug preparations. Med Toxicol 1987;2:287— 293.
Merli GJ, Weitz H, Martin JH, McKay EF, Adler AG et al. Cardiac dysrhythmias associated with ophthalmic atropine. Arch Intern Med 1986;146:45-47.
Johns KJ, Head WS, O'Day DM. Corneal toxicity of propamidine. Arch Ophthalmol 1988;106:68-69.
Cydulka RK, Betzelos S. Seizures following the use of proparacaine hydrochloride eye drops. J Emerg Med 1990;8:131-133.
Gerber SL, Cantor LB, Brater DC. Systemic drug interactions with topical glaucoma medications. Survey Ophthalmol 1990;35:205-218.
Fitzgerald DA, Hanson RM, West C, Martin F, Brown J, Kilham HA. Seizures associated with 1 % cyclopentolate eye drops. J Paediatr Child Health 1990;26:106— 107.
Adcock EW 111. Cyclopentolate (Cyclogyl) toxicity in pediatric patients. J Pediatr 1971;79:127-129.
Kennerdell JS, Wucher FR. Cyclopentolate associated with two cases of grand mal seizures. Arch Ophthalmol 1972;87:6374-6375.
Pringle SD, MacEwen CJ. Severe bradycardia due to interaction of timolol eye drops and verapamil. Br Med J 1987;294:155-156.
Prince DS, Carliner NH. Respiratory arrest following first dose of timolol ophthalmic solution. Chest 1983;84:640-641.
Glauline withdrawn. Br Med J 1991 ;302:132.
Tracqui A, Kintz P, Hinber J, Lugnier AAJ, Mangin P. A specific HPLS method for determination of betablockers topically used in ophthalmological diseases. Forensic Sci Int 1988;38:37-41.
Chairelli D. Phospholine iodide ophthalmic drops and skeletal muscle relaxants. Can J Hosp Pharm 1985;38:58.
Turchen SG, Whitney C, Clark PF, Manoguerra AS. Chronic phospholine intoxication mimicking myasthenia gravis. Vet Hum Toxicol 1993;35:347.
Strauss R. Accidental dopamine in the eye. West J Med 1985;142:397-398.
Margo CE, Trobe JD. Tarsorrhaphy from accidental instillation of cyanoacrylate adhesive in the eye. JAMA 1982;24:660-661.
Morgan SJ, Astbury NJ. Inadvertent self-administration of Superglue: a consumer hazard. Br Med J 1984;289:226-227.
De Respiris RA. Cyanoacrylate nail glue mistaken for eye drops. JAMA 1990;263:230L
Cromie BW. Superglue inadvertently used as eye drops. Br Med J 1990;300:680.
Raynor LA. Treatment for inadvertent cyanoacrylate tarsorrhaphy. Arch Ophthalmol 1988;106:1033-1084.
Frenkel REP, Honig YJ, Shin DH. Misuse of eye drops due to interchanged caps. Arch Ophthalmol 1988; 106:17.
Ling RTK, Villalobos R, Latina M. Inadvertent instillation of hemoccult developer in the eyes. Arch Ophthalmol 1988;106:1033-1034.
Hill ЕМ, Flaitz CM, Frost GR. Sweetener content of common pediatric oral liquid medications. Am J Hosp Pharm 1988;41:135-142.
Kumar A, Rawlings RD, Beaman DC. The mystery ingredients: sweeteners, flavorings, dyes, preservatives in analgesic/antipyretic, antihistamine/decongestants, cough and colds, antidiarrhea and liquid theophylline preparations. Pediatrics 1993;91:927-933.
Greeley A. Not only sugar is sweet. FDA Consumer 1992;26(3): 17-21.
Buss NE, Renwick AG, Donaldson K, George CE. Cyclamate (CHS), cyclohexylamine (CHA) and cardiovascular (CV) toxicity in man. An initial population study. Hum Exp Toxicol 1990;9:359-360.
Martz W, Schutz HW. Synthetic sweetener cyclamate as a potential source of false-positive amphetamine results in the TDx system. Clin Chem 1991;37:2016-2017.
Derfler K, Meryn S, Herold C, Neuhold N, Mostbeck G, Gangl A. Reversible malabsorption caused by high doses of cyclamate. Am J Med 1988;85:446-447.
Shaban HM, Albert ML. Aspartame. An evaluation of adverse effects. Hosp Formal 1988;23:543-546.
Schiffman SS, Buckley CE, Campsor HA, Massey EW, Baranjuk JM et al. Aspartame and susceptibility to headache. N Engl J Med 1987;317:1181 -1185.
Letters. N Engl J Med 1988;318:1200-1202.
Koehler SM, Glaros A. The effect of aspartame on migraine headache. Headache 1988;28:10-13.
Lapierre KA, Greenblatt DJ, Goddard JE, Harmatz JS, Shader RL The neuropsychiatric effects of aspartame in normal volunteers. J Clin Pharmacol 1990;30:454-460.
Leon SS, Hunninghake DB, Bell C, Rassin DK, Tephley TR. Safety in long-term large doses of aspartame. Arch Intern Med 1989;149:2318-2324.
Stegink LD, Brummel MC, McMartin K, Martin-Amat G, Filer U Jr, Baker GL, Tephly TR. Blood methanol concentrations in normal adult subjects administered abuse doses of aspartame. J Toxicol Environ Health 1981;7:281-290.
Saravis S, Schachar R, Zlotkin S, Leiter LA, Anderson GH. Aspartame: effects on learning, behavior and mood. Pediatrics 1990;86:75-83.
Camfield PR, Camfield CS, Dooley JM, Gordon K, Jollyman S, Weaver DF. Aspartame exacerbated EEG spike-wave discharge in children with generalized.'absence epilepsy: a double-blinded controlled study: Neurology 1992;42:1000-1003.
New sweetener approved. FDA Consumer 1988;28(6):4.
Van der Heijden A, Van der Wei H, Peer HG. Structureactivity relationships in sweeteners. II. Saccharins, acesulfames, chlorosugars, tryptophans and ureas. Chem Senses (1RL Press Ltd, Oxford, England) 1985; 10:73— 88.
Acesulfame — a new artificial sweetener. Med Lett Drug Ther 1988;30(Issue 781):116.
Haberer JP, Jouve P, Bedock В et al. Severe hypokalae— mia secondary to overindulgence in alcohol-free "Pastis!" Lancet 1984; 1:575.
Baker ME, Fanestil DD. Liquorice as a regulator of steroid and prostaglandin metabolism. Lancet 1991;337:428-429.
Farese RV Jr, Biglieri EG, Schakleton CHL, Irony I, Gomez-Fontes R. Licorice-induced hypermineralocor-ticoidism. N Engl J Med 1991;325:1223-1227.
Martin JC. Anaphylactoid reactions and vitamin K. Med J Austral 1991;155:851.
Siddall SJ, Martin J, Nunn AJ. Anaphylactoid reactions to teniposide. Lancet 1989; 1:394.
Blexrud MD, Windebank AJ, de Groen PC. Potential neurotoxicity of the solvent vehicle in which intravenous cyclosporine is formulated. Neurology 1990;40(Siiopl 1):344.
Hoefnagels WAJ, Gerritsen EJA, Brouwer OF, Souverijn JHM. Cyclosporine encephalopathy associated with fat embolism induced by the drug’s solvent. Lancet 1988;2:901.
Wason S, Gibler R, Hassan M. Ventricular tachycardia associated with non-freon aerosol propellants. JAMA 1986;256:78-80.
Terzian CG, Simon PA. Aminophylline hypersensitivity apparently due to ethylenediamine. Ann Emerg Med 1992;21:312-317.
Meek JH, Pettit BR. Avoidable accumulation of potentially toxic levels of benzothiazoles in babies receiving intravenous therapy. Lancet 1985;2:1090-1092.
American Academy of Pediatrics Committee on Drugs. "Inactive” ingredients in pharmaceutical products. Pediatrics 1985;76:635-645.
Smith JM, Dodd TRP. Adverse reactions to pharmaceutical excipients. Adverse Drug React Acute Poisoning Rev 1982;1:93-142.
Federal Register, August 8, 1991, Vol 56 No 153, p. 37797.
Napke E, Stevens DGH. Excipients and additives. Hidden hazards in drug products and in product substitution. CMA J 1984;131:1449-1452.
Smolinske SC. Toxicity of drug excipients. Rocky Mountain Poison Center General Syllabus. Poisoning Symposium: Legal Issues/Toxicology Controversies for the Clinician, Cooper Mountain, CO, March 4—8, 1985, pp. 181-191.
Golightly LK, Smolinske SS, Bennett ML, Sutherland EW 111, Rumack BH. Pharmaceutical excipients adverse drug effects associated with "inactive" ingredients in drug products. Parts I and II. Med Toxicol 1988;3:128-135; 209-240.
Dietemann-Molard A, Braun JJ, Solier PJ, Pauli G. Extrinsic allergic alveolitis secondary to carmine. Lancet 1991 ;338:460.
Bell T. Colourants and drug reactions. Lancet 1991;338:55-56.
Dine DJ, Wilkinson JA. Acute exposure to rhodamine B. Clin Toxicol 1987;25:603-607.
Kelner MJ. Rhodamine ingestion as a cause of fluorescent red urine. West J Med 1985;143:523-534.
Windholz M, ed. The Merck Index. 9th ed. Rahway, NJ: Merck & Co, 1976, p. 1061.
International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogenesis Risk of Chemical to Man, 1978;16:221-231.
Mason RW, Edwards 1R. High-performance liquid chromatographic determination of rhodamine В in rabbit and human plasma. J Chromatograph Biomed Applic 1989;491:468-472.
Webb JM, Hansen WH. Studies on the metabolism of rhodamine B. Toxicol AppI Pharmacol 1961;3:86-95.
Webb JM, Hansen WH, Desmond A et al. Biochemical and toxicologic studies of rhodamine band 3,6-di-aminofluran. Toxicol Appl Pharmacol 1961;3:696-706.
BuringJE, HennekensCH. Carbonless copy paper: are-view of published epidemiologic studies. J Occup Med 1991;33:486-495.
Marks JG Jr, Trautlein JJ, Zwillich CW, Demers LM. Contact urticaria and airway obstruction from carbonless copy paper. JAMA 1984;252:1038-1040.
Morgan MS, CampJE. Upper respiratory irritation from controlled exposure to vapor from carbonless copy forms. J Occup Med 1986;28:415-419.
La Marte FP, Merchant JA, Casale ТВ. Acute systemic reactions to carbonless copy paper associated with histamine release. JAMA 1988;260:242-243.
Jeansson 1, Lofstrom A, Lidblom A. Complaints relating to the handling of carbonless copy paper in Sweden. Am Ind Hyg Assoc J 1984;45:B24—B25.
National Institute for Occupational Safety and Health. Request for comments and secondary data on the toxicity of carbonless copy paper. Fed Reg 1987;52:2534-2535.
Reynolds JEF, ed. Martindale: the extra pharmacopoeia. 13th ed. London: Pharmaceutical Press, 1993.
Koppel C, Tenczer J, Ibe K. Urinary metabolism of dextromethorphan in men. Azzneimittel-Forsch/Drug Des 1987;37:1304-1306.
Sauter D, MacNeil P, Weinstein E, Azar A. Phenelzine sulfatedextromethorphan interaction: a case report. Vet Hum Toxicol 1991; 133:365.
Sovner R, Wolfe J. Interaction between dextromethorphan an monoamine oxidase inhibitor therapy with isocarboxazid. N Engl J Med 1988;319:1671.
Yoon YH, Marmor MF. Dextromethorphan protects retinal against ischemic injury in vivo. Arch Ophthalmol 1989;10:409-411.
Albers GW, Saenz RE, Noses JA Jr, Chai DW. Pilot study of oral dextromethorphan patients at risk for brain ischemia. Neurology 1990;40(Suppl 1): 193.
Koyuncuoglu H, Saydam B. The treatment of heroin addicts with dextromethorphan. A double-blind comparison of dextromethorphan with chlorpromazine. Int J Clin Pharmacol Ther Toxicol 1990;28:147-152.
Wolfe TR, Caravati EM. Massive dextromethorphan ingestion and abuse. Am J Emerg Med 1995;13:174-176.
NG YY, Lin WL, Chen TW et al. Spurious hyperchloremia and decreased anion gap in a patient with dextromethorphan bromide. Am J Nephrol 1992;12:268— 270.
Fisher RS, Cysyk BJ, Lesser RP, Pontecorvo MJ, Fer-kany JT, Schwerdt PR et al. Dextromethorphan for treatment of complex partial seizures. Neurology 1990;40:547-548.
Chen ZR, Somogyi AA, Bachner F. Simultaneous determination of dextromethorphan and the metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 1990;12:97-108.
Storrow AB, Magoon MR, Norton J. The dextromethorphan defense: dextromethorphan and the opioid screen. Acad Emerg Med 1995;2:791-794.
Rammer L, Holmgren P, Sandler H. Fatal intoxication by dextromethorphan: a report on two cases. Forensic Sci Int 1988;37:233-236.
East T, Dye D. Determination of dextromethorphan metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1985;338:99-112.
Houz Y, Pickle L, Meyer PS, Woosley RL. Salivary analyses for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 1990;47:150.
Schneider SM, Michelson EA, BaucekCD, llkhanipour K. Dextromethorphan poisoning reversed by naloxone. Am J Emerg Med 1991;9:237-238.
Henretig F, Cugini D, Durbin D, Kearney T, Insley BV, Torrey S et al. Dextromethorphan (DM) overdose in children. Vet Hum Toxicol 1988;3:364.
Skoutakis VA, Koumbourlis TC. Camphor intoxication: diagnosis and management. Clin Toxicol Consult 1981;4:131-136.
Alsop J A. Camphor toxicity from accidental ingestions. Vet Hum Toxicol 1993;35:346.
Gonzalez de Rey J, Baker R, Holloway M, Wason S. Pediatric camphor ingestion. Hum Toxicol 1990;32:371.
Infante-Rivard С, Fernandez A, Gauthier R, David M, Rivard GE. Fetal loss associated with caffeine intake before and during pregnancy. JAMA 1993;270:2940-2943.
McGowan JD, Altman RE, Kanto WP Jr. Neonatal withdrawal symptoms after chronic maternal ingestion of caffeine. South Med J 1988;8:1092-1094.
Caan BJ, Goldhaber MK. Caffeinated beverages and low birthweight: a case-control study. Am J Public Health 1989;29:1299-1300.
Fenster L, Eskenazi B, Windham GC, Swan SM. Caffeine consumption during pregnancy and fetal growth. AM J Public Health, 1991;8:458-461.
Narod SA, de Sanjose S, Victoria C. Coffee during pregnancy: a reproductive hazard? AM J Obstet Gynecol 1991;161:1109-1114.
Oei SG, Vusters RPL, van der Hagen NU. Fetal arrhythmia caused by excessive intake of caffeine by pregnant women. Br Med J 1989;298:568.
Mills JL, Conley MR, Graubard Bl, Brown ZA, Simpson JL, Holmer LP. Caffeine use during pregnancy: how much is safe? JAMA 1993;270:45-46.
Strain EC, Mumford GK, Silverman K, Griffiths RR. Caffeine dependency syndrome. Evidence for case histories and experimental evaluations. JAMA 1994;272:1043-1048.
Glass RM. Caffeine dependence. What are the implications? JAMA 1994;272:1065-1066.
Graboys ТВ, Blatt CM, Lown B. The effect of caffeine on ventricular ectopic activity in patients with malignant ventricular arrhythmia. Arch Intern Med 1989;149:637— 638.
Myers MG. Caffeine and cardiac arrhythmia. Chest 1988;94:4-5.
Grobbee DE, Rimn EB, Giovannucci E, Colditz G, Stumpfer M, Willett W. Coffee, caffeine and cardiovascular disease in man. N Engl J Med 1990;323:1026— 1032.
Rejent T, Michalek R, Krajewski M. Caffeine fatality with coincident ephedrine. Bull Int Assoc Forensic Toxicol 1981;16(1):18-19.
Price KP, Fligner DJ. Treatment of caffeine toxicity with esmolol. Ann Emerg Med 1990;19:44-46.
Michaelis HC, Sharifi S, Schoed G. Rhabdomyolysis after suicidal ingestion of an overdose of caffeine, acetaminophen and phenazone as a fixed-dose combination (Spalt N). Clin Toxicol 1991;29:521-526.
Morrow PL. Caffeine toxicity: a case of child abuse by drug ingestion. J Forensic Sci 1987;32:1801-1805.
Kiel DP, Felson DT, Hannan MT, Anderson JJ, Wilson DWF. Caffeine and the risk of hip fracture: the Framingham Study. Am J Epidemiol 1990;132:675-684.
Wahllander A, Renner E, Kanlaganis G. J Chromatograph (Biomed Appln) 1985;338:369-375 in Bull Intern Assoc for Tox J 1981; 19(2):59.
Fligner CL, Opheim KE. Caffeine and its phenethylxanthine metabolites in two cases of caffeine overdose: a case of falsely elevated theophylline concentrations in serum. J Anal Toxicol 1988;12:339-343.
Walsh I, Wasserman GS, Mestad P, Lanman RC. Near-fatal caffeine intoxication treated with peritoneal dialysis. Pediatr Emerg Care 1987;3:244-249.
Mrvos RM, Reilly PI, Dean BS, Krenzelok EP. Massive caffeine ingestion resulting in death. Vet Hum Toxicol 1989;31:571-572.
Bak AAA, Groobbee DE. The effect on serum cholesterol levels of coffee brewed by filtering or boiling. N Engl J Med 1989;321:1432-1437.
Ahola I, Jauhiainen M, Aro A. The hypercholesterolae-mic factor in boiled coffee is retained by a paper filter. J Intern Med 1991;230:392-397.
Tverdal A, Stensvold I, Solvoll K, Foss OP, Lund-larsen P, Bjartveit K. Coffee consumption and death from coronary heart disease in middle-aged Norwegian men and women. Br Med J 1990;300:566-569.
Dietrich AM, Mortensen ME. Presentation and management of an acute caffeine overdose. Pediatr Emerg Care 1990;6:296-298.
Jorens DG, Van Hauwaert JM, Selala M, Schepens PJC. Acute caffeine poisoning in a child. Eur J Pediatr 1991 ;150:860.
Price KP, Fligner DJ. Treatment of caffeine toxicity with esmolol. Ann Emerg Med 1990;19:44-46.
Palatucci DM. Paradoxical halide levels in bromide intoxication. Neurology 1978;28:1189-1191.
Elin RJ, Robertson ЁА, Johnson F. Bromide interferes with determination of chloride by each of four methods. Clin Chem 1981;27:778-779.
Pronczuk J, Laborde A, Heukes L, Moyna P et al. Matedrinking. Another source of caffeine. Vet Hum Toxicol 1987;29(Suppl 2):70—71.
Denaro CP, Brown CR, Wilson M, Jacob PHI, Benowitz NL. Dose-dependency of caffeine metabolism with repeated dosing. Clin Pharmacol Ther 1990;48:277— 285.
Strain EC, Griffiths RR. Caffeine dependency: fact or fiction? J Roy Soc Med 1995;88:437-440.
Leson CL, McGuigan MA, Bryson SM. Caffeine overdose in an adolescent male. Clin Toxicol 1988;26:407— 415.
Brown NJ, Ryder D, Branch RA. A pharmacodynamic interaction between caffeine and phenylpropanolamine. Clin Pharmacol Ther 1991;50:363-371.
Nawoot S, Wong D, Mays DC, Gerber W. Inhibitor of caffeine elimination by verapamil. Clin Pharmacol Ther 1986;43:148.
Wiethholz H, Zysset T, Kreiten K, Kohl D, Buchsel R, Matern S. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol 1989;3:401-406.
Derlet RW, Tseng JC, Albertson ТЕ. Potentiation of cocaine and d-amphetamine toxicity with caffeine. Am J Emerg Med 1992;10:211-216.
Mills JL, Holms LB, Aarons JH et al. Moderate caffeine use and the risk of spontaneous abortion and intrauterine growth retardation. JAMA 1993;269:593-597.
Eskenazi B. Caffeine during pregnancy: grounds for concern? JAMA 1993;270:2973-2974.
Eisenga В, Saxema К, Anthony SL et al. Discussion of case of the month bromism. Vet Hum Toxicol 1985;27:57-58.
Iberti TJ, Patterson BK, Fisher CJ Jr. Prolonged bromide intoxication resulting from a gastric bezoar. Arch Intern Med 1984;144:402-403.
Downs NM, Stonebridge РА. Gastric rupture due to excessive sodium bicarbonate ingestion. Scott Med J 1989;34:534-535.
Murdfield P. Rupture of stomach from sodium bicarbonate. Klin Wochenschr 1926;5:1612-1615.
Tonetti F, Gorini P. Un caso di rottura dello stomaco dopo ingestiore du bicarbonato di sodio. A case of stomach rupture following ingestion of bicarbonate of soda. Minerva Chir 1988;43:1737-1739.
Mastrangelo MR, Moore EW. Spontaneous rupture of the stomach in a healthy adult man after sodium bicarbonate ingestion. Ann Intern Med 1984;101:649-650.
Lemmon WT, Paschal Glu Jr. Rupture of the stomach following ingestion of sodium bicarbonate. Ann Surg 1941;114:997-1003.
Glassman O. Subcutaneous rupture of the stomach is traumatic and spontaneous. Ann Surg 1929;89:247-263.
Fordtran JS, Morawski SG, Santa Ana CA, Rector FC Jr. Gas production after reaction of sodium bicarbonate and hydrochloric acid. Gastroenterology 1984;87:1014— 1021.
Zer M, Chaimoff C, Dintsman M. Spontaneous rupture of the stomach following ingestion of sodium bicarbonate. Arch Surg 1970;101:522-533.
Lazebnik N, lellin A, Michowitz M. Spontaneous rupture of the normal stomach after sodium bicarbonate ingestion. J Clin Gastroenterol 1986;8:454-456.
Puczynski MS, Cunningham DG, Mortimer JC. Sodium intoxication caused by use of baking soda as a home remedy. Can Med Assoc J 1983;128:821-822.
Revilloid E. Rupture I’estomec. Rev Med Suisse Ro-mande 1885;5:5.
Kennedy S. Sodium bicarbonate abuse in anorexia nervosa. J Clin Psychiatry 1988;49:18.
Linford SMJ, Janey HD. Sodium bicarbonate abuse. A case report.
Mennen M, Slovis CM. Severe metabolic alkalosis in the emergency department. Ann Emerg Med 1988; 17:354— 357.
Fuchs S, Listernich R. Hypernatremia and metabolic alkalosis as a consequence of the therapeutic misuse of baking soda. Pediatr Emerg Care 1987;3:242-243.
Del Beccaro M, Robertson WO. Baking soda poisoning. Vet Hum Toxicol 1988;30:164-165.
Wechsler D, Ibsen L, Focarelli P. Apparent proteinuria as a consequence of sodium bicarbonate ingestion. Pediatrics 1990;86:318-319.
Finberg L. Hypernatremia (hypertonic) dehydration in infants. N Engl J Med 1973;289:196-198.
Barton JR, Riely CA, Sibai BM. Baby powder pica mimicking preeclampsia. Am J Obstet Gynecol 1992;167:98-99.
ReifS, Holzman M, Barak S, SpirerZ. Absence seizures associated with bicarbonate therapy and normal serum pH. JAMA 1989;262:1328-1329.
Holloway M, Wason S. Baking soda: a potentially fatal home remedy. Vet Hum Toxicol 1990;32:371.
Thomas SH, Stone CK. Acute toxicity from baking soda ingestion. Am J Emerg Med 1994;12:57-59.
Veltri JC, Bradford DC, Dring T, Kassner S, McEwee NE et al. Acute exposure to phenylpropanolamine: an analysis of 5447 cases reported to poison control centers from 1984—1987. Postmarket Surveill 1992;6:95—106.
Lake CR, Rosenberg DB, Gallant S, Zaloga G, Chernow R. Phenylpropanolamine increases plasma caffeine levels. Clin Pharmacol Ther 1990;47:675-685.
Craig DF. Psychosis and Vicks Formula 44-D abuse. Can Med Assoc J 1992;146:1199-1200.
Brown CR. Phenylpropanolamine — an ongoing problem. Clin Toxicol Update 1987;9(2):5—8.
Prisant LM, Carr AA. Over-the-counter drugs that may increase blood pressure. Postgrad Med 1989;86:205— 208.
Kroenke K, Omori DM, Simons JO, Wood DR, Meier NJ. The safety of phenylpropanolamine in patients with stable hypertension. Ann Intern Med 1989; 111:1043— 1044.
Lake CR, Zaloga G, Bray J, Rosenberg D, Chernow B. Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine. A placebo-controlled follow-up study. Am J Med 1989;86:427-432.
Stockley CS, Wing LMH, Miners JO. Stereospecific high-performance liquid chromatographic assay for the enantiomers of phenylpropanolamine in human plasma. Ther Drug Monit 1991;13:322-338.
Paradis МА, Koscove ЕМ. Epinephrine in cardiac arrest: a critical review. Ann Emerg Med 1990;19:1288-1301.
McCauley WA, Gerace RV, Scilley C. Treatment of accidental injection of epinephrine with an auto-injector. Vet Hum Toxicol 1990;33:375.
Maguire WA, Reisdorff EJ, Smith D, Wiegenstein JG. Epinephrine-induced vasospasm reversed by phen-tolamine digital block. Am J Emerg Med 1990;8:46-47.
Deshmukh N, Tollard JT. Treatment of accidental epinephrine injection in a finger. J Emerg Med 19S9;7:408.
Roberts JR, KrisandaTJ. Accidental intra-arterial injection of epinephrine treated with phentolamine. Ann Emerg Med 1989;18:424-453.
Hicks PR, Rankin APN. Massive adrenaline doses in la-betalol overdose. Anaesth Intensive Care 1991; 19:447— 450.
Karch SB. Coronary artery spasm induced by intravenous epinephrine overdose. Am J Emerg Med 1989;7:485-488.
Egoz N, Firestone SC. Adrenaline-induced pulmonary edema and its treatment. A report of two cases. Br J Anaesth 1971;43:709-712.
Novey HS, Meleyco IN. Alarming reaction after intravenous administration of 30 mL of epinephrine. JAMA 1969;209:2435-2441.
Fyke Al, Daly PA, Dorian P, Tough J. Reversible "cardiomyopathy" after accidental adrenalin overdose. Am J Cardiol 1991;67:318-319.
Hall AH, Kulig NN, Rumack BH. Intravenous epinephrine abuse. Ann J Emerg Med 1987;5:64-65.
Callaham M. High-dose epinephrine in cardiac arrest. West J Med 1991;155:289-292.
Barton C, Callaham M. High-dose epinephrine improves the return of spontaneous circulation rates in human victims of cardiac arrest. Ann Emerg Med 1991;20:722-725.
Martin D, Werman HA, Brown CG. Four case studies: high dose epinephrine in cardiac arrest. Ann Emerg Med 1990;19:232-236.
Callaham M, Barton CW, Kayser S. Potential complications of high-dose epinephrine therapy in patients resuscitating from cardiac arrest. JAMA 1991 ;265:1117—1122.
Friedman B. Accidental adrenaline overdose and its treatment with piperoxan. Lancet 1955;266:575-578.
Hebert P, Weitzman BN, Stiell G, Stark RM. Epinephrine in cardiopulmonary resuscitation. J Emerg Med 1991;9:487-495.
Brown CG, Martin DR, Peper PE, Stueven H, Cummins RO, Gonzalez E et al. A comparison of standard dose and high dose epinephrine in cardiac arrest outside the hospital. N Engl J Med 1992;327:1051-1055.
Paradio NA, Kossone EM. Epinephrine in cardiac arrest: a critical review. Ann Emerg Med 1990;19:1288-1301.
Stiell IG, Hebert PC, Weitzman BN, Wells GA, Raman S, Stark RM et al. High-dose epinephrine in adult cardiac arrest. N Engl J Med 1992;327:1045—1050
Sica DA, Comstock TJ. Case report. Pseudoephedrine accumulation in renal failure. Am J Med Sci 1989;29:261-263.
Clark RF, Curry SS. Pseudoephedrine dangers. Pediatrics 1990;85:389-391.
Salmon J, Nicholson D. D1C and rhabdomyolysis following pseudoephedrine overdoses. Am J Emerg Med 1988;6:545-546.
Vin PA. Ephedrine-induced intracerebral hemorrhage and central nervous system vasculitis. Stroke 1990;21:1641.
Cavanah DK, Ballas ZK. Pseudoephedrine reaction presenting as recurrent toxic shock syndrome. Ann Intern Med 1993;119:302-303.
Lai Y-K. Adverse effects of intraoperative phenylephrine 10 %: case report. Br J Ophthalmol 1989;73:468-469.
Roberts JR. Pseudocerebral herniation due to phenylephrine nasal spray. N Engl J Med 1989;320:1757.
Snook C, Otten M, Hassan M. Massive ephedrine overdose: case report and toxicokinetic analysis. Vet Hum Toxicol 1992;34:335.
Burkhart KK. Intravenous propranolol reverse hypertension after sympathomimetic overdose. J Toxicol Clin Toxicol 1992;30:109-114.
Bruno A, Nolte KB, Chapin J. Stroke associated with ephedrine use. Neurology 1993;43:1313-1316.
Wezorek C, Kurta D, Dean B, Krenzelok E. Pediatric pseudoephedrine ingestions. A retrospective study. Vet Hum Toxicol 1991;33:362.
Rose SR, German RL, Oderda GM, Klein-Schwartz W. Prospective evaluation of pseudoephedrine ingestion. Vet Hum Toxicol 1988;3:359.
Garriott JC, Simmons LM, Poklis A et al. Five cases of fatal overdose from caffeine-containing "look-alike" drugs. J Anal Toxicol 1985;9:141-143.
Registry of Human Toxicology. American Academy of Forensic Sciences, 1978.
Snook C, Otten M, Hasan M. Massive ephedrine overdose: case report and toxicokinetic analysis. Vet Hum Toxicol 1992;34:335.
Terr Al. American College of Physicians: Clinical ecology. Ann Intern Med 1989;111:168-178.
Cullen MP. The worker with multiple chemical sensitivities: An overview. In: Cullen MP, ed. Occupational Medicine: State of the Art Reviews. Philadelphia: Hanley & Belfus 1987:655-666.
Nethercott JR, Davidoff LL, Curbow B, Abbey H. Multiple chemical sensitivities syndrome: Toward a working case definition. Arch Environ Health 1993;48:19-26.
Robertson WO. MCS (multiple chemical sensitivity) by proxy. Vet Hum Toxicol 1994;36:579-580.
Cone JE, Harrison R, Reiter R. Patients with multiple chemical sensitivities: Clinical diagnostic subsets among an occupational health clinic population. Occup Med State of the Ait Reviews. 1987;2:721-738.
Kilburn KH. Symptoms, syndrome and semantics: Multiple chemical sensitivity and chronic fatigue syndrome. Arch Environ Health 1993;48:368-369.
KurtTL. Multiple chemical sensitivities. Presented at the American Academy of Clinical Toxicology Meeting, Salt Lake City, September 24, 1994.
Sparks PJ, Daniell W, Black DW, et al. Multiple chemical sensitivity syndrome: A clinical perspective: I. Case definition, theories of pathogenesis, and research needs. J Occup Med 1994;36:718-730.
Simon GE, Daniell W, Stockbrjdge H, et al. Immunologic, psychological and neuropsychological factors in multiple chemical sensitivity. Ann Intern Med 1993;119:97-108.
Sparks PJ, Daniell W, Black DW, Kipen HM, Altman LC, Simon: Multiple chemical sensitivity syndrome: A clinical perspective: II. Evaluation, diagnostic testing, treatment and social considerations. J Occup Med 1994;36:731-737.
Spyker DA. Multiple chemical sensitivities. Presented at the American Academy of Clinical Toxicology Meeting, Salt Lake City, September 24, 1994.
Grismon ML. Tacrine: First drug approved for Alzheimer’s disease. Ann Pharmacother 1994;28:744-751.
Wagstaff AJ, McTavish D. Tacrine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in Alzheimer’s disease. Drugs Aging 1994;4:510-540.
Reiman AS. Tacrine as a treatment for Alzheimer’s dementia. N Engl J Med 1991;324:349-352. Editor’s Note.
New Product Approvals: First Alzheimer’s drug. FDA Med Bull 1993;23(3):5—46.
First Alzheimer’s drug approval. FDA Consumer 1992;27:2.
Wilcock GK, Surmon DJ, Scott M, et al. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer’s disease. Age Aging 1993;22:316-324.
Farlow M, Gracon SL, Hershey LA, et al. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992;268:2523-2529.
Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994;271:985— 991.
Eagger SA, Morant N, Levy R, Sahakian BJ. Tacrine in Alzheimer’s disease: Time course of changes in cognitive function and practice effects. Br J Psychiatry 1992;160:36-40.
Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer’s disease. Lancet 1991;337:989-992.
Maltby N, Broe GA, Creasey H, et al. Efficacy of tacrine and lecithin in mild to moderate Alzheimer’s disease; Double blind trials. Br Med J 1994;309:879-883.
Byrne EJ, Arieg T. Tetrahydroaminoacridine and Alzheimer’s disease: For the few but we don’t know which few. Br Med J 1994;308:868-869.
Molloy DW, Guyatt GH, Wilson DB, et al. Effect of tetrahydroaminoacridine on cognition, function and behavior in Alzheimer’s disease. Can Med Assoc J 1991;144:29-34.
Benezra DA. Personal communication. Parke-Davis, April 27, 1994.
Sumners WK, Kaufman KR, Altman F Jr, Fischer JM. THA: A review of the literature and its use in treatment of five overdose patients. Clin Toxicol 1980;16:269-281.
Forsyth DR, Wilcock GK, Morgan RA, et al. Pharmacokinetics of tacrine hydrochloride in Alzheimer’s disease. Clin Pharmacol Ther 1989;46:634-641.
Freeman SE, Dawson RM. Tacrine: A pharmacological review. Progress Neurobiol 1991;36:257-277.
Levy R, Eagger SA, Griffiths M, et al. Lewy bodies and response to tacrine in Alzheimer’s disease. Lancet 1994;343:176.
Fricke RF, Koplowitz 1, Scharf BA, Rockwood GA. Efficacy of tacrine as a nerve agent pretreatment. Drug Chem Toxicol 1994;17:15-34.
Liu S, Sylvester DM. The inhibitory effect of 9-amino-1.2.3.4-tetrahydroacridine (THA) on platelet function. Thromb Res 1992;67:533-544.
Tacrine for Alzheimer’s disease. Med Lett Drugs Ther 1993;35(905):87—88.
Hartvig P, Askmark H, Aquilonius SM, et al. Clinical pharmacokinetics of intravenous and oral 9-amino-1.2.3.4-tetrahydroacridine, tacrine. Eur J Clin Pharmacol 1990;38:259-263.
Davis KL, Powchik P. Tacrine. Lancet 1995;345:625— 630.
Sitar DS, Lou GL, Montgomery PR. Bioavailability and pharmacokinetic disposition of tacrine hydrochloride in elderly patients with Alzheimer's disease. Clin Pharmacol Ther 1995;57:Abstract PHI—17.
Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepa-totoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994;271:992-998.
Ott BR, Lannon MC. Exacerbation of parkinsonism by Tacrine. Clin Neuropharmacol 1992;15:322-325.
Ford JM, Truman CA, Wilcock GK, Roberts CJ. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer’s disease. Clin Pharmacol Ther 1993;53:691-695.
Roberts C, Ford J, Makela P, Truman C. Serum tacrine concentrations too low. Br Med J 1994;308:1501.
Wagstaff AJ, McTavish D. Tacrine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in Alzheimer’s disease. Drugs Aging 1994;4:510-540.
Clarke G FC. Isolation and Identification of Drugs. London: Pharmaceutical Press, 1995:500—501.
Cordner SM, Fysh RP, Gordon H, Whitaker SJ. Deaths of two hospital inpatients poisoned by pilocarpine. Br Med J 1986;293:1285-1287.
Pfliegler GP, Palatka K. Attempted suicide with pilocarpine eyedrops. Am J Ophthalmol 1995;120:398-400.
Littmann L, Kempler P, Rohla M, Fenyresi T. Severe symptomatic atrioventricular block induced by pilocarpine eye drops. Arch Intern Med 1987;147:586-587.
Havener WH. Ocular Pharmacology. St. Louis: Mosby, 1983:319-347.
Bayne WF, Shu IC, Tao FT. Subnanogram assay for pilocarpine in biological fluids. J Pharm Sci 1976;65:1724-1727.
Weaver ML, Tanzer JM, Kramer PA. High-performance liquid chromatographic determination of pilocarpine in plasma. J Chromatogr Biomed Appl 1992;581:293-296.
Roesch RP, Stelting RK, Lingeman JE, et al. Ammonia toxicity resulting from glycine absorption during a transurethral resection of the prostate. Anesthesiology 1983;58:577-579.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1043.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:1728-1730.
Norlen H, Allgen L-G, Vinnars E, Bedrelidou-Classon G. Glycine solution as an irrigating agent during transurethral prostatic resection: Glycine concentrations in blood plasma. Scand J Urol Nephrol 1986;20:19-26.
Hahn RG. Early detection of the TURP syndrome by making the irrigating fluid with 1 % ethanol. Acta An-aesthesiol Scand 1989;23:146-151.
Hahn RG. Prevention of TURP syndrome by detection of trace ethanol in the expired breath. Anaesthesia 1990;45:577-581.
Sherwood RA, Bayliss EM, Chappatte O. Assay of plasma glycine by HPLC with electrochemical detection in patients undergoing glycine irrigation during gynaecological surgery. Clin Chim Acta 1991;203:275-284.
Brady AY, Chyka PA. Glycine toxicity during hystero-scopic resection of the endometrium. Vet Hum Toxicol 1991;33:365.
Patel DK, Ogunbona A, Notarianni U, Bennett PN. Depletion of plasma glycine and effect of glycine by mouth on salicylate metabolism during aspirin overdose. Hum Exp Toxicol 1990;9:389-395.
Hutchesson ACJ, Wilkinson PA, Rattenbury JM, Manning N. Transient hyperglycinemia after transurethral surgery: Are metabolites of glycine significant? Clin Chem 1990;36:704-705.
Nathans D, Fahey JL, Ship AG. Sites of origin and removal of blood ammonia formed during glycine infusion: Effect of L-arginine. J Lab Clin Med 1958;51:124-133.
Ovassapian A, Voshi CW, Brunner MD. Visual disturbances: An unusual symptom, a transurethral prostate resection reaction. Anesthesiology 1982;57:332-334.
Wright N, Seggie J. Glycine associated blindness: A case report and animal data. Vet Hum Toxicol 1987;29:478.
Hahn RG, Stalberg HP, Ekengren J, Rundgren M. Effects of 1.5 % glycine solution with and without 1 % ethanol on the fluid balance in elderly men. Acta Anaesthe-siol Scand 1991;35:725—730.
Hahn RG. Blood ammonia concentrations resulting from absorption of irrigating fluid containing glycine and ethanol during transurethral resection of the prostate. Scand J Urol Nephrol 1991;25:115-119.
Burkhart SS, Barnett CR, Snyder SJ. Transient postoperative blindness as a possible effect of glycine toxicity. Arthroscopy 1990;6:112-114.
Bernstein GT, Loughlin KR, Gittes RF. The physiologic basis of the TURP Syndrome. J Surg Res 1989;46:135— 141.
Hahn RG. Glycine absorption and visually evoked potentials. Anaesthesia 1992;47:78.
Baumann R, Magos AL, Kay JDS, Turnbull AC. Absorption of glycine irrigating solution during transcervical resection of endometrium. BrMedJ 1990;300:304-305.
Fitzpatrick JM, Kasidar GP, Rose GA. Hyperoxaluria following glycine irrigation for transurethral prostatectomy. Br J Urol 1981;53:250-252.
Hahn RG, Stalberg HP, Gustafsson SA. Vasopressin and cortisol levels in response to glycine infusion. Scand J Urol Nephrol 1991;25:121-123.
Hirse M, Tanaka Y. Serum potassium change during the TURP syndrome by cell volume regulation. Can J Anaesth 1992;39:300-301.
Jensen V. Serum potassium change during the TURP syndrome by cell volume regulation. Can J Anaesth 1992;39:300.
Nairns RG. Therapy of hyponatremia: Does haste make waste? N Engl J Med 1986;314:1573-1575.
Fahey JL Toxicity and blood ammonia rise resulting from intravenous amino acid administration in man: The protective effect of L-arginine. J Clin Invest 1957;36:1647-1655.
Spyker DA, Lynch С, Shabanowitz J, Sinn JA. Poisoning with 4-aminopyridine: Report of three cases. Clin Toxicol 1980;16:487-497.
Van Diemen HAM, Polman CH, Van Dongen MMMM, et al. 4-Aminopyridine induced functional improvement in multiple sclerosis patients: A neurophysiological study. J Neurol Sci 1993;116:220-226.
Morgan D. Recognition and Management of Pesticide Poisonings. EPA-540/9-88-001. Washington, DC: U. S. Environmental Protection Agency, March 1989:148—149.
Lundh H, Nilsson O, Rosen I, Johansson S. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand 1993;88:136-140.
Rosen 1, Lundh H, Nilsson O. Improvement of neuromuscular transmission by 3,4-diaminopyridine in the Lambert—Eaton myasthenic syndrome and in myasthenia gravis. Ann NY Acad Sci 1987;505:776-779.
Murray NMF, Newson-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981;31:265-271.
Agoston S, Van Weeden T, Westra P, Brockert A. Effects of 4-aminopyridine in Eaton—Lambert syndrome. Br J Anaesth 1978;50:383-389.
Stefoski D, Davis FA, Faut M, Schauf CL. 4-Aminopy-ridine improves clinical signs in multiple sclerosis. Ann Neurol 1987;21:71-77.
Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:186-192.
Wesseling H, Agoston S, Van Dam GBP, et al. Effects of 4-aminopyridine in elderly patients with Alzheimer’s disease. N Engl J Med 1984;310:988-989.
Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-Ami-nopyridine in chronic spinal cord injury: A controlled double-blind crossover study in eight patients. J Neurotrauma 1993;10:1-18.
Agoston S, Salt PJ, Erdmann W, et al. Antagonism of ketamine-diazepam anaesthesia by 4-aminopyridine in human volunteers. Br J Anaesth 1980;52:367-370.
Mofenson HC, Caraccio TR, Brody G, et al. Poison perspectives for health professionals. LI Regional Poison Control Center at Winthrop University Hospital. 1993;12(9):37—41.
Uges DRA, Buirs B, Sangster B. Treatment of 4-ami-nopyridine poisoning after oral overdose: A proposal. Pharm Acta Helv 1984;59:172-176.
Miller RD, Booij LHDJ, Agoston S, Crui JF. 4-Anii-nopyridine potentiates neostigmine and pyridostigmine in man. Anesthesiology 1979;50:416-420.
Evenhuis J, Agoston S, Salt PJ, et al. Pharmacokinetics of 4-aminopyridine in human volunteers. Br J Anaesth 1981;53:567-570.
Uges DRA, Sohn YJ, Greijdanus B, et al. 4-Aminopy-ridine kinetics. Clin Pharmacol Ther 1982;31:587— 593.
Wood M. Cholinergic and parasympathomimetic drugs: Cholinesterases and anticholinesterases. In: Wood M, Wood AJJ, eds. Drugs and Anesthesia: Pharmacology for Anesthesiologists. 2nd ed. Baltimore: Williams & Wilkins, 1990:104.
Mitzov V, Vlaskovska M. Effects of anticurare agents produced in Bulgaria on the smooth muscles of the gastrointestinal tract. Acta Physiol Pharmacol Bulg 1987;13:56-65.
Carlesson C, Rosen I, Nilsson E. Can 4-aminopyridine be used to reverse anaesthesia and muscle relaxation? Acta Anaesthesiol Scand 1983;27:87-90.
Stork CM, Howland MA, Hoffman RS. 4-Aminopyrid-ine overdose. Vet Hum Toxicol 1994;36:375.
Salagen Tablets. In: Physicians’ Desk Reference. 49th ed. Montvale, NJ: Medical Economics, 1995:1378—1379.
Kastl RR. Inadvertent systemic injection of pilocarpine. Arch Ophthalmol 1987;105:28-29.
Cordner SM, Fysh RR, Gordon H, Whitaker SJ. Deaths of two hospital inpatients poisoned by pilocarpine. Br Med J 1986;293:1285-1287.
Epstein E, Kaufman I. Systemic pilocarpine toxicity from overdosage. Am J Ophthalmol 1965;59:109—110.
Pfliegler GP, Palatka K. Attempted suicide with pilocarpine drops. Am J Ophthalmol 1995;120:399-400.
Clarke EGC. Isolation and identification of drugs. Lond Pharm Press 1969;1:500-501.
Bayne WF, Chu LC, Tao FT. Subnanogram assay for pilocarpine in biological fluids. J Pharm Sci 1976;65:1724-1727.
Ferner RE, Simmonds НА, Bateman DN. Allopurinol kinetics after massive overdosage. Hum Toxicol 1988;7:293-294.
Hauser ER, Finkelstein JE, Valle D, Brusilow SW. Allopurinol-induced orotidinuria: A test for mutations at the ornithine carbamoyltransferase focus in women. N Engl J Med 1990;322:1641-1645.
Howard RJMW, Blake DR, Pall H, et al. Allopurinol/ V-acetylcysteine for carbon monoxide poisoning. Lancet 1987;2:628-629.
De Marco P, Zagnoni P. Allopurinol and severe epilepsy. Neurology 1986;36:1538-1539.
Tada H, Morooka K, Arimoto K, Matsuo T. Clinical effects of allopurinol on intractable epilepsy. Epilepsia 1991;32:279-283.
Kramer LD, Loche GE, Nelson LG, Ogunyemi AO. Status epilepticus following withdrawal of allopurinol. Ann Neurol 1990;27:691.
Martinez S, Marr JJ. Allopurinol in the treatment of cutaneous leishmaniasis. N Engl J Med 1992;326:741-744.
Marr JJ, Berous RL, Nelson PJ. Antitrypanosomal effect of allopurinol: Conversion in vivo to aminopyrazolopy-rimidine nucleotides by Trypanosoma cruzi- Science 1978;201:1018-1020.
Shapiro TA, Were JBO, Danso K, et al. Pharmacokinetics and metabolism of allopurinol riboside. Clin Pharmacol Ther 1991;49:506-514.
Cameron JS, Simmonds HA. Use and abuse of allopurinol. Br Med J 1987;294:1504-1505.
Hande K, Reed E, Chabner B. Allopurinol kinetics. Clin Pharmacol Ther 1978;23:598-605.
Wood MH, Sebel E, O’Sullivan WJ. Allopurinol and thiazide. Lancet 1972; 1:751.
Reiter S, Simmonds HA, Webster DR, Watson AR. On the metabolism of allopurinol: Formation of allopurinol-1-riboside in purine nucleoside phosphorylase deficiency. Biochem Pharmacol 1983;32:2167-2174.
Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47— 56.
Frauenfelder F, Lerman S. Allopurinol therapy. Am J Ophthalmol 1985;99:215-216.
Raman GV, Sharman VL, Lee HA. Azathioprine and allopurinol: A potentially dangerous combination. J Intern Med 1990;228:69-71.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:2423-2426.
Barry M, Feely J. Allopurinol influences aminophenazone elimination. Clin Pharmacokinet 1990; 19:167— 169.
Gorrie M, Beaman M, Nicholls A, Backwell P. Allopurinol interaction with cyclosporine. Br Med J 1984;308:113.
Stevens SL, Goldman MH. Cyclosporine toxicity associated with allopurinol. South Med J 19 092;85:1265— 1266.
McCollister RJ, Gilbert WR, Ashton DM, Wyngaarden JB. Pseudofeedback inhibition of purine synthesis by 6-mercaptopurine ribonucleotide and other purine analogues. J Biol Chem 1977;239:1560-1563.
Hanger HC, Pillans PL Death following allopurinol hypersensitivity syndrome. N Z Med J 1994; 107:229.
Conrad ME. Fatal aplastic anemia associated with allopurinol therapy. Am J Hematol 1986;22:107-108.
Shinohara K, Okafuji K, Ayame H, Tanaka M. Aplastic anemia caused by allopurinol in renal insufficiency. Am J Hematol 1990;35:68.
Tain S, Carroll W. Allopurinol therapy. Am J Ophthalmol 1985;99:215-216.
Middleberg R, Fossum PM, Sanders DE, Brown SL. An acute death involving allopurinol. In: Proceedings, Annual Meeting of American Academy of Forensic Sciences, San Antonio, February 14, /994: Abstract G61.
Elion GB, Benezra FM, Beardmore TD, Kelley WN. Studies with allopurinol in patients with impaired renal function. Adv Exp Med Biol 1980;122A:263—267.
Millar WM. Deaths after overdoses of orphenadrine. Lancet 1977;2:566.
Clarke B, Mair J, Rudolf M. Acute poisoning with orphenadrine. Lancet 1985; 1:1386.
Bozza-Marrubini M, Frigerio A, Ghezzi R, et al. Two cases of severe orphenadrine poisoning with atypical features. Acta Pharmacol Toxicol 1977;41 (suppl. 2): 137— 152.
Bassett JR, Story M, Cairncross KD. The influence of orphenadrine upon the actions of a series of sympathico-mimetic drugs. Eur J Pharmacol 1968;4:198.
Ginzel KH. The blockade of reticular and spinal facilitation of motor-function by orphenadrine. J Pharmacol Exp Ther 1966;154:128-141.
Heinonen J, Heikkila J, Mattila MJ, et al. Orphenadrine poisoning: A case report supplemented with animal experiments. Arch Toxicol 1968;23:264-272.
Physicians’ Desk Reference. 49th ed. Montvale, NJ: Medical Economics, 1995:1386—1387.
Furlanut M, Bettio D, Bertin 1, et al. Orphenadrine serum levels in a poisoned patient. Hum Toxicol 1985;4:331-333.
Edwards SE, Kumar V. A survey of prescribing of psychotropic drugs in a Birmingham psychiatric hospital. Br J Psychiatry 1984;145:502-507.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Phannacists, 1994:851-852.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:428—429.
Blomquist M, Bonnichsen R, Schubert B. Lethal orphenadrine intoxications: A report of five cases. Z Re-chtsmed 1971 ;68:111.
Bosche J, Mallach HJ. Uber anatomische und chemisch toxikologische Befunde bei einer todlichen Vergiftung durch Orphenadrin. Arch Toxikol 1969;25:76-82.
Stoddard JC, Parkin JH, Wynne NA. Orphenadrine: A case report. Br J Anaesth 1968;40:789-790.
Deceuninck F, Silverman RM, Veltman JGJ. A patient with psychosis following orphenadrine poisoning. Ned Tijdschr Geneesk 1973;117:25-27.
Sangster B, Van Heijst ANP, Zimmerman ANE, et al. Intoxication by orphenadrine HCI: Mechanism and therapy. Acta Pharmacol Toxicol 1977;41(suppl. 2):129—136.
Sangster B, Van Heijst ANP, Zimmerman ANE. Treatment of orphenadrine overdose. N Engl J Med 1977;296:1006.
Sangster B, van Heijst ANP, Zimmerman ANE. Vergiftiging door orphenadrine (Disipal). Ned Tijdschr Ge-neesk 1978;122:988-992.
Wineck CL. Tabulation of therapeutic, toxic and lethal concentrations of drugs and chemicals in blood. Clin Chem 1976;22:832.
Robinson AE, Holder AT, McDowall RD, et al. Forensic toxicology of some orphenadrine-related deaths. Forens Sci 1977;9:53-62.
Bennet MB, Kohn J. Orphenadrine overdose: Cerebral manifestations treated with physostigmine. Anaesth In-, tens Care 1976;4:67. Case Report.
Snyder BD, Kane M, Plocher D. Orphenadrine overdose treatment with physostigmine. N Engl J Med 1976;295:1435.
Ellison T, Snyder A, Bolger J, et al. Metabolism of orphenadrine citrate in man. J Pharmacol Exp Ther 1971;176:284-295.
Labout JJM, Thijssen CT, Keijser GGJ, et al. Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man. Eur J Clin Pharmacol 1982;21:343-350.
Rutigliano G, Labout JJM. The bioavailability of orphenadrine hydrochloride after intramuscular and oral administration. J Int Med Res 1982;10:447-450.
Heel RC, Avery GS. Appendix A. In: Avery G, ed. Drug Data Information in Drug Treatment. Sydney: ADIS Press, 1980:1222.
Hespe W, De Roos AM, Nauta WT. Investigation into the metabolic fate of orphenadrine hydrochloride after oral administration to male rats. Arch Int Pharmacodyn 1965;156:180-200.
Prins H, Hespe W. Autoradiographic study of the distribution of radioactivity in mice after oral administration of tritium-labelled orphenadrine hydrochloride. Arch Int Pharmacodyn 1968;171:47-57.
Labout JJM, Thijssen CT, Hespe W. Sensitivity and specific gas chromatographic and extraction method for the determination of orphenadrine in human body fluids. J Chromatogr 1977;144:201-208.
Chaplin S, Sanders GL, Smith JM. Drug excretion in human breast milk. Adverse Drug React Acute Poison Rev 1982;1:255-287.
Beall JR. A teratogenic study of chlorpromazine, orphenadrine, perphenazine and LSD-25 in rats. Toxicol Appl Pharmacol 1972;21:230-236.
Schifano F, Marra R, Magni G. Orphenadrine abuse. South Med J 1988;8:546-547.
Elder NC. Abuse of skeletal muscle relaxants. AFHJ 1991;44:1223-1227.
Suckow RF, Cooper ТВ. Simultaneous determination of amitriptyline, nortriptyline and their respective isomeric 10-hydroxy metabolites in plasma by liquid chromatography. J Chromatogr 1982;230:391-400.
Henderson RA, LaneS, Henry JA. Life-threatening ventricular arrhythmia (Torsade de pointes) after haloperidol overdose. Hum Exp Toxicol 1991;10:59-62.
Danze LK, Langdorf ML Reversal of orphenadrine induced ventricular tachycardia with physostigmine. J Emerg Med 1991;9:453-457.
Molina-Negro P, Illingworth RH. MK-130: Line nouv-elle drogue pour le traitement de hypertonie musculaire: Essai preliminaire chez dix patients avec spasticitae d’origine spinale. Union Med Can 1971;100:1947-1951.
Bercel NA. Cyclobenzaprine in the treatment of skeletal muscle spasm in osteoarthritis of the cervical and lumbar spine. Curr Ther Res 1977;22:462-468.
Nibbelink DW, Strickland SC, McLean LF, et al. Cyclobenzaprine, diazepam and placebo in the treatment of skeletal muscle spasm of local origin. Clin Ther 1978;1:409-424.
Azoury FJ. Double-blind comparison of Parafon ForteR and FlexerilR in the treatment of acute musculoskeletal disorders. Curr Ther Res 1979;26:189-197.
Beeber AR, Manning JM Jr. Psychosis following Cy-clobenzaprine use. J Clin Psychiatry 1983;44:151-152.
Basmajian JV. Cyclobenzaprine hydrochloride effects on skeletal muscle spasm in the lumbar region and neck: Two double-blind controlled clinical and laboratory studies. Arch Phys Med Rehabil 1978;59:58-163.
Ashby P, Burke D. Rao S, et al. Assessment of cyclobenzaprine in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1979;35:599-605.
Brown BR, Womble J. Cyclobenzaprine in intractable pain syndromes with muscle spasm. JAMA 1978;240:1151-1152.
Nibbelink DW, Strickland SC. Cyclobenzaprine (Flex-eril™): Report of postmarketing surveillance program. Curr Ther Res 1980;28:894-903.
Litovitz TL, Normann SA, Veltri JC. Case 260: 1985 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1986;4:457.
Litovitz TL, Bailey KM, Schmitz BF, et al. Case 539: 1990 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1991 ;9:539.
Hucker HB, Stauffer SC, Albert KS, et al. Plasma levels and bioavailability of Cyclobenzaprine in human subjects. J Clin Pharmacol 1977;17:719-727.
Hucker HB, Stauffer SC. GLC determination of Cyclobenzaprine in plasma and urine. J Pharm Sci 1976;65:1253-1255.
Benesova O, Nahunek K. Correlation between the experimental data from animal studies and therapeutical effects of antidepressant drugs. Psychopharmacologia 1971;20:337-347.
Hughes MJ, Lemons S, Barles C. Cyclobenzaprine: Some pharmacological cardiac actions. Life Sci 1978;23:2779-2786.
Biggs JT, Spiker DA, Petit JM, et al. Tricyclic antidepressant overdose: Incidence of symptoms. JAMA 1977;238:135-138.
Stephen JM, Ghezzi KT, Bailey K, Shesser R. Post-tri-athalon delirium. J Emerg Med 1991;9:265-269.
Engel PA, Chapron D. Cyclobenzaprine-induced delirium in two octogenarians. J Clin Psychiatry 1993;51:39.
Tasset JJ, Schroeder TJ, Pesce AJ. Cyclobenzaprine overdose: The importance of a clinical history in analytical toxicology. J Anal Toxicol 1985; 10:258.
Newton RW. Physostigmine salicylate in the treatment of tricyclic antidepressant overdosage. JAMA 1975;231:941-943.
Elder NC. Abuse of skeletal muscle relaxants. Am Fam Physician 1991;40:1223-1226.
Cornette М, Gillard С, Borlee-Hermans G. Hepatite toxique mortelle associee a I’usage du dantrolene. Acta Neurol Belg 1980;80:336-347.
White WB. Aggravated CNS depression with urinary retention secondary to baclofen administration. Arch Intern Med 1984;145:1717-1718.
Lalande M, Mills P, Peterson RG. Determination of dantrolene and its reduced and oxidized metabolites in plasma by high-performance liquid chromatography. J Chromatogr 1988;430:187-191.
Wuis EW, Dirks RJM, Vree ТВ, Van den Kleyn E. High performance liquid chromatographic analysis of baclofen in plasma and urine of man after precolumn extraction and derivitization with o-phthaldialdehyde. J Chromatogr Biomed Appl 1985;337:341-350.
Wuis EW, Van Beijsterveldt LEC, Dirks RJM, et al. Rapid simultaneous determination of baclofen and its gamma-hydroxy metabolite in urine by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1987;420:212-216.
Saissy JM, Vitris M, Demaziere J, et al. Flumazenil counter-acts intrathecal and baclofen-induced central nervous system depression in tetanus. Anesthesiology 1992;76:1051-1053.
Kochak G, Hone F. An unproved gas-liquid chromatographic method for the determination of baclofen in plasma and urine. J Chromatogr 1984;310:319-326.
McEvoy GK, ed. AHFS Drug Information 86. Bethesda, MD: American Society of Hospital Pharmacists, 1986:617-618.
Goldberg D. Carisoprodol toxicity. Milit Med 1969;134:597-601.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1202.
Adams HR, Kerzee T, Morehead CD. Carisoprodol related death in a child. J Forens Sci 1975; 20: 200— 202.
Brandslung I, Klitgaard NA, Kristensen O. A case of acute intoxication with carisoprodol: Symptoms and metabolism. Ugeskr Laeg 1976;138:281-283.
Van der Kleijn E. Kinetics of distribution and metabolism of ataractics of the meprobamate group in mice. Arch Int Pharmacodyn 1969;178:457-480.
Kato R, Vasanelli P, Frontino G, et al. Metabolism and distribution of carisoprodol in tissues and organs of the rats. Med Exp 1962;6:149-157.
Hoffman AJ, Ludwig BJ. An improved colorimetric method for the determination of meprobamate in biological fluids. J Am Pharm Assoc 1959;48:740-742.
O’Brien ТЕ. Excretion of drugs in human milk. Am J Hosp Pham 1974;31:844-854.
Elder NC. Abuse of skeletal muscle relaxants. Am Fam Physician 1991;44:1223-1226.
Luehr JG, Meyerle KA, Larson EU. Mail order (veterinary) drug dependence. JAMA 1990;263:657.
Maes R, Bouche R, Laruelle L. Determination quantitative de meprobamate et de carisoprodol par chromatographic en phase gazeuse, dans differents cas d’intoxications. Eur J Toxicol 1970;3:140-143.
Ten Holter JBM, Schellens RLLAM. Dantrolene sodium for treatment of carbon monoxide poisoning. Br Med J 1988;296;1772—1773.
Kaplan RF, Feinglass NG, Webster W, Mudra S. Phenelzine overdose treated with dantrolene sodium. JAMA 1986;255:642-644.
Shemesh I, Bourvin A, Gold D, Kutscherowsky M. Chlorpyrifos poisoning treated with ipratropium and dantrolene: A case report. Clin Toxicol 1988;26:495— 498.
Bouchama A, Cafege A, Devol EB, et al. Ineffectiveness of dantrolene sodium in the treatment of heat stroke. Crit Care Med 1991;19:176-180.
Channa AB, Seraj MA, Saddique AA, et al. Is dantrolene effective in heat stroke patients? Crit Care Med 1990;18:290-293.
Parr MJA, Willatts SM. Fatal theophylline poisoning with rhabdomyolysis: A potential role for dantrolene treatment. Anaesthesia 1991;46:557-559.
Bhalotra R. Baclofen therapy for intractable hiccoughs. J Clin Gastroenterol 1990; 12:122.
Intractable hiccup: Baclofen and nifedipine are worth trying. Drug Ther Bull 1990; 12(9):36.
Durham J A, Gandolfi AJ, Bentley J B. Hepatotoxicolog-ical evaluation of dantrolene sodium. Drug Chem Toxicol 1984;7( 1 ):23—40.
Sallerin-Caute B, Lazorthes Y, Monsarrat B, et al. CSF baclofen levels after intrathecal administration in severe spasticity. Eur J Clin Pharmacol 1991;40:363-365.
Netter P, Lambert H, Larcan A, et al. Diclofenac sodi-um-chlormezanone poisoning. Eur J Clin Pharmacol 1984;26:535-536.
Kochak GM, Rakhit A, Wagner WE, et al. The pharmacokinetics of baclofen derived from intestinal infusion. Clin Pharmacol Ther 1985;38:251-257.
Garabedian-Ruffalo SM, Ruffalo RL. Adverse effects secondary to baclofen withdrawal. Drug Intell Clin Pharm 1985;19:304-306.
Flewellyn EH, Nelson ТЕ. Intravenous dantrolene pharmacokinetics in malignant hyperthermia suspect patients. Anesthesiology 1985;63(suppl. 3A):300.
Lerman J, McLeod ME, Strong HA. Pharmacokinetics of intravenous dantrolene in children. Anesthesiology 1989;70:625-629.
Allen GC, Cattran CB, Peterson RG, Lalande M. Plasma levels of dantrolene following oral administration in malignant hyperthermia susceptible patients. Anesthesiology 1988;69:900-904.
Sica DA, Comstock TJ, Davis J, et al. Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol 1990;39:193-194.
Ferslew KE, Hagardorn AN, McCormick WF. A fatal interaction of methocarbamol and ethanol in an accidental poisoning. J Forens Sci 1990;35:477-482.
Comunale ME, DiNardo JA, Schwartz MJ. Pharmacokinetics of dantrolene in an adult patient undergoing cardiopulmonary bypass. J Cardiothor Vase Anesth 1991;5:153-155.
McChesney EW, Banks WF Jr, Portmann GA, et al. Metabolism of chlormezanone in man and laboratory animals. Biochem Pharmacol 1967;16:813-826.
Ward A, Chaffman MO, Sorkin EM. Dantrolene: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986;32:130-168.
Tayeb OS. A serious interaction of dantrolene and theophylline. Vet Hum Toxicol 1990;32:442-443.
Salzman LS, Kates RA, Corke GC, et al. Hyperkalemia and cardiovascular collapse after verapamil and dantrolene administration in swine. Anesth Analg 1984;63:473-478.
Dahlin PA, George J. Baclofen toxicity associated with declining renal clearing after ibuprofen. Drug Intell Clin Pharm 1984;18:805-808.
Bowery NG, Hill DR, Hudson AL, et al. (-) Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature 1980;283:92-94.
Van de Kelft E, de Hert M, Heytens L, et al. Management of lethal catatonia with dantrolene sodium. Crit Care Med 1991;19:1449-1451.
Cooke DEM, Glasstone MA. Baclofen poisoning in children. Vet Hum Toxicol 1994;35:448-450.
Arnold ES, Rudd SM, Kirshner H. Manic psychosis following rapid withdrawal from baclofen. Am J Psychiatry 1980;137:1466-1467.
Muller-Schwefer G, Penn RD. Physostigmine in the treatment of intrathecal baclofen overdose. J Neurosurg 1989;71:273-275.
Saltuari L, Marosi MJ, Kopler M, Bauer G. Status epi-lepticus complicating intrathecal overdose. Lancet 1992;339:373-374.
Parmar MS. Akinetic mutism after baclofen. Ann Intern Med 1991;115:499-500.
Delhaas EM, Brouwers JRBJ. Intrathecal baclofen overdose: Report of 7 events in 5 patients and review of the literature. Int J Clin Pharmacol Ther Toxicol 1991;29:274-280.
Fraser AD, MacNeil W, IsnerAF. Toxicological analysis of a fatal baclofen (LioresalR) ingestion. J Forens Sci 1991;36:1596-1602.
Roberge RJ, Marton TG, Hodgman M, et al. Supraventricular tachyarrhythmia associated with baclofen overdose. Clin Toxicol 1994;32:291-297.
Kofler M, Saltuari L, Schumatzhard E, et al. Electrophysiological findings in a case of severe intrathecal baclofen overdose. Electroencephalogr Clin Neurophysiol 1992;83:83-86.
Nugent S, Katz MD, Little ТЕ. Baclofen overdose with cardiac conduction abnormalities: Case report and review of the literature. Clin Toxicol 1986;24:321-328.
.Lees AJ, Clarke CRA, Harrison MJ. Hallucinations after withdrawal of baclofen. Lancet 1977; 1:858.
Siegfried RN, Jacobson L, Chabal C. Development of an acute withdrawal syndrome following the cessation of intrathecal baclofen in a patient with spasticity. Anesthesiology 1992;77:1048-1050.
Kofler M, Leis AA. Prolonged seizure activity after baclofen withdrawal. Neurology 1992;42:697-698.
Sheu B-S, Lin C-Y, Chen K-W, Chi C-H, et al. Severe hepatocellular damage induced by chlormezanone overdose. Am J Gastroenterol 1995;90:833-835.
Paloucek FP, Erickson ТЕ, Lundquist S, Ferraro C. Oral dantrolene ingestion: A case series. Vet Hum Toxicol 1991;33:362.
Robillart A, Bopp P, Vailly B, Dupeyron JP. Cardiac failure due to dantrolene overdose. Ann Fr Anesth Re-anim 1986;5:617-619.
Chan CH. Dantrolene sodium and hepatic injury. Neurology 1990;40:1427-1432.
Wilkinson SP, Portmann B, Williams R. Hepatitis from dantrolene sodium. Gut 1979;20:33-36.
Schneider JA, Sigg ЕВ. Neuropharmacological studies on ibogaine, an indole alkaloid with central stimulant properties. Ann NY Acad Sci 1956;66:766-776.
EndabuseR (ibogaine hydrochloride). Staten Island, NY: NDA International.
Isbell H. Preliminary trials with ibogaine. Personal communication to Ciba. USPHS Hospital, Addiction Research Center, Lexington, KY. November 1956.
Dhahir HI. A comparative study on the toxicity of serotonin. Doctoral dissertation, Indiana University, University Microfilms Intenational 71—25—34. 1971 .-pharmacology, p. 151.
Maissoneuve IM, Keller RW, Glick SD. Interactions between ibogaine, a potential anti-addictive agent, and morphine: An in vivo microdialysis study. Eur J Pharmacol 1991;199:35-42.
Schneider JA, Rinhart RR. Analysis of the cardiovascular action of ibogaine hydrochloride. Arch Int Pharmacodyn 1957;110:92-102.
Mash DC, Staley JK, Baumann MH, etal. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci 1995;57:45— 50.
Clouet NH. Personal communication.
O’Hearn EO, Molliver ME. Degeneration of Purkinje cells in parasagittal zones of cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 1993;55:363-370.
Drugs to relieve spasticity. Drugs Ther Bull 1983;21(I):1—3.
Paulson GW. Overdose of LioresaL Neurology 1976;26:1105-1106.
Lipscomb DJ, Meredith TJ. Baclofen overdose. Postgrad Med J 1980;56:108-109.
Ghose K, Holmes KM, Matthewson K. Complications of baclofen overdosage. Postgrad Med J 1980;56:865— 867.
Ferner RE. Atropine treatment for baclofen overdose. Postgrad Med J 1981;57:580-581.
Blankenship JMK, Moses ES. Baclofen overdose in a child resulting in respiratory arrest. Vet Hum Toxicol 1983;25(suppl. 1):45—46.
Haubenstock A, Aruby K, Jager U, et al. Baclofen (Li-oresalR) intoxication: Report of 4 cases and review of the literature. Clin Toxicol 1983;20(l):59—68.
May CR. Baclofen overdose. Ann Emerg Med 1983;12:171-173.
Kemal M, Imami R, Poklis A. A fatal methocarbamol intoxication. J Forensic Sci 1982;27:217-222.
Faigle JW, Keberle H. The chemistry and kinetics of Li-oresal. Postgrad Med J 1972; October suppl.:9—13.
Katogi Y, Tamaki N, Adachi M, et al. Simultaneous determination of dantrolene and its metabolite, 5-hydrox-ydantrolene, in human plasma by high-performance liquid chromatography. J Chromatogr 1982;228:404-408.
Chlormezanone. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:1521.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1205— 1206.
Brogden RN, Speight TM, Avery GS. Baclofen: A preliminary report of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1974;8:1-14.
Muller H, Borner V, Zierski J, Hempelmann G. Intrathecal baclofen in tetanus. Lancet 1986;1:317-318.
Promising drugs available under treatment IND. FDA Drug Bull 1990(April);20( 1): 10.
Penn RD, Kroin JS. Intrathecal baclofen. N Engl J Med 1989;321:1414-1415.
Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Gilman AG, Goodman LS, Rail TW, et al., eds. The Pharmacological Basis of Therapeutics. 7th ed. New York: Macmillan, 1985:437.
Waterman PM. Malignant hyperthermia syndrome. Am J Ophthalmol 1981;92:461-465.
Bismuth C, de Rohan-Chabot P, Goulon M, et al. Dan-troline: A new therapeutic approach to the neuroleptic malignant syndrome. Acta Neurol Scand 1984;70(suppl. 100):193—198.
Fullerton Т, Gengo FR. Sumatriptan: A selective 5-hy-droxytryptamine receptor agonist for the acute treatment of migraine. Ann Pharmacother 1992;26:800-808.
Рое ТЕ. Personal Communication. Cerenex, Division of Glaxo, February 8, 1993.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. London: Phannaceutical Press, 1993:417.
Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-2835.
Sumatriptan Auto-injection Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto injection device. Eur Neurol 1991 ;31:323— 331.
Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med 1991;325:322-326.
Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-321.
Edvinsson L, Jansen I. Characterization of 5-HT receptors mediating contraction of human cerebral, meningeal and temporal arteries: Target for GR 43 175 in acute treatment of migraine? Cephalgia 1989;9(suppl. 10):49— 55.
Buikena H, Grandjean JG. Potentiation of alpha-adren-oceptor-mediated vasoconstriction by sumatriptan. Lancet 1993;342:1121.
Cavazos JE, Caress JB, Chilukuri VL, et al. Sumatriptan-induced stroke in sagittal sinus thrombosis. Lancet 1994;334:1105-1106.
Lance JW. 5-Hydroxytryptamine and its role in migraine. Eur Neurol 1991;31:279-281.
Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: Reversal by sumatriptan. Lancet 1991;338:13-17.
Yaskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-311.
Brown EG, Endersby СА, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: An overview. Eru Neurol 1991;31:339-344.
Stricker BHC. Coronary vasospasm and sumatriptan. Br Med J 1992;305:118.
Inmana W, Kubota K. Cardiorespiratory distress after sumatriptan given by injection. Br Med J 1992;305:714.
Curtin T, Brooks AP, Roberts JA. Cardiorespiratory distress after sumatriptan given by injection. Br Med J 1992;305:713-714.
McIntyre P, Gemmill J, Hogg K, et al. The effect of subcutaneous sumatriptan (GR 43 175) on central haemodynamics and the coronary circulation. Clin Pharmacol Ther 1992;51:152.
Hillis WS, MacIntyre PD. Sumatriptan and chest pain. Lancet 1993;341:1564-1565.
Ottervanger JP, van Witsen PB, Valkenburg HA, Stricker BHC. Postmarketing study of cardiovascular adverse reactions associated with sumatriptan. Br Med J 1993;307:1185.
Neighbor ML. Sumatriptan: A new treatment of migraine. West J Med 1993;159:597-598.
Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991:31:323—331.
Willett F, Curzen N, Adams J, Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan. Br Med J 1992;304:1415.
Mannens G, Huang M-L, Meuldermans W, et al. Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos 1993;21:1134—1141.
Meco G, Bedini L, Bonifati V, et al. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. Curr Ther Res 1989;46:876-883.
Mesotten F, Suy E, Pietquin M, et al. Therapeutic effect and safety of increasing doses of risperidone (R64 766) in psychotic patients. Psychopharmacology 1992;99:445-449.
Kane JM. Newer antipsychotic drugs: A review of their pharmacology and therapeutic potential. Drugs 1993;46:585-593.
Claus A, Bollen J, De Coyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
Brown K, Levy H, Brenner C, et al. Overdose of risperidone. Ann Emerg Med 1993;22:1908-1910.
Edwards JG. Risperidone for schizophrenia: Encouraging results await further research. Br Med J 1994;308:1311-1312.
Janssen RAJ, Niemegeers CJE, Awouters F, et al. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-C2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685-693.
Heather GS, Vicas IMO. Risperidone overdose: A case series. Vet Hum Toxicol 1994;36:371.
Webston P, Wijeratne C. Risperidone-induced neuroleptic malignant syndrome. Lancet 1994;344:1228-1229.
Lee H, Ryan J, Mullett G, Lawlor PA. Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent. Hum Psychopharmacol 1994;9:303-305.
Kopala L, Homer WG. Risperidone, serotonergic mechanisms and obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 1994;151:1714-1715.
Cohen U. Risperidone. Pharmacopsychotherapy 1994;14:253-265.
Guthrie SK. Sertraline: A new specific reuptake blocker DICP Ann Pharmacother 1991;25:952-961.
De Vane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992;53(sup-pl.):12—30.
Package Insert: ZoloftR (sertraline hydrochloride) tablets. New York: Roerig, Division of Pfizer. January 1992.
Doogan DR. Tolerance and safety of sertraline: Experience. worldwide. Int Clin Psychopharmacol 1991;6(sup-pl. 2):47—56.
Myer LB, Dean BS, Krenzelok EP. Sertraline (ZoloftR): Overdose assessment of a new antidepressant. Vet Hum Toxicol 1993;34:341.
Jambor L. Analysis of two new antidepressants: Paroxetine and sertraline. Calif Assoc Toxicol Newslett, Spring 1992:19-20.
Ostrosky DD. Personal communication. Roerig-Pfizer, April 21, 1992.
Tremaine LM, Welch WM, Romfeld RA. Metabolism and disposition of 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug Metab Dispos 1989;17:542-550.
Fonda HG, Ronfeld RA. Gas chromatographic-mass spectrometric analysis and preliminary pharmacokinetics of sertraline, a new antidepressant drug. J Chromatogr 1987;417:197-207.
Кое PK, Weissman A, Welch WM, et al. Sertraline, IS,4S- A-methyl-4-(3,4dichlorophenyl)-1,2,3,4-tetrahydro-l-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 1983;226:686-700.
Waalinder J, Feighnner JP. Novel selective serotonin reuptake inhibitors: Part I. J Clin Psychiatr 1992;53:107— 117.
Doogan DP, Caillard V. Sertraline: A new antidepressant. J Clin Psychiatry 1988;49(suppl. 9):461.
Ifat first you do succeed. Lancet 1991;337:650-651. Editorial.
Iruela LM. Sudden chest pain with sertraline. Lancet 1994;343:1106.
Reinherr FW, Chauminard G, Cohm CK, et al. Antidepressant efficacy of sertraline: A double-blind, placebo and amitriptyline-controlled, multicenter comparison study in patients with major depression. J Clin Psychiatry 1990;51(12, suppl. B):28-33.
La Porta M, Chouinard G, Goldbloom D, Beauclair L. Hypomania induced by sertraline, a new serotonin reuptake inhibitor. Am J Psychiatry 1987;144:1513-1514.
Gupta S, Freimer M, Popli A. Paradoxical sedation with sertraline. Am J Psychiatry 1993;150:1427-1428.
Crews JR, Potts NLS, Schreiber J, Lippe S. Hyponatremia in a patient with sertraline. Am J Psychiatry 1993;150:1564.
Kaminski CA, Robbins MS, Weibley RE. Sertraline intoxication in a child. Ann Emerg Med 1994;23:1371— 1374.
Shihabuddin L, Rapport D. Sertraline and extrapyrami-dal side effects. Am J Psychiatry 1994; 151:288.
Murdock D, McTavish D. Sertraline: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992;44:604-624.
Kassner J, Woolf A. Sertraline HCI: A new antidepressant. Vet Hum Toxicol 1992;34:343.
Myers LB, Dean BS, Krenzelok ER. Sertraline (Zoloft®): Overdose assessment of a new antidepressant. Vet Hum Toxicol 1993;35:341.
Guy S, Silke B. The electrocardiogram as a tool for therapeutic monitoring: A critical analysis. J Clin Psychiatry 1990;51(12, suppl. B):37—39.
Constantin М, Pognat JF. Comparative study of oxaflo-zane urinary metabolism in man, the dog and the rat. Arzneimittelforschung 1979;29:107-114.
Dutertre JP, Barbier P, Sue AL, et al. Oxaflozane overdose in a child. Clin Toxicol 1992;30:1231-1236.
Aussems G, Bauthier J, Chaillet F, et al. Research on a series of benzofurans: XLV. Pharmacologic profile of ox-etorone. Therapie 1971;261:1135-1155.
Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992;53(suppl.):61 — 66.
Myers LB, Dean BS, Krenzelok ER. A pediatric focus: Paroxetine (PAXL) overdose. Clin Toxicol 1995;33:475-486 (Abstract 172).
De Vane CL. Pharmacokinetics of the selective serotonin reuptake inhibitor. J Clin Psychiatry 1992;52(2, suppl. ):13—20.
Tulloch IF, Johnson AM. The pharmacological profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry 1992;52(2, suppl.):7—12.
Jambon L. Analysis of two new antidepressants, paroxetine and sertraline. Cal Assoc Toxicol Newslett, Spring 1992:19-20.
Kaye CM, Hadock RT, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989;8(suppl. 350):60—75.
Sindrup SH, Brosen K, Gram LF, et al. The relationship between paroxetine and sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-287.
Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-295.
Baldwin JA, Davidson EJ, Pritchard AL, et al. The reproductive toxicology of paroxetine. Acta Psychiatr Scand 1989;8(suppl. 350):37—39.
Adler LA, Angrist BM. Paroxetine and akathisia. Biol Psychiatry 1995;37:336-337.
Paroxetine and extrapyramidal reactions. Lancet 1993;341:624. Editorial.
Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-241.
Tasler TCG, Kaye CM, Zussnam BD, et al. Paroxetine plasma levels: Lack of correlation with efficacy or adverse events. Acta Psychiatr Scand 1989;80(suppl. 350): 152— 155.
Edwards JG, Goldie A, Papayanni-Papasthatis S. Effect of paroxetine on the electrocardiogram. Psychopharmacology 1989;95:96-98.
Jenner PN. Paroxetine: An overview of dosage, tolerability and safety. Int Clin Psychopharmacol 1992;6(sup-pl. 14):69—80.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:416—417.
Griffiths AP, Penn ND, Tindall H. A report of acute overdosage of the anti-serotonergic drug pizotifen. Postgrad Med J 1987;63:59-60.
Gillies D, Sills M, Forsythe I. Pizotifen (Sanoragran) in childhood migraine: A double-blind controlled trial. Eur Neurol 1886;25:32-35.
Peet BMS. Use of pizotifen in severe migraine: A long term study. Curr Med Res Opin 1977;5:192-199.
Behan PO. Prophylactic treatments for migraine: A comparison of pizotifen as clonidine. Cephalalgia 1975;5 (suppl. 3):524— 527.
Speight TM, Avery GS. Pizotifen: A review of its pharmacological properties and its therapeutic efficacy in vascular headaches. Drugs 1972;3:159-203.
Meier J, Schreier E. Human plasma levels of some antimigraine drugs. Headache 1976;16:96-104.
Laplanche R. Determination of BC105 (pizotifen) in body fluids by gas chromatography-mass spectrometry. In: Usdin E, Eckert H, Forrest IS, eds. Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies. Developments in Neurosciences, Vol 7. Amsterdam: Elsevier, 137—140.
Drife JO. Answer. Br Med J 1984;288:375.
Myers RD. Serotonin and thermoregulation: Old and new views. J Physiol (Paris) 1981;77:505-513.
Elghczi JL, Laude D, Duprat P, Mignot E. Pizotifen increases 5-HIAA urinary excretion in male healthy volunteers. Eur J Clin Pharmacol 1984;27:191-196.
Physicians’ Desk Reference. 49th ed. Montvale, NJ: Medical Economics, 1995:858—862.
Drugs recently released in Belgium: Ondansetron. Acta Clin Belg 1991;46:58-60.
Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dose ranging phase I study of the serotonin antagonist GR38 032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989;7:137-141.
Reed MD, Marx CM. Ondansetron: Optimal antiemetic therapy for the poisoned patient. Vet Hum Toxicol 1992;34:336.
Dundee JW, McMillan CM, Yang J, Wright MMC. Is ondansetron a less effective antiemetic against moderately emetic as compared with highly emetic chemotherapy. Br J Clin Pharmacol 1992;33:200-201.
Green JA, Watkin SW, Hammond P, et al. The efficacy and safety of GR38 032F in the prophylaxis of ifosfa-mide-induced nausea and vomiting. Cancer Chemother Pharmacol 1989;24:137-139.
Derswitz M, Rosow CE, Di Biase PM, et al. Ondansetron is effective in decreasing postoperative nausea and vomiting. Clin Pharmacol Ther 1992;52:96-101.
Rosenthal SA, Marquez CM, Hourigan HP, Ryce JH. Ondansetron for patients given abdominal radiotherapy. Lancet 1992;339:490.
Vohra S. High-dose and long-term use of ondansetron. Ann Pharmacother 1992;26:128-129.
Nicholson S, Evans C, Mansi J. Ondansetron in intractable nausea and vomiting. Lancet 1992;339:490.
Stott JRR, Barner GR, Wright RJ, Ruddock CJS. The effect on motion sickness and oculomotor function of GR 38 032F, a 5HT3-receptor antagonist with antiemetic properties. Br J Clin Pharmacol 1989;27:147— 157.
Platt AJ, Heddle RM, Rake MO, Smedley H. Ondansetron in carcinoid syndrome. Lancet 1992;339:1416— 1417.
Steadman SJ, Talley NJ, Phillips SF, Zinsmeister AR. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: A pilot study. Mayo Clin Proc 1992;67:732-738.
Brown SGA, Prentice DA. Ondansetron in the treatment of theophylline overdose. Med J Aust 1992; 156:512.
Chen M, Tanner A, Gallo-Torres H. Anaphylactoid-anaphylactic reactions associated with ondansetron. Ann Intern Med 1993;119:862.
Finn AL. Toxicity and side effects of ondansetron. Semin Oncol 1992; 19(4, suppl. 10):53—60.
Pritchard JF, Wells CD. The relationships between systemic exposure and efficacy of ondansetron. Clin Pharmacol Ther 1990;47:206(Abstract 111).
Davidson JS. Personal communication. Glaxo Pharmaceuticals, August 12, 1992.
Hainsworth J, Harvey W, Pendergrass K, et al. A singleblind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 1991;9:721-728.
Bryson JC. Clinical safety of ondansetron. Semin Oncol 1992;19(suppl. I5):26—32.
Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989;25(suppl. 1):S21—S24.
Colthup PV, Palmer JL. The determination in plasma and pharmacokinetics of ondansetron. Eur J Cancer Clin Oncol 1989;25(stippl. 1):S71— S74.
Pritchard JF, Bryson JC, Kernadle NE, et al. Age and gender effects on ondansetron pharmacokinetics: Evaluation of healthy aged volunteers. Clin Pharmacol Ther 1992;51:51-55.
Lazarus HM, Bryson JC, Lemon E, et al. Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR 38 032F) during multipledrug chemotherapy with cisplatin prior to autologous bone marrow transplantation. J Natl Cancer Inst 1990;82:1776-1778.
Saynor DA, Dixon CM. The metabolism of ondansetron. Eur J Cancer Clin Oncol 1989;25(suppl. 1):S75—S77.
Burnett PK, Perkins J. Parenteral ondansetron for the treatment of chemotherapy and radiation-induced nausea and vomiting. Pharmacotherapy 1992;12:120-131.
Halperin JR, Murphy В. Extrapyramidal reaction to ondansetron. Cancer 1992;69:1275.
Smith RN. Safety of ondansetron. Eur J Cancer Clin Oncol 1989;25(suppl. 1):S47—S50.
Sargent Al, Deppe SA, Chan FA. Seizure associated with ondansetron. Clin Pharm 1993;14:613-615.
Joss RA, Dott CS, Granisteron Study Group. Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. Eur J Cancer 1993;29A(suppl. 1 ):S22— S29.
Sorbe B, Berlind A-M. Tropisetron, a new 5-HT3-recep-tor antagonist, in the prevention of radiation-induced nausea, vomiting and diarrhea. Drugs 1992;43(suppl. 3):33—39.
Kris MG, Tyson LB. Tropisetron (ICS 205-930): A selective 5-hydroxytryptamine antagonist. Eur J Cancer 1993;29A (suppl. l):S30—S32.
Van der Velden JW. Overview of overdose cases with flu-voxamine. Personal communication. The Netherlands: Duphar BV, July 19, 1989 and March 2, 1991.
Henry JA. Overdose and safety with fluvoxamine. Int Clin Psychopharmacol 1991 ;6(suppl. 3):41— 47.
Claassen V, Davies JE, Hertting G, Placheta P. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol 1977;60:505-516.
Claassen V. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol 1983; 15:349S—355S.
Benfield P, Ward A. Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1986;32:313-334.
Flett SR, Szabadi E, Bradshaw CM. Comparison of fluvoxamine and amitriptyline on autonomic functions in healthy volunteers. Br J Clin Pharmacol 1991 ;31:6044.
Stimmel GL, Skowron DM, Chameides WA. Focus on fluvoxamine: A serotonin reuptake inhibitor for major depression and obsessive-compulsive disorder. Hosp Formal 1991;26:635-643.
Mullin J, Pandita-Gunawardena VR, Whitehead AM. A double blind comparison of fluvoxamine and dothepin in the treatment of major affective disorder. Br J Clin Pract 1988;42:51-55.
March JS, Kobak KA, Jefferson JW, et al. A doubleblind placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. J Clin Psychiatry 1990;51:200-202.
Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47:577— 585.
Marin PR, Adinoff B, Eckardt MJ, et al. Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Arch Gen Psychiatry 1989;46:617-621.
Banerjee AK. Recovery from prolonged cerebral depression after fluvoxamine overdose. Br Med J 1988;296:1774.
Lebeque B. Survivable fluvoxamine overdose. Am J Psychiatry 1990; 147:1689.
Azoyan PH, Garnier R, Chataigner D, Efthymiou MI. Toxicokinetics of fluvoxamine in overdose. In: Proceedings, Fourteenth International Congress of the European Association of Poison Centres, Milan, Italy, September 25-29, 1990.
Pitchot W, Gonzalez-Moreno A, Ansseau M. Therapeutic window for 5-HT reuptake inhibitors. Lancet 1992;32:689.
Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk. Br J Clin Pharmacol 1991 ;31:209.
Overmars H, Scherpenisse PM, Post LC. Fluvoxamine maleate: Metabolism in man. Eur J Drug Metab Pharmacokinet 1987;1:269-280.
Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11 year old boy. Drug Saf 1991;6:460-462.
Bertschy G, Vandel S, Vandel B, et al. Fluvoxamine-tri-cyclic antidepressant interaction: An accidental finding. Eur J Clin Pharmacol 1991;40:119-120.
Warnings from the Committee on Safety of Medicine: Fluvoxamine and fluoxetine interactions with MAOIs, lithium and tryptophan. Int Pharm J 1989;3:137.
Deahl M, Trimble M. Serotonin reuptake inhibitors, epilepsy and myoclonus. Br J Psychiatry 1991;159:433— 435.
Lenzi A, Raffaeli S, Marazzit D. Serotonin syndromelike symptoms in patients with obsessive-compulsive disorder following inappropriate increase in fluvoxamine dosage. Pharmacopsychiatry 1993;26:100—101.
Wills V. Extrapyramidal symptoms in a patient treated with fluvoxamine. J Neurol Neurosurg Psychiatry 1992;55:330-331.
Mallya G, White K, Gunderson C. Is there a serotonergic withdrawal syndrome? Biol Psychiatry 1993;33:851 — 852.
Foglia JP, Perel JM, Nathan RS, et al. Therapeutic drug monitoring (TDM) of fluvoxamine: A selective antidepressant. Clin Chem 1990;36:1043.
Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;34:146-149.
Arnott S, Nutt D. Successful treatment of fluvoxamine-induced anorgasmia by cypropheptadine. Br J Psychiatry 1994;164:833-836.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:366—367.
Roffe C, Tidmarsh M, Howlett TA. Ketanserin overdose: A case report. Postgrad Med J 1991 ;67:857.
Waller PC, Tucker GT, Ramsay LE. The pharmacokinetics of ketanserin after a single dose and at steady-state in hypertensive subjects. Eur J Clin Pharmacol 1887;33:423-426.
Persson B, Heykants J, Hedner T. Clinical pharmacokinetics of ketanserin. Clin Pharmacokinet 1991;2:263— 279.
Waller PC, Cameron HA, Ramsay LE. Profound hypotension after the first dose of ketanserin. Postgrad Med J 1987;63:305-307.
Andren L, Svensson A, Dahlof B, et al. Ketanserin in hypertension. Acta Med Scand 1983;210:125-130.
Barendregt JNM, Van Peer A, Van der Hoeven JG, et al. Ketanserin pharmacokinetics in patients with renal failure. Br J Clin Pharmacol 1990;29:715-727.
Reimann IV, Okonkwo PO, Klotz U. Pharmacokinetics ofketanserin in man. Eur J Clin Pharmacol 1983;25:73— 76.
Brogden RN, Sorkin ЕМ. Ketanserin: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in hypertension and peripheral vascular disease. Drugs 1990;40:903-949.
Lebrec D, Hadengue A, Gaudin C, et al. Pharmacokinetics of ketanserin in patients with cirrhosis. Clin Pharmacokinet 1990;19:160-166.
Ketanserin Trial Group. Prevention of atherosclerotic complications: Controlled trial of ketanserin. Br Med J 1989;298:424-430.
Kirkendall WM. Prolonged QTC, thiazides and sudden death. Arch Intern Med 1991;151:398-399.
Vandermotten M, Verhaeghe R, de Geest H. Ventricular arrhythmias and QTprolongation during therapy with ketanserin: Report of a case. Acta Cardiol 1989;44:431-437.
Vanhoutte P, Amery A, Birkenhager W, et al. Serotonergic mechanisms in hypertension: Focus on the effects of ketanserin. Hypertension 1988; 11:1113—1133.
Singh B, Nademanee K, Symoens J, Janssens M. Ketanserin and Qtc prolongation. Eur Heart J 1987;8:667— 668.
Donnelly R, Elliott HL, Meredith PA, et al. Ketanserin concentration-effect relationship in individual hypertension patients. Br J Clin Pharmacol 1988;26:61-62.
Nademanee K, Lockhart E, Pruitt C, Singh BN. Cardiac electrophysiologic effects of intravenous ketanserin in humans. J Cardiovasc Pharmacol1987; 10(suppl.3):581—585.
Weiner CP, Socol ML, Vaisrab N. Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist. Am J Obstet Gynecol 1984; 149:496— 500.
Bogle RG. Ketanserin for hypertension after upper gastrointestinal surgery. Lancet 1991;337:1219-1220.
Blauw GJ, Van Brummelen P, Doorenbos CJ, et al. The acute and chronic antihypertensive effects of ketanserin cannot be explained by blockade of vascular serotonin, type 2, receptors or alpha, adrenergic receptors. Clin Pharmacol Ther 1991;49:377-384.
O’Rangero EA, White WB, Chow MSS. Focus on ketanserin: A serotonin antagonist for the treatment of mild to moderate essential hypertension. Hosp Formul 1991;26:99-106.
Cazzola M, Matera MG, Santangelo G, et al. Effect of the selective 5HT2 antagonist ketanserin on adenosine-induced bronchoconstriction in asthmatic subjects. Immunopharmacology 1992;23:21-28.
Van Gool N. Personal communication. Janssen Research Foundation, September 8, 1992.
Okonkwo PO, Reimans IV, Woestenborghs R, Klotz U. High performance liquid chromatography assay with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma. J Chromatogr 1983;272:411-416.
Lindelauf F. Determination of ketanserin and its major metabolite (reduced ketanserin) in human plasma by high performance liquid chromatography. J Chromatogr 1983;277:396-400.
Van Camp G, Dereppe H, Renard M, Bernard R. Ketanserin and syncope. Acta Cardiol 1989;44:429-430.
Ooi ТК. The serotonin syndrome. Anaesthesia 1991;46:507-508.
Sternbach H. Danger of MAO1 therapy after fluoxetine withdrawal. Lancet 1988;2:850-851.
Bodkin JA, Teicher MH. Fluoxetine may antagonize the anxiolytic buspirone. J Clin Psychopharmacol 1989;9:150.
Tanquary J, Masand P. Paradoxical reaction to buspirone augmentation of fluoxetine. J Clin Psychopharmacol 1990;10:377.
Metz A. Interaction between fluoxetine and buspirone. Can J Psychiatry 1990;35:722-723.
Naranjo CA, Kadlec KE, Sanhueza P, et al. Fluoxetine differentially alters alcohol intake and other consumatory behaviors in problem drinkers. Clin Pharmacol Ther 1990;47:490-498.
Lemberger L, Rowe H, Bergstrom RF, et al. Effect of fluoxetine on psychomotor performance, physiologic response and kinetics of ethanol. Clin Pharmacol Ther 1985;37:658-664.
Noveske FG, Hahn KR, Flynn RJ. Possible toxicity of combined fluoxetine and lithium. Am J Psychiatry 1989; 146:1515.
Pope HG Jr, McElroy SL, Nixon RA. Possible synergism between fluoxetine and lithium in refractory depression. Am J Psychiatry 1988;145:1292-1294.
Hadley A, Cason MP. Mania resulting from lithiumfluoxetine combination. Am J Psychiatry 1989;146:1637-1638.
Sacristan JA, Iglesias C, Arellano F, Lequerica J. Absence seizures induced by lithium: Possible interaction with fluoxetine. Am J Psychiatry 1991;148:146-147.
Salana AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry 1989; 146:278.
Wright R, Ram S. Lithium toxicity, hypomania and leu-cocytosis with fluoxetine. Ir J Psychol Med 1992;9:59— 60.
Suchowersky O, Devries J. Possible interactions between Deprenyl and Prozac. Can J Neurol Sci 1990;17:352— 353.
Stoll AL, Cole JO, Lukas SE. A case of mania as a result of fluoxetine-marijuana interaction. J Can Psychiatry 1991;32:280-281.
Goodwin FK. Fluoxetine lowers rat cocaine use. JAMA 1990;263:1610.
Goldbloom DS, Kennedy SH. Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. J Clin Psychiatry 1991;52:261-262.
Feder R. Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. J Clin Psychiatry 1991;52:163-164.
Hansen ТЕ, Dieter K, Keepers GA. Interaction of fluoxetine and pentazocine. Am J Psychiatry 1990; 147:949— 950.
Stein MH. Tardive dyskinesia in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1991; 148:683.
Nightingale LL. Fluoxetine labeling revised to identify phenytoin interaction and to recommend against use in nursing mothers. JAMA 1994;271:1067.
Stark P, Fuller RW, Wong DT. The pharmacologic profile of fluoxetine. J Clin Psychiatry 1985;46(3, sect. 2]:7—13.
Chiang WK, Ford M, Wax P, et al. Prospective evaluation of fluoxetine ingestions. Vet Hum Toxicol 1990;32:348.
Spiller HA, Morse S, Muir C. Fluoxetine ingestion: A one year retrospective study. Vet Hum Toxicol 1990;32:153-155.
Jenkins J, Shannon MW, Woolf A. Fluoxetine intoxication: Clinical course and serum concentrations. Vet Hum Toxicol 1990;32:348.
Moore JL, Rodriguez R. Toxicity of fluoxetine in overdose. Am J Psychiatry 1990; 147:1089.
Borys DJ, Seltzer SC, Ling U, et al. Acute fluoxetine overdose. Vet Hum Toxicol 1990;32:348.
Borys DJ, Seltzer SC, Ling LJ, et al. The effects of fluoxetine in the overdose patient. J Toxicol Clin Toxicol 1990;28:331-340.
Kim SW, Pentel PR. Flu-like symptoms associated with fluoxetine overdose: A case report. Clin Toxicol 1989;27:389-393.
Braitberg G, Curry S. Fluoxetine-induced seizure after overdose. Vet Hum Toxicol 1994;36:372.
Ogilvie AD. Hair loss during fluoxetine treatment. Lancet 1993'342:1423.
Gram LF. Fluoxetine. N Engl J Med 1995;332:960— 961.
Fishbain DA, Dominguez M, Goldberg M, et al. Dyskinesia associated with fluoxetine use. Neuropsychiatry Neuropsychol Behav Neurol 1992;5:97-100. Case report.
LitovitzTL, Schmitz BF, Bailey KM. 1989 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1990;8:438.
Chiang WK, Ford M, Wax P, et al. Prospective evaluation of fluoxetine ingestions. Ann Emerg Med 1991 ;20:1084.
Teicher MH, Glod C, Cole JO. Emergency of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207-210.
Papp LA, Gorman JM. Suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147:1380.
Teicher MH, Glod C, Gole JO. Suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:1380-1381.
Dasgupta K. Additional cases of suicidal ideation associated with fluoxetine. Am J Psychiatry 1990; 147:1570.
Fichtner CG, Jobe TH, Braun BG. Does fluoxetine have a therapeutic window? Lancet 1991;338:520-521.
Downs J, Ward J, Farmer R. Preoccupation with suicide in patients treated with fluoxetine. Am J Psychiatry 1991;148:1090-1091.
Tollefson GD. Fluoxetine and suicidal ideation. Am J Psychiatry 1990;147:1691-1692.
Healy D, Creasey W. Fluoxetine and suicide. Br Med J 1991;303:1058-1059.
Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: The role of akathisia. J Clin Psychiatry 1991;52:491-493.
Ahmad SR. USA: Fluoxetine "not linked to suicide." Lancet 1991;338:875-876.
Mann JJ, Kapur S. The emergency of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry 1991;48:1027-1033.
Fava M, Rosenbaum JF: Suicidality and fluoxetine: Is there a relationship? J Clin Psychiatry 1991;52:108-111.
Beasley CM Jr, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. Br Med J 1991 ;303:685.
Fluoxetine, suicide and aggression. Drug Ther Bull 1992;30:5-6.
Miller LG, Bowman RC, Mann D, Tripathy A. A case of fluoxetine-induced serum sickness. Am J Psychiatry 1989;146:1616-1617.
Ware MR, Stewart RB. Seizures associated with fluoxetine therapy. DICP Ann Pharmacother 1989;23:428.
Ahmad S. Fluoxetine and glaucoma. DICP Ann Pharmacother 1991;25:436.
Guthrie S, Greenhaus L. Fluoxetine-induced stuttering. J Clin Psychiatry 1990;51:85.
Lazarus A. Rhabdomyolysis in a depressed patient following overdose with combined drug therapy and alcohol. J Clin Psychopharmacol 1990;10:154-155.
Browning WN. Exacerbation of symptoms of multiple sclerosis in a patient taking fluoxetine. Am J Psychiatry 1990; 147:1089.
Buff DD, Bremmer R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991 ;52: 174-176.
Ellison JM, Milofsky JE, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990;51:385-386.
Gardner SF, Rutherford WF, Munger MA, Panacek EA. Drug-induced supraventricular tachycardia: A case report of fluoxetine. Ann Emerg Med 1991;20:194-197.
Cunningham M, Cunningham K, Lydiard RB. Eye tics and subjective hearing impairment during fluoxetine therapy. Am J Psychiatry 1990;147:947-948.
Reccoppa L, Welch WA, Ware MR. Acute dystonia and fluoxetine. J Clin Psychiatry 1990;51:487.
Hughes T, Sugarman P. Assault after ingestion of antidepressant. Br Med J 1991 ;303:1552.
Pagliano LA, Pagliaro AM. Fluoxetine abuse by an intravenous drug use. Am J Psychiatry 1993; 150:1818.
Goldstein DJ, Williams ML, Pearson DK. Fluoxetine-exposed pregnancies. Clin Res 1991 ;39:768A.
Isenberg KE. Excretion of fluoxetine in human breast milk. J Clin Psychiatry 1990;51:169.
Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 1994;92:721-722.
Nash JF, Bopp RJ, Carmichael RH, et al. Determination of fluoxetine and norfluoxetine in plasma by gas chromatography with electron-capture detection. Clin Chem 1982;28:2100-2102.
Column CN. Liquid-chromatographic assays of tricyclic antidepressants and metabolites. Clin Chem 1991;37:1304-1305.
Kelly MW, Perry PJ, Holstad SG, Gravey JJ. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 1989;11:165-170.
Natasimhachari N, Silverman J, Landa B. Quantitation of fluoxetine and norfluoxetine in serum samples by HPLC. Clin Pharmacol Ther 1990;47:192.
Hoover CE. Fluoxetine as a cause of SIADH. Am J Psychiatry 1991;148:542-543.
Gommans JH, Edwards RA. Fluoxetine and hyponatraemia. NZ Med J 1990; 103:106.
Hwang AS, Magraw RM. Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine. Am J Psychiatry 1989; 146:399.
Brown RP, Kocis JH, Cohen SK. Delusional depression and inappropriate antidiuretic hormone secretion. Biol Psychiatry 1983;18:1059-1063.
Staab JP, Yerkes SA, Cheney AM, Clayton AH. Transient SIADH associated with fluoxetine. Am J Psychiatry 1990;147:1569-1570.
Humphries JE, Wheby MS, Vanden Berg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med 1990;114:727-728.
Evans TG, Buys SS, Rodgers GM. Acquired abnormalities of platelet dysfunction. N Engl J Med 1991 ;324: 1671.
Hoehn-Saric R, Harris GJ, Pearlson GD, et al. A fluoxetine-induced frontal lobe syndrome in an obsessive-compulsive patient. J Clin Psychiatry 1991;52:131-133.
Mars F, Dumas de la Roque G, Goissen P. Acute hepatitis during treatment with fluoxetine. Gastroenterol Clin Biol 1991;15:270-271.
Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985;46(3, sect. 2):42—44.
Goodnick PJ. Pharmacokinetics of second generation antidepressants: Fluoxetine. Psychopharmacol Bull 1991;27:503-512.
Bronson K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6: The source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991:32:136—137.
Bell 1R, Cole JO. Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsy-chotic depression. J Clin Psychopharmacol 1988;8:447— 448.
Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 1988; 145:1478.
Westermeyer J. Fluoxetine-induced tricyclic toxicity: Extent and duration. J Clin Pharmacol 1991 ;31:388— 392.
Kahn DG. Increased plasma concentration in a patient cotreated with fluoxetine. J Clin Psychiatry 1990;51.36.
Aranow RB, Hudson JI, Pope HG Jr, et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 1989;146:911-913.
Cavanaugh SVA. Drug-drug interactions of fluoxetine with tricyclics. Psychosomatics 1990;31:273-276.
Preskorn SH, Beber JH, Faul JC, Hirschfield RMA. Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am J Psychiatry 1990; 147:532.
Swerdlow NR, Andia AM. Trazodone-fluoxetine combination for treatment of obsessive-compulsive disorder. Am J Psychiatry 1989:146:1637.
Metz A, Shader Rl. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. Int Clin Psychopharmacol 1990;5:191-194.
Tate JL. Extrapyramidol symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989;146:399-400.
Goff DC, Midha KK, Brotman AW, et al. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 1991;148:790-792.
Lemberger L, Rowe H, Bosomworth JC, et al. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988;43:412-419.
Lock JD, Gwirtsman HE, Targ EF. Possible adverse drug reactions between fluoxetine and other psychotropics. J Clin Pharmacol 1990;10:383-384.
Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and 1-tryptophan: Five case reports. Biol Psychiatry 1986;21:1067—1071.
Hynes MD, Lochner MA, Bemis KG, Hymson DL. Fluoxetine, a selective inhibitor of serotonin uptake, potentiates morphine analgesia without altering its discriminative stimulus properties or affinity for opioid receptors. Life Sci 1985;36:2317-2323.
Grimsley SR, Jann MW, D’Mello AP, et al. Pharmacodynamics and pharmacokinetics of fluoxetine/car-bamazepine interaction. Clin Pharmacol Ther 1991 ;49:135.
Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 1990;51:126.
Grimsley SR, Jann MW, Carter HG, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50:10-15.
Hunger HC, Thomas F. Fluoxetine and warfarin interactions. NZ Med J 1995;108:157.
Graham PM, llett KF. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988;2:1255-1256.
Chiang WK, Smilkstein MJ. Fluoxetine-monoamine oxidase inhibitor interaction. Vet Hum Toxicol 1989;31:369.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:935—937.
Hakkou F, Jaouven C, Iraki L. A comparative study of cypropheptadine and dl-carnitine on psychomotor performance and memory in healthy volunteers. Fundam Clin Pharmacol 1990;4:191-200.
Bharucha BA, KalawalaTY, Pandya AL, et al. Cypropheptadine poisoning. Indian Pediatr 1987;24:165-169.
Muhlendahl KE, Krienke EG. The toxicity of cypropheptadine, side effects and accidental poisoning. Monatss-chr Kinderheilkd 1978;126:123-126.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:16-17.
McCormick S, Olin J, Brotman AW. Reversal of fluoxetine in induced inorgasmia by cypropheptadine in two patients. J Clin Psychiatry 1990;51:383-384.
Fasanella RM, Aghajanian GK. Treatment of benign essential blepharospasm with cypropheptadine. N Engl J Med 1990;322:778.
Bacher NM, Lewis HA, Field PB. Cypropheptadine in movement disorders. Am J Psychiatry 1989; 146:557— 558.
Bjorkman A, Willcox M, Kihamia CM, et al. Field study of cypropheptadine/chloroquine synergism in falciparum malaria. Lancet 1990;336:59-60.
Peters W, Ekong R, Robinson BL, et al. Antihistamine drugs that reverse chloroquine resistance in Plasmodium falciparum. Lancet 1989;2:334-335.
Brophy MH. Cypropheptadine for combat nightmare in posttraumatic Shers disorder and dream anxiety disorder. Milit Med 1991;156:100-101.
Hintze KL, Wold JC, Fischer U. Disposition of cypropheptadine and dl-carnitine on psychomotor performance and memory in healthy volunteers. Fundam Clin Pharmacol 1990;4:191-200.
Hucker HB, Hutt JE. Determination of cypropheptadine in plasma and urine by GLC with a nitrogen-sensitive detector. J Pharmacol Sci 1983;72:1069-1070.
Novak EA, Stanley M, McIntyre IM, Hryhorczuk L. High performance liquid chromatographic method for quantification of cypropheptadine in serum or plasma. J Chromatogr 1985;339:457-461.
Byerley WF, Reimhert FW, Wood DR, Grosser Bl. Fluoxetine, a selective serotonin uptake inhibitor for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988;8:112—115.
Chouinard G. A double blind controlled trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorders. J Clin Psychiatry 1985;46(3, sect. 2):32—37.
Feighner JP, Cohn JB. Double blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry 1985;46(3, sect. 2):20—25.
Leibowitz MR, Hollander E, Schneier F, et al. Fluoxetine treatment of obsessive-compulsive disorder: An open clinical trial. J Clin Psychopharmacol 1989;9:423-427.
Debus JR, Rush AJ, Hummel C, et al. Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry 1988;49:422-426.
Kinney-Parker JL, Smith D, Ingle SF. Fluoxetine and weight: Something lost and something gained? Clin Pharm 1989;8:727-733.
Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparison of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:926-932.
Liebowitz MR, Hollander E, Fairbanks J, Campeas R. Fluoxetine for adolescents with obsessive-compulsive disorder. Am J Psychiatry 1990;147:370-371.
Como PG, Kurlan R. An open-label trial of fluoxetine for obsessive-compulsive disorder in Gilles de la Tourette’s syndrome. Neurology 1991;41:872-874.
Fava M, Herzog DB, Hamburg P, et al. Long-term use of fluoxetine in bulimia nervosa: A retrospective study. Ann Clin Psychiatry 1990;2:53-56.
Ramirez LC, Rosenstock J, Strowig S, et al. Effective treatment of bulimia with fluoxetine in a patient with type 1 diabetes mellitus. Am J Med 1990;88:540-541.
Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: A multicenter placebo-controlled double-blind trial. Arch Gen Psychiatry 1992;49:139-147.
Gwirtsman HE, Guze BH, Yager J, Gainsley B. Fluoxetine treatment of anorexia nervosa: An open clinical trial. J Clin Psychiatry 1990;51:378-382.
Lee S. Fluoxetine in anorexia nervosa. J Clin Psychiatry 1991;52:240-241.
Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP. Fluoxetine effect on weight loss in obese subjects. Am J Clin Nutr 1991;54:321-325.
McEvoy GK, ed. AHFS Drug Information 42. Bethesda, MD: American Society of Hospital Pharmacists, 1992:1236-1246.
Frey J. Fluoxetine suppresses human cataplexy: A pilot study. Neurology 1990;40(suppl. 1): 13T.
Schneier FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990;10:119-121.
Sobin P, Schneider L, McDermott H. Fluoxetine in the treatment of agitated dementia. Am J Psychiatry 1989:146:1636.
Metz A. Fluoxetine treatment of premenstrual syndrome. J Clin Psychiatry 1990;51:260.
Lorefice LS. Fluoxetine treatment of a fetish. J Clin Psychiatry 1991;52:41.
Alexander RC. Fluoxetine treatment of trichotillomania. J Clin Psychiatry 1991 ;52:88.
Gross MD. Treatment of pathological jealousy by fluoxetine. Am J Psychiatry 1991;148:683-684.
Todd RD. Fluoxetine in autism. Am J Psychiatry 1991:1118:1089.
Theesen KA, Marsh WR. Relief of diabetic neuropathy with fluoxetine. DICP Ann Pharmacother 1989;23:572— 576.
Stoll AL, Pope HG Jr, McElroy SL. High dose fluoxetine: Safety and efficacy in 27 cases. J Clin Psychopharmacol 1991;11:225-226.
Beasley CM Jr. Personal communication. Lilly Research Laboratories, September 30, 1991.
Rohrig TP, Prouty RW. Fluoxetine overdose: A case report. J Anal Toxicol 1989;13:305-307.
Fraser AD, Isner AF, Susnik E. A fluoxetine related fatality. Bull I nt Assoc Forens Toxicol 1991 ;21 (3):23—25.
Kincaid RL, McMullin MM, Crookham SB, Riedero F. Report of a fluoxetine fatality. J Anal Toxicol 1990;14:327-329.
Roettger JR. The importance of blood collection site for determination of basic drugs: A case with fluoxetine and diphenhydramine overdose. J Anal Toxicol 1990;14:191-192.
Benfield P, Heel RC, Lewis SP. Fluoxetine: A review of its pharmacodynamics and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1986;32:481-508.
Aronoff GR, Bergstrom RF, Pottratz ST, et al. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 1984;36: 238-244.
Pato MT, Murphy DL, DeVane CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 1991; 11:224—225.
Orsulak PJ, Kenney JT, Debas JR, et al. Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reverse-phase HPLC with ultraviolet detection. Clin Chem 1988;34:1875-1878.
Goldstein DJ, Williams ML. Fluoxetine exposed pregnancies. Clin Res 1992;40:168A.
Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first trimester exposure to fluoxetine (ProzacR). JAMA 1993;269:2246-2248.
Burch KJ, Wells GB. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics 1991 ;89(pt I):676— 677.
Levinson ML, Lipsy RJ, Fuller DK. Adverse effects and drug interactions associated with fluoxetine therapy. DICP Ann Pharmacother 1991;25:657-661.
Ciraulo DA, Shader RL Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. J Clin Psychopharmacol 1990;10:48-50.
Keuthen NJ, Cyr Р, Ricciardi JA, et al: Medical withdrawal symptoms in obsessive-compulsive disordered patients treated with paroxetine. J Clin Psychopharmacol 1994;14:206-207.
Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuance. Am J Psychiatry 1994; 15:289.
Louie AK, Lannon RA, Ajari U. Withdrawal reaction after sertraline discontinuation. Am J Psychiatry 1994;151:450-451.
Lauterbach EC. Fluoxetine withdrawal and chronic pain. Neurology 1994;44:983-984.
Eison AS. Azapirones: History of development. J Clin Psychopharmacol 1990; 10:25—55.
Batki SL. Buspirone in drug users with AIDS or AIDS-related complex. J Clin Psychopharmacol 1990;10:l 1 IS—115S.
Neppe VM. High dose buspirone in case of tardive dyskinesia. Lancet 1989;2:1458.
Garvin F, Compton M, Byck R. Buspirone reduces smoking. Arch Gen Psychiatry 1989;46:288-289.
Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorders. Am J Psychiatry 1990;147:798-800.
Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991;149:512-516.
Tiller JWG, Burrows GD, O’Sullivan ВТ. Buspirone overdose. Med J Aust 1989;150:54-55.
Goetz CM, Krenzelok EP, Lopez G, Borys D. Buspirone toxicity: A prospective study. Ann Emerg Med 1990; 19:630.
Mayol RF, Adamson DS, Gammans RE, La Budde JA. Pharmacokinetics and disposition of l4C-buspirone HCI after intravenous and oral dosing in man. Clin Pharmacol Ther 1985;37:210.
Bullen WW, Bivens DL, Gammans RE, La Budde JA. The binding of buspirone to human plasma proteins. Fed Proc 1985;44:1123.
Bodkin J A, Teicher MH. Fluoxetine may antagonize the anxiolytic action of buspirone. J Clin Psychopharmacol 1989:9:150.
Balster RL. Abuse potential of buspirone and related drugs. J Clin Psychopharmacol 1990; 10:31S—37S.
Raleigh FR. Buspirone: Potential for abuse? DICP Ann Pharmacother 1989;23:1035.
Lader M. Assessing the potential for buspirone dependence or abuse and effects of its withdrawal. Am J Med 1987;82(suppl. 5A):20-26.
Rock NL. Possible adverse effects of buspirone when used with other psychotropic drugs. J Clin Psychopharmacol 1990,10:380—381.
Yocca FD. Neurochemistry and neurophysiology of buspirone and gepirone: Interactions at presynaptic and postsynaptic 5-HTia receptors. J Clin Psychopharmacol 1990;10:6S—12S.
Tan SA, Tan LG. The effects of buspirone on the peripheral beta-endorphin and norepinephrine levels. Clin Res 1989;37:104A.
Raleigh FR. Buspirone: Potential for abuse? DICP Ann Pharmacother 1989;23; 1035.
Boylan K. Persistent dystonia associated with buspirone. Neurology 1990;40:1904.
Le Witt PA, Walters A, Hening W, McHale D. Persistent movement disorders induced by buspirone. Mov Disord 1993;8:331-334.
Mclvor RJ, Sinanan K. Buspirone-induced mania. Br J Psychiatry 1991;158:136-137.
Pols HJ, Griez E, Zandbergen J. Does buspirone have anxiogenic properties? Lancet 1989;2:682-683.
Liegghio NE, Yeragani VK. Buspirone-induced hypomania: A case report. J Clin Psychopharmacol 1988;8:226.
Price WA, Bielefeld M. Buspirone-induced mania. J Clin Psychopharmacol 1989;9:150-151.
McDaniel JS, Ninan PT, Magnuson JV. Possible induction of mania by buspirone. Am J Psychiatry 1990;140:125-126.
Fuller RW. Buspirone metabolite and panic attacks. Lancet 1990;2:470.
Chignon JM, Lepine JP. Panic and hypertension associated with single dose of buspirone 1989;2:46-47.
Coates NE. Priapism associated with Buspar. South Med J 1990;83:983.
Napoliello MJ, Domantay AG. Buspirone: A world wide update. BrJ Psychiatry 1991; 159(suppl. 12):40—44.
Eudy SF, Conch LH, Morrow MG, et al. Analysis of buspirone, a new anxiolytic agent by high pressure liquid chromatography. AJCP 1989.
Kerns EH. Quantitative analysis of l,2-(2-pyrimidi-nyl)piperazine in plasma by capillary gas chromatogra-phy/mass spectrometry. J Chromatogr 1986;377:195— 203.
Sternbach Н. The serotonin syndrome. Am J Psychiatry 1991;148:705-713.
Mills КС. Serotonin toxicity: A comprehensive review of emergency medicine. Top Emerg Med 1993;15:54-73.
Luck I, Nobler MS, Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther 1989;1:133-139.
Azmitia EC, Whitaker-Azmitia PM. Awakening the sleeping giant: Anatomy and plasticity of the brain serotonergic system. J Clin Psychiatry 1991 ;52(suppl.):4—16.
Miller F, Friedman R, Tanenbaum J, Griffin A. Disseminated intravascular coagulation and acute myoglobinuric renal failure: A consequence of the serotonergic syndrome. J Clin Psychophannacol 1991;11:277-279.
Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharm Ther 1993;5:84— 88.
Klein SS, Mauro LS, Scala-Barnett DM, Zick D. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm 1989;8:510-514.
Sporer KA. The serotonin syndrome: Implicated drugs, pathophysiology and management. Drug Saf 1995;13:94-104.
Tueth MJ. The serotonin syndrome in the emergency department. Ann Emerg Med 1993;22:1369.
Feighner JP, Boyes WF, Tyler DL, et al. Adverse consequences of fluoxetine-MAO I combination therapy. J Clin Psychiatry 1990;51:222-225.
Neuvonen PJ, Pohjoia-Sontonen S, Tacke U, Vuor L. Five fatal cases of serotonin syndrome after mo-clobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993;342:1410.
Insel TR, Roy BF, Cohen RM, et al. Possible development of the serotonin syndrome in man. Am J Psychiatry 1982;139:954-955.
Brown TCK, Cass NM. Beware: The use of MAO inhibitors is increasing again. Anaesth Intens Care 1979;7:65-68.
Rivers N, Hornier B. Possible lethal reaction between NardilR and dextromethorphan. Can Med Assoc J 1970; 103:85.
Hansen ТЕ, Dieter K, Keepers GA. Interaction of fluoxetine and pentazocine. Am J Psychiatry 1990;147:949— 950.
Lenzi A, Raffaeli S, Marazziti D. Serotonin syndromelike symptoms in a patient with obsessive-compulsive disorder following inappropriate increase in fluvoxamine dosage. Pharmacopsychiatry 1993;26:100-101.
Ohman R, Spigset O. Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry 1993;26:263-264.
Reeves RR, Bullen JA. Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics 1995;36:159-160.
Dursun SM, Mathew VM, Revelrey MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 1993;342:442-443.
Henry JA. Serotonin syndrome. Lancet 1994;343:607.
Lappin Rl, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 1994;331:1091-1092.
Blier Р, de Montigny С, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: Preclinical evidence. J Clin Psychiatry 1990;51 (suppl.): 14-20.
Bockaert J, Fozard JR, Dumuis A, Clarke DC. The 5-HTj receptor: A place in the sun. Trends Pharmacol Sci 1992;13:141-144.
Cowen PJ. A role for 5-HT in the action of antidepressant drugs. Pharmacol Ther 1990;46:43-51.
Drugs acting on 5-hydroxytryptamine receptors. Lancet 1989;2:717-719. Editorial.
Peroutka SJ. VI. Serotonin receptor subtypes and neuropsychiatric diseases: Four of 5-HT1D and 5-HT3 receptor agents.
Van Heuven-Nolsen. 5-HT receptor subtype-specific drugs and the cardiovascular system. Trends Pharmacol Sci 1988;9:423-425.
Zifa E, Fillion G. 5-Hydroxytryptamine receptors. Pharmacol Rev 1992;44:402-458.
5-HT blockers and all that. Lancet 1990;336:345-346. Editorial.
Price LH, Charney DS, Delgado DL, et al. Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. J Clin Psychiatry 1990;5 l(sup-pl.):44—50.
If at first you do succeed. Lancet 1991;337:650-651. Editorial.
Talley NJ. 5-Hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: Clinical implications. Aliment Pharmacol Ther 1992;6:273-289. Review Article.
Ashton CH, Teoh R, Davies DM. Drug-induced stupor and coma: Some physical signs and their pharmacological basis. Adverse Drug React Acute Poison Rev 1989;8:1-59.
Huebner GD. Piscataway, NJ: Personal communication. Janssen Research Foundation, February 28, 1989.
Tobin JR, Doyle TP, Ackerman AD, Brenne JI. Astem-Izole-induced cardiac conduction disturbances in a child. JAMA 1991;266:2737-2740.
Non-sedating antihistamines. Aust Adverse Drug React Bull, May 1991;10.
Cook CE, Williams DL, Myers M, et al. Bioavailability of terfenadine in man. Biopharm Drug Dispos 1981;2:185-190.
Woestenborghs R, Embrects LL, Heykants J. Simultaneous determination of astemizole and its demethylated metabolites in animal plasma and tissues by high performance liquid chromatography. J Chromatogr 1983;278:359-366.
Saviuc P, Dane) V, Dixmerias F. Prolonged QT interval and Torsade de pointes following astemizole overdose. Clin Toxicol 1993;31:121-125.
New boxed warnings added for seldane, hismanal. FDA Med Bull 1992;22(2): 1—2.
Pohjola-Sintoren S, Viitasalo M, Toivonen L, Neuvonen P. Torsade de pointes after terfenadine-itraconazole interaction. Br Med J 1993;306:186.
Craft TM. Torsade de pointes after astemizole overdose. Br Med J 1986;292:660.
Nightingale SL. US Food and Drug Administration warnings issued on nonsedating antihistamines, terfenadine and astemizole. JAMA 1992;268:705.
Rao KA, Adiakha A, Verna-Ansil B, et al. Torsade de pointes ventricular tachycardia associated with overdose of astemizole. Mayo Clin Proc 1994;6:589-593.
Bertaccini G, Coruzzi G, Poli E. Review article: The histamine H3 receptor: A novel prejunctional receptor regulating gastrointestinal function. Aliment Pharmacol Ther 1991;5:585-591.
Kelloway JS, Pongowski МА, Schoenwetter WF. Additional causes of Torsade de pointes. Mayo Clin Proc 1995;70:197-200.
Woodward J K. Pharmacology and toxicology of neoclassical antihistamines. Cutis 1988;42:5-9.
Monahan BP, Ferguson CL, Killearny ES, et al. Torsade de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-2790.
BastockyJ, Krasnicka J, Vortel J, et al. Severe intoxication with antihistamines complicated by ventricular tachycardia. Vnitrni Lekarstri 1990;36:266-269.
MacConnell TJ, Stanneis AJ. Torsade de pointes: Complication of treatment with terfenadine. Br Med J 1991;30:1469.
Roney JE. Personal communication. Marion Merrell Dow, May 15, 1991.
Spiller HA, Picciotti M, Perez E. Accidental terfenadine ingestion in children. Vet Hum Toxicol 1989;31:154— 156.
Barenholtz HA, McLeod DC. Loratidine: A nonsedating antihistamine with once daily dosing. DICP Ann Phar-macother 1989;23:445-450.
Eller MG, Walker BJ, Westmark PA, et al. Pharmacokinetics of terfenadine in healthy elderly subjects. J Clin Pharmacol 1992;32:267-277.
Wiley JF II, Gelber ML, Henretig FM, et al. Cardiotoxic effects of astemizole overdose in children. J Pediatr 1992;120:799-802.
Clissold SP, Sorkin EM, Goa KL. Loratidine: A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1989;27:42-57.
Simons FER, Kesselman MS, Giddins NG, et al. Astemizole induced Torsade de pointes. Lancet 1988;2:624.
Brogden RN, McTavish D. Acrivastine: A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs 1991;41:927-940.
Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-238.
Safety of terfenadine and astemizole. Med Lett Drugs Ther 1992;34(863):9—10.
Dear Health Care Professional Letter. Marion Merrell Dow, 1991.
Labelling changes to reflect drug interaction between terfenadine and ketoconazole. FDA Med Bull 1991 ;21 (2):4.
Eller MG, Okerholm RA. Pharmacokinetic interaction between terfenadine and ketoconazole. Clin Pharmacol Ther 1991;49:130.
Leor J, Harman M, Rabinowitz B, Mozes B. Giant Uwaves and associated ventricular tachycardia complicating astemizole overdose: Successful therapy with intravenous magnesium. Am J Med 1991;91:94-97.
Mathews DR, McNutt B, Okerholm R, et al. Torsade de pointes occurring in association with terfenadine use. JAMA 1991;266:2375-2376.
Cuttin T, Bogart T, Horowitz RS, et al. Refractory Torsade de pointes (TdP) associated with therapeutic levels of astemizole (HismanalR). Vet Hum Toxicol 1993;35:344.
Hilbert J, Radwanski E, Affrime MP, et al. Excretion of loratidine in human breast milk. J Clin Pharmacol 1988;28:234-239.
McTavish D, Goa KL, Ferrill M. Terfenadine: An update review of its pharmacological properties and therapeutic efficacy. Drugs 1990;39:552-574.
Okerholm RA, Weiner DL, Hook RH, et al. Bioavailability of terfenadine in man. Biopharm Drug Dispos 1981;2:185-190.
Sorkin EM, Heal RC. Terfenadine: A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985;29:34-56.
Garteiz DA, Hook RH, Walker RJ, Okerholm RA. Pharmacokinetic and biotransformation studies of terfenadine in man. Arzneimittelforschung 1982;32:1185-1190.
Davies AJ, Harinadra V, McEvan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdoses. Br Med J 1989;298:325.
Kingwood JC, Routledge PA, Lazarus JH. A report of overdose with astemizole. Hum Toxicol 1986;5:43—44.
Норри K, Tikanoja T, Tapanainen P, et al. Accidental astemizole overdose in young children. Lancet 1991;338:538-540.
Burke TG, Mutnick AH. Ventricular fibrillation and anoxic encephalopathy secondary to astemizole overdose. Ann Pharmacother 1993;27:239-241.
McEvoy GK, ed. AHFS Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, 1992:1368-1370.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 29th ed. London: Pharmaceutical Press, 1989:455—456.
Recognition and Management of Acute Toxicity From Overdosage With Selected Pfizer Laboratories Drugs. New York: Pfizer, 1978.
Magera BE, Betlach CJ, Sweatt AP, Derrick CW Jr. Hydroxyzine intoxication in a 13-month-old child. Pediatrics 1981;67:280-283.
Spiehler VR, Fukumoto RL Another fatal case involving hydroxyzine. J Anal Toxicol 1984;8:242-243.
Johnson GR. A fatal case involving hydroxyzine. J Anal Toxicol 1982;6:69-70.
Fouda HG, Hobbs DC, Stambaugh JE. Sensitive assay for determination of hydroxyzine and plasma and its human pharmacokinetics. J Pharm Sci 1979;68:1456— 1458.
Simons FER, Simons KJ, Frith EM. The pharmacokinetics and antihistaminic effects of H,-receptor antagonist hydroxyzine. J Allergy Clin Immunol 1984;73:69— 75.
Simons KJ, Watson WTA, Chen XY, Simons FER. Pharmacokinetic and pharmacodynamic studies of the Ht-receptor antagonist hydroxyzine in the elderly. Clin Pharmacol Ther 1989;45:9-14.
Gengo FM, Dabronzo J, Yurchak A, et al. The relative antihistaminic and psychomotor effects of hydroxyzine and cetirizine. Clin Pharmacol Ther 1987;42:265-272.
Premier BM. Neonatal withdrawal syndrome associated with hydroxyzine hydrochloride. Am J Dis Child 1977; 131:529.
Kintz P, Godelare B, Mangin P. Gas chromatographic identification and quantification of hydroxyzine: Application in a fatal self-poisoning. Forens Sci Int 1990;48:139-143.
Hartvig P, Handl W. Gas chromatography and electroncapture detection of benzophenones. Acta Pharm Suec 1975;12:349-360.
Wood SG, John BA, Chasseaud LF, et al. The metabo-lismand pharmacokinetics of l4C cetirizine in humans. Ann Allergy 1987;59:31-34.
Singh K.D, Rho YM, Galante L, Bastas ML. Fatal use of methypyrilene and salicylamide poisoning. Bull Int Assoc Forens Toxicol 1987;14:35-36.
Chan LFT, Ailender MW. A fatal case involving an overdose of pheniramine. Bull Int Assoc Forens Toxicol 1983; 17(2):25—26.
Csillag ER, Landauer AA. Alleged hallucinogenic effects of a toxic overdose of an antihistamine preparation. Med J Aust 1973;1:653-657.
Johnson GR. A fatal case involving pyrilamine. Clin Toxicol 1981;18:907-909.
Huxtable RF, Landwirth J. Diphenhydramine poisoning treated by exchange transfusion. Am J Dis Child 1963;106:496-500.
Freedberg RS, Friedman GR, Palu PN, Feit F. Cardiogenic shock due to antihistamine overdose: Reversed with intraaortic balloon counter pulsation. JAMA 1987;257:660-661.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:938— 939.
Friedman H, Greenblatt DJ. The pharmacokinetics of doxylamine: Use of automated gas chromatography with nitrogen-phosphorus detection. J Clin Pharmacol 1985;25:448-451.
McEvoy GK, ed. AHFS Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, 1992:20.
Wurmli K. Vergiftungen mit antihistaminica. Pharm Acta Helv 1973;4:200-205.
Koppel C, Tenczer J, Ibe K. Poisoning with over the counter doxylamine preparations: An evaluation of 109 cases. Hum Toxicol 1987;6:355-359.
Bayley M, Walsh FM, Valaske MJ. Fatal overdose from Bendectin. Clin Pediatr 1975;14:507-509.
Friedman H, Greenblatt DJ, Scavone JM, et al. Clearance of the antihistamine doxylamine reduced in elderly men but not in elderly women. Clin Pharmacokinet 1989;16:312-316.
Kohlhof KJ, Stump D, Zizzamia JA. Analysis of doxylamine in plasma by high performance liquid chromatography. J Pharm Sci 1983;72:961-962.
Gieldorf W, Schubert K. Biotransformation of doxylamine: Isolation, identification and synthesis of some metabolites. J Clin Chem Clin Biochem 1981; 19:485— 490.
Leeder JS, Spielberg SP. Teratogenicity and litigation. In: Koren G, ed. Maternal-fetal Toxicology: A Clinician’s Guide. New York: Marcel Dekker, 1990:415—125.
Wax PM. Fulminant rhabdomyolysis without renal compromise from doxylamine overdose. In: Proceedings, European Association of Poison Centres and Clinical Toxicologists, Scientific Meeting: Metabolic complications of poisoning. Birmingham, UK, May 26, 1993.
Koppel C, Ibe K, Oberdisse U. Rhabdomyolysis in doxylamine overdose. Lancet 1987;1:442-443.
Clarkson SG, Glanville AP. Debendox overdosage in children. Br Med J 1977;2:459-460.
Meadow SR. Poisoning from delayed release tablets. Br Med J 1972;1:512.
Fontan CR, Smith WC, Kirk PL. Gas chromatography of the antihistamines. Anal Chem 1963;35:591-593.
Wu Chen NB, Schaffer MI, Liu R-L, et al. The general toxicology unknown: II. A case report: Doxylamine and pyrilamine intoxication. J Forens Sci I989;28:398— 403.
Gott PH. Cyclizine toxicity: Intentional drug abuse of a proprietary antihistamine. N Engl J Med 1968;279:596.
Resch F, Bachner I, Hruby K, Lenz K. Die intoxikation mit cyclizin in kindes und envachenenalter (Erfahrungen einer Vergiftungs Informations Zentrale). Klin Padiatr 1982;191:42-45.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 29th ed. London: Pharmaceutical Press, 1989:450— 451.
Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press, 1991:585.
McEvoy GK, ed. AHFS Drug Information 91. Bethesda, MD: American Society of Hospital Pharmacists, 1991:1743-1744.
Battista HJ, Henn R, Schnabel F. Verlauf, morpholo-gische and toxikologische befunde eine todlichen cy-clizin-vergiftung in kindesalter. Beitr Gerichtl Med 1978;36:429-431.
Land G, Dean K, Bye A. Determination of cyclizine and nor-cyclizine in plasma and urine using gas-liquid chromatography with nitrogen selective detection. J Chromatogr 1981;222:235-240.
Griffin DS, Baselt RC. Blood and urine concentrations of cyclizine by nitrogen-phosphorus gas-liquid chromatography. J Anal Toxicol 1984;8:97-99.
Kuntzman R, Tsai I, Burns JJ. Importance of tissue and plasma binding in determining the retention of norchlo-rcyclizine and norcyclizine in man, dog and rat. J Pharmacol Exp Ther 1967;158:332-339.
Kuntzman R, Kutch A, Tsai I, Burns JJ. Physiological distribution and metabolic inactivation of chlorcyclizine and cyclizine. J Pharmacol Exp Ther 1965;149:29-35.
Backer RC, McFeeley P, Wohlenberg N. Fatality resulting from cyclizine overdose. J Anal Toxicol 1989;13:308-309.
Patterson SC, Smith GT, Fieldstead K. Plasma levels of cyclizine and dipipanone as measured by HPLC and GLC after a single oral dose. In: Proceedings, International Association of Forensic Toxicologists, TIAFT, Newmarket, England, 1984.
Lewin JF. Personal communication, 1981. In: Baselt RC, Cravey RH. Disposition of Toxic Drugs and Chemicals in Man. 3rd ed. Chicago: Year Book Medical, 1989:229-230.
Sengupta A. Personal communication, 1976. In Baselt RC, Cravey RH. Disposition of Toxic Drugs and Chemicals in Man. 3rd ed. Chicago: Year Book Medical, 1989.
Tan LB, Bryant S, Murray RG. Detrimental haemodynamic effects of cyclizine in heart failure. Lancet 1988;1:560-561.
Kew MC, Segel J, Zoutendyk A. "Hypersensitivity hepatitis" associated with administration of cyclizine. Br Med J 1973;2:307.
Winn RE, McDonnell КР. Fatality secondary to massive overdose of dimenhydrinate. Ann Emerg Med 1993;22:1481-1484.
Craig DF, Mellor SS. Dimenhydrinate dependence and withdrawal. Can Med Assoc J 1990;142:970-973.
Farrell M, Heinrichs M, Tilelli JA. Response of life threatening dimenhydrinate intoxication to sodium bicarbonate administration. Clin Toxicol 1991;29:527— 535.
RinderCS, D’Amato SL, Rinder HM, Cox PM. Survival in complicated diphenhydramine overdose. Crit Care Med 1988;16:1161-1162.
Clark BF, Vance MR. Diphenhydramine poisoning resulting in a wide complex tachycardia: Treated with sodium bicarbonate. Vet Hum Toxicol 1991 ;3:356.
Paton DM, Webster DR. Clinical pharmacokinetics of H |-receptor antagonists (the antihistamines). Clin Phar-macokinet 1985;10:477-497.
Koppel C, Ibe K, Tenczer J. Clinical symptomatology of diphenhydramine overdose: An evaluation of 136 cases in 1982 to 1985. Clin Toxicol 1987;25:53-70.
Peters DH, Faulds D. Tiapride: A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 1994:47:1010—1073.
Simons FER, Simons KJ: The pharmacology and use of H |-receptor-antagonist drugs. N Engl J Med 1994;330:1663-1670.
Desager JP, Dab 1, Horsmans Y, Harvingt C. A pharmacokinetic evaluation of the second-generation H,-receptor antagonist cetirizine in very young children. Clin Pharmacol Ther 1993;53:431-435.
Horsmans Y, Oesager JP, Hulhoven R, Harvingt C. Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. J Clin Pharmacol 1993;33:929— 932.
Snyder SH, Snowman AM. Receptor effects of cetirizine. Ann Allergy 1987;59:4-8.
Rimmer SJ, Church MK. The pharmacology and mechanism of action of histamine H,-antagonists. Clin Exp Allergy 1990;20(suppl. 2):3—17.
Barnes CL, McKenzie CA, Webster KD, Poisett-Holm-es K. Cetirizine: A new nonsedating antihistamine. Ann Pharmacother 1993;27:464-470.
Rihoux J-P, Mariz S. Cetirizine: An updated review of its pharmacological properties and therapeutic efficacy. Clin Rev Allergy 1993;11:65-88.
Capella D, Laporte J-P, Castell J-M, et al. Parkinsonism, tremor and depression induced by cinnarizine and flunarizine. Br Med J 1988;29:722-723.
Benvenuti F, Baroni A, Bandinelli S, et al. Flunarizine-induced parkinsonism in the elderly. J Clin Pharmacol 1988;28:600-608.
Yamaji A, Kataoko K, Oiski M, et al. Simple method for determination of flunarizine in serum by gas chromatography. J Chromatogr Biomed Appl 1987;421: 372-376.
Mielke DH, Gallant DM, Roniger JJ, et al. Sulpiride: Evaluation of antipsychotic activity in schizophrenic patients. Dis Nerv Syst 1977;38:569-571.
Linazasoro G, Masso JFM, Olasagasti B. Acute dystonia induced by sulpiride. Clin Neuropharmacol 1991;14: 463-464.
Miller LG, Jankovic J. Sulpiride induced tardive dyskinesia. Mov Disord 1990;5:83-84.
Achiron A, Zoldom Y, Melamd E. Tardive dyskinesia induced by sulpiride. Clin Neuropharmacol 1990; 13:248— 252.
Zarebinski JM, Royds JNA. Sulpiride in tardive dyskinesia. South Afr Med J 1990;78:374-375.
Alfredsson G, Bjerkenstedt L, Edman G, et al. Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine. Acta Psychiatr Scand 1984;69:49-74.
Wiesel FA, Alfredsson G, Ehrenebo M, Sedvall G. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 1980;17:385-391.
Bressolle F, Bres J, Nourad G. Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function. Clin Pharmacokinet 1989; 17: 367-373.
Alfredsson G, Sedvall G, Wiesel FA. Quantitative analysis of sulpiride in body fluids by high performance liquid chromatography with fluorescence detection. J Chromatogr 1979;164:187-193.
Lenhard G, Kieferndir FU, Berner G, et al. The importance of pharmacokinetic data on sulpiride 200 mg preparations following oral administration. Int J Clin Pharmacol Ther Toxicol 1991;29:231-237.
Imondi AR, Alam AS, Brennan JJ, Hagerman LM. Metabolism of sulpiride in man and rhesus monkeys. Arch Int Pharmacol Ther 1978;232:799.
Rees DM. Analysis of sulpiride in body fluids. In: Proceedings, 25th International Meeting, International Association of Forensic Toxicologists, Groningen, June 27—30, 1988.
Gaultier M, Frejaville JP. A propos de 20 surdosages en sulpiride. Eur J Toxicol Hyg Environ 1979;6:42-44.
Kintz P, Tracqui A, Parent Y, et al. Fatal sulpiride intoxication. Bull Int Assoc Forens Toxicol 1994;24:37.
Duffield AD, Kemmenol AV. A fatality involving theophylline and sulpiride. Bull Int Assoc Forens Toxicol 1990;20(3):9—12.
Lopez de Minian A, Poza JJ, Gorospe A, et al. Tardive akathisia due to sulpiride. Clin Neuropharmacol 1994;17:481-483.
De Сессо L, Venturini PL, Ragni N, et al. Effect of lisu-ride on inhibition of lactation and serum prolactin. Br J Obstet Gynecol 1979;86:905-908.
Krause W, Magen T. Kuhne G, Duka T, Voet B. The pharmacokinetics and pharmacodynamics of lisuride in healthy volunteers after intravenous, intramuscular and subcutaneous injection. Eur J Clin Pharmacol 1991;40:399-403.
Burns RS, Gopinatham G, Humpel M, et al. Disposition of oral lisuride in Parkinson’s disease. Clin Pharmacol Ther 1984;35:548-556.
Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 1989;39:336— 339.
Ulm G. Experiences with lisuride in the treatment of Parkinson’s disease. In: Calme DB, et al., ed. Lisuride and Other Dopamine Agonists. New York: Raven Press, 1983:463-472.
Bassi S, Ferrarese C, Frattola L, et al. Lisuride in generalized dystonia and spasmodic torticollis. Lancet 1982;1:1514-1515.
Liebermann AN, Leibowitz M, Gopinthan G, et al. Review: The use of pergolide and lisuride, two experimental dopamine agonists, in patients with advanced Parkinson’s disease. Am J Med Sci 1985;290:102-106.
Humpel M. The pharmacokinetics of lisuride in animal species and humans. In; Calme DB, Horowski R, McDonald RJ, Wuttke W, eds. Lisuride and Other Dopamine Agonists. New York: Raven Press, 1983.
Capria A, Attanasio A, Frongillo D, et al. Transient left bundle branch block following intravenous lisuride bolus. Fundam Clin Pharmacol 1993;7:115-117.
Dopamine agonists for Parkinson’s disease. Drug Ther Bull 1991;29:7-8.
Langtry HD, Clissold SP. Pergolide: A review of its pharmacological properties and therapeutic potential in Parkinson’s disease. Drugs 1990;39:491-501.
Bouckoms A, Mangini L. Pergolide: An antidepressant adjuvant for mood disorders? Psychopharmacol Bull 1993;29:207-211.
Fuller RW, Clemens JA. Pergolide: A dopamine agonist at both Dt and D2 receptors. Life Sci 1982;49:925-930.
Arky RT, Medical Consultant. In: Physicians’ Desk Reference. 48th ed. Montvale, NJ: Medical Economics, 1994.
British National Formulary, No. 24. September 1992:195.
Tauveron I, Gesta J-M, Jalenques I, Thieblot P. Acute overdose of a new dopamine agonist (CV205-502). Clin Endocrinol 1994;40:551-553.
Smith GW, O’Connor SE. An introduction to the pharmacologic properties of Dopacard (dopexamine hydrochloride). Am J Cardiol 1988;62:9C-17C.
Fitton A, Benfield P. Dopexamine hydrochloride: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency. Drugs 1990;39:308-330.
Stephan H, Sonntag H, Henning H, Yoshimine K. Cardiovascular and renal haemodynamic effects of dopexamine comparison with dopamine. Br J Anaesth 1990;65:380-387.
Tan L-B, Littler WA, Murray RG. Comparison of the haemodynamic effects of dopexamine and dobutamine in patients with severe congestive heart failure. Int J Cardiol 1991;30:203-208.
Hoff R. Personal communication. Fisons Pharmaceuticals, January 28, 1992.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. London: Pharmaceutical Press. 1989:1462.
Hoehn ММ, Rutledge СО. Acute overdose with levodopa. Neurology 1975;25:792-794.
Sporer KA. Carbidopa-levodopa overdose. Am J Emerg Med 1991;9:47-48.
Sechi GP, Tanda F, Mutani R. Fatal hyperpyrexia after withdrawal of levodopa. Neurology 1984;34:249-251.
Jameson HD. Pyridoxine for levodopa induced dystonia. JAMA 1970;211:1700.
Greene SI, Smith JW. Dopamine gangrene. N Engl J Med 1976;294:114.
Ebels TJ, Homan van der Heide JN. Dopamine-induced ischaemia. Lancet 1977;2:762.
Boltax RS, Dineen JP, Scarpa FJ. Gangrene resulting from infiltrated dopamine solution. N Engl J Med 1977;296:823.
Opremcak EM, Davidorf FH. Bilateral retinal infarction associated with high dose dopamine. Ann Ophthalmol 1985;17:141-144.
Curel HE. Personal communication. DuPont Pharmaceuticals, January 30, 1992.
Ensinger H, Schulich S, Grunert A, Ahnefeld FW. Dopamine: Cardiovascular and metabolic effects in relation to plasma levels. Crit Care Med 1990; 18:S 179.
Padbury JF, Agata Y, Baylen BG, et al. Pharmacokinetics of dopamine in critically ill newborn infants. J Pediatr 1990;17:472-476.
Eldrup E, Hagen C, Christensen NJ, Olgaard K. Plasma free and sulfoconjugated dopamine in man: Relationship to sympathetic activity, adrenal function and meals. Dan Med Bull 1988;35:291-294.
Bhatt-Mehta V, Nahata MC, McClead RE, Menke JA. Dopamine pharmacokinetics in critically ill newborn infants. Eur J Clin Pharmacol 1991;40:593-597.
Eldadah MK, Schwartz PH, Harrison R, Newth CJL. Pharmacokinetics of dopamine in infants and children. Crit Care Med 1991;19:1008-1011.
Notterman DA, Greenwald BM, Moran F, et al. Dopamine clearance in critically ill infants and children: Effect of age and organ system dysfunction. Clin Pharmacol Ther 1990;48:138-147.
Sumikawa K, Hayashi Y, Yamatodani A, Yoshiya 1. Contribution of the lungs to the clearance of exogenous dopamine in humans. Anesth Analg 1991;72:622-626.
Weir MR, Keniston RC, Enriquez JI Sr, McNamee GA. Depression of vitamin B6 levels due to dopamine. Vet Hum Toxicol 1991;33:118-121.
Frederickson Ed, Bradley TJ, Goldberg LI. Block of the renal effects of dopamine in the dog by the DAj antagonist, SCH 23 390. Am J Physiol 1985;249:F236—F240.
Levinson PD, Goldstein PS, Mundson PJ, et al. Endocrine, renal and hemodynamic responses to graded dopamine infusions in normal men. J Clin Endocrinol Metab 1985;60:821-826.
McDonald RH, Goldberg LI, McNay JL. Effects of dopamine in man: Augmentation of sodium excretion, glomerular filtration rate and renal plasma flow. J Clin Invest 1964;43:1116-1124.
Goldberg LL Cardiovascular and renal actions of dopamine: Potential clinical applications. Pharmacol Rev 1972;24:1-29.
Parker S, Carlon GC, Isaacs M, et al. Dopamine administration in oliguria and oliguric renal failure. Crit Care Med 1981;9:630-632.
Greenlaw CW, Null LW II. Dopamine-induced ischemia. Lancet 1977;2:555.
Alexander CS, Sako Y, Mikulic E. Pedal gangrene associated with the use of dopamine. N Engl J Med 1975;293:591.
Valdes ME. Post-dopamine ischemia treated with chlorpromazine. N Engl J Med 1976;295:1081-1082.
Goldbranson FL, Lurie L, Vance RM, Vondell RF. Multiple extremity amputations in hypotensive patients treated with dopamine. JAMA 1980;243:1145-1146.
Maggi JC, Angelats J, Scott JP. Gangrene in a neonate following dopamine therapy. J Pediatr 1982; 100:323— 325.
Prada M, Zurcher G. Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline, and dopamine within the femtomole range. Life Sci 1976;19:1161-1174.
Intropin* (dopamine HCI injection, USP): Product Literature. 6227-1/Rev. Du Pont Pharmaceuticals, January 1991.
Cooper BE. High-dose phentolamine for extravasation of pressors. Clin Pharm 1989;8:689.
Siwy BK, Sadove AM. Acute management of dopamine infiltration injury with Regitine. Plast Reconstruct Surg 1987;80:610-612.
Halbreich U, Rojansky N, Bakhai Y, Wang K. Menstrual irregularities associated with bupropion treatment. J Clin Psychiatry 1991;52:15-16.
Cooper ТВ, Suckow RF, Glassman A. Determination of bupropion and its basic metabolites in plasma by liquid chromatography with dual wavelength UV detection. J Pharm Sci 1984;73:1104-1107.
Oslin DW, Duffy K. The rise of serum aminotransferases in a patient treated with bupropion. J Clin Psychophar-macol 1993;13:364-365.
Sempere АР, Duarte J, Palomares JM, et al. Parkinsonism and tardive dyskinesias after chronic use of clebo-pride. Mov Disord 1994;9:114-115.
Martinez-Martin P. Transient dyskinesia induced by clebopride. Mov Disord 1993;8:125-126.
Goethals М, Demey Н. Massive dobutamine overdose in a cardiovascular compromised patient. Acta Cardiol 1984;39:373-378.
Gillespie TA, Ambos HD, Sobel BE, Roberts R. Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol 1977;39:588-593.
GabryAL, Pourriat J-L, Hoang The Dan Ph, et al. Choc cardiogenique an cours d’une intoxication neuroleptique: Reversibilite par bolus de dobutamine. Presse 1982;11:2225-2226.
Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation 1977;56:468-472.
Wood M. Drugs and the sympathetic nervous system. In: Wood M, Wood AJJ, eds. Drugs and Anesthesia: Pharmacology for Anesthesiologists. Baltimore: Williams & Wilkins, 1990:395.
Physicians’ Desk Reference. 46th ed. Montvale, NJ: Medical Economics, 1992:1259—1260.
Mueller HS. Inotropic agents in the treatment of cardiogenic shock. World J Surg 1985;9:3-10.
McEvoy GK, ed. AHFS Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, 1992:669-670.
Parmley WW, Chatterjee K, Francis GS, et al. Congestive heart failure: New frontiers. West J Med 1991;154:427-441.
Waagstein F, Malek I, Hjalmarson AC. The use of dobutamine in myocardial infarction for reversal of the car-diodepressive effect of metoprolol. Br J Clin Phannacol 1978;5:515-521.
Leiser CV, Unverferth DV, Kates RE. The relationship between plasma dobutamine concentrations and cardiovascular responses in cardiac failure. Am J Med 1979;66:238-242.
Kates RE, Leier CV. Dobutamine pharmacokinetics in severe heart failure. Clin Pharmacol Ther 1978;24:537— 541.
Banner W, Vernon DD, Minton SD, Dean JM. Nonlinear dobutamine pharmacokinetics in a pediatric population. Crit Care Med 1991;19:871-873.
Habil DM, Padbury JF, Anas NG, et al. Dobutamine pharmacokinetics and pharmacodynamics in pediatric intensive care patients. Crit Care Med 1992;20:601-608.
Padbury JF, Perkin RM, Anas NG, et al. Dobutamine pharmacokinetics in pediatric intensive care patients. Clin Res 1989; 37Т76А.
Blunter JL, Ruggerie DP, Witte WK, et al. Polymorphic clearance (I) of dopamine (DA) and dobutamine (DB) in children (K). Clin Pharmacol Ther 1989;45:140.
Murphy PJ, Williams TL, Kare DLK. Disposition of dobutamine in the dog. J Pharmacol Exp Ther 1976;199:423-431.
Broadley KJ. Cardiac adrenoceptors. J Auton Pharmacol 1982;2:119.
Ruffalo RR Jr, Spradlin TA, Pollock GD, et al. Alpha-and beta-adrenergic effects of the stereoisomers of dobutamine. J Pharmacol Exp Ther 1981;219:447-452.
Ruffalo RR Jr, Yaden EL. Vascular effects of the stereoisomers of dobutamine. J Pharmacol Exp Ther 1983;224:46-50.
Wu C-C, Chen W-J, Cheng J-J, et al. Local dermal hypersensitivity from dobutamine hydrochloride (Dobutrex solution) injection. Chest 1991;99:1547-1548.
Majerus TC, Dasta JF, Bauman JL, et al. Dobutamine: Ten years later. Pharmacotherapy 1989;9:245-249.
Mutnick AH, Szymusiak-Mutnick B, Drea EJ. Dopamine versus dobutamine: Are all the facts there? Pharmacotherapy 1990;10:224-229.
Binkley PF, Starling RC, Hammer DF, Leier CV. Usefulness of hydralazine to withdraw from dobutamine in severe congestive heart failure. Am J Cardiol 1991;68: 1103-1106.
Pierard LA, Berthe C, Albert A, et al. Haemodynamic alterations during ischaemia induced by dobutamine stress testing. Eur Heart J 1989;10:783-790.
James WA, Lippmann S. Bupropion: Overview and prescribing guidelines in depression. South Med J 1991;84:222-224.
Spiller HA, Ramoska EA, Krenzelok EP, et al.: Bupropion overdose: A 3 year multicenter retrospective analysis. Am J Emerg Med 1994;12:43-45.
Storrow AB. Bupropion overdose and seizures. Am J Emerg Med 1994;12:183-184.
Wender PH, Reimherr FW. Bupropion treatment of attentiondeficit hyperactivity disorder in adults. Am J Psychiatry 1990;147:1018-1020.
Bloomingdale LM. Change from Mg-pemoline to bupropion in a 12 year old boy with attention deficit hyperactivity disorder. J Clin Psychopharmacol 1990;10:382-383.
Margolin A, Kosten T, Petrakis I, et al. Bupropion reduces cocaine abuse in methadone-maintained patients. Arch Gen Psychiatry 1991 ;48:87.
Haykal RF, Akiskal HS. Bupropion as a promising approach to rapid cycling bipolar II patients. J Clin Psychiatry 1990;51:450-455.
Michell GF, Mebane AH, Billings CK. Effect of bupropion on chocolate craving. Am J Psychiatry 1989;146:119-120.
Collins GE, McConnell B. Personal communications. Burroughs-Wellcome, March 7, 1991; August 12, 1991.
Findlay JWA, Fleet JVW, Smith PG, et al. Pharmacokinetics of bupropion, a novel antidepressant agent following oral administration to healthy subjects. Eur J Clin Pharmacol 1981;21:127-135.
Ramcharitar V, Levine BS, Golderberger BA, Caplan IH. Bupropion and alcohol fatal intoxication. Forens Sci Int 1992;56:151. Case report.
Lai AA, Schroeder DH. Clinical pharmacokinetics of bupropion: A review. J Clin Psychiatry 1983;44:5(sect. 2):82—84.
Schroeder DH. Metabolism and kinetics of bupropion. J Clin Psychiatry 1983;44:79-81.
Preskorn SH, Fleck RJ, Schroeder DH. Therapeutic drug monitoring of bupropion. Am J Psychiatry 1990;147:1690-1691.
Preskorn SH, Katz SE. Bupropion plasma levels: Intraindividual and interindividual variability. Ann Clin Psychiatry 1989;1:59-61.
Golden RN, DeVane CL, Laizure SC, et al. Bupropion in depression: II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 1988;45:145-149.
Golden RN, Rudorfer WV, Sherer MA, et al. Bupropion in depression: 1. Biochemical effects and clinical response. Arch Gen Psychiatry 1988;45:139-143.
De Vane CL, Laizure SC, Stewart JT, et al. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990;10:328-332.
Dager SR, Heritch AJ. A case of bupropion-associated delirium. J Clin Psychiatry 1990;51:307-308.
Van Putten T, Shaffer I. Delirium associated with bupropion. J Clin Psychopharmacol 1990; 10:234.
Liberzon I, Dequardo JR, Silk KR. Bupropion and delirium. Am J Psychiatry 1990;147:1689-1690.
Briggs GG, Samson JH, Ambrose PJ, Schroeder DH. Excretion of bupropion in breast milk. Ann Pharmaco-ther 1993;27:431-437.
Wenger TL, Stern WC. The cardiovascular profile of bupropion. J Clin Psychiatry 1983;44(5, sect. 2): 176—182.
Davidson J. Seizures and bupropion: A review. J Clin Psychiatry 1989;50:256-261.
Roose SP, Glassman AH, Giardina EGV, et al. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol 1987;7:247-251.
Physicians’ desk Reference. 49th ed. Montvale, NJ: Medical Economics, 1995:2178—2180.
Mehta AE, Tolis G. Pharmacology of bromocriptine in health and disease. Drugs 1979;17:313-325.
Tukali I, Brown P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA. 1982;247:2589-2591.
Kulig K, Moore LL, Kirk M, et al. Bromocriptine-associated headache: Possible life-threatening sympathomimetic interaction. Obstet Gynecol 1991;78:941-943.
Miller LG, Bakht FR, Baker T, Kirshon B. Possible cocaine predisposition to adverse cerebrovascular and cardiovascular sequelae of bromocriptine administered postpartum. J Clin Pharmacol 1989;29:781-785.
Thorner MO, Flackiger E, Caine DB. Bromocriptine: A Clinical and Pharmacological Review. New York: Raven Press, 1989.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Phannacists, 1974:2431-2435.
Wass JAH, Thorner MO, Morris DV, et al. Long-term treatment of acromegaly with bromocriptine. Br Med J 1977;1:875-878.
Guerrero RW, Shifrar KA. Diagnosis and treatment of neuroleptic malignant syndrome. Clin Pharm 1988;7:697-701.
Dorr C, Sathananthan K. Treatment of mania with bromocriptine. Br Med J 1976;1:1342-1343.
Dackis CA, Gold MS, Sweeney DR, et al. Single-dose bromocriptine reverses cocaine craving. Psychiatry Res 1987;20:261-264.
Parlodel indication withdrawn in Italy. Scrip 1995;2022:23.
Vance ML, Evans WS, Thornier MO. Bromocriptine. Ann Intern Med 1984;100:78-91.
Price P, Debono A, Parkes JD, et al. Plasma bromocriptine levels, clinical and growth hormone response in parkinsonism. Br J Clin Pharmacol 1978;6:303-309.
Nelson MV, Berchov RC, Kareti D, Le Witt PA. Pharmacokinetic evaluation of erythrocin and caffeine administered with bromocriptine. Clin Pharmacol Ther 1990;47:694-697.
Figa-Talamanca L, Gualandi C, Di Meo L, et al. Hyperthermia after discontinuation of levodopa and bromocriptine therapy: Impaired dopamine receptors a possible cause. Neurology 1985;35:258-261.
Schmid PA, Suter T, Speich R, et al. Pleuropulmonary changes during bromocriptine treatment. Dtsch Med Wochnschr 1994;119:1542-1546.
Tunca Z, Alkin T, Guven H. A case of bromocriptine poisoning that resembles Pickwick syndrome. Pharmacol Toxicol 1993;73(suppl.):78.
Griffiths RW. Toxicity studies with 2-bromo-alpha-er-gocryptine mesylate (CB154) effect of prolonged oral administration in rats. IRSS Med Sci 1974;2:1661.
Creese I, Sibley DR, LeffS, Hamblin M. Dopamine receptors: Subtypes, localization and regulation. Fed Proc 1981;40:147-152.
Waddington JL, O’Boyle KM. Dogs acting on brain dopamine receptors: A conceptual re-evaluation five years after the first selective D, antagonist. Pharmacol Ther 1989;43:1-52.
Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992; 13:61 — 69.
Rosenkrantz RP, McClelland DL. An historical perspective of dopamine and its analogs. Proc West Pharmacol Soc 1990;33:15-19.
Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. 6th ed. New York: Oxford University Press, 1991:285—337.
Strange PG. D,/D2 dopamine receptor interaction at the biochemical level. Trends Pharmacol Sci 1991;12:48— 49.
Strange PG. Aspects of the structure of the D2 dopamine receptor. Trends Neurol Sci 1990;13:373-378.
Sokoloff P, Girus B, Martres M-P, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146— 151.
Mercuri NB, Calabresi P, Bernardi G. Physiology and pharmacology of dopamine D2-receptors: Their implications in dopamine-substitute therapy for Parkinson’s disease. Neurology 1989;39:1106-1108.
Hom PT, Murphy MB. New dopamine receptor agonists in heart failure and hypertension: Implications tor further therapy. Drugs 1990;40:487-492.
Ashton CH, Teoh R, Davies DM. Drug-induced stupor and coma: Some physical signs and their pharmacological basis. Adverse Drug React Acute Poison Rev 1989;8:1-59.
Stoof JC, Kebabian JW. Two dopamine receptors: Biochemistry, physiology and pharmacology. Life Sci 1984;34:2281-2286.
Haeusler G, Lues I, Minck K-O, et al. Pharmacological basis for antihypertensive therapy with a novel dopamine agonist. Eur Heart J 1992;13(supp. D):129—135.
Budny J, Anderson-Drews К. IV inotropic agents: Dopamine, dobutamine and amrinone. Crit Care Nurse 1991;10:54-62.
Whipple JK, Medicus-Bringa MA, Schimel BA, et al. Selected vasoactive drugs: A readily available chart reference. Crit Care Nurs 1992;12:23-29.
Cohen JN. Recognition and management of shock and acute failure. In Hurst JW, ed. The Heart. 5th ed. New York: McGraw-Hill, 1982:463-476.
White T, Brown K. Low serum iron levels and neuroleptic malignant syndrome. Am J Psychol 1991; 148:148.
Dopamine agonists for Parkinson’s disease. Drug Ther Bull 1991;29(2):7—8.
Bhatt MP, Keenan SP, Fletthan JA, Calme DB. Pleu-ropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991;30:613-616.
Ren JH, Unverferth DV, Leier CV. The dopamine congener, ibopamine, in congestive heart failure. J Cardio-vasc Pharmacol 1985;6:748-755.
Harvey JN, Worth DR, Brown J, Lee MR. Lack of effect of ibopamine, a dopamine pro-drug, on renal function in normal subjects. Br J Clin Pharmacol 1984;17:671 — 677.
Milner AR, Zwaveling JH, Girbes ARJ. Ibopamine substitution in a dopamine-dependent patient. Lancet 1993;342:1555.
De Mey C, Enterling D, Brendel E, Wesche H. Pharmacokinetics and pharmacodynamics of single oral doses of ibopamine, quinidine and their combination in normal man. Eur J Clin Pharmacol 1988;34:415-418.
Henwood JM, Todd PA. Ibopamine: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1988;36:11 — 31.
Boomsma F, Alberts G, Van der Hoom FAJ, et al. Simultaneous determination of free catecholamines and epinine and estimation of total epinine and dopamine in plasma and urine by high performance liquid chromatography with fluorometric detection. J Chromatogr Biomed Appl 1992;574:109-117.
Meyer W, Buhrmy K-U, Steiner K, et al. Pharmacokinetics and first clinical experiences with an antihypertensive dopamine (DA2) agonist. Eur Heart J 1992; 13(suppl. D):121—128.
Rich SS. Drug-induced movement disorders. Rhode Island Med 1993;76:556-562.
Weller MPI. Neuroleptic-induced deficit syndrome. Postgrad Med J 1993;69:957-958.
Langtry HD, McTavish D. Terodiline: A review of its pharmacological properties and therapeutic use in the treatment of urinary incontinence. Drugs 1990;40:748— 761.
Karlen B, Andersson K-E, Ekman G, et al. Pharmacokinetics of terodiline in human volunteers. Eur J Clin Pharmacol 1982;23:267-270.
Terodiline (Micturine) and adverse cardiac reactions. London: Committee on Safety of Medicines, 1991.
Boyd G. A correction to "An apparent fatal overdose of terodiline." J Anal Toxicol 1990; 14:194.
Cattini RAP, Makin HLD, Trafford DJH, Vanezis P. An apparent fatal overdose of terodiline. J Anal Toxicol 1989;13:110-112.
Stewart DA, Taylor J, Ghosh S, et al. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of Q— T interval. Eur J Clin Pharmacol 1992;42:577-580.
Walt AH. Terodiline and Torsades de pointes. Br Med J 1991;303:519.
UK doctors and pharmacists reactivate a warning about terodiline reaction. August 10, 1991. Editorial.
Connolly MJ, Astridge PS, White EG, et al. Torsade de pointes ventricular tachycardia and terodiline. Lancet 1991;338:344-345.
Worldwide withdrawal of terodiline. Reactions, October5,199 - p.2.
Triazolam and terodiline withdrawn in Britain. NZ Med J 1991;101.
Geraint M. Terodiline and Torsade de pointes. Br Med J 1991;303:519-520.
Dans SW, Brecker SJ, Stevenson RN. Terodiline for treating detrusion instability in elderly patients. Br Med J 1991 ;302:1276.
Burke RE, Fahn S, Marsden CD. Torsion dystonia: A double-blind prospective trial of high dosage trihexyphenidyl. Neurology 1986;36:160-164.
Lennox WJ, Harris LW, Anderson DR, et al. Successful pretreatment therapy of soman, sarin and VX intoxication. Drug Chem Toxicol 1992;15:271-283.
Kammer Y, Munitz H, Wijsenbeek H. Trihexyphenidyl (Artane) abuse: Euphoriant and anxiolytic. Br J Psychiatry 1982;140:473-474.
Morgenstern GF. Trihexyphenidyl (Artane) intoxication due to overdosage with suicidal intent. Can Med Assoc J 1962;87:79-80.
Ananth JV, Lehman HE, Ban TA. Toxic psychosis caused by benzhexol hydrochloride. Can Med Assoc J 1970; 103:771.
Stephens DA. Psychotoxic effects of benzhexol hydrochloride (Artane). Br J Psychiatry 1967;113:213-218.
Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 1985;18:35-40.
Burke RE, Fahn S. Serum trihexyphenidyl levels in the treatment of torsion dysphonia. Neurology 1985;35:1066-1069.
Nation RL, Triggs EJ, Vine J. Metabolism and urinary excretion of benzhexol in humans. Xenobiotica 1978;8:165-169.
Mengech HNKA. Psychiatric manifestations of benzhexol toxicity. East Afr Med J 1984;61:78-81.
Crawshaw JA, Mullen RC. A study of benzhexol abuse. Br J Psychiatry 1984;145:300-303.
Kajimura N, Mizuki Y, Kai S, et al. Memory and cognitive impairment in a case of long-term trihexyphenidyl abuse. Pharmacopsychiatry 1993;26:59-62.
Enchava D. Trihexyphenidyl overdose: Clinical presentation and management. Vet Hum Toxicol 1993;35:370.
Smith JM. Abuse of antiparkinson drugs: A review of the literature. J Clin Psychiatry 1980;41:351-354.
Bargo E. GLC determination of trihexyphenidyl hydrochloride dosage forms. J Pharm Sci 1978;68:503— 505.
Thuroff JW, Bunke В, Ebner A, et al. Randomized double-blind multi-center trial on treatment of frequency, urgency and incontinence related to detrusion hyperactivity: Oxybutinin versus propantheline versus placebo. J Urol 1991;125:813-817.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:429.
Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988;35:515-520.
Banerjee S, Routledge PA, Pugh S, Smith PM. Poisoning with oxybutynin. Hum Exp Toxicol 1991; 10:222— 226.
Malone-Lee J, Lubel D, Szonyi G. Low dose oxybutynin for the unstable bladder. Br Med J 1992;304:1053.
Physicians’ Desk Reference. 46th ed. Montvale NJ: Medical Economics, 1992:1332—1333.
Diokno AC, Lapides J. Oxybutynin: A new drug with analgesic and anticholinergic properties. J Urol 1972;108:307-309.
Moisey CU, Stephenson TP. Brendler ОВ. The urodynamic and subjective results of treatment of detrusion instability with oxybutinin chloride. Br J Urol 1980;52: 472-475.
Aaltonen L, Allonen H, lisalo E, et al. Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay. Acta Pharmacol Toxicol 1984 55:100-103.
Lindeke D, Brotell H, Karlen B, et al. Determination of oxybutynin (4-diethylamino but-2-ynyl-2-cyclohexyl-2-phenylglycolate) in serum and urine by gas chromatog-raphy/mass spectrometry with single ion detection. Acta Pharma Suec 1981;18:25-34.
Mozer CM. Personal communication. Marion Merrell Dow, November 15, 1993.
Hammer R, Giachetti A. Muscarinic receptor subtypes М, and M2: Biochemical and functional characterization. Life Sci 1982;31:291-298.
Tryba M, Huchzermeyer H, Torok M, et al. Single drug and combined medication with cimetidine, antacids and pirenzepine in the prophylaxis of acute upper gastrointestinal bleeding. Hepto-gastroenterology 1983;30:154— 157.
Lauritsen K, Laursen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part I). Clin Pharmacokinet 1990; 19: 11-31.
Meinecke I, Witsch D, Brendel E. Sensitive high performance liquid chromatographic determination of pirenzepine in plasma. J Chromatogr 1986;375:369-375.
Ashton PG. Two fatalities involving procyclidine and the identification of a procyclidine metabolite. Bull Int Assoc Forens Toxicol 1980;15:9-11.
Baselt RC, Cravey RH. Disposition of Toxic Drugs and Chemicals in Man. 3rd ed. Chicago: Year Book Medical, 1989:720-721.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:431.
Procyclidine hydrochloride. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:732—733.
Whiteman PD, Fowbe ASE, Hamilton MJ, et al. Pharmacokinetics and pharmacodynamics of procyclidine in man. Eur J Clin Pharmacol 1985;28:73-78.
Dean K, Land G, Bye A. Analysis of procyclidine in human plasma and urine by gas-liquid chromatography. J Chromatogr 1980;221:408-413.
Wood М. Anticholinergic drugs: Anesthetic premedication. In: Wood M, Wood AJJ, eds. Drugs and Anesthesia: Pharmacology for Anesthesiologists. Baltimore: Williams & Wilkins, 1991:111-127.
Sennhauser FH, Schwarz HP. Toxic psychosis from transdermal scopolamine in a child. Lancet 1986;2:1033.
Kriegman AG. Personal communication. Ciba-Geigy, July 10, 1989.
Transdermal scopolamine: Product literature. Ciba-Geigy, February 1988.
Kjeldaas L. Scopderm reservoir plaster: State of confusion and hallucinations. Tidsskr Nor Laegeforen 1986: No. 5.
Van der Willigram AH, Oranje AP, Stolz E, van Joost T. Delayed hypersensitivity to scopolamine in transdermal therapeutic systems. J Am Acad Dermatol 1988;18:146-147.
Trozak D. Delayed hypersensitivity to scopolamine delivered by a transdermal device. J Am Acad Dermatol 1985;13:247-251.
McCauley ME, Royal JW, Shaw JE, Schmitt LG. Effect of transdermally administered scopolamine in preventing motion sickness. Aviat Space Environ Med 1979;50:1108-1111.
Price NM, Schmitt LG, McGuire J, et al. Transdermal scopolamine in the prevention of motion sickness at sea. Clin Pharmacol Ther 1981;29:414-419.
Lebuisson DA, Risvegliato M. La mydriase unilaterale du voyageur. Presse Med 1983; 12:2214.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:754-757.
Muir C, Metcalfe R. A comparison of plasma levels of hyoscine after oral and transdermal administration. J Pharm Biomed Anal 1983;1:363-367.
Golding JF, Gosden E, Gerrell J. Scopolamine blood levels following buccal versus ingested tablets. Aviat Space Environ Med 1991;62:521-526.
Schnabel J, Ray M, Sandy J, et al. Applications of a scopolamine radioreceptor assay to pharmacokinetic studies in rats and humans. Clin Chem I99O;36:1045.
Saxena K, Saxena S. Scopolamine withdrawal syndrome. Postgrad Med 1990;87:63-66.
Simpson A. Bilateral scopolamine mydriasis in a traveller. Br Med J 1987; 194:775.
Wilkinson JA. Side effects of transdermal scopolamine. J Emerg Med 1987;5:389-392.
Strom BL, Carson JL, Schinnar R, et al. Seizures from transdermal scopolamine. Clin Pharmacol Ther 1989;45:155.
Strom BL, Carson JL, Schinnar R, et al. No causal relationship between transdermal scopolamine and seizures: Methodologic lesson for pharmacoepidemiology. Clin Pharmacol Ther 1991;50:107-113.
Rozzini M, Inzoli M, Trabucchi. Delirium from transdermal scopolamine in an elderly women. JAMA 1988;260:478.
Gordon CR, Mankuta D, Shupak A, et al. Recurrent classic migraine attacks following transdermal scopolamine intoxication. Headache 1991;31:172-174.
Marcon GM, Schiavo F. Bilateral scopolamine mydriasis in a traveller. Br Med J 1987;294:250.
Price BH. Anisocoria from scopolamine patch. JAMA 1985;253:1561.
Cugell DW. Chemical pharmacology and toxicology of ipratropium bromide. Am J Med 1986;8(suppl. 5A):18— 22.
Rominger KL. Chemistry and pharmacokinetics of ipratropium bromide. Scand J Respir Dis 1979;suppl. 130:116-126.
Shah P, Dharjon L, Metcalfe T, Gibson JM. Acute angle closure glaucoma associated with nebulised ipratropium bromide and salbutamol. Br Med J 1992;304:40-41.
Humphreys DM. Acute angle closure glaucoma association with nebulised ipratropium bromide and salbutamol. Br Med J 1992;264:320.
High AS. Pharangeal blistering with combined inhalation therapy. Br Med J 1986;292:380.
Tiernan SM, Cellucci PP, Dire DJ. Adjunctive use of ipratropium bromide in the emergency treatment of acute asthma. Ann Emerg Med 1989;18:466-467.
Higgins RM, Stradling JR, Lane DJ. Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma? Chest 1988;94:718-722.
O’Driscoll BR, Taylor RJ, Horsley MG, et al. Nebulised salbutamol with and without ipratropium bromide in acute air flow obstruction. Lancet 1989;1: 1418-1420.
Henry RL. Ipratropium bromide: An additive effect? J Paediatr Child Health 1990;26:124-125.
Spencer PA. Buccal ulceration with ipratropium bromide. Br Med J 1986;292:380.
Mulherin D, Fitzgerald MV. Meconium ileus equivalent in association with nebulised ipratropium bromide in cystic fibrosis. Lancet 1990; 1:552.
Markus HS. Paralytic ileus associated with ipratropium. Lancet 1990;335:1224.
Lozewicz S. Blood outflow obstruction induced by ipratropium bromide. Postgrad Med J 1989;65:260— 261.
O’Callaghan C, Milner AD, Swarbrick A. Paradoxical bronchoconstriction in wheezing infants after nebulised preservative free iso-osmolar ipratropium bronchitis. Br Med J 1989;299:1433-1434.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:730-731.
Howrie DL, Rowley AH, Krenzelok EP. Benztropine-induced acute dystonic reaction. Ann Emerg Med 1986;15:594-596.
Fahy P, Arnold P, Curry SC, Bond R. Serial serum drug concentrations and prolonged anticholinergic toxicity after benztropine (Cogentin) overdose. Am J Emerg Med 1989;7:199-202.
Baselt RC, Cravey RH. Disposition of Toxic Drugs and Chemicals in Man. 3rd ed. Chicago: Year Book Medical, 1989:84-85.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:421—422.
Costa JF, Sramek J, Bera RB, et al. Control of bedwetting with benztropine. Am J Psychiatry 1990; 147:674.
Perry PJ, Wilding DC, Juhl RP. Anticholinergic psychosis. Am J Hosp Pharm 1978;35:725- 727.
Stern TA. Continuous infusion of physostigmine in anticholinergic delirium. J Clin Psychiatry 1983;44:463— 464. Case Report.
Goldstein MR, Kasper R. Hyperpyrexia and coma due to overdose of benztropine. South Med J 1968;61:988— 989.
Jindal SP, Lutz T, Hallstrom C, Vestergaard P. A stable isotope dilution assay for the antiparkinsonian drug benztropine in biological fluids. Clin Chim Acta 1981;112:267-273.
Woody GE, O’Brien CP. Anticholinergic toxic psychosis in drug abusers treated with benztropine. Compr Psychiatry 1974;15:439-442.
Rosano TG, Meola JM, Jindal SP, et al. Benztropine in-dentification and quantitation in a suicidal overdose case. In: Proceedings, California Association of Toxicologists, October 1993.
Moffat AC, Jackson JV, Moss MS, et al. Clarke’s Isolation and Identification of Drugs. 2nd ed. London: Pharmaceutical Press, 1986:388.
Weissbluth М, Christoffel КК, Todd Davis A. Treatment of infantile colic with dicyclomine hydrochloride. J Pediatr 1984;104:951-955.
Fischer CP, Dioko A, Lapides J. The anticholinergic effects of dicyclomine hydrochloride in uninhibited neurogenic bladder dysfunction. J Urol 1978; 120: 328— 329.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:423.
McEvoy GK, ed. AHFS Drug Information 94, Bethesda, MD: American Society of Hospital Pharmacists, 1994:747-748.
Physicians’ Desk Reference. 46th ed. Montvale, NJ: Medical Economics, 1992:1322—1324.
Pittman AR Jr. Accidental administration of dicyclomine (BentylR) hydrochloride in overdosage. NC Med J 1952;13:486.
Wise GW, Green VA. Toxicant cases: Bendectin ingestion. Aaction 1974;2:5.
Meadow SR, Leeson GA. Poisoning with delayed release tablets: Treatment of Debendox poisoning with purgation and dialysis. Arch Dis Child 1974;49:310-312.
Greenblatt DJ, Allen MD, Koch-Weser J, Shader RL Accidental poisoning with psychotropic drugs in children. Am J Dis Child 1976;130:507-511.
Clarkson SG, Glanvill. Debendox overdosage in children. Br Med J 1977;2:459-460.
Williams J, Watkin-Jones R. Dicyclomine: Worrying symptoms associated with its use in some small babies. Br Med J 1984;288:901.
Edwards PDL. Dicyclomine in babies. Br Med J 1984;288:1230.
Spoudeas H, Shribman S. Dicyclomine in babies. Br Med J 1984;288:1230.
Bayley M, Walsh FM, Valaske MJ. Fatal overdose from Bendectin. Clin Pediatr 1975;14:507-514.
Meffin PJ, Moore G, Thomas J. Determinations of dicyclomine in plasma by gas chromatography. Anal Chem 1973;45:1964-1966.
Danhof IE, Schreiber EC, Wiggans DS, Leyland HM. Metabolic dynamics of dicyclomine hydrochloride in man as influenced by various dose schedules and formulations. Toxicol Appl Pharmacol 1968;13:16-23.
Kalter H, Warkary J. Congenital malformations (second of two parts). N Engl J Med 1983;308:491-497.
McCredie J, Kricher A, Elliott J, Forrest J. The innocent bystander: Doxylamine/dicyclomine/pyridoxime and congenital limb defects. Med J Aust 1984;140:525-527.
Friedman JM, Little BB, Brent RL, et al. Potential human teratogenicity of frequently prescribed drugs. Obstet Gynecol 1990;75:594-599.
Fleming DM, Knox J DE, Crombie DL. Debendox in early pregnancy and fetal malformation. Br Med J 1981;283:99-101.
Garriott JC, Rodriguez R, Norton LE. Two cases of death involving dicyclomine in infants: Measurement of therapeutic and toxic concentrations in blood. Clin Toxicol 1984;22:455-462.
Death syndrome (SIDS): A cause of death or an incidental finding? J Forens Sci 1986;31:1470-1474.
Walker BJ, Lang JF, Okerholm RA. Quantitative analysis of dicyclomine in human plasma by capillary gas chromatography and nitrogen-selective detection. J Chromatogr Biomed Appl 1987;416:150-153.
Chin TH. Personal correspondence. Boehringer Ingle-heim Pharmaceuticals, June 19, 1989; March 21, 1991.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia.30th ed. London: Pharmaceutical Press, 1993:427—428.
Atrovent. In: Physicians’ Desk Reference. Montvale, NJ: Medical Economics, 1992:675—676.
Gross MJ. Ipratropium bromide. N Engl J Med 1988;319:486-494.
Atsman J. Topics in clinical pharmacology: Ipratropium bromide in COPD and asthma. Am J Med Sci 1988;296:140-142.
Ipratropium. Med Lett Drugs Ther 1087;29(745):71 — 72.
Wood M. Anticholinergic drugs: Anesthetic predmedica-tion. In: Wood M, Wood AJJ, eds. Drugs and Anesthesia. 2nd ed. Baltimore: Williams & Wilkins, 1990:120—121.
Shemesh I, Bourvin A, Gold D, Kutscherowsky M. Chlorpyrifos poisoning treated with ipratropium and dantrolene: A case report. Clin Toxicol 1988;26:495— 498.
Beasley CRW, Rafferty P, Holgate ST. Bronchoconstriction properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. Br Med J 1987;29:1197— 1198.
Adlung VJ, Hohlen KD, Zeren S, Wahl D. Studies on the pharmacokinetics and biotransformation of ipratropium bromide in man. Arzneimittelforschung 1976;26:1005-1010.
Easing K, de Zeeuw RA, Nossent GD, et al. Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. Eur J Clin Pharmacol 1989;36:189-194.
Engelhardt A, KJupp H. The pharmacology and toxicology of a new tropane alkaloid derivative. Postgrad Med J 1975;5l(suppl. 7):82-94.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:418.
Tyson WJ. Toxic effects of atropine drops. Br Med J 1889;2;921.
Owens SM. Notes on two cases of atropine poisoning. Lancet 1890;2:443-444.
Kelynack TN. Atropine poisoning by absorption from the conjunctiva. Br Med J 1890;l:421.
Harris WJ. A case of rapid development of symptoms of belladonna poisoning from use of sulphate of atropine eye drops. Lancet 1898; 1:98.
Rodger WG. Case of acute poisoning after instillation of a small dose of atropine into the eye. Glasgow Med J 1903;60:102-105.
Wise CH. Case of poisoning from atropine eye drops. Br Med J 1904;1:189-190.
Spurgin PB. Two cases of poisoning from the application of atropine to the eyes. Lancet 1905;2:964.
White PJ. Atropine fever in early infancy. Am J Dis Child 1929;37:745-750.
Munns GF. Atropine hyperpyrexia in early infancy. JAMA 1929;93:171-173.
Metivier VM. A case of atropine poisoning. Lancet 1935;2:1232.
Scally CM. Poisoning after one instillation of atropine drops. Br Med J 1936; 1:311.
Hopkins F, Robyns-Jones J. Psychosis associated with atropine administration. Br Med J 1937;1:663.
Duggan PJ. Mental disturbance following atropine administration. Br Med J 1937; 1:918.
Baker JP, Farley JD. Toxic psychosis following atropine eye drops. Br Med J 1958;2:1390-1392.
Hill DW. Toxic psychosis after atropine eye drops. Br Med J 1958;2:1594.
Garlington LN, Bailey PJ. Is atropine a poison? Anesth Analg 1959;38:254-258.
Hoefnagel D. Toxic effects of atropine and homatropine eye drops in children. N Engl J Med 1961;264:168-171.
Karliner W. Accidental convulsion induced by atropine. Am J Psychiatry 1965;122:578-579.
Shah PM. Toxic effects of atropine eye drops. Indian J Pediatr 1966;33:13-17.
Erikssen J. Atropine psychosis. Lancet 1969;1:53-54.
German E, Siddiqui N. Atropine toxicity from eyedrops. N Engl J Med 1970;282:689.
Weinstock FJ. Dilated fixed pupils from atropine. JAMA 1974;229:267-268.
Gillick JS. Atropine toxicity in a neonate. Br J Anaesth 1974;46:793-794.
Gooding JM, Holcomb MC. Transient blindness following intravenous administration of atropine. Anesth Analg 1977;56:872-873.
Hoffman GM, Gay JR. Accidental atropine poisoning. Pa Med J 1959;62:1340-1341.
Leczycka F, Trembla K. The course and consequences of coma after huge doses of atropine. Pol Med J 1969;8:381-383.
Mackenzie AL, Pigott JFG. Atropine overdose in three children. Br J Anesth 1971;43:1088-1090.
Arthurs GJ, Davison R. Atropine: A safe drug. Anaesthesia 1980;35:1077-1079.
Worth DP, Davison AM, Roberts TG, et al. Ineffectiveness of haemodialysis in atropine poisoning. Br Med J 1983;286:2023-2024.
Forrer GR. Atropine toxicity in the treatment of mental disease. Am J Psychiatry 1951;108:107-117.
Forrer GR. Symposium on atropine toxicity therapy: History and future research. J Nerv Ment Dis 1956;124:256-259.
Miller JJ. Symposium on atropine toxicity therapy. J Nerv Ment Dis 1956;124:260-264.
O’Connor PS, Mumma JV. Atropine toxicity. Am J Ophthalmol 1985;99:613-614.
Rockliffe W. Notes on a death supposed to be from atropine drops applied to the eye. Trans Ophthalmol Soc UK 1902;22:302-305.
Morton HG. Atropine intoxication: Its manifestations in infants and children. J Pediatr 1939;14:755-760.
Heath WE. Death from atropine poisoning. Br Med J 1950;2:608.
Legroux P. A propos d’un cas d’intoxication mortelle par tin collyre a 1’atropine. Ann Ocul 1962;195:48-52.
Weiner N. Atropine, scopolamine and related antimus-carinic drugs. In: Gilman A, Goodman LS, Rail TW, et al., eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 7th ed. New York: Macmillan, 1985:138.
McEvoy GK, ed. Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:516— 519, 741-744, 1827-1829.
Merli GJ, Weitz H, Martin JH, et al. Cardiac dysrhythmias associated with ophthalmic atropine. Arch Intern Med 1986;146:45-47.
Gotlieb A. Spider bites. Lancet 1970;2:246.
Seidman DS. Atropine for self-defence. Ann Emerg Med 1987;16:732-734.
Ketchum JS, Sidell FR, Crowell EB Jr, et al. Atropine, scopolamine and ditran: Comparative pharmacology and antagonists in man. Psychopharmacologia 1973;28:I21 — 145.
Hirschman ZJ, Silverstein J, Blumberg G, Lehrfield J. Central nervous system toxicity from nebulized atropine sulfate. Clin Toxicol 1991;29:273-277.
Cullumbine H, McKee WHE, Creasey NH: The effects of atropine sulphate upon healthy male subjects. Q J Exp Physiol 1955;40:309-319.
Janes RG, Stiles JF. The penetration of C'4 labeled atropine into the eye. Arch Ophthalmol 1959;67:97-102.
Davies DS. Pharmacokinetics of inhaled substances. Postgrad Med J 1975;51 (suppl. 7):69—75.
Moller J, Rosen A. Comparative studies on intramuscular and oral effective doses of some anticholinergic drugs. Acta Med Scand 1968;184:201-209.
Adams RG, Verma P, Jackson AJ, et al. Plasma pharmacokinetics of intravenously administered atropine in normal human subjects. J Clin Pharmacol 1982;22:477— 481.
Lahdes K, Kaila T, Hunponen R, et al. Systemic absorption of topically applied ocular atropine. Clin Pharmacol Ther 1988;44:310-314.
Kaiser SC. The fate of atropine in man. Ann NY Acad Sci 1971;179:667-683.
Kaiser SC, McClain PL. Atropine metabolism in man. Clin Pharmacol Ther 1970;11:214-227.
Kentala E, Kaila T, Kanto J. Intramuscular atropine in elderly people: Pharmacokinetic studies using the radioreceptors assay and some pharmacodynamic responses. Pharmacol Toxicol 1989;65:110-113.
Beermann B, Hellstrom, Rosen A. The gastrointestinal absorption of atropine in man. Clin Sci 1971;40:95-106.
Kradjan WA, Smallridge RC, David R, et al. Atropine serum concentrations after multiple inhaled doses of atropine sulfate. Clin Pharmacol Ther 1985;38:12-15.
Kradjan WA, Lakshminarayan S, Hayden PW, et al. Serum atropine concentrations after inhalation of atropine sulfate. Am Rev Respir Dis 1981;123:471-472.
Hayden PW, Larson SM, Lakshminarayan S. Atropine clearance from human plasma. J Nucl Med 1979;20:366-367.
Shutt LE, Bowes JB. Atropine and hyoscine. Anesthesia 1979;34:476-490.
Gosselin RE, Gabourel JD, Wills JH: The fate of atropine in man. Clin Pharmacol Ther 1960;1:597-603.
Berghem L, Bergman U, Schildt B, et al. Plasma atropine concentrations determined by radioimmunoassay after single dose I. V. and I. M. administration. Br J Anaesth 1980;52:597-601.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:419—421.
Sidell FR. Modification by diluents of effects of intramuscular atropine on heart rate in man. Clin Pharmacol Ther 1974;16:711-715.
Holland P, Parkes DC, White RG. Pralidoxime mesylate absorption and heart rate response to atropine sulphate following intramuscular administration of solution mixtures. Br J Clin Pharmacol 1975;2:333-338.
Atropine. In: Long JW, ed. Clinical Management of Prescription Drugs. Philadelphia: Harper & Row, 1984:110— 119.
Hellman LM, Fillisti LP. Analysis of the atropine test for placental transfer in gravidas with toxemia and diabetes. Am J Obstet Gynecol 1965;91:797-808.
Barrier G, Olive G, Onnen I, et al. La pharmacocinet-ique de 1’atropine chez la femme enceinte et la foetus en fin de grossesse. Anesth Analg Reanimat 1976;33:795— 800.
Onnen I, Barrier G, d’Athis P, et al. Placental transfer of atropine at the end of pregnancy. Eur J Clin Pharmacol 1979;15:443-446.
Kivalo 1, Saarikoski S. Quantitative measurements of placental transfer and distribution of radioactive atropine in human fetus. Ann Chir Gynaecol Fem 1970;59:80— 81.
Kivalo I, Saarikoski S. Placental transmission of atropine at full-term pregnancy. Br J Anaesth 1977;49:1017— 1021.
Chaplin S, Sanders GL, Smith JM. Drug excretion in human breast milk. Adverse Drug React Acute Poison Rev 1982;1:255-287.
O’Brien ТЕ. Excretion of drugs in human milk. Am J Hosp Pharm 1974;31:844-854.
Arcuri PA, Gautieri RF. Morphine induced fetal malformations: 3. Possible mechanisms of action. J Pharm Sci 1973;62:1626-1634.
Beuker ED, Plainer WS. Effect of cholinergic drugs on development of chick embryo. Proc Soc Exp Biol Med 1956;91:539-543.
Lowe RF. Eyes in mongolism. Br J Ophthalmol 1949;33:131-174.
Harris WS, Goodman RM. Hyper-reactivity to atropine in Down’s syndrome. N Engl J Med 1968;279:407-410.
Jahnke W. Atropinvergiftigungen im heiszen Klima. Arch Toxi koi 1957;16:243-247.
Horne GD. Sensitivity to atropine in anhydrotic heat exhaustion. Trans R Soc Trop Med Hyg 1984;48:153-155.
Larkin GL. Occupational atropine poisoning via aerosol. Lancet 1991 ;337:917.
Schafer WD, Sauerland H-J. Observations after long term atropine administration [Beobachtungen nach atropine-Langzeit verordnung]. Klin Monatsblaetter Au-genheilkunde 1976;68:421-423.
Cooper MJ, Abinader EG. Atropine induced ventricular fibrillation: Case report and review of the literature. Am Heart J 1979;97:225-228.
Coates W. Belladonna poisoning. Br Med J 1947;2:886.
Seelye HH. Atropia poisoning from eating turkey. Med Rec 1894;45:14.
Lapan D, Smith JW. Atropine coma: Physostigmine reversal. Ariz Med 1977;34:159-160.
Michelson EA, Schneider SM, Martin TG. Adult inadvertent massive oral atropine overdose. Vet Hum Toxicol 1991;33:360.
Corbett BW, McBay AJ. Atropine poisoning. Bull Int Assoc Forens Toxicol 1978; 14( 1 ):37—38.
Amitai Y, Singer R, Almog S, Bentur Y. Atropine poisoning in children from automatic injectors during the Gulf Crisis. Vet Hum Toxicol 1991;33:360.
Greenblatt DJ, Shader RL Atropine overdose in three children. Br J Anaesth 1972;44:750.
Listwan IA, Whealy NG. Mental symptoms in poisoning with atropine and its derivatives. Med J Aust 1953;1:581-583.
Whittemore JB. Mental symptoms in poisoning with atropine and its derivatives. Med J Aust 1952; 1:752.
Gross NJ, Skorodin MS. Massive overdose of atropine methonitrate with only slight untoward effects. Lancet 1985;2:386.
Purcell MJ. Atropine poisoning in infancy. Br Med J 1966;1:738. 31 1/4
Stephenson J BP. Atropine methonitrate in management of near fatal reflex anoxic seizures. Lancet 1979;2:955.
Meerstadt PWD. Atropine poisoning in early infancy due to eumydrin drops. Br Med J 1982;285:196-197.
Barazarte V, Rodriguez Z, Caballos S, et al. Exchange transfusion in a case of severe theophylline poisoning. Vet Hum Toxicol 1992;34:526.
Laggner AN, Kaik G, Lenz K, et al. Treatment of severe poisoning with slow release theophylline. Br Med J 1985;288:1497.
Tenenbein M, Cohen S, Sitar DS. Whole bowel irrigation as a decontamination procedure after acute drug overdose. Arch Intern Med 1987;147:905-907.
Burkhart KK, Wuerz RC, Donovan JW. Whole bowel irrigation as adjunctive treatment for sustained-release theophylline poisoning. Vet Hum Toxicol 1991 ;33:353.
Burkhart KK, Wuerz RC, Donovan JW. Whole bowel irrigation as adjunctive treatment for sustained-release theophylline overdose. Ann Emerg Med 1992;21:1316— 1320.
Hoffman RS, Chiang WR, Howland MA, et al. Drug desorption from activated charcoal caused by whole bowel irrigating solution. Vet Hum Toxicol 1989;31:336.
Hoffman RS, Chiang WH, Howland MA, et al. Theophylline desorption from activated charcoal caused by whole bowel irrigation solution. Clin Toxicol 1991;29:191-201.
Henry JA, Minton NA. Adenosine as a theophylline antidote? In: Proceedings, Meeting of European Association of Poison Centres and Clinical Toxicologists, Lyon, France, May 22, 1991.
Glenn GM, Krober MS, Kelly P, et al. Pyridoxine as therapy in theophylline-induced seizures. Vet Hum Toxicol 1995;37:342-343.
Dean LS, Brown JW. Massive theophylline overdose: Survival without hemoperfusion. JAMA 1982;248:1742.
Brown SGA, Prentice DA. Ondansetron in the treatment of theophylline overdose. Med J Aust 1992; 156:512.
Roberts JR, Carney S, Boyle SM, Lee DC. Ondansetron quells drug-resistant emesis in theophylline poisoning. Am J Emerg Med 1993;11:609-610.
Parr MJA, Willatts SM. Fatal theophylline poisoning with rhabdomyolysis: A potential role for dantrolene treatment. Anaesthesia 1991;46:557-559.
Amin DN, Henry JA. Propranolol administration in theophylline overdose. Lancet 1985;1:520-521.
Dawson AH, Whyte IM. The assessment and treatment of theophylline poisoning. Med J Aust 1989; 151:689— 693.
Britt A, Burkhart KK. Theophylline toxicity. Top Emerg Med 1992;15:72-77.
Detleff RW, Touchette MA, Zarowitz BJ. Vasopressorresistant hypotension following a massive ingestion of theophylline. Ann Pharmacother 1993;27:781-784.
McGuigan MA, Tenenbein M, Goldman B. Planning an effective strategy for theophylline poisoning in adults. Emerg Med Rep 1987;8(6):41 —48.
Jouglard J. Zipeprol abuse: Ап opportunity for assessment of its neurotoxicity. Eur Assoc Pois Control Centres Toxicol Newslett 1991:5—13. Oslo, Norway.
Slobodkin D, Thompson D, Levin G, Jesurun CA. Habituation to zipeprol hydrochloride during pregnancy. J Subst Abuse Treat 1992;9:129-131.
Yohai D, Barnett SH. Absence and atonic seizures induced by piperazine. Pediatr Neurol 1989;5:393-394.
Crippa O, Polettini A, Avat FM. Lethal poisoning by zipeprol in drug addicts. J Forens Sci 1990;35:992-997.
Moroni C, Cerchiari EL, Gasparin M, Roter E. Overdosage of zipeprol, an non-opioid antitussive agent. Lancet 1984; 1:45.
Perroro F, Bearchi A. Convulsions and cerebral oedema associated with zipeprol abuse. Lancet 1984;1:45-46.
Schuch P, Stephan U, Jacobi F. Neurotoxic side effects of piperazines. Lancet 1966;1:1218.
Beckett AH, Achar R. Plasma concentrations and excretion of zipeprol in man under acidic urine conditions. J Pharm Pharmacol 1977;29:589-592.
Merigot PH, Garnier R, Efthymious ML. Seizure with three piperazine compounds used as antitussive agents (zipeprol, eprazinone and eprozinol). Ann Pediatr (Paris) 1985;32:504-511.
Roche J, Hamici R, Danel T, et al. Zipeprol addiction: A report of three cases. Semin Hop Paris 1991 ;67:1725— 1727.
Bahls FH, Мак К, Bird TD. Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: Risk factors for serious outcome in adults. Neurology 1991;41:1309-1312.
Baker MD. Theophylline toxicity in children. J Pediatr 1986;109:538-542.
Shannon M. Therapeutic theophylline levels and adverse cardiac events. Ann Intern Med 1994; 120:891.
Levine JH, Michael JR, Guarnieri T. Multifocal atrial tachycardia: A toxic effect of theophylline. Lancet 1985;1:12-14.
Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity: A prospective continuous electrocardiographic study. Chest 1990;98:672-678.
Parr MJ, Anaes FC, Day AC, et al. Theophylline poisoning: A review of 64 cases. Intens Care Med 1990;16:394-398.
Hantson P, Gautier P, Vekemans MC, et al. Acute myocardial infarction in a young woman: Possible relationship with sustained-release theophylline acute overdose. Intens Care Med 1992; 18:496.
Lloyd DM, Payne SPK, Tomson CRV, et al. Acute compartment syndrome secondary to theophylline overdose. Lancet 1990;2:312.
Ryan MF, Vale JA. Acute compartment syndrome secondary to theophylline poisoning. Lancet 1990;2:882.
Terzian CG, Simon PA. Aminophylline hypersensitivity apparently due to ethylenediamine. Ann Emerg Med 1992;21:312-317.
Poklis A, Saady JJ, Edinboro LE. Evaluation of the Abbott Vision AnalyzerR for determination of theophylline and implementation of a program for on-site emergency room testing. Clin Chem 1990;36:1040.
Jones LA, Gonzalez ER, Venitz J, et al. Evaluation of the Vision” theophylline assays in the emergency department setting. Ann Emerg Med 1992;21:777-781.
Gal P, Roop C, Robinson H, Erkan NV. Theophylline-induced seizures in accidentally overdosed neonates. Pediatrics 1980;65:547-549.
Augenstein WL, Kulig KW, Riggs BS. Theophylline toxicity in infants treated for bronchiolitis or asthma. In: Proceedings, AACT/AAPCC/ABMT/CAPCC Annual Scientific Meeting, Vancouver, 19S7: Abstract 68.
Olson KR, Benowitz NL, Woo OF, Pond SM. Theophylline overdose: Acute single ingestion versus chronic repeated overmedication. Am J Emerg Med 1985;3:386-394.
Zwililich CW, Sutton FD Jr, Neff TA, et al. Theophylline induced seizures in adults: Correlation with serum concentration. Ann Intern Med 1975;82:784-787.
Gaudreault P, Guay J. Theophylline poisoning: Pharmacological considerations and clinical management. Med Toxicol 1986;1:169-191.
Powell EC, Reynolds SL, Rubenstein JS. Theophylline toxicity in children: A retrospective review. Pediatr Emerg Care 1993;9:129-133.
Coupe M. Self-poisoning with sustained-release aminophylline: A mechanism for observed secondary rise in serum theophylline. Hum Toxicol 1986;5:341-342.
Shannon M, Lovejoy FH Jr. The influence of age vs peak serum concentration on life-threatening events after chronic theophylline intoxication. Arch Intern Med 1990;150:2045-2048.
Shannon AW, Lovejoy FH Jr, Woolf A. Prediction of serum theophylline concentration after acute theophylline intoxication. Ann Emerg Med 1990; 19:627.
Leventhal LJ, Kochan G, Feldman NH, et al. Lactic acidosis in theophylline overdose. Am J Emerg Med 1989;7:417-418.
Weber CA, Santiago RM. Hypermagnesemia: A potential complication during treatment of theophylline intoxication with oral activated charcoal and magnesium-con-taining cathartics. Chest 1989;95:56-59.
Gazda-Smith E, Synhavsky A. Hypernatremia following treatment of theophylline toxicity with activated charcoal and sorbitol. Arch Intern Med 1990;150:689-690.
Garrelts JG, Watson WA, Holloway KD, Sweet DE. Magnesium toxicity secondary to catharsis during management of theophylline poisoning. Am J Emerg Med 1989;7:34-37.
Henderson A, Wright DM, Pond SM. Management of theophylline overdose patients in the intensive care unit. Anaesth Intens Care 1992;20:56-62.
Day C, Crone D, Rankin N. Theophylline poisoning. Anaesth Intens Care 1992;20:531-532.
Biberstein MP, Ziegler MG, Ward DM. Use of betablockade and hemoperfusion for acute theophylline poisoning. West J Med 1984;141:485-490.
Renton KW, Gray JD, Hall Rl. Decreased elimination of theophylline after influenza vaccination. Can Med Assoc J 1980;123:288-290.
Seneff M, Scott J, Friedman B, Smith M. Acute theophylline toxicity and the use of esmolol to reverse cardiovascular irritability. Ann Emerg Med 1990;19:671-673.
Amitai Y. Lovejoy FH Jr. Characteristics of vomiting associated with acute release theophylline poisoning: Implications for management with oral activated charcoal. Clin Toxicol 1987;27:539-554.
Jain R, Tholl DA. Activated charcoal for theophylline toxicity in a premature infant on the second day of life. Dev Pharmacol Ther 1992;19:106-110.
Henderson A, Salin P, Pond SM. Rapid rise in serum theophylline concentration after overdose with sustained release theophylline. Med J Aust 1992;157:354-355.
Woo OF, Pond SM, Benowitz NL, et al. Benefit of hemoperfusion in acute theophylline intoxication. Clin Toxicol 1984:22:411—424.
Shannon M, Amitai Y, Lovejoy FH Jr. Multiple dose activated charcoal for theophylline poisoning in young infants. Pediatrics 1987;80:368-370.
Shannon MW, Woolf A. Does extracorporeal removal alter the course of major toxicity after theophylline intoxication? Vet Hum Toxicol 1992;34:320.
Jefferys DB, Raper SM, Helliwell M, et al. Haemoperfusion for theophylline overdose. Br Med J 1980;280:1167.
Laussen P, Shann F, Butt W, Tibballs J: Use of plasmapheresis in acute theophylline toxicity. Crit Care Med 1991;19:288-290.
Bania TC, Hoffmann RS, Howland MA, Goldfrank LR. Plasmapheresis for theophylline intoxication. Vet Hum Toxicol 1992;34:330.
Miceli JN, Clay B, Fleischmann LE, et al. Pharmacokinetics of severe theophylline intoxication managed by peritoneal dialysis. Dev Pharmacol Ther 1980;1:16-25.
Cooling OS. Theophylline toxicity. J Emerg Med 1993;11:415-425.
Agnone F, Gorkin D, Curry S. ’High flux’ hemodialysis for theophylline intoxication. Vet Hum Toxicol 1993;35:336.
Shannon MW, Wernovsky G, Morris C. Exchange transfusion in the treatment of severe theophylline intoxication. Vet Hum Toxicol 1991 ;33:354.
Shannon M, Wernovsky G, Morris C. Exchange transfusion in the treatment of severe theophylline poisoning. Pediatrics 1992;89:145-147.
Henry GC, Wax PM, Howland MA, et al. Exchange transfusion for the treatment of a theophylline overdose in a premature neonate. Vet Hum Toxicol 1991 ;33:356.
Osborn HN, Henry G, Wax P, et al. Theophylline toxicity in a premature neonate: Elimination kinetics of exchange transfusion. Clin Toxicol 1993;31:639-544.
Stark CM, Howland МА, Goldfrank LR. Concepts and controversies of bronchodilator overdose. Emerg Med Clin North Am 1994;12:415-436.
Baker MD. Theophylline toxicity in children. J Pediatr 1986;109:538-542.
Skopnik H, Bertl U, Heimann G. Neonatal theophylline intoxication: Pharmacokinetics and clinical evaluation. Eur J Pediatr 1992;151:221-224.
Jenne JW, Nagasawa HT, Thompson RD. Relationship of urinary metabolites of theophylline to serum theophylline levels. Clin Pharmacol Ther 1976;19:375-381.
Fuhr U, Woodcock BG, Siewert M. Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2. Eur J Clin Pharmacol 1992;42:463-464.
Greenburg A, Piraino BH, Kroboth PD, et al. Severe theophylline toxicity: Role of conservative measures, an-tiarrhythmic agents and charcoal hemoperfusion. Am J Med 1984;76:854-860.
Bory C, Baltassat P, Porthault M, et al. Metabolism of theophylline to caffeine in premature newborn infants. J Pediatr 1979;94:988-993.
Upton RA. Pharmacokinetic interactions between theophylline and other medications (Part I). Clin Pharmacokinetics 1991;20:66-80.
Skinner NH. Adverse reactions and interactions with theophylline. Drug Saf 1990;5:275-285.
Dal Negro R, Pomari C, Turco P. Famotidine and theophylline pharmacokinetics: An unexpected cimetidinelike interaction in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet 1993;24:255-258.
Neff RK, Leviton A. Maternal theophylline consumption and the risk of stillbirth. Chest 1990;97:1266-1267.
Park JM, Schmer V, Myers TL. Cardiovascular anomalies associated with prenatal exposure to theophylline. South Med J 1990;83:1487-1488.
Stec GP, Greenberger P, Ruo Tl, et al. Kinetics of theophylline transfer to breast milk. Clin Pharmacol Ther 1980;28:404-408.
Frederiksen MC, Ruo Tl, Chow MJ, et al. Theophylline pharmacokinetics in pregnancy. Clin Pharmacol Ther 1986;40:321-328.
Banner AS. Theophylline: Should we discard an old friend? Lancet 1993;343:618.
Shannon M. Hypokalemia, hyperglycemia and plasma catecholamine activity after severe theophylline intoxication. Clin Toxicol 1994;32:41-47.
Shannon M, Lovejoy FH Jr. Hypokalemia after theophylline intoxication: The effects of acute vs chronic poisoning. Arch Intern Med 1989;149:2725-2729.
Sawyer WT, Caravati EM, Ellison MJ, et al. Hypokalemia, hyperglycemia and acidosis after intentional theophylline overdose. Am J Emerg Med 1985;3:408-411.
Park GD, Spector R, Roberts RJ, et al. Use of hemoperfusion for treatment of theophylline intoxication. Am J Med 1983;74:961-966.
McPherson ML, Prince SR, Atamer ER, et al. Theo-phylline-induced hypercalcemia. Ann Intern Med 1986.
Shannon M. Predictors of major toxicity after theophylline overdose. Ann Intern Med 1993;119:1161-1167.
Shannon M, Lovejoy FH Jr. Effect of acute versus chronic intoxication on clinical features of theophylline poisoning in children. J Pediatr 1992;121:125-130.
Shannon MW, Lovejoy FH, Woolf A. Acute complications and predictions of major toxicity after theophylline overdose. Vet Hum Toxicol 1992;34:328.
Modi KB, Horn EH, Bryson SM. Theophylline poisoning and rhabdomyolysis. Lancet 1985;2:160-161.
MacDonald JB, Jones HM, Cowan RA. Rhabdomyolysis and acute renal failure after theophylline overdose. Lancet 1985;1:932-933.
Ramirez MS, Rojas AM, Perez LA, et al. Grand mal seizures and clobutinol overdose. Vet Hum Toxicol 1993;35:444.
Zimmer A, Bucheler A, Kascke S. Pharmacokinetic comparison of clobutinol-HCI (with and without orci-prenaline-SO4), as solution, juice and syrup in man. Arzneimittelforschung 1977;27:2012-2017.
Salonen RO. Comparison of the effects of two opioid an-titussives, vadocaine hydrochloride, clobutinol and lidocaine on lung-mechanics in guinea pigs. Arzneimittelforschung 1988;38:609-612.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda: American Society of Hospital Pharmacists, 1994:1759— 1760.
Reynolds JEF, Ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:970.
Becker CB, Gordon JM. Iodinated glycerol and thyroid function: Four cases: A review of the literature. Chest 1993;103:188-192.
Huseby JS, Bennett SW, Hagensee ME. Hyperthyroidism induced by iodinated glycerol. Am Rev Respir Dis 1991;144:1403.
Gomolin IH. Iodinated glycerol-induced hypothyroidism. Drug Intell Clin Pharm 1987;21:726-727.
Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in asthma and allergic disorders. Drugs 1990;40:412-448.
Le Blaye 1, Donatini B, Hall M, Krupp P. Acute ketotifen overdosage: A review of present clinical experience. Drug Saf 1992;7:387-392.
Perhaj Z, Laplanche R. Documenta Sandoz. Basle: Sandoz, March 1979.
Jefferys DR, Volans GN. Ketotifen overdose: Surveillance of the toxicity of a new drug. Br Med J 1981;282:1755-1756.
Maclay WP, Crowder D, Spiro S, Turner P. Postmarketing surveillance: Practical experience with ketotifen. Br Med J 1984;288:911-914.
Rackham A, Brown CA, Chardra RK, et al. A Canadian multicenter study with Zaditen (ketotifen) in the treatment of bronchial asthma in children aged 5 to 17 years. J Allergy Clin Immunol 1989;84:286-296.
MacDonald GF. An overview of ketotifen. Chest 1982;82(suppl.):30A-32S.
Edwards G. Orciprenaline in treatment of airways obstruction in chronic bronchitis. Br Med J 1964;1:1015-1017.
Beardshaw J, MacLean L, Chan-Yeung M. Comparison of the bronchodilation and cardiac effects of hydroxy-phenyl-orciprenaline and orciprenaline. Chest 1974;65:507-511.
Reynolds JEF, 30th ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1950.
Barnewolt BA, Walter FG. Metabolic effects of metapro-terenol orciprenaline overdose: Hypokalemia, hyperglycemia and hyperlactatemia. Vet Hum Toxicol 1990;32:346.
Macgregor TR, Nastasi L, Farine PR, Keims JJ. Isolation and characterization of metaproterenol-O-sulfate: A conjugate of metaproterenol in human urine. Drug Metab Dispos 1983;11:568-573.
Whitsett TL, Manion CV, Wilson MF. Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo. Br J Clin Pharmacol 1981;12:195-200.
Muscling in on clenbuterol. Lancet 1992;340:403. Editorial.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1241.
Whitsett TL, Manion CV, Wilson MF. Cardiac, pulmonary and neuromuscular effects of clenbuterol, terbutaline and placebo. Clin Pharmacol Ther 1980;27:294— 295.
MacLennan PA, Edward RHT. Effect of clenbuterol and propranolol on muscle mass: Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy. Biochem J 1989;264:573-579.
Delday Ml, Williams PE, Maltin CA. Effect of clenbuterol on immobilized muscle. J Neurol Sci 1990;98:376.
Zahn V, Krumbacher G. Clenbuterol: A long term uterine relaxant. J Perinat Med 1981;9:96-100.
Beckett AH. Clenbuterol and sports. Lancet 1992;340:1165.
Blom-Bulow P, Boe J, Bulow K, Hagelqvist I. A comparison of oral beta2-agonists Clenbuterol and salbutamol in obstructive lung disease: A double blind cross-over study. Curr Ther Res 1985;37:51-57.
Michel F, Gatto E, Gene R, Pardal MF Clenbuterol-induced tardive dyskinesia. Clin Neuropharmacol 1991;14:427-431.
World Health Organization. Wkly Epidemiol Rec 1992;67:273-280.
Haahtela Т, Jarvinen М, Kava Т, et al. Comparison of a beta2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325:388-392.
Toogood JH. Complication of topical steroid therapy for asthma. Am Rev Respir Dis 1990; 141 (suppl.):89—96.
Connett G, Lenney W. Inhaled budesonide and behavioral disturbances. Lancet 1991;338:634-635.
Ryrfeldt A, Andersson P, Edsbacker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982;62(suppl. 22):86—95.
Barnes PJ. Pulmonary disorders. In: Melmon KL, Mor-relli HF, Hoffman BB, Nierenberg DW, eds. Clinical Pharmacology: Basic Principles in Therapeutics. 3rd ed. New York: McGraw Hill, 1992:198-202.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:726.
Ryrfeldt A, Edsbacker S, Pauwels R. Kinetics of the epimeric glucocorticoid budesonide. Clin Pharmacol Ther 1984;35:525-530.
Wolthers OD, Pedersen S. Growth of asthmatic children during treatment with budesonide: A double blind trial. Br Med J 1991;303:163-165.
Boe J, Skoogh BE. Is long term treatment with inhaled steroids in adults hazardous? Eur Respir J 1992;5:1037— 1039.
Holmes P, Cowen P. Spongiotic (eczematous-type) dermatitis after inhaled budesonide. Aust NZ J Med 1992;22:511.
Balfour-Lynn L. Growth retardation in asthmatic children treated with inhaled beclomethasone dipropionate. Lancet 1988;1:475-476.
Lewis LD, Cochrane GM. Psychosis in a child inhaling budesonide. Lancet 1983;2:634.
Aherne W, Littleton P, Marks V. A sensitive radioimmunoassay for budesonide in plasma. Eur J Respir Dis 1982;63(suppl. 122):254—256.
Evan MM, O’Connor BJ, Fulder RW, et al. Effect of inhaled budesonide on eosinophil density in asthma. Br J Clin Pharmacol 1991 ;31:616P.
Oosterhuis В, Braat Р, Ross CM, etal. Pharmacokinetic-pharmacodynamic modeling of terbutaline bronchodilator in asthma. Clin Pharmacol Ther 1986;40:469-475.
Leferink JG, Lamont H, Wagemaker-Engles I, et al. Pharmacokinetics of terbutaline after subcutaneous administration. Int J Clin Pharmacol Biopharm 1979;17:181-185.
Gandar R, de Zoeten LW, Der School JB. Serum levels of ritodrine in man. Eur J Clin Pharmacol 1980;17:117-122.
Evans ME, Walker SR, Brittain RT, Paterson JW. The metabolism of salbutamol in man. Xenobiotica 1973;3:113-120.
Salbutamol. In: Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1255-1257.
Albuterol. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:757—760.
Ventolin. In: Physicians’ Desk Reference. 49th ed. Montvale, NJ: Medical Economics, 1995:485—488.
Schatz M, Zeiger RS, Harden KM, et al. The safety of inhaled beta-agonist bronchodilators during pregnancy. J Allergy Clin Immunol 1988;82:686-695.
Hudgens DR, Conradi SE. Sudden death associated with terbutaline sulfate administration. Am J Obstet Gynecol 1993;169:120-121.
Boreus L, de Chateau P, Lindberg C, Nyberg L. Terbutaline in breast milk. Br J Clin Pharmacol 1982;13:731-732.
Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med 1995;333:499-506.
Whyte KF, Addis GJ, Whitesmith R, Reid JL. The mechanism of salbutamol-induced hypokalaemia. Br J Clin Pharmacol 1987;23:65-71.
Montoliu J, Lens XM, Revert L. Potassium-lowering effect of albuterol for hyperkalemia in renal failure. Arch Intern Med 1987;147:713-717.
Crane J, Burgess C, Beasley R. Cardiovascular and hy-pokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline. Thorax 1989;44:136-140.
Windom HH, Burgess CD, Siebers RWL, et al. The pulmonary and extrapulmonary effects of inhaled beta-agonists in patients with asthma. Clin Pharmacol Ther 1990;48:296-301.
Wasserman D, Amitai Y. Hypoglycemia following albuterol overdose in a child. Am J Emerg Med 1992;10:556-557.
Spiller HA, Wiley JF, Krenzelok EP, Bory D, Accidental albuterol ingestion in children. Vet Hum Toxicol 1992;34:325.
Tye K-H, Desser KB, Benchimol A. Angina pectoris associated with use of terbutaline for premature labor. JAMA 1980;244:692-693.
Gluckman L. Ventolin psychosis. NZ Med J 1974;80:411.
Whitehouse AM, Novosel S. Salbutamol psychosis. Biol Psychiatry 1989;26:631-633.
Gaultier M, Gervais P, Lagier G, Danan L. Pharma-codependence psychique au salbutamol en aerosol chez une asthmatique. Therapie 1976;31:465-470.
Brennan PO. Inhaled salbutamol: A new form of drug abuse? Lancet 1983;2:1030—1031.
Edwards JG, Holgate ST. Dependency upon salbutamol inhalers. Br J Psychiat 1979;134:624-626.
Thompson PJ, Dhillon P, Cole P. Addiction to aerosol treatment: The asthmatic alternative to glue sniffing. Br Med J 1983;287:1515-1516.
Faulds D, Hollingshead LM, Goa KL. Formoterol: A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991;42:115-137.
Kamura H, Sasaki H, Higuchi S, Shiobara Y. Quantitative determination of the beta-adrenoceptor formoterol in urine by gas chromatography-mass spectrometry. J Chromatogr 1982;229:337-345.
Yokoi K, Murase K, Shiobara Y. The development of a radioimmunoassay for formoterol. Life Sci 1983;33:1665-1672.
Tanner RJN, Martin LE, Oxford J. An automatic GC-MS assay for salbutamol in plasma. Anal Proc 1983;20:38-47.
Ong H, Adam A, Perreault S, et al. Monitoring of salbutamol (albuterol) in humans: Application of an immunoaffinity clean up procedure combined with HPLC with fluorometric detection. Drug Saf 1990;5(suppl. 2): 164.
Tripp SL, Williams E, Roth WJ, et al. Analysis of terbutaline in human serum by thin layer fluorometry. Anal Lett 1978;BII:727—740.
Jacobson SE, Jonsson S, Lindberg C, Svensson LA. Determination of terbutaline in plasma by gas chromatography chemical ionization mass spectrometry. Biomed Mass Spectrom 1980;7:265-268.
Billing B, Dahlqvist R, Garles M, et al. Separate and combined use of terbutaline and theophylline in asthmatics. Eur J Respir Dis 1982;63:399-409.
Lewis LD, Essex E, Volans GN, Cochrane GM. A study of self-poisoning with oral salbutamol: Laboratory and clinical features. Hum Exp Toxicol 1993;12:39-41.
Hornblad Y, Ripe E, Magnusson PO, Tegner K. The metabolism and clinical activity of terbutaline and its prodrug ibuterol. Eur J Clin Pharmacol 1976;10:9-18
Van den Berg W, Leferink JG, Maes RAA, Kreukniet J, Bruynzeel PLR. Correlation between terbutaline serum levels, c-AMP plasma levels and FEV, in normals and asthmatics after subcutaneous administration. Ann Allergy 1980;44:235-239.
Ramoska EA, Henretig F, Joffe M, Spiller HA. Propranolol treatment of albuterol poisoning in two asthmatic patients. Ann Emerg Med 1993;22:1474-1476.
Hoffner CA, Kendall MJ. Metabolic effects of beta2-ag-onists. J Clin Pharm Ther 1992;17:155-164.
Waller DG. Beta-adrenoceptor partial agonists, a renaissance in cardiovascular therapy? Br J Clin Pharmacol 1990;30:157-171.
Minton NA, Baird AR, Henry JA. Modulation of the effects of salbutamol by propranolol and atenolol. Eur J Clin Pharmacol 1989;36:449-453.
Robin ED, McCauley R. Sudden cardiac death in bronchial asthma and inhaled beta-adrenergic agonists. Chest 1992;101:1699-1702.
Spiller HA, Ramoska EA, Henretig FM, Joffe M. A two-year retrospective study of accidental pediatric albuterol ingestions. Pediatr Emerg Care 1993;9:338-340.
Ahlquist RP. A study of adrenotropic receptors. Am J Physiol 1948;153:586-600.
Morgan DJ. Clinical pharmacokinetics of beta-agonists. Clin Pharmacokinet 1990;18:270-294.
Lands AM, Arnold A, McAuliff JP, et al. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967;214:597-598.
Ahrens RC, Smith GD. Albuterol: An adrenergic agent for use in the treatment of asthma: Pharmacology, pharmacokinetics and clinical use. Pharmacotherapy 1984;4:105-121.
Woolcock AJ. Beta-agonists and asthma mortality: What have we learned? What questions remain? Drugs 1990;40:653-656.
Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. Br Med J 1968; 1:335— 339.
Burrows B, Lebowitz MD. The beta-agonist dilemma. N Engl J Med 1992;326:560-561.
Spitzer WO, Suissa S, Ernst P, et al. The use of betaagonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-506.
Sears MR. Beta2 agonists and asthma. Br Med J 1991 ;303:123.
Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-1396.
Lipworth BJ. Risks versus benefits of inhaled beta2-ago-nists in the management of asthma. Drug Saf 1992;7:54— 70.
Haalbom J RE, Deenstra M, Struyvenberg A. Effect of fenoterol on plasma potassium and cardiac ectopic activity. Lancet 1989;2:45.
Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand 1981 — 1983: Case control study. Lancet 1989;1:917-922.
Pearce N, Crane J, Burgess C, et al. Fenoterol and asthma mortality. Lancet 1989;1:1196-1197.
Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed Venoterol and death from asthma in New Zealand, 1977-81. Thorax 1990;45:170-175.
Grand IWB. Fenoterol and asthma deaths in New Zealand. NZ Med J 1990;April 11:160-161.
Green WF. Fenoterol and its bromide. Lancet 1991;337:1613.
Nicklas RA. Paradoxical bronchospasm associated with the use of inhaled beta agonists. J Allergy Clin Immunol 1990;85:959-964.
Fenoterol. Lancet 1989; 1:971.
Elwood JM. Fenoterol: The evidence leading to restriction of its use. NZ Med J 1990;103:395-397.
Revised indications for fenoterol. Aust Adverse Drug React Bull, May 1990.
British Thoracic Society Research Unit of the Royal College of Physicians of London, King’s Fund Centre, National Asthma Campaign. Guidelines for management of asthma in adults: I. Chronic persistent asthma. Br Med J 1990;301:651-653; II. Acute severe asthma. Br Med J 1990;301:797-800.
National Asthma Education Program. Guidelines for the Diagnosis and Management of Asthma. Publication No. 91—3042. Bethesda, MD: Department of Health and Human Services, 1991.
Bone RC. Another word of caution regarding a new long-acting bronchodilator. JAMA 1995;273:967-968.
Morrison GW, Farebrother MJB. Overdose of salbutamol. Lancet 1973;2:681.
O’Brien IAD, Fitzgerald-Fraser J, Lewin IG, Corral! RJM. Hypokalaemia due to salbutamol overdosage. Br Med J 1981;282:1515-1516.
Connell JMC, Cook GM, Mclnnes GT. Metabolic consequences of salbutamol poisoning reversed by propranolol. Br Med J 1982;285:779.
Whyte KF, Addis GJ. Toxicity of salbutamol and theophylline together. Lancet 1983;2:618-619.
MacKay MJ. Overdose of salbutamol during an asthma attack. Br Med J 1985;290:286.
Jarvie DR, Thompson AM, Dyson EH. Laboratory and clinical features of self-poisoning with salbutamol and terbutaline. Clin Chim Acta 1987;168:313-322.
Prior JG, Cochrane GM, Raper SM, et al. Self-poisoning with oral salbumatomol. Br Med J 1981 ;282:1932.
Spiller HA, Henvetig FM, Ramoska E, Jaffe M. Two year retrospective study of pediatric albuterol ingestions. Vet Hum Toxicol 1990;32:352.
Jaffe M, Ramoska E, Schwartz S, et al. Severe albuterol poisoning treated with propranolol. Vet Hum Toxicol 1990;32:351.
King W, Holloway M, Palmisano P. Albuterol overdose in a preschooler: A case report. Vet Hum Toxicol 1991:33:357.
Lawyer C, Pond A. Problems with terbutaline. N Engl J Med 1977;296:821.
Gomolin I, Ingelfinger JA. Terbutaline overdose. N Engl J Med 1979;300:143.
Brandstetter RD, Gotz V. Inadvertent overdose of parenteral terbutaline. Lancet 1980;1:485-486.
Kaul AF, Stubblefield PG. Terbutaline sulfate overdosage. Drug Intell Clin Pharm 1980; 14:866.
Host A, Foged N. Terbutaline intoxication in a three-year-old child. Ugeskr Laeger 1983; 145:1450.
Heath A, Hulten В-A. Terbutaline concentrations in self-poisoning: A case report. Hum Toxicol 1987;6:525— 526.
Blake PG, Ryan F. Rhabdomyolysis and acute renal failure after terbutaline overdose. Nephron 1989;53:76-77.
Evans ME, Shenfield GM, Paterson JW. The clinical pharmacology of salmefamol. Br J Clin Pharmacol 1974;1:391-397.
Blackwell E, Briant RH, Conolly ME, et al. Metabolism of isoprenaline after aerosol and direct intrabronchial administration in man and dog. Br J Pharmacol 1974;50:597-601.
Nilsson HT, Simonsson BG, Strom B. The fate of ’H-terbutaline sulphate administered to man as an aerosol. Eur J Clin Pharmacol 1976;10:1-7.
Laros CD, Van Urk P, Rominger KL. Absorption, distribution and excretion of the tritium-labelled beta2-stimulator fenoterol hydrobromide following aerosol administration and instillation into the bronchial tree. Respiration 1977;34:131-134.
Shenfield GM, Evans ME, Paterson JW. Absorption of drugs by the lung. Br J Clin Pharmacol 1976;3:583-589.
Shenfield GM, Evans ME, Paterson JW. The effect of different nebulizers with and without intermittent positive pressure breathing on the absorption and metabolism of salbutamol. BrJ Clin Pharmacol 1974;1:295-300.
Berti F, Magni F, Rossoni G, et al. New pharmacological data on the bronchospasmolytic activity of bamifyl-line. Arzneimittelforschung 1988;38:40-44.
Schiantarelli Р, Acerbi D, Botta GC, et al. Evidence of pulmonary tropism of bamifylline and its main active metabolite. Arzneimittelforschung 1989;39:215— 219.
Offidani C, Ottaviano V, Chiarotti M. Fatal case of bamifylline intoxication. Am J Forens Med Pathol 1993;14:244-245.
Segre G, Cerretani D, Moltoni L, et al. Pharmacokinetics of bamifylline during chronic therapy. Arzneimittelforschung 1990:40:450—452.
Barre J, Didey F, Urien S, et al. In vitro studies on the blood distribution of almitrine. Pharmacology 1989.
Belu L, Larry D, de Cremoux H, et al. Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy. Br J Clin Pharmacol 1989;27:387-390.
Bouche P, Lacomblez L, Leger JM, et al. Peripheral neuropathies during treatment with almitrine: Report of 46 cases. J Neurol 1989;236:29-33.
Bromet N, Courte S, Anbut Y, et al. Pharmacokinetics of almitrine bismesylate: Studies in patients. Eur J Respir Dis 1983;64(suppl. 126):363—375.
Lerebours G, Moore N, Senant J. Almitrine and peripheral nerve function. Lancet 1988;2:799-800.
Racine A, Bromet N, Courte S, Voisin C. Dosage de 1’almitrine dans les milieux biologiques. J Chromatogr Biomed Appl 1981;223:219-224.
Touaty E, Viau F, Pariente R. A therapeutic trial of intravenous almitrine and exacerbation of chronic respiratory failure. Rev Fr Mai Respir 1980;8:621-628.
Bakran J, Vrhovac В, Stangl В, et al. Double blind placebo controlled clinical trial of almitrine bismesylate in patients with chronic respiratory insufficiency. Eur J clin Pharmacol 1990;38:249-253.
Bardsley РА, Howard Р, De Bache et al. Two years treatment with almifrine osmesylate in patients with hypoxic chronic obstructive airways disease. Eur Respir J 1991;4:308-310.
Bardsley PA, Tweney J, Morgan N, Howard P. Oral almitrine in treatment of acute respiratory failure and cor pulmoonale in patients with an exacerbation of chronic obstructive airway disease. Thorax 1991;46:493-498.
Howard P. Hypoxia almitrine and peripheral neuropathy. Thorax 1989;44:247-250.
Vidon N, Chaussade S, Jeanniot P, et al. Almitrine bismesylate disposition in the human digestive tract. Eur J Clin Pharmacol 1989;37:487-491.
Bromet N, Singla E. Pharmacokinetique clinique de bismesylate d’almitrine. Presse Med 1984;13:2071-2077.
Watanabe S, Kauner RE, Cutillo AG, et al. Long term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;140:1269-1273.
Campbell OB, Gordon B, Taylor D, Williams J. The biodisposition of almitrine bismesylate in man: A review. Eur J Respir Dis 1983;64:337-348.
Belie L, Laurray D, De Cremoux H, et al. Extensive oxidative metabolism of dextromethorphan patients with almitrine neuropathy. Br J Clin Pharmacol 1989;27:387-390.
Herchuelz A, Gangji D, Derenne F, et al. Metabolism of almitrine in extensive and poor metabolizers of de-brisoquine/sparteine. Br J Clin Pharmacol 1991 ;31:73— 76.
Wouters EFM, Greve LH, Steenhuis ES, Gimeno F. Almitrine and peripheral neuropathy. Lancet 1988;2: 336.
Voisin C, Howard P, Ansquard C. Almitrine bimesylate: A long-term placebo controlled double-blind study in COAD-Vectarian International Multicentre Study Group. Bull Eur Physiopathol Respir 1987;23(suppl. 11): 1695-1825.
Allen MB. Almitrine and peripheral neuropathy. Lancet 1988;2:571.
Reyes A, Roca J, Rodriguez-Roisin R, et al. Effect of almitrine in ventricular perfusion distribution in adult respiratory distress syndrome. Am Rev Respir Dis 1989;137:1062-1067.
Herve J, Musset D, Simmoneau G, et al. Almitrine decreases the distensibility of the large pulmonary arteries in man. Chest 1989;96:572-577.
Ghirardi R, Belec L, Louarn F. Almitrine-induced peripheral neuropathy and weight loss. J Neurol 1989;236:374.
Tweney J. Almitrine bismesylate: Current status. Bull Eur Physiopathol Respir 1987;23(suppl. 1): 156—163.
Report of an IUIS/WHO Working Group. Use and abuse of laboratory tests in clinical immunology: Critical considerations of eight widely used diagnostic procedures. Clin Exp Immunol 1981;46:662-674.
De Shazo RD, Lopez M, Salvaggio JE. Use and interpretation of diagnostic immunologic laboratory tests. JAMA 1987;258:3011-3031.
Leikin JB, Heyn-Lamb R, Aks S, et al. The toxic patient as a potential organ donor. Am J Emerg Med 1994;12:151-154.
Baselt RC, Carvey RH. Disposition of Toxic Doses and Chemicals in Man. 3rd ed. Chicago: Year Book Medical, 1989.
Adair JC, Gilmore RL. Meperidine neurotoxicity after organ transplantations. Clin Toxicol 1994;32:325— 328.
Taliercio CP, Olney BA, Lie JT: Myocarditis related to drug hypersensitivity. Mayo Clin Proc 1985;60:463— 468.
Anderson J A, Adkinson NF Jr. Allergic reactions to drugs and biologic agents. JAMA 1987(258:2891 — 2899.
Spiera Н. Scleroderma after silicone augmentation mammoplasty. JAMA 1988;260:236-238.
Uretsky BF, O’Brien JJ, Courtisi EH, et al. Augmentation mammoplasty with a severe systemic illness. Ann Plast Surg 1979;3:445-447.
Walsh FW, Solomon DA, Espinoza LR, et al. Human adjuvant disease: A new cause of chylous effusions. Arch Intern Med 1989;149:1194-1196.
Miyoshi K, MiyamuraT, Kobayashi Y, et al. Hypergammaglobulinemia by prolonged adjuvanticity in men: Disorders developed after augmentation mammaplasty. Jpn Med J 1964;2122:9-14.
Miyoshi K, Shiragami H, Yoshida K. Adjuvant disease of man. Clin Immunol (Tokyo) 1973:785—794.
Kumagai Y, Abe C, Shiokawa Y. Scleroderma after cosmetic surgery: Four cases of human adjuvant disease. Arthritis Rheum 1979;22:532-537.
Osebold JW. Mechanisms of action by immunologic adjuvants. JAMA 1982;181:983-987.
Van Nunen SA, Gatenby PA, Basten A. Post-mammo-plasty connective tissue disease. Arthritis Rheum 1982;25:694-697.
Baldwin CM Jr, Kaplan EN. Silicone-induced human adjuvant disease? Ann Plast Surg 1983;10:270-273.
Kumagai Y, Shiokawa Y, Medsger TA Jr, Rodman GP. Clinical spectrum of connective tissue disease after cosmetic surgery: Observations on eighteen patients and a review of the Japanese literature. Arthritis Rheum 1984;27:1-12.
Okano Y, Nishikai M, Sato A. Scleroderma, primary biliary cirrhosis and Sjogren’s syndrome after cosmetic breast augmentation with silicone injection: A case report of possible human adjuvant disease. Ann Rheum Dis 1984;43:520-522.
Fock KM, Feng PH, Tey BH. Autoimmune disease developing after augmentation mammoplasty: Report of 3 cases. J Rheumatol 1984;11:98-100.
Byron MA, Venning VA, Mowat AG. Post-mammo-plasty human adjuvant disease. Br J Rheumatol 1984;23:227-229.
Sergott TJ, Limoli JP, Baldwin CM Jr, Laub DR. Human adjuvant disease, possible autoimmune disease after silicone implantation: A review of the literature, case studies and speculation for the future. Plast Reconstr Surg 1986;78:104-114.
Freund J, McDermott K. Sensitization to horse serum by means of adjuvants. Proc Soc Exp Biol Med 1942;49:548-553.
Lise LD, Audibert F. Immunoadjuvants and analogs of immunomodulatory bacterial structures. Curr Opin Immunol 1989;2:269-274.
Vargas A. Shedding of silicone particles from infected breast implants. Plast Reconstr Surg 1979;64:252-253.
Conklin HB, Curtis RM, Ben-Efraim S. Koch’s phenomenon involving the flexor tendon sheath: Adjuvant-induced tenosynovitis in man. J Bone Joint Surg 1964;51A:1413—1419.
Drachman DA, Paterson P, Bornstein MB. Experimental allergic encephalomyelitis in man: A laboratory accident. Neurology 1974;24:364.
Berry EM, Geltner D, Chajek T. Accidental injection of Freund’s adjuvant. Lancet 1975;1:863-864.
Sanchez-Guerrero J, Colditz GA, Karlson EW, Silicone breast implants and the risk of connective tissue diseases and symptoms. N Engl J Med 1995;332:1666-1670.
Recommendations on Silicone Breast Implants. FDA Med Bull 1992;22(1):3—4.
Tomas S, Pedro-Botet J, Auguet T. Ciprofloxacin and immunocomplex-mediated disease. J Intern Med 1991;23:550-551.
Stejskal V, Nilsson R, Crepe A. Immunologic basis for adverse reactions to radiographic contrast media. Acta Radiol 1990;31:605-612.
Thrasher JD, Broughton A, Micovich P. Antibodies and immune profile of individuals occupationally exposed to formaldehyde: Six case reports. Am J Ind Med 1988;14:479-488.
Thrasher JD, Broughton A, Madison R. Human activation and autoantibodies in humans with long-term inhalation exposure to formaldehyde. Arch Environ Health 1990;45:217-223.
Almroth G, Enestrom S, Hed J, et al. Autoantibodies to leucocyte antigens in hydralazine-associated nephritis. J Intern Med 1992;231:37-42.
Soto-Aguilar MC, de Shazo RD, Morgan JEet al. Total IgG and IgG subclass specific antibody responses to insulin in diabetic patients. Ann Allergy 1991 ;67:499—-503.
Uchigata Y, Kawata S, Tokunaga K, et al. Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet 1992;339:393-394.
Meschi F, Dozio N, Bognetti E, et al. An unusual case of recurrent hypoglycemia: 10 year follow-up of a child with insulin autoimmunity. Eur J Pediatr 1992; 151:32— 34.
Sobel JD. Acquired immunodeficiency syndrome in intravenous drug abusers. In: Levine DP, Sobel JD, eds. Infections in Intravenous Drug Abusers. New York: Oxford University Press, 1991:342—379.
Novick DM, Ochsharn M, Ghali V, et al. Natural killer call activity and lymphocyte subsets in parenteral heroin users and long term methadone maintenance patients. J Pharmacol Exp Ther 1989;250:606-610.
Novick DM, Kreek MJ. Methadone and immune function. Am J Med 1992;92:113-114.
Kauffman CA, Bradley SF. Host defense mechanisms in intravenous drug abusers. In: Levine DP, Sobel JD, eds. Infections in Intravenous Drug Abusers. New York: Oxford University Press, 1991:27—33.
Koller LD. Immunotoxicology of heavy metals. Int J Im-munopharmacol 1980; 2:269—279.
Warner GL, Lawrence DA. The effect of metals on IL-2 related lymphocyte proliferation. Int J Immunophar-macol 1988;10:629-637.
McCabe MJ Jr, Lawrence DA. Lead, a major environmental pollutant, is immunomodulatory by its differential effects on CD4+T-cell subsets. Toxicol Appl Pharmacol 1991;111:13-23.
Wedeen RP. Occupational renal disease. Am J Kidney Dis 1984;3:241-258.
Reigart JR, Graber CD. Evaluation of the humoral immune response of children with low level lead exposure. Bull Environ Contain Toxicol 1976;16:112-117.
Sachs HK. Intercurrent infections in lead poisoning. Am J Dis Child 1978;132:315-316.
Pospischil E, Wolf C, Meisinger V, Jahn O. Immunological parameters in occupational lead poisoning: Trace elements in human health and disease. In: Proceedings, Second Nordic Symposium. WHO/CEC/EPA. Geneva: World Health Organization, 1987:110—114.
Inorganic mercury. Environmental Health Criteria 118 Geneva: World Health Organization, 1991.
Druet P, Hirsch F, Pelletier L, et al. Mechanisms of chemical-induced glomerulonephritis. In: Fowler BA, ed. Mechanisms of Cell Injury: Complications for Human Health. Dahlein Konferenzen. Chichester: John Wiley & Sons, 1987:153-173.
Druet P, Bernard A, Hirsch F, et al. Immunologically mediated glomerulonephritis induced by heavy metals. Arch Toxicol 1982;50:187-194.
Kibukamusoke JW, Daires DR, Hutt MSR. Membranous nephropathy due to skin-lightening cream. Br Med J 1974;2:646-647.
Sunderman FW. A review of the metabolism and toxicity of nickel. Ann Clin Lab Sci 1977;7:377-398.
Sunderman FW Jr. Mechanisms of nickel carcinogenesis. Scand J Work Environ Health 1989;15:1-12.
Haley PJ, Bice DE, Muggenburg BA, et al. Immunopathology: Effects of nickel subsulfide on the primate pulmonary immune system. Toxicol Appl Pharmacol 1987;88:1-12.
Fisher AA. Unusual reaction associated with allergic reactions to nickel. Cutis 1991;47:86-88.
Buchet JP, Lauwerys R, Roels H, et aL Renal effects of cadmium body burden of the general population. Lancet 1990;336:699-702.
Koller LD, Exon JH, Roan JG. Antibody suppression by cadmium. Arch Environ Health 1975;30:598-601.
Davis RL, Milham S Jr. Altered immune status in aluminum reduction plant workers. Am J Ind Med 1990;18:79-85.
Kreiss K, Newman LS, Mroz MM, Campbell PN. Screening blood test identified subcliniCal berryilium disease. J Occup Med 1989;31:602-608.
Saltini C, Winestock K, Kirby M, et al. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989;320:1103-1109.
Botham PA. Are pesticides immunotoxic? Adverse Drug React Acute Poison Rev 1990;9:91-101.
Sawaishi Y, Komatsu K, Takeda O, et al. A case of tubulointerstitial nephritis with exfoliative dermatitis and hepatitis due to phenobarbital hypersensitivity. Eur J Pediatr 1992;151:69-72.
Huang J, Wang X-p, Chen B-m, et al. Immunologic effects of toluence diisocyante exposure on painters. Arch Environ Contain Toxicol 1991;21:607-611.
Gleichmann E, Kimber I, Purchase IFH. Immunotoxicology: Suppressive and stimulatory effects of drugs and environmental chemicals on the immune system. Arch Toxicol 1989;63:257-273.
Back J-F. The new era of immunosuppressive therapy in autoimmune disease. Transplant Proc 1991 ;23:3319— 3321.
Hess E. Drug-related lupus. N Engl J Med 1988;318:1460-1462.
Bigazzi PE. Autoimmunity induced by chemicals. Clin Toxicol 1988;26:125-156.
Spears CJ, Batchelor JR. Drug-induced autoimmune disease. Adv Nephrol 1987;16:219-230.
Mach PS, Brouilhet H, Amor B. D-Penicillamine, a modulator of anti-DNA antibodies production. Clin Exp Immunol 1986;63:414-418.
Descotes J. Immunotoxicology of Drugs and Chemicals. Amsterdam: Elsevier, 1986:359.
Sergott TJ, Limoli JP, Baldwin CM Jr, Laub DR. Human adjuvant disease, possible autoimmune disease after silicone implantation: A review of the literature, case studies and speculation for the future. Plast Reconstr Surg 1986;78:104-114.
Comdemi JJ. The autoimmune diseases. JAMA 1987;258:2920-2929.
Abdi EA, Brien W, Venue PM. Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol 1986;36:515-519.
Jaffe W. Adverse effects profile of sulfhydryl compounds in man. Am J Med 1986;80:471-476.
Smith C1E, Hammarstrom L. Immunologic abnormalities induced by D-penicillamine. PAR Pseudo-allergic Reactions 1985;4:138-180.
Howard-Lock HE, Lock CJL, Mewa A, Kean WF. D-Penicillamine: Chemistry and clinical use in rheumatic disease. Semin Arthritis Rheum 1986;15:261-281.
Jaffe IA. Induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseases. Spring Semin Immunopathol 1981;4:193-207.
Rehan A, Johnson K. IgM nephropathy associated with penicillamine. Am J Nephrol 1986;6:71-74.
Arnaiz-Villena A, Vicario JL, Serrano-Rios M, et al. Glomerular basement-membrane antibodies and HLA-DR2 in Spanish rapeseed oil disease. N Engl J Med 1982;307:1404-1405.
Safran M, Paul TL, Roti E, Braverman E. Environmental factors affecting autoimmune thyroid diseases. Endocrinol Metab Clin North Am 1987;16:327-342.
Nishiyama S, Matsukura M, Fujimoto S, Matsuda I. Reports of two cases of autoimmune thyroiditis while receiving anticonvulsant therapy. Eur J Pediatr 1983;140:116-117.
Goldman М, Abramowicz D, De Pauw L, et al. OKT3 induced cytokine release attenuation by high dose methylprednisolone. Lancet 1989;2:802-803.
Gaughan WJ, Francos BB, Dunn SR, et al. A retrospective analysis of the effect of indomethacin on adverse reactions to Orthoclone OKT3 in the therapy of acute renal allograft rejection. Am J Kidney Dis 1994;24:486-490.
Misbah SA, Chapel НМ. Adverse effects of intravenous immunoglobulin. Drug Saf 1993;9:254-262.
Stiehm ER. New developments: Recent progress on the use of intravenous immunoglobulin. Curr Prob Pediatr 1992;22:335-349.
Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulin. Ann Intern Med 1990;112:278-292.
Buckley RH, Schiff Rl. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325:110-117.
NIH Consensus Conference. Intravenous immunoglobulin: Prevention and treatment of disease. JAMA 1990;264:3189-3193.
Webster ADB. Intravenous immunoglobulins of benefit in primary hypogammaglobulinemia. Br Med J 1991;303:375-376.
Appropriate use of human immunoglobulin in clinical practice: Memorandum for an IVIS/WHO meeting. Bull WHO 1982;60:43-47.
Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-116.
National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991;325:73-80.
Connolly MB, Jan JE, Junker AK. Intravenous immunoglobulin and pyridoxine-dependent seizures. Neurology 1991;41:1524.
Pirofsky B. Intravenous immune globulin therapy in hypogammaglobulinemia: A review. Am J Med 1984;76:53-60.
Gardulf A, Hammarstrom L, Edvard Smith CI. Treatment of hypogammaglobulinemia with subcutaneous gamma globulin by rapid infusion. Lancet 1991;338:162-166.
Smith EL, Hill RL, Lehman IR, et al. Principles of Biochemistry: Mammalian Biochemistry. 7th ed. Tokyo: McGraw-Hill, 1983:40.
Wordell CJ. Use of intravenous immune globulin therapy: An overview. DICP Ann Pharmacother 1991;25:805-817.
Buckley RH. Long term use of intravenous immune globulin patients with primary immunodeficiency disease: Inadequacy of current dosage practices and approaches to the problem. J Clin Immunol 1982;2:15S— 21S.
Ochs HD, Fisher SH, Wedgwood RJ. Modified im-muneglobulin: Its use in the prophylactic treatment of patients with immune deficiency. J Clin Immunol 1982;2:22S—30S.
Montanaro A, Pirofsky B. Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states. Am J Med 1984;76:67-72.
Nolte MT, Pirofsky B, Gerritz GA, Golding B. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol 1979;36:237-243.
Potter M, Stockley R, Storry J, Slade R. ABO alloim-munisation after intravenous immunoglobulin infusion. Lancet 1988;1:932-933.
Noya FJD, Rench MA, Courtney JT, et al. Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates. Pediatr Infect Dis J 1989;8:759-763.
Parke A, Maier D, Wilson D, et al. Intravenous gamma globulin, antiphospholipid antibodies and pregnancy. Ann Intern Med 1989;110:495-496.
Gibson J, Laird PP, Joshua DE, et al. Very high dose intravenous gamma globulin in thrombocytopenia of pregnancy. Aust NZ J Med 1989;19:151-153.
Chirico G, Maccario R, Montagna D, et al. Natural killer cell activity in preterm infants: Effect of intravenous immune globulin administration. J Pediatr 1990;117:465-466.
Day NK, Good RA, Wahn V. Adverse reactions in selected patients following intravenous infusions of gamma globulin. Am J Med 1984;76:25-32.
Branigan EF, Stevenson MM, Charles D. Blood transfusion reaction in a patient with immunoglobulin A deficiency. Obstet Gynecol 1983;61 (suppl. 3):47S—49S.
Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986;2:217-218.
Lane RS. Non-А, non-В hepatitis from intravenous immunoglobulin. Lancet 1983;2:974-975.
Lever AM, Brown D, Webster AD, Thomas HC. Non-A, non-В hepatitis occurring in agammaglobulinemia patients after intravenous immunoglobulin. Lancet 1984;2:1062-1064.
Ochs HD, Fischer SH, Vivant FS, et al. Non-А, non-B hepatitis and • intravenous immunoglobulin. Lancet 1985;1:404-405.
Webster AD, Lever AM. Non-А, non-B hepatitis after intravenous immunoglobulin. Lancet 1986;1:323.
Schiff Rl. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994;331:1649.
Kato E, Shindo S, Eto Y, et al. Administration of immune globulin associated with aseptic meningitis. JAMA 1988;259:3269-3270.
Capone PM, Cohen ME. Seizures and cerebritis associated with administration of OKT3. Pediatr Neurol 1991;7:299-301.
D’Allesanro AM, Pirsch JD, Stratta RJ, et al. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation. Transplantation. 1989;47:297-300.
Shennib H, Mercado M, Nguyen D, et al. Successful treatment of steroid-resistant double lung allograft rejection with Orthoclone1* OKT3. Am Rev Respir Dis 1991;144:224-226.
Konertz W, Weyand M, Friedl A. Prophylactic use of OKT3 in cardiac transplantation. Transplant Proc 1989;21:2494-2496.
Li PKT, Nicholls MG, Lai KN. The complications of newer transplant antirejection drugs: Treatment with cyclosporin A, OKT3 and FK 506. Adverse Drug React Acute Poison Rev 1990;9:123-155.
Goldstein G, Norman DJ, Henell KR, Smith IL. Pharmacokinetic study of Orthoclone OKT3 serum levels during treatment of acute renal allograft rejection. Transplantation 1988;46:587-589.
Thistlethwaite JR Jr, Stuart JK, Mayes JT, et al. Monitoring and complications of monoclonal therapy: Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988;9:112-119.
Chang TW, Kung PC, Gingras SP, Goldstein G. Does OKT3 monoclonal antibody react with an antigen recognition structure on human T-cells? Proc Natl Acad Sci USA 1981;78:1805-1808.
Gaston RS, Deierhoi MH, Patterson T, et al. OKT3 first-dose reaction: Association with T-cell subsets and cytokine release. Kidney Int 1991;39:141-148.
Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981;32:535-539.
Orthomulticenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985;313:337-342.
Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and inter-feron-alpha. N Engl J Med 1989;320:420-421.
Miller RA, Maloney DG, McKillop J, et al. In vivo effects of murine monoclonal antibody in a patient with T-cell leukemia. Blood 1981;58:78-86.
Spieker C, Zidek W, Barenbrock M, et al. Acute hypertension after renal allograft rejection therapy with OKT3 monoclonal antibody. J Int Med Res 1991;19:419-423.
Rome PA, Rocher GM, Morgan Ag, Shale DJ. OKT3 and pulmonary capillary permeability. Br Med J 1987;295:1099-1100.
Richards JM, Vogelzang NJ, Bluestone JA. Neurotoxicity after treatment with muromonab-CD3. N Engl J Med 1990;323:487-488.
Emmons C, Smith J, Flanigan M. Cerebrospinal fluid inflammation during OKT3 therapy. Lancet 1986;2:510-511.
Rello J, Vallaverdu 1, Coll P, et al. Aseptic meningitis associated with muromonab-CD3. DICP Ann Pharmacother 1990;24:1233.
Joy ME, Michals ML, Canafax DM. Aseptic meningitis associated with muromonab-CD3 therapy. Clin Pharm 1988;7:721.
Figg WD. Aseptic meningitis associated with muronion-ab-CD3. DICP Ann Pharmacother 1991 ;25:1395.
Adair JC, Woodley SL, O’Connell JB, et al. Immunosuppression with OKT3 monoclonal antibody: A cause of fever and neurologic dysfunction after cardiac transplantation. Neurology 1990;40(suppL 1 ):252.
Min DI, Fallo SA. Encephalopathy associated with muromonab-CD3. Clin Pharm 1993;12:610-612.
Coleman AE, Norman DJ. OKT3 encephalopathy. Ann Neurol 1990;28:837-838.
Thomas DM, Nicholls AJ, Feest TG, Riad H. OKT3 and cerebral edema. Br Med J 1987;295:1486.
Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990;323:1723-1728.
Emery RW, Lake KD. Post-transplantation lymphoproliferative disorder and OKT3. N Engl J Med 1991;324:1437.
Brouwer RML, Balk AHMM, Weimar W. Post-transplantation lymphoproliferative disorder and OKT3. N Engl J Med 1991 ;324:1437.
Cohen JL Post-transplantation lymphoproliferative disorder and OKT3. N Engl J Med 1991 ;324:1438.
Penn I. Cancers complicating organ transplantation. N Engl J Med 1990;323:1767-1769.
Roth S, Kupferberg JP. Adverse responses following intraoperative administration of orthoclone OKT3. Anesth Analg 1989;69:822-825.
Georgitis JW, Browning MC, Steiner D, Lorentz WB. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy 1991;66:343-347.
Goldstein G, Fuccello AJ, Norman DJ, et al. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 1986;42:507-511.
Sutton JD, Prioleau MH, Wordell CJ, Francos GC. Aseptic meningitis associated with muromonab-CD3 administration. DICP Ann Pharmacother 1989;23:257— 258.
Martin MA, Massanari M, Nghien DD, et al. Nosocomial aseptic meningitis associated with administration of OKT3. JAMA 1988;259:2002-2005.
Nalensnik МА, Demetris AJ, Fung JJ, Strazel ТЕ. Lymphoproliferative disorders arising under immunosuppression with FK 506: Initial observations in a large transplant population. Transplant Proc 1991;23:1108-1110.
Barabas RE, Painter MJ. Cerebral vasculopathy in patients receiving organ transplantation who are treated with FK 506. Ann Neurol 1991 ;30:472. Abstract.
Mrvos R, Hodgman M, Dean B, Krenzelok E. FK 404 overdose: A report of four cases. Clin Toxicol 1995;33:475-486. Abstract.
Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK 506. Transplant Proc 1991;23:3175-3178.
Cadoff EM, Venkataramanan R, Krajack A, et al. Assay of FK 506 in plasma. Transplant Proc 1990;22(No. 1, suppl. l):50—51.
Sewing K-F, Christians U. FK 506. Lancet 1991;337:499.
Grenier FC, Luczkiw J, Bergmann M, et al. A whole blood FK 506 assay for the IMxR analyzer. Transplant Proc 1991;23:2748-2749.
Beysens AJ, Wijnen RMH, Beuman GH, et al. FK 506 monitoring in plasma or in whole blood? Transplant Proc 1991;23:2745-2747.
Winkler M, Jost V, Ringe B, et al. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. Transplant Proc 1991;23:3153-3155.
Mieles L, Todo S, Fung JJ, et al. Oral glucose tolerance test in liver recipients treated with FK506. Transplant Proc !990;22(No. 1, suppl. 1):41— 43.
Van Thiel DH, Iqbal M, Jain A, et al. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. Transplant Proc 1990;22(No. 1, suppl. 1):37—40.
Starzl ТЕ, Todo S, Fung J. FK 506 for liver, kidney and pancreas transplantation. Lancet 1989;2:1000-1004.
FK 506: An investigation immunosuppressant. Med Lett Drugs Ther 1991 ;33(854):94.
Goto T, Kino T, Hatanaka H, et al. FK 506: Historical perspectives. Transplant Proc 1991;23:2713-2717.
McCauley J, Bronsther O, Fung J, et al. Treatment of cyclosporin-induced haemolytic uremic syndrome with FK 506. Lancet 1989;2:1516.
Abu-Elmagd K, Van Thiel D, Jegasothy BV, et al. FK 506: A new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 1991;23:3322-3324.
Japanese FK 506 Study Group on Refractory Uveitis. A multicenter clinical open trial of FK 506 in refractory uveitis following Behcet’s disease. Transplant Proc 1991;23:3343-3346.
Carroll PB, Tzakis AG, Ricordi C, et al. The use of FK 506 in new-onset type 1 diabetes in man. Transplant Proc 1991;23:3351-3353.
Li PKT, Nicholls MG, Lai KN. The complications of newer transplant antirejection drugs: Treatment with cyclosporin A, OKT3 and FK 506. Adverse Drug React Acute Poison Rev 1990;9:123-155.
Jusko WJ, D’Ambrosio R. Monitoring FK 506 concentrations in plasma and whole blood. Transplant Proc 1991;23:2732-2735.
Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK 506 in transplant patients. Transplant Proc 1991;23:2736-2740.
Thomson AW, Woo J. Immunosuppressive properties of FK 506 and rapamycin. Lancet 1989;2:443-444.
Venkataramanan R, Jain A, Codoff E, et al. Pharmacokinetics of FK 506: Preclinical and clinical studies. Transplant Proc 1990;22(No. 1, suppl. 1):52—56.
Nossal GJV. Summary of the First International FK 506 Congress: Perspectives and prospects. Transplant Proc 1991;23:3371-3375.
Kobayashi M, Tamura K, Katayama N, et al. FK 506 assay past and present: Characteristics of FK 506. Elisa Transplant Proc 1991;23:2725-2729.
Macleod AM, Thomson AW. FK 506: An immunosuppressant for the 1990’s? Lancet 1991;337:25-27.
Wallemacq PE, Reding R. FK 506 (tacrolimus). Clin Chem 1993;39:2219-2228.
Shapiro R, Venkatataramanan R, Warty US, et al. FK 506 interaction with danazol. Lancet 1993; 341:1344— 1345.
Morris RE, Wu J, Shorthouse R. Comparative immu-nopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. Transplant Proc 1990;22(No. 1, suppl. 1):110—112.
Fischer G, Wittman-Liebold B, Lang K, et al. Cy-closphilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 1981;337:476-478.
Thomson AW. FK 506: How much potential? Immunol Today 1989;10:6-9.
Sawada S, Suziki G, Kawase Y, Takakre F. Novel immunosuppressive agent FK 506: In vitro effects on the cloned T cell activation. J Immunol 1987; 139:1797.
McCauley J, Fung J, Jain A, et al. The effects of FK 506 on renal function after liver transplantation. Transplant Proc 1990;22(No. 1, suppl. I):17—20.
Alessiani M, Kusne S, Martin FM, et al. Infections with FK 506 immunosuppression: Preliminary results with primary therapy. Transplant Proc 1990;22(No. 1, suppl. l):44-46.
Lai KN. Adverse effects of immunosuppressant agents. Adverse Drug React Bull 1991 (December):No. 151:510.
Shapiro R, Fung JJ, Jain AB, et al. The side effects of FK 506 in humans. Transplant Proc 1990;22(No. 1, suppl. 1):35—36.
Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK 506. Transplant Proc 1991;23:3105-3108.
Brand PLD, Brus F. Immunosuppressive drugs and hypertrophic cardiomyopathy. Lancet 1995;345:1644.
Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein—Barr virus infection and lymphoproliferative disorder in young children on FK 506 after liver transplantation. Transplantation 1995;59:524-529.
Kitahara S, Makuuchi M, Kawasaki S, et al. Lymphoproliferative disorders after FK 506. Lancet 1991;337:1234.
De Groen PC. Cyclosporin: A review and its specific use in liver transplantation. Mayo Clin Proc 1989;64:680— 689.
Kahan BD. Cyclosporins. N Engl J Med 1989;321:1725-1738.
Avellano F, Monka C, Krupp PF. Acute cyclosporin overdose: A review of present clinical experience. Drug Saf 1991;6:226-276.
Cyclosporin. In: McEvoy G, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:2443—2449.
Baumhefner RW, Myers LW, Ellison GW, et al. Huge cyclosporin overdose with favourable outcome. Lancet 1987;2:332.
Honcharik N, Anthone S. Activated charcoal in acute cyclosporin overdose. Lancet 1985; 1:1051.
Schroeder TJ, Wadhawa NK, Pesce AJ, First MR. An acute overdose of cyclosporin. Transplantation 1986;41:406-409.
Kruger H-V, Bross-Back V, Proksch B, et al. A case of accidental cyclosporin overdose with pharmacokinetic analysis. Bone Marrow Transplant 1988;3:167-169.
Cantineau A, Breurec JY, Baert A, et al. Intoxication aigue volontaire par la ciclosporine. Presse Med 1987;16:589.
Wallemacq PE, Lesne ML. Accidental massive IV administration of cyclosporin in man. Drug Intell Clin Pharm 1985;19:29-30.
Kokado Y, Takahara S, Ishibashi M, Sonoda T. An acute overdose of cyclosporin. Transplantation 1989;47:1096— 1097.
Lindholm A. Monitoring of the free concentration of cyclosporin in plasma in man. Eur J Clin Pharmacol 1991;40:571-575.
Lindholm A, Henricsson S. Intra- and interindividual variability in the free fraction of cyclosporin in plasma in recipients of renal transplants. Ther Drug Monit 1989;11:230-623.
Clandy CW, Schroeder TJ, Myre SA, et al. Clinical variability of cyclosporin pharmacokinetics in adult and pediatric patients after renal, cardiac, hepatic and bone-marrow transplants. Clin Chem 1988;34:2012-2015.
Frey FJ, Horber FF, Frey BM. Trough levels and concentration time curves of cyclosporin in patients undergoing renal transplantation. Clin Pharmacol Ther 1988;43:550-562.
Wandstrat TL, Schroeder TJ, Myre SA. Cyclosporin pharmacokinetics in pediatric transplant recipients. Ther Drug Monit 1989;11:493-496.
Kolars JC, Awni WM, Merior RM, Watkins PG. First-pass metabolism of cyclosporin by the gut. Lancet 1991;338:1488-1490.
Grevel J. Significance of cyclosporin pharmacokinetics. Transplant Proc 1988;20(suppl. 2):428—434.
Lui SF, Varghese Z, Sweny P, et al. Blood cyclosporin concentrations and renal allograft dysfunction. Br Med J 1986;293:1435.
Henry ML, Bowers VD, Fanning WJ, et al. Cyclosporin levels are not helpful. Transplant Proc 1988;20(suppl. 2):419-421.
Scharan HF, Hassell AE, Baumhefner RW, et al. Distribution of cyclosporin in cerebrospinal fluid. Neurology 1988;38(suppl. 1):99.
Reymond J-P, Steimer J-L, Niederberger W. On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. J Pharmacokinet Biopharm 1988;16:331-351.
Copeland KR, Yatscoff RW, McKenna RM. Immunosuppressive activity of cyclosporin metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance. Clin Chem 1990;36:225-229.
Lucey MR, Kolars JC, Merion RM, et al. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 III A. Lancet 1990;335:11-15.
Kunzendorg V, Brocmoller J, Jochimsen F, et al. Cyclosporin metabolites and central nervous system toxicity. Lancet 1988;1:1223.
Leunissen KML, Beuman G-H, Bosman F, Van Hooff JP. Cyclosporin metabolites and nephrotoxicity. Lancet 1986;2:1398.
Sharpe MD, Gelb AW. Cyclosporin potentiates vecuronium blockade and prolonged recovery time in humans. Can J Anaesth 1992;39(5,pt 1I):A126.
De Ligny BH, Camsonne R, Ryckelynck JP, et al. Intoxication aigue par la ciclosporine. Presse Med 1987;16:830.
De Meer K, Houwen RHJ, Bijleveld CMA, et al. Blood concentrations after accidental cyclosporin overdose. Eur J Pediatr 1989;149:219-220.
Truwitt CL, Denaro CP, Lake JR, DeMarco T. MR imaging of reversible cyclosporin А-induced neurotoxicity. Am J Radiol 1991;157:857-859.
Humphreys TR, Leyden JJ. Acute reversible central nervous system toxicity associated with low-dose oral cyclosporin therapy. J Am Acad Dermatol 1993;29:490— 492.
Feutren G, Mihatsch MJ. Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992;326:1654-1660.
Shannon M. Cyclosporin. Clin Toxicol Rev I993;15(l):l—2.
Goy J-J, Deruaz JP, Avellano F, Krupp P. Cyclosporin and muscle. Lancet 1992;339:254.
Ball PE, Munzer H, Keller HP, et al. Specific 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporin in blood. Clin Chem 1988;34:257-260.
Christians U, Schlitt HJ, Bieck JS, et al. Measurement of cyclosporin and 18 metabolites in blood, bile, and urine by high performance liquid chromatography. Transplant Proc 1988;20(suppl. 2):609—613.
Yee GC, Rosano T, Ptachcinski R. Pharmacology: Profiles, parameters, interpretations and drug interactions. Transplant Proc 1988;20(suppl. 2):715—721.
Anderson AB, Primack W. Treatment of a child with acute cyclosporin overdose. Pediatr Nephrol 1992;6:222-223.
Pace MT, Slovins TL, Kelly JK, Abella SD. Cyclosporin A toxicity: MRI appearance of the brain. Pediatr Radiol 1995;25:180-183.
Feutren G, Mason J. Serum creatinine or glomerular filtration rate for monitoring cyclosporin therapy. Lancet 1991;338:1017.
Hadden JW. Immunopharmacology: Immunomodulation and immunotherapy. JAMA 1987;258:3005-3010.
Aweeka F, Amend W, Garavoy M, et al. The effects of H2 antagonists in immunological function. Clin Pharmacol Ther 1988;43:128.
Gifford RRM, Tilberg AF. Histamine type-2 receptor antagonist immune modulation: II. Cimetidine and ranitidine increase interleukin-2 production. Surgery 1987;102:242-247.
Sahasrabudhe DM, McCuineCS, O’Donnell RW, Henshaw EC. Inhibition of suppressor T lymphocytes by cimetidine. J Immunol 1987;138:2760-2763.
Kumar A. Cimetidine: An immunomodulator. DICP Ann Pharmacother 1990;24:289-295.
Hiraide A, Yoshioka T, Ohshima S. IgE-mediated drug fever due to histamine H2-receptor blockers. Drug Saf 1990;5:455-457.
Haboubi N, Asquith P. Rash mediated by immune complexes associated with ranitidine treatment. Br Med J 1988;296:897.
Tonnessen H, Bulow S, Fischerman K, et al. Effect of cimetidine on survival after gastric cancer. Lancet 1988;2:990-992.
White WB, Ballow M. Modulation of suppressor-cell activity by cimetidine in patients with common variable hypogamma globulinuria. N Engl J Med 1985;312:198-202.
Smith T, Clark JW, Popp MB. Regression of melanoma nodules in a patient treated with ranitidine. Arch Intern Med 1987:1815-1816.
James DG. Which immunomodulator? Br J Clin Pract 1991;45:52-56.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:2428-2431.
Carney DM, Zukoski CF, Ogden DA. Massive azathio-prine overdose: Case report and review of the literature. Am J Med 1974;56:133-136.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:457—458.
Dorr RT, Fritz WL. Cancer Chemotherapy Handbook. New York: Elsevier, 1980:246—250, 513—518.
Lennard L, Van Loon J A, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyl transferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-154.
Klemetsdal B, Tollefsen E, Loennechen T, et al. Interethnic differences in thiopurine methyltransferase activity. Clin Pharmacol Ther 1992;51:24-31.
Raman GV, Sharman VL, Lee HA. Azathioprine and allopurinol: A potentially dangerous combination. J hit Med 1990;228:69-71.
Alstead ЕМ, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990;99:443-446.
Beeley L. Drugs and breast feeding. Clin Obstet Gynecol 1986;13:247-251.
James DG. Which immunomodulator? Br J Clin Pract 1991;45:53-56.
Small P, Lichter M. Probable azathioprine hepatotoxicity: A case report. Ann Allergy 1989;62:518-520.
Perini GP, Bonadiman C, Fraccaroli GP, Vantini I. Azathioprine-related cholestatic jaundice in heart transplant patients. J Heart Transplant 1990;9:577-578.
Katzka DA, Saul SH, Jorkasky D, et al. Azathioprine and hepatic veno-occlusive disease in renal transplant patients. Gastroenterology 1986;90:446-454.
Mion F, Napolean B, Berger F, et al. Azathioprine induced liver disease: Nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 1991;32:715-717.
Wijnands MJ, Perret CM, van Riel PL, van de Putte LB. Generalized urticarial eruption during azathioprine treatment for rheumatoid arthritis. Scand J Rheumatol 1990;19:167-169.
Bergman SM, Krane NK, Leonard G, et al. Azathioprine and hypersensitivity vasculitis. Ann Intern Med 1988;109:83-84.
Vanderpitte K, Vanrenterghem Y, Michielsen P. Azathioprine hypersensitivity in a renal transplant recipient. Transplant Int 1990;3:47-48.
Pitt PI, Sultan AH, Malone M, et al. Association between azathioprine therapy and lymphoma in rheumatoid disease. J R Soc Med 1987;80:428-429.
Lawson DH, Lovatt GE, Gurton CS, Hennings RC. Adverse effects of azathioprine. Adverse Drug React Acute Poison Rev 1984;3:161-171.
Penn I. Lymphomas complicating organ transplantation. Transplant Proc 1983;15:2790-2797.
Penn 1. The occurrence of cancer in immune deficiencies. Curr Probl Cancer 1982;6:1-64.
Berlin A, Dean J, Draper M, et al. Synopsis, conclusions and recommendations. In: Berlin A, Dean J, Draper M (eds). Proceedings of the International Seminar on the Immunological System as a Target for Toxic Damage: Present Status, Open Problems and Future Perspectives. Boston: Martinus Nijhoff, 1987:XI—XXVII.
Bates DV. The health effects of air pollution. J Respir Dis 1980;1:29-37.
Graham JA, Gardner DE. Immunotoxicity of air pollutants. In: Dean J, Luster Ml, Munson AE, Amos H (eds). Immunotoxicology and Immunopharmacology. New York: Raven Press, 1985;367—380.
Identifying and controlling immunotoxic substances: Background paper. Congress of the United States, Office of Technology Assessment, Landrigan PC, Chairman. Washington, DC: U. S. Government Printing Office, April 1991.
Rossi SJ, Schroeder TJ, Hariharan S, Finst MR. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf 1993;9:104— 131.
Cote CJ, Meuwissen WJ, Pickering RJ. Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr 1974;85:324— 328.
Wilkinson AH, Smith JL, Hunsicher LG, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporin, azathioprine, and prednisone. Transplantation 1989;47:293-296.
Cancer following organ transplantation. WHO Drug Info 1991;5:56-59.
Spreafico F. Immunotoxicology in 1987: problems and challenges. Fundam Clin Pharmacol 1988;2:353-367.
Descotes J. Drug-Induced Human Diseases. Amsterdam: Elsevier, 1990:222.
Descotes J. Immunotoxicology of Drugs and Chemicals. 2nd ed. Amsterdam: Elsevier, 1988:444.
Burrell R. Human immune toxicity. Mol Aspects Med 1993;14:1-81.
Stevenson GW, Hall SC, Rudnick S, et al. The effect of anesthetic agents on the human immune response. Anesthesiology 1990;72:542-552.
Identifying and controlling immunotoxic substances: Background paper. Congress of the United States. Office of Technology Assessment. OTA-BP-BA-75. Washington DC: U. S. Government Printing Office, April 1991:1-93.
Brooks BO, Sullivan JB Jr. Immunotoxicology. In: Sullivan JB Jr, Krieger GR, eds. Hazardous Materials Toxicology: Clinical Principles of Environmental Health. Baltimore: Williams & Wilkins, 1991:190—214.
Landon J. An immunology primer: Some definitions and how to make a Fab. Personal Communication. Lyon Poison Center’s 30th Anniversary and European Association of Poison Centres and Clinical Toxicologists, Technical Meeting, May 22—24, 1991.
Scherrmann J-M, Urtizberea M, Sabouraud A. Toxicokinetics, mechanisms and prerequisites of immunotherapy. Personal communication. In: Proceedings, European Association of Poison Centres and Clinical Toxicologists, Technical Meeting, Lyon, May 22—24, 1991.
Scherrmann J-M, Terrien N, Urtizberea M, et al. Im-munotoxicotherapy: Present status and future trends. Clin Toxicol 1989;27:1-35.
Sabouraud A, Redureau M, Gires P, et al. Effect of colchicine-specific Fab fragments on the hepatic clearance of colchicine. Drug Metab Dispos 1993;21:997-1002.
Sabouraud A, Urtizberea M, Scherrmann JM. Immunotherapy of tricyclic antidepressant poisoning: Recent experimental data. Personal Communication. In: Proceedings, European Association of Poison Centres and Clinical Toxicologists, Technical Meeting, Lyon, France, May 22— 24, 1991.
Pentel PR, Schoof DD, Pond SM. Redistribution into plasma of tracer doses of 3H-desipramine by anti-DMl antiserum in rats. Biochem Pharmacol 1985;36:293— 295.
Sabouraud A, Denis H, Urtizberea M, et al. The effect of nortriptyline-specific active immunization on amitriptyline toxicity and disposition in the rabbit. Toxicology 1990;62:349-360.
Bursting MJ, Opheim KE, Raisys VA, et al. Tricyclic antidepressant-specific Fab fragments alter the distribution and elimination of desipramine in the rabbit: A model for overdose treatment. Toxicology 1989;27:53— 66.
Pentel PR, Keyler DE, Brunn GJ, et al. Redistribution of tricyclic antidepressants in rats using a drug-specific monoclonal antibody: Dose-response relationship. Drug Metab Dispos 1991;19:24-28.
Pentel PR, Brunn GJ, Pond SM, Keyler DE. Pretreatment with drug-specific antibody reduces desipramine cardiotoxicity in rats. Life Sci 1991;48:675-683.
Heath AJ. Immunotherapy for tricyclic antidepresant poisoning: A clinical perspective. In: Proceedings, European Association of Poison Centres and Clinical Toxicologists, Technical Meeting, Lyon, France, May 22—24, 1991.
Brunn GJ, Keyler DE, Pond SM, Pentel PR. Interaction of drug-specific antibody Fab1 fragment and NaHCO3 for reversal of desipramine cardiotoxicity in rats. Vet Hum Toxicol 1991 ;33:350.
Jaeger A, Sander PH, Kopferschmitt J, Flesch F. Clinical features and management of colchicine poisonings: Rationale for immunotherapy. In: Proceedings, European Association of Poison Centres and Clinical Toxicologists, Technical Meeting, Lyon, France, May 22—24, 1991.
Bismuth C, Gaultier M, Conso F. Aplasie medullaire apres intoxication. In: Proceedings, Association of Poison Centres and Clinical Toxicologists, Technical Meeting, Lyon, France, May 22—24, 1991.
Putterman C, Ben-Chetrit E, Caraco Y, Levy M. Colchicine intoxication: Clinical pharmacology, risk factors, features and management. Semin Arthritis Rheum 1991;21:143-155.
Scherrmann JM, Sabouraud A, Urtizberea M, et al. Immunotherapy of colchicine poisoning. In: Proceedings, European Association of Poison Centres and Clinical Toxicologists, Technical Meeting, Lyon, France May 22—24, 1991.
Terrien N, Urtizberea M, Scherrmann JM. Reversal of advanced colchicine toxicity in mice with goat colchicine-specific antibodies. Toxicol Appl Pharmacol 1990;104:504-510.
Wolff J, Capraro HG, Brossi A, Cook GH. Colchicine binding to antibodies. J Biol Chem 1980;255:7144— 7148.
Clark RF, Selden BS, Curry SC. Antidigoxin-Fab fragments in the treatment of a canine model of oleander toxicity: Vet Hum Toxicol 1990;32:358.
Nagao M, Takatori T, Wu B, et al. Immunotherapy for the treatment of acute paraquat poisoning. Hum Toxicol 1989;8:121-123.
MacDonald DL New treatment for PCP toxicity? JAMA 1987;257:3188.
Owens SM, Mayersohn M. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metab Dispos 1986;14:52-58.
Leikin JB, Goldman-Leikin RE, Evans MA, et al. Immunotherapy in acute arsenic poisoning. Clin Toxicol 1991;29:59-70.
Cappell MS, Simon Т. Colonic toxicity of administered medications and chemicals. Am J Gastroenterol 1993;88:1684-1699.
Hammer R, Giachetti A. Muscarinic receptor subtypes M) and M2: Biochemical and functional characterization. Life Sci 1982;31:2991-2998.
Tryba M, Huchzermeyer H, Torok M, et al. Single drug and combined medication with cimetidine, antacids and pirenzepine in the prophylaxis of acute upper gastrointestinal bleeding. Hepato-gastroenterol 1983;30:154— 157.
Lauritsen K, Lauritsen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part I). Clin Pharmacokinet 1990;19:11-31.
Meinecke I, Witsch D, Brendel E. Sensitive high performance liquid chromatographic determination of pirenzepine in plasma. J Chromatogr 1986;375:369— 375.
Anderson W, Weatherstone G, Ved C. Esophageal medication bezoar in a patient receiving enteral feedings and sucralfate. Am J Gastroenterol 1989;8:205-206.
Harrankova J, Lahaie R. Levothyroxine binding by sucralfate. Ann Intern Med 1992;117:445-446.
Bevardi RR, Kirking DM, Townsend KA, Melonakos TK. Identifying potential interactions of sucralfate with other drugs in hospitalized patients. Am J Hosp Pharm 1992;49:1488-1490.
Rey AM, Gums JG. Altered absorption of digoxin, sustained-release quinidine and warfarin with sucralfate administration. DICP Ann Pharmacother 1991;25:745— 746.
Robertson JA, Salusky IB, Goodman WG, et al. Sucralfate, intestinal aluminum absorption and aluminum toxicity in a patient on dialysis. Ann Intern Med 1989;111:179-181.
Min DI, D’Elia JA. Sucralfate-associated aluminum toxicity in a patient with renal failure: Treatment with deferoxamine. Clin Pharm 1992;11:636-639.
Steffers М, Esnard J, Meyer R, Bellucci A. Salicylate toxicity from bismuth subsalicylate overuse. Clin Res 1989;32:336A.
Ching CK, Long RG, O'Hara R, Richardson J. Iatrogenic bismuth toxicity associated with inadvertent long term De-Nortab ingestion. Int J Pharm Pract 1993;2:111-113.
Feldman S, Chew S-L, Pickering LK, et al. Salicylate absorption from a bismuth subsalicylate preparation. Clin Pharmacol Ther 1981;29:788-792.
Pickering LK, Feldman S, Ericsson CD, Cleary TG. Absorption of salicylate and bismuth from a bismuth subsalicylate containing compound (Pepto-bismol). J Pediatr 1981;99:654-656.
Sainsbury SJ. Fatal salicylate toxicity from bismuth subsalicylate. West J Med 1991;155:637-639.
Rowbotham DJ, Milligan К, McHugh Р. Effects of single doses of cisapride and ranitidine administered simultaneously on plasma concentrations of cisapride and ranitidine. Br J Anaesth 1991;67:302-305.
Brogden RN, Carmine AA, Heel RC, et al. Domperidone: A review of its pharmacologic activity, pharmacokinetics and therapeutic efficacy in the treatment of chronic dyspepsia and as an antiemetic drug. Drugs 1982;24:360-400.
Talley NJ. Review article: 5-Hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal mobility and sensation: Clinical implications. Aliment Pharmacol Ther 1992;6:279-289.
Miller LG, Jankovic J. Metoclopramide induced movement disorders: Clinical findings with a review of the literature. Arch Intern Med 1989;149:2486-2492.
Humphrey PPA, Bunce KT. Tachycardia during cisapride treatment. Br Med J 1992;303:1019-1020.
Olsson S, Edwards IR. Tachycardia during cisapride treatment. Br Med J 1992;305:748-749.
Fournier A, Pauli A, Ducoulombier H, Cousin J. Effets du surdosage en metoclopramide chez 1 ’enfant. Pediatric 1969;24:799-805.
Midttun M, Oberg B. Total heart block after intravenous metoclopramide. Lancet 1994;343:182-183.
Osborne RJ, Slevin ML, Hunter RW, Hamer J. Cardiotoxicity of intravenous domperidone. Lancet 1985;2:385.
Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J 1984:289:1579.
Giaccone G, Bertello O, Calciati A. Two sudden deaths during prophylactic treatment with high doses of domperidone and methylprednisolone. Lancet 1984;2:1336— 1337.
Quinn N, Parkes D, Jackson G, Upward J. Cardiotoxicity of domperidone. Lancet 1985;2:724.
Weaving A, Bezwoda WR, Derman DP. Seizures after antiemetic treatment with high dose domperidone: Report of four cases. Br Med J 1984;288:1728.
Sethi KD, Patel B, Meador KJ. Metoclopramide induced parkinsonism. South Med J 1989; 82: 1581 — 1582.
Pollera CF, Cognetti F, Nardi M, Maza D. Sudden death after acute dystonic reaction to high dose metoclopramide. Lancet 1984;2:440-446.
Reasbeckand P, Hossenbouis A. Death following dystonic reaction to oral metoclopramide. Br J Clin Pract 1979;33:31-33.
Breitbart W. Tardive dyskinesia associated with high dose intravenous metoclopramide. N Engl J Med 1986;:315:518.
Robinson MB, Kennett RP, Harding AE, et al. Neuroleptic malignant syndrome associated with metoclopramide. J Neurol Neurosurg Psychiatry 1985;40:1304— 1312.
Noll AM, Pinsky D. Withdrawal effects of metoclopramide. West J Med 1991;154:726-728.
Spirt AJ, Chan W, Thieberg M, Sachar DB. Neuroleptic malignant syndrome induced by domperidone. Drug Dis Sci 1992;37:946-948.
Sempere AP, Duarte J, Cabezax C, et al. Aggravation of Parkinson tremor by cisapride. Clin Neuropharmacol 1995;18:76-78.
Bucci KK, Haverstick DE, Abercrombie SA. Dystonic-like reaction following cisapride therapy. J Fam Pract 1995;40:86-88.
Ahmad SR, Wolfe SM. Cisapride and Torsade de pointes. Lancet 1995;345:508.
Buss DC, Hutchings AD, Scott S, Routledge PA. A rapid liquid chromatographic method for determination of metoceopramide in human plasma. Ther Drug Monit 1990;12:293-296.
Woestenborghs R, Lorreyne W, Van Rompacy F, Heykants J. Determination of cisapride in plasma and animal tissues by high performance liquid chromatography. J Chromatogr 1988;424:195-200.
Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high dose cisapride. Arch Intern Med 1995;155:765-768.
Gladziwa V, Bares R, Klotz V, et al. Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. Clin Pharmacol Ther 1991;50:673— 681.
Henderson AS, Longdon P. Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene. Aust NZ J Med 1991;21:741-743.
Chaudhuri ТК, Fink S. Update: Pharmaceuticals and gastric emptying. Am J Gastroenterol 1990;85:223— 230.
Hastening drug transit. Lancet 1990;336:974-975. Editorial.
Boyson SJ. Bethanechol for anticholinergic side effects. Ann Neurol 19 088;23:422—423.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 29th ed. London: Pharmaceutical Press, 1989.
McCallum RW and the American College of Gastroenterology Committee on FDA Related Matters. Cisapride: A new class of prokinetic agent. Am J Gastroenterol 1991;86:135-149.
Cisapride: More selective than metoclopramide. Drug Ther Bull 1990;28(23):89—90.
Reynolds JC, Putnam PE. Prokinetic agents. Gastroenterol Clin North Am 1992;21:567-596.
Brown CK, Khanderia V. Use of metoclopramide, domperidone and cisapride in the management of diabetic gastroparesis. Clin Pharmacol 1990;9:357-365.
Sills JA, Glass EJ. Metoclopramide in young children. Br Med J 1978;2:431.
Low LCK, Goel KM. Metoclopramide poisoning in children. Arch Dis Child 1980;55:310-312.
Beno JM, Nemeth DR. Diltiazem and metoclopramide overdose. J Anal Toxicol 1991;15:285-287.
Joss RA, Goldhirsch A, Brunner KW, Galeazi RL. Sudden death in cancer patient on high dose domperidone. Lancet 1982; 1:1019.
Jay GT, Chow MSS, Feldman TA. Focus on domperidone: A selective dopamine antagonist for diabetic gastroparesis and idiopathic gastric stasis. Hosp Formul 1991;26:171-183.
Lauritsen K, Lauritsen LS, Rask-Madsen J. Clinical pharmacokinetics of drug use in the treatment of gastrointestinal disease (Part 1). Clin Pharmacokinet 1990;19:11-31.
Rowbotham DJ, Nimms WS. Effect of Cisapride on morphine-induced delay in gastric emptying. Br J Anaesth 1987;59:536-539.
Ranitidine (Zantac). Med Lett Drugs Ther 1982;24: 111-113.
Sewing KF, Biliam A, Malchow H. Comparative study with ranitidine and cimetidine on gastric secretion. Scand J Gastroenterol 1981 ;16(suppl. 69):45—48.
Berner BD, Conner CS, Sawyer DR, et al. Ranitidine: A new H2 receptor antagonist. Clin Pharm 1981; 1:499— 509.
Abernethy DR, Greenblatt DJ, Eshelman FN, et al. Ranitidine does not impair oxidative or conjugative metabolism: Noninteraction with antipyrine, diazepam, and lorazepam. Clin Pharmacol Ther 1984:35:188— 192.
BlumerJL, Rothstein FC, Kaplan BS, etal. Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. J Pediatr 1985;107:301-306.
Kagevi I, Whalby L. CSF concentrations of ranitidine. Lancet 1985;1:164-165.
Zeldis JB, Friedman LS, Isselbacker KJ. Ranitidine: A new H2 receptor antagonist. N Engl J Med 1983;309:1368-1373.
Leiden JS, Harding L, MacLeod SM, et al. Ranitidine pharmacokinetics in children. Clin Pharmacol Ther 1985;37:201.
Ilett KF, Nation RL, Tjokrosetio R, et al. Pharmacokinetics of ranitidine in critically ill patients. Br J Clin Pharmacol 1986;21:279-288.
Kearns GL, McConnell RF Jr, Trang JM, et al. Appearance of ranitidine in breast milk following multiple dosing. Clin Pharm 1983;4:322-324.
Henry DA, MacDonald IA, Kitchingman G, et al. Cimetidine and ranitidine: Comparison of effect on hepatic drug metabolism. Br Med J 1980;281:775-777.
Fischer J. Ranitidine and warfarin interaction. Drug Intel! Clin Pharm 1985;19:664-665.
Spahn H, Mutschler E, Krich W, et al. Influence of ranitidine on plasma metoprolol and atenolol concentration. Br Med J 1983;286:1547-1564.
McCarthy DM. Ranitidine or cimetidine. Ann Intern Med 1983;99:551-553.
McAllister RG Jr. Questions and answers. JAMA 1984;252:3253.
Kelly HW, Powell JR, Donohue JF. Ranitidine at very large doses does not inhibit theophylline elimination. Clin Pharmacol Ther 1986;39:577-581.
Kearns GL, McConnell RF Jr, Trang JM, Kluza RB. Appearance of ranitidine in breast milk following multiple dosing. Clin Pharm 1985;4:322-324.
Lima MA. Hepatitis associated with ranitidine. JAMA 1984:252:3253.
Hiesse C, Cantarovich M, Santelli C, et al. Ranitidine: Hepatotoxicity in renal transplant recipient. Lancet 1985;1:1280.
Karachalios GN. Ranitidine and hepatitis. Ann Intern Med 1985;103:634-635.
Lima MAS. Ranitidine and hepatic injury. Ann Intern Med 1986; 105:140.
Camarri E, Chirone E, Fanteria G, et al. Ranitidine induced bradycardia. Lancet 1982;2:160.
Tosi S, Cagnoli M. Painful gynaecomastia with ranitidine. Lancet 1982;2:160.
Spychai RT, Wickham NWR. Thrombocytopenia associated with ranitidine. Br Med J 1985;291:1687.
Bajjoka AE. Ranitidine-induced thrombocytopenia. Arch Intern Med 1991; 151:203.
Brenner LO. Agranulocytosis and ranitidine. Ann Intern Med 1986;104:896.
Shields LI, Files JA, Doll DC, et al. Ranitidine and agranulocytosis. Ann Intern Med 1986; 104:128.
Maack DK, Spiller HA. Rare dystonic reaction from accidental overdose of ranitidine in a 3 month old. Vet Hum Toxicol 1993;35:343.
Rustum AM. High performance liquid chromatographic determination of ranitidine in whole blood and plasma by using a short polymeric column. J Chromatogr Biomed Appl 1987;321:418-424.
Grinstead GF. Ranitidine and high concentrations of phenyl propanolamine crossreact in the EMIT Monoclonal Amphetamine/Methamphetamine Assay. Clin Chem 1989;35:1998-1999. Technical Brief.
Sica DA, Harford A, Comstock T. Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1985;37:229.
Bertaccini G, Coruzzi G, Poll E. Review article: The histamine H3-receptor: A novel prejunctional receptor regulating gastrointestinal function. Aliment Pharmacol Ther 1991;5:585-591.
Callaghan JT, Bergstrom RF, Obermayer BD, et al. Intravenous nizatidine kinetics and acid suppression. Clin Pharmacol Ther 1985;37:162-165.
Nizatidine (AX1D). Med Lett Drugs Ther 1988;30(772):77—78.
Aranoff GR, Bergstrom RF, Boff RJ, et al. Nizatidine disposition in subjects with normal and impaired renal function. Clin Pharmacol Ther 1988;43:688-695.
Halabi A, Kirch W. Negative chronotropic effects of nizatidine. Gut 1991;32:630-634.
Feely J, Warmsley KG. Н2 receptor antagonists: Cimetidine and ranitidine. Br Med J 1983;286:695-697.
Jenkins SA. Somatostatin in acute bleeding oesophageal varices. Drugs 1992;44(suppL 2):36—55.
Torres AJ, Landa I, Hernandez F, et al. Somatostatin in the treatment of severe upper gastrointestinal bleeding: A multi-centre controlled trial. Br J Surg 1986;73:786— 789.
Halma C, Jansen JBMJ, Janssens AP, et al. Life-threatening water intoxication during Somatostatin therapy. Ann Intern Med 1987;107:518-520.
Black JW, Duncan WAM, Durant CJ, et al. Definition and antagonism of histamine H-2 receptors. Nature 1972;236:385-390.
Freston JW. Cimetidine: I. Developments, pharmacology and efficacy. Ann Intern Med 1982;97:573-580.
Hiss J, Hepler BR, Falkowski AJ, et al. Fatal bradycardia after intentional overdose of cimetidine and diazepam. Lancet 1982;2:982.
Feldman M. Pros and cons of over-the counter availability of histamine2-receptor antagonists. Arch Intern Med 1993;153:2415-2425.
Physicians’ Desk Reference. 49th ed. Oradell, NJ: Medical Economics, 1995:2401—2404.
Illingworth RN, Jarvie DR. Absence of toxicity in cimetidine overdosage. Br Med J 1979;1:453-454.
Meredith TJ, Volans GN. Management of cimetidine overdose. Lancet 1979;2:1367.
Gugler R, Fucho G, Dieckmann M, et al. Cimetidine plasma concentration relationship. Clin Pharmacol Ther 1981;29:744-748.
Case 399. Litovitz TL, Schmitz BF, Bailey KM. 1989 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1990;8:439.
Sawyer D, Conner CS, Scalby R. Cimetidine: Adverse reactions and acute toxicity. Am J Hosp Pharm 1981;38:188-197.
Martyn JAJ, Greenblatt DJ, Abernethy DR. Increased cimetidine clearance in burn patients. JAMA 1985;253:1288-1291.
Bauer LA. Wareing-Tran C, Edwards WAD, et al. Cimetidine clearance in the obese. Clin Pharmacol Ther 1985;37:425-430.
Jackson JE, Bentley J, Powell JR, et al. Cimetidine-gen-tamicin interaction. Clin Res 1986;34:400A.
Mangini RJ. Clinically important cimetidine drug interactions. Clin Pharm 1982;1:433-440.
Feely J, Wilkinson GR, Wood AJJ. Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 1981;304:992-996.
Hansten PD. Overview of the safety profile of the H2 receptor antagonists. DICP Ann Pharmacother 1990;24(suppl.):S38-S41.
Feely J, Wood AJ. Effects of cimetidine on the elimination and actions of ethanol. JAMA 1982;247:2819— 2821.
Steinberg W, Lewis JH. Katz DM. Antacids inhibit absorption of cimetidine. N Engl J Med 1982;307:400.
Fine A, Churchill DW. Potentially lethal interaction of cimetidine and morphine. Can Med Assoc J 1981;125:1212.
Weinberger MM, Smith G, Milavetz G, et al. Decreased theophylline clearance due to cimetidine. N Engl J Med 1981;304:672.
Cusack BJ, Dawson GW, Mercer GD, et al. Cigarette smoking and theophylline metabolism: Effects of cimetidine. Clin Pharmacol Ther 1985;37:330-336.
Bartie WR, Walker SE, Shapero T. Dose dependent effects of cimetidine on phenytoin kinetics. Clin Pharmacol Ther 1983;33:649-655.
Knapp AB, Maguire W, Keren G, et al. The cimetidine-lidocaine interaction. Ann Intern Med 1983;98:174— 177.
Jackson JE, Bentley JB, Glass SJ, et al. Effects of hista-mine-2 receptor blockade on lidocaine kinetics. Clin Pharmacol Ther 1985;37:544-548.
Grahnen A, von Bahr C, Lindstrom B, et al. Bioavailability and pharmacokinetics of cimetidine. Eur J Clin Pharmacol 1979;16:335-340.
Greenblatt DJ, Abernethy DR, Morse OS, et al. Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 1984;310:1639-1643.
Loi C-M, Rollins DE, Dukes GE, et al. Effect of cimetidine on verapamil disposition. Clin Pharmacol Ther 1985;37:654-657.
Lalonde RL, Koob RA, McLean WM, et al. The effects of cimetidine on theophylline pharmacokinetics at steady state. Chest 1983;83:221-224.
Serbin JH, Mossman S, Sibeon RG, et al. Cimetidine: Interaction with oral anticoagulants in man. Lancet 1979;2:317-319.
Henry DA, MacDonald IA, Kitchingman G, et al. Cimetidine and ranitidine: Comparison of effect on hepatic drug metabolism. Br Med J 1980;281:775-777.
Reimann IW, Klotz D, Frolich JC. Effects of cimetidine and ranitidine on steady state propranolol kinetics and dynamics. Clin Pharmacol Ther 1982;32:749-757.
Kelly HW, Powell JR, Donohue JF. Ranitidine at very large doses does not inhibit theophylline elimination. Clin Pharmacol Ther 1986;39:577-581.
Powell JR, Donn KH. Histamine H,-antagonist drug interactions in perspective: Mechanistic concepts and clinical implications. Am J Med 1984;77(suppl. 5B):57—84.
Delhotal-Landes B, Flouvat B, Liote F, et al. Pharmacokinetic interactions between NSAIDs (indomethacin or sulindac) and H2-receptor antagonists (cimetidine or ranitidine) in human volunteers. Clin Pharmacol Ther 1988;44:442-452.
Gisclon LG, Boyd RA, Williams RL, Giacomim. The effect of probenicid on the renal elimination of cimetidine. Clin Pharmacol Ther 1989;45:444-452.
Koren G, Zemlickis DM. Outcome of pregnancy after first trimester exposure to H2 receptor antagonists. Am J Perinatal 1991;8:37-38.
Lehmann AB. Reversible chorea due to ranitidine and cimetidine. Lancet 1988;2:158.
Romisher S, Felter R, Dougherty J. TagametR-induced acute dystonia. Ann Emerg Med 1987;16:1162-1164.
Walls TJ, Pearce SJ, Venables GS. Motor neuropathy associated with cimetidine. Br Med J 1980;281:974-975.
Vincent D, Penicaud-Vedrine A, Rancurel G, et al. Neuropathic peripherique au cours d’un traitment par la cimetidine. Presse Med 1988;17:589-590.
Chang HK, Morrison SL. Bone marrow suppression associated with cimetidine. Ann Intern Med 1979;71: 580.
Colin-Jones DG, Langman MJS, Lawson DH, et al. Safety of cimetidine. Br Med J 1985;291:1721-1722.
Pitone JM, Santoro JJ, Biondi RJ, et al. Cimetidine induced acute interstitial nephritis. Am J Gastroenterol 1982;77:169-171.
Enzmann GD, Leonard JM, Paulsen CA. Effect of cimetidine on reproductive function in men. Clin Res 1981;29:26A. Abstract.
Lardinois CK, Mazzaferri EL. Cimetidine blocks testosterone synthesis. Arch Intern Med 1985;145:920-922.
Palmer FJ, Sawyers TM, Wierzbinski SJ. Cimetidine and hyperparathyroidism. N Engl J Med 1980;302:692.
Shaw RG, Mashford MI, Desmond PV. Cardiac arrest after intravenous injection of cimetidine. Med J Aust 1980;2:629-630.
Cohen J, Weetman AP, Dargie HJ, et al. Life-threatening arrhythmias and intravenous cimetidine. Br Med J 1979;2:768.
Taylor RH, Lovell D, Menzies-Gow N, et al. Misleading response of malignant gastric ulcers to cimetidine. Lancet 1978;1:686-688.
Neal KR, Brij S, Slack RCB, et al. Recent treatment with H, antagonists and antibiotics and gastric surgery as risk factors for salmonella infection. Br Med J 1994;308:176.
Krenzelok EP, LitovitzT, Lippold KP, McNally CF. Cimetidine toxicity: An assessment of 881 cases. Ann Emerg Med 1987;16:1217-1221.
Cimetidine. In: Long JW, ed. Clinical Management of Prescription Drugs. Philadelphia: Harper & Row, 1984: 229.
MilanderJH. PepcidR: Poison control monograph. Personal communication. Merck, Sharp and Dohme, May 23, 1989.
Humphries JE. Thrombocytopenia associated with famotidine in a hemophiliac. Ann Pharmacother 1992;26:262.
Norwood J, Smith TM, Stein DS. Famotidine and hyperpyrexia. Ann Intern Med 1990;l 12:632.
Andreo JA, Vivancos F, Lopez VM, Soriano J. Leuco-cytoclastic vasculitis and famotidine. Med Clin 1990;95:234-235. In: Reactions ADIS International, Sept 15, 1990.
Ahmad S. Famotidine and cardiac arrhythmia. DICP Ann Pharmacother 1991 ;25:315.
Roblin X, Becot F, Jacquot JM, et al. Acute rhabdomyolysis and famotidine. Semin Hop 1991;67:337-338.
Henann NE, Carpenter DV, Janda SM. Famotidine-associated mental confusion in elderly patients. Drug Intell Clin Pharm 1988;22:976-978.
Hinrichsen H, Halabi A, Kirch W. Hemodynamic effects of different H7 receptor antagonists. Clin Pharmacol Ther 1990;48:302-307.
Dalpre G, Lapidot M, Lipchitz A, et al. Hyperprolactinemia during famotidine therapy. Lancet 1993:342:868.
Lansoprazole. Med Lett Drugs Ther I995;37(953):63— 64.
Spencer CM, Faulds D. Lansoprazole: A reappraisal of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1994;48:404-430.
Clarke CB (Katia). Personal communication. Medical services, TAP Pharmaceuticals, September 14, 1995.
Tucker GI. The interaction of proton pump inhibitors with cytochrome PL-450. Pharmacol Ther 1994;8(suppL 1):13—38.
Gladziwa V, Klotz V. Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure. Clin Pharmacokinet 1994;27:29-48.
Brand JM, Greer FR. Hypermagnesemia and intestinal perforation following antacid administration in a premature infant. Pediatrics 1990;85:121-124.
Mofenson HC, Caraccio TR. Magnesium intoxication in a neonate from oral magnesium hydroxide laxative. J Toxicol Clin Toxicol 1981;29:215-222.
McAlister NH, Abrams HB, Schlosser R, Sturtridge W. Unintentional self-intoxication with inorganic calcium. J Intern Med 1990;228:193-195.
Harmeln DL, Martin FIR, Wark JD. Antacid induced phosphate depletion syndrome presenting as nephrolithiasis. Aust NZ J Med 1990;20:803-805.
Carmichael KA, Fallon MD, Dalinka M, et al. Osteomalacia and osteitis fibrosa in a man ingesting aluminum hydroxide antacid. Am J Med 1984;76:1137-1140.
Vezzadini Р, Tomassetti Р, Marrano D, Labo G. Lifethreatening gastrointestinal hemorrhage with omeprazole. Dig Sci 1988;33:766-768.
Shackleford RW. Personal communication. Merck Sharp and Dohme, April 1, 1991.
Ferner RE, Allison TR. Omeprazole overdose. Hum Exp Toxicol 1993;12:541-542.
Alliet P, Raes M, Gillis P, Zimmerman A. Optional dose of omeprazole in infants and children. J Pediatr 1994;125:332-333.
Andersson T, Cederberg C, Regardh CG, Skanberg I. Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharmacol 1990;39:1971.
Andersson T. Andren K, Cederberg C, et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990;29:557-563.
Scott G. Omeprazole. Hosp Phys 1990;26(2):48—51.
Weintraub M, Evans P. Omeprazole: A long acting acid secretion inhibitor. Hosp Formul 1988;23:875-882.
Lampkin TA, Ouellet D, Hak U, Dukes GE. Omeprazole: A novel antisecretory agent for the treatment of acid peptic disorders. DICP Ann Pharmacother 1990;24:393-402.
Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991;20:38-49.
Lauritsen K, Lauritsen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part 1). Clin Pharmacokinet 1990;19:11-31.
Regardh CG, Andersson T, Lagerstrom PA, et al. The pharmacokinetics of omeprazole in humans: A study of single intravenous and oral doses. Ther Drug Monit 1990;12:163-172.
Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinetics 1991 ;21:195—212.
Humphries TJ. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Dig Dis Sci 1991;36:1665-1669.
Hajela R, Cunningham GM, Kapur BM, et al. Catatonic reaction to omeprazole and disulfiram in a patient with alcohol dependence. Can Med Assoc J 1990; 145:1207— 1208.
Marti-Masso JF, de Munain AL, Dicastillo GL. Ataxia following gastric bleeding due to omeprazole-benzodi-azepine interaction. Ann Pharmacother 1992;26:429.
Ekman L, Hansson E, Harn N, et al. Toxicological studies on omeprazole. Scand J Gastroenterol 1985;20(suppl. 108):53—69.
Garrotte FJ, LaCambra C, de SerT, et al. Subacute myopathy during omeprazole therapy. Lancet 1992;340:672.
Marks DR, Joy JV, Bonheur NA. Hemolytic anemia associated with the use of omeprazole. Am J Gastroenterol 1991;86:217-218.
Santucci L, Farroni F, Fiorucci S, Morelli A. Gynecomastia during omeprazole therapy. N Engl J Med 1991;324:635.
Convene C, Verheist J, Mahler C. Painful gynaecomastia during omeprazole therapy. Lancet 1991;338:1153.
Dutertre JP, Soutif D, Jonville AP, et al. Sexual disturbances during omeprazole therapy. Lancet 1991 ;338: 1022.
Jochem V, Kirkpatrick R, Greenson J, et al. Fulminant hepatic failure related to omeprazole. Am J Gastroenterol 1992;87:523-525.
Graham JR. Gastric polyposis: Onset during long-term therapy with omeprazole. Med J Aust 1992; 157:287— 288.
Sellapah S. An unusual side effect of omeprazole: Case report. Br J Gen Pract 1990;40:389.
Goldfain D, Le Bodie MF, Lavergne A, et al. Gastric carcinoid tumors in patients with Zollinger—Ellison syndrome on long-term omeprazole. Lancet 1989; 1:776— 777.
First in new class of G1 drugs approved. FDA Consumer 1990(March):3.
Roggo A, Filippini L, Colombi A. The effect of hemodialysis on omeprazole plasma concentrations in the anuric patient: A case report. Int J Clin Pharmacol Ther Toxicol 1990;28:115-117.
Graham DY. Prevention of gastrointestinal injury induced by chronic nonsteroidal antiinflammatory drug therapy. Gastroenterology 1989;96:675-681.
Ams PA. Misoprostol. Am J Med Sci 1991;301:133-137.
Stern WR. Summary of the 33rd meeting of the Food and Drug Administration’s Gastrointestinal Drugs Advisory Committee, September 15—16, 1988. Am J Gastroenterol 1989;84:351-354.
Feldman M. Southwestern Internal Medicine Conference: Prostaglandins and gastric ulcers: From seminal vesicle to misoprostol (Cytotec®). Am J Med Sci 1990;300:116-132.
Garris RE, Kirkwood CF. Misoprostol: A prostaglandin E, analogue. Clin Pharm 1989;8:627-644.
Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal antiinflammatory drug-induced gastrointestinal tract bleeding. JAMA 1990;264:41-47.
Barnworth B, Schaeverbeke T, Dehais J, Doumayrou F. NSAIDs, misoprostol and gastrointestinal bleeding. Lancet 1991;337:973-974.
Bond GR, Van Zee A. Intentional misoprostol (Cy-totek®) overdosage in pregnancy. Vet Hum Toxicol 1990;32:352.
Grober DJ, Meier KH. Acute misoprostol toxicity. Ann Emerg Med 1991;20:549-551.
Moran M, Mozes MF, Maddux MS, et al. Prevention of acute graft rejection by the prostaglandin E analogue misoprostol in renal transplant recipients treated with cyclosporine and prednisone. N Engl J Med 1990;322:1183-1188.
Karim A. Antiulcer prostaglandin misoprostol: Single and multiple dose pharmacokinetic profile. Prostaglandins 1987;33(suppl):40—50.
Karim A, Bums TS, Miller SR. Pharmacokinetics and safety of the anti-ulcer prostaglandin misoprostol in elderly male subjects. Clin Pharmacol Ther 1987;41:205.
Halstenson CE, Lee DR, Karim A. Misoprostol disposition in patients with various degrees of renal function. J Clin Pharmacol 1990;30:838.
Karim A, Rozek LF, Burns TS. Pharmacokinetic profile of antiulcer prostaglandin (misoprostol) in humans. Postgrad Med J 1988;64(suppl. 1 ):80. Abstract.
Karim A, Nicholson P. Misoprostol in elderly patients on NSAIDs: Pharmacokinetics and drug interactions: Protection from NSAID beyond stomach and duodenum. In: Cheli R, ed. Treatments and Prevention of NSAID-Induced Gastropathy. New York: Royal Society of Medicine Series, 1989:43—45.
Small RE, Wilmont-Pater MG, Mcgee BA, Willis HE. Effects of misoprostol on ranitidine or ibuprofen pharmacokinetics. Clin Pharm 1991;10:870-872.
Bennett PN, Fenn GC, Notarianni U. Potential drug interactions with misoprostol: Effects on the Pharmacokinetics of antipyrine and propranolol. Postgrad Med J 1988;64(suppl. 1):21—24.
Bennett PN, Fenn GC, Notarianni U, Lee CE. Misoprostol does not alter the Pharmacokinetics of propranolol. Postgrad Med J 1991;67:455-457.
Schonhofer PS. Brazil: Misuse of misoprostol as an abor-tifacient may induce malformations. Lancet 1991;337:1534-1535.
Fonseca W, Alencai AJC, Mota FSB, Coelho HLL. Misoprostol and congenital malformations. Lancet 1991;338:1241-1242.
Aubery E, Baulieu E-E. Activite contragestive de l"asso-ciation au RU486 di’une prostaglandin active par voie orale. CR Acad Sci III 1991;312:539-545.
Norman JE, Thong KJ, Baird DT. Urine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 1991;338:1233-1236.
Misoprostol and legal medical abortion. Lancet 1991;338:1241-1242. Editorial.
Morton MR, Robbins ME. Delirium in an elderly woman possibly associated with administration of misoprostol. DICP Ann Pharmacother 1991;25:133-134.
Fossaluzza V, di Benedetto P, Zampa A, De Vita S. Misoprostol induced urinary incontinence. J Intern Med 1991;230:463-464.
Bobrove AM. Misoprostol, diarrhea and psyllium muci-lloid. Ann Intern Med 1990;l 12:386.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists 1994:1880-1881.
Heel RC, Brogden NN, Speight TM, Avery GS. Loperamide: A review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs 1978; 15:33— 52.
Bhutta FL, Tahir KL Loperamide poisoning in children. Lancet 1990;335:363.
Bhutta IL Anti-motility drug for infants. Lancet 1990;331:314.
Gussin RZ. Withdrawal of loperamide drops. Lancet 1990;335:1603-1604.
Minton NA, Smith PGD. Loperamide toxicity in a child after a single dose. Br Med J 1987;294:1383.
Blum D, Kahn A. Poisoning and near-miss cot death. Vet Hum Toxicol 1987;29(suppl. 2):27.
Lauritsen K, Lauritsen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II). Clin Pharmacokinet 1990;19:94-125.
Sandhu BF, Tripp JH, Candy DCA, Haries JT. Loperamide: Studies on its mechanism of action. Gut 1981;22:658-662.
Sandhu BF, Tripp JH, Milla RJ, Harries JT. Loperamide in severe protracted diarrhoea. Arch Dis Child 1983;58:39-43.
Walley T, Milson D. Loperamide related toxic megacolon in Clostridium difficile colitis. Postgrad Med J 1990;66:582-584.
Marcovitch H. Loperamide in ’toddler’ diarrheoea. Lancet 1980;l:1413.
Jaffe JH, Kanzler M, Green J. Abuse potential of loperamide. Clin Pharmacol Ther 1980;28:812-819.
Michiels M, Hendriks R, Heykants J. Radioimmunoassay of the antidiarrhoeal loperamide. Life Sci 1977;21:451-460.
Ramirez MS, Bastidas O, Berudez EL. A suspected case of loperamide toxicity. Vet Hum Toxicol 1983;25:341.
Hart LM, Dean BS, Krenzelok EP. Loperamide overdose in children: Is it as bad as Lomotil? Vet Hum Toxicol 1992;34:332.
Litovitz TL, Clancy C, Koverly BH, et al. Surveillance of loperamide ingestions: Analysis of 216 poison center reports. Vet Hum Toxicol 1993;35:369.
Lauritsen К, Lauritsen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part 1). Clin Pharmacokinet 1990;119:11-31.
Lauritsen K, Lauritsen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal disease (Part 11). Clin Pharmacokinet 1990;19:94-125.
Jarnerot G. Newer 5-aminosalicylic based drugs in chronic inflammatory bowel disease. Drugs 1989;37:73-86.
Sulphasalazine: Drug or pro-drug. Lancet 1987; 1:1299— 1330. Editorial.
Bruckstein AH. New salicylate therapies for ulcerative colitis. Postgrad Med 1990;88:79-89.
Minocha A, Dean HA, Mayle JE. Acute sulfasalazine overdose. Clin Toxicol 1991;29:543-551; Am J Gastroenterol 1991 ;86:1358.
Peppercorn MA. Advances in drug therapy for inflammatory bowel disease. Ann Intern Med 1990; 112:50—60.
Wadworth AN, Fitton A. Olsalazine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in inflammatory bowel disease. Drugs 1991;41:647-664.
Hessemer CA. Personal communication. Kabi Pharmacia, March 22, 1991.
Brogden RN, Sorkin EM. Mesalazine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in chronic inflammatory bowel disease. Drugs 1989;38:500-523.
Mehta RP. Acute .Interstitial nephritis due to 5-aminosalicylic acid. Can Med Assoc J 1990;143:1031-1032.
Isaacs KL, Murplly D. Pancreatitis after rectal administration of 5-aminosalicylic acid. J Clin Gastroenterol 1990;12:198-199.
Fraser D. Personal communication. Reid Powell, April 18, 1991.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1427.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:2489-2490.
Med Lett Drugs Ther 1985;27(698):87-88.
Barnes N, Thomas N. Overdose of trilostane. Br Med J 1983;286:1784-1785.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1427.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:2489-2490.
Med Lett Drugs Ther 1985;27(698):87—88.
Barnes N, Thomas N. Overdose of trilostane. Br Med J 1983;286:1784-1785.
Narayan Р, Indudhara R. Pharmacotherapy for benign prostatic hyperplasia. West J Med 1994;161:495-501.
Smith AY. Pharmacologic management of benign prostatic hyperplasia: Changing times. West J Med 1994;161:521-523.
Hypertension Symposium. Clinical applications of alpha|-receptor blockade: Terazosin in the management of hypertension. J Clin Pharmacol 1993;33:866-899.
Terazosin for benign prostatic hyperplasia. Med Lett Drugs Ther 1994;36(916): 15-16.
Hill SJ, Lawrence SL, Lepor H. New use for alpha blockers: Benign prostatic hyperplasia. Amer Fam Phys 1994;45:1885-1888.
Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia. A combined analysis. Urology 1994;44:46-51.
Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-1191.
Winchell GA, Gregoire S, Taylor AM, et al. Finasteride: A steroid 5-alpha reductive inhibitor does not affect the oxidative metabolism of antipyrine. J Clin Pharmacol 1993;33:967-970.
Steiner JF. Finasteride: A 5-alpha-reductase inhibitor. Clin Pharm 1993;12:15-23.
Browley OW, Ford LG, Thompson 1, et al. 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epid Biomarkers Prev 1994;3:177-182.
Gregoretti S. Intraoperative hypotension in a patient treated with terazosin, a new alpha-adrenergic receptor antagonist. J Clin Anesth 1994;6:170-171.
Reichert UM, De Rooy HAM. Treatment of amiodarone induced hyperthyroidism with potassium perchlorate and methimazole during amiodarone treatment. Br Med J 1989;298:1547-1548.
Modebe O. Experience with carbimazole in the drug treatment of the hyperthyroidism of Graves’ disease in Nigerians. East Afr Med J 1992;69:153-156.
Elias AN, Goodman MM, Rohan MK, et al. Methimazole (2-mercaptol-methylimidazole) in psoriasis: Results of an open trial. Dermatology 1993;187:24-29.
Jackson GL, Flickinger FW, Wells LW. Massive overdosage of propylthiouracil. Ann Intern Med 1979;91:418-419.
Peter SA. Propylthiouracil-associated hepatitis. J Natl Med Assoc 1991;83:75-77.
Melander A, Hallengren B, Rozendal-Helgesen S, et al. Comparative in vitro effects and in vivo kinetics of antithyroid drugs. Eur J Clin Pharmacol 1980; 17:295— 299.
Skellern GG, Stenlack JB, Williams WD, McLarty DG. Plasma concentrations of methimazole, a metabolite of carbimazole, in hyperthyroid patients. Br J Clin Pharmacol 1974;1:265-269.
Kellett HA, Sawers JSA, Boulton FE, et al. Problems of anticoagulating with warfarin in hyperthyroidism. Q J Med 1986;225:43-51.
Chatral P, Sidhu R, Joplin CF, Hawkins DF. Treatment of thyrotoxicosis in pregnancy. J Obstet Gynecol 1981;2:11-19.
Ramsay I, Kaur S, Krassas G. Thyrotoxicosis in pregnancy: Results of treatment by antithyroid drugs combined with T4. Clin Endocrinol 1983;18:73-85.
Hayashida CY, Durate AJS, Sato AE, Yamashiro-Kana-shiro EH. Neonatal hepatitis and lymphocyte sensitization by placental transfer of propylthiouracil. J Endocrinol Invest 1990;13:937-941.
Waldhauser L, Uetrecht J. Oxidation of propylthiouracil to reactive metabolites by activated neutrophils: Implications for agranulocytosis. Drug Metab Dispos 1991;19:354-359.
Dolman KM, Grans ROB, Vervaat TJ, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993:342:651 — 652.
Romaldini JN, Werner MC, Bromberg N, Werner RS. Adverse effects related to antithyroid drugs and their dose regimen. Exp Clin Endocrinol 1991;97:261-264.
Hanson JJS. Propylthiouracil and hepatitis. Arch Intern Med 1982;14:994-996.
Wiberg JJ, Nuttall FQ. Methimazole toxicity from high doses. Ann Intern Med 1972;77:414-416.
Werner MC, Romeldini JH, Bromberg N, et al. Adverse effects related to thionamide drugs and their dosage regimen. Am J Med Sci 1989;297:216-219.
Lin T-H, Kirkland RT, Kirkland JL. Clinical features and management of overdosage with thyroid drugs. Med Toxicol 1988;3:264-272.
Haynes RC Jr, Murad F. Thyroid and antithyroid drugs. In: Gilman AE, Goodman LS, Rail TW, et al., eds. The Pharmacologic Basis of Therapeutics. 7th ed. New York: Mac-Millan, 1985:1398-1408.
Bhasin S, Wallace W, Lawrence JB. Sudden death associated with thyroid hormone abuse. Am J Med 1981;71:887-890.
Todd CH, Allain T, Gonio ZAR, et al. increase in thyrotoxicosis associated with iodine supplements in Zimbabwe. Lancet 1995;346:1563-1564.
Quin JP, Thomson JA. Adverse effects of drugs on the thyroid gland. Adverse Drug React Toxicol Rev 1994;13:43-50.
Singh GK, Winterborn MH. Massive overdose with thyroxine: Toxicity and treatment. Eur J Pediatr 1991;150:217-218.
Litovitz TL, White JD. Levothyroxine ingestions in children: An analysis of 78 cases. Am J Emerg Med 1985;3:297-300.
Tenenbein M, Dean HJ. Benign course after massive ingestion of levothyroxine. Vet Hum Toxicol 1981;23(sup-pl. 1 ):50. Abstract.
Lewander WJ, Lacouture PG, Silva JE, et al. Acute thyroxine ingesiton in pediatric patients. Pediatrics 1989;48:262-265.
Tunget CL, Turchen SG, Manoguerra AS, Clark RF. Determination of an acute safe exposure dose in overdoses for thyroid containing products. Vet Hum Toxicol 1993;35:348.
Roti E, Montermini M, Roti S, et al. The effect of diltiazem, a calcium channel-blocking drug on cardiac rate and rhythm in hyperthyroid patients. Arch Intern Med 1988;148:1919-1921.
Binimelis J, Bassas L, Marruecos L, et al. Massive thyroxine intoxication: Evaluation of plasma extraction. In-tens Care Med 1987;13:33-38.
Page SR, Scott AR. Thyroid storm in a young woman resulting in bilateral basal ganglia infarction. Postgrad Med J 1993;69:813-831.
Wilson BE, Hobbs WN. Case report: Pseudoephedrin-eassociated thyroid storm: Thyroid hormone — catecholamine interactions. Am J Med Sci 1993;306:317— 319.
Matthews SJ. Acute thyroxine overdosage: Two cases of parasuicide. Ulster Med J 1993;63:170-173.
Shimura H, Takazawa K, Endo T, et al. Thyroid storm after CT scan with iodinated contrast media. J Endocrinol Invest 1991;13:73-76.
Gerard P, Malraux P, de Visscher M. Accidental poisoning with thyroid extract treated by exchange transfusion. Arch Dis Child 1972;47:980-982.
May ME, Mintz PD, Lowry P, et al. Plasmapheresis in thyroxine overdose: A case report. J Toxicol Clin Toxicol 1983;20:517-520.
Herrmann J, Rudorff KH, Gockenjan G, et al. Charcoal haemoperfusion in thyroid storm. Lancet 1977; 1: 248.
Herrmann J, Kruskemper HL, Grosser KD, et al. Peritoneal-dialysis in der Behandlung der thyreotoxischen Krise. Dtsch Med Wochenschr 1971;96:742-745.
Braunstein CD, Koblin R, Sugawara M, et al. Unintentional thyrotoxicosis factitia due to a diet pill. West J Med 1986;145:388-391.
Mariotti S, Martino E, Cupin C, et al. Low serum thyroglobulin as a clue to the diagnosis of thyrotoxicosis factitia. N Engl J Med 1982;307:410-412.
Hamolsky MW. Truth is stranger than factitious. N Engl J Med 1982;307:436-437.
Beggs EJ, Atkinson НС, Gianarkis N. The pharmacokinetics of corticosteroid agents. Med J Aust 1987;146:37-41.
Martin LE, Tanner RJN, Clark TJH, Cochrane GM. Absorption and metabolism of orally administered be-clomethasone dipropionate. Clin Pharmacol Ther 1974;15:267-275.
Derendorf H, Mollmann H, Gruner A, et al. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intraarticular administration. Clin Pharmacol Ther 1986;39:313-317.
Szefler SJ, Ebling WF, Georgitis JW, Jusko WJ. Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. Eur J Clin Pharmacol 1986;30:323-329.
Al-Habet SMH, Rogers HJ. Methylprednisolone pharmacokinetics of intravenous and oral administration. Br J Clin Pharmacol 1989;27:285-290.
Shenfield GM, Griffin JM, Griffin JM. Clinical pharmacokinetics of contraceptive steroids: An update. Clin Pharmacokinet 1991;20:15-37.
Kanarkowski R, Tornatore KM, D’Ambrosia R, et al. Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clin Pharmacol Ther 1988;43:23-31.
Goebelsmann U. Pharmacokinetics of contraceptive steroids in man. In: Gregoire AT, Blye RR, eds. Contraceptive Steroids: Pharmacology and Safety. New York: Plenum, 1986:67—111.
Gambertoglio JG, Ammend WJC Jr, Benet LZ. Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: A review. J Pharmacokinet Biopharm 1980;8:1-51.
Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1990;19:126-146.
Bergren H, Grottum P, Rugstad HE. Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. Eur J Clin Pharmacol 1983;24:415-419.
Mollmann H, Rohdewald P, Schmidt EW, et al. Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol 1985;29:85-89.
Hall AH, Hogan DJ. Skin lesions and environmental exposures: Rash decisions. Atlanta: ASTDR Case Studies in Environmental Medicine, May 28, 1993.
Teelucksingh S, Bahall M, Coomansingh D, et al. Cushing’s syndrome from topical glucocorticoids. Wis Med J 1993;42:77-78.
Cote RJ, Urmacher C. Rhabdomyosarcoma of the liver associated with long-term oral contraceptive use: Possible role of estrogens in the genesis of embryologically distinct liver tumors. Am J Surg Pathol 1990;14:784-790.
Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynecol 1991;9:1245-1253.
Wong J, Black P. Acute adrenal insufficiency associated with high dose inhaled steroids. BrMedJ 1992;304:1415.
Zwaan CM, Odink RJH, Delemarre-Van de Waal HA, et al. Acute adrenal insufficiency after discontinuation of inhaled corticosteroid therapy. Lancet 1992;340:1230— 1289.
Rao RH, Vagmicci AH, Amino JA. Bilateral massive adrenal hemorrhage: Early recognition and treatment. Ann Intern Med 1989;110:227-236.
Kornbluth AA, Salomon P, Sachar DB, et al. ACTH-induced adrenal hemorrhage: A complication of therapy masquerading as an acute abdomen. J Clin Gastroenterol 1990;12:371-377.
Doherty M, Garstin 1, McClelland RJ, et al. A steroid stupor in a surgical ward. BrJ Psychiatry 1991; 158:125— 127.
Rome HP, Braceland FJ. Psychological response to cor-ticotrophin, cortisone and related steroid substances. JAMA 1952;142:27-30.
Kaufman MW, Casadonte PE, Peslow ED. Steroid psychosis: Treatment advances. NY State J Med 1981;81:1795-1797.
Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972;13:694-698.
Connett G, Lenney W. Inhaled budesonide and behavioral disturbances. Lancet 1991;338:634-635.
Hall RC, Popkin MK, Kirkpatrick B. Tricyclic exacerbation of steroid psychosis. J Nerv Ment Dis 1978;166:738-742.
Punch MR, Ansbacher R. Autogenic masculinization. Am J Obstet Gynecol 1990;163:114-116.
Eden JA. Sustained effects of oestrogen implant overdose. Lancet 1988;2:1061.
Eden J. Too much of a good thing? Two cases of oestrogen overdosage associated with oestradiol implants. Med J Aust 1990; 152:558.
Pnnonen R, Salmi T. Effects of a massive single oral dose of oestradiol valerate in a young woman. Ann Clin Res 1983;15:134-136.
Girre G, Vincens M, Compel A, Fournier PE. Iatrogenic Cushing’s syndrome due to acute triamcinolone overdosage. Therapie 1987;42:317-318.
Mazanek-Szymanska E, Gasinska T, Starzewska H, et al. Effect of excessive doses of Kenalog given for short time periods. Pol Tyg Lek 1979;34:997-1001. [in Polish] (From Mickiewicz CW. Personal communication. Lederle Laboratories, June 29, 1989.)
Malone DA Jr, Dimeff RJ. The use of fluoxetine in depression associated with anabolic steroid withdrawal: A case series. J Clin Psychiatry 1992;51:130-132.
Dalby JT. Brief anabolic steroid use and sustained behavioral reactions. Am J Psychiatry 1992;149:271-272.
Uzych L. Anabolic androgenic steroids and psychi-atricrelated effects: A review. Can J Psychiatry 1992;37:23-28.
Tully MP, Cooper RG, Jayson MIV. Intracranial hypertension associated with stanozolol. DICP Am Pharmacother 1990;24:1234.
French GS, Adelman S. Myocardial infarction associated with anabolic steroid use in a previously healthy 31-year old weight lifter. Am Heart J 1992;124:507-508.
Montine TJ, Garede JT. Massive pulmonary embolus and anabolic steroid abuse. JAMA 1992;267:2238-2239.
Perry HM, Littlepage BNC. Misusing anabolic drugs: A drug history from well muscled patients. Br Med J 1992;305:1241-1242.
Forbes GM, Bramston BA, Collins BJ. Anabolic steroid hepatotoxicity: Lessons to be learned? Aust NZ J Med 1993;23:308-310.
Johnson MD. Anabolic steroid use in adolescent athletes. Pediatr Clin North Am 1990;37:1 111 — 1123.
Goodwin FK. Anabolic steroids and dependence. JAMA 1991;266:1619.
Hatton CK, Catlin DN. Detection of androgenic anabolic steroids in urine. Clin Lab Med 1987;7:655-668.
Bickelman C, Ferries L, Eaton RP. Impotence related to anabolic steroid use in a body builder: Response to clomiphenyl citrate. West J Med 1995;162:158-160.
British National Formulary No. 24. September 1992:124-125.
Barnes PJ. Pulmonary disorders. In: Melmon KL, Mor-relli HF, Hoffman BB, Nierenberg DW, eds. Clinical Pharmacology: Basic Principles in Therapeutics. 3rd ed. New York: McGraw Hill, 1992:198-202.
Deutsch SI, Mastropaolo J. Hitri A. GABA-active steroids: Endogenous modulation of GABA-gated chloride ion conductance. Clin Neuropharmacol 1992;15:352— 364.
Petrie RH. The pharmacology and use of oxytocin. Clin Perinatol 1981;8:35-47.
Syntocinon. In: Physicians' Desk Reference. 47th ed. 1993. Montvale, NJ: Medical Economics, 1993:2128— 2129.
Higby K, Xenakis EMJ, Pauerstein CJ. Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety. Am J Obstet Gynecol 1993;168:1247-1259.
Pauerstein CJ. Use and abuse of oxytocic agents. Clin Obstet Gynecol 1973;16:262-277.
Dawood MY, Ylikorkala O, Trivedi D, Gupta R. Oxytocin levels and disappearance rate and plasma follicle-stimulating hormone and luteinizing hormone after oxytocin infusion in man. J Clin Endocrin Metab 1980;50:397-400.
Fabian M, Forsling ML, Jones JJ, Pryor JS. The clearance and antidiuretic potency of neurohypophyseal hormones in man and their plasma binding and stability. J Physiol 1969;204:653-668.
Propping D, Stubblefield PG, Golub J, Zuckerman J. Uterine rupture following midtrimester abortion by laminaria, prostaglandin F2alpha, and oxytocin: Report of two cases. Am J Obstet Gynecol 1977;128:689-690.
Dawood MY, Wang CF, Gupta R, Fuchs F. Fetal contribution to oxytocin in human labor. Obstet Gynecol 1978;52:205-209.
Seitchik J, Chatkoff ML, Hayaski RH. Intrauterine pressure waveform characteristics of spontaneous and oxytocin or prostaglandin F2alpha-induced active labor. Am J Obstet Gynecol 1977;127:223-227.
Morgan DB, Kirway NA, Hancock KW, et al. Water intoxication and oxytocin infusion. Br J Obstet Gynecol 1977;84:6-12.
Dawood MV, Raghavan KS, Pociask C. Radioimmunoassay of oxytocin. J Endocrinol 19,78;76:270—271.
Chard T. The radioimmunoassay of oxytocin and vasopressin. J Endocrinol 1973;58:143-160.
Octreotide for endocrine tumours. Drug Ther Bull 1991 ;29(5): 19-20.
Tulassay Z, Flautner L, Vadasz A, Fehervari I. Octreotide in the treatment of external pancreatic fistulas. Aliment Pharmacol Ther 1993;7:323-325. Short Report.
Boyle PJ, Justice K, Krentz AJ, et al. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 1993;76:752-756.
Chanson P, Weintraub BD, Harris AG. Ocreotide therapy for thyroid-stimulating-hormone-secretory pituitary adenomas: A follow-up of 52 patients. Ann Intern Med 1993;119:236-240.
Antaraki A, Piadites G, Vergados J, et al. Octreotide benign intracranial hypertension. Lancet 1993;342:1170.
Meijer JL, Jansen JBMJ, Crobach LFSJ, etal. Inhibition of omeprazole induced hypergastrinemia by SMS201-995, a long acting somatostatin analogue in man. Gut 1993;34:1186-1190.
Caron P, Gerbeau C, Pradayrol L. Maternal-fetal transfer of octreotide. N Engl J Med 1995;333:601-602.
Sadoul J-L, Benchimol D, Thyss A, Freychet R. Side effects of octreotide withdrawal. Lancet 1992;339:376.
Leclerq F, Fille A, Albat R, et al. Congestive heart failure worsening with octreotide in acromegalic patient. Lancet 1991;338:1272-1273.
Chanson P, Timsit J, Harris AG. Heart failure and octreotide in acromegaly. Lancet 1992;339:242-243.
Minocha A, Dean HA Jr. Octreotide-induced acute hepatic toxicity. Am J Gastroenterol 1991 ;86:526.
Jonsson A, Manhem P. Octreotide and loss of scalp hair. Ann Intern Med 1991 ;115:913.
Gradon JD: Schulman RH, Chapnick EK, Sepkowitz DL. Octreotide-induced acute pancreatitis in a patient with acquired immunodeficiency syndrome. South Med J 1991;81:1410-1411.
Bigg-WitherGW, Kok KY, Greenstein RR, etal. Effects of long term octreotide on gallstone formation and gallbladder function. Br Med J 1992;304:1611-1612.
James RA, Rhodes M, Rose P, Kendall-Taylor P. Biliary colic in abrupt withdrawal of octreotide. Lancet 1991;338:1527.
Sadoul J-L, Benchomal D, Thyss A, Freychet R. Acute pancreatitis following octreotide withdrawal. Am J Med 1991;90:763-784.
Kutz K, Nuesch E, Rosenthaler J. Pharmacokinetics of SMS 201—995 in healthy subjects. Scand J Gastroenterol 1986;21 (suppl. 119):65—72.
French abortion pill reinstated. Lancet 1988;2:1153/ Editorial.
Haak HP, de Keizer RJW, Hagenouw-Taal JCW, et al. Successful mifepristone treatment of recurrent inoperable meningioma. Lancet 1990;336:124-125.
Hill NCW, Ferguson J, MacKenzie 1Z. The efficacy of oral mifepristone (R.U-38, 486) with a prostaglandin E, analog vaginal pessary for the termination of early pregnancy: Complications and patient acceptability. Am J Obstet Gynecol 1990;162:414-417.
Lamberts SWJ, Tanghe SU, Avezaat CJJ, et al. Mifepristone (RU486) treatment of meningiomas. J Neurol Neu-rosurg Psychiatry 1992;55:486-490.
Mifepristone: Application for UK license. Lancet 1990; 336:240. Editorial.
Segal SJ. Mifepristone (RU-486). N Engl J Med 1990;322:691-693.
Silvestre L, Dubois C, Renault M, et al. Voluntary interception of pregnancy witn mifepristone (Ru-486) as a prostaglandin analogue: A large-scale French experience. N Engl J Med 1990;322:645-648.
Urquhart DR, Templeton AA. Mifepristone (RU-486) and second trimester termination. Lancet 1987;2:1405.
Van der Lely A-J, Foeken K, Van der Mast RC, Lamberts SWJ. Rapid reversal of acute psychosis in the Cushing’s syndrome witn the cortisol-receptor antagonist mifepristone (RU-486). Ann Intern Med 1991; 114:143—144.
Baulieu EE. RU-486 as an antiprogesterone steroid: From receptor to contragestion and beyond. JAMA 1989;262:1808-1814.
Paeyron R, Aubeny E, Targosz V, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993;328:1503-1513.
Reproductive health and mifepristone. Lancet 1990;336:1480-1481. Editorial.
Lim RH, Lees PAR, Bjomsson S, et al. Normal development after exposure to mifepristone in early pregnancy. Lancet 1990;336:257-258.
Guillebaud J. Medical termination of pregnancy combined with prostaglandin RU-486 is effective. Br Med J 1990;301:352-354.
Brogden RN, Goa KL, Faulds D. Mifepristone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1993;45:384-409.
Norman J. Antiprogesterones. Br J Hosp Med 1991;45:372-375.
Deraedt R, Bonnat C, Busigny M, et al. Pharmacokinetics of RU 486. In: Beaulieu EE, Egal SD, eds. The Antiprogestin Steroid RU 486 and Human Fertility Control. New York: Plenum, 1985:103—132.
Swabor HL, Wang G, Aaedo AR, et al. Plasma levels of antiprogestin RU 486 following oral administration in non-pregnant and early pregnant women. Contraception 1986;34:469-481.
World Health Organization Task Force on Post-ovula-tory Method of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. Br Med J 1993;307:532-537.
Henrion R. RU-486 abortions. Nature 1989;338:110.
Herrmann W. The clinical use of RU-486 (mifepristone). Res Reprod 1989;21 (4):3.
Grunberg S, Weiss M, Spitz I, Dubois C. Effects of long term oral treatment with RU-486 on unresectable meningioma. Eur J Cancer 1990; 172.
Spitz IM, Bardin CW. Mifepristone (RU486): A modulator of progestin and glucocorticoid action. N Engl J Med 1993;329:404-412.
Product Labeling: Metyrapone. С86-6. Summit, NJ: Ci-ba Pharmaceutical, March 1986.
Signs, symptoms and treatment of acute poisoning. Basel: Ciba-Geigy, 1976:94-95.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:776.
Leisti S. Evaluation of 3 hour metyrapone test in children and adolescents. Clin Endocrinol 1977;6:305-320.
Sprunt JG, Browning MCK, Hannah DM. Some aspects of the pharmacology of metyrapone: Mem Soc Endocrinol 1968;17:193-203.
Jubiz W, Matsukura S, Meikle AW, et al. Plasma metyrapone, adrenocorticotropic hormone and deoxycortisol levels sequential changes during oral and intravenous metyrapone administration. Arch Intern Med 1987;125:468-471.
Kennedy JA, Hartman N, Sbriglio R, et al. Metyrap-oneinduced withdrawal symptoms. Br J Addict 1990;85:1133-1140.
Harries-Jones R, Overstall P. Metyrapone-induced alopecia. Postgrad Med J 1990;66:584.
Usansky JI, Damani LA, Houston JB. The pharmacokinetics of metyrapone in the rat. J Pharm Pharmcol 1984;36(suppl.):280.
Bailey CJ. Metformin — An update. Gen Pharmacol 1993;14:1299-1309.
Product Information: Glucophage (metformin hydrochloride). Bristol—Myers—Squibb, F5-K001, May 1995.
McLellan J. Recovery from metformin overdose. Diabetic Med 1985;2:410-411.
Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (V.A-demethyl-biguanide) in man. Clin Pharmacol Ther 1978;24:683-693.
Schaffalitsky de Muckadell OB, Mortensen H, Lyngsoe J. Metabolic effects of glucocorticoid and ethanol administration in phenformin and metformin-treated obese diabetics. Acta Med Scand 1979;206:269-273.
DeFronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-549.
Crofford OB. Metformin. N Engl J Med 1995;333:588— 589.
Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12:235-246.
Charles BG, Jacobsen NW, Ravencroft PJ. Rapid liquid chromatographic determination of metformin P in plasma and urine. Clin Chem 1981;27:434-436.
Campbell IW. Metformin and the sulphonylureas: The comparative risk. Horm Metab Res Suppl Ser 1984;15:105-111.
Ewy GA, Pabico RC, Maher JF, et al. Lactic acidosis associated with phenformin therapy and localized tissue hypoxia. Ann Intern Med 1963;59:878-883.
Althoff P-H, Fassbinder W, Neubauer M, et al. Hamo-dialyse bei der Behandlung der Biguanid-induzierten Lactacidose. Dtsch Med Wochenschr 1978; 103: 61 — 68.
Marri G, Cozzolino G, Palumbo R. Glucagon in sulpho-nylurea hypoglycemia. Lancet 1968;1:303-304.
Schafer G. Some new aspects on the interaction of hypoglycemia producing biguanides with biological membranes. Biochem Pharmacol 1976;25:2015-2034.
Taylor JR, Sherratt HSA, Davies DM. Intramuscular or intravenous glucagon for sulphonyhirea hypoglycaemia. Eur J Clin Pharmacol 1978;14:125-127.
Johnson HK, Waterhouse C. Lactic acidosis and phenformin. Arch Intern Med 1968;122:367-370.
Medical Staff Conference: Lactic acidosis. Calif Med 1969;110:330-336.
Gonadotrophin-releasing hormone analogues for advanced prostate cancer. Drug Ther Bull 1992;30( 17):65—67.
Veronesi A, Re GL, Bo VD, et al. Buserelin treatment of advanced prostatic carcinoma: Prognostic factor analysis. Eur Urol 1992;21:274-279.
Herman A, Ron-El R, Golan A, et al. Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophic-releasing hormone. Hum Reprod 1992;7:465-468.
Reichel RP, Schweppe K-N. Goserlin (ZoladexR) depot in the treatment of endometriosis. Ferti) Steril 1992;57:1197-1202.
Dowsett M, Mehta A, Mansi J, Smith IE. A dose-comparative endocrine clinical study of leuprorelin in premenopausal breast cancer patients. Br J Cancer 1990;62:834-837.
Derman SG, Adashi EY. Adverse effects of fertility drug. Drug Saf 1994;11:408-421.
Rabe T, Feldmann K, Grunwald K, Runnebaum B. Three cases of hepatocellular carcinoma among cyprot-erone users. Lancet 1994;344:1567-1568.
Rabe T, Feldmann K, Grunwald K, Runnebaum B. Liver tumours in women on oral contraceptives. Lancet 1994;344:1868-1869.
Bosisio Е, Kienle MG, Galli G, et al. Defective hydroxylation of phenformin as a determinant of drug toxicity. Diabetes 1981;30:644-649.
Asmal AC, Marble A. Oral hypoglycaemic agents: An update. Drugs 1984;28:62-78.
Peden N, Newton RW, Feely J. Oral hypoglycaemic agents. Br Med J 1983;286:1564-1567.
KorhonerT, Idanpaan-Heikkila J, Aro A. Biguanide induced lactic acidosis in Finland. Eur J Clin Pharmacol 1979;15:407-410.
Biron P. Metformin monitoring. Can Med Assoc J 1980;123:11-12.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:289—290.
Butterfield WJH, Whichelow MJ. The hypoglycemic action of phenformin: Effect of phenformin on glucose metabolism in peripheral tissues. Diabetes 1962;11:281 — 286.
Haeckel R, Haeckel H. Inhibition of gluconeogenesis from lactate by phenylethylbiguanide in the perfused guinea pig liver. Diabetologia 1972;8:117—124.
Czyzyk A, Tawecki J, Sadowski J, et al. Effect of bigua-nides on intestinal absorption of glucose. Diabetes 1968;17:492-498.
Schafer G. Some new aspects on the interaction of hypoglycemia producing biguanides with biological membranes. Biochem Pharmacol 1976;25:2015-2034.
Tomkin GH, Hadden DR, Weaver JA, et al. Vitamin B,2 status of patients on long term metformin therapy. Br Med J 1971;2:685-687.
Tomkin GH. Malabsorption of vitamin B,2 in diabetes patients treated with phenformin: A comparison with metformin. Br Med J 1973;3:673-675.
Davidson MB, Bozarth WR, Chailoner DR, et al. Phenformin hypoglycemia and lactic acidosis: Report of attempted suicide. N Engl J Med 1966;275:886-888.
Fajans SS, Moorhouse JA, Doorenbos H, et al. Metabolic effects of phenethylbiguanide in normal subjects and in diabetic patients. Diabetes 1960;9:194-201.
Lyngsoe J, Trap-Jensen J. Phenformin induced hypoglycaemia in normal subjects. Br Med J 1969;2:224-226.
Guttler F, Petersen FB, Kjeldsen K. Influence of phenformin on blood lactic acid in normal and diabetic subjects during exercise. Diabetes 1973;12:420-423.
Medical Staff Conference. Lactic acidosis. Calif Med 1969;110:330-336.
Dobson HL. Attempted suicide with phenformin. Diabetes 1965;14:811-812.
Pashley NRT, Felix RH. Phenformin overdose. Br Med J 1972;1:112-113.
Bingle JP, Storey GW, Winter JM. Fatal self poisoning with phenformin. Br Med J 1970;3:752.
Bergman U, Boman G, Wiholm B-E. Epidemiology of adverse drug reactions to phenformin and metformin. Br Med J 1978;2:464-466.
Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (A,jV-demethyl-biguanide) in man. Clin Pharmacol Ther 1978;24:683-693.
UG DP: A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes: V. Evaluation of phenformin therapy. Diabetes 1975;24(suppl. 1):65—184.
Klapholz L, Leitersdorf E, Weinrauch L. Leucocytoclas-tic vasculitis and pneumonitis induced by metformin. Br Med J 1986;293:483.
Huckabee WE. Lactic acidosis. Am J Cardiol 1963;12:663-666.
Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide treated diabetes: A review of 330 cases. Dia-betologia 1978;14:75-78.
Steiner DF, Williams RH. Actions of phenethylbigua-nide and related compounds. Diabetes 1959;8:154— 157.
Bernier GM, Miller M, Sporingate CS. Lactic acid and phenformin hydrochloride. JAMA 1963;184:43-46.
Tranquada RE, Bernstein S, Martin HE. Irreversible lactic acidosis associated with phenformin therapy. JAMA 1963;184:37-42.
Tucker GT, Casey C, Philips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mel-litus. Br J Clin Pharmacol 1981;12:235-246.
Paterson KR, Paice BJ, Lawson DH. Undesired effects of biguanide therapy. Adverse Drug React Acute Poison Rev 1984;3:173-182.
Wittman P, Haslbeck M, Bachmann W, et al. Lactaci-dosen bei Diabetikern unter Biguanidbehandlung. Dtsch Med Wochenschr 1977;102:5-10.
Walker RS, Lindon AL. Phenethyldiguanide: A dangerous side effect. Br Med J 1959;2:1005-1006.
McGavackTH. Discussion. Diabetes 1958;7:91-92.
Baruh S, Sherman L, Kolodny HD, et al: Fasting hypoglycemia. Med Clin North Am 1973;57:1441 — 1462.
Gin H, Larnaudie B, Aubertin J. Attempted suicide by insulin injection treated with artificial pancreas. Br Med J 1983;287:249-250.
Stumer WQ, Putnam RS. Suicidal insulin poisoning with nine day survival. Recovery in bile at autopsy by radioimmunoassay. J Forens Sci 1972;17:514-521.
Colsky LC, Campo AE, Gonzalez-Blanco M. Insulin and the suicidal patient. West J Med 1985; 143:679.
Levy WJ, Gardner D, Moseley J, et al. Unusual problems for the physician in managing a hospital patient who received a malicious insulin overdose. Neurosurgery 1985;17:992-996.
Orr DP, Eccles T, Lawlor R. et al. Surreptitious insulin administration in adolescents with insulin-dependent diabetes mellitus. JAMA 1986;256:3227-3230.
Wilson DE. Excessive insulin therapy: Biochemical effects and clinical repercussions: Current concepts of counterregulation in type 1 diabetes. Ann Intern Med 1983;98:219-227.
Shapiro DJ, Blumenkrantz MJ, Levin SR, et al. Absorption and action of insulin added to peritoneal dialysate in dogs. Nephron 1979;23:174-180.
Christensen NJ, Orskov H. The relationship between endogenous serum insulin concentration and glucose uptake in the forearm muscles of nondiabetics. J Clin Invest 1986;47:1262-1268.
Levine DF, Bulstrode C. Managing suicidal insulin overdose. Br Med J 1982;285:974-975.
Peden N, Newton RW, Feely J. Oral hypoglycaemic agents. Br Med J 1983;286:1564-1567.
Gerich JE. Sulfonylureas in the treatment of diabetes mellitus. 1985. Mayo Clin Proc 1985;60:439-443.
Jordan RM, Kanmer H, Riddle MR. Sulfonylurea induced factitious hypoglycemia. Arch Intern Med 1977;137:390-393. '
Scarlett JA, Mako ME, Rubenstein AH, et al. Factitious hypoglycemia: Diagnosis by measurement of serum C-peptide immunoreactivity and insulin binding antibodies. N Engl J Med 1977;297:1029-1032.
Crowson TW, Kriel RL. Hypoglycemia from inadvertent use of hypoglycemic agents. Ann Intern Med 1980;92:134.
Aderka D, Pinkhas J. Inadvertently induced hypoglycemia. JAMA 1978;240:1140.
Ahlquist DA, Nelson RL, Callaway CW. Pseudoinsulinoma syndrome from inadvertent tolazamide ingestion. Ann Intern Med 1980;93:281-282.
Berger W. 88 Schwere Hypoglykamiezwischenfalle unter der Behandlung mit Sulphonylharnstoffen. Schweiz Med Wochenschr 1971;71:1013-1022.
Alexander RW. Prolonged hypoglycemia following acetohexamide administration: Report of two cases with impaired renal function. Diabetes 1966;15:362-364.
Asplund K, Wiholm BE, Lithner F. Glibenclamide associated hypoglycaemia: A report on 57 cases. Diabeto-logia 1983;24:412-417.
Blohme G, Branegard B, Fahler M, et al. Glipizide induced severe hypoglycemia. Acta Endocrinol 1981;98(suppl. 245): 13.
Shen S, Bressler R. Clinical pharmacology of oral antidiabetic agents. N Engl J Med 1977;296:493-497.
Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents. Drugs 1981;22: 211-245, 295-320.
Skillman TG, Feldman JM. The pharmacology of sulfonylureas. Am J Med 1981;70:361-372.
Balant L. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin Pharmacokinet 1981 ;6:215— 241.
Asmal AC, Marble A. Oral hypoglycaemic agents: An update. Drugs 1984;28:62-78.
Campbell RK, Hansten PD. Metabolism of chlorpropamide, correspondence. Diabetes Care 1981 ;4:332.
Ings RMJ, Lawrence JR, McDonald A, et al. Glibenclamide pharmacokinetics in healthy volunteers: Evidence for zero order drug absorption. Br J Clin Pharmacol 1982; 13:264P—265P.
Sartor G. Melander A, Schersten B, et al. Comparative single dose kinetics and effects of four sulfonylureas in healthy volunteers. Acta Med Scand 1980;208:301-307.
Brown KF, Crooks MJ. Displacement of tolbutamide, glibenclamide and chlorpropamide from serum albumin by anionic drugs. Biochem Pharmacol I976;25:1175.
McKillop G, Fallon M, Slater SD. Possible interaction between heparin and a sulphonylurea a cause of prolonged hypoglycaemia. Br Med J 1986;293:1073.
Harris EL. Adverse reactions to oral antidiabetic agents. Br Med J 1971;3:29-30.
Seltzer HS. Severe drug induced hypoglycemia: A review. Compr Ther 1979;5:21-29.
Paice BJ, Paterson KR, Lawson DH. Undesired effects of the sulphonylurea drugs. Adverse Drug React Acute Poison Rev 1985;1:23-26.
Mandario LJ, Campbell PJ, Gottesman IS, Gerich JE. Abnormal coupling of insulin receptor binding in noninsulin dependent diabetes. Am J Physiol 1984;247:E688—E692.
Prendergast BD. Glyburide and glipizide: Second generation oral sulfonylurea hypoglycemic agents. Clin Pharm 1984;31:473-485.
Sharpe GWG. The adenylate—cyclase—cyclic AMP system in islets of Langerhans and its roles in the control of insulin release. Diabetologia 1979;16:196-289.
Melander A, Wahlin-Boll E. Clinical pharmacology of glipizide. Am J Med 1983;75(5B):41 — 45.
Shuman CR. Glipizide: An overview. Am J Med 1983;75(5B):55—59.
Kullavanijaya P. Recovery from overdose with glibenclamide. Br Med J 1970;4:53-54.
Sturgess NC, Ashford MLJ, Cook DL, et al. The sulphonyl receptor may be an ATP-sensitive potassium channel. Lancet 1985;2:474-475.
Meatherall RC, Green PT, Kennick S, et al. Diazoxide in the management of chlorpropamide overdose. J Anal Toxicol 1981;5:287-291.
Cowen DL, Burtis B, Youmans J. Prolonged coma after acetohexamide ingestion. JAMA 1967;201:155-156.
Greenberg B, Weihl C, Hug G. Chlorpropamide poisoning. Pediatrics 1968;41:145-147.
Sillence DO, Court JM. Glibenclamide induced hypoglycaemia. Br Med J 1975;3:490-491.
De Troyer A, Ectors M, Hubert JP. Chlorpropamide poisoning and diabetes insipidus. Lancet 1975;2:514.
Pavone L, Mollica F, Musumeci S, et al. Accidental glibenclamide ingestion in an infant: Clinical and electroencephalographic aspects. Dev Med Child Neurol 1980;22:366-371.
Scala-Barnett DM, Donoghue ER. Dispensing error causing fatal chlorpropamide intoxication in a non-dia-betic. J Forens Sci 1986;31:293-295.
Dall JLC, Conway H, McAlpine SG. Hypoglycaemia due to chlorpropamide. Scott Med J 1967;12:403-404.
Dowell RC, Mirie AH. Chlorpropamide poisoning in non-diabetics. Scott Med J 1972;17:305-309.
University Group Diabetes Program. A study of the effects of hypoglycemic agents in vascular complications in patients with adult onset diabetes: II. Mortality results. Diabetes 1970; 19(suppl. 2):785—830.
Feinstein AR. Clinical biostatistics: XXXV. The persistent clinical failures and fallacies of the UGPD study. Clin Pharmacol Ther 1976;19:78-93.
Shen S, Bressler R. Clinical pharmacology of oral antidiabetic agents. N Engl J Med 1977;296:787-793.
Hunton RB, Wells MV, Skipper EW. Hypothyroidism in diabetics treated with sulphonylurea. Lancet 1965;2:449-451.
Signorelli S. Tolerance for alcohol in patients on chlorpropamide. Ann NY Acad Sci 1959;74:900-903.
Singer DL, Hurwitz D. Long term experience with sul-fonylureas and placebo. N Engl J Med 1967;277:450— 456.
Jerntorp P, Aimer L-O, Ohlin H, et al. Plasma chlorpropamide: A critical factor in chlorpropamide alcohol flush. Eur J Clin Pharmacol 1983;24:237-242.
Glyburide and glipizide. Med Lett Drugs Ther 1984;26(669):79—80.
Ludman B, Mason P, Joplin GF. Dangerous misuse of sulphonylureas. Br Med J 1986;293:1287-1288.
Parker CE, Tisdell EJ. Chlorpropamide poisoning: A case report of accidental ingestion in a two year old child. Clin Pediatr 1963;2:185-186.
Cosnett JE. Tolbutamide overdosage and irreversible cerebral damage. S Afr Med J 1961;35:43-44.
Kaplinsky N, Frankl O. The significance of cerebrospinal fluid examination in the management of chlorpropamide induced hypoglycemia. Diabetes Care 1980;3:248-249.
Lilien LD, Pildes RS, Srinivasan G, et al. Treatment of neonatal hypoglycemia with minibolus and intravenous glucose infusion. J Pediatr 1980;97:295-298.
Davies DM, MacIntyre A, Millar EJ, et al. Need for glucagon in severe hypoglycaemia induced by sulphonylurea drugs. Lancet 1967;1:363-364.
Davies DM. Glucagon in sulphonylurea hypoglycaemia. Lancet 1968; 1:1154.
Johnson SF, Schade DS, Peake GT. Chlorpropamide induced hypoglycemia: Successful treatment with diazoxide. Am J Med 1977;63:699-803.
Taylor JR, Sherratt HSA, Davies DM. Intramuscular or intravenous glucagon for sulphonylurea hypoglycaemia. Eur J Clin Pharmacol 1978;14:125-127.
Marri G, Cozzolino G, Palumbo R. Glucagon in sulphonylurea hypoglycaemia? Lancet 1968;1:303-304.
Altszuler N, Hampshire J, Moraru E. On the mechanism of diazoxide induced hyperglycemia. Diabetes 1977;26:931-935.
Huff BB, ed. Physicians’ Desk Reference. 49th ed. Montvale, NJ: Medical Economics, 1995:2261—2263.
Bobzien SF 111. Author’s reply: Treatment of drug induced hypoglycemia. Ann Emerg Med 1980;9:233.
Palatnick W, Meatherall RC, Tenenbein M. Clinical spectrum of sulfonylurea overdose and experience with diazoxide therapy. Arch Intern Med 1991;151:1859— 1862.
Neuvonen PJ, Karkkainen S. Effects of charcoal, sodium bicarbonate and ammonium chloride on chlorpropamide kinetics. Clin Pharmacol Ther 1983;33:386-393.
Spiller HA, Villalobos D, Krenzelok EP, et al. Prospective multicenter study of sulfonylurea ingestion in children. Clin Toxicol 1995;33:475-485 (Abstract 60).
Neuvonen PJ, Kannisto H, Hirvisalo EL. Effect of activated charcoal on absorption of tolbutamide and valproate in man. Eur J Clin Pharmacol 1983;24:243-246.
Kannisto H, Neuvonen PJ. Adsorption of sulfonylureas onto activated charcoal in vitro. J Pharm Sci 1984;73:253-256.
Forman BH, Feeney E, Boas L. Drug induced hypoglycemia. JAMA 1974:229:522.
Vukmir RB, Yealy DM. Glucagon: Prehospital therapy for hypoglycemia. Ann Emerg Med 1989; 18:479.
Boyle PJ, Justice K, Krentz AJ, et al. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdose. J Clin Endocrinol Metab 1993;76:752-756.
Derman SG, Adashi EY. Adverse effects of fertility drugs. Drug Saf 1994;11:408-421.
Giusti RM, Iwamoto K, Hatch EE. Diethylstilbestrol revisited: A review of the long-term health effects. Ann Intern Med 1995;122:778-788.
Noller KL. Role of colposcopy in the examination of di-ethylstilbestrol-exposed women. Obstet Gynecol Clin North Am 1993;20:165-176.
Levine RU, Berkowitz KM. Conservative management and pregnancy outcome in diethylstilbestrol-exposed women with and without gross genital tract abnormalities. Am J Obstet Gynecol 1993;169:1125-1129.
Roberge RJ, Martin TG, DelbridgeTR. Intentional massive insulin overdose. Ann Emerg Med 1993;22:228— 234.
Birkinshaw VJ, Gurd MR, Randall SS. Investigations in a case of murder by insulin poisoning. Br Med J 1958;2:463-468.
Scarlett JA, Makoi ME, Robenstein AH, et al. Factitious hypoglycemia: Diagnosis by measurement of serum C-peptide immunoreactivity and insulin binding antibodies. N Engl J Med 1977;297:1029-1032.
Bauman WA, Yalow RS. Insulin as a lethal weapon. J Forens Sci 1981;26:594-598.
Beardwood JT. A case of attempted suicide with insulin. JAMA 1934;102:765-766.
Jordan H. Unusual sequel of a large overdose of insulin. Br Med J 1946;1:276.
Vogl A, Youngwirth SH. The effects of a single dose of 2,000 units of Protamine Zinc Insulin taken by a diabetic patient with suicidal intent. N Engl J Med 1949;241:606-609.
Nicholson WA. Attempted suicide with insulin. Practitioner 1965;195:790-793.
Stapczynski JS, Haskell RJ. Duration of hypoglycemia and need for intravenous glucose following intentional overdoses of insulin. Ann Emerg Med 1984; 13:505—511.
Lindgren L. Enormous dose of insulin with suicidal intent. Acta Med Scand 1960;167:297-300.
Martin FIR, Hansen N, Warne GL. Attempted suicide by insulin overdose in insulin requiring diabetics. Med J Aust 1977;1:58-60.
Gale E. Hypoglycemia. Clin Endocrinol Metab 1980;9:461-475.
Critchley JAJH, Proudfoot AT, Boyd SG, et al. Deaths and paradoxes after intentional insulin overdosage. Br Med J 1984;289:225.
Munck O, Quaade F. Suicide attempted with insulin. Dan Med Bull 1963;10:139-141.
Service FJ. Hyperglycemic disorders. N Engl J Med 1995;332:1144-1152.
Transferring diabetic patients to human insulin. Lancet 1989;1:762-763. Editorial.
Peacock I, Tattersail RD, Taylor A, et al. Effects of new insulins on insulin and C-peptide antibodies, insulin dose and diabetic control. Lancet 1983;1:149-152.
Gorden P. Human insulin and hypoglycemia. N Engl J Med 1990;322:1007-1008.
Jick SS, Derby LE, Gross KM, Jick H. Hospitalizations because of hypoglycemia in uses of animal and human insulins: 2. Experience in the United States. Pharmacotherapy 1990;10:398-399.
Williams RH, Porte D Jr. The pancreas. In: Williams RH, ed. Textbook of Endocrinology. 5th ed. Philadelphia: WB Saunders, 1974:523-527, 591-597, 627-659.
Katzen HM, Tietze F, Stetten D Jr. Further studies on the properties of hepatic glutathione insulin transhydrogenase. J Biol Chem 1973;238:1006—1011.
Berson SA, Yalow RS. Insulin in blood and insulin antibody. Am J Med 1966;40:676-690.
McEvoy GK, ed. Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:2046— 2056.
Campbell IW, Ratcliffe JG. Suicidal insulin overdose managed by excision of insulin injection site. Br Med J 1982;285:408-409.
Chaplin S, Sanders GL, Smith JM. Drug excretion in human breast milk. Adverse Drug React Acute Poison Rev 1982;1:255-287.
Simon R. Management of prolonged coma and determination of brain death: Symposium on poisonings and toxicological emergencies. Presented at San Francisco Bay Area Regional Poison Center, June 24, 1983:33—47.
Bobzien WF III. Suicidal overdoses with hypoglycemic agents. JACEP J Am Coll Emerg Physicians 1979;8:467-470.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Hospital Formulary Service, 1994:2083-2086.
Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985;103:228-239.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:952—953.
Ziai F, Walter F, Rosenthal IM. Treatment of central diabetes insipidus in adults and children with desmopressin: A synthetic analogue of vasopressin. Arch Intern Med 1978;138:1382-1385.
Robertson GL, Harris A. Clinical use of vasopressin analogues. Hosp Pract 1989;24(10): 114—139.
Stasior D, Kikeri D, Duel B, Seifter JL. Nephrogenic diabetes insipidus responsive to indomethacin plus DDAVP. N Engl J Med 1991;324:850-851.
Mannucci PM. Desmopressin: A nontransfusional form of treatment for congenital and acquired bleeding disorder. Blood 1988;72:1449-1455.
Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand’s disease. Ann Intern Med 1991;114:563-568.
Soslau G, Schwartz AB, Putatunda B, et al. Desmo-pressininduced improvement in bleeding times in chronic renal failure patients correlates with platelet serotonin uptake and ATP release. Am J Med Sci 1990;300:372— 379.
Quitt M, Froom P, Veisler A, et al. The effect of desmopressin on massive gastrointestinal bleeding in hereditary telangiectasia unresponsive to treatment with cryoprecipitate. Arch Intern Med 1990;150:1744-1746.
Meadow SR, Evans JHC. Desmopressin for enuresis: Useful in the short term. BrMedJ 1989;298:1596-1597.
Desmopressin for nocturnal enuresis. Med Lett Drugs Ther 1990;32(816):38—39.
Baldrie LA, Ault BH, Chesney CM, Stapleton FB. Intravenous desmopressin acetate in children with sickle tract and persistent macroscopic hematuria. Pediatrics 1990;86:238-243.
Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989;31:199-202.
Kohler M, Harris A. Pharmacokinetics and haematological effects of desmopressin. Eur J Clin Pharmacol 1988;35:281-285.
Anderson K-E, Amer B, Furst E, Hedner P. Antidiuretic responses to hypertonic saline infusion, water deprivation, and a synthetic analogue of vasopressin in patients with hereditary, hypothalamic diabetes insipidus. Acta Med Scand 1974;195:17-23.
Davison JM, Gilmore EA, Durr J, et al. Altered osmotic thresholds for vasopressin secretion and thirst in human pregnancy. Am J Physiol 1984;246:F105— F109.
Desmopressin and arterial thrombosis. Lancet 1989;1:938-939. Editorial.
Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988;318:121.
McLeod BC. Myocardial infarction in a blood donor after administration of desmopressin. Lancet 1990;336:1 137-1138.
Weinstein RE, Bona RD, Altman AJ, et al. Severe hyponatremia after repeated intravenous administration of desmopressin. Am J Hematol 1989;32:258-261.
Bamford MFM, Cruickshank G. Dangers of intranasal desmopressin for nocturnal enuresis. J R Coll Gen Pract 1989;39:345-346.
Simmonds EJ, Mahony MJ, Littlewood JM. Convulsions and coma after intranasal desmopressin in cystic fibrosis. Br Med J 1988;297:1614.
Shepherd LL, Hutchinson RJ, Worden EK, et al. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr 1989;114:470-472.
Cone A, Riley R. DDAVP and pulmonary edema. Anaesthesia Intens Care 1994;22:502-503.
Beach BS, Beach RE, Smith LR. Hyponatremic seizures in a child treated with desmopressin to control enuresis: A rational approach to fluid intake. Clin Pediatr 1992;31:566-570.
Humphries JE, Siragy H. Significant hyponatremia following DDAVP administration in a healthy adult. Am J Hematol 1993;44:12-15.
Harris AH, Nilsson IM, Wagner ZG, Alkner U. Intranasal administration of peptides: Nasal disposition, biological response and absorption of desmopressin. J Pharm Sci 1986;75:1085-1088.
Donaldson VH. Danazol. Am J Med 1989;87:3—49N— 3-50N.
Dmowski WP. Danazol: Steroid derivative with multiple and diverse biological effects. Br J Clin Pract 1988;24:343-347.
Mylvaganam R, Ahn YS, Garcia RO, et al. Very low dose danazol in idiopathic thrombocytopenic purpura and its role as an immune modulator. Am J Med Sci 1989;298:215-220.
Stadlmauer EA, Cassileth PA, Edelstein M, et al. Danazol treatment of myelodysplastic syndrome. Br J Haematol 1991;77:502-505.
Noel P, Solberg LA Jr. Myelodysplastic syndromes: Pathogenesis, diagnosis and treatment. Crit Rev Oncol/ Hematol 1992;12:193-215.
Potts GO, Schane HP, Edelson J. Pharmacology and pharmacokinetics of danazol. Drugs 1980;19:321-331.
Davison C, Banks W, Fritz A. The absorption, distribution and metabolic fate of danazol in rats, monkeys and human volunteers. Arch Int Pharmacodyn 1976;221:294-310.
Marshall E. The drug of champions. Science 1988;242:183-184.
Brunskill PJ. The effects of fetal exposure to danazol. Br J Obstet Gyenecol 1992;99:212-215.
Kingsbury AC. Danazol and fetal masculinization: A warning. Med J Aust 1985;143:410-411.
Silva MO, Reddy KP, McDonald T, et al. Danazol-in-duced cholestasis. Am J Gastroenterol 1989;84:426— 428.
Middleton C, McCaughan GW, Pointer DM, et al. Danazol and hepatic neoplasm: A case report. Aust NZ J Med 1989;19:733-735.
Fermand JP, Levy Y, Bouscary D, et al. Danazol-in-duced hepatocellular adenoma. Am J Med 1990;88:529-530.
Qaseen T, Jafri W, Khurshod M, Kahn H. Cholestatic jaundice associated with danazol therapy. Postgrad Med J 1992;68:984-986.
Spooner JB. Classification of side-effects to danazol therapy. J Int Med Res 1977;5(suppl. 3): 15—17.
Peterson JE, King ME, Banks WF, et al. Radioimmunoassay for danazol in human and monkey plasma. J Pharm Sci 1978;67:1425-1432.
Seifer DB, Freedman LN, Cavender JR, Baker RA. Insulin-dependent diabetes mellitus associated with danazol. Am J Obstet Gynecol 1990;162:474-475.
Bray GP, Tredger JM, Williams R. Resolution of dana-zol-induced cholestasis with 5-adenosylmethionine. Postgrad Med J 1993;69:237-239.
Nicholson AN. Zopiclone: A third generation of hypnotics. Pharmacology 1983;27(suppl. 2): 1—2.
Zopiclone: Another carriage in the tranquilizer train. Lancet 1990;335:507-508. Editorial.
Autret E, Maillard F, Autret A. Comparison of the clinical hypnotic effects of zopiclone and triazolam. Eur J Clin Pharmacol 1987;31:621-623.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:622.
Boissl K, Dreyfus JF, Delmotte M. Studies in the dependence-inducing potential of zopiclone and triazolam. Pharmacology 1983;27(suppl. 2):242—247.
Fleming JAE, Bourgouin J, Hamilton P. A sleep laboratory evaluation of the long-term efficacy of zopiclone. Can J Psychiatry 1988;33:103-107.
Wheatley P. Zopiclone: A non-benzodiazepine hypnotic: Controlled comparison to temazepam in insomnia. Br J Psychiatry 1985;146:312-314.
Aantaa R, Salmen M, Nyrte T. Difference in action between oral triazolam and zopiclone. Eur J Clin Pharmacol 1990;38:47-51.
Royer-Morrat MJ, Rambourg M, Jacob 1, et al. Determination of zopiclone in plasma using column liquid chromatography with ultraviolet detection. J Chroma-togr Biomed Appl 1992;581:291-299.
Boniface PJ, Martin IC, Nolan SL, Tan S. Development of an HPLC method of analysing for zopiclone in biological samples. In: Kaempe B, ed. Proceedings, 29th International Meeting, International Association of Forensic Toxicologists, Copenhagen, June 1991:334—339.
Gaillot J, Heusse P, Houghton GW, et al. Pharmacokinetics and metabolism of zopiclone. Pharmacology 1983;2(suppl.2):76—91.
Matheson I, Sunde HA, Garillot J. The excretion of zopiclone into breast milk. Br J Clin Pharmacol 1990;30:267-271.
Houghton GW, Dennis MJ, Templeton R, Martin BK. A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane®). Int J Clin Pharmacol Ther Toxicol 1985;23:97-100.
Treatment of insomnia. Drug Ther Bull 1990;28:98.
Kelly F, Cross NL, Sheffield F. Zopiclone. Lancet 1990;335:1033-1034.
Faii-weather DB, Hindmarch 1. Zopiclone: Cyclopyrrolone hydrate. J New Dev Clin Med 1992;10:1-10.
Wadworth AN, McTavish D. Zopiclone: A review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs Aging 1993;3:441-459.
Kuitunen T, Mattila MJ, Seppala T, et al. Actions of zopiclone and carbamazepine alone and in combination on human skilled performance in laboratory and clinical tests. Br J Clin Pharmacol 1990;30:453-461.
Tyrer P. Zopiclone. Br J Hosp Med 1990;44:264-265.
Blanchard JC, Boireau A, Garret C, Julou L. In vitro and in vivo inhibition by zopiclone of benzodiazepine binding in rodent brain receptors. Life Sci 1979;24:2417-2420.
Julou L, Bardone MC, Blanchard JC, et al. Pharmacological studies on zopiclone. Pharmacology 1983;27(sup-pl. 2):46—58.
Rendle MA. Zopiclone (Imovane®): Evaluation in general practice. NZ Med J 1990; 103:225.
Billiard M, Besset A, de Lustrac C, Brussaud L. Doseresponse effect of zopiclone on night sleep and in nighttime and daytime functioning. Sleep 1982;10(suppl. 1):27—34.
Anderson A. Imovane (zopiclone). NZ Med J 1989; 102:647.
Dorian P, Sellers EM, Kaplan H, Hamilton C. Evaluation of zopiclone physical dependence liability in normal volunteers. Pharmacology 1983;27(suppL 2):228—234.
Thakore J, Dinan TG. Physical dependence following zopiclone usage: A case report. Hum Psychopharmacol 1992;7:143-145.
Sutherland JC. Imovan and narcotic addiction. NZ Med J 1991 ;104:103.
Vertraete A, Deros M, Buysse A-M. Measurement of serum zopiclone concentration by HPLC in cases of acute poisoning. Clin Chem 1990;36:1047.
Regouby Y, Delomez G, Tisserant A. First degree atrioventricular block in self poisoning with zopiclone. Ther-apie 1990;45:161-166.
Guerault E, Garnier R, Efthymiou ML. Intoxication aigue voluntaire par la zopiclone: 239 cas. Therapie 1992;47:223. Abstract.
Ahmad Z, Herepath M, Ebden P. Diagnostic utility of flumazenil in coma with suspected poisoning. Br Med J 1991;302:292.
Lariviere L. Personal communication. Rhone-Poulenc Pharmaceuticals, October 23, 1992.
Jorens PG, Coucke V, Selala M, Schepens PJC. Fatal intoxication due to the combined use of heroin and py-rithyldione. Hum Exp Toxicol 1992;11:296-297.
Langer-Groetzbach R, Martens V, Hochrein H. Chro-nische intoxikation mit pyrithyldine. Notfallmedizin 1985;11:1410-1411.
Langtry HD, Benfield Р. Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40:291-313.
Meram D, Descotes J. Intoxication aigue par le zolpidem. Rev Med Intern 1989; 10:466.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:622.
Fullerton T, Frost M. Focus on zolpidem: A novel agent for the treatment of insomnia. Hosp Formul 1992;27:773-791.
Physicians’ Desk Reference. 49th ed. Montvale, NJ: Medical Economics, 1995:2304—2307.
Wheatley D. Zolpidem: A new imidazopyridine hypnotic. Psychopharm Bull 1989;25:124-127.
Lheureux P, Debailleul G, De Witte O, Askenazi R. Zolpidem intoxication mimicking narcotic overdose: Response to flumazenil. Hum Exp Toxicol 1990;9:105— 107.
Guinebault P, Dubruc C, Hermann P, Thenot JP. High performance liquid chromatographic determination of zolpidem, a new sleep inducer, in biological fluids with fluorometric detection. J Chromatogr Biomed Appl 1986;383:208-211.
Thenot JP, Hermann P, Durand A, et al. Pharmacokinetics and metabolism of ZOLPIDEM in various animal species and in humans. In: Sauvanet JP, Langer SP, Morsel! RL, et al., eds. Imidazopyridines in Sleep Disorders. New York: Raven Press, 1988:139—153.
Pons G, Francoual C, Guillet P, et al. Zolpidem excretion in breast milk. Eur J Clin Pharmacol 1989;37:245— 248.
Nicolson AN, Pascoe PA. Hypnotic activity of an imi-dazopyridine (Zolpidem). Br J Clin Pharmacol 1986;21:205-211.
Gillin JC. The long and the short of sleeping pills. N Engl J Med 1991;324:1733-1735.
Maarek L, Cramer P, Attali P, et al. The safety and efficacy of zolpidem in insomniac patients: A long-term open study in general practice. J Int Med Res 1992;20:162-170.
Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E. Tolerance and withdrawal with zolpidem. Lancet 1993;342:374-375.
Gericke CA, Ludolph AC. Chronic abuse of zolpidem. JAMA 1994;272:1721-1722.
Ansseau M, Pitchot W, Hansenne M, Moreno AG. Psychotic reactions to zolpidem. Lancet 1992;339:809.
Oswald I. Triazolam syndrome 10 years on. Lancet 1989;2:451.
Debailleul G, Khalil FA, Lheureux P. HPLC quantification of zolpidem and prothipendyl in a voluntary intoxication. J Anal Toxicol 1991;15:35-37.
Garnier R, Guerault E, Muzard D, et al. Acute zolpidem poisoning: Analysis of 344 cases. Clin Toxicol 1994;32:391-404.
Naef MM, Forster A, Mahory A, et al. Flumazenil antagonizes the sedative action of zolpidem as new imida-zopyridine hypnotic. Anesthesiology 1989;71:A297.
Coutos DA, Dixon KF, Guthrie RM, et al. Nonlinear elimination of methyprylon (Noludar) in an overdosed patient: Correlation of clinical effects with plasma concentration. J Pharm Sci 1991;80:768-771.
Bailey DN, Jatlow Pl. Methyprylon overdose: Interpretation of serum drug concentrations. Clin Toxicol 1973;6:563-569.
Pancorbo AS, Palagi PA, Piecoro JJ, et al. Hemodialysis in methyprylon overdose: Some pharmacokinetic considerations. JAMA 1977;237:470-471.
Polin RA, Henry D, Pippinger CE. Peritoneal dialysis for severe methyprylon intoxication. J Pediatr 1977;90:831-833.
Hayashida М, Nihira М, Kurose М, et al. Investigation of acute poisoning substances and its medico-legal practice of emergency analysis. Jpn J Leg Med 1985;39:539.
Miyauchi H, Ameno K, Fuke C, et al. Simultaneous determination of bromvalerylurea, bromodiethylacetylurea and allylisopropylacetylurea in serum and urine by high performance liquid chromatography with a multiwavelength UV detection and thin-layer chromatography. J Anal Toxicol 1991 ;123—125.
Kageyama Y, Yamauchi H, Nakayama S, et al. A case of bromvalerylurea intoxication associated with acute hepatitis and pancreatitis. Jpn J Med 1990;29:121.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:600.
Noirfalise A. Cinq cas de suspicion d’intoxication par 1’hexapropymate. J Eur Toxicol 1971;1:50-52.
Robbins G, Brown AK. Hexapropymate self-poisoning. Br Med J 1978;!: 1593.
Yamarellos P, Dimopoulos G. Three cases of hexapropymate (Merinax) poisoning. Bull Int Assoc Forens Toxicol 1979; 14(3):29—30.
Hassoun A, Van Binst R. Fatal hexapropymate intoxication. Bull Int Assoc Forens Toxicol 1979; 14(3):28.
Addlerfligel C. Personal communication: Report on 31 cases of hexapropymate poisoning. Brussels: Centre Antipoisons, November 2, 1989.
Gustaffson LL, Berg A, Magnusson A, et al. Hexapropymate self-poisoning causes severe and long lasting clinical symptoms. Med Toxicol Adverse Drug Experience 1989;4:295-301.
Bismuth С, Baud FJ, Muczynski J. Meprobamate hepatic metabolism: Its calculation in clinical toxicology. In: Proceedings, XVth Congress of European Association of Poison Centres and Clinical Toxicologists, Istanbul, May 24—27, 1992:67.
Trenque T, Lamiable D, Millart H, et al. Gas chromatographic determination of meprobamate in human plasma. J Chromatogr Biomed Appl 1993;615:343-346.
Lambert WE, de Leenheer AP, Van Bocxlaer JF, Piette M. Meprobamate intoxication: Rare and difficult to find. Clin Toxicol 1992;30:683-684.
Axelson JA, Hagaman JF. Meprobamate poisoning and pulmonary edema. N Engl J Med 1977;296:1481.
Lin J-L, Lim P-S, Lai B-C, Lin W-L. Continuous arteriovenous hemoperfusion in meprobamate poisoning. Clin Toxicol 1993;31:645-652.
Lopez A, Rebollo J. Benzodiazepine withdrawal syndrome after a benzodiazepine antagonist. Crit Care Med 1990;18:1480-1481.
Burr W, Sandham P. Death after flumazenil. Br Med J 1989;298:1713.
Herd B, Clarke F. Complete heart block after flumazenil. Hum Exp Toxicol 1991;10:289.
Lim AG. Death after flumazenil. Br Med J 1989;299:858-859.
Mapelli A, Bellinzona G, Lorini FL, et al. Diagnostic and therapeutic use of flumazenil in emergency medicine. Eur J Anaesth 1988;(suppl. 2):295—317.
Marty J. Nitenberg A. The use of midazolam and flumazenil in cardiovascular diagnostic and therapeutic procedures. Acta Anaesthesiol Scand 1990;34(suppl. 92):33— 34.
Seebach J, Jost R Flumazenil-induced psychotic disorder in hepatic encephalopathy. Lancet 1992;339:488— 489.
Abernethy DR, Arendt RM, Lauven PM, Greenblatt DJ. Determination of RO 15-1788, a benzodiazepine antagonist, in human plasma by gas liquid chromatography with nitrogen-phosphorus detection. Pharmacology 1983;26:285-289.
Koppel C, Wagemann A, Tencze RJ. Identification of the benzodiazepine antagonist flumazenil in plasma and urine after treatment of patients with benzodiazepine overdose. In: Uges DRA, de Zeeuw RA, eds. Proceedings, International Association of Forensic Toxicologists, 25th International Meeting, Groningen, June 27—30, 7W326-334.
Kintz P, Mangin P. Plasma determination of flumazenil, a benzodiazepine antagonist, by immunotoxicology and by capillary gas chromatography/mass spectrometry. J Anal Toxicol 1991;15:202-203.
ParkGR, Podkowik Bl. Plasma concentrations of flumazenil during liver transplantation. Anaesthesia 1992;47:887-889.
Hart YM, Meinardi H, Sander JWAS, et al. The effect of intravenous flumazenil on electroencephalographic activity: Results of a placebo-controlled study. J Neurol Neurosurg Psychiatry 1991;54:305-509.
Pollard BJ, Masters AP, Bunting R. The use of flumazenil (Ancrate, RO 15-1788) in the management of drug overdose. Anaesthesia 1989;44:137-138.
Olsen KM, Pablo CS, Ackerman BH. Postoperative analgesic requirements following flumazenil administration. DICP Ann Pharmacother 1990;24:1159-1163.
Appel M, Bron HNL, Hooymans PM, Janknegt R. Efficacy of flumazenil in COPD patient with therapeutic diazepam levels. Lancet 1989; 1:392.
Wolff J. Cerebrovascular and metabolic effects of midazolam and flumazenil. Acta Anaesth Scand 1990;34(sup-pl. 92):75-77.
Pearson RC, McCloy RF, Morns P, Bardhas KD. Midazolam and flumazenil in gastroenterology. Acta Anaesthesiol Scand 1990;34(suppL 92):21— 24.
Gobeaux D, Sardnal F. Midazolam and flumazenil in ophthalmology. Acta Anesthesiol Scand 1990;34(suppl. 92):35—38.
Flache WE, Ritter J. Lack of adrenergic response to flumazenil: Reversal of midazolam sedation. Clin Pharmacol Ther 1988;43:149.
Fisher GC, Clapham MCC, Hutton P. Flumazenil in intensive care: The duration of arousal after an assessment dose. Anaesthesia 1991;41:413-416.
Lucas RE. Montgomery WS. Glutethimide withdrawal: The ethics of supply and demand. Aust NZ J Med 1992;22:708.
Sugarman JM, Paul Rl. Flumazenil: A review. Pediatr Emerg Care 1994;10:37-43.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:682.
Janssen U, Walker S, Maier K, et al. Flumazenil disposition and elimination in cirrhosis. Clin Pharmacol Ther 1989;46:317-323.
Benzodiazepine antagonist approved by FDA. Clin Pharm 1992;1:287-288. Editorial.
Galletly DC, Ure R, Turley A. Flumazenil: A twelvemonth survey on use in a New Zealand public hospital. Anaesth Intens Care 1990;18:229-233.
O’Sullivan GF, Wade DN. Flumazenil in the management of acute drug overdosage with benzodiazepines and other agents. Clin Pharmacol Ther 1987;42:254-259.
Grimm G, Katzenschlager R, Holzner F, et al. Effect of flumazenil in hepatic encephalopathy. Eur J Anaesth 1988;suppl. 2:147-149.
Grimm G, Ferenci P, Katzenschlager R, et al. Improvement of hepatic encephalopathy treated with flumazenil. Lancet 1988;2:1392-1394.
Basile AS, Gamma! SH. Evidence for the involvement of the benzodiazepine receptor complex in hepatic encephalopathy: Implications for treatment with benzodiazepine receptor antagonists. Clin Neuropharmacol 1988;11:401-422.
Jones EA, Basile AS, Mullen KD, Gammal SH. Flumazenil: Potential implications for hepatic encephalopathy. Pharmacol Ther 1990;45:331-343.
Jones EA, Skolnick P, Gammal SH, et al. The gamma-aminobutyric acid A (GABAa) receptor complex and hepatic encephalopathy: Some recent advances. Ann Intern Med 1989;110:532-546.
Jones EA, Gammal SH, Martin P. Hepatic encephalopathy: New light on an old problem. J Med 1988;69:857— 867.
Record CO. Neurochemistry of hepatic encephalopathy. Gut 1991;32:1261-1263.
Scollo-Lavizzari G, Steinmann E. Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-7788). Lancet 1985; 1:324.
Bosman DK, Van den Bults ACG, De Haan JG, et al. The effects of benzodiazepines, receptor antagonists and partial agonists in acute hepatic encephalopathy in the rat. Gastroenterology 1991;101:772-781.
Naef MM, Forster A, Nahory A, et al. Flumazenil antagonizes the sedative action of zolpidem, a new iminoazopyridine hypnotic. Anesthesiology 1989;4(3A):A297.
Hojer J, Baehrendtz S, Magnusson A, Gustafsson LL. A placebo-controlled trial of flumazenil given by continuous infusion in severe benzodiazepine overdosage. Acta Anaesthesiol Scand 1991;35:584-590.
Hojer J, Baehrendtz S. The effect of flumazenil (RO15-1788) in the management of self-induced benzodiazepine poisoning: A double-blind controlled study. Acta Med Scand 1988;224:357-365.
Hojer J, Baehrendtz S, Matell G, Gustafsson LL. Diagnostic utility of flumazenil in coma with suspected poisoning: A double blind randomised controlled study. Br Med J 1990;301:1308-1311.
Roald OK, Forsman M, Steen PA. Partial reversal of the cerebral effects of isoflurane in the dog by the benzodiazepine antagonist flumazenil. Acta Anaesthesiol Scand 1988;32:209-212.
Murayana T, Shingu K, Ogawa T, et al. Flumazenil does not antagonize halothane thiamylal or propofol anaesthesia in rats. Br J Anaesth 1992;69:61-64.
Votey SR. Flumazenil: A new benzodiazepine antagonist. Ann Emerg Med 1991;70:181-188.
Mora ST, Torjman A, White PF. Effects of diazepam and flumazenil on sedation and hypoxic ventilatory response. Anesth Analg 1989;68:473-478.
Sage DJ. Reversal of sedation with flumazenil in regional anaesthesia: A review. Eur J Anaesthesiol 1988;suppl. 2:201-207.
Whitman JG. Flumazenil: A benzodiazepine antagonist: Many uses possibly including withdrawal from benzodiazepines. Br Med J 1988;297:999-1000.
Whitman JG. The use of midazolam and flumazenil in diagnostic and short surgical procedures. Acta Anaesthesiol Scand 1990;34(suppl. 92): 16—20.
McKay AC, McKinney MS, Clarke RSJ. Effect of flumazenil on midazolam-induced amnesia. Br J Anaesth 1990;65:190-196.
Richard P, Autret E, Bardol J, et al. The use of flumazenil in a neonate. Clin Toxicol 1991;29:137-141.
Eldar I, Lieberman N, Shiber R, et al. Use of flumazenil for intraoperative arousal during spine fusion. Anaesth Analg 1992;75:580-583.
Donovan KL, Fisher DJ. Reversal of chloral hydrate overdose with flumazenil. Br Med J 1989;298:1253.
Ahmad Z, Herepath M, Ebden P. Diagnostic utility of flumazenil In coma with suspected poisoning. Br Med J 1991;302:292.
Lariviere L. Personal communication. Rhone-Poulenc Pharmaceuticals, October 21, 1992.
Saissy JM, Vitris M, Demaziere J, et al. Flumazenil counteracts intrathecal baclofen-induced central nervous system depression in tetanus. Anesthesiology 1991;76:1051-1053.
Scollo-Lavizzari G. The clinical anticonvulsant effect of flumazenil, a benzodiazepine antagonist. Eur J Anaesthesiol 1988;suppl. 2:129—138.
Scollo-Lavizzari G. The anticonvulsant effects of the benzodiazepine antagonist, RO15-1788: An EEG study in 4 cases. Eur Neurol 1984;23:1-6.
Zuber M, ElsasserS, Ritz R, Scollo-Lavizzari G. Flumazenil (AnexateR) in severe intoxication with carbamazepine (Tegretol"). Eur Neurol 1988:28:161 — 163.
Restall J, Johnston IG, Robinson DN. Flumazenil in ketamine and midazolam anaesthesia. Anaesthesia 1990;45:938-940.
Flukiger A, Hartmann D, Leishman B, Ziegler WH. Lack of effect of benzodiazepine antagonist flumazenil (RO 15-1788) on the performance of healthy subjects during experimentally induced ethanol intoxication. Eur J Clin Pharmacol 1988;34:273-276.
Clausen TG, Wolff J, Carl P, Theilgaard A. The effect of the benzodiazepine antagonist, flumazenil, on psychometric performance in acute ethanol intoxication in man. Eur J Clin Pharmacol 1990;38:233-236.
Lheureux P, Askenasi R. Flumazenil in acute alcohol intoxication: A randomized double blind study. In: Proceedings, Int Cong Clin Toxicol Pois Cont Ana! Toxicol, Lux Tox’90, Luxembourg, May 25, /99(9:488.
Short TG, Maling T, Galletly DC. Ventricular arrhythmia precipitated by flumazenil. Br Med J 1988;2906:1070-1071.
Bansky G, Meier PJ, Riederer E, et al. Effects of a benzodiazepine antagonist in hepatic encephalopathy in man. Hepatology 1987;7:1103.
La Fleche RF. Flumazenil. Clin Toxicol Rev 1990; 12(5): 1-2.
Weinbroum A, Halpern P, Geller E. The use of flumazenil in the management of acute drug poisoning: A review. Intens Care Med 1991; 17:S32—S38.
Amrein R, Leishman B, Bentzinger C, Roncer G. Flumazenil in benzodiazepine antagonism: Actions and clinical use in intoxications and anaesthesiology. Med Toxicol 1987;21:411-429.
Amrein R. Discussion. Eur J Anaesthesiol 1988;suppl. 2:123-125.
Amrein R, Hetzel W: Pharmacology of Dormicum" (midazolam) and Anexate" (flumazenil). Acta Anaesthesiol Scand 1990;34(suppl. 92):6—15.
Katz J A, Fragen RJ, Dunn KL. Flumazenil reversal of midazolam sedation in the elderly. Region Anesth 1991;16:247-252.
Klotz V, Kanto J. Pharmacokinetics and clinical use of flumazenil (RO15-1788). Clin Pharmacokinet 1988;14:1-12.
Klotz V, Ziegler G, Reimann N. Pharmacokinetics of the selective benzodiazepine antagonist RO 15-1788 in man. Eur J Clin Pharmacol 1984;27:115-117.
Klotz V. Drug interactions and clinical pharmacokinetics of flumazenil. Eur J Anaesthesiol 1988;suppl. 2: ЮЗ-108.
Basile AS, Hughes PD, Harrison PH, et al. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med 1991;325:475-478.
Breimer LTM, Hennis PJ, Burnt AGL, et al. Pharmacokinetics and EEG effects of flumazenil in volunteers. Clin Pharmacokinet 1991;30:491-496.
Kasson BJ. Flumazenil: A specific benzodiazepine antagonist. J Am Assoc Nurse Anaesth 1992;60:472-476.
Amrein R, Hetzel W. Pharmacology of drugs frequently used in ICU’s: Midazolam and flumazenil. Intensive Care Med 1991; 17:S 1 —S10.
Marshall DE, Haradona AN, Orcutt RH, et al. GC/MS method for the determination of flumazenil in plasma and urine. Res Common Substance Abuse 1991; 12:228— 236.
Van der Rijk CCD, Drost RH, Schalen SW, Schramel M. Pharmacokinetics of flumazenil in fulminant hepatic failure. Eur J Clin Pharmacol 1991;41:501.
Whitwan JG. Flumazenil: A benzodiazepine antagonist: Many uses, possibly including withdrawal from benzodiazepines. Br Med J 1988;297:999-1000.
Rodwell PJL, Maclaren HM, Hughes EW, et al. The pharmacokinetics of flumazenil used as a bolus and an infusion regimen in the treatment of major benzodiazepine self-poisonings. Ann Emerg Med 1992;21:471.
Geller E. Flumazenil in clinical medicine: Indications and precautions. Eur J Anaesthesiol I988;suppl. 2:325— 329.
Geller E, Halpern P, Chernilas J, et al. Cardiorespiratory effects of antagonism of diazepam sedation with flumazenil in patients with cardiac disease. Anesth Analg 1991;72:207-211.
Geller E, Niv D, Weinbrun A, et al. The use of flumazenil in the treatment of 34 intoxicated patients. Resuscitation 1988; 16(suppl.):S57— S62.
Stolarek 1H, Ford MJ. Acute dystonia induced by midazolam and abolished by flumazenil. Br Med J 1990;30:614.
Nutt D, Costello M. Flumazenil and benzodiazepine withdrawal. Lancet 1987;2:463.
Marchant B, Wray R, Leach A, Naina M. Flumazenil causing convulsions and ventricular tachycardia. Br Med J 1989;299:860.
Karavokivos KAT, Tsipis GB. Flumazenil: A benzodiazepine antagonist. DICP Ann Pharmacother 1990;24:976-981.
Weisman RS, Hoffman RS, Howland MA, Goldfrank L. Flumazenil’s effect on the isoniazid seizure threshold in mice. Vet Hum Toxicol 1992;34:345.
Lampi Y, Eshol Y, Gilad F, Saroua-Pinchas I. Chloral hydrate in intractable status epilepticus. Ann Emerg Med 1990;19:674-676.
Salmon AG, Kizer WW, Zeise L, et al. Potential carcinogenicity of chloral hydrate: A review. Clin Toxicol 1995;33:115-121.
Graham SR, Day RO, Lee R, Fulder GWO. Overdose with chloral hydrate: A pharmacological and therapeutic review. Med J Aust 1988;149:668-688.
Committee on Drugs and Committee on Environmental Health, American Academy of Pediatrics. Use of chloral hydrate for sedation in children. Pediatrics 1993;92:471-473.
Meyer E, Van Bocxiaer JF, Lambert WE, et al. Determination of chloral hydrate and metabolites in a fatal intoxication. J Anal Toxicol 1995;19:124-126.
Donovan KL, Fisher DJ. Reversal of chloral hydrate overdose with flumazenil. Br Med J 1989;298:1253.
Kovacs G, Gerau R, Dreyer J, et al. Bretylium in the treatment of chloral hydrate induced ventricular arrhythmias. Vet Hum Toxicol 1993;35:339.
Tischler Е. Intravenous chlormethiazole in the management of severe pre-eclampsia. Aust NZ J Obstet Gynaecol 1973;13:137-142.
Burmeister H, Ibe K, Beyer K-H. Klinik under toxicologic einer akuten chlormethiazole (DistraneurinR)-in-toxikation. Arch Toxikol 1966;22:137-149.
Mclnnes GT. Chlormethiazole and alcohol: A lethal cocktail. Br Med J 1987; 194:592.
Shaw GK. Chlormethiazole and alcohol: A lethal cocktail. Br Med J 1987;294:975.
Chich J. Delirium tremens. Br Med J 1989;298:3-4.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia.30th ed. London: Pharmaceutical Press, 1993:371.
Glatt MM. Chlormethiazole ("Heminevrin"). Prescribers J 1966;5:90-91.
Illingworth RN, Stewart MJ, Jarvie DR. Severe poisoning with chlormethiazole. Br Med J 1979;2:902-903.
Foster A. Sedatives for alcoholics. BrMedJ I977;l:1355.
Baselt RC, Cravey RH. Disposition of Toxic Drugs and Chemicals in Man. 3rd ed. Chicago: Year Book Medical, 1989:159-161.
Baxt R. Fatal chlormethiazole and alcohol poisoning. Bull Int Assoc Forens Toxicol 1974; 14(3):31—32.
Nation RL, Vine J, Triggs EJ, Learoyd B. Plasma level of chlormethiazole and two metabolites after oral administration to young and aged human subjects. Eur J Clin Pharmacol 1977;12:137-145.
Moore RG, Triggs EJ, Shanks CA, Thomas J. Pharmacokinetics of chlormethiazole in humans. Eur J Clin Pharmacol 1975;8:353-357.
Neuvonen PJ, Pentikainen PJ, Jostell KG, Syvalahti E. The pharmacokinetics of chlormethiazole in healthy subjects as affected by ethanol. Clin Pharmacol Ther 1981;29:268-269.
Linnoila M, Mattila MJ, Kitchell BS. Drug interactions with alcohol, Drugs 1979;18:299-311.
Horder JM. Fatal chlormethiazole poisoning in alcoholics. Br Med J 1978;1:693-694.
Flanagan RJ, LeeTD, Rutherford DM. Analysis of chlormethiazole, ethchlorvynol and trichloroethanol in biological fluids by gas-liquid chromatography as an aid to the diagnosis of acute poisoning. J Chromatogr 1978;153:473-479.
Ferner RE, Pottage A, Ryan DW, Bateman DN. Charcoalcolumn haemoperfusion does not significantly enhance chlormethiazole removal. Hum Toxicol 1986;5:367-368.
Yell RH. Ethychiorvynol overdose. Am J Emerg Med 1990;8:246-250.
Meier PJ, Wyss РА, Radovanovic DI. Differential acute overdose toxicity of various benzodiazepine derivatives. Vet Hum Toxicol 1993;35:338.
Drummer OH, Syrjanen ML, Cordner SM. Deaths involving the benzodiazepine flunitrazepam. Am J Forens Med Pathol 1993;14:238-243.
Cree JE, Meeger J, Hailey DM. Diazepam in labor: Its metabolism and effect on clinical condition and thermogenesis in the newborn. Br Med J 1973;4:251-260.
Roman TSR, Krishnamurthy L. Diazepam intoxication in neonates. Indian Pediatr 1993;30:377-379.
Reiter PD, Stiles AD. Lorazepam toxicity in a premature infant. Ann Pharmacother 1993;27:727-730.
Laegried L, Olegard R, Conradi N, et al. Congenital malformations and maternal consumption of benzodiazepines: A case control study. Dev Med Child Neurol 1990;32:432-444.
Bergman V, Boethius G, Swartling PG, et al. Teratogenic effects of benzodiazepine use during pregnancy. J Pediatr 1990;116:490-492.
Bergman V, Rosa FW, Baum C, et al. Effects of exposure to benzodiazepines during fetal life. Lancet 1992;340:694-696.
Dusci LJ, Good SM, Hall RW, Ilett KF. Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. Br J Clin Pharmacol 1990;29:123-126.
Sutton LR, Hinderliter SA. Diazepam abuse in pregnant women on methadone maintenance: Implications for the neonate. Clin Pediatr 1990;29:108-111.
Anderson PO, McGuire GG. Neonatal alprazolam withdrawal: Possible effect of breast feeding. DICP Ann Pharmacother 1989;23:614.
Wiley J, Wiley C. Benzodiazepine ingestions in children. Clin Toxicol 1995;33:475-486 (Abstract 87).
Gaudreault P, Guay J, Thivierge RL, Verdy 1. Benzodiazepine poisoning: Clinical and pharmacological concentrations and treatment. Drug Saf 1991;6:247-265.
French AP. Dangerously aggressive behavior as a side effect of alprazolam. Am J Psychiatry 1989; 146:276.
McCormick SR, Nielsen J, Jatlow Pl. Alprazolam overdose: Clinical findings and serum concentrations in two cases. J Clin Psychiatry 1985;416:247-248.
Munoz M, Johnson R. Suicide by alprazolam (ZanaxR). Calif Assoc Toxicol Newslett, Summer 1988:28—29.
Kintz P, Boukhabza A, Tracqui A, et al. Tissue disposition after bromazepam, secobarbital and amobarbital self poisoning. Bull I nt Assoc Forens Toxicol 1991.
Brehmer C, Hem PX. A fatal bromazepam poisoning. Bull Int Assoc Forens Toxicol 1992;24(4):21—22.
Kosnett M, Larson S, McCarthy T, Osterloh J. Investigation of an anion gap of minus 88 in a patient taking bromazepam. Clin Chem 1990;36:1040.
Minder El. Toxicity in a case of acute and massive overdose of chlordiazepoxide and its correlation to blood concentration. Clin Toxicol 1989;27:117-127.
Sandvik H. Clearance of paranoid schizophrenic delusions after diazepam. Lancet 1991;337:237-238.
Goenechea S, Brzezinka H, Holtz J. A fatal case involving diazepam. Bull Int Assoc Forens Toxicol 1988;20:19-20.
Van der Kleijn E, van Rossum JM, Mustens ETJM, Ri-jntjes NVM. Pharmacokinetics of diazepam in dogs, mice and humans. Acta Pharmacol Toxicol 1971;29:109-127.
Dumont D, Mathe D, Piva C. Poisoning by a new benzodiazepine estazolam (France). Med Leg Toxicol 1980;23:257-259.
Deleu D, de Keyser J. Flunitrazepam intoxication simulating a structure brainstem lesion. J Neurol Neurosurg Psychiatry 1987;50:236-237.
Heyndrickx B. Fatal intoxication due to flunitrazepam. J Anal Toxicol 1987; 11:278.
Garnier R, Medernach C, Haibach S, Fournier E. Agitation and hallucination in children with acute lorazepam poisoning: Report of 65 cases. Ann Pediatr''1:3:286—289. [in French).
Guterman B, Sebastian P, Sodha N. Recovery from alpha coma after lorazepam overdose. Clin Electroen-cephalogr 1981;12:205-208.
Bixler EO, Kalis A, Manfredi RC, et al. Next-day memory impairment with triazolam use. Lancet 1991;337:827-831.
Jeffrey DI, Whitfield MF. Lorazepam poisoning. Br Med J 1974;2:719.
Bogusz M. Fatal lidocaine and midazolam overdose in the course of diphenhydramine poisoning therapy. Bull Int Assoc Forens Toxicol 1992;22:32-33.
Crevat-Pisano P, Dragna S, Granthil C, et al. Plasma concentrations and pharmacokinetics of midazolam during anaesthesia. J Pharm Pharmacol 1986;38:578-582.
Lineaweaver WC, Anderson K, Hing DN. Massive doses of midazolam infusion for delirium tremens without respiratory depression. Crit Care Med 1988;16:294-295.
Marsch SCU, Schafer HG. Accidental intraarterial injection of midazolam through a 3-way stopcock in arterial line. Anesthetist 1990;39:337-338.
Taylor JW, Simon KB. Possible intramuscular midazolam-associated cardiorespiratory arrest and death. DICP Ann Pharmacother 1990;24:695-697.
Bergman I, Steeves M, Burchart G, Thompson A. Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fentanyl administration. J Pediatr 1991;119:644-649.
Murphy JV, Sawasky F, Marquardt KM, Harris DJ. Deaths in young children receiving nitrazepam. J Pediatr 1987;111:145-147.
Baselt RC, Cravey RH. Disposition of Toxic Drugs and Chemicals in Man. 3rd ed. Chicago: Year Book Medical, 1989:598-599.
Moshkowitz M, Pines A, Finkelstein A, et al. Skin blisters as a manifestation of oxazepam toxicity. Clin Toxicol 1990;28:383-386.
Marris HH III, Estes ML. Traveler’s amnesia: Transient global amnesia secondary to triazolam. JAMA 1987;258:945-946.
Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-1698.
New Halcion labeling. FDA Med Bull 1992;22( 1 ):7—8.
Wretlind M, Pilbrandt A, Sundwell A, Vessman J. Disposition of three benzodiazepines after single oral administration in man. Acta Pharmacol Toxicol 1977;40:28— 39.
Zileli MS, Teletor F, Deniz S, et al. Oxazepam intoxication simulating non-ketotic diabetic coma. JAMA 1986;21:1971.
Baktir G, Fisch HV, Huguenin P, Bircher J. Triazolam concentration effect relationships on healthy subjects. Clin Pharmacol Ther 1983;24:195-201.
Robins AJ. A fatality due to carbon monoxide poisoning associated with triazolam overdose. Bull Int Assoc Forens Toxicol 1990;20(3): 18—20.
Sunter JP, Bal TS, Cowan WK. Three cases of fatal triazolam poisoning. Br Med J 1988;297:719.
O’Dowd JJ. Fatal triazolam poisoning. Br Med J 1988:297:1048.
Olson KR, Yin L, Osterloh J, Tani A. Coma caused by trivial triazolam overdoses. Am J Emerg Med 1985;3:210-211.
The sudden withdrawal of triazolam: Reasons and consequences. Drug Ther Bull 1991;29:89-90.
Juergens SM. Problems with benzodiazepines in elderly patients. Mayo Clin Proc 1993;68:818-820.
Landry MJ, Smith DE, McDuff DR, Baughman OL III. Benzodiazepine dependence and withdrawal: Identification and medical management. J Am Board Fam Pract 1992;5:167-176.
Leung FW, Guze PA. Diazepam withdrawal. West J Med 1983;138:98-101.
Preskorn SH, Denner U. Benzodiazepines and withdrawal psychosis. JAMA 1977;237:36-38.
Higgitt AC, Lader MH, Fonagy P. Clinical management of benzodiazepine dependence. Br Med J 1985;291:688-690.
Busto U, Sellers EM, Naranjo CA, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986;315:854-859.
Smith DE, Wesson DR. Benzodiazepine dependency syndromes. J Psychoactive Drugs 1983;15:85-95.
Walsh JK, Schweitzer PK, Parwatikar S. Effects of lorazepam and its withdrawal on sleep, performance and subjective states. Clin Pharmacol Ther 1983;34:496— 500.
Ashton H. Benzodiazepine withdrawal: An unfinished story. Br Med J 1984;288:1135-1140.
Tyrer PJ. Benzodiazepines on trial. Br Med J 1984;288:1601-1602.
Mule SJ, Casella GA. Quantitation and confirmation of the diazolo- and triazolobenzodiazepines in human urine by gas chromatography/mass spectrometry. J Anal Toxicol 1989;13:179-184.
Wong Y-S, Lee C-W. Fatalities involving fast-acting benzodiazepines in Hong Kong. In: Kaemp B, ed. Proceedings, 29th International Meeting of International Association of Forensic Toxicologists Copenhagen, June /997:418-434.
Bonfiglio MF, Daste JF. Clinical significance of the ben-zodiazepine-theophylline interaction. Pharmacotherapy 1991;1 1:85-87.
Gallen JS. Aminophylline reversal of midazolam sedation Anesth Analg 1989;69:260-268.
Katz Y, Gavish M. Aminophylline reversal of diazepam intoxication. Lancet 1989;1:1990-1991.
Treatment of benzodiazepine dependence. Lancet 1987;1:78-79. Editorial.
Roy-Byrne PP. Benzodiazepine dependence. J Am Board Fam Pract 1992;5:245-247. Editorial.
Jay SJ, Johanson WG Jr, Pierce AK. Respiratory complications of overdose with sedative drugs. Am Rev Respir Dis 1975;112:591-598.
Glauser FL, Smith R. Physiologic and biochemical abnormalities in self induced overdosage. Arch Intern Med 1975;135:1468-1473.
Khantzian EJ, McKenna GJ. Acute toxic and withdrawal reactions associated with drug use and abuse. Ann Intern Med 1979;80:361-372.
Smith DE, Wesson DR. Phenobarbital technique for treatment of barbiturate dependence. Arch Gen Psychiatry 1971;24:56-60.
Toscano J, Kussin PS, Samuelson W, Fulkerson WJ. Pulmonary embolism complicating barbiturate overdose. Crit Care Med 1990;18:777-778.
Haider I, Matthew H, Oswald I. Electroencephalographic changes in acute drug poisoning. Electroencephalogr Clin Neurophysiol 1971;30:23-31.
Guterman B, Sebastian P, Sodha N. Recovery from alpha coma after lorazepam overdose. Clin Electroencephalogr 1986;12:205-208.
Carroll WM, Mastiglia FL. Alpha and beta coma in drug intoxication. Br Med J 1977;2:1518-1519.
Austin EJ, Wikus RJ, Longstreet WT Jr. Alpha coma with sedative overdose. Neurology 1989;38:156-157.
De BoerWB, Kendall РА, Breheny FX. Alpha coma and barbiturate poisoning. Anaesth Intens Care 1989;17:503-504.
McCarron MM, Schulze BW, Walberg CB, et al. Shortacting barbiturate overdosage correlation of intoxication score with serum barbiturate concentration. JAMA 1982;248:55-61.
Amitai Y, Degani Y. Treatment of phenobarbital poisoning with multiple dose activated charcoal in an infant. J Emerg Med 1990;5:450-499.
Veerman M, Espejo MG, Christopher MA, Knight M. Use of activated charcoal to reduce elevated serum phenobarbital concentration in a neonate. Clin Toxicol 1991;29:53-58.
Vale J A, Ruddock FS, Boldy DAR. Multiple doses of activated charcoal in the management of phenobarbitone and carbamazepine poisoning. Vet Hum Toxicol 1987;29(suppl. 2): 152.
Lindberg MC, Cunningham A, Lindberg NH. Acute phenobarbital intoxication. South Med J 1992;85:803— 807.
Boldy DAR, Vale JA, Prescott LF. Treatment of phenobarbitone poisoning with repeated oral administration of activated charcoal. Q J Med 1986;61:997-1002.
Kerwin R. Adverse reaction reporting and new antipsychotics. Lancet 1993;342:1440.
Laidlaw ST, Snowden J A, Brown MJ. Aplastic anemia and remoxipride. Lancet 1993;342:1244-1245.
Murphy PT, Sivakumaran M, Ghosh K, et al. Cytopenia and remoxipride. Lancet 1994:343:352—353.
Le Blaye I, Donatini В, Hall M, Krupp P. Acute overdosage with thioridazine: A review of the available clinical exposure. Vet Hum Toxicol 1993;35:147—150.
Hulisz DT, Dasa SL, Black LD, Heiselman DE. Complete heart block and Torsade de pointes associated with thioridazine poisoning. Pharmacotherapy I994;l4:239— 245.
Buckley NA, Whyte I A, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. Clin Toxicol 1995;33:199-204.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 29th ed. London: Pharmaceutical Press, 1989:775.
British National Formulas. Number 24, September 1992. Zuclopenthixol dihydrochloride, p. 153; zuclopenthixol decanoate, p. 155.
Viala A, Ba B, Durand A, Gouezo F, ef al. Comparative study of pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology 1988;94:293-297.
Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol and chlorpromazine in chronic schizophrenia: Chemically unrelated antipsychotics as therapeutic alternatives. J Nerv Ment Dis 1972;154:31-42.
Chakravarti SK, Muthu A. Muthu PK, et al. Zuclopenthixol acetate (5 % in Viscolea): Single dose treatment for acutely disturbed psychotic patients. Curr Med Res Opin 1990;12:58-65.
Aaes-Jorgensen T. Serum concentrations of cis(Z)- and rraflsffj-clopenthixol after administration of cis(Z)-clopenthixol and clopenthixol to human volunteers. Acta Psychiatr Scand 1986;64:64-77.
Aaes-Jorgensen T, Gravem A, Jorgensen A. Serum levels of the isomers of clopenthixol in patients given cis(Z)-clopenthixol or c/s’(Zj//ransf?J-clopenthixol. Acta Psychiatr Scand 1981 ;64(suppl. 294):70—77.
Matar AM, Abdel-Mawgoud M, Skov S. Zuclopenthixol: A new generation of antipsychotic drugs: An open clinical trial. J Clin Psychopharmacol 1990;10:283-287.
Amdisen A, Nielsen MS, Dencker SJ, et al. Zuclopenthixol acetate in ViscoleoR: A new drug formulation: An open Nordic multi-centre study of zuclopenthixol acetate in ViscoleoR in patients with acute psychoses including mania and exacerbation of chronic psychoses. Acta Psychiatr Scand 1987;75:99-107.
Gravem A, Eigen K. cfsfZJ-Clopenthixol: The neurolep-tically active isomer of clopenthixol: A presentation of five double-blind clinical investigations and other studies with cA(ZJ-clopenthixol (CisordinalR, ClopixolR). Acta Psychiatr Scand 1981 ;64(suppl. 294):5—12.
Gravem A, Bugge A. c/VZJ-Clopenthixol and clopenthixol in the treatment of acute psychoses and exacerbations of acute psychoses: A double-blind clinical investigation. Acta Psychiatr Scand 1981 ;64(suppl. 294): 13— 19.
Sechter D, Caillard V, Cuche H, Deniker P. Open clinical study of c/sfZJ-clopenthixol. Acta Psychiatr Scand 1981 ;64(suppl.294):20—24.
Heikkila L, Karsten D, Valii K. A double-blind clinical investigation of c/ifZJ-clopenthixol and clopenthixol in chronic schizophrenia patients. Acta Psychiatr Scand 1986;64(suppl. 29):25—29.
Heikkila L, Laitinen J, Vartianen H. c«YZ)-Clopentliixol and haloperidol in chronic schizophrenic patients: A double blind clinical multicentre investigation. Acta Psychiatr Scand 1981 ;64(suppL294):30—38.
Karsten D, Kivimaki T, Linna S-L, et al. Neuroleptic treatment of oligophrenic patients: A double-blind clinical multicentre trial of cL/Zj-clopciithixol and haloperidol. Acta Psychiatr Scand 1981 ;64(suppl. 294):39—45.
Gotestam KG, Ljunghall S, Olsson B. A double-blind comparison of the effects of haloperidol and cis(Z)-clopenthixol in senile dementia. Acta Psychiatr Scand 1981;64(suppl. 294):46—53.
Gotestam KG. A geriatric rating scale empirically derived from three rating scales for geriatric behaviour. Acta Psychiatr Scand 1981 ;64(suppl. 294):54—63.
Aaes-Jorgensen T. Serum concentrations of cis(Z)- and Zran.s/E)-clopenthixol after administration of cis(Z)-clopenthixol and clopenthixol to human volunteers. Acta Psychiatr Scand 1981 ;64(suppl. 294):64—69.
Larsen N, Prof Services. Personal communication, Copenhagen, Luncbeck and Co, January 6, 1993.
Amdisen A, Aaes-Jorgenson T, Thomsen NJ, et al. Serum concentrations and clinical effects of zuclopenthixol in acute disturbed, psychotic patients treated with zuclopenthixol acetate in Viscoleof Psychopharmacology 1986;90:412-416.
Aaes-Jorgensen T, Bjorndal F, Bartels U. Zuclopenthixol levels in serum and breast milk. Psychopharmacology 1986;90:417-418.
Jorgensen A, Aaes-Jorgensen T, Graven! A, et al. Zuclopenthixol decanoate in schizophrenia: Serum levels and clinical state. Psychopharmacology 1985;87:364-367.
Aaes-Jorgensen Т. Specific high-performance liquid chromatography method for estimation of cis(Z)- and trans(?7-isomers of clopenthixol and a A-dealkyl-metab-olite. J Chromatogr 1980;183:239-245.
Tas AC, van der Greef J, ten Noever de Brauw MC, et al. LC/MS determination of bromazepam, clopenthixol and reserpine in serum of a non-fatal case of intoxication. J Anal Toxicol 1986;10:46-48.
Bloch M, Gur E, Shaler AJ. Hypouricemic effect of zuclopenthixol: A potential marker of drug compliance? Psychopharmacology 1992; 109:377—378.
Colvin CL, Tankonow RM. Pimozide: Use in Tourette’s syndrome. Drug Intell Clin Pharm 1985;19:421-424.
Pinder RM, Brogden RM, Sawyer PR, et al. Pimozide: A review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 1976;12:1-40.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:610—611.
Opier LA, Feinberg SS. The role of pimozide in clinical psychiatry: A review. J Clin Psychiatry 1991;52:221 — 233.
Holmes VF. Treatment of nonsymptomatic hypochondriacal psychosis with pimozide in an AIDS patient. Am J Psychiatry 1989;164:554-555.
Debray P, Messerschmitt P, Longchamp D, Herbault M. The use of pimozide in pediatric psychiatry. Presse Med 1972;1:2917-2918.
Shapiro AK, Shapiro E, Fulop G. Pimozide treatment of tic and Tourette disorders. Pediatrics 1987;79:1032— 1039.
McCreadie RG, Heykants JJP, Chalmers A, Anderson AM. Plasma pimozide profiles in chronic schizophrenics. Br J Clin Pharmacol 1979;7:533-534.
Kline F, Burgoyne RW, Yamomoto J. Comparison of pimozide, trifluoroperazine as once-daily therapy in chronic schizoprenic outpatients. Curr Ther Res 1974;16:696-705.
Fulop G, Phillips RA, Shapiro AK, et al. ECG changes during haloperidol and pimozide treatment of Tourette’s disorder. Am J Psychiatry 1987;144:673-678.
Salness RA, Goetz CM, Gorman RL, et al. Two cases of pimozide ingestion. Vet Hum Toxicol 1992;34:334.
Michiels LJM, Heykants JJP, Knaeps AG, Janssen JAJ: Radioimmunoassay of the neuroleptic drug pimozide. Life Sci 1975;16:937-944.
Peclet C, Rousseau JJ, Gaudet M, Picotte P. Four cases involving pimozide. Bull Int Assoc Forens Toxicol 1991;21:26-28.
Krahenbuhl SI, Sauter B, Kupferschmidt H, et al. Reversible QT prolongation with torsade de pointes in a patient with pimozide intoxication. Am J Med Sci 1995;309:315-316. Case Report.
Physicians’ Desk Reference. 49th ed. Montvale, NJ: Medical Economics, 1995:2510—2513.
Tracqui A, Kintz Р, Jamey С, Mangin Р. Toxicological data in a fatality involving cyamemazine. J Anal Toxicol 1993;17:386-388.
Eyles DW, McLennan HR, Jones A, et al. Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin Pharm Ther 1994;56:512-520.
Yoshida I, Sakaguchi Y, Matsuishi T, et al. Acute accidental overdosage of haloperidol in children. Acta Pae-diatr 1993;82:855-880.
Lawson GM. Monitoring of serum haloperidol. Mayo Clin Proc 1994;69:189-190.
Sinaniotis CA, Spyrides P, Vlachos P, Papdatos C. Acute haloperidol poisoning in children. J Pediatr 1978;9:1038-1039.
McMullin MM, Selavka CM, Wheeler MT, et al. Forensic hair testing for haloperidol: A tale of two cases. In: Proceedings, American Academy of Forensic Sciences, 46th Annual Meeting, San Antonio, February 14—19, 1994: Abstract 3.
Deshaies G, Lanteri-Laura G, Fargeon A. The therapeutic use of levopromazine ih psychiatry. Ann Med Psychol 1958;5:965-979.
Lambert PA, Beaujard M, Achaintre A, et al. Therapeutic trials using a new phenothiazine derivative: Levome-promazine. Ann Med Psychol 1957;2:291-296.
Nasilowski W, Sybirska H, Gajdzinska H. Legal-medical and lexicological evaluation of 18 lethal cases of poisoning by phenothiazine derivatives. Z Rechtsmedizin 1974;74:293-299.
Dahl SG, Bartlid T, Lingjaerde O. Plasma and erythrocyte levels of methotrimeprazine and two of its non-polar metabolites in psychiatric patients. Ther Drug Monit 1982;4:81-87.
Oliver DJ. The use of methotrimeprazine in terminal care. Br J Clin Pract 1985;39:339-340.
Shell IG, Dufour DG, Moher D, et al. Methotrimeprazine versus meperidine and dimenhydrinate in the treatment of severe migraine: A randomized controlled trial. Ann Emerg Med 1991;20:1201-1205.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:1530-1531.
Dollery DT, ed. Therapeutic Drugs. Edinburgh: Churchill Livingstone 1991; I: M 110— M 114.
Freislederer A, Mallach JH, Moosmayer A. Fatal lev-omepromazine poisoning. Med Welt 1988;39:1473— 1476.
Dahl SG. Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther 1976;19:435-442.
Dahl SG, Strandjord RE, Siggusson S. Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. Eur J Clin Pharmacol 1977;11:305-310.
Allgen LG, Hellstrom L, Sant’orp CJ. On the metabolism and elimination of the psychotropic phenothiazine drug levomepromazine 537 (NozinanR) in man. Acta Psychiatr Scand Suppl 1963;39:366-381.
Johnsen H, Dahl SG. Identification of o-demethylated and ring-hydroxylated metabolites of methotrimeprazine (levomepromazine) in man. Drug Metab Disp 1982;10:63-67.
Loennechen T, Andersen A, Hals PA, Dahl SG. High performance liquid chromatographic determination of levopromazine (methotrimeprazine) and its main metabolites in serum and urine. Ther Drug Monit 1990;12:574-581.
Sjoqvist F. Psychotropic drugs: 2. Interaction between MAO inhibitors and other substances. Proc R Soc Med 1965;58:967-978.
St John AE, Born CK. Characterization of analgesic activity effects of methotrimeprazine and morphine. Res Commun Chem Pathol Pharmacol 1979;26:25-34.
Amore M, Montanari M, Cerisoli M. Severe immune thrombocytopenia induced by neuroleptic. Am J Psychiatry 1991; 148:1266.
Eshel G, Usher M, Barr J, et al: Phenothiazine treatment and respiratory distress syndrome in a child. J Toxicol Clin Toxicol 1994;32:191-197.
Murakami K, Murakami K, Ueno T, et al. Simultaneous determination of chlorpromazine and levomepromazine in human plasma and urine by high performance liquid chromatography using electrochemical detection. J Chromatogr 1982;227:103-112.
Dahl SG, Garle M. Identification of nonpolar methotrimeprazine metabolites in plasma and urine by GLC-mass spectrometry. J Pharm Sci 1977;66:190-193.
Baselt RC, Cravey RH. Disposition of Toxic Drugs and Chemicals in Man. Chicago: Year Book, 1989:535—537.
Bonnichsen R, Geertinger P, Maehly AC. Toxicological data on phenothiazine drugs in autopsy cases. Z Rech-tsmedizin 1970;67:158-169.
Anderson S-B, Forshell GP, Schulman A, et al. Levomepromazine elimination in patients during active and sham hemodialysis. Artif Organs 1982;7:340-343.
Gerson SL, Lieberman JA, Friedenberg WR, et al. Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet 1991;338:262-263.
Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva IP. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977;11:193-198.
Report on Clozaril1' (clozapine). East Hanover, NJ: Sandoz Pharmaceuticals, February 1991:CLO—0291—01.
Lovdahl MJ, Perry PJ, Miller DD. The assay of clozapine and N-desmethylclozapine in human plasma by high performance liquid chromatography. Ther Drug Monit 1991;13:69-72.
Meeker JE, Herrmann PW, Som SW, Reynolds PC. Clozapine tissue concentrations following an apparent suicidal overdose of Clozaril". J Anal Toxicol 1992;16:54-56.
Clozapine (systemic). USP DI Update 1990; 1 (4):243— 246.
Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991;41:369-371.
Haller E, Binder RL. Clozapine and seizures. Am J Psychiatry 1990;147:1069-1071.
Haring C, Fleischacker W, Schett P, et al. Influence of patient related variables on clozapine plasma levels. Am J Psychiatry 1990;147:1471-1475.
Krassner MB. Personal communication, East Hanover, NJ: Sandoz Pharmaceuticals, February 26, 1991.
Pall H, Weinberger G, Kotzaurek R, et al. Schwere Lep-onex": Vergiftung und ihre intensive behandlung. Wien Klin Wochenschr 1976;88:179-182.
Wolf LR, Otten EJ. A case report of clozapine overdose. Vet Hum Toxicol 1991 ;33:370.
Ogilvie AD, Croy MF. Clozapine and hyponatremia. Lancet 1992;340:672.
Fitton A, Heel RC. Clozapine: A review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990;40:722-747.
Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991;148:231-235.
Baldessarini RJ, Frankenburg FR. Clozapine: A novel antipsychotic agent. N Engl J Med 1991;324:746-754.
Choc MG, Lehr RG, Hsuan F, et al: Multiple dose pharmacokinetics of clozapine in patients. Pharm Res 1987;4:402-405.
Gauch R, Michaelis W. The metabolism of 8-chloro-l 1-(4-methyl-4-piperzinyl)-5//-dibenzo[6,c] 11,4]diazepam (clozapine) in mice, dogs, and human subjects. Farmaco 1971;26:667-681.
Szymanski S, Lieberman J A, Picou D, et al. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry 1991;52:21-22.
Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991;52:23-25.
Hiemke C, Weigmann H, Hartter S, et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-281.
Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994;36:487-488.
Clozapine and loxapine for schizophrenia. Drug Ther Bull 1991 ;29(11):41—42.
Hirsch SR, Puri BK. Clozapine: Progress in treating refractory schizophrenia. Side effects, but a cost-benefit analysis supports treatment. Br Med J 1993;306:1427— 1428.
Shaikh S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine. Lancet 1993;116-341.
Gupta S. Paradoxical hypertension associated with clozapine. Am J Psychiatry 1994; 131:148.
Jubert P. Clozapine-related pancreatitis. Ann Intern Med 1994;121:722-723.
Kaempe B, Vesterby A, Thomsen NJ, Rosenthal J. Cloz-apine-a fatal case. Bull Int Assoc Forens Toxicol 1979;15(1):15—16.
Gossweiler B. Vergiftungen mit Leponex". Personal communication. Swiss Toxicological Information Center, January 14, 1992.
Vesterby A, Pedersen JH, Kaempe B, Thomsen NJ. Sudden death during clozapine (Leponex") therapy. Ugeskr Laeg 1980;142:170-171.
Schuster P, Gabriel E, Keifferle B, et al. Reversal by physostigmine of clozapine-induced delirium. Clin Toxicol 1977;10:437-441.
Goetz CM, Love RC, Schuster P. Overdose of clozapine in a child. Vet Hum Toxicol 1993;35:338.
Mady SP, Wax P. Clozapine intoxication in a young child. Vet Hum Toxicol 1993;35:338.
Hadley CM, Walson PD. Pediatric clozapine (Clozaril") ingestion. Vet Hum Toxicol 1993;35:338.
Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: A double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
Krupp P, Barnes P. Leponex-associated granulocytopenia: A review of the situation. Psychopharmacology 1989;99:S118—S121.
Tiihonen J, Paanila J. Eosinophilia associated with clozapine. Lancet 1992;339:488.
DasGupta K, Young A. Clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 1991 ;52:105— 107.
Anderson ES, Powers PS. Neuroleptic malignant syndrome associated with clozapine use. J Clin Psychiatry 1991;52:102-104.
Miller DD, Sharafuddin MJA, Kathol RG. A case of clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 1991;52:99-101.
Dave M. Clozapine related tardive dyskinesia. Biol Psychiatry 1994;36:886-887.
Lieberman JA, Saltz BL, Johns CA, et al. The effect of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-510.
Van Putten T, Wirshing WC, Marder SR. Tardive Meige syndrome responsive to clozapine. J Clin Psychopharmacol 1990;10:381-382.
Patil VJ. Development of transient obsessive compulsive symptoms during treatment with clozapine. Am J Psychiatry 1992; 149:272.
Kastrup O, Gastpar M, Schwarz M. Acute dystonia due to clozapine. J Neurol Neurosurg Psychiatry 1994;57:119.
Le Blaye I, Donatini B, Hall M, Krupp P. Acute overdose with clozapine: A review of the available clinical experience. Pharm Med 1992;6:169-178.
Simpson GM, Cooper TA. Clozapine plasma levels and convulsions. Eur J Psychiatry 1978;135:99-100.
Beal M. Clozapine update. West J Med 1994; 160:53—54.
Karper PP, Salloway SP, Seibyl JP, Krystal JH. Prolonged postictal encephalopathy in two patients with clozapine-induced seizures. J Neuropsychiatry Clin Neurosci 1992;4:454-457.
Breier A, Buchanan RW, Waltrip RW II, et al. The effect of clozapine on plasma norepinephrine: Relationship to clinical efficacy. Neuropsychopharmacology 1994; 10:1 —7.
Kamras A, Doraiswany PM, Jane JL, et al. Severe hyperglycemia associated with high doses of clozapine. Am J Psychiatry 1994; 131:1395.
Levinson В. Clozapine (Leponex) overdosage. South Afr Med J 1975;49:5.
Norris DL, Israelstam K. Clozapine (Leponex) overdosage. South Afr Med J 1975;49:385.
Weide R, Koppler H, Heymanns J, et al. Successful treatment of clozapine induced agranulocytosis with granulocytecolony stimulating factor (G-CSF). Br J Haematol 1992;80:557-559.
Gerson SL, Gullion G, Yeh H-S, Moson C. Granulocyte colony-stimulating factor for clozapine-induced agranulocytosis. Lancet 1992;340:1097.
Li С, Gefter WB. Acute pulmonary edema induced by overdosage of phenothiazines. Chest 1992; 101:102—104.
Power WJ, Travers SP, Mooney DJ. Welding arc mac-ulopathy and fluphenazine. Br J Ophthalmol 1991;75:433-435.
Bristow MF, Kohen D: How "malignant" is the neuromuscular malignant syndrome? In early mild cases it may not be malignant at all. Br Med J 1993;307:1223— 1224.
Bond WS. Detection and management of the neuroleptic malignant syndrome. Clin Pharm 1984;3:302-307.
Yoshida 1, Sakaguchi Y, Matsuishi T, et al. Acute accidental overdosage of haloperidol in children. Acta Pae-diatr 1993;82:877-880.
Bezchlibryk-Butler KZ, Remington GJ. Antiparkinsonian drugs in the treatment of neuroleptic induced extrapy-ramidal symptoms. Can J Psychiatry 1994;39:74-84.
Morgan JP, Baltch AL. Acute oliguria from overdose of chlorprothixene. NY State J Med 1979;69:1340-1342.
Rossen B, Steiness I. The pathophysiology of acute renal failure after chlorprothixene overdosage. Acta Med Scand 1981;209:525-527.
Lawson GM. Monitoring of serum haloperidol. Mayo Clin Proc 1994;69:189-190.
Park KH, Lee MH, Lee MG. Simultaneous determination of haloperidol and its metabolite, reduced haloperidol, in plasma, blood, urine and tissue homogenates by high-performance liquid chromatography. J Chromatogr Biomed AppI 1991:572:259—267.
Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL. Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 1983;81:354-356.
Barr AN, Fischer JH, Koller WC, etal. Serum haloperidol concentrations and choreiform movements in Huntington’s disease. Neurology 1988;38:84-88.
Vatassery GT, Herzan LA, Dyskin MW. Liquid chromatographic determination of reduced haloperidol and haloperidol concentrations in packed red blood cells from humans. J Anal Toxicol 1990;14:25-28.
Matsuno H, Uematsu T, Nakashima M. The measurement of haloperidol and reduced haloperidol in hair as an index of dosage history. Br J Clin Pharmacol 1990;29:187-194.
Davis CM, Harrington CA. Quantitation of thiothixene in plasma by high-performance thin layer chromatography and fluorometric detection. Ther Drug Monit 1988;10:215-223.
McKay G, Cooper JK, Gurnsey T, Midha KK. Asimple, sensitive and simultaneous assay of thioridazine, sulphoridazine and mesoridazine in plasma by HPLC. Liq Chromatogr 1985;3:256-258.
Von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the de-brisoquine hydroxylation phenotype. Clin Pharmacol Ther 1991;49:234-240.
Vasilrades J, Sahawneh TM, Owens C. Determination of therapeutic and toxic concentrations of doxepin and loxapine using gas-liquid chromatography with a nitrogen-sensitive detector and gas chromatography-mass spectrometry of loxapine. J Chromatogr 1979; 164:457— 470.
Reynolds PC, Som LW, Hurman PW. Loxapine fatalities. Clin Toxicol 1979;14:181-185.
Baldi ML, Rocchi L, Papa P, et al. Clothiapine poisonings: Toxic versus therapeutic serum drug levels. In: Proceedings, XlCth International Congress of European Association of Poison Centres, Milan, Italy, September 25—29, 1990:49.
El-Mallakh RS, Donaldson JO, Kranzler HR, Racy A. Phenothiazine associated lupus anticoagulant and thrombotic disease. Psychosomatics 1988;29:109-113.
Kaslow KA, Rosse RB, Zeller JA, et al. Phenothiazine-induced lupus anticoagulant. J Clin Psychiatry 1992;53:103-104.
Zucker S, Zarrabi HM, Schubach WH, et al. Chlorpromazine-induced immunopathy: Progressive increase in serum IgM. Medicine 1990;69:92-100.
Koppel C, Schirop T, Ibe K, et al. Hemoperfusion in severe chlorprothixene overdose. Intensive Care Med 1987;13:358-360.
Ott DA, Goeden SR. Treatment of acute phenothiazine reaction. J Am Coll Emerg Physicians 1979;8:471-472.
Dorevitch A, Durst R, Ginath Y. Propranolol in the treatment of akathisia caused by antipsychotic drugs. South Med J 1991;84:1505-1506.
Casey DE. Tardive dyskinesia. West J Med 1990;153:535-541.
Kendra JR, Rugman FP, Flaherty TA, et al. First use of G-CSF in chlorpromazine-induced agranulocytosis: A report of two cases. Postgrad Med J 1993;69:885-887.
Rumeau-Rouquette С, Goujard J, Huel G. Possible teratogenic effects of phenothiazines in human beings. Teratology 1977;15:57-64.
Milkovich L, van den Berg BJ. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 1976;125:244-248.
Guze BH, Guze PA. Psychotropic medication use during pregnancy. West J Med 1989;151:296-298.
Olesen OV, Bartels U, Poulson JH. Perphenazine in breast milk and serum. Am J Psychiatry 1990; 147:1378— 1379.
Whalley U, Blain PG, Prime JK. Haloperidol secreted in breast milk. Br Med J 1981;282:1746-1747.
Wilens ТЕ, Shim TA, O’Gara PT. Adverse cardiac effects of combined neuroleptic ingestion and tricyclic antidepressant overdose. J Clin Psychopharmacol 1990;10:51-54.
Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993.
Le Blaye I, Donatini B, Hall M, Krupp T. Acute overdosage with thioridazine: A review of the available clinical exposure. Vet Hum Toxicol 1993;35:147-150.
Hulisz DT, Dasa SL, Black LD, Heiselman DE. Complete heart block and torsade de pointes associated with thioridazine poisoning. Pharmacotherapy 1994;14:239— 245.
Gelenberg AJ. Major complications of neuroleptic drug use. West J Med 1994;160:55-56.
Gratz SS, Levinson DF, Simpson GM. The treatment and management of neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:425-443.
Shapiro MF. Despair, trifluoperazine, exercise and temperature of 108°F. Am J Psychiatry 1967;124:705-707.
Platts MM, Maher A, Stentiford NH. Phenelzine and trifluoperazine poisoning. Lancet 1965;2:738.
Lev R, Clark RF. Neuroleptic malignant syndrome presenting without fever: Case report and review of the literature. J Emerg Med 1994;12:49-55.
Caroff SN, Mannh SC, Lazarus A, et al. Neuroleptic malignant syndrome: Diagnostic issues. Psychiatr Ann 1991;21:130-147.
Lang AE. Withdrawal akathisia: Case reports and proposed classification of chronic akathisia. Move Disord 1994;9:188.
Sovner R, Dimascio A. The effect of benztropine mesylate in the rabbit syndrome and tardive dyskinesia. Am J Psychiatry 1977;134:1301-1302.
Deshmukh DK, Joshi VS, Agarwal MR. Rabbit syndrome: A rare complication of long-term neuroleptic medication. Br J Psychiatry 1990; 157:293.
Weiss KJ, Ciranto DA, Shader RI. Physostigmine test in rabbit syndrome and tardive dyskinesia. Am J Psychiatry 1980;137:627-628.
Silva RR, Fridhoff AJ, Alpert M. Neuroleptic withdrawal psychosis in Tourette’s disorder. Biol Psychiatry 1993;34:341-342.
Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis, diagnostic criteria for the disorder and its treatment. Schizophrenia Res 1990;5:21-33.
Henderson RA, Lane S, Henry J A. Life-threatening ventricular arrhythmia (torsade de pointes) after haloperidol overdose. Hum Exp Toxicol 1991;10:59-62.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:271.
Benedetti MS, Rovei V, Dencker SJ, et al. Pharmacokinetics of toloxatone in man following intravenous and oral administration. Arzneimittelforschung 1982;32:276-280.
Azoyan P, Garnier R, Baud FJ, Efthymiou ML. Toxicokinetics of toloxatone in overdose. In: Proceedings, XIVth International Congress of the European Association of Poison Centres, Milan, Italy, September 25—29, 1990:41.
LeFebre H, Richard R, Noblet C, Moore N, Wolf L-M. Life-threatening pseudo-phaeochromocytoma after toloxatone, terbutaline and phenylephrine. Lancet 1993;341:555-556.
Pateron D, Babany G, Hadengue A, et al. Toloxatone-induced fulminant hepatitis. Gastroenterol Clin Biol 1990;14:504-506.
Raub W. Selegiline delays progression of early Parkinson’s. JAMA 1990:213:21.
Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989;321:1364-1371.
Elizan TS, Yahr MD, Moros DA, et al. Selegiline as an adjunct to conventional levodopa therapy in Parkinson’s disease: Experience with this type В monoamine oxidase inhibitor in 200 patients. Arch Neurol 1989;46:1208— 1283.
Rinne JO, Royta M, Paljarri L, et al. Selegiline (Depryl) treatment and death of nigra neurons in Parkinson’s disease. Neurology 1991;41:859-861.
Wessel K, Szelenyi I. Selegiline: An overview of its role in the treatment of Parkinson’s disease. Clin Invest 1992;70:459-462.
Golbe LI, Langston JW, Shoulson I. Selegiline and Parkinson’s disease: Protective and symptomatic considerations. Drugs 1990;39:646-651.
Hietanen MH. Selegiline and cognitive function in Parkinson’s disease. Ada Neurol Scand 1991;84:407-410.
Calesnick B. Selegiline for Parkinson’s disease. Am Fam Physician 1990;41:589-591.
Kurth MC, Langston JW, Tetrud JW. "Stelazine" versus "selegiline": A hazard in prescription writing. Arch Intern Med 1990;150:2379-2384.
McGrath BJ, Stewart JW, Quitker FM. A possible L-de-prenyl induced hypertension reaction. J Psychopharmed 1989;9:310-311.
Meeker JE, Reynolds PC. Postmortem tissue methamphetamine concentrations following selegiline administration. J Anal Toxicol 1990;14:330-331.
British National Formulary Number 24. British Medical Association and Royal Pharmaceutical Society of Great Britain, September 1992:195.
Physicians’ Desk Reference. 49th ed. Montvale, NJ: Medical Economics, 1994:2430—2432.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:849—850.
Suchowersky O, de Vries JD. Interaction of fluoxetine and selegiline. Canad J Psychiatry 1990;35:571-572.
Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interactions between pethidine and selegiline. Lancet 1991;337:246.
Blume CD. Inc. Dear Doctor Letter. Denville, NJ: Somerset Pharmaceuticals, November 14, 1994.
Reynolds GP, Elsworth JD, Blau K, et al. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 1978;6:542-544.
Mann J J, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-de-prenyl: A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989;46:45-50.
Fuller MA, Tolbert SR. Selegiline: Initial or adjunctive therapy of Parkinson’s disease? DICP Ann Pharmacother 1991;25:36-40.
Boyson SJ. Psychiatric effects of selegiline. Arch Neurol 1991 ;48:902.
Hetzel W. Safety of moclobemide taken in overdose for attempted suicide. Psychopharmacology 1992; 106:S 127—S129.
Guelfi JD, Payan C, Fermanian J, et al. Moclobemide versus clomipramine in endogenous depression: A double-blind randomised clinical trial. Br J Psychiatry 1992;160:519-524.
Freeman H. Moclobemide. Lancet 1993;342:1528— 1532.
Angst J, Stabl M. Efficacy of moclobemide in different patient groups: A meta-analysis of studies. Psychopharmacology 1992; 106:S 109—SI 13.
Wiesel F-A, Raaflaub J, Kettler R. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. Am J Clin Pharmacol 1985;28:89-95.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 29th ed. London: Pharmaceutical Press, 1989:374.
Fitton A, Faulds D, Goa KL. Moclobemide: A review of the pharmacological properties and therapeutic use in depressive illness. Drugs 1992;43:561-596.
Raaflaub J, Haefelfmger P, Trautmann KM. Single dose pharmacokinetics of the MAO-inhibitor moclobemide in man. Arzneimittelforschung 1984;34:80-82.
Pons G, Schoerlin MP, Tam YK, et al. Moclobemide excretion in human milk. Br J Clin Pharmacol 1990;29:27-31.
Schoerlin M-P, Mayersohn M, Korn A, Eggers H. Disposition kinetics of moclobemide, a monoamine oxi-dase-A enzyme inhibitor: Single and multiple dosing in normal subjects. Clin Pharmacol Ther 1987;42:395— 404.
Dingemanse J. An update of recent moclobemide interaction data. Clin Psychopharmacol 1993;7:167-180.
Neuvonen PJ, Pohjola-Sintonen S, Таске V, Vuori E. Five fatal cases of serotonin syndrome after mo-clobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993;342:1410.
Brannan SK, Talley BJ, Bouden CL. Sertraline and iso-carboxazide cause a serotonin syndrome. J Clin Psychopharmacol 1994;14:144-145.
Vine R, Norman TR, Burrows GD. A case of moclobemide overdose. Int Clin Psychopharmacol 1988;3:325-326.
Heinze G, Sanchez A. Overdose with moclobemide. J Clin Psychiatry 1986;47:438.
Beaumond G, Hetzel W. Patients at risk of suicide and overdose. Psychopharmacology 1992; 106:S 123—S126.
Myvenfors PG, Eriksson T, Sandstedt LS, Sjoberg G. Moclobemide overdose. J Intern Med 1993;233:113— 115.
Hackett LP, Joyce DA, Hall RW, et al. Disposition and clinical effects of moclobemide and three of its metabolites following overdose. Drug Invest 1993;5:281-284.
Chen DT, Ruch R. Safety of moclobemide in clinical use. Clin Neuropharmacology 1993;16(suppl. 2):S63— S68.
Coulter DM, Pillans Pl. Hypertension with moclobemide. Lancet 1995;346:1032.
Medd BH. Discontinuation of manufacture of isocarboxazid.
Livingston MG. Interactions with selective MAOIs. Lancet 1995;345:533-534.
Rossiter A, Souney PF. Interaction between MAOIs and opioids: Pharmacologic and clinical considerations. Hosp Formul 1993;28:692-698.
Davis JM, Bartlett E, Termini BA. Overdosage of psychotropic drugs: A review. Part II: Antidepressants and other psychotropic agents. Dis Nerv Syst 1968;29:246-256.
Power BM, Hackett LP, Dusci LJ, Ilett KF. Antidepressant toxicity and the need for identification and concentration monitoring in overdose. Clin Pharmacokinet 1995;29:154-171.
Viala AR, Cano J-P, Durand AG, et al. Determination of metapramine in plasma by gas chromatography with nitrogen-selective and electron-capture detection. Anal Chem 1977;49:2354-2357.
Rouquette C, Hecquet D, Pommereau X, et al. Metapramine overdose: Report of two cases and analytical determinations. J Anal Toxicol 1985;9:275-277.
Sumirtapura YC, Leroux Y, Komar AR, et al. Pharmacokinetics of metapramine (19 560RP) in man after infusion and intravenous ingestion. Eur J Clin Pharmacol 1983;25:673-677.
Decouvelaere B, Terlain B, BiederA. Biotransformation of metapramine in three animal species (dog, rabbit, rat) and in man. Therapie 1982;37:249-257.
Sommadossi JP, Lemar M, Necciari J, et al. High performance liquid chromatographic method for determination of plasma and urine metapramine after demethylation. J Chromatogr 1982;228:205-231.
Reynolds JF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:265.
Roynard JL, Pouirriat JL, Fournier JL, et al. Fatal intoxication with minaprine. Press Med 1989; 18:986.
Bertrand J, Deny N, Weber B, et al. Emergency therapy in acute minaprine intoxication. Presse Med 1983; 12:2057.
Bastim Y, Vial T, Espinouse D, et al. Three cases of acute agranulcytosis: Was minaprine the culprit? Presse Med 1993;22:82-93.
Zajecka JM, Fawcett J, Guy С. Coexisting major depression and obsessive-impulsive disorder treated with venlafaxine. J Clin Psychopharmacol 1990;10:152-153.
Montgomery, SA. Venlafaxine: A new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54:119-126.
New antidepressant approved. FDA Consumer 1994;28:2.
Venlafaxine: A new antidepressant. Med Lett Drugs Ther 1994;36(929):49—51.
Albano DL. Personal communication. Wyeth-Ayerst Laboratories, May 12, 1994.
Saletu B, Grunberger J, Anderer P, et al. Pharmacodynamics of venlafaxine evaluated by EEG grain mapping, psychometry and psychophysiology. BrJ Clin Pharmacol 1992;33:589-601.
Klamerus KJ, Maloney K, Rudolph RL, et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active o-desmethyl metabolite. J Clin Pharmacol 1992;32:714-724.
Product Information: Effexon. Wyeth-Ayerst Laboratories, December 19, 1993.
Fantasky A, Burkhart KK. A case report of venlafaxin toxicity. Clin Toxicol 1995;33:359-361.
Tzallas PJ, Rynn KO. Extrapyramidal side effects secondary to venlafaxine. Clin Toxicol 1995;33:475-489.
Venlafaxine: A new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54:119-121.
Update of antidepressants: Lofepramine, amoxapine and viloxazine. Drug Ther Bull 1990;28(21 ):82—84.
Lancaster SG, Gonzalez JP. Lofepramine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1989;37:123-140.
Virgili P, Henry JA. Determination of lofepramine and desipramine using high performance liquid chromatography and electrochemical detection. J Chromatogr 1989;496:228-233.
Reid F, Henry JA. Lofepramine overdose. Pharmacopsychiatry 1990;23(suppl. 1):23—27.
Forshell GP, Siweris B, Tucks JR. Pharmacokinetics of lofepramine in man: Relationship to inhibition of noradrenaline uptake. Eur J Clin Pharmacol 1976;9:291 — 298.
Ghose K, Spragg BP. Pharmacokinetics of lofepramine and amitriptyline in elderly healthy subjects. Int Clin Psychopharmacol 1989; 4:201 —215.
Heath A. Suicidal overdoses of antidepressants with special reference to lofepramine. Int Med 1984;suppL 10:27-30.
Plym Forshell G. The absorption, excretion and plasma protein binding of lofepramine in the rat, dog and man. Zenobiotica 1977;7:153-164.
D’Arcy PF. Drug reactions and interactions. Int Pharm J 1989;3:3.
Anderson PO. Drug use during breastfeeding. Clin Pharm 1991;10:594-624.
Hla KK, Virgili P, Henry JA. Is decreased bioavailability of lofepramine the cause of its safety in overdose? In: Proceedings, 14th International Congress of European Association of Poison Centres, Milan, Italy, September 25— 29, 1990:45.
Dutt JE. On the clinical response/serum level relationship for antidepressants: IL Lofepramine and imi-pramine. Psychopharmacol Bull 1982;18:17-27.
Hewitt JA, Glinn J. Lofepramine and motor neuropathy. Br Med J 1989;299:1223-1224.
Lock T, Kenyan W, Abou-Saleh MT. Sudden cardiac death and antidepressants. Br J Psychiatry 1991;159:736-737.
Lundgren R, Olsson A, Forshell GP. Gas chromatographic determination of lofepramine and desmethyl-imipramine in plasma. Acta Pharm Suec 1977; 14:81 — 94.
Crome P, Ali C. Clinical features and management of self poisoning with newer antidepressants. Med Toxicol 1986;1:411-420.
Heath A, Hutton BA. Lofepramine toxicity in overdose. In: Proceedings, VI World Congress of Psychiatry, Vienna, 1983. Abstract.
Kelly C, Roche S, Naguib M, et al. A prospective evaluation of the hepatotoxicity of lofepramine in the elderly. Int Clin Psychopharmacol 1983;8:83-86.
Maguire КР, Burrows GD, Norman TR, Scoggins BA. Metabolism and pharmacokinetics of dothiepin. Br J Clin Pharmacol 1981;12:405-409.
Zusky P, Manschreck TC, Blanchard C, et al. Dothiepin hydrochloride: Treatment of efficacy and safety. J Clin Psychiatry 1986;47:504-507.
llett KF, Hackett LP, Dusci LJ, Paterson JW. Disposition of dothiepin after overdose: Effects of repeated-dose activated charcoal. Ther Drug Monit 1991; 13: 485-489.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:253.
Hoegholm A, Clementsen P. Hypertonic sodium chloride in severe antidepressant overdosage. J Toxicol Clin Toxicol 1991;29:297-298.
Robinson AE, Coffee Al, McDowall RD. Toxicology of some autopsy cases involving tricyclic antidepressant drugs. Z Rechtsmedizin 1974;74:261-266.
Robinson AE, McDowell RD, Sattar H, et al. Tricyclic and tetracyclic antidepressant drugs: Forensic toxicology of some autopsy cases. J Anal Toxicol 1979;23:3— 13.
Maguire KP, Norman TR, Burrows GD, Scoggins BA. Simultaneous measurement of dothiepin and its major metabolites in plasma and whole blood by gas chromatography-mass fragmentography. J Chromatogr 1981; 222:399-409.
Montgomery SA, Baldwin D, Green M. Why do amitriptyline and dothiepin appear to be so dangerous in overdose Acta Psychiatr Scand 1989;80(suppl. 354):47— 52.
Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. Br Med J 1987;295:1021-1024.
llett KF, Lebeders TH, Wojnar-Horton RE, et al. The excretion of dothiepin and its primary metabolites in breast milk. Br J Clin Pharmacol 1992;3:635-639.
Tracqui A. Kintz P, Mangin P. A fatal case of dothiepin self-poisoning. Bull int Assoc Forens Toxicol 1992;22:28-30.
Goldberg MJ, Park GD, Spector R, et al. Lack of effect of oral activated charcoal on imipramine clearance. Clin Pharmacol Ther 1985;38:350-352.
Scheinin M, Virtanen R, Tisalo E. Effect of activated charcoal on the pharmacokinetics of doxepin. Int J Clin Pharmacol Ther Toxicol 1985;23:38-42.
Karkkainen S, Neuvonen PJ. Pharmacokinetics of amitriptyline influenced by oral charcoal and urine pH. Int J Clin Pharmacol Ther Toxicol 1985;24:326-332.
Lancaster SG, Gonzalez JP. Dothiepin: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1989;38:123-147.
Buckley NA, Dawson AH, Whyte IM, Henry DA. Toxicity of dothiepin in overdose. Lancet 1994;343:735.
Crampton EL, Glkass RC, Marchant B, Rees JA. Chemical ionisation mass fragmentographic measurement of dothiepin placebo concentrations following a single oral dose in man. J Chromatogr 1980;183:141-148.
McGrady H, Reis JA. Toxicity of dothiepin in overdose. Lancet 1944;343:292-293.
Wolfe FR, Caravati ЕМ, Rollins DE. Terminal 40 ms frontal plasma QRS axis as a marker for tricyclic antidepressant overdose. Ann Emerg Med 1989;18:348-351.
Caravati EM. Bossart DJ. Demographic and electrocardiographic factors associated with severe tricyclic antidepressant toxicity. Clin Toxicol 1991;29:31-43.
Liebelt FL, Francis PD, Woolf AD. ECG lead AVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med 1995;26:195-206.
Lavoie FW, Gansert GG, Weiss RE. Value in initial ECG findings and plasma drug levels in cyclic antidepressant overdose. Ann Emerg Med 1990;19:696-702.
Phillips L, Kearns G. Pediatric tricyclic antidepressant ingestions: Predictors of morbidity. Clin Res 1992;40:838A.
Shannon M. Serum enzyme disturbances after tricyclic antidepressant overdose. Vet Hum Toxicol 1989;31:171-172.
Rosselini SR, Grilli F, Gaudio M, et al. Hepatic injury associated with amineptine therapy. Ital J Gastroenterol 1990;22:40-43.
Lachatre G, Pira C, Riche C, et al. Single-dose pharmacokinetics of amineptine and of its main metabolite in healthy young adults. Fundam Clin Pharmacol 1989;2:19-26.
Vexiau P, Gourmel B, Castot A, et al. Severe acne due to chronic amineptine overdose. Arch Dermatol Res 1990;282:103-107.
Poignant JC. Revue pharmacologique sur I’amineptine. Encephale 1979;5:709-720.
Sbarra C, Castelli MG, Noseda A, Fanelli R. Pharmacokinetics of amineptine in man. Eur J Drug Metab Pharmacokinet 1981;6:123-126.
Sbarra C, Negrini P, Fanelli R. Quantitative analysis of amineptine (SI694) in biological samples by gas chromatography-mass fragmentography. J Chromatogr 1979;162:31-38.
Andrieu J, Doll J, Coffinier C. Hepatites dues a 1’ami-noptine: Quatre observations. Gastroenterol Clin Biol 1982;6:915-918.
Domingo JJS, Marco AS, Echeberria RV. Hepatic and pancreatic injury associated with amineptine therapy. J Clin Gastroenterol 1994;18:168-169.
Jeanmougin M, Civatte J, Cavellier-Balloy B. Toxider-mie Rosacieforme a I’amineptine (Survector*). Ann Dermatol Venereol 1988;115:1185-1186.
Levigne V, Faisant M, Mourier C, et al. Acne mon-streuse de 1’adulte: Role inducteur du survector? Ann Dermatol Venereol 1988;115:1184-1185.
Vandel S, Bertschy G, Bizouard P, et al. Modalite d’installation d’une dependance a I’amineptine. Therapie 1990;45:47-52.
Castot A, Benzaken C, Wagniart F, Erthymious ML. Amineptine abuse: Analysis of 155 cases: An official cooperative report of the Regional Centre of Pharmacovig-ilance. Therapie 1990;45:399-405.
Sgro C, Lacroix D, Waldner A, et al. Anaphylactic shock with amineptine: First report. Rev Med Intern 1989;10:461-462.
Clomipramine approved for severe obsessive compulsive disorder: From the FDA. JAMA 1990:263:1896.
German GE. USFDA: FDA’s approval of prescription drug clomipramine for severe obsessive-compulsive disorder, January 10, 1990.
Shader RI, Greenblatt DJ. Newly marketed medications: ABCs and mind your Qs. J Clin Psychopharmacol 1990;10:81-82.
Kahne GJ, Wray RW. Clomipramine for bowel obsessions. Am J Psychiatry 1989;146:120-121.
Obsessive-compulsive disorder. Harvard Med School Health Lett 1990; 15(6):4—8.
Clomipramine for obsessive compulsive disorder. Med Lett Drugs Ther 1988;30(778): 102-104.
Umrath T. CIBA-Geigy Corporation. Personal communication.
Fraser AD, Isner AF, Moss MA. A fatality involving clomipramine. J Forens Sci 1986;31:762-767.
Swanson-Bierman B, Goetz M, Dean BS, Krenzelok EP. Anafranil overdose: A fatal outcome. Vet Hum Toxicol 1990;31:378.
Balant-Gorgia AE, Gex-Fabry M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin Pharmacokinet 1991;20:447-462.
De Cuyper HJA, van Praag HM, Mulder-Hajonides WREM, et al. Pharmacokinetics of clomipramine in depressive patients. Psychol Res 1981;4:147-156.
Linnoila M, Insel T, Kilts C, et al. Plasma steady-state concentrations of hydroxylated metabolites of clomipramine. Clir Pharmacol Ther 1982;32:208-211.
Nagy A, Johansson R. The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. Psychopharmacology 1977;54:125-131.
Bertilsson L, Braithwaite R, Tybring G, et al. Techniques for plasma protein binding of desmethylclomipramine. Clin Pharmacol Ther 1979;26:265-271.
Burch JE, Shaw DM, Michalakeas A, et al. Time course of plasma drug levels during one-daily oral administration of clomipramine. Psychopharmacology 1982;77: 344-347.
Kuss HJ, Jungkunz G. Nonlinear pharmacokinetics of clomipramine after infusion and oral administration in patients. Prog Neuropsychopharmacol Biol Psychiatry 1986;10:739-748.
Feder R. Lithium augmentation of clomipramine. J Clin Psychiatry 1988;49:458.
Schimmell MS, Katz EZ, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. Clin Toxicol 1991;29:479-484.
Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human breast milk. Pediatrics 1983;72:375-383.
Singh S, Gulati S, Narang A, Bhakoo ON. Non-narcotic withdrawal syndrome in a neonate due to maternal clomipramine therapy. J Paediatr Child Health 1990;26:l 10.
Peters MD, Davis SK, Austin LS. Clomipramine: An an-tiobsessional tricyclic antidepressant. Clin Pharmacol 1990;9:165-178.
Asberg M, Ringberger VA, Sjoqvist F, et al. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with clomipramine. Clin Pharmacol Ther 1977;21:201-207.
Chen CN. Sleep, depression and antidepressants. Br J Psychiatry 1979;135:385-402.
Jones RB, Luscomber DK, Groom BV. Plasma prolactin concentrations in normal subjects and depressive patients following oral clomipramine. Postgrad Med J 1977;55(suppl. 4): 166—171.
Burckhardt D, Raeder E, Muller V, et al. Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA 1978;239:213-216.
McTavish D, Benfield P. Clomipramine: An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 1990;39:136-153.
Vieta E, Bernardo M, Vallejo J. Clompiramine-induced mania in obsessive-compulsive disorder. Hum Psychop-harmacol Clin Exp 1991;6:72-73.
Price J, Grunhaus LJ. Treatment of clomipramine-induced anorgasmia with yohimbine: A case report. J Clin Psychiatry 1990;51:32-33.
Katz LM, Fochtmann LK, Pato MT. Clomipramine, fluoxetine and glucose control. Ann Clin Psychiatry 1991;3:271-274.
Roberge RJ, Martin TG, Hodgman M, Benitez JG. Acute chemical pancreatitis associated with a tricyclic antidepressant (clomipramine) overdose. Clin Toxicol 1994;32:425-429.
Tunca Z, Tunca MI, Dilsiz A, et al. Clomipramine-induced pseudocyanotic pigmentation. Am J Psychiatry 1989;146:552-553.
Diamond BI, Borison RL, Katz R, De Veaugh-Geiss J. Rebound withdrawal reactions due to clomipramine. Psychopharmacol Bull 1989;25:209-212.
Notes JM, Befort JP, Remy JM. A case of clomipramine addiction. ActaTher 1991;17:311-312.
Matthews HJS: The management of self-poisoning due to clomipramine (Anafranil). J Int Med Res 1973;1:485-488.
Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. Br Med J 1987;295:1021-1024.
Meatherall RC, Guay DRP, Chalmers JL, Keenan JR. A fatal overdose with clomipramine. J Anal Toxicol 1983;7:168-171.
Ward N, Dawling S. A fatal case involving chlorpromazine and clomipramine. Bull Int Assoc Forens Toxicol 1987;19(2):I6—17.
Haqqani MT, Gutteridge DR. Two cases of clomipramine hydrochloride (Anafranil) poisoning. Forens Sci 1974;3:83-87.
Edelbroek PM, Koelma IA, de Wolff FA. A fatal multidose poisoning: The role of clomipramine. In: Proceedings, International Congress of Clin Toxicol Poison Control Anal Toxicol, Lux-Tox ’90, Luxembourg May 2—5, 1990: PO 3.15.
Gaskell SJ. Gas chromatography/high resolution mass spectrometry as a reference method for clomipramine determination. Postgrad Med J 1980;56(suppl. l):90— 93.
James WA, Lippmann SB. Clomipramine for obsessive-compulsive disorder: Prescribing guidelines. South Med J 1991;84:1242-1245.
Baldi ML, Rocchi L, Papa P, et al. Clothiapine poisonings: Toxic versus therapeutic serum drug levels. In: Proceedings, XIVth International Congress of European Association of Poison Centres, Milan, Italy, September 25—29, 1990:49.
Romano G, Di Bono G. A fatality involving clothiapine and clomipramine. J Forens Sci 1994;34:877-882.
Yergani WK, Pohl R, Balon R, et al. Increased serum total cholesterol to HDL-cholesterol ratio after imipramine. Psychol Res 1990;21:207-209.
Shrivatstava RK, Edwards D. Hypoglycemia associated with imipramine. Biol Psychiatry 1983;18:1509-1510.
Sherman KE, Bornemann M. Amitriptyline and asymptomatic hypoglycemia. Ann Intern Med 1988; 109:683— 684.
Osiewicz RJ, Middleberg R. Detection of a novel compound after overdoses of aspirin and amoxapine. J Anal Toxicol 1989;13:97-99.
Hulten PA, Heath A, Knudsen K, et al. Amitriptyline and amitriptyline metabolites in blood and cerebrospinal fluid following human overdose. Clin Toxicol 1992;30:181-201.
Dziukas LJ, Vohra J. Tricyclic antidepressant poisoning. Med J Aust 1991;154:344-350.
Orr DA, Bramble MG. Tricyclic antidepressant poisoning and prolonged external cardiac massage during asystole. Br Med J 1981 ;283:1107-1108.
Tokarski GF, Young J. Criteria for admitting patients with tricyclic antidepressant overdose. J Emerg Med 1988;6:121-124.
Ware WR. Tricyclic antidepressant overdose: Pharmacology and treatment. South Med J 1987;80:1410— 1415.
Newton EH, Shih RD, Hoffman RS. Cyclic antidepressant overdose: A review of current management strategies. Am J Emerg Med 1994;12:376-379.
Sener EK, Gabe S, Henry JA. Response to glucagon in imipramine overdose. Clin Toxicol 1995;33:51-53.
McCabe JL, Cobaugh DJ, Menegazzi JJ, Fata JM. A comparison of hypertonic saline, sodium bicarbonate and hyperventilation in severe tricyclic antidepressant overdose in swine. Vet Hum Toxicol 1993;35:367.
Hoegholm A, Clenetsen P. Hypertonic sodium chloride in severe antidepressant overdosage. Clin Toxicol 1991;29:297-298.
Brown TCK. Sodium bicarbonate treatment for tricyclic antidepressant arrhythmias in children. Med J Aust 1976;2:380-382.
Hoffman JR, McElroy CR. Bicarbonate therapy for dysrhythmia and hypotension in tricyclic antidepressant overdose. West J Med 1981;134:60-65.
Pentel PR, Benowitz NL. Tricyclic antidepressant poisoning management of arrhythmias. Med Toxicol 1986;1:101-121.
Wrenn K, Smith BA, Slovis CM. A potential hazard of combined hyperventilation and intravenous bicarbonate. Ann Emerg Med 1992;10:553-555.
Martin JG, Roberg RJ. Hypokalemia and electrolyte imbalance associated with antidepressant overdoses. Vet Hum Toxicol 1993:35:340.
Wrenn K, Smith BA, Slovis CM. Profound alkalemia during treatment of tricyclic antidepressant overdose: A potential hazard of combined hyperventilation and intravenous bicarbonate. Am J Emerg Med 1992:10:553— 559.
Merigian KS, Browning RG, Leeper KV. Successful treatment of amoxapine-induced refractory status epilep-ticus with propofol (DiprivanR). Acad Emerg Med 1995;2:128-133.
Tzivoni D, Banai S, Schuzer C, et al. Treatment of Torsade de pointes with magnesium sulfate. Circulation 1988;77:392-397.
Perticone F, Adinolfi L, Bonaduce D. Efficacy of magnesium sulfate in the treatment of Torsade de pointes. Am Heart J 1986;112:847-849.
Tsivoni D, Keren A. Suppression of ventricular arrhythmias by magnesium. Am J Cardiol 1990;65:1297-1399.
Buchman AL, Dauer J, Geiderman J. The use of vasoactive agents in the treatment of refractory hypotension seen in tricyclic antidepressant overdose. J Clin Psychop-harmacol 1990;10:409-413.
Knudsen K, Ricksten S-E, Heath A. Clonidine interaction in amitriptyline poisoning. Clin Toxicol 1988;26:223-232.
Teba L, Schiebel F, Dedhic HV, Lazzell VA. Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose. Am J Emerg Med 1988;6:566-568.
Vernon DD, Banner W, et al. Efficacy of dopamine and norepinephrine for treatment of hemodynamic compromise in amitriptyline intoxication. Crit Care Med 1991;19:544-549.
Watson WA, Leighton J, Guy J, et al. Recovery of cyclic antidepressants with gastric lavage. J Emerg Med 1989;7:373-377.
Givens T, Holloway M, Wason S. Pulmonary aspiration of activated charcoal after tricyclic antidepressant overdose. Vet Hum Toxicol 1990;32:375.
Ray TM, Ossorio HA, Cipolla LM, et al. Pulmonary complications after tricyclic antidepressant overdose. Chest 1989;96:852-856.
Keyler DE, Brunn GJ, Pentel PB. Monoclonal antibody effects on imipramine distribution in rats. Vet Hum Toxicol 1989;31:364.
Sullivan JB, Egen NB. Methods in production and isolation of antibodies to nortriptyline. Vet Hum Toxicol 1987;29:483.
Hursting MJ, Opheim KE, Raisys VA, et al. Tricyclic antidepressant-specific Fab fragments alter the distribution and elimination of desipramine in the rabbit: A model for overdose treatment. Clin Toxicol 1989;27:53— 66.
Pentel PR, Brunn GJ, Pond SM, Keyler DE. Pretreatment with drug-specific antibody reduces desipramine cardiotoxicity in rats. Ann Emerg Med 1991;20:1083.
Brunn GJ, Keyler DE, Pond SM, Pentel PR. Interaction of drug-specific antibody Fab fragment and NaHCO, for reversal of desipramine cardiotoxicity in rats. Vet Hum Toxicol 1991;33:359.
Sabourand A, Urtizberea M, Chafifey O, et al. Nortriptylinespecific active immunization in the rabbit: A mode to study the effect of antibodies on amitriptyline toxicity and disposition. In: Proceedings, International Congress of Clin Toxicol, Pois Cont, Anal Toxicol, Lux Tox, 90, Luxembourg, May 2—5, 1990:233—237.
Denis H, Marulo S, Terrien N, et al. Specific IgG and Fab as main tool in tricyclic antidepressant animal poisoning. Vet Hum Toxicol 1987;29(suppl. 2): 157.
Liu D, Purssell R, Levy JG. Production and characterization of high affinity monoclonal antibodies to cyclic antidepressants. Mol Clin Toxicol 1987;25:527-538.
Emerman CL, Connors AF Jr, Burma GM. Loss of consciousness as a predictor of complications following tricyclic overdoses. Ann Emerg Med 1987;16:326-330.
Pentel P, Sioric L. Incidence of late arrhythmias following tricyclic antidepressant overdose. Clin Toxicol 1981;18:543-548.
Hulten BA. TCA poisoning treated in the intensive care unit. Pharmacopsychiatry 1990;23:16-18.
Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients: Risk-benefit reconsidered. JAMA 1993;269:2673-2675.
Williams JM, Hollingshead MJ, Vasilakis A, et al. Extracorporeal circulation in the management of severe tricyclic antidepressant overdose. Am J Emerg Med 1994;12:456-488.
Knudsen K, Abrahamsson J. Effects of amrinone, norepinephrine, magnesium sulfate and milrinone in survival on the occurrence of arrhythmias in amitriptyline poisoning in the rat. Crit Care Med 1994;22:1851-1855.
Merigian KS, Browning RG, Leeper KV. Successful treatment of amoxapine-induced refractory status epilep-ticus with propofol (DiprivanR). Acad Emerg Med 1995;2:128-133.
Rudorfer MV, Potter WZ. Antidepressants: A comparative review of the clinical pharmacology and therapeutic use of the ’newer’ versus the ’older’ drugs. Drugs 1989;37:713— 738.
Preskorn SH. Pharmacokinetics of antidepressants: Why and how they are relevant to treatment. J Clin Psychiatry 1993;54(9, suppl.): 14-34.
Dziukas LJ, Vohra J. Tricyclic antidepressant poisoning. Med J Aust 1991;154:344-350.
Isacsson G, Holmgren P, Wasserman D, Bergman U. Use of antidepressants among people committing suicide in Sweden. Br Med J 1994;308:506-509.
Antidepressant drugs and the risk of suicide. WHO Drug Inform 1995;7:18-20.
Lesar T, Kingston R, Dahms R, et al. Trazodone overdose. Ann Emerg Med 1983;12:221-223.
Burroughs-Wellcome Company. Personal communication, July 31, 1986.
Fagins J, Osterman PO, Siden A, Wiholm B-E. Guillain-Barre syndrome following zimeldine treatment. J Neurol Neurosurg Psychiatry 1985;48:65-69.
Pomara N, Coffman KL, Bush DF, Gerhon S. Myalgia and elevation in muscle creatine phosphokinase during zimeldine treatment. J Clin Psychopharmacol I984;4: 220-222.
Langlois R, Cournoyer G, de Montigny C, Caille G. High incidence of multisystemic reactions to zimeldine. Eur J Clin Pharmacol 1985;28:67-71.
Simpson GK, Davidson MM. Possible hepatotoxicity of zimeldine. Br Med J 1983;287:1181.
Balestrieri G, Cerudelli B, Ciaccio S, Rizzoni D. Hyponatremia and seizures due to overdose of trazodone. Br Med J 1992;304:686.
Augenstein WL, Smolinske SC, Kulig KW, Rumack BH. Trazodone overdose and severe cardiac toxicity. Vet Hum Toxicol 1987;29:478.
Baughan E, Jawod SSM. Effects of overdose of trazodone. Br Med J 1992;303:1114.
Goldberg MJ, Park GD, Spector R, et al. Lack of effect of oral activated charcoal on imipramine clearance. Clin Pharmacol Ther 1985;38:350-353.
Nagy A, Johansson R. Plasma levels of imipramine and desipramine in man after different routes of administration. Naunyn Schmiedeberg’s Arch Pharmacol 1975;290:145-160.
Schulz P, Dick P, Blaschke TF, et al. Discrepancies between pharmacokinetic studies of amitriptyline. Clin Pharmacokinet 1985;10:257-268.
Rollins DE, Alvan G, Bertilsson L, et al. Interindividual differences in amitriptyline demethylation. Clin Pharmacol Ther 1980;28:121-129.
Heel RC, Avery GS. Drug data information, Appendix A. In: Avery GS, ed. Drug Treatment. 2nd ed. Sydney: ADIS Press, 1980:1217.
Levitt MA, Sullivan JB, Owens SM, et al. Amitriptyline plasma protein binding: Effect of plasma pH and relevance to clinical overdose. Am J Emerg Med 1986;4:121-125.
Alexanderson B. Pharmacokinetics of desmethylimi-pramine and nortriptyline in man after single and multiple oral doses: A cross-over study. Eur J Clin Pharmacol 1972;5:1-10.
Ziegler VE, Biggs JT, Wylie LT, et al. Protriptyline kinetics. Clin Pharmacol Ther 1978;23:580-584.
Joyce PR, Sharman JR. Doxepin plasma concentrations in clinical practice: Could there be a pharmacokinetic explanation for low concentrations? Clin Pharmacokinet 1985;10:365-370.
Jauch R. Kopitar Z, Prox A, et al. Pharmakokinetik und stoff-wechsel von trazodone beim menschen. Arzneim-ittelforschung 1976;26:2084-2089.
Ankier SI, Martin BK, Rogers MS, et al. Trazodone: A new assay procedure and some pharmacokinetic parameters. Br J Clin Pharmacol 1981;11:505-509.
Dugas JE, Weber SS. Amoxapine. Drug Intel! Clin Pharm 1982;16:199-204.
Cooper ТВ, Kelly RG. GLS analysis of loxapine, amoxapine and their metabolites in serum and urine. J Pharm Sci 1979;68:216-219.
Riess W, Dubey L, Funfgelt EW, et al. The pharmacokinetic properties of maprotiline (LudiomilR) in man. J Intern Med Res 1974;3(suppl. 2): 16—41.
Jarvis MR. Clinical pharmacokinetics of tricyclic antidepressant overdose. Psychopharmacol Bull 1991;27:541-550.
Jandhyala BS, Steenberg ML, Pered JM, et al. Effects of several tricyclic antidepressants on the hemodynamics and myocardial contractility of the anesthetized dog. Eur J Pharmacol 1977;42:403-410.
Amitai Y, Kennedy EJ, De Sandre P, Frischer H. Distribution of amitriptyline and nortriptyline in blood: Role of alpha-1-glycoprotein. Ther Drug Monit 1993; 15: 267-273.
Amitai Y, Erickson T, Kennedy EJ, et al. Tricyclic antidepressants in red cells and plasma: Correlation with impaired intraventricular conduction in acute overdose. Clin Pharmacother 1993;54:219-227.
Lane EA. Renal function and the disposition of antidepressants and their metabolites. Psychopharmacol Bull 1991;27:533-540.
Young RC. Hydroxylated metabolites of antidepressants. Psychopharmacol Bull 1991;27:521-532.
Spiker PG, Biggs JT. Tricyclic antidepressants: Prolonged plasma levels after overdose. JAMA 1976;236:1711-1712.
Brosman RD, Busby AM, Holland PRC. Cases of overdosage with viloxazine hydrochloride (Vivalen). J Int Med Res 1976;4:83-85.
Faller JP, Feissel M, Ruyes O, et al. Cardiogenic shock with conduction difficulties in the course of a serious intoxication with viloxazine. Presse Med 1988; 17:1412.
Regouby Y. Inferior coronary ischemia during massive viloxazine and clotrazepam intoxication. Therapie 1991;46:409-410.
Langs T, Thomas F, Jupas JJ, Ravard Y. Seizures with viloxazine. Presse Med 1991 ;20:477.
Update of antidepressants: Lofepramine, amoxapine and viloxazine. Drug Ther Bull 1990;28(2):82—83.
Tsegos IK, Ekdani MY. A double blind controlled study of viloxazine and imipramine in depression. Curr Med Res Opin 1974;2:455-460.
Bayliss PFC, Case DE. Blood level studies with viloxazine hydrochloride in man. Br J Clin Pharmacol 1975;2:209-214.
Groppi A, Papa P. One stage extraction procedures for gas chromatography determination of viloxazine as its acetyl derivative in human plasma. J Chromatogr 1985;337:142-145.
Pinder RM, Bragden RN, Speight TM, Avery RS. Viloxazine: A review of its pharmacological and therapeutic efficacy in depressive illness. Drugs 1977; 13:401 — 421.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 29th ed. London: Pharmaceutical Press 1989:384—385.
Thomson AH, Addus GJ, McGobern EM, McDonald NJ. Theophylline toxicity following coadministration of vitoxazine. Ther Drug Monit 1988;10:359-360.
Pisani F, Narbone MC, Fazio A, et al. Effect of viloxazine on serum carbamazepine levels in epileptic patients. Epilepsia 1984;25:482-485.
Spina E, Campo GM, Avenoso M, et al. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992;14:194-196.
Dolan RJ. Answer. Br Med J 1990;301:171.
Li P, Benitez J. Roden D, Branch RA. Angiotensin 11 facilitates tricyclic antidepressant-induced changes in QRS duration in the rat. Clin Toxicol 1992;30:83-98.
Baldessarini RJ, Teicher MH, Cassidy JW, Stein MH. Anticonvulsant со-treatment may increase toxic metabolites of antidepressants and other psychotropic drugs. J Clin Psychopharmacol 1988;8:381-382.
Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1991 ;51:239— 248.
Bertschy G, Vandel S, Vandel B, et al. Fluvoxamine-tri-cyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol 1991;40:114-120.
Ventafridda V, Ripamont C, De Conno F, et al. Antidepressants increase bioavailability of morphine in cancer patients. Lancet 1987;l:l204.
Katz MP. Raised serum levels of desipramine with the antiarrhythmic propafenone. J Clin Psychiatry 1991;52:432-433.
Saiz-Ruiz J, Moral L. Delirium induced by association of propranolol and maprotiline. J Clin Psychopharmacol 1988;8:77-78.
Wilens ТЕ, Stern TA, O’Gara PT. Adverse cardiac effects of combined neuroleptic ingestion and tricyclic antidepressant overdose. J Clin Psychopharmacol 1990;10:51-54.
Johnson PN, Lewander WJ, Mello MJ, Savitt DL. A fatal drug interaction: Phenelzine/imipramine. Vet Hum Toxicol 1988;30:351.
Wisner K.L, Perel JM. Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry 1991;148:1234-1236.
Kuennsberg EV, Knox JD. Imipramine in pregnancy. Br Med J 1972;2:292.
Crombie DL, Pinsent RJ, Fleming DM, et al. Fetal effects of tranquilizers in pregnancy. N Engl J Med 1975;293:198-199.
Guze BH, Guze PH. Psychotropic medication use during pregnancy. West J Med 1989;151:296-298.
Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress (first of two parts). N Engl J Med 1988;319:413-420.
Mills КС. Trazodone toxicity: Current concepts. Top Emerg Med 1993;15:37-46.
Merigian KG, Hedges JR, Kaplan LA, et al. Plasma catecholamines in cyclic antidepressant overdose. Ann Emerg Med 1988; 17:403.
Giller EJ Jr, Bialos DS, Docherty JP, et al. Chronic amitriptyline toxicity. Am J Psychiatry 1979; 136:4518— 4519.
Noble J, Matthew J. Acute poisonings by tricyclic antidepressants: Clinical features and management of 100 patients. Clin Toxicol 1969;2:403-421.
Hulten BA, Heath A. Clinical aspects of tricyclic antidepressant poisoning. Acta Med Scand 1983.
Marcoupoulos BA, Graves RE. A depressant effect on memory in depressed older persons. J Clin Exp Neu-ropsychol 1990;12:655-663.
Ornadel D, Barnes EA, Dick DJ. Acute dystonia due to amitriptyline. J Neurol Neurosurg Psychiatry 1992;55:44.
Edward JG. Antidepressants and convulsions. Lancet 1979;2:1368-1369.
Lipper B, Bell A, Gaynor B. Recurrent hypotension immediately after seizures in nortriptyline overdose. Am J Emerg Med 1994;12:451-457.
Preskorn SH, Fast GA. Tricyclic antidepressants induced seizures and plasma drug concentration. J Clin Psychiatry 1992;53:160-162.
Skowron DM, Stimmel LL. Antidepressants and the risk of seizures. Pharmacotherapy 1992;12:18-22.
Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: A review. J Clin Psychiatry 1993;54:289-299.
Lejoyeux M, Rouillon F, Ades J, Gorwood P. Neural symptoms induced by tricyclic antidepressants: Phenomenology and pathophysiology. Acta Psychiatr Scand 1992;85:249-256.
Baca L, Martinelli L. Neuroleptic malignant syndrome: A unique association with a tricyclic antidepressant. Neurology 1990;40:1797-1798.
Lipschitz A. Antidepressants and mania. Am J Psychiatry 1990; 147:372.
Sugarman P, Hughes T. Assault after ingestion of antidepressants. Br Med J 1991 ;303:720.
Leys D, Pasquirer F, Lamblin MD, et al. Acute polyradiculoneuropathy after amitriptyline overdose. Br Med J 1982;294:608.
Marley J. Acute polyradiculoneuropathy after amitriptyline overdose. Br Med J 1987;294:1616.
Tribble J, Weinhouse E, Garland J, Wendelberger K. Treatment of a severe imipramine poisoning complicated by a negative history of drug ingestion. Pediatr Emerg Care 1989;5:234-237.
Wyss PA, Serena S, Meier PJ. Dose-dependency of seizures in maprotiline (LudiomilR) intoxications. Vet Hum Toxicol 1993;35:321-341.
Donovan JW, Britt A. Incidence and risk factors of rhabdomyolysis in anticholinergic toxicity. In: Proceedings, International Congress of European Association Poison Centres and Clinical Toxicologists, Birmingham, UK, May 1993.
Zuckerman GB, Conway EE Jr. Pulmonary complications follow tricyclic antidepressant overdose in an adolescent. Ann Pharmacother 1993;27:572-574.
Roy TM, Ossorio MA, Cipolla LM, et al. Pulmonary complications after tricyclic antidepressant overdose. Chest 1989;96:852-856.'
Shannon M, Lovejoy FH Jr. Pulmonary consequences of severe tricyclic antidepressant ingestion. Clin Toxicol 1987;24:443-461.
Varnell RM, Godwin JD, Richardson ML, Vincent JM. Adult respiratory distress syndrome from overdose of tricyclic antidepressants. Radiology 1989;170:667-670.
Power BM, Hackett LP, Dusci LI, llett KF. Antidepressant toxicity and the need for identification and concentration monitoring in overdose. Clin Pharmacokinet 1995;29:154-171.
Chamsi-Pasha H, Barner PC. Myocardial infarction: A complication of amitriptyline overdose. Postgrad Med J 1988;64:968-970.
Shannon M, Merola J, Lovejoy FH Jr. Hypotension in severe tricyclic antidepressant overdose. Am J Emerg Med 1988;6:439-442.
Groleau G, Jotte R, Barish R. The electrocardiographic manifestations of cyclic antidepressant therapy and overdose: A review. J Emerg Med 1990;8:597-605.
Keegan AD. Doxapine-induced recurent acute hepatitis. Aust NZ J Med 1993;23:523.
Wallace DE. Bowel ischemia in two patients following tricyclic antidepressant overdose. Vet Hum Toxicol 1989;31:377.
McMahon AJ. Amitriptyline overdose complicated by intestinal pseudo-obstruction and caecal perforation. Postgrad Med J 1989;65:948-949.
Ray MJ, Padin DR, Condie JD, Halls JM. Charcoal bezoar: Small bowel obstruction secondary to amitriptyline overdose therapy. Dig Dis Sci 1988;33:1061-1067.
Stokes PE. Fluoxetine: A five-year review. Clin Ther 1993;15:216-246.
Fuller GN, Calibour J. Pinpoint pupils in mianserin overdose. Br Med J 1987;294:1233.
Haefeli WE, Schoenenberger RA. Recurrent ventricular fibrillation in mianserin intoxication. Br Med J 1991;302:415-416.
Gamble DE, Peterson LG. Trazodone overdose: Four years of experience from voluntary reports. J Clin Psychiatry 1986;47:544-546.
Kuhn R. The treatment of depressive states with G 223JJ (imipramine hydrochloride). Am J Psychiatry 1959;115:459-464.
Mann AM, Catterson Ag, McPherson AS. Toxicity of imipramine: Report of serious side effects and massive overdosage. Can Med Assoc J 1959;81:23-28.
Noack CH. A death from overdosage of "Tofranil." Med J Aust 1960;2:182.
Lee FL Imipramine overdosage: Report of a fatal case. Br Med J 1961;1:338-339.
Steel CM, O’Duffy J, Brown SS. Clinical effects and treatment of imipramine and amitriptyline poisoning in children. Br Med J 1967;3:663-667.
Callaham M, Kassel D. Epidemiology of fatal tricyclic antidepressant ingestion: Implications for management. Ann Emerg Med 1985;14:1-9.
Carlier P, Garnier R, Benzaken C, et al. Acute car-pipramine overdosage: Report of 26 cases. Therapie 1982;37:89-94.
Fraser AD, Isner AF. A carpipramine related fatality. J Forens Sci 1987;32:1103-1108.
Liebelt FL, Francis PD, Woolf AD. ECG lead RaVR improves prediction of acute tricyclic antidepressant (TCA) toxicity. Vet Hum Toxicol 1993;35:368.
Asselin WM, Leslie JM. Direct detection of therapeutic concentrations of tricyclic antidepressants in whole hemolyzed blood rising to EMIT serum tricyclic antidepressant assay. J Anal Toxicol 1991;15:167-173.
Nebinger P, Koel M. Specificity data of the tricyclic antidepressant assay by fluorescent polarization immunoassay. J Anal Toxicol 1990;14:219-221.
Poklis A, Soghoian D, Crooks CR, Sandy JJ. Evaluation of the Abbot ADx total serum tricyclic immunoassay. Clin Toxicol 1990;28:235-248.
Drebit R, Baker GB, Dewhurst GB. Determination of maprotiline and desmethylmaprotiline in plasma and urine by gas chromatography with nitrogen-phosphorus detection. J Chromatogr 1988;432:334-339.
Orsulak PJ. Therapeutic monitoring of antidepressant drugs: Guidelines updated. Ther Drug Monit 1989;11:497-507.
Meador-Woodruff JH, Akil M, Wisner-Carlson R, Grunhaus L. Behavioral and cognitive toxicity related to elevated plasma tricyclic antidepressant levels. J Clin Psychopharmacol 1988;8:28-32.
Yang KL, Dantzkes DR. Reversible brain death: A manifestation of amitriptyline overdose. Chest 1991;99:1037-1038.
Hulten RA, Adams R, Askenasi R, et al. Predicting severity of tricyclic antidepressant overdosage. Clin Toxicol 1992;30:161-171.
Hulten BA, Martensson E, Knudsen K, Heath A. Difference in arterial and venous concentrations of amitriptyline and its metabolites after overdose. Vet Hum Toxicol 1987;29:484.
Hadac JP, An TL, Konakai Y, et al. Analysis of blood and tissue in three trazodone related deaths. In: Proceedings, American Academy of Forensic Sciences, 43rd Annual Meeting, Chicago, February 18—23, 1991: Abstract K37.
Brown P, Tribby P. Analysis of trazodone by normal phase liquid chromatography. Clin Chem 1990;36:1045 (Abstract 0436).
Stead AH, Moffat AC. A collection of therapeutic, toxic and fatal blood drug concentrations in man. Hum Toxicol 1983;3:437-464.
Rohrig TP, Prouty RW. A nortriptyline death with unusually high tissue concentrations. J Anal Toxicol 1989;13:303-304.
Tracqui A, Kintz P, Ritter-Lohrer S, et al. Toxicological findings after fatal amitriptyline self-poisoning. Hum Exp Toxicol 1990;9:257-261.
Fraser AJ, Susnik E, Isner AF. Analysis of 2-hydroxy-imipramine in an imipramine-related fatality. J Forens Sci 1987;32:543-545.
Hulten BA, Heath A, Knudsen K, et al. Severe amitriptyline overdose: Relationship between toxicokinetics and toxicodynamics. Clin Toxicol 1992;30:171-179.
Amitai Y, Erickson T, Leikin JB, et al. Acute tricyclic antidepressant overdose: Cardiac toxicity and levels in red cells and plasma. Vet Hum Toxicol I993;35:34O.
Amitai Y, Erickson T, Kennedy EJ, et al. Tricyclic antidepressants in red cells and plasma correlation with impaired intraventricular conduction in acute overdosage. Clin Pharmacol Ther 1993;54:219-227.
Frommer DA, Kulig KW, Marx JA, Rumack B. Tricyclic antidepressant overdose: A review. JAMA 1987;257:521-526.
Apple FS, Bandt CB. Liver and blood post-mortem tricyclic antidepressant concentrations. Am J Clin Pathol 1988;89:794-796.
Apple FS. Post-mortem tricyclic antidepressant concentrations: Assessing cause of death using parent drug to metabolite rate. J Anal Toxicol 1989;13:197-198.
Bailey DN, Shaw RF. Tricyclic antidepressants: Interpretation of blood and tissue levels in fatal overdoses. J Anal Toxicol 1979;3:43-46.
Hulten BA, Dawling S, Volans GM, Heath AJW. Predicting severity of tricyclic antidepressant overdose. In: Proceedings, 14th International Congress of European Association of Poison Centres, Milan, Italy, September 25— 29, 1990:149.
Niemann JT, Bessen HA, Rothstein RJ, Lake MM. Electrocardiographic criteria for tricyclic antidepressant cardiotoxicity. Am J Cardiol 1986;57:1154—1159.
Power ВМ, Hackett LP, Dnsci LI, llett KF. Antidepressant toxicity and the need for identification and concentration monitoring in overdose. Clin Pharmacokinet 1995;29:154-171.
Rudorfer MW, Manji HE, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994;10:18-42.
De Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992;43(suppl. 2):40—47.
Carpenter WT, Buchanan BRN. Schizophrenia. N Engl J Med 1994;330:681-690.
Rosenthal RM, Hellerstein DJ, Minter CR. Positive and negative syndrome typology in schizophrenic patients with psychoactive substance use disorder. Compr Psychiatry 1994;35:91-98.
Arinami T, Itokawa M, Engushi M, et al. Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 1994;343:703-704.
Kerwin R, Dumon V. Dopamine receptor genes and schizophrenia: The tail wags the dog? Lancet 1994;343:686.
Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharm Sci 1994;15:264-270.
Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand 1994;89(suppl. 380):8—13.
Carpenter WT Jr. The deficit syndrome. Am J Psychiatry 1994;15:327-328.
Weller MP1. Neuroleptic-induced deficit syndrome. Postgrad Med J 1993;69:957-958.
Crow TJ. Molecular pathology of schizophrenia: More than one disease process. Br Med J 1980;280:66-86.
Brodie MJ, Porter RJ. New and potential anticonvulsants. Lancet 1990;2:425-426.
Shimizu A, Yamamoto J, Yamada Y, et al. The antiepileptic effect of zonisamide in patients with refractory seizures. Curr Ther Res 1987;42:147-155.
Wilensky AJ, Friel NP, Ojemanni LM, et al. Zonisamide in epilepsy: A pilot study. Epilepsia 1985;26:212— 220.
Matsumoto K, Miyazaki H, Fujii T, et al. Absorption, distribution and excretion of 3-(sulfamoyl [14C]methyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men. Arzneimitt-Forschung Drug Res 1983;33:961-968.
Taylor CP, McLean JR, Bockbrader HN, et al. Zonisamide (AD-810, Cl-912). In: Meldrum BS, Porter RJ, eds. New Anticonvulsant Drills. London: John Wiley, 1986:277-294.
Berent S, Sackellares JC, Giordani B, et al. Zonisamide (Cl-912) and cognition: Results from preliminary study. Epilepsia 1987;28:61-67.
Naito H, Itoh N, Matsui N, Eguchi T. Monitoring plasma concentrations of zonisamide and clonazepam in an epileptic attempting suicide by an overdose of the drugs. Curr Ther Res 1988;43:463-467.
Sackellares JC, Donofrio PD, Wagner JG, et al. Pilot study of zonisamide (l,2-benzisoxazole-3-methanesul-fonamide) in patients with refractory partial seizures. Epilepsia 1985;26:206-211.
King DW, Gallagher BB, Murvin AJ, et al. Pseudoseizures: Diagnostic evaluation. Neurology 1982;32:18-23.
Brodie MJ, Porter RJ. New and potential anticonvulsants. Lancet 1990;336:425-426.
Tsanaclis LM, Wichs J, Williams J, Richens A. Determination of vigabatrin in plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 1991;13:251-253.
Clinical Investigation Brochure 1988: Vigabatrin (GABA transaminase inhibitor). Cincinnati, OH: Merrell Dow Research Institute. Merrell Dow Pharmaceuticals, 1988.
Brodie MJ. Established anticonvulsants and treatment of refractory epilepsy. Lancet 1990;336:350-354.
Hoke JF, Ruberg SJ, Antony KK, Okerholm RA. Pharmacokinetics and dose proportionality of gamma-vinyl GABA (vigabatrin) following multiple oral doses. Neurology 1991:41 (suppl. 1):139.
Tassinan CA, Michelucci R, Ambrosetto G, Salvi F. Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Arch Neurol 1987;44:907-910.
Sjoerdsma A. Suicide enzyme inhibitors as potential drugs. Clin Pharmacol Ther 1981;30:3-22.
Remy C, Beaumont D. Efficacy and safety of vigabatrin in the long term treatment of refractory epilepsy. Br J Clin Pharmacol 1989;27:125S—129S.
Ring HA, Reynolds EHJ. Vigabatrin and behavior disturbance. Lancet 1990;335:970.
Ring HA, Heller AJ, Farr IN, Reynolds EH. Vigabatrin: Rational treatment for chronic epilepsy. J Neurol Neurosurg Psychiatry 1990;53:1051-1055.
Olive G, Rey E, Pons G, Richard MO, et al. Pharmacokinetics of R(-) and S(+) vigabatrin (GVG) in children. Clin Pharmacol Ther 1989;45:39.
Robinson MK, Richens A, Oxley R. Vigabatrin and psychiatric disturbances. Lancet 1990;2:504.
Sander JWAS, Hart YM. Vigabatrin and behavior disturbances. Lancet 1990;335:57.
Brodie MJ, McKee PJW. Vigabatrin and psychosis. Lancet 1990;l:1279.
Dann M. Vigabatrin and behavior disturbances. Lancet 1990;335:605-606.
Grant SM, Heel RC. Vigabatrin: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991;41:889-926.
Liegeois-Chauvel C, Marquis P, Gisselbrecht D, et al. Effects of long term vigabatrin on somatosensory evoked potentials in epileptic patients. Br J Clin Pharmacol 1989;27:69S—72S.
Neufeld MY, Vishnevska S. Vigabatrin and multifocal myoclonus in adults with partial seizures. Clin Neurop-harmacol 1995;18:280-283.
Paljarvi L, Vapalahti M, Sivenius J, Riekkonen P. Neuropathological findings in 5 patients with vigabatrin treatment. Neurology 1990;40(suppl. 1):151.
Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989;27:43S-45S.
Staples CI, King MA, Boyle RS. Acute psychosis after withdrawal of vigabatrin. Med J Aust 1992; 156:291.
Gram L, Lyon BB, Dam M. Gamma-vinyl GABA: A single blind trial in patients with epilepsy. Acta Neurol Scand 1983;68:34-39.
Shih VE, Tenanbaum A. Aminoaciduria due to vinyl-GABA administration. N Engl J Med 1990;323:1353.
Bonham JR, Rattenbury JM. Meeks A, Pollitt RJ. Pyroglutamic aciduria from vigabatrin. Lancet 1989;1:1452-1453.
Williams A, Goldsmith R, Coakley J. Profound suppression of plasma alanine aminotransferase activity in children taking vigabatrin. Aust NZ J Med 1993;23:65.
Reynolds EH. Vigabatrin: Rational treatment for chronic epilepsy. Br Med J 1990;300:177-178.
Xie KJ, Xiao В, Yan СХ, Не ZW. Several studies on magnesium valproate. Clin Pharmacol Ther 1991 ;49:137.
Bialer M. Clinical Pharmacology of valpromide. Clin Pharmacokinet 1991; 1:20:114—122.
Lindhout D, Schmidt D. In utero exposure to valproate and neural tube defects. Lancet 1986;1:1392-1393.
Lammer EJ, Sever LE, Oakley GP Jr. Teratogen update: Valproic acid. Teratology 1987;35:465-473.
DiLiberti JD, Farndon PA, Dennis NR, Curry CJR. The fetal valproate syndrome. Am J Med Genet 1984;19:473-481.
Omtzigt JGC, Nau H, Los FJ, Pijpers L, Lindhout D. The disposition of valproate and its metabolites in the late first trimester and early second trimester of pregnancy in maternal serum, urine and amniotic fluid: Effect of dose, comedication, and the presence of spina bifida. Eur J Clin Pharmacol 1992;43:381-388.
Papazian O, Canizales E, Alfonso 1, et al. Reversible dementia and apparent brain atrophy during valproate therapy. Ann Neurol 1995;38:687-691.
Settle EC. Valproate and associated encephalopathy with coma. Am J Psychiatry 1995;152:1236-1237.
Lande MB, Kim MS, Bartlett C, Guay-Woodford LM. Reversible Fanconi syndrome associated with valproate therapy. J Pediatr 1993;123:320-322.
Pond SM. Role of repeated oral doses of activated charcoal in clinical toxicology. Med Toxicol 1986;1:3-11.
Neuvonen PJ, Olkolla KT. Oral activated charcoal in the treatment of intoxications: Role of single and repeated doses. Med Toxicol 1988;3:33-58.
Williams SR, Clark RF. Hemodialysis of a valproic acid poisoning. Clin Toxicol 1995;33:475-486 (Abstract 13).
Graudins A, Aaron CK. Delayed peak serum valproic acid level in massive divalproex overdose: Successful treatment with charcoal hemoperfusion. Clin Toxicol 1995;33:475-486.
Alberto G, Erickson T, Popiel R, et al. Central nervous system manifestations of a valproic acid overdose responsive to naloxone. Ann Emerg Med 1989; 18:889— 891.
Anderson GO, Ritland S. Life threatening intoxication with sodium valproate. Clin Toxicol 1995;33:279-284.
Bell EA, Shaefer MS, Markin RS, et al. Treatment of valproic acid-associated hepatic failure with orthotopic liver transplantation. Ann Pharmacother 1992;26:118— 121.
Chadwick DW, Gumming WJK, Livingstone I, et al. Acute intoxication with sodium valproate. Ann Neurol 1978;6:552-553.
Steiman GS, Woerpe! RW, Sherard ES Jr. Treatment of an accidental sodium valproate overdose with an opiate antagonist. Ann Neurol 1979;6:274.
Eeg-Olofsson O, Lindskog (J. Acute intoxication with valproate. Lancet 1982; 1:1306.
Karlsen RL, Kett K, Henriksen O. Intoxication with sodium valproate: A case report. Acta Med Scand 1983;213:405-406.
Garnier R, Boudignat O, Fournier PE. Valproate poisoning. Lancet 1982;2:97.
Closson RG. Interaction between valproic acid and phenytoin. West J Med 1983; 138:1 OS.
Keys PA. Valproic acid: Interactions with phenytoin and phenobarbital. Drug Intell Clin Pharm 1982; 16:737— 739.
Palm R, Silseth C, Alvan G. Phenytoin intoxication as the first symptom of fatal liver damage induced by sodium valproate. BrJ Clin Pharmacol 1984;17:597-599.
Sugimoto T, Nishida N, Yasuhara A, et al. Reye-like syndrome associated with valproic acid. Brain Dev 1983;5:334-337.
Hojer B, Rane A. Fatal hepatic failure in a child treated with phenytoin and valproic acid. Dev Med Clin Neurol 1980;24:846-849.
Ware S, Milward-Sadler CH. Acute liver disease associated with sodium valproate. Lancet 1980;2:1110—1113.
Turnbull DM. Adverse effects of valproate. Adverse Drug React Acute Poison Rev 1983;2:191-216.
Schmidt D. Adverse effects of valproate. Epilepsia 1984;25(suppl.l):S44—S49.
Isom JB. On the toxicity of valproic acid. Am J Dis Child 1984;138:901-903.
Wyllie E, Wyllie R, Cruse RP, et al. Pancreatitis associated with valproic acid therapy. Am J Dis Child 1984; 138:912-914.
Williams I HP, Reynolds RP, Emery JL. Pancreatitis during sodium valproate treatment. Arch Dis Child 1983;58:543-544.
Loiseau P, Bracket A, Henry P. Concentration of dipropylacetate in plasma. Epilepsia 1974;16:609-615.
Bauer LA, Davis R, Wilensky A, et al. Valproic acid clearance: Unbound fraction and diurnal variation in young and elderly patients. Clin Pharmacol Ther 1985;32:697-700.
Bryson SM, Verma N, Scott PJW, et al. Pharmacokinetics of valproic acid in young and elderly subjects. Br J Clin Pharmacol 1983;16:104-105.
Hvidberg EF, Dam M. Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1976;1:161-188.
Gugler R, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1980;5:67-83.
Pinder RM, Borgden RN, Speight TM, et al. Sodium valproate: A review of its pharmacological and therapeutic efficacy in epilepsy. Drugs 1977;13:81-123.
Hvidberg EF, Dam М. Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1976;1:161-188.
Schottelius DD. Primidone: Absorption, distribution and excretion. In: Woodbury DM, PenryJK, Pippenger CE, eds. Antiepileptic Drugs. New York: Raven Press, 1982:405-413.
Booker HE, Hosokawa K, Burdette RD, et al. A clinical study of primidone levels. Epilepsia 1970;11:395-402.
Lee CC, Marbury TC, Perchalski RT, et al. Pharmacokinetics of primidone elimination by uremic patients. J Clin Pharmacol 1982;22:301-308.
Houghton GW, Richens A, Toseland PA, et al. Brain concentrations of phenytoin, phenobarbital and primidone in epileptic patients. Eur J Clin Pharmacol 1975;9:73-78.
Reynolds EH, Fenton G, Fenwick P, et al. Interaction of phenytoin and primidone. Br Med J 1975;2:594-595.
Finchman RW, Schottelius DD, Salis AL. The influence of diphenylhydantoin on primidone metabolism. Arch Neurol 1974;30:259.
Physicians’ Desk Reference. 49th ed. Oradell, NJ: Medical Economics, 1995:2692—2693.
O’Brien ТЕ. Excretion of drugs in human milk. Am J Hosp Phann 1974;31:844-854.
Battino D, Binelli S, Bossi L. Changes in primidone/ phenobarbital ratio during pregnancy and the puerper-ium. Clin Pharmacokinet 1984;9:252-260.
Gallagher BB, Baumel IP, Mattson RH, et al. Primidone, diphenylhydantoin and phenobarbital aspects of acute and chronic toxicity. Neurology 1973;23:145—149.
Van Heijst ANP, de Jong W, Seldenrijk R, et al. Coma and crystalluria: A massive primidone intoxication treated with hemoperfusion. J Toxicol Clin Toxicol 1983;20(4):307—318.
Bailey DN, Jatlow PL Chemical analysis of massive crystalluria following primidone overdose. Am J Clin Pathol 1972;58:583-589.
Haga HJ 1П, Hastings H. Extravasation of phenytoin in the hand. J Hand Surg 1988; 13A:942—943.
Spengler RF, Arrowsmith JB, Kilarski DJ, et al. Severe softtissue injury following intravenous infusion of phenytoin: Patient and drug administration risk factors. Arch Intern Med 1988;148:1329-1333.
MacCara ME. Extravasation: A hazard of intravenous therapy Drug Intell Clin Pharm 1983;17:713-717.
Wilder BJ, Buchanan RA, Serrano EE. Correlation of acute diphenylhydantoin intoxication with plasma levels and metabolic excretion. Neurology 1973;23:1329— 1332.
Jung D, Powell JR, Walson P, et al. Effect of dose on phenytoin absorption. Clin Pharmacol Ther 1980;28:479-485.
Kutt H. Interactions of antiepileptic drugs. Epilepsia 1975;16:393-402.
Robinson JD, Morris BA, Aherne GW, et al. Pharmacokinetics of a single dose of phenytoin in man measured by radioimmunoassay. BrJ Clin Pharmacol I975;2:345— 349.
Gugler R, Manion CV, Azarnoff D. Phenytoin: Pharmacokinetics and bioavailability. Clin Pharmacol Ther 1976;19:135-142.
Gordon MF, Gerstenblitt D. The use of free phenytoin levels in averting phenytoin toxicity. NY State J Med 1990;90:469-470.
Lesko U, Ruangtrakool T. In vitro displacement of phenytoin from protein binding sites by amiodarone. Clin Pharmacol Ter 1987;41:238.
Nolan РЕ, Marcus FI, Hoyer GL, et al. Pharmacokinetic interaction between intravenous phenytoin and amiodarine in healthy volunteers. Clin Pharmacol Ther 1989;46:43-50.
Zifkin B. Sherwin A, Andermann F. Phenytoin toxicity due to interaction with clobazan. Neurology 1991;41:313-314.
Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991;49:420-425.
Bramhall D, Levine M. Possible interaction of ranitidine with phenytoin. Drug Intell Clin Pharm 1988;22:979— 980.
Dofferhoff ASM, Berendsen HH. Decreased phenytoin level after carboplatin treatment. Am J Med 1990;89:247-248.
Abajo FJ. Phenytoin interaction with rifampicin. Br Med J 1988:297:1048.
Hendeles L, Wyatt R, Weinberger M, et al. Decreased oral phenytoin absorption following concurrent theophylline administration. J Allergy Clin Immunol 1979;63:156.
Smith CD, Bledsoe MA, Curran R, et al. Effect of influenza vaccine on serum concentrations of total and free phenytoin. Clin Pharm 1988;7:828-832.
Wesseling H, Mols-Thurkow I. Interaction of diphenylhydantoin (DPH) and tolbutamide in man. Eur J Clin Pharmacol 1975;8:75.
Beech E, Mathur SVS, Harrold BP. Phenytoin toxicity produced by tolbutamide. Br Med J 1988;297:1613— 1614.
Cusack BJ, Tesnohlidek DA, Loeske VL, et al. The effect of phenytoin on doxorubicin and doxorubicinol pharmacokinetics. Clin Res 1988;36:117A.
Hvidberg EF, Dam M. Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1976;1:161-188.
Lander CM, Smith MT, Chalk JB. Bioavailability and pharmacokinetics of phenytoin during pregnancy. Eur J Clin Pharmacol 1984;27:105-110.
Bodendorfer TW. Fetal effects of anticonvulsant drugs and seizure disorders. Drug Intell Clin Pharm 1978;12:14-21.
Committee on Drugs, American Academy of Pediatrics. Anticonvulsants and pregnancy. Pediatrics 1977;63: 331-333.
Wilson JT, Huff JG, Kilroy AW. Prolonged toxicity following acute phenytoin overdose in a child. J Pediatr 1979;95:135-138.
Briggs GG, Bodendorfer TW, Freeman RK, et al. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Baltimore: Williams & Wilkins, 1983:288.
Mack RB. Medical exorcism: Acute dilantin intoxication. NC Med J 1984;45(2):99—100.
Booker HE, Darcey B. Serum concentrations of free diphenylhydantoin and their relationship to intoxication. Epilepsia 1973; 14:177.
Discoil DF, McMahon M, Blackbum GL, Bistrian BR. Phenytoin toxicity in a critically ill hypoalbuminemic patient with normal serum drug concentrations. Crit Care Med 1988;16:1248-1249.
Toler SM, Wilkerson MA, Porter WH, et al. Severe phenytoin intoxication as a result of altered protein binding in AIDS. DICP Ann Pharmacother 1990;24:698— 700.
Pruitt AW, Zwiren GT, Patterson JH, et al. A complex pattern of disposition of phenytoin in severe intoxication. Clin Pharmacol Ther 1975;18:112-120.
Subik M, Robinson DS. Phenytoin overdose with high plasma levels. West VA Med J 1982;78(1 1):781— 782. Case Report.
Baird-Lambert J, Jager-Roman E, Buchanan N. Phenytoin elimination after intoxication during long term treatment. Med J Aust 1982;2:228-229.
Curtis DL, Pilbe R, Ellenhorn M, et al. Phenytoin toxicity: Predictions of clinical course. Vet Hum Toxicol 1989;31:162-163.
Kushnir M, Weinstein R, Landau B, et al. Hypothyroidism and phenytoin intoxication. Ann Intern Med 1984;102:341-342.
Weichbrodt GD, Elliott DR. A treatment of phenytoin toxicity with repeated doses of activated charcoal. Ann Emerg Med 1987;16:1387-1389.
Rowden AM, Spoor J E, Bertino JS Jr. The effect of activated charcoal on phenytoin pharmacokinetics. Ann Emerg Med 1990;19:1144-1147.
Dolgin JG, Nix DE, Sanchez J, Watson WA. Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning: Report of two pediatric cases. DICP Ann Pharmacother 1991;25:646— 649.
Biale Y, Lewenthal H. Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. Eur J Obstet Gynecol Reprod Biol 1984; 18:211 — 216.
Curtis DL, Pirbe R, Ellenhorn MJ, et al. Phenytoin toxicity: A review of 94 cases. Vet Hum Toxicol 1989;31:164-165.
Earnest EP, Marx JA, Drury LR. Complications of IV phenytoin for acute treatment of seizures: Recommendations for usage. JAMA 1983;6:762-765.
Bostrom В. Paraldehyde toxicity during treatment of status epilepticus. Am J Dis Child 1982;136:414-415.
Anthony RM, Andorn AC, Sunshine 1, et al. Paraldehyde pharmacokinetics in ethanol abusers. Fed Proc 1977;36:285.
Thurston JH, Liang HS, Smith JS, et al. New enzymatic method for measurement of paraldehyde: Correlation of effects with serum and CSF levels. J Lab Clin Med 1968;72:699-704.
Levine H, Gilbert AJ, Bodansky M. The pulmonary and urinary excretion of paraldehyde in normal dogs and in dogs with liver damage. J Pharm Exp Ther 1940;69:316— 323.
Hitchcock P, Nelson EE. The metabolism of paraldehyde. 1943;79:286-294.
Emmett M, Narins PG. Clinical use of the anion gap. Medicine 1977;56:38-54.
Gooch WM III, Kennedy J, Banner W Jr, et al. Generalized arterial and venous thrombosis following intra-arterial paraldehyde. Clin Toxicol 1979;15:39-44.
Waterhouse C, Stern EA. Metabolic acidosis occurring during administration of paraldehyde. Am J Med 1957;23:987-989.
Browne TR. Drug therapy reviews: Drug therapy of status epilepticus. Am J Hosp Pharm 1978;35:915-927.
Mendelson J, Wexler D, Leiderman PH, et al. A study of addiction to nonethyl alcohols and other poisonous compounds. Q J Stud Alcohol 1957;18:561-580.
Hessel DW. The analysis of blood serum for paraldehyde by ultrafiltration and gas chromatography with a wide-bone capillary column. J Anal Toxicol 1988;12:350-353.
Beier LS, Pitt WH, Gonick HC. Metabolic acidosis occurring during paraldehyde intoxication. Ann Intern Med 1963;58:155-158.
Gutman RA, Burnell JM, Solak F. Paraldehyde acidosis. Am J Med 1967;42:435-440.
Seyffart G. Paraldehyde. In: Haddad LM, Winchester JF, eds. Clinical Management of Poisoning and Drug Overdose. Philadelphia: WB Saunders, 1983:410—413.
Timmings PL, Richens A. Lamotrigine in primary generalised epilepsy. Lancet 1992;339:1300-1301.
Goa KL, Ross SR, Chrisp P. Lamotrigine: A review of its pharmacological properties and clinical efficiacy in epilepsy. Drugs 1993;46:152-176.
Mikati MA, Schachter SC, Schomer DL, et al. Longterm tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. Clin Neuropharmacol 1989;12:312-321
Brodie MJ, Porter RJ. New and potential anticonvulsants. Lancet 1990;2:425-426.
Binnie CD, Ven Ende Boas W, Kasteleijn-Nolste-Trem-ited GA, et al. Acute effect of lamotrigine (BW 430C) in persons with epilepsy. Epilepsia; 1986;27:348—357.
Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-541.
Jawad S, Yuen WC, Peck AW, et al. Lamotrigine: Singledose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987;1:194-201.
Warner T, Patsalos PN, Prevett M, et al. Lamotrigine-induced carbamazepine toxicity: An interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992; 11:147— 150.
Depot M, Powell JR, Messenheimer JA Jr, et al. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 1990;48:346-355.
Cociglio M, Alric R, Bouvier O. Performance analysis of a reversed-phase liquid chromatographic assay of lamotrigine in plasma using solvent-demixing extraction. J Chromatogr Biomed Appl 1991;572:269-276.
Biddlecombe RA, Dean KL, Smith CD, Jeal SC. Validation of a radioimmunoassay for the determination of human plasma concentrations of lamotrigine. J Pharm Biomed Analg 1990;8:691-694.
Nicholson RJ, Kelly KP, Grant IS. Leucopenia associated with lamotrigine. Br Med J 1995;310:504.
Betts T, Goodwin G, Withers RM, Yuen AWC. Human safety of lamotrigine. Epilepsia 1991 ;32(suppl. 2):S 17—S21.
Buckley A, White JM, Dawson АН. Self-poisoning with lamotrigine. Med J Aust 1993; 159:488.
Brodie MJ, Porter RJ. New and potential anticonvulsants. Lancet 1990;336:425-426.
Kessler D, FDA Director, Statement, August 1994.
Ahmad SR. Felbamate and aplastic anemia. Lancet 1994;344:465.
Luciano D, Devinsky O, Raguthu S, et al. Movement disorders during felbamate therapy. Epilepsia 1994;35(suppl. 18):159.
Felbamate product literature. Cranbury, NJ: Wallace Laboratories, July 31, 1993.
Wilensky AJ, Friel PN, Ojemann LM, et al. Pharmacokinetics of W-554 (ADD 03 055) in epileptic patients. Epilepsia 1985;26:602-606.
Jachel RA. Stevens—Johnson syndrome after treatment with felbamate. Epilepsia 1994;35:98.
De Giorgio CM, Lopez J, Lekht ZN, Rabinowicz A. Status epilepticus induced by felbamate withdrawal. Neurology 1995;45:1021-1022.
Gabapentin: A new anticonvulsant Med Lett Drugs Ther 1994;36(921):39—40.
Gabapentin: A new antiepileptic drugs. Drug Ther Bull 1994;32(4):29—30.
Fischer JH, Barr AN, Rogers SL, et al. Lack of serious toxicity following gabapentin overdose. Neurology 1994;4:982-983.
Garofalo E, Koto E, Feuerstein T. Experience with gabapentin overdose: Five case studies. Epilepsia 1993;34:157.
Tyndel F. Interaction of gabapentin with other antiepileptics. Lancet 1994;242:1363-1364.
Radulovic LL, Wilder BJ, Leppik IE, et al. Lack of interaction of gabapentin with carbamazepine or valproate. Epilepsia 1994;35:155-161.
UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:1114— 1119.
Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:300.
New drugs for epilepsy on the way. Pharm J 1991;247:534.
Hengy WD, Kavanagh MC, Diskinson RB. Determination of gabapentin in plasma and urine by high-performance liquid chromatography and pre-column labelling for ultraviolet detection. J Chromatogr 1985;341:473—-478.
Harper WD, Kavanagh MC, Diskinson RB. Determination of gabapentin in plasma and urine by capillary column gas chromatography. J Chromatogr 1990;529:167— 174.
Browne TR. Efficacy and safety of gabapentin. In: Chadwick D, ed. New Trends in Epilepsy Management. London: Royal Society of Medicine Series, 1993:47—57.
Fernandez M, Walter F, Peterson L, Walkotte S. Gabapentin overdose: Elevated levels with minimal clinical effects. Clin Toxicol 1995;33:475-486 (Abstract 92).
Welch TR, Rumack BH, Hammond К. Clonazepam overdose resulting in cyclic coma. Clin Toxicol 1977;10:433-436.
Greenblatt DJ, Miller LG, Schader RI. Clonazepam pharmacokinetics, brain uptake and receptor interactions. J Clin Psychiatry 1987;48( 10, suppl.):4—9.
Berlin A, Dahlstron H. Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses and by repeated oral administration. Eur J Clin Pharm 1975;9:155-159.
Andre M, Boutray MJ, Bianchetti G, et al. Clonazepam in neonatal seizures: Dose regimens and therapeutic efficacy. Eur J Clin Pharmacol 1991;40:193-195.
Cohen LS, Rosenbaum JF. Clonazepam: New uses and potential problems. J Clin Psychiatry 1987;48( 10, sup-pl):50—55.
Binder RL. Three case reports of behavioral disinhibitors with clonazepam. Gen Hosp Psychiatry 1987;9:151 — 153.
Olsson R, Zettergron L. Anticonvulsant-induced liver damage. Am J Gastroenterol 1988;83:576-577.
De Carvalho D, Lancote VL. Measurement of plasma clonazepam for therapeutic control: A comparison of chromatographic methods. Ther Drug Monitor 1991;13:55-61.
Rey E, d’Athis P, deLauture D, et al. Pharmacokinetics of carbamazepine in the neonate and in the child. Int J Clin Pharmacol Biopharm 1979;17:90-96.
Tomson T, Tybring G, Bertilsson L. Single dose kinetics and metabolism of carbamazepine-10, 11-epoxide. Clin Pharmacol Ther 1983;33:58-65.
Yerby MS, Friel PN, Miller DQ. Carbamazepine protein binding and disposition in pregnancy. Ther Drug Monit 1985;7:269-273.
Eichelbaum M, Ekbom K, Bertilsson L, et al. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol 1974;8:337-341.
Luke DR, Rocci ML Jr, Schaible DH, et al. Toxicokinetics of carbamazepine and its 10,11-epoxide. Vet Hum Toxicol 1985;28:315.
Pynnonen S, Sillanpaa M, Frey H, et al. Carbamazepine and 10,11-epoxy carbamazepine levels in children. Proc Eur Soc Toxicol 1977;18:192-194.
Westenberg HGM, Van der Kleijn E, Oei TT, et al. Kinetics of carbamazepine and carbamazepine-epoxide determined by use of plasma and saliva. Clin Pharmacol Ther 1978;23:320-328.
Tegretol* (carbamazepine). In: Physicians’ Desk Reference. 41st ed. Oradell, NJ: Medical Economics, 1987:962-964.
Valsalan VC, Cooper GL. Carbamazepine intoxication caused by interaction with isoniazid. Br Med J 1982;285:261-262.
Grimsley SR, Jann MW, D’Mello AP, et al. Pharmacodynamics and pharmacokinetics of fluoxetine/car-bamazepine interaction. Clin Pharmacol Ther 1991;49:!35.
Mitsch RA. Carbamazepine toxicity precipitated by intravenous erythrocin. DICP Ann Pharmacother 1989;232:878-879.
Allen S. Cerebella dysfunction following dextropropoxyphene-induced carbamazepine toxicity. Postgrad Med J 1994;70:764-769.
Arana GW, Epstein S. Molloy M, Greenblatt DJ. Carbamazepine-induced reduction of plasma alprazolam concentrations: A clinical case report. J Clin Psychiatry 1988;49:448-449.
Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-677.
Vestermark V, Vestermark S. Teratogenic effect of carbamazepine. Arch Dis Child 1991;66:641-642.
Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320:1661-1666.
Donaldson JO. The pregnant epileptic fetal risks from anticonvulsant therapy. JAMA 1990;264:1044.
Frey B, Schubiger G, Musy JP. Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breast feeding. Eur J Pediat 1990;150:136-138.
Weaver DF, Camfield P, Fraser A. Massive carbamazepine overdose: Clinical and pharmacologic observations in five episodes. Neurology 1988;38:755-759.
Kasarskis EJ, Juo C-S, Berzer R, Nelson KR. Carbamazepine-induced cardiac dysfunction: Characterization of two distinct clinical syndromes. Arch Intern Med 1992;152:186-191.
Meissner C. Carbamazepine (Finlepsin*): Vergiftung mit toxischer Myokardschadigung. Eine Kasuitsik. Z Klin Med 1990;45:261-264.
Appleby L. Rapid development of hyponatremia during low dose carbamazepine therapy. J Neurol Neurosurg Psychiatry 1984;47:1138-1140.
Livingston S, Pauli L, Berman W. Carbamazepine (Tegretol) in epilepsy. Dis Nerv Syst 1974;35:103-107.
Mack RB. Julius seizure: Carbamazepine (Tegretol) poisoning. NC Med J 1985;46( 1 ):41 —42.
Jubert P, Almirall J, Casanovas A, Garcia M. Carbamazepine-induced acute renal failure. Nephron 1994;66:121.
Di Giorgio CM, Rabinowicz AL, Olivas RD. Carbamazepine-induced antinuclear antibodies and systemic lupus erythematosus-like syndrome. Epilepsia 1991;32:128-129.
Carbamazepine and "pseudolymphoma." Aust Adverse Drug React Bull 1991; 10(l):3.
Sinnige HAM, Boender CA, Kuypers EW, Ruitenberg HM. Carbamazepine-induced pseudolymphoma and immune dysregulation. J Intern Med 1990;227:355-358. Case Report.
Cochran EB, Massey KL, Phelps SJ. A rapid noninstrumented whole blood carbamazepine assay for pediatric patients. J Pediatr 1990;116:307-310.
Hojer J, Malmlund H-A, Berg A. Clinical features in 28 consecutive cases of laboratory confirmed massive poisoning with carbamazepine abuse. Clin Toxicol 1993;25:449-458.
Spiller HA, Krenzelok EP. Carbamazepine overdose: Serum concentration less predictive in children. Clin Toxicol 1993;31:459-460.
Howard RS, Trend PSTJ, Townsend HRA. EEG appearances in acute carbamazepine toxicity. Hum Exp Toxicol 1990;9:313-315.
Seymour JF. Carbamazepine overdose: Features of 33 cases. Drug Saf 1993;8:81-88.
Apfelbaum JD, Caravati EM, Kenis WP, et al. Cardiovascular effects of carbamazepine toxicity. Ann Emerg Med 1994;33:31.
Lahr MB. Hyponatremia during carbamazepine therapy. Clin Pharmacol Ther 1985;37:693-696.
Wason S, Baher RC, Carolan P, et al. Carbamazepine overdose: The effects of multiple dose activated charcoal. Clin Toxicol 1992;30:39-48.
Leslie PJ, Heyworth R, Prescott LF. Cardiac complications of carbamazepine intoxication: Treatment by haemoperfusion. Br Med J 1983;286:1018.
Gary NE, Byra WM, Eisinger RP. Carbamazepine poisoning: Treatment by haemoperfusion. Nephron 1981;27:202-203.
De Groot, Van Heijst ANP, Maes RAA. Charcoal hemoperfusion in the treatment of two cases of acute carbamazepine poisoning. Clin Toxicol 1984;22:349— 369.
Chan KM, Aguanno JJ, Jansen R, et al. Charcoal hemoperfusion for treatment of carbamazepine poisoning. Clin Chem 1981 ;27(7): 1300— 1302.
Vuignier Bl, Woo OF, Becker CE. Fatal carbamazepine overdose with seizures: Role of charcoal hemoperfusion. Vet Hum Toxicol 1986;28(5):304 (Abstract 158).
Nilsson C, Sterner G, Idvall J. Charcoal hemoperfusion for treatment of serious carbamazepine poisoning. Acta Med Scand 1984;216:137-140.
Zuber M, ElsasserS, Ritz R, Scollo-Lavizzari G. Fluma-zenil (Anexate*) in severe intoxication with carbamazepine (Tegretol*). Eur Neurol 1988;28:161-163.
Baselt RC, Cravey RH. Disposition of Toxic Drugs and Chemicals in Man. 3rd ed. Chicago: Year Book, 1989:199-201.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda: American Society of Hospital Pharmacists, 1994:1353— 1355.
Browne TR. Clonazepam. Arch Neurol 1976;3:326— 332.
Coutselinis A, Poulos L. An unusual case of carbamazepine poisoning with a near-fatal relapse after two days. Clin Toxicol 1980;16:385-387.
Bridge TA, Norton RL, Robertson WA. Pediatric carbamazepine overdose. Pediatr Emerg Care 1994;10:200-263.
Eadie MJ. Anticonvulsant drugs: An update. Drugs 1984;27:328-362.
Morselli PL, Frigerio A. Metabolism and pharmacokinetics of carbamazepine. Drug Metab Rev 1975;4:97— 113.
Rey E, d’Athis P, deLauture D, et al. Pharmacokinetics of carbamazepine in the neonate and in the child, hit J Clin Pharmacol Biopharm 1979;17:90-96.
Tomson T, Tybring G, Bertilsson L. Single dose kinetics and metabolism of carbamazepine-10, 11-epoxide. Clin Pharmacol Ther 1983;33:58-65.
Yerby MS, Friel PN, Miller DQ. Carbamazepine protein binding and disposition in pregnancy. Ther Drug Monit 1985;7:269-273.
Eichelbaum M, Ekbom K, Bertilsson L, et al. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol 1974;8:337-341.
Luke DR, Rocci ML Jr, Schaible DH, et al. Toxicokinetics of carbamazepine and its 10,11-epoxide. Vet Hum Toxicol 1985;28:315.
Pynnonen S, Sillanpaa M, Frey H, et al. Carbamazepine and 10,11-epoxy carbamazepine levels in children. Proc Eur Soc Toxicol 1977;18:192-194.
Westenberg HGM, Van der Kleijn E, Oei TT, et al. Kinetics of carbamazepine and carbamazepine-epoxide determined by use of plasma and saliva. Clin Pharmacol Ther 1978;23:320-328.
Tegretol* (carbamazepine). In: Physicians’ Desk Reference. 41st ed. Oradell, NJ: Medical Economics, 1987:962-964.
Valsalan VC, Cooper GL. Carbamazepine intoxication caused by interaction with isoniazid. Br Med J 1982;285:261-262.
Grimsley SR, Jann MW, D’Mello AP, et al. Pharmacodynamics and pharmacokinetics of fluoxetine/car-bamazepine interaction. Clin Pharmacol Ther 1991 ;49:135.
Mitsch RA. Carbamazepine toxicity precipitated by intravenous erythrocin. DICP Ann Pharmacother 1989;232:878-879.
Allen S. Cerebella dysfunction following dextropropoxyphene-induced carbamazepine toxicity. Postgrad Med J 1994;70:764-769.
Arana GW, Epstein S. Molloy M, Greenblatt DJ. Carbamazepine-induced reduction of plasma alprazolam concentrations: A clinical case report. J Clin Psychiatry 1988;49:448-449.
Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-677.
Vestermark V, Vestermark S. Teratogenic effect of carbamazepine. Arch Dis Child 1991;66:641-642.
Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320:1661-1666.
Donaldson JO. The pregnant epileptic fetal risks from anticonvulsant therapy. JAMA 1990;264:1044.
Frey B, Schubiger G, Musy JP. Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breast feeding. Eur J Pediat 1990;150:136-138.
Weaver DF, Camfield P, Fraser A. Massive carbamazepine overdose: Clinical and pharmacologic observations in five episodes. Neurology 1988;38:755-759.
Kasarskis EJ, Juo C-S, Berzer R, Nelson KR. Carbamazepine-induced cardiac dysfunction: Characterization of two distinct clinical syndromes. Arch Intern Med 1992;152:186-191.
Meissner C. Carbamazepine (Finlepsin*): Vergiftung mit toxischer Myokardschadigung. Eine Kasuitsik. Z Klin Med 1990;45:261-264.
Appleby L. Rapid development of hyponatremia during low dose carbamazepine therapy. J Neurol Neurosurg Psychiatry 1984;47:1138-1140.
Livingston S, Pauli L, Berman W. Carbamazepine (Tegretol) in epilepsy. Dis Nerv Syst 1974;35:103-107.
Mack RB. Julius seizure: Carbamazepine (Tegretol) poisoning. NC Med J 1985;46( 1 ):41 —42.
Jubert P, Almirall J, Casanovas A, Garcia M. Carbamazepine-induced acute renal failure. Nephron 1994;66:121.
Di Giorgio CM, Rabinowicz AL, Olivas RD. Carbamazepine-induced antinuclear antibodies and systemic lupus erythematosus-1 ike syndrome. Epilepsia 1991;32:128-129.
Carbamazepine and "pseudolymphoma." Aust Adverse Drug React Bull 1991; 10( 1 ):3.
Sinnige HAM, Boender CA, Kuypers EW, Ruitenberg HM. Carbamazepine-induced pseudolymphoma and immune dysregulation. J Intern Med 1990;227:355-358. Case Report.
Cochran EB, Massey KL, Phelps SJ. A rapid noninstrumented whole blood carbamazepine assay for pediatric patients. J Pediatr 1990;116:307-310.
Hojer J, Malmlund H-A, Berg A. Clinical features in 28 consecutive cases of laboratory confirmed massive poisoning with carbamazepine abuse. Clin Toxicol 1993;25:449-458.
Spiller HA, Krenzelok EP. Carbamazepine overdose: Serum concentration less predictive in children. Clin Toxicol 1993;31:459-460.
Howard RS, Trend PSTJ, Townsend HRA. EEG appearances in acute carbamazepine toxicity. Hum Exp Toxicol 1990;9:313-315.
Seymour JF. Carbamazepine overdose: Features of 33 cases. Drug Saf 1993;8:81-88.
Apfelbaum JD, Caravati EM, Kerns WP, et al. Cardiovascular effects of carbamazepine toxicity. Ann Emerg Med 1994;33:31.
Lahr MB. Hyponatremia during carbamazepine therapy. Clin Pharmacol Ther 1985;37:693-696.
Wason S, Baher RC, Carolan P, et al. Carbamazepine overdose: The effects of multiple dose activated charcoal. Clin Toxicol 1992;30:39-48.
Leslie PJ, Heyworth R, Prescott LF. Cardiac complications of carbamazepine intoxication: Treatment by haemoperfusion. Br Med J 1983;286:1018.
Gary NE, Byra WM, Eisinger RP. Carbamazepine poisoning: Treatment by haemoperfusion. Nephron 1981;27:202-203.
De Groot, Van Heijst ANP, Maes RAA. Charcoal hemoperfusion in the treatment of two cases of acute carbamazepine poisoning. Clin Toxicol 1984;22:349— 369.
Chan KM, Aguanno JJ, Jansen R, et al. Charcoal hemoperfusion for treatment of carbamazepine poisoning. Clin Chem 1981 ;27(7):1300-1302.
Vuignier Bl, Woo OF, Becker CE. Fatal carbamazepine overdose with seizures: Role of charcoal hemoperfusion. Vet Hum Toxicol 1986;28(5):304 (Abstract 158).
Nilsson C, Sterner G, Idvall J. Charcoal hemoperfusion for treatment of serious carbamazepine poisoning. Acta Med Scand 1984;216:137-140.
Zuber M, ElsasserS, Ritz R, Scollo-Lavizzari G. Fluma-zenil (Anexate*) in severe intoxication with carbamazepine (Tegretol*). Eur Neurol 1988;28:161-163.
French J. The long-term therapeutic management of epilepsy. Ann Intern Med 1994;120:411-422.
Morrow JI, Routledge PA. Poisoning by anticonvulsants. Adverse Drug React Acute Poison Rev 1989;8(2):97— 109.
Alldredge BK, Knutsen AP, Ferriero D. Antiepileptic drug hypersensitivity syndrome: In vitro and clinical observations. Pediatr Neurol 1994;10:169-171.
Scerri L, Shall L, Zaki I. Carbamazepine-induced anticonvulsant hypersensitivity syndrome: Pathogenic and diagnostic considerations. Clin Exp Dermatol 1993;18:540-542.
Handfield-Jones SE, Jankins RE, Whittaker SJ, et al. The anticonvulsant hypersensitivity syndrome. Br J Dermatol 1993;129:175-177.
Meadow R. Anticonvulsants in pregnancy. Arch Dis Child 1991;66:62-65.
De Krom MCTFM, Verduin N, Visser E, et al. Three cases with status epilepticus during vigabatrin treatment. J Neurol Neurosurg Psychiatry 1994;57:1294-1295.
Liporace JD, Sperling MP, Dichter MA. Absence seizures and carbamazepine in adults. Epilepsia 1994;35:1026-1028.
Walker JF, Shapiro DR. Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia. Am J Cardiol 1990;65:19F—22F.
Maker VMG, Thompson GR. HMG CoA reductase inhibitors as lipid-lowering agents: Five years experience with lova-statin and an appraisal of simvastatin and pravastatin. Q J Med 1990;74:165-175.
Dunnigan MG. Should clofibrate still be prescribed? Further trials with harder end points are needed for all lipid-lowering drugs. Br Med J 1992;205:379-380.
Krukemyer JJ, Talbert RL. Lovastatin: a new cholesterol-lowering agent. Pharmacotherapy 1987;7:198-210.
Smellie WAS, Lorimer AR. Adverse effects of the lipid-lowering drugs. Adverse Drug React Toxicol Rev 1992;11:71-92.
Boselli BA. Parke-Davis, personal communication, March 1991.
Pan HY. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. EurJ Clin Pharmacol 1991 ;40(suppl. 1):515—518.
Henwood JM, Heel RC. Lovastatin: A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 1988;36:429-454.
Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-32.
Singvhi SM, Pan HY, Morrison RA, Willard DA. Disposition of pravastatin sodium, a tissue selective HMG-CoA reductase inhibitor in healthy subjects. Br J Clin Pharmacol 1990;29:239-243.
Pan HY, de Vault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990;48:201-207.
Pravastatin and simvastatin for hypercholesterolemia. Med Lett Drugs Ther 1991 ;33(830): 18-20.
Mauro VF, MacDonald JL. Simvastatin: A review of its pharmacology and clinical use. DICP Ann Pharmacoth-er 1991;25:257-264.
Pentikainen PJ, Saraheimo M, Schwartz JI, et al. Comparative pharmacokinetics of lovastatin, simvastatin, pravastatin in humans. J Clin Pharmacol 1992;32:136— 140.
Endele R. A gas chromatographic method for the determination of bezafibrate in serum and urine. J Chroma-togr 1978;154:261-263.
Okerholm RA, Keeley FJ, Peterson FE, Glazko AJ. The metabolism of gemfibrozil. Proc R Soc Med 1976;69(suppl. 2): 11-14.
Zimetbaum P, Eder H, Frishman W. Probucol: Pharmacology and clinical application. J Clin Pharmacol 1990;30:3-9.
McTavish D, Sorkin EM. Pravastatin: A review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs 1991;42:65-89.
Halstenson CE, Triscari J, de Vault A, et al: Single dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 1992;32:124-132.
Farmer JA, Gotto AA Jr. Antihyperlipidaemia agents: Drug interactions of clinical significance. Drug Saf 1994;11:301-309.
Gaw A, Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinemia. Lancet 1992;340:979-980.
Ahmad S. Lovastatin-induced lupus erythematosus. Arch Intern Med 1991;151:1667-1668.
Broisman L, Englster P, Chow MSS. Focus on pravastatin, an HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Hosp Formal 1991;76:552-563.
Ghidini A, Sicherer S, Willner J. Congenital abnormal-ities/(VATER) in baby born to mother using lovastatin. Lancet 1992;339:1416-1417.
Armstrong K, Kelly AJ. Bezafibrate and cholelithiasis. Eur J Gastroenterol Hepatol 1993;5:665.
Bannwarth B, Miremont G, Papapietro P-M. Lupus-like syndrome associated with simvastatin. Arch Intern Med 1992; 152:1093.
French J, White H. Transient symptomatic hypotension in patients on simvastatin. Lancet 1989;2:807-808.
Deslypere JP, Delanghe J, Vermeulen A. Proteinuria as complication of simvastatin treatment. Lancet 1990;336:1093.
Paresthesias and neuropathy with hypolipidemic agents. Aust Adverse Drug React Bull 1993; 12(2):6.
Probucol (LorelcoR): Product literature. Merrell Dow, November 1985.
Milander JH. Merck Sharp Dohme, personal communication, January 1989.
Randinitis E, Kirkel AW, Nelson C, Parker TD. Gas chromatographic determination of gemfibrozil and its metabolites in plasma and urine. J Chromatogr 1984;307:210-215.
Hengy H, Kolle V. Determination of gemfibrozil in plasma by high performance liquid chromatography. Arzne-imittelforschung 1985; 35:1637— 1639.
Lavazzari M, Milanesi G, Oggioni E, Pamparana F. Results of a phase IV study carried out with acipimox in type 11 diabetic patients with concomitant hyperlipoproteinemia. J Int Med Res 1989;17:373-380.
Series JJ, Gaw A, Kilday C, et al. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia. Br J Clin Pharmacol 1990;30:49-54.
Stubbs RJ, Schwartz M, Bayne WM. Determination of mevinolin and merivolinic acid in plasma and bile by reverse phase HPLC. J Chromatogr 1986;383:438-443.
Fimke PT, Ivashkir E, Arnold HE, Cohen Al. Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatogra-phy/negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom 1989;18:949-959.
Schoneshofer M, Heilmann P, Schwab L, Schwartzkopff W. Automatic column liquid chromatographic determination of probucol in human serum and lipoprotein fraction. J Chromatogr 1989;49:230-235.
Smith HT, Jokabaitis LA, Troendle AJ, et al: Pharmacokinetics of fluvastatin and specific drug interaction. Am Hypotension 1993;6:375S— 382S.
Pirarro S, Bargoy V, D’Agostin P. Gemfibrozil-induced impotence. Lancet 1990;336:155.
Ohya Y, Kumamoto K, Trubota Y, Fujishima M. Factors related to QT interval prolongation during probucol treatment. Eur J Clin Pharmacol 1993;345:47-52.
Kajinami K, Takekoshi M, Mabuchi H. Propranolol for probucol-induced QT prolongation with polymorphic ventricular tachycardia. Lancet 1993;34:124-125.
Gohn DC, Simmons TW. Polymorphic ventricular tachycardia (Torsade de pointes) associated with the use of probucol. N Engl J Med 1992;326:1435-1436.
Henkin Y, Como JA, Oberman A. Secondary dyslipidemia: Inadvertent effects of drugs in clinical practice. JAMA 1992;267:961-968.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 29th ed. London: Pharamceutical Press, 1989:1514— 1515.
Pentoxifylline. In: McEvoy GK, ed. AHFS Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, 1992:796—799.
Ambrus JL, Anain JM, Anain SM, et al. Dose-response effects of pentoxifylline on erythrocyte filterability: Clinical and animal model studies. Clin Pharmacol Ther 1990;48:50-56.
Radack K, Wyderski AJ. Conservative management of intermittent claudication. Ann Intern Med 1990;113:134-146.
Dannenhoffer MA, Rozek S. Pentoxifylline in sickle cell anemia. Drug Intell Clin Pharm 1987;21:620.
Cocci AMT, Waxman K, Soliman MH, et al. Pentoxifylline improves survival following hemorrhagic shock. Crit Care Med 1989;17:36-38.
Colgan M-P, Dormandy JA, Jones PW, et al. Oxpenti-fylline treatment of venous ulcers of the leg. Br Med J 1990;30:972-975.
Ely H, Bard JW. Therapy of livedo vasculitis with pen-toxifyiline. Cutis 1988;42:448-453.
Cohen KL, Harris S. Pentoxifylline and diabetic neuropathy. Ann Intern Med 1987;107:600-601.
Garnier R, Riboulet-Delmas G, Chatenet T, Efthymiou ML. Acute pentoxifylline poisoning in children. Ann Pediatr (Paris) 1986;33:62-63.
Ward A, Clissold SP. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs 1987;34:50-97.
Szinajder IJ, Bentur Y, Taitelman U. First and second degree atrioventricular block in oxpentifylline overdose. Br Med J 1984;288:26.
Chatenet T. Bilan de sept annees d’observation de toren-tel (pentoxifylline) par le Centre Anti-Poisons de Paris These de Medecine. [Balance sheet of seven years of observation ofTorental® (pentoxifylline) by the Paris AntiPoison Center.) Paris: Anti-Poison Center, 1983.
Fischer JM. Hoechst-Roussel Pharmaceuticals, Somerville, NJ, personal communication, December I, 1988.
Rames A, Poirier J-M, Le Coz F, et al. Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther 1990;47:354-359.
Bearman B, Ings R, Mansky J, et al. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther 1985;37:25-28.
Barclay LL, Blass JP, Bondy DA. Pentoxifylline and aspirin in circulatory dementias. Clin Res 1989;37:527A.
Brunner U, Vadiei K, Iyer LV, Luke DR. Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. Renal Failure 1989:11:97 — 104.
Witter FR, Smith RV. The excretion of pentoxifylline and its metabolites into human breast milk. Am J Obstet Gynecol 1985:151:1094-1097.
Rao KMK, Some! DL, Crawford J, et al. Leukocyte function and blood viscosity in patients receiving pentoxifylline. Clin Res 1989:37:341 A.
Sarina PSA. Pentoxifylline in septic shock. Postgrad Med J 1990:66:980-982.
Mandell GL. ARDS, neutrophils and pentoxifylline. Am Rev Respir Dis 1988:1103—1105.
Welsh CH, Lien D, Worthen S, Weil JV. Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog. Am Rev Respir Dis 1988:138:1106—1114.
Deizube BJ, Fridovich-Keil JL, Bouvard 1, et al. Pentoxifylline and well-being in patients with cancer. Lancet 1990; 335:662.
Grasela DM, Rocci M Jr. High performance liquid chro-mato-graphic analysis of pentoxifylline and l-(5’-hy-droxylexyl)-3,7-dimethylxanthine in whole blood. J Chromatogr 1987:419: 368—379.
Garnier-Moiroux A, Poirier J-M, Cheymol G. High performance liquid chromatographic determination of pentoxifylline and its hydroxy metabolite in human plasma. J Chromatogr Biomed Appl 1987:416:183—188.
Lambert WE, Yousouf MA, Van Liedekerke BM, et al. Simultaneous determination of pentoxifylline and three metabolites in biological fluids by liquid chromatography. Clin Chem 1989:35:298-311.
Walmsley LM, Wilkinson РА, Brodie RR, Chasseaud LF. Determination of naftidofuryl in human plasma by high performance liquid chromatography with fluorescence detection. J Chromatogr Biomed Appl 1985;338:433-437.
Steiner TJ. Naftidofuryl in the treatment of recent stroke: Results of a controlled clinical trial. Vasa Suppl 1988;24:44-47.
Krieglstein J, Sauer D, Nuglisch J, et al. Naftidofuryl protects neurons against ischemic damage. Eur Neurol 1989;29:224-228.
Connolly MJ, Young JB, Naylor JR. Treating leg cramps: Naftidofuryl is a safe and effective alternative. Br Med J 1995;310:1138.
Rey JL, Marek A, Tribouilloy C, et al. Massive naftidofuryl poisoning with severe disorders of cardiac rhythm and conduction. Arch Mai Coeur 1989;82: 1467-1471.
Khan SA, Pace JE, Cox ML. Respiratory distress secondary to naftidofuryl. Br Med J 1990;301:1219.
Fujikura H, Kato H, Nakano S, Kogure K. A serotonin S2 antagonist, naftidofuryl, exhibited a protective effect on ischemic neuronal damage in the gerbil. Brain Res 1989;494:387-390.
Sadler DW, Quigley C. A fatal overdose of naftidofuryl (Praxilene®)). Bull Int Assoc Forens Toxicol 1991;21(4):29—32.
Ducloux G, Marchand X, Lasurent JM, et al. Cardiovascular complications due to naftidofuryl overdose. Ann Cardiol Angeiol 1985;34:167-169. Case report.
Moesch C, Rince M, Daudon M, et al. Renal intratubular crystallization of calcium oxalate and naftidofuryl oxalate. Lancet 1991;338:1219-1220.
Cuvelier C, Goffin E, Cosyns J-P, et al. Acute renal failure due to naftidofuryl oxalate (PraloxineR) overdose in a kidney transplant recipient. Nephrol Dial Transplant 1995;10:1756-1758.
Le Meur Y, Moesch C, Rince M, et al. Potential nephrotoxicity of intravenous infusions of naftidofuryl oxalate. Nephrol Dial Transplant 1995; 10: 1751 — 1755.
Med Lett Drugs Ther 1993;35(892):23—24.
Barnett DB. Flosequinan. Lancet 1993;341:733-736.
Haynes WG, Webb DJ. Flosequinan in heart failure. Lancet 1993;341:1100-1101.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:360.
Mayor GH. Boots Pharmaceuticals, Lincolnshire, IL, Dear Doctor Letter, April 23, 1993.
Flosequinan withdrawn. Lancet 1993;342:235.
Noble J, Farrer M, McComb JM. Flosequinan and ar-rhythmogenesis. Lancet 1993;341:1100.
Mayor GH. Boots Pharmaceuticals, Lincolnshire, IL, personal communication, June 28, 1993.
Laporte J-R, Capella D. Useless drugs are not placebos: Lessons from flunarizine and cinnarizine. Lancet 1986;2:853-854.
Todd PA, Benfield P. Flunarizine: A reappraisal of its pharmacological properties and therapeutic use in neurological disorders. Drugs 1989;38:487-499.
Micheli F, Pardal MF, Gatto M, et al. Flunarizine and cinnarizine-induced extrapyramidal reactions. Neurology 1987;37:881-884.
Nitsche V, Mascher H. Rapid high-performance liquid chromatographic assay of cinnarizine in human plasma. J Chromatogr 1982;227:521-525.
German DC, Krechich VM, Bjomsson TD. Oral dipyridamole increases plasma adenosine levels in human beings. Clin Pharmacol Ther 1989;45:80-84.
Wolfram KM, Bjornsson TD. High-performance liquid chromatographic analysis of dipyridamole in plasma and whole blood. J Chromatogr Biomed Appl 1980; 183:57— 64.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:225—226.
Dypyridamole. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:1180—1181.
Physicians' Desk Reference. 49th ed. Montvale, NJ: Medical Economics, 1994:43.
Beeley L. Dipyridamole in prevention of myocardial infarct and strokes. Br Med J 1987;295:1553.
Friedman HZ, Goldberg SF, Hauser AM, O’Neill WW. Death with dipyridamole thallium imaging. Ann Intern Med 1988;109:990-991.
Tellier P, Paycha F, Antony I, et al: Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis. Am J Med 1988;85:189-193.
Bowers PA. Boehringer-Ingelheim Pharmaceuticals, personal communication, January 23, 1992.
Ranhosky A. Dipyridamole-induced myocardial ischemia. JAMA 1987;258:2O3.
Pennell DJ, Underwood SR, Ell PJ. Symptomatic bradycardia complicating the use of intravenous dipyridamole for thallium-201 myocardial perfusion imaging. Int J Cardiol 1990;27:272-274.
Keltz TN, Innerfteld M, Gitler B, Cooper JA. Dipyridamole-induced myocardial ischemia. JAMA 1987;257:1516-1517.
Kwai AH, Jacobson AF, McIntyre KM, et al. Persistent chest pain following oral dipyridamole for thallium-201 myocardial imaging. Eur J Nucl Med 1990;16:745-746.
Jahangiri M, Holdright DR. Myocardial infarction secondary to dipyridamole overdose. Arch Emerg Med 1992;9:62-64.
Yamamoto S, Matsuura H, Umezawa T, et al: Dipyridamole-induced ischemia in a child with jeopardized collaterals after Kawasaki syndrome. Jpn Heart J 1990;31:867-874.
Mellinger TJ, Bohorfusch JG. Pathways and tissue distribution of dipyridamole (Persantin®)). Arch Int Phar-macodyn 1965;156:380-388.
Bjornsson TD, Mahony C. Clinical pharmacokinetics of dipyridamole. Thromb Res 1983;suppl. IV:93—104.
Kopitar Z, Weisenberger H. Spezifische bindung von dipyridamol an ein menschliches serumprotein. Arznei-mittelforschung 1971;21(6):859—862.
Kubler W. Die bindung des koronarcilatators dipyridamol and die plasma eiweisskorper des menschen. Arch Kreislaufforsch 1971;64:115-128.
Beisenherz G, Koss F, Klatt L, Binder B. The absorption and excretion of 2,6-bis(diethanolamino)-4,8-dipiperid-inopyrimido-(5,4-d)pyrimidine after oral administration. Arch Int Pharmacodyn 1965;158:380-388.
Beisenherz G, Koss FW, Schule A, et al. Das schicksal des 2,6-bis(diathanlamino)-4,8-dipiperidine-pyrimi-do(5,4-d) pyrimidin im menschlichen und tierischen or-ganismus. Arzneimittelforschung 1960;10:307-312.
Wyngaarden JB. Dipyridamole may enhance effectiveness of AIDS therapy. JAMA 1989;262:17.
Szebeni J, Wahl SM, Popovic M, et al. Dipyridamole potentiates the inhibition by 3’-azido-3’-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocytes-macrophages. Proc Natl Acad Sci USA 1989;86:3842-3846.
Klabunde RE. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 1983;93:21 — 26.
Smits P, Straatman C, Pijpers E, Thien T. Dose-dependent inhibitions of the hemodynamic response to dipyridamole by caffeine. Clin Pharmacol Ther 1991;50:529— 537.
Taguchi K. Pregnancy in patients with a prosthetic heart valve. Surg Gynecol Obstet 1977;145:206-208.
Biale Y, Cantor A, Lewenthal H, Gueron M. The course of pregnancy in patients with artificial heart valves treated with dipyridamole. Int J Gynaecol Obstet 1980;18:128-132.
Ibara-Perez C, Arevalo-Toledo N, Alvarez de la Cadena O, Noriega-Guerra L. The course of pregnancy in patients with artificial heart valves. Am J Med 1976;61:504-512.
Chen WWC, Chan CS, Lee PK, et al. Pregnancy in patients with prosthetic heart valves: An experience with 45 pregnancies. Q J Med 1982;51:358-365.
Deviri E, Levinsky L, Yechezkel M, Levy MJ. Pregnancy after valve replacement with porcine xenograft prosthesis. Surg Gynecol Obstet 1985;160:437-443.
Sareli P, England MJ, Berk MR, et al. Maternal and fetal sequelae of anticoagulation during pregnancy in patients with mechanical heart valve prostheses. Am J Cardiol 1989;63:1462-1465.
Rajah SM, Crow MJ, Penny AF, et al. The effect of dipyridamole on platelet function: Correlation with blood levels in man. Br J Clin Pharmacol 1977;4:129— 133.
Wiener K. Interference in fluorescene/nephelometry assays by dipyridamole. Lancet 1981;2:634.
Eagle KA, Boucher CA. Intravenous dipyridamole infusion causes severe bronchospasm in asthmatic patients. Chest 1989;95:258-259.
Lette J, Cerino M, Laverdiere M, et al. Severe bronchospasm followed by respiratory arrest during thallium-dipy-ridamole imaging. Chest 1989;95:1345-1349.
Clissold SP, Lynch S, Sorkin EM. Buflomedil: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peripheral and cerebral vascular diseases. Drugs 1987;33:430-460.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1308.
Medernach C, Garnier R, Efthymiou M-L. Intoxication aigue par le buflomedil. Presse Med 1981; 10:3496.
Leys D, Pavy G, Bourgeois P, Petit H. Myoclonies au cours d’un traitement par buflomedil. Therapie 1985;40:481.
Otmane-Telba M, Gury B, Paulien R, et al. Toxicite neurologique reversible du surdosage au bufloniedil. Presse Med 1985; 14:286.
Treves R, Desproges-Gotteron R. Encephalopathie my-oclonique chez une malade traitee par une dose excessive de buflomedil. Presse Med 1983; 12:645.
Dane! V, Saviuc P, Vincent F, et al. Intoxication aigue mortelle au buflomedil. J Toxicol Clin Exp 1988;8:243— 246.
Bohn G, Ogbuihi S, Audick W. Buflomedil intoxication. Bull Int Assoc Forens Toxicol 1990;20(3):32—34.
Rop PP, Bresson M, Antoine J, et al. Quantitation and ultraviolet spectrum identification of buflomedil in whole blood and plasma by HPLC. J Anal Toxicol 1990; 14:18— 21.
Athanaselis S, Maravetias C, Michalodimitrakis M, Koutselinis A. Buflomedil concentrations in blood and viscera in a case of fatal intoxication. Clin Chem 1984;30:157.
Rey E, Barrier G, D’Athis P, et al. Pharmacokinetics of buflomedil after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 1980;18:437— 441.
Gundert-Remy U, Weber E, Lam G, et al. The clinical pharmacokinetics of buflomedil in normal subjects after intravenous and oral administration. Eur J Clin Pharmacol 1981;20:459-463.
Fredj G, Clenet M, Rousselet F. Dosage du buflomedil dans les millieux biologiques: Determination des differ-ents parametres pharmacocinetiques. Therapie 1978;33: 321-332.
Bachand RT, Dubourg AY. A review of long-term safety data with buflomedil. J Int Med Res 1990; 18:245— 252.
Martinez-Sierra R, Lara B, Torres A. Buflomedil intoxications The little-known risk. Clin Toxicol 1992;30:305-308.
Ghysel MH, Haguenoer JM. Three cases of fatal intoxication by buflomedil associated with alcohol or paracetamol. In: Proceedings, 29th International Meeting, International Association of Forensic Toxicologists, Copenhagen, Denmark, June 24—27, 1991:435—439.
Bepridil for angina pectoris. Med Lett Drugs Ther 1991;33(84S):53—54.
Bepridil. Lancet 1988;1:278-279. Editorial.
Lanneyde Courien JF, Martin J, Richalet A. Etude Clinique d’un nouvel anti-angineux le bepridil (a propos de 92 cas). Vie Med 1979;60:1675-1676.
Funck-Brentano C, Coudray P, Planellas J, et al. Effects of bepridil and diltiazem on ventricular repolarization in angina pectoris. Am J Cardiol 1990;66:812-817.
Deedwania P, Carbajal E, Bobba V, Linn L. Calcium channel block by bepridil compared to propranolol in the treatment of patients with chronic stable angina. Clin Pharmacol Ther 1987;41:241.
Shapiro W, Di Bianco R, Thadani U, Bepridil Collaborative Study Group. Comparative efficacy of 200, 300 and 400 mg of bepridil for chronic stable angina pectoris. Am J Cardiol 1985;55:36C-42C.
Hill JA, O’Brien JT, Alpert JS, et al. Effect of bepridil in patients with chronic stable angina: Results of a multicenter trial. Circulation 1985;71:98-103.
Benet LZ. Pharmacokinetics and metabolism of bepridil. Am J Cardiol 1985;55:8C-13C.
Malicier D, Malicier F, Gallet M, et al. Troubles du rythme ventriculaire graves lors d’un surdosage en bepridil (Cordium): A propos de deux observations. J Med Leg Droit Med 1986;29:157-164.
Coumel P. Safety of bepridil: From review of the European data. Am J Cardiol 1992;69:75D—78D.
Ng K-T, Phitte JA, Galante U. Determination of bepridil in biological fluids by high performance liquid chromatography. J Chromatogr Biomed Appl 1984;309:125— 131.
Vink J, Van Hal HJM, Pognat J-F, Bouquet des Chaux J-L. Determination of the anti-ischemic drug bepridil in human plasma using gas chromatography with nitrogensensitive detection. J Chromatogr Biomed Appl 1983;272:87-94.
Singh BN. Bepridil therapy: Guidelines for patient selection and monitoring of therapy. Am J Cardiol 1992;69:79D—85D.
Product Literature: Vascor (bepridil hydrochloride). McNeil Pharmaceuticals, December 27, 1990.
Nayak RK, Halstenson CE, Opsahl JA, et al. Pharmacokinetics of bepridil in hemodialysis patients. Clin Pharmacol Ther 1987;41:238.
Hollingshead LM, Faulds D, Fitton A. Bepridil: A review of its pharmacological properties and therapeutic use for stable angina pectoris. Drugs 1992;44:835— 857.
Ward A, Brogden RN, Heel RC, et al. Amrinone: A preliminary review of its pharmacological properties and therapeutic use. Drugs 1983;26:468-502.
Maisel AS, Wright CM, Carter SM, et al. Tachyphylaxis with amrinone therapy: Association with sequestration and down-regulation of lymphocyte beta-adrenergic receptors. Ann Intern Med 1989; 110:195— 201.
Treadway G. Clinical safety of intravenous amrinone: A review. Am J Cardiol 1985;56:39B—40B.
Product Literature: InocorR lactate injection. Brand of amrinone lactate: Sterile intravenous solution. Winthrop Pharmaceuticals, September 1989:1W161— X.
Amrinone. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:974—978.
Fita G, Gomar C, Jimenez MJ, et al. Amrinone in perioperative low cardiac output syndrome. Acta Anaesthe-siol Scand 1990;34:482-485.
Braunwald E, Julian D, eds. The Acute Therapy of Heart Failure. Intravenous Milrinone: A New Therapeutic Option. London: Royal Society of Medicine, 1991.
Prielipp RC, Butterworth JF IV, Zaloga GP, et al. Effects of amrinone on cardiac index, venous oxygen saturation and venous admixture in patients recovering from cardiac surgery. Chest 1991;99:820-825.
Berner M, Jaccard C, Oberhansli 1, et al. Hemodynamic effects of amrinone in children after cardiac surgery. Intensive Care Med 1990;16:85-88.
Hess W, Arnold B, Veit S. The haemodynamic effects of amrinone in patients with mitral stenosis and pulmonary hypertension. Eur Heart J 1986;7:800-807.
Hess W. Effects of amrinone on the right side of the heart. J Cardiothorac Anesth 1989;3:38-44.
Lawless S, Burckart G, Diven W, et al. Amrinone pharmacokinetics in neonates and infants. J Clin Pharmacol 1988;28:283-284.
Reich L. Winthrop Pharmaceuticals, personal communication, May 29, 1991. Submitted to the U. S. Food and Drug Administration as a Drug Experience Report, December 4, 1984.
Edelson J, LeJemtel TH, Alousi AA, et al. Relationship between amrinone plasma concentration and cardiac index. Clin Pharmacol Ther 1981;29:723-728.
Lawless S, Burckart G, Piccola G, et al. Simplified assay of amrinone in plasma by high-performance liquid chromatography. Ther Drug Monit 1990;12:570-573.
Wilmshurst PT, Webb-Peploe MM. Side effects of amrinone therapy. Br Heart J 1983;49:447-451.
Mattingly PM, Burnette PK, Weston MW, Manhy RP. Pancytopenia secondary to short-term, high-dose intravenous infusion of amrinone. DICP Ann Pharmacother 1990;24:1172-1174.
Franciosa J A. Intravenous amrinone: An advance or a wrong step? Ann Intern Med 1985;102:399-400.
Mancini D, LeJemtel T, Sonnenblick E. Intravenous use of amrinone for the treatment of the failing heart. Am J Cardiol 1985;56:8B—15B.
Silverman BD, Merrill AJ Jr, Gerber L Clinical effects and side effects of amrinone: A study of 24 patients with chronic congestive heart failure. Arch Intern Med 1985;145:825-829.
Case 460: American Association of Poison Control Centers Annual Report 1990. Am J Emerg Med 1991;9:507.
Lebovitz DJ, Lawless ST, Weise KL Fatal amrinone overdose in a pediatric patient. Crit Care Med 1995;23:977-986.
Lawless S, Restaino I, Azin S, Corddry D. Effects of continuous arteriovenous haemofiltration on pharmacokinetics of amrinone. Clin Pharmacokinet 1993;25:80-82.
Skoyles JR, Sherry КМ. Pharmacology: Mechanisms of action and uses of selective phosphodiesterase inhibitors. Br J Anaesth 1992;68:293-302.
Estafanous FG. Con: Amrinone is not a first-choice in-otrope following cardiopulmonary bypass. J Cardiotho-rac Vase Anesth 1991 ;5:184— 186.
Enoximone and milrinone: Inotropic vasodilators for severe heart failure. Drug Ther Bull 1991 ;9(20):39—40.
Picker M, Carver JR, Rodeheffer RJ, et al. The effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991:23:325:1468-1475.
Anderson J L, Baim DS, Fein SA, et al. Efficacy and safety of sustained (48 hours) intravenous infusions of milrinone in patients with severe congestive heart failure: A multicenter study. J Am Coll Cardiol 1987;9:711-722.
Poole-Wilson PA, Lindsay D. Advances in the treatment of chronic heart failure: Two steps forward, one step back. Br Med J 1992;304:1069-1070.
Feldman AM. Can we alter survival in patients with congestive heart failure? JAMA 1992;267:1956-1961.
Vernon MW, Heel RC, Brogden RN. Enoximone: A review of its pharmacological properties and therapeutic potentials. Drugs 1991;42:997-1017.
Appardurai I, Edmunds M, Wyatt R, Spyt TJ, Convulsions induced by enoximone administered as a continuous intravenous infusion. Br Med J 1990;300:613— 614.
Gershick AH: Commentary. Adverse effects of milrinone for heart failure. ACP J Child 1992;March/April:46.
Schleman MM. Marian Merrell Dow, personal communication, March 12,1992.
Reich L. Winthrop Pharmaceuticals, personal communication, May 29, 1991.
Huggon 1, James I, Macrae D. Hyperosmolarity related to propylene glycol in an infant treated with enoximone infusion. Br Med J 1990;301:19-30.
Friesen К, Palatnick W, Tenenbein М. Benign course after massive ingestion of yohimbine. J Emerg Med 1993;11:287-288.
Abraham AS, Rosenmann D, Kramer M, et al. Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. Arch Intern Med 1987;147:753-755.
Weaver K, Merrell CL, Griffin G. Effect of magnesium on cocaine induced, catecholamine-mediated platelet and vascular response in term pregnant ewes. Am J Obstet Gynecol 1989;161:1331-1337.
Goldman RS, Finkbeiner SM. Therapeutic use of magnesium sulfate in selected cases of cerebral ischemia and seizure. N Engl J Med 1988;319:1224-1225.
Kafiluddi R, Kennedy RH, Seifen E. Effects of buffer magnesium on positive inotropic agents in guinea pig cardiac muscle. Eur J Pharmacol 1989;165:181-189.
Szabo MD, Crosby G. Central nervous system effects of magnesium. Anesth Analg 1989;69:691-692.
Okayama H, Aikawa T, Okayama M, et al. Bronchodilating effect of intravenous magnesium sulfate in bronchial asthma. JAMA 1987;257:1076-1078.
Noppen M, Vanmuele L, Impens N, Schandevyl W. Bronchodilating effect of intravenous magnesium sulfate in acute severe bronchial asthma. Chest 1990;97:272— 276.
Reisdorff EJ, Clark MR, Walters BL. Acute digitalis poisoning: The role of intravenous magnesium sulfate. J Emerg Med 1986;4:463-469.
Tsivoni D, Banai S, Schuger C, et al. Treatment of Torsade de pointes with magnesium sulfate. Circulation 1988;77:392-397.
Tsivoni D, Keren A, Cohen AM, et al. Magnesium therapy for Torsade de pointes. Am J Cardiol 1984;53:528— 530.
Wesley RC Jr, Haines DE, Lerman BR, et al. Effect of intravenous magnesium sulfate on supraventricular tachycardia. Am J Cardiol 1989;63:1129-1131.
DiPalma JR. Magnesium replacement therapy. Am Fam Physician 1990;42:173-176.
Paddle BM, Haugaard N. Role of magnesium in effects of epinephrine on heart contraction and metabolism. Am J Physiol 1971;221:1178-1184.
Altura BM, Altura ВТ. Ouabain, membrane Na+K+-AT-Pase and the extracellular action of magnesium ions in arterial smooth muscle. Artery 1977;3:72-83.
Altura BM, Altura ВТ. Magnesium, electrolyte transport and coronary vascular tone. Drugs 1984;28:120— 142.
Prielipp RC, Zaloga GP, Butterworth JF, et al. Magnesium inhibits the alpha-1 but not the beta-1 adrenergic actions of epinephrine in postoperative coronary artery bypass graft patients. Anesthesiology 1990;73:A282.
Cohen L, Kitzes R. Magnesium sulfate in the treatment of variant angina. Magnesium 1984;3:46-49.
Dror A, Henriksen E. Accidental magnesium sulfate injection. Anesth Analg 1987;66:1020—1021.
Matthey F, Gelder CM, Schon FEG. Isolated hypomagnesemia presenting as focal seizures in diabetes mellitus. Br Med J 1986;293:1409.
Vincent RD Jr, Chestnut DH, Sipes SL, et al. Magnesium sulfate decreases maternal blood pressure but not uterine blood flow during epidural anesthesia in gravid ewes. Anesthesiology 1990;74:77-82.
Elin RJ. Assessment of magnesium status. Clin Chem 1987;33:1965-1970.
Zaloga GP. Interpretation of the serum magnesium level. Chest 1989;95:257-258.
McCubbin JH, Sibai BM, Abdella TN, Anderson GD. Cardiopulmonary arrest due to acute maternal hypermagnesemia. Lancet 1981; 1:1058.
Grant HI, Yeston NS. Cardiac arrest secondary to emotional stress and Torsade de pointes in a patient with associated magnesium and potassium deficiency. Crit Care Med 1991;19:292-294.
Levine BS, Coburn JW. Magnesium, the mimic/antag-onist of calcium. N Engl J Med 1984;310:1253-1255. Editorial.
Higgins GL III. Magnesium medicine comes of age. Emerg Med 1991 ;23(4):83—95.
Mosqueda-Garcia R. Guanfacine: A second generation alpha2 adrenergic blocker. Am J Med Sci 1990;299:73— 76.
Van Dyke MW, Bonace AL, Ellenhorn MJ. Guanfacine overdose in a pediatric patient. Vet Hum Toxicol 1990;32:46-47.
Granier P, Arsac P, Debru JL. Intoxication par la guanfacine. Nouv Presse Med 1982;11:1636-1637.
Coyne ME. Wyeth-Ayerst Laboratories, personal communication, May 29, 1991.
Raber JH, Shinar, С, Finkelstein S. Clonidine patch ingestion in an adult. Ann Pharmacother 1993;27:719— 722.
Henretig F, Wiley J, Brown L. Clonidine patch toxicity: The proofs in the poop! Clin Toxicol 1995;33:475-485.
Selevan J, Cada D. Review of amiodiplne (NorvascR). Hosp Pharm 1992;27:440-449.
Stopher DA, Beresford AP, Macrae PV, Humphrey MJ. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 1888;12(suppl. 7):S55-S59.
Product Literature. NorvascR. Pfizer Laboratories, August 1992.
Amlodipine: A new calcium channel blocker. Med Lett Drugs Ther 1992;34(882):99—102.
Campbell MG. Pfizer Laboratories, personal communication, January 21, 1993.
Koch AR, Vogelaers DP, Decruyenaere JM, et al. Fatal intoxication with amlodipine. Clin Toxicol 1995;33:253-256.
Elliott HL, Meredith PA. The clinical consequences of the absorption, distribution, metabolism and excretion of amiodipine. Postgrad Med J 1991 ;67(suppl. 3):S2O—S23.
Burges RA. The pharmacological profile of amlodipine in relation to ischaemic heart disease. Postgrad Med J I99l;67(suppl. 3):S9—Sl5.
Amlodipine besylate. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:974—978.
Beresford AP, Macrae PV, Stopher DA, Wood SA. Analysis of amlodipine in human plasma by gas chromatography. J Chromatogr 1987;20:178-183.
Beresford AP, McGibney D, Humphrey MJ, et al. Metabolism and kinetics of amlodipine in man. Xenobiotica 1988;18:245-254.
Osterloh 1. The safety of amlodipine. Am Heart J 1989; 118:1114-1120.
Walter FG, Frye G, Mullen JT, et al. Amelioration of nifedipine poisoning associated with glucagon therapy. Ann Emerg Med 1993;22:1234-1237.
Parmley WW. New calcium antagonists: Relevance of vasoselectivity. Am Heart J 1990;120:1408-1413.
Weiner DA. Calcium channel blockers. Med Clin North Am 1988;72:83-115.
Pepine C. Nicardipine, a new calcium channel blocker: Role for vascular selectivity. Clin Cardiol 1989; 12:240— 246.
Capewell S, Freestone S, Critchley JAJH, et al. Reduced felodipine bioavailability in patients taking anticonvulsants. Lancet 1988;2:480-482.
Nicardipine: A new calcium entry blocker. Med Lett Drugs Ther 1989;31 (791 ):41 —43.
Nimodipine. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:1182—1187.
Van Harten J, Ban Brummelen P, Lodewijks MTM, et al. Pharmacokinetics and hemodynamic effects of isol-dipine and its interaction with cimetidine. Clin Pharmacol Ther 1988;43:332-341.
Follath F, Taeschner W. Clinical pharmacology of calcium antagonists. J Cardiovasc Pharmacol 1988; 12(sup-pi. 6):S98—S100.
Lewis RH. Syntex Laboratories, personal communication, April 30, 1991.
Passeron D, Peschaud JL. Intoxication aigue par le nicardipine. J Toxicol Clin Exp 1990;10:257-259.
French Antipoison Centers and Droy JM, Daridon E, Leroy J, Massari P. Intoxications aigues par nicardipine et nifedipine etude multicentrique. J Toxicol Clin Exp 1990;10:249-256.
Nagasaki Y, Kotani J, Funao T, et al. Fatal poisoning by nicardipine. Kitasata Med 1988;18:287-291.
Pearigen PD. Death from accidental nifedipine ingestion in a toddler. Vet Hum Toxicol 1993;35:345.
Spiller HA, Ramoska EA. Isradipine ingestion in a two year old child. Vet Hum Toxicol 1993;35:233.
Murray LM, Seger DL Isradipine overdose managed with glucagon and dopamine and complicated by rapid atrial fibrillation and myocardial infarction. In: Proceedings, Meeting of the European Association of Poison Centres and Clinical Toxicologists, Birmingham, UK, May 26—28, 1993.
Koch AR, Vogelaers DP, Decruyenaere JM, et al. Fatal intoxication with amiodipine. Clin Toxicol 1995;33:253-256.
Clavijo GA, De Clavijo IV, Weart CW. Amiodipine: A new calcium antagonist. Am J Hosp Pharm 1994;51:59— 68.
Walter FG, Frye G, Mullen JT, et al. Amelioration of nifedipine in poisoning associated with glucagon therapy. Ann Emerg Med 1993;22:1234-1237.
Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists: A new class of antihypertensive drugs. Arch Intern Med 1995;155:1361-1368.
Product information: Losartan. Merck and Company, April 1995; J5C001 (908).
Hartenbaum D. Losartan potassium (COZAARR). Merck and Company, personal communication. November 20, 1995.
Schlanz KQ, Thomas RL. Penbutolol: A new beta-adrenergic blocking agent. DICP Ann Pharmacother 1990;24:403-408.
Van den Meiracker AH, Man in’t Veld AJ, Van Eck HJR, et al. The clinical pharmacology of bopindolol, a new long-acting beta-adrenoceptor antagonist in hypertension. Clin Pharmacol Ther 19'87:42:411—419.
Milne RJ, Buckley MMT. Celiprolol: An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in cardiovascular disease. Drugs 1991;4:941-969.
Steck JD. Betaxolol. Lorex Pharmaceuticals, personal communication, March 12, 1991.
Love JN. Beta blocker toxicity: A clinical diagnosis. Am J Emerg Med 1994;12:356-357.
Boutroy MJ, Morselli PL, Bianchetti G, et al. Betaxolol: A pilot study of its pharmacological and therapeutic properties in pregnancy. Eur J Clin Pharmacol 1990;38:535-539.
Morselli PL, Boutroy MJ, Bianchetti G, et al. Placental transfer and perinatal pharmacokinetics of betaxolol. Eur J Clin Pharmacol 1990;38:477-483.
Harron DWC, Goa KL, Langtry HD. Bopindolol: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1991;41:130-149.
Perkins SL, Tattrie B, Johnson PM, Rabin EZ. Analytical problems encountered during high-performance liquid chromatographic separation and coulometric detection of bopindolol metabolites in human plasma. Ther Drug Monit 1988;10:480-485.
Chrisp P, Goa KL. Dilevalol: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in hypertension. Drugs 1990;39:234-263.
Hicks PR, Rankin APN. Massive adrenaline doses and labetalol overdose. Anesth Intensive Care 1991; 19:447— 449.
Donnelly R, MacPhee GJA. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol. Clin Pharmacokinet 1991;21:95-106.
Aguirre C, Calvo R, Saiain J MR. Serum protein binding of penbutolol in patients with hepatic cirrhosis. Int J Clin Pharmacol Ther Toxicol 1988;26:566-569.
Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNICV). Arch Intern Med 1993;153:154-163.
Raia JJ Jr, Barone J A, Byerly WG, Lacy CR. Angiotensin-converting enzyme inhibitors: A comparative review. DICP Ann Pharmacother 1990;24:506-525.
Kelly JG, O’Malley K. Clinical pharmacokinetics of the newer ACE inhibitors: A review. Clin Pharmacokinet 1990;19:177-196.
Kelly JG, Doyle GD, Carmody M, et al. Pharmacokinetics of lisinopril, enalapril and enalprilat in renal failure: Effects of hemodialysis. Br J Clin Pharmacol 1988;26:781-786.
Harrigan JR, Lees KR, Meredith PA. Age and the physiologically realistic characterization of benazeprilate pharmacokinetics. Br J Clin Pharmacol 1990;29:589P.
Deget F, Grogden RN. Cilazapril: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in cardiovascular disease. Drugs 1991;41:799-820.
Hvik K, Duchin KL, Kripalani KJ, et al. Pharmacokinetics of forsinopril in patients with various degrees of renal function. Clin Pharmacol Ther 1991;49:457-467.
Shionioiri H, Yasuda G, Ikeda A, et al. Pharmacokinetics and depressor effect of delapril in patients with essential hypertension. Clin Pharmacol Ther 1987;41:74— 79.
Van Schaik BAM, Geyskes GG, Van der Wauw PA, et al. Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function. Eur J Clin Pharmacol 1988;34:61-65.
Lecocq B, Funck-Brentano C, Lecocq V, et al. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibitor in serum. Clin Pharmacol Ther 1990;47:397-402.
Macfadyen RJ, Lees KR, Reid JL Perindopril: A review of its pharmacokinetics and clinical phannacology. Drugs 1990;39(suppl. 1 ):49—63.
Lees KR, Green ST, Reid JL. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. Clin Pharmacol Ther 1988;44:418-425.
Cetnarowski-Cropp AB. Quinapril: A new second-generation ACE inhibitor. DICP Ann Pharmacother 1991;25:499-504.
Todd PA, Benfield P. Ramipril: A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 1990;39:110-135.
Use of ACE inhibitors in pregnancy and neonate. Int Pharm J 1990;4:95.
Brent RL, Beckman DA. Angiotensin-converting enzyme inhibitors: An embryopathic class of drugs with unique properties: Information for clinical teratology counselors. Teratology 1991;43:543-546.
De Carolis MP, Muzii U, Romagnoli C, et al. Neonatal necrotizing enterocolitis (NEC) and maternal treatment with captopril. Clin Exp Hypertension 1991 ;Pt B10:264.
Knott PD, Thorpe SS, Lamont CAR. Congenital renal dysgenesis possibly due to captopril. Lancet 1989; 1:451.
Hogue-Murray K, Horowitz R, Dart RC. Outcome of ACE inhibitor ingestion in children under the age of six years. Clin Toxicol 1995;33:475-486 (Abstract 61).
Trilli LE, Johnson KA. Lisinopril overdose and management with intravenous angiotensin II. Ann Pharmacother 1994;28:1165-1168.
Finley CJ, Silverman MA, Nunez AE. Angiotensin-converting enzyme inhibitor-induced angioedema if unrecognized. Am J Emerg Med 1992;10:550-552.
Mooradian AD, MorlyJE, Kaiser FE, etal. Biweekly in-tracavernous administration of papaverine for erectile dysfunction. West J Med 1989;151:515-517.
Al-Juburi AZ, O'Donnell DD. Follow-up outcome of intracavernous papaverine. J Ark Med Soc 1990;86:383— 385.
Vasoactive intracavernous pharmacotherapy for impotence: Papaverine and phentolamine: Diagnostic and therapeutic technology assessment. JAMA 1990;264: 752-754.
Fried FA. The use of vasoactive agents in the treatment of erectile impotence. NC Med J 1990;51:295-296.
Corriere JN Jr, Fishman IJ, Benson GS, Carlton CE Jr: Development of fibrotic penile lesions secondary to the intracorporeal injection of vasoactive agents. J Urol 1988;140:615-617.
Vaziri ND, Stokes J, Treadwell TR. Lactic acidosis, a complication of papaverine overdose. Clin Toxicol 1981;18:417-423.
Ilan Y, Gemer O. Papaverine-induced coma. Eur J Clin Pharmacol 1988;33:651.
Talman CL, Winniford MD, Rasser JD, et al. Polymorphous ventricular tachycardia: a side effect of intracoronary papaverine. J Am Coll Cardiol 1990;15:275-278.
Belpaire FM, Rossul MT, Gogaert MG. Pharmacokinetics of papaverine IV: Urinary elimination of papaverine metabolites in man. Xenobiotica 1978;8:297-300.
Kramer WG, Romagnoli A. Papaverine disposition in cardiac surgery patients. Eur J Clin Pharmacol 1984;27:127-130.
Garrett ER, Roseboom H, Green JR, Schuermann W. Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. Int J Clin Pharmacol Biopharm 1978;16:192-208.
Krivoy N, Jakobi Р, Paldi Е, Alroy G. Total digoxin-like immunoreactive factor(s) in healthy population, uncomplicated term pregnancies and neonates. J Endocrinol Invest 1990;13:9-12.
Jakobi P, Krivoy N, Weissman A, Paldi E. Digoxin-like immunoreactive factor in twin and pregnancy-associated hypertensive pregnancies. Obstet Gynecol 1989;74:29— 33.
Morris RG, Frewin DB, Sarcoia NC, et al. Digoxinlike immunoreactive substance levels in cord blood obtained from twins. Eur J Clin Pharmacol 1991 ;40:199— 200.
Wolach B, Carmi D, Shilo L, et al. Endogenous digoxinlike factor in neonates: Effect of age and relation to serum bilirubin levels. Acta Paediatr Scand 1989;78:364— 368.
Jakobi P, Lewit N, Koi S, Krivoy N. Protein bound and free digoxin-like immunoreactive factor in normal pregnancy: A longitudinal study. In: Proceedings, Society of Perinatal Obstetricians, Tenth Annual Meeting, Houston, Texas, Jan. 23, 1990.
Jakobi P, Koi S, Weissman A, Krivoy N. Peripartum changes in free and protein bound digoxin-like immunoreactive factor. In: Proceedings, Society of Perinatal Obstetricians, Tenth Annual Meeting, Houston, Texas, Jan. 23, 1990.
Yosselson-Superstine S. Drug interferences with plasma assays in therapeutic monitoring. Clin Pharmacokinet 1984;9:67-87.
Pleasants RA, Williams DM, Porter RS, Gadsden RH Sr. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays. Ther Drug Monit 1989;11:200-204.
Fushimi R, Tachi J, Amino N, Miyai K. Chinese medicine interfering with digoxin immunoassays. Lancet 1989;1:339.
Kim JQ, Lee DH, Kim SI. The effect of digoxin-like immunoreactive substance on therapeutic drug monitoring of digoxin in patients with liver diseases. Clin Chem 1990;36:1032.
Gervais A, Nanji AA, Greenway DC, McLean W. Dig-oxin-like immunoreactive substance (DLIS) in liver disease: Comparison of clinical and laboratory parameters in patients with and without DLIS. Drug Intell Clin Pharm 1987;21:450-452.
Shilo L, Adawi A, Solomon G, Shenkman L. Endogenous digoxin-like immunoreactivity in congestive heart failure. Br Med J 1987;295:415-416.
Dasgupta A, Saldana S, Heimann P. Monitoring free digoxin instead of total digoxin in patients with congestive heart failure and high concentrations of digoxin-like immunoreactive substances. Clin Chem 1990;36:2121 — 2123.
Ng LL, Hockaday TDR. Endogenous digitalis-like factors in acromegaly. N Engl J Med 1987;317:572-573.
Stone J, BenturY, Zaistein E, et al. Effect of endogenous digoxin-like substances on the interpretation of high concentrations of digoxin in children. J Pediatr 1990;117:321-325.
Goodlin RC. Antidigoxin antibodies in eclampsia. N Engl J Med 1988;318:518-519.
Goodlin RC, Makowski EL. Fetal endotoxins and complications of pregnancy. West J Med 1988;148:590-592.
Lichtstein D, Kachalsky S, Deutsch J. Identification of a ouabain-like compound in toad skin and plasma as a bufodienolide derivative. Life Sci 1986;38:1261-1270.
Flier JS, Maratos-Flier E, Pallotta JA, Mclsaac D. Endogenous digitalis-like activity in the plasma of the toad Bufo marinus. Nature 1979;279:341-343.
Chem M-S, Ray C-Y, Wu D. Biologic intoxication due to digitalis-like substance after ingestion of cooked toad soup. Am J Cardiol 1991;67:443-444.
Longerich L, Johnson E, Gault MH. Digoxin-like factors in herbal teas. Clin Invest Med 1993;16:210-218.
Lalonde RL, Deshpande R, Hamilton PP, et al. Acceleration of digoxin clearance by activated charcoal. Clin Pharmacol Ther 1985;37:367-371.
Caldwell JH, Clin CT. Biliary excretion of digoxin in man. Clin Pharmacol Ther 1976;19:410-415.
Kuhlmann J. Effects of verapamil, diltiazem and nifedipine on plasma levels and renal excretion of digitoxin. Clin Pharmacol Ther 1985;38:667-673.
Morton MR, Cooper JW. Erythromycin-induced digoxin toxicity. DICP Ann Pharmacother 1989;23:668-670.
Maxwell DL, Gilmour-White SK, Hall MR. Digoxin toxicity due to interaction of digoxin with erythromycin. Br Med J 1989;298:572.
Linday L, Dobkin JF, Wang TC, et al. Digoxin inactivation by the gut flora in infancy and childhood. Pediatrics 1987;79:544-548.
Whang R, Oei TO, Watanabe A. Frequency of hypomagnesemia in hospitalized patients receiving digitalis. Arch Intern Med 1985;145:655-656.
Sonnenblick M. Correlation between manifestations of digoxin toxicity and serum calcium, magnesium and potassium concentrations and arterial pH. Br Med J 1983;286:1089-1091.
Taboulet P, Baud FJ, Bismuth C. Clinical features and management of digitalis poison: Rationale for immunotherapy. Clin Toxicol 1993;31:247-260.
Moorman JR, Pritchett ELC. The arrhythmias of digitalis intoxication. Arch Intern Med 1985; 145:1289— 1291.
Springer M, Olson KR, Feaster W. Acute massive digoxin overdose: Survival without use of digitalis-specific antibodies. Am J Emerg Med 1986;4:364-368.
Ukhelyi MR, Cummings DM, Green P, et al. Effect of digoxin Fab antibodies on five digoxin immunoassays. Ther Drug Monit 1990;12:288-292.
Ingelfinger JA, Goldman P. The serum digitalis concentration: Does it diagnose digitalis toxicity? N Engl J Med 1976;294:867-870.
Lasagna L. How useful are serum digitalis measurements? N Engl J Med 1976;294:898-899.
Urtizberea M, Rochdi M, Sabourand A, et al. Relationship between red blood cell potassium and plasma digitoxin concentrations in intoxicated patients. Pharmacol Toxicol 1991;68:237-242.
Wood WG, Farber P, Kurowski V. A case of divergent digitoxin values under treatment of a patient with acute digitoxin overdose with digitalis antibody fragments. Klin Wochenschr 1990;68:324-327.
Hess T, Zeugin T, Wess M. Swizidale digitalis intoxika-tion: Uberlegnungen zur behandlungs strategic mit antikorpern. Schweiz Med Wochenschr 1989; 199:1466— 1469.
Urtizberea M, Sabourand A, Terrien N, Schermann M. Reversal of advanced digitoxin poisoning in rabbits by monoclonal anti-digitoxin Fab fragment. In: Abstracts of Vth International Congress of Toxicology, Brighton, England, July 16, 1989. London: Taylor & Francis, 1989.
Dick M, Curwin J, Tepper D. Digitalis intoxication recognition and management. J Clin Pharmacol 1991;31:444-447.
Henderson RP, Solomon CP. Use of cholestyramine in the treatment of digoxin intoxication. Arch Intern Med 1988;148:745-746.
Neuvonen PJ, Kivisti KT. Activated charcoal should replace the resins in the treatment of digoxin intoxication. Arch Intern Med 1989;149:2603-2604.
Neuvonen PJ, Kivisto K, Hirvisalo EL. Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and furosemide. Br J Clin Pharmacol 1988;25:229-233.
Woolf AD, Wenger T, Smith TW, Lovejoy FH Jr. The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. N Engl J Med 1992;326:1734— 1744.
Woolf AD, Wenger T, Smith TW, Lovejoy FH Jr. Results of multicenter studies of digoxin specific antibody fragments in managing digitalis intoxication in the pediatric population. Am J Emerg Med 1991 ;9(suppl. 1): 16—20.
Varriole P, Mossari A. Rapid reversal of digitalis delirium using digoxin immune Fab therapy. Clin Cardiol 1995;18:351-352.
Scumaik GM. Oleander poisoning: Treatment with digoxin-specific Fab antibody fragment. Ann Emerg Med 1988;17:732-735.
Clark RF, Selden BS, Curry SC. Digoxin-specific Fab fragments in treatment of oleander toxicity in the canine model. Ann Emerg Med 1991;20:1073-1077.
Woolf AD. Digoxin specific Fab antibody fragments. Clin Toxicol Rev 1991; 13( 10): 1 —2.
Kurowski V, Iven H, Djonlagic H. Treatment of a patient with severe digitoxin intoxication by Fab fragments of antidigitalis antibodies. Intensive Care Med 1992;18:439-442.
Taboulet P, Baud FJ, Bismuth C. Clinical features and management of digitalis poisoning: Rationale for immunotherapy. In: Proceedings, European Association of Poison Control Centers Meeting, Lyon, France, May 22, 1991.
Zilker T, Bihlmayr J, Felgenhauer N, v. Clarmann M. Comparison of cases of digitalis intoxications before and after introduction of anti digoxin FAB fragments (AD-FABF) into therapy. In: Proceedings, European Association of Poison Centres Meeting, Lyon, France, May 22, 1991.
Martiny SS, Phelps SJ, Massey КС. Treatment of severe digitalis intoxication with digoxin-specific antibody fragments: A clinical review. Crit Care Med 1988; 16:629— 635.
Heath AJ. How do we dose Fab antibody fragments in digitalis intoxication? In: Proceedings, European Association of Poison Centres Meeting, Lyon, France, May 22, 1991.
Green SM, Nefbl J. Antiarrhythmic efficacy of magnesium in the setting of life-threatening digoxin toxicity. Am Emerg Med 1989;7:374-378.
Tzivoni D, Keren D. Suppression of ventricular arrhythmia by magnesium. Am J Cardiol 1990;65:1397-1399.
Park CD, Spector R, Goldberg MJ, Feldman RD. Digoxin toxicity in patients with high serum digoxin concentrations. Am J Med Sci 1987;294:423-428.
Reisdorff EJ, Clark MR, Walters BL. Acute digitalis poisoning: The role of intravenous magnesium sulfate. Ann Emerg Med 1986;4:463.
Taboulet P, Baud FJ, Bismuth C, Vicaut E. Acute digitalis intoxication: Is pacing still appropriate? Clin Toxicol 1993;31:261-273.
Woolf A. Revising the management of digitalis poisoning. Clin Toxicol 1993;31:275-276. Editorial.
Kinlay S, Buckley NA. Magnesium sulfate in the treatment of ventricular arrhythmias due to digoxin toxicity. Clin Toxicol 1995;33:55-59.
Johnston LN. Digoxin toxicity presenting with visual disturbance and trigeminal neuralgia. Neurology 1990;40:1469-1470.
Sharff JA, Bayer MJ. Acute and chronic digitalis toxicity: Presentation and treatment. Ann Emerg Med 1982;11:327-330.
Park GD, Spector R, Goldberg MJ, Feldman RD. Digoxin toxicity in patients with high serum digoxin concentrations. Am J Med Sci 1987;294:423-428.
Sabourand A, Urtizberrea M, Cano N, et al. Specific antidigoxin Fab fragments: An available antidote for pro-scillaridin and scilliroside poisoning. Hum Exp Toxicol 1990;9:191-193.
Gruber KA, Whitaker JM, Buckalew VM Jr. Endogenous digitalis-like substance in plasma of volume-expanded dogs. Nature 1980;28:743-745.
Graves SW, Brown B, Valdes R Jr. An endogenous digoxin-like substance in patients with renal impairment. Ann Intern Med 1983;99:604-608.
Schoner W. Endogenous digitalis-like factors. Trends Pharmacol Sci 1991;12:209-211.
Morris RG, Frewin DB, Saccoia NC, et al. Interference from digoxin-like immunoreactive substances in commercial digoxin kit assay methods. Eur J Clin Pharmacol 1990;39:359-363.
Jakobi P, Krivoy N, Schwartz K, et al. Digoxin-like immunoreactivity in saliva and plasma of pregnant women. Clin Chem 1991;37:135-136.
Siegfried BA, Valdes R Jr. Excretion of endogenous digoxin-like immunoreactive factors in human urine is a function of urine flow rate. Clin Chem 1988;34:960— 964.
Krivoy N, Lalkin A, Jakobi P. Digoxin-like immunoreactivity detected in cerebrospinal fluid of humans with fever. Clin Chem 1990;36:703-704.
Toseland PA, Oldfield PR, Murphy GM, Lawson AM. Tentative identification of a digoxin-like immunoreactive substance. Ther Drug Monit 1988;10:168-171.
Graves SW, Valdes R, Brown BA, et al. Endogenous-like immunoreactive substance in human pregnancies. J Clin Endocrinol Metab 1984;58:748-751.
Jakobi P, Krivoy N, Eibschitz I, et al. Digoxin-like immunoreactive factors(s) in human gonadotropin stimulated follicular fluid. J Clin Endocrinol Metab 1989;69:209-211.
Valdes R. Endogenous digoxin-like immunoreactive factors impact on digoxin measurements and potential physiological implications. Clin Chem 1985;31:1525— 1532.
Mueller BA, Bussey HI, Casto DT, et al. Lack of endogenous crossreactivity with three radioimmunoassays in adults with renal insufficiency. Clin Pharm 1988;7:825— 828.
Virge E, Ekman R. Partial characterization of endogenous digoxin-like substance in human urine. Ther Drug Monit 1988;10:8-15.
Goto A, Yamada K, Ishi M, Sugimoto T. Release of endogenous digitalis-like factor with sodium loading. N Engl J Med 1989;320:124-125.
Wahyono D, Piechaczyk M, Scherrmann JM, et al. Highly specific radioimmunoassay for digoxin using a monoclonal antibody selected for lack of interference by digoxin-like immunoreactive substances in cord blood sera. Ther Drug Monit 1991;13:113-119.
Clark CF, Hanna ТС. Calcium channel blocker toxicity. Top Emerg Med 1993;15:15-26.
Todd PA, Benfield P. Flunarizine: A reappraisal of its pharmacological properties and therapeutic use in neurological disorders. Drugs 1989;38:481-499.
Shimell CJ, Fritz VU, Levien SL. A comparative trial of flunarizine and propranolol in the prevention of migraine. South Afr Med J 1990:77—78.
Benvenuti F, Baroni A, Bandinelli S, et al. Flunarizine-induced parkinsonism in the elderly. J Clin Pharmacol 1988;28:600-608.
Reynolds JFK, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:734.
Pearigen PD. Death from accidental nifedipine ingestion in a toddler. Vet Hum Toxicol 1993;35:345.
Ferner RE, Odemuyiwa O, Field AB, et al. Pharmacokinetics and toxic effects of diltiazem in massive overdose. Hum Toxicol 1989;8:497-499.
Wells TG, Graham CJ, Moss M, Kearns GC. Nifedipine poisoning in a child. Pediatrics 1990;86:91-94.
Schiffl H, Ziupa J, Schollmeyer P. Clinical features and management of nifedipine overdosage in a patient with renal insufficiency. Clin Toxicol 1984;22:387-395.
Ramoska EA, Spiller HA, Myers A. Calcium channel blocker toxicity. Ann Emerg Med 1990;19:649-653.
Riggs BS, Hall AH, Kulig KW, et al. Calcium channel blockers in children: A review of 18 cases. Vet Hum Toxicol 1987;29:484-485 (Abstract 127).
Doyon S, Roberts JR. The use of glucagon in a case of calcium channel blocker overdose. Ann Emerg Med 1993;22:1229-1233.
Erickson FC, Ling U, Grande GA, Anderson DL. Diltiazem overdose: Case report and review. J Emerg Med 1991;9:357-366.
Harchelroad F. ARDS associated with calcium channel blocker overdose. Vet Hum Toxicol 1992;34:328.
Beno JM, Nemeth DR. Diltiazem and metoclopramide overdose. J Anal Toxicol 1991;15:285-286.
Minella RA, Schulman DS. Fatal verapamil toxicity and hypokalemia. Am Heart J 1991;121:1810-1812.
MacDonald D, Alguire PC. Case report: Fatal overdose with sustained release verapamil. Am J Med Sci 1992;303:115-117.
Pearigen PD. Death from accidental nifedipine ingestion in a toddler. Vet Hum Toxicol 1993;35:345.
Proano L, Chiang WK, Wang RY. Calcium channel blocker overdose. Am J Emerg Med 1995;13:444-450.
Lubbe WF. Use of diltiazem during pregnancy. NZ Med J 1987;100:121.
Ehrenkranz RA, Ackerman BA, Hulse JD. Nifedipine transfer into human milk. J Pediatr 1989;114:478-479.
Penny WJ, Leurs MJ. Nifedipine is excreted in human milk. Eur J Clin Pharmacol 1989;36:427-428.
Purcell H, Waller DG, Fox K. Therapeutic focus: Calcium antagonists in cardiovascular disease. Br J Clin Pract 1989;34:369.
Pentel PR, Salerno DM. Cardiac drug toxicity: Digitalis, glycosides and calcium channel and beta blocking agents. Med J Aust 1990;152:88-94.
Dimmitt SB, Beilin LJ, Hockings BEF. Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram. Med J Aust 1988; 149:218.
Heupler FA, Proudfoot WL. Nifedipine therapy for refractory coronary arterial spasm. Am J Cardiol 1979;44:798-803.
Sporer KA, Manning JJ. Massive ingestion of sustained release verapamil with a concretion and bowel infarction. Ann Intern Med 1993;22:603-605.
Buckley N, Dawson AH, Howarth D, Whyte IM. Slow-release verapamil poisoning: Use of polyethylene glycol wholebowel lavage and high-dose calcium. Med J Aust 1993;158:202-204.
Spiller HA, Meyers A, Ziemba T, Riley M. Delayed onset of cardiac arrhythmias from sustained release verapamil. Ann Emerg Med 1991;20:201-203.
Quezado Z, Lippmann M, Wertheimer J. Severe cardiac, respiratory and metabolic complications of massive verapamil overdose. Crit Care Med 1991;19:436-438.
Krick SE, Gums JG, Grauer K, Cooper GR. Severe verapamil (sustained release) overdose. DICP Ann Pharmacother 1990;24:705-706.
Rankin RJ, Edwards 1R. Overdose of sustained release verapamil. NZ Med J 1990; 103:165.
Kozlowski JH, Kozlowski J A, Shriller D. Poisoning with sustained release verapamil. Am J Med 1988;85:127.
Samniah N, Schlaeffer F. Cerebral infarction associated with oral verapamil overdose. Clin Toxicol 1988;26:365-369.
Shah AR, Passalacqua VR. Sustained-release verapamil overdose causing stroke: An unusual complication. Am J Med Sci 1992;304:357-359. Case report.
Kenny J. Treating overdose with calcium channel blockers. Br Med J 1994;308:992-993.
Koppel C, Wagemann A. Plasma level monitoring of D,L-verapamil and three of its metabolites by reversed-phase high-performance liquid chromatography. J Chro-matogr Biomed Appl 1991;570:229-234.
Caille G, Duke LM, Theoret Y, et al. Stability study of diltiazem and two of its metabolites using a high performance liquid chromatographic method. Biopharm Drug Dispos 1989;10:107-114.
Roper TA, Sykes R, Gray C. Fatal diltiazem overdose: Report of four cases and review of the literature. Postgrad Med J 1993;69:474-476.
Welch RD, Todd K. Nifedipine overdose accompanied by ethanol intoxication in a patient with congenital heart disease. J Emerg Med 1990;8:169-172.
Ferner RE, Monkman S, Riley J, et al. Pharmacokinetics and toxic effects of nifedipine in massive overdose. Hum Exp Toxicol 1990;9:309-311.
Herrington DM, Insley BM, Weinmann GG. Nifedipine overdose. Am J Med 1986;81:344-346.
Kvo MJ. Tseng YZ, Chen TF, Fong DE. Verapamil overdose and severe hypocalcemia. Clin Toxicol 1992;30:309-311.
Watson NA. Management of massive verapamil overdose. Med J Aust 1991 ;55:728.
Pearigen PD, Benowitz NL. Poisoning due to calcium antagonists: Experience with verapamil, diltiazem and nifedipine. Drug Saf 1991;6:408-430.
Spivey WH, Schoffstall JM, Gambone LM, et al. Effects of calcium channel blocker overdose-induced toxicity on systemic hemodynamics and cardiac output distribution in the conscious dog. Ann Emerg Med 1988; 17:402.
Spurlock BW, Virani NA, Henry CA. Verapamil overdose. West J Med 1991;154:208-211.
Watson NA, Fitzgerald CP. Management of massive verapamil overdose. Med J Aust 1991;155:124-125.
Roberts D, Honcharik N, Sitar DS, Tenenbein M. Diltiazem overdose: Pharmacokinetics of diltiazem and its metabolites and effect of multiple dose charcoal therapy. Clin Toxicol 1991;29:45-52.
Jakubowski AT, Mizgala HF. Effect of diltiazem overdose. Am J Cardiol 1987;60:932-933.
Kirshenbaum LA, Mathews SC, Sitar DS, Tenenbein M. Whole bowel irrigation versus activated charcoal in sorbitol for the ingestion of modified-release pharmaceuticals. Clin Pharmacol Ther 1989;46:264-271.
Walter FG, Frye G, Mullen JT, et al. Amelioration of nifedipine poisoning associated with glucagon therapy. Ann Emerg Med 1993;22:1234-1237.
Wolf LR, Spadaforo MP, Otten EJ. Use of amrinone and glucagon in a case of calcium channel blocker overdose. Ann Emerg Med 1993;22:1225-1228.
TerWee PM, Kremer-Hovinga TK, Uges DRA, van der Geest S. 4-Aminopyridine and hemodialysis in the treatment of verapamil intoxication. Hum Toxicol 1985;4:227-229.
Jaeger A, Sauder P, Bianchetti G, et al. Intoxications aigues par le diltiazem etude cinetique et hemody-namique. J Toxicol Clin Exp 1990;10:243-248.
Melanson P, Shih RD, De Roos F, et al. Intraaortic balloon counterpulsation in calcium channel blocker overdose. Vet Hum Toxicol 1993;35:345.
Tom PA, Morrow CT, Kelen GD. Delayed hypotension after overdose of sustained release verapamil. J Emerg Med 1994;12:621.
Brayer A, Wax P. Accidental ingestions of sustained release calcium channel blockers in children. Clin Toxicol 1995;33:475-486 (Abstract 75).
Harron DWG, Brogden RN. Acecainide (N-acetylprocainamide): A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Drugs 1990;39:720-740.
Atkinson AJ Jr, Ruo Tl, Piergies AA, et al. Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method. Clin Pharmacol Ther 1989;46:182-189.
Piergies AA, Ruo TI, Jansyn EM, et al. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. Clin Pharmacol Ther 1987;42:107-112.
Utrecht JP. Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J Pharmacol Exp Ther 1985;232:420-425.
Stratmann HG, Walter KE, Kennedy HL. Torsade de pointes associated with elevated N-acetylprocainamide levels. Am Heart J 1985;109:375-376.
Braden GL, Fitzgibbons JP, Germain MJ, Ledewitz HM. Hemoperfusion for N-acetylprocainamide intoxication. Ann Intern Med 1986;105:965-966.
Domoto DT, Brown WW, Bruggensmith KP. Removal of toxic levels of N-acetylprocainamide with continuous arteriovenous hemofiltration or continuous arteriovenous hemodiafiltration. Ann Intern Med 1987;106:550-552.
Karr RM, Kellner K, Ing TS, Leehey DJ. Combined high efficiency hemodialysis and charcoal hemoperfusion in severe N-acetylprocainamide intoxication. Am J Kidney Dis 1992;20:403-406.
Martin WJ, Miller FA Jr. Amiodarone toxicity. Mayo Clin Proc 1985;60:638-639.
Alves LE, Rose EP, Cahill ТВ. Amiodarone and the thyroid. Ann Intern Med 1985; 102:412.
Garson A, Gillette PC, McVey P, et al. Amiodarone treatment of critical arrhythmia in children and young adults. J Am Coll Cardiol 1984;4:749-755.
Oreto G, Lapresa V, Melluso C, et al. Amiodarone overdose: A case report. Arch Mai Coeur Vasseaux 1980;73:857-862.
Goddard DJR, Whorwell PJ. Amiodarone overdose and its management. Br J Clin Pract 1989;34:184-186.
Riva E, Gerna M, Latini R, et al. Pharmacokinetics of amiodarone in man. J Cardiovasc Pharmacol 1982;4:264-269.
Harris L, McKenna WJ, Krikler SJ, et al. Renal elimination of amiodarone and its desethyl metabolite. Postgrad Med J 1983;59:440-442.
Middlekauff NR, Wiener I, Saxon LA, Stevenson WG. Low dose amiodarone for ventricular fibrillation: Time for a prospective study? Ann Intern Med 1992;! 16(12, pt l):1017—1020.
Bonati M, D’Aronno V, Galletti F, et al. Acute overdosage of amiodarone in a suicide attempt. J Toxicol Clin Toxicol 1983;20:181-186.
Flannagan RJ, Storey GCA, Holt DW, et al. Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone treated patients. J Pharm Pharmacol 1982;34:638-643.
Gill J, Heel RC, Fitton A. Amiodarone: An overview of its pharmacological properties and review of its therapeutic use in cardiac amythmias. Drugs 1992;43:69— 110.
Estes MAM III. Evolving strategies for the management of atrial fibrillation: The role of amiodarone. JAMA 1992;267:3332-3333.
Lesko JL. Pharmacokinetic drug interactions with amiodarone. Clin Pharmacokinet 1989;17:130-140.
Widerhorn J, Bhandai A, Bughi S, et al. Fetal and neonatal adverse effects profile of amiodarone treatment during pregnancy. Am Heart J 1991; 122:1162—1166.
Rey E, Bachrach LK, Burrow GN. Effects of amiodarone during pregnancy. Can Med Assoc J 1987; 136:959— 960.
Kourides IAS, Berkowitz RL, Pang S, et al. Antepartum diagnosis of goitrous hypothyroidism by fetal ultrasonography and amniotic fluid thyrotropin concentration. J Clin Endocrinol Metab 1984;59:1016-1018.
Marcus FI, Fontaine GH, Frank F, et al. Clinical pharmacology and therapeutic applications of the an-tiarrhythmic agent amiodarone. Am Heart J 1981;101:480-493.
Wood DL, Osborn MJ, Rooke J, et al. Amiodarone pulmonary toxicity: Report of two cases associated with rapidly progressive fatal adult respiratory distress syndrome after pulmonary angiography. Mayo Clin Proc 1985;60:601-603.
Sclarovsky S, Lewin RF, Kracoff O, et al. Amiodarone induced polymorphous ventricular tachycardia. Am Heart J 1985;105:6-12.
Unger J, Lambert M, Jonckheer MH, Dehayer P. Amiodarone and the thyroid: Pharmacological, toxic and therapeutic effects. J Intern Med 1993;233:435-443.
McNeil KD, Firouz-Abadi A. Amiodarone pulmonary toxicity: Three unusual manifestations. Aust NZ J Med 1992;22:14-18.
Pitche WD. Southwestern Internal Medicine Conference: Amiodarone pulmonary toxicity. Am J Med Sci 1992;303:206-212.
Retz JL, Martin WJ 11. Amiodarone pulmonary toxicity. Intensive Care Med 1992;18:388-390.
Rubin DA, McAllister A, Sorbera C, Kay RH. Subacute pulmonary toxicity from amiodarone. NY State J Med 1991;9:403-405.
Fraire AE, Guntupalli KK, Greenberg SD, et al. Amiodarone pulmonary toxicity: A multidisciplinary review of current status. South Med J 1993;86:67-77.
Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990;82:51-59.
Richer M, Robert S. Fatal hepatotoxicity following oral administration of amiodarone. Ann Pharmacother 1995;29:582-586.
Ahmed Z, Goldman JM. Reevaluation of amiodarone. Ann Intern Med 1995; 123:809.
Nadamanee K, Piwonka RW, Singh BN, Hershman JM. Amiodarone and thyroid function. Prog Cardiovasc Dis 1989;31:427-437.
Wiersinga WM, Trip MD. Amiodarone and thyroid hormone metabolism. Postgrad Med J 1986;62:909-914.
Lombardi A, Martino E, Braverman LE. Amiodarone and the thyroid. Thyroid Today 1990; 13:1—7.
Till JA, Baxenda IIM, Benetar A. Acceleration of the ventricular response to actual flutter by amiodarone in an infant with Wolff—Parkinson—White syndrome. Br Heart J 1993;70:84-87.
Flaherty KK, Chase SL, Yaghezian HM, Rubin R. Hepatotoxicity associated with amiodarone therapy. Pharmacotherapy 1989;9:39-44.
Lwakatare J ML, Morris-Jones S, Knight EJ. Fatal fulminating liver failure possibly related to amiodarone treatment. Br J Hosp Med 1990;44:60-61.
Fananapazir L, Leon MB, Bonow RO, et al. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991;67:169-174.
Wilson FS. Wyeth-Ayerst Laboratories. Personal communication. Feb. 19, 1991.
Nitsch J, Luderit Z. Enhanced elimination of amiodarone by cholestyramine. Dtsch Med Wochenschr 1986;111:1241-1244.
Uzzan B, Pussard E, Leon A, et al. The effects of plasmapheresis on thyroid hormone and plasma drug concentrations in amiodarone-induced thyrotoxicosis. Br J Clin Pharmacol 1991;31:371-372.
Thompson AE, Sussman JB. Bretylium intoxication resembling clinical brain death. Crit Care Med 1989;17:194-195.
Gibson JS, Munter DW. Intravenous bretylium overdoses. Am J Emerg Med 1995;13:177-179.
Bodnar T, Nowak R, Tomlanovich C. Massive intravenous bolus: Bretylium tosylate. Ann Emerg Med 1980;9:630-633.
Reynolds JFK, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:61—62.
Kivisto KT, Neuvonen PJ. Effect of activated charcoal in the absorption of amiodarone. Hum Exp Toxicol 1991;10:327-329.
Henry J, Volans G. ABC of poisoning: Cardiac drugs. Br Med J 1984;289:1062-1064.
Browning RG, Merigian KS. Acute beta blocker poisoning. Top Emerg Med 1993;15:1-14.
Lang DM. Anaphylactoid and anaphylactic reactions: Hazards of beta blockers. Drug Saf 1995;12:299-304.
Shanahan FU, Counihan ТВ. Atenolol self-poisoning. Br Med J 1978;2:773.
Weinstein RS, Cole S, Knaster HB, et al. Beta blocker overdose with ropranolol and with atenolol. Ann Emerg Med I985;l4:l6l —163.
Stinson J, Walsh M, Feely J. Ventricular asystole and overdose with atenolol. Br Med J 1992;305:693.
Saitz R, Williams BW, Farber HW. Atenolol-induced cardiovascular collapse treated with hemodialysis. Crit Care Med 1991 ;19:116-118.
Trancqui A, Kintz P, Mangin P, Lenoir B. Self-poisoning with a beta-blocker bisoprolol. Hum Exp Toxicol 1990;9:255-256.
Bisoprolol: Another cardioselective beta-blocker. Drug Ther Bull 1989;27:55.
Lancaster SG, Sorkin EM. Bisoprolol: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 1988;36:256-285.
Hicks PR, Rankin APN. Massive adrenaline doses in la-betolol overdose. Anaesth intensive Care 1991; 19:447— 449.
Kovzets A, Danby P, Edmunds ME, et al. Acute renal failure associated with a labetolol overdose. Postgrad Med J 1990;66:66-67.
Miller A, White S. Survival following massive intravenous esmolol overdose. Clin Toxicol 1995;533:475-486.
Hayes LP, Stewart CJ, Kim J, Mohr JA. Timolol side effects and inadvertent overdose. J Am Geriatr Soc 1989;37:261-262.
Haraldsson A, Geven W. Severe adverse effects of maternal labetalol in a premature infant. Acta Paediatr Scand 1989;78:956-958.
Rubin PC. Current concepts: Beta blockers in pregnancy. N Engl J Med 1981;305:1323-1326.
Hackett LP, Wojnar-Hutton RE, Dusci LJ, et al. Excretion of sotalol in breast milk. Br J Clin Pharmacol 1990;29:277-278.
Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk: Clinical pharmacokinetic considerations. Clin Pharmacokinet 1988; 14:217—240.
Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta blockers. JAMA 1990;263:1653-1657.
Bolli P, Buhler FR, Raeder EA. Lack of beta adrenoreceptor hypersensitivity after abrupt withdrawal of longterm therapy with oxprenolol. Circulation 1981;64:1130-1134.
Walden RJ, Hernandez J, Yu Y, et al. Withdrawal of beta-blocking drugs. Am Heart J 1982;104:515-520.
Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. Am J Cardiol 1988;61:1219-1222.
Al-Qassat H, Cleeves LA, Francis PL, et al. Is there a central nervous system withdrawal syndrome associated with discontinuing long-term treatment with propranolol? Hum Toxicol 1988;7:249-254.
Rosenthal S, Ellison J. Propranolol withdrawal in psychosis. Am J Psychiatry 1990; 147:534.
Walden RJ, Tomlinson B, Graham B, et al. Withdrawal phenomena after atenolol and bopindolol: Haemodynamic responses in healthy volunteers. Br J Clin Pharmacol 1990;30:557-565.
Trancqui A, Kintz P, Wendling P, et al. Toxicological findings in a fatal case of acebutolol self-poisoning. J Anal Toxicol 1992;16:398-400.
Ashouri OS. Metoprolol-induced hyperkalemia in a diabetic with advanced renal failure. Arch Intern Med 1985; 145:578.
Hesse B, Pederson JG. Hypoglycaemia after propranolol in children. Acta Med Scand 1973;193:551-552.
Perrot D, Bui-Xuan B, Lang J, et al. A case of sotalol poisoning with fatal outcome. Clin Toxicol 1988;26:384-396.
Browning RG, Merigian KS. Acute beta-blocker poisoning. Top Emerg Med 1993;15:1-14.
Cristall MA, Hii JRY, Lehman RG, Horowitz JD. So-talol-induced Torsade de pointes: Management with magnesium infusion. Postgrad Med J 1992;68:289-290.
Singh SN, Lazin A, Cohen A, et al. Sotalol-induced Torsade de pointes successfully treated with hemodialysis after failure of conventional therapy. Am Heart J 1991;121:601-602.
McVey FK, Corke CF. Extracorporeal circulation in the management of massive propranolol overdose. Anaesthesia 1991;46:744-746.
Agura ED, Wexler LF, Witzburg RA. Massive propranolol overdose: Successful treatment with high dose isoproterenol and glucagon. Am J Med 1986; 180:755— 757.
Lewis M, Kallenbach J, Germond C, et al. Survival following massive overdose of adrenergic blocking agents (acebutolol and labetalol). Eur Heart J 1983;4:328-332.
DeLima LGR, Kharasch ED, Butler S. Successful pharmacologic treatment of massive atenolol overdose: Sequential hemodynamics and plasma atenolol concentrations. Anesthesiology 1995;83:204-207.
Kollef MR Labetalol overdose successfully treated with amrinone and alpha-adrenergic receptor agonists. Chest 1994;105:626-627.
Brimacomber JR, Scully M, Swanston R. Propranolol overdose: A dramatic response to calcium chloride. Med J Aust 1991;155:267-268.
Dukes ID, Vaughn Williams EM. The multiple models of action of propafenone. Eur Heart J 1984;5:115-125.
Chow MSS, Lebsack С, Dillerman D. Propafenone: A new antiarrhythmic agent. Clin Pharm 1988;7:869-877.
Propafenone (systemic). USP DI update 1990; 10:660— 662.
Funch-Brentano C, Kroemer HK, Lee JT, Roden DM. N Engl J Med 1990;322:518-525.
Pritchett ELC, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: A randomized, placebo-controlled crossover trial in patients tolerating oral therapy. Ann Intern Med 1991;114:539-544.
Shen EN. Propafenone: A promising new antiarrhythmic agent. Chest 1990;98:434-441.
Conte F, Latini R, Meroni M, Castel JM. Propafenone acute intoxication removed by plasma exchange. In: Proceedings of the Fourteenth International Congress of the European Association of Poison Centers, September 25, 199ОЛХ1.
Ohayon J, Colle J-P, Besse P. Intoxication volontaire a la propafenone sur coeur sain (A propos d’une observation). Coeur 1985;16:629-634.
McHugh TP, Perina DG. Propafenone ingestion. Ann Emerg Med 1987;16:437-440.
Hettinger M, Siebner H. Intoxikation mit propafenone. Mediz Welt 1989;40:1495-1497.
Friocourt P, Martin C, Lozach L. Intoxication volontaire par la propafenone: A propos d’un cas. Ann Cardiol Angeiol 1988;37(3): 133—136.
Brzezinka H, Holtz J, Goenechea S. Propafenone fatality. Bull Int Assoc Forens Toxicol 1988;20( 1 ):30—32.
Budde T, Meyer M, Breithardt G, et al. Therapie der schweren propafenoneintoxikation: Eliminations versuch mittels hamoperfusion. Z Kardiol 1986;75:764-769.
Kerns W, English B, Ford M. Severe adult propafenone toxicity. Vet Hum Toxicol 1992;34:329.
Hii JTY, Duff HJ, Burgess ED. Clinical pharmacokinetics of propafenone. Clin Pharmacokinet 1991;21:1-10.
Somberg JC, Tepper D, Landau S. Propafenone: A new antiarrhythmic agent. Am Heart J 1988;115:1274— 1279.
Giani P, Landolina M, Giudici V, et al. Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration. Eur J Clin Pharmacol 1988;34:187-194.
Haefeli WE, Vozeh S, Ha H-R, et al. Concentration effect relations of 5-hydroxypropafenone in normal subjects. Am J Cardiol 1991;67:1022-1026.
Haefeli W, Vozeh S, Ha H-R, et al. Pharmacodynamics of 5-hydroxypropafenone. Clin Pharmacol Ther 1990;47:139.
Tyberg J, Macnab J, Giesbrecht E, McGuigan M. Toxicokinetics of propafenone and its metabolites in a near fatal overdose. Vet Hum Toxicol 1993;35:344.
Parker RB, McCollam PL, Bauman JL. Propafenone: A novell type IC antiarrhythmic agent. DICP Ann Phar-macother 1989;23:196-203.
Gilles AM, Yee YG, Kates RE. Binding of antiarrhythmic drugs to purified human alpha 1 -acid glycoprotein. Biochem Pharmacol 1985;34:4279-4282.
Zoble RG, Kirsten EB, Brewington J, Propafenone Research Group. Pharmacokinetics and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Clin Pharmacol Ther 1989;45:535-541.
Siddoway LA, Roden DM, Woosley RL. Clinical pharmacology of propafenone: Pharmacokinetics, metabolism and concentration response relations. Am J Cardiol 1984;54:9D—12D.
Siddoway LA, Thompson KA, McAllister CB, et al. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences. Circulation 1987;75:785-791.
Burgess E, Duff H, Wilkes P. Propafenone disposition in renal insufficiency and renal failure. J Clin Pharmacol 1989;29:112-113.
Seipel L, Breithardt G. Propafenone: A new antiarrhythmic drug. Eur Heart J 1980;1:309-313.
Funck-Brentano C, Kroemer H, Pavlou H, et al. Inhibition of propafenone metabolism by low doses of quinidine in man. Clin Res 1988;36:363A.
Castel JM, Cappiello E, Leopaldi D, Latini R. Rifampicin lowers plasma concentrations of propafenone and its antiarrhythmic effect. Br J Clin Pharmacol 1990;30:155-156.
Wagner F, Kalusche D, Trenk E, et al. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol 1987;24:213-220.
Kates RE, Yee T-G, Kirsten ER. Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther 1987;42:305-311.
Zalzstein E, Koren G, Bryson SM, Freedom RM. Interaction between digoxin and propafenone in children. J Pediat 1990;! 16:310-312.
Calvo MV, Martin-Suarez A, Luengo CM, et al. Interaction between digoxin and propafenone. Ther Drug Monit 1989;11:10-15.
Nolan PE Jr, Marcus Fl, Erstad BL, et al. Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects. J Clin Pharmacol 1989;29:46-52.
Birgot M-C, Debruyne D, Bonnefoy L, et al. Serum digoxin levels related to plasma propafenone levels during concomitant treatment. J Clin Pharmacol 1991;31:521 — 526.
Libardoni M, Piovan D, Busato E, Padrini R. Transfer of propafenone and 5-hydroxypropafenone to foetal plasma and maternal milk. Br J Clin Pharmacol 1991;32:527-528.
Connolly SJ, Kates RE, Lebsack CS, et al. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol 1983;52:1208-1213.
Lee JT, Kroemer HK, Silberstein DJ, et al. The role of genetically determined polymorphic drug metabolism in the beta blockade produced by propafenone. N Engl J Med 1990;322:1764-1768.
Stoschitzky K, Klein W, Stark G, et al. Different stereoselective effects of (R)- and (S)-propafenone: Clinical pharmacologic, electrophysiologic and radioligand binding studies. Clin Pharmacol Ther 1990;47:740-746.
Burnett DM, Gal J, ZahniserNR, Nies AS. Propafenone interacts stereoselectively with beta-1 and beta-2 adrenergic receptors. J Cardiovasc Pharmacol 1988; 12:615— 619.
Lecky BRF, Weir D, Chong E. Exacerbation of myasthenia by propafenone. J Neurol Neurosurg Psychiatry 1991;54:377.
Olm M, Jimenez MJ, Munne P. Efficacite de la meth-osamine par voie veineuse los des intoxications a la propafenone. [Efficacy of intravenous methoxamine in propafenone poisoning.| Presse Med 1989;18:1124.
Schlepper M. Propafenone: A review of its profile. Eur Heart J 1987;8(suppl.A):27—32.
Nathan AW, Bexton RS, Hellstrand KJ, Camm AJ. Fatal ventricular tachycardia in association with propafenone, a new class IC antiarrhythmic agent. Postgrad Med J 1984;60:155-156.
Ravid S, Podrid PJ, Novrit B. Safety of long term propafenone therapy for cardiac arrhythmia: Experience with 774 patients. J Electrophysiol 1987;1:580-590.
Siebenlist D, Nurnberger M, Hermann G, Gattenlohner. Intoxikation mid propafenone. Intensivmed 1982;19:151-156.
Bosche J, Mattern R. Todlichen vergiftungstall mid dem antiarrhythmikum propafenone. Beitr Geriche Med 1980;38:231-234.
Dimopoulos G. A case of fatal propafenone poisoning. Bull Int Assoc Forens Toxicol 1987; 19(3):31—32.
Camous JP, Ichai C, Meyer P, et al. Traitement des intoxications aux nouveaux antiarrhythmiques (cibenzo-line, flecainide, propafenone). Presse Med 1987; 16:2076.
Kates RE, Yee YG, Winkle RA. Metabolite cumulation during chronic propafenone dosing in arrhythmia. Clin Pharmacol Ther 1984;37:610-614.
Harrison DC, Kates RE, Quart BD. Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide. Am J Cardiol 1986;58:66C—73C.
Woosley RL, Wood AJJ, Roder DM. Encainide. N Engl J Med 1988;318:1107-1115.
Dasgupta A, Rosenzweig IB, Turgeon J, Raisys V. Encainide and metabolites analysis in serum or plasma using a reversed phase high performance liquid chromatographic technique. J Chromatogr 1990;526:260-265.
Pentel PR, Goldsmith SR, Salerno DM, et al. Effect of hypertonic sodium bicarbonate on encainide overdose. Am J Cardiol 1986;57:878-879.
Mortensen ME, Bolon CE, Kelley MT, et al. Encainide overdose in an infant. Ann Emerg Med 1992;21:998— 1001.
Thomas GS. Death following withdrawal of encainide. N Engl J Med 1989;321:393.
Salerno DM, Fifield J, Krejci J, Hodges M. Encainide-induced hyperglycemia. Am J Med 1988;84:39-44.
Nappi JM, Anderson JL. Flecainide: A new prototype antiarrhythmic agent. Pharmacotherapy 1985;5:209— 218.
Leclercq JF, Denjoy L, Mentere F, Coumel P. Flecainide acetate dose concentration relationship in cardiac arrhythmias: Influence of heart failure and amiodarone. Cardiovasc Drug Ther 1990;4:1161 — 1165.
Holtzman JL, Weeks CE, Kvam DC, et al. Identification of drug interactions by meta-analysis of premarketing trials: The effect of smoking on the pharmacokinetics and dosage requirements of flecainide acetate. Clin Pharmacol Ther 1989;46:1-8.
Wagner X, Jouglard J, Moulin M, et al. Coadministration of flecainide acetate and sotolol during pregnancy: Lack of teratogenic effects, passage across the placenta and excretion in human breast milk. Am Heart J 1990;119:700-702.
PalmerCM, Morris MC. Placental transfer of flecainide. Am J Dis Child 1990; 144:144.
Wren C, HunterS. Maternal administration of flecainide to terminate and suppress fetal tachycardia. Br Med J 1988;296:249.
Woodbum JD Jr. Cardiac arrest from a daily newspaper article. Ann Emerg Med 1989;18:1375-1376.
McQuinn RL, Pisani A, Wafa S, et al. Flecainide excretion in human breast milk. Clin Pharmacol Ther 1990;48:262-267.
Sellers TD, Di Marco JP. Sinusoidal ventricular tachycardia association with flecainide acetate. Chest 1984;85:647-649.
Kennerdy A, Thomas P, Sheridan DJ. Generalized seizures as the presentation of flecainide toxicity. Eur Heart J 1989;10:950-954.
Plomp TA, Boom HT, Maes RAA. Measurement of flecainide plasma concentrations by high performance liquid chromatography with fluorescence detection. J Anal Toxicol 1986;10:102-106.
Bartek MJ, Mayol RF, Boarman MP, et al. Analysis of encainide and metabolites in plasma and urine by high-performance liquid chromatography. Ther Drug Monit 1988;10:446-452.
Conrad GJ, Ober RE: Metabolism of flecainide. Am J Cardiol 1984;53:41 B—51B.
Forrest ARW, Marsh I, Galloway JH, Gray PB. A rapidly fatal dose with flecainide. J Anal Toxicol 1991;15:41-43.
Rosen DM, Woosely RL. Drug therapy: Flecainide. N Engl J Med 1986;315:36-41.
Holmes B, Heel RC. Flecainide: A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985;29:1-33.
Malikin G, Murphy M, Lam S. Assay of flecainide in serum by high performance liquid chromatography after microscale protein precipitation. Ther Drug Monit 1989;11:210-213.
Ray J. Flecainide. What are we measuring? Ther Drug Monit 1990;12:416.
Crijns HJGM, Kingma JH, Viersma JW, Lie KI. Transient giant inverted T waves during flecainide ingestion. Am Heart J 1987;113:214-215.
Xing-Sheng Y, Jing-Ping S, Guang Z. Acute flecainide toxicity. Chin Med J 1990;103:606-607.
Winkelmann BR, Leinberger H. Life-threatening flecainide toxicity: A pharmacodynamic approach. Ann Intern Med 1987;106:807-814.
Pentel PR, Fifield J, Salerno DM. Lack of effect of hypertonic sodium bicarbonate on QRS duration in patients taking therapeutic doses of class IC antiarrhythmic drugs. J Clin Pharmacol 1990;301:789-794.
Chouty F, Funck-Brentano C, Leehardt A, et al. Intravenous sodium lactate as a treatment for class 1 anti-ar-rhythmic agents overdose. Circulation 1989;80(suppl.II):II-430.
Sagie A, Strasberg B, Kusniec J, et al. Rapid suppression of flecainide induced incessant ventricular tachycardia with high dose intravenous amiodarone. Chest 1988;93:879-880.
Palitzcsch KD, Bode H, Huck K, Vsadel KH. Multiple successful resuscitations after flecainide intoxication with suicidal threat. Dtsch Med Wochenschr 1992;! 17:56— 60.
Schaller M-D, Fischer AP, Wasserfallen JB, et al. Cardiac arrest after volunteer intoxication with flecainide: Resuscitation by prolonged partial extracorporeal circulation. Schweiz Med Wochenschr 1992; 122:786.
Braun J, Kollert JR, Gessler V, Becker JV. Failure of haemoperfusion to reduce flecainide intoxication: A case study. Med Toxicol 1987;2:463-467.
Wurzberger R, Witter E, Avenhaus H, et al. Hamoperfusion bei flecainidintoxikation. Klin Wochenschr 1986;64:442-444.
Gotz D, Pohle S, Barchow D. Primary and secondary detoxification in severe flecainide intoxication. Intensive Care Med 1991;17:181-187.
Ruskin JN. The Cardiac Arrhythmia Suppression Trial (CAST). N Engl J Med 1989;321:386-388.
The Cardiac Arrhythmia Suppression Trial (CAST) investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmic suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo. The cardiac arrhythmic suppression trial. N Engl J Med 1991;324:781-788.
Change urged in use of two drugs. FDA Consumer 1989;23(6):2.
Pritchett ELC, Wilkinson WE. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 1991;67:976-980.
Feld GK, Chen P-S, Nicod P, et al. Possible atrial proar-rhythmic effects of class 1C antiarrhythmic drugs. Am J Cardiol 1990;66:378-383.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:62.
Aronoff G, Brier M, Mayer ML, et al. Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function. J Clin Pharmacol 1991 ;31:38— 44.
Miller JS, Vaughan Williams EM. Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia. Br J Pharmacol 1982;75:469-478.
Kostis JB, Krieger S, Moreynra A, Cosgrove N. Cibenzoline for treatment of ventricular arrhythmias: A double blind placebo controlled study. J Am Coll Cardiol 1984;4:372-377.
Brazzell RK, Aogaiche K, Heber JJ, et al. Cibenzoline plasma concentrations and antiarrhythmic effect. Clin Pharmacol Ther 1984;35:307-316.
Browne KF, Prystowsky EN, Zipes DP, et al. Clinical efficacy and electrophysiologic effects of cibenzoline therapy in patients with ventricular arrhythmias. J Am Coll Cardiol 1984;3:857-864.
Nolan PE Jr. The new antiarrhythmics: Cibenzoline, moricizine, and pirmenol. Hosp Ther 1990; 15:323— 331.
Manz M, Pfitzner P, Luderitz b. Cibenzoline: Electrophysiologic effects in patients with supraventricular tachycardia. Eur Heart J 1989; 10(suppl):302.
Massarella JW, Khoo K-C, Aogaichi K, et al. Effect of renal impairment on the pharamcokinetics of cibenzoline. Clin Pharmacol Ther 1988;43:317-323.
Reidenberg MM, Lorenzo BJ, Drayer DE, et al. A nonradioactive iothalamate method for measuring glomerular filtration rate and its use to study the renal handling of cibenzoline. Ther Drug Monit 1988;10:434-437.
Massarella JW, Defeo TM, Liguori J, et al. The effects of cimetidine and ranitidine on the pharmacokinetics of cifenline. Br J Clin Pharmacol 1991;31:481-483.
Hilleman DE, Mohbiuddin SM, Ahmed IS, Dahl JM. Cibenzoline-induced hypoglycemia. Drug Intell Clin Pharm 1987;21:38-40.
Chouty F, Funck-Brentano CF, Leenhardt A, et al. Treatment of new class I anti-arrhythmic agent poisoning with intravenous sodium molar lactate or bicarbonate. Eur Heart J 1989; 10(suppl.):302 (Abstract 1521).
Wyss E. Karp P, Mons P, et al. Cardiogenic shock resistant to sodium lactate during cibenzoline overdosage. Therapie 1990;45:455.
Lefort G, Haissaguerre M, Floro J, et al. Hypoglycemies au cours de surdosages par tin novel antiarrhythmique: La cibenzoline. Presse Med 1988;17:687-691.
Jeandel C, Preiss MA, Pierson H, et al. Hypoglycemia induced by cibenzoline. Lancet 1988;1:1232-1233.
Hachman MR, Lee TL, Brooks MA. Determination of cibenzoline in plashma and urine by high pressure liquid chromatography. J Chromatogr 1983;273:347— 356.
Min BH, Garland WA. Quantitation of cibenzoline in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. J Chromatogr 1984;336:403-409.
TenczerJ, Lappenberg-Pelzer М, Schneider V, et al. Fatal poisoning with detajmium: Identification of deta-jmium and its metabolites and artifacts by gas chromatography-mass spectrometry and quantification by high-performance liquid chromatography. J Chromatogr 1994:661:47-55.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:58.
Koppel C, Tenczer J, Arndt I. Metabolic disposition of ajmaline. Eur J Drug Metab Pharmacokinet 1989;14:309-316.
Grenadier E, Alpan G, Keidar S, et al. The efficacy of ajmaline in ventricular arrhythmias after failure of lidocaine therapy in the acute phase of myocardial infarction. Angiology 1983;34:204-214.
Lengfelder W, Senges J, Rizos 1. Intraindividual comparison of intravenous ajmaline and quinidine in patients with sustained ventricular tachycardia: Effects on normal myocardium and on arrhythmia characteristics. Eur Heart J 1985;6:312-322.
Chiale PA, Przybylski J, Halpern MS, et al. Comparative effects of ajmaline on intermittent bundle branch block and the Wolff—Parkinson—White syndrome. Am J Cardiol 1977;39:651-657.
Kleinsorge H. Klinische untersuchungen uber die wirkungs-weise des rauwolfia-alkaloids ajmaline by herzzythmusstonmgen insbesondere der extrasystole. Med Klin 1959;54:409.
Riboulet G, Efthymiou ML, Conso F, et al. Acute intoxication by ajmaline. Vet Hum Toxicol 1979;2:(sup-pl.):91—92.
Koppel C, Oberdisse V, Heinemeyer G. Clinical course and outcome in class IC antiarrhythmic overdose. Clin Toxicol 1990;28:433-444.
Ben Schachar C, Kishon Y. Intoxication with ajmaline in an infant. Chest 1979;76:97-98.
Binder C, Wimmer M. Einfall von ajmalin-intoxication in klein-kindes alter. Wien Klin Wochenschr 1972;84:67-69.
Almog C, Maidan A, Pik A, Schlesinger Z. Acute intoxication with ajmaline. Isr J Med Sci 1979;15:570-572.
Jonrod JC, Barrelet JA. Suicidal attempt by overdosage of ajmaline. Am Heart J 1965;70:719-720.
Kleinsorge H, Gaida P. Das verhalten des serumspiegels nach intravenoeser injektion von ajmaline. Klin Wochenschr 1962;40:149.
Ikeda N, Umetsu K, Suzuki T, et al. An infant fatality involving ajmaline. J Forens Sci 1988;33:558-561.
Hager W, Friedreich KH, Wink K, Wegehaupt L. Suiz-idversuch mit ajmalin. Dtsch Med Wochenschr 1968;93:1809-1812.
HrubyK, MissliwetzJ. Poisoning with oral antiarrhythmic drugs. Int J Clin Pharm Ther Toxicol 1985;23:253-257.
Koppel C, Wagemann A, Martens F. Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmias of recent onset. Eur J Drug Metab Pharmacokinet 1989;14:161-167.
Koppel C, Tenczer J. Mass spectral characterization of urinary metabolites of ajmaline. Pharamcol Toxicol 1988;65:25.
Kallfelz HC, Rotthauwe HW. Ajmalin-intoxikation in kinde-salter. Med Klin 1964;59:336-342.
Rautenburg HW, Meitner K, Knothe W. Herzstillstand nach ajmaline injection bei Herz Katheterisierung unter Halothane. Narkose Med Welt 1962;27:2329.
Batalow Z, Apostolov L. Stir certaines actions toxiques de Г ajmaline avec contribution de deux cas. Folia Med 1968,10:403.
Clarke EGC, ed. Isolation and Identification of Drugs. London: Pharmaceutical Press, 1969:177.
Nitsch J, Kohler U, Luderlitz B. Hemmung der flecai-nidresorption dutch Aktivkohle. 2 Kardiol 1987,76:289— 291.
Riegger AJG, Dilger J, Roth W, et al. Elimination von ajmalin dutch verschiedene entgiftungsverfahren. Inten-sivmed 1980;17:57-60.
Jequier Р, Jones R, Mackintosh A. Fatal mexiletine overdose. Lancet 1976; 1:429.
Chambers SC, Milsom SM, Ikram H. Mexiletine overdose. NZ Med J 1982;95:898-899.
Hruby K, Missliwetz J. Poisoning with oral antiarrhyth-mic drugs. Int J Clin Pharmacol Ther Toxicol 1985;23:253-257.
Frank SE, Snyder JT. Survival following severe overdose with mexiletine, nifedipine and nitroglycerin. Am J Emerg Med 1991;9:43-46.
Nelson LS, Hoffman RS. Mexiletine overdose producing status epilepticus without cardiovascular abnormalities. Clin Toxicol 1994;32:731-736.
Wilson JH. Breast milk tocainide levels. J Cardiovasc Pharmacol 1988; 12:497.
Cohen A. Accidental overdose of tocainide successfully treated. Angiology 1987;38:614.
MonkJP, Brogden RN. Mexiletine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the treatment of arrhythmias. Drugs 1990;40:374-411.
Kerin NZ, Aragon A, Marinescu G, et al. Mexiletine: Long term efficacy and side effects in patients with chronic drug-resistant potentially lethal ventricular arrhythmias. Arch Intern Med 1990;150:381-384.
Harris SC, Guerra C, Wallace JE. Assay of free and total tocainide by high performance liquid chromatography (HPLC) with ultraviolet (UV) detection. J Forens Sci 1989;34:912-917.
Sperry К, Wohlenberg N, Standefer JC. Fatal intoxications by tocainide. J Forens Sci 1987;32:1440-1446.
Fasola GP, D’Osvaldo F, De Pangher V, et al. Thrombocytopenia and mexiletine. Ann Intern Med 1984; 100: 162.
Jonville АР, Barbier Р, Blond МН, et al. Accidental lidocaine overdosage in an infant. Clin Toxicol 1990;28:101-106.
Poklis A, Mackell MA, Tucker EF. Tissue distribution of lidocaine after fatal accidental injection. J Forens Sci 1984;29:1229-1236.
Finkelstein F, Kreeft J. Massive lidocaine poisoning. N Engl J Med 1979;301:50.
Howard JJ, Mohsenufar Z, Simons SM. Adult respiratory distress syndrome following administration of lidocaine. Chest 1982;81:644-645.
O'Donohue WJ, Moss LM, Angelillo VA. Acute methemoglobinemia induced by topical benzocaine and lidocaine. Arch Intern Med 1980;140:1508-1509.
Armstrong DK, Bremseth DL, Lima JJ. Clinical response and total and unbound plasma concentrations after lidocaine overdose. Ther Drug Monit 1988.
Peat MA, Deyman ME, Crouch DJ, et al. Concentrations of lidocaine and monoethylglycylxylidide (MEGX) in lidocaine associated deaths. J Forens Sci 1985;30:1048-1057.
Dawling S, Flanagan RJ, Widdop B. Fatal lignocaine poisoning: Report of two cases and review of the literature. Hum Toxicol 1989;8:389-392.
Edgren B, Tilelli J, Gehrz, R. Intravenous lidocaine overdosage in a child. Clin Toxicol 1986;24:51-58.
Amitai Y, Whitesell L, Lovejoy FH Jr. Death following accidental lidocaine overdose in a child. N Engl J Med 1986;314:182-183.
Moore DC, Crawford RD, Scurlock JE. Severe hypoxia and acidosis following local anesthetic induced convulsions. Anesthesiology 1980;53:259-260.
Freedman MD, Gal J, Freed CR. Extracorporeal pump assistance: Novel treatment for acute lidocaine poisoning. Eur J Clin Pharmacol 1982;22:129-135.
Shub С. Gau GT, Sidell PM, et al. The management of acute quinidine intoxication. Chest 1978;73:173-178.
Kerr F, Kenoyer G, Bilitch M. Quinidine overdose: Neurological and cardiovascular toxicity in normal person. Br Heart J 1971;33:629-631.
Woic L, Oyri A. Quinidine intoxication treated with hemodialysis. Acta Med Scand 1974;195:237-239.
Conrad KA, Molk BL, Chidsey CA. Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation 1977;55:1-7.
Lesne M, Devas DM, Reynaert M. Enterogastric cycle and intoxication with hydroquinidine: A case report. Clin Toxicol 1981;18:659-662.
Thompson KA, Murray JJ, Blair IA, et al. Plasma concentrations of quinidine, its major active metabolites and dihydroquinidine in patients with Torsade de pointes. Clin Res 1986;34:408A. Abstract.
Mackichan JJ, Badoulas H, Schaal SF. Effect of cimetidine on quinidine bioavailability. Biopharm Drug Dis-pos 1989;10:121-125.
McNulty RM, Lazor J A, Sketch M. Transient increase in plasma quinidine concentrations during ketoconazolequinidine therapy. Clin Pharm 1989;8:222-225.
Edwards D, Lavoie R, Beckman H, et al. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. Clin Pharmacother 1987;41:68-73.
Killeen AA, Bowers LD. Fetal supraventricular tachycardia treated with high dose quinidine: Toxicity associated with marked elevation of the metabolite, 3(S)-3-hy-droxyquinidine. Obstet Gynecol 1987;70:445-449.
Hoffman BF, Rosen MR, Wit AL. Electrophysiology and pharmacology of cardiac arrhythmias: VII. Cardiac effects of quinidine and procainamide. Am Heart J 1975;90:117-122.
Finnegan TRL, Trainee JR. Depression of the heart by quinidine and its treatment. Br Heart J 1954; 16:341 — 350.
Lavie CJ, Biundo J, Quinet RJ, et al. Systemic lupus erythematosus (SLE) induced by quinidine. Arch Intern Med 1985;145:446-448.
Shalit M, Flugelman MY, Harats N, et al. Quinidine induced vasculitis. Arch Intern Med 1985;145:2051-2052.
Summers WK, Allen RE, Pitts FN. Does physostigmine reverse quinidine delirium. West J Med 1981 ;135:411 — 412.
Murray SB, Jay JL. Loss of sight after self poisoning with quinine. Br Med J 1983;281:1700.
Bailey DJ. Cardiotoxic effects of quinidine and their treatment. Arch Intern Med 1960;105:13-22.
Dextraze PG, Foreman J, Griffiths WC, et al. Comparison of an enzyme immunoassay and a high performance liquid chromatographic method for quantitation of quinidine in serum. Clin Toxicol 1981;18:291-297.
Phillips RE, Warrell DA, White NJ, et al. Intravenous quinidine for the treatment of severe falciparum malaria: Clinical and pharmacokinetic studies. N Eng] J Med 1985;312:1273-1278.
Gaudreault P. Quinidine. Clin Toxicol Rev 1982;4(12): 1—2.
De Azevedo RM, Watanabe Y, Dreifus LS. Electrophysiologic antagonism of quinidine and bretylium tosylate. Am J Cardiol 1974;33:633-638.
Miller В, Skupin A, Rubenfire М, Bigman О. Respiratory failure produced by severe procainamide intoxication in a patient with preexisting peripheral neuropathy caused by amiodarone. Chest 1988;94:663-665.
Bauer LA, Black D, Gensler A. Procainamide-cimeti-dine during interaction in elderly male patients. J Am Geriatr Soc 1990;38:467-469.
Saal AK, Werner JA, Greene HL, et al. Effect of amiodarone on serum quinidine and procainamide levels. Am J Cardiol 1984;53:1264-1267.
Kosoglou T, Rocci ML Jr, Vlasses PH. Trimethoprim alters the disposition of procainamide and A-acetyl procainamide. Clin Pharmacol Ther 1988;44:467-477.
Vlasses PH, Kosoglou T, Chase SL, et al. Trimethoprim inhibition of the renal clearance of procainamide and A-acetylprocainamide. Arch Intern Med 1989:149:1350— 1353.
Habbab MA, El-Sherif N. Drug-induced Torsade de pointes: Role of early afterdepolarizations and dispersion of repolarization. Am J Med 1990;89:241-246.
Godley PJ, Morton TA, Karbhoski JA, Tami JA. Procainamide-induced myasthenia crisis. Ther Drug Monit 1990;12:411-414.
Putnam JB, Bolling SF, Kirsch MM. Procainamide-induced respiratory insufficiency after cardiopulmonary bypass. Ann Thorac Surg 1991;51:482-483.
Giannone L, Kugler JW, Krantz SB. Pure red cell aplasia associated with administration of sustained-release procainamide. Arch Intern Med 1987;147:1179-1180.
Henry PA, Dhruv RA. More sensitive enzyme mediated immunoassay technique for procainamide and A-acetyl-procainamide in plasma, serum and urine. Clin Chem 1988;34:957-960.
Koch-Weser J, Klein SW. Procainamide dosage schedules, plasma concentrations and clinical effects. JAMA 1971;215:1454-1460.
Chen ML, Loo MG, Chiou WL. Pharmacokinetics of drugs in blood: 111. Metabolism of procainamide and storage effects of blood samples. J Pharm Sci 1985;72: 572-574.
Totoritis MC, Tan EM, McNally EM, Rubin RL. Association of antibody to histone complex H2A-H2B with symptomatic procainamide induced lupus. N Engl J Med 1988;318:1431-1436.
Heiselman DE, Litman Gl. Risk factors for procainamide-induced Torsade de pointes. Clin Res 1986; 34:7A.
Atkinson AJ, Krumlovsky FA, Huang CM, et al. Hemodialysis for severe procainamide toxicity: Clinical and pharmacokinetic observations. Clin Pharmacol Ther 1976;20:585-592.
Koppel С, Oberdisse V, Heinemeyer G. Clinical course and outcome in classic antiarrhythmic overdose. Clin Toxicol 1990;28:433-444.
Lederle RM, Harbig K, Wermuth G, Klaus D. Hamop-erfusion mit Kunsharz-Adsorben bei schwerer Intoxika-tion mit N-Propyl-Ajmalinium-Bitartrat. Intensivmed 1981;18:77-82.
Gelbke HP, Schlicht HJ. Suicide by an overdose of N-propylajmalinium bitartrate. Arch Toxikol 1977;37:135— 141.
Grubb BP. Moricizine: A new agent for the treatment of ventricular arrhythmias. Am J Med Sci 1991 ;301:298— 401.
Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129-147.
Moricizine for cardiac arrhythmias. Med Lett Drugs Ther 1990;32(830):99—100.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:69.
Vaughan Williams EM. Classification of antiarrhythmic action of moricizine. J Clin Pharmacol 1991;31:216— 221.
Physicians’ Desk Reference. 45th ed. Oradel, NJ: Medical Economics, 1991:923—926.
Mann HJ. Moricizine: A new class 1 antiarrhythmic. Clin Pharm 1990;9:842-852.
Siddoway LA, Schwartz SL, Barbey JT, et al. Clinical pharmacokinetics of moricizine. Am J Cardiol 1990;65:2l D—25D.
Rosenshtraukh L, Anyukhovsky E, Nesterenko V. Electrophysiologic aspects of moricizine HCI. Am J Cardiol 1987;60:27-34.
Bigger T. Cardiac electrophysiologic effects of moricizine hydrochloride. Am J Cardiol 1990;65:15-20.
Ruffy R, Rosenshtraukh L, Elharrar V, Zipes D. Electrophysiologic effects of ethmozine on the canine myocardium. Cardiovasc Res 1979;13:354-363.
Kennedy H. Noncardiac adverse effects and organ toxicity of moricizine during short term and long term studies. Am J Cardiol 1990;65:47-50.
Morganroth J, Pratt C. Prevalence and characteristics of proarrhythmia from moricizine. Am J Cardiol 1989;63:172-176.
Ellsworth AJ, Horn JR, Raisys VA, et al. Disopyramide and N-monodesalkyl disopyramide in serum and breast milk. DICP Ann Pharmacother 1989;23:56-57.
Ragosta M, Weihl AC, Rosenfeld LE. Potentially fatal interaction between erythromycin and disopyramide. Am J Med 1989;86:465-466.
Staum JM. Enzyme induction: Rifampin-disopyramide interaction. DICP Ann Pharmacother 1990;24:701 — 703.
Michaelek RW, Rejent TA, Spencer RA. Disopyramide fatality: Case report and GC/FID analysis. J Anal Toxicol 1982;6:255-257.
Orloff KG, Thompson BC, Caplan YH. Fatal dose with disopyramide. Bull Int Assoc Forens Toxicol 1980:15:4—5.
Karim A. Disopyramide dialyzability. Lancet 1978;2:214.
Gosselin B, Matthieu D, Chopin C, et al. Acute intoxication with disopyramide: Clinical and experimental study by hemoperfusion on amberlite XAD 4 resin. Clin Toxicol 1980;17:439-449.
Jaeger A, Sauder PH, Kopferschmitt J, et al. Acute disopyramide poisoning: A multicenter study of 106 cases. Vet Hum Toxicol 1982;24:285. Abstract.
Accomero F, Pellanda A, Ruffini C, et al. Prolonged cardiac resuscitation during acute disopyramide poisoning. Vet Hum Toxicol 1993;35:231-237.
Schattner A, Gindin J, Geltner D. Fatal Torsade de pointes following jaundice in a patient treated with disopyramide. Postgrad Med J 1989;65:333-334.
Adenosine approved for treatment of paroxysmal supraventricular tachycardia. Clin Pharm 1990;9:79.
Cabrera R, Lucas FJ, Pevalver C, et al. Adenosine triphosphate as a diagnostic to identify tachycardias at the emergency room. Chest 1993; 104(suppl.): 167S.
Pinski SL, Maloney JD. Adenosine: A new drug for acute termination of supraventricular tachycardia. Cleve Clin J Med 1190;57:383-388.
Faulds D, Chrisp P, Buckley MM-T. Adenosine: An evaluation of its use in cardiac diagnostic procedures and in the treatment of paroxysmal supraventricular tachycardia. Drugs 1991;41:596-624.
Sellers TD, Kirchhoffer JG, Modesto TA. Adenosine: A clinical experience and comparison with verapamil for the termination of supraventricular tachycardias. Prog Clin Biol Res 1987;230:283-299.
Overhold ED, Rheuban KS, Gutgesell HP, et al. Usefulness of adenosine for arrhythmias in infants and children. Am J Cardiol 1988;61:336-340.
Cairns CB, Niemann JT. Intravenous adenosine in the emergency department: Management of paroxysmal supraventricular tachycardia. Ann Emerg Med 1991;20: 717-721.
Roelke M, Yurchak PM. Adenosine and supraventricular tachycardia. N Engl J Med 1992;326:1221.
Podolsky SM, Varon J. Adenosine use during pregnancy. Ann Emerg Med 1991;20:1027-1028.
Webster DR, Daar AA. Prolonged bradysystole and seizures following intravenous adenosine for supraventricular tachycardia. Am J Emerg Med 1993;11:192-194.
White RD. Acceleration of the ventricular response in paroxysmal bone atrial fibrillation following the injection of adenosine. Am J Emerg Med 1993;11:245-246.
Camm AJ, Garratt CJ. Adenosine and supraventricular tachycardia. N Engl J Med 1992;226:1221-1222.
Reed R, Falk JL, O’Brien J. Untoward reactions to adenosine therapy for supraventricular tachycardia. Am J Emerg Med 1991;9:566-570.
Shen W-K, Kurachi Y. Mechanisms of adenosine-me-diated actions on cellular and clinical cardiac electrophysiology. Mayo Clin Proc 1995;70:274-291.
Cushley MJ, Tattersfield AE, Holgate ST. Adenosine-induced bronchoconstriction in asthma: Antagonism by inhaled theophylline. Am Rev Respir Dis 1984; 129:380— 384.
Harrington GR, Froelich EG. Adenosine-induced Torsade de pointes. Chest 1993;103:1299-1301.
Wesley RC, Turaquest P. Torsade de pointes after intravenous adenosine in the presence of prolonged QT syndrome. Am Heart J 1992;123:794-796.
Adenosine and the diagnosis of tachycardias. Lancet 1992;339:464-465.
Exner DV, Muzylla T, Gillis AM. Proarrhythmia in patients with the Wolff—Parkinson—White syndrome after standard doses of intravenous adenosine. Ann Intent Med 1995;122:351-352.
Rankin AC, McGovern BA. Adenosine or verapamil for the acute treatment of supraventricular tachycardia. Ann Intern Med 1991;114:513-515.
Sobel RM. Untoward reaction to adenosine therapy for supraventricular tachycardia. Am J Emerg Med 1992;10:393.
Nathan J. Terminating paroxysmal supraventricular tachycardias with adenosine. West J Med 1991;156:290— 291.
Burkhart KK. Respiratory failure following adenosine administration. Am J Emerg Med 1993;11:249-250.
Ben-David J, Zipes DP. Torsade de pointes and proarrhythmia. Lancet 1993;341:1578—1582.
Campbell TJ. Proarrhythmic actions of antiarrhythmic drugs: A review. Aust NZ J Med 1990;20:275-282.
Tzivoni D, Banai S, Schuger C, et al. Treatment of Torsade de pointes with magnesium sulfate. Circulation 1988;77:392-399.
Tzivoni D, Keren A. Suppression of ventricular arrhythmias by magnesium. Am J Cardiol 1990;65:1397-1399.
Perticone F, Adinolfi L, Bonaduce D. Efficacy of magnesium sulfate in the treatment of Torsade de pointes. Am Heart J 1986;112:847-849.
Maurer HH. Identification of antiarrhythmic drugs and their metabolites in urine. Arch Toxicol 1990;64:218— 230.
Smilkstein MJ. Presentation on Cardiovascular Pharmacology, North American Congress of Clinical Toxicology-94, Salt Lake City, Utah, September 1994.
Ellenhorn MJ, Barceloux DG. Medical Toxicology. New York: Elsevier Science, 1988.
Page RL. Treatment of arrhythmias during pregnancy. Am Heart J 1995;130:871-876.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:234—235.
Ito MK, Smith AR, Lee ML. Ticlopidine: A new platelet aggregation inhibitor. Clin Pharm 1992;11:603-617.
Ticlopidine. Lancet 1991;337:459-460. Editorial.
Gent M, Blakely JA, Easton JD, et al. The CATS Group, The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-1220.
Haynes RB, Sandler RS, Larson EB, et al. A critical appraisal of ticlopidine: a new antiplatelet agent: Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1992;152:1376-1378.
Macko R. Ticlopidine hydrochloride and prevention of stroke. West J Med 1993; 159:182.
Lewis RH. Personal communication, Syntex Laboratories, Palo Alto, CA, June 3, 1992.
Horowitz RS, Bogart T, McCubbin T, et al. Cardiopulmonary instability, mental status changes and hemorrhage associated with overdose of ticlopidine (TiclodR). Vet Hum Toxicol 1993;35:344.
Picard-Fraire C. Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function. Agents Actions Suppl 1984;15:68-75.
Ticlopidine for prevention of stroke. Med Lett Drugs Ther 1992;34(874):65.
Vargas R, Reitran M, Teitelbaum P, et al. Study of the effect of ticlopidine on digoxin blood levels. Clin Pharmacol Ther 1988;43:176.
Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990;322:33-42.
Saltiel E, Ward A. Ticlopidine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states. Drugs 1987;34:222-262.
Guedon C, Bruna T, Ducrotte P, et al. Altered small bowel motility in severe chronic diarrhea with ticlopidine. Gastroenterol Clin Biol 1989;13:934-937.
Chasany O, Bacq Y, Metman EH, et al. Chronic severe diarrhea in the course of ticlopidine treatment. Gastroenterol Clin Biol 1989; 11:950.
Balsano F, Cocchei S, Libretti A, et al. Ticlopidine in the treatment of intermittent claudication: A 21 month double-blind trial. J Lab Clin Med 1989; 114:84—91.
Grimm IS, Litynski JJ. Cholestasis associated with ticlopidine. Am J Gastroenterol 1994;8:279-280.
Garnier G, Taillan B, Pesce A, et al. Ticlopidine and severe aplastic anemia. Br J Haematol 1992;81:1459— 1460.
Mataix R, Ojeda E, Perez MDC, Jimenez S. Ticlopidine and severe aplastic anemia. BrJ Haematol 1992;80:125— 132.
Ellie E, Durrieu C, Besse P, et al. Thrombotic thrombocytopenia purpura associated with ticlopidine. Stroke 1992;23:922-923.
Tardy B, Page Y, Tardy-Poncet B, et al. Thrombotic thrombocytopenia purpura related to ticlopidine. Thromb Haemostasl991 ;65(suppl.): 1082.
Di Minno G, Cerbone AM, Mattioli PL, et al. Functionally thrombasthenia state in normal platelets following the administration of ticlopidine. J Clin Invest 1985;75:328-338.
Shah J, Teitelbaum P, Molony B, et al. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. BrJ Clin Pharmacol 1991;32:761-764.
Ruiz-lrastorza G, Alonso JJ, Iglesias JJ, Aguirre C. Granulocyte colony-stimulating factor for neutropenia secondary to ticlopidine. Acta Haematol 1994;91:106— 107.
Soni N. Wonderful albumin? Not all it is cracked up to be. Br Med J 1995;310:887-888.
Stumpf JL, Lechner JL, Ryan ML. Use of albumin in a university hospital: The value of targeted physician intervention. DICP Ann Pharmacother 1991;25:239-243.
Chamubeau RAFM, Jorning GGA, Korse FG, Roos PJ. Ammonium in intravenous albumin preparations. Lancet 1993;342:1110-1111.
Tsou VM, Young RM, Hart MH. Vanderhoof JA. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. Pediatrics 1991;87:148— 151.
Shoemaker WC. Appel PL, Karin HB, et al. Prospective trial of supernormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 1988;94:1176— 1186.
Shoemaker WC. Monitoring and management of acute circulatory problems: The expanded role of the physiologically oriented critical care nurse. Am J Crit Care 1992;1:38-53.
Wagner BKJ, D’Amelio LF. Pharmacologic and clinical considerations in selecting crystalloid, colloidal and oxygen-causing resuscitation fluids, part 1. Clin Pharmacol 1993;12:335-346.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:864-865.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:652— 653.
Fisher MM, Brady BW. Adverse reactions to plasma volume expanders. Drug Saf 1990;5:86-93.
Bergqvist D. Dextran in the prophylaxis of deep vein thrombosis. JAMA 1987;258:324-325.
Abrams DI, Kuno S, Wong R, et al. Oral dextran sulfate (LJADDI) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1989;110:183-188.
Lorentsen KJ, Hendrix CW, Collins JM, et al. Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med 1989;111:561-566.
Kale PB, Sklar GE, Wesloocicz LA, Di Lisio E. Flusol: Therapeutic failure in severe anemia. Ann Pharmacother 1993;27:1452-1453.
Reynolds JEF, ed. Martindale: The Extra Pharmacopeia. 30th ed. London: Pharmaceutical Press, 1993:653.
Klotz V. Kroemer H. Clinical pharmacokinetic considerations in the use of plasma expanders. Clin Pharma-cokinet 1987;12:123-135.
Boon JC, Jench F, Ring J, Messmer K. Intravascular persistence of hydroxyethyl starch in man. Eur Surg Res 1976;8:497-503.
Yacobi A, Staill RG, Sum CY, et al. Pharmacokinetics of hydroxyethyl starch in normal subjects. J Clin Pharmacol 1982;22:206-212.
Maguire LS, Strauss RG, Koepke JA, et al. The elimination of hydroxyethyl starch from the blood of donors experiencing single or multiple intermittent-flow centrifugation leukapheresis. Transfusion 1981;24:347— 353.
Barbier P, Jonville А-P, Autret E, Coureau C. Fetal risks with dextrans during delivery. Drug Saf 1992;7:71-73.
Zwaveling JH, Meulenbelt J, Van Xanten NHW. Effectiveness of plasma exchange in reversing elevated plasma osmotic pressure associated with dextran 40 overdose. In: Proceedings, European Association of Poison Centres and Clinical Toxicologists, 1988.7 Zwaveling JH, Meulenbelt J, Van Xanten NWW, Heine RJ. Renal failure associated with the use of dextran 40. Neth J Med 1989;35:321-326.
Kurnik BRC, Singer F, Groh WC. Dextran-induced acute anuric renal failure. Am J Med Sci 1991 ;302:28— 30. Case report.
Drum! W, Polzleitner D, Laggner AN, et al. Dextran 40, acute renal failure and elevated plasma oncotic pressure. N Engl J Med 1988;318:252-253.
Taylor MA, Diblasi SL, Bender RM, et al. Adult respiratory distress syndrome complicating intravenous infusion of low molecular weight dextran. Cathet Cardiovasc Diagn 1994;32:249-253.
Choban MJ, Kalhan SB, Anderson RJ, Collins R. Pulmonary edema and coagulopathy following intrauterine instillation of 32 % dextran 70 (Hyskar). J Clin Anesth 1991;3:317-319.
Ljungstrom K-G, Revenas B, Smedegard G, et al. Histopathological lung changes in immune complex mediated anaphylactic shock in humans elicited by dextran. Forens Sci Int 1988;38:251-258.
Mangar D. Documentation of high molecular weight dextran (Hyskan) solution entering the serum during hysteroscopy. Am J Obstet Gynecol 1992; 166:771.
Golan A, Siedner M, Bahar M, et al: High output left ventricular failure after dextran use in an operative hysteroscopy. Fert Steril 1990;54:939-941.
Cron TA, Gerber H. Anaphylactoid reaction to Physiogel (Rm) SRK 5 %: A contribution to the plasma substitutes controversy. Schweiz Med Wochenschr 1991;21:1773-1776.
Cullen MJ, Singer M. Severe anaphylactoid reaction to hydroxyethyl starch. Anaesthesia 1990;45:1041-1042.
Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substrates. Lancet 1977;1:466-469.
Ring J, Seifert J, Messmer K, Brendel W. Anaphylactoid reactions due to hydroxyethyl starch infusion. Eur Surg Res 1976;8:389-399.
Prevedoros HP, Bradburn NT, Harrison GA. Three cases of anaphylactoid reaction to Haemacce. Anaesth Intensive Care 1990;18:409-412.
Chang JC. Gross HM. Jang NS. Disseminated intravascular coagulation due to intravenous administration of Hetastarch. Am J Med Sci 1990;300:301-303.
Dalrymple-Hay M, Aitchison R, Collins P, et al. Hydroxyethyl starch induced acquired von Willebrand’s disease. Clin Lab Haematol 1992;14:209-211.
Spence RK, McCoy S, Costabile J, et al. Fluosol DA-20 in the treatment of severe anemia: Randomized, controlled study of 46 patients. Crit Care Med 1990;18:1227-1230.
Gales BJ, Ersted BL. Adverse reactions to human serum albumin. Ann Pharmacother 1992;27:87-94.
Hussain SF, Drew PJT. Acute renal failure after infusion of gelatin. Br Med J 1989;299:1137-1138.
Frazer RS, MacMillan RR. Acute renal failure after infusion of gelatin. Br Med J 1989;299:1399.
Moran M, KapsnerC. Acute renal failure associated with elevated plasma oncotic pressure. N Engl J Med 1987;317:150-153.
Bergonzi G, Paties C, Vassolo G, et al. Dextran deposits in tissues of patients undergoing hemodialysis. Nephrol Dial Transplant 1990;5:54-58.
Weet JF, Cobb CA, Lebrie SJ. A sensoautomated micromethod for dextran in the presence of glucose. J Lab Clin Med 1976;87:898-902.
Gabel LF, Kerkkamp HEM, Nederstigt JN. Dextran determination in human serum with the aid of an enzymatic glucose method. J Clin Chem Clin Biochem 1988;26:655-658.
Grootendorst AF, Van Wilgenburg MGM, de Laat PHJM, van der Howen B. Albumin use in intensive care medicine. Intensive Care Med 1988;14:554-557.
Plasma substitute: The choice during surgery and intensive care. Drug Ther Bull 1987;25( 10):37—39.
Stump DC, Strauss RG, Henriksen RA, et al. Effects of hydroxyethyl starch or blood coagulation particularly factor VIII. Transfusion 1985;29:349-350.
Guthrie RD Jr, Hines C Jr. Use of intravenous albumin in the critically ill patient. Am J Gastroenterol 1991;86:255-263.
Mishler JM. Synthetic plasma volume expanders: Their pharmacology, safety and clinical efficacy. Clin Haematol 1984;13:75-92.
Moss GS, Gould SA. Plasma expanders: An update. Am J Surg 1988;155:425-434.
Estal BL, Gales BJ, Rappaport WD. The use of albumin in clinical practice. Arch Intern Med 1991;151:901-911.
Waxman К, Tremper KK, Mason GR. Blood and plasma substitutes: Plasma expansion and oxygen transport properties. West J Med 1985;143:202-206.
Vermuelen LC Jr, Ratko TA, Erstad BL, Breaker ME, Matuszewski KA, and members of the University Hospital Consortium Consensus Exercise on the use of albumin, nonprotein colloid and crystalloid solutions. Arch Intern Med 1995;155:373-379.
Moss GS, Gould SA. Plasma expanders: An update. Am J Surg 1988;155:425-434.
Machin S. Developments in plasma volume expanders, in: Proceedings of a Symposium: Recent Advances in Plasma Volume Expanders, Royal College of Surgeons, Dublin, May 1989.
Galvani DN. Cytokines, biological function and clinical use. J R Coll Physicians Lond 1988;22:226-231.
Windebaal KP. The cytokines are coming. Arch Dis Childh 1990;65:1285-1286.
Henderson B, Blake S. Therapeutic potential of cytokine manipulation. Trends Pharm Sci 1993;14:145-146.
Balmer LM. Clinical use of biological response modifies a cancer treatment: An overview. Part I. The interferons. DICP Ann Pharmacother 1990;24:761-769.
Goldstein D, Laszlo J. The role of interferons in cancer therapy: A current perspective. CA J Clinipharm 1988;38:258-265.
Stuart-Harris RC, Lauchlan P, Day P. NSW therapeutic assessment group. Med J Aust 1992;156:869-872.
Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990; 19:390—399.
Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989;9:273-277.
Fent K, Zbinden G. Toxicity of interferon and interleukin. Trends Pharm Sci 1987;8:100-105.
Miranda-Guardiola F, Fdez-Liama P, Badia JR, et al. Acute renal failure associated with alpha-interferon therapy for chronic hepatitis B. Nephrol Dial Transplant 1995;10:1441-1443.
Crum E. Biological response: Modified-induced emergencies. Semin Oncol 1989;16:579-587.
Hamblin TJ. Interleukin 2: Side effects are acceptable. Br Med J 1990;300:275-276.
Kragel AH, Travis WD, Stein RG, et al. Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer 1990;66:1513-1516.
Denicoff LD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated kilter cells. Ann Intern Med 1987;107:293-300.
Vecht CJ, Keohane C, Manon RS, et al. Acute fatal leukoencephalopathy after interleukin-2 therapy. N Engl J Med 1990;323:1146-1147.
Rubin JT, Lotze MT. Acute gastric mucosal injury associated with systemic administration of interleukin-4. Surgery 1992;111:274-280.
Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Saf 1992;7:417-433.
Eberlein TJ, Schoof DD, Michie HR, et al. Ibuprofen causes reduced toxic effects of interleukin-2 administration in patients with metastatic cancer. Arch Surg 1989;124:542-547.
Lee RE, Lotze MT, Skibbher JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989;7:7-20.
Adamson JW, Vapnek D. Recombinant erythropoietin to improve athletic performance. N Engl J Med 1991;324:698-699.
Brien AJ, Simon TL. The effect of red blood cell infusion on 10 km race time. JAMA 1987;257:2761-2765.
Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990;300:573-578.
Wong КС, Li PKT, Lui SF, et al. The adverse effects of recombinant human erythropoietin therapy. Adverse Drug React Acute Poison Rev 1990;9:183-206.
Watson AJ. Adverse effects of therapy for the correction of anemia in hemodialysis patients. Semin Nephrol 1989;9(suppl. l):30—34.
Schwenk MH, Halstenson CE. Recombinant human erythropoietin. DICP Ann Pharmacother 1989;23:528— 536.
Undetectable dialysis drug is tied to athletes’ deaths. Los Angeles Times, May 22, 1990, p. 1.
Berglund B, Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med 1991;229:125-130.
International Olympic Committee. Preliminary minutes from the Meeting of the IOC Medical Commission, Lausanne, April 7, 1990.
Cowart V. Erythropoietin: A dangerous new form of blood doping? Physician Sports Med 1989;17:115-118.
Lai P-H, Everett R, Wang F-F, et al. Structural characterisation of human erythropoietin. J Biol Chem 1986;261:3116-3121.
Hambley H, Mufti GJ. Erythropoietin: An old friend revisited. Br Med J 1990;300:621-622.
Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet I991;2O:99— 113.
Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration of healthy subjects. Br J Clin Pharmacol 1990;29:709-713.
Flaherty KK, Caro J, Erslev A, et al. Pharmacokinetics and erythropoietin response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990;47:557-564.
Rosenlof K, Fyhrquist F, Tenhunen R. Erythropoietin, aluminum and anemia in patients on hemodialysis. Lancet 1990;335:247-249.
Jacquot C, Masselot JP, Berthelot JM, et al. Addition of desmopressin to recombinant human erythropoietin in treatment of haemostatic defect of uremia. Lancet 1988; 1:420.
Bakris GL, Sauter ER, Hussey JL, et al. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 1990;323:86-90.
Lin AC, Goldwasser E, Burnard EM, Chapman SW. Amphotericin В blunts erythropoietin response to anemia. J Infect Dis 1990;161:348-351.
Eschbach JW, Adamson JW. Guidelines for recombinant human erythropoietin therapy. Am J Kid Dis 1989;14(suppl. l):2-8.
Scott WC. The abuse of erythropoietin to enhance athletic performance. JAMA 1990;264:1660.
Egrie JC, Strickland TW, Lane J, et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology 1986;172:213-224.
Schlageter M-H, Toubert M-E, Podgorniak M-P, Na-jean Y. Radioimmunoassay of erythropoietin: Analytical performance and clinical use in hematology. Clin Chem 1990;36:1731-1735.
Steward WP. Granulocyte and granulocyte-macrophage colony stimulating factors. Lancet 1993;342:153-157.
Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rG-CSF): A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991;42:300-330.
Stern AC, Jones TC. The side effect profile of GM-CSF. Infection 1992;20(suppl. 2):S 124-S127.
Sal Rubia J, Bonanad S, Palau J, et al. Rapid progression of multiple myeloma following G-CSF mobilization. Bone Marrow Transplant 1994;14:475-476.
Einzig Al, Dutcher JP, Wiernik PH. Life-threatening hyperleucocytosis and pulmonary compromise after priming with recombinant human granulocyte-macrophage colony-stimulating factor in patient with acute myelomonocytic leukemia. J Clin Oncol 1995; 13:304— 305.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:851—853.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:1642-1644.
Wood JK, Milner PFA, Pathak UN. The metabolism of iron-dextran given as a total-dose infusion to iron-deficient Jamaican subjects. Br J Haematol 1968;14:119— 129.
McIntosh ME, Lynn JK, Meyerriecks N, Contant I. Serum iron determination in patients receiving therapy with iron-dextran ("Imferon"). Clin Chem 1976;22:524-527.
Shuttleworth D, Spence C, Slade R. Meningism due to intravenous iron-dextran. Lancet 1983;2:453.
Rodgers G, Matyunas N, Ross M. Lack of toxicity following a large inadvertent overdose of iron-dextran: A case report. Clin Toxicol 1995;33:475-486 (Abstract 76).
Davidar SM, Snodgrass WR. Fatal iron-dextran poisoning: A combined iron toxicity and dextran induced immune block. Vet Hum Toxicol 1989;31:34L.
Fleming LW, Hopwood D, Shepherd AN, Stewart WK. Hepatic iron in dialysed patients given intravenous iron-dextran. J Clin Pathol 1990;43:119-124.
Kanakakorn K, Cavill 1, Jacobs A. The metabolism of intravenously administered iron-dextran. Br J Trace Haematol 1973;25:637-643.
Duke AB, Kelleher J, Walters G. Serum iron and iron binding capacity after total dose infusion of iron-dextran for iron deficiency anaemia in pregnancy. J Obstet Gynaecol Br Commonw 1974;81:895-900.
Bielory L. Serum sickness from iron-dextran administration. Acta Haematol 1990;83:166-168.
Altman LC, Petersen PE. Successful prevention of an anaphylactoid reaction to iron-dextran. Ann Intern Med 1988;109:346-347.
Foulkes WD, Sewry C, Calam J, Hodgson HJC. Rhabdomyolysis after intramuscular iron-dextran in malabsorption. Ann Rheum Dis 1991;50:184-186.
OH VMS. Iron-dextran and systemic lupus erythematosus. Br Med J 1992;305:1000.
Harchelroad F, RiceS. Iron-dextran: Treatment or overdose. Vet Hum Toxicol 1992;34:329.
Rees JKH, Coles GA. Calciphylaxis in man. Br Med J 1969;2:670-672.
Weinbren K, Salm R, Greenberg G. Intramuscular injections of iron compounds and oncogenesis in man. Br Med J 1978;1:683-685.
Hvisman W. Interference of Imferon in colorimetric tests for iron. Clin Chem 1980;26:635-637.
Jacobs JC, Alexander NM. Colorimetric and constantpotential colorimetry determinations of transferrin-bound iron, total iron binding capacity, and total iron in serum containing iron-dextran with use of sodium dithionite and alumina columns. Clin Chem 1990;36:1803-1807.
Vercammen M, Goedhuys W, Boeyckens A, et al. Iron and total iron-binding capacity in serum of patients receiving iron-dextran: Kodak Ektachen methodologies, spectrophotometry and atomic absorption spectrometry compared. Clin Chem 1990;36:1812-1815.
Rudolph R, Boyd CR. Massive transfusion: Complications and their management. South Med J 1990;83:1065-1070.
Westphal RG. Handbook of Transfusion Medicine. Washington, DC: The American Red Cross Blood Series. Fayetteville, NY: Roberts Press, 1990:76.
Hwland WS, Belleville JW, Zucker MB, et al. Massive blood replacement: V. Failure to observe citrate intoxication. Surg Gynecol Obstet 1957;105:529-540.
Nolan ТЕ, Galiup DG. Massive transfusion: A current review. Obstet Gynecol Surv 1991;46:289-295.
Michelsen T, Salmela L, Tigerstedt I, et al. Massive blood transfusion: Is there a limit? Crit Care Med 1989;17:699-700.
Wolf PL, McCarty LJ, Hafleigh B. Extreme hypercalcemia following blood transfusion combined with intravenous calcium. Vox Sang 1970;19:544-545.
Ludbrook J, Wynn W. Citrate intoxication: A clinical and experimental study. Br Med J 1985;2:523-528.
Lee-Chow BL, Auerbach PS, Olson KR, et al. Cardiac arrest following direct intravenous administration of a citrate anticoagulant solution. Vet Hum Toxicol 1985;28:296.
Kulkaris P, Bhattacharya S, Petros AJ. Torsade de Pointes and long QT syndrome following major blood transfusion. Anaesthesia 1992;47:125-127.
McLellan BA, Reid SP, Lane PC. Massive blood transfusion causing hypomagnesemia. Crit Care Med 1984;12:146-147.
Abbott ТК. Changes seen in calcium fractions and citrate concentrations during massive blood transfusions and cardiopulmonary bypass. BrJ Anaesth 1983;55:753-760.
Hubbard TF, Neis DD, Barmore JL. Severe citrate intoxication during cardiovascular surgery. JAMA 1956;162:1534-1535.
Stuiz PM, Scheidegger D, Drop U, et al. Ventricular pump performance during hypocalcemia: Clinical and experimental studies. J Thorac Cardiovasc Surg 1979;78:185-194.
Bunker JP, Dendixen HH, Murphy AJ. Hemodynamic effects of intravenously administered sodium citrate. N Engl J Med 1962;266:372-377.
Jennings ER, Beland AJ, Cope JA, et al. Citrate toxicity and the use of anticoagulant and citrate dextrose blood for extracorporeal circulation. Surg Gynecol Obstet 1965;120:997-1008.
Lee BL, Auerbach PS, Olson KR, et al. Cardiac arrest following intravenous administration of a citrate anticoagulant solution. Ann Emerg Med 1986;15:1352-1356.
Kahn RC, Jascott D, Carlon GC, et al. Massive blood replacement: Correlation of ionized calcium, citrate and hydrogen in concentration. Anesth Analg 1979;58:274— 278.
Hewson JR, Neame PB, Kumar N, et al. Coagulopathy related to dilution and hypotension during massive transfusion. Grit Care Med 1985;13:387-391.
Ferner RE, Chaplin S, Dunstan J A, Baird GM. Drugs in donated blood. Lancet 1989;2:93-94.
Fears R. Biochemical pharmacology and therapeutic aspects of thrombolytic agents. Pharmacol Rev 1990;42:201-222.
Ziller FP, Spinier SA. Alteplase: A tissue plasminogen activator for acute myocardial infarction. Drug Intell Clin Pharm 1988;22:6-14.
Verstraete M. The pharmacokinetics of anisoylated plasminogen streptokinase activation complex, tissue-type plasminogen activator, and simple-chain urokinase-type plasminogen activator. In: Julian DG, Kubler W, Norris RM, et al., eds. Thrombolysis in Cardiovascular Disease. New York: Marcel Dekker, 1989:69—86.
Nazar J, Davison R, Kaplan K, Fintel D. Adverse reactions to thrombolytic agents: Implications for coronary reperfusion following myocardial infarction. Med Toxicol 1987;2:274-286.
Guidry JR, Raschke RA, Mortunas AE. Anticoagulants and thrombolytics. Crit Care Clin 1991;7:533-554.
Sane DC, Califf RM, Topol EJ, et al. Bleeding during thrombolytic therapy for acute myocardial infarction: Mechanisms and management. Ann Intern Med 1989;111:1010-1022.
Verstraete M, Vaughan DE. Latest update in thrombolysis. In: Julian DG, Kubler W, Norris RM, et al., ed. Thrombolysis in Cardiovascular Disease. New York: Marcel Dekker 1Q8Q-40Q441
Califf RM,’ Topol EJ, George BS, et al. Hemorrhagic complications associated with use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med 1988;85:353-359.
Cairns JA, Collins R, Fuster V. Coronary thrombolysis. Chest 1989;95:235.
Fletcher AP, Alkjaersig NR. The hematologic consequences of thrombolytic therapy. Proc Hematol 1986;14:183-200.
Tisdale JE, Stringer KA, Antaiek M, Matthews GE. Streptokinase-induced anaphylaxis. DICP Ann Pharma-cother 1989;23:984-987.
Kalra PA, Coady AM, Iqbal A, et al. Acute tubular neurosis induced by coronary thrombolytic therapy. Postgrad Med 1991;67:212.
Mathiesen O, Grunner N. Haemolysis after intravenous streptokinase. Lancet 1989;1:1016-1017.
Tissue-type plasminogen activator for acute coronary thrombosis. Med Lett Drugs Ther 1987;29(754): 107— 109.
Williams РЕ, Dawes J, Dearden NM, et al. Coagulation disorder due to apparent inadvertent heparin administration. Clin Lab Haematol 1989;! 1:101 —104.
Slivka A, Levy DE, Lapinski RH. Risk associated with heparin withdrawal in ischaemic cerebrovascular disease. J Neurol Neurosurg Psychiatry 1989;52:1332-1336.
Schmidt B, Mitchell L, Ofosu F, Andrew M. Standard assays underestimate the concentration of heparin in neonatal plasma. J Lab Clin Med 1988;112:641-643.
Maner JR. Pharmacological aspects of renal failure and dialysis. In: DrukkerW, Parsons FM, Maher JF, eds. Replacement of Renal Function by Dialysis. 2nd ed. Boston: Martinus Nijhoff, 1983:781.
Kuitunen AH, Salmenpera MT, Heinonen J, et al. Heparin rebound: A comparative study of protamine chloride and protamine sulfate in patients undergoing coronary artery bvpass surgery. J Cardiothorac Vase An-esth 1991;5:221-226.
Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985;29:236-261.
Bidstrup BP. Royston P, Sapsford RN, et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364-372.
Van Coveren W, Jansen NJG, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-645.
Bidstrup B. Aprotinin for bleeding after cardiopulmonary bypass. Lancet 1990;335:1535-1536.
Mallet SV, Cos E, Burroughs AK, Rolles K. Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation. Lancet 1990;336:886-887.
Saffitz JE, Strohl DJ, Sundt TM, et al. Disseminated intravascular coagulation after administration of aprotinin in combination with deep hypothermia circulatory arrest. Am J Cardiol 1993;22:1080-1082.
Bohrer H, Bach A, Fleischer F, Lang J. Adverse haemodynamic effects of high dose aprotinin in a pediatric cardiac surgical patient. Anaesthesia 1990;45:853-854.
Withrich B, Schmid P, Schmid ER, et al. IgE-mediated anaphylactic reaction to aprotinin during anaesthesia. Lancet 1992;340:173-174.
Kane MJ, Silverman LR, Rand JH, et al. Myonecrosis as a complication of the use of epsilon aminocaproic acid: A case report and review of the literature. Am J Med 1988;85:861-863.
Randall J, Taylor K. Epsilon-aminocaproic acid myopathy. Aust NZ J Med 1990;20:851.
Biswas CK, Milligan DAR, Agte SD, et al. Acute renal failure and myopathy after treatment with aminocaproic acid. Br Med J 1980;2:115-116.
Glick R, Green D, Ts’ao C-h, et al. High dose e-ami-nocaproic acid prolongs the bleeding time and increases rebleeding and intraoperative hemorrhage in patients with subarachnoid hemorrhage. Neurosurgery 1981;9:398-401.
Steffen RO. Lederle Laboratories. Personal communication. March 21, 1991.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:890-892.
Wysenbeak AJ, Sella A, Vardi M, Yeshurun D. Acute delirious state after s-aminocaproic acid. Lancet 1978; 1:221.
Burchiel KJ, Schmer G. A method for monitoring antifibrinolytic therapy in patients with ruptured intracranial aneurysms. J Neurosurg 1981;54:12-15.
Frederiksen MC, Bowsher DJ, Ruo Tl, et al. Kinetics of epsilon-aminocaproic acid distribution, elimination, and antifibrinolytic effects in normal subjects. Clin Pharmacol Ther 1984;35:387-393.
Pagliano LA, Benet LZ. Critical compilation of terminal half-lives, percent excreted unchanged and changes of half-life in renal and hepatic dysfunction for studies in humans with references. J Pharmacokinet Biopharm 1975;3:333-383.
Evans BE, Aledort LM. Inhibition of ejaculation due to epsilon-aminocaproic acid. N Engl J Med 1978;298:166-167.
Rabinovici R, Heyman A, Kluger Y, Shinar E. Convulsions induced by aminocaproic acid infusion. DICP Ann Pharmacother 1989;23:780-781.
Quandt CM, De Los Reyes RA, Diaz FG, Austrian JI. Pharmacologic management of subarachnoid hemorrhage. Drug Intell Clin Pharm 1982;16:909-915.
Johansson S-A. Acute right heart failure during treatment with epsilon-aminocaproic acid (E-ACA). Acta Med Scand 1967;182:331-334.
Tubbs RR, Benjamin SP, Dohn DE. Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. J Neurosurg 1979;51:94-97. Case report.
Hoffman ER, Koo AH. Cerebral thrombosis associated with AmicarR therapy. Radiology 1979;131:687-689.
Keucher TR, Solow EB, Metaxas J, Campbell RL. Gas chromatographic determination of an antifibrinolytic drug, e-aminocaproic acid. Clin Chem 1976;22:806— 809.
Haug MT, Mauro VF, Davis HH. Effect of renal failure and hemodialysis on aminocaproic acid plasma concentrations. DICP Ann Pharmacother 1989;23:922-923.
Becker GJ. Ancrod in glomerulonephritis. Q J Med 1988;69:849-850.
Reid HA, Thean PC, Chan KE, Baharam AR. Clinical effects of bites by Malayan viper (Agkistrodon rhodosto-ma). Lancet 1963;1:617-621.
Kim S, Wadhwa NK, Kant KS, et al. Fibrinolysis in glomerulonephritis treated with ancrod: Renal, functional, immunologic and histopathologic effects. Q J Med 1988;69:879-895, 896-905.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:225.
Pollak VE, Glas-Greenwalt P, Olinger CP, et al: Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci 1990;299:319-325.
Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991;28:2194-2197.
Hirsh J, Dalen JE, Deykin D, Poller L. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1992; 102 (suppl. ):337S—351S.
Wallerstein RO Jr. Laboratory evaluation of a bleeding patient. West J Med 1989;150:51-58.
Meyer BH, Luus HG, Muller FO, et al. The pharmacology of recombinant hirudin, a new anticoagulant. South Afr Med J 1990;78:268-270.
Markwardt F. Pharmacology of hirudin: One hundred years after the first report of the anticoagulant agent in medicinal leeches. Biomed Biochim Acta 1985;44:1007-1013.
Wallis RB. Hirudins and the role of thrombin: Lessons from leeches. Trends Pharm Sci 1988;9:425-427.
Bittl JA, Strony J, Brinker J A, et al. Treatment with bi-valirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769.
Meyer BH, Muller FO, Luus HG. The clinical pharmacology of anticoagulant DNA-hirudin. Clin Pharmacol Ther 1991 ;49:189.
Conrad KA. Clinical pharmacology and drug safety: Lessons from hirudin. Clin Pharmacol Ther 1995;58:123— 126.
Irani MS, White HJ Jr, Sexon RG. Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate. Am J Cardiol 1995;75:422-423.
Reynolds JEF. ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:924—925.
Tranexamic acid. Med Lett Drugs Ther 1987;29(749):89—90.
Arrisati G, TenCate JW, Buller HR, Mandelli F. Tranexamic acid for control of hemorrhage in acute promy-elocytic leukemia. Lancet 1989;2:122-124.
Reynolds JEF. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:338.
Henry DA, O’Connell DL. Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal hemorrhage. Br Med J 1989;298:1142-1146.
Ramirez-Lassepas M. Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial aneurysm. Neurology 1984;31:316-322.
Boylan JF, Sandler AN, Sheiner P, et al. Reduced blood product usage with tranexamic acid prophylaxis in primary liver transplantation. Anesthesiology 1992;7:A1092.
Kullander S, Nilsson IM. Human placental transfer of an antifibrinolytic agent (AMCA). Acta Obstet Gynecol Scand 1970;49:241-242.
Woo KS, Tse LKK, Woo JLF, Vallance-Owen J. Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy. Br J Clin Pract 1989;43:465— 466. (Also, Ann Emerg Med 1989;18:116—117.)
Vessman J, Stromberg S. Determination of tranexamic acid in biological material by electron capture gas chromatography after direct derivatization in an aqueous medium. Anal Chem 1977;49:369-373.
O’Reilly RA. Anticoagulant, antithrombotic and thrombolytic drugs. In: Gilman AG, Goodman LS, Rail TW, Murad F, eds. The Pharmacological Basis of Therapeutics. 7th ed. New York: Macmillan, 1985:1338-1357.
Giddings JC, Evans BK. Drugs affecting blood coagulation and hemostasis. Int Anesthesiol Clin 1985;23(2): 103— 123.
Katz J, Metz J. Hemorrhages in a young boy due to unsuspected diphenadione (Didandin) intoxication. Clin Pediatr 1969;8:291-293.
Seiler K, Duckert F. Intoxication with phenprocoumon (Marcoumar): Pharmacokinetics and side effects. Thromb Diath Haemorrh 1969;21:320-324.
De Wolff FA, van Kempen GMJ. Three cases of phen-procoumon (MarcoumarR) intoxication. Proc Eur Soc Toxicol 1977; 18:189-191.
Hvidzala EV, Gellady AM. Intentional poisoning of two siblings by prescription drugs. Clin Pediatr 1978;17:480— 482.
Toolis F, Robson RH, Critchley JAJH. Warfarin poisoning in patients with prosthetic heart valves. Br Med J 1981;283:581-582.
Saunderson H, Fernandez L. Confusion between warfarin and propranolol leading to warfarin overdosage. Can Med Assoc 1981; 124:366.
Renowden S, Westmoreland D, White JP, et al. Oral cholestyramine increases elimination of warfarin after overdose. Br Med J 1985;291:513-514.
Hackett LP, Belt KF, Chester A. Plasma warfarin concentrations after a massive overdose. Med J Aust 1985;142:642-643.
Olchovsky D. Pines A, Zwas ST. et al. Apathetic thyrotoxicosis due to hemorrhage into a hyperfunctioning thyroid nodule after excessive anticoagulation. South Med J 1985;78:609-611.
Holmes RW, Love J. Suicide attempt with warfarin, a bishydroxycoumarin like rodenticide. JAMA 1952;148:935-937.
Fristedt B, Sterner N. Warfarin intoxication from percutaneous absorption. Arch Environ Health 1965; 11:205— 208.
Barlow AM, Gay AL, Park BK. Difenacoum (Neoso-rexa) poisoning. Br Med J 1982;285:541.
Murdoch DA. Prolonged anticoagulation in chlorphaci-none poisoning. Lancet 1983;1:355-356.
Lipton RA, Klass EM. Human ingestion of a ’superwarfarin’ rodenticide resulting in a prolonged anticoagulant effect. JAMA 1984;252:3004-3005.
Jones EC, Growe GH, Naiman SC. Prolonged anticoagulation in rat poisoning. JAMA 1984;252:3005.
Pachman DJ. Accidental heparin poisoning in an infant. Am J Dis Child 1965;110:210-212.
Schreiner RL, Wynn RJ, McNulty C. Accidental heparin toxicity in the newborn intensive care unit. J Pediatr 1978;92:115.
Kwaan HC, Simon NM, del Greco F. Hemorrhagic diathesis induced by surreptitious ingestion of coumarin drugs. Med Clin North Am 1972;56:263-273.
Moster KM, Hajjar GL. Effect of heparin on the one-stage prothrombin time. Ann Intern Med 1967;66:1207— 1213.
Morgan DP. Recognition and Management of Pesticide Poisonings. 3rd ed. EPA-540/9-80-005. Washington, DC: USEPA, 1982.
Mandel HG, Cohn VH. Fat soluble vitamins: Vitamin A, K, and E. In: Gilman AG, Goodman LS, Rail TW, Murad F, eds. The Pharmacological Basis of Therapeutics. 7th ed. New York: Macmillan, 1985:1582—1586.
Hart RG, Coull BM. Hypercoagulability following Coumadin withdrawal. Am Heart J 1983;106:169-170.
McLean J. The thromboplastin action of heparin. Am J Physiol 1916;41:250-257.
Purandare SV, Parulkar GB, Panday SR, et al. Heparin rebound: A cause of bleeding following open heart surgery. J Postgrad Med 1979;25(2):70—74.
Katona B, Sigell LT, Wason S. Anticoagulant rodenticide poisoning. Vet Hum Toxicol 1986;28:478. Abstract.
Katona B, Wason S. Anticoagulant rodenticide. Clin Toxicol Rev 1986;8(12): 1-2.
Chen TW, Deng J F. A brodifacoum intoxication case of mouthful amount. Vet Hum Toxicol 1986;28:488. Abstract.
Heparin and other anticoagulants. In: Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:225—242.
Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs 1983;25:610-620.
Koch-Wesser J, Sellers EM. Drug interactions with coumarin anticoagulants. N Engl J Med 1971;285:487-498, 547-558.
Abell TL, Merigian KS, Lee JM, et al. Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: A case report. Clin Toxicol 1994;34:69-73.
Yacobi A, Udall J A, Levy G. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 1976;19:552-558.
Meinertz T, Gilfrich H-J, Groth U, et al. Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Clin Pharmacol Ther 1977;21:731-735.
Jahnchen E, Meinertz T, Gilfrich H-J, et al. Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol 1978;5:437-440.
Lewis RJ, Trager WF. Warfarin metabolism in man: Identification of metabolites in urine. J Clin Invest 1970;49:907-913.
Yacobi A, Levy G. Pharmacokinetics of the warfarin enantiomers in rats. J Pharmacokinet Biopharm 1974;2:239-255.
Solomon HM, Schrogie JJ, Williams D. The displacement of phenylbutazone-14C and warfarin-l4C from human albumin by various drugs and fatty acids. Biochem Pharmacol 1968;17:143-151.
Standing Advisory Committee for Haematology of the Royal College of Pathologists. Drug interaction with coumarin derivative anticoagulants. Br Med J 1982;285:274-275.
Robinson DS, Benjamin DM, McCormack JJ: Interaction of warfarin and non-systemic gastrointestinal drugs. Clin Pharmacol Ther 1971;12:491-495.
Bailie M, Allen ED, Elkington AR. The congenital warfarin syndrome: A case report. Br J Ophthalmol 1980;64:633-635.
Disaia PJ. Pregnancy and delivery of a patient with a Starr—Edwards mitral valve prosthesis. Obstet Gynecol 1966;28:469-472.
Ginsberg JS, Hirsh J, Turner DC, et al. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989;61:197-203.
Quenneville G, Barton B, McDevitt E, et al. The use of anticoagulants for thrombo-phlebitis during pregnancy. Am J Obstet Gynecol 1959;77:1135-1149.
Villasanta U. Thromboembolic disease in pregnancy. Am J Obstet Gynecol 1965;93:142-160.
Kazmier FJ. Thromboembolism, coumarin necrosis and protein C. Mayo Clin Proc 1985;60:673-674.
Menon IS. Side effects of phenindione. Br Med J 1968;2:622.
Sternberg ML, Pettyjohn FS. Warfarin sodium-induced skin necrosis. Ann Emerg Med 1995;26:94-97.
Sheth SB, Carvalho AC. Protein S and C alterations in acutely ill patients. Am J Hematol 1991;36:14-19.
Rick ME. Protein C and protein S. Vitamin K-depend-ent inhibitors of blood coagulation. JAMA 1990;263:701-703.
Israels SJ, Seshia SS. Childhood stroke associated with protein C or S deficiency. J Pediatr 1987; 111:562—563.
Lewandowski K, Zawilsky K. Protein C concentrate in the treatment of warfarin-induced necrosis in the protein C deficiency. Thromb Haemost 1994;71:395-399.
O’Reilly RA, Aggeler PM. Surreptitious ingestion of coumarin anticoagulant drugs. Ann Intern Med 1966;64:1034-1041.
O’Reilly RA, Aggeler PM. Covert anticoagulant ingestion: Study of 25 patients and review of world literature. Medicine 1976;55:389-399.
Smolinske SC, Scherger DL, Kearns PS, et al. Superwarfarin poisoning in children: A prospective study. Pediatrics 1989;84:490-494.
Kruse JA, Carlson RW. Fatal rodenticide poisoning with brodifacoum. Ann Emerg Med 1992;21:331-336.
Felice U, Chalermchaikit T, Murphy MJ. Multicomponent determination of 4-hydroxycoumarin anticoagulant rodenticides in blood serum by liquid chromatography with fluorescence detection. J Anal Toxicol 1991;15:126-129.
Poller L. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1991;325:129-130.
Warfarin. Poisindex. Englewood, Colo, Micromedex, Inc. Reviewed by Rumack BH (02/82, 12/84), Troutman WG (01/85). Revised by Flomenbaum N (10/84), Smo-linske SC (01/85).
Morrissey B, Burgess JL, Robertson WO. Washington’s experience and recommendations. Re: Anticoagulant rodenticides. Vet Hum Toxicol 1995;37:362-363.
Consensus Conference: Fresh-frozen plasma indications and risks. JAMA 1985;253:551-553.
Meinertz T, Kaspar W, Kahl C, Ahnrchen E. Anticoagulant activity of the enantiomers of acenocoumarol. Br J Clin Pharmacol 1978;5:187-188.
Bjornsson TD, Blaschke TF. Vitamin K, disposition and therapy of warfarin overdose. Lancet 1978;2:846-847.
De la Rubia J, Grau E, Montserrat 1, et al. Anaphylactic shock and vitamin K,. Ann Intern Med 1989;110:943.
Hirsh J, Poller L. Subcutaneous or intravenous phytonadione? Arch Intern Med 1995; 135:1337.
Finkel MJ: Vitamin K, and vitamin К analogues. Clin Pharmacol Ther 1961;2:794-814.
Centers for Disease Control. Non-А, non-B hepatitis associated with a factor IX complex infused during cardiovascular surgery — Arizona. MMWR 1986;35(24):391—399.
Jason J, Holman RC, Dixon G, et al. Effects of exposure to factor concentrates containing donations from identified AIDS patients. JAMA 1986;256:1758-1762.
Safer factor VII and IX. Lancet 1986;2:255-256. Editorial.
Taberner DA, Thomson JM, Poller L. Comparison of prothrombin complex concentrate and vitamin K, in oral anticoagulant reversal. Br Med J 1976;2:83-85.
Ikeda M, Conney AH, Burns JJ. Stimulatory effect of phenobarbital and insecticides on warfarin metabolism in the rat. J Pharmacol Exp Ther 1968;162:338-343.
Becker RC, Ansell J. Antithrombotic therapy: An abbreviated reference for clinicians. Arch Intern Med 1995;155:149-161.
Martin CM, Engstrom PF, Barrett О Jr. Surreptitious self-administration of heparin. JAMA 1970;212:475— 476.
Olin JW, de Wolfe VG. Paradoxical thromboembolism associated with heparin therapy. Cleve Clin Q 1981;48:378-384.
Weisman RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg 1958;76:219-227.
Rice L, Jackson D. Can heparin cause clotting? Heart Lung 1981;10:331-335.
Cipolle RJ, Rodvoid KA, Seifert R, et al. Heparin associated thrombocytopenia: A prospective evaluation of 211 patients. Ther Drug Monit 1983;5:205-211.
Bennett WM, Mutner RS, Parker RA, et al. Drug therapy in renal failure: Dosing guidelines for adults. Ann Intern Med 1980;93:286-325.
Ordog GJ, Wasserberger J, Balasubramaniam S. Effect of heparin on arterial blood gases. Ann Emerg Med 1985;14:233-238.
Stevenson RE, Burton AM, Ferlauto GJ, et al. Hazards of oral anticoagulants during pregnancy. JAMA 1980;243:1549-1551.
Pauli RM, Hall JG, Wilson KM. Risks of anticoagulation during pregnancy. Am Heart J 1980;100:761-762.
Merrill LK, VerBurg DJ. The choice of long-term anticoagulants for the pregnant patient. Obstet Gynecol 1976;47:711-717.
Dahlman TC, Sjoberg KE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994;170:1315-1320.
Chaplin S, Sanders GL, Smith JM. Drug excretion in human breast milk. Adverse Drug React Acute Poison Rev 1982;1:255-287.
Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574.
Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA 1980;244:1209-1212.
Oster JR, Singer 1, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995;98:575-586.
Hougardy N, Machiels J-P, Ravo ETC. Heparin-induced thrombocytopenia. N Engl J Med 1995;333:1007.
Mehta DP, Yoder EL, Appel J, Bergsman KL. Heparin-induced thrombocytopenia and thrombosis: Reversal with streptokinase: A case report and review of literature. Am J Hematol 1991;36:275-279.
Dieck JA, Rizo-Patron C, Unisa A, et al. A new manifestation and treatment alternative for heparin-induced thromboses. Chest 1990;98:1524-1526.
Frame JM, Mulvey KP, Phares JC, Anderson MJ. Correction of severe heparin-associated thrombocytopenia with intravenous immunoglobulin. Ann Intern Med 1989;111:946-947.
Laster JL, Nichols WK, Silver D. Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies. Arch Intern Med 1989;149:2285-2287.
Chamberlin JR, Lewis B, Leya F, et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol 1995;! 1:515— 517.
Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990;40:498-530.
Levesque H, Verdier S, Cailleux N, et al. Low molecular weight heparins and hypoaldosteronism. Br Med J 1990;300:1437-1438.
Eichinger S, Kyrle PA, Brenner B, et al. Thrombocytopenia associated with low-molecular-weight heparin. Lancet 1991;337:1425-1426.
Passannante A, Macik BG. The heparin flush syndrome: A cause of iatrogenic hemorrhage. Am J Med Sci 1988;296:71-73. Case report.
Jones G, Sambrook PN. Drug-induced disorders of bone metabolism: Incidence, management and avoidance. Drug Saf 1994;10:480-489.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:655—666.
Feely J, ed. New Drugs. 3rd ed. London: British Medical Journal Publishing Group, 1994:288—290.
Compston JE. The therapeutic use of bisphosphonates. Br Med J 1994;309:711-715.
Coakley G, Isenberg DA. Toxic epidermal necrolysis, pancytopenia and adult respiratory syndrome. Br J Rheumatol 1995;34:739.
ArediaR: Pamidronate disodium for injection. In: Physicians’ Desk Reference, 1994. Montvale, NJ: Medical Economics, 1994:813—815. DidronelR I. V. Infusion: Etidronate disodium, p. 1272. Didronel”: Etidronate disodium, pp. 1808—1810.
Adamson BB, Gallacher SJ, Byars J, et al. Mineralisation defects with pamidronate therapy for Paget’s disease. Lancet 1993;342:1459-1461.
Silverman SL, Hurvitz EA, Nelson VS. et al. Rachites syndrome after disodium etidronate therapy in an adolescent. Arch Phys Med Rehab 1994;75:118-120.
Rolla G, Висса C, Brussino L. Bisphosphonate induced bronchoconstriction in aspirin-sensitive asthma. Lancet 1994;343:426-427.
Liotz F, Boval-Boizard B, Fritz P, Kuntz D. Lymphocyte subgroups in lymphopenia induced by pamidronate. Therapie 1994;46:63.
O’Donnell NP, Rao GP, Aguis-Fernandez A. Paget’s disease ocular complications of disodium pamidronate treatment. Br J Clin Pract 1995;49:272-273.
Sunshine A, Olson NZ, Zighelboim 1, et al. Analgesic oral efficacy of tramadol hydrochloride in postoperative pain. Clin Pharmacol Ther 1992;51:740-746.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1097— 1098.
Bianchetti MG, Beutler A, Ferrier PE. Intoxication severe avec uoprace (tramadol) chez un nourisson de cinque semaines. Helv Paediatr Acta 1988;43:241-244.
Fricke JR, Minn F, Cunningham PD, et al. Tramadol HCI: Dose response to pain from oral surgery. Clin Pharmacol Ther 1991 ;59:182.
Riedel F, v Stockhausen H-B. Severe cerebral depression after intoxication with tramadol in a 6 month old infant. Eur J Clin Pharmacol 1984;26:631-632.
Lee SR, McTavish D, Sorkin EM. Tramadol: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute and chronic pain status. Drugs 1993;46:313-347.
Richter W, Barth H, Flohe L, Giertz H. Clinical investigation in the development of dependence during oral therapy with tramadol. Arzneimittelforschung 1985;35:1742-1744.
Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Goodman LS, Rail TW, et al., eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 7th ed. New York: MacMillan, 1985:519— 520.
Proudfoot AT. Clinical features and management of dis-talgenic overdose. Hum Toxicol 1984;3(suppl.):85S— 94S.
Restrepo JF, Guzman R, Pena MA, et al. Fibrous myopathy induced by propoxyphene injections. J Rheumatol 1993;20:596-597.
Strom J. Acute propoxyphene self-poisoning with special reference to propoxyphene cardiotoxicity and treatment. Dan Med Bull 1989;36:316-336.
Lawson AAH, Northridge DB. Dextropropoxyphene overdose, epidemiology, clinical presentation and management. Med Toxicol 1987;2:430-444.
Stork GM, Redd JT, Fine K, Hoffman RS. Propoxypheneinduced wide QRS complex dysrhythmia responsive to sodium bicarbonate: A case report. Clin Toxicol 1995;33:179-183.
Van Boven М, Daenens Р, Bruneel N. A death case involving tilidine. Arch Toxicol 1976;36:121-125.
Romagnoli A, Keats AS. Comparative respiratory depression of tilidine and morphine. Clin Pharmacol Ther 1975;17:523-528.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1097.
Klapetek J. Valoron intoxikation by selbsmod vers. Munch Med Wochenschr 1973;115:113-115.
Vollmer К-A, Thomann P, Hengy H. Pharmacokinetics of tilidine and metabolites in man. Aznneimittelforsc-hung 1989;39:1283-1288.
Vollmer К-A, Poisson A. On the metabolism of ethyl-DL-/ra«5-2-dimethylamino-1 -phenyl-cyclohex-3-ene-trans-1 -carboxylate hydrochloride (tilidine HC1). Second communication: studies with l4C-labelled substances in rats and dogs. Arzneimittelforschung 1976;26:1827— 1836.
Klapatek J. Critical comments on a case history ’A death case involving tilidine’. Arch Toxicol 1978;40:1-4.
Condonnier JA, van den Heede MA, Heyndrickx AM. In vitro adsorption of tilidine HC1 by activated charcoal. Clin Toxicol 1986/1987;24:503—517.
Condonnier JA, van den Heede M, Heyndrickx AM. Activated charcoal and ipecac syrup in prevention of tilidine absorption in man. Vet Hum Toxicol 1987;29(suppl. 2): 105—106.
Martin W. Naloxone. Ann Intern Med 1976;85:765— 768.
Challoner KR, McCarron MM, Newton EJ. Pentazocine (TalwinR) intoxication: Report of 57 cases. J Emerg Med 1990;8:67-74.
Roytblat L, Bear R, Gesztes T. Seizures after pentazocine overdose. Isr J Med Sci 1986;27:385-386.
Moeller N, Dietzel K, Nuernberg B, et al. High performance liquid chromatographic determination of pentazocine in plasma. J Chromatogr Biomed Appl 1990;530:200-205.
Carter HS, Watson WA. IV pentazocine/methylpheni-date abuse: The clinical toxicity of another T’s and Blues combination. Clin Toxicol 1994;32:541-554.
Showalter CV. T’s and Blues: Abuse of pentazocine and tripelennamine. JAMA 1980;244:1224-1225.
McGwier BW, Altert MA, Panayiotou H, Lauber CR. Acute myocardial infarction associated with intravenous injection of pentazocine and tripelennamine. Chest 1992;101:1730-1732.
Poyhia R, Olkkola КТ, Sepalla Т, Kalso Е. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol 1991;32:516-518.
Turturro MA, O’Toole KS. Oxycodone-induced pulmonary edema. Am J Emerg Med 1991;9:201-207.
Wong HY, Parker RK, Fragen R, White PF. Pentamorphone for management of postoperative pain. Anesth Analg 1991;72:656-666.
Ruds FG, Wynn RL, Ossipov M, et al. Antinociceptive activity of pentamorphone, a 14 beta-amino morphone derivative, compared to fentanyl and morphine. Anesth Analg 1989;69:450-456.
Afifi MS, Glass PSA, Cohen WA, et al. Depression of ventilatory responses to hypoxia and hypercapnia after pentamorphone. Anesth Analg 1990;71:377-383.
Goldberg JS, Martz MD, Berend JS. A comparison of pain sedation and respiratory depression following pentamorphone or fentanyl general anesthesia. Clin Pharmacol Ther 1991 ;49:182.
Glass PSA, Camporesi EM, Shafron D, et al. Evaluation of pentamorphone in humans: A new potent opiate. Anesth Analg 1989;68:302-307.
Remorgida V, Venturini RL, Anserini P, et al. Naltrexone in functional hypothalamic amenorrhea and in the normal luteal phase. Obstet Gynecol 1990;76:1115—1120.
Leboyer M, Bouvard MP, Dugas M. Effects of naltrexone on infantile autism. Lancet 1988;1:715.
Campbell M, Anderson LT, Small AM, et al. Naltrexone in autistic children: A double blind and placebo-control-led study. Psychopharmacol Bull 1990;26:130-135.
Herman BH, Hannock MK, Smith AA, et al. Effects of acute administration of naltrexone on cardiovascular function, body temperature, body weight and serum concentrations of liver enzymes in autistic children. Dev Pharmacol Ther 1989;12:118-127.
Sandyk R. Naltrexone suppresses abnormal sexual behavior in Tourette’s syndrome. Neurology 1988;38(suppl 1):291.
Thompson DF, Thompson GD. Naltrexone in the management of seizures associated with Rett syndrome. Drug Intell Clin Pharm 1987;21:874.
Smith КС, Pittelbow RR. Naltrexone for neurotic excoriations. J Am Acad Dermatol 1985;20:861-866.
Mitchell JE, Christenson G, Jennings J, et al. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia. J Clin Psychopharmacol 1989;9:94-97.
Froehlich JC, Li TK. Recent developments in alcoholism: Opioid peptides. Recent Dev Alcohol 1993;11:187—205.
Swift RM, Whelihan W, Kuznetsov O, et al. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 1994;151:1463-1467.
O’Brien CP. Treatment of alcoholism as a chronic disorder. EXS 1994;71:349-359.
Volpicelli JR, Alterman Al, Hayashida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-880.
Abbond TK. Preparation of oral naltrexone solution. Anesthesiology 1990;73:190-191.
Abboud TK, Lee K, Zhu J, et al. Prophylactic oral naltrexone with intrathecal morphine for cesarean section: Effects on adverse reactions and analgesia. Anesth Analg 1990;71:367-370.
Naltrexone for alcohol dependence. Med Lett Drugs Ther 1995;37(953):64—66.
Lerner AG, Sigal M, Bacolu A, Gelkopf M. Naltrexone abuse potential. J Nerv Ment Dis 1992;180:734-735.
Monti KM, Foltz RL, Chinn DM. Analysis of naltrexone and 6-beta-naltrexol in plasma and urine by gas chromatography-negative ion chemical ionization mass spectrometry. J Anal Toxicol 1991;15:136-140.
DeMaria A, Hefferman JJ, Grindlinger GA, et al. Naloxone versus placebo in treatment of spetic shock. Lancet I985;l:l363— 1365.
Loimer N, Schmid RW, Presslich O, Lenz K. Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. J Psychiatr Res 1989;23:81-86.
Varon J, Dumas SR. Naloxone reversal of hypotension due to captopril overdose. Ann Emerg Med 1991;20:1125-1127.
Elberto G, Erickson T, Popiel R, et al. Central nervous system manifestations of a valproic acid overdose responsive to naloxone. Ann Emerg Med 1989;18:889-891.
Cami J, de la Torre R, Garcia-Sevilla L, et al. Alcohol antagonism of hypercortisolism induced by naloxone. Clin Pharmacol Ther 1988;43:559-604.
Pickar D, Bunney WE, Douillet P, et al. Repeated naloxone administration in schizophrenia: A Phase II World Health Organization study. Biol Psychiatry 1989;25:440-448.
Chernick V, Manfreda J, de Booy V, et al. Clinical trial of naloxone in birth asphyxia. J Pediatr 1988; 113:519— 525.
Kunkel DB. Narcotic antagonist update. Emerg Med 1987;19:97-108.
Culpepper-Morgan JA, Inturris CE, et al. Treatment of opioidinduced constipation with oral naloxone: A pilot study. Clin Pharmacol Ther 1992;52:90-95.
Maio RF, Gaukel B, Freeman B. Intralingual naloxone injection for narcotic-induced respiratory depression. Ann Emerg Med 1987;16:572-577.
Wasserberger J, Ordog GJ, Kolodny M. Intralingual naloxone injections. Ann Emerg Med 1988; 17:874.
Mofenson HC, Caraccio TC. Continuous infusion of intravenous naloxone. Ann Emerg Med 1987; 16:600.
Bonfiglio MF, Mauro VC. Naloxone in the treatment of meperidine-induced seizures. Drug Intell Clin Pharm 1987;21:174-175.
Tenenbein M. Continuous naloxone infusion for opiate poisoning in infancy. J Pediatr 1984;105:645-648.
Gibbs J, Newson T, Williams J, Davidson DC. Naloxone hazard in infant of opioid abuser. Lancet 1989;2:159— 160.
Committee on Drugs: Kaufman RE, Banner W Jr, Blunter JL, et al. Naloxone dosage and route of administration for infants and children: Addendum to energy drug doses for infants and children. Pediatrics 1990;86:484-485.
Manmell M, Maggi M, de Feo ML, et al. Naloxone administration releases catecholamines. N Engl J Med 1983;308:654-655.
Shibanoki S, Kubo T, Kogura M, Ishikawa K. Naloxone affects both pharmacokinetics and pharmacodynamics of morphine: Application of direct correlation analysis. Bi-ochem Pharmacol 1991;42:1107-1114.
Peters G, Gaylor S. Human central nervous system effects of a selective kappa opioid agonist. Personal communication. American Society of Clinical Pharmacology and Therapeutics, Nashville, TN, 19th Annual Meeting, March 1990.
Schoenfeld A, Friedman S, Stein LB, et al. Severe hypertensive reaction after naloxone injection during labor. Arch Gynecol 1987;240:45-47:*
Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther 1989;45:66-71.
Loimer N, Schmid R, Lenz K, et al. Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. Br J Psychiatry 1990;157:748-752.
Rockford J, Daves P. Clonidine and yohimbine modulate the effects of naloxone on novelty-induced hypoalgesia. Psychopharmacology 1992;107:575-580.
Brimacomber J, Archdeacne J, Newell S, Martin J. Two cases of naloxone-induced pulmonary oedema: The possible use of phentolamine in management. Anaesth Intensive Care 1991;19:578-582.
Wasserberger J, Ordog GJ. Naloxone-induced hypertension in patients on clonidine. Ann Emerg Med 1988; 17:557.
Mariani RJ. Seizure associated with low-dose naloxone. Am J Emerg Med 1989;7:127-128.
Schwartz J A, Koenigsberg MD. Naloxone-induced pulmonary edema. Ann Emerg Med 1987;16:1294-1296.
Reid RW, Deakin A, Lechey DJ. Measurement of naloxone in plasma using high performance liquid chromatography with electrochemical detection. J Chroma-togr Biomed Appl 1993;614:1 17—122.
Crighton FJ, Ghodse AH. Naloxone applied to conjunctiva as a test for physical opiate dependency. Lancet 1989;1:748-750.
Loimer N, Hofmann P, Chaudhry HR. Nasal administration of naloxone for detection of opiate dependence. J Psychiatr Res 1992;26:39-43.
Thornton JR, Losowsy MS. Opioid peptides and primary biliary cirrhosis. Br Med J 1988;:297:1501 —1503.
Kaplan JL, Marx JA. Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: A pilot study. Ann Emerg Med 1993;22:187-190.
Fudala PJ, Johnson RE, Heishman SJ, Henningfield JE. Evaluation of the abuse liability of nalmefene. Clin Pharmacol Ther 1991 ;49:167.
Fudala PJ, Heishman SJ, Henningfield JE, Johnson RE. Human pharmacology and abuse potential of nalmefene. Clin Pharmacol Ther 1991;49:300-306.
Gal TJ, di Fazio CA, Dixon R. Prolonged blockade of opioid effects with oral nalmefene. Clin Pharmacol Ther 1986;40:537-542.
Konieczko KM, Jones JG, Barrowcliffe MP, et al. Antagonism of morphine-induced respiratory depression with nalmefene. Br J Anesth 1988;61:318-323.
Barsan WG, Seger D, Danzl DF, et al. Duration of antagonistic effects of nalmefene and naloxone in opiate-induced sedation for emergency department procedures. Ann Emerg Med 1987; 16:477.
Barsan WG, Seger D, Danzl DF, et al. Duration of antagonistic effects of nalmefene and naloxone in opiate-induced sedation for emergency department procedures. Am J Emerg Med 1989;7:155-161.
Levinson B, Reynolds R, Kisiski J, Lee JW. The pharmacokinetics of nalmefene, an opioid antagonist. Anesthesiology 1990;73:A355.
Dixon R, Howes J, Gentile J, et al. Nalmefene: Intravenous safety and kinetics of a new opioid antagonist. Clin Pharmacol Ther 1986;39:49-53.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:685.
Gal TJ, di Fazio CA. Prolonged antagonism of opioid action with intravenous nalmefene in man. Anesthesiology 1986;64:175-180.
Steve JK, Stofberg L, MacDonald G, et al. Nalbuphine analgesia in the prehospital setting. Am J Emerg Med 1988;6:634-639.
Jailion Р, Gardin ME, Lecocq В, et al. Pharmacokinetics of nalbuphine in infants, young healthy volunteers and elderly patients. Clin Pharmacol Ther 1989;46:226— 233.
Guillonneau M, Jacqz-Aigrain E, de Crey A, Zeggout H. Perinatal adverse effects of nalbuphine given during parturition. Lancet 1990; 1:1588.
Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans: Enterohepatic cycling and relative contributions of metabolites to active opioid concentrations. Clin Pharmacokinet 1993;24:344-354.
Mikkelsen S, Feilberg VL, Christensen CB, Lundstrom KE. Morphine pharmacokinetics in premature and mature newborn infants. Acta Paediatr 1994;83:1025— 1028.
Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990;47:12-19.
McQuay JH, Carrol D, Faura CC, et al. Oral morphine in cancer pain: Influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990;48:236-244.
Bowsher D. Paradoxical pain: When the metabolites of morphine are in the wrong ratio. Br Med J 1993;306:473-474.
Morley JS, Miles JB, Walls JC, Bowsher D. Paradoxical pain. Lancet 1992;540:1045.
Fehn J, Megges G. Detection of O6-monoacetylmor-phine in urine samples by GC/MS as evidence for heroin use. J Anal Toxicol 1985;9:134-138.
Mule SJ, Casella GA. Rendering the poppy seed defence defenceless: Identification of 6-monoacetylmorphine in urine by gas chromatography/mass spectroscopy. Clin Chem 1988;34:1427-1430.
Bowie LJ, Kirkpatrick PB. Simultaneous determination of monoacetylmorphine, morphine, codeine and other opiates by GC/MS. J Anal Toxicol 1989;13:326-329.
Beck O, Vitols S, Stensio M. Positive urine screening for opiates after consumption of sandwich bread with poppy seed flavoring. Ther Drug Monit 1990;1:585-586.
El Sohly NH, El Sohly MA, Stanford DF. Poppy seed ingestion and opiates urinalysis: A closer look. J Anal Toxicol 1990;14:308-310.
Struempler PE. Excretion of codeine and morphine following ingestion of poppy seeds. J Anal Toxicol 1987;11:92-99.
Salerno S, Wisniewski HM, Rudelli RD. Effect of poppy seed ingestion on the TDx opiates assay. Ther Drug Monit 1990;12:210-213.
Drummer ОН, Opeskin К, Syrjanen М, Cordner SM. Methadone toxicity causing death in the subjects starting on a methadone maintenance program. Am J Forens Med Pathol 1992;13:346-350.
Harding-Pink D. Methadone: One person's maintenance dose is another poison. Lancet 1993;341:665— 666.
Section 291.501: Methadone in the maintenance treatment of narcotic addicts. Part 310: New Drugs. Recodification of Methadone Regulations. Title 21: Food and Drugs. Fed Regist 1977;42:46 698—46 710.
Wolff K, Hay A. Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem 1992;38:438-439.
Baselt R. Disposition of Toxic Drugs and Chemicals in Man. 3rd ed. Chicago: Year Book, 1989:512—516.
Wolff K, Sanderson M, Hay AWM, Raistrick D. Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem 1991;37:205-209.
Baugh LD, Liu RH. Walia AS. Simultaneous gas chro-matography/mass spectrometry assay of methadone and EDP in urine. J Forens Sci 1991;36:548-555.
Roland EK, Lickitch G, Dunn HG, et al. Methadone poisoning due to accidental contamination of prescribed medication. Can Med Assoc J 1984; 131:1357— 1358.
Rayle MO, Ryan CA, Nazarli S. Unusual cause of methadone poisoning. Acta Paediatr Scand 1991;80:486-487.
Binchy JM, Molyneux EM, Manning J. Accidental ingestion of methadone by children in Merseyside. Br Med J 1994;308:1335-1336.
Garrettson LK. Delayed onset of toxicity after methadone ingestion due to therapeutic error. Vet Hum Toxicol 1994;36:367.
Norbury НМ, Franklin RA, Graham DF. Pharmacokinetics of the new analgesic meptazinol after oral and intravenous administration to volunteers. Eur J Clin Pharmacol 1983;25:77-80.
Johnson RE, Jasinski DR. Human pharmacology and abuse potential of meptazinol. Clin Pharmacol Ther 1987;41:426-433.
Holmes B, Ward A. Meptazinol: A preview of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1985;30:285-212.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1080— 1081.
Franklin RA. The influence of gastric emptying on plasma concentrations of the analgesic meptazinol. Br J Pharmacol 1977;59:565-569.
Franklin RA, Aldridge A, White C de B. Studies on the metabolism of meptazinol, a new analgesic drug. Br J Clin Pharmacol 1976;3:497-502.
Frost T. Determination of meptazinol in plasma by high performance liquid chromatography with fluorescence detection. Analyst 1981; 106:999—1001.
Hardy DAJ. Meptazinol and respiratory depression. Lancet 1983;2:576.
Slattery RJ, Harmer M, Rosen M, Vickers MD. Naloxone reversal of meptazinol-induced respiratory depression. Anaesthesia 1982;37:1163-1166.
Ali NA, Marshall RW, Allen EM, et al. Comparison of the effects of therapeutic doses of meptazinol and a dex-tropropoxyphene/paracetamol mixture alone and in combination with ethanol on ventilatory function and saccadic eye movements. Br J Clin Pharmacol 1978;20:631-637
Simmsen KW. Four cases involving ketobemidone. Bull hit Assoc Forens Toxicol 1992;22(4):28—31.
LAAM approved to treat drug dependence. FDA Consumer 1993;27:5-6.
Julius НС, Levine HL, Williams WD. Meperidine binding to isolated alpha, acid glycoprotein and albumin. DICP Ann Pharmacother 1989;23:568-572.
Wittels B, Scott DT, Sinatra RS. Exogenous opioids in human breast milk and acute neonatal neurobehavior: A preliminary study. Anesthesiology 1990;73:864-869.
Danziger LH, Martin SJ, Blum RA. Central nervous system toxicity associated with meperidine use in hepatic disease. Pharmacotherapy 1994;14:235-238.
Goetting MG. Neurotoxicity of meperidine. Ann Emerg Med 1985;14:1007-1009.
Kaiko R, Foley K, Heidrich G, et al. Normeperidine plasma levels and central nervous system (CNS) irritability in cancer patients. Fed Proc 1978;37:568.
Hershey LA. Meperidine and central neurotoxicity. Ann Intern Med 1983;98:548-549.
Tang R, Shimomura S, Rotblatt M. Meperidine induced seizures in sickle cell patients. Hosp Formul 1980;15:764-772.
Pryre BJ, Grech H, Stoddart PA, et al. Toxicity of nor-pethidone in sickle cell crisis. Br Med J 1992;304:1478— 1479.
Shochet RB, Murray GB. Neuropsychiatric toxicity of meperidine. J Intens Care Med 1988;3:246-252.
Moulin DE, Kreeft JH, Murray-Poisons N, Bouqillon AJ. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 1991;337:465-468.
Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 3rd ed. Chicago: Year Book, 1989:415—416.
Reidenberg MM, Goodman H, Erie H, et al. Hydromorphone levels and pain control in patients with severe chronic pain. Clin Pharmacol Ther 1988;44:376-382.
Babal N, Hager N, Thirdwell M, et al. Steady-state disposition of hydromorphone and hydromorphone-3-glu-curonide in cancer patients. Clin Pharmacol Ther 1995;57:165.
Baselt RC. Two hydromorphone fatalities. Bull hit Assoc Forens Toxicol 1978; 14(2):20.
CDS: DilaudidR-related deaths — District of Columbia 1987. MMWR 1988;37:425-427.
Hill HF, Coda BA, Tanaka A, Schaffer R. Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. Anesth Analg 1991;72:330-336.
Eisele JH Jr, Grigsby EJ, Dea G. Clonazepam treatment of myoclonic contractions associated with high dose opioids: Case report. Pain 1992;49:231-232.
Treaster JB. With supply and purity up heroin use expands. NYTimes, August 1, 1993.
Treaster B. 7 hospitalized in Bronx after using heroin mix: Police warn users of potent new blend. NY Times, March 18, 1995, p. 9.
Hamilton R, Perrone J, Meggs WJ, et al. Epidemic anticholinergic poisoning from scopolamine tainted heroin. Clin Toxicol 1993; 33:475—486 (Abstract 42).
Hendrickse RG, Maxwell SM, Young R. Aflatoxins and heroin. Br Med J 1989; 299:492-493.
Utrecht MJ, Stone AF, McCarron MM. Heroin body packers. J Emerg Med 1993; 11:33—40.
Karhunen PJ, Pennttila A, Panula A. Detection of heroin "body-packers" at Helsinki airport. Lancet 1987; 1:1265.
Mofenson HC, Caraccio TR. Continuous infusion of Intravenous naloxone. Ann Emerg Med 1987; 16:600.
Goldfrank L, Weisman RS, Errick JK, Lo M-W. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 1986; 15:566—570.
Wang M-L, Lin JL, Liau S-J, Bullard RJ. Heroin in lung: Report of two cases. J Formosa Med Assoc 1994; 93:170-172.
McDonald FW, Cienki JJ, Horowitz RS, et al. Delayed encephalopathy after heroin use. Clin Toxicol 1995; 33:478-485 (Abstract 20).
Cone EJ, Holicky BA, Grant TM, et al. Pharmacokinetics and pharmacodynamics of intranasal "snorted" heroin. J Anal Toxicol 1993; 17:327—337.
Kleber HD, Topazian M, Gaspari J, et al. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 1987; 13:1 — 17.
Novick DM, Ochshorn M, Ghali V, et al. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J Pharmacol Exp Ther 1989; 250:606—610.
Update: Acquired immunodeficiency syndrome — United States. MMWR 1985; 34:245-248.
Cone EJ, Welch P, Mitchell JM, Paul BD. Forensic drug testing for opiates: 1. Detection of 6-acetylmorphine in urine as an indication of recent heroin exposure: Drug and assay considerations and detection times. J Anal Toxicol 1991; 15:1-7.
Havier RG, Lin R-L. Confirmation of heroin use by stomach content analysis. In: Proceedings, 46th Annual Meeting, American Academy of Forensic Sciences, February 14, 1994: 188 (Abstract K-l 1).
Moeller MR, Worth S, Mueller C. The detection of monoacetylmorphine in serum and hair by GC/MS and RIA. In: Proceedings, 46th Annual Meeting, American Academy of Forensic Sciences, February 14, 1994A9\ (Abstract K31).
U. S. Department of Transportation Employers’ Guide to 49 CFT. Part 40: Procedures for transportation workplace drug testing programs. October 1989.
Gutierrez-Cebollada J, Cami J, de la Torre R. Heroin intoxication: The relation between plasma morphine concentration and clinical status at admission. Eur J Clin Pharmacol 1991; 40:635.
Lora-Tomayo С, Тепа T, Tena G. Concentrations of free and conjugated morphine in blood in twenty cases of heroin-related deaths. J Chromatogr Biomed AppI 1987; 422:267-273.
Kintz P, Mangen P, Lugnier AA, Chument AJ. Toxicological data after heroin overdose. Hum Toxicol 1989;
Goldberger BA, Caplan YH, Maguire T, Cone IJ. Testing human hair for drugs of abuse: 111. Identification of heroin and 6-acetylmorphine as indicators of heroin use. J Anal Toxicol 1991; 15:222—231.
Smith DA, Yealy DM. Discharging heroin overdose patients after observation. Ann Emerg Med 1993; 22:1638-1639.
Mendelson J, Jones RT. Assessing new pharmacothera-peutics on opiate dependence: Buprenorphine and naloxone combinations in opiate-dependent volunteers. Clin Pharmacol Ther 1995; 57:160.
Wasserman G. Antidiarrheal agent can be toxic to children. JAMA 1974;230:14. Editorial.
Wasserman GS, Green VA, Wise GW. Lomotil ingestions in children. Am Fam Physician 1975;1:93-97.
Curtis JA, Goel KM. Lomotil poisoning in children. Arch Dis Child 1979;54:222-225.
Ahmad SR. Lomotil overdose. Pediatrics 1992;89:980— 981.
Litovitz T, Holm КС, Bailey KM, Schuster BB. 1991 Annual Report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1992;10:452-505.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:1877-1879.
Henderson W, Psaila A. Lomotil poisoning. Lancet 1969;1:306-307.
Ginsberg CM, Angle CR. Diphenoxylate-atropine (Lomotil) poisoning. Clin Toxicol 1969;2:377-382.
Penfold D, Volans GN. Overdose from Lomotil. Br Med J 1977;2:1401-1402.
Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: Morphine, methadone and naloxone. Clin Pharmacokinet 1976;1:219-230.
Baselt R. Disposition of Toxic Drugs and Chemicals in Man. 3rd ed. Chicago: Year Book, 1989:295—296.
Karim A, Ranney RE, Evensen KL, et al. Pharmacokinetics and metabolism of diphenoxylate in man. Clin Pharmacol Ther 1972;13:407-419.
Snyder R, Mofenson HC, Greensher J. Toxicity from Lomotil: Accidental ingestion by a 22 month old child. Clin Pediatr 1973;12:47-49.
McCormick RA, O’Donoghue D, Brennan N. Diphenoxylate and pancreatitis. Lancet 1985; 1:752.
McCarron MM, Chailoner KR, Thompson GA. Diphenoxylateatropine (Lomotil) overdose in children: An update (Report of 8 cases and review of the literature). Pediatrics 1991 ;87P;694:697-700.
Ives TJ. Illicit use of diphenoxylate hydrochloride to prevent narcotic withdrawal symptoms. Drug Intell Clin Pharmacol 1980;14:715-716.
Ford GC, Haskins NJ, Palmer RF, et al. The measurement of diphenoxylic acid in plasma following administration of diphenoxylate. Biomed Mass Spect 1976;3:45-47.
Jackson LS, Stafford JE. The evaluation and applications of a radioimmunoassay for the measurement of diphenoxylic acid, the major metabolite of diphenoxylate hydrochloride (Lomotil) in human plasma. J Pharmacol Methodol 1987; 18:189—197.
Mack RB. Toxic encounters of the dangerous kind. Diphenoxylate (Lomotil). NC Med J 1981 ;42:858.
McGuigan M, Lovejoy FH Jr. Overdose of Lomotil. Br Med J 1978;l:990.
O’Brien JJ, Benfield Р. Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1989;38:226-248.
Stambaugh JE Jr, McAdams J. Comparison of intramuscular dezocine with butorphanol and placebo in chronic cancer pain: A method to evaluate analgesia after both single and repeated doses. Clin Pharmacol Ther 1987;42:211-219.
Dezocine (systemic). USP DI Update 1991;1:106-109.
Dezocine (DalganR), Astra. Calif Assoc Toxicol Newslett Spring 1991:12—13.
Locniskar A, Greenblatt DJ, Zinny MA. Pharmacokinetics of dezocine, a new analgesic: Effect of dose and route of administration. Eur J Clin Pharmacol 1986;30:121-123.
Dezocine. Med Lett Drugs Ther 1990;32(829):95—96.
Romagnoli A, Keats AS. Ceiling respiratory depression by dezocine. Clin Pharmacol Ther 1984;35:367-373.
Rothbard RL, Schreiner BF, Yu PN. Hemodynamic and respiratory effects of dezocine, ciramadol and morphine. Clin Pharmacol Ther 1985;38:84-88.
Jasinski DR, Preston КС. Assessment of dezocine for morphine-like subjective effects and miosis. Clin Pharmacol Ther 1985;38:544-548.
Locniskar A, Greenblatt DJ. Determination of ciramadol and dezocine, two new analgesics, by high performance liquid chromatography using electrochemical detection. J Chromatogr Biomed Appl 1986;374:215-220.
Brewer Е. A dextromoramide related fatality. J Forens Sci 1990;35:483-489.
Kintz P, Tracqui A, Mangin P, et al. Toxicological findings after fatal dextromoramide injection. Clin Toxicol 1989;27:385-388.
Kintz P, Tracqui A, Mangin P, et al. Fatal intoxication by dextromoramide: A report on two cases. J Anal Toxicol 1989;13:238-239.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1071
Carmack J. Dependence on dextromoramide. Br Med J 1967; 1:362.
Juby BA. Dependence on dextromoramide. Br Med J 1967;1:362-363.
Hansson RC. Fifteen deaths associated with dextromoramide. Bull I nt Assoc Forens Toxicol 1986; 19( 1 ):39—41.
Kintz P, Mangin, Lugnier AA, Chaumont AJ. Gas chromatographic assay for dextromoramide in human plasma. J Chromatogr 1988;432:329-333.
Pagani 1, Barzaghi N, Crema F, et al. Pharmacokinetics of dextromoramide in surgical patients. Fundam Clin Pharmacol 1989;3:27-35.
Kintz P, Tracqui A, Mangin P, et al. Tissue distribution of dextromoramide in the rat. Fundam Clin Pharmacol 1990;4:163-167.
Jurand A, Martin LVH. Teratogenic potential of two neurotropic drugs, haloperidol and dextromoramide, tested on mouse embryos. Teratology 1990;42:45-54.
Wuster M, Schulz R, Herz A. Specificity of opioids towards the mu, delta and epsilon opiate receptors. Neu-rosci Lett 1978;15:193-198.
Janssen PAJ, Jageneau AH. A new series of potent analgesics:Dextro-2.2-diphenyl-3-methyl-4-morpholinobutyrylpyrrolidine and related amides, Part I. J Pharm Pharmacol 1957;9:381-400.
Chaumant AJ, Mangin P, Lugnier AA. Intoxications mortelles par le dextromoramide et toxicomanie. J Med Leg Droit Med 1981;24:687-692.
Ashton, Franc, Haynes: Home Office Forensic Science Laboratory, Aldermaston, Berks, UK. Two fatalities involving dextromoramide. Bull Int Assoc Forens Toxicol 1978; 14(2):22—23.
Sheehan TMT. Dextromoramide: A challenge to the analyst. In: Proceedings, 25th International Meeting, International Association of Forensic Toxicologists, Banff, July 28—31, 1987AM-MQ.
Klein RFX, Sperling AR. Cooper DA, Kram TC. The stereoisomers of 4-methylaminorex. J Forens Sci 1989;34:962-979.
Yelnosky J, Katz R. Sympathomimetic actions of cis-2-amino-4-methyl-5-phenyl-2-oxazoline. J Pharmacol Exp Ther 1963;141:180-184.
Patil PN, Yamauchi D. Influence of optical isomers of some centrally acting drugs on norepinephrine responses. Eur J Pharmacol 1970;12:132-135.
Lawn JC. Schedules of controlled substances: Temporary placement of 2-amino-4-methyl-5-phenyl-2-oxazoline (4-methylaminorex) into Schedule I. Fed Regist 1987;52:30 174-30 175.
Davis FT, Brewster ME. A fatality involving U4EUh, a cyclic derivative of phenylpropanolamine. J Forens Sci 1988;33:549-553.
Sudmeier SJ, Smith FP, Reuschel SA, Kidwell DA. Four isomers of methylaminore in urine examined by immunoassay and GC/MS. In: Proceedings, American Academy of Forensic Scientists, New Orleans, 44th Annual Meeting, February 17—22, 1992.VM, (Abstract K.-47).
Brewster ME, Davis FT. Appearance of aminorex as a designer analogue of methylaminorex. J Forens Sci 1991;36:587-592.
Gurtner H. Aminorex and pulmonary hypertension. Cor Vasa 1985;27:160-171.
Seiler K. Aminorex and pulmonary circulation. Arznei-tmittelforschung 1975;25:837.
Jenner Р. МРТР-induced Parkinsonism: Chemical basis of an age related disease. In: Volans GN, Sims J, Sullivan FM, Turner P, eds. Basic Science in Toxicology. London: Taylor & Francis, 1990:615—625.
Maret G, Testa B, Jenner P, et al. The MPTP story: MDA activates tetrahydropyridine derivatives to toxins causing parkinsonism. Drug Metab Rev 9990;22:291 — 332.
Shulgin AT. What is MDMA. Pharm Client Newslett 1985;14:3-5, 10-11.
FDA Consumer 1985;19(7):36—37.
Buchanan J. Ecstasy in the emergency department. San Francisco Bay Area Region Poison Center Clin Toxicol Update 1985;7(4): 1—3.
Rohrig TP, Prouty RW. Tissue distribution of methylenedioxymethamphetamine. J Anal Toxicol 1992;16:52-53.
Verebey K, Alrazi J, Jaffe JH. The complications of "ecstasy" (MDMA). JAMA 1988;259:1649-1650.
Dalcason TA. The characterization of some 3,4-methyl-enephenylisopropylamine (MDA) analoqs. J Forens Sci 1989;34:928-961.
Ruagyuttiharn W, Samathanun G, Moody DW. Comparison of RIA, ENRIR, and TDX1' detection for amphetamine-like designer drugs. In: Proceedings, 2nd International Meeting, International Association of Forensic Toxicologists, Banff, July 28—31, 1987.2\3—217.
Henderson GL. Pharmacology and toxicology of fentanyl and related compounds. Calif Assoc Toxicol News-lett, July 1983.
Sternbach GL, Varon J. ’Designer drugs’: Recognizing and managing their toxic effects. Postgrad Med 1992;92:169-176.
Ford M, Hoffman RS, Goldfrank LR. Opioids and designer drugs. Emerg Med Clin North Am 1990;8:495— 511.
Jerrard DA. ’Designer drugs’: A current perspective. J Emerg Med 1990;8:733-741.
Sidford C. Designer drugs. Clin Toxicol Rev 1989;! 1(11):1—2.
U. S. Congress CSA (Controlled Substance Analogue) Enforcement Act (21 Provision USC813: Treatment of CSA) Defer 21 USC 802 32A. Public Law 990 570. 99th Congress, Oct. 27, 1986.
Martros M, Hecker J, Clark R, et al. "China White" epidemic: An eastern United States emergency department experience. Ann Emerg Med 1989; 18:441.
Buchanan JF, Brown CR. ’Designer drugs’: A problem in clinical toxicology. Med Toxicol 1988;3:1-17.
Beebe DK, Walley E. Substance abuse: The designer drugs. AFP 1991;43:1689-1698.
Bureau of Narcotic Enforcement, California Department of Justice, Statement, November 1989.
Marquardt KA, Tharratt RS. Inhalation abuse of fentanyl patch. Clin Toxicol 1994;32:75-78.
Henderson GL Designer drugs: Past history and future prospects. J Forens Sci 1988;33:569-575.
Martin M, Hecker J, Clark R, et al. China White epidemic: An eastern United States emergency department experience. Ann Emerg Med 1991;20:158-164.
Hibbs J, Perper J, Winek CL. An outbreak of designer drugrelated deaths in Pennsylvania. JAMA 1991;265:1011-1013.
Hudson RJ. Apnoea and unconsciousness after apparent recovery from alfentanil-supplemental anaesthesia. Can J Anaesth 1990;37:255-257.
Bartkowski R, Mcdonnell E. Prolonged alfentanil effect following erythromycin administration. Anesthesiology 1990;73:566-568.
Kissin I, Vinik HR, Castillo R, Bradley EL Jr. Alfentanil potentiates midazolam-induced unconsciousness in subanalgesic doses. Anesth Analg 1990;71:65-69.
Lammerts HJM, Bovill JG, Hennis PJ, et al. Alcohol consumption alters the pharmacodynamics of alfentanil. Anesthesiology 1989;71:669-679.
Poklis A. Fentanyl: A review for clinical and analytical toxicologists. Clin Toxicol 1995;33:439-447.
Ananthanrayan C. Tissue effect of fentanyl. Anaesthesia 1990;45:595.
Strong WE, Matson M. Probable seizure after alfentanyl. Anesth Analg 1989;68:692-693.
Rosenberg M, Lisman SR. Major seizure after fentanyl administration: Two case reports. J Oral Maxillofac Surg 1986;44:577-579.
Steinstra R, van Poorten F. Immediate respiratory arrest after caudal epidural sufentanil. Anesthesiology 1989;71:993-994.
De Sio JM, Bacon Dr, Peer G, Lerna MJ. Intravenous abuse of transdermal fentanyl therapy in a chronic pain patient. Anesthesiology 1993;79:1139—1141.
Nieves E. 6 addicts die and police warn of toxic drug. NYTimes, Feb. 3, 1991.
Hays LR, Stillner V, Littrell R. Fentanyl dependency associated with oral ingestion. Anesthesiology 1992;77:819-820.
Henderson GL. Fentanyl related deaths: Demographics, circumstances and toxicology of 112 cases. J Forens Sci 1991;36:422-433.
Michiels M, Hendriks R, Heykants JJ. Radioimmunoassay of the new opioid analgesics alfentanil and sufentanil. J Phann Pharmacol 1983;35:86-93.
HansdottirV, HednerT, Woestenborghs R, NordbergG. The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. Anesthesiology 1991;74:264-269.
Ferslew KE, Hagordorn AN, McCormick WF. Post-morten determination of the biological distribution of sufentanil and midazolam after an acute intoxication. J Forens Sci 1989;34:249-257.
Stiller RL, Scierka AM, Davis PJ, et al. A method to increase recovery of fentanyl from urine. Clin Toxicol 1989;27:101-108.
Henderson GL, El Shanni AS, Wilson HA, et al. Fentanyl in urine and serum by solid phase 125—1 radioimmunoassay. In: Uges DRA, de Zeeuw RA, eds. Proceedings, 25th International Meeting, International Association of Forensic Toxicologists, Groningen, 1988.
Watts V, Caplan Y. Determination of fentanyl in whole blood at subnanogram concentrations by dual capillary column gas chromatography with nitrogen sensitive detectors and gas chromatography/mass spectrometry. J Anal Toxicol 1988;12:246-254.
Chaturvedi AK, RaoNGS, Baird JR. A death due to selfadministered fentanyl. J Anal Toxicol 1990;14:385-387.
Henderson GL. Blood concentrations of fentanyl and its analogs in overdose victims. Proc West Pharmacol Soc 1983;26:287-290.
Henderson GL, Harkey MR, Jones AD. Rapid screening of fentanyl (China White) powder samples by solid-phase radioimmunoassay. J Anal Toxicol 1990;14:172-175.
Lunn JK, Stanley SH, Eisele J. High dose fentanyl anesthesia for coronary artery surgery: Plasma fentanyl concentrations and influence of nitrous oxide on cardiovascular responses. Anesth Analg 1979;58:390-395.
Bovill JG, Sebel PS. Pharmacokinetics of high-dose fentanyl. Br J Anaesth 1980;52:795-801.
Chudnofsky CR, Wright SW, Dronen SC, et al. The safety of fentanyl use in the emergency department. Ann Emerg Med 1989;18:635-639.
Bedford KR, Nolan SL, Onrust R, Siegers JD. The illicit preparation of morphine and heroin from pharmaceutical products containing codeine: ’Homebake’ Laboratories in New Zealand. Forens Sci Int 1987;34:197— 204.
Chen ZR, Somagy AA, Reynolds G, Bochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol 1991;31:381-392.
Vree ТВ, Verwey-Van Wissen CPWGM. Pharmacokinetics and metabolism of codeine in humans. Biopharm Drug Dispos 1991;13:445-460.
Posey BL, Kimble SN. High-performance liquid chromatographic study of codeine, norcodeine and morphine is indication of codeine ingestion. J Anal Toxicol 1984;8:68-74.
Cone EJ, Welch F, Paul BD, Mitchel JM. Forensic drug testing for opiates: III. Urinary excretion rates of morphine and codeine following codeine administration. J Anal Toxicol 1991;15:161-166.
Havier RG, Lin R. Deaths as a result of a combination of codeine and glutethimide. J Forens Sci 1985.
Bender FH, Cooper JV, Dreyfus R. Fatalities associated with an acute overdose of glutethimide (Doriden) and codeine. Vet Hum Toxicol 1988;30:332-333.
Park GR, Shelly MP, Ammum K, Roberts P. Dihydrocodeine: A reversible cause of renal failure? Eur J Anaes-thesiol 1989;6:303-334.
Gjerde H, Fongen U, Gundersen H, Christophersen AS. Evaluation of a method for simultaneous quantification of codeine, ethylmorphine and morphine in blood. Forens Sci Int 1991;51:105-110.
Verwez-Van Wissen CPWGM, Koopman-Kimenai PM. Direct determination of codeine, norcodeine, morphine and normorphine with their corresponding O-glucuro-nide conjugates by high-performance liquid chromatography with electrochemical detection. J Chromatogr Biomed Appl 1991;570:309-320.
Nakamura GR, Stoll WJ, Meeks RD. Analysis of dihydrocodeine for urine using Sep-PakR C,8 cartridges for sample cleanup. J Forens Sci 1987;32:535-538.
Dawling S, Widdop B. A fatal case involving dihydrocodeine. Bull IntAssoc Forens Toxicol 1981; 16( 1 ):25—26.
Barnhart JW, Caldwell WJ. Gas chromatographic determination of hydrocodone in serum. J Chromatogr 1977;130:234-249.
Rogers JF, Findlay JWA, Hill J H, et al. Codeine disposition in smokers and non-smokers. Clin Pharmacol Ther 1982;32:218-227.
Baselt R, Cravey RH. A compendium of therapeutic and toxic concentrations of toxicologically significant drugs in human biofiuids. J Anal Toxicol 1977;1:81-103.
Vivian D. Three deaths due to hydrocodone in a resin complex cough medicine. Drug Intell Clin Pharmacol 1979;13:445-446.
Morrow PL, Faris EC. Death associated with inadvertent hydrocodone overdose in a child with a respiratory tract infection. Am J Forens Med Pathol 1987;8:60-63.
Park JL, Nakamura GR, Griesimer EG, et al. Hydromorphine detected in bile following hydrocodone ingestion. J Forens Sci 1982;27:223-224.
Hart LM, Dean BS, Krenzelok EP. Massive pediatric codeine overdose with survival. Vet Hum Toxicol 1993;35:341.
Butorphanol nasal spray for pain. Med Lett Drugs Ther 1993;35(909): 105-106.
Robbins L. StadolR nasal spray: Treatment for migraine? Headache 1993;33:220.
Physicians' Desk Reference. 49th ed. Montvale, NJ: Medical Economics, 1994:739—742.
Heel RC, Brogden RN, Speight TM, et al. Butorphanol: A review of its pharmacological properties and therapeutic efficacy. Drugs 1978;16:473-505.
Pittman KA, Smyth RD, Mayol RF. Serum levels of butorphanol by radioimmunoassay. J Pharm Sci 1980;69.
Gaver RC, Vasiljer M, Wong H, et al. Disposition of parenteral butorphanol in man. Drug Metab Disp 1980.
Pfeffer M, Smyth RD, Pittman KA, Nardella PA. Pharmacokinetics of subcutaneous and intramuscular butorphanol in dogs. J Pharm Sci 1980;69:801-803.
Hearn WL, Rose S, Andollo W, Hime G. Fatality associated with enfiurane and butorphanol. In: Proceedings, American Academy of Forensic Sciences, 43rd Annual Meeting, February 18—23, 1991: Abstract K35.
Heel RC, Brogden RN, Speight ТМ, et al. Buprenorphine: A review. Drugs 1979;17:82-110.
Debrabandere L, Van Boven M, Daenens P. Development of a fluoroimmunoassay for the detection of buprenorphine in urine. J Forens Sci 1995;40:250-253.
Resnick RB, Galanter M, Pycha C, et al. Buprenorphine: An alternative to methadone for heroin dependency treatment. Psychopharmacol Bull 1993;28:109.
Johnson RE, Cone EJ, Hemingfield JE, Fudala PJ. Use of buprenorphine in the treatment of opiate addiction: 1. Psychologic and behavioral effects during a rapid dose induction. Clin Pharmacol Ther 1989;46:335-347.
Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992;287:2750-2755.
Banks CD. Overdosage of buprenorphine: Case Report. NZ Med J 1979;89:255-256.
MacEvilly M, O’Caurall C. Hallucinations after epidural buprenorphine. Br Med J 1989;298:928-929.
Fullerton T, Tinu EG, Kolski GB, Bertius JS. Prolonged nausea and vomiting associated with buprenorphine. Pharmacotherapy 1991; 11:90—93.
Thorn SE, Rowal N, Wennhager M. Prolonged respiratory depression caused by sublingual buprenorphine. Lancet 1988;1:179-180.
Tantucci C, Paoletti F, Bruni B, et al. Acute respiratory effects of sublingual buprenorphine: Comparison with intramuscular morphine. Int J Clin Pharmacol Ther Toxicol 1992;30:202-207.
Chowdhury AN, Chowdhury S. Buprenorphine abuse: Report from India. Br J Addict 1990;85:1349-1350.
Strang J. Abuse of buprenorphine (Temgesic) by snorting. Br Med J 1991 ;302:969.
Sakol MS, Stark C, Sykes R. Buprenorphine and temazepam abuse by drug takers in Glasgow: An increase. Br J Addict 1989;84:439-441.
O’Connor JJ, Moloney E, Travers R, Campbell A. Buprenorphine abuse among opiate addicts. Br J Addict 1988;83:1085-1087.
Debrabandere L, Van Boven M, Daenens P. Analysis of buprenorphine in urine specimens. J Forens Sci 1991.
Hand CW, Ryan KE, Dutt SK, et al. Radioimmunoassay of buprenorphine in urine: Studies in patients and in a drug clinic. J Anal Toxicol 1989;33:100-104.
Bullingham RES, McQuay HJ, Porter EJB, et al. Sublingual buprenorphine used postoperativeiy: Ten hour plasma drug concentration analysis. Br J Clin Pharm 1982;13:665-673.
Kintz P, Cirimele V, Edel Y, et al. Hair analysis for buprenorphine and its dealkylated metabolite by RIA and confirmation by LC/ECD. J Forens Sci 1994;39:1497.
Kintz P, Tracqin A, Pfitzinger H, Mangin P. Hair analysis for buprenorphine and its dealkylated metabolites. In: Proceedings, American Academy of Forensic Sciences, February 1994:192 (Abstract K25).
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:1067.
Baselt RC, Cravey RH. Disposition of Toxic Drugs and Chemicals in Man. 3rd ed. Chicago: Year Book, 1989:56-57.
Lin SC, Way EL. N-dealkylation of anileridine to normeperidine. J Pharmacol Exp Ther 1965; 150:209— 215.
Peclet C, Rousseau JJ, Rousseau M. Anileridine intoxication. Bull Int Assoc Forens Toxicol 1981; 16( 1 ):27—28.
Peat MA, Kopjak L. An anileridine death. Bull Int Assoc Forens Toxicol 1979; 14(3): 19.
Opiates or opioids. Lancet 1983; 1:687. Editorial.
Thompson JW. Clinical pharmacology of opioid agonists and partial agonists. In: Doyle D, ed. Opioids in the Treatment of Cancer Pain. International Congress and Symposium Series No. 146. London: Royal Society of Medicine Services. 1990:17—38.
Jacox A, Carr DB, Payne R. New clinical practice guidelines for the management of pain in patients with cancer. N Engl J Med 1994;330:651-655.
Dale G, Fleetwood J A, Weddell A, et al. Beta-endorphin: A factor in "fun run" collapse? Br Med J 1987;294:1004.
Ling W, Wesson DR. Drugs of abuse: opiates. In: Addiction Medicine (Special Issue). West J Med 1990;152:565-572.
Tempelhoft R, White PF. Pro and anticonvulsant effects of anesthetics: Part I. Anesth Analg 1990;70:303-315.
Traub SL. Clonidine for opiate withdrawal. Hosp Formal 1985;20:77-80.
Bakris GL, Cross PD, Hammarsten JE. The use of clonidine for management of opiate abstinence in a chronic pain patient. Mayo Clin Proc 1982;57:657-660.
Kleber HD, Topazan M, Gaspari J, et al. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 1987;13:1-17.
Cox S, Alcorn R. Lofexidine and opioid withdrawal. Lancet 1995;345:1385-1386.
Gillman MA, Lichtigfeld FJ. Analgesic nitrous oxide for alcohol withdrawal: A critical review after 10 year’s use. Postgrad Med J 1990;66:543-546.
Gillman MA, Lichtigfeld FJ. The drug management of severe alcohol withdrawal syndrome. Postgrad Med 1990;66:1005-1010.
Ojutkangas R. Analgesic nitrous oxide: Rapid, safe therapy for addictive withdrawal. Postgrad Med J 1991;67:1027-1030.
Braithwaite RA, Jarvie DR, Minty PSB, et al. Screening for drugs of abuse: I. Opiates, amphetamines and cocaine. Ann Clin Biochem 1995;32:123-153.
Milhorn НТ. Diagnosis and management of phencyclidine intoxication. Am Fam Physician 1991;43:1293— 1302.
UCLA Drug Abuse Research Groups funded by the National Institute of Justice. Los Angeles Times, June 17, 1991.
Shesser R, Jotte R, Olshaker J. The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med 1991;9:336-342.
Cook CE, Brine DR, Jeffecote AR. Phencyclidine deposition after intravenous and oral doses. Clin Pharmacol Ther 1982;31:625-634.
Giles HG, Corrigall WA, Khouw V, et al. Plasma protein binding of phencyclidine. Clin Pharmacol Ther 1982;31:77-82.
Baldridge ЕВ, Bessen НА. Phencyclidine. Emerg Med Clin North Am 1990;8:541-550.
Simpson GM, Khajawall AM, Alatorre E, et al. Urinary phencyclidine excretion in chronic abusers. J Toxicol Clin Toxicol 1982/1983;19:1051 —1059.
Khajawall AM, Simpson GM. Peculiarities of phencyclidine urinary excretion and monitoring. J Toxicol Clin Toxicol 1982/1983; 19:835-842.
Wachsman L, Schuetz S, Chan LS, Wingert WA. What happens to babies exposed to phencyclidine (PCP in ute-ro?) Am J Drug Alcohol Abuse 1989;15:31-39.
McCarron MM, Schulze BW, Thompson GA, et al. Acute phencyclidine intoxication: Incidence of clinical findings in 1,000 cases. Ann Emerg Med 1981 ;10:237— 242.
Aniline O, Pitts FN, Allen RE, et al. Incidental intoxication with phencyclidine. J Clin Psychiatry 1980;41:393-394.
Pitts FN Jr, Allen RE, Aniline O, et al. Occupational intoxication and long-term persistence of phencyclidine (PCP) in law enforcement personnel. Clin Toxicol 1981;18:1015-1020.
Jackson JE. Phencyclidine pharmacokinetics after a massive overdose. Ann Intern Med 1989; 111:613— 615.
Levine BS, Smith ML. Effects of diphenhydramine or immunoassay of phencyclidine in urine. Clin Chem 1990;36:1258.
MacDonald DI. New treatment for PCP? JAMA 1987;257:3188.
Owens SM, Mayersohn M. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metab Dispos 1986;14:52-58.
Wasserberger J, Ordog GJ, Hardin E, et al. Violence in the emergency department. Top Emerg Med 1992;14:71-78.
Mofenson HC, Caraccio TR. The agitated, violent or acutely psychotic patient: PP/T Review. Nassau County Medical Center Regional Poison Control Center. 1992;11(5):301—306.
Thomas H, Schwartz E, Petrilli R. Droperidol versus haloperidol for chemical restraint of agitative and combative patients. Ann Emerg Med 1992;21:407-413.
Wasserberger JL. Personal communication, Drew/ UCLA Medical Center.
Jerrard DA. "Designer drugs": A current perspective. J Emerg Med 1990;8:733-741.
National Household Survey on Drug Abuse. Washington, DC: National Institute of Drug Abuse, 1991.
Young FL. Opinion and recommended ruling, marijuana rescheduling petition. Washington, DC: Department of Justice, Drug Enforcement Administration, September 1988: Docket 86—22.
Grinspoon L, Bakalar JB, Doblin R. Marijuana, the AIDS wasting syndrome and US government. N Engl J Med 1995;333:670-671.
Doblin R, Kleiman MAR. Medical use of marijuana. Ann Intern Med 1991;114:809-810.
U. S. Department of Justice, Drug Enforcement Administration. Marijuana scheduling petition: Final order. Fed Regist 1992;57:10 499-10 508.
U. S. Public Health Service. Denying new requests for medicinal marijuana. Int Med News Cardiol News 1992;25:31.
Treaster JB. Survey finds marijuana use is up in high schools. NYTimes, February 1, 1994.
Pollan M. How pot has grown. NY Times Mag, February 19, 1995, pp.31-57.
Senkowsky S. Marijuana ’blunts’: The adolescent craze. City of Phoenix: The DRE 1995;7:11-13.
Johansson E, Halldin MM, Agurell S, et al. Terminal elimination plasma half-life of delta’-tetrahydrocannab-inol (delta9-THC) in heavy users of marijuana. Eur J Clin Pharmacol 1989;37:273-277.
Lukas SE, Benedikt R, Mendelson JH, et al. Marijuana attenuates the rise in plasma ethanol levels in human subjects. Neuropsychopharmacology 1992;7:77-81.
Foltin RW, Fischman MW, Pedroso JJ, Pearlson GD. Marijuana and cocaine interactions in humans: Cardiovascular consequences. Pharmacol Biochem Behav 1987;28:459-464.
Soderstrom CA, Trifillis AL, Shankar DS, et al. Marijuana and alcohol use among 1,023 trauma patients. Arch Surg 1988;123:733-737.
Du Pont RL, Saylor KE. Marijuana and benzodiazepines in patients receiving methadone treatment. JAMA 1989;2611:3409.
Miller NS, Klahr AL, Gold MS, et al. The prevalence of marijuana (cannabis) use and dependence in cocaine dependence. NY State J Med 1990;90:491-492.
Lanska DJ, Lanska MJ. PCP use among adolescent marijuana users. J Pediatr 1988;113:950-951.
Zuckerman R, Frank DA, Kingson R, et al. Effects of material marijuana and cocaine use on fetal growth. N Engl J Med 1989;320:767-768.
Richardson GA, Day NL, McGaughey PJ. The impact of prenatal marijuana and cocaine use on the infant and child. Clin Obstet Gynecol 1993;36:302-328.
Robison LL, Buckley JD, Daigle AE, et al. Maternal drug use and risk of childhood non-lymphoblastic leukemia among offspring: An epidemiologic investigation implicating marijuana (a report from the Children’s Cancer Study Group). Cancer 1989;63:1904-1910.
Matsuda LA, Lolait J, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned DI^A. Nature 1990;346:561-564.
Nahas G, Latour C. The human toxicity of marijuana. Med J Aust 1992;15:495-497.
Johnson D, Convadi A, McGuigan M. Hashish ingestion in toddlers. Vet Hum Toxicol 1991 ;33:393.
Talbot JA, Teague JW. Marihuana psychosis: Acute toxic psychosis associated with the use of cannabis derivatives. JAMA 1969;210:299-302.
Halikas JA, Goodwin DW, Gage SB. Marijuana use and psychiatric illness. Arch Gen Psychiatry 1972;27:162— 165.
Carney MWP, Bacelle L, Robinson B. Psychosis after cannabis use. Br Med J 1984;288:1047.
Rottanburg D, Robins AH, Ben-Arie O, et al. Cannabis associated psychosis with hypomanic features. Lancet 1982;2:1364-1366.
Wu T-C, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med 1988;318:347-351.
Caplan GA. Marijuana and mouth cancer. J R Soc Med 1991;84:386.
Taylor FM. Marijuana as a potential respiratory tract carcinogen: A retrospective analysis of a community hospital population. South Med J 1988;81:1213-1216.
Tashkin DP. Is frequent marijuana smoking harmful to health? West J Med 1993;158:635-636.
Chesid MJ, Gelfand JA, Nutter C, Fauci AS. Pulmonary aspergillosis, inhalation of contaminated marijuana smoke, a chronic granulomatosis disease. Ann Intern Med 1975;82:682-683.
Levitz SM, Diamond RD. Aspergillosis and marijuana. Ann Intern Med 1991;115:578-579.
Baris Yl, Tan E, Kalyoncu F, et al. Chest 1990;98:1545-1546.
Kelly P, Jones PT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 1992;16:228-235.
MacNab A, Anderson E, Susak L. Ingestion of cannabis: A cause of coma in children. Pediatr Emerg Care 1989;5:238-239.
Rubio F, Quintero S, Hernandez A, et al. Flumazenil for coma reversal in children after cannabis. Lancet 1993;341:1028-1029.
Stein IN. Marijuana testing. West J Med 1988; 148:78.
Ellis BM Jr, Mann MA, Judson BA, et al. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 1985;38:572— 578.
Cone EJ, Johnson RE. Contact highs and urinary cannabinoid excretion after passive exposure to marijuana smoke. Clin Pharmacol Ther 1986;40:245-256.
Morland J, Bugge A, Shuterud B, et al. Cannabinoids in blood and urine after passive inhalation of cannabis smoke. J Forens Sci 1985;30:997-1002.
Perez-Reyes M, Di Guiseppi S, Mason AP, et al. Passive inhalation of marijuana smoke and urinary excretion of cannabinoids. Clin Pharmacol Ther 1983;34:36-41.
Podkowik B-I, Repka ML, Smith MC. Interference by ritodrine in GC/MS confirmation of delta-9-tetrahydro-cannabinol-9-carboxylic acid in urine. Clin Chem 1991;37:1305-1306.
Gerostamoulos J, Drummer OH. Incidence of psychoactive cannabinoids in drivers killed in motor vehicle accidents. J Forens Sci 1993;38:649-656.
Leirer VO, Yesavage JA, Morrow DG. Marijuana carryover effects on aircraft pilot performance. Aviat Space Environ Med 1991;62:221-227.
Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995;345:579.
Bhargava HN. Potential therapeutic application of naturally occurring and synthetic cannabinoids. Gen Pharmacol 1978;9:195-213.
Abromowicz M, ed. Nabilone and other antiemetics for cancer patients. Med Lett Drugs Ther 1988;29:1-3.
Brunton LL. Agents affecting gastrointestinal water flux and motility, digestants and bile acids. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press, 1990:914—932.
Hellinger FJ. The cost of Marinol (dronabinol). JAMA 1993;270:2810.
Jaffe JH. Drug addiction and drug abuse. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman ’s the Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press, 1990:549—553,
Rubin A, Lemberger L, Warrick P, et al. Physiologic disposition of nabilone, a cannabinol derivative, in man. Clin Pharmacol Ther 1977;22:85-91.
Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans: 1. Neuroendocrine, autonomic and cardiovascular effects. Arch Gen Psychiatry 1994;56:85-97.
Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans: 11. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 1994;56:98-108.
Anderson 1, Cowan P, Grahame-Smith D. The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology 1990;100:498-503.
Walker R, Mandell L, Kleinman J, et al. Improved selective ion monitoring mass-spectrometric assay for the determination of /V,/V-dimethyltryptarnine in human blood utilizing capillary column gas chromatography. J Chromatogr 1979;162:539-546.
Gallagher L. Smoking toad. NY Times Mag, June 5, 1994, pp. 48-49.
Hitt M, Ettinger DD. Toad toxicity. N Engl J Med 1986;314:1517-1518.
Leikin J, Krantz AJ, Zell-Kanter M, et al. Clinical features and management of intoxication due to hallucinogenic drugs. Med Toxicol Adverse Drug Experience 1989;40:324-352.
Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans: I. Neuroendocrine, autonomic and cardiovascular effects. Arch Gen Psychiatry 1994;56:85-97.
Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 1994;56:98-108.
Treaster JB. Use of LSD, drug of allure and risk, rises with new generation’s interest. NYTimes, December 27, 1991, p. All.
Drug dealings: LSD is back. Forens Drug Abuse Advisor 1993;5(8):63.
Maslanta AM, Scott SK. LSD overdose in an eight-month-old boy. J Emerg Med 1992;10:481-483.
Jackson TW, Hornfeldt CS. Seizure activity following recreational LSD use in patients treated with lithium and fluoxetine. Vet Hum Toxicol 1991 ;33:387.
Markel H, Lee A, Holms RD, Domino EF. LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents. J Pediatr 1994;125:817-819.
Aghajanian GK. Serotonin and the action of LSD in the brain. PsychiatrAnn 1994;24:137-141.
Smith DE, Seymour RD. LSD: History and toxicity: Today, there is group concern over long-term post hallucinogenic disorder. PsychiatrAnn 1994;24:145— 147.
Madden JS. LSD and post-hallucinogen perceptual disorder. Addiction 1994;89:762-763.
Behan WMH, Bakheit AMO, Behan PO, More I AR. The muscle findings in the neuroleptic malignant syndrome associated with lysergic acid diethylamide. J Neurol Neurosurg Psychiatry 1991;54:741-743.
Sun JV, Bonelli EJ. Lysergic acid diethylamide (LSD): Specificity: Sensitivity and linearity of HP5971A MSD. In: Proceedings, American Academy of Forensic Sciences, 1989: Abstract K4.
Blum LM, Carenzo EF, Rieders F. Determination of lysergic acid diethylamide (LSD) in urine by instrumental highperformance thin-layer chromatography. J Anal Toxicol 1990;14:285-287.
Vu-Duc T, Vermay A, Calamca A. Detection de 1’acide lysergique diethylamide (LSD) dans Purine humaine: Elimination, depistage et confirmation analytique. Schweiz-Med Wochenschr 1991;121:1887-1890.
McCarron MM, Walberg CB, Baselt RC. Confirmation of LSD intoxication by analysis of serum and urine. J Anal Toxicol 1990;14:165-167.
Solursh LP, Clement WR. Hallucinogenic drug abuse: Manifestations and management. Can Med Assoc J 1968;98:407-413.
Tarver J. A. Amphetamine-positive drug screens from use of clobenzorex hydrochlorate. J Anal Toxicol 1994; 18:183.
Perez J, Burton ВТ, McGirr JG. Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med 1994;6:795-797.
Elsohly МА, Brenneisen R, Jones АВ. Coca paste: Chemical analysis and smoking experiments. J Forens Sci 1991;36:93-103.
Cravey RH. Cocaine deaths in infants. J Anal Toxicol 1988;12:354-355.
Garland JS, Smith DS, Rice ТВ, Siker D. Accidental cocaine intoxication in a nine-month-old infant: Presentation and treatment. Pediatr Emerg Care 1989;5:245— 247.
Edlin BR, Irwin KL, Faruque S, et al. Intersecting epidemics: Crack cocaine use and HIV infection among inner-city young adults. N Engl J Med 1994.
Lovejoy FH Jr, Shannon M, Woolf AD. Recent advances in clinical toxicology. Curr Prob Pediatr 1992,22:119— 129.
Stumer WQ, Sweeney KG, Gallery RT, Haley NR. Cocaine babies: The scourge of the 90s. J Forens Sci 1991;36:34-39.
Meeker J E, Reynolds PC. Fetal and newborn death as sociated with maternal cocaine use. J Anal Toxicol 1990;14:379-382.
Chasnoff IJ, Burns KA, Burns WJ. Cocaine use in pregnancy: Perinatal morbidity and mortality. Neurotoxicol Teratol 1987;9:291-293.
Durand DJ, Espinoza AM, Nickerson BG. Association between prenatal cocaine exposure and sudden infant death syndrome. J Pediatr 1990;! 17:909—911.
Chasnoff 1J, Hunt CE, Kletter R, Kaplan D. Prenatal cocaine exposure is associated with respiratory pattern abnormalities. Am J Dis Child 1989;143:583-587.
Bauchner H, Zuckerman B. Cocaine, sudden infant death syndrome, and home monitoring. J Pediatr 1990;117:904-906.
Bauchner H, Zuckerman B, McClain M, et al. Risk of sudden infant death syndrome among infants with in utero exposure to cocaine. J Pediatr 1988; 113:831—834.
Rosenberg NM, Meert KL, Knazik SR, et al. Occult cocaine exposure in children. Am J Dis Child 1991;145:1430-1432.
Kharasch SJ, Glotzer D, Vinci R, et al. Unexplained cocaine exposure in young children. Am J Dis Child 1991;145:204-206.
Dinnies JD, Darr CD, Saulys AJ. Cocaine toxicity in toddlers. Am J Dis Child 1990;144:743-744.
Heagarty MC. Crack cocaine: A new danger for children. Am J Dis Child 1990;144:756-757.
Conway EE, Mezey AP, Powers K. Status epilepticus following the oral ingestion of cocaine in an infant. Pediatr Emerg Care 1990;6:189-190.
Riggs D, Weibley RE. Acute hemorrhagic diarrhea and cardiovascular collapse in a young child owing to environmentally acquired cocaine. Pediatr Emerg Care 1991;7:154-155.
Shannon M, Lacouture PG, Roa J, Woolf A. Cocaine exposure among children seen at a pediatric hospital. Pediatrics 1989;83:337-342.
Bateman DA, Heagarty MC. Passive freebase cocaine ("crack"): Inhalation by infants and toddlers. Am J Dis Child 1989;143:25-27.
Bouknight LG, Bouknight RR. Cocaine: A particularly addictive drug. Postgrad Med 1988;83:122.
Brewer LM, Allen A. N-Formylcocaine: A study of cocaine comparison parameters. J Forens Sci 1991;36:697-707.
Janzen KE. Ethyibenzoylecgonine: A novel component in illicit cocaine. J Forens Sci 1991;36:1224-1228.
EnsingJG, Hummelen JC. Isolation, identification and origin of three previously unknown congeners in illicit cocaine. J Forens Sci 1991;36:1666-1687.
Ensing JG, de Zeeuw RA. Detection, isolation and identification of truxilles in illicit cocaine by means of thin layer chromatography and mass spectrometry. J Forens Sci 1991;36:1299-1311.
Casale JF. Detection of pseudoecgonine and differentiation from ecgonine In illicit cocaine. Forens Sci Int 1990;47:277-287.
Le Belle M, Callahan S, Latham D, et al. Comparison of illicit cocaine by determination of minor components. J Forens Sci 1991 ;36:1102-1120.
Casale JF, Waggoner RW Jr. A chromatographic impurity signature profile analysis for cocaine using capillary gas chromatography. J Forens Sci 1991; 36: 1312— 1330.
U. S. Drug Enforcement Administration. Los Angeles Times, December 20, 1994, p. A21.
Miller NS, Klahr AL, Gold MS, et al. The prevalence of marijuana (cannabis) use and dependence in cocaine dependence. NY State J Med 1990;90:491-492.
Rich JA, Singer DE. Cocaine-related symptoms in patients presenting to an urban emergency department. Ann Emerg Med 1991;20:616-621.
Laposata ЕА, Mayo GL. A review of pulmonary pathology and mechanisms associated with inhalation of free-base cocaine ("crack"). Am J Forens Med Pathol 1993;14:1-9.
Jacob P, Jones RT, Benowitz NL, et al. Cocaine smokers excrete a pyrolysis product, anhydroecgonine methyl ester. Clin Toxicol 1990;28:121-125.
Jacob P, Lewis ER, Elias-Baker BA, Jones RT. A pyrolysis product, anhydroecgonine methyl ester (methylecgonidine), is in the urine of cocaine smokers. J Anal Toxicol 1990;14:353-357.
Merigian KS, Park LJ, Leeper KW, et al. Adrenergic crisis from crack cocaine ingestion: Report of five cases. J Emerg Med 1994;12:485-490.
Paly D, Jatlow P, Van Dyke C, et al. Plasma cocaine concentrations during cocaine pack smoking. Life Sci 1982;30:731-738.
Tendrup ТЕ, Walls HC, Mariani PJ, et al. Plasma cocaine and tetracaine levels following application of topical anesthesia in children. Ann Emerg Med 1992;21:162-166.
Zhang JY, Foltz RL. Cocaine metabolism in man: Identification of four previously unreported cocaine metabolites in human urine. J Anal Toxicol 1990;14:201-205.
Burke WM, Ravi NV. Urinary excretion of cocaine. Ann Intern Med 1990;112:548-549.
Martin BR, Lue LP, Boni JP. Pyrolysis and utilization of cocaine. J Anal Toxicol 1989;13:158-162.
Jackson GF, Snady JJ, Poklis A. Urinary excretion of benzoylecgonine following ingestion of Health Inca Tea. Forens Sci Int 1991;49:57-64.
Altieri M, Bogema S, Schwartz RH. TAC topical anesthetic produces positive urine tests for cocaine. Ann Emerg Med 1990;19:577-579.
Handler A, Kiston N, Davis F, Ferri C. Cocaine use during pregnancy: Perinatal outcomes. Am J Epidemiol 1991;133:818-825.
Collins E, Hardwich RJ, Jeffrey H. Perinatal cocaine intoxication. Med J Aust 1989;150:331-334.
Chasnoff I, Griffith DR, MacGregor S, et al. Temporal patterns of cocaine use in pregnancy: Perinatal outcome. JAMA 1989;261:1741-1744.
Hadeed AJ, Siegel SR. Maternal cocaine use during pregnancy: Effect on the newborn infant. Pediatrics 1989;84:205-210.
Rosenak D, Diamont YZ, Haffe H, Hornstein E. Cocaine: maternal use during pregnancy and its effect on the mother, the fetus, and the infant. Obstet Gynecol Surv 1990;45:348-359.
Telsey AM, Merrit A, Dixon SD. Cocaine experience in a term neonate: Necrotizing enterocolitis as a complication. Clin Pediatr 1988;27:547-550.
Spinazzola R, Kenigsberg K, Usmani SS, Harper RG. Neonatal gastrointestinal complications of maternal cocaine abuse. NY State J Med 1992;92:22-23.
Van den Anker JN, Cohen-Overbeek ТЕ, Wladimiroff JW, Sauer PJJ. Prenatal diagnosis of limb reduction defects due to maternal cocaine use. Lancet 1991 ;338: 1332.
Hoyme HE, Lyons Jones K, Dixon SD, et al. Prenatal cocaine exposure and fetal vascular disruption. Pediatrics 1990;85:743-747.
Lyons Jones K. Developmental pathogenesis of defects associated with prenatal cocaine exposure: Fetal vascular disruption. Clin Perinatol 1991;18:139-146.
Hannig VL, Phillips JA III. Maternal cocaine abuse and fetal anomalies: Evidence for teratogenic effects of cocaine. Sotith Med J 1991;84:498-499.
Spires MC, Gordon EF, Choudhuri M, et al. Intracranial hemorrhage in a neonate following prenatal cocaine exposure. Pediatr Neurol 1989;5:324-326.
Maynard EC, Dreyer SA, Oh W. Prenatal cocaine exposure and hyaline membrane disease (HMD). Pediatr Res 1989;24:223A.
Zuckerman B, Maynard EC, Cabral H. A preliminary report of prenatal cocaine exposure and respiratory distress syndrome in premature infants. Am J Dis Child 1991;145:695-698.
Kain ZN, Kain TS, Scarpell EM. Cocaine exposure in utero: Perinatal development and neonatal manifestations — review. Clin Toxicol 1992;30:607-636.
Young SL, Vosper HJ, Phillips SA. Cocaine: Its effects on maternal and child health. Pharmacotherapy 1993;12:2-17.
Zuckerman B, Frank DA. Prenatal cocaine exposure: Nine years later. J Pediatr 1994;124:731-733.
Griffith DR, Azuma SD, Chasnoff IJ. Three-year outcome of children exposed prenatally to drugs. J Am Acad Child Adolescent Psychiatry 1994;33:20-27.
Kliegman RM, Madura D, Kiwi R, et al. Relation of maternal cocaine use to the risks of prematurity and low birthweight. J Pediatr 1994;124:751-756.
Singer LT, Yamashita TS, Hawkins S, et al. Increased incidence of intraventricular hemorrhage and developmental delay in cocaine-exposed, very low birthweight infants. J Pediatr 1994;124:756-771.
Chasnoff IJ, Griffith DR, Frier C, Murray J. Cocaine/ polydrug use in pregnancy: Two year follow-up. Pediatrics 1992;89:284-289.
Simone C, Derewlany LO, Oskamp M, et al. Transfer of cocaine and benzoylecgonine across the perfused human placental cotyledon. Am J Obstet Gynecol 1994;170:1404-1410.
Schenker S, Yang Y, Johanson RF, et al. The transfer of cocaine and its metabolites across the term human placenta. Clin Pharmacol Ther 1993;53:329-339.
Koren G. Personal communication.
Plessinger MA, Woods JR Jr. The cardiovascular effects of cocaine use in pregnancy. Reprod Toxicol 1991 ;5:99— 113.
Slutsker L. Risks associated with cocaine use during pregnancy. Obstet Gynecol 1992;79:778-779.
Graham KA, Dimitrakoudis D, Pellegrini E, Koren G. Outcome of pregnancy after first trimester exposure to cocaine. Vet Hum Toxicol 1988;30:376.
Koren G, Graham K. Cocaine in pregnancy. Vet Hum Toxicol 1992;34:263-265.
Astley SJ, Clarren SK, Little RE, et al. Analysis of facial shape in children gestationally exposed to marijuana, alcohol and/or cocaine. Pediatrics 1992;89:67-77.
Plessinger MA, Woods JR Jr. Maternal placental and fetal pathophysiology of cocaine exposure during pregnancy. Clin Obstet Gynecol 1993;36:267-278.
Chasnoff IJ, Lewis DE, Squires L. Cocaine intoxication in a breast fed infant. Pediatrics 1987;80:836-838.
Giacoia GP. Cocaine in the cradle: A hidden epidemic. South Med J 1990;83:947-951.
Chaney NE, Franke J, Wadlington WB. Cocaine convulsions in a breast-feeding baby. J Pediatr 1988;112:134-135.
Graham K, Dimitrakoudis D, Pellegrini E, Koren G. Pregnancy outcome following first trimester exposure to cocaine in social users in Toronto, Canada. Vet Hum Toxicol 1989;31:143-148.
Browne SP, Tebbett JR, Moore SM, et al. Analysis of meconium for cocaine in neonates. J Chromatogr Biomed Appl 1992;575:158-161.
Callahan GM, Grant TM, Phipps P, et al. Measurement of gestational cocaine exposure: Sensitivity of infants’ hair, meconium and urine. J Pediatr 1992;120:763-768.
Clark GD, Rosenzweig IB, Raisys VA, et al. The analysis of cocaine and benzoylecgonine in meconium. J Anal Toxicol 1992;16:261-263.
Casanova OQ, Lombardero N, Behnke M, et al. Detection of cocaine exposure in the neonate: Analyses of urine, meconium and amniotic fluid from mothers and infants exposed to cocaine. Arch Pathol Lab Med 1994;118:988-993.
Welch E, Fleming LE, Peyser I, et al. Rapid cocaine screening of urine in a newborn nursery. J Pediatr 1993;123:468-470.
Ahluwalia SS, Clark JFJ, Westney SL, et al. Amniotic fluid and umbilical artery levels of hormone and prostaglandins in human users. Reprod Toxicol 1992;6:57-62.
Zuckerman B, Bresnahan K. Developmental and behavioral consequences of prenatal drug and alcohol exposure. Pediatr Clin North Am 1991;38:1387-1406.
Zuckerman B, Frank DA. "Crack kids" not broken. Pediatrics 1992;89:337-339.
Chasnoff IJ, Burns WJ, Schnoll SH, et al. Cocaine use in pregnancy. N Engl J Med 1985;313:666-669.
Volpe JJ. Effect of cocaine use on the fetus. N Engl J Med 1992;327:399-407.
Kramer LD, Locke GE, Ogunyemi A, Nelson L. Neonatal cocaine-related seizures. J Child Neurol 1990;5:60-64.
Foltin RW, Fischman MW, Pedroso JJ, Pearlson GD. Marijuana and cocaine interactions in humans: Cardiovascular consequences. Pharmacol Biochem Behav 1987;28:459-464.
Anton AH. Unexpected cocaine-induced fatalities: A possible cause. Drug Intell Clin Pharm 1988;22:914.
Hoftman RS, Henry GC, Howland MA, et al. Association between life-threatening cocaine toxicity and plasma cholinesterase activity. Ann Emerg Med 1992;21:247—253.
Jatlow P, Barash PG, Van Dyke C, et al. Cocaine and succinylcholine sensitivity: A new caution. Anesth Analg 1978;58:235-238.
Delaney K, Hoffman RS. Effects of cocaine on the in vitro determination of plasma cholinesterase activity: Analysis of kinetics of inhibition. Vet Hum Toxicol 1991;33:385.
Devenyi P: Cocaine complications and pseudocholinesterase. Ann Intern Med 1989;110:167-168.
Henry GC, Hoffman RS, Thompson T, et al. Effects of low dose short-term cocaine use on human plasma cholinesterase activity. In: Proceedings, International Congress on Clinical Toxicology, New York, September 8— 13, 1993: Abstract 132.
Hershman Z, Aaron C. Prolongation of cocaine effect. Anesthesiology 1991;74:631-632.
Derlet RW, Albertson ТЕ. Potentiation of cocaine toxicity with calcium channel blockers. Am J Emerg Med 1989;7:464-468.
Dean RA, Harper ET, Dumaual N, et al. Effects of ethanol on cocaine metabolism: Formation of cocaethylene and norcocaethylene. Toxicol Appl Pharmacol 1992;117:1-8.
Lewis D, Muldoon K, Leikin JB. Cocaethylene in meconium specimens. Vet Hum Toxicol 1993;35:351.
Hime GW, Hearn WL, Rose S, Cofino J. Analysis of cocaine and cocaethylene in blood and tissues of GC-NPD and GC-ion trap mass spectrometry. J Anal Toxicol 1991;15:241-245.
Hearn WL, Hime GW, Cofino J, Rose S. Detection of cocaethylene as a major metabolite. In: Proceedings, American Academy of Forensic Sciences, February 18—23, /997:174 (Abstract KI 8).
De la Torre R, Farre M, Ortuno J, et al. The relevance of urinary cocaethylene following the simultaneous administration of alcohol and cocaine. J Anal Toxicol 1991;15:223.
Rose S, Cofino J, Hearn WL, Hime GW. Investigation of the metabolite formation of cocaethylene. In: Proceedings, American Academy of Forensic Sciences, February 18—23, 1991:114 (Abstract K19).
Uszenski RT, Grillis RA, Schaer GL, et al. Additive myocardial depressant effects of cocaine and ethanol. Am Heart J 1992;124:1276-1283.
Randall T. Cocaine, alcohol mix in body to form even longer lasting, more lethal drug. JAMA 1992;267:1043— 1044.
Pirwitz MJ, Willard JE, Landau C, et al. Influence of cocaine, ethanol or their combination on epicardial coronary arterial dimensions in humans. Arch Intern Med 1995;155:1186-1191.
Hearn WL, Rose S, Wagner J, et al. Cocaethylene is more potent than cocaine in mediating lethality. Pharmacol Biochem Behav 1991;39:531-533.
Mash DC, Flynn DD, Wetli CV, Hearn WL. Potency of cocaethylene at monoamine neurotransmitter uptake sites and neuroreceptors in the human brain. In: Proceedings, American Academy of Forensic Sciences, February 18—23, 1991Л14 (Abstract K20).
Woodward JJ, Mansbach R, Carroll Fl, Balster RL. Cocaethyiene inhibits dopamine uptake and produces cocaine-like actions in drug discrimination studies. Eur J Pharmacol 1991;197:235-236.
Wu AHB, Onigbirde TA, Johnson KG, Winbish GH. Alcohol specific cocaine metabolites in serum and urine of hospitalized patients. J Anal Toxicol 1992;16:132-136.
Brookoff D, Shaw L, Campbell E, Fields L. Cocaethylene, cocaine and ethanol levels in trauma patients. Ann Emerg Med 1993;22:989.
Lewis DE. Cocaethylene in meconium specimens. J Toxicol Clin Toxicol 1994;32:697-703.
Kissner DG, Lawrence WD, Selis JE, Flint A. Crack lung: Pulmonary disease caused by cocaine abuse. Am Rev Respir Dis 1987;136:1250-1252.
Samuels J, Schwalbe SS, Marx GF. Speedballs: A new cause for intraoperative tachycardia and hypertension. Anesth Analg 1991;72:397-398.
Merigian KS. Cocaine-induced ventricular arrhythmias and rapid atrial fibrillation temporally related to naloxone administration. Am J Emerg Med 1993.
Shesser R, Jotte P, Olshaker J. The contribution of impurities in the acute morbidity of illegal drug use. Am J Emerg Med 1991;9:336-342.
Katz A, Hoffman RS, Silverman R. Phenytoin toxicity from smoking "crack" cocaine adulterated with dilantin. Vet Hum Toxicol 1992;34:347.
Pascual-Leone A, Dhuna A, Anderson DC. Long term neurological complications of chronic habitual cocaine abuse. Neurotoxicology 1991;12:393-402.
Chambers HF, Morris L, Tauber MG, Modin G. Cocaine use and the risk for endocarditis in intravenous drug users. Ann Intern Med 1987;106:833-836.
Rezkalla SH, Hale S, Kloner RA. Cocaine-induced heart disease. Am Heart J 1990;120:1403-1408.
Henter DC. Cardiovascular effects of cocaine. JAMA 1987;257:979-980.
Lange RA, Cigarroa RG, Yancy CW Jr, et al. Cocaine-induced coronary artery vasoconstriction. N Engl J Med 1989;321:1557-1562.
Majid P, Cheirif JB, Rolley R, et al. Does cocaine cause coronary vasospasm in chronic cocaine abuser? A study of coronary and systemic hemodynamics. Clin Cardiol 1992;15:253-258.
Chitwood DD. Patterns and consequences of cocaine use. Natl Inst Drug Abuse Res Monogr Ser 1985;61:111-129.
Boehrer JD, Moliterno DJ, Willard JE, et al. Hemodynamic effects of intranasal cocaine in humans. J Am Coll Cardiol 1992;20:90-93.
Konkol RJ, Olsen GD, Aks S, et al. Gastric alkalinization in the treatment of cocaine toxicity. Ann Emerg Med 1993;22:1238-1239.
Godwin JE, Harley RA, Miller KS, Hefner JE. Cocaine, pulmonary hemorrhage, and hemoptysis. Ann Intern Med 1989;! 10:843.
Murray R, Smiaiek J, Golle M, et al. Pulmonary vascular abnormalities in cocaine users. Am Rev Respir Dis 1988; 137:459.
Suhl J, Gorelick A. Pulmonary function in male freebase cocaine users. Am Rev Respir Dis 1988; 137:488.
Tashkin DP, Khalsa M-E, Gorelick D, et al. Pulmonary status of habitual cocaine smokers. Am Rev Respir Dis 1992;145:92-100.
Greenebaum E, Copeland A, Grewal R. Blackened bronchoalveolar lavage fluid in crack smokers: A preliminary study. Am J Clin Pathol 1993;100:481-487.
Marks V, Chapple PAL. Hepatic dysfunction in heroin and cocaine users. Br J Addict 1967;62:189-195.
Wanless IR, Dore S, Gopinath N, et al. Histopathology of cocaine hepatotoxicity: Report of four patients. Gastroenterology 1990;98:497-501.
Comer GM, Mittal MK, Donelson SS, Lee T-P. Cluster of fulminant hepatitis В in crack users. Am J Gastroenterol 1991;86:331-334.
Wasserberger J, Ellenhorn MJ, Landers S, et al. The emergency management of acute cocaine toxicity. Top Emerg Med 1993;15:27-40.
Klosten TR, Kleber HD. Rapid death during cocaine abuse: A variant of the neuroleptic malignant syndrome? Am J Drug Alcohol Abuse 1988;14:335-346.
Benowitz NL. Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 1993;72:3-12.
Prahlow JA, Davis GJ. Death due to cocaine intoxication initially thought to be a homicide. South Med J 1994;87:295-298.
Burkett G, Bandstra ES, Cohen J, et al.: Cocaine-related maternal death. Am J Obstet Gynecol 1990;163:40-41.
Chiasson MS, Stoneburner RL, Hidebrand DS, et al. Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack). AIDS 1991;5:1121.
Goldfrank L. Consultations. Ann Emerg Med 1987;16:240.
Lange RE, Flores EP, Cigarroa RG, Hillis LD. Cocaine-induced myocardial ischemia and infarction. Cardiology 1990;8:74-79.
Gitter MJ, Goldsmith SR, Dunbar DN, Sharkey SW. Cocaine and chest pain: Clinical features and outcome of patients hospitalized to rub out myocardial infarction. Ann Intern Med 1991;115:277-282.
Hollander JE, Hoffman RS. Cocaine-induced myocardial infarction: An analysis and review of the literature. J Emerg Med 1992;10:169-177.
Hollander JE, Carter WA, Hoffman RS. Use of phentolamine for cocaine-induced myocardial ischemia. N Engl J Med 1992;327:361.
Minor RL Jr, Winniford MD. Cocaine and coronary artery thrombosis. Ann Intern Med 1992; 116:776— 777.
Minor RL Jr, Scott BD, Brown DD, Winniford MD. Cocaine-induced myocardial infarction in patients with normal coronary arteries. Ann Intern Med 1991;115:797-806.
Brogan WC III, Lange RA, Glamann B, Hillis LD. Recurrent coronary vasoconstriction caused by intranasal cocaine: Possible role for metabolites. Ann Intern Med 1992;116:556-561.
Flores ED, Lange RA, Ciguaroa RG, et al. Effect of cocaine on coronary artery dimensions in atherosclerotic coronary artery disease: Enhanced vasoconstriction at sites of significant stenoses. J Am Coll Cardiol 1990;16:74-79.
Hoekstra JW. Diagnosis of myocardial ischemia and infarction. Acad Emerg Med 1994;1:143-146.
Tokarski GF, Paganussi P, Urbanski R, et al. An evaluation of cocaine-induced chest pain. Ann Emerg Med 1990;19:1088-1092.
Brody SL, Slovis CM, Wrenn KD. Cocaine-related medical problems: Consecutive series of 233 patients. Am J Med 1990;88:325-331.
Hollander JE, Hoffman RS, Gennis P, et al. Prospective multicenter evaluation of cocaine-associated chest pain. Acad Emerg Med 1994;1:330-339.
Hedges JR, Young GP, Henkel GK, et al. Early CK-MB elevations predict ischemic events in stable chest pain patients. Acad Emerg Med 1994;1:9-16.
Hollander JE, Hoffman RS, Fairweather P, et al. Cocaine associated chest pain: Long term follow-up. Vet Hum Toxicol 1993;35:350.
Southern JF. Case records of the Massachusetts General Hospital: Case 15-1988. N Engl J Med 1988;318:970-981.
Hogya PT, Wolfson AB. Chronic cocaine abuse associated with dilated cardiomyopathy. Am J Emerg Med 1990;8:203-204.
Karch SB, Billingham ME. The pathology and etiology of cocaine-induced heart disease. Arch Pathol Lab Med 1988;112:225-230.
Chokshi SK, Moore R, Pandian NG, Isner JM. Reversible cardiomyopathy associated with cocaine intoxication. Ann Intern Med 1989;111:1039—1040.
Tapia JF. Weekly clinicopathological exercises: Case 27-1993. N Engl J Med 1993;329:117-124.
Sloan MA, Kittner JK, Rigamonti D, Puce TR. Occurrence of stroke associated with use/abuse of drugs. Neurology 1991;41:1358-1364.
Kaku DA, Lowenstein DH. Emergence of recreational drug abuse as major risk factor for stroke in young adults. Ann Intern Med 1990;1 13:821-827.
Levine SR, Brust JCM, Futrell N, et al. Cerebrovascular complication of the use of the "crack" form of alkaloidal cocaine. N Engl J Med 1990;323:699-704.
Levine SR, Brust JCM, Futrell N, Brass LM, et al. A comparative study of the cerebrovascular complications of cocaine: Alkaloidal versus hydrochloride — a review. Neurology 1991;41:1173-1177.
Peterson PL, Roszler M, Jacobs I, Wihier Hl. Neurovascular complications of cocaine abuse. J Neuropsychiatry 1991;3:143-149.
Krendel DA, Ditter SM, Frankel MR, Ross WK. Biopsy-proven cerebral vasculitis associated with cocaine abuse. Neurology 1990;40:1092-1094.
Mody CK, Miller BL, McIntyre HB, et al. Neurological complications of cocaine abuse. Neurology 1988;38:1189-1 193.
Spivey WH, Euerle B. Neurologic complications of cocaine abuse. Ann Emerg Med 1990;19:1422-1428.
Chasnoff IJ, Bussey ME, Savich R, Stack CM. Perinatal cerebral infarction and maternal cocaine use. J Pediatr 1986;108:456-459.
Chasnoff IJ, MacGregor S. Maternal cocaine use and neonatal morbidity. Pediatr Res 1987;21:356A.
Lowenstein DH, Massa SM, Rowbotham MC, et al. Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med 1987;83:841-846.
Dhuna A, Pascual-Leone A, Langendorf F, Anderson DC. Epileptogenic properties of cocaine in humans. Neurotoxicology 1991; 12:621 —626.
Ernst АА, Sanders WM. Unexpected cocaine intoxication presenting as seizures in children. Ann Emerg Med 1989;18:774-777.
Krug SE, Marble RD, Lubitz DL, Long TJ. Screening for cocaine intoxication in children with unexplained seizures in the emergency department. Ann Emerg Med 1991;20:448.
Jonsson S, O’Meara M, Young JB. Acute cocaine poisoning. Am J Med 1983;75:1061-1064.
Cooper LJ, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. New York: Oxford University Press, 1986.
Roberts JR. Discussion. In: Year Book of Emergency Medicine. Chicago: Year Book, 1991:182.
Pearigen PD. Medical complications of cocaine abuse. N Engl J Med 1986;315:1495-1500.
Pascual-Leone A, Dhuna A. Cocaine-associated multifocal tics. Neurology 1990;40:999-1000.
Hegarty AM, Lipton RB, Meriam AE, Freeman K. Cocaine as a risk factor for acute dystonic reactions. Neurology 1991;41:1670-1672.
Habal R, Sauter D, Olowe O, Duras M. Cocaine and chorea. Am J Emerg Med 1991;9:618-620.
Rao AN. Brain abscess: A complication of cocaine inhalation. NY State J Med 1988;88:548-550.
Pascual-Leone A, Dhuma A, Anderson DC. Cerebral atrophy in habitual cocaine abusers: A planimetric CT study. Neurology 1991;41:34-38.
Sporer KA, Lesser SH. Cocaine washed-out syndrome. Ann Emerg Med 1992;21:112.
Pollack CV, Biggers DW, Carlton FB Jr, et al. Two crack cocaine body stuffers. Ann Emerg Med 1992;21:1370— 1380.
Roberts JR, Wason S, Merigian KS. Crackpacking: A new radiographic diagnosis. Ann Emerg Med 1989;18:800-801.
Riggs D, Weibley RE. Acute toxicity from oral ingestion of crack cocaine: A report of four cases. Pediatr Emerg Care 1990;6:24-26.
Makosiej FJ, Hoffman RS, Howland MA, Goldfrank LR. An in vitro evaluation of cocaine hydrochloride absorption by activated charcoal and desorption upon addition of polyethylene glycol electrolyte lavage solution. Clin Toxicol 1993;31:381-395.
Introna F Jr, Smialek JE. The "mini-packer" syndrome: Fatal ingestion of drug containers in Baltimore, Maryland. Am J Forens Med Pathol 1989;10:21-24.
Vilensky W. Illicit and licit drugs causing perforation of the nasal septum. J Forens Sci 1982;27:958-962.
Slavin SA. The cocaine user: The potential problem patient for rhinoplasty. Plast Reconstr Surg 1990;86:436— 442.
Berciano J, Oterino A, Rebollo M, Pascual J. Myasthenia gravis unmasked by cocaine abuse. N Engl J Med 1991 ;326:892.
Wang SJ. Cocaine-induced iritis. Ann Emerg Med 1991;20:192-193.
Cohen S. Cocaine: Acute medical and psychiatric complications. Psychiatr Ann 1984;14:747-749.
Newman NM, DiLoreto DA, Ho JT, et al. Bilateral optic neuropathy and osteolytic sinusitis: Complications of cocaine abuse. JAMA 1988;259:72-74.
Schweitzer VG. Osteolytic sinusitis and pneumomediastinum: Deceptive otolaryngological complications of cocaine abuse. Laryngoscope 1985;96:206-210.
Kudrow DB, Henry DA, Haake DA, etal. Botulism associated with Clostridium botulinum sinusitis after intranasal cocaine abuse. Ann Intern Med 1988; 109:984— 985.
Cooper CB, Bai TR, Heyderman E, et al. Cellulose granulomas in the lung of a cocaine sniffer. Br Med J 1983;286:2021-2022.
Sawicka EH, Trosser A. Cerebrospinal fluid rhinorrhea after cocaine sniffing. Br Med J 1983;286:1476-1477.
Krutchkoff DJ, Eisenberg E, O’Brien JE, Ponzillo JJ. Cocaine induced dental erosion. N Engl J Med 1990;322:408.
Dick AD, Prentice MG. Cocaine and acute porphyria. Lancet 1987;2:1150.
Leissinger CA. Severe thrombocytopenia associated with cocaine use. Ann Intern Med 1990;112:708-709.
Devenyi P, Schneiderman JF, Devenyi RG, Lawby L. Cocaine induced central retinal artery occlusion. Can Med Assoc J 1988;138:129-130.
Joseph SC. A methadone clone for cocaine. New York Times, January 11, 1989.
Farrell M. Cocaine and HIV. Br Med J 1991 ;3O3:33O.
Nanda D, Feldman J, Deike I, et al. Syphilis among parturients at an inner city hospital: Association with cocaine use and implications for congenital syphilis rates. NY State J Med 1990;90:448-490.
Minkoff HL, McCalla S, Delke I, et al. The relationship of cocaine use to syphilis and human immunodeficiency virus infections among inner city parturient women. Ob-stet Gynecol 1990;163:521-526.
Marmor M, Des Jarlais DC, Cohen H, et al. Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS 1987;1:39-44.
Weiss SH. Links between cocaine and retroviral infection. JAMA 1989;261:607-608.
Marmor M. Friedman-Kiens E, Laubenstein L, et al. Risk factors to Kaposi’s sarcoma in homosexual men. Lancet 1982;1:1083-1086.
Biggar RJ, Melbye M, Elbesen P, et al. Low T-lymphocyte ratios in homosexual men. JAMA 1984;251:1441-1446.
Welch RD, Todd K, Krause GS. Incidence of cocaine-associated rhabdomyolysis. Ann Emerg Med 1991;20:154-157.
Merigian K, Roberts JR. Cocaine intoxication: Hyperpyrexia, rhabdomyolysis and acute renal failure. Clin Toxicol 1987;25:135-148.
Shessor R, Davis C, Edelstein S. Pneumomediastinum and pneumothorax after inhaling alkaloidal cocaine. Ann Emerg Med 1981;10:213-215.
Ettinger NA, Albin RJ. A review of the respiratory effects of smoking cocaine. Am J Med 1989;87:655.
Tashkin DP, Khalsa M-E, Gorelick D, et al. Pulmonary status of habitual cocaine smokers. Am Rev Respir Dis 1992;145:92-100.
Larkin RF. The callus of crack cocaine. N Engl J Med 1990;323:685.
Burton KR, Marin CA, Murray FT, Muniz CE. Hyperthyroidism in a cocaine-dependent patient. J Clin Psychiatry 1989;50:305-306.
Goetz C, Harchelroud F. Severe hypocalcemia associated with cocaine-induced rhabdomyolysis. Vet Hum Toxicol 1991;33:387.
Lombard J, Levin 1H, Weiner WJ. Arsenic intoxication in a cocaine abuser. N Engl J Med 1989;320:869.
Mahler JC, Perry S, Sutton B. Intraurethral cocaine administration JAMA 1988;259:3126.
Del Aguila C, Rosman H. Myocardial infarction during cocaine withdrawal. Ann Intern Med 1990;! 12:712.
Levine MAH, Nishikawa J. Acute myocardial infarction associated with cocaine withdrawal. Can Med Assoc J 1991;144:1139-1140.
Nademanee K, Gorelick DA, Josephson MA, et al. Myocardial ischemia during cocaine withdrawal. Ann Intern Med 1989;111:876-880.
Choy-Kwong M, Lipton RB. Dystonia related to cocaine withdrawal: A case report and pathogenic hypothesis. Neurology 1989;39:996-997.
Miller NS, Summers GL, Gold MS. Cocaine dependence: Alcohol and other drug dependence and withdrawal characteristics. J Addict Dis 1993;12:25-35.
Stine SM, Burns B, Kosten T. Methadone dose for cocaine abuse. Am J Psychiatry 1991; 148:1268.
Wallace JE, Hamilton HE, Christenson JG, et al. An evaluation of selected methods for determining cocaine and benzoylecgonine in urine. J Anal Toxicol 1977;1:20-25.
Budd RD, Mathis DF, Yang FC. TLC analysis of urine for benzoylecgonine and norpropoxyphene. Clin Toxicol 1980;16:1-5.
Rafia FK, Epstein RL. Identification of cocaine and its metabolites in human urine in the presence of ethyl alcohol. J Anal Toxicol 1979;3:59-63.
Kogan MJ, Verebey KG, De Pace AC, et al. Quantitative determination of benzoylecgonine and cocaine in human biofluids by gas-liquid chromatography. Anal Chem 1977;49:1965-1969.
Wallace JE, Hamilton HE, King DE, et al. Gas-liquid chromatographic determination of cocaine and benzoylecgonine in urine. Anal Chem 1976;48:34-48.
Masoud AN, Knipski DM. High performance liquid chromatographic analysis of cocaine in human plasma. J Anal Toxicol 1980;4:305-310.
Jatlow P. Cocaine: Analysis, pharmacokinetics and metabolic disposition. Yale J Biol Med 1988;61:105-113.
Schramm W, Craig PA, Smith RH. Berger GE. Cocaine and benzoylecgonine in saliva, serum and urine. Clin Chem 1993;39:481-487.
Harkey MR, Henderson GL, Zhou C. Simultaneous quantitation of cocaine and its major metabolites in human hair by gas chromatography/chemical ionization mass spectrometry. J Anal Toxicol 1991;15:260-265.
Cone EJ, Youselnejad D, Darwin WD, Maguire T. Testing human hair for drugs of abuse: II. Identification of unique cocaine metabolites in hair of drug abusers and evaluation of decontamination procedures. J Anal Toxicol 1991;15:250-255.
Reuschel SA, Smith FP. Benzoylecgonine (cocaine metabolite) detection in hair sample of jail detainees using radioimmunoassay (RIA) and gas chromatography/mass spectrometry (GC/MS). J Forens Sci 1991;36:1179— 1185.
Martz R, Donnelly B, Fetterolf D, et al. The use of hair analysis to document a cocaine overdose following sustained survival period before death. J Anal Toxicol 1991;15:279-281.
Koren GB, Klein J, Forman R, Graham K. Hair analysis of cocaine: Differentiation between systemic exposure and external contamination. J Clin Pharmacol 1992;32:671-675.
Graham K, Koren G, Klein J, et al. Determination of gestational cocaine exposure by hair analysis. JAMA 1989;262:3328-3330.
Ttinier WA, Reuland DJ. Unequivocal determination of cocaine in simulated street drugs by a combination of high performance liquid chromatography and infrared spectrophotometry. J Forens Sci 1978;23:37-43.
Rosenberg NM, Meert KL, Knazik S, et al. Occult cocaine exposure. Pediatr Emerg Care 1991 ;7:393.
Isner JM, Estes NAM, Thompson PD, et al. Acute cardiac event temporally related to cocaine abuse. N Engl J Med 1986;315:1438-1443.
Malbrain MLMG, De Medts P, Wanters A, et al. Drug smuggler’s delirium. Br Med J 1993;306:102.
Madder JA, Powers RH. Effect of cocaine and cocaine metabolites on cerebral arteries in vitro. Life Sci 1990;44:1109-1114.
Jain L, Meyer W, Moore C, et al. Detection of fetal cocaine exposure by analysis of amniotic fluid. Obstet Gynecol 1993;81 (p 1):787—790.
Szeti HH. Kinetics of drug transfer to the fetus. Clin Obstet Gynecol 1993;36:246-254.
Chakko S, Sepulveda S, Kessler KM, et al. Frequency and type of electrocardiographic abnormalities in cocaine abusers (electrocardiogram in cocaine abuse). Am J Cardiol 1994;74:710-713.
Watson WA, Stevens DK, Campbell J P, Carter J E. Acidbase effects associated with cocaine use in emergency department (ED) patients. Personal communication at Scientific Meeting of European Association of Poison Centers and Clinical Toxicologists, Birmingham, UK, May 26-28, 1993.
Stevens DC, Campbell JP, Carter JE, Watson WA. Acidbase abnormalities associated with cocaine toxicity in emergency department patients. Clin Toxicol 1994;32:31-39.
Foltin RW, Fischman MW. Smoked and intravenous cocaine in humans: Acute tolerance, cardiovascular and subjective effects. J Pharmacol Exp Ther 1991 ;257:247— 261.
Hamilton HE, Wallace JE, Shimak EL, et al. Cocaine and benzoylecgonine excretion in humans, J Forens Sci 1977;22:697-707.
Osterloh J. Testing for drugs of abuse: Pharmacokinetic considerations for cocaine in urine. Clin Pharmacokinet 1993;24:355-361.
Baselt RC, Chang JY, Yoshikawa DM. On the dermal absorption of cocaine. J Anal Toxicol 1990;14:383-384.
Dixon SD, Bejar R. Echoencephalographic findings in neonates associated with maternal cocaine and amphetamine use: Incidence and clinical correlates. J Pediatr 1989;115:770-778.
Rais-Bahrami K, Nagvi M. Hydroencephaly and maternal cocaine use: A case report. Clin Pediatr 1990;29:729-730.
McCarron MM, Wood JD. The cocaine ’body-packer’ syndrome. JAMA 1983;250:1417-1420.
Gherardi R, Marc B, Alberti X, et al. A cocaine body packer with normal abdominal plain radiograms: Value of drug detection in urine and contrast study of the bowel. Am J Forens Med Pathol 1990;11:154-157.
Marc B, Baud FJ, Aelion MJ, et al. The cocaine bodypacker syndrome: Evaluation of a method of contrast study of the bowel. J Forens Sci 1990;35:345-355.
Gay GR, Loper KA. The use of labetalol in the management of cocaine crisis. Ann Emerg Med 1988.
Polan S, Tadjziechy M. Esmolol in the management of epinephrine- and cocaine-induced cardiovascular toxicity. Anesth Analg 1989;69:663-664.
Sand 1C, Brody SL, Wrenn KD, Slovis CM. Experience with esmolol for the treatment of cocaine-associated cardiovascular complications. Am J Emerg Med 1991;9:161-163.
Abol Fl. The effects of nifedipine in cocaine toxicity. Am J Med Sci 1992;303:372-378.
Ramoska E, Sacchetti AD. Propranolol-induced hypertension in treatment of cocaine intoxication. Ann Emerg Med 1985;14:112-113.
Patel R, Harder B, Ahmed S, Regan TJ. Cocaine related myocardial infarction: High prevalence of occlusive coronary thrombi without significant obstructive atherosclerosis. Circulation 1988;78(suppl. I1):II—430.
Kossowsky WA, Lyon AF. Cocaine and acute myocardial infarction: A probable connection. Chest 1984;86: 729-731.
Smith HWB III, Liberman HA, Brody SL, et al. Acute myocardial infarction temporally related to cocaine use: Clinical, angiographic and pathophysiologic observations. Ann Intern Med 1987;107:13-18.
Anderson HV, Willerson JT. Thrombolysis in myocardial infarction. N Engl J Med 1993;329:703-709.
Wasserberger J. The ten commandments of treating cocaine chest pain. King/Drew Medical Center, 1995.
Om A, Ellahhan S, Di Sciascio G. Management of cocaine-induced cardiovascular complications. Am Heart J 1993;125:469-475.
Boehrer JD, Moliterno DJ, Willard JE, et al. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med 1993;94:608-618.
Hoffman B, Derlet R. Cocaine intoxication considerations, complications and strategies: Point and counterpoint. Emerg Med 1992;1:1-6.
Bechman KJ, Parker RB, Hariman RJ, et al. Hemodynamic and electrophysiological actions of cocaine: Effects of sodium bicarbonate as an antidote in dogs. Circulation 1991;83:1799-1807.
Kaukonen L, Hoffman RS. Cocaine. NY State J Med 1990;90:39.
Derlet RW, Albertson ТЕ, Tharratt RS. Lidocaine potentiation of cocaine toxicity. Ann Emerg Med 1991;20:135-138.
Hale SL, Alker KJ, Rezkalla SH, et al. Nifedipine protects the heart from the acute deleterious effects of cocaine if administered before but not after cocaine. Circulation 1991;83:1437-1443.
Lucatello A, Sturani A, Cocchi R, Fusaroli M. Dopamine plus furosemide in cocaine-associated acute myoglobinuric renal failure. Nephron 1991;60:242-243.
Zimmerman JL, Dellinger RP, Majid PA. Cocaine-associated chest pain. Ann Emerg Med 1991;20:611-615.
Hollander JE, Hoffman RD. Letter to editor. Acad Emerg Med I995;2:232.
Hollander J E, Hoffman RS, Gennis P, et al. Cocaine associated chest pain: One year follow-up. Acad Emerg Med 1995;2:179-184.
Hollander JE, Thone HC Jr, Hoffman RS. Chest discomfort, cocaine and tobacco. Acad Emerg Med 1995;2:238.
Hollander JE, Hoffman RS, Shiti DR. Cocaine-associated Ml (CAMI) study group. Acad Emerg Med I995;2:456.
Pitts S. ST-segment elevation as a discrimination in cocaine-associated chest pain. Acad Emerg Med 1995;2:331-332.
Michels R, Narzuk PM. Progress in psychiatry. N Engl J Med 1993;329:634.
Hoffman RS, Smilkstein MJ, Goldfrank LR. Whole bowel irrigation and the cocaine body-packer: A new approach to a common problem. Am J Emerg Med 1990;8:523-527.
Aks S, Vanden Hoek T, Tebbett I, et al. Cocaine liberation from body packets in an in vitro model. Vet Hum Toxicol 1991 ;33:354.
Dretcher K. Butyrylcholinesterase in cocaine overdose. In: Proceedings, FASEB Meeting, Anaheim, California, April 5- 9, 1992.
Bouskey HA, Warnock DG, Smith LH. Neurologic aspects of cocaine abuse. West J Med 1988;149:442-448.
Dhuna A, Pascual-Leone A. Cocaine-associated status epilepticus. J Epilepsy 1990;3:165-169.
Garvin FH, Ellinwood EH Jr. Cocaine and other stimulants. Actions, abuse and treatment. N Engl J Med 1988;318:1 173-1182.
Weiss RD. Relapse to cocaine abuse after initiating desipramine treatment. JAMA 1988;260:2545-2546.
Halikas JA, Crosby RD, Carlson GA, et al. Cocaine reduction in unmotivated crack users using carbamazepine versus placebo in a short-term, double-blind crossover design. Clin Pharmacol Ther 1991;50:81-95.
Halikas JA, Kuhn KL, Maddux TL. Reduction of cocaine use among methadone maintenance patients using concurrent carbamazepine maintenance. Ann Clin Psychiatry 1990;2:3-6.
Hatsukami D, Keenan R, Halikas J, et al. Effects of carbamazepine on acute responses to smoked cocaine-base in human cocaine users. Psychopharmacology 1991;104:120-124.
Crosby RD, Pearson MT, Eller C. A double-blind study of phenytoin in the treatment of cocaine abuse. Clin Pharmacol Ther 1995;57:160 (Abstract PI—102).
Friedman SR, Stark C, Sulfian M, DesJarlais DC. Will bleach decontaminate needles during cocaine binges in shooting galleries? JAMA 1989;262:1467.
DesJarlais DC. Intravenous cocaine, crack and HIV infection. JAMA 1988;259:1945-1956.
Sallee F, Stiller R, Perel J, Bates F. Oral pemoline kinetics in hyperactive children. Clin Pharmacol Ther 1985;37:606-609.
Polchert SE, Morse RM. Pemoline abuse. JAMA 1985;254:946-947.
Young R, Glennon RA. Cocaine-stimulus generalization to two new designer drugs; Methcathinone and 4-meth-ylaminorex. Pharmacol Biochem Behav 1993;45:229— 231.
Glennon FA, Yousif M, Naiman N, Kalix P. Methcathinone: A new and potent amphetamine-like agent. Pharmacol Biochem Behav 1987;26:547-551.
Emerson TS, Cisek JE. Methcathinone ("Cat"): A Russian designer amphetamine infiltrates the rural Midwest. Vet Hum Toxicol 1993;34:362.
Zhingel KY, Dovensky W, Crossman A, Alien A. Ephedrone: 2-Methylamino-l-phenylpropan-l-one (Jeff). J Forens Sci 1991;36:915-920.
Carrell S. Methcathinone: The next drug epidemic? Emerg Med News 1993;15:1-24.
Goldstone MS. "Cat: Methcathinone — a new drug of abuse. JAMA 1993;269:2508.
Bonner RC. Schedule of controlled substances: Temporary placement of methcathinone into Schedule I. Fed Regist 1992;57:9080-9081.
Bonner RD. Schedules of controlled substances: Temporary placement of methcathinone into Schedule I. Fed Regist 1992; 18 824-18 825.
Emerson TC, Cisek JE. Methcathione: A Russian designer amphetamine infiltrates the rural midwest. Ann Emerg Med 1993;22:1897-1903.
Bowles S. Designer drugs potency dwarfs crack cocaine: Cat’ produces high that can last up to six days. Seattle Times, September 28, 1992, p. Al.
Cohen S. Amphetamine abuse. JAMA 1975;231:414— 415.
Council on Scientific Affairs. Clinical aspects of amphetamine abuse. JAMA 1978;240:2317-2319.
Smith DE. Physical vs psychological dependence and tolerance in high dose methamphetamine abuse. Clin Toxicol 1969;2:99-103.
Smith DE, Fisher CM. An analysis of 310 cases of acute high dose methamphetamine toxicity in Haight Ashbury. Clin Toxicol 1970;3:117-124.
Monroe RR, Drell HJ. Oral use of stimulants obtained from inhalers. JAMA 1947;135:909-915.
Anderson RJ, Reed WG, Hillis LD, et al. History, epidemiology, and medical complications of nasal inhaler abuse. J Toxicol Clin Toxicol 1982;19:95-107.
Di Maio VJM, Garriott JC. Intravenous abuse of propylhexedrine. J Forens Sci 1977;22:152-158.
Gal J. Amphetamines in nasal inhalers. J Toxicol Clin Toxicol 1982;19:577-578.
Kendrick WC, Hull AR, Knochel JP. Rhabdomyolysis and shock after intravenous amphetamine administration. Ann Intern Med 1977;86:381-387.
Shulgin AT. 3-Methoxy-4,5-methylenedioxyamphetamine: A new psychotomimetic agent. Nature 1964;201:1120-1121.
Sottolano SM. The quantitation of phenyl-2-propanone using high-performance liquid chromatography. J Forens Sci 1988;33:1415-1420.
Dal Cason TA, Angelos SA, Raney J K. A clandestine approach to the synthesis of phenyl-2-propanone from phenyl-propenes. J Forens Sci 1984;29:1187-1208.
Frank RS. The clandestine drug laboratory situation in the United States. J Forens Sci 1983;28:18-31.
Cantrell TS, John B, Johnson L, Alien AC. A study of impurities found in methamphetamine synthesized from ephedrine. Forens Sci Int 1988;39:39-53.
Агах M, Gorman T. California’s illicit farm belt export. Los Angeles Times, March 13, 1995, pp. Al, Al5.
Allen AC, Kiser WO. Methamphetamines from ephedrine: 1. Chloroephedrines and aziridines. J Forens Sci 1987;32:953-962.
Ely RA, McGrath DC. Lithium-ammonia reduction of ephedrine to methamphetamine: An unusual clandestine synthesis. J Forens Sci 1990;35:720-723.
Allen A, Cantrell TS. Synthetic reductions in clandestine amphetamine and methamphetamine laboratories: A review. Forens Sci Int 1989;42:183-199.
Dal Cason TA. An evaluation of the potential for clandestine manufacture of 3,4-methylenedioxyamphetamine (MDA) analogs and homologs. J Forens Sci 1990;35:675-697.
By AW, Dawson BA, Lodge BA, et al. Synthesis and spectral properties of 2,5-dimethoxy-4-ethoxyamphetamirie and its precursors. J Forens Sci 1990;35:316-335.
By AW, Duhaime R, Lodge BA. The synthesis and spectra of 4-ethoxyamphetamine and its isomers. Forens Sci Int 1991;49:159-170.
Zhingel KY, Dovensky W, Crossman A, Allen A. Ephedrone: 2-Methylamino-1-phenylpropan-l-one (Jeff). J Forens Sci 1991;36:915-920.
Smith DE. Physical vs psychological dependence and tolerance in high dose methamphetamine abuse. Clin Toxicol 1979;2:99-103.
Mineo RM. Facts About... CRYSTAL. La Jolla, CA: Scripps Memorial Hospital, the McDonald Center for Alcoholism and Drug Addiction Treatment, 1992.
Jackson JG. Hazards of smokable methamphetamine. N Engl J Med 1989;321:907.
Largent DR, Desha A, Stevenson P, et al. "Ice": Crystal methamphetamine. California Department of Justice, Bureau of Narcotic Enforcement, September, 1989.
Monroe RR, Drell HJ. Oral use of stimulants obtained from inhalers. JAMA 1947;135:909-915.
Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991;265:1151-1154.
Sachdeva K, Woodward KG. Caudal thalamic infarction following intranasal methamphetamine use. Neurology 1989;39:305-306.
Gospe SM Jr. Transient cortical blindness in an infant exposed to methamphetamine. Ann Emerg Med 1995;26:380-382.
Furst SR, Fullon SP, Reznik GN, Shah PK. Myocardial infarction after inhalation of methamphetamine. N Engl J Med 1990;323:1 147-1148.
Nestor TA, Tamamotoa WI, Kam TH, Schultz T. Acute pulmonary edema caused by crystalline methamphetamine. Lancet 1989;2:1277-1278.
Bailey DN, Manoguerra AS. Survey of drug abuse patterns and toxicology analysis in an emergency room population. J Anal Toxicol 1980;4:199-203.
Mendelson J, Jones RT, Upton R, Jacob P HI. Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther 1995;57:559-568.
Mack RB. The iceman cometh and killeth: Smokable methamphetamine. NC Med J 1990;51:276-278.
Sekine H, Nakahara Y. Abuse of smoking methamphetamine mixed with tobacco: 1. Inhalation efficiency and pyrolysis products of methamphetamine. J Forens Sci 1987;32:1271-1280.
Sekine H, Nakahara Y. Abuse of smoking methamphetamine mixed with tobacco, II: The formation mechanism of pyrolysis products. J Forens Sci 1990;35:580— 590.
Catanzarite VA, Stein DA. ’Crystal’ and pregnancy: Methamphetamine-associated maternal deaths. West J Med 1995;162:454-457.
Dixon SD, Bejar R. Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: Incidence and clinical correlates. J Pediatr 1989; 115:770-778.
Elliott RH, Rees GB. Amphetamine ingestion presenting as eclampsia. Can J Anaesth 1990;37:130-133.
Dearlove JC, Betteridge TJ, Henry JA. Stillbirth due to intravenous amphetamine. Br Med J 1992;304:548.
Oro AS, Dixon SD. Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates. J Pediatr 1987; I 11:571-578.
Dixon SD. Effects of transplacental exposure to cocaine and methamphetamine in the neonate. West J Med 1989;150:436-442.
Bost RO, Kemp P, Hnilica V. Tissue distribution of methamphetamine and amphetamine in premature infants. J Anal Toxicol 1989;13:300-302.
Klein RFX, Sperling AR, Cooper DA, Kram TC. The stereoisomers of 4-methylaminorex. J Forens Sci 1989;34:962-979.
Yelnosky J, Katz R. Sympathomimetic actions of cis-2-amino-4-methyl-5-phenyl-2-oxazoline. J Pharmacol Exp Ther 1963;141:180-184.
Patil PN, Yamauchi D. Influence of optical isomers of some centrally acting drugs on norepinephrine responses. Eur J Pharmacol 1970;12:132-135.
Lawn JC. Schedules of controlled substances: Temporary placement of 2-amino-4-methyl-5-phenyl-2-oxazoline (4-methylaminorex) into Schedule I. Fed Regist 1987;52:30 174-175.
Davis FT, Brewster ME. A fatality involving U4Euh, a cyclic derivative of phenylpropanolamine. J Forens Sci 1988;33:549-553.
Sudmeier SJ, Smith FP, Reuschel SA, Kidwell DA. Four isomers of methylaminorex in urine examined by immunoassay and GC/MS. In: Proceedings American Academy of Forensic Sciences, 44th Annual Meeting, New Orleans, February 17—22, 1992:Abstract K-47, p. 198.
Brewster ME, Davis FT. Appearance of aminorex as a designer analog of methylaminorex. J Forens Sci 1991;36:587-592.
Gurtner H. Aminorex and pulmonary hypertension. Cor Vasa 1985;27:160-171.
Seiler K. Aminorex and pulmonary circulation. Arzneitmittelforschung 1975; 25:8 37.
Solowij N. Ecstasy (3,4-methylenedioxymethamphetamine). Curr Opin Psychiatry 1993;6:411-415.
Peroutka SJ. Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, ’Ecstasy’) on an undergraduate campus. N Engl J Med 1987;317:1542-1543.
Peroutka SJ. ’Ecstasy’: A human neurotoxin? Arch Gen Psychiatry 1989;416:191.
Dowling GP, McDonough ET, Bost RO. ’Eve’ and ’Ecstasy’: A report of five deaths associated with the use of MDEA and MDMA. JAMA 1987;257:1615-1617.
Davis WM, Hatoum HT, Waters W. Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevance to hazards of MDMA (ecstasy) abuse. Alcohol Drug Res 1987;7:127-134.
Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA ("Ecstasy"). JAMA 1987;258:780-781.
Wolff K, Hay AWM, Sherlock K, Conner M. Contents of'Ecstasy.' Lancet 1995;346:1100-1105.
Ricaurte GA, Gorno LS, Wilson MA, et al. (+/-)-3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 1988;260:51-55.
Battaglia G, Yen SY, O’Hearn E, et al. 3,4-Methylene-dioxymethamphetamine and 3,4-methylenedioxymeth-amphetamine destroy serotonin terminals in rat brain: Quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1987;242:911-916.
Stikker W Jr, Ali SF, Scallet AC, et al.: Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 1988;94:448-457.
Rittoo DB, Rittoo D. Complications of "Ecstasy" misuse. Lancet 1992;340:725-727.
Randall T. Ecstasy-fueled ’rave’ parties become dances of death for English youths. JAMA 1992.
Henry JA. Ecstasy and the dance of death: Severe reactions are unpredictable. Br Med J 1992;305:566.
Chadwick IS, Curry PD, Linsley A, et al. Ecstasy, 3-4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and amphetamine. J R Soc Med I99l;8:371.
Campkin NTA, Davies VM. Another death from Ecstasy. J R Soc Med 1992;85:861.
Gorard DA, Davier SE, Clark ML. Misuse of Ecstasy. Br Med J 1992;305:309.
Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("Ecstasy"). Lancet 1992;340:384-387.
Fahal I, Sallomi DF, Yaqoob M, Bell GM. Acute renal failure after Ecstasy. Br Med J 1992;35:29.
Rittoo D, Rittoo DR, Rittoo D. Misuse of Ecstasy. Br Med J 1992;305:309-310.
Sawyer J, Stephens WP. Misuse of Ecstasy. Br Med J 1992;305:310.
De Silva RN, Harries DP. Misuse of Ecstasy. Br Med J 1992;305:310.
Schmidt CJ, Black CK, Abbate GM, Taylor VL. Methylenedioxyamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT, receptors. Brain Res 1990;529:85-90.
Garbino J, Joliet P, Metha G. Liver transplantation after fulminant hepatic failure due to ’Ecstasy’ hepatitis. In: Proceedings, 5th World Congress of the World Federation of Association of Clinical Toxicology Centers and Poison Control Centers, Taipei, Novembers, 1994: Abstract H28.
Rudnick G, Wall SC. The molecular mechanism of Ecstasy [3,4-methylenedioxymethamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 1992;89:1817-1821.
Warder C, Winger J. Choreoathetoid reaction associated with a methylphenidate reaction in a toddler. Clin Toxicol 1995;33:475-486 (Abstract 94).
Allcott JV Ill, Barnhart RA, Mooney LA. Acute lead poisoning in two users of illicit methamphetamine. JAMA 1987;258:510-511.
Norton RL, Kauffman KW, Chandler DB, et al. Intravenous lead poisoning associated with methamphetamine use. Vet Hum Toxicol 1989;31:379.,
Lead poisoning associated with intravenous methamphetamine use: Oregon, 1988. MMWR 1989;38:830— 831.
Kintz P, Mangin P. Toxicological findings after fatal fenfluramine self-poisoning. Hum Exp Toxicol 1992;11:51-52.
Evans MA, Martz R, Lemberger L, et al. Effects of dextroamphetamine on psychomotor skills. Clin Pharmacol Ther 1976;19:777-781.
Perez-Reyes M, White WL, McDonald SA, et al. Clinical effects of methamphetamine vapor inhalation. Life Sci 1991;49:953-959.
Hood I, Monforte J, Gault R, Mirchandani H. Fatality from illicit phendimetrazine use. Clin Toxicol 1988;26:249-255.
Bost RO, Sutheimer CA, Sunshine 1. Relative merits of some methods for amphetamine assay in biological fluids. Clin Chem 1976;22:789-801.
Christophersen AS, Bugge A, Dahlin E, et al. Interference with analysis of amphetamine in blood by N-ethyl-benzenamine from rubber septums. J Anal Toxicol 1988;12:147-149.
Lewis JH. The use of HPLC fluorescence detection and FMOC in the detection of amphetamine and methylamphetamine in the urine of drug abusers. In: Uges DRA, de Zeeuw RA, eds. T1AFT, Proceedings of the 25th International Meeting, International Association of Forensic Toxicologists, Groningen, 1988:272—276.
Rasmussen S, Cole R, Spiehler V. Methamphetamine antemortem blood and urine by radioimmunoassay and GC/MS. J Anal Toxicol 1989; 13:263—267.
Gan BK, Baugh D, Liu RH, Walia AS. Simultaneous analysis of amphetamine, methamphetamine and 3,4-dioxymethamphetamine (MDMA) in urine samples by solid-phase extraction, derivatization and gas chromatography/mass spectrometry. J Forens Sci 1991 ;36:1331 — 1341.
Paton DM, Bell JI, Yee R, et al. Pharmacology and toxicity of 3.4-methylenedioxyamphetamine, paramethoxamphetamine and related dimethoxyamphetamines. Proc West Pharmacol Soc 1975;18:229-231.
Merigian KS, Browning RG. Desipramine and amantadine causing false-positive urine test for amphetamine. Ann Emerg Med 1993;22:1927-1928.
Shaw RF. The forensic toxicology of methamphetamine in San Diego County, 1989. Calif Assoc Toxicol Newslett 1991 (Spring):23.
Hornbeck CL, Czarny RJ. Evaluation of a fluorescence polarization immunoassay for methamphetamine/am-phetamine. In: Proceedings of Meeting of American Academy of Forensic Sciences, Anaheim, California, 1990^133 (Abstract K6).
Carrico J, Freeman J, Graham B, Jones C. A new Emit assay for amphetamine/methamphetamine. In. Proceedings of Meeting of American Academy of Forensic Sciences, 199&. 141-142 (Abstract K37).
Gaff SL, Ward CD, Vitone S, Wu R, et al. Abuscreen radioimmunoassay for methamphetamine (high specificity): A selective RIA for detection of (/-methamphetamine abuse. In: Proceedings of Meeting of American Academy of Forensic Sciences, Anaheim, California, 1990^164 (Abstract K23).
Suzuki S-I, Inoue T, Hori H, Inayama S. Analysis of methamphetamine in hair, nail, sweat and saliva by mass fragmentography. J Anal Toxicol 1989;13:176-178.
Poklis A, Moore KA. Stereoselectivity of the TDxADx/ Fix amphetamine/methamphetamine II amphetamine/ methamphetamine immunoassay: Response of urine specimens following nasal inhaler use. Clin Toxicol 1995;33:35-41.
Gary NE, Saidi P. Methamphetamine intoxication: A speedy new treatment. Am J Med 1978;64:537-540.
Singarajah C, Lavies NG. An overdose of Ecstasy: A role for dantrolene. Anaesthesia 1992;47:686-687.
Barrett PJ. ’Ecstasy’ misuse: Overdose or normal dose? Anaesthesia 1993;48:83.
Cregg MT, Tracey JA. Ecstasy abuse in Ireland. Irish Med J 1993;86:118-120.
Callaway CW, Clark RF. Hyperthermia in psychostimulant overdose. Ann Emerg Med 1994;24:68-76.
Watson CJE, Thomson HJ, Johnston PS. Body-packing with amphetamines: An indication for surgery. J R Soc Med 1991;84:311-312.
Nichol AM. The nontherapeutic use of psychoactive drugs: A modem epidemic. N Engl J Med 1983;308:925-933.
Sherman JP. Dexamphetamine for "speed" addiction. Med J Austral 1990; 153:306.
Skeers VM. Illegal methamphetamine drug laboratories: A new challenge for environmental health personnel. J Environ Health 1992;55:6-10.
Symptoms and signs of drug abuse. Med Lett Drugs Ther 1987;29(748):86.
U. S. Department of Health and Human Services, Public Health Service. The health consequences of smoking nicotine addiction: A report of the Surgeon General. Washington, DC: U. S. Government Printing Office, 1988.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., rev. Washington, DC: American Psychiatric Association, 1987.
Hoffman RS. Street drugs. Prehosp Dis Med 1991;6(2):252.
Treaster JB. U. S. reports rise in drug emergencies. NY Times, October 5, 1993.
Current tobacco, alcohol, marijuana, cocaine use. MMWR 1991;40:659-663.
Wilford BB. Abuse of prescription drugs. West J Med 1990;152:609-612.
Koran L, Litt I. House staff well-being. West J Med 1988;148:97-101.
Hughes PH, Conard SE, Baldwin DC Jr, et al. Resident physician substance use in the United States. JAMA 1991;265:2069-2073.
Menk EJ, Baumgarten RK, Kingsley CP, et al. Success of reentry into anesthesiology training programs by residents with a history of substance abuse. JAMA 1990;263:3060-3062.
The drugs on the street where you live. Emerg Med 1986; 18(3): 129-177.
Ammon TK, Anglin MD. Update on illicit drug use in Los Angeles County. In: Proceedings, Community Epidemiology Work Group, Epidemiologic Trends in Drug Abuse. National Institute on Drug Abuse, U. S. Department of Health and Human Services, June 1992 and December 15—18, 1992 meeting.
Golding AM P. Two hundred years of drug abuse. J R Soc Med 1993;86:282-286.
Schydlower M, Chairman, Committee on Substance Abuse, 1992—1993, American Academy of Pediatrics. Role of the pediatrician in prevention and management of substance abuse. Pediatrics 1993;91:1010—1013.
Rinaldi RC, Steindler EM, Wilford BB, Goodwin D. Clarification and standardization of substance abuse terminology. JAMA 1988;259:555-557.
Gerstein DR, Harwood HJ, eds. Treating Drug Problems. Washington, DC: National Academy Press, 1990.
Gerstein DR, Lewin LS. Special report: Treating drug problems. N Engl J Med 1990;323:847-848.
Pruitt AW, Chairman and Committee on Substance Abuse. Drug-exposed infants. Pediatrics 1990;86:639— 642.
Ward SLD, Bautista D, Chan L, et al. Sudden infant death syndrome in infants of substance-abusing mothers. J Pediatr 1990;117:876-881.
Committee on Adolescence, Committee on Bioethics, also Provisional Committee on Substance Abuse. Screening for drugs of abuse in children and adolescents. Pediatrics 1989;84:396-398.
Richardson JL, Dwyer K, McGuigan K, et al. Substance abuse among eighth grade students who take care of themselves after school. Pediatrics 1989;84:556-566.
Janofsky M. Drug use rising among teenagers, study says. NYTimes, December 13, 1994.
Walsh SS, Pierce AM, Hart CA. Drug abuse: A new problem. Br Med J 1987;295:526-527.
Woolf A. The epidemiology of poisonings and drug abuse in adolescents and adults. Clin Toxicol Rev 1988;10(4):l—2.
Loiselle JM, Baker MD, Templeton MJ Jr, et al. Substance abuse in adolescent trauma. Ann Emerg Med 1993;22:1530-1534.
Harman C. Rh-negative women who share needles run risk of being childless, MD says. Can Med Assoc J 1990;142:975.
Bowman JM, Manning FA, Harman CR. Alloimmunization and intravenous drug abuse. Can Med Assoc J 1990; 142:439.
Jessup M. The treatment of perinatal addiction, identification, intervention and advocacy. West J Med 1990;152:553-558.
Deren S, Frank B, Schneidler J. Children of substance abusers in New York State. NY State J Med 1990;90:179-184.
Dattel BJ. Substance abuse in pregnancy. Semin Perinatol 1990;14:179-187.
Ostrea EM Jr, Brady MJ, Parks PM, et al. Drug screening of meconium in infants of drug-dependent mothers: An alternative to urine testing. J Pediatr 1989;115:474— 477.
Ostrea EM Jr, Porter T, Balun J, et al. Effects of chronic maternal drug addiction on placental drug metabolism. Dev Pharmacol Ther 1989;12:42-48.
Rosenzweig IV, Clark GD, Thiersch NJ, Raisys VA. Neonatal drugs of abuse screening in meconium: A comparison between Abbot TDx and Syva ETS. Clin Chem 1990;36:1023.
Ward SLD, Schuetz S, Wachsman L, et al. Elevated plasma norepinephrine levels in infants of substanceabusing mothers. Am J Dis Child 1991;145:44-48.
Senay EC. Drug abuse and public health: A global perspective. Drug Saf 1991 ;6(suppl. 1):1—65.
Drugs on stickers. Lancet 1991;336:1501.
Duback DC, Rosner B, Stunner T. An epidemiologic study of abuse of analgesic drugs: Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968-1987). N Engl J Med 1991;324:155-160.
Kuster G, Ritz E. Analgesic abuse and hypertension. Lancet 1989;2:1105.
Stewart MJ, Fraser DM, Boon N. Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler. Br Heart J 1992;68:221-222.
Whitehouse AM, Novosel S. Salbutamol psychosis. Biol Psychiatry 1989;26:631-633.
Brennan PO. Inhaled salbutamol: A new form of drug abuse? Lancet 1983;2:1030-1031.
Add LysolR to list of abused drugs. Forens Drug Abuse Advisor 1991 ;3(3): 19—20.
Kuhlman JJ Jr, Magluilo J Jr, Levine B, Smith ML. Two deaths involving isoflurane abuse. J Forens Sci 1993;38:968-971.
Yamashita M, Matsuki A, Oyama T. Illicit use of modern volatile anesthetics. Can Anaesth Soc J 1984;31:76-79.
Kunkel DB. The toxic toll of keeping thin. Emerg Med 1985; 17(1): 176-180.
Pellini EJ, Wallace GB. The pharmacology of emetine. Am J Med Sci 1916;152:325-336.
Santangelo WC, Richey J E, Rivera L, Fordtran JS. Surreptitious ipecac administration simulating intestinal pseudo obstruction. Ann Intern Med 1989.
Tolstoi LG. Ipecac-induced toxicity in eating disorders. Int J Eating Disorders 1990;9:371-375.
Bulimia nervosa: common in women. Drug Ther Bull 1992;30:13-15.
Garner DM. Pathogenesis of anorexia nervosa. Lancet 1933;341:1631-1635.
Beumont PJV, Russell JD, Touyz SW. Treatment of anorexia nervosa. Lancet 1993;341:1635-1640.
Mitchell JE, Seim HC, Colon E, Pomeroy C. Medical complications and medical management of bulimia. Ann Intern Med 1987;107:71-77.
Devlin MJ, Walshin DT, Krai JG, et al. Metabolic abnormalities in bulimia nervosa. Arch Gen Psychiatry 1990;47:144-148.
Franko DL, Banitt PF. Abusing potassium by a patient with bulimia nervosa. Am J Psychiatry 1991 ;48:682.
Woolf AD, Gren JM. Acute poisonings among adolescents and young adults with anorexia nervosa. Am J Dis Child 1990;144:785-788.
Hudson JI, Poper HG Jr, Keck PE Jr, McElroy SL. Treatment of bulimia nervosa with trazodone: Shortterm response and long-term follow-up. Clin Neurop-harmacol 1989; 12(suppl. 1):538—546.
Solyom L, Solyom C, Ledwidge B. The fluoxetine treatment for low weight chronic bulimia nervosa. J Clin Psy-chopharmacol 1990; 110:421—425.
Fava M, Herzog DB, Hamburg P, et al. Long-term use of fluoxetine in bulimia nervosa: A retrospective study. Ann Clin Psychiatry 1990;2:53-56.
Mitchell JE, Christenson G, Jennings J, et al. A placebo controlled double-blind crossover study of naltrexone hydrochloride in outpatients with normal-weight bulimia. J Clin Psychopharmacol 1989;9:94-97.
Kennedy SH, Goldblood DS. Current perspectives on drug therapies for anorexia nervosa and bulimia nervosa. Drugs 1991;4:367-377.
Rosenwasse GOD, Holland S, Pfugfelder SC, et al. Topical anesthetic abuse. Ophthalmology 1990;97:967-972.
Sato EH. de Freitas D, Foster CS. Abuse of cyclopentolate hydrochloride (Cyclogyl) drops. N Engl J Med 1992;326:1363-1364.
Harmelin DL, Martin FIR, Wark JD. Antacid induced phosphate depletion syndrome presenting as nephrolithiasis. Aust NZ J Med 1990;20:803-805.
Ruben SM, McLean PC, Melville J. Cyclizine abuse among a group of opiate dependents receiving methadone. Br J Addict 1989;84:929-934.
Multistate outbreak of poisonings associated with illicit use of gamma hydroxybutyrate. MMWR 1990.
Warning about GHB: Food and Drug Administration. JAMA 1991 ;265:1802.
Centers for Disease Control and Prevention. Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. MMWR 1990;39:861-863.
Illness with GHB use. FDA Consumer 1991 ;25(2):5.
Adornato ВТ, Tse V. Another health food hazard: gamma hydroxy butyrate induced seizures. West J Med 1992;157:471.
Chin M-Y, Kreutzer RA, Dyer J E. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992;56:380-384.
Dyer JE. Gamma-hydroxybutyrate a health food product producing coma and seizure-like activity. Am J Emerg Med 1991;9:321-326.
Mamelak M. Gamma hydroxy butyrate: An endogenous regulator of energy metabolism. Neurosci Biobehav Rev 1989;13:187-190.
Gilmore DA, Freed CR, Bronstein AC. Central nervous system depression and weakness following ingestion of gamma hydroxybutyrate. Vet Hum Toxicol 1991 ;33:366.
Lane RB. Gamma hydroxy butyrate (GHB). JAMA 1991;265:2959.
Gallimberti L, Canton G, Gentile N, et al. Gamma hydroxy butyric acid for treatment of alcohol withdrawal syndrome. Lancet 1989;2:787-789.
U. S. Pharmaceutical Convention Inc. USP Dispensing Information: vol. 1B: Drug Information for the Health Care Professional. Easton, PA: Mack, 1990:2914.
Vickers MD. Gamma hydroxybutyric acid. Proc R Soc Med 1968;61:821-824.
Vayer P, Mandel P, Maitre M. Mini review: Gamma hydroxybutyrate, a possible neurotransmitter. Life Sci 1987;41:1547-1557.
Jaeken J, Casaer P, de Cock P, Francois B. Vigabatrin in GABA metabolism disorders. Lancet 1989;1:1074.
Ferrara SD, Tedeschi L, Prison G, Rossi A. Fatality due to gamma hydroxybutyric acid (GHB) and heroin intoxication. J Forens Sci 1995;40:501-504.
Helrich M, McAslan Tc, Skolnik S, et al. Correlation of blood levels of 4-hydroxybutyrate with state of consciousness. Anesthesiology 1964;25:771-775.
Gibson KM, DeViro DC, Jakobs C. Vigabatrin therapy in patient with succinic semialdehyde dehydrogenase deficiency. Lancet 1989;2:1105-1106.
Jensen D, Burton ВТ, Magnusson AB. Recreational intravenous injection of elemental mercury. Vet Hum Toxicol 1988;30:372.
Bloor RN, Smalldridge NJF. Intravenous use of slow release morphine sulfate tablets. Br Med J 1990;300:640— 641.
Gray RF, Ferez A, Janhar P. Emergence of bupreno-phine dependence. Br J Addict 1989;84:1373-1374.
Mahesh VK, Stern HP, Kearns GL, Stroh SE. Application of pharmacokinetics in the diagnosis of chemical abuse in Munchausen’s syndrome by proxy. Clin Pediatr 1988;27:243-246.
McElwee NE, Veltri JC. Intentional abuse of dextromethorphan (DM) products: 1985 to 1988 statewide data. Vet Hum Toxicol 1990;32:355.
Helfer J, Kim OM. Psychoactive abuse potential of Ro-bitussin-DMR. Am J Psychiatry 1990; 147:672.
Walker J, Yatham LN. Beylin (dextromethorphan) abuse and mania. Br Med J 1993;306:896.
Young GB, Body D, Kreeft J. Dimenhydrinate: Evidence for dependence and tolerance. Can Med Assoc J 1988;138:437-438.
Bartlik B, Galanter M, Angrist B. Dimenhydrinate addiction in a schizophrenic woman. J Clin Psychiatry 1989;50:476.
Craig DL, Mellor CS. Dimenhydrinate dependence and withdrawal. Can Med Assoc J 1990;142:970-973.
Kaplan R. Poppy sead dependence. Med J Aust 1994;161:176.
Rotenberg A, Chaveinc L, Rault P, et al. Lesions rectales secondaire a 1’abus de suppositoires de dextropropoxyphene et paracetamol: Deux nouvelles observations. Presse Med 1988; 17(30): 1545.
Hedenmalm K. A case of severe withdrawal syndrome due to dextropropoxyphene. Ann Intern Med 1995; 123:473.
Scott WC. Abuse of erythropoietin to enhance athletic performance. JAMA 1990;264:1660.
Tennant F, Black DL, Voy RO. Anabolic steroid dependence with opioid type features. N Engl J Med 1988;319:578.
Stevens DJ. Cushing’s syndrome due to the abuse of betamethasone nasal drops. J Laryngol Otol 1988; 102:219— 221.
Borde М, Nizamie SH. Dependence on a common cough syrup. Lancet 1988; 1:760.
Bhasin S, Wallace W, Lawrence JB, Lesch M. Sudden death associated with thyroid hormone abuse. Am J Med 1981;71:887-890.
Griffiths RR, Wolf B. Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol 1990;10:237-243.
Middleman AB, Faulkner AH, Woods ER, et al. High-risk behaviors among high school students in Massachusetts who use anabolic steroids. Pediatrics 1995;96:268— 272.
Park J, Park S, Lho D, et al. Drug testing at the 10th Asian games and 24th Seoul Olympic games. J Anal Toxicol 1990;14:66-72. Park J, Chung B. Drug abuse in sports (doping): Analytical Procedures: 41 st Meeting of the American Academy of Forensic Scientists, Feb. 14, 1989: 1—244. DCC-KAIST, PO Box 131, Cheongryang, South Korea.
Rockhold BRW. Cardiovascular toxicity of anabolic steroids. Annu Rev Pharmacol Toxicol 1993:497—520.
Kennedy MC, Lawrence C. Anabolic steroid use and cardiac death. Med J Aust 1993;158:346-348.
Bray GP, Tredger JM, Williams R. Resolution of danazol-induced cholestasis with 5-adenosylmethionine. Postgrad Med J 1993;69:237-239.
Moss-Newport J. Anabolic steroid use and cerebellar hemorrhage. Med J Aust 1993; 158:794.
Fradkin JE, Schonberger LB, Mills JL, et al. Creutzfeldt—Jakob disease in pituitary growth hormone recipients in the United States. JAMA 1991;265:880-884.
Winter FD Jr, Snell PG, Stray-Gunderson J. Effects of 100 % oxygen on performance of professional soccer players. JAMA 1989;262:227-229.
Murray TM. Erythropoietin: Another violation of ethics. Phys Sports Med 1989;17:39-40.
Donaldson VH. Danazol. Am J Med 1989;87:3—49N— 3-55N.
Lee YJ, Horstman LL, Ahn YS. Danazol for Henoch— Schonlein pupura. Ann Intern Med 1993;! 18:827.
Kahn H, Manzarbeitia C, Theise N, et al. Danazol-induced hepatocellular adenomas. Arch Pathol Lab Med 1991;115:1054-1057.
Ferenchik G, Schwartz D, Ball M, Schwartz K. Androgenic-anabolic steroid abuse and platelet aggregation: A pilot study in weight lifters. Am J Med Sci 1992;303:78— 82.
Gerrard DF, Fawcett JP, Farquhar SJ. Venadium use by athletes. NZ Med J 1993; 106:259.
Shesser R, Jotte R, Olshaker J. The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med 1991;9:336-342.
Orser B. Thrombocytopenia and cocaine abuse. Anesthesiology 1991 ;74( 1): 195—196.
Leikin JB, Krantz AJ, Zell-Kanter M, et al. Clinical features and management of intoxication due to hallucinogenic drugs. Med Toxicol Adverse Drug Experience 1989;4:324-350.
Spoerke DG, Hall AH. Plants and mushrooms of abuse. Emerg Med Clin North Am 1990;8:589.
Marquardt KA, Tharratt RS. Fentanyl smokes. Vet Hum Toxicol 1993;35:362.
Stephens DA. Psychotoxic effects of benzhexol hydrochloride (Artane). Br J Psychiatry 1967;113:213-218.
Macvicar K. Abuse of antiparkinsonian drugs by psychiatric patients. Am J Psychiatry 1977;134:809-811.
Lowry TP. Trihexyphenidyl abuse. Am J Psychiatry 1977;134:1315.
Goggin DA, Solomon GF. Trihexyphenidyl abuse for euphorigenic effect. Am J Psychiatry 1979; 136:459— 460.
McEvoy GK. AHFSDrug Information 90. Bethesda, MD: American Hospital Formulary Service, 1990.
Smith JM. Abuse of the antiparkinson drugs: A review of the literature. J Clin Psychiatry 1980;41:351-354.
Kajimura N, Nizuki Y, Kai S, et al. Memory and cognitive impairments in a case of long-term trihexyphenidyl abuse. Pharmacopsychology 1993;26:59-62.
Rubinstein JS. Abuse of antiparkinsonian drugs. JAMA 1978;239:2365-2366.
Craig DH, Rosen Р. Abuse of antiparkinsonian drugs. Ann Emerg Med 1981;10:98-100.
Hidalgo HA, Mowers RM: Anticholinergic drug abuse. DICP Ann Pharmacother 1990;24:40-41.
Kaminer Y, Munitz H, Wijsenbee K. Trihexyphenidyl (Artane) abuse: Euphoriant and anxiolytic. Br J Psychiatry 1982;140:473-474.
Crawshaw JA, Mullen PE. A study of benzhexol abuse. Br J Psychiatry 1984;145:300-303.
Whitsett TL, Manion CV, Wilson MF. Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo. Br J Clin Pharmacol 1981;12:195-200.
Muscling in on clenbuterol. Lancet 1992;340:403. Editorial.
Reynolds JEF, ed. Martindale'. The Extra Pharmacopoeia. 29th ed. London: Pharmaceutical Press, 1989:1458.
Whitsett TL, Manion CV, Wilson MR Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo. Clin Pharmacol Ther 1980;27:294-295.
MacLennan PA, Edward RHT. Effect of clenbuterol and propranolol on muscle mass: Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy. Biochem J 1989;264:573-579.
Delday Ml, Williams PE, Maltin CA. Effect of clenbuterol on immobilized muscle. J Neurol Sci 1990;98:376.
Zahn V, Krumbacher G. Clenbuterol: A long term uterine relaxant. J Perinat Med 1981;9:96-100.
Beckett AH. Clenbuterol and sports. Lancet 1992;340:l 165.
Blom-Bulow P, Boe J, Bulow K, Hagelqvist I. A comparison of oral beta2-agonists clenbuterol and salbutamol in obstructive lung disease: A double blind cross-over study. Curr Ther Res 1985;37:51-57.
Jensen S, Hansen AC. Abuse of codeine separated from over-the-counter drugs containing acetylsalicylic acid and codeine, hit J Legal Med 1993;105:279-281.
Davis L. The use of castor oil to stimulate labor in patients with premature rupture of membranes. J Nurse-Midwifery 1984;29:366.
Cummings M. Types of laxatives. FDA Consumer 1991 (April):34.
Asher R. Munchausen’s syndrome. Lancet 1951.
Chapman JS. Peregrinating problem patients: Munchausen’s syndrome. JAMA 1957;165:927-933.
L’Hommedieu CS, Nicholas D, Armes DA. Potentiation of magnesium sulfate-induced neuromuscular weakness by gentamicin, tobramycin and amikacin. J Pediatr 1983;102:629-631.
Beuers B, Spengler U, Pape GR. Hepatitis after chronic abuse of senna. Lancet 1991;337:372-373.
De Wolff TA, de Haas EJM, Verweij M. A screening method for establishing laxative abuse. Clin Chem 1981;27:914-917.
Faber DB, Kok RM. The comparison ofTLC with GLC and GC/MS as well as TLC/GLC as screening methods for synthetic chemical stimulating laxatives in case of abuse. In: Proceedings, Annual European Meeting of International Association of Forensic Toxicologists, Glasgow, August 1979. Bull hit Assoc Forens Toxicol 1979;15( 1):15—16.
Silk DBA, Gibson JA, Murray CRH. Reversible finger clubbing in a case of purgative abuse. Gastroenterology 1975;6:790-794.
Binder HJ. The gastroenterologist’s osmotic gap: Fact or fiction? Gastroenterology 1992;103:702-704.
Duncan A, Robertson C, Russell Rl. The fecal osmotic gap: Technical aspects regarding its calculation. J Lab Clin Med 1992;119:359-363.
Donowitz M, Kokke FT, Said R. Evaluation of patients with chronic diarrhea. N Engl J Med 1995;332:725-729.
Giorgi DF. Munchausen syndrome. NY State J Med 1992;92:301-303.
Hunter SE, Sussman N. Chronic factitious disorder with physical symptoms (Munchausen syndrome). Psychiatr Clin North Am 1981;4:365-377.
Rosenberg DA. Web of deceit: A literature review of Munchausen’s syndrome by proxy. Child Abuse Negl 1987;11:547-563.
Parker G, Barrett E. Factitious patients with fictitious disorders: A note on Munchausen’s syndrome. Med J Aust 1991;155:772-773.
Meadow R. Munchausen’s syndrome by proxy. Arch Dis Child 1982;57:92-98.
Zuger A, O’Dowd MA. The Baron has AIDS: A case of factitious human immunodeficiency virus infection and review. Clin Infect Dis 1992;14:211-216.
Belchetz PE, Cohen RD, O’Riordan JLH, Tomlinson S. Factitious hypercalcemia. Br Med J 1976;1:690-691.
Makesh VK, Stern HP, Kearns GL, Stroh SE. Application of pharmacokinetics in the diagnosis of chemical abuse in Munchausen’s syndrome by proxy. Clin Pediatr 1988;27:243-246.
Feldman KW, Christopher DM, Oppenheim KE. Anorexia nervosa/Munchausen’s syndrome by proxy and ipecac. Vet Hum Toxicol 1987;29:482.
Nichols GR, Davis GJ, Coney TG. In the shadow of the Baron: Sudden death due to Munchausen’s syndrome. Am J Emerg Med 1990;8:216-219.
Ackerman NB Jr, Strobel CT. Polle syndrome: Chronic diarrhea in Munchausen’s child. Gastroenterology 1981;81:1140-1142.
Karnik AM, Farah S, Khadadalh M, et al. A unique case of Munchausen’s syndrome. Br J Clin Pract 1990;44:699-700.
Klatt EC, Mills NA, Noguchi TT. Causes of death in hospitalized intravenous drug abusers. J Forens Sci 1990;25:1143-1148.
Perkins HA, Samson S, Garner J, et al. Risk of acquired immunodeficiency syndrome (AIDS) for recipients of blood components from donors who subsequently developed AIDS. Blood 1987;70:1604-1610.
Nelson KE, Vlahov D, Margolick J, et al. Blood and plasma donations among a cohort of intravenous drug users. JAMA 1990;263:2194-2197.
Glassroth J, Adams GD, Schnoll S. The impact of substance abuse on the respiratory system. Chest 1987;91:596-602.
Harrison DW, Walls RM. ’Cotton fever’: A benign febrile syndrome in intravenous drug abusers. J Emerg Med 1990;8:135-139.
Levine DP, Sobel JD. Infections in Intravenous Drug Abusers. New York: Oxford University Press, 1991.
Sloan MA, Kittner SJ, Rigamonti D, Price TR. Occurrence of stroke associated with use/abuse of drugs. Neurology 1991;41:1358-1364.
Chitwood DD, Page JB, Comerford M, et al. The donation and sale of blood by intravenous drug users. Am J Pub Health 1991;81:631-633.
Steger KA, Craven DE, Shea BF, et al. Use of paperabsorbed fingerstick blood samples for studies of antibody to human immunodeficiency virus type 1 in intravenous drug users. J Infect Dis 1990;162:964-967.
Goodwin FK. Tuberculosis in drug users. JAMA 1989;262:1439.
Rothmann S, Tourani J-M, Andrieu J-M. Hodgkin’s disease in HIV-infected intravenous drug abusers. N Engl J Med 1990;323:275-276.
Joliet P, Widmann J-J. Reye’s syndrome in adult with AIDS. Lancet 1990;335:1457.
Graham NMH, Nelson KE, Solomon L, et al. Prevalence of tuberculin test positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA 1992;267:369-373.
Reichman L, Felton C, Edsall J. Drug dependence a possible new risk factor for tuberculosis disease. Arch Intern Med 1979;139:337-339.
Handwerger S, Mildvan D, Senie R, McKinley F. Tuberculosis and the acquired immunodeficiency syndrome at a New York City Hospital: 1978—1985. Chest 1987;91:176-180.
O’Donnell A, Pappas LS. Pulmonary complications of intravenous drug abuse: Experience at an inner-city hospital. Chest 1988;94:251-253.
Froner GA, Rutherford GW, Rokeach M. Injection of sodium hypochlorite by intravenous drug users. JAMA 1987;258:325.
Becker GL, Cohen S, Borer R. The sequelae of accidentally injecting sodium hypochlorite beyond the root apex. Oral Surg Oral Med Oral Pathol 1974;38:633-638.
Felser JM, Orban DJ. Dystonic reaction after ketamine abuse. Ann Emerg Med 1982;11:673.
Baselt RC, Cravey RH. Disposition of Toxic Drugs and Chemicals in Man. 3rd ed. Chicago: Year Book, 1989:444-446.
Wood M. Intravenous anesthetics. In: Wood M, Wood AJJ, eds. Drugs and Anesthesia: Pharmacology for Anesthesiologists. 2nd ed. Baltimore: Williams & Wilkins, 1990:179-223.
Koppel C, Arndt I, Ibe K. Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation. Eur J Drug Metab Pharmacokinet 1990;15:259-263.
Reich DL, Silvay G. Ketamine: An update on the first twentyfive years of clinical experience. Can J Anaesth 1989;36:186-197.
Green SM, Johnson NE. Ketamine sedation for pediatric procedures: Part 2: Review and implications. Ann Emerg Med 1990;19:1033-1046.
Schorn TOF, Whitwann JG. Are there long-term effects of ketamine on the central nervous system? Br J Anaesth 1980;52:967-968.
Johnstone RE. A ketamine trip. Anesthesiology 1973;39:460-461.
Ketamine abuse. FDA Drug Bull 1979;9:24.
Ahmed SN, Petchkovsky L. Abuse of ketamine. Br J Psychiatry 1980; 137:303.
Fine J, Firestone SC. Sensory disturbances following ketamine anesthesia: Recurrent hallucinations. Anesth Analg 1973;52:428-430.
Green SM, Nakamura R, Johnson NE. Ketamine sedation for pediatric procedures: Part 1: Prospective series. Ann Emerg Med 1990; 19:1024—1032.
Bloomquist E. Drug dangers. JAMA 1971 ;218:1301.
Stella L, Crescenti A, Torn G. Effect of naloxone on the loss of consciousness induced by IV anaesthetic agents in man. Br J Anaesth 1984;56:369-373.
Amiot JF, Bouju P, Palacci JH. Effect of naloxone on loss of consciousness induced by IV ketamine. Br J Anaesth 1985;57:930.
Bescey L, Malamed S, Radnay P, et al. Reduction of the psychotomimetic and circulatory effects of ketamine by droperidol. Anesthesiology 1972;37:536-542.
Kaplan JA, Cooperman LJ. Alarming reactions to ketamine in patients taking thyroid medication: Treatment with propranolol. Anesthesiology 1971;35:229-230.
Jansen KLR. Non-medical use of ketamine: Dissociative states in unprotected settings may be harmful. Br Med J 1993;306:601-602.
Schwartz RH. Urine testing in the detection of drugs of abuse. Arch Intern Med 1988;148:2402-2412.
Goldberger BA, Cone EJ. Confirmatory tests for drugs in the workplace by gas chromatography-mass spectrometry J Chromatogr A 1994;674:73-86.
Osterloh JD, Becker CE. Chemical dependency and drug testing in the workplace. West J Med 1990;152:506-513.
McCunney RJ. Drug testing: Technical complications of a complex social issue. Am J Ind Med 19 089; 15:589— 600.
Adulterated urine samples: An interview with Bob Fogerson. Syva Monitor 1987;5(2):1—3.
Person NB, Ehrenkranz JRL Fake urine sample for drug analysis: Hot, but not hot enough. JAMA 1988;259:841.
Johnson CA, Cary PL. Intentional adulteration of urine specimen for drugs of abuse testing to produce false positive results. J Anal Toxicol 1990;14:195-196.
Warner A. Interference of common household chemicals in immunoassay methods for drugs of abuse. Clin Chem 1989;35:648-651.
Rollins DE, Jennison TA, Jones G. Investigation of interference by non-steroidal anti-inflammatory drugs in urine tests for abused drugs. Clin Chem 1990;36:602— 606.
Hawks RL, Chiang CN. Urine Testing for Drugs of Abuse. NIDA Research Monograph No. 73, DHHS Publication No. (ADM) 87—1481,1981.
Goldberger BA, Caplan YH. Effect of glutaraldehyde (UrinAID) on detection of abused drugs in urine by immunoassay. Clin Chem 1994;40:1605-1606.
Sanson HL, Fraser MD, Botelho C, et al. Detection of urine specimens adulterated with UrinAID. In: Proceedings, California Association of Toxicologists, October 1993.
La Foie P, Beck O, Blennow G, et al. Importance of creatinine analysis of urine when screening for abused drugs. Clin Chem 1991;37:1927-1931.
Baumgarten WA, Hill VA, Bland WH. Hair analysis for drugs of abuse. J Forens Sci 1989;34:1433-1453.
Cone EJ. Testing human hair for drugs of abuse: I. Individual dose and time profiles of morphine and codeine in plasma, saliva, urine and beard compared to drug-induced effects on pupils and behavior. J Anal Toxicol 1990;14:1-7.
Strang J, Marsh A, Desouza N. Hair analysis for drugs of abuse. Lancet 1990; 1:740.
Carroll WM, Mastiglia FL. Alpha and beta coma in drug intoxication. Br Med J 1977;2:1518-1519.
Kuroiwa Y, Furukawa T. EEG prognostication in drug-related alpha cone. Arch Neurol 1981 ;38:200.
Schramm W, Smith RH, Craig PA, Kidwell DA. Drugs of abuse in saliva: A review. J Anal Toxicol 1992;16:1-9.
FDA Consumer 1995;29:5.
Baselt RC, Cravey RH. Disposition of Toxic Drugs and Chemicals in Man. Chicago: Year Book Medical. 1989:32.
Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am 1987; 1:459— 478.
Zuckerman MA, Oxford JS. Amantadine for influenza A. Br Med J 1991;302:1022.
Nicholson KG, Wiselka MJ. Amantadine for influenza A. Br Med J 1991;302:425-426.
Schwab RS, England AC, Poskanzer DC, et al. Amantadine in the treatment of Parkinson’s disease. JAMA 1969;208:1168-1170.
Di Mascio A, Bernardo DL, Greenblatt DJ, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976;33:599-602.
Tennant FS Jr, Sagherian AA. Double blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch Intern Med 1987;147:109-112.
Handelsman L, Chordia PL, Escovar IM, et al. Amantadine for treatment of cocaine dependence in methadonemaintained patients. Am J Psychiatry 1988; 145:533.
Sartori M, Pratt CM, Young JB. Torsade de pointes: Malignant cardiac arrhythmia induced by amantadine poisoning. Am J Med 1984;77:388-391.
Cook PE, Dermer SW, McCurg T. Fatal overdose with amantadine. Can J Psychiatry 1986;31:757-758.
Simpson DM, Ramos F, Ramirez LF. Death of a psychiatric patient from amantadine poisoning. Am J Psychiatry 1988;145:267-268.
Brown CR, Hernandez S, Kelly MT. Hyperthermia and death from amantadine overdose. Vet Hum Toxicol 1987;29:463.
BleidnerWE, Harmon JB, Hewes WE, et al. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther 1965;150:484-490.
Fahn S, Craddock G, Kuman G. Acute toxic psychosis from suicidal overdosage of amantadine. Arch Neurol 1971;25:45-48.
Amantadine. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:392-395, 2426-2428.
Speeg KV, Leighton JA, Maldonado AL. Case report: Toxic delirium in a patient taking amantadine and tri-methoprim-sulfmethoxazole. Am J Med Sci 1989;298:410-412.
Snoey ER, Bessen HA. Acute psychosis after amantadine overdose. Ann Emerg Med 1990;19:668-670.
Levy M, Pastuszak A, Koren G. Fetal outcome following intrauterine amantadine exposure. Reprod Toxicol 1991;5:79-81.
Reynolds PC, Van Meter S. A death involving amantadine. J Anal Toxicol 1984;8:100.
Priddis C. A fatal case involving amantadine. Bull Int Assoc Forens Toxicol 1986; 19( 1 ):35—36.
Ing TS, Daugirdas JT, Soung LS, et al. Toxic effects of amantadine in patients with renal failure. Can Med Assoc J 1979;120:695-698.
Haradam VW, Sharp JG, Smilack JD, et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med I98l;94(pt l):454—458.
Aoki FY, Sitar DS, Ogilvie Rl. Amantadine kinetics in healthy young subjects after long-term dosing. Clin Pharmacol Ther 1979;16:729-736.
Sande MA, Mandell GL. Antimicrobial agents. In: Gilman AG, Goodman LS, Rail TW, Murad F, eds. The Pharmacological Basis of Therapeutics. New York: Macmillan, 1985:1232.
Pacific GM, Nardini M, Ferrari P, et al. Effects of amantadine on drug-induced parkinsonism: Relationship between plasma levels and effect. Br J Clin Pharmacol 1976;3:883-889.
Liu P, Cheng PJ, Ing TS, et al. In vitro binding of amantadine to plasma proteins. Neuropharmacology 1962;2:149.
Wilson TW, Rajput AH. Amantadine-dyazide interaction. Can Med Assoc J 1983;129:974-975.
Degelau S, Somani S, Cooper SL, Irvine PW. Occurrence of adverse effects and high amantadine concentrations with influenza prophylaxis in the nursing home. J Am Geriatr Soc 1990;33:428-432.
Frauenfelder FT, Meyer SM. Amantadine and corneal deposits. Am J Ophthalmol 1990;110:96-97.
Vale J A, Maclean KS. Amantadine induced heart failure. Lancet 1976;1:548.
Atkinson WL, Arden NH, Patriarca PA, et al. Amantadine prophylaxis during an institutional outbreak of type A (HINI) influenza. Arch Intern Med 1986;146:1751 — 1756.
Douglas RG. Prophylaxis and treatment of influenza. N Engl J Med 1990;322:443-450.
Pimental L, Hughes B. Amantadine toxicity presenting with complex ventricular ectopy and hallucinations. Pediatr Emerg Care 1991;7:89-92.
Rizzo M, Biandrate P, Tognoni G, Morselli PL. Amantadine in depression: Relationship between behavioral effects and plasma levels. Eur J Clin Pharmacol 1973;5:226-228.
Berkowitz CD. Treatment of acute amantadine toxicity with physostigmine. J Pediatr 1979;95:144-145.
Casey DE. Amantadine intoxication reversed by physostigmine. N Engl J Med 1978;278:516.
McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (F1AU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-1105.
Swartz MN. Mitochondrial toxicity: New adverse drug effects. N Engl J Med 1995;333:1146-1148.
Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 1994;10:281-291.
Saran BR, Maguire AM. Retinal toxicity of high dose intravitreal ganciclovir. Retina 1994;14:248-252.
Gilstrap LC, Lawdon RE, Robert SW, Sohh S. The transfer of the nucleoside analog ganciclovir across the perfused human placenta. Am J Obstet Gynecol 1994;170:967-973.
Infectious Diseases and Immunization Committee, Canadian Paediatric Society. Ribavirin: Is there a risk to hospital personnel? Can Med Assoc J 1991; 144:285— 286.
Dolin R. Antiviral chemotherapy and chemoprophylaxis. Science 1985;227:1296-1303.
Zlydnikov DM, KubarOI, Ovaleva TP. Kamforin: Study of rimantadine in the USSR: A review of the literature. Rev Infect Dis 1981;3:408-421.
Nicholson KG, Wiselka MJ. Amantadine for influenza A. Br Med J 1991;302:425-426.
Wills RJ, Belshe R, Tomlinson D, et al. Pharmacokinetics of rimantadine hydrochloride in patients with chronic liver disease. Clin Pharmacol Ther 1987;42:449-454.
Tominack RL, Wills RJ, Gustavson LE, Hayden FG. Multiple dose pharmacokinetics of rimantadine in elderly adults. Antimicrob Agents Chemother 1988;32: 1813-1819.
Holazo AA, Choma N, Brown SY, et al. Effect of cimetidine on the disposition of rimantadine in healthy subjects. Antimicrob Agents Chemother 1989;33:820-823.
Douglas RG. Prophylaxis and treatment of influenza. N Engl J Med 1990:322:443-450.
Bentley DW, Karki ISD, Betts RF. Rimantadine and seizures. Ann Intern Med 1989;110:323-324.
Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am 1987;1:459-478.
Fillastre J-P, Singlas E. Pharmacokinetics of newer drugs in patients with renal impairment, Part 1. Clin Pharmacokinet 1991;20:294-310.
Drugs for поп-HIV viral infections. Med Lett Drugs Ther 1994;36(919):27—31.
Nilsen AE, Aasen T, Halsos AM, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 1982;2:571-572.
Johnson RE, Mullooly JP, Valanus BG, et al. Acyclovir use and its surveillance in a general population. DICP Ann Pharmacother 1990;24:624-628.
Fletcher CV, Chnnock BJ, Chace B, Balfour HH Jr. Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation. Clin Pharmacol Ther 1988;44:158-163.
Acyclovir. In: McEvoy G, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994;383—391, 2268-2670.
Fischer A, Fellay G, Regamey C. Toxicite renale et neurologique de Г acyclovir. Schweiz Med Wochenschr 1990;120:1200-1203.
Centers for Disease Control and Prevention. Pregnancy outcome following systemic prenatal acyclovir exposure: June 1, 1984—June 1, 1993. MMWR 1993;42: 806-809.
O'Brien JJ, Campoli-Richards DM. Acyclovir: An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989;27:233— 309.
Blum MR, Liao SHT, De Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med 1982;73( 1 A): 186-192.
Hopefl AW. The diurnal use of intravenous acyclovir. Drug Intell Clin Pharm 1983;17:623-628.
De Miranda P, Good SS, Krsney HC, et al. Metabolic fate of radioactive acyclovir in humans. Am J Med 1982;73(1 A):215—220.
Laskin OL, Longstreth JA, Whelton A, et al. Acyclovir kinetics in end-state renal disease. Clin Pharmacol Ther 1982;31:594-601.
Laskin OL. Acyclovir pharmacology and clinical experience. Arch Intern Med 1984:144:1241 — 1246.
King DH. History, pharmacokinetics and pharmacology of acyclovir. J Am Acad Dermatol 1988;18:176-179.
Bach MC. Possible drug interaction during therapy with azidothymidine and acyclovir in AIDS. N Engl J Med 1987;316:547.
Klug S, Lewandowski C, Blankenburg G, et al. Effect of acyclovir on mammalian embryonic development in culture. Arch Toxicol 1985;58:29-96.
Frieden FJ, Ordorica SA, Goodgold AL, et al. Successful pregnancy with isolated herpes simplex virus encephalitis: Case report and review of the literature. Obstet Gynecol 1990;175:511-513.
Brocklehurst P, Carney O, Helson K, et al. Acyclovir, herpes and pregnancy. Lancet 1990;226:1594-1595.
Haefeli WE, Schoenenberger PAZ, Weiss P. Acyclovir-induced neurotoxicity: Concentration-side effect relationship in acyclovir overdose. Am J Med 1993;94:212— 215.
Centers for Disease Control and Prevention. Pregnancy outcomes following systemic prenatal acyclovir exposure: June 1, 1984—June 30, 1993. Arch Dermatol 1994;130:153-154.
Centers for Disease Control and Prevention. From the MMWR: Pregnancy outcomes following systemic prenatal acyclovir exposure: June 1, 1984—June 30, 1993. Arch Dermatol 1994;130:153-154.
Dorsky DI, Crumpacker CS. Drugs five years later: Acyclovir. Ann Intern Med 1987;107:859-871.
Wade JC, Meyers JD. Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation. Ann Intern Med 1983;98:921-925.
Rubin J. Overdose with acyclovir in a CAPD patient. Perit Dial Bull 1987;7:42-53.
Adair JC, Gold M, Bond RE. Acyclovir neurotoxicity: Clinical experience and review of the literature. South Med J 1994;87:1227-1231.
Giustina A, Romanelli G, Cimino A, Brunori G. Low dose acyclovir and acute renal failure. Ann Intern Med 1988; 108:312.
Rashed A, Azedeh B, Abu Romeh SH. Acyclovir-induced acute tubulo-interstitial nephritis. Nephron 1990;56:436-438.
Gill MJ, Burgess E. Neurotoxicity of acyclovir in end state renal disease. J Antimicrob Chemother 1990;25:300-301.
Sougawa M, Akagik K, Murata T, et al. Enhancement of radiation effects of acyclovir. I nt J Radiat Oncol Biol Phys 1986;12:1537-1540.
Davey PG. New antiviral and antifungal drugs. Br Med J 1990;300:793-798.
Englund JA, Fletcher CV, Johnson D, et al. Effect of blood exchange on acyclovir clearance in an infant with neonatal herpes. J Pediatr 1987;110:151-153.
Eck P, Silver SM, Clark EC. Acute renal failure and coma after a high dose of oral acyclovir. N Engl J Med 1991;325:1178.
McDonald L, Tartaglione TA, Mendelman PM, et al. Lack of toxicity in two cases of neonatal acyclovir overdose. Pediatr Infect Dis J 1989;8:529-532.
Collins GE. Personal correspondence from Drug Information Department, Burroughs Wellcome Co., March 7, 1991.
Quinn RP, De Miranda GL, Good SS. A sensitive radioimmunoassay for the antiviral agent BW248U(9-(2-hy-droxyethoxymethyl)guanine). Anal Biochem 1979;98: 319-328.
Skubitz KM, Quinn RP, Lietman PS. A rapid acyclovir radioimmunoassay using charcoal adsorption. Antimicrob Agents Chemother 1982;21:352-354.
Rudd C, Rivadeneira ED, Gutman LI. Dosing considerations for oral acyclovir following neonatal herpes disease. Acta Pediatr 1994;83:1237-1243.
Leikin JB, Schicker L, Orlowski J, et al. Hemodialysis removal of acyclovir. Vet Hum Toxicol 1995;37:233-234.
Moore DF, Taylor SC, Bryson YJ. Virus inhibition assay for measurement of acyclovir levels in human plasma and urine. Antimicrob Agents Chemother 1981;20:787-792.
Keeney RE, Kirk LE, Bridgen D. Acyclovir tolerance in humans. Am J Med 1982;73( 1 A): 176—181.
Laskin OL, Longstreth J A, Whelton A, et al. Effect of renal failure on the pharmacokinetics of acyclovir. Am J Med 1982;(1A): 197-201.
Krasney HC, Liao SHT, De Miranda P, et al. Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. Am J Med 1982;73(1 A):202—204.
Dannenberg AL, Dorfman SF, Johnson J. Use of quinine for self induced abortion. South Med J 1983;76:846-849.
Nishimura H, Tanimura T. Clinical Aspects of the Teratogenicity of Drugs. Amsterdam: Excerpta Medica, 1976:140-143.
Quinine. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:464—467.
Elliott RH. Quinine poisoning: Its ocular lesions and visual disturbances. Am J Ophthalmol 1918:1:547—560, 650-658.
Quinine. In: Reynolds JEF, ed. Martindale: The Extra Pharmacopeia. 30th ed. London: Pharmaceutical Press, 1993:408-411.
Rollo IM. Drugs used in the chemotherapy of malaria. In: Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics. 5th ed. New York: MacMillan, 1975:1062-1065.
Banerji NK, Martin VAF. Myelo-optico-neuropathy following quinine poisoning. J Irish Med Assoc 1974;67:46-47.
Diamondstone AH, Braveman BL, Baker LA. Ventricular tachycardia and bilateral amaurosis produced by quinine poisoning. Arch Intern Med 1947;80:763-770.
La Greca G, Biasioli S, Borin D, et al. Drugs and dialysis. Int J Artif Organs 1983;6:139-156.
Grant WM. Toxicology of the Eye. 3rd ed. Springfield, IL: Charles C Thomas, 1986:778-784.
Brinton GS, Norton EWD, Zahn JR, et al. Ocular quinine toxicity. Am J Ophthalmol 1980;90:403-410.
Roche RJ, Silamut К, Pukrittayakaniee S, et al. Quinine induces reversible high tone hearing loss. Br J Clin Pharmacol 1990;29:780-782.
Schonwald S, Shannon M. Unsuspected quinine intoxication presenting as acute deafness and mutism. Am J Emerg Med 1991;9:318-320.
Wolf LR, Otten EJ, Spadafora MP. Cinchonism: Two case reports and review of acute quinine toxicity and treatment. J Emerg Med 1992;10:295-301.
Prescott LF, Hamilton AR, Heyworth R. Treatment of quinine overdosage with repeated oral charcoal. Br J Clin Pharmacol 1989;27:95-97.
Bateman DN, Blain PG, Woodhouse KW, et al. Pharmacokinetics and clinical toxicity of quinine overdosage: Lack of efficacy of techniques intended to enhance elimination. Q J Med N Ser 1985;54:125-131.
Gibbs JL, Trafford A, Sharpstone P. Quinine amblyopia treated by combined haemodialysis and activated resin haemoperfusion. Lancet 1985;1:752-753.
Lupovich P, Pilewski R, Sapira JD, et al. Cardiotoxicity of quinine as adulterant in drugs. JAMA 1970;212: 1216.
Salako LA. Pharmacokinetics of antimalarial drugs: Their therapeutic and toxicological implications. Ann 1st Super Sanita 1985;21:315-326.
Rosenblatt JE. Antiparasitic agents. Mayo Clin Proc 1992;67:276-287.
Winstanley PA, Edwards G, Orme ML’E, Breckenridge AM. Effect of dose size on amodiaquine pharmacokinetics after oral administration. Eur J Clin Pharmacol 1987;33:331-333.
Hatton C, Peto T, Bunch C, et al. Frequency of severe neutropaenia associated with amodiaquine prophylaxis against malaria. Lancet 1986;1:411-414.
Neftel KA, Woodtly W, Schmid M, et al. Amodiaquineinduced agranulocytosis and liver damage. Br Med J 1986;292:721-723.
Mack RB. 4-Aminoquinolines can be dangerous to your health: Chloroquine (Aralen) intoxication. NC Med J 1984;45:245-246.
Chloroquine and other antimalarials. In: Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:393—411.
Chloroquine hydrochloride. Chloroquine phosphate. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:452-456.
Marr JJ. Antiparasitic agents. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Anti-Infective Therapy. New York: Wiley, 1985:381-383.
Halofantrine in the treatment of malaria. Lancet 1989;2:537-538. Editorial.
Watkins WM, Oloo J A, Lury JD, et al. Efficacy of multiple dose halofantrine in treatment of chloroquine-resistant falciparum malaria in children in Kenya. Lancet 1988;2:247-250.
Bandon D, Bernard J, Moulia-Pelat JP, et al. Halofantrine to prevent falciparum malaria on return from malarious areas. Lancet 1990;336:377-378.
Hydroxychloroquine. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:456—458.
Hydroxychloroquine. In: Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:401—402.
Miller D, Fiechtner J. Hydroxychloroquine overdosage. J Rheumatol 1989;16:142-143.
Ivermectin. In: Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:43-44.
Ette El, Thomas WOA, Achumba JJ. Ivermectin: A long acting microfilaricidal agent. DICP Ann Pharmacother 1990;24:426-433.
Pyrimethamine. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:460—464.
Calcium leucovorin. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:2465—2467.
Hitchings GH. The utilisation of biochemical differences between host and parasites as a basis for chemotherapy. In; Goodwin LG, Nimmo-Smith RH, eds. Drugs, Parasites and Hosts. London: J & A Churchill, 1962:200.
Tracqui A, Mikail 1, Kintz P, Mangin P. Non-fatal prolonged overdose of pyrimethamine in an infant: Measurement of plasma and urine levels using HPLC with diode-array detection. J Anal Toxicol 1993;17:248-250.
Boland ME, Roper SMG, Henry JA. Complications of quinine poisoning. Lancet 1985;1:384-385.
Dyson EH, Proudfoot AT, Prescott LF, et al. Death and blindness due to overdose of quinine. Br Med J 1985;291:31-33.
Murray SF, Jay J L. Loss of sight after self poisoning with quinine. Br Med J 1983;287:1700.
Bateman DN, Blain PG, Woodhouse KW, et al. Pharmacokinetics and clinical toxicity of quinine overdosage: Lack of efficacy of techniques intended to enhance elimination. QJ Med N Ser 1985;54:125-131.
Dannenberg AL, Dorfman SF, Johnson J. Use of quinine for self induced abortion. South Med J 1983;76:846-849.
Licciardello AT, Stanbury JB. Acute hemolytic anemia from quinine used as an abortifacient. N Engl J Med 1948;238:120-121.
Rollo IM. Drugs used in the chemotherapy of malaria. In: Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics. 5th ed. New York: MacMillan, 1975:1062-1065.
Quinine. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, M D: American Society of Hospital Pharmacists, 1994:464—467.
Handbook of Antimicrobial Therapy, rev ed. New Rochelle, NY: Medical Letter, 1984:101.
Quinine. In: Reynolds JEF, ed. Martindale: The Extra Pharmacopeia. 30th ed. London: Pharmaceutical Press, 1993:408-411.
Winek CL, Davis ER, Collom WD, et al. Quinine fatality: Case report. Clin Toxicol 1974;7(2): 129—132.
Winek CL, Schweighardt FK, Fochtman FW, et al. Quinine in urinalysis for heroin. JAMA 1971;217:1243— 1244.
Lupovich P, Pilewski R, Sapira JD, et al. Cardiotoxicity of quinine as adulterant in drugs. JAMA 1970;2I2:1216.
Akindele O, Odejide AO. Amodiaquine-induced involuntary movements. Br Med J 1976;2:214-215.
Kjaer K. Effects of an overdose of chloroquine in a pregnant woman. Am J Trop Med Hyg 1955;4:259-262.
Frisk-Holmberg M, Bergqvist Y, Englund U. Chloroquine intoxication. Br J Clin Pharmacol 1983;15:502— 503.
Wilkinson R, Mahatane J, Wade P, Parvol G. Chloroquine poisoning. Br Med J 1993;307:504.
Chemmessy JL, Favier C, Borrow SW, et al. Hypokalemia related to acute chloroquine ingestion. Clin Toxicol 1995;33:475-486. Abstract 73.
Vachon F, Fajac I, Gachot B, et al. Halofantrine and acute intravascular haemolysis. Lancet !992;340:909— 910.
Hallwood PM, Horton RJ, O’Sullivan KM, Parr SN. Halofantrine and pruritus. Lancet 1989;2:397-398.
Halofantrine in the treatment of malaria. Lancet 1989;2:537-538. Editorial.
Wisekegle FY. A Survey of Antimalarial Drugs 1941 — 1945. Ann Arbor Ml: JW Edwards, 1946:309—324.
Nosten F, Ter Kuik FA, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993;341:1054-1056.
Wang R. Hydroxychloroquine cardiotoxicity. Clin Toxicol 1995;33:475-486. Abstract 164.
Kemmenoe AJ. An infant fatality due to hydroxychloroquine poisoning. J Anal Toxicol 1990;14:186-188.
Qverdose of hydroxychloroquine. Pharm J, 1 June 1 1963, p. 504.
Getz МА, Subramanian R, Logemann Т, Bellantyne F. Acute necrotizing eosinophilic myocarditis as a manifestation of severe hypersensitivity myocarditis. Ann Intern Med 1991;! 15:201-202.
Kunze K, Kauerz V, Scheldt A. Drug induced myopathy by hydroxychloroquine. Vet Hum Toxicol 1987;29(suppl. 2):59—60.
Makin AJ, Wendon J, Fitt S, et al. Fulminant hepatic failure secondary to hydroxychloroquine. Gut 1994;35:569-571.
Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 1987;104:139-144.
Hall AH, Spoerke DG, Bronsten AC, et al. Human ivermectin exposure. J Emerg Med 1985;3:217-219.
Ivermectin Poison Control Monograph. West Point, PA: Merck, Sharp and Dohme, Division of Merck, 1985:1 — 18.
Awadzi K, Dadzie KY, Shulz-Key H, et al. The chemotherapy of onchocerciasis. X. An assessment of four simple dose treatment regimens of MK-933 (ivermectin) in human onchocerciasis. Am Trop Med Parasitol 1985;79:63-78.
Dadzie KY, Bird AC, Awadzi K, et al. Ocular findings in a double-blind study of ivermectin versus diethylcar-bamazine versus placebo in the treatment of onchocerciasis. Br J Ophthalmol 1987;7:78-85.
Homeida MMA, Bagi 1A, Ghalib HW, et al. Prolongation of prothrombin time with ivermectin. Lancet 1988;1:1346-1347.
White AT, Newland HS, Taylor HR, et al. Controlled trial and dose finding study of ivermectin for treatment of onchocerciasis. J Infect Dis 1987;156:463-470.
Iliff-Sizemore SA, Partlow MR, Kelley ST. Ivermectin toxicology in a rhesus macaque. Vet Hum Toxicol 1990;32:530-532.
Hennequin C, Bouree P, Bazin N, et al. Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch Intern Med 1994;154:2360-2362.
Boots M, Phillips M, Curtis JR. Megaloblastic anemia and pancytopenia due to proguanil in patients with chronic renal failure. Clin Nephrol 1982;18:106-108.
Maegrath BG, Tottey MM, Adams ARD, et al. The absorption and excretion of paludrine in the human subject. Ann Trop Med Parasitol 1946;40:493-501.
Luzzi GA, Peto TEA. Adverse effects of antimalarials: An update. Drug Saf 1992;8:295-311.
Hla KK, Leahy N, Henry J. Accidental quinine poisoning in children under five. Vet Hum Toxicol 1987;29(suppl. 2): 121 —123.
Gottschall JL, Elliott W, Lianos E, et al. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: A new clinical entity. Blood 1991;77:306-310.
Spearing RL, Hickton CM, Sizeland P, et al. Quinine-induced disseminated intravascular coagulation. Lancet 1990;336:1535-1537.
Banerji NK, Martin VAF. Myelo-optico-neuropathy following quinine poisoning. J Irish Med Assoc 1974;67:46-47.
White NJ, Looareesuwan S, Warrell DA, et al. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated falciparum malaria. Am J Med 1982;73:564-572.
Winstanley PA, Edwards G, Orme ML’E, Breckenridge AM. The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol 1987;33:1-7.
Bergqvist Y, Frisk-Holmberg M. Sensitive method for the determination of chloroquine and its metabolite desethylchloroquine in human plasma and urine by high performance liquid chromatography. J Chromatogr 1980;221:119-127.
Broom C. The human pharmacokinetics of halofantrine hydrochloride. In: Warhurst DC, Schofield CJ, eds. Halofantrine in the Treatment of Multidrug Resistant Malaria. Cambridge: Elsevier, 1989:15—20.
Chiou R, Stubbs RJ, Bayre WF. Determination of ivermectin in human plasma and milk by fluorescence detection. J Chromatogr 1987;416:196-202.
Arnold PJ, Stetten OV. High performance liquid chromatographic analysis of mefloquine and its main metabolite by direct plasma injection with pre-column enrichment and column switching techniques. J Chromatogr 1986;353:193-200.
Helsby NA, Ward SA, Edwards G, et al. The pharmacokinetics and activations of proguanil in man: Consequences of variability in drug metabolism. Br J Clin Pharmacol 1990;30:593-598.
Zoest AR, Wanwinolruk S, Hung CT. Simple high performance liquid chromatographic method for the analysis of quinine in human plasma without extraction. J Liq Chromatogr 1990;13:3481-3491.
Patchen LC, Campbell CC, Williams SB. Neurologic reactions after a therapeutic dose of mefloquine. N Engl J Med 1989;321:1415-1416.
Rouveix B, Bricaire F, Michon C, et al. Mefloquine and an acute brain syndrome. Ann Intern Med 1989;110:577-578.
Hall A. Dangers of high dose quinine and overhydration in severe malaria. Lancet 1985; 1:1453.
Riou B, Barriot P, Rimailho A, Baud FJ. Treatment of severe chloroquine poisoning. IN Engl J Med 1988;319:50.
Mofenson H, Caraccio TR. Treatment of severe chloroquine poisoning. N Engl J Med 1988;319:50.
Stiff G, Robinson D, Cugnosi HL, et al. Massive chloroquine overdose: A survivor. Postgrad Med J 1991;67:678-679.
Bauer P, Maine B, Weber M, et al. Full recovery after a chloroquine suicide attempt. Clin Toxicol 1991 ;29:12— 30.
Crouzette J, Vicaut E, Palombo S, et al. Experimental assessment of the protective activity of diazepam on the acute toxicity of chloroquine. J Toxicol Clin Toxicol 1983;20:271-279.
Kivisto KT, Neuvonen PJ. Activated charcoal for chloroquine poisoning. Br Med J 1993;307:1068.
Neuvonen PJ, Kivisto K, Laine К, Pyykko K. Prevention of chloroquine absorption by activated charcoal. Clin Pharmacol Ther 1991 ;49:132.
Laurenson IF, Lalloo DG, Naragi S, et al. Chloroquine overdose in Papua New Guinea. BrMedJ 1993;307:564.
Meearan K, Jacob MG. Discussion group: Chloroquine poisoning rapidly fatal without treatment. Br Med J 1993;307:49-50.
Kelly JC, Wasserman GS, Bernard WD, et al. Chloroquine poisoning in a child. Ann Emerg Med 1990;19:47-50.
Sanghri LM, Mathur BB. Electrocardiogram after chloroquine and emetine. Circulation 1965;32:281-289.
Michael TAD, Aiwazzadeh S. The effects of acute chloroquine poisoning with special reference to the heart. Am Heart J 1976;79:831-842.
Ratliff NB, Estes ML, Myles J L, etal. Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Engl J Med 1987;316:191-193.
Hantson P, Ronveau JL, Coninck B, et al. Amrinone for refractory cardiogenic shock following chloroquine poisoning. Intens Care Med 1991;17:430-431.
Mofenson HC, Caraccio TR, Brody G, et al. Chloroquines and aminoquinolones. PP/T News. NCMC Regional Poison Control Center 1990 (Sept/Oct);9:(9— 1O):23O—232.
Garnier R, Elmalem J. Haemoperfusion in chloroquine poisoning. Br Med J 1985;291:141.
Robertson DH, Raman KRK. Quinine poisoning: An unusual indication for stellate ganglion blockade. Anesthesia 1979;34:1041-1042.
Boscoe MJ, Calver DM, Keyte C, et al. Quinine overdose: Prevention of visual damage by stellate ganglion block. Anesthesia 1983;38:1669-1671.
Scott DL, Ghia JN, Teeple E. Aphasia and hemiparesis following stellate ganglion block. Anesth Analg 1983;62:1038-1040.
Bacon P, Spalton DJ, Smith SE. Blindness from quinine toxicity. Br J Ophthalmol 1988;72:219-224.
Jones RG, Sue-Ling НМ, Kear C, et al. Severe symptomatic hypoglycaemia due to quinine therapy. J R Soc Med 1986;79:426-428.
Brent J, Hunt M, Kulig K, Rumack BH. Amphotericin В overdoses in infants: Is there a role for exchange transfusion? Vet Hum Toxicol 1990;32:124-125.
Brent J, Hunt M, Kulig K, Rumack BH. Amphotericin В overdoses in infants: Is there a role for exchange transfusion? Vet Hum Toxicol 1989;31:347. Abstract.
Koren G, Lau A, Kenyon CF, et al. Clinical course and pharmacokinetics following a massive overdose of amphotericin В in a neonate. Clin Toxicol 1990;28:37l — 378.
Spoerke DG. Amphotericin B. PoisindexR Toxicologic Management, July 1990.
Cleary JD, Hayman J, Sherwood J, et al. Amphotericin В overdose in pediatric patients with associated cardiac arrest. Ann Pharmacother 1993;27:715-719.
Davey PG. New antiviral and antifungal drugs. Br Med J 1990;300:793-798.
Kanarek KS, Williams PR. Toxicity of intravenous miconazole overdosage in a pre-term infant. Pediatr Infect Dis 1986;5:486-488.
Coulthard K, Martin J, Matthew N. Convulsions after miconazole overdose. Med J Aust 1987;146:57-58.
Araujo DE, Flowers FP, King MM. Griseofulvin: A new look at an old drug. DICP Ann Pharmacother 1990;24:851-854.
Lackner ТЕ, Clissold SP. Bifonazole: A review of its antimicrobial activity and therapeutic use in superficial myoses. Drugs 1989;38:204-225.
Naftifme for fungal skin infections. Med Lett Drugs Ther 1988;30:(177):98—99.
Stoughton RB, Sefton J, Zeleznick L. In vitro and in vivo cutaneous penetration and antifungal activity of naftifme. Cutis 1989;44:333-335.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:94-95, 2288-2289.
Benfield P, Clissold SP. Sulconazole: A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs 1988;35:143-153.
Lever LR, Thomas R, Dykes PJ, et al. Investigation of the pharmacokinetics of oral and topical terbinafine. Clin Res 1989;37(2):726A. Onychomycosis and terbinafine. Lancet 1990; 1:636. Editorial.
Terconazole for Candida vaginitis. Med Lett Drugs Ther 1988;30(782):l 18—119.
Moebius U. Influenza-like syndrome after terconazole. Lancet 1988;2:966-967.
Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-272.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists 1994:70-74, 2270-2271.
Graybill JR, Carven PC. Antifungal agents used in systemic mycoses: Activity and therapeutic use. Drugs 1983;25:41-62.
Douglas KG Jr, Bennett JE. Anti-infective Therapy. New York: Wiley, 1985:307-324.
Dismukes WE. Azole antifungal drugs: Old and new. Ann Intern Med 1988;109:177-179.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:315—319.
Louria DB. Some aspects of the absorption, distribution and excretion of amphotericin В in man. Antibiot Med Chem Therl 958;5:295—301.
Atkinson AJ Jr, Bennett JE. Amphotericin В pharmacokinetics in humans. Antimicrob Agents Chemother 1978;13:271-276.
Atkinson AJ Jr, Bindschadler DD. Pharmacokinetics of intrathecally administered amphotericin B. Am Rev Respir Dis'1969;99:917-924.
Starkie JR, Mason EO Jr, Kramer WG, Kaplan SL. Pharmacokinetics of amphotericin В in infants and children. J Infect Dis 1987;155:766-774.
Katikaneni LP. Amphotericin В eliminations and serum levels in very low birth weight infants. Clin Res 1989;37:342A.
Drugs for treatment of deep fungal infections. Med Lett Drugs Ther 1988;30(761 ):30—32.
Drugs for treatment of fungal infections. Med Letter Drugs Ther 1990;32(820):58-60.
Koren G, Lau A, Klein J, et al. Pharmacokinetics and adverse effects of amphotericin В in infants and children. J Pediatr 1988;113:559-563.
Baley J E, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment and toxic effects of amphotericin В and 5-fluorocytosine in neonates. J Pediatr 1990;116:791-797.
Churchill DN, Seely J. Nephrotoxicity associated with combined amphotericin B-gentamicin therapy. Nephron 1977;19:176-181.
Antoniskis D, Larsen RA. Acute rapidly progressive renal failure with simultaneous use of amphotericin В and pentamidine. Antimicrob Agents Chemother 1990;34:470— 472.
Drutz DJ, Fan JH, Tai TY, et al. Hypokalemic rhabdomyolysis and myoglobinuria following amphotericin В therapy. JAMA 1970;211:824-826.
Physicians’ Desk Reference. 49th ed. Oradell, NJ: Medical Economics, 1995:523—525.
Christiansen KJ, Bernard EM, Gold JWM, Armstrong D. Distribution and activity of amphotericin В in humans. J Infect Dis 1985;152:1037-1043.
Katz PZ, Cohn RA. Amphotericin В and hypertension. Pediatr Infect Dis J 1994;13:839-840.
Maddux MS, Barrier SL. A review of complications of amphotericin В therapy: Recommendations for prevention and management. Drug Intell Clin Pharm 1980;14:177-181.
Carnecchia BM, Kurtzke JF. Fatal toxic reaction to amphotericin В in cryptococcal meningo-encephalitis. Ann Intern Med 1960;53:1027-1036.
Levine SJ, Walsh TJ, Martinez A, et al. Cardiopulmonary toxicity after liposomal amphotericin В infusion. Ann Intern Med 1991;114:664-666.
Roncoroni AJ, Corrado C, Besuschio S, et al. Bronchiolitis obliterans possibly associated with amphotericin B. J Infect Dis 1990; 161:589.
Bindschadler DD, Bennett JE. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis 1969; 120:427.
Mayhew JW, Fiore C, Murray T, et al. An internally standardized assay for amphotericin В in tissues and plasma. J Chromatogr 1983;274:271.
Block ER, Bennett JE, Livoti LG, et al. Flucytosine and amphotericin B: Hemodialysis effects on the plasma concentration and clearance. Ann Intern Med 1974;80:613— 617.
Burnett RJ, Reents SB. Premedication for amphotericin В-induced chills. Clin Pharm 1989;8:836-837.
Oldfield EC HI, Burnett RJ, Reents SB. Meperidine for prevention of amphotericin В-induced chills. Clin Pharm 1990;9:251-252.
Fincannon J. Meperidine addiction associated with amphotericin treatment in leukemia: Case study and staff reaction. Arch Psychiatr Nurs 1988;2:302-306.
DaCamara CC, Lane TW. Dantrolene for amphotericin В-induced rigors. Arch Intern Med 1987; 147:2220.
Smith SR, Galloway MJ, Reilly JT, et al. Amiloride prevents amphotericin В related hypokalemia in neutropenic patients. J Clin Pathol 1988;41:494-497.
Branch RA. Prevention of amphotericin В-induced renal impairment: A review on the use of sodium supplementation. Arch Intern Med 1988;148:2389-2394.
Stein RS, Alexander JA. Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am J Med Sci 1989;298:299-304.
Harder EJ, Hermans PE. Treatment of fungal infections with flucytosine. Arch Intern Med 1975;135:231-237.
Harper KJ, Sawyer WT. Malabsorption of flucytosine in a pediatric patient with Shwachman syndrome. DICP Ann Pharmacother 1989;23:782-783.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:74-81, 2104-2106.
Kauffman C, Frame PT. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother 1977;11:244-247.
Kotani S, Hirose S, Niiya K, et al. Anaphylaxis to flucytosine in a patient with AIDS. JAMA 1988;260:3275— 3276.
Kaspar RL, Drutz DJ. Rapid simple bioassay for 5-fluorocytosine in the presence of amphotericin B. Antimicrob Agents Chemother 1975;7:462-465.
Harding SA, Johnson GF, Solomon HM. Gas chromatographic determination of 5-fluorocytosine in human serum. Clin Chem 1976;22:772-776.
Williams KM, Chinwah M, Cobcroft R. Crystalluria during flucytosine therapy. Med J Aust 1979;2:617.
McEvoy GK, ed. AHFS Drug Information 91. Bethesda, MD: American Society of Hospital Pharmacists, 1991:80-82.
Becker LE. Griseofulvin. Dermatol Clin 1984;2:115— 120.
Anderson DW. Griseofulvin: Biology and clinical usefulness. Ann Allergy 1965;23:103-110.
Liu C-C, Magat J, Chang R, et al. Absorption, metabolism and excretion of l4C-griseofulvin in man. J Pharmacol Exp Ther 1973;187:415-422.
Vasiliou V, Malamas M, Marselos M. The mechanism of alcohol intolerance produced by various therapeutic agents. Acta Pharmacol Toxicol 1986;58:305-310.
Metneki J, Czeizel A. Griseofulvin teratology. Lancet 1987;l:1042.
Haskell LP, Mennemyer RP, Greenman R, Pelezar C. Isolated erythroid hypoplasia and renal insufficiency induced by long-term griseofulvin therapy. South Med J 1990;83:1327-1330.
Mion G, Verdon R, Le Gulluche Y, et al. Fatal toxic epidermal necrolysis after griseofulvin. Lancet 1989;2:1331.
Ormerod AD, White Ml. Cold urticaria triggered by griseofulvin. Br Med J 1987;295:612.
Yang DJ, Rankin GO. Nephrotoxicity of antifungal agents. Adv Drug React Ac Pois Rev 1985;1:37-49.
Kowalsky SF, Dixon DM. Fluconazole: A new antifungal agent. Clin Pharm 1991;10:179-194.
Antifungal: Fluconazole. In: McEvoy GK, ed. AHFS Drug Information 94 Bethesda, MD: American Society of Hospital Pharmacists, 1994:74— 81.
Fluconazole. Med Lett Drugs Ther 1990;32 (818):50— 52.
Franklin IM, Elias E, Hirsch C. Fluconazole-induced jaundice. Lancet 1990;336:565.
Fluconazole (systemic). USP DI Update 1990, August 8:466-469.
Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12(suppl. 3):S318—S326.
Toon S, Ross CE, Gokal R, Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 1990;29:221-226.
Debruyne D, Ryckelynck J-P, Moulin M, et al. Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacokinet 1990;18:491-498.
Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991;! 14:755.
Ebden P, Neill P, Farrow PR. Sputum levels of fluconazole in humans. Antimicrob Agents Chemother 1989;33:963-964.
Arndt CA, Walsh TJ, McCully CL, et al. Fluconazole penetration into cerebrospinal fluid: Implications for treating fungal infections of the central nervous system. J Infect Dis 1988;157:178-180.
Foulds G, Brennan DR, Wajszczuk C, et al. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988;28:363-366.
Lazar JD, Hilligoss DM. The clinical pharmacology of fluconazole. Semin Oncol 1990; 17 (suppl. 6): 14—18.
Richardson K, Cooper K, Marriott MS, et al. Discovery of fluconazole, a novel antifungal agent. Rev Infect Dis 1990;12(suppl.3):S267—S271.
Saxen H, Норри K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther 1993;54:269-277.
Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12(suppl. 3):S327—S333.
Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991;49:420-450.
Force RW. Fluconazole concentrations in breast milk. Pediatr Infect Dis 1995;14:235-236.
Pasko MT, Piscitelli SC, Van Slooton AD. Fluconazole: A new triazole antifungal agent. DiCP Ann Pharmacother 1990;24:860-867.
Pappas PG, Kauffman CA, Perfect J, et al. Alopecia associated with fluconazole therapy. Ann Intern Med 1995;123:354-357.
German GE. FDA approves the drug fluconazole (alternate treatment for AIDS). FDA Information Bulletin, January 29, 1990.
Kidd D, Ranaghan EA, Morris TCM. Hypokalaemia in patients with acute myeloid leukaemia after treatment with fluconazole. Lancet 1989; 1:1017.
Lake-Bahaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J 1987;294:419-422.
Drugs for treatment of fungal infections. Med Lett Drugs Ther 1990;32(82a):58—60.
Tabor E. Hepatotoxicity of ketoconazole in men and in patients under 50. N Engl J Med 1987;316:1606-1607.
Gradnor JD, Sepkowitz DV. Massive hepatic enlargement with fatty change associated with ketoconazole. DICP Ann Pharmacother 1990;24:1175-1176.
Van Tyle JH. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy 1984;4:343-373.
Jacobs PH, Nael N. The action and safety of ketoconazole: A brief literature review. Cutis 1988;42:276-282.
Daneshmend TK. Diseases and drugs but not food decrease ketoconazole ’bioavailability’. Br J Clin Pharmacol 1990;29:783-784.
Wali JP, Aggarwal P, Gupta V, et al. Ketoconazole in treatment of visceral leishmaniasis. Lancet 1990;2:810— 811.
Glynn AM, Slaughter RL, Brass C, et al. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretions. Clin Pharmacol Ther 1986;39:654-659.
McNulty RM, Lazor JA, Sketch M. Transient increase in plasma quinidine concentrations during ketoconazolequinidine therapy. Clin Pharm 1989;8:222-225.
Varhe A, Olkkola T, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimy-cotics: Ketoconazole as itraconazole. Clin Pharmacol Ther 1994;56:601-607.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:87-91, 2282-2284.
Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987;317:812-818.
McCance DR, Ritchie CM, Sheridan B, Atkinson AB. Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet 1987; 1:573.
Khosla S, Wolfson JS. Demerjian Z, Godine JE. Adrenal crises in the setting of high-dose ketoconazole therapy. Arch Intern Med 1989;149:802-804.
Umstead GS, Babiak LM, Tejwani S. Immune hemolytic anemia associated with ketoconazole therapy. Clin Pharm 1987;6:499-500.
Lobo BL, Miwa LJ, Jungnickel PW. Possible ketoconazoleinduced hypoglycemia. Drug Intell Clin Pharm 1988;22:632.
Aabo K, De Coster R. Hypertension during high-dose ketoconazole treatment: A probably mineralocorticosteroid effect. Lancet 1987;2:637-638.
Fisch RZ, Lahad A. Adverse psychiatric reaction to ketoconazole. Am J Psychiatry 1989;146:939-940.
Jorgensen JH, Alexander GA, Graybill JR, Drutz DJ. Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid. Antimicrob Agents Chemother 1981;20:59-63.
Turner CA, Turner A, Warnock DW. High performance liquid chromatographic determination of ketoconazole in human serum. J Antimicrob Chemother 1986; 18: 757-763.
Blomley M, Teare EL, de Beider A, et al. Itraconazole and anti-tuberculosis drugs. Lancet 1990;336:1255.
Sachs MK, Paluzzi RG, Morre JH Jr, et al. Amphotericinresistant Aspergillus osteomyelitis controlled by itraconazole. Lancet 1990:335:1475.
Frontling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1988; 1:187— 217.
Denning DW, Tucker RM, Hanson LH. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86(suppl. 2):791-800.
Tucker RM, Hag Y, Denning DQ, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990;26:561 — 566.
Smith AG. Potentiation of anticoagulants by ketoconazole. Br Med J 1984;288:188-189.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:91-94, 2284-2286.
Fainstein V, Bodey GP. Cardiorespiratory toxicity due to miconazole. Ann Intern Med 1980;93:432-433.
Jordan WM, Bodey GP, Rodriguez V, et al. Miconazole therapy for treatment of fungal infections in cancer patients. Antimicrob Agents Chemother 1979;16:792-797.
U. S. Food and Drug Administration. Stavudine approved for certain patients with advanced HIV. JAMA 1994;272:382.
Fischl MA. Treatment of HIV disease in 1993/1994. AIDS Clin Rev 1993:167-187.
Safety Profile of Stavudine (ZeriP in Clinical Trials. Monograph P9-W003. Bristol-Meyers Squibb, August 1994.
Burgen DM, Rosing H, van Gijn R, et al. Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr Biomed Appl 1992;584:239-247.
FDA Consumer 1993;27:8.
Atovaquone, systemic. USD DI Update 1993:413—414.
Epstein U, Mohsenifar Z, Daar ES, et al. Clinical experience with atovaquone: A new drug for treating Pneumocystis carinii. Am J Med Sci 1994;308:5-8.
Spencer CM, Goa GL. Atovaquone: A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drug Saf 1995;50:176-196.
Masur H, Lane HC, Palestine A, et al. Effect of9-(l,3-dihydroxy-2-propoxymethyl)-guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Ann Intern Med 1986; 104:41—44.
Dorfman JS, Syntex Laboratories, Medical Services Department. Personal communication, April 19, 1991.
Haas DP, Hale KN. Policies and procedures for handling ganciclovir. Am J Hosp Pharm 1990;47:511-512.
Jacobson MA, de Miranda P, Gordon SM, et al. Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy. J Infect Dis 1988;158:489-490.
Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Ann Intern Med 1990;113:111-117.
Erice A, Jordan MC, Chace BA, et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987;257:3082-3087.
Faulds D, Heel RC. Ganciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990;39: 597-638.
Laskin OL, Stahl-Bayliss CM, Kalman CM, Rosecan LR. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. J Infect Dis 1987;155:323-327.
Shepp DH, Dandliker PS, Miranda P, et al. Activity of 9-[2-hydroxy-1 -(hydroxymethyl)-ethoxymethyl] guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985;103:368-373.
Sommadossi JP, Bevan R, Ling T, et al. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis 1988; 10(suppl. 3):507—514.
Stevens PE, Davies SP, Brown EA, et al. Continuous arteriovenous hemodialysis in critically ill patients. Lancet 1988;2:150-152.
Rello J, Roglan A, Garcia-Cases C, et al. Effect of continuous hemodialysis on ganciclovir pharmacokinetics. DICP Ann Pharmacother 1990;24:544-545.
Jisor GC, Lin LH, Jackson SE, et al. Stability of ganciclovirsodium (DHPG sodium) in 5 % dextrose or 0.9 % sodium chloride injections. Am J Hosp Pharm 1986;43:2810-2812.
Grossberg HS, Bonnem EM, Buhles WC. GM-CSF with ganciclovir for the treatment of CMV retinitis in AIDS. N Engl J Med 1989;320:1560.
Sulicki M. Rosenfeld CS, Przepiorka D, et al. Treatment of ganciclovir-induced neutropenia with recombinant human GM-CSF. Am J Med 1991;90:401-402.
Kleyman TR, Roberts С, Ling BN. A mechanism for pentamidine-induced hyperkalemia: Inhibition of distal nephron sodium transport. Ann Intern Med 1995;122:103-106.
Wood G, Hogan P, Wetzig N, Whitby M. Survival from pentamidine induced pancreatitis and diabetes mellitus. Aust NZ J Med 1991;21:341-342.
Monk JP, Benfield P. Inhaled pentamidine: An overview of its pharmacological properties and a review of its therapeutic use in Pneumocystis carinii pneumonia. Drugs 1990;39:741-756.
Hoo GWS, Mohsenifar Z, Meyer RD. Inhaled or intravenous pentamidine therapy for Pneumocystis carinii pneumonia in AIDS. Ann Intern Med 1990;l 13:195— 202.
Conte JE Jr, Chernoff D, Feigal DW Jr, et al. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. Ann Intern Med 1990;113:203-209.
Leoung GS, Feigal DW Jr, Montgomery AB, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia: The San Francisco Community Prophylaxis Trial. N Engl J Med 1990;323:769— 775.
Hirschel B, Lazzarin A, Chopard P, et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991;324:1079-1083.
Reynolds JEF, ed. Martindale. The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:524— 525.
Pentamidine isethionate. In: McEvoy GK, ed. AHFS Drug Information 91. Bethesda, MD: American Society of Hospital Pharmacists, 1991:480—488.
Taylor AJ, Hull RW, Coyne PE. et al. Pentamidine-induced Torsade de pointes: Safe completion of therapy with inhaled pentamidine. Clin Pharmacol Ther 1991;49:698-700.
Otterness IG, Torchia AJ, Doshan HD. Complement inhibition by amidines and guanidines: In vivo and in vitro results. Biochem Pharmacol 1978;27:1873-1878.
Conte JE Jr. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J Infect Dis 1991;163:169-175.
Montgomery AB, Corkery KJ, Brunette ER, et al. Occupational exposure to aerosolized pentamidine. Chest 1990;98:386-388.
Conover B, Goldsmith JC, Buehler BA, et al. Aerosolized pentamidine and pregnancy. Ann Intern Med 1988; 109:927.
Harshad TW, Little BB, Bawdon RE, et al. Embryofetal effects of pentamidine isethionate administered to pregnant Sprague-Dawley rats. Am J Obstet Gynecol 1990;163:912-916.
Pentamidine Isethionate Product Monograph. Rosemont, IL: Lyphomed, June 1989.
Wispelwey B, Pearson R. Pentamidine: A risk-benefit analysis. Drug Saf 1990;5:212-219.
Sands M, Kron MA, Brown RB. Pentamidine: A review. Rev Infect Dis 1985;7:625-634.
Sattler FR, Waskin H. Pentamidine and fatal hypoglycemia. Ann Intern Med 1987;107:789-790.
Yurdakok M. Diabetogenic effect of pentamidine. JAMA 1987;257:1177.
Wharton JM, Demopulos PA, Goldschlager N. Torsade de pointes during administration of pentamidine isethionate. Am J Med 1987;83:571-576.
Mitchell P, Dodek P, Lawson L, et al. Torsade de pointes during intravenous pentamidine isethionate therapy. Can Med Assoc J 1989;140:173-174.
Stein KM, Haronian H, Mensah GA, et al. Ventricular tachycardia and Torsade de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am J Cardiol 1990;66:888-889.
Kumar S, Schnadig VJ, MacGregor MG. Fatal acute pancreatitis associated with pentamidine therapy. Am J Gastroenterol 1989;451—453.
Zuger A, Wolf BZ, El-Sadr W, et al. Pentamidine associated fatal acute pancreatitis. JAMA 1986;256:2383— 2385.
Herer B, Chinet T, LaBrune S, et al. Pancreatitis associated with pentamidine by aerosol. Br Med J 1989;298:605.
Gradon JD, Fricchione L, Sepkowitz D. Severe hypomagnesemia associated with pentamidine therapy. Rev Infect Dis 1991;13:511-512.
Youle MS, Ciarbour J, Gazzard B, Chanas A. Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine. Lancet 1988;1:1455-1456.
Shah GM, Alvarado P, Kirschenbaum MA. Symptomatic hypocalcemia and hypomagnesemia with renal magnesium wasting associated with pentamidine therapy in a patient with AIDS. Am J Med 1990;89:380-382.
Collins RJ, Pien FD, Houk JH. Case report: Insulin dependent diabetes mellitus associated with pentamidine. Am J Med Sci 1989;297:174-175.
Peltz S, Hashimi S. Pentamidine induced severe hyperkalemia. Am J Med 1989;87:698-699.
Miller RF, Delany S, Semple SJG. Acute renal failure after nebulized pentamidine. Lancet 1989;1:1271 — 1272.
Miller RF, Semple SJG. Bronchial bleeding with nebulized pentamidine. Lancet 1988;2:1488.
Sneed SR, Blodi CF, Berger BB, et al. Pneumocystis carinii choroiditis in patients receiving inhaled pentamidine. N Engl J Med 1990;322:936-937.
Engrav MB, Coodley G, Magnusson AR. Torsade de pointes after inhaled pentamidine. Ann Emerg Med 1992;21:1403-1405.
Ericsson O, Rais M. Determination of pentamidine in whole blood, plasma and urine by high performance liquid chromatography. Ther Drug Monit 1990; 12:362— 365.
Conte JE Jr, Upton RA, Phelps RT, et al. Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. J Infect Dis 1986;154:923-929.
Bernard EM, Donnelly HJ, Maher MP, Armstrong D. Use of a new bioassay to study pentamidine pharmacokinetics. J Infect Dis 1985;152:750-754.
Tzivoni D, Banai S, Schuger C, et al. Treatment of Torsade de pointes with magnesium sulfate. Circulation 1988;77:392-397.
Chrisp Р, Clissold SP. Foscarnet: A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991;41:104-129.
Minor JR, BaltzJK. Foscarnet sodium. DICP Ann Phar-macother 1991;25:41-47.
Balfour HH Jr. Management of cytomegalovirus disease with antiviral drugs. Rev Infect Dis 1990;12(suppL 7):S849—S860.
Ringden O, Lonnqvist B, Paulin T, et al. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother 1986;17:373-387.
Bergdal S, Sonnerborg A, Larsson A, Strannegard O. Declining levels of HIV P24 antigen in serum during treatment with foscarnet. Lancet 1988; 1:1052.
Foscarnet: Drugs for viral infections. Med Lett Drugs Ther 1990;32:75-76.
Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325: 551-555.
Safrin S, Berger TG, Gilson 1, et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant Varicella-zoster virus infection. Ann Intern Med 1991;! 15: 19-21.
Sjovall J, Karlsson A, Ogenstad S, et al. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther 1988;44:65-73.
Sjovall J, Bergdahl S, Movin G, et al. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1989; 1023—1031.
Dercey G, Cacoub P, LeHoang P, et al. Foscarnet-induced acute renal failure and effectiveness of haemodialysis. Lancet 1987;2:216.
Lambert JS, Seidlin М, Reichman RC, etal. 2’,3’-Dide-oxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AlDS-rclated complex: A phase 1 trial. N Engl J Med 1990;322:1333-1340.
Dolin R, Lambert JS, Morse GD, et al. 2’,3’-Dideoxyi-nosine in patients with AIDS or AIDS-related complex. Rev Infect Dis 1990; 12(suppl. 5):S540-S551.
Butler KM, Husson RN, Balis FM, et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991;324:137-144.
Bouvet E, Casalino E, Prevost MH, Vachon F. Fatal case of 2’,3’-dideoxyinosine-associated hypokaelemia. Lancet 1990;336:1515.
Sahai J. Avoiding the ciprofloxacin-didanosine interaction. Ann Intern Med 1995;123:394-395.
Manson SJ, Greenfield SM, Turner JL. Acute dideoxyinosine pancreatitis as a common complication of 2’,3’-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol 1992;87:708-713.
Pancreatitis with ddl. FDA Consumer 1990;24:5.
Schindzielorz A, Pike 1, Daniels M, et al. Rates and risk factors for adverse events associated with didanosine in the expanded access program. Clin Infect Dis 1994;19:1076-1083.
Rozencweig M, McLaren C, Beltangady M, et al. Overview of phase I trials of 2’,3’-dideoxyinosine (ddl) conducted in adult patients. Rev Infect Dis 1990; 12(suppl. 5):S570—S575.
Bach MC. Clinical response to dideoxyinosine in patients with HIV infection resistant to zidovudine. N Engl J Med 1990;323:275.
Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2’,3'-dideoxyinosine (ddl). Ann Intern Med 1991 ;115:283—284.
Whitcup SM, Butler KM, Pizzo PA, Nussenblat RB. Retinal lesions in children treated with dideoxyinosine. N Engl J Med 1992;326:1226-1227.
Cooley TP, Kunches LM, Saunders CA, et al. Treatment of AIDS and AIDS-related complex with 2’,3’-dideoxyinosine given once daily. Rev Infect Dis 1990; 12(suppl. 5):S552—S560.
Dunkle LM. Bristol Myers Squibb. Letter to Videx (ddl) Investigators. March 28, 1990.
De Jong MD, Borleffs JCC. Didanosine and heart failure. Lancet 1992;339:806-807.
Carpen ME, Poplock DG, Pizzo PA, Balis FM. High-performance liquid chromatographic method for analysis of 2’,3’-dideoxyinosine in human body fluids. J Chromatogr 1990;526:69-75.
Katlama C, Tubiana R, Rosenheim M, et al. Dideoxyinosineassociated hypokalaemia. Lancet 1991 ;337:183.
Sachs MK. Antiretroviral chemotherapy of human immunodeficiency virus infections other than with azidothymidine. Arch Intern Med 1992;152:485-501.
Broder S. Dideoxycytidine (ddC): A potent antiretroviral agent for human immunodeficiency virus infection: An introduction. Am J Med 1990;88(suppl. 5B):5B— IS.
Broder S. Pharmacodynamics of 2’,3’-dideoxycytidine: An inhibitor of human immunodeficiency virus. Am J Med 1990;88(suppl. 5B):5B-2S-5B-7S.
Merigian TC, Skowron G. ddC Study Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Safety and tolerance of dideoxycytidine as a single agent: Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Am J Med 1990;88(suppl. 5B):5B— 1 IS—5B— 15S.
Broder S, Yarchoan R. Dideoxycytidine: Current clinical experience and future prospects. Am J Med 1990;88(sup-pl. 5B):5B 31S-5B-33S.
Yarchoan R, Perno CF, Thomas RV, et al. Phase 1 studies of 2’,3’-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988;1:76-81.
Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3’-azido-2’,3’-dideoxycytidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989;321:726-738.
Nightingale SL. Zaicitabine approved for use in combination with zidovudine for HIV infection. JAMA 1992;268:705.
Moore RD, Creagh-Kirk Т, Keruly J, et al. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Arch Intern Med 1991;151:981-986.
McKinney RE Jr, Maha MA, Connor FM, et al. A multicentertrial of oral zidovudine in children with advanced human immunodeficiency virus disease. N Engl J Med 1991;324:1018-1025.
Fisch! MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990;323:1009-1014.
Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD-4 positive cells per cubic millimeter. N Engl J Med 1990;322:941-949.
Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiencyvirus type 1 (HIV) infection: A double-blind, placebo-controlled trial. Ann Intern Med 1990;! 12:727— 731.
Coller AC, Bozzette S, Coombs RW, et al. A pilot study of low dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990;323:1015-1021.
Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192-197.
Valentine C, Williams O, Davis A, et al. Case study of zidovudine overdose. AIDS 1993;7:436-437.
Zidovudine. In: McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:438—451.
Swart AM, Weller 1, Darbyshire JH. Early HIV infection: to treat or not to treat? Cautiously until trials produce answers on long term efficacy and safety. Br Med J 1990;301:825-826.
Zidovudine. Med Letter Drugs Ther 1990;32:78.
Terragna A, Mazzarello G, Anselmo M, et al. Suicidal attempts with zidovudine. AIDS 1990;4:88.
Selwyn PA, lezza A. Zidovudine overdose in an intravenous drug user. AIDS 1990;4:822-824.
Staszewski S, Rehmet S, Odewald J, et al. Overdosage of zidovudine. Lancet 1989; 1:385.
Heard JM, Slovis CM. Zidovudine (AZT) (Retrovir®) overdose. Vet Hum Toxicol 1988;30:365-366.
Routy JP, Prajs E, Blanc AP, et al. Seizure after zidovudine overdose. Lancet 1989;1:384-385.
Spear JB, Kessler HA, Lehrman SN, de Miranda P. Zidovudineoverdosage. Ann Intern Med 1988;109:76-77.
Hargreaves M, Fuller G, Costello C, Gazzard B. Zidovudine overdose. Lancet 1988;2:509.
Casals A, Ribelles N, Clotet B, Fox M. Zidovudine overdose. Med Clin 1989;5:199.
Pickus OB. Overdose of zidovudine. N Engl J Med 1988;318:1206.
Moore EC, Cohen F, Kauffman RE, Aravind MK. Zidovudine overdose in a child. N Engl J Med 1990;322:408-409.
Lefeuillade A, Poizot-Martin I, Dhiver C, et al. Zidovudine overdose: A case with bone marrow toxicity. AIDS 1991;5:116-117.
Sacho H, Schoub BD. Guidelines for the use of zidovudine for post-exposure prophylaxis after needlestick injuries in health care settings. S Afr Med J 1990;77:619— 622.
Henderson DK, Gerberding JL. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: An interim analysis. J Infect Dis 1989;160:321-327.
Jeffries DJ. Zidovudine after occupational exposure to HIV: Hospitals should be able to give it within an hour. Br Med J 1991;302:1349-1351.
Elkharrat D, Wautier JI, Caulin C, Bonnet N. Zidovudine after occupational exposure to HIV. Br Med J I991;3O3:3O9.
Lange JMA, Boucher CAB, Hollak CEM, et al. Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med 1990;322:1375-1377.
Lucey D, Milum S, Lindquist C, et al. Pseudofailure of zidovudine prophylaxis after a human immunodeficiency virus: Positive needlestick. J Infect Dis 1990;162:1211 — 1212.
Durand E, Le Jeunne C, Hughes F-C. Failure of prophylactic zidovudine after suicidal self-inoculation of HIV-infected blood. N Engl J Med 1991 ;324:1062.
Zidovudine and needlestick exposure. Lancet 1990;335:1271. Editorial.
Singlas E, Pioger JC, Taburet AM, et al. Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (GAZT) in healthy subjects and HIV seropositive patients. Eur J Clin Pharmacol 1989;36:639-640.
Klecker RW, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3’-azido-3’-deoxythymidine: A novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987;41:407-412.
Collins JM, Unadkat JD. Clinical pharmacokinetics of zidovudine: An overview of current data. Clin Pharmacokinet 1989; 17:1—9.
Blum MR, Liao SHT, Good SS, de Miranda P: Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988;85(suppL 1A): 189—194.
Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3’-azido-2’,3’-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989:321:726-738.
Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989;110:279-285.
Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991;163:226-232.
Steffe EM, King H, Inciardi JF, et aL The effect of acetaminophen on zidovudine metabolism in HIV-infected patients. J Acquir Immune Deftc Syndr 1990;3:691-694.
Ameer B. Acetaminophen hepatoxicity augmented by zidovudine. Am J Med 1993;95:342.
Kavesh NG, Hoizman RS, Seidlin M. The combined activity of azidothymidine and antimycobacterial agents: A retrospective study. Annu Rev Respir Dis 1989;139:1094-1097.
Rajaonarison JF, Lacarelle B, Catalin J, Rahmani R. 3’-Azido-3’-deoxythymidine drug interactions: Screening for inhibitors in human liver microsomes. Drug Metab Disp 1992;20:578-584.
Liebes L, Mendoza S, Wilson D, Dancis J. Transfer of zidovudine (AZT) by human placenta. J Infect Dis 1990;161:203-207.
Schenker S, Johnson RF, King TS, et al. Azidothymidine (zidovudine) transport by the human placenta. Am J Med Sci 1990;299:16-20.
Gillet JY, Garraffo R, Barar D, et al. Fetoplacental passage of zidovudine. Lancet 1989;2:269-270.
Chavanet P, Diquet B, Waldner A, Bortier H. Perinatal pharmacokinetics of zidovudine. N Engl J Med 1989;321:1548-1549.
Bernard N, Boulley A-M, Perol R, et al. Failure of zidovudine prophylaxis after exposure to HIV-1. N Engl J Med 1990;323:916.
Sperling RS, Stratton P, O’Sullivan MJ, et al. A survey of zidovudine use in pregnant women with human immunodeficiency virus infection. N Engl J Med 1992;326:857-861.
Tadapalli SM, Puchett L, Jeal S, et al. Differential assay of zidovudine and its glucuronide metabolite in serum and urine with a radioimmunoassay kit. Clin Chem 1990;36:897-900.
Lacroix C, Hoang TP, Wojciechowski F, et al. Simultaneous quantification of zidovudine and its metabolites in serum and urine by high performance liquid chromatography using a column-switching technique. J Chromatogr 1990;525:240-245.
Tadapalli SM, Puchett L, Jeal S, et al. Differential assay of zidovudine and its glucuronide metabolite in serum and urine with a radioimmunoassay kit. Clin Chem 1990;36:897-900.
Lacroix C, Hoang TP, Wojciechowski F, et al. Simultaneous quantification of zidovudine and its metabolites in serum and urine by high performance liquid chromatography using a column-switching technique. J Chroma-togr 1990;525:240-245.
Drugs for AIDS and associated infections. Med Lett Drugs Ther 1993;35:79-81.
Lee BL, Safrin S. Drug interactions and toxicities in patients with AIDS. CurrOpin Infect Dis 1992;5:231-240.
FDA Consumer 1993;27:14.
McKegney FP, O’Dowd MA. Suicidality and HIV status. Am J Psychiatry 1992;149:396-398.
Cote TC, Biggar RJ, Dannenberg AL. Risk of suicide among persons with Al DS: A national assessment. JAMA 1992;268:2066-2068.
Marztik PM, Tierney H, Tardiff K, et al. Increased risk of suicide in persons with AIDS. JAMA 1988;259:1333— 1337.
Rajs J, Fugelstad A. Suicide related to human immunodeficiency virus infection in Stockholm. Acta Psychiatr Scand 1992;85:234-239.
Sobel JD. Acquired immunodeficiency syndrome in intravenous drug abusers. In: Levine DP, Sobel JD, eds: Infections in Intravenous Drug Abusers. New York: Oxford University Press, 1990:342—379.
Green ST, Taylor A, Frischer М, Goldberg DJ. "Frontloading" ("halting") among Glasgow drug injectors as a continuing risk behavior for HIV transmission. Addiction 1993;88:1581-1582.
Froner GA, Rutherford GW, Rokeach M. Injection of sodium hypochlorite by intravenous drug users. JAMA 1987;258:325.
Morgan DL: Intravenous injection of household bleach. Ann Emerg Med 1992;21:1394-1395.
Use of bleach for disinfection of drug injection equipment. MMWR 1993;42:418-419.
Centers for Disease Control and Prevention, Center for Substance Abuse Treatment, National Institute of Drug Abuse. HIV/AIDS Prevention Bulletin, April 19, 1993.
Curran JW. CDC, Public Health services letter, May 24, 1993.
Watters JK, Jones TS, Shapshak P, et al. Household bleach as disinfectant for use by injecting drug users. Lancet 1993;342:742-743.
Krepcho MA, Fernandez-Esquer ME, Fleeman AC, et al. Predictors of bleach use among current African-American injecting drug users: A community study. J Psychoactive Drugs 1993;25:135-141.
Haverkos HW. Nitrite inhalant abuse in AIDS-related Kaposi’s sarcoma (KS). AIDS Res Hum Retroviruses 1992;8:878.
Haverkos HW, Dougherty JA, eds. Health Hazards of Nitrite Inhalants. NIDA Research Monograph 83. DHHS Publication No. (ADM) 89—1573. Washington, DC: Alcohol, Drug Abuse and Mental Health Administration, 1988.
Seage GR Ill, Mayer KH, Horsburgh CR, et al. The relation between nitrite inhalants, unprotected receptive anal intercourse, and the risk of human immunodeficiency virus infection. Am J Epidemiol 1992;135:1 —11.
Haverkos HW, Dougherty J. Health hazards nitrite inhalants. Am J Med 1988;84:479-482.
Haverkos HW. The search for cofactors in AIDS including an analysis of the association of nitrite inhalant abuse and Kaposi’s sarcoma. In: Geminara D, Watson RR, eds. Alcohol, Immunomodulation and AIDS. New York: Alan R. Liss, 1990:93-102.
Drotman DP, Haverkos HW. What causes Kaposi’s sarcoma? Inquiring epidemiologists want to know. Epidemiology 1992;3:191-193.
Haverkos HW, Drotman DP, Morgan WM. Kaposi’s sarcoma in patients with AIDS: Sex, transmission node, and race. Biomed Pharmacother 1990;44:461-466.
Berel V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: A sexually transmitted infection? Lancet 1990;335:123-128.
Archibald CP, Schechter MT, Craib KJP, et al. Risk factors for Kaposi’s sarcoma in the Vancouver Lymphade-nopathy-AIDS study. J Acquir Immune Defic Syndr 1990;3(suppl. 1):S18—S28.
Cockerill FR 111, Edson RS. Trimethoprim-sulfameth-oxazole. Mayo Clin Proc 1991;66:1260-1269.
Mirvish SS, Williamson J, Babcock D, Chen S-C. Mutagenicity of iso-butyl nitrite vapor in the Ames test and some relevant chemical properties including the reaction of isobutyl nitrite with phosphate. Environ Mol Mutagen 1993;21:247-252.
Haverkos HW, Kopstein AN, Wilson H, Drotman P. Nitrite inhalants: History, epidemiology and possible links to AIDS. Environ Health Perspect 1994;102:858-861.
Yarchoan R, Mitsuya F, Myers CE, Broden S. Clinical pharmacology of 3’-azido-2’-3’-dideoxythymidine (zi-dovidine) and related dideoxynucleosides. N Engl J Med 1989;34:726-738.
Peters BS, Carlin E, Weston RJ, et al. Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection. Drug Saf 1994; 10 439— 454.
Lee BL, Safrin S. AIDS commentary: Interactions and toxicities of drugs used in patients with AIDS. Clin Infect Dis 1992;14:773-779.
PludaJM, Mitsuya H, Yarchoan R. Hematologic effects of AIDS therapies. Hematol/Oncol Clin North Am 1991;5:229-248.
Williams I, Weller 1VD, Malin A, et al. Lancet 1991;337:436-437.
Jost R, Stey C, Salomon F. Fatal drug-induced pancreatitis in HIV. Lancet 1993:341:1412.
Battegay M, Opravil M. Wuthrich B, Luthy R. Rash with amoxicillin-clavulanate therapy in HIV-infected patients. Lancet 1989;2:110.
Lee BL, Wong D, Benowitz NL, Sullain PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993;53:529-535.
Porteous DM, Berger TG. Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. Arch Dermatol 1991;127:740-741.
Coopman SA, Stern RS. Cutaneous drug reactions in human immunodeficiency virus infection. Arch Dermatol 1991;127:714-717.
Saiag P, Caumes E, Chosidow O, et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992;26:567-574.
AIDS drugs being studied. FDA Consumer 1992;26(3):8—9.
Van der Ven AJAM, Koopmans PP, Vree ТВ, Van der Meer JWM. Adverse reactions to Co-trimoxazole in HIV infection. Lancet 1991;338:431-433.
Toma E, Fournier S. Adverse reactions to Co-trimoxazole in HIV infection. Lancet 1991 ;338:954.
Pozniak A, Weinberg J, MacLeod G. HIV and Co-trimoxazole toxicity. Lancet 1991;338:760-761.
Slattery JT, Unadkat JD. Adverse reactions to Co-trimoxazole in HIV infection. Lancet 1991;338:1216.
Whitaker RED, Ostrow DG. Psychiatric and psychopharmacologic problems in HIV-1 infection. Hosp Formul 1991;26:948-959.
Cohen MAA. Biopsychosocial approach to the human immunodeficiency virus epidemic: A clinician’s primer. Gen Hosp Psychiatry 1990;12:98-123.
Pozniak AL, McLeod GA, Mahari M, et al. The influence of HIV status on single and multiple drug reactions to antituberculosis therapy in Africa. AIDS 1992.
Hriso E, Kuhn T, Masdeu JC, Grundman M. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 1991;148:1558-1161.
Renton KW, Cribb AE, Armstrong S. Role of altered drug metabolism in viral drug interactions. Rev Infect Dis 1991;13:1256-1257.
Hersh EM, Brewton G, Abrams D, et al. Dithiocarb sodium (diethyldithiocarbmate) therapy in patients with symptomatic HIV infection and AIDS: A randomized double-blind, placebo-controlled, multicenter study. JAMA 1991;265:1538-1544.
Gougerot-Pocidalo M-A, Levacher M. Glutathione and HIV infection. Lancet 1990;335:234.
Dupuy J-M, Revillard J-P, Hersh EM,etal. Glutathione and HIV infection. Lancet 1990;335:234-235.
Staal FJT, Roederer M, Israelski DM, et al. Intracellular glutathione levels in T-cell subsets decrease in HIV-infected individuals. AIDS Res Hum Retroviruses 1992;8:305-311.
Roederer М, Ela SW, Staal FJT, et al. A-Acetylcysteine: A new approach to anti-HIV therapy. AIDS Res Hum Retroviruses 1992;8:209-219.
Staal FJT, Roederer M, Herzenberg LA, Herzenberg LA. Intracellular thiols regulate activation of nuclear factor KB and transcription of human immunodeficiency virus. Proc Natl Acad Sci USA 1990;87:9943-9947.
Roederer M, Staal FJT, Raju PA, et al. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci USA 1990;87:4884-4888.
Roederer M, Raju PA, Staal FJT, et al. A-Acetylcysteine inhibits latent HIV expression in chronically infected cells. AIDS Res Hum Retroviruses 1991;7: 491-495.
Roederer M, Staal FJT, Osado H, et al. CD4 and CD8 T-cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses. Int Immunol 1991;3:933-937.
Staal FJT, Ela SW, Roederer M, et al. Glutathione deficiency and human immunodeficiency virus infection. Lancet 1992;339:909-912.
Roederer M, Staal FJT, Ela SW, et al. A-Acetylcysteine: Potential for AIDS therapy. Pharmacology 1993;46: 121-129.
Buhl R, Jaffe HA, Holvoyd KJ, et al. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989;2:1294-1298.
Buhl Jaffe HA, Holroyd KJ, Wells FB, et al. Glutathione deficiency and HIV Lancet 1990;335:546.
Ruffman R, Wendel A. GSH rescue by A'-acetylcystcine. Klin Wochenschr 1991;69:857-862.
Kalebic T, Kinter A, Poli G, et al. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and A-acetylcysteine. Proc Natl Acad Sci USA 1991 ;88: 986-990.
Harb GE, Jacobson MA. Human immunodeficiency virus (HIV) infection: Does it increase susceptibility to adverse drug reactions? Drug Saf 1993;9:1-8.
Smith KJ, Skelton HG III, Vogel P, et al. Exaggerated insect bite reactions in patients positive for HIV. J Am Acad Dermatol 1993;29:269-272.
Jones ME, Brettle PP, Busuttil A, et al. Sudden death in HIV infected drug users: Presumptive overdose in an HIV-positive narcotic addict. J Infect 1993;27:79-81.
Fekety R, Shah АВ. Diagnosis and treatment of Clostridium colitis. JAMA 1993;269:71-75.
McFarlane LV, Mulligan ME, Kwok RY, Stanm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204-210.
Riley TV, Golledge CL. Clindamycin and pseudomembranous colitis. Lancet 1995;346:639.
Barclay ML, Begg EJ. Aminoglycoside toxicity and relation to dose regimen. Adverse Drug React Toxicol Rev 1994;13:207-234.
Saxon A, Beall GN, Rohr AS, Adelman DC. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med 1987;107:204-215.
Donowitz GR, Mandell GL. Beta-lactam antibiotics (second of two parts). N Engl J Med 1988;318:490-500.
Westley-Horton E, Koestner JA. Aztreonam: A review of first monobactam. Am J Med Sci 1991;302:46-49.
Aztreonam (Azactam). Med Lett Drugs Ther 1987;29:45-47.
Cadarson Al, Jimenez SAS, Pan CV, Mosquera MR. Aztreonam-induced anaphylaxis. Lancet 1990;336:746— 747.
Dallal MM, Dzachor JS. Aztreonam-induced myelosuppression during treatment of Pseudomonas aeruginosa pneumonia. DICP Ann Pharmacother 199l;25:294— 297.
Neu HC: Carbapenems: Special properties contributing to their activity. Am J Med 1985:78(suppl. 6A):33—40.
Imipenem + cilastatin: A new type of antibiotic. Drug Ther Bull 1991;29(11):43.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Hospital Formulary Service, 1994:182— 190.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:247— 250.
Boucher BA, Hickerson WL, Kuhl DA, et al. Imipenem pharmacokinetics in patients with burns. Clin Pharmacol Ther 1990;48:130-137.
Job ML, Dretler RH. Seizure activity with imipenem therapy: Incidence and risk factors. DICP Ann Pharmacother 1990;24:467-469.
Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: Experience with imipenem/cilastatin. Am J Med 1988;84:911-918.
Riancho JA, Olmos JM, Sedano C. Life-threatening bleeding in a patient treated with cefonicid. Ann Intern Med 1995; 123:472.
Kanatani MS, Guglieimo BJ. The new macrolides. Azithromycin and clarithromycin. West J Med 1994;160:31-37.
Berger TM, Cook WJ, O’Marcaigh AS, Zimmerman D. Acute pancreatitis in a 12 year old girl after an Erythrocin overdose. Pediatrics 1992;90:624-626.
Gumaste UV. Erythromycin-induced pancreatitis. Am J Med 1989;76(part 1):725.
Haefeli WE, Schoenenberger RA, Weiss P, Ritz R. Possible risk for cardiac arrhythmias related to intravenous erythromycin. Intensive Care Med 1992;18:469-473.
Farrar HC, Walsh-Sukys MC, Kyllonen K, Blumer JL. Cardiac toxicity associated with intravenous erythromycin lactobionate: Two case reports and a review of the literature. Pediatr Infect Dis J 1993;12:688-691.
Gitler B, Berger LS, Buffa SD. Torsade de pointes induced by erythromycin. Chest 1994;105:368-370.
Brandress MW, Richardson WS, Barold SS. Erythromycin induced QT prolongation and polymorphic ventricular tachycardia (Torsade de pointes): Case report and review. Clin Infect Dis 1994;18:995-999.
Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991;324:384-394.
Percival A, ed. Quinolones: Their future in clinical practice. London: Royal Society of Medicine Services, 1986.
Walker RC, Wright AJ. The quinolones. Mayo Clin Proc 1987;62:1007-1012.
Andersen RD, Goldstein EJC. The introduction of the quinolones: A new class of antiinfectives. Hosp Formul 1987;22:36-47.
Paton JH, Reeves DS. Clinical features and management of adverse effects of quinolone antibacterials. Drug Saf 1991;6:8-27.
Baciewicz AM, Ashar BH, Locke TW. Interaction of oflaxacin and warfarin. Ann Intern Med 1993;119:1223.
Giamarellou H, Kolokythas E, Petrikkos G, et al. Pharmacokinetics of three new quinolones in pregnant and lactating women. Am J Med 1989;87(suppl. 5A):49.
Peled Y, Friedman S, Hod M, Merlob P. Ofloxacin during the second trimester of pregnancy. DICP Ann Pharmacother 1991 ;25:1 181 — 1182.
Christ W. Central nervous system toxicity of quinolones: Human and animal findings. J Antimicrob Chemother 1990;26(suppl. B):219—225.
Bergan T, Rohwedder R, Thorsteinsson SB. Significance of crystalluria caused by quinolones. Rev Infect Dis 1989;2(suppl. 5):S 1395—S1396.
Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother 1990;26(suppL D):31— 44.
Stricker BHC, Slagboom G, Demaeseneer R, et al. Anaphylactic reactions to cinoxacin. Br Med J 1988;297:1434-1435.
Henwood JM, Monk JP. Enoxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1988;36:32-66.
Davila I, Diez ML. Quirce S, et al. Cross-reactivity between quinolones: Report of three cases. Allergy 1993;48:388-390.
Islem MA, Sreedharan T. Convulsions, hyperglycaemia and glycosuria from overdose of nalidixic acid. JAMA 1965;192:1100-1111.
Fraser AG, Harrower ADB. Convulsions and hyperglycaemia associated with nalidixic acid. Br Med J 1977;2:1518.
Dash H, Mills J. Severe metabolic acidosis associated with nalidixic acid overdose. Ann Intern Med 1976;84:570-571.
Mukherjee A, Dutta P, Lahiri M, et al. Benign intracranial hypertension after nalidixic acid overdose in infants. Lancet 1990; 1:1602.
Leslie PJA, Cregeen RJ, Proudfoot AT. Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage. Hum Toxicol 1984;3:239-243.
Singlas E, Taburet AM, Landru I, et al. Pharmacokinetics of ciprofloxacin tablets in renal failure: Influence of hemodialysis. Eur J Clin Pharmacol 1987;31:589— 593.
Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989;46:700-705.
Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:145—147.
Temofloxacin withdrawn. FDA Med Bull 1992;22(2):4.
Terp DK, Rybak MJ. Ciprofloxacin. Drug Intell Clin Pharm 1987;21:568-570.
Ball AP. Overview of clinical experience with ciprofloxacin. Eur J Clin Microbial 1986;5:214-219.
Ciprofloxacin. Med Lett Drugs Ther 1988;30:11-13.
Bouchayer D, Vial T, Mercatello A, et al. Acute renal failure secondary to ciprofloxacin overdose. In: Proceedings, European Association of Poison Centres, Lyon, France, May 22, 1991.
George MJ, Dew RB Ill, Daly JS. Acute renal failure after an overdose of ciprofloxacin. Arch Intern Med 1991;151:620.
Drusano GL, Standiford HC, Plaisance K, et al. Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1986;30:444-446.
Wise R, Lockley RM, Webberly M, Dent J. Pharmacokinetics of intravenous administered ciprofloxacin. Antimicrob Agents Chemother 1984;26:208-210.
Wolff M, Boutron L, Decazes J, et al. Diffusion of ciprofloxacin into CSF of patients with purulent meningitis. In: Program and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1986: 1984. Abstract.
Cover DL, Mueller BA. Ciprofloxacin. Penetration into human breast milk: A case report. DICP Ann Pharmacother 1990;24:703-704.
Richardson JP. Theophylline toxicity associated with the administration of ciprofloxacin in a nursing home patient. J Am Geriatr Soc 1990;38:236-238.
Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med 1989;87(suppl. 5A):76S—81S.
Davis H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment with ciprofloxacin. Ann Intern Med 1989;111:1041-1043.
Kamada AK. Possible interaction between ciprofloxacin and warfarin. DICP Ann Pharmacother 1990;24:27-28.
Jim LK. Physical and clinical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacother 1993;27:704-707.
Semel JD, Allen N. Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole. South Med J 1991;84:465-468.
Slavich IL, Gleffee RF, Haas EJ. Grand mal epileptic seizures during ciprofloxacin therapy. JAMA 1989;261:558-559.
Knapp R, Judmaier W, Frauscher F, Birbamer G. Fatal hepatic failure associated with ciprofloxacin. Lancet 1994;343:738-739.
Karki SD, Bentley DW, Ragharan M. Seizure with ciprofloxacin and theophylline combined therapy. DICP Ann Pharmacother 1990:24:595—596.
Mumford CJ, Ginsberg L. Ciprofloxacin and myasthenia gravis. Br Med J 1990;301—318.
Winrow AP, Supramaniam G. Benign intracranial hypertension after ciprofloxacin administration. Arch Dis Child 1990;65:1165-1166.
Vriabec TR, Sergott RC, Jaeger EA, et al. Reversible visual loss in a patient receiving high-dose ciprofloxacin hydrochloride (Cipro). Ophthalmology 1990;97:707-710.
Peters B, Pinching AJ. Fatal anaphylaxis associated with ciprofloxacin in a patient with AIDS related complex. Br Med J 1989;298:605.
Rastogi S, Atkinson JLD, McCarthy JT. Allergic nephropathy associated with ciprofloxacin. Mayo Clin Proc 1990;65:987-989.
Murray KM, Wilson MG. Suspected ciprofloxacin-induced interstitial nephritis. DICP Ann Pharmacother 1990;24:379-380.
Ying LS, Johnson CA. Ciprofloxacin-induced interstitial nephritis. Clin Pharm 1989;8:518-521.
Hootkins R, Fenves AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: A presentation of three cases and a review of the literature. Clin Nephrol 1989;32:75-78.
Teja-Isavadham P, Keeratithakul D, Watt G, et al. Measurement of ciprofloxacin in human plasma, whole blood and erythrocytes by high-performance liquid chromatography. Ther Drug Monit 1991;13:263-267.
Ball P. Ciprofloxacin, an overview of adverse experiences. J Antimicrob Chemother 1986; 18(suppl. D):187— 193.
Drysdale L, Gilbert L, Thomson A, et al. Pseudoglycosuria and ciprofloxacin. Lancet 1988;2:961.
Todd PA, Faulds D. Ofloxacin: A reappraisal of its an timicrobial activity, pharmacology and therapeutic use. Drugs 1991;42:825-876.
Kohler PB, Arkins N, Tack NJ. Accidental overdose of intravenous ofloxacin with benign outcome. Antimicrob Agents Chemother 1991;35:1239-1240.
Koppel С, Норке T, Menzel J. Central anticholinergic syndrome after ofloxacin overdose and therapeutic doses of diphenhydramine and chlormezanone. Clin Toxicol 1990;28:249-253.
Walker RC, Wright AJ. The fluoroquinolones. Mayo Clin Proc 1991;66:1249-1259.
Glum A. Ofloxacin-induced acute severe hepatitis. South Med J 1991 ;84:1158.
Szarfman A, Chen M, Blum MD. More on fluoroquinolone antibiotics and tendon rupture. N Engl J Med 1995;323:193-194.
Ofloxacin. Med Lett Drugs Ther 1991;33:71-73.
Monk JP, Campoli-Richards DM. Ofloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1987;33:346-391.
Zaudig M, von Bose M, Weber MM, et al. Psychotic effects of ofloxacin. Pharmacopsychiatry 1989;22:11-15.
Zaudig M, von Bose M. Ofloxacin-induced psychosis. Br J Psychiatry 1987;151:563-564.
Cockerill FR Ill, Edson RS. Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1987;62:921-929.
McEvoy GK, ed. AHFS Drug Information 91. Bethesda, MD: American Hospital Formulary Service, 1991:461 — 464, 468-474.
Reynolds JEF, ed. Martindate: The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993:153—156, 221-223.
Goff O. Renal failure induced by co-trimoxazole. Hosp Ther 1989;14:61-67.
Норри K, Koskimies O, Turmisto J. Trimethoprim pharmacokinetics in children with renal insufficiency. Clin Pharmacol Ther 1987;42:181-186.
Stevens RC, Laizare SC, Stein DS, Holden CL. Pharmacokinetics and toxicity of co-trimexazole following pneumocystis-dosing in healthy subjects. Clin Pharmacol Ther 1991 ;49:199.
Hutabarat RM, Unadkat JP, Sahajwalla C, et al. Disposition of drugs in cystic fibrosis. 1. Sulfamethoxazole and trimethoprim. Clin Pharmacol Ther 1991;49:402-409.
Wathen GG, Winney RJ. High dose co-trimoxazole for patients receiving hemodialysis. Br Med J 1987;295:333.
Kosoglou T, Rocci ML, Vlasses PH. Trimethoprim alters the disposition of procainamide and A-acetylprocainamide. Clin Pharmacol Ther 1988;44:467-477.
Taraszewski R, Harvey R, Rosman P: Death from drug-induced hemolytic anemia. Postgrad Med 1989.
Carmichael AJ, Tan CY. Fatal toxic epidermal necrolysis associated with co-trimexazole. Lancet 1989;2:808-809.
Smith GW, Cohen SB. Hyperkalemia and non-oliguric renal failure associated with trimethoprim. Br Med J 1994;308:454.
Metherall R. High performance liquid chromatographic determination of trimethoprim in serum. Ther Drug Monit 1989;11:79-83.
De Angelis DV, Woolley JL, Sigel CW. High performance liquid chromatographic assay for the simultaneous measurement of trimethoprim and Sulfamethoxazole in plasma or urine. Ther Drug Monit 1990;12:382-392.
Dawling S, Widdop B. A fatal case involving trimethoprim. Bull I nt Assoc Forens Toxicol 1986; 19( 1): 34— 35.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:355-359.
Walczyk MH, Hill D, Arai A, Wolfson M. Acute renal failure owing to inadvertent vancomycin overdose: Vancomycin removal by continuous arteriovenous hemofiltration. Ann Clin Lab Sci 1988; 18:440—443.
Burkhart K, Metcalf S, Shurnas E, et al. Exchange transfusion and multidose activated charcoal following vancomycin overdose. Vet Hum Toxicol 1990;32:253.
Kildoo CW, Lin L-M, Gabriel MH, et al. Vancomycin pharmacokinetics in infants: Relationship to postconceptional age and serum creatinine. Dev Pharmacol Ther 1990;14:77-83.
Pauly DJ, Musa DM, Lestico MR, et al. Risk of nephrotoxicity and combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990; 10: 378-382.
Huang КС, Huse A, Shrader AK, Tureda K. Vancomycin enhances the neuromuscular blockade of vecuronium. Anesth Analg 1990;71:194-196.
Reyes MP, Ostrea EM Jr, Cabinan AE, et al. Vancomycin during pregnancy: Does it cause hearing loss of nephrotoxicity in the infant? Am J Obstet Gynecol 1989;161:977-981.
Gouyon JB, Petion AM. Toxicity of vancomycin given during pregnancy. Am J Obstet Gynecol 1990;163:1375-1376.
Glicklich D, Figura I. Vancomycin and cardiac arrest. Ann Intern Med 1984;101:880-881.
Wallace MR, Mascola JR, Oldfield EC Ill. Red man syndrome: Incidence, etiology, prophylaxis. J Infect Dis 1991;164:1180-1185.
Knudsen JD, Pedersen M. IgE-mediated reaction to vancomycin and teicoplanin after treatment with vancomycin. Scand J Infect Dis 1992;24:395-396.
Red men should go: Vancomycin and histamine release. Lancet 1990;335:1006-1007. Editorial.
Sahai J, Healey DP, Garris R, et al. Influence of antihistamine pretreatment in vancomycin-induced red man syndrome. J Infect Dis 1989;160:876-881.
Dubettier S, Boibieux A, Lagable M, et al. Red man syndrome with teicoplanin. Rev Infect Dis 1991; 13:770.
Estrada V, Algarra J, Vargas E, Jimenez de Diego L. Red neck syndrome induced by erythromycin. Rev Clin Espan 1992;190:100-101.
Bingley PJ, Harding GM. Clostridium difficile colitis following treatment with metronidazole and vancomycin. Postgrad Med J 1987;63:993-994.
Hannah BA, Kimmel PL, Dosa S, Turner ML. Vancomycin-induced toxic epidermal necrolysis. South Med J 1990;83:720-722.
Morris A, Ward C. High incidence of vancomycin-associated leucopenia and neutropenia in a cardiothoracic surgical unit. J Infect 1991;22:217-233.
Hu MW, Anne L, Forni T, Gottwald K. Measurement of vancomycin in renally impaired patient samples using a new high performance liquid chromatography method with vitamin B,2 internal standard: Comparison of high performance liquid chromatography, EMIT and fluorescence polarization immunoassay methods. Ther Drug Monit 1990;12:562-569.
Bailie GR, Neal D. Vancomycin in ototoxicity and nephrotoxicity: A review. Med Toxicol 1988;3:376-386.
Thomas RJ. Neurotoxicity of antibacterial therapy. South Med J 1994;87:869-874.
Yawalker SJ, Vischer W. Lamprene (clofazimine) in leprosy. Lepr Rev 1979;50:135-144.
Mason GH, Ellis-Pegler RB, Arthur JF. Clofazimine and eosinophilic enteritis. Lepr Rev 1977;48:175-180.
Jopling WH. Complications of treatment with clofazimine (Lamprene;B663). Lepr Rev 1976;14:1-2.
McDougall AC, Horsfall WR, Hede JE, Chaplin AJ. Splenic infarction and tissue accumulation of crystals associated with the use of clofazimine (Lampere; B663) in the treatment of pyoderma gangrenosum. Br J Dermatol 1980;102:227-230.
Schaad-Lanyi Z, Dieterle W, Debois JP, et al. Pharmacokinetics of clofazimine in healthy volunteers. Int J Lepr 1987;55:9-15.
Feng PCC, Fenselau CC, Jacobson RR. Metabolism of clofazimine in leprosy patients. Drug Metab Dispos 1981;9:521-524.
Holdiness MR. Clinical pharmacokinetics of clofazimine: A review. Clin Pharmacokinet 1989;16:74-85.
Farb H, West DR, Pedvis-Leftick A. Clofazimine in pregnancy complicated by leprosy. Obstet Gynecol 1982;59:122-123.
Girdhar A, Venkatesan K, Chauhan SL, et al. Red discoloration of the sputum by clofazimine simulating haemoptysis: A case report. Lepr Rev 1992;63:47-50.
Forster DJ, Causey DM, Ro NA. Bull’s eye retinopathy and clofazimine. Ann Intern Med 1992;116:876-877.
Sandler ED. Ng LV. Hadley WK. Clofazimine crystals in alveolar macrophages from a patient with the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1992;116:541-543.
Lanyi Z, Dubois JP. Determination of clofazimine in human plasma by thin-layer chromatography. J Chromatogr Biomed Appl 1982;232:219-223.
De Bergeyck E, Janssens PG, de Muynck A. Radiological abnormalities of the ileus associated with the use of clofazimine (Lamprene; B663) in the treatment of skin ulceration due to Mycobacterium ulcerans. Lepr Rev 1980;51:221-228.
Alford RH. Antimicrobacterial agents. In: Mandell GI, Douglas RG Jr, Bennett JE, eds. Anti-infective Therapy. New York: Wiley, 1985:285-286.
Gulliford M, Mackay AD, Prowse K. Cholestatic jaundice caused by ethambutol. Br Med J 1986;292:866.
Ethambutol hydrochloride. In: Physicians’ Desk Reference. Montvale, NJ: Medical Economics, 1995:1271.
Ducobu J, DuPont P, Laurent M, et al. Acute isoniazid/ ethambutol, rifampicin overdosage. Lancet 1982;1:632.
Myambutol. In: Guide to Recognition and Treatment of Acute Overdosage with Lederle Products. Lederle Laboratories, Feb. 1976.
Coyer JR, Nicholson DP. isoniazid induced convulsions. Part 1. Clinical. South Med J 1976;69:294-296.
Mack RB. Mimi Viletta and the "captain of all the men of death": INH (isoniazid) poisoning. NC Med J 1984;45:321-322.
Alford RH. Antimycobacterial agents. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Anti-infective Therapy. New York: Wiley, 1985:281-284.
Handbook of Antimicrobial Therapy, rev ed. New Rochelle, NY: The Medical Letter, Inc, 1984.
McEvoy GK, ed. AHFS Drug Information Bethesda, MD: American Society of Hospital Pharmacists, 1994.
Starke H, Williams S. Acute poisoning from overdose of isoniazid: A case report. Lancet 1963;83:406-408.
Kingston RL, Saxena K. Management of acute isoniazid overdosages. Clin Toxicol Consult 1980;2:37-44.
McBay AJ. Fatal isoniazid poisoning. Bull Int Assoc Forens Toxicol 1968;5(3):2.
Sievers ML, Herrier RN, Chin L, et al. Treatment of isoniazid overdose. JAMA 1982;247:583-584.
Manoguerra AS. Acute isoniazid toxicity. San Francisco Bay Area Regional Poison Center Newlett 1980;2(3): 1-2.
Wason S. Isoniazid. Clin Toxicol Rev 1981;3(5):1—2.
Yarbrough BE, Wood J P. Isoniazid overdose treated with high dose pyridoxine. Ann Emerg Med 1983;12:303— 305.
Sievers ML, Herrier RN. Treatment of acute isonizid toxicity. Am J Hosp Pharm 1975;32:202-206.
Brown CV. Acute isoniazid poisoning. Am Rev Respir Dis 1972;105:206-216.
Gold CH, Buchanan N, Tringham V, et al. Isoniazid pharmacokinetics in patients in chronic renal failure. Clin Nephrol 1976;6:365-369.
Ducobu J, Dupont P, Laurent M, et al. Acute isoniazid/ ethambutol/rifamicin overdosage. Lancet 1982;L632.
La Greca G, Biasioli S, Boren D, et al. Drugs and dialysis. Int J Art if Organs 1983;6:139-156.
Winchester JF, Gelfand MC, Knepshield JH, et al. Dialysis and hemoperfusion of poisons and drugs: Update. Trans Am Soc Artif Intern Organs 1977;23:762-827.
Cocco AE, Pazourek U. Acute isoniazid intoxication: Management by peritoneal dialysis. N Engl J Med 1963;269:852-853.
Katz GA, Jobin GC. Large doses of pyridoxine in the treatment of massive ingestion of isoniazid. Am Rev Respir Dis 1970;101:991-992.
Konigshausen TH, Altrogge G, Hein D, et al. Hemodialysis and hemoperfusion in the treatment of most severe INH poisoning. Vet Hum Toxicol 1979;21 (suppi.): 12— 15.
Katz BE, Carver MW. Acute poisoning with isoniazid treated by exchange transfusion. Pediatrics 1956; 18:72— 76.
Nelson LG. Grand mal seizures following overdose of isoniazid: A report of four cases. Am Rev Respir Dis 1965;91:600-604.
Sievers ML, Herrier RN. Sensory neuropathy from pyridoxine abuse. N Engl J Med 1984;310:197-198. Letter.
Biehl JP, Nimitz HJ. Studies on the use of a high dose of isoniazid: I. Toxicity studies. Am Rev Tuberc 1954;69:759-765.
Whitefield CL, Klein RG. Isoniazid overdose: Report of 40 patients with a critical analysis of treatment and suggestions for prevention. Am Rev Respir Dis 1971 ;103:887.
Blanchard PD, YaoJDC, McAlpine DE, etal. Isoniazid overdose in the Cambodian population of Olmsted Country, Minnesota. JAMA 1986;256:3131-3133.
Friedman SA. Death following massive ingestion of isoniazid. Am Rev Respir Dis 1969;100:859-862.
Jeanes CWL, Schaefer O, Eidus L. Inactivation of isoniazid by Canadian Eskimos and Indians. Can Med Assoc J 1972;106:331-335.
Bennett WM, Singer I, Golper T, et al. Guidelines for drug therapy in renal failure. Ann Intern Med 1977;86:754-783.
Tuchman AJ, Berger S, Daras M. Cerebrospinal fluid penetration of anti-infective agents. South Med J 1984;77:1443-1445.
Kunin CM. A guide to use of antibiotics in patients with renal disease: A table of recommended doses and factors governing serum levels. Ann Intern Med 1967;67:151 — 158.
Chaplan S, Sanders GL, Smith JM. Drug excretion in human breast milk. Adverse Drug React Acute Poison Rev 1982;1:255-287.
Comstock GW, New data on preventive treatment with isoniazid. Ann Intern Med 1983;98:22:518—519.
Chin L, Sievers ML, Laird HE, et al. Evaluation of diazepam and pyridoxine as antidotes to isoniazid intoxication in rats and dogs. Toxicol Appl Pharmacol 1978;45:713-722.
Wason S, LaCouture PG, Lovejoy FH Jr. Single high dose pyridoxine treatment for isoniazid overdose. JAMA 1981;246:1102-1104.
Sievers ML, Herrier RD. Megavitamin therapy for overdose. Arch Intern Med 1980; 140:1676.
Nunn P, Porter J, Winstanley P. Thioacetazone: Avoid like poison or use with care? Trans R Soc Trop Med Hyg 1993;87:578-582.
World Health Organization. Severe hypersensitivity reactions among HIV-seropositive patients with tuberculosis treatment with thioacetazone. Wkly Epidemiol Rec 1992;67:1-3.
Holdiness MR. Adverse cutaneous reactions to antituberculosis drugs. Int J Dermatol 1985;24:280-285.
Jenner PJ, Ellard GA, Swai OB. A study of thioacetazone blood levels and urinary excretion in man using high performance liquid chromatography. Lepr Rev 1984;55:121-128.
Holdiness MR. Neurological manifestations and toxicities of the antituberculosis drugs: A review. Med Toxicol 1987;2:33-51.
Holdiness MR. Clinical pharamcokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984;9:511-544.
Ellard GA, Dickinson JM, Gammon PT, Mitchison DA. Serum concentrations and antituberculosis activity of thioacetazone. Tubercle 1974;55:41-54.
Jenner PJ. High performance liquid chromatography determination of thioacetazone in body fluids. J Chromatogr Biomed Appl 1983;276:463-470.
Scharman EJ, Rosencrance JE. Isoniazid toxicity: A survey of pyridoxine availability. Am J Emerg Med 1994;12:386-388.
Corbella X, Vadillo M, Cabellos C, et al. Hypersensitivity hepatitis due to pyrazinamide. Scand J Infect Dis 1995;27:93-94.
Nair PM, Philip E. Accidental dapsone poisoning in children. Ann Trop Paediatr 1984;4:241-242.
Woodhouse K.W, Henderson DB, Charlton B, et al. Acute dapsone poisoning: Clinical features and pharmacokinetic studies. Hum Toxicol 1983;3:507-510.
Davis R. Fatal poisoning with Udolac (diaminodiphenyl sulphone). Lancet 1950;1:905-906.
Neuvonen PJ, Elonen E, Haapanen EJ. Acute dapsone intoxication: Clinical findings and effect of oral charcoal and haemodialysis on dapsone elimination. Acta Med Scand 1983;214:215-220.
Kenner DJ, Holt K, Agnello R, et al. Permanent retinal damage following massive dapsone overdose. Br J Ophthalmol 1980;64:741-744.
Lambert M, Sonnett J, Mahieu P, et al. Delayed sulfhemoglobinemia after acute dapsone intoxication. J Toxicol Clin Toxicol 1982;19:45-50.
Shah RR, Wade G. Reappraisal of the risk/benefit of nitrofurantoin: Review of toxicity and efficacy. Adverse Drug React Acute Poison Rev 1989;8:183-201.
Chudnofsky DR, Otten EJ. Acute pulmonary toxicity to nitrofurantoin. J Emerg Med 1989;7:15-19.
Mollison LC, Angus P, Richards M, et al. Hepatitis due to nitrofurantoin. Med J Aust 1992;156:347-349.
Mannisto PT, Lamminsiu V. Nitrofurantoin is highly bound to plasma protein. J Antimicrob Chemother 1982;9:327-328.
Cunha BA. Nitrofurantoin: Current concepts. Urology 1988;32:67-71.
SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;:338:1345—1349.
Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-1596.
Manson JE, Grobbee DE, Stampfer MJ, et al. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med 1990;89:772-776.
BuringJE, Peto R, HennekensCH. Low-dose aspirin for migraine prophylaxis. JAMA 1990;264:1711-1713.
Rummore MM, Goldstein GS. Prevention of recurrent myocardial infarction and sudden death with aspirin therapy. Drug Intell Clin Pharm 1987;21:961-962.
Vandenberg SA, Smolinske SC, Spoerke DG. Non-as-pirin salicylates: Conversion factors for estimating aspirin equivalence. Vet Hum Toxicol 1989;31:49-50.
Vandenberg SA, Smolinske SC, Spoerke DG, Rumack BH. Non-aspirin salicylates: Conversion factors for estimating aspirin equivalence. Vet Hum Toxicol 1987;29:469.
Patel DK, Ogunbona A, Notarianni LI, Bennet PN. Depletion of plasma glycine and effect of glycine by mouth on salicylate metabolism during aspirin overdose. Hum Exp Toxicol 1990;9:389-396.
Notarianni L. A reassessment of the treatment of salicylate poisoning. Drug Saf 1992;7:292-303.
Patel DK, Hesse A, Ogunbona A, et al. Metabolism of aspirin after therapeutic and toxic doses. Hum Exp Toxicol 1990;8:131-136.
Buck ML, Grebe TA, Bond GR. Toxic reaction to salicylates in a newborn infant: Similarities to neonatal sepsis. J Pediatr 1993;122:955-958.
Bond GR, Grebe TA, Arnold-Capell PA. Transplacental salicylate poisoning masquerading as neonatal sepsis. Vet Hum Toxicol 1989;31:346.
Wallenburg HC, Dekker GA, Makovitz JW, Rotmans P. Low-dose aspirin prevents pregnancy-induced hypertension and preeclampsia in angiotensin-sensitive primigravidae. Lancet 1986;1:1-3.
Wallenburg HC, Rotmans N. Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. Am J Obstet Gynecol 1987; 157:1230— 1235.
Benigni A, Gregorini G, Frascca T, et al. Effects of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989;321:357-362.
Schiff E, Pelel E, Goldenberg M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A, to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989;32:351-356.
Imperiale TF, Petrulis AS. A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertension disease. JAMA 1991;266:260-264.
Lubbe WF. Low dose aspirin in prevention of toxaemia of pregnancy. Does it have a place? Drugs 1987;34:515— 518.
Rumack CM, Guggenheim MA, Rumack BH, et al. Neonatal intracranial hemorrhage and maternal use of aspirin. Obstet Gynecol 1981;58:525-565.
Zierler S, Rothman KJ. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med 1985;313:347-352.
Heinonen DP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Science Corp., 1977.
Wexler MM, Michell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 1989;321:1639— 1642.
Osiewicz RJ, Middleberg R. Detection of a novel compound after overdoses of aspirin and amoxapine. J Anal Toxicol 1989;13:97-99.
Yip ASB, Chow WH, Tai YT, Cheung KL. Adverse effects of topical methylsalicylate ointment on warfarin anticoagulation: An unrecognized potential hazard. Postgrad Med J 1990:66:367-369.
Bartels PD, Lund-Jacobsen H. Blood lactate and ketone body concentrations in salicylate intoxication. Hum Toxicol 1986;5:363-366.
Proudfoot AT. Metabolic abnormalities: Aspirin poisoning. Personal presentation. Presented at the Scientific Meeting of the European Association of Poison Control Centers and Clinical Toxicologists, Birmingham, UK, May 26-28, 1993.
Bartley GB, Warndahl RA. Surgical bleeding associated with aspirin and nonsteroidal antiinflammatory agents. Mayo Clin Proc 1992;67:402-403.
Leventhal LJ, Kuritsky L, Ginsburg R, Bomalaski JS. Salicylate-induced rhabdomyolysis. Am J Emerg Med 1989;7:409-410.
Berk WA, Andersen JC. Salicylate-associated asystole: Report of two cases. Am J Med 1989;86:505-506.
McGuigan MA. A two-year review of salicylate deaths in Ontario. Arch Intern Med 1987;147:510-512.
McGuigan MA. Death due to salicylate poisoning in Ontario. Can Med Assoc J 1986;135:891-894.
Chapman BJ, Proudfoot AT. Adult salicylate poisoning: Deaths and outcome in patients with high plasma salicylate concentrations. Q J Med 1989;72:699-707.
Jacobsen D, Wiik-Larsen E, Bredeson JE. Hemodialysis or haemoperfusion in severe salicylate poisoning? Hum Toxicol 1988;7:161-163.
Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med 1989;320:1238-1243.
Bennett WM, De Broe ME. Analgesic nephropathy: a preventable renal disease. N Engl J Med 1989;320:1269-1271.
Rowe PC, Valle D, Brusilow SW. Inborn errors of metabolism in children referred with Reye's syndrome. JAMA 1988;260:3167-3170.
Gauthier M, Guary J, Lacroix J, Lortie A. Reye’s syndrome: A reappraisal of diagnosis in 49 presumptive cases. Am J Dis Child 1989;143:1181-1185.
Reye's syndrome surveillance — United States, 1989. MMWR 1991;40:88-89.
Porter JDH, Robinson PH, Glasgow JFT, et al. Trends in the incidence of Reye’s syndrome and the use of aspirin. Arch Dis Child 1990;65:826-829.
Orlowski JP, Gillis J, Killam HA. A catch in the Reye. Pediatrics 1987;80:638-642.
Pranzatelli MR, De Vivo DC. Pharmacology of Reye’s syndrome. Clin Neuropharmacol 1987;10:96-125.
National Institutes of Health. Diagnosis and treatment of Reye’s syndrome. JAMA 1981;246:2441-2444.
Meythalen JM, Varma RR. Reye’s syndrome in adults: Diagnostic considerations. Arch Intern Med 1987;147:61-64.
Ede RJ, Williams R. Reye’s syndrome in adults. Br Med J 1988;296:517-518.
Osterloh J, Cunningham W, Dixon A, Combest D. Biochemical relationships between Reye’s and Reye’s-like metabolic and toxicological syndromes. Med Toxicol Adverse Drug Experience 1989;4:272-294.
Perrault J, Fleming CR, Dozois RR. Surreptitious use of salicylates: A cause of chronic recurrent gastroduodenal ulcers. Mayo Clin Proc 1988;63:337-342.
Lindsley CR. Use of non-steroidal antiinflammatory drugs in pediatrics. Am J Dis Child 1993;147:229-236.
Levy G. Aspirin and bismuth subsalicylate. Am J Dis Child 1993; 147:1281.
Sainsbury SJ. Fatal salicylate toxicity from bismuth subsalicylate. West J Med 1991;155:637-639.
Steffers M, Esnard J, Meyer R, Bellucci A. Salicylate toxicity from bismuth subsalicylate overuse. Clin Res I989;32:336A.
Ching CK, Long RG, O’Hara R, Richardson J. Iatrogenic bismuth toxicity associated with inadvertent long term De-Nortab ingestion. I nt J Pharm Pract 1993;2:111-113.
Feldman S, Chew S-L, Pickering LK, et al. Salicylate absorption from a bismuth subsalicylate preparation. Clin Pharmacol Ther 1981;29:788-792.
Pickering LK, Feldman S, Ericsson CD, Cleary TG. Absorption of salicylate and bismuth from a bismuth subsalicylate containing compound (Pepto-Bismol). J Pediatr 1981;99:654-656.
Gordon MF, Abrams R, Rubin D, Barr B, Correa D. Bismuth subsalicylate toxicity as a cause for prolonged encephalopathy associated with myoclonus. Neurology 1994;44(suppl. 22):A305.
Montgomery H, Porter JC, Bradey RD. Salicylate intoxication causing a severe inflammatory response and rhabdomyolysis. Am J Emerg Med 1994;12:531-532.
Brien J-A: Ototoxicity associated with salicylates: a brief review. Drug Saf 1993;9:143-148.
Day RO, Graham GG, Bieri D, et al. Concentrationresponse relationships for salicylate-induced Ototoxicity in normal volunteers. Br J Clin Pharmacol 1989;28:695—702.
Leatherman JW, Schmitz RG. Fever, hyperdynamic shock and multiple system organ failure: A pseudo-sepsis syndrome associated with chronic salicylate intoxication. Chest 1991;100:1391-1397.
Bailey RB, Jones SR. Chronic salicylate intoxication: A common cause of morbidity in the elderly. J Am Geriat Soc 1989;37:556-561.
Krause DS, Wolf BA, Shaw LM. Acute aspirin overdose: Mechanisms of toxicity. Ther Drug Monk 1992; 14:441 — 451.
Trinder P. Rapid determination of salicylate in biological fluids. Biochem J 1954;57:301-303.
Krause DS, Wolf BA, Shaw LM. Acute aspirin overdose: Mechanisms of toxicity. Ther Drug Monit 1992.
King JA, Storrow AB, Finkelstein JA. Urine Trinder spot test: A rapid salicylate screen for the emergency department. Ann Emerg Med 1995;26:330-333.
McConnell RJ. Abnormal thyroid function test results in patients taking salicylates. JAMA 1992;267:1242-1243.
Done AK. Salicylate intoxication: Significance of measurements of salicylates in blood in cases of acute ingestion. Pediatrics 1960;26:800-807.
Dugandzic RM, Tierney MG, Dickinson GE, et al. Evaluation of the validity of the Done nomogram in the management of acute salicylate intoxication. Ann Emerg Med 1989;18:1186-1190.
Bergman J-F, Chassany О, Simoneau G, et al. Protection against aspirin-induced gastric lesions by lansoprazole: Simultaneous evaluation by functional and morphologic responses. Clin Pharmacol Ther 1992;52:413— 416.
Bigard MA, Isal JP. Complete prevention by omeprazole of aspirin-induced gastric lesions in healthy subjects. Gut 1988;29:A712.
Daneshmend TK, Stein AG, Bheskar NK, Haroly CJ. Abolition by omeprazole of aspirin-induced gastric mucosal injury in man. Gut 1990;31:514-517.
Loeb DS, Ahlquist DA, Talley NJ. Management of gastroduodenopathy associated with use of non-steroidal antiinflammatory drugs. Mayo Clin Proc 1992;67:354— 364.
Danel V, Henry JA, Glucksman E. Activated charcoal, emesis and gastric lavage in aspirin overdose. Br Med J 1988;296:1507.
Danel V, Glucksman E, Henry JA. A comparative study of gastric lavage, emesis and activated charcoal in the management of a simulated aspirin overdose. Vet Hum Toxicol 1987;29(suppl. 2): 107.
Tenenbein M, Kirschenbaum LA, Sitar DS. Multipledose charcoal therapy for salicylate poisoning. Ann Emerg Med 1989; 18:444.
Yeakel D, Stemple C, Dougherty J. A prospective human crossover study on single versus multiple dose charcoal in salicylate ingestion. Ann Emerg Med 1988; 17:439.
Filippone GA, Fish SS, Lacouture PG, et al. Reversible adsorption (desorption) of aspirin from activated charcoal. Arch Intern Med 1987;147:1390-1392.
Tenenbein M. Desorption of aspirin from activated charcoal. Arch Intern Med 1989; 149:717.
Tenenbein M, Sitar DS, Kirschenbaum L. Does multiple dose charcoal hemoperfusion enhance salicylate excretion? Vet Hum Toxicol 1989;31:335.
Barone JA, RaiaJJ, Huang YC. Evaluation of the effects of multiple-dose activated charcoal on the absorption of orally administered salicylate in a simulated toxic ingestion model. Ann Emerg Med 1988;17:34-37.
Dillon E, Wilton JH, Barlow J, Watson WA. The effect of two activated charcoal preparations on aspirin absorption in man. Vet Hum Toxicol 1987;39:491-492.
Augenstein WL, Killing KW, Rumack BH. Delayed rise in serum levels in overdose patients despite multiple dose charcoal and after charcoal stool. Vet Hum Toxicol I987;29:491.
Tenenbein M, Sitar DS, Meyer L. Does oral multiple dose charcoal therapy or whole bowel irrigation increase the clearance of previously absorbed salicylate. Vet Hum Toxicol 1991;33:368.
Kirshenbaum LA, Mathews SC, Sitar DS, Tenenbein M. Does multiple-dose charcoal therapy enhance salicylate excretion? Arch intern Med 1990; 150:1281 —1283.
Gren J, Woolf A. Hypermagnesemia associated with catharsis in a salicylate-intoxicated patient with anorexia nervosa. Ann Emerg Med 1989;18:200-203.
Mayersohn M, Perrier D, Pichioni AL. Evaluation of charcoalsorbitol mixture as an antidote for oral aspirin overdose. Clin Toxicol 1977;11:561-567.
Easom JM, Carraccio TR, Lovejoy FH Jr. Evaluation of activated charcoal and magnesium citrate in the prevention of aspirin absorption in humans. Clin Pharm 1982;1:154-156.
Sketris IS, Mowry JB, Czajka PA, et al. Saline catharsis: Effect on aspirin bioavailability in combination with activated charcoal. J Clin Pharmacol 1982;22:59-64.
Neuvonen PJ, Oikkola KT. Effect of purgatives on antidote efficacy of oral activated charcoal. Hum Toxicol 1986;5:255-263.
Brent J, Kulig K, Rumack BH. Iatrogenic deaths from sorbitol and magnesium sulfate during treatment forsalicylism. Vet HumToxicol 1989;31:334.
Gavish D, Knobler H, Gottebrer N, et al. Methemoglobinemia, muscle damage and renal failure complicating phenzaopyridine overdose. Isr J Med Sci 1986;22:45— 47.
Green ED, Zimmerman RC, Ghurabi WH, Colohar DR. Phenazopyridine hydrochloride toxicity: A cause of drug-induced methemoglobinemia. JACEP 1979;8: 426-431.
Alano FA, Webster GD. Acute renal failure and pigmentation due to phenazopyridine (Pyridium). Ann Intern Med 1970;72:89-91.
Kearney ТЕ, Manoguerra AS, Dunford JV. Chemically induced methemoglobinemia from aniline poisoning. West J Med 1984;140:282-286.
Johnson WJ, Chartrand A. The metabolism and excretion of phenazopyridine hydrochloride in animals and man. Toxicol Appl Pharmacol 1976;37:371-376.
Fincher ME, Campbell HT. Methemoglobinemia and hemolytic anemia after phenazopyridine hydrochloride (Pyridium) administration in end-stage renal disease. South Med J 1989;82:372-374.
Nathan DM, Siegel AJ, Bunn HF. Acute methemoglobinemia and hemolytic anemia with phenazopyridine. Arch Intern Med 1977;137:1636-1638.
Feinfeld DA, Ranieri R, Lipnes Hl, Avram MM. Renal failure in phenazopyridine overdose. JAMA 1978;240:2661.
Eybel CE, Armbruster KFW, Ing TS. Skin pigmentation and acute renal failure in a patient receiving phenazopyridine therapy. JAMA 1974;228:1027-1028.
Sharon M, Puente G, Cohen LB. Phenazopyridine (Pyridium) poisoning: Possible toxicity of methylene blue administration in renal failure. Mt Sinai J Med 1986;53:280-282.
Ponte CD, Lewis MJ, Rogers JS 11. Heinz-body hemolytic anemia associated with phenazopyridine and sulfonamide. DICP Ann Pharmacother 1989;23:140-142.
Cohen BL, Bovasso GJ Jr. Acquired methemoglobinemia and neurologic anemia following excessive Pyridium (phenazopyridine hydrochloride) ingestion. Clin Pediatr 1971;10:537-540.
Zimmerman RC, Green ED, Ghurabi WH, Colohan Dr. Methemoglobinemia from overdose of phenazopyridine hydrochloride. Ann Emerg Med 1980;9:147-149.
Galun E, Oren R, Glikson M, et al. Phenazopyridineinduced hemolytic anemia in G-6-PD deficiency. Drug Intell Clin Pharm 1987;21:921-922.
Halvorsen SM, Dull WL. Phenazopyridine-induced sulfhemoglobinemia: Inadvertent rechallenge. Am J Med 1991;91:317-319.
Herlihy ТЕ. Phenazopyridine and aseptic meningitis. Ann Intern Med 1987;106:172-173.
Bruton ОС. Exchange transfusion for acute poisoning in children. U. S. Armed Forces Med J 1958;9:1128— 1131.
Chakraborty TK, Rilshie RJA, Lee Mr. methaemoglobinernia produced by phenozopyridine (Pyridium) in a man with chronic obstructive airways disease. Scot Med J 1987;32:185-186.
Dubose TD Jr, Molony DA, Verani I, McDonald GA. Nephrotoxicity of non-steroidal antiinflammatory drugs. Lancet 1994;344:515-518.
Loeb DS, Ahlquist DA, Talley NJ. Management of gastroduodenopathy associated with use of non-steroidal antiinflammatory drugs. Mayo Clin Proc 1992;67:354— 364.
Jick H, Rodriguez LAG. Risk upper gastrointestinal bleeding and perforation associated with individual nonsteroidal antiinflammatory drugs. Lancet 1994;343:769— 772.
Rodriguez LAG, Williams R, Derby LE, et al. Acute liver injury associated with nonsteroidal antiinflammatory drugs and the role of risk factors. Arch Intern Med 1994;154:311-316.
Stron BL, Carson JL, Schinnar R, et al. Nonsteroidal antiinflammatory drugs and neutropenia. Arch Intern Med 1993;153:2119-2124.
Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-anal-ysis. Ann Intern Med 1994;121:289-300.
Important prescribing information. Washington, DC: U. S. Food and Drug Administration, Feb. 3, 1989.
Macdougall LG, Taylor-Smith A, Rothberg AD, Thomson PD. Piroxicam poisoning in a 2 year old child: A case report. S Afr Med J 1984;66:31-33.
Important drug warning: ToradolR (ketoralac tromethamine). Palo Alto, CA: Syntex Laboratories, 1995.
Choo V, Lewis S. Ketorolac doses reduced. Lancet 1993;342:109.
Ross-Degman D, Soumerai SB, Fortess EE, Gurwitz JH. Examining product risk in content: Market withdrawal of zomepirac as a case study. JAMA 1993;270:1937-1942.
Court H, Volans GN. Poisoning after overdose with nonsteroidal anti-inflammatory drugs. Adverse Drug React Acute Poisoning Rev 1984;3:1-21.
Murray MD, Brater DC. Renal toxicity of the nonsteroidal antiinflammatory drugs. Annu Rev Pharmacol Toxicol 1993;33:435-465.
Mizushima Y. Pro-drugs of non-steroidal antiinflammatory agents. EurJ Rheumatol Inflamm 1983;6:141-142.
Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs: Differences and similarities. N Engl J Med 1991;324:1716-1725.
Stewart CF, Evans WE. Drug-drug interactions with anti rheumatic agents: Review of selected clinically important interactions. J Rheumatol 1990; 17(suppl. 22): 16-23.
Verbeeck RK. Pharmacokinetic drug interactions with nonsteroidal antiinflammatory drugs. Clin Pharmacokinet 1990;19:44-68.
Hayllar J, Bjarnason I. NSAIDs, Cox-2 inhibitors and the gut. Lancet 1995;346:521-522.
Graham DY, Smith JL, Holmes GI, et al. Non-steroidal antiinflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa. Clin Pharmacol Ther 1985;38:65-70.
Downie A, Ali A, Bell D. Severe metabolic acidosis complicating massive ibuprofen overdose. Postgrad Med J 1993;69:575-577.
Halperin SM, Fitzpatrick R, Volans GN. Ibuprofen toxicity. A review of adverse reactions and overdose. Adverse Drug React Toxicol Rev 1993;12:107-128.
Kim J, Gazarian M, Johnson D. Acute renal failure and ibuprofen overdose: A pediatric case report. Vet Hum Toxicol 1993;35:340.
Hall AH, Smolinske SC, Stover B, et al. Ibuprofen overdose in adults. Ciin Toxicol 1992;30:23-37.
McElwee NE, Veltri JC, Bradford DC, Rollins DE. A prospective population-based study of acute ibuprofen overdose: Complications are rare and routine serum levels are not warranted. Ann Emerg Med 1990; 19:657— 662.
Aabakken L. Review articles: Non-steroidal, anti-inflammatory drugs: Extending the scope of gastrointestinal side effects. Aliment Pharmacol Ther 1992;6:143— 162.
Bush TM, Shotzhauer TL, Imai K. Nonsteroidal antiinflammatory drugs: Proposed guidelines for monitoring toxicity. West J Med 1991;155:39-42.
Sievero W, Stern Al, Lambert JR, Peacock T. Low dose antacids and non-steroidal antiinflammatory drug-induced gastropathy in humans. J Clin Gastroenterol 1991;13(suppl. 1):S145—S148.
Kwo PY, Tremaine WJ. Non-steroidal antiinflammatory drug-induced enteropathy: Case discussions and review of the literature. Mayo Clin Proc 1995;70:50-51.
Bright TP, McNulty CJ. Suspected central nervous system toxicity from inadvertent nonsteroidal antiinflammatory drug overdose. DICP Ann Pharmacother 1991;25:1066-1067.
Khalil H, Molinary E, Stoller J K. Diclofenac (Voltaren)-induced eosinophilic pneumonitis: Case report and review of the literature. Arch Intern Med 1993; 153:1649— 1652.
McCune KH, O’Brien CJ. Atrial fibrillation induced by ibuprofen overdose. Postgrad Med J 1993;69:325-328.
Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of non-steroidal antiinflammatory drugs on blood pressure. Arch Intern Med 1993;152:477-484.
Appleby DH. Fenoprofen (Nalfon) overdose. Drug Intell Clin Pharm 1981;15:129-130.
Lee CY, Finkler A. Acute intoxication due to ibuprofen overdose. Arch Pathol Lab Med 1986;110:747-749.
Bush TM, Shotzhauer TL, Imai K. Nonsteroidal antiinflammatory drugs: Proposed guidelines for monitoring toxicity. West J Med 1991;155:39-42.
Boletis J, Williams AJ, Shortland JR, Brown CB. Irreversible renal failure following mefenamic acid. Nephron 1989;51:575-576.
Quan DJ, Kaysen SR. Ketoralac-induced acute renal failure following a single dose. Clin Toxicol 1994;32:305-309.
Baterman DM. Tiaprofenic acid and cystitis: Grounds for withdrawal? Br Med J 1994;309:552-553.
Kulling PEJ, Beckman EA, Skagius ASM. Renal impairment after acute diclofenac, naproxen and sulindac overdoses. Clin Toxicol 1995;33:173-177.
Hart D, Ward M, Lifshitz MD. Suprofen-related nephrotoxicity: A distinct clinical syndrome. Ann Intern Med 1987;106:235-238.
Strom BL, West SL, Sim E, Carson JL. The epidemiology of the acute flank pain syndrome from suprofen. Clin Pharmacol Ther 1989;46:693-699.
Rossi AC, Bosco L, Faich GA, Tanner A, Temple R: The importance of adverse reaction reporting by physicians: Suprofen and the flank pain syndrome. JAMA 1988;259:1203-1204.
Rare complication with sulindac. FDA Drug Bull 1989;19(1):4.
Wen S-F, Parthasarathy R, Iliopoalos O, Oberley FD. Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs. Am J Kidney Dis 1992;30:281-285.
Bush TM, Shotzhauer TL, Imai K. Nonsteroidal antiinflammatory drugs: Proposed guidelines for monitoring toxicity. West J Med 1991;155:39-42.
Bartley GB, Warndahl RA. Surgical bleeding associated with aspirin and nonsteroidal antiinflammatory agents. Mayo Clin Proc 1992;67:402.
Strom BL, Carson JL, Schinnar R, et al. Non-steroidal antiinflammatory drugs and neutropenia. Arch Intern Med 1993;153:2119-2124.
Roura M, Lopez-Gill F, Umbert P. Systemic lupus erythematosus exacerbated by piroxicam. Dermatologica 1990;182:56-58.
Halasz CLG. Photosensitivity to the nonsteroidal antiinflammatory drug piroxicam. Cutis 1987;39:37-39.
Levine B, Smyth DF, Caplan YH. A diflunisal related fatality: A case report. Forens Sci Int 1987;35:45-50.
Vale JA, Meredith TJ. Acute poisoning due to non-steroidal anti-inflammatory drugs: Clinical features and management. Med Toxicol 1986;1:12-31.
De Flines EW, Bolwerk CJ, Komen BJ, Veenhoven WA. Abnormal metabolism of phenylbutazone after overdosage. DICP Ann Pharmacother 1990;24:783.
Newton TA, Rose SR. Poisoning with equine phenylbutazone in a racetrack worker. Ann Emerg Med 1991;20:204-207.
Robson RH, Balali M, CritchleyJ, et al. Mefenamic acid poisoning and epilepsy. Br Med J 1979;2:1438.
Shipton EA, Muller FO. Severe mefenamic acid poisoning: A case report. S Afr Med J 1985;67:823-824.
Mosvoid J, Mellem H, Stave R, et al. Overdosage of piroxicam. Acta Med Scand 1984;216:335-336.
Netter P, Lambert H, Larcan A, et al. Diclofenac sodiumchlormezanone poisoning. Eur J Clin Pharmacol 1984;26:535-536.
Del Puppo M, Cigghetti G, Kienie MG, et al. Determination of diclofenac in human plasma by selected ion monitoring. Biol Mass Spectrom 1991;20:426-430.
Willis JV, Kendall MJ, Flinn RM, et al. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 1979;16:405-410.
Menzies DG, Conn AG, Williamson 1J, Prescott LF. Fulminant hyperkalaemia and multiple complications following ibuprofen overdose. Med Toxicol Adverse Drug Experience 1989;4:468-471.
Kunsman GW, Rohrig TP. Tissue distribution of ibuprofen in a fatal overdose. Am J Forens Med Pathol 1993;14:48-50.
Schultz M, Schmoldt A. HPLC-determination of nonsteroidal anti-inflammatory drugs in human plasma. In: Proceedings, 25th International Meeting, International Association of Forensic Toxicologists, Groningen, January 27—30, 1988:471-479.
Rustum AM. Measurement of ibuprofen in human whole blood by reversed-phase ion-paired high-performance liquid chromatography using a pH-stable polymeric column. J Chromatogr Biomed Appl 1990;526:246-253.
Johnson AG, Ray JE. Improved high-performance liquid chromatographic method for the determination indomethacin in plasma. Ther Drug Monit 1992; 14:61 — 65.
Musson DG, Vincek WC, Constanzer ML, Detty ТЕ. Analytical methods for the determination of sulindac and metabolites in plasma, urine, bile and gastric fluid by liquid chromatography using ultraviolet detection. J Pharm Sci 1984;73:1270-1273.
Larsen J, Fogerson R. Nonsteroidal anti-inflammatory drug interference in TDxR assays for abused drugs. Clin Chem 1988;34:987-988.
De Flines EW, Bolwerk CJ, Komen BJ, Veenhoven WA. Abnormal metabolism of phenylbutazone after overdosage. DICP Ann Pharmacother 1990;24:783.
Riedel К-D, Laufen H. High-performance thin-layer chromatographic assay for the routine determination of piroxacam in plasma, urine and tissue. J Chromatogr 1983;276:243-248.
Miller KP, Lazar EJ, Fotino S. Severe hyperkalemia during piroxicam therapy. Arch Intern Med 1984;144:2414-2415.
Alun-Jones E, Williams J. Hyponatremia and fluid retention in a neonate associated with maternal naproxen overdosage. Clin Toxicol 1986;24:257-260.
Kelker KH. Hypoprothrombinemia without hepatocellular injury in ibuprofen overdose. Clin Toxicol 1995;33:492. Abstract 17.
Koel M, Nebinger P. Specificity data of the salicylate assay by fluorescent polarization immunoassay. J Anal Toxicol 1989;13:358-360.
Musson DG, Lin JH, Lyon KA, et al. Assay methodology for quantification of the ester and ether glucuronide conjugates of diflunisal in human urine. J Chromatogr Biomed Appl 1985;337:363-378.
Smolinske SC, Hall AH, Vandenberg SA, et al. Toxic effects of nonsteroidal antiinflammatory drugs in overdose: An overview of recent evidence on clinical effects and dose-response relationships. Drug Saf 1990;5:252-274.
Roberts JR. NSAlDs: G1 protection and overdose. Emerg Med News, May 1990:4—5.
Vale JA, Meredith TJ. Acute poisoning due to non-steroidal anti-inflammatory drugs: Clinical features and management. Med Toxicol 1986;1:12-31.
Guentert TW, Detain R, Mosberg H. Accelerated elimination of temoxicam and piroxicam by cholestyramine. Clin Pharmacol Ther 1988;43:179.
Narjes H, Heinzel G, Busch U. Cholestyramine affects pharmacokinetics of meloxicam, a new non-steroidal antiinflammatory drug (NSAID), in man. Clin Pharmacol Ther 1991 ;49:169.
Henry J, Volans G. Analgesic poisoning. I. Salicylates. Br Med J 1984;289:820-822.
Jones RW, Collins AJ, Jotarianni LJ, Sedman E. The comparative pharmacokinetics of acemetacin in young subjects and elderly patients. Br J Clin Pharmacol 1991;31:543-545.
inman WHW, Wilton LV, Pearce GL, Waller PC. Prescription event monitory of nabumetone. Pharm Med 1990;4:309-317.
Bernhard GC. Worldwide safety experience with nabumetone. J Rheumatol 1992; 19(suppl. 36):48—57.
Friedel HA, Langtry HD, Buckley MM. Nabumetone: A reappraisal of its pharmacology and therapeutic use in rheumatic disease. Drug 1993;45:131-156.
Kraml M, Hicks DR, McKean M, et al. The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis. Clin Pharmacol Ther 1988;43:571 — 576.
Boldy DAR, Hale KA, Vale JA. Etodolac overdose. Hum Toxicol 1988;7:203-204.
Foulds RA. An overview of human safety data with nedocromil sodium. J Allergy Clin Immunol 1993;92:202— 204.
Clark B. General pharmacology, pharmacokinetics and toxicology of nedocromil sodium. J Allergy Clin Immunol 1993;92:200-202.
Gonzalez JP, Brogden RN. Nedocromil sodium: A preliminary review of its pharmacodynamic and pharmacokinetic properties and the therapeutic efficacy in the treatment of reversible obstructive airways disease. Drugs 1987;34:560-577.
Neal MG, Brown K, Foulds RA, Lal S, et al. The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease. BrJ Clin Pharmacol 1987;24:493-501.
Bevlicqua M, Magni E. Recent contributions to knowledge of the mechanism of action of nimesulide. Drugs 1993;46(suppl. l):40—47.
Bernareggi A. The pharmacokinetic profile of nimesulide in healthy volunteers. Drugs 1993;46(suppl. 1): 64-72.
Prescott LF, Highley MS. Drugs prescribed for self-poisoners. Br Med J 1985;290:1633-1636.
Platt S, Hawton K, Kreitman N, et al. Recent clinical and epidemiological trends in parasuicide in Edinburgh and Oxford: A tale of two cities. Psychol Med 1988;18:405-418.
LitovitzTL, Clark LR, Soloway RA. 1993 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1994;12:546-584.
Meredith TJ, Jacobsen D, Haines JA, Berger J-C, eds. Antidotes for poisoning by paracetamol. Cambridge: Cambridge University Press, 1995.
Corcoran GB, Mitchell Jr, Vaishnaw YN, et al. Evidence that acetaminophen and A-hydroxyacetaminophen form a common arylating intermediate, A-acetyl-p-benzoqui-noneimine. Mol Pharmacol 1980;18:536-542.
Prescott LF. Drug conjugation in clinical toxicology. Bi-ochem Soc Trans 1984;12:96-99.
Mitchell JR, Thorgeirsson SS, Potter WZ, et al. Acetaminophen-induced hepatic injury: Protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther 1974;16:676-684.
Mitchell JR, Jollow DJ, Potter WZ, et al. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 1973;187:211-217.
Crippin JC. Acetaminophen hepatotoxicity: Potentiation by isoniazid. Am J Gastroenterol 1993;88:590-592.
Minton NA, Henry JA, Frankel RJ. Fatal paracetamol poisoning in an epileptic. Hum Toxicol 1988;7:33-34.
Mathis RD, Walker JS, Kuhns DW. Subacute acetaminophen overdose after incremental dosing. J Emerg Med 1988;6:37-40.
Ashbourne JF, Olson KR, Khayam-Bashi H. Value of rapid screening for acetaminophen in all patients with intentional drug overdose. Ann Emerg Med 1989;18:1035-1038.
Mitchell JR. Host susceptibility and acetaminophen liver injury. Ann Intern Med 1977;87:377-388.
Rumack BH. Acetaminophen overdose in young children. Am J Dis Child 1984;138:428-433.
Vale J A, Proudfoot A. Paracetamol (acetaminophen) poisoning. Lancet 1995;346:547-552.
Slattery JT, Wilson JM, Kalhom TF, Nelson SD. Dosedependent pharmacokinetics of acetaminophen: Evidence of glutathione depletion in humans. Clin Pharmacol Ther 1987;41:413-418.
Lee HS, Ti TY, Koh YK, Prescott LF. Paracetamol elimination in Chinese and Indians in Singapore. Eur J Clin Pharmacol 1992;43:81-84.
Slattery JT, Koup JR, Levy G, et al. Acetaminophen pharmacokinetics after overdose. Clin Toxicol 1981;18:111-117.
Sonne J, Poulsen HE, Loft S, et al. Therapeutic doses of codeine have no effect on acetaminophen clearance or metabolism. Eur J Clin Pharmacol 1988;35:109-111.
Jack D, Thomas M, Skidmore IF. Ranitidine and paracetamol metabolism. Lancet 1985;2:1067.
Tredger JM, Thuluvah P, William R, Murray-Lyon IM. Metabolic basis for high paracetamol dosage without hepatic injury: A case study. Hum Exp Toxicol 1995;14:8— 12.
Ameer B. Acetaminophen hepatotoxicity augmented by zidovudine. Am J Med 1993;95:342.
James RC, Harbison RD, Roberts SM. Phenylpropanolamine potentiation of acetaminophen-induced hepatotoxicity: Evidence for a glutathione-dependent mechanisms. Toxicol Appl Pharmacol 1993;118:159—168.
Roberts I, Robinson MJ, Mughal MZ, et al. Paracetamol metabolites in the neonate following maternal overdose. Br J Clin Pharmacol 1984;18:201-206.
Settipane RA, Stevenson DD. Cross sensitivity with acetaminophen in aspirin-sensitive subjects with asthma. J Allergy Clin Immunol 1989;84:26-33.
Bronstein AC, Rumack BH. Abstract A-12, ААРСС/ ABMT/CAPCC Annual Scientific Meeting, October 7, 1984, San Diego, California. Vet Hum Toxicol 1984;26(suppl. 2):44.
Ruthrum P, Goel KM. ABC of poisoning: Paracetamol. Br Med J 1984;289:1538-1539.
Byer AJ, Traylor TR, Semmer JR. Acetaminophen overdose in the third trimester of pregnancy. JAMA 1982;247:3114-31 15.
McElhatton PK, Sullivan FM, Volans GN, Fitzpatrick R. Paracetamol poisoning in pregnancy: An analysis of the outcome of cases referred to the Teratology Information Service of the National Poisons Information Service. Hum Exp Toxicol 1990;9:147-153.
Rollins DE, von Bahr C, Glaumann H, et al. Acetaminophen: Potentially toxic metabolite formed by human fetal and adult liver microsomes and isolated fetal liver cells. Science 1979;205:1414-1416.
Roberts JR. Acetaminophen toxicity: Issues for children and pregnant women. Emerg Med News 1994;16:4-8.
Clark R, Thompson RPH, Borirakchanyavat V, et al. Hepatic damage and death from overdose of paracetamol. Lancet 1973;1:66-70.
Canalese J, Gimson AES, Davis M, et al. Factors contributing to mortality in paracetamol induced hepatic failure. Br Med J 1981;282:199-201.
Gall GD, Cutz E, McLung HJ, et al. Acute liver disease and encephalopathy mimicking Reye syndrome. J Pediatr 1975;87:869-874.
Kaul A, Cohen ME, Brottman G, et al. Reye-like syndrome associated with Coxsackie B2 virus infection. J Pediatr 1979;94:67-69.
Andrews PA, Koffman CG. Kidney donation after paracetamol overdose. Br Med J 1993;306:1129.
Prescott LF, Illingworth RN, Critchley JAJH, et al. Intravenous ^acetylcysteine: The treatment of choice for paracetamol poisoning. Br Med J 1979;2:1097-1100.
Smilkstein MJ, Bronstein AC, Linden C, et aL Acetaminophen overdose: A 48-hour intravenous /V-acetylcysteine treatment protocol. Ann Emerg Med 1991;20:1058-1063.
Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral A-acetylcysteine in the treatment of acetaminophen overdose: Analysis of the National Multicenter study (1976 to 1985). N Engl J Med 1988.
Prescott LF, Speirs GC, Critchley JAJH, et al. Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. Eur J Clin Pharmacol 1989;36:291-297.
Campbell NRC, Baylis B. Renal impairment associated with an acute paracetamol overdose in the absence of hepatotoxicity. Postgrad Med J 1992;68:116-118.
McMurtry RJ, Snodgrass WR, Mitchell JR. Renal necrosis, glutathione depletion and covalent binding after acetaminophen. Toxicol Appl Pharmacol 1978;46: 87-100.
Bjorck S, Svalander CT, Aurell M. Acute renal failure after analgesic drugs including paracetamol (acetaminophen). Nephron 1988;49:45-53.
Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med 1989;320: 1238-1243.
Segasothy M, Suleiman AB, Puvaneswary M, Rohana A. Paracetamol: A cause for analgesic nephropathy and end-stage renal disease. Nephron 1988;50:50-54.
Ronco PM, Flahault A. Drug-induced end-stage renal disease. N Engl J Med 1994;331:1711-1712.
Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure with the use of acetaminophen, aspirin and nonsteroidal antiinflammatory drugs. N Engl J Med 1994;331:1675-1679.
Curry RW, Robinson JD, Sughrue MJ. Acute renal failure after acetaminophen ingestion. JAMA 1982;247:1012-1014.
Gabriel R. Paracetamol-induced acute renal failure in the absence of fulminant liver damage. Br Med J 1982;284:505-506.
Cobden I, Record CO, Ward MK, Kerr DNS. Paracetamol-induced acute renal failure in the absence of fulminant liver damage. Br Med J 1982;284:21-22.
Davenport A, Finn R. Paracetamol (acetaminophen) poisoning resulting in acute renal failure without hepatic coma. Nephron 1988;50:55-56.
Wilkinson SP, Moodie H, Arroya VA, Williams R. Frequency of renal impairment in paracetamol overdose compared with other causes of liver failure. J Clin Pathol 1977;30:141-143.
Jones AF, Jolley A, Buckley BM, Vale JA. Effect of indomethacin on polyuria following a paracetamol overdose. Presented at the Meeting of the European Association of Poison Centres, Edinburgh, 1988.
Bennett WM, Debroe ME. Analgesic nephropathy: A preventable disease. N Engl J Med 1989;320:1269-1271.
Mitchell SR. Tell your kidneys to take a powder. Arch Intern Med 1991; 151:617.
Mann JM, Pieer-Louis M, Kragel PJ, et al. Cardiac consequences of massive acetaminophen overdose. Am J Cardiol 1989;63:1018-1021.
Wakeel RA, Davies HT, Williams J D. Toxic myocarditis in paracetamol poisoning. Br Med J 1987;295:1097.
Price LM, Poklis A, Johnson DE. Fatal acetaminophen poisoning with evidence of subendocardial necrosis of the heart. J Forens Sci 1991;36:930-935.
Pimstone BL, Uys CJ. Liver necrosis and myocardiopathy following paracetamol overdosage. S Afr Med J 1968;42:259-262.
Armour A, Slater SD. Paracetamol cardiotoxicity. Postgrad Med J 1993;69:52-54.
Ellis M, Haydik I, Gilman S, et al. Immediate adverse reactions to acetaminophen in children: Evaluation of histamine release and spirometry. J Pediatr 1989;114:654-656.
Diem LV, Grilliat JP. Anaphylactic shock induced by paracetamol. Eur J Clin Pharmacol 1990;38:389-390.
Gray ТА, Buckley ВМ, Vale JA. Hyperlactataemia and metabolic acidosis following paracetamol overdose. Q J Med 1987;65:811-821.
Clark R, Borirakchanyavat V, Gazzard BG, et al. Disordered haemostatis in liver damage from paracetamol overdose. Gastroenterology 1973;65:788-795.
Gilmore IT, Tourvas E. Paracetamol-induced acute pancreatitis. Br Med J 1977;1:753-754.
Record CO, Chase RA, Alberti KG MM, Williams R. Disturbances in glucose metabolism in patients with liver damage due to paracetamol overdose. Clin Sci Mol Med 1975;49:473-479.
Knockel JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch Intern Med 1977;137:203-220.
Skokan JD, Hewlett JS, Hoffman GD. Thrombocytopenic purpura associated with ingestion of acetaminophen (Tylenol). Cleve Clin Q 1973;40:89-91.
Saunders JB, Wright N, Lewis KO. Predicting outcome of paracetamol poisoning by using l4C-aminopyrine breath test. Br Med J 1980;280:279-280.
Harrison PM, O’Grady JG, Keays RT, et al. Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. Br Med J 1990;301:964-966.
Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975;55:871-876.
Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994;272:1845-1850.
Bray GP, Mowat DF, Muir DF, et al. The effect of chronic alcohol intake on prognosis and outcome in paracetamol overdose. Hum Exp Toxicol 1992;! 1:265— 270.
Lauterburg BH, Velez ME. Glutathione deficiency in alcoholics: Risk factor for paracetamol hepatotoxicity. Gut 1988;29:1153-1157.
Lauterburg BH, Davis S, Mitchell JR. Ethanol suppresses hepatic glutathione synthesis in rats in vivo. J Pharmacol Exp Ther 1984;230:7-11.
Henretig FM, Selbst SM, Forrest C, et al. Repeated acetaminophen overdosing causing hepatotoxicity in children: Clinical reports and literature review. Clin Pediatr 1989;28:525-528.
Greene JW, Craft L, Ghishan F. Acetaminophen poisoning in infancy. Am J Dis Child 1983; 137:387.
Nogen AG, BremmerJE. Fatal acetaminophen overdosage in a young child. J Pediatr 1984;92:832-833.
Hickson GB, Greene JW, Ghishan FK, Craft LT. Apparent intentional poisoning of an infant with acetaminophen. Am J Dis Child 1983; 137:917.
Agran PF, Zenk KE, Romansky SG. Acute liver failure and encephalopathy in a 15-month-old infant. Am J Dis Child 1983;137:1107-1114.
Swetnam SM, Florman AL. Probably acetaminophen toxicity in an 18-month-old infant due to repeated overdosing. Clin Pediatr 1984;23:104-105.
Baeg N-J, Bodenheimer HC Jr, Burchard K. Long-term sequelae of acetaminophen-associated fulminant hepatic failure: Relevance of early histology. Am J Gastroenterol 1988;83:569-571.
Temple AR. Pediatric dosing of acetaminophen. Pediatr Pharmacol 1983;3:321-329.
Walson PD, Groth J F Jr. Acetaminophen hepatotoxicity after a prolonged ingestion. Pediatrics 1993;91:1021 — 1022.
Tighe TV, Walter FG. Delayed toxic acetaminophen level after initial four hour nontoxic levels. Clin Toxicol 1994;32:431-434.
Johnson GK, Tolman KG. Chronic liver disease and acetaminophen. Ann Intern Med 1977;87:302-304.
Bidault I, Lagier G, Garnier G, et al. Les hepatites partoxicite subaique du paracetamol existent elles? A propos de 3 cas eventuels. Therapie 1987;42:387-388.
Barker JD Jr, de Carle DJ, Anuras S. Chronic excessive acetaminophen use and liver damage. Ann Intern Med 1977;87:299-301.
James O, Lesna M, Roberts SH, et al. Liver damage after paracetamol overdose. Lancet 1975;2:579-581.
Walker RM, McElligott TF, Power EM, et al. Increased acetaminophen-induced hepatotoxicity after chronic ethanol consumption in mice. Toxicology 1983;128:193-200.
Pezzano M, Richard CL, Lampl E, et al. Toxicite hepatique et renale due paracetamol chez 1'alcoholique chronique. Presse Med 1988;17:21-24.
Seeff LB, Cuccherini BA, Zimmerman HJ, et al. Acetaminophen hepatotoxicity in alcoholics: A therapeutic misadventure. Ann Intern Med 1986;104:399-404.
Floren C-H, Thesieff P, Nilsson A. Severe liver damage caused by therapeutic doses of acetaminophen. Acta Med Scand 1987;222:285-288.
Wootton FT, Lee WM. Acetaminophen hepatotoxicity in the alcoholic. South Med J 1990;83:1047-1049.
McClain CJ, Holtzman J, Allen J, et al. Clinical features of acetaminophen toxicity. J Clin Gastroenterol 1988;10:76-80.
Kunar S, Rex DFK. Failure of physicians to recognize acetaminophen hepatotoxicity in chronic alcoholics. Arch Intern Med 1991;151:1189-1191.
Zimmerman HJ. Acetaminophen toxicity in alcoholics. West J Med 1989; 150:722.
Eriksson LS, Broome U, Kaline M, Lindholm M. Hepatotoxicity due to repeated intake of low doses of paracetamol. J Intern Med 1992;231:567-570.
Cheung L, Potts RG, Mayer КС. Acetaminophen treatment nomogram. N Engl J Med 1994;330:1907-1908.
Lee WM. Acute liver failure. N Engl J Med 1993;329:1862-1872.
Farah DA, Boag D, Moran F, McIntosh S. Paracetamol interference with blood glucose analysis: A potentially fatal phenomenon. Br Med J 1982;285:172.
Poon B, Hinberg I, Peterson PG. V-Acetylcysteine causes false-positive ketone results with urinary dipsticks. Clin Chem 1990;36:818-820.
Bridges RR, Kinniburgh DW, Keehn BJ, et al. An evaluation of common methods for acetaminophen quantitation for small hospitals. Clin Toxicol 1983;20:1-17.
Osterloh J. Limitations of acetaminophen assays. Clin Toxicol 1983;20:1-17.
Edinboro LE, Jackson GF, Jortani SA, Poklis A. Determination of serum acetaminophen in emergency toxicology: Evaluation of newer methods: Abbott TDx and second derivative ultraviolet spectrophotometry. Clin Toxicol 1991;29:241-255.
Beckett GJ, Hayes JD. Plasma glutathione S-transferase measurements and liver disease in man. J Clin Biochem Nutr 1987;2:1-24.
Beckett GJ, Foster GR, Hussey AJ, et al. Plasma glutathione S-transferase and F protein are more sensitive than alanine aminotransferase as markers of paracetamol (acetaminophen)-induced liver damage. Clin Chem 1989;35:2186-2189.
Thornton JR, Losowsky MS. Severe thrombocytopenia after paracetamol overdose. Gut 1990;31:1159—1160.
Armour A, Slater SD. Paracetamol cardiotoxicity. Postgrad Med J 1993;69:52-54.
Hinson J A, Roberts DW, Benson RW, et al. Mechanism of paracetamol toxicity. Lancet 1990; 1:732.
Jones AF, Harvey JM, Vale JA. Hypophosphatemia and phosphaturia in paracetamol poisoning. Lancet 1989;2:608-609.
Jones AF, McAleer JF, Braithwaite RA, et al. Rapid side 100m test for paracetamol. Lancet 1990;335:793-794.
Medi Sense (U. К.), Abingdon, Oxfordshire, U. К.
Shannon M, Saladino R, McCarty D, et al. Clinical evaluation of an acetaminophen meter for the rapid diagnosis of acetaminophen intoxication. Ann Emerg Med 1990;19:1133-1136.
Rose SR, Gorman RL, Oderda GM, et al. Simulated acetaminophen overdose: Pharmacokinetics and effectiveness of activated charcoal. Ann Emerg Med 1991;20:1064-1068.
Bond GR, Krenzelok EP, Normann SA, et al. Acetaminophen ingestion in childhood: Cost and relative risk of alternative referral strategies. Clin Toxicol 1994;32:513— 525.
Klein-Schwartz W, Oderda GM. Adsorption of oral antidotes for acetaminophen poisoning (methionine and N-acetylcysteine) by activated charcoal. Clin Toxicol 1981;18:283-290.
Spiller HA, Krenzelok EP, Grande GA, et al. A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose. Ann Emerg Med 1994;23:519-523.
Brent J. Are activated charcoal V-acetylcysteine interactions of clinical significance? Ann Emerg Med 1993;22:1860-1861.
Lederman S, Fyech WJ, Tredger M, Gamsu AR. Neonatal paracetamol poisoning: Treatment by exchange transfusion. Arch Dis Child 1983;58:631-633.
Claas A, Gaude M, Schroeder H. Paracetamol poisoning in an infant. Dtsch Med Wochnschr 1993;! 18:898—902.
Kritharides L, Fassett R, Singh B. Paracetamol associated coma, metabolic acidosis, renal and hepatic failure. Intensive Care Med 1988;14:439-440.
Pond SM, Tong TG, Kaysen GA, et al. Massive intoxication with acetaminophen and propoxyphene: Unexpected survival and unusual pharmacokinetics of acetaminophen. J Toxicol Clin Toxicol 1982;19:1-16.
O’Grady JG, Gimson AES, O’Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94:1186-1192.
McLean AEM, Day PA: The effect of diet on the toxicity of paracetamol and the safety of paracetamol-methio-nine mixtures. Biochem Pharmacol 1975;24:37-42.
Vina J, Hems R, Krebs HA. Maintenance of glutathione content in isolated hepatocytes. Biochem J 1978;170:627-630.
Vina J, Romero FJ, Estrela JM, Vina JR. Effect of acetaminophen (paracetamol) and its antagonists on glutathione (GSH) content in rat liver. Biochem Pharmacol 1980;29:1968-1970.
Meredith TJ, Crome P, Volans GN, Goulding R. Treatment of paracetamol poisoning. Br Med J 1978; 1:1215— 1216.
Meredith TJ. Paracetamol poisoning in England and Wales. MD thesis, University of Cambridge, 1987:93— 112.
Vale J A, Meredith TJ, Goulding R. Treatment of acetaminophen poisoning: The use of oral methionine. Arch Intern Med 1981;141:394-396.
Meredith TJ, Prescott LF, Vale JA. Why do patients still die from paracetamol poisoning? Br Med J 1986;293:345-346.
Paracetamol and methionine: Pameton. Drug Ther Bull 1987;25:99-100.
Prescott LF, Donovan JW, Jarvie DR, Proudfoot AT. The disposition and kinetics of intravenous V-acetyl-cysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol 1989;37:501-506.
Makin A, Williams R. The current management of paracetamol overdosage. Br J Clin Pract 1994;48:144— 148.
Janes J, Routledge PA. Recent developments in the management of paracetamol (acetaminophen) poisoning. Drug Saf 1992;7:170-177.
Ferner R. Paracetamol poisoning; An update. Prescribers J 1993:33:45-49.
Keays R, Harrison PM, Wendon JA, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective controlled trial. Br Med J 1991;303:1026-1029.
Parker D, White JP, Paton D, Routledge PA. Safety of late acetylcysteine treatment in paracetamol poisoning. Hum Exp Toxicol 1990;9:25-27.
Beckett GJ, Donovan JW, Hussey AJ, et al. Intravenous N-acetylcysteine, hepatotoxicity and plasma glutathione 5-transferase in patients with paracetamol overdosage. Hum Exp Toxicol 1990;9:183-186.
Tobias JD, Gregory DF, Deshpande JK. Ondansetron to prevent emesis following V-acetylcysteine for acetaminophen intoxication. Pediatr Emerg Care 1992;8:345— 346.
Bonfiglio MF, Traeger SM, Hulisz DT, Martin BR. Anaphylactoid reaction to intravenous acetylcysteine associated with electrocardiographic abnormalities. Ann Pharmacother 1992;26:22-25.
Rodgers G, Matyanes N, Ross M, et al. Sulfhemoglobinemia associated with V-acetylcysteine (NAC) therapy of acetaminophen (APAP) overdose: A case report. Clin Toxicol 1995;33:475-486.
Dawson AH, Henry DA, McEwen J. Adverse reactions to V-acetylcysteine during treatment for paracetamol poisoning. Med J Aust 1989;150:329-331.
Ho SW, Beilin JJ. Asthma associated with V-acetylcysteine infusion and paracetamol poisoning: Report of two cases. Br Med J 1983;287:876-877.
Temple AR. McNeil Consumer Products Company. Dear Doctor Letter, January 23, 1995.
Douglas DR, Smilkstein MJ, Sholar JB. Overdose with ’Extended Relief acetaminophen: Is a new approach necessary? Ann Emerg Med 1995;2:397-398.
Graudins A, Aaron CK, Linden CH. Overdose of extendedrelease acetaminophen. N Engl J Med 1995;333:196.
Mant TGK, Tempowski JH, Volans GN, et al. Adverse reactions to acetylcysteine and effects of overdose. Br Med J 1984;289:217-220.
Death after V-acetylcysteine, news and notes. Lancet 1984;1:1421.
Slattery JT, McRorieTl, Reynolds R, et al. Lack of effect of cimetidine on acetaminophen disposition in humans. Clin Pharmacol Ther 1989;46:591-597.
Burkhart KK, Janco N, Kulig KW, Rumack BH. Cimetidine as adjunctive treatment for acetaminophen overdose. Hum Exp Toxicol 1995;14:229-304.
Speeg KV. Potential use of cimetidine for treatment of acetaminophen overdose. Pharmacotherapy 1987;7(6, pt 2): 125S—133S.
Brennan RJ, Mankes RF, Lefevere R, et al. 4-Methyl-pyrazole blocks acetaminophen hepatotoxicity in the rat. Ann Emerg Med 1993;22:894.
O’Grady JG, Wendon JA, Tan КС, et al. Liver transplantation after paracetamol overdose. Br Med J 1991;303:221-223.
Pereira LMMB, Langley PG, Hayliar KM, et al. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: Relation to other prognostic indicators. Gut 1992;33:98-102.
Bradberry SM. Factor V and factor VIILV ratio as prognostic indicators in paracetamol poisoning. Personal Communication 0-58. In: Proceedings, XVIth International Congress of European Association of Poison Centres and Clinical Toxicologists, Vienna, April 12, 1994.
O’Grady JG, Alexander GJM, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439-445.
Jackson S, Nightingale P, Shelly MR Organ donation of paracetamol overdose. Br Med J 1993;306:718.
Williams FM, Moore U, Seymour RA, et al. Benorylate hydrolysis by human plasma and human liver. Br J Clin Pharmacol 1989;28:703-708.
Sacher M, Thaler H. Toxic hepatitis after therapeutic doses of benorylate and D-penicillamine. Lancet 1977;1:481-482.
Symon DNK, Gray ES, Hanmer OJ, Russell G. Fatal paracetamol poisoning from benorylate therapy in a child with cystic fibrosis. Lancet 1982;2:1152—1154.
Gaultier М, Bismuth С, Efthymiou ML, et al. Nephropathie tubulo-interstitielle aigue. Au cours d’une intoxication par la glafenine. Presse Ved 1972; 1:3125— 3128. [Acute tubulointestitial nephropathy due to glafenine poisoning.]
Mirouze J, Barjon P, Mion CH, et al. Insuffisance renal aigue consecutive a I’absorption de glafenine. [Acute renal insufficiency following glafenine ingestion.] Therapie 1974; 29:587-592.
Gaultier M, Bismuth C, Morel-Maroger M, Dauchy F. Nephropathie tubulo-intestitielle aigue au cours d’intoxications par la glafenine: A propos de 5 cas. [Acute tubulointerstitial nephropathy due to glafenine poisoning. Therapie 1974;29:579-585.
Duplay H, Mattei M, Barillon D, et al. Nephrite tubulointerstitielle aigue par intoxication a la glafenine. [Acute tubulointerstitial nephritis due to glafenine poisoning.] Therapie 1974;29:593-597.
Chevet D, Rainee M-P, Garre M, et al. Nephropathie aigue tubulo-interstitielle anurique due a tine intoxication par la glafenine. [Acute anuric tubulointerstitial nephropathy due to glafenine poisoning]. Therapie 1974;29:575-578.
Renier J-C, Boasson M, Pitois M, Alquier Ph. Insuffisance renale aique recidivante apres ingestion de glafenine a dose therapeutique. [Recurrent acute renal insufficiency after ingestion of a therapeutic dose of glafenine.] Presse Med I975;4:670.
Geboes K, Stevens E, Bossaert H, Dooms T. Renal injury associated with 'glafenine' overdose. Acta Clin Belg 1978; 33:401-402.
D’Enfert J, Monteil AL, Beraud JJ, Mirouze J. Anurie apres glafenine. Role d’un traitment diuretique associe. [Enhanced renal toxicity of glafenine by diuretics?] Presse Med 1980;9:716.
Proesmans W, Sina J KA, Begucquoy P, et al. Recurrent acute renal failure due to nonaccidental poisoning with glafenine in a child. Clin Nephrol 1981;16:207-210.
Ypma RThJM, Festen JJM, De Bruin CD. Hepatotoxicity of glafenine. Lancet 1978;2:480-481.
Dttche M, Durand H, Boi Ph, et al. Hepatite provoquee par laglafenine. [Hepatitis provoked by glafenine.) Therapie 1982;37:327-330.
Verhamme M, De Wolfe-Peelers C, Van Steenbergen W. Hepatic injuty due to glafenine: Report of two cases and review of the literature. Neth J Med 1984;27:35-39.
Brissot P, Gie S, Colobert A, et al. Un nouveau cas de’hepatite due a la glafenine. Gastroenterol Clin Bull 1982;6:948.
Stricker BHC, Blok APR, Bronkhorst FB. Glafenine-associated hepatic injury: Analysis of 38 cases and review of the literature. Liver 1986;6:63-73.
Stricker BHC, De Groot RRM, Wilson JHP. Anaphylaxis to glafenine. Lancet 1990;336:943-944.
Stricker BH Ch, de Groot RRM, Wilson JHP. Glafenineas-sociated anaphylaxis as a cause of hospital admission in the Netherlands. EurJ Clin Pharmacol 1991;40:367-371.
Glafenine: Withdrawal on grounds of safety. WHO Drug inform 1991 ;No. 1;5—8.
Withdrawal of glafenine. Lancet 1992;339:357.
Reynolds JEE, ed. Vartindale: The extra pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993.
Heel RC, Brogden RN, Parker GE, et al. Nefopam: A review of its pharmacological properties and therapeutic efficacy. Drugs 1980;19:249-267.
Burnett I, Information Scientist, 3M Health Care Limited. Personal communication, May 24, 1991.
Piercy DM, Cumming JA, Dawing S, Henry JA. Death due to overdose of nefopam. Br Med J 1981 ;283:1508— 1509.
Schuffan D, Hansen CS, Ober BE. GLC determination of nanogram quantities of a new analgesic nefopam in human plasma. J Pharm Sci 1978;67:1720-1723.
Widdop P, Dawling S. Suicidal poisoning by nefopam: A new analgesis drug. Bull Int Assoc Forens Toxicol 1981;16(2):33—34.
Bal TS, Oxley 1, Johnson B, Hiscuitt AA. A fatal case involving nefopam and paracetamol. Bull Int Assoc Forens Toxicol I986;19(l):32—34.
Neuvonen PJ. Activated charcoal in nefopam. Br Med J 1984;289:1626.
Neuvonen PJ, Jannisto H. Capacity of two forms of activated charcoal to adsorb nefopam in vitro and to reduce its toxicity in vivo. Clin Toxicol 1983/ 1984;21:333-342.
Longo LD. Physiologic assessment of fetal compromise: Biomarkers of toxic exposure. Environ Health Perspect 1987;74:93-101.
Rubin PC, Craig GF, Gavin K, Sumner D. Prospective survey of use of therapeutic drugs, alcohol and cigarettes during pregnancy. Br Med J 1986;292:81-83.
Evans Ml, Pryde PG, Reichler A, et al. Fetal drug therapy. West J Med 1993;159:328-332.
Huong TTT, Szentesi 1, Czeizell A. Lower prevalence of chromosome aberrations and SCE’s in self-poisoned pregnant women. Mutat Res 1988;198:255-259.
McElhatton PR, Sullivan FM, Volans GM, Fitzpatrick R. Paracetamol poisoning in pregnancy: An analysis of the outcome of cases referred to the teratology information service of the National Poisons Information Service. Hum Exp Toxicol 1990;9:147-153.
Riggs BS, Bronstein AC, Kulig K, et al. Acute acetaminophen overdose during pregnancy. Obstet Gynecol 1989;74:247-253.
Wise R. Prescribing in pregnancy: Antibiotics. Br Med J 1987;294:42-46.
Thorpe-Beeston JG, Armar NA, Dancy M, et al. Pregnancy and ACE inhibitors. Br J Obstet Gynaecol 1993;100:692-693.
Safety of antimicrobial drugs in pregnancy. Med Lett Drugs Ther 1987;29:61-63.
Chow AW, Jewesson PJ. Use and safety of antimicrobial agents during pregnancy. West J Med 1987;146:761 — 767.
Peled Y, Friedman S, Hod M, Merlob P. Ofloxacin during the second trimester of pregnancy. DICP Ann Phar-macother 1991;25:1181-1182.
Heim K, Alge A, Marth C. Anaphylactic reaction to ampicillin and severe complication in the fetus. Lancet 1991;337:859-860.
Nau H. Clinical pharmacokinetics in pregnancy and perinatology. IL Penicillins. Dev Pharmacol Ther 1987;10:174-198.
Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1992; 102(suppl. 4):385—390.
Cerqueira MJ, Olle C, Bellart J, et al. Intoxication by benzodiazepines during pregnancy. Lancet 1988;1:1341.
Haraldsson A, Geven W. Severe adverse effects of maternal labetalol in a premature infant. Acta Paediatr Scand 1989;78:956-958.
Rubin PC. Current concepts: Beta blockers in pregnancy. N Engl J Med 1981;305:1323-1326.
Bhandari NR, Syal AK, Kambo I, et al. Pregnancy outcome in women exposed to toxic gas at Bhopal. Indian J Med Res |B| 1990;91:28-31.
Wilcox A, Weinberg C, Baird D. Caffeinated beverages and decreased fertility. Lancet 1988;2:1453—1456.
Christianson RE, Oechsli FW, Van den Berg BJ. Caffeinated beverages and decreased fertility. Lancet 19S9;2:378.
Weathersby PS, Lodge JR. Caffeine, its direct and indirect influence on reproduction. J Reprod Med 1977;19:55-63.
Oei SG, Vosters RPL, van der Hagen NU, et al. Arrhythmia caused by excessive intake of caffeine by pregnant women. Br Med J 1989;298:568.
McGowan JD, Altman RE, Kanto WP Jr. Neonatal withdrawal symptoms after chronic maternal ingestion of caffeine. South Med J 1988;81:1092-1094.
Myers VAS, Miwa U. Caffeine consumption during pregnancy. Drug Intell Clin Pharm 1988;22:614-616.
Hill EP, Hill JR, Power GG, Longon LD. Carbon monoxide exchanges between the human fetus and mother: A mathematical model. Am J Physiol 1977.
Koren G, Sharav T, Pastuszak A, et al. A multicenter, prospective study of fetal outcome following accidental carbon monoxide poisoning in pregnancy. Reprod Toxicol 1991;5:397-403.
Elkharrat D, Raphael JC, Korack JM, et al. Acute carbon monoxide intoxication and hyperbaric oxygen in pregnancy. Intensive Care Med 1991;17:289-298.
Lees KR, Rubin PC. Prescribing in pregnancy: Treatment of cardiovascular disease. Br Med J 1987;294:358— 360.
Senecal P-E, Osterloh JD. Normal fetal outcome after maternal ciguatera toxin exposure in the second trimester. Clin Toxicol 1991;29:473-478.
Ostrea EM Jr, Brady M, Gause S, et al. Drug screening of newborns by meconium analysis: A large-scale prospective epidemiologic study. Pediatrics 1992;89:107— 113.
Jessup M. The treatment of perinatal addiction: Identification, intervention and advocacy. West J Med 1990;152:553-558.
Levy M, Spiro M. Neonatal withdrawal syndrome: Associated drugs and pharmacologic management. Pharmacotherapy 1993;13:202-211.
Jacobson SJ, Jones K, Johnson K, et al. Prospective multicenter study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992;339:530-533.
Raybum W, Aronow R, DeLancey B, Hogan MJ. Drug overdose during pregnancy: An overview from a metropolitan poison control center. Obstet Gynecol 1984;64:611-614.
Blanc P, Hryhorczuk D, Dave! 1. Deferoxamine treatment of acute iron intoxication in pregnancy. Obstet Gynecol 1984;65:125-145.
Curry S, Bond R, Rashke R, et al. Fetal iron kinetics is a mode of maternal iron poisoning with and without maternal deferoxamine therapy. Vet Hum Toxicol 1988;30:372.
Elias S, Gerbie AB, Simpson JL, et al. Genetic amniocentesis in twin gestations. Am J Obstet Gynecol 1980;138:169-173.
Alay RD, Southerst JR. Premature rupture of the fetal membranes confirmed by intra-amniotic injection of dye. Am J Obstet Gynecol 1970; 108:993.
Troche BI. The methylene blue baby. N Engl J Med 1989;320:1756-1757.
Katz Z, Lancet MN. Inadvertent intrauterine injection of methylene blue in early pregnancy. N Engl J Med 1981;30:1427.
Nicolini U, Monni G. Intestinal obstruction babies exposed in utero to methylene blue. Lancet 1990;336:1758-1759.
Wood SM, Hytten FE. The fate of drugs of pregnancy. Clin Obstet Gynecol 1981;8:255-259.
Cowell RM, Hakanson DO, Kocon RW, Oh W. Untoward neonatal effect of intraamniotic administration of methylene blue. Obstet Gynecol 1976;48(suppl.):74S— 75S.
Serota FT, Bernbaum JC, Schwartz E. The methylene-blue baby. Lancet 1979;2:1142-1143.
Crooks J. Hemolytic jaundice in a neonate after intraamniotic injection of methylene blue. Arch Dis Child 1982;57:872-886.
McEnemeyJK, McEnerney LN. Unfavorable neonatal outcome after intra-amniotic injection of methylene blue. Obstet Gynecol 1983;61:355-375.
Vincer MJ, Allen AC, Evans JR, et al. Methylene-blue induced hemolytic anemia in a neonate. Can Med Assoc J 1987;136:503-504.
Dolk H. Methylene blue and atresia or stenosis of ileum and jejunum. Lancet 1991;338:1021-1022.
McFadyen 1. The dangers of intra-amniotic methylene blue. Br J Obstet Gynecol 1992;99:89-90.
Van der Pol JG, Wolf H, Boer K, et al. Jejunal atresia related to the use of methylene blue in genetic amniocentesis in man. Br J Obstet Gynecol 1992;99:141-143.
Belliardo P, Massano G, Accono S. Amatoxins do not cross the placental barrier. Lancet 1983; 1:1381.
Levy G. Nutmeg intoxication in pregnancy: a case report. J Reprod Med 1987;32:63-64.
Tylden E, Duokens D, Colley N. Pregnancy and opiate addiction. Br Med J 1987;295:551-552.
Michell AA. Oral retinoids: What should the prescriber know about their teratogenic hazards among women of childbearing potential? Drug Saf 1992;7:79-85.
Koren G. Study of the safety of ribavirin in human pregnancy. Pediatr Infect Dis J 1990;9:S106—S107.
Kizer K. Study raises concerns about exposure of health workers to antiviral ribavirin. Action Report 36, California Department of Health Services, March 1989.
Nieburg P, Marks JS, McLaren NM, Remington PL. The fetal tobacco syndrome. JAMA 1985;253:2998— 2999.
Werler MM, Lammer EJ, Rosenberg L, Mitchell AA. Maternal cigarette smoking during pregnancy in relation to oral clefts. Am J Epidemiol 1990;132:926-932.
Seidman DS, Ever-Hadani P, Gale R. Effect of maternal smoking and age on congenital anomalies. Obstet Gynecol 1990;76:1046-1050.
Tafuri J, Roberts J. Organophosphate poisoning. Ann Emerg Med 1987;16:193-202.
Dunne J, Wise C. The pump that gave too much: Accidental overfusion of prostacyclin. Anaesthesia 1991 ;46:75.
Douglas M, Farquharson DF, Ross PLE, Renwich JE. Cardiovascular collapse following an overdose of prostaglandin F2 alpha: A case report. Can J Anaesth 1989;36:466-468.
Kilpatrick AWA, Thorbum J. Severe hypotension due to intramyometrial injection of prostaglandin E2. Anaesthesia 1990;45:848-849.
Meyer WJ, Benton SL, Moon TJ, et al. Acute myocardial infarction associated with prostaglandin E2. Obstet Gynecol 1991:165:359-360.
Cooley DM, Glosten B, Roberts JR, et al. Bronchospasm after intramuscular 15-methyl prostaglandin F, alpha and endotracheal intubation in a nonasthmatic patient. Anesth Analg 1991;73:87-89.
Brandenburg H, Jahoda MGJ, Welodminiroff JW, et al. Convulsions in epileptic woman after administration of prostaglandin E2 derivatives. Lancet 1990;336:l 138.
Wiener JJ, Evans AS. Uterine rupture in midtrimester abortion: A complication of Gemeprost vaginal pessaries in oxytocin. Case report. Br J Obstet Gynecol 1990;97:1061-1062.
Less A, Goldberger SB, Bernheim J, et al. Vaginal prostaglandin E2 and fatal amniotic fluid emblem. JAMA 1990;263:3259-3260.
Moran DJ. Gemeprost vaginal pessaries for inducing third trimester intrauterine deaths. Br J Obstet Gynecol 1989;96:1245-1251.
Shoham Z, Ezri T. Ventricular tachycardia associated with injection of prostaglandin F2 alpha into the uterine cervix during anesthesia. Anesthesiology 1990;72:775— 771.
Peled N, Dagan O, Babyn P, et al. Gastric outlet obstruction induced by prostaglandin therapy in neonates. N Engl J Med 1992;327:505-512.
Andersson S, Paetau P, Hallman M, et al. Neonatal respiratory distress caused by aspiration of a vaginal tablet containing prostaglandin. Br Med J 1987;295:25-26.
Egarter CH, Husslein PW, Rayburn WF. Uterine hyperstimulation after low dose prostaglandin E, therapy: Tricyclic treatment in 181 cases. Am J Obstet Gynecol 1990;163:794-796.
Burt RL, Connor ED, Davidson IWF. Hypokalemia and cardiac arrhythmia associated with prostaglandin-induced abortion. Obstet Gynecol 1977;50(suppl.):455— 465.
Popat MT, Suppiah N, White JB. Cardiac arrest following intramyometrial injection of prostaglandin E2. Anaesthesia 1991;46:236.
Zilberstein ME, Gleicher M. Endocrinology. In: Gleicher N, ed. Principles and Practice of Medical Therapy in Pregnancy. 2nd ed. Norwalk, CT: Appleton-Lange, 1992;292—293.
Burt RL, Connor ED, Davidson IWF. Hypokalemia and cardiac arrhythmia associated with prostaglandin-induced abortion. Obstet Gynecol 1977;50(suppl.):455— 465.
Douglas M, Farquharson DF, Ross PLE, Renwich JE. Cardiovascular collapse following an overdose of prostaglandin F2 alpha: A case report. Can J Anaesth 1989;36:466-468.
King SJ, Kelly RW, Sutton JG. The development of an enzyme-linked immunosorbent assay for 19-OH-PG Fl alpha/F2 alpha. Forens Sci Int 1989;40:211—216.
Pearson R. Radiography in women of childbearing ability. Br Med J 1989;299:1175-1176.
Hooper K. The hazard evaluation system and information service: A physician’s resource in toxicology and occupational medicine. West J Med 1982; 137:560— 571.
McDonald AD, McDonald JC, Armstrong B, et al. Fetal death and work in pregnancy. Br J Ind Med 1988;45:148-157.
Schenker MB, Samuels SJ, Green RS, Wiggins P. Adverse reproductive outcome among female veterinarians. Am J Epidemiol 1990;132:96-106.
McDonald AD, La Voie J, Cote R, McDonald JC. Spontaneous abortion in women employed in plastics manufacture. Am J Ind Med 1988;14:9-14.
Bentur Y, Koren G. The three most common occupational exposures reported by pregnant women: An update. Am J Obstet Gynecol 1991;165:429-437.
Mattison DR, Plowchalk DR, Meadows MJ, et al. Reproductive toxicity: Male and female reproductive systems as targets for chemical injury. Med Clin North Am 1990;74:391-411.
Jagoda A, Riggio S. Emergency department approach to managing seizures in pregnancy. Ann Emerg Med 1991;20:80-85.
Konje JC, Otolorin EO, Sotunmbi PT, Ladipo OA. Insecticide poisoning in pregnancy: A case report. J Reprod Med 1992;37:992-994.
McDonald AD, McDonald JC, Armstrong B, et al. Father’s occupation and pregnancy outcome. Br J Ind Med 1989;46:329-333.
Brender JD, Suarez L. Paternal occupation and anencephaly. Am J Epidemiol 1990;131:512-521.
Olshan AF, Teschke K, Baird PA. Birth defects among offspring of firemen. Am J Epidemiol 1990;131:312— 321.
Olshan AF, Teschke K, Baird PA. Paternal occupation and congenital anomalies. Am J Ind Med 1991;20:447-475.
Lindbohm ML, Sailmen M, Antilla A, et al. Paternal occupational lead exposure and spontaneous abortion. Scand J Environ Health 1991;17:95-103.
Cordier S, Deplan F, Mandereau L, Hemon D. Paternal exposure to mercury and spontaneous abortions. Br J Ind Med 1991;48:375-381.
Savitz DA, Schwingl PJ, Kells MA. Influence of paternal age, smoking and alcohol consumption on congenital anomalies. Teratology 1991;44:429-440.
Davis DL. Paternal smoking and fetal health. Lancet 1991;1:123.
Robaire B, Hales BF. Paternal exposure to chemicals before conception: Some children may be at risk. Br Med J 1993;307:341-342.
Tomatis L, Narod S, Yamasaki L. Transgeneration transmission of carcinogenic risk. Cardiogenesis 1992;43:145-151.
Dodds L, Marrett LD, Tomkins DJ, et al. Case-control study of congenital anomalies of children of cancer patients. Br Med J 1993;307:164-168.
Savitz DA, Whelan EA, Kleckner RC. Effect of parents’ occupational exposures on risk of stillbirt h, pre-term delivery and small-for gestational-age infants. Am J Epidemiol 1989;129:1201-1218.
Einarson TR, Koren G, Mattice D, Schechter-lsafriri O. Maternal spermicide use and adverse reproductive outcome: A meta-analysis. Am J Obstet Gynecol 1990;162:655-660.
Warburton D, Neugut RH, Lustenberger A, et al. Lack of association between spermicide use and trisomies. N Engl J Med 1987;317:478-482.
Besinger RE, Niebyl JR. The safety and efficacy of tox-olytic agents for the treatment of pre-term labor. Obstet Gynecol Surg 1990;45:415.
Chamberlain G. Pre-term labor. BrMedJ 1991;3O3:44— 48.
Pisani RJ, Rosenoid EC III. Pulmonary edema associated with toxolytic therapy. Ann Intern Med 1989;110:714-718.
Creasy RK. Preventing pre-term birth. N Engl J Med 1991;325:727-729.
Wischnik A. Risk-benefit assessment of tocolytic drugs. Drug Saf 1991;6:371-380.
Halmesmaki E, Yiikorkala O. A retrospective study on the safety of prenatal ethanol treatment. Obstet Gynecol 1988;27:545.
Abel EL. Critical evaluation of the obstetric use of alcohol in pre-term labor. Drug Alcohol Depend 1981 ;7:367.
Brazy JE, Pupkin MJ. Effects of maternal isoxsuprine administration on pre-term infants. J Pediatr 1979;94:444.
Benedetti TJ. Treatment of pre-term labor with the beta-adrenergic agonist ritodrine. N Engl J Med 1992;327:1758.
Ferguson JE II, Dyson DC, Schutz T, Stevenson DC. A comparison of tocolysis with nifedipine or ritodrine: Analysis of efficacy and maternal, fetal and neonatal outcome. Am J Obstet Gynecol 1990;163:105-111.
Van Lierde M, Desager JP, Harvengt C, Thomas K. Ritodrine serum levels: Influence of dose and route of administration. Int J Clin Pharmacol Ther Toxicol 1984;22:382-385.
Caritis SN, Venkataramanan R, Darby MJ, et al. Pharmacokinetics of ritodrine administered intravenously: Recommendations for changes in the current regimen. Am J Obstet Gynecol 1990;162:429-437.
Caritis SM, Lin LS, Venkataramanan R, Wong LK. Effect of pregnancy on ritodrine pharmacokinetics. Am J Obstet Gynecol 1988;159:328-332.
Witter FR, Benedetti TJ, Petty BG, et al. Pharmacodynamics and tolerance of oral sustained release ritodrine. Am J Obstet Gynecol 1988;159:690-695.
Gupta RC, Foster S, Romano PM, Thomas HM. Acute pulmonary edema associated with the use of oral ritodrine for premature labor. Chest 1989;95:479-481.
Ben-Shtona 1, Zohar S, Marmor A, et al. Myocardial ischemia during intravenous ritodrine treatment: Is it so rare? Lancet 1986;2:917-918.
Faidley CK, Dix PM, Morgan MA, Schechter Z. Electrocardiographic abnormalities during ritodrine administration. South Med J 1990;83:503-506.
Hendricks SK, Kerves J, Katz M. Electrocardiographic changes associated with ritodrine-induced maternal tachycardia and hypokalemia. Am J Obstet Gynecol 1986;154:921-923.
Hadi HA, Albazzaz SJ. Cardiac isoenzymes and electrocardiographic changes during ritodrine tocolysis. Am J Obstet Gynecol 1989;161:318-321.
Ikushima Y, Kobayashi H, Imaishi K, et al. Ritodrine-induced agranulocytosis. Arch Gynecol Obstet 1990;248:53-54.
Muro M, Shono H, Oga M, et al. Ritodrine-induced agranulocytosis. Int J Gynecol Obstet 1991;36:329-331.
Minakani W, Takahashi T, Izuni A, et al. Enlargement of the salivary gland after ritodrine treatment in pregnant women. Br Med J 1992;304:1668.
Spellacy WN, Cruz AC, Buhi WC, Birk SA. The acute effects of ritodrine infusion on maternal metabolism: Measurements of levels of glucose, insulin, glucagon, triglycerides, cholesterol, placental lactogen, and chorionic gonadotropin. Am J Obstet Gynecol 1978;131:637-642.
Bricker RSW. Overdose of ritodrine. Anaesthesia 1989;44:864.
Levy DL. Morbidity caused by terbutaline infusion during therapy. Am J Obstet Gynecol 1994;170:1835-1836.
Hudgens DR, Conradi SE. Sudden death associated with terbutaline sulfate administration. J Obstet Gynecol 1993;169:120-121.
Fletcher SE, Fyfer DA, Case CL, et al. Myocardial necrosis in a newborn after long-term maternal subcutaneous terbutaline infusion for suppression of pre-term labor. Am J Obstet Gynecol 991; 165:1401 —1404.
D’Hooghe TM, Odendaal HJ. Severe fatal tachycardia after administration of hexoprenaline to the mother: A case report. S Afr Med J 1991;80:594-596.
RivierG, Nicole A, Stuchi D, Regumy C. Lesional pulmonary edema associated with tocolysis by hexoprenaline sulfate. Schweiz Med Wochenschr 1992; 122:237— 241.
Van Iddekinge B, Gobertz L, Seaward PGR, Hofmeyr GJ. Pulmonary oedema after hexaprenaline administration in preterm labor. S Afr Med J 1991;79:620-622.
Lees C, Campbell S, Jauniaux E, et al. Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor. Lancet 1994;343:1325-1326.
Duley L, Elbourne D. Glyceryl trinitrate in management of preterm labour. Lancet 1994;344:553.
Kotzot D, Weigl J, Huk W, Rott H-D. Hydantoin syndrome with holoprosencephaly: A possible rare teratogenic effect. Teratology 1993;48:15-19.
Cox SM, Sherman L, Levens KJ. Randomized investigation of magnesium sulfate for prevention of pre-term birth. Am J Obstet Gynecol 1990;163:767-772.
Carban SJ, O’Brien WF. The effect of magnesium sulfate on the biophysical profile of normal term fetuses. Obstet Gynecol 1991;77:681-684.
Kaplan PW, Lesser RP, Fisher RS, et al. A continuing controversy: Magnesium sulfate in the treatment of eclamptic seizures. Arch Neurol 1990;47:1031-1039.
Wright JW, Ridgway LE III, Patterson RM. Adjusting the loading dose of magnesium sulfate for tocolysis. Am J Obstet Gynecol 1990;163:889-892.
Sherer DM, Cialone PR, Abramowicz JC, Woods JR Jr. Transient symptomatic subendocardial ischemia during intravenous sulfate toxolytic therapy. Am J Obstet Gynecol 1992;166:33-35.
Worrell JA, Brunner JP, O’Donnell DM, Carroll FE. Chest case of the day. Case I. Pulmonary edema associated with toxolytic therapy. Am J Radiol 1992;158:1356-1362.
Holcomb WA Jr, Shackeford GD, Petrie RH. Magnesium tocolysis and neonatal bone abnormalities: A controlled study. Obstet Gynecol 1991 ;78:611—614.
Cann CI, Norton KI, Murphy RJC, et al. Congenital rickets associated with magnesium sulfate infusion for tocolysis. J Pediatr 1988; 113:1078—1082.
McCubbin JH, Sibai MM, Abdella TN, Anderson GD. Cardiopulmonary arrest due to acute maternal hypermagnesemia. Lancet 1981; 1:1058.
Moise KJ Jr, Huhta JC, Sharif DS, et al. Indomethacin in the treatment of premature labor: Effects on the fetal ductus arteriosus. N Engl J Med 1988;319:327-331.
Demanat E, Legius E, Devlieger H, et al. Prenatal indomethacin toxicity in one member of monozygous twins: A case report. Eur J Obstet Gynecol Reprod Biol 1990;35:267-269.
Norton ME, Merrill J, Cooper BAB, et al. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993;329:1602-1607.
Ng TP, Foo SC, Yoong T. Risk of spontaneous abortion in workers exposed to toluene. Br J Ind Med 1992;49:804-808.
Wilkins-Haug L, Gabow PA. Toluene abuse during pregnancy: Obstetric complications and perinatal outcomes. Obstet Gynecol 1991;77:505-509.
Pearson MA, Hoyme HE, Seaver LH, Rimsza ME. Toluene embroyopathy: Delineation of the phenotype and comparison with fetal alcohol syndrome. Pediatrics 1994;93:211-215.
Arnold GL, Kirby RS, Landendoerfer S, Wilkins-Houg L. Toluene embryopathy: Clinical delineation and developmental follow-up. Pediatrics 1994;93:216-220.
Hall JG. Vitamin A: A newly recognized human teratogen. Harbinger of things to come? J Pediatr 1984;105:583-584.
Rosa FW, Wilk AL, Kiliey FO. Teratogen update: Vitamin A congeners. Teratology 1986;33:355-366.
Teratology Society. Recommendations for Vitamin A use during pregnancy. Teratology 1987;35:269-275.
Nelson M. Vitamin A, liver consumption and risk of birth defects. Br Med J 1990;301:1176.
Kizer KW, Fan AM, Bankowska J, et al. Vitamin A: A pregnancy hazard alert. West J Med 1990;152:72-87.
Tenenbein M. Poisoning in pregnancy. In: Koren G, ed. Maternal-Fetal Toxicology: A Clinician’s Guide. New York: Marcel Dekker, 1990:89— 114.
Balaskas TN. Common poisons. In: Gleicher N, ed. Principles and Practice of Medical Therapy in Pregnancy. 2nd ed. Norwalk, CT: Appleton—Lange, 1992:236—245.
Milunsky A, Jick H, Hick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989;262:2847-2852.
MRC Vitamin Study Research Group. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-137.
Czeizel AE. Prevention of congenital abnormalities by preconsectional multivitamin supplementation. Br Med J 1993;306:1645-1648.
Centers for Disease Control and Prevention. Use of folic acid for prevention of spina bifida and other neural tube defects, 1983-1991. MMWR 1991;40:513-516.
Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR 1992;41:1-7.
Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of concurrence of neural tube defects. JAMA 1993;269:1257-1261.
Shaw GM, Lammer U, Wasserman CR, et al. Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally. Lancet 1995;345:393-396.
Paul M, Himmelstein J. Reproductive hazards in the workplace: What the practitioner needs to know about chemical resources. Obstet Gynecol 1988;7:921-938.
Koren G, Graham K, Feigenbaum A, Einarson T. Evaluation and counseling of teratogenic risk: The Motherisk approach. J Clin Pharmacol 1993;33:405-411.
Vogt BL. Teratogen information programs. In: Koren G, ed. Maternal-Fetal Toxicology: A Clinician’s Guide. New York: Marcel Dekker, 1990:332-333.
U. S. Food and Drug Administration. Labeling and prescription drug advertising: Content and format for labeling for human prescription drugs. Fed Regist 1979;44( 124):3743—3747.
Teratology Society Public Affairs Committee: FDA classification of drugs for teratogenic risk. Teratology 1994;49:446-447.
McIntyre KM, Lewis AJ, eds. Textbook of Advanced Cardiac Life Support. Dallas: American Heart Association, 1983:119.
Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness: Controversies in the use of a "coma cocktail". JAMA 1995;274:562-569.
Danzl DK, Pozos RS. Accidental hypothermia. N Engl J Med 1994;331:1756-1760.
Physicians' Desk Reference. 49th ed. Montvale, N: Medical Economics, 1995:280—286.
Martin TG. Personal communication.
Brennan S, Lederer ED. Severe electrolyte disturbances. In: Hall JB, Schmidt GA, Wood LDH, eds. Principles of Critical Care. New York: McGraw-Hill, 1992:1939— 1940.
Browning RG, Olson DW, Stueven HA, Mateer JR. 50% dextrose: Antidote or toxin? Ann Emerg Med 1990;19:683-687.
Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. Treatment of convulsive status epileptics. JAMA 1993;270:854-859.
Tzivoni D, Banai S, Schuzer C, et al. Treatment of Torsade de pointes with magnesium sulfate. Circulation 1988;77:392-397.
Tzivoni D, Keren A. Suppression of ventricular arrhythmias by magnesium. Am J Cardiol 1990;65:1297-1299.
Wasserberger JL. Drew/UCLA Medical Center, personal communication.
Wasserberger J, Ordog GJ, Hardin E, et al. Violence in the emergency department. Top Emerg Med 1992;14:71-78.
Freedberg RS, Friedman GR, Palm RN, Feit F. Cardiogenic shock due to antihistamine overdose: Reversal with intraaortic balloon counterpulsation. JAMA 1987;257:660-661.
Melanson P, Shih DD, De Roos S, et al. Intraaortic balloon counterpulsation in calcium channel blockers overdose. Vet Hum Toxicol 1993;35:345.
Sanders KM, Stern TA, O'Gara PT, et al. Medical and neuropsychiatric complications associated with use of the intraaortic balloon pump. Intensive Care Med 1992;7:154-164.
Sosnowski AW, Bonser SJ, Field DJ, et al. Extracorporeal membrane oxygenation: Britain needs units equipped to perform the procedure and a controlled trial. Br Med J 1990;201:303-304.
Kallis P, Al-Sandy NM, Bennett D, Treasure T. Clinical use of intravascular oxygenation. Lancet 1991 ;337:549.
Banner W Jr, Timmons OD, Vernon DD. Advances in the critical care of poisoned paediatric patients. Drug Saf 1994;10:83-92.
Frader J, Lantos S. Extracorporeal membrane oxygenation in neonates. N Engl J Med 1991;324:849-850.
Elliott SJ. Neonatal extracorporeal membrane oxygenation: How not to assess novel technologies. Lancet 1991;337:476-478.
Lantos JD, Frader J. Extracorporeal membrane oxygenation and the ethics of clinical research in pediatrics. N Engl J Med 1990;323:409-413.
Kearny MF III, Hal! J. Hypothermia. In: Hall JB, Schmidt GA, Wood LDH, eds. Principles of Critical Care. New York: McGraw-Hill, 1992:848—857.
Petersdorf RG. Hypothermia and hyperthermia. In: Wilson JD, Braunwald E, Isselbacker KJ, et al., eds. Harrison’s Principles of Internal Medicine. 12th ed. New York: McGraw-Hill, 1991:2194-2198.
Whipple JK, Medicris-Bringa MA, Schimel RA, et al. Selected vasoactive drugs: A readily available chart reference. Crit Care Nurs 1992;12:23-29.
Haber RJ. A practical approach to acid-base disorders. West J Med 1991;155:146-151.
Bleske BE, Rice TL, Warren EW, et al. The effect of sodium bicarbonate administration on the vasopressor effect of high-dose epinephrine during cardiopulmonary resuscitation in swine. Am J Emerg Med 1993;! 1:439— 443.
Callaham ML. High-dose epinephrine therapy and other advances in treating cardiac arrest. Aust J Med 1990;152:697-703.
Brown DH, KasuyaA, Leikin JB. Endotracheal drug administration in the critical care setting. J Emerg Med 1987;5:407-414.
Factor P, SznajderJl. Vascular cannulation. In: Hall JB, Schmidt GA, Wood LDH, eds. Principles of Critical Care. New York: McGraw-Hill, 1992:308—321.
Zaritsky A. Members of the Medications in Pediatric Resuscitation Panel: Pediatric resuscitation pharmacology. Ann Emerg Med 1993;22 (2, pt 2):445-455.
Mueller PS, Vester JW, Fermaglich J. Neuroleptic malignant syndrome: Successful treatment with bromocriptine. JAMA 1983;249:386-388.
Kolacinski Z. Early parenteral nutrition in patients unconscious because of acute drug poisoning. J Parenter Enteral Nutr 1993;17:25-29.
Mizock BA. Controversies in lactic acidosis: Implications in critically ill patients. JAMA 1987;258:497-501.
Bersin RM, Chatterjee K, Arieff Al. Metabolic and hemodynamic consequences of sodium bicarbonate administration in patients with heart disease. Am J Med 1989;87:7-14.
Gazmuri RJ, Van Planta M, Weil MH, Rachow EC. Cardiac effects of carbon dioxide-consuming and carbon dioxide-generation buffers during cardiopulmonary resuscitation. J Am Coll Cardiol 1990;15:482-490.
Ayers JC, Krothapalli RK: Effect of bicarbonate administration on cardiac function. Am J Med 1989;85:5-6.
Bates BA, Burke PA, Jenkins RL, Woolf AD. Toxin associated liver failure: The New England Liver Transplant Service. Vet Hum Toxicol 1992;34:344.
Holmdahl J, Blohme I. Renal transplantation after Cortinarius speciosissimus poisoning. In: Proceedings, XVth Congress of European Association of Poison Centres and Clinical Toxicologists, Istanbul, Turkey, May 1992:102.
Bell EA, Shaefer MS, Marin RS, et al. Treatment of valproic acid-associated hepatic failure with orthotropic liver transplantation. Ann Pharmacother 1992;26:18-21.
Jaeger A, Kopferschmitt J, Flesch F, et al. Liver transplantation for amanita poisoning. In: Proceedings, XVth Congress of European Association of Poison Centres and Clinical Toxicologists, Istanbul, Turkey, May 1992ЛМ.
Kern C, Zilker T, v Clarmann M. Successful liver transplantation in a child after amanita poisoning. In: Proceedings, XVth Congress of European Association of Poison Centres and Clinical Toxicologists, Istanbul, Turkey, May 1992Л26.
Galler GW, Weisenberg E, Brasitus TA. Mushroom poisoning: The role of orthoptic liver transplantation. Clin Gastroenterol 1992;15:229-231.
Murphy GE. The physician’s responsibility for suicide. I. An error of commission. Ann Intern Med 1975;82:301-305.
Mrvos R, Schneide SM, Dean BS, Krenzelok EF. Orthotopic liver transplants necessitated by acetaminophen-induced hepatotoxicity. Vet Hum Toxicol 1992;34:425-427.
Comes J, Walter FG, Kozak K, et al. Liver transplantation for fulminant hepatic failure due to iron poisoning. Vet Hum Toxicol 1993;35:337.
Polakoff JM, Lacouture PG, Lovejoy FH Jr. The environment away from home as a source of potential poisoning. Am J Dis Child 1984; 138:1014—1017.
Gardner R, Hanka R, Roberts SJ, et al. Psychological and social evaluation in cases of deliberate self poisoning seen in an accident department. Br Med J 1982;284:491-493.
Delong W, Robin Е. The communication of suicide intent prior to psychiatric hospitalization: A study of 87 patients. Am J Psychiatry I96l;l 17:695—705.
Butkus DE, Herrera GA, Praju SS. Successful renal transplantation after cyclosporine-associated hemolyticuremic syndrome following bilateral lung transplantation. Transplantation 1992;54:159-161.
Ernst DC. The suicidal patient. Top Emerg Med 1992;14:45-55.
Leikin JB, Heyn-Lamb R, Aks S, Erickson T. Transplantation of organs donated by poisoning victims. Vet Hum Toxicol 1992;34:359.
Swanson-Biearman B, Krenzelok EP, Snyder JW, et al. Successful donation and transplantation of multiple organs from a victim of cyanide poisoning. Clin Toxicol 1993;31:95-99.
Lindquist T, Oiland D, Weber K. Cyanide poisoning victims as corneal transplant donors. Am J Ophthalmol 1988;106:354-355.
Brown P, Buchels J, Jain A, McMaster P. Successful cadaveric renal transplantation from a donor who died of cyanide poisoning. Br Med J 1987;294:1325.
Hebert M-J, Boucher A, Beaucage G, et al. Transplant tation of kidneys from a donor with carbon monoxide poisoning. N Engl J Med 1992;326:1571.
Vekemans M-C, Hantson P, Squifflet JP, et al. Organ procurement from poisoned donors: An 11 case experience. In: Proceedings, XTth Congress of European /кж/-1 ation of Poison Centres and Clinical Toxicologists, lstan- \ bul, Turkey, May /992:106.
Leikin JB, Heyn-Lamb R, Aks S, Erickson T. The toxic patient as a potential organ donor: One year follow-up. Vet Hum Toxicol 1993;35:318.
Alsina AE, Hull D, Bartus SA, Schweizer RT. Liver] transplantation for acute fulminant hepatic failure. Conn Med 1992;56:235-236.
Shragg TA. Compelling treatment after suicide attempts. West J Med 1983; 138-86.
Barre J, Didey F, Delion F, Tillement JP. Problems in therapeutic drug monitoring: Free drug level monitoring. Ther Drug Monit 1988;10:133-143.
Sue Y-J, Shannon M. Pharmacokinetics of drugs in over-dose. Clin Pharmacokinet 1992;23:93-105.
Atkinson AJ, Krumlovsky FA, Huang CM, del Greco F. Hemodialysis for severe procainamide toxicity: Clinical and pharmacokinetic observations. Clin Pharmacol Ther 1976;20:585-592.
Levy G, Yaffe SJ. Relationship between dose and apparent volume of distribution in children. Pediatrics 1974;54:713-717.
Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 1992;21:511-526.
Murray M. P450 enzymes: Inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992;23:132-141.
Kyriakopoulus AA, Greenblatt DJ, Schader Rl. Clinical pharmacokinetics of lorazepam: A review. J Clin Psychiatry 1978;39:16-23.
Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992; 13:435.
Caporaso NE, Shaw GL. Clinical implications of the competitive inhibition of the debrisoquine-metabolizing isozyme by quinidine. Arch Intern Med 1991; 151:1985— 1992.
Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-409.
Waller DG, George CF. Prodrugs. Br J Clin Pharmacol 1989;28:497-507.
Mazze RI. Metabolism of the inhaled anaesthetics: Implications of enzyme induction. Br J Anaesth 1984;56:365.
Cohen GM. Pulmonary metabolism of foreign compounds: Its role in metabolic activation. Environ Health Perspect 1990;85:31-41.
Macleod CM. Clinical implications of drug metabolism: Toxic metabolites. Res Staff Phys 1992;38:78.
Aronson JK. Receptors and their relevance to drug therapy. Med Int (Israel Edition) 1989;59:2429-2435.
Poitrast BJ, Keller WC, Elves RG. Estimation of chemical hazards in breast milk: Aviat Space Environ Med 1988;59(11, suppl.):A87—A92.
Committee on Drugs, American Academy of Pediatrics, Roberts RJ, Chairman. Transfer of drugs and other chemicals into breast milk. Pediatrics 1989;84:924-936.
Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk: Clinical pharmacokinetic considerations. Clin Pharmacokinet 1988; 14:217—240.
Giroux D, LaPointe G, Baril M. Toxicological index and the presence in the workplace of chemical hazards for workers who breast-feed infants. Am Ind Hyg Assoc J 1992;53:471-474.
Paul M, Himmelstein J. Reproductive hazards in the workplace: What the practitioner needs to know about chemical resources. Obstet Gynecol 1988;7:921-938.
Brodie MJ, Feely J. Adverse drug interactions. Br Med J 1988;29:845-849.
Dean BS, Krenzelok EP. Poisoning in the elderly: An increasing problem for health care providers. Clin Toxicol 1987;25:411-418.
Woolf A, Fish S, Azzara C, Dean D. Serious poisonings among older adults: A study of hospitalization and mortality rates in Massachusetts 1983—1985. Am J Pub Health 1990;8:867-869.
Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly: An update. Clin Pharmacokinet 1989;17:236-263.
Owens NJ, Silliman RA, Fretwell MD. The relationship between comprehensive functional assessment and optimal pharmacotherapy in the older patient. DICP Ann Pharmacother 1989;23:847-854.
Dumas C, Loi C-M, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990;19:359-389.
Baldwin JG. Hematopoietic function in the elderly. Arch Intern Med 1988;148:2544-2546.
Need we poison the elderly so often. Lancet 1988;2:20— 22. Editorial.
Vestal RE. Geriatric clinical pharmacology: An overview. In: Vestal RE, ed. Drug Treatment in the Elderly. Sydney: ADIS Health Science Press, 1984:12—29.
Everitt DE, Avorn J. Drug prescribing for the elderly. Arch Intern Med 1986;146:2393-2396.
Ramsay LE, Tucker GT. Clinical pharmacology: Drugs and the elderly. Br Med J 1981;282:125-127.
Loi C-M, Vestal ER. Drug metabolism in the elderly. Pharmacol Ther 1988;36:131-149.
Kroner BA, Scott RB, Waring ER, Zanga JR. Poisoning in the elderly: Characterization of exposures reported to a poison control center. J Am Geriatr Soc 1993.
Flanagan RJ, Caldwell R, Lewis RR, Corless D. Toxicological investigations in the detection of drug-induced decrease in elderly patients. Hum Toxicol 1983;2:371 — 380.
Cadieux RJ. Drug interactions in the elderly: How multiple drug use increases risk exponentially. Postgrad Med 1989;86:179-184.
Stevenson 1H. Susceptibility of different age groups to toxic damage. In: Volans GN, Sims J, Sullivan FM, Turner P, eds. Basic Science in Toxicology. London: Taylor & Francis, 1990:406.
Rylance GW. Prescribing for infants and children. Br Med J 1988;296:984-986.
Graham R. Transdermal non-steroidal antiinflammatory agents. Br J Clin Pract 1995;49:33-35.
Berti JJ, Lipsky JJ. Transcutaneous drug delivery: A practical review. Mayo Clin Proc 1995;70:581-586.
Allen L, Kimura K, MacKickin J, Ritschel WA. Manual of symbols, equations and definitions in pharmacokinetics. J Clin Pharmacol 1982;22(suppl.):3S-23S.
Done AK. Helpful half-life. Emerg Med 1977;9(1):211—220. Everything you’ve always wanted to know about pharmacokinetics but were afraid to ask. Emerg Med 1978; 10(6):67—69, 75—76, 81. Acid-base disturbances: Aids to evaluation. Emerg Med 1981; 13( 15): 159—171. Acid-base disturbances: Aids to differential diagnosis. Emerg Med 1981;13(17):68—86. Ion trapping in the pathogenesis and treatment of poisoning. Vet Hum Toxicol 1980;22(suppl.):2—9.
George CF. Disease of the alimentary system: Absorption, distribution and metabolism of drugs; effects of disease of the gut. Br Med J 1976;2:742-744.
Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1982.
Gibaldi M, Levy G. Pharmacokinetics in clinical practice: 1. Concepts. JAMA 1976;235:1864-1867; IL JAMA 1976-235:1987-1992.
Greenblatt DJ, Koch-Weser J. Clinical pharmacokinetics. Part I. N Engl J Med 1975;293:702-705; Part 11. N Engl J Med 1975;293:963-969.
Mills КС. Essential emergency medicine pharmacokinetics: Prevention of iatrogenic patient poisoning. Top Emerg Med 1993;15:18-29.
Nelson E. Kinetics of drug absorption, distribution, metabolism and excretion. J Pharm Sci 1961;50:181-192.
O’Reilly WJ. Pharmacokinetics in drug metabolism and toxicology. Can J Pharm Sci 1972;7:66-77.
Paxton JW. Pharmacokinetics. NZ Med J 1982;95:150-153.
Sue Y-J, Shannon M. Pharmacokinetics of drugs in overdose. Clin Pharmacokinet 1992;23:93-105.
Wagner JG. Pharmacokinetics. Annu Rev Pharmacol 1968;8:67-94.
Wilkinson GR. Pharmacokinetics of drug disposition: Hemodynamic considerations. Annu Rev Pharmacol 1975;15:11-27.
Gibaldi M, Nagashima R, Levy G. Relationship between drug concentration in plasma or serum and amount of drug in the body. J Pharm Sci 1969;58:193-197.
Niazi S. Volume of distribution as a function of time. J Pharm Sci 1976;65:452-454.
Riegelman S, Loo J, Rowland M. Concept of a volume of distribution and possible errors in evaluation of this parameter. J Pharm Sci 1968;57:128-133.
George CF. Drug kinetics and hepatic blood flow. Clin Pharmacokinet 1979;4:433-448.
Laika D, Griffith RK, Cronemberger CL. The hepatic first-pass metabolism of problematic drugs. J Clin Pharmacol 1993;33:657-669.
Nies AS, Shand DG, Wilkinson GR. Altered hepatic blood flow and drug disposition. Clin Pharmacokinet 1976;1:135-155.
Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1973;1:123-136.
Weigand UW, Levy G. Hepatic extraction of endogenous inhibitors of plasma protein binding. J Pharm Sci 1980;69:480-481.
Gibaldi М, Weintraub Н. Some considerations as to the determination and significance of biologic half-life. J Pharm Sci 1971;60:624-626.
Wagner JG. Intrasubject variation in elimination half-lives of drugs which are appreciably metabolized. J Pharmacokinet Biopharm 1973;1:165-173.
Garrett ER. Pharmacokinetics and clearances related to renal processes. Int J Clin Pharmacol 1978;16:155-172.
Levy G. Effect of plasma protein binding on renal clearance of drugs. J Pharm Sci 1980;69:482-483.
Martin BK. Treatment of data from drug urinary excretion. Nature 1967;56:489-494.
Niebergall PJ, et al. Rapid methods for bioavailability determination utilizing urinary excretion data. J Pharm Sci 1975;64:1721-1722.
Wagner JG. Method for estimating rate constants for absorption, metabolism and elimination from urinary excretion data. J Pharm Sci 1967;56:489-494.
Kruger-Thiemer E. Continuous intravenous infusion and multicompartment accumulation. Eur J Pharmacol 1968;4:317-324.
Loo JCK, Riegelman S. Assessment of pharmacokinetic constants from post infusion blood curves obtained after IV infusion. J Pharm Sci 1970;59:53-55.
Azarnoff DL, Huffman DH. Therapeutic implications of bioavailability. Annu Rev Pharmacol Toxicol 1976;16:53-66.
Food and Drug Administration. Drug product bioequivalence requirements and in vivo bioavailability procedures. Fed Regist 1977;42:1624-1653.
Guidelines for biopharmaceutical studies in man. Washington, DC: APHA Academy of Pharmaceutical Sciences, 1972.
Koch-Weser J. Bioavailability of drugs. N Engl J Med (first of two parts) 1974;291:233-236; (second of two parts) 1974;291:503-508.
Ritschel WA. Bioavailability in the clinical evaluation of drugs. Drug Intell Clin Pharm 1972;6:246-256.
Wagner JG. Method of estimating relative absorption of a drug in a series of clinical studies in which blood levels are measured after single and/or multiple doses. J Pharm Sci 1967;56:652-653.
Wagner JG. Design of clinical studies to assess physiological availability. Drug Info Bull 1969;3:45-52.
Feinberg M. The problems of anticholinergic side effects in older patients. Drugs Aging 1993;3:335-348.
Kroner BA, Scott RB, Waring ER, Zanga JR. Poisoning in the elderly: Characterization of exposures reported to a poison center. J Am Geriatr Soc 1993;41:842-846.
Adverse Drug Interaction Program. New Rochelle, NY: The Medical Letter, 1993.
Alvares AP, Kappas A, Eiseman JL, et al. Intraindividual variation in drug disposition. Clin Pharmacol Ther 1979;26:407-419.
Gillette JR. Factors affecting drug metabolism. Ann NY Acad Sci 1971;179:43-66.
Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994;26:165-183.
Halpert JR, Guengerich FP, Bend JR, Correia MA. Selective inhibitors of cytochrome P450. Toxicol Appl Pharmacol 1994;125:163-175.
Koymans L, D-О de Kelder GM, Koppele ТЕ, JM Vermeulen NPE. Cytochrome P450: Their active-silt structure and mechanisms of oxidation. Drug Metab Rev 1993;25:325-385.
Pang KS, Gillette JR. Metabolite pharmacokinetics: Methods for simultaneous estimates of elimination rate constants of a drug and its metabolites. Drug Metab Dispos 1980;8:39-43.
Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 1992;21:511-526.
Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
Adverse interactions of drugs. Med Lett Drugs Ther 1981;23(5): 17-28.
Drug interactions update. Med Lett Drugs Ther 1984;26(654): 11-14.
Gillette JR, Pang KS. Theoretic aspects of pharmacokinetic drug interactions. Clin Pharmacol Ther 1977;22:623-639.
Levy G. Pharmacokinetic approaches to the study of drug interactions. Ann NY Acad Sci 1976;281:24-39.
Luecke RH, Wosilait WE. Drug elimination interactions: Analysis using a mathematical model. J Pharmacokinet Biopharm 1979;7:629-641.
Garrettson LK, Seller RJ. Acid and alkaline diuresis: When are they of value in the treatment of poisoning? Drug Saf 1990;5:220-232.
Pond SM. Extracorporeal techniques in the management of poisoned patients. Med J Aust 1991;154:617-622.
Koppel C. Position paper: Hemofiltration, plasmapheresis and other techniques. Personal communication at Congress of European Association of Poison Centres and Clinical Toxicologists, Vienna, April 1994.
Bismuth C, Muczinski J. Are extracorporeal techniques of elimination validated in acute poisoning? In: Proceedings, European Association of Poison Centres and Clinical Toxicologists, Istanbul, May 1992:69.
Health and Public Policy Committee, American College of Physicians. Clinical competence in continuous arteriovenous hemofiltration. Ann Intern Med 1988; 108:902— 907.
Health and Public Policy Committee, American College of Physicians. Clinical competence in acute hemodialysis. Ann Intern Med 1988;108:632-634.
Health and Public Policy Committee, American College of Physicians. Clinical competence in acute peritoneal dialysis. Ann Intern Med 1988;108:763-765.
Litovitz T, Veltri JC. The role of hemoperfusion and hemodialysis in toxicology. Am J Emerg Med 1988;6:80.
Litowitz TL, Holm КС, Clancy C, et al. 1992 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance system. Am J Emerg Med 1993;11:494-555.
Cutler RE, Forland SC, Hammond St JPG, Evans JR. Extracorporeal removal of drugs and poisons by hemodialysis and hemoperfusion. Annu Rev Pharmacol Toxicol 1987;27:169-191.
Gwilt PR, Perrier D. Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability. Clin Pharmacol Ther 1978;24:154-161.
Rommes JH. Haemoperfusion, indications and side effects. Arch Toxicol 1992;suppl. 15:40—49.
Winchester JF. Poisoning: Is the role of nephrologist diminishing? Am J Kid Dis 1989;13:171-183.
Zilker T. Personal communication. In: Proceedings, XVIth International Congress of the European Association of Poison Centres and Clinical Toxicologists, Vienna, April 1994.
Shannon M. Extracorporeal drug removal. II. Other methods. Clin Toxicol Rev 199O;I2(9):1—2.
Blye E, Lorch J, Cortrell S. Extracorporeal therapy in the treatment of intoxication. Am J Kid Dis 1984;3:321 — 338.
Golper TA, Bennett WM. Drug removal by continuous arteriovenous haemofiltration: A review of the evidence in poisoned patients. Med Toxicol Adverse Drug Experience 1988;3:341-349.
Bressolle F, Kinowski J-M, de la Coussaye JE, et al. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet 1994;26:457-471.
Horton MW, Godley PJ. Continuous arteriovenous hemofiltration: An alternative to hemodialysis. Am J Hosp Pharm 1988;45:1361-1368.
Banner W, Vernon DD, Ward R, et al. Continuous arteriovenous hemofiltration (CAVH) in experimental iron intoxication. Vet Hum Toxicol 1988;30:355.
Bellomo R, Kearly Y, Parkin G, et al. Treatment of lifethreatening lithium toxicity with continuous arteriovenous hemodiafiltration. Crit Care Med 1991; 19:836— 837.
Cnzhnikov EA, Yasoslavsky AA, Molondenkov MV, et al. Plasma perfusion through charcoal in methylparathion poisoning. Lancet 1977;1:38-39.
Berning T, Krummner T, Glaser T, et al. Plasma perfusion in life-threatening exogenous poisoning. Schweiz Med Wochen-schr 1987;117:1368-1370.
Buylaert WA, Herregots LL, Montier EP, Bogaert MG. Cardiopulmonary bypass and the pharmacokinetics of drugs: An update. Clin Pharmacokinet 1989;17:10-26.
Hendren WG, Schieber RS, Garrettson LP. Extracorporeal bypass for the treatment of verapamil poisoning. Ann Emerg Med 1989;18:984-987.
Freedman MD, Gal J, Freed CR. Extracorporeal pump assistance: Novel treatment of acute lidocaine poisoning. Eur J Clin Pharmacol 1982;22:129-135.
Kennedy JH, Barnette J, Flasterstein A, Higgs W. Experimental barbiturate intoxication: Treatment by partial cardiopulmonary bypass and hemodialysis. Cardiovasc Res Center Bull 1976;14:61-69.
Martin TG, Tisherman SA, Stein K. Massive diltiazem OD unresponsive to cardiopulmonary bypass: Personal Communication. In: Proceedings, XVlth International Congress of European Association of Poison Centres and Clinical Toxicologists, Vienna, April 1994.
Meredith TJ, Jacobsen D, Haines J A, Berger J-C, eds. International Program on Chemical Safety/Commission of the European Communities Evaluation of Antidotes Series. Vol. 1: Naloxone, Flumazenil and Dantrolene as Antidotes. EUR 14 797 EN. Vol. 2: Antidotes for Poisoning by Cyanide (van Heijst APVP, guest ed.). EUR 14 280EN. Cambridge: Cambridge University Press, 1993.
Kiilig K. Initial management of ingestions of toxic substances. N Engl J Med 1992;326:1677-1681.
Martin TG, Donovan JW. Facility assessment guidelines for regional poison treatment centers. Vet Hum Toxicol 1991;33:394-397.
Stirt JA. Aminophylline as a diazepam antagonist. An-esth Analg 1981;60:767-768.
Wangler MA, Kirkpatrick DS. Aminophylline is an antagonist of lorazepam. Anesth Analg 1985;64:834-836.
Phyllis JW, Edstrom JP, Ellis SW, Kirkpatrick JR. Theophylline antagonizes flurazepam-induced depression of cerebral cortical neurons. Can J Physiol Pharmacol 1979;57:917-920.
Meyer BH, Weis OF, Muller FO. Antagonism of diazepam by aminophylline in healthy volunteers. Anesth Analg 1984;63:900-902.
Katz Y, Gavish M. Aminophylline reversal of diazepam intoxication. Lancet 1989;1:900-901.
Gurel A, Eleuli IM, Hamulu A. Aminophylline reversal of flumitrazepam sedation. Anesth Analg 1987;66:333— 336.
Niemand D, Martinell S, Arvidsson S, et al. Aminophylline inhibition of diazepam sedation: Is adenosine blockade of GABA-receptors the mechanism? Lancet 1984;1:463-464.
Sibai AN, Sibai AM, Baraka A. Comparison of flumazenil with aminophylline to antagonize midazolam in elderly patients. Br J Anaesth 1991;66:591-595.
Kuzemko J A, Paala J. Apnoeic attacks in the newborn treated with aminophylline. Arch Dis Child 1973;48:404-406.
Mainzer F. Treatment of incipient apoplexy with intravenous aminophylline. Aeon Med Scand 1953; 146:362— 377.
Dowell AR, Heyman A, Sieker HA, Tripathy K. Effect of aminophylline on respiratory center sensitivity in Cheyne-Stokes respiration and in pulmonary emphysema. N Engl J Med 1963;273:1447-1453.
Daller JA, Erstad B, Rosado L, et al. Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium. Crit Care Med 1991;19:983-985.
Stirt JA. Aminophylline may act as a morphine antagonist. Anaesthesia 1983;38:275-278.
Renzhen-Lia WMD. Aminophylline antagonism of the residual effects of fentanyl anesthesia. Anesth Analg 1985;64:1029.
Krintell JJ, Wegmann F. Aminophylline reduces the depth and duration of sedation with barbiturates. Acta Anaesth Scand 1987;31:352-354.
Bone MF, Kalra L, Phillips A, Ariaraj S. Reversal of the adverse effects of nifedipine by aminophylline, a calcium channel facilitator in cor pulmonale. Thorax 1990;45:328P.
TerWee PM, Kremer Horinga TK, Uges DRA, van der Geest S. 4-Aminopyridine and hemodialysis in the treatment of verapamil intoxication. Hum Toxicol 1985;4:327-329.
Bull AP, Hopkinson RB, Farrell ID, et al. Human botulism caused by Clostridium botulinum Type E: The Birmingham outbreak. Q J Med 1979;48:473-491.
Murray NMF, Newson-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981;31:265-271.
Stefoski D, Davis FA, Fitsimmons WE, et al. 4-Aminopyridine in multiple sclerosis: Prolonged administration. Neurology 1991;4:1344-1348.
Spyker DA, Lynch C, Shabanowitz J, Sinn J A. Poisoning with 4-aminopyridine: Report of three cases. Clin Toxicol 1980;16:487-497.
Miller RD, Booij LHDJ, Agoston S, Crul JF. 4-Ami-nopyridine potentiates neostigmine and pyridostigmine in man. Anesthesiology 1979;50:416-420.
Barone-J A, Peppers MR Use of dantrolene in the management of amphetamine-induced hyperthermia. Clin Pharm 1989;8:324-325.
Ten Holter JBM, Schellens RLLAM. Dantrolene sodium for treatment of carbon monoxide poisoning. Br Med J 1988;296:1772-1773.
Kaplan RF, Feinglass NG, Webster W, Mudra S. Phenelzine overdose treated with dantrolene sodium. JAMA 1986;255:642-644.
Shemesh I, Bourvin A, Gold D, Kutscherowsky M. Chlorpyrifos poisoning treated with ipratropium and dantrole: A case report. Clin Toxicol 1988;26:495-498.
Bouchama A, Cafege A, Devol EB, et al. Ineffectiveness of dantrolene sodium in the treatment of heat stroke. Crit Care Med 1991;19:176-180.
Channa АВ, Seraj МА, Saddique АА, et al. Is dantrolene effective in heat stroke patients? Crit Care Med 1990;18:290-293.
Parr MJ A, Willatts SM. Fatal theophylline poisoning with rhabdomyolysis: A potential role for dantrolene treatment. Anaesthesia 1991;46:557-559.
Van de Kelft E, de Hert M, Heytens L, et al. Management of lethal catatonia with dantrolene sodium. Crit Care Med 1991;19:1449-1451.
Robillart A, Bopp P, Vailly B, Dupeyron JP. Cardiac failure due to dantrolene overdose. Ann Fr Anesth Reanim 1986;5:617-619.
Paloucek FP, Erickson ТЕ, Lundquist S, Ferraro C. Oral dantrolene ingestion: A case series. Vet Hum Toxicol 1991;33:362.
Tayeb OS. A serious interaction of dantrolene and theophylline. Vet Hum Toxicol 1990;32:442-443.
Saltzman LS, Kates RA, Corke GC, et al. Hyperkalemia and cardiovascular collapse after verapamil and dantrolene administration in swine. Anesth Analg 1984;63:473-478.
Wedel DJ, Quinlan JG, laizzzo PA. Clinical effects of intravenously administered dantrolene. Mayo Clin Proc 1995;70:241-246.
Chan CH. Dantrolene sodium and hepatic injury. Neurology 1990;40:1427-1432.
Wilkinson SP, Portmann B, Williams R. Hepatitis from dantrolene sodium. Gut 1979;20:33-36.
Cornett M, Gillard C, Borlee-Hermans G. Hepatite toxique mortelle associee at I’usage du dantrolene. Acta Neurol Belg 1980;80:336-347.
Hillman B, Bardham KD, Bain JTB. The use of dicobalt edetate (Kelocyanor) in cyanide poisoning. Postgrad Med J 1974;50:171-174.
Naughton M. Acute cyanide poisoning. Anaesth Intensive Care 1974;4:351-356.
Reynolds JEF. Martindale. The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1991:680.
Weger NP. Treatment of cyanide poisoning with 4-dimethylaminophenol (DMAP): Experimental and clinical overview. Fundam AppI Toxicol 1983;3:387— 396.
Weger NP. Aminophenole als Blausaure: Antidote. Arch Toxicol 1968;24:49-50.
Klinimek R, Krettek C, Szinicz L, et al. Effects of biotransformation of 4-dimethylaminophenol in man and dog. Arch Toxicol 1983;53:275-288.
Ram Z, Spiegelman R, Findler G, Hadani M. Delayed postoperative neurological deterioration from prolonged sodium nitroprusside administration. J Neurosurg 1989;71:605-607. Case report.
Van Dijk A, Glerum JH, Van Heijst ANP, Douze JMC. Clinical evaluation of the cyanide antagonist 4-DMAP in a lethal cyanide poisoning case. Vet Hum Toxicol 1987;29(suppl. 2):38—39.
Van Heijst ANP, Douze JMC, Van Kesteren RG, et al. Therapeutic problems in cyanide poisoning. Clin Toxicol 1987;25:383-398.
Kiese M, Lorcher W, Weger N, Zierer A. Comparative studies on the effects of toluidine blue and methylene blue on the reduction of ferrihemoglobin in man and dog. Eur J Clin Pharmacol 1972;4:115-118.
Succimer approved to treat severe lead poisoning in children. FDA Med Bull 1991 ;21 (1 ):5.
Graziano JH, Lolacono NJ, Meyer P. Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. J Pediatr 1988;113:751-757.
Bentur Y, Brook JG, Behar R, Taitelman U. Meso-2,3-dimercaptosuccinic acid in the diagnosis and treatment of lead poisoning. Clin Toxicol 1987;25:39-51.
Mortensen ME, Valenzuela PM. Dimercaptosuccinic acid (DMSA) chelation for childhood lead poisoning. Clin Pharmacol Ther 1991 ;49:162.
Hurlbut KM, Dart RC, Sullivan JB, Campbell DC. Use of DMSA in severe thallium toxicity. Vet Hum Toxicol 1990;32:363.
Mortensen ME, Valenzuela PM. 2,3-Dimercaptosuccinic acid (DMSA) chelation in mercury (Hg) vapor poisoning. Vet Hum Toxicol 1990;32:382.
Kosnett MJ, Becker CE. Dimercaptosuccinic acid: Acute and chronic arsenic poisoning. Vet Hum Toxicol 1988;30:369.
Aposhian HV, Maiorino RM, Rivera M, et al. Human studies with the chelating agents. DM PS and DMSA. Clin Toxicol 1992;30:505-528.
Lheureux P, Askenasi R. Efficacy of flumazenil in acute alcohol intoxication: Double blind placebo-controlled evaluation. Hum Exp Toxicol 1991;10:235-239.
Momose T. A study on the effects of regaining consciousness with flumazenil from anesthesia supplemented with a benzodiazepine and pentazocine. Clin Pharmacol Ther 1991 ;49:185.
Apple M, Bron HNLM, Hooymans DM, Janknegt R. Efficacy of flumazenil in COPD patient with therapeutic diazepam levels. Lancet 1989; 1:392.
Short TG, Maling T, Galletly DC. Ventricular arrhythmias precipitated bv flumazenil. Br Med J 1988;296:1070-1071.
Burr W, Sandham P. Death after flumazenil. Br Med J 1989;298:1713.
Marchant B, Wray R, Leach A, Nama M. Flumazenil causing convulsions and ventricular tachycardia. Br Med J 1989;299:860.
Herd B, Clarke F. Complete heart block after flumazenil. Hum Exp Toxicol 1991; 10:289.
Geller E, Crome P, Schaller MD, et al. Risks and benefits of therapy with flumazenil (Anexate) in mixed drug intoxications. Eur Neurol 1991;31:241-250.
Hojer JH, Baehrendtz S, Matell G, Gustafsson LL. Diagnostic utility of flumazenil in coma with suspected poisoning: A double blind, controlled, randomized controlled study. Br Med J 1990;301:1308-1311.
Kulka PJ, Lauren PM. Benzodiazepine antagonists. Drug Saf 1992;7:381-386.
Weinbroum A, Halpern P, Geller E. The use of fluma-zenil in the management of acute drug poisoning: a review. Intensive Care Med 1991;17:32-38.
Clausen TG, Wolff J, Carl P, Theilgaard A. The effect of benzodiazepine antagonist, flumazenil, on psychometric performance in acute ethanol intoxication in man. Eur J Clin Pharmacol 1990;38:233-236.
Pollack CV Jr. Utility of glucagon in the emergency department. J Emerg Med 1993;11:195-205.
Blume CM, Thompson MW, Scalzo AJ. Use of IV glucagon to facilitate the passage of a penny from the distal esophagus into the stomach. Vet Hum Toxicol 1993;35:335.
Doyon S, Roberts JP. The use of glucagon in a case of calcium channel blocker overdose. Ann Emerg Med 1993;22:1229-1233. IT Walter FG, Frye G, Mullen JT, et al. Amelioration of nifedipine poisoning associated with glucagon therapy. Ann Emerg Med 1993;22:1234-1237.
Wolf LR, Spadafora MP, Otten EJ. Use of amrinoneand glucagon in a case of calcium channel blocker overdose Ann Emerg Med 1993;22:1225-1228.
Linden CH, Aghababian RW. Further uses of glucagon Crit Care Med 1985; 13:248.
Baud F, Toffis V, Barriot P, et al. Kinetics of cobalamins in cyanide intoxications treated with hydroxocobalamin In: Proceedings, Vth International Congress of Toxicology, Brighton, England, July 16, 1989. London: Taylor & Francis, 1989.
Mueller PD, Hall AH, Osterloh JD, et al. Hydroxocobalamin kinetics and cyanide elimination in heavy smokers. Vet Hum Toxicol 1990;32:361.
Espinoza OB, Perez M, Ramirez MS. Bitter cassava poisoning in eight children: A case report. Hum Toxicol 1992;34:65.
Forsyth JC, Mueler PD, Becker CE, et al. Hydroxocobalamin as a cyanide antidote: Safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. Clin Toxicol 1993;31:277-294.
Curry SC, Connor DA, Raschke RA. Effect of the cyanide antidote hydroxocobalamin on commonly ordered serum chemistry studies. Ann Emerg Med 1994.
Zerbe NF, Wagner BKJ. Use of vitamin Bi2 in the treatment and prevention of nitroprusside-induced cyanide toxicity. Crit Care Med 1993;21:465-467.
Bismuth C. 4-Methylpyrazole simplified the treatment of ethyleneglycol poisoning. In: Proceedings, Seventh World Congress on Emergency and Disaster Medicine in Prehospital and Disaster Medicine, Montreal, May 12, 1991 (April—June):203. Abstract.
Woodyear WE, Campbell PT, Corey GR. Not so good to the last drop: Ethylene glycol poisoning in a coffeeconsuming camper. NC Med J 1992;53:134-136.
Baud FJ, Galliot M, Astier A, et al. Treatment of ethylene glycol poisoning with intravenous 4-methylpyrazole. N Engl J Med 1988;319:97-100.
Jacobsen D, Sebastian CS, Blomstrand R, McMartin KE. 4-Methylpyrazole: A controlled study of safety in healthy human subjects after single ascending doses. Alcohol Clin Exp Res 1988;12:516-522.
Brennan RJ, Mankes RJ, Lefevre R, et al. 4-Methyipyra-zole blocks acetaminophen hepatotoxicity in the rat. Ann Emerg Med 1994;23:487-493.
McMartin KE, Heath A. Treatment of ethylene glycol poisoning with intravenous 4-methylpyrazole. N Engl J Med 1989;320:125.
McMartin KE, Jacobsen D, Sebastian S, Barron SK. Safety and metabolism of multiple doses of 4-methylpyrazole in humans. Vet Hum Toxicol 1988;30:363.
Jacobsen D, Sebastian CS, Barron SK, et al. Effects of 4-methylpyrazole, methanol/ethylene glycol antidote in healthy humans. J Emerg Med 1990;8:455-461.
Tournoud C, Kopferschmitt J, Sander P, et al. Ethylene glycol poisoning treated with 4-methylpyrazole. In: Proceedings, European Association of Poison Toxicologists, Istanbul, Turkey, May 24—27, 1992:30.
Harrison PM, Keays R, Bray GP, et al. Improved outcome in paracetamol-induced fulminant hepatic failure following late administration of acetylcysteine. Lancet 1990;335:1572-1573.
Keays RT, Gove C, Forbes A, et al. Use of late V-acetylcysteine in severe paracetamol overdose. Gut 1989;30:A 1512. Abstract.
Flanagan RJ. The role of acetylcysteine in clinical toxicology. Med Toxicol 1987;2:93-104.
Meredith TJ, Ruprak M, Liddle A, Flanagan RJ. Diagnosis and treatment of acute poisoning with volatile substances. Hum Toxicol 1989;8:277-286.
Wegener T, Sandhagen B, Chan KW, Saldien T. N-Acetyl-cysteine in paraquat toxicity: Toxicological and histological evaluation in rats. Ups J Med Sci 1988;93:81-89.
Cramp TP. Failure of V-acetylcysteine to reduce renal damage due to paraquat in rats. Hum Toxicol 1985;4:107.
Holoye PV, Duelge J, Hansen RM, et al. Prophylaxis of ifosfamide toxicity with oral acetylcysteine. Semin Oncol 1983; 10(suppl 1):66—71.
Shahzeidi S, Saistrandt B, Jeffery PK, et al. V-Acetylcysteine partially protects lung fibrosis caused by bleomycin. Thorax 1990;45: 323P.
Giri SN, Hyde DM, Schiedt MJ. Effects of repeated administration of V-acetyl-L-cysteine on sulfhiydryl levels of different tissues and bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1988;111:714-724.
Howard RJM, Blake DR, Paell H, et al. Allopurinol/V-acetylcysteine for carbon monoxide poisoning. Lancet 1987;2:628-629.
Linden W, Wieslander E, Eklund A, et al. Effects of oral V-acetylcysteine in cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur Respir J 1988;1:645-650.
KalebicT, Kinter A, Poli G, et al. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and V-acetylcysteine. Proc Natl Acad Sci USA 1991;88:986-990.
Roederer M, Staal FJT, Ela SW, et al. V-Acetylcysteine: Potential for AIDS therapy. Pharmacology 1993;46:121-129.
Droge W. Cysteine and glutathione deficiency in AIDS patients: A rationale for the treatment with V-acetylcysteine. Pharmacology 1993;46:61-65.
Roederer M, Ela SW, Staal FJT, et al. V-Acetylcysteine: A new approach to anti-HIV therapy. AIDS Res Hum Retrovir 1992;8:209-219.
Jepsen S, Herlevsen P, Knudsen P, et al. Antioxidant treatment with V-acetylcysteine during adult respiratory distress syndrome: A prospective randomized placebo-controlled study. Crit Care Med 1992;20:918— 923.
Bernard GR. Potential of V-acetylcysteine as treatment for the adult respiratory distress syndrome. Eur Respir J 1990;3(suppl. 11):496—498.
Horowitz JD, Antman EM, Lorell BH, et al. Potentiation of the cardiovascular effects of nitroglycerin by V-acetylcysteine. Circulation 1983;68:1247-1253.
Svendsen JH, Klarlund K, Aldershvile J, Waldortf S. V-Acetylcysteine modifies the acute effects of isosorbide-5-mononitrate in angina pectoris patients evaluated by exercise testing. J Cardiovasc Pharmacol 1991; 13:320—323.
Vassallo S, Howland MA. Severe dichromate poisoning: Survival after therapy with V-acetylcysteine and hemodialysis. Vet Hum Toxicol 1988;30:347.
Locatelli C, Travaglia CA, Maccarini D, et al. Amanita poisoning: Forced diuresis and intravenous V-acetylcysteine combined therapy. In: Proceedings, 14th International Congress of European Association of Poison Centres, Milan, Italy, September 25—29, 1990:32.
Schneider SM, Vanscoy GJ, Michelson EA. Failure of V-acetylcysteine to reduce alpha amanitin toxicity. Vet Hum Toxicol 1989;31:359.
Gavish D, Breslow JL. Lipoprotein a reduction by V-acetylcysteine. Lancet 1991;337:203-204.
Hanson PR. Lipoprotein a reduction by V-acetylcysteine. Lancet 1991;337:672-677.
Breslow JL, Azrolan N, Boston A. V-Acetylcysteine and lipoprotein 1. Lancet 1992;239:126-127.
Kroon AA, Demacher PMN, Stalenhoef AFH. V-Acetylcysteine and serum concentrations of lipoprotein a. J Intern Med 1991;230:519-526.
Mohammed S, Jamal AZ, Robisun LR. Serum sicknesslike illness associated with V-acetylcysteine therapy. Ann Phannacother 1994;28:285.
Flanagan RJ, Meredith TJ. Use of V-acetylcysteine in clinical toxicology. Am J Med 1991;91 (suppl. 36): 131S— 139S.
Spiller HA, Krenzelok EP, Grande GA, etal. A prospective evaluation of the effect of activated charcoal before oral А-acetylcysteine in acetaminophen overdose. Ann Emerg Med 1994;23:519-523.
Simon GA, Tirosk MS, Edery H. Administration of obi-doxime tablets to man: Plasma levels and side reactions. Arch Toxicol 1976;36:83-88.
Bentur Y, Nutenko 1, Tsipiniuk A, et al. Pharmacokinetics of obidoxime in organophosphate poisoning associated with renal failure. Clin Toxicol 1993;31:315-322.
Siwy BK, Sadove AM. Acute management of dopamine infiltration injury with regitine. Plast Reconstr Surg 1987;80:610-612.
McCauley WA, Gerace RV, Scilley C. Treatment of accidental digital injection of epinephrine. Ann Emerg Med 1991;20:665-668.
Markovchik V, Burkhart KK. The reversal of the ischemic effects of epinephrine on a finger with local injections of phentolamine. J Emerg Med 1991 ;9:323—324.
Brimacombe J, Archdeacon J, Newell S, Martin J. Two cases of naloxone-induced pulmonary oedema: The possible use of phentolamine in management. Anesth Intensive Care 1991;19:578-580.
Rasthaus EM, Landy PJ. Methyl bromide poisoning. Br J Ind Med 1961;18:53-57.
Verzijl JM, Joore HCA, van Dijk A, et al. In vitro cyanide release of four Prussian blue salts used for the treatment of cesium contaminated persons. Clin Toxicol 1993;31:553-562.
McEvoy GK, ed. AHFS Drug Information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:726-728.
Wood M. Cholinergic and parasympathomimetic drugs: Cholinesterases and anticholinesterases, in: Wood M, Wood AJJ, eds. Drugs and anesthesia: Pharmacology for Anesthesiologists. 2nd ed. Baltimore: Williams & Wilkins, 1990.
Keeler JR, Hurst CG, Dunn MA. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. JAMA 1991;266:693-695.
Menne T, Kaaber K. Treatment of pompholyx due to allergy with chelating agents. Contact Dermatitis 1978;4:289-290.
Sunderman F. The treatment of acute nickel carbonyl poisoning with sodium diethyldithiocarbamate. Ann Clin Res 1971;3:182-185.
Hersh EM, Brewton G, Abrams D, et al. Dithiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS: A randomized, double-blind, placebo-controlled multicenter study. JAMA 1991;265:1538-1544.
Kurte DL, Dean BS, Krenzelok EP. Acute nickel carbonyl poisoning. Am J Emerg Med 1993;11:64-66.
Hersh EM. Dithiocarb sodium and HIV infection. JAMA 1991 ;266:796.
Rusinger EC, Kern P, Ernst M, et al. Inhibition of HIV progression by dithiocarb. Lancet 1990;335:679-682.
Albertson ТЕ, Derlet RW, Foulke GE, et al. Superiority of activated charcoal alone compared with ipecac andactivated charcoal in the treatment of acute toxic ingesl tions. Ann Emerg Med 1989;18:101-104.
Donovan JW. Selective gastric decontamination in the poisoned patient. Top Emerg Med 1993;15:1-12.
Jawary D, Cameron PA, Dziukas L, McNeil JJ. Drug overdose: Reducing the load. Med J Aust 1992;156:343-436.
Neuvonen PJ, Olkolla KT. Oral activated charcoal in the treatment of intoxications: Role of single and repeated dose. Med Toxicol 1988;3:33-58.
Olson KR. Is gut emptying all washed up? Am J Emerg Med 1990;8:560-561. Editorial.
Perrone J, Hoffman RS, Goldfrank LR. Special considerations in gastrointestinal decontamination. Emerg Med Clin North Am 1994; 12:285.
Saetta JP. Gastric decontaminating procedures: Is it time to call a stop? J R Soc Med 1993;86:396-399.
Tenenbein M. Multiple doses of activated charcoal: Time for reappraisal? Ann Emerg Med 1991;20:529-531.
Tenenbein M. Whole bowel irrigation as a gastrointestinal decontamination procedure after acute poisoning. Med Toxicol 1988;3:77-84.
Tenenbein M, Silar DS, Banner W, et al. Symposium: Advances in the management of drug intoxication. Ann RCPSC 1990 23:453—457.
Vale JA. Clinical toxicology. Postgrad Med J 1993;69:19-32
Vale JA, Proudfoot AT. How useful is activated charcoal? Studies have left many unanswered questions. Br Med J 1993;308:78-79.
Lovejoy FH Jr, Shannon M, Woolf AD. Recent advances in clinical toxicology. Curr Problems Pediatr 1992(Mar.):119-129.
Abdallah AH, Tye A. A comparison of the efficacy of emetic drugs and stomach lavage. Am J Dis Child 1967;113:571-574.
Corby DG, Lisciandro RC, Lehman RG, et al. The efficacy of methods used to evacuate the stomach after acute ingestions. Pediatrics 1967;40:871-874.
Tandberg D, Diven BG, McLeod JW. Ipecac-induced emesis versus gastric lavage: A controlled study in normal adults. Am J Emerg Med 1986;4:205-209.
Litovitz TL. Emesis versus lavage for poisoning victims. Am J Emerg Med 1986;4:294-295.
Jawary D, Cameron PA, Dziukas L, McNeil JJ. Drug overdose: Reducing the load. Med J Aust 1992; 156:343— 436.
Tenenbein M, Cohen S, Sitar DS. Efficacy of ipecac-induced emesis, orogastric lavage, and activated charcoal for acute drug overdose. Ann Emerg Med 1987; 16:838— 841.
Albertson ТЕ, Derlet RW, Foulke GE, et al. Superiority of activated charcoal alone compared with ipecac and activated charcoal in the treatment of acute toxic ingestions. Ann Emerg Med 1989;18:101-104.
Merigian KS, Woodard M, Hedges JR, et al. Prospective evaluation of gastric emptying in the self-poisoned patient. Am J Emerg Med 1990;8:479-483.
Olson KR. Is gut emptying all washed up? Am J Emerg Med 1990;8:560-561. Editorial.
Saetta JP, Marsh S, Gaunt ME, Quinton DN. Gastric emptying procedures in the self-poisoning patients: Are we forcing gastric content beyond the pylorus? J R Soc Med 1991;84:274-276.
Saetta JP, Quinton DN. Residual gastric content after gastric lavage and ipecacuanha-induced emesis in selfpoisoned patients: An endoscopic study. J R Soc Med 1991;84:35-38.
Merigian KS, Woodard M, Hedges JR, et al. Prospective evaluation of gastric emptying in the self-poisoned patient. Am J Emerg Med 1990;8:479-483.
Robertson WO: Syrup of ipecac: A slow or fast emetic? Am J Dis Child 1962;103:136-139.
Neuvonen PJ, Olkolla KT. Oral activated charcoal in the treatment of intoxications: Role of single and repeated dose. Med Toxicol 1988;3:33-58.
Litovitz T. In defense of retaining ipecac syrup as an overthe-counter drug. Pediatrics 1988;82(3, pt 2):514— 516.
Watson WA, Leighton J, Guy J, et al. Recovery of cyclic anti-depressants with gastric lavage. J Emerg Med 1989;7:373-377.
Vale JA. The relevance of gastrointestinal decontamination in acute poisoning: What should we be advising? Personal presentation, 1994.
Litovitz TL, Bailey KM, Schmitz BF, et al. 1990 Annua] report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1991;9:461-509.
Kornberg AE, Dolgin J. Pediatric ingestions: Charcoal alone versus ipecac and charcoal. Ann Emerg Med 1991;20:648-651.
Freedman GE, Pasternak S, Krenzelok EP. A clinical trial using syrup of ipecac and activated charcoal concurrently. Ann Emerg Med 1987;16:164-166.
Dean BS, Krenzelok EP. Syrup of ipecac: 15 mL versus 30 mL in pediatric patients. Clin Toxicol 1985;23:165— 170.
Varipapu RJ, Oderda GM. Effect of milk on ipecac induced emesis. J Am Pharm Assoc 1977; 17:510.
Rodgers GC, Matyunas NJ. Gastrointestinal decontamination for acute poisoning. Pediatr Clin North Am 1986;33:261-285.
Wrenn K, Rodewald L, Dockstader L. Potential misuse of ipecac. Ann Emerg Med 1993;22:1408-1412.
Saincher A, Sitar D, Tenenbein M. Efficacy of ipecac during the feral hour??? After drug ingestion. Vet Hum Toxicol 1993;36:375.
Auerbach PS, Osterloh J, Braun O, et al. Efficacy of gastric emptying: Gastric lavage versus emesis induced with ipecac. Ann Emerg Med 1986;55:692-698.
Danel V, Henry JA, Glucksman E. Activated charcoal, emesis, and gastric lavage in aspirin overdose. Br Med J 1988;296:1507.
Comstock EG, Boisaubin EV, Comstock BS, et al. Assessment of the efficacy of activated charcoal following gastric lavage in acute drug emergencies. J Toxicol Clin Toxicol 1982—1983;19:149-165.
Hodgkinson DW, Jellett LB, Ashby RH. A review of the management of oral drug overdose in the accident and emergency department of the Royal Brisbane Hospital. Arch Emerg Med 1991;8:8-16.
Vale A. Gastric lavage. In: Proceedings, Meeting of American Academy of Clinical Toxicology; European Association of Poison Centres and Clinical Toxicologists; and American Academy of Poison Control Centers, Vienna, April 1994. Draft of position paper.
Kulig K, Bar-Or D, Cantrill JV, et al. Management of acutely poisoned patients without gastric emptying. Ann Emerg Med 1984;14:562-567.
Burke M. Gastric lavage and emesis in the treatment of ingested poisons: A review and a clinical study of lavage in ten adults. Resuscitation 1972;1:91-105.
Palatnick W, Tenenbein M. Activated charcoal in the treatment of drug overdose: An update. Drug Saf 1992;7:3-7.
Kulig K. Initial management of ingestions of toxic substances. N Engl J Med 1992;326:1677-1681.
Atkinson SW, Young Y, Trotter GA. Treatment with activated charcoal complicated by gastrointestinal obstruction requiring surgery. Br Med J 1992;305:563.
Flores F, Battle WS. Intestinal obstruction secondary to activated charcoal. Con Surg 1987;30:57-59.
Watson WA, Cremer KF, Chapman JA. Gastrointestinal obstruction associated with multiple-dose activated charcoal. J Emerg Med 1986;4:401-407.
Farley TA. Severe hypernatremic dehydration after use of an activated charcoal-sorbitol suspension. J Pediatr 1986;109:719-722.
Linden C. Activated charcoal. Clin Toxicol Rev 1987.
Vale J A, Proudfoot AT. How useful is activated charcoal? Studies have left many unanswered questions. Br Med J 1993;308:78-79.
Tenenbein M. Multiple doses of activated charcoal: Time for reappraisal? Ann Emerg Med 1991;20:529-531.
Harvey RF, Read AE. Mode of action of the saline purgatives. Am Heart J 1975;89:810-813.
Cooke AR. Control of gastric emptying and motility. Gastroenterology 1975 ;68:804—816.
Harchelroad F, Cottington E, Krenzelok EP. Gastrointestinal transit times of a charcoal/sorbitol slurry in overdose patients. Clin Toxicol 1989;27:91-99.
Riegal JM, Becker CE. Use of cathartics in toxic ingestions. Ann Emerg Med 1981;10:254-258.
Minocha A, Herold DA, Barth JT, et al. Activated charcoal in oral ethanol absorption: Lack of effect in humans. Clin Toxicol 1986;24:225-234.
Krenzelok EP, Keller R, Stewart RD. Gastrointestinal transit times of cathartics combined with charcoal. Ann Emerg Med 1985;14:1152-1155.
Minocha A, Krenzelok EP, Spyker DA. Dosage recommendations for sorbitol-charcoal treatment. Clin Toxicol 1985;23:579-587.
Allerton JP, Strom JA. Hypernatremia due to repeated doses of charcoal-sorbitol. Am J Kidney Dis 1991;17:581-584.
Veerman MW. Excipients in valproic acid syrup may cause diarrhea: A case report. DCIP Ann Pharmacother 1990;24:832-833.
Perrone J, Hoffman RS, Goldfrank LR. Special considerations in gastrointestinal decontamination. Emerg Med Clin North Am 1994;12:285-289.
Rude RK, Singer FR. Magnesium deficiency and excess. Annu Rev Med 1981;32:245-259.
Humphrey M, Kennon S, Pramanik AK. Hypermagnesemia from antacid administration in a newborn infant. J Pediatr 1981;98:313-314.
Mofenson HC, Caraccio TR. Magnesium intoxication in a neonate from oral magnesium hydroxide laxative. Clin Toxicol 1991;29:215-222.
Jones J, Heiselman D, Dougherty J, Eddy A. Cathartic induced magnesium toxicity during overdose management. Ann Emerg Med 1986;15:1214-1218.
Smilkstein MJ, Smolinske SC, Kulig KW, Rumack BH. Severe hypermagnesemia due to multiple dose cathartic therapy. West J Med 1988;148:208-211.
Woodard JA, Shannon M, LaCouture PG, Woolf A. Serum magnesium concentrations after repetitive magnesium cathartic administration. Am J Emerg Med 1990;8:297-300.
Fine KD, Santa Ana CA, Fordtran JS. Diagnosis of magnesium induced diarrhea. N Engl J Med 1991;324:1012-1017.
Hoffman RS, Smilkstein MJ, Rubenstein F. An ’amp’ by any other name: The hazards of intravenous magnesium dosing. JAMA 1989;261:557.
Ortiz-Interian CJ, Schlessinger FB, Oster JR. Severe hypermagnesemia without reduction in the anion gap. Magnesium Trace Elem 19 910;9:110— 114.
Gerard SK, Hernandez C, Khayam-Bashi H. Extreme hypermagnesemia caused by an overdose of magnesium-containing cathartics. Ann Emerg Med 1988;17:728— 731.
McCubbin JH, Sibai BM, Abdulla TN, Anderson GD. Cardiopulmonary arrest due to acute maternal hypermagnesemia. Lancet 1981;l:1058.
Vigorito C, Giordano A, Ferraro P, et al. Hemodynamic effects of magnesium sulfate on the normal human heart. Am J Cardiol 1991;67:1435-1437.
Kulik DL, Hong R, Ryzen E, et al. Electrophysiologic effects of intravenous magnesium in patients with normal conduction system and no clinical evidence of significant cardiac disease. Am Heart J 1988;1 15:367— 373.
Tsivoni D, Banai S, Schuger C, et al. Treatment of Torsade de pointes with magnesium sulfate. Circulation 1988;77:392-397.
Tsivoni D, Keren A, Cohen AM, et al. Magnesium therapy for Torsade de pointes. Am J Cardiol 1984;53:528— 530.
L’Hommedieu CS, Nicholas N, Armes DA. Potentiation of magnesium sulfate-induced neuromuscular weakness by gentamicin, tobramycin and amikacin. J Pediatr 1983;102:629-631.
Davis GR, Santa Ana CA, Morawski SG, Fordtran JS. Development of a lavage solution associated with minimal water and electrolyte absorption or secretion. Gastroenterology 1980;78:991-995.
Tenenbein M, Cohen S, Sitar D. Whole bowel irrigation as a decontamination procedure after acute drug overdose. Arch Intern Med 1987;147:905-907.
Brady CE III, DiPalma JA, Morawski SG, et al. Urinary excretion of polyethylene glycol 3350 and sulfate aftergut lavage with a polyethylene glycol electrolyte lavage solution. Gastroenterology 1986:90:1914-1918.
Hoffman RS, Chiang WK, Howland MA, et al. Theophylline desorption from activated charcoal caused by whole bowel irrigation solution. J Toxicol Clin Toxicol 1991:29:191-201.
Kirshenbaum LA, Sitar DS, Tenenbein M. Interaction between whole-bowel irrigation solution and activated charcoal: Implications for the treatment of toxic ingestions. Ann Emerg Med 1990:19:1129-1132.
Mayer AL, Sitar DS, Tenenbein M. Multiple-dose charcoal and whole-bowel irrigation do not increase clearance of absorbed salicylate. Arch Intern Med 1992:152:393-396.
Tenenbein M. Whole bowel irrigation as a gastrointestinal decontamination procedure after acute poisoning. Med Toxicol 1988:3:77-84.
Kirshenbaum LA, Mathews SC, Sitar DS, Tenenbein M. Whole-bowel irrigation versus activated charcoal in sorbitol for the ingestion of modified-release pharmaceuticals. Clin Pharmacol Ther 1989:46:264-271.
Buckley NA, Dawson AH, Reitz DA. Controlled release drugs in overdose: Clinical considerations. Drug Saf 1995:12:73-86.
Hoffman RS, Smilkstein MR, Goldfrank LR. Whole bowel irrigation and the cocaine body-packer: A new approach to a common problem. Am J Emerg Med 1990:8:523-527.
Boba A. Whole bowel irrigation. Am J Emerg Med 1994:12:257.
Roberge RJ, Martin TG. Whole bowel irrigation in an acute oral lead intoxication. Am J Emerg Med 1992:10:577-583.
Tenenbein M. Whole bowel irrigation in iron poisoning. J Pediatr 1987:111:142-145.
Tenenbein M. Whole bowel irrigation for toxic ingestions. Clin Toxicol 1985:23:177-184.
Sondheimer JM, Sokol RJ, Taylor SF, et al. Safety, efficacy, and tolerance of intestinal lavage in pediatric patients undergoing diagnostic colonoscopy. J Pediatr 1991;110:148-152.
Goldman J, Reichelderfer M. Evaluation of a rapid colonoscopy preparation using a new gut lavage solution. Gastrointest Endosc 1982:28:9-11.
DiPalma JA, Brady CE. Colon cleansing for diagnostic and surgical procedures: Polyethylene glycol-electrolyte lavage solution. Am J Gastroenterol 1989:84:1008-1016.
Hoffman RS, Chiang WK, Howland MA, et al. Theophylline desorption from activated charcoal caused by whole bowel irrigation. J Toxicol Clin Toxicol 1991:29:191-202.
Snyder JW, Vlasses PH. The role of the laboratory in treatment of the poisoned patient. Arch Intern Med 1988;148:279-280.
Brett AS. Implications of discordance between clinical impression and toxicology analysis in drug overdose. Arch Intern Med 1988;148:437-441.
Cridland JS. How effective are pharmacologic laboratories in big hospitals? Clin Pharmacol Ther 1994;56:117— 121.
Di Nubile MJ. The increment in the anion gap: Overextension of a concept? Lancet 1988;2:951-953.
Toto RD. Metabolic acid-base disorders. In: Kokko VP, Tanner RL, eds. Fluids and Electrolytes. 2nd ed. Philadelphia: WB Saunders 1990:326.
Emmett M, Narins RG. Clinical use of the anion gap. Medicine 1977;56:38-54.
Oh MS, Carroll HJ. The anion gap. N Engl J Med 1977;297:814-817.
Iberti TJ, Leibowitz AB, Papadokos PJ, Fisher ET. Low sensitivity of the anion gap as a screen to detect hyper-lactatemia in critically ill patients. Crit Care Med 1990;18:275-277.
Gabow PA, Kachney WD, Fennessey PV, et al. Diagnostic importance of an increased serum anion gap. N Engl J Med 1980;303:854-858.
Adrogue HJ, Wilson H, Boyd AE III, et al. Plasma acidbase patterns in diabetic ketoacidosis. N Engl J Med 1982;307:1603-1610.
Oh MS, Carroll HJ, Goldstein DA, Fein IA. Hyperchloremic acidosis during the recovery phase of diabetic ketosis. Ann Intern Med 1978;89:925-927.
Kosnett M, Larson S, McCarthy T, Osterloh J. Investigation of an anion gap of minus 88 in a patient taking bromazepam. Clin Chem 1990;36:1040.
Winter SD, Pearson JR, Gabow PA, et al. The fall of the serum anion gap. Arch Intern Med 1990;150:311-313.
Wrenn K. The delta (S) gap. An approach to mixed acidbase disorders. Ann Emerg Med 1990;19:1310-1319.
Braden GL, Strayhorn CH, Germain MJ, et al. Increased osmolal gap in alcoholic acidosis. Arch Intern Med 1993;153:2377-2380.
Price EA, D’Alessandro A, Kearney T, Olson KR, Blanc PD. Osmolar gap with minimal acidosis in combined methanol and methyl ethyl ketone ingestion. Clin Toxicol 1994;32(1):79—84.
Aabakken L, Johansen KS, Rydningen E-B, et al. Osmolal and anion gaps in patients admitted to an emergency medical department. Hum Exp Toxicol 1994;13:131-134.
Osterloh JD. Alcoholics and the osmolal gap: Not such a simple diagnostic puzzle. AACT Clin Toxicol Update 1994;7(3):2.
American Academy of Clinical Toxicology Facility Assessment Guidelines for Regional Toxicology Treatment Centers. Clin Toxicol 1993;31:209-210.
Wasserberger J, Ordog GJ. Personal communication.
Hoffman RS. Comment. Measured serum osmolality — caution: Know your hospital lab. AACT Clin Toxicol Update. Abstract of Eisen TF, et al. Serum osmolality in alcohol ingestions: Differences in availability among laboratories of teaching hospitals, non-teaching hospitals and commercial facilities. Am J Emerg Med 1989;7:256-259.
Hoffman RS, Smilkstein MJ, Howland MA, Goldfrank LR. Osmolal gaps revisited: Normal values and limitations. Clin Toxicol 1993;31:81-93.
Aabakken L, Johansen KS, Rydningen E-R, et al. Osmolal and anion gaps in patients admitted to an emergency medical department. Hum Exp Toxicol 1994;13:131-134.
Mahoney JD, Gross PL, Stern TA, et al. Quantitative serum toxic screening in the management of suspected drug overdose. Am J Emerg Med 1990;8:16-22.
Gaudreault P, Timberlake S. Toxic compounds quantification: Type of samples and proper timing. Toxic screens, Part I. Clin Toxicol Rev 1989; 12(2):32.
Hepler BR, Sutheimer CA, Sunshine I. The role of the toxicology laboratory in emergency medicine. J Toxicol Clin Toxicol 1982;19:353-365.
Woolf AD, Shannon MW. Clinical toxicology for the pediatrician. Pediatr Clin North Am 1995;42:317-337.
Analysis of trace metals for occupationally exposed. MMWR 1984;33:664-665.
Savitt DL, Hawkins HH, Roberts DR. The radiopacity of ingested medications. Ann Emerg Med 1987; 16:331 — 339.
Tillman DJ, Ruggles DL, Leikin JB. Radiopacity study of extended-release formulations using digitalized radiography. Am J Emerg Med 1994;12:310-314.
Nelson JC, Liu D, Olson KR. Radiopacity of modified release medications. Vet Hum Toxicol 1993;35:317.
Woo OF, Jackson GM. Radiopacity of chewable PeptoBismol tablets: Report of two patients. Vet Hum Toxicol 1993;35:317.
Amitai Y, Silver B, Leikin JB, Frischer H. Visualization of ingested medications in the stomach by ultrasound. Am J Emerg Med 1992;10:18-23.
Anderson A, Share J, Woolf A. The use of ultrasound in the diagnosis of toxic ingestions. Pediatr Emerg Care 1989;5:281.
Binder L, Fredrickson L. Poisoning in laboratory personnel and health care professionals. Am J Emerg Med 1991;9:11-15.
White PF, Proctor SP. Research and clinical criteria for development of neurobehavioral test batteries. J Occup Med 1992(Feb.): 140-148.
McBayAJ. Hair drug testing review and update. In: Proceedings, 29th International Meeting of the International Association of Forensic Toxicologists, Copenhagen, June 1991:19-91.
Cone EJ. Testing human hair for drugs of abuse. I. Individual dose and time profiles of morphine and codeine in plasma, saliva, urine and beard compared to drug-induced effects on pupils and behavior. J Anal Toxicol 1990;14:1-7.
Anstadt GW. Occupational medicine forum: Hair analysis in drug screening. J Occup Med 1990;32:668-669.
Baumgartner AM, Jones PF, Baumgartner WA, Black CT. Radioimmunoassay of hair for determining opiateabuse histories. J Nucl Med 1979;20:749-752.
Baumgartner WA, Hill VA, Blahd WH. Hair analysis for drugs of abuse. J Forens Sci 1989;34:1433-1453.
Kintz P, Tracqui A, Mangin P. Detection of drugs in human hair for clinical and forensic applications. Int J Leg Med 1992;105:1-4.
Shoemaker WC. What should be monitored? The past, present and future of physiological monitoring. Clin Chem 1990;36:1543-1563.
Bailey DN. Drug screening in an unconventional matrix: Hair analysis. JAMA 1989;262:3331.
Ostrea EM Jr, Knapp K, Romero A, et al. Meconium analysis to assess fetal exposure to nicotine by active and passive maternal smoking. J Pediatr 1994;124: 471-476.
Ostrea EM Jr, Romero A, Knapp K, et al. Postmortem drug analysis of meconium in early gestation human fetuses exposed to cocaine: Clinical complications. J Pediatr 1994;124:477-479.
Koren G, Klein J, Forman R, et al. Biological markers of intrauterine exposure to cocaine and cigarette smoking. Dev Pharmacol Ther 1992;18:228-233.
Wasserman E, Slobody LB. Survey of Clinical Pediatrics 6th ed. International Students Edition. Tokyo: McGrain Hill Kogakusha, 1974.
Lewis D, Muldoon K, Leikin JB. Cocaethylene in meconium specimens. Vet Hum Toxicol 1993;35:350.
Ostrea EM Jr, Brady M, Qause S, et al. Drug screening of newborns by meconium analysis: A large-scale prospective epidemiologic study. Pediatrics 1992;89:107-113.
Code of Federal Regulations: Title 49, Part 40. Procedures for transportation workplace drug testing programs, 1993:528—553. Part 40.29. Laboratory analysis procedures.
Lee EJ, Williams KM. Chiralty. Clinical pharmacokinetic and pharmacodynamic considerations. Clin Phannacokinet 1990;18:339-345.
Schramm W, Smith RH, Craig PA, Kidwell DA. Drugs of abuse in saliva: A review. J Anal Toxicol 1992;16:1-9.
Vale JA. Medical toxicology: Clinical aspects. Arch Toxicol 1991;suppl. 15:12—13.
Meredith TJ. Epidemiology of poisoning. Pharmacol Ther 1993;49:251-256.
Centers for Disease Control and Prevention. Unintentional poisoning mortality: United States, 1980—1986. MMWR 1989;38:153-158.
Centers for Disease Control and Prevention. Unintentional ingestion of prescription drugs in children under five years old. MMWR 1987;36:124-132.
LitovitzTL, Flagler SL, Manoguerra AS, et al. Recurrent poisoning among pediatric poisoning victims. Med Toxicol Adverse Drug Experience 1989;4:381-386.
Herrington LF, Geller RJ, Lopez GP, Garrettson LK. Poisoning in infants under 12 months. Who, which, when, where and why. Vet Hum Toxicol 1990;32:34.
Woolf AD, Lovejoy FH Jr: Epidemiology of drug overdose in children. Drug Saf 1993;9:291-304.
Litovitz TL, Clark LR, Soloway RA. 1993 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1994;12:546-583.
Litovitz TL, Schmitz BF, Holm КС. 1988 Annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1989;7:495-545.
Klein-Schwartz W, OderdaGM, Booze L. Poisoning in the elderly. J Am Geriatr Soc 1983;31:195-199.
Litovitz T, Manoguerra A. Comparison of pediatric poisoning hazards: An analysis of 3.8 million exposure incidents: A report from the American Association of Poison Control Centers. Pediatrics 1992;89:999-1005.
Michell L-J, Dexter EM, Bradberry SM, et al. Assessment of 1PCS/CEC/EAPCTT. Dexter EM, Michell L-J, Casey PB: The role and value of phonetoxscore in cases of poisoning. Phonetoxscore by staff of the PNP1S (Birmingham Centre). In: Proceedings. XVlth International Congress of the European Association of Poison Centres and Clinical Toxicologists, Vienna, April 12, 1994:Abstracts 0.83 and 0.84.
March AG, Bet N, Persino MG, et al. Severity grading of childhood poisoning: The Matti Center study of poisoning children (MPXC) scare. Clin Toxicol 1995;33:223-231.
Koren G. Medications which can kill a toddler with one tablet or teaspoonful. Clin Toxicol 1993;31:407-413.
Geller RJ, Fisher JG III, Leeper JD, Ranganathon S. American Poison Control Centers: Still not all the same? Ann Emerg Med 1988;17:599-603.
Sibert R, Routledge PA. Accidental poisoning in children: Can we admit fewer children with safety? Arch Dis Child 1991;66:263-266.
Henretig FM. Special considerations in the poisoned pediatric patient. Emerg Med Clin North Am 1994; 12:552.
Haslam R. Drug safety and medication systems in hospitals. Adverse Drug React Acute Poison Rev 1988;3:133-146.
Mayer GA. Chlorpropamide or chlorpromazine? Can Med Assoc J 1991; 144:119.
Hoffman JP. More on Losec or Lasix? N Engl J Med 1990;323:1428.
Landis SJ. Azathioprine or azidothyridine. Can Med Assoc J 1990; 143:611.
Olsen LA, Miller DR, Goswani A, McAskill AC, Newman WP. Inadvertent administration of acetohexamide instead of acetazolamide. DICP Ann Pharmacother 1991 ;25:100.
Pincus JM, Ike PW. Norflox or Norflex? N Engl J Med 1992;326:1030.
Garvey CW. Desipramine sent when it’s disopyramide. JAMA 1989;262:210.
Brierton D, Nunn-Thompson CW. Warning: Acetaminophen and aprolidine both labeled Apronal. DICP Ann Pharmacother 1990;24: 1232.
Hooper PL, Tello RJ, Burstein PJ, Abrams RS. Pseudoinsulinoma: The Diamox-Diabinese switch. N Engl J Med 1990; 1323:488.
Fallis G. Quinine or quinidine? Can Med Assoc J 1991;144:540-541.
Kurth MC, Langston JW, Tetrud WW. "Stelazine" versus "selegiline": A hazard in prescription writing. N Engl J Med 1990; 1323:1776.
Ahlquist DA, Nelson RL, Callaway CW. Pseudoinsulinoma syndrome from inadvertent tolazamide ingestion. Ann Intern Med 1980;93:281-282.
Kramer JM. More он drug name confusion. N Engl J Med 1995;332:753-754.
LesarTS, Briceland LL, Delcoure K, et al. Medical prescribing errors in a teaching hospital. JAMA 1990;263:2329-2334.
Janda SM. Look-alike and sound-alike medication pairs. Vet Hum Toxicol 1994;36:256.
Mrvos R, Dean BS, Krenzelok EP. Illiteracy: A contributing factor to poisoning. Vet Hum Toxicol 1993;35:466-468.
Perlstein PH, Callison C, White M, et al. Errors in drug computations during newborn intensive care. Am J Dis Child 1979;133:376-379.
BleyerWA, KoupJR. Medication errors during intensive care. Am J Dis Child 1979;133:366-367.
Koren G. Barzilay Z, Greenwald M. Tenfold errors in administration of drug doses: A neglected iatrogenic disease in pediatrics. Pediatrics 1986;77: 848—849.
Bury G. Errors in drug administration. Pediatrics 1987;79:170.
Lamont JH. Errors in drug administration. Pediatrics 1987; 79:171-177.
Rieder WJ, Goldstein D, Zinman H, Koren G. Tenfold errors in drug dosage. Can Med Assoc J 1988;139:12-13.
Hoen E, Hodgkin C, Milkevicius D. Harmful use of donated veterinary drugs. Lancet 1993;342:308-309.
Joubert PH, Mathibe L. Acute poisoning in developing countries. Adverse Drug React Acute Poisoning Rev 1989;8:165-178.
Kulig K. Initial management of ingestions of toxic substances. N Engl J Med 1992;326:1678.
Lloyd-Thomas AP. Paediatric Glasgow Coma Scale. Br Med J 1990;301:382.
Yaeger JY, Johnston B, Sesshia SS. Coma scales in pediatric practice. Am J Dis Child 1990; 144:1088—1091.
Stanmark J-E, Stalhammer D, Holmgren E. The reaction level scale (RLS85): Manual and guidelines. Acta Neurochir 1988;91:12-20.
Stanczak DE, White JG, Gouview W, et al. Assessment of level of consciousness following severe neurological insult. J Neurosurg 1984;60:955-961.
Crosby L, Parsons LC. Clinical neurologic assessment tool: Development and testing of an instrument to index neurologic status. Heart Lung 1989;18:121-129.
Giacino JT, Kezmarsky MA, De Luca J, Cicerone KD. Monitoring rate of recovery to predict outcome in minimally responsive patients. Arch Phys Med Rehabil 1991;72:897-901.
Born JD. The Glasgow-Liege Scale. Acta Neurochir (Wien) 1988;91:1-11.
BenzerA, Mittershiffthaler G, Marosi M, et al. Pediatric measures of non-survival after trauma: Innsbruck Coma Scale. Lancet 1991;338:977-978.
Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975;1:484-485.
Segatore M, Way C. The Glasgow Coma Scale: Time for change. Heart Lung 1992;21:548-555.
Olson KR, Kerney ТЕ, Dyer JE, Benowitz HL. Seizures associated with poisoning and drug overdose: Changing patterns of causes and poison center consultations. Vet Hum Toxicol 1990;32:361.
Working Group on Status Epilepticus. Treatment of convulsive status epilepticus: Recommendations of the Epilepsy Foundation of America Working Group on Status Epilepticus. JAMA 1993;270:854-859.
Zaccara G, Muscas GC, Messori A. Clinical features, pathogenesis and management of drug-induced seizures. Drug Saf 1990;5:109-151.
Hoffman R. Nervous system toxicity. Personal presentation, American College of Medical Toxicology, Board Examination Review Course, September 1994.
Morrow JI, Routledge BA. Drug-induced neurological disorders. Adverse Drug React Acute Poison Rev 1988;3:105-133.
Francis J, Kapoor WN. Delirium in hospitalized elderly. J Gen Intern Med 1990;5:65-79.
Bruno A, Nolte KB, Chapinj J. Stroke associated with ephedrine use. Neurology 1993;43:1313-1316.
Griffen JP. A review of the literature on benign intracranial hypertension associated with medication. Adverse Drug React Toxicol Rev 1992;! 1:41—58.
Patter SB, Love EJ. Drug-induced depression: Incidence, avoidance and management. Drug Saf 1994;10:203-219.
Turner P. Clinical pharmacology in criminal cases: Discussion paper. J R Soc Med 1987;8:438-439.
Suiter DL, Cummings JL. Drug-induced mania-causative agents, clinical characteristics and management: A retrospective analysis of the literature. Med Toxicol Adverse Drug Experience 1989;4:127-143.
Evans L. Psychological effects caused by drugs in overdose. Drugs 1980;19:220-242.
Mofenson HC, Caraccio TR. The agitated, violent or acutely psychotic patient. PP/T Review. Nassau County Medical Center Regional Poison Control Center. 1992; ll(5):301-306.
Chapman SA, Stephan T, Lake KD, et al. Fever induced by dobutamine infusion. Am J Cardiol 1994;74:517.
Thomas SHL. Drug-induced systemic hypertension. Adverse Drug React Bull 1993;5:559-562.
Kristensen TS. Cardiovascular diseases and the work environment: A critical review of the epidemiologic literature on chemical factors. Scand J Work Environ Health 1989;15:245-264.
Benowitz NL. Cardiotoxicity in the workplace. Occup Med 1992;7(3):468—478.
Talieraco CP, Olney BA, Lie JT. Myocarditis related to drug hypersensitivity. Mayo Clin Proc 1985;60:463-468.
Hoff JS, Syverrud SA, Tucci MA. Case conference: Complete heart block in a young man. Acad Emerg Med 1995;2:751-756.
Dufresne RG. Skin necrosis from intravenously infused materials. Cutis 1987;39:197-198.
Dolan PA, Flowers FP, Araujo OE, Shuertz EF. Toxic epidermal necrolysis. J Emerg Med 1989;7:65-69.
Krop LC. Drug-induced systemic lupus erythematosus. DICP Ann Pharmacokinet 1991;25:212-213.
Kale SA: Drug-induced systemic lupus erythematosus: Differentiating it from the real thing. Interstate Postgrad Med Assoc 1985;77:231-242.
Cohen MG, Prowse MV. Drug-induced rheumatic symptoms: Diagnosis, clinical features and management. Med Toxicol Adverse Drug Experience 1989;4:199-218.
Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285.
Tosti A, Misciali C, Piraccini BM, et al. Drug induced hair loss and hair growth: Incidence, management and avoidance. Drug Saf 1994;10:317-318.
Huang MY, Schacht J. Drug induced ototoxicity: Pathogenesis and prevention. Med Toxicol Adverse Drug Experience 1989;4:452-467.
Drug-induced hearing disorders. Aust Adverse Drug React Bull 1995;10(l):2.
Prendergast BD, George CP. Drug-induced rhabdomyolysis: Mechanisms and management. Postgrad Med J 1993;66:333-336.
Koppel C. Clinical features, pathogenesis and management of drug-induced rhabdomyolysis. Med Toxicol Adverse Drug Experience 1989;4:108-126.
Curry SC, Chang D, Connor D. Drug- and toxin-induced rhabdomyolysis. Ann Emerg Med 1989; 18:1068— 1084.
Stone MJ, Willerson JT, Gomez-Sanchez CE, et al. Radioimmunoassay of myoglobin in human serum: Results in patients with acute myocardial infarction. J Clin Invest 1975;56:1334-1339.
Sabaawi M, Holmes TF, Fragala MR. Drug-induced akathisias: Subjective experience and objective findings. Milit Med 1994;159:286-291.
Godley PJ, Morton TA, Karboski JA, Tani JA. Procain-amideinduced myasthenic crisis. Ther Drug Monit 1990;12:411-414.
Mastaglia FL. Adverse effects of drugs on muscle. Drugs 1982;24:304-321.
Plotz PH, Rider LG, Targoff IN, et al. Myositis: Immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995; 122: 715-725.
Goldsmith JR. Herishanu Y, Abarband JM, Weinbaum Z. Clustering of Parkinson's disease points to environmental etiology. Arch Environ Health 1990;45:88-94.
Ross RT. Drug-induced parkinsonism and other movement disorders. Can J Neurol Sci 1990;17:155-162.
Martyn CN. Neurological clues from environmental neurotoxins. Br Med J 1987;295:346-347.
Lane RJM, Dick JPR, de Belleroche J. Glycine and neu-rodegenerative disease. Lancet 1991;337:732-733.
Feldman RG, Mayer RM, Taub A. Evidence for peripheral neurotoxic effects of trichlorethylene. Neurology 1970;20:599.
Spencer PS, Nunn PB, Hugon J, et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 1987;237:517-522.
Spencer PS. Guam ALS/parkinsonism-dementia: A long-lasting neurotoxic disorder caused by "slow tox-in(s)" in food? Can J Neurol Sci 1987;14:347-357.
Boothby JA, de Jesus PV, Rowland LP. Reversible form of motor neuron disease: Lead "neuritis." Arch Neurol 1974;31:18-25.
Stober T, Stelte W, Kunze K. Lead concentrations in blood, plasma, erythrocytes and cerebrospinal fluid in amyotrophic lateral sclerosis. J Neurol Sci 1983:61:21 — 26.
Hawkes CH, Cavanagh JB, Fox AJ. Motoneuron disease: A disorder secondary to solvent exposure? Lancet 1989;1:73-76.
Tylleskar T, Banea M, Bikangi N, et al. Cassava cyanogens and konzo, an upper motoneuron disease found in Africa. Lancet 1992;339:208-211.
Roelofs-Ivenson RA, Mulder DW, Elveback LP, et al. ALS and heavy metals: A pilot case-control study. Neurology 1984;34:393-395.
Conradi S, Ronnevi L-O, Nise G, Vesterberg O. Longtime penicillamine treatment in amyotrophic lateral sclerosis with parallel determination of lead in blood, plasma and urine. Acta Neurol Scand 1982;65:203-211.
Yanagihara R. Heavy metals and essential minerals in motor neuron disease, in: Rowland LP, ed. Human Motor Neuron Disease. New York: Raven Press; 1982:233— 247.
Duncan MW, Steele JC, Kopin IJ, Markey SP. 2-Amino-3-(methylamino)-propanoic acid (BMAA) in cycad flow: An unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neurology 1990;40:767-772.
Abnelo JG. Renal failure caused by chemicals, foods, plants, animal venoms and misuse of drugs. Arch Intern Med 1990;150:505-510.
Nelid GH. Haemolytic syndrome in practice. Lancet 1994;334:338-340.
Urinary incontinence. Harvard Med School Health Lett 1990; 15( 10): 10.
Oral drug effects. Aust Adverse Drug React Bull 1992;! 1(4).
Klegan KL, Young TL. Pill-induced esophageal injury. J Tenn Med Assoc 1992;85:417-418.
Iredale JP, George CF. Drugs causing gastrointestinal obstruction. Adverse Drug React Toxicol Rev 1993;12:163-175.
Committee on Safety of Medicines UK. CSM update: Adverse drug reactions and the liver. Br Med J 1985;291:46.
Hanson JS. Propylthiouracil and hepatitis: Two cases and a review of the literature. Arch Intern Med 1984;144:994-996.
Ishii M, Miyazaki Y, Yamamoto T, et al. A case of drug-induced ductopenia resulting in fatal biliary cirrhosis. Liver 1993;13:227-231.
Cappell MS, Simon T. Colonic toxicity of administered medications and chemicals. Am J Gastroenterol 1993;88:1684-1697.
Driscoll DF. Drug-induced metabolic disorders and parenteral nutrition in the intensive care unit: A pharmaceutical and metabolic perspective. DICP Ann Phar-macother 1989;23:363-371.
